PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Togias, A				Togias, A			Unique mechanistic features of allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on Advances in Allergic Diseases - An Update for the New Millennium	FEB   11, 1999	WASHINGTON, D.C.			allergic rhinitis; asthma; nerve growth factor; neurogenic inflammation	NEURAL HYPERRESPONSIVENESS; NEURONAL STIMULATION; NASAL-MUCOSA; RESPONSIVENESS; PROVOCATION	Symptoms of allergic rhinitis are produced by inflammatory mediators that are released upon activation of mast cells by antigen-IgE interaction These mediators target the end organs directly or indirectly Stimulation of sensory nerves by histamine, for example, leads to sneezing, pruritus, rhinorrhea, and nasal congestion. The clinical presentation of allergic rhinitis is also characterized by the phenomenon of hyperresponsiveness to nonallergic stimuli, such as cold air and various irritants. This phenomenon is believed to result from the effect of allergic inflammation on the sensory nerves that supply the upper airway mucosa. Various nonallergic triggers have been shown to act on the nasal mucosa through sensorineural stimulation. In allergic rhinitis, responsiveness to these stimuli is increased compared with the healthy state. A similar phenomenon is observed against such products of the allergic reaction as histamine and bradykinin. Also, in allergic rhinitis, stimulation of sensory nerves per se can produce inflammatory changes, a phenomenon known as neurogenic inflammation. The mechanism behind the development of sensorineural hyperresponsiveness and of increased propensity for neurogenic inflammation is unknown. However, evidence exists that the neurotrophin nerve growth factor, which can induce all these changes on sensory nerves, is produced in the human nasal mucosa and found in higher quantities in nasal secretions of patients with perennial allergic rhinitis as compared with healthy control subjects. Also, nerve growth factor is acutely released into nasal fluids after allergen provocation of patients with allergic disease. In patients with asthma of atopic origin, allergic rhinitis is almost ubiquitous. Because the nose is the air conditioner of the respiratory system, its dysfunction may negatively affect the lower airways. In addition to the conditioning of inhaled air, the association between allergic rhinitis and asthma may involve various mechanisms. For example, allergen provocation in the nose of a patient with asthma can lead to reductions in pulmonary function and to increased lower airway responsiveness after several hours. Also, nasal inflammation may propagate through a systemic route to affect the lower airways.			Togias, A (corresponding author), 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.							BEDARD PM, 1989, AM J RHINOL, V3, P211; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Kapsali T., 1997, Journal of Allergy and Clinical Immunology, V99, pS138; NOUREDDINE G, 1994, J ALLERGY CLIN IMMUN, V193, P177; PEEBLES R, 1997, ALLERGY ALLERGY DIS, P1139; Riccio MM, 1996, J ALLERGY CLIN IMMUN, V97, P1252, DOI 10.1016/S0091-6749(96)70193-8; Sanico AM, 1998, CLIN EXP ALLERGY, V28, P92; Sanico AM, 1998, J APPL PHYSIOL, V84, P537, DOI 10.1152/jappl.1998.84.2.537; Sanico AM, 1999, J APPL PHYSIOL, V86, P1202, DOI 10.1152/jappl.1999.86.4.1202; Sanico AM, 1999, INT ARCH ALLERGY IMM, V118, P154, DOI 10.1159/000024054; SANICO AM, IN PRESS AM J RESP C; Togias A, 1999, J ALLERGY CLIN IMMUN, V103, pS7; WINDOM HH, 1992, J ALLERGY CLIN IMMUN, V89, P334	14	92	96	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	2	S			S599	S604		10.1067/mai.2000.106885	http://dx.doi.org/10.1067/mai.2000.106885			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	328QU	10856164				2022-12-18	WOS:000087862200002
J	Parry, DE; Busse, WW; Sukow, KA; Dick, CR; Swenson, C; Gern, JE				Parry, DE; Busse, WW; Sukow, KA; Dick, CR; Swenson, C; Gern, JE			Rhinovirus-induced PBMC responses and outcome of experimental infection in allergic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinovirus; mononuclear cells; proliferation; common cold; blood; allergy; asthma	PRECHALLENGE ANTIBODIES; NONALLERGIC SUBJECTS; ASTHMATIC SUBJECTS; INTERFERON-GAMMA; COMMON COLD; T-CELLS; CHILDREN; ADULTS; INTERLEUKIN-2; EXACERBATIONS	Background: The immune response to rhinovirus (RV) infections is considered to contribute to upper respiratory symptoms and may also be an important contributor to lower airway dysfunction in patients with asthma. Objective: This study was conducted to determine the relationship of RV-specific responses in PBMCs to the outcome of experimentally induced infection with RV16. Methods: Twenty-two subjects with either allergic rhinitis or asthma were inoculated with RV16: virus-induced proliferation and cytokine production were determined on PBMCs obtained before and then again 7 and 28 days after inoculation. Results: Several subjects had proliferative responses to RV16 before inoculation, and precold RV-specific proliferative responses were inversely correlated (r(s) = -0.62, P <.005) with RV shedding after inoculation. In addition, there was a negative correlation (r(s) = -0.58, P = 0.01) between precold RV-induced IFN-gamma secretion ex vivo and peak RV shedding during the cold. Conclusions: Certain RV-specific lymphocyte responses before the fold (vigorous proliferation or IFN-gamma secretion) were associated with reduced viral shedding after inoculation. These Endings suggest that variations in mononuclear cell responses to RV could contribute to the individual variability in viral shedding during experimentally induced, and perhaps naturally acquired, RV infections in subjects with respiratory allergy or asthma.	Univ Wisconsin Hosp, Dept Pediat, Madison, WI 54792 USA; Univ Wisconsin Hosp, Dept Med, Madison, WI 54792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gern, JE (corresponding author), Univ Wisconsin Hosp, Dept Pediat, H4-438 CSC, Madison, WI 54792 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040685] Funding Source: NIH RePORTER; NIAID NIH HHS [R29 AI40685] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alper CM, 1996, LARYNGOSCOPE, V106, P1298, DOI 10.1097/00005537-199610000-00025; Alper CM, 1998, CLIN INFECT DIS, V27, P119, DOI 10.1086/514634; ALWAN WH, 1994, J EXP MED, V179, P81, DOI 10.1084/jem.179.1.81; CALHOUN WJ, 1991, AM REV RESPIR DIS, V144, P1267, DOI 10.1164/ajrccm/144.6.1267; CHEUNG D, 1995, AM J RESP CRIT CARE, V152, P1490, DOI 10.1164/ajrccm.152.5.7582282; Doherty PC, 1997, IMMUNOL REV, V159, P105, DOI 10.1111/j.1600-065X.1997.tb01010.x; DOYLE WJ, 1992, J ALLERGY CLIN IMMUN, V89, P968, DOI 10.1016/0091-6749(92)90219-R; DUFF AL, 1993, PEDIATRICS, V92, P535; EGGLESTON PA, 1984, ACTA OTO-LARYNGOL, P25; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708, DOI 10.1164/ajrccm.157.6.9707163; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Gern JE, 1996, J INFECT DIS, V174, P1143, DOI 10.1093/infdis/174.6.1143; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1872, DOI 10.1164/ajrccm.155.6.9196088; Gern JE, 1999, CLIN MICROBIOL REV, V12, P9, DOI 10.1128/CMR.12.1.9; Gern JE, 1997, J INFECT DIS, V175, P1108, DOI 10.1086/516449; HIGGINS PG, 1988, J INTERFERON RES, V8, P591, DOI 10.1089/jir.1988.8.591; HORSNELL C, 1995, J GEN VIROL, V76, P2549, DOI 10.1099/0022-1317-76-10-2549; HSIA J, 1990, J INFECT DIS, V162, P591, DOI 10.1093/infdis/162.3.591; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; LEE WM, 1995, VIRUS GENES, V9, P177, DOI 10.1007/BF01702661; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; Lennette EH, 1964, GEN PRINCIPLES UNDER; LEVANDOWSKI RA, 1986, J INFECT DIS, V153, P743, DOI 10.1093/infdis/153.4.743; LEVANDOWSKI RA, 1988, J MED VIROL, V25, P423, DOI 10.1002/jmv.1890250406; Neal ZC, 1998, J VIROL, V72, P8052, DOI 10.1128/JVI.72.10.8052-8060.1998; NEAL ZC, 1995, J VIROL, V69, P4914, DOI 10.1128/JVI.69.8.4914-4923.1995; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Rueckert R., 1996, FIELDS VIROLOGY, P609; SARAWAR SR, 1994, J VIROL, V68, P3112, DOI 10.1128/JVI.68.5.3112-3119.1994; SARAWAR SR, 1994, J IMMUNOL, V153, P1246; SKONER DP, 1993, J ALLERGY CLIN IMMUN, V92, P732, DOI 10.1016/0091-6749(93)90017-A; Turner RB, 1998, CLIN INFECT DIS, V26, P840, DOI 10.1086/513922; Wimalasundera SS, 1997, J INFECT DIS, V176, P755, DOI 10.1086/514101	33	92	96	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					692	698		10.1067/mai.2000.104785	http://dx.doi.org/10.1067/mai.2000.104785			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756217				2022-12-18	WOS:000086604100005
J	del Val, G; Yee, BC; Lozano, RM; Buchanan, BB; Ermel, RW; Lee, YM; Frick, OL				del Val, G; Yee, BC; Lozano, RM; Buchanan, BB; Ermel, RW; Lee, YM; Frick, OL			Thioredoxin treatment increases digestibility and lowers allergenicity of milk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						thioredoxin; milk allergy; NADP-thioredoxin reductase; beta-lactoglobulin allergenicity; beta-lactoglobulin digestibility; milk allergy alleviation; milk allergy mitigation; thioredoxin and allergy alleviation/mitigation; dog model	BOVINE BETA-LACTOGLOBULIN; INDUCED AIRWAY HYPERRESPONSIVENESS; TRYPSIN-INHIBITOR PROTEINS; DUST MITE ALLERGEN; ALPHA-AMYLASE; IGE BINDING; REDUCTION; FOOD; SYNTHETASE; STABILITY	Background: By resisting digestion in the stomach, the major bovine milk allergen, beta-lactoglobulin, is believed to act as a transporter of vitamin A and retinol to the intestines. beta-Lactoglobulin has 2 intramolecular disulfide bonds that may be responsible for its allergic effects. Objective: This study was carried out to assess the importance of disulfide bonds to the allergenicity and digestibility of beta-lactoglobulin, Methods: beta-Lactoglobulin was subjected to reduction by the ubiquitous protein thioredoxin, which was itself reduced by the reduced form of nicotinamide adenine dinucleotide phosphate by means of nicotinamide adenine dinucleotide phosphate-thioredoxin reductase, Digestibility was measured with a simulated gastric fluid; results were analyzed by SDS-PAGE, Allergenicity was assessed with an inbred colony of high IgE-producing dogs sensitized to milk. Results: As found for other proteins with intramolecular disulfide bonds,beta-lactoglobulin was reduced specifically by the thioredoxin system, After reduction of one or both of its disulfide bonds, beta-lactoglobulin became strikingly sensitive to pepsin and lost allergenicity as determined by skin test responses and gastrointestinal symptoms in the dog model. Conclusion: The results provide new evidence that thioredoxin can be applied to enhance digestibility and lower allergenicity of food proteins.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Univ Calif Davis, Prot Struct Lab, Davis, CA 95616 USA; Univ Calif Davis, Sch Vet Med, Anim Resources Serv, Davis, CA 95616 USA; Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California Berkeley; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California San Francisco	Buchanan, BB (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, 111 Koshland Hall, Berkeley, CA 94720 USA.			Lozano, Rosa Maria/0000-0003-2762-6938				Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; BALL G, 1994, CLIN EXP ALLERGY, V24, P758, DOI 10.1111/j.1365-2222.1994.tb00987.x; Besse I, 1997, BOT BULL ACAD SINICA, V38, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brownlow S, 1997, STRUCTURE, V5, P481, DOI 10.1016/S0969-2126(97)00205-0; Buchanan BB, 1997, P NATL ACAD SCI USA, V94, P5372, DOI 10.1073/pnas.94.10.5372; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; BUISSERET PD, 1978, LANCET, V11, P304; CHUNG KF, 1986, AM REV RESPIR DIS, V134, P258; CHUNG KF, 1985, J APPL PHYSIOL, V58, P1347, DOI 10.1152/jappl.1985.58.4.1347; Del Val G., 1997, 16 INT C ALL CLIN IM, P26; Docena GH, 1996, ALLERGY, V51, P412, DOI 10.1111/j.1398-9995.1996.tb04639.x; Ermel RW, 1997, LAB ANIM SCI, V47, P40; FRICK OL, 1999, IN PRESS J ALLERGY C; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HILL RL, 1975, ADV ENZYMOL RAMB, V43, P411; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.biochem.54.1.237; Hutinel VH, 1908, CLINIQUE PARIS, V3, P227; Hwang BJ, 1996, J CHROMATOGR B, V686, P165, DOI 10.1016/S0378-4347(96)00230-7; IACONO G, 1995, J PEDIATR-US, V126, P34, DOI 10.1016/S0022-3476(95)70496-5; JIAO JA, 1993, PLANT PHYSIOL BIOCH, V31, P799; JIAO JA, 1992, J AGR FOOD CHEM, V40, P2333, DOI 10.1021/jf00024a002; KAMINOGAWA S, 1989, BIOCHIM BIOPHYS ACTA, V998, P50, DOI 10.1016/0167-4838(89)90117-9; KOBREHEL K, 1991, J BIOL CHEM, V266, P16135; KOBREHEL K, 1992, PLANT PHYSIOL, V99, P919, DOI 10.1104/pp.99.3.919; LEE CM, 1993, AM J GASTROENTEROL, V88, P70; LOZANO RM, 1994, ARCH BIOCHEM BIOPHYS, V309, P356, DOI 10.1006/abbi.1994.1124; MATSUDA T, 1985, AGR BIOL CHEM TOKYO, V49, P2237, DOI 10.1080/00021369.1985.10867063; Metcalfe DD, 1996, CRIT REV FOOD SCI, V36, pS165, DOI 10.1080/10408399609527763; MORTON JI, 1961, ARCH BIOCHEM BIOPHYS, V93, P661, DOI 10.1016/S0003-9861(61)80065-9; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PEREZ MD, 1995, J DAIRY SCI, V78, P978, DOI 10.3168/jds.S0022-0302(95)76713-3; Qi XL, 1997, BIOCHEM J, V324, P341, DOI 10.1042/bj3240341; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SAVILAHTI E, 1992, J PEDIATR-US, V121, pS12, DOI 10.1016/S0022-3476(05)81401-5; SHIN SH, 1993, PLANTA, V189, P557, DOI 10.1007/BF00198219; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; TANFORD C, 1959, J AM CHEM SOC, V81, P4032, DOI 10.1021/ja01524a054; WONG JH, 1995, METHOD ENZYMOL, V252, P228; YADAV SP, 1991, J BIOL CHEM, V266, P698	42	92	97	0	14	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					690	697		10.1016/S0091-6749(99)70244-7	http://dx.doi.org/10.1016/S0091-6749(99)70244-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200021				2022-12-18	WOS:000079723900025
J	Schubert, MS; Goetz, DW				Schubert, MS; Goetz, DW			Evaluation and treatment of allergic fungal sinusitis. II. Treatment and follow-up	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic mucin; antibodies, fungal; diagnosis; Deuteromycetes; fungi; fungus diseases; hypersensitivity, type I; IgE; prednisone; serodiagnosis; spores, fungal; rhinosinusitis; sinusitis; treatment outcome	NEWLY RECOGNIZED FORM; ASPERGILLUS SINUSITIS; PEDIATRIC POPULATION; DIAGNOSIS	Background: Previous allergic fungal sinusitis case reports have speculated that oral corticosteroids might reduce the severity of disease and possibly forestall the high rate of recurrent sinus surgery. Objectives: Our objective was to comprehensively review 67 consecutive cases of allergic fungal sinusitis for their response to treatment and the utility of monitoring patient serologies during clinical follow-up. Methods: Allergic fungal sinusitis cases from a private practice were evaluated and treated with consistent diagnostic criteria and treatment paradigms. An 8-year retrospective review of serologic parameters and clinical response to treatment with or without oral corticosteroids is described. Results: The total serum IgE was found to correlate with the clinical rhinosinusitis severity (P =.0002). The fungal-specific IgG also correlated with clinical rhinosinusitis severity but less rigorously (P =.004). An increase of 10% or more in total serum IgE during follow-up was found to have significant predictive value for recurrent surgical intervention, with a sensitivity of 79%, specificity of 77%, positive predictive value of 48%, and negative predictive value of 93% (P <.0001). With the use of a modified corticosteroid treatment regimen adapted from allergic bronchopulmonary aspergillosis, as little as 2 months of oral corticosteroids after surgery provided significant clinical improvement for up to 12 months (P <.0001), although patients taking 12 months of treatment fared the best clinically (P =.03). By survival analysis, oral corticosteroids prolonged the time between subsequent sinus surgeries (P =.01) in this highly recurrent disease, No significant side effects of oral corticosteroids were observed during treatment with this dosing regimen. Conclusions: Postoperative oral corticosteroids appear to be an effective treatment option for allergic fungal sinusitis, and monitoring of total serum IgE ran be helpful in the clinical follow-up of these patients.	Wilford Hall USAF Med Ctr, Allergy Asthma Clin, Phoenix, AZ 85013 USA; Wilford Hall USAF Med Ctr, Dept Allergy Immunol, Phoenix, AZ 85013 USA		Schubert, MS (corresponding author), Wilford Hall USAF Med Ctr, Allergy Asthma Clin, Phoenix, AZ 85013 USA.							Bent JP, 1996, LARYNGOSCOPE, V106, P1331, DOI 10.1097/00005537-199611000-00005; Bent JP, 1996, ALLERGY ASTHMA PROC, V17, P259, DOI 10.2500/108854196778662273; BENT JP, 1994, OTOLARYNG HEAD NECK, V111, P580, DOI 10.1016/S0194-5998(94)70525-9; CLEVELAND CH, 1992, PEDIATR ASTHMA ALLER, V6, P189, DOI 10.1089/pai.1992.6.189; COREY JP, 1995, OTOLARYNG HEAD NECK, V113, P110, DOI 10.1016/S0194-5998(95)70153-2; DESHAZO RD, 1995, J ALLERGY CLIN IMMUN, V96, P24, DOI 10.1016/S0091-6749(95)70029-3; FRENKEL L, 1987, PEDIATR INFECT DIS J, V6, P1130, DOI 10.1097/00006454-198706120-00012; GOLDSTEIN MF, 1985, J ALLERGY CLIN IMMUN, V76, P515, DOI 10.1016/0091-6749(85)90737-7; GOURLEY DS, 1990, J ALLERGY CLIN IMMUN, V85, P583, DOI 10.1016/0091-6749(90)90097-N; GREENBERGER PA, 1993, ALLERGY PRINCIPLES P; JONATHAN D, 1989, J LARYNGOL OTOL, V103, P1181, DOI 10.1017/S0022215100111296; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; Kinsella JB, 1996, CLIN OTOLARYNGOL, V21, P389, DOI 10.1046/j.1365-2273.1996.00807.x; Kupferberg SB, 1996, ARCH OTOLARYNGOL, V122, P1381, DOI 10.1001/archotol.1996.01890240087019; Mabry RL, 1995, OTOLARYNG HEAD NECK, V113, P721, DOI 10.1016/S0194-5998(95)70011-0; Mabry RL, 1997, OTOLARYNG HEAD NECK, V116, P31, DOI 10.1016/S0194-5998(97)70348-6; MANNING SC, 1989, LARYNGOSCOPE, V99, P681; MANNING SC, 1993, LARYNGOSCOPE, V103, P717, DOI 10.1288/00005537-199307000-00002; Morpeth JF, 1996, ANN ALLERG ASTHMA IM, V76, P128, DOI 10.1016/S1081-1206(10)63411-4; PATTERSON R, 1977, AM J MED, V63, P257, DOI 10.1016/0002-9343(77)90240-6; REILLY JS, 1990, OTOLARYNG HEAD NECK, V103, P856, DOI 10.1177/01945998901030S504; Roth M, 1994, Ear Nose Throat J, V73, P928; STAMMBERGER H, 1985, ANN OTO RHINOL LARYN, V94, P1; Torres C, 1996, HUM PATHOL, V27, P793, DOI 10.1016/S0046-8177(96)90451-7; WASHBURN RG, 1988, MEDICINE, V67, P231, DOI 10.1097/00005792-198807000-00004; WAXMAN JE, 1987, LARYNGOSCOPE, V97, P261; WICKERN GM, 1993, PEDIATR ASTHMA ALLER, V7, P147, DOI 10.1089/pai.1993.7.147	28	92	101	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					395	402		10.1016/S0091-6749(98)70126-5	http://dx.doi.org/10.1016/S0091-6749(98)70126-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768579				2022-12-18	WOS:000076212800010
J	Abdelaziz, MM; Devalia, JL; Khair, OA; Bayram, H; Prior, AJ; Davies, RJ				Abdelaziz, MM; Devalia, JL; Khair, OA; Bayram, H; Prior, AJ; Davies, RJ			Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; nasal epithelial cells; eosinophils; epithelial permeability; cytokines; fexofenadine	MEDIATOR RELEASE; IN-VITRO; INHALED CORTICOSTEROIDS; TERFENADINE SELDANE; ASTHMA; HISTAMINE; CETIRIZINE; EXPRESSION; LORATADINE; ANTAGONIST	Recent studies have suggested that antihistamines, widely used in the treatment of symptoms of patients with allergic rhinitis, may also possess antiinflammatory properties. The mechanisms underlying this property, however, are not clearly understood. We have cultured epithelial cells from nasal biopsy specimens Born patients with seasonal allergic rhinitis outside the pollen season and studied the effect of 0 to 10(-3) mol/L fexofenadine, the main active metabolite of terfenadine, on eosinophil-induced changes in electrical resistance (measure of permeability) and release of proinflammatory mediators from these cells. Additionally, we have studied the effect of this drug on eosinophil chemotaxis and adherence to endothelial cells induced by conditioned medium from these human nasal epithelial cell (HNEC) cultures. Incubation of HNEC in the presence of eosinophils treated with opsonized latex beads significantly decreased the electrical resistance of these cultures, an effect that was abrogated bf treatment of the cultures with 10(-9) to 10(-3) mol/L, fexofenadine. Similarly, incubation of HNEC in the presence of eosinophils treated with latex: beads also significantly increased the basal release of the chemokine "regulated upon activation, normal T cell ex pressed and secreted" (RANTES) (from 96.0 to 613.0 fg/mu g cellular protein; p < 0.05), IL-8 (from 42.0 to 198.5 pg/mu g cellular protein; p < 0.05), granulocyte-macrophage colony-stimulating factor (GM-CSF) (from 0.54 to 3.4 pg/mu g cellular protein: p < 0.05), and soluble intercellular adhesion molecole-1 (sICAM-1) from 7.5 to 18.4 pg/mu g cellular protein; p < 0.05) from HNEC. The eosinophil-induced release of PL-S, GM-CSF, and sICAM-1 from the HNEC was significantly attenuated by treatment with fexofenadine. Analysis of the effects of conditioned medium from HNEC demonstrated that this significantly increased both eosinophil chemotaxis and adherence to endothelial cells. Addition of 10(-6) to 10(-3) mol/L fexofenadine to the conditioned medium significantly attenuated eosinophil chemotaxis and adherence to endothelial cells. These results suggest that fexofenadine may reduce nasal inflammation by modulating the release of proinflammatory mediators and adhesion molecules from HNEC.	London Chest Hosp, St Bartholomews & Royal London Sch Med & Dent, Acad Dept Resp Med, London E2 9JX, England	University of London; Queen Mary University London	Devalia, JL (corresponding author), London Chest Hosp, St Bartholomews & Royal London Sch Med & Dent, Acad Dept Resp Med, Bonner Rd, London E2 9JX, England.		Bayram, Hasan/ABE-5094-2021	Bayram, Hasan/0000-0002-5236-766X				ABDELAZIZ MM, 1995, AM J RESP CELL MOL, V13, P728, DOI 10.1165/ajrcmb.13.6.7576711; AKAGI M, 1987, IMMUNOPHARM IMMUNOT, V9, P257, DOI 10.3109/08923978709035214; AlvaradoValdes CA, 1997, CLIN THER, V19, P273, DOI 10.1016/S0149-2918(97)80115-4; ANDREWS PC, 1981, J BIOL CHEM, V256, P4211; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BURGOYNE RD, 1991, TRENDS BIOCHEM SCI, V16, P319, DOI 10.1016/0968-0004(91)90131-E; Calderon MA, 1997, J ALLERGY CLIN IMMUN, V99, P65, DOI 10.1016/S0091-6749(97)70302-6; CATES KL, 1978, LEUKOCYTE CHEMOTAXIS, P67; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; CIPRANDI G, 1995, CLIN EXP ALLERGY, V25, P871, DOI 10.1111/j.1365-2222.1995.tb00030.x; Ciprandi G, 1996, J ALLERGY CLIN IMMUN, V98, P1088, DOI 10.1016/S0091-6749(96)80196-5; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V143, P1165, DOI 10.1164/ajrccm/143.5_Pt_1.1165; CROMWELL O, 1992, IMMUNOLOGY, V77, P330; DENBURG JA, 1990, PHARM ALLERGY RES F, P15; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271, DOI 10.1165/ajrcmb/9.3.271; DEVALIA JL, 1990, RESP MED, V84, P303, DOI 10.1016/S0954-6111(08)80058-3; DEVALIA JL, 1992, AM J RESP CELL MOL, V7, P270, DOI 10.1165/ajrcmb/7.3.270; DEVALIA JL, 1994, EUR RESPIR J, V7, P1958; DEVOS C, 1989, INT ARCH ALLER A IMM, V88, P212, DOI 10.1159/000234789; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; GREIFF L, 1995, J ALLERGY CLIN IMMUN, V96, P97, DOI 10.1016/S0091-6749(95)70038-2; HAZAMA H, 1994, EUR J PHARMACOL, V259, P143, DOI 10.1016/0014-2999(94)90503-7; HOLGATE ST, 1991, AM REV RESPIR DIS, V143, pS66, DOI 10.1164/ajrccm/143.3_Pt_2.S66; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; KAY AB, 1992, BRIT MED BULL, V48, P51, DOI 10.1093/oxfordjournals.bmb.a072541; KENNERLY DA, 1993, ALLERGY; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; KLOPROGGE E, 1989, J ALLERGY CLIN IMMUN, V83, P393, DOI 10.1016/0091-6749(89)90124-3; KYANAUNG U, 1992, J ALLERGY CLIN IMMUN, V90, P270, DOI 10.1016/0091-6749(92)90083-E; LEURS R, 1995, PHARMACOL THERAPEUT, V66, P413, DOI 10.1016/0163-7258(95)00006-3; LEVINE SJ, 1995, J INVEST MED, V43, P241; Lippert Christina, 1995, Pharmaceutical Research (New York), V12, pS390; Lippert U, 1995, Exp Dermatol, V4, P272, DOI 10.1111/j.1600-0625.1995.tb00257.x; MALMBERG H, 1979, ALLERGY, V34, P389, DOI 10.1111/j.1398-9995.1979.tb02008.x; MASUO M, 1992, J PHARMACOL EXP THER, V260, P1300; MATTOLI S, 1990, PHARM ALLERGY RES FD, P25; MCTAVISH D, 1990, DRUGS, V39, P552, DOI 10.2165/00003495-199039040-00006; MIADONNA A, 1994, INT ARCH ALLERGY IMM, V105, P12, DOI 10.1159/000236797; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; MUEGGE K, 1989, New Biologist, V1, P239; NABE M, 1989, CLIN EXP ALLERGY, V19, P515, DOI 10.1111/j.1365-2222.1989.tb02426.x; PATEL KR, 1984, BRIT MED J, V288, P1496, DOI 10.1136/bmj.288.6429.1496; PELIKAN Z, 1989, J ALLERGY CLIN IMMUN, V83, P1068, DOI 10.1016/0091-6749(89)90448-X; PIPKORN U, 1989, CLIN EXP ALLERGY, V26, P585; PIPKORN U, 1983, J ALLERGY CLIN IMMUN, V63, P1046; Pratt CM, 1996, AM HEART J, V131, P472, DOI 10.1016/S0002-8703(96)90525-6; Pratt CM, 1997, ALLERGY S37, V52, P67; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; SEIFERT R, 1992, MOL PHARMACOL, V42, P235; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557, DOI 10.1164/ajrccm/147.6_Pt_1.1557; STERN M, 1996, FEXOFENADINE HCI VER, P10; TAYTARD A, 1987, BRIT J CLIN PHARMACO, V24, P743, DOI 10.1111/j.1365-2125.1987.tb03240.x; Trigg CJ, 1996, CLIN EXP ALLERGY, V26, P1108, DOI 10.1046/j.1365-2222.1996.d01-264.x; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; VENGE P, 1989, European Respiratory Journal, V2, p430S; VIGNOLA AM, 1995, ALLERGY, V50, P200, DOI 10.1111/j.1398-9995.1995.tb01133.x; Wang DY, 1996, ACTA OTO-LARYNGOL, V116, P91, DOI 10.3109/00016489609137720; WANG JH, 1996, AM J RESP CELL MOL B, V9, P271; WHITE MV, 1987, AM REV RESPIR DIS, V135, P1165	61	92	97	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					410	420		10.1016/S0091-6749(98)70256-8	http://dx.doi.org/10.1016/S0091-6749(98)70256-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525460	Bronze			2022-12-18	WOS:000072593900021
J	Baur, X; Chen, ZP; Allmers, H				Baur, X; Chen, ZP; Allmers, H			Can a threshold limit value for natural rubber latex airborne allergens be defined?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex; latex allergy; latex aeroallergen; occupational asthma; threshold value	GLOVES	Background: Recent studies have shown that systemic or respiratory occupational responses to latex can be induced by inhalation of latex aeroallergens. Objective: Our objectives were to study the relationship between exposure to different latex aeroallergen levels and type I allergic reactions in subjects with occupational contact with latex and to assess a threshold value for latex airborne allergens required for sensitization and symptom elicitation. Methods: We screened 145 subjects working in 32 hospitals or operating rooms with different latex aeroallergen levels. The quantified latex aeroallergen concentrations in the 32 rooms mere compared with latex-related allergic symptoms. Results: Different latex aeroallergen concentrations could be detected in rooms where powdered latex gloves were used and no effective ventilation systems were installed. In environments with latex aeroallergen levels of 0.6 ng/m(3) or greater, the reported workplace-related symptoms were significantly increased (p < 0.02). All 22 subjects with latex-specific IgE antibodies worked in rooms contaminated with latex aeroallergens (p < 0.05). Conclusions: Our results demonstrate that symptoms and presence of latex-specific IgE antibodies in subjects are significantly associated with measurable levels of latex aeroallergens. A latex aeroallergen level of 0.6 ng/m(3) is a critical threshold, especially for health care workers who are sensitized to natural rubber latex.	Ruhr Univ Bochum, Res Inst Occupat Med, D-4630 Bochum, Germany	Ruhr University Bochum	Baur, X (corresponding author), Ruhr Univ Bochum, Res Inst Occupat Med, Buerkle Camp Pl 1, D-44789 Bochum, Germany.							BAUR X, 1993, LANCET, V342, P1148, DOI 10.1016/0140-6736(93)92127-F; Baur X.ChenZ.AllmersH, 1996, ALLERGOL INT, V20, P105; BUBAK ME, 1992, MAYO CLIN PROC, V67, P1075, DOI 10.1016/S0025-6196(12)61122-7; Grzybowski M, 1996, J ALLERGY CLIN IMMUN, V98, P535, DOI 10.1016/S0091-6749(96)70087-8; Heilman DK, 1996, J ALLERGY CLIN IMMUN, V98, P325, DOI 10.1016/S0091-6749(96)70157-4; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; Kelly KJ, 1996, J ALLERGY CLIN IMMUN, V98, P857, DOI 10.1016/S0091-6749(96)80001-7; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P887; YASSIN MS, 1994, ANN ALLERGY, V72, P245	11	92	98	3	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				24	27		10.1016/S0091-6749(98)70188-5	http://dx.doi.org/10.1016/S0091-6749(98)70188-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449496				2022-12-18	WOS:000071539800004
J	Wood, RP; Milgrom, H				Wood, RP; Milgrom, H			Vocal cord dysfunction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							LARYNGEAL DYSFUNCTION; EXTRATHORACIC AIRWAY; ASTHMA; EPIGLOTTITIS; MANAGEMENT; SYMPTOMS; ALLERGY; MOTION; CROUP		NATL JEWISH CTR IMMUNOL & RESP MED,DIV ALLERGY & IMMUNOL,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DIV OTOLARYNGOL,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DENVER,CO	National Jewish Health; National Jewish Health; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BLAGER FB, 1988, J COMMUN DISORD, V21, P393, DOI 10.1016/0021-9924(88)90024-X; Brugman S. M., 1994, AM J RESP CRIT CARE, V149, pA353; BUCCA C, 1991, ALLERGY, V46, P147, DOI 10.1111/j.1398-9995.1991.tb00559.x; BUCCA C, 1995, LANCET, V346, P791, DOI 10.1016/S0140-6736(95)91617-2; CHRISTOPHER KL, 1983, NEW ENGL J MED, V308, P1566, DOI 10.1056/NEJM198306303082605; CRESSMAN WR, 1994, PEDIATR CLIN N AM, V41, P265; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; GEORGITIS JW, 1993, J ALLERGY CLIN IMMUN, V91, P961, DOI 10.1016/0091-6749(93)90355-J; GOLDMAN J, 1991, THORAX, V46, P401, DOI 10.1136/thx.46.6.401; LANDWEHR L, IN PRESS PEDIATRICS; MARTIN RJ, 1987, SEMIN RESPIR MED, V8, P332, DOI 10.1055/s-2007-1012672; MCFADDEN ER, 1987, J ALLERGY CLIN IMMUN, V79, P707, DOI 10.1016/0091-6749(87)90200-4; MUNRO HM, 1995, BR J HOSP MED, V53, P174; NEWMAN KB, 1994, SEM RESP CRIT CARE M, V15, P161, DOI 10.1055/s-2007-1006358; NEWMAN KB, 1995, AM J RESP CRIT CARE, V152, P1382, DOI 10.1164/ajrccm.152.4.7551399; OCONNELL MA, 1995, ANN ALLERG ASTHMA IM, V74, P341; OHOLLAREN MT, 1990, ANN ALLERGY, V65, P351; SASAKI CT, 1992, NEUROLOGIC DISORDERS, P45; SCHWARTZ AR, 1994, TXB RESP MED, P1451; SELNER JC, 1988, CLIN REV ALLERG, V6, P303; SELNER JC, 1985, ANN ALLERGY, V54, P479; SELNER JC, 1987, J ALLERGY CLIN IMMUN, V79, P726, DOI 10.1016/0091-6749(87)90203-X; SMITH MS, 1983, PEDIATRICS, V72, P247; SMITH RJH, 1995, ANN OTO RHINOL LARYN, V104, P537, DOI 10.1177/000348949510400707; WALKER P, 1992, INT ANESTHESIOL CLIN, V30, P57; WOOD RP, 1986, OTOLARYNG HEAD NECK, V94, P374, DOI 10.1177/019459988609400322	26	92	95	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					481	485		10.1016/S0091-6749(96)70079-9	http://dx.doi.org/10.1016/S0091-6749(96)70079-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828523				2022-12-18	WOS:A1996VJ42800002
J	EVANS, PM; OCONNOR, BJ; FULLER, RW; BARNES, PJ; CHUNG, KF				EVANS, PM; OCONNOR, BJ; FULLER, RW; BARNES, PJ; CHUNG, KF			EFFECT OF INHALED CORTICOSTEROIDS ON PERIPHERAL-BLOOD EOSINOPHIL COUNTS AND DENSITY PROFILES IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CORTICOSTEROIDS; EOSINOPHILS; EOSINOPHIL DENSITY; BUDESONIDE; BRONCHIAL HYPERRESPONSIVENESS	COLONY-STIMULATING FACTOR; LONG-TERM TREATMENT; BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE; HYPODENSE EOSINOPHILS; NONALLERGIC ASTHMA; 3T3 FIBROBLASTS; BUDESONIDE; GLUCOCORTICOIDS; HETEROGENEITY	Background: Inhaled corticosteroids are effective in the treatment of asthma and reduce bronchial hyperresponsiveness. We examined the effect of inhaled budesonide (1600 mug/day for 14 days) on the number and density profile of peripheral blood eosinophils in 10 patients with mild stable asthma in a double-blind, placebo-controlled, crossover trial. Methods: At the end of each study period, blood was collected immediately before measurement of bronchial responsiveness calculated as the concentration of methacholine causing a 20% fall in forced expiratory volume in 1 second (PC20). Plasma leukocyte suspension obtained after sedimentation of blood with 46% dextran was layered on a Percoll continuous-density gradient. After centrifugation, 20 sequential aliquots of increasing density gradients were removed for differential counts. Eosinophils recovered from density of gradients less than 1.080 gm/ml were defined as hypodense. Results: Budesonide treatment resulted in a fall in mean eosinophil count from 0.37 +/- 0.05 x 10(9) L-1 after placebo to 0.16 +/- 0.03 x 10(9) L-1 (p < 0.01). A significant reduction occurred in the hypodense eosinophil population from 51.6% +/- 4.3% after placebo to 38.1% +/- 3.1% after budesonide (p < 0.05). Mean log PC20 increased from -0.26 +/- 0.12 after placebo to -0.004 +/- 0.14 after budesonide (p < 0.01). Conclusion: We conclude that inhaled steroid therapy reduces the number of circulating hypodense eosinophils, which is an effect that may underlie the improvement in bronchial hyperresponsiveness.	ROYAL BROMPTON NATL HEART & LUNG HOSP,NATL HEART & LUNG INST,DEPT THORAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND	Imperial College London			Chung, Kian Fan/B-1872-2012; Chung, Kian Fan/I-8456-2019	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Barnes, Peter/0000-0002-5122-4018				ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; ALTMAN DG, 1991, PRACTICAL STAT MED R, P466; BJORNSON BH, 1985, J CLIN INVEST, V76, P924, DOI 10.1172/JCI112091; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CHUNG K, 1992, ASTHMA, P416; CULPEPPER JA, 1985, J IMMUNOL, V135, P3191; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; FRICK WE, 1989, AM REV RESPIR DIS, V139, P685; FRIEDMAN B, 1990, J ALLERGY CLIN IMMUN, V85, P223; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; FUKUDA T, 1989, J ALLERGY CLIN IMMUN, V83, P369, DOI 10.1016/0091-6749(89)90120-6; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HODGES MK, 1988, AM REV RESPIR DIS, V138, P799, DOI 10.1164/ajrccm/138.4.799; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LAITINEN LA, 1991, EUR RESPIR J, V4, P342; LAMAS AM, 1991, J IMMUNOL, V147, P254; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V87, P794, DOI 10.1016/0091-6749(91)90125-8; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; RYRFELDT A, 1982, EUR J RESPIR DIS, V63, P86; SAUNDERS AM, 1972, ADV AUTOMAT ANAL, V3, P27; SHULT PA, 1988, J ALLERGY CLIN IMMUN, V81, P429, DOI 10.1016/0091-6749(88)90912-8; TOOGOOD JH, 1989, GLUCOCORTICOIDS MECH, P105; WALKER C, 1991, J IMMUNOL, V146, P1829	30	92	93	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1993	91	2					643	650		10.1016/0091-6749(93)90270-P	http://dx.doi.org/10.1016/0091-6749(93)90270-P			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KN548	8436777				2022-12-18	WOS:A1993KN54800012
J	BURROWS, B; SEARS, MR; FLANNERY, EM; HERBISON, GP; HOLDAWAY, MD				BURROWS, B; SEARS, MR; FLANNERY, EM; HERBISON, GP; HOLDAWAY, MD			RELATIONSHIPS OF BRONCHIAL RESPONSIVENESS ASSESSED BY METHACHOLINE TO SERUM IGE, LUNG-FUNCTION, SYMPTOMS, AND DIAGNOSES IN 11-YEAR-OLD NEW-ZEALAND CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; BRONCHIAL RESPONSIVENESS; IGE; LUNG FUNCTION	HOUSE-DUST MITE; RESPIRATORY SYMPTOMS; AUSTRALIAN SCHOOLCHILDREN; PULMONARY-FUNCTION; 2 POPULATIONS; ASTHMA; REACTIVITY; HYPERRESPONSIVENESS; PREVALENCE; CHILDHOOD	The relationship of bronchial responsiveness (BR), assessed by methacholine challenge, to serum IgE, baseline ventilatory function, and symptoms or diagnoses suggesting an atopic disorder were examined in 522 11-year-old New Zealand children. BR was assessed by the presence or absence of a PC20 25 mg/ml or less and by calculating a continuous index of the decline of the FEV1 during the methacholine test. The latter facilitated multivariate analyses and revealed significant relationships to predictor variables even in those considered "nonresponsive" by PC20 criteria. There was a close relationship of BR to the baseline FEV1/vital capacity ratio, seen even in patients with known asthma, but this relationship was seen only in subjects with at least moderate levels of serum IgE. There was a less close relation of BR to percent predicted FEV1, but this persisted even after accounting for the FEV1/vital capacity ratio and was present regardless of the level of serum IgE. Reported asthma was associated with increased BR independent of all other factors, but other diagnoses and symptoms contributed relatively little to the prediction of BR once the serum IgE and lung function were taken into account. The overall results are compatible with the concept that IgE is a critical factor in the development of bronchial responsiveness in childhood.	MCMASTER UNIV,ST JOSEPHS HOSP,FIRESTONE REG CHEST & ALLERGY UNIT,HAMILTON L8S 4L8,ONTARIO,CANADA; UNIV OTAGO,DEPT MED,DUNEDIN,NEW ZEALAND; UNIV OTAGO,DEPT PREVENT & SOCIAL MED,DUNEDIN,NEW ZEALAND; UNIV OTAGO,DEPT PAEDIAT & CHILD HLTH,DUNEDIN,NEW ZEALAND	McGill University; McMaster University; University of Otago; University of Otago; University of Otago	BURROWS, B (corresponding author), UNIV ARIZONA,COLL MED,CTR RESP SCI,TUCSON,AZ 85724, USA.			Herbison, Graham Peter/0000-0002-5684-024X	NHLBI NIH HHS [HL-14136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURNEY PGJ, 1987, THORAX, V42, P38, DOI 10.1136/thx.42.1.38; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1133, DOI 10.1136/adc.64.8.1133; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; MORTAGY AK, 1986, BRIT MED J, V293, P525, DOI 10.1136/bmj.293.6546.525; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; PEAT JK, 1991, AM REV RESPIR DIS, V144, P663, DOI 10.1164/ajrccm/144.3_Pt_1.663; PEAT JK, 1987, CLIN ALLERGY, V17, P283, DOI 10.1111/j.1365-2222.1987.tb02016.x; RIJCKEN B, 1987, B EUR PHYSIOPATH RES, V23, P391; RUBINFELD AR, 1977, AM REV RESPIR DIS, V115, P381; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Silva P. A., 1990, PAEDIATRIC PERINATAL, V4, P96, DOI [DOI 10.1111/J.1365-3016.1990.TB00621.X, 10.1111/j.1365-3016.1990.tb00621.x]; SPARROW D, 1987, AM REV RESPIR DIS, V135, P1255; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; WEISS ST, 1989, AIRWAYS RESPONSIVENE, P194	17	92	99	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				376	385		10.1016/S0091-6749(05)80018-1	http://dx.doi.org/10.1016/S0091-6749(05)80018-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1527320				2022-12-18	WOS:A1992JP52000016
J	CARLSON, M; HAKANSSON, L; KAMPE, M; STALENHEIM, G; PETERSON, C; VENGE, P				CARLSON, M; HAKANSSON, L; KAMPE, M; STALENHEIM, G; PETERSON, C; VENGE, P			DEGRANULATION OF EOSINOPHILS FROM POLLEN-ATOPIC PATIENTS WITH ASTHMA IS INCREASED DURING POLLEN SEASON	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DEGRANULATION; ECP; EOSINOPHIL; EOSINOPHIL PROTEIN-X; MYELOPEROXIDASE; NEUTROPHIL; PATIENTS WITH ASTHMA; POLLEN-ATOPIC PATIENTS; POLLEN SEASON	CATIONIC PROTEIN; BRONCHIAL HYPERREACTIVITY; GRANULE PROTEINS; BLOOD; SERUM; INTERLEUKIN-3; NEUTROPHILS; MEDICATION; HYPODENSE	The secretion of granule proteins from eosinophils and neutrophils was studied in isolated cells, obtained from 11 pollen-atopic patients with asthma, twice during and twice outside pollen season. Granulocytes were stimulated with serum-opsonized Sephadex particles, and the released amount of eosinophil cationic protein (ECP), eosinophil protein X (EPX), and myeloperoxidase (MPO) were measured by means of specific radioimmunoassay (RIA). Eosinophils from the pollen-atopic patients obtained during pollen season released significantly more (p < 0.02) ECP and EPX than cells from the same patients obtained before pollen season. The released amount of ECP and EPX was correlated (r = 0.54; p < 0.003) to the total pollen count. The release of MPO from neutrophils was only raised (p < 0.01) at the end of the pollen season. Serum concentrations of ECP and EPX and blood eosinophil counts were significantly raised (p < 0.002, p < 0.001, and p < 0.009, respectively) before pollen season and increased further at the end of the pollen season. There were no changes in lung function during pollen season and consequently no discernible relationships to eosinophil and neutrophil degranulation. We conclude that eosinophils and, to some extent, neutrophils from birch pollen-atopic subjects have an increased propensity to secrete their granule proteins during a pollen season. We suggest that these cells have been primed as a consequence of allergen exposure.	UNIV HOSP UPPSALA,DEPT LUNG MED,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital	CARLSON, M (corresponding author), UNIV HOSP UPPSALA,DEPT CLIN CHEM,INFLAMMAT RES LAB,S-75185 UPPSALA,SWEDEN.							CARLSON M, 1991, J ALLERGY CLIN IMMUN, V87, P27, DOI 10.1016/0091-6749(91)90209-7; DAHL R, 1978, SCAND J RESPIR DIS, V59, P319; DAHL R, 1978, ALLERGY, V33, P152, DOI 10.1111/j.1398-9995.1978.tb01526.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; EMA H, 1990, BLOOD, V76, P1956; FORSHAM PH, 1948, J CLIN ENDOCRINOL, V8, P15, DOI 10.1210/jcem-8-1-15; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; GROOPMAN JE, 1989, NEW ENGL J MED, V321, P1449, DOI 10.1056/NEJM198911233212106; HAKANSSON L, 1980, SCAND J IMMUNOL, V11, P271, DOI 10.1111/j.1365-3083.1980.tb00235.x; HAKANSSON L, 1990, J ALLERGY CLIN IMMUN, V85, P743, DOI 10.1016/0091-6749(90)90193-8; HARRIMAN GR, 1989, YEAR IMMUNOLOGY 1988, P160; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HIRST JM, 1952, ANN APPL BIOL, V39, P257, DOI 10.1111/j.1744-7348.1952.tb00904.x; KAPYLA M, 1981, Grana, V20, P131; LEE TC, 1984, J BIOL CHEM, V259, P5526; OBERG G, 1983, BRIT J HAEMATOL, V55, P701, DOI 10.1111/j.1365-2141.1983.tb02853.x; OGDEN EC, 1974, MANUAL SAMPLING AIRB, P1; OLOFSSON T, 1977, SCAND J HAEMATOL, V18, P73; PETERSON CGB, 1987, BIOCHEM J, V245, P781, DOI 10.1042/bj2450781; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; Sanderson C J, 1988, Dev Biol Stand, V69, P23; SHAW RJ, 1984, CLIN EXP IMMUNOL, V56, P716; SILBERSTEIN DS, 1987, IMMUNOL TODAY, V8, P380, DOI 10.1016/0167-5699(87)90214-3; SPRY CJF, 1988, EOSINOPHILS COMPREHE, P45; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; VENGE P, 1988, INT ARCH ALLER A IMM, V87, P306, DOI 10.1159/000234690; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; Venge P, 1989, EOSINOPHILS ASTHMA, P163; WINQVIST I, 1984, IMMUNOLOGY, V51, P1	32	92	92	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	1				131	139		10.1016/S0091-6749(05)80050-8	http://dx.doi.org/10.1016/S0091-6749(05)80050-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ908	1309840				2022-12-18	WOS:A1992GZ90800016
J	NGUYEN, KL; GILLIS, S; MACGLASHAN, DW				NGUYEN, KL; GILLIS, S; MACGLASHAN, DW			A COMPARATIVE-STUDY OF RELEASING AND NONRELEASING HUMAN BASOPHILS - NONRELEASING BASOPHILS LACK AN EARLY COMPONENT OF THE SIGNAL TRANSDUCTION PATHWAY THAT FOLLOWS IGE CROSS-LINKING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BAYVIEW RES CAMPUS,301 BAYVIEW BLVD,BALTIMORE,MD 21224; IMMUNEX CORP,SEATTLE,WA	Johns Hopkins University; Immunex Corporation					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020253] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20253, AI7290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1976, MANUAL CLIN IMMUNOLO, P590; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOCHNER BS, 1989, J IMMUNOL, V142, P3180; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; BUSSE WW, 1986, J ALLERGY CLIN IMMUN, V78, P90, DOI 10.1016/0091-6749(86)90119-3; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CONROY MC, 1977, J IMMUNOL, V118, P1317; CONROY MC, 1978, FED PROC, V37, P1216; DEMBO M, 1978, J IMMUNOL, V121, P354; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; FOREMAN JC, 1979, J IMMUNOL, V123, P153; GALLI SJ, 1988, ALLERGY PRINCIPLES P, P106; GILBERT HS, 1975, BLOOD, V46, P279; GILLESPIE E, 1972, J CLIN INVEST, V51, P2941, DOI 10.1172/JCI107118; GILLIS S, 1988, PRODUCTION RECOMBINA; HAYES EC, 1983, J IMMUNOL, V131, P429; HIRAI K, 1988, J IMMUNOL, V141, P3958; HOOK WA, 1976, J IMMUNOL, V117, P594; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; KINGS MA, 1986, DIAGN CLIN IMMUNOL, V4, P89; LICHTENSTEIN LM, 1975, J IMMUNOL, V114, P1692; MACDONALD SM, 1989, J IMMUNOL, V142, P3527; MACGLASHAN DW, 1985, J IMMUNOL, V135, P4129; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MACGLASHAN DW, 1980, J IMMUNOL, V124, P2519; MAEYAMA K, 1988, J IMMUNOL, V140, P3919; MARONE G, 1986, J ALLERGY CLIN IMMUN, V77, P377, DOI 10.1016/S0091-6749(86)80121-X; MARONE G, 1986, J INVEST DERMATOL, V87, P19, DOI 10.1111/1523-1747.ep12523520; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SCHLEIMER RP, 1982, J IMMUNOL, V128, P136; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SIRAGANIAN RP, 1977, J IMMUNOL, V119, P2078; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; TUNG R, 1982, J IMMUNOL, V128, P2067; TUNG RS, 1981, J PHARMACOL EXP THER, V218, P642; WARNER J, 1988, IMMUNOL LETT, V18, P129, DOI 10.1016/0165-2478(88)90053-3; WARNER JA, 1989, J IMMUNOL, V142, P1669	43	92	93	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1990	85	6					1020	1029		10.1016/0091-6749(90)90046-7	http://dx.doi.org/10.1016/0091-6749(90)90046-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DK509	1693929				2022-12-18	WOS:A1990DK50900007
J	BOUSQUET, J; MAASCH, HJ; HEJJAOUI, A; SKASSABROCIEK, W; WAHL, R; DHIVERT, H; MICHEL, FB				BOUSQUET, J; MAASCH, HJ; HEJJAOUI, A; SKASSABROCIEK, W; WAHL, R; DHIVERT, H; MICHEL, FB			DOUBLE-BLIND, PLACEBO-CONTROLLED IMMUNOTHERAPY WITH MIXED GRASS-POLLEN ALLERGOIDS .3. EFFICACY AND SAFETY OF UNFRACTIONATED AND HIGH-MOLECULAR-WEIGHT PREPARATIONS IN RHINOCONJUNCTIVITIS AND ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALLERGOPHARMA JOACHIM GANZER,REINBEK,FED REP GER	Allergopharma	BOUSQUET, J (corresponding author), CHU MONTPELLIER,HOP AIGUELONGUE,MALAD RESP CLIN,F-34059 MONTPELLIER,FRANCE.		Bousquet, Jean/O-4221-2019					ARMITAGE P, 1977, STATISTICAL METHODS; BERG T, 1980, INT ARCH ALLER A IMM, V63, P266, DOI 10.1159/000232636; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; DREBORG S, 1983, 2ND P P EHRL S ALL S, P77; FRANKLAND AW, 1954, LANCET, V1, P1055; FROSTAD AB, 1983, CLIN ALLERGY, V13, P337, DOI 10.1111/j.1365-2222.1983.tb02609.x; GRAMMER LC, 1983, J ALLERGY CLIN IMMUN, V72, P160, DOI 10.1016/0091-6749(83)90524-9; HILL DJ, 1982, BRIT MED J, V284, P306, DOI 10.1136/bmj.284.6312.306; JUNIPER EF, 1985, J ALLERGY CLIN IMMUN, V75, P578, DOI 10.1016/0091-6749(85)90033-8; KELLY JF, 1980, J ALLERGY CLIN IMMUN, V65, P50, DOI 10.1016/0091-6749(80)90176-1; KJELLMAN NIM, 1980, ALLERGY, V35, P323, DOI 10.1111/j.1398-9995.1980.tb01774.x; MARSH DG, 1970, IMMUNOLOGY, V18, P705; MARSH DG, 1981, J ALLERGY CLIN IMMUN, V68, P449, DOI 10.1016/0091-6749(81)90199-8; MERINEY DK, 1986, ANN ALLERGY, V56, P34; METZGER WJ, 1976, NEW ENGL J MED, V295, P1160, DOI 10.1056/NEJM197611182952103; NORDVALL SL, 1978, INT ARCH ALLER A IMM, V67, P132; NORMAN PS, 1982, J ALLERGY CLIN IMMUN, V70, P248, DOI 10.1016/0091-6749(82)90061-6; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; OSTERBALLE O, 1982, ALLERGY, V37, P491, DOI 10.1111/j.1398-9995.1982.tb02332.x; OSTERBALLE O, 1982, ALLERGY, V37, P379, DOI 10.1111/j.1398-9995.1982.tb02316.x; OSTERBALLE O, 1982, ALLERGY, V37, P169, DOI 10.1111/j.1398-9995.1982.tb01893.x; PATTERSON R, 1979, J ALLERGY CLIN IMMUN, V63, P47, DOI 10.1016/0091-6749(79)90161-1; Pepys J., 1975, BR J HOSP MED, V14, P412; PUTTONEN E, 1981, INT ARCH ALLER A IMM, V64, P157, DOI 10.1159/000232687; PUTTONEN E, 1980, INT ARCH ALLER A IMM, V61, P299, DOI 10.1159/000232452; PUTTONEN E, 1982, INT ARCH ALLER A IMM, V68, P1, DOI 10.1159/000233058; TIPTON WR, 1982, J ALLERGY CLIN IMMUN, V69, P194, DOI 10.1016/0091-6749(82)90099-9; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; WAHL R, 1986, J CHROMATOGR, V351, P39, DOI 10.1016/S0021-9673(01)83470-1; 1975, EUROPAISCHES ARZNEIB, V2, P37	36	92	93	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	1				546	556		10.1016/0091-6749(89)90369-2	http://dx.doi.org/10.1016/0091-6749(89)90369-2			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW760	2677092				2022-12-18	WOS:A1989AW76000017
J	SCHATZ, M; ZEIGER, RS; HARDEN, KM; HOFFMAN, CP; FORSYTHE, AB; CHILINGAR, LM; PORRECO, RP; BENENSON, AS; SPERLING, WL; SAUNDERS, BS; KAGNOFF, MC				SCHATZ, M; ZEIGER, RS; HARDEN, KM; HOFFMAN, CP; FORSYTHE, AB; CHILINGAR, LM; PORRECO, RP; BENENSON, AS; SPERLING, WL; SAUNDERS, BS; KAGNOFF, MC			THE SAFETY OF INHALED BETA-AGONIST BRONCHODILATORS DURING PREGNANCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									KAISER PERMANENTE MED CTR,DEPT OBSTET & GYNECOL,SAN DIEGO,CA 92111; KAISER PERMANENTE MED CTR,DEPT PEDIAT,SAN DIEGO,CA 92111; KAISER PERMANENTE MED CTR,DEPT PULM MED,SAN DIEGO,CA 92111; KAISER PERMANENTE MED CTR,PSYCHOLSOCIAL SERV,SAN DIEGO,CA 92111; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOMATH,LOS ANGELES,CA 90024; SAN DIEGO STATE UNIV,GRAD SCH PUBL HLTH,DIV EPIDEMIOL & BIOSTAT,SAN DIEGO,CA 92182	Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; California State University System; San Diego State University	SCHATZ, M (corresponding author), KAISER PERMANENTE MED CTR,DEPT ALLERGY IMMUNOL,7060 CLAIREMONT MESA BLVD,SAN DIEGO,CA 92111, USA.			Zeiger, Robert/0000-0001-5788-5063	NIAID NIH HHS [AI20426] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020426] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVERY ME, 1984, SCHAFFERS DISEASES N; BAHNA SL, 1972, ACTA ALLERGOL, V27, P397, DOI 10.1111/j.1398-9995.1972.tb01439.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; CREASY RK, 1984, MATERNAL FETAL MED; EVANS DR, 1979, BRIT MED J, V2, P171, DOI 10.1136/bmj.2.6183.171; FITZSIMONS R, 1986, J ALLERGY CLIN IMMUN, V78, P349, DOI 10.1016/S0091-6749(86)80088-4; GARN SM, 1981, AM J DIS CHILD, V135, P503, DOI 10.1001/archpedi.1981.02130300003003; GORDON M, 1970, AM J OBSTET GYNECOL, V106, P421, DOI 10.1016/0002-9378(70)90371-6; GREENBERGER PA, 1985, NEW ENGL J MED, V312, P897, DOI 10.1056/NEJM198504043121406; GREENBERGER PA, 1983, ANN INTERN MED, V98, P478, DOI 10.7326/0003-4819-98-4-478; Heinonen OP, 1977, BIRTH DEFECTS DRUGS; HUFF BB, 1986, PHYSICIANS DESK REFE; KALTER H, 1983, NEW ENGL J MED, V308, P424, DOI 10.1056/NEJM198302243080804; MCFADDEN ER, 1986, INHALED AEROSOL BRON, P114; MEYER MB, 1982, DRUG USE PREGNANCY, P133; MILLS JL, 1986, NEW ENGL J MED, V315, P1234, DOI 10.1056/NEJM198611063151925; MOORE LG, 1982, J APPL PHYSIOL, V52, P695, DOI 10.1152/jappl.1982.52.3.695; MOTOYAMA EK, 1966, LANCET, P286; NELSON HS, 1988, ALLERGY PRINCIPLES P, V1, P647; OAKLEY GP, 1986, CLIN PERINATOL, V13, P545, DOI 10.1016/S0095-5108(18)30809-1; PENNOCK BE, 1981, CHEST, V80, P97, DOI 10.1378/chest.80.1.97; PRITCHARD JA, 1985, WILLIAMS OBSTETRICS; SCHATZ M, 1975, JAMA-J AM MED ASSOC, V233, P804, DOI 10.1001/jama.233.7.804; SCHATZ M, 1988, ALLERGY PRINCIPLES P, V2, P1093; Spector S L, 1984, Chest, V86, p1S; Stablein J J, 1984, Compr Ther, V10, P45; WEBER RW, 1986, ANN ALLERGY, V57, P159; WILLIAMS RL, 1984, 1978 1982 MATERNAL C; Wilson J, 1982, ACTA THERAP, V8, P45; WULF KH, 1972, DHEW NIH73361 PUBL, P505; 1979, FED REG, V44, P37462	32	92	93	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					686	695		10.1016/0091-6749(88)90984-0	http://dx.doi.org/10.1016/0091-6749(88)90984-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	3171009				2022-12-18	WOS:A1988Q639900024
J	BERNSTEIN, DI; BERNSTEIN, IL; BODENHEIMER, SS; PIETRUSKO, RG				BERNSTEIN, DI; BERNSTEIN, IL; BODENHEIMER, SS; PIETRUSKO, RG			AN OPEN STUDY OF AURANOFIN IN THE TREATMENT OF STEROID-DEPENDENT ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SK&F LABS,DEPT CLIN RES & DEV,PHILADELPHIA,PA 19101	GlaxoSmithKline	BERNSTEIN, DI (corresponding author), UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,231 BETHESDA AVE,ML SUITE 563,CINCINNATI,OH 45267, USA.							CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; HARTH M, 1977, CLIN EXP IMMUNOL, V27, P357; HEUER MA, 1985, J RHEUMATOL, V12, P695; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MALO PE, 1986, J ALLERGY CLIN IMMUN, V77, P371, DOI 10.1016/S0091-6749(86)80120-8; MARONE G, 1986, AGENTS ACTIONS, V18, P100, DOI 10.1007/BF01987994; MIRZA AM, 1975, INT ARCH ALLER A IMM, V49, P782, DOI 10.1159/000231462; MURANAKA M, 1978, ANN ALLERGY, V40, P132; MURANAKA M, 1981, J ALLERGY CLIN IMMUN, V67, P350, DOI 10.1016/0091-6749(81)90079-8; NICKLAS RA, 1986, J ALLERGY CLIN IMMUN, V78, P507, DOI 10.1016/0091-6749(86)90097-7; Okatani Y, 1970, JPN MED J, V2432, P17; PARENTE JE, 1986, J RHEUMATOL, V13, P47; TAKAISHI T, 1984, J ALLERGY CLIN IMMUN, V74, P296, DOI 10.1016/0091-6749(84)90261-6; THURMAN GB, 1973, CLIN EXP IMMUNOL, V15, P289; WALZ DT, 1983, AM J MED, V75, P90, DOI 10.1016/0002-9343(83)90481-3; WARD JR, 1983, ARTHRITIS RHEUM, V26, P1303, DOI 10.1002/art.1780261102; WOJTECKALUKASIK E, 1986, AGENTS ACTIONS, V18, P68, DOI 10.1007/BF01987985; 1962, AM REV RESPIR DIS, V85, P762	18	92	92	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					6	16		10.1016/0091-6749(88)90213-8	http://dx.doi.org/10.1016/0091-6749(88)90213-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	3276761				2022-12-18	WOS:A1988M027400002
J	AGOSTI, JM; ALTMAN, LC; AYARS, GH; LOEGERING, DA; GLEICH, GJ; KLEBANOFF, SJ				AGOSTI, JM; ALTMAN, LC; AYARS, GH; LOEGERING, DA; GLEICH, GJ; KLEBANOFF, SJ			THE INJURIOUS EFFECT OF EOSINOPHIL PEROXIDASE, HYDROGEN-PEROXIDE, AND HALIDES ON PNEUMOCYTES INVITRO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,DEPT MED RM-13,DIV ALLERGY & INFECT DIS,SEATTLE,WA 98195; MAYO MED SCH,DEPT IMMUNOL,ROCHESTER,MN 55901	University of Washington; University of Washington Seattle; Mayo Clinic					NIAID NIH HHS [AI07763, AI15231, AI17758] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015231, R37AI007763, R37AI015231, R01AI017758, R01AI007763] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AYARS GH, 1985, J ALLERGY CLIN IMMUN, V76, P595, DOI 10.1016/0091-6749(85)90781-X; BAEHNER RL, 1971, BRIT J HAEMATOL, V20, P277, DOI 10.1111/j.1365-2141.1971.tb07038.x; BERNARD GR, 1984, J CLIN INVEST, V73, P1772, DOI 10.1172/JCI111386; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P177, DOI 10.1016/0167-4838(84)90125-0; BUJAK JS, 1974, BLOOD, V43, P727, DOI 10.1182/blood.V43.5.727.727; BUTTERWORTH AE, 1979, J IMMUNOL, V122, P221; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; CARRINGT.CB, 1969, NEW ENGL J MED, V280, P787, DOI 10.1056/NEJM196904102801501; CLINE MJ, 1972, J RETICULOENDOTH SOC, V12, P332; DAVIS WB, 1984, J CLIN INVEST, V74, P269, DOI 10.1172/JCI111411; DECHATELET LR, 1977, BLOOD, V50, P526; DENSEN P, 1978, INFECT IMMUN, V22, P282, DOI 10.1128/IAI.22.1.282-285.1978; DOBBS LG, 1980, BIOCHIM BIOPHYS ACTA, V618, P510, DOI 10.1016/0005-2760(80)90270-2; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; FANTONE JC, 1982, AM J PATHOL, V107, P397; FANTONE JC, 1983, CHEST S, V82, pS46; FISHER AB, 1980, J APPL PHYSIOL, V49, P743, DOI 10.1152/jappl.1980.49.4.743; FOX B, 1980, THORAX, V35, P570, DOI 10.1136/thx.35.8.570; FRIGAS E, 1980, LAB INVEST, V42, P35; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GLAUERT AM, 1978, J CELL SCI, V34, P173, DOI 10.1007/BF01944659; GLEICH GJ, 1974, J EXP MED, V140, P313, DOI 10.1084/jem.140.2.313; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; Grignaschi V. J., 1963, REV ASOC MED ARGENT, V77, P218; HENDERSON WR, 1980, J EXP MED, V152, P265, DOI 10.1084/jem.152.2.265; JOHNSON KJ, 1981, J CLIN INVEST, V67, P983, DOI 10.1172/JCI110149; JONG EC, 1984, AM J TROP MED HYG, V33, P104, DOI 10.4269/ajtmh.1984.33.104; JONG EC, 1980, J IMMUNOL, V124, P1949; JONG EC, 1980, J IMMUNOL, V124, P1378; JORG A, 1982, BIOCHIM BIOPHYS ACTA, V701, P185, DOI 10.1016/0167-4838(82)90112-1; KAZURA JW, 1981, J CLIN INVEST, V67, P93, DOI 10.1172/JCI110037; KIERSZENBAUM F, 1981, AM J TROP MED HYG, V30, P775, DOI 10.4269/ajtmh.1981.30.775; KIKKAWA Y, 1974, LAB INVEST, V30, P76; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; LEHRER RI, 1969, J BACTERIOL, V99, P361, DOI 10.1128/JB.99.2.361-365.1969; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; LOCKSLEY RM, 1982, J CLIN INVEST, V69, P1099, DOI 10.1172/JCI110545; MASON RJ, 1977, AM REV RESPIR DIS, V115, P1015; MCLAREN DJ, 1978, PARASITOLOGY, V77, P313, DOI 10.1017/S0031182000050277; MICKENBERG ID, 1974, BLOOD, V32, P922; MIGLER R, 1978, BIOCHEM MED METAB B, V19, P16, DOI 10.1016/0006-2944(78)90003-0; MIGLER R, 1978, BLOOD, V51, P445; NARDONE L, 1982, J CELL BIOL, V95, pA134; NATHAN CF, 1982, J EXP MED, V155, P1291, DOI 10.1084/jem.155.5.1291; NOGUEIRA NM, 1982, J IMMUNOL, V128, P1705; OLSEN RL, 1983, BIOCHEM J, V209, P781, DOI 10.1042/bj2090781; PEARSON DJ, 1978, MAYO CLIN PROC, V53, P73; PINCUS SH, 1984, CELL IMMUNOL, V87, P424, DOI 10.1016/0008-8749(84)90011-X; PINCUS SH, 1981, J IMMUNOL, V126, P1794; RAMSEY PG, 1982, J IMMUNOL, V128, P415; SACKS T, 1978, J CLIN INVEST, V61, P1161, DOI 10.1172/JCI109031; SUN XH, 1985, AM REV RESPIR DIS, V131, P103; TATE RM, 1982, CHEST, V81, pS57, DOI 10.1378/chest.81.5_Supplement.57S; WASSOM DL, 1979, AM J TROP MED HYG, V28, P860, DOI 10.4269/ajtmh.1979.28.860	54	92	92	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1987	79	3					496	504		10.1016/0091-6749(87)90368-X	http://dx.doi.org/10.1016/0091-6749(87)90368-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G4795	3029204				2022-12-18	WOS:A1987G479500013
J	ORTOLANI, C; PASTORELLO, E; MOSS, RB; HSU, YP; RESTUCCIA, M; JOPPOLO, G; MIADONNA, A; CORNELLI, U; HALPERN, G; ZANUSSI, C				ORTOLANI, C; PASTORELLO, E; MOSS, RB; HSU, YP; RESTUCCIA, M; JOPPOLO, G; MIADONNA, A; CORNELLI, U; HALPERN, G; ZANUSSI, C			GRASS-POLLEN IMMUNOTHERAPY - A SINGLE YEAR DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN PATIENTS WITH GRASS POLLEN-INDUCED ASTHMA AND RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STANFORD UNIV,CHILDRENS HOSP STANFORD,SCH MED,DEPT PEDIAT,DIV ALLERGY,PALO ALTO,CA 94304; UNIV MILAN,INST MED CLIN 2,I-20122 MILAN,ITALY	Stanford University; University of Milan			Moss, Richard B./S-9218-2019; PASTORELLO, ELIDE ANNA/E-3897-2017	Moss, Richard B./0000-0003-3611-4221; PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; ANTRACH SPJ, 1980, ANN ALLERGY, V45, P130; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; CONNELL JT, 1967, J ALLERGY, V39, P358, DOI 10.1016/0021-8707(67)90048-2; FOUCARD T, 1978, CLIN ALLERGY, V8, P349; FRANKLAND AW, 1954, LANCET, V1, P1055; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HOFFMAN DR, 1981, ANN ALLERGY, V46, P17; HSU YP, 1983, CLIN REV ALLERG, V1, P231; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; MERRETT TG, 1976, CLIN ALLERGY, V6, P69, DOI 10.1111/j.1365-2222.1976.tb01413.x; MOSS RB, 1981, J PEDIATR-US, V99, P215, DOI 10.1016/S0022-3476(81)80453-2; NICKELSEN J, 1980, J ALLERGY CLIN IMMUN, V65, P192; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1980, J ALLERGY CLIN IMMUN, V65, P87, DOI 10.1016/0091-6749(80)90191-8; NORMAN PS, 1979, J ALLERGY CLIN IMMUN, V63, P180; ORTOLANI C, 1981, CLIN ALLERGY, V11, P241; OSTERHAGE F, 1977, Z IMMUNITATSFORSCH, V153, P189; PATTERSON R, 1978, ALLERGY PRINCIPLES P, P877; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; REISMAN RE, 1975, J ALLERGY CLIN IMMUN, V56, P443, DOI 10.1016/0091-6749(75)90062-7; REISMAN RE, 1979, CLIN ALLERGY, V9, P303, DOI 10.1111/j.1365-2222.1979.tb01557.x; ROSENTHAL R, 1979, J ALLERGY CLIN IMMUN, V64, P569; SANCHIS J, 1972, J APPL PHYSIOL, V33, P757, DOI 10.1152/jappl.1972.33.6.757; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TSE KS, 1973, J ALLERGY CLIN IMMUN, V51, P208, DOI 10.1016/0091-6749(73)90140-1; TUCHINDA M, 1973, J ALLERGY CLIN IMMUN, V51, P131, DOI 10.1016/0091-6749(73)90018-3; VANDERGIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625, DOI 10.1159/000231566; WEYER A, 1981, ALLERGY, V36, P319, DOI 10.1111/j.1398-9995.1981.tb01583.x; WIDE L, 1976, INT ARCH ALLER A IMM, V52, P219, DOI 10.1159/000231685	34	92	93	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	2					283	290		10.1016/S0091-6749(84)80021-4	http://dx.doi.org/10.1016/S0091-6749(84)80021-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SF020	6366027				2022-12-18	WOS:A1984SF02000011
J	MALO, JL; CARTIER, A; DOEPNER, M; NIEBOER, E; EVANS, S; DOLOVICH, J				MALO, JL; CARTIER, A; DOEPNER, M; NIEBOER, E; EVANS, S; DOLOVICH, J			OCCUPATIONAL ASTHMA CAUSED BY NICKEL SULFATE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV, DEPT BIOCHEM, HAMILTON L8S 4L8, ONTARIO, CANADA; MCMASTER UNIV, DEPT PEDIAT, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University; McMaster University	MALO, JL (corresponding author), HOP SACRE COEUR, SERV PNEUMOL, MONTREAL H4J 1C5, QUEBEC, CANADA.							BURGE PS, 1979, THORAX, V24, P308; COCKCROFT DW, 1980, J ALLERGY CLIN IMMUN, V66, P458, DOI 10.1016/0091-6749(80)90006-8; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CROMWELL O, 1979, CLIN ALLERGY, V9, P109, DOI 10.1111/j.1365-2222.1979.tb01529.x; DOLOVICH J, 1980, CAN MED ASSOC J, V123, P292; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HARGREAVE FE, 1980, AIRWAY REACTIVITY ME, P145; MCCONNELL LH, 1973, ANN INTERN MED, V78, P888, DOI 10.7326/0003-4819-78-6-888; MINDEN P, 1967, HDB EXPT IMMUNOLOGY, P493; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; WIDE L, 1967, LANCET, V2, P1105	13	92	93	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	1					55	59		10.1016/0091-6749(82)90088-4	http://dx.doi.org/10.1016/0091-6749(82)90088-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ377	7054253				2022-12-18	WOS:A1982MZ37700010
J	FISH, JE; KELLY, JF				FISH, JE; KELLY, JF			MEASUREMENTS OF RESPONSIVENESS IN BRONCHOPROVOCATION TESTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,PULM SECT,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY SECT,CHICAGO,IL 60611	Northwestern University; Northwestern University								CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; FISH JE, 1977, J ALLERGY CLIN IMMUN, V60, P41, DOI 10.1016/0091-6749(77)90081-1; MCCARTHY DS, 1975, AM REV RESPIR DIS, V112, P407; NADEL JA, 1961, J APPL PHYSIOL, V16, P717, DOI 10.1152/jappl.1961.16.4.717; PELZER AM, 1966, J APPL PHYSIOL, V21, P469, DOI 10.1152/jappl.1966.21.2.469; ROSENTHAL RR, 1977, J APPL PHYSIOL, V42, P600, DOI 10.1152/jappl.1977.42.4.600; STANESCU DC, 1973, THORAX, V28, P716, DOI 10.1136/thx.28.6.716	7	92	92	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					592	596		10.1016/0091-6749(79)90019-8	http://dx.doi.org/10.1016/0091-6749(79)90019-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX843	512252				2022-12-18	WOS:A1979HX84300007
J	POSEY, WC; NELSON, HS; BRANCH, B; PEARLMAN, DS				POSEY, WC; NELSON, HS; BRANCH, B; PEARLMAN, DS			EFFECTS OF ACUTE CORTICOSTEROID-THERAPY FOR ASTHMA ON SERUM IMMUNOGLOBULIN LEVELS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FITZSIMONS ARMY MED CTR,DEPT ALLERGY & CLIN IMMUNOL,DENVER,CO 80240; NATL JEWISH HOSP & RES CTR,DEPT PEDIAT,DENVER,CO 80206	National Jewish Health								BERG T, 1969, INT ARCH ALLER A IMM, V36, P219, DOI 10.1159/000230745; BERGER W, 1978, J ALLERGY CLIN IMMUN, V61, P155, DOI 10.1016/0091-6749(78)90328-7; BUTLER WT, 1975, TRANSPLANT P, V7, P49; BUTLER WT, 1973, J CLIN INVEST, V52, P2629, DOI 10.1172/JCI107455; CLAMAN HN, 1971, J LAB CLIN MED, V78, P499; CLAMAN HN, 1972, NEW ENGL J MED, V287, P388, DOI 10.1056/NEJM197208242870806; CLAMAN HN, 1975, J ALLERGY CLIN IMMUN, V55, P145, DOI 10.1016/0091-6749(75)90010-X; FAHEY JL, 1965, J IMMUNOL, V94, P84; Gabrielsen A E, 1967, Adv Immunol, V6, P91, DOI 10.1016/S0065-2776(08)60522-2; GRIGGS RC, 1972, J ALLERGY CLIN IMMUN, V49, P267, DOI 10.1016/0091-6749(72)90094-2; GRUNDBACHER FJ, 1975, J ALLERGY CLIN IMMUN, V56, P104, DOI 10.1016/0091-6749(75)90114-1; HUFFMAN PJ, 1969, J ALLERGY, V43, P170; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; JOHANSSO.SG, 1967, LANCET, V2, P951; JOHANSSON S G O, 1970, British Journal of Dermatology, V82, P10, DOI 10.1111/j.1365-2133.1970.tb02185.x; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; JOHANSSON SG, 1968, IMMUNOLOGY, V14, P265; KUMAR L, 1971, J ALLERGY CLIN IMMUN, V48, P305, DOI 10.1016/0091-6749(71)90032-7; KUMAR L, 1971, PEDIATRICS, V47, P848; LEVY AL, 1970, J CLIN INVEST, V49, P1679, DOI 10.1172/JCI106385; LEVY DA, 1967, J IMMUNOL, V99, P1068; LIN MS, 1977, J PEDIATR-US, V91, P222, DOI 10.1016/S0022-3476(77)80816-0; MCMILLAN R, 1976, J IMMUNOL, V116, P1592; NORDBRING F, 1969, Scandinavian Journal of Infectious Diseases, V1, P99; ROSCH JM, 1975, OCT AM AC PED WASH; SCHONELL ME, 1971, CLIN EXP IMMUNOL, V8, P63; SCHWARTZ RS, 1968, RAPPAPORT, P440; Steele RGD, 1960, PRINCIPLES PROCEDURE; TAI E, 1974, AUST NZ J MED, V4, P3; TUCHINDA M, 1972, INT ARCH ALLER A IMM, V42, P533, DOI 10.1159/000230634; WIDE L, 1967, LANCET, V2, P1105; WIDE L, 1966, BIOCHIM BIOPHYS ACTA, V130, P257, DOI 10.1016/0304-4165(66)90032-8; WINER BJ, 1962, STATISTICAL PRINCIPL	33	92	92	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	6					340	348		10.1016/0091-6749(78)90134-3	http://dx.doi.org/10.1016/0091-6749(78)90134-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GA292	712020				2022-12-18	WOS:A1978GA29200005
J	CASTERLINE, CL; EVANS, R; WARD, GW				CASTERLINE, CL; EVANS, R; WARD, GW			EFFECT OF ATROPINE AND ALBUTEROL AEROSOLS ON HUMAN BRONCHIAL RESPONSE TO HISTAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WALTER REED ARMY MED CTR,DEPT ALLERGY & CLIN IMMUNOL,WASHINGTON,DC 20012	United States Department of Defense; United States Army; Walter Reed National Military Medical Center								CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CROPP G, 1975, AM REV RESPIR DIS, P112; CROPP G, 1974, 4TH ANN WORKSH ASTHM, P166; DEKOCK MA, 1966, J APPL PHYSIOL, V21, P185, DOI 10.1152/jappl.1966.21.1.185; GOLD WM, 1972, J APPL PHYSIOL, V33, P719, DOI 10.1152/jappl.1972.33.6.719; HERXHEIMER H, 1959, BRIT MED J, V2, P167, DOI 10.1136/bmj.2.5145.167; MCNEILL R, 1964, LANCET, V2, P1191; ROSENTHA.RR, 1974, J ALLERGY CLIN IMMUN, V53, P73; SELLICK H, 1971, J APPL PHYSIOL, V31, P15, DOI 10.1152/jappl.1971.31.1.15; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; WIDDICOMBE JG, 1970, ARCH INTERN MED, V126, P311, DOI 10.1001/archinte.126.2.311; YU DYC, 1972, J APPL PHYSIOL, V32, P823, DOI 10.1152/jappl.1972.32.6.823; ZARD G, 1966, NEW ENGL J MED, V275, P580	13	92	92	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	5					607	613		10.1016/0091-6749(76)90207-4	http://dx.doi.org/10.1016/0091-6749(76)90207-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CL088	61977				2022-12-18	WOS:A1976CL08800009
J	ZUSKIN, E; LEWIS, AJ; BOUHUYS, A				ZUSKIN, E; LEWIS, AJ; BOUHUYS, A			INHIBITION OF HISTAMINE-INDUCED AIRWAY CONSTRICTION BY ASCORBIC-ACID	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHN B PIERCE FDN LAB, NEW HAVEN, CT 06519 USA; YALE UNIV, LUNG RES CTR, NEW HAVEN, CT 06510 USA	Yale University; The John B Pierce Laboratory, Inc; Yale University								BOUHUYS A, 1960, CLIN SCI, V19, P79; BOUHUYS A, 1961, EXPERIENTIA, V17, P211, DOI 10.1007/BF02160619; BOUHUYS A, 1969, J CLIN INVEST, V48, P1159, DOI 10.1172/JCI106073; BOUHUYS A, 1970, AIRWAY DYNAMICS PHYS, P263; CONSTANTINE JW, 1965, J PHARM PHARMACOL, V17, P384, DOI 10.1111/j.2042-7158.1965.tb07688.x; DAUTREBANDE L, 1970, AIRWAY DYNAMICS, P153; DAWSON W, 1965, J PHARM PHARMACOL, V17, P595, DOI 10.1111/j.2042-7158.1965.tb07729.x; GOODMAN LS, 1965, PHARMACOL BASIS THER, P1665; GROLLMAN A, 1960, PHARMACOLOGY THERAPE, P879; HAGIESCO D, 1938, JAMA-J AM MED ASSOC, V111, P1885; HAGIESCO D, 1938, PRESSE MED, V46, P1435; Hunt HB, 1938, BMJ-BRIT MED J, V1938, P726; NICHOLLS PJ, 1966, HISTAMINE RELEASE CO, P69; ORECKINDUCHEMIN H, 1971, CITED INDIRECTLY; PAULING L, 1970, P NATL ACAD SCI USA, V67, P1643, DOI 10.1073/pnas.67.4.1643; PAULING L, 1971, P NATL ACAD SCI USA, V68, P2678, DOI 10.1073/pnas.68.11.2678; REISSEISSEN FD, 1803, PULMONIS STRUCTURA; SHAND DG, 1970, CLIN PHARMACOL THER, V11, P112; TURNER P, 1971, ARCH INT PHARMACOD T, V191, P104; Wright IS, 1937, ARCH INTERN MED, V60, P264, DOI 10.1001/archinte.1937.00180020088007	20	92	92	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	4					218	226		10.1016/0091-6749(73)90141-3	http://dx.doi.org/10.1016/0091-6749(73)90141-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P3010	4689139				2022-12-18	WOS:A1973P301000004
J	Thijs, JL; Strickland, I; Bruijnzeel-Koomen, CAFM; Nierkens, S; Giovannone, B; Csomor, E; Sellman, BR; Mustelin, T; Sleeman, MA; de Bruin-Weller, MS; Herath, A; Drylewicz, J; May, RD; Hijnen, D				Thijs, Judith L.; Strickland, Ian; Bruijnzeel-Koomen, Carla A. F. M.; Nierkens, Stefan; Giovannone, Barbara; Csomor, Eszter; Sellman, Bret R.; Mustelin, Tomas; Sleeman, Matthew A.; de Bruin-Weller, Marjolein S.; Herath, Athula; Drylewicz, Julia; May, Richard D.; Hijnen, DirkJan			Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; unsupervised cluster analysis; disease heterogeneity; clusters; phenotypes; endotypes; personalized medicine; principal component analysis	PRECISION MEDICINE; ASTHMA; DISEASE; PLACEBO; IMMUNOLOGY; PHENOTYPE; DUPILUMAB; SEVERITY; FEATURES; ADULTS	Background: Atopic dermatitis (AD) is a complex, chronic, inflammatory skin disease with a diverse clinical presentation. However, it is unclear whether this diversity exists at a biological level. Objective: We sought to test the hypothesis that AD is heterogeneous at the biological level of individual inflammatory mediators. Methods: Sera from 193 adult patients with moderate-to-severe AD(six area, six sign atopic dermatitis [SASSAD] score: geometric mean, 22.3 [95% CI, 21.3-23.3] and 39.1 [95% CI, 37.5-40.9], respectively) and 30 healthy control subjects without AD were analyzed for 147 serum mediators, total IgE levels, and 130 allergen-specific IgE levels. Population heterogeneity was assessed by using principal component analysis, followed by unsupervised k-means cluster analysis of the principal components. Results: Patients with AD showed pronounced evidence of inflammation compared with healthy control subjects. Principal component analysis of data on sera from patients with AD revealed the presence of 4 potential clusters. Fifty-seven principal components described approximately 90% of the variance. Unsupervised k-means cluster analysis of the 57 largest principal components delivered 4 distinct clusters of patients with AD. Cluster 1 had high SASSAD scores and body surface areas with the highest levels of pulmonary and activation-regulated chemokine, tissue inhibitor of metalloproteinases 1, and soluble CD14. Cluster 2 had low SASSAD scores with the lowest levels of IFN-alpha, tissue inhibitor of metalloproteinases 1, and vascular endothelial growth factor. Cluster 3 had high SASSAD scores with the lowest levels of IFN-beta, IL-1, and epithelial cytokines. Cluster 4 had low SASSAD scores but the highest levels of the inflammatory markers IL-1, IL-4, IL-13, and thymic stromal lymphopoietin. Conclusion: AD is a heterogeneous disease both clinically and biologically. Four distinct clusters of patients with AD have been identified that could represent endotypes with unique biological mechanisms. Elucidation of these endotypes warrants further investigation and will require future intervention trials with specific agents, such as biologics.	[Thijs, Judith L.; Bruijnzeel-Koomen, Carla A. F. M.; Giovannone, Barbara; de Bruin-Weller, Marjolein S.; Hijnen, DirkJan] Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands; [Thijs, Judith L.; Nierkens, Stefan; Giovannone, Barbara; Drylewicz, Julia; Hijnen, DirkJan] Univ Med Ctr Utrecht, Lab Translat Immunol, Utrecht, Netherlands; [Strickland, Ian; Csomor, Eszter; Sleeman, Matthew A.; Herath, Athula; May, Richard D.] MedImmune, Cambridge, England; [Sellman, Bret R.; Mustelin, Tomas] MedImmune, Gaithersburg, MD USA	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; AstraZeneca; Medimmune; AstraZeneca; Medimmune	Hijnen, D (corresponding author), Univ Med Ctr Utrecht, Dept Dermatol, Utrecht, Netherlands.	dirkjanhijnen@gmail.com	Drylewicz, Julia/I-4703-2019; Nierkens, Stefan/AAQ-5564-2021; Hijnen, DirkJan/L-1387-2015	Drylewicz, Julia/0000-0002-9434-8459; Nierkens, Stefan/0000-0003-3406-817X; Hijnen, DirkJan/0000-0003-3379-3425; Herath, Athula/0000-0002-9465-7841; Mustelin, Tomas/0000-0001-5912-8840; Giovannone, Barbara/0000-0003-3143-1922; May, Richard/0000-0001-7825-2716	MedImmune	MedImmune(AstraZenecaMedimmune)	Supported in part by MedImmune.	Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; BerthJones J, 1996, BRIT J DERMATOL, V135, P25, DOI 10.1111/j.1365-2133.1996.tb00706.x; Bieber T, 2012, ALLERGY, V67, P1475, DOI 10.1111/all.12049; Brightling CE, 2015, LANCET RESP MED, V3, P692, DOI 10.1016/S2213-2600(15)00197-6; Castro M, 2014, LANCET RESP MED, V2, P879, DOI 10.1016/S2213-2600(14)70201-2; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Ewald DA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0133-x; Eyerich K, 2013, ALLERGY, V68, P974, DOI 10.1111/all.12184; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Ghebre MA, 2015, J ALLERGY CLIN IMMUN, V135, P63, DOI 10.1016/j.jaci.2014.06.035; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hatcher L, 2013, STEP BY STEP APPROAC; Hinks TSC, 2016, J ALLERGY CLIN IMMUN, V138, P61, DOI 10.1016/j.jaci.2015.11.020; Jameson JL, 2015, NEW ENGL J MED, V372, P2229, DOI 10.1056/NEJMsb1503104; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Muraro A, 2016, J ALLERGY CLIN IMMUN, V137, P1347, DOI 10.1016/j.jaci.2016.03.010; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Rose S, 2013, AM J CARDIOVASC DIS, V3, P273; Silverberg JI, 2015, ALLERGY, V70, P1300, DOI 10.1111/all.12685; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Thijs JL, 2015, CLIN EXP ALLERGY, V45, P698, DOI 10.1111/cea.12486; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Wu W, 2014, J ALLERGY CLIN IMMUN, V133, P1280, DOI 10.1016/j.jaci.2013.11.042	26	91	91	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					730	737		10.1016/j.jaci.2017.03.023	http://dx.doi.org/10.1016/j.jaci.2017.03.023			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28412391	Bronze			2022-12-18	WOS:000409241500012
J	Blumenthal, KG; Wickner, PG; Hurwitz, S; Pricco, N; Nee, AE; Laskowski, K; Shenoy, ES; Walensky, RP				Blumenthal, Kimberly G.; Wickner, Paige G.; Hurwitz, Shelley; Pricco, Nicholas; Nee, Alexandra E.; Laskowski, Karl; Shenoy, Erica S.; Walensky, Rochelle P.			Tackling inpatient penicillin allergies: Assessing tools for antimicrobial stewardship	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Stewardship; skin test; test dose; decision support; computerized guideline	REPORTING PENICILLIN; GUIDELINE	Background: Reported penicillin allergy rarely reflects penicillin intolerance. Failure to address inpatient penicillin allergies results in more broad-spectrum antibiotic use, treatment failures, and adverse drug events. Objective: We aimed to determine the optimal approach to penicillin allergies among medical inpatients. Methods: We evaluated internal medicine inpatients reporting penicillin allergy in 3 periods: (1) standard of care (SOC), (2) penicillin skin testing (ST), and (3) computerized guideline application with decision support (APP). The primary outcome was use of a penicillin or cephalosporin, comparing interventions to SOC using multivariable logistic regression. Results: There were 625 patients: SOC, 148; ST, 278; and APP, 199. Of 278 ST patients, 179 (64%) were skin test eligible; 43 (24%) received testing and none were allergic. In the APP period, there were 292 unique Web site views; 112 users (38%) completed clinical decision support. Although ST period patients did not have increased odds of penicillin or cephalosporin use overall (adjusted odds ratio [aOR] 1.3; 95% CI, 0.8-2.0), we observed significant increased odds of penicillin or cephalosporin use overall in the APP period (aOR, 1.8; 95% CI, 1.1-2.9) and in a per-protocol analysis of the skin tested subset (aOR, 5.7; 95% CI, 2.6-12.5). Conclusions: Both APP and ST-when completed-increased the use of penicillin and cephalosporin antibiotics among inpatients reporting penicillin allergy. While the skin tested subset showed an almost 6-fold impact, the computerized guideline significantly increased penicillin or cephalosporin use overall nearly 2-fold and was readily implemented.	[Blumenthal, Kimberly G.] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Blumenthal, Kimberly G.; Shenoy, Erica S.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, 50 Staniford St,9th Fl, Boston, MA 02114 USA; [Blumenthal, Kimberly G.] Massachusetts Gen Hosp, Edward P Lawrence Ctr Qual & Safety, Boston, MA 02114 USA; [Blumenthal, Kimberly G.] Massachusetts Gen Profess Org, Boston, MA USA; [Blumenthal, Kimberly G.; Wickner, Paige G.; Hurwitz, Shelley; Laskowski, Karl; Shenoy, Erica S.; Walensky, Rochelle P.] Harvard Med Sch, Boston, MA USA; [Wickner, Paige G.] Brigham & Womens Hosp, Dept Med, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA; [Hurwitz, Shelley; Laskowski, Karl] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Pricco, Nicholas] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; [Nee, Alexandra E.] New York Med Coll, Valhalla, NY 10595 USA; [Shenoy, Erica S.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA; [Shenoy, Erica S.] Massachusetts Gen Hosp, Infect Control Unit, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of Minnesota System; University of Minnesota Twin Cities; New York Medical College; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Blumenthal, KG (corresponding author), Massachusetts Gen Hosp, Med Practice Evaluat Ctr, 50 Staniford St,9th Fl, Boston, MA 02114 USA.	kblumenthal1@partners.org	Shenoy, Erica/AAD-7521-2021; Blumenthal, Kimberly/AAG-8290-2019	Blumenthal, Kimberly/0000-0003-4773-9817; Walensky, Rochelle P./0000-0002-8795-379X	Brigham Care Redesign Incubator and Start-Up Program (BCRISP); Harvard Catalyst \ The Harvard Clinical and Translational Science Center (the National Center for Research Resources, National Institutes of Health [NIH]) [UL1 TR001102]; Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health [NIH]) [UL1 TR001102]; Harvard University; NIH [K01AI125631-01]; American Academy of Allergy Asthma and Immunology Foundation; Steven and Deborah Gorlin MGH Research Scholars Award; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K01AI125631] Funding Source: NIH RePORTER	Brigham Care Redesign Incubator and Start-Up Program (BCRISP); Harvard Catalyst \ The Harvard Clinical and Translational Science Center (the National Center for Research Resources, National Institutes of Health [NIH]); Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health [NIH]); Harvard University; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Academy of Allergy Asthma and Immunology Foundation; Steven and Deborah Gorlin MGH Research Scholars Award; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the Brigham Care Redesign Incubator and Start-Up Program (BCRISP) from 2014 to 2016. K.G.B. receives/received support from the Harvard Catalyst vertical bar The Harvard Clinical and Translational Science Center (the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health [NIH] Award no. UL1 TR001102) and financial contributions from Harvard University and its affiliated academic health care centers, the NIH (grant no. K01AI125631-01), and the American Academy of Allergy Asthma and Immunology Foundation. R.P.W. was supported by the Steven and Deborah Gorlin MGH Research Scholars Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the NIH.	[Anonymous], 1963, CLIN ASPECTS IMMUNOL; Blumenthal KG, 2016, DRUG ALLERGY VIDSCRI; Blumenthal KG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159406; Blumenthal KG, 2015, ANN ALLERG ASTHMA IM, V115, P294, DOI 10.1016/j.anai.2015.05.011; Blumenthal KG, 2014, J ALLER CL IMM-PRACT, V2, P407, DOI 10.1016/j.jaip.2014.02.003; Iammatteo M, 2014, J ALLER CL IMM-PRACT, V2, P768, DOI 10.1016/j.jaip.2014.08.001; Marshall GD, 2016, ANN ALLERG ASTHMA IM, V116, P2, DOI 10.1016/j.anai.2015.10.025; Solensky R, 2015, ANN ALLERG ASTHMA IM, V115, P257, DOI 10.1016/j.anai.2015.07.001	8	91	90	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					154	+		10.1016/j.jaci.2017.02.005	http://dx.doi.org/10.1016/j.jaci.2017.02.005			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28254470	hybrid, Green Accepted			2022-12-18	WOS:000404542000015
J	Lee, S; Hess, EP; Lohse, C; Gilani, W; Chamberlain, AM; Campbell, RL				Lee, Sangil; Hess, Erik P.; Lohse, Christine; Gilani, Waqas; Chamberlain, Alanna M.; Campbell, Ronna L.			Trends, characteristics, and incidence of anaphylaxis in 2001-2010: A population-based study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; food allergy; venom allergy; medication allergy; epidemiology; incidence rate	EMERGENCY-DEPARTMENT VISITS; MEDICAL-RECORDS-LINKAGE; PEANUT ALLERGY; OLMSTED COUNTY; EPIDEMIOLOGY; ROCHESTER; MANAGEMENT; DIAGNOSIS; HOSPITALIZATIONS; MULTICENTER	Background: Anaphylaxis is a potentially life-threatening systemic allergic reaction. Objective: We aimed to determine the incidence rate and causes of anaphylaxis during a 10-year period in Olmsted County, Minnesota. Methods: Using the resources of the Rochester Epidemiology Project, a comprehensive records linkage system, we performed a population-based incidence study in Olmsted County, Minnesota, from 2001 through 2010. All cases with a diagnosis of anaphylactic shock and 20% of cases with related diagnoses were manually reviewed. The relationships of age group, sex, and year of anaphylaxis with incidence rates were assessed by fitting Poisson regression models. Results: Six hundred thirty-one cases of anaphylaxis were identified. The median age was 31 years (interquartile range, 19-44 years). The overall age-and sex-adjusted incidence rate was 42 (95% CI, 38.7-45.3) per 100,000 person-years. There was a significant increase in the overall incidence of anaphylaxis during the study period, with an average increase of 4.3% per year (P < .001). In addition, there was a 9.8% increase per year in the incidence rate of food-related anaphylaxis. Food-related anaphylaxis was most common in children aged 0 to 9 years, venom-related anaphylaxis was most common in those 20 to 39 years of age, and medication-related anaphylaxis was most common in those 30 to 39 years of age. Conclusion: The overall incidence rate of anaphylaxis was 42 per 100,000 person-years from 2001-2010 in Olmsted County, Minnesota. The incidence of anaphylaxis increased over time, and several inciting triggers were uniquely associated with different age groups.	[Lee, Sangil] Mayo Clin Hlth Syst, Dept Emergency Med, Mankato, MN USA; [Hess, Erik P.; Lohse, Christine; Gilani, Waqas; Campbell, Ronna L.] Mayo Clin, Dept Emergency Med, Rochester, MN USA; [Chamberlain, Alanna M.] Mayo Clin, Dept Epidemiol, Rochester, MN USA	Mayo Clinic; Mayo Clinic	Lee, S (corresponding author), 1453 Marsh St, Mankato, MN 56001 USA.	lee.sangil@mayo.edu		Campbell, Ronna/0000-0001-6305-6990; Lee, Sangil/0000-0001-8529-4500; Chamberlain, Alanna/0000-0003-1888-9584	National Institute on Aging of the National Institutes of Health [R01AG034676]; CTSA grant from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1 TR000135]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG034676] Funding Source: NIH RePORTER	National Institute on Aging of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); CTSA grant from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was made possible by using the resources of the REP, which is supported by the National Institute on Aging of the National Institutes of Health under award no. R01AG034676 and by CTSA grant no. UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the NIH.	Anderson HR, 2007, THORAX, V62, P85, DOI 10.1136/thx.2006.066407; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Baalmann DV, 2016, AM J EMERG MED, V34, P174, DOI 10.1016/j.ajem.2015.10.003; Banerji A, 2014, J ALLER CL IMM-PRACT, V2, P46, DOI 10.1016/j.jaip.2013.08.012; Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Campbell RL, 2014, ANN ALLERG ASTHMA IM, V113, P599, DOI 10.1016/j.anai.2014.10.007; Campbell RL, 2012, J ALLERGY CLIN IMMUN, V129, P748, DOI 10.1016/j.jaci.2011.09.030; Clark S, 2005, J ALLERGY CLIN IMMUN, V116, P643, DOI 10.1016/j.jaci.2005.06.026; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Dyer AA, 2015, ANN ALLERG ASTHMA IM, V115, P56, DOI 10.1016/j.anai.2015.05.006; Gavalas M, 1998, J ACCID EMERG MED, V15, P96; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Huang F, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Huang F, 2012, J ALLERGY CLIN IMMUN, V129, P162, DOI 10.1016/j.jaci.2011.09.018; Jackson K, 2013, BFI FILM CLASSICS, P1, DOI 10.1007/978-1-84457-702-6; Jacobsen RC, 2011, PREHOSP EMERG CARE, V15, P570, DOI 10.3109/10903127.2011.598619; Jerschow E, 2014, J ALLERGY CLIN IMMUN, V134, P1318, DOI 10.1016/j.jaci.2014.08.018; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; Mullins RJ, 2003, CLIN EXP ALLERGY, V33, P1033, DOI 10.1046/j.1365-2222.2003.01671.x; Nowak RM, 2014, AM J MED, V127, pS34, DOI 10.1016/j.amjmed.2013.09.012; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Rinaldi M, 2012, J ALLERGY CLIN IMMUN, V130, P945, DOI 10.1016/j.jaci.2012.07.042; Rocca WA, 2012, MAYO CLIN PROC, V87, P1202, DOI 10.1016/j.mayocp.2012.08.012; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sheikh A, 2001, CLIN EXP ALLERGY, V31, P1571, DOI 10.1046/j.1365-2222.2001.01203.x; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Simons FER, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0080-1; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, P587, DOI 10.1016/j.jaci.2011.01.038; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, pe1; St Sauver JL, 2012, INT J EPIDEMIOL, V41, P1614, DOI 10.1093/ije/dys195; St Sauver JL, 2012, MAYO CLIN PROC, V87, P151, DOI 10.1016/j.mayocp.2011.11.009; St Sauver JL, 2011, AM J EPIDEMIOL, V173, P1059, DOI 10.1093/aje/kwq482; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	40	91	94	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					182	U258		10.1016/j.jaci.2016.04.029	http://dx.doi.org/10.1016/j.jaci.2016.04.029			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27378753	Green Accepted, Bronze			2022-12-18	WOS:000393996800020
J	Ierodiakonou, D; Zanobetti, A; Coull, BA; Melly, S; Postma, DS; Boezen, HM; Vonk, JM; Williams, PV; Shapiro, GG; McKone, EF; Hallstrand, TS; Koenig, JQ; Schildcrout, JS; Lumley, T; Fuhlbrigge, AN; Koutrakis, P; Schwartz, J; Weiss, ST; Gold, DR				Ierodiakonou, Despo; Zanobetti, Antonella; Coull, Brent A.; Melly, Steve; Postma, Dirkje S.; Boezen, H. Marike; Vonk, Judith M.; Williams, Paul V.; Shapiro, Gail G.; McKone, Edward F.; Hallstrand, Teal S.; Koenig, Jane Q.; Schildcrout, Jonathan S.; Lumley, Thomas; Fuhlbrigge, Anne N.; Koutrakis, Petros; Schwartz, Joel; Weiss, Scott T.; Gold, Diane R.		Childhood Asthma Management Progra	Ambient air pollution, lung function, and airway responsiveness in asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; ambient air pollution; airway hyperresponsiveness; inhaled corticosteroids; lung function	LONG-TERM EXPOSURE; CARBON-MONOXIDE; SULFUR-DIOXIDE; OXIDATIVE STRESS; RESPIRATORY SYMPTOMS; PULMONARY-FUNCTION; PARTICULATE MATTER; EUROPEAN CITIES; HEALTH; INFLAMMATION	Background: Although ambient air pollution has been linked to reduced lung function in healthy children, longitudinal analysesreduced lung function in healthy children, longitudinal analyses of pollution effects in asthmatic patients are lacking. Objective: We sought to investigate pollution effects in a longitudinal asthma study and effect modification by controller medications. Methods: We examined associations of lung function and methacholine responsiveness (PC20) with ozone, carbon monoxide (CO), nitrogen dioxide, and sulfur dioxide concentrations in 1003 asthmatic children participating in a 4-year clinical trial. We further investigated whether budesonide and nedocromil modified pollution effects. Daily pollutant concentrations were linked to ZIP/postal code of residence. Linear mixed models tested associations of within-subject pollutant concentrations with FEV1 and forced vital capacity (FVC) percent predicted, FEV1/FVC ratio, and PC20, adjusting for seasonality and confounders. Results: Same-day and 1-week average CO concentrations were negatively associated with postbronchodilator percent predicted FEV1 (change per interquartile range, -0.33 [95% CI, -0.49 to -0.16] and -0.41 [95% CI, -0.62 to -0.21], respectively) and FVC (-20.19 [95% CI, -0.25 to -0.07] and -0.25 [95% CI, -0.43 to -0.07], respectively). Longer-term 4-month CO averages were negatively associated with prebronchodilator percent predicted FEV1 and FVC (-0.36 [95% CI, -0.62 to -0.10] and -0.21 [95% CI, -0.42 to -0.01], respectively). Four-month averaged CO and ozone concentrations were negatively associated with FEV1/FVC ratio (P<.05). Increased 4-month average nitrogen dioxide concentrations were associated with reduced postbronchodilator FEV1 and FVC percent predicted. Long-term exposures to sulfur dioxide were associated with reduced PC20 (percent change per interquartile range, 26% [95% CI, -11% to -1.5%]). Treatment augmented the negative short-term CO effect on PC20. Conclusions: Air pollution adversely influences lung function and PC20 in asthmatic children. Treatment with controller medications might not protect but rather worsens the effects of CO on PC20. This clinical trial design evaluates modification of pollution effects by treatment without confounding by indication.	[Ierodiakonou, Despo; Boezen, H. Marike; Vonk, Judith M.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 AB Groningen, Netherlands; [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, NL-9700 AB Groningen, Netherlands; [Ierodiakonou, Despo; Postma, Dirkje S.; Boezen, H. Marike; Vonk, Judith M.] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, Groningen, Netherlands; [Zanobetti, Antonella; Melly, Steve; Koutrakis, Petros; Schwartz, Joel; Gold, Diane R.] Harvard Univ, TH Chan Sch Publ Hlth, Environm Epidemiol & Risk Program, Boston, MA 02115 USA; [Coull, Brent A.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Williams, Paul V.; Shapiro, Gail G.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Hallstrand, Teal S.] Univ Washington, Sch Med, Dept Pulm & Crit Care, Seattle, WA USA; [Koenig, Jane Q.] Univ Washington, Sch Med, Dept Environm Hlth, Seattle, WA USA; [McKone, Edward F.] St Vincent Univ Hosp, Dept Resp Med, Dublin, Ireland; [Schildcrout, Jonathan S.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA; [Lumley, Thomas] Univ Auckland, Dept Stat, Auckland 1, New Zealand; [Fuhlbrigge, Anne N.; Weiss, Scott T.; Gold, Diane R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab,Dept Med, Boston, MA 02115 USA	University of Groningen; University of Groningen; University of Groningen; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University College Dublin; Vanderbilt University; University of Auckland; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ierodiakonou, D (corresponding author), European Univ Cyprus, Sch Med, 6 Diogenis Str,POB 22006, CY-1516 Nicosia, Cyprus.; Gold, DR (corresponding author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.	d.ierodiakonou@euc.ac.cy; diane.gold@channing.harvard.edu	Wolfson, Mike/B-3682-2019; Vonk, Judith M/ABA-3009-2020; Vonk, Judith/K-8477-2019	Vonk, Judith M/0000-0001-7531-4547; Vonk, Judith/0000-0001-7531-4547; Hallstrand, Teal/0000-0002-5059-6872; Ierodiakonou, Despo/0000-0002-7862-2016	National Institutes of Health [NHLBI P01 HL083069, U01 HL075419, U01 HL65899, R01 HL 086601, NIEHS P01 ES09825, R21 ES020194, P30 ES000002]; US Environmental Protection Agency [RD 83241601, RD 83479801]; International Initiative for Environment and Public Health Cyprus Program of HSPH; NHLBI [U01HL075409, U01HL075415, U01HL075416, U01HL075417, U01HL075419, U01HL075420, U01HL075408, NO1-HR-16044, NO1-HR-16045, NO1-HR-16046, NO1-HR-16047, NO1-HR-16048, NO1-HR-16049, NO1-HR-16050, NO1-HR-16051, NO1-HR-16052, U01HL075232, U01HL075407]; General Clinical Research Center grants [M01RR00051, M01RR0099718-24, M01RR02719-14]; National Center for Research Resources [RR00036]; Colorado CTSA grant from NCRR/NIH [UL1RR025780]; NCATS/NIH [UL1TR000154]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL083069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009825, P30ES000002] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Environmental Protection Agency(United States Environmental Protection Agency); International Initiative for Environment and Public Health Cyprus Program of HSPH; NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); General Clinical Research Center grants; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Colorado CTSA grant from NCRR/NIH; NCATS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the National Institutes of Health (NHLBI P01 HL083069, U01 HL075419, U01 HL65899, R01 HL 086601; NIEHS P01 ES09825, R21 ES020194, P30 ES000002), the US Environmental Protection Agency (RD 83241601, RD 83479801), and the International Initiative for Environment and Public Health Cyprus Program of HSPH. The contents of this publication are solely the responsibility of the grantee and do not necessarily represent the official views of the US Environmental Protection Agency. Further, the US Environmental Protection Agency does not endorse the purchase of any commercial products or services mentioned in the publication. The CAMP trial and CAMP Continuation Study were supported by contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the NHLBI and General Clinical Research Center grants M01RR00051, M01RR0099718-24, M01RR02719-14, and RR00036 from the National Center for Research Resources. The CAMP Continuation Study/phases 2 and 3 were supported by grants U01HL075232, U01HL075407, U01HL075408, U01HL075409, U01HL075415, U01HL075416, U01HL075417, U01HL075419, U01HL075420, and U01HL075408 from the NHLBI. The National Jewish Health site was also supported in part by Colorado CTSA grant UL1RR025780 from NCRR/NIH and UL1TR000154 from NCATS/NIH.	Aekplakorn W, 2003, INT J EPIDEMIOL, V32, P854, DOI 10.1093/ije/dyg237; Ameredes BT, 2003, AM J PHYSIOL-LUNG C, V285, pL1270, DOI 10.1152/ajplung.00145.2003; [Anonymous], 1999, Control Clin Trials, V20, P91; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Canova C, 2010, EUR RESPIR J, V35, P266, DOI 10.1183/09031936.00043709; Cardell LO, 1998, PULM PHARMACOL THER, V11, P309, DOI 10.1006/pupt.1998.0152; Chae EJ, 2011, ALLERGY ASTHMA IMMUN, V3, P111, DOI 10.4168/aair.2011.3.2.111; Chapman JT, 2001, AM J PHYSIOL-LUNG C, V281, pL209, DOI 10.1152/ajplung.2001.281.1.L209; Clougherty JE, 2010, ENVIRON HEALTH PERSP, V118, P167, DOI 10.1289/ehp.0900994; Cohen RT, 2010, J ALLERGY CLIN IMMUN, V126, P491, DOI 10.1016/j.jaci.2010.06.016; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, pA607, DOI 10.1289/ehp.021100607; Gao Y, 2013, ARCH DIS CHILD, V98, P128, DOI 10.1136/archdischild-2011-301541; Gauderman WJ, 2007, LANCET, V369, P571, DOI 10.1016/S0140-6736(07)60037-3; Gauderman WJ, 2002, AM J RESP CRIT CARE, V166, P76, DOI 10.1164/rccm.2111021; Helth Effects Institute,, 2010, 17 HEI; HOEK G, 1994, ENVIRON RES, V64, P136, DOI 10.1006/enrs.1994.1012; Jang AS, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-24; Kelly FJ, 2003, OCCUP ENVIRON MED, V60, P612, DOI 10.1136/oem.60.8.612; Kinhult J, 2001, LUNG, V179, P1, DOI 10.1007/s004080000043; Kourembanas S, 2002, ANTIOXID REDOX SIGN, V4, P291, DOI 10.1089/152308602753666343; LAWTHER PJ, 1975, ENVIRON RES, V10, P355, DOI 10.1016/0013-9351(75)90031-6; Lewis TC, 2013, SCI TOTAL ENVIRON, V448, P48, DOI 10.1016/j.scitotenv.2012.11.070; Li SS, 2012, J ASTHMA, V49, P895, DOI 10.3109/02770903.2012.724129; Liu L, 2009, ENVIRON HEALTH PERSP, V117, P668, DOI 10.1289/ehp11813; Lodovici M, 2011, J TOXICOL-US, V2011, DOI 10.1155/2011/487074; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; Millstein J, 2004, ARCH ENVIRON HEALTH, V59, P505, DOI 10.1080/00039890409605166; Miyabara Y, 1998, AM J RESP CRIT CARE, V157, P1138, DOI 10.1164/ajrccm.157.4.9708066; Molter A, 2013, ENVIRON HEALTH PERSP, V121, P1232, DOI 10.1289/ehp.1205961; Nakao A, 2006, J CELL MOL MED, V10, P650, DOI 10.1111/j.1582-4934.2006.tb00426.x; Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090; Nowak D, 1997, AM J RESP CRIT CARE, V156, P1151, DOI 10.1164/ajrccm.156.4.9607025; Patel MM, 2013, ENVIRON RES, V121, P71, DOI 10.1016/j.envres.2012.10.012; Perez L, 2013, EUR RESPIR J, V42, P594, DOI 10.1183/09031936.00031112; Peters A, 1996, AM J EPIDEMIOL, V144, P570, DOI 10.1093/oxfordjournals.aje.a008967; Pinkerton KE, 2000, ENVIRON HEALTH PERSP, V108, P1063, DOI 10.2307/3434960; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300, DOI 10.1164/ajrccm.154.2.8756798; Rosenlund M, 2009, THORAX, V64, P573, DOI 10.1136/thx.2007.094953; Sarnat JA, 2005, EPIDEMIOLOGY, V16, P385, DOI 10.1097/01.ede.0000155505.04775.33; Schildcrout JS, 2006, AM J EPIDEMIOL, V164, P505, DOI 10.1093/aje/kwj225; SCHWARTZ J, 1989, ENVIRON RES, V50, P309, DOI 10.1016/S0013-9351(89)80012-X; Searing DA, 2011, CURR OPIN PEDIATR, V23, P314, DOI 10.1097/MOP.0b013e3283461926; Song AJ, 2012, TOXICOL LETT, V214, P320, DOI 10.1016/j.toxlet.2012.09.010; Souza MB, 1998, CHEST, V113, P1312, DOI 10.1378/chest.113.5.1312; SPEKTOR DM, 1991, ENVIRON RES, V55, P107, DOI 10.1016/S0013-9351(05)80167-7; Stolwijk AM, 1999, J EPIDEMIOL COMMUN H, V53, P235, DOI 10.1136/jech.53.4.235; Strunk RC, 2007, J ALLERGY CLIN IMMUN, V119, P36, DOI 10.1016/j.jaci.2006.09.038; Sunyer J, 1997, THORAX, V52, P760, DOI 10.1136/thx.52.9.760; Svartengren M, 2000, EUR RESPIR J, V15, P716, DOI 10.1034/j.1399-3003.2000.15d15.x; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Thorup C, 1999, AM J PHYSIOL-RENAL, V277, pF882, DOI 10.1152/ajprenal.1999.277.6.F882; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056; Tzivian L, 2011, J ASTHMA, V48, P470, DOI 10.3109/02770903.2011.570407; Winterton DL, 2001, ANN ALLERG ASTHMA IM, V86, P232, DOI 10.1016/S1081-1206(10)62697-X; World Health Organization, EFF AIR POLL CHILDR; World Health Organization (WHO), 2003, HLTH ASP AIR POLL PA; Zora JE, 2013, SCI TOTAL ENVIRON, V448, P56, DOI 10.1016/j.scitotenv.2012.11.067	58	91	91	0	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					390	399		10.1016/j.jaci.2015.05.028	http://dx.doi.org/10.1016/j.jaci.2015.05.028			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26187234	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000369235500007
J	Juhn, YJ				Juhn, Young J.			Risks for infection in patients with asthma (or other atopic conditions): Is asthma more than a chronic airway disease?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adaptive immunity; allergic rhinitis; asthma; atopic dermatitis; epidemiology; immune dysfunction; immune incompetence; infection; innate immunity; phenotype; risk; susceptibility	VARICELLA-ZOSTER-VIRUS; COMMON VARIABLE IMMUNODEFICIENCY; INVASIVE PNEUMOCOCCAL DISEASE; SERUM 25-HYDROXYVITAMIN D; ACUTE OTITIS-MEDIA; IMMUNE-RESPONSE; STAPHYLOCOCCUS-AUREUS; ALLERGIC RHINITIS; UNITED-STATES; HERPES-ZOSTER	Most of the research effort regarding asthma has been devoted to its causes, therapy, and prognosis. There is also evidence that the presence of asthma can influence patients' susceptibility to infections, yet research in this aspect of asthma has been limited. There is additional debate in this field, with current literature tending to view the increased risk of infection among atopic patients as caused by opportunistic infections secondary to airway inflammation, especially in patients with severe atopic diseases. However, other evidence suggests that such risk and its underlying immune dysfunction might be a phenotypic or clinical feature of atopic conditions. This review argues (1) that improved understanding of the effects of asthma or other atopic conditions on the risk of microbial infections will bring important and new perspectives to clinical practice, research, and public health concerning atopic conditions and (2) that research efforts into the causes and effects of asthma must be juxtaposed because they are likely to guide each other.	Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA	Mayo Clinic	Juhn, YJ (corresponding author), Mayo Clin, Dept Pediat & Adolescent Med, 200 First St SW, Rochester, MN 55905 USA.	juhn.young@mayo.edu			National Institute of Allergy and Infectious Diseases [R21 AI101277]; Agency for Healthcare Research and Quality of the United States [R01HS018431-01A1]; NIH; Mayo Foundation; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS018431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI101277] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Agency for Healthcare Research and Quality of the United States; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institute of Allergy and Infectious Diseases (R21 AI101277), the Agency for Healthcare Research and Quality of the United States (R01HS018431-01A1), and the NIH Relief Fund and a Scholarly Clinician Award from the Mayo Foundation.	Accordini S, 2013, INT ARCH ALLERGY IMM, V160, P93, DOI 10.1159/000338998; Agency for Health Care Research and Quality US Department of Health and Human Services, 2006, HIGH CONC US HLTH CA; AKINBAMI LJ, 2011, NATL HLTH STAT REPOR, V32, P1; Al-Hasan MN, 2009, J ANTIMICROB CHEMOTH, V64, P169, DOI 10.1093/jac/dkp162; Amelink M, 2013, ALLERGY, V68, P674, DOI 10.1111/all.12136; Anandan C, 2010, ALLERGY, V65, P152, DOI 10.1111/j.1398-9995.2009.02244.x; [Anonymous], 2010, PERT REP; Arkwright PD, 2000, CLIN EXP IMMUNOL, V122, P16, DOI 10.1046/j.1365-2249.2000.01338.x; ARVIN AM, 1980, J CLIN INVEST, V65, P869, DOI 10.1172/JCI109739; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Asquith KL, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001339; Azad MB, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6471; Bang DW, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003857; BARKER E, 1995, P NATL ACAD SCI USA, V92, P11135, DOI 10.1073/pnas.92.24.11135; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Beisswenger C, 2006, J IMMUNOL, V177, P1833, DOI 10.4049/jimmunol.177.3.1833; Bentdal YE, 2007, INT J PEDIATR OTORHI, V71, P1251, DOI 10.1016/j.ijporl.2007.04.017; Bentdal YE, 2007, ACTA OTO-LARYNGOL, V127, P480, DOI 10.1080/00016480600895128; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2012, AM J RESP CRIT CARE, V185, P1183, DOI 10.1164/rccm.201110-1922OC; Bjur KA, 2012, ALLERGY ASTHMA PROC, V33, P289, DOI 10.2500/aap.2012.33.3529; Boikos C, 2013, VACCINE, V31, P4820, DOI 10.1016/j.vaccine.2013.07.079; BOLDUR I, 1986, ISRAEL J MED SCI, V22, P733; Borkar DS, 2014, JAMA OPHTHALMOL, V132, P326, DOI 10.1001/jamaophthalmol.2013.6277; BURKE BL, 1982, ARCH INTERN MED, V142, P291, DOI 10.1001/archinte.142.2.291; Busse WW, 2012, J ALLERGY CLIN IMMUN, V129, pS1, DOI 10.1016/j.jaci.2011.12.985; BUSSE WW, 1991, REV INFECT DIS, V13, pS477; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Capili CR, 2012, J ALLERGY CLIN IMMUN, V129, P957, DOI 10.1016/j.jaci.2011.11.020; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; CERNELC D, 1975, ACTA ALLERGOL, V30, P423, DOI 10.1111/j.1398-9995.1975.tb01676.x; Cerutti A, 2008, NAT REV IMMUNOL, V8, P421, DOI 10.1038/nri2322; Chen Chien-Fu, 2001, Journal of Microbiology Immunology and Infection, V34, P57; Cho I, 2012, NATURE, V488, P621, DOI 10.1038/nature11400; CLERICI M, 1994, IMMUNOL TODAY, V15, P575, DOI 10.1016/0167-5699(94)90220-8; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; de Marco R, 2006, J ALLERGY CLIN IMMUN, V117, P1249, DOI 10.1016/j.jaci.2006.03.019; De Serres G, 2012, CLIN INFECT DIS, V55, P394, DOI 10.1093/cid/cis439; DeMore JP, 2009, J ALLERGY CLIN IMMUN, V124, P245, DOI 10.1016/j.jaci.2009.05.030; DOLIN R, 1978, ANN INTERN MED, V89, P375, DOI 10.7326/0003-4819-89-3-375; Doull IJM, 1997, BMJ-BRIT MED J, V315, P858, DOI 10.1136/bmj.315.7112.858; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ferreira RC, 2010, NAT GENET, V42, P777, DOI 10.1038/ng.644; Fischer JE, 1997, J VIROL, V71, P8672, DOI 10.1128/JVI.71.11.8672-8677.1997; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Frey D, 2009, ALLERGY ASTHMA PROC, V30, P540, DOI 10.2500/aap.2009.30.3268; Gordon B, 2008, J ALLERGY CLIN IMMUN, V121, pS209, DOI 10.1016/j.jaci.2007.12.778; GRAHAM MB, 1994, J EXP MED, V180, P1273, DOI 10.1084/jem.180.4.1273; Graham PL, 2006, ANN INTERN MED, V144, P318, DOI 10.7326/0003-4819-144-5-200603070-00006; GROVE DI, 1975, J ALLERGY CLIN IMMUN, V55, P152, DOI 10.1016/0091-6749(75)90011-1; GROVE DI, 1975, BRIT J DERMATOL, V92, P611, DOI 10.1111/j.1365-2133.1975.tb03139.x; Habibzay M, 2012, MUCOSAL IMMUNOL, V5, P524, DOI 10.1038/mi.2012.28; Halablab MA, 2010, EPIDEMIOL INFECT, V138, P702, DOI 10.1017/S0950268809991233; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hales BJ, 2012, THORAX, V67, P321, DOI 10.1136/thoraxjnl-2011-200650; Hanania NA, 2004, J ALLERGY CLIN IMMUN, V113, P717, DOI 10.1016/j.jaci.2003.12.584; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; HARDY I, 1991, NEW ENGL J MED, V325, P1545, DOI 10.1056/NEJM199111283252204; Hasturk H, 2007, J IMMUNOL, V179, P7021, DOI 10.4049/jimmunol.179.10.7021; Ho CY, 2002, CHEST, V122, P1751, DOI 10.1378/chest.122.5.1751; Holt PG, 2012, NAT MED, V18, P726, DOI 10.1038/nm.2768; HOSEA SW, 1981, NEW ENGL J MED, V304, P245, DOI 10.1056/NEJM198101293040501; Jackson LA, 2005, J INFECT DIS, V191, P1523, DOI 10.1086/429344; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; James KM, 2012, J ALLERGY CLIN IMMUN, V130, P343, DOI 10.1016/j.jaci.2012.05.056; JAMES SL, 1990, CURR TOP MICROBIOL, V155, P21; Janoff EN, 1997, MICROB DRUG RESIST, V3, P215, DOI 10.1089/mdr.1997.3.215; Janzi M, 2012, GENES IMMUN, V13, P59, DOI 10.1038/gene.2011.55; Javed A, 2013, J ASTHMA, V50, P472, DOI 10.3109/02770903.2013.787625; Joseph AO, 2009, J ALLERGY CLIN IMMUN, V124; Juhn YJ, 2008, J ALLERGY CLIN IMMUN, V122, P719, DOI 10.1016/j.jaci.2008.07.029; Juhn YJ, 2012, PRIM CARE RESP J, V21, P153, DOI 10.4104/pcrj.2011.00110; Juhn YJ, 2012, ALLERGY ASTHMA IMMUN, V4, P122, DOI 10.4168/aair.2012.4.3.122; Jung JA, 2010, POSTGRAD MED, V122, P116, DOI 10.3810/pgm.2010.09.2208; Jung JA, 2010, J ALLERGY CLIN IMMUN, V125, P217, DOI 10.1016/j.jaci.2009.10.045; Keenan H, 2007, BRIT J GEN PRACT, V57, P359; Khan AQ, 2002, INFECT IMMUN, V70, P749, DOI 10.1128/IAI.70.2.749-761.2002; Kilgore Paul E., 2003, Journal of Medical Virology, V70, pS111, DOI 10.1002/jmv.10364; Kim BS, 2013, J PEDIATR-US, V163, P816, DOI 10.1016/j.jpeds.2013.03.010; KincyCain T, 1996, INFECT IMMUN, V64, P1437, DOI 10.1128/IAI.64.4.1437-1440.1996; Klemets P, 2010, THORAX, V65, P698, DOI 10.1136/thx.2009.132670; Kloepfer KM, 2012, AM J RESP CRIT CARE, V185, P1275, DOI 10.1164/rccm.201109-1635OC; Koch A, 2007, CLIN IMMUNOL, V125, P194, DOI 10.1016/j.clim.2007.07.012; Kremer JR, 2006, VACCINE, V24, P2594, DOI 10.1016/j.vaccine.2005.12.015; LAHOOD N, 1993, ANN ALLERGY, V70, P289; Laza-Stanca V, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002114; Lazic N, 2013, ALLERGY, V68, P764, DOI 10.1111/all.12134; LEE HJ, 1995, VACCINE, V13, P1533, DOI 10.1016/0264-410X(95)00093-G; Lee J, 2011, ALLERGY ASTHMA PROC, V32, P445, DOI 10.2500/aap.2011.32.3494; Lethbridge-Cejku M, 2005, SUMMARY HLTH STAT US; Leung AD, 2008, CLIN EXP ALLERGY, V38, P789, DOI 10.1111/j.1365-2222.2008.02964.x; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Leung DY, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Leung DYM, 2003, CURR OPIN PEDIATR, V15, P399, DOI 10.1097/00008480-200308000-00008; Levin MJ, 2003, J INFECT DIS, V188, P1336, DOI 10.1086/379048; Li C, 2013, CLIN EXP HYPERTENS; Lloyd CM, 2013, J ALLERGY CLIN IMMUN, V131, P1267, DOI 10.1016/j.jaci.2013.02.016; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Lu PJ, 2009, AM J PREV MED, V37, P109, DOI 10.1016/j.amepre.2009.03.021; MAHON BP, 1995, J EXP MED, V181, P1285, DOI 10.1084/jem.181.4.1285; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; Martin RJ, 2001, J ALLERGY CLIN IMMUN, V107, P595, DOI 10.1067/mai.2001.113563; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 2013, LANCET, V382, P1360, DOI 10.1016/S0140-6736(13)61536-6; Meltzer Eli O, 2012, Allergy Asthma Proc, V33 Suppl 1, pS113, DOI 10.2500/aap.2012.33.3603; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Moran TM, 1996, J VIROL, V70, P5230, DOI 10.1128/JVI.70.8.5230-5235.1996; Mossong J, 2003, VACCINE, V21, P4597, DOI 10.1016/S0264-410X(03)00449-3; Mullane D, 2013, JAMA PEDIATR, V167, P368, DOI 10.1001/jamapediatrics.2013.633; Nathan R, 2008, J ALLERGY CLIN IMMUN, V121, pS208, DOI 10.1016/j.jaci.2007.12.777; Noseworthy ME, 2005, ANN AM THOR SOC M SA; Nuorti J. P., 2010, Morbidity and Mortality Weekly Report, V59, P1102; O'Byrne PM, 2011, AM J RESP CRIT CARE, V183, P589, DOI 10.1164/rccm.201005-0694OC; Onozawa M, 2006, J CLIN MICROBIOL, V44, P4441, DOI 10.1128/JCM.01312-06; Otero C, 2013, CLIN EXP IMMUNOL, V173, P92, DOI 10.1111/cei.12082; Patel AR, 2013, PRIM CARE RESP J, V22, P278, DOI 10.4104/pcrj.2013.00039; Patel H, 1996, ARCH PEDIAT ADOL MED, V150, P409, DOI 10.1001/archpedi.1996.02170290075012; Pillai SG, 2010, AM J RESP CRIT CARE, V182, P1498, DOI 10.1164/rccm.201002-0151OC; Plummeridge MJ, 2000, THORAX, V55, P842, DOI 10.1136/thorax.55.10.842; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Ramakrishnan VR, 2013, INT FORUM ALLERGY RH, V3, P267, DOI 10.1002/alr.21101; Remmelts HHF, 2013, THORAX, V68, P990, DOI 10.1136/thoraxjnl-2013-203623; Reynolds MA, 2010, PUBLIC HEALTH REP, V125, P860, DOI 10.1177/003335491012500613; Rezende RA, 2006, AM J OPHTHALMOL, V141, P1120, DOI 10.1016/j.ajo.2006.01.072; Riechelmann H, 2005, ALLERGY, V60, P1418, DOI 10.1111/j.1398-9995.2005.00902.x; Romagnani S, 1996, TRENDS MICROBIOL, V4, P470, DOI 10.1016/S0966-842X(97)82906-X; ROMANI L, 1991, INFECT IMMUN, V59, P4647, DOI 10.1128/IAI.59.12.4647-4654.1991; Ryoo E, 2013, ALLERGY ASTHMA PROC, V34, P370, DOI 10.2500/aap.2013.34.3656; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; Salas CFS, 2013, J ASTHMA, V50, P1069, DOI 10.3109/02770903.2013.834505; Salas CFS, 2013, ALLERGY ASTHMA PROC, V34, P459, DOI 10.2500/aap.2013.34.3686; Salzer U, 2009, BLOOD, V113, P1967, DOI 10.1182/blood-2008-02-141937; Santos JCH, 2011, PEDIATR INT, V53, P576, DOI 10.1111/j.1442-200X.2011.03333.x; Schiller Jeannine S, 2012, Vital Health Stat 10, P1; Schneider L, 2010, J ALLERGY CLIN IMMUN, V126, P1306, DOI 10.1016/j.jaci.2010.08.010; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Skarbinski J, 2011, CLIN INFECT DIS, V52, pS50, DOI 10.1093/cid/ciq021; Smith-Norowitz TA, 2013, PEDIATR INFECT DIS J, V32, P599, DOI 10.1097/INF.0b013e3182862ea8; SPIKA JS, 1982, PEDIATRICS, V69, P219; STEVENS DA, 1972, J CLIN INVEST, V51, P1170, DOI 10.1172/JCI106910; Suissa S, 2013, THORAX, V68, P1029, DOI 10.1136/thoraxjnl-2012-202872; Sykes A, 2014, THORAX, V69, P240, DOI 10.1136/thoraxjnl-2012-202909; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204; Tseng HF, 2009, PEDIATR INFECT DIS J, V28, P1069, DOI 10.1097/INF.0b013e3181acf84f; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC; Urm SH, 2013, MAYO CLIN PROC, V88, P813, DOI 10.1016/j.mayocp.2013.05.021; Van Kerkhove MD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001053; Vartiainen E, 2002, J ALLERGY CLIN IMMUN, V109, P643, DOI 10.1067/mai.2002.123307; Vos Q, 2000, INT IMMUNOL, V12, P1337, DOI 10.1093/intimm/12.9.1337; Wang N, 2011, MOL MED, V17, P1383, DOI 10.2119/molmed.2011.00195; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Warner JA, 2009, BRIT J DERMATOL, V160, P183, DOI 10.1111/j.1365-2133.2008.08905.x; Weatherall D., 2005, LANCET, V366, P445, DOI [DOI 10.1016/S0140-6736(05)67043-2, 10.1016/S0140-6736(05)67043-2]; Webb SAR, 2009, NEW ENGL J MED, V361, P1925, DOI 10.1056/NEJMoa0908481; WEBSTER A, 1989, J MED VIROL, V27, P117, DOI 10.1002/jmv.1890270209; WELCH MJ, 1994, J ASTHMA, V31, P43, DOI 10.3109/02770909409056768; Wiertsema SP, 2007, VACCINE, V25, P306, DOI 10.1016/j.vaccine.2006.07.024; Yawn BP, 2007, MAYO CLIN PROC, V82, P1341, DOI 10.4065/82.11.1341; Yoo KH, 2014, PEDIAT INFE IN PRESS; Yoo KH, 2010, ALLERGY ASTHMA PROC, V31, P499, DOI 10.2500/aap.2010.31.3399; Zahran Hatice S., 2011, Morbidity and Mortality Weekly Report, V60, P547; Zhang Y, 2014, ALLERGY ASTHMA IMMUN, V6, P105, DOI 10.4168/aair.2014.6.2.105; Zhao H, 2013, INFECTION, V41, P927, DOI 10.1007/s15010-013-0482-3	170	91	93	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					247	+		10.1016/j.jaci.2014.04.024	http://dx.doi.org/10.1016/j.jaci.2014.04.024			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	25087224	Green Accepted			2022-12-18	WOS:000341370800001
J	Turvey, SE; Durandy, A; Fischer, A; Fung, SY; Geha, RS; Gewies, A; Giese, T; Greil, J; Keller, B; McKinnon, ML; Neven, B; Rozmus, J; Ruland, J; Snow, AL; Stepensky, P; Warnatz, K				Turvey, Stuart E.; Durandy, Anne; Fischer, Alain; Fung, Shan-Yu; Geha, Raif S.; Gewies, Andreas; Giese, Thomas; Greil, Johann; Keller, Baerbel; McKinnon, Margaret L.; Neven, Benedicte; Rozmus, Jacob; Ruland, Juegen; Snow, Andrew L.; Stepensky, Polina; Warnatz, Klaus			The CARD11-BCL10-MALT1 (CBM) signalosome complex: Stepping into the limelight of human primary immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CARD11-BCL10-MALT1 signalosome complex; primary immunodeficiency diseases; combined immunodeficiency; congenital B-cell lymphocytosis; paracaspase; next-generation sequencing; nuclear factor kappa B; CARMA1	NF-KAPPA-B; T-CELL; IMMUNE-DEFICIENCY; ECTODERMAL DYSPLASIA; CARD11 MUTATIONS; JNK ACTIVATION; MALT LYMPHOMA; CARMA1; BCL10; CLEAVAGE	Next-generation DNA sequencing has accelerated the genetic characterization of many human primary immunodeficiency diseases (PIDs). These discoveries can be lifesaving for the affected patients and also provide a unique opportunity to study the effect of specific genes on human immune function. In the past 18 months, a number of independent groups have begun to define novel PIDs caused by defects in the caspase recruitment domain family, member 11 (CARD11)-B-cell chronic lymphocytic leukemia/lymphoma 10 (BCL10)-mucosa-associated lymphoid tissue lymphoma translocation gene 1 (MALT1 [CBM]) signalosome complex. The CBM complex forms an essential molecular link between the triggering of cell-surface antigen receptors and nuclear factor kappa B activation. Germline mutations affecting the CBM complex are now recognized as the cause of novel combined immunodeficiency phenotypes, which all share abnormal nuclear factor kappa B activation and dysregulated B-cell development as defining features. For this "Current perspectives'' article, we have engaged experts in both basic biology and clinical immunology to capture the worldwide experience in recognizing and managing patients with PIDs caused by CBM complex mutations.	[Turvey, Stuart E.; Fung, Shan-Yu; Rozmus, Jacob] Child & Family Res Inst, Dept Pediat, Vancouver, BC V5Z 4H4, Canada; [Turvey, Stuart E.; Fung, Shan-Yu; Rozmus, Jacob] Univ British Columbia, BC Childrens Hosp, Vancouver, BC V5Z 1M9, Canada; [Durandy, Anne; Fischer, Alain] Necker Childrens Hosp, Assistance Publ Hop Paris, Natl Inst Hlth & Med Res, Paris, France; [Durandy, Anne; Fischer, Alain] Necker Childrens Hosp, Assistance Publ Hop Paris, Dept Immunol & Hematol, Paris, France; [Durandy, Anne; Fischer, Alain] Univ Paris, Descartes Sorbonne Paris Cite, Imagine Inst, F-75252 Paris, France; [Fischer, Alain; Neven, Benedicte] Hop Necker Enfant Malades, APHP, Unite Immunohematol Pediat, Paris, France; [Geha, Raif S.] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Gewies, Andreas] Tech Univ Munich, German Canc Consortium DKTK, Klinikum Rechts Isar, Partner Site Munich Inst Klin Chem & Pathobiochem, D-80290 Munich, Germany; [Giese, Thomas] Heidelberg Univ, Inst Immunol, D-69115 Heidelberg, Germany; [Greil, Johann] Heidelberg Univ, Dept Pediat Oncol Hematol & Immunol, D-69115 Heidelberg, Germany; [Keller, Baerbel; Warnatz, Klaus] Univ Med Ctr Freiburg, CCI, Freiburg, Germany; [Keller, Baerbel; Warnatz, Klaus] Univ Freiburg, Freiburg, Germany; [McKinnon, Margaret L.] Univ British Columbia, Dept Med Genet, Child & Family Res Inst, Vancouver, BC V5Z 1M9, Canada; [McKinnon, Margaret L.] Univ British Columbia, BC Childrens Hosp, Vancouver, BC V5Z 1M9, Canada; [Ruland, Juegen] Tech Univ Munich, Klinikum Rechts Isar, Inst Klin Chem & Pathobiochem, D-80290 Munich, Germany; [Snow, Andrew L.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; [Stepensky, Polina] Hadassah Hebrew Univ Med Ctr, Jerusalem, Israel	Child & Family Research Institute; BC Childrens Hospital; University of British Columbia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Necker-Enfants Malades - APHP; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Helmholtz Association; German Cancer Research Center (DKFZ); Technical University of Munich; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Freiburg; University of Freiburg; Child & Family Research Institute; University of British Columbia; BC Childrens Hospital; University of British Columbia; Technical University of Munich; Uniformed Services University of the Health Sciences - USA; Hebrew University of Jerusalem	Turvey, SE (corresponding author), Child & Family Res Inst, 950 West 28 Ave, Vancouver, BC V5Z 4H4, Canada.	sturvey@cw.bc.ca	Durandy, Anne/H-7475-2017; Warnatz, Klaus/AAD-3464-2022; Ruland, Jürgen/Q-6680-2018; Fung, Shan-Yu/E-3477-2014; Turvey, Stuart/HGV-1191-2022	Durandy, Anne/0000-0001-7706-8466; Ruland, Jürgen/0000-0002-8381-3597; Fung, Shan-Yu/0000-0002-4547-8740; Turvey, Stuart/0000-0003-1599-1065; Snow, Andrew/0000-0002-8728-6691; McKinnon, Margaret/0000-0002-3161-414X; Gewies, Andreas/0000-0002-7606-6482; , Jacob/0000-0003-4036-2105	Canadian Institutes of Health Research [MOP133691]; National Institutes of Health [AI100315, AI094017]; Dubai-Harvard Foundation of Medical Research; DZIF (German Center for Infection Research); European Research Council under the European Union's Seventh Framework Programme (FP7)/European Research Council [322865]; Concern Foundation; Federal Ministry of Education and Research [BMBF 01 EO1303]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI100315, R03AI094017, R21AI109187] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dubai-Harvard Foundation of Medical Research; DZIF (German Center for Infection Research); European Research Council under the European Union's Seventh Framework Programme (FP7)/European Research Council(European Research Council (ERC)); Concern Foundation; Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	S. E. T. holds the Aubrey J. Tingle Professorship in Pediatric Immunology and is a clinical scholar of the Michael Smith Foundation for Health Research. J. R. is a Vanier Canada Graduate Scholar. Supported in part by funding from the Canadian Institutes of Health Research (MOP133691 to S. E. T.); the National Institutes of Health (AI100315 and AI094017) and a Dubai-Harvard Foundation of Medical Research grant (both to R. S. G.); DZIF (German Center for Infection Research) and the European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013)/European Research Council grant agreement no. 322865 (to J. R.); a Concern Foundation Conquer Cancer Now Award (to A. L. S.); and the Federal Ministry of Education and Research (BMBF 01 EO1303 to K. W.).	Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; Al-Herz W, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00054; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Blonska M, 2009, IMMUNOL REV, V228, P199, DOI 10.1111/j.1600-065X.2008.00749.x; Boyle RJ, 2006, CLIN EXP IMMUNOL, V146, P486, DOI 10.1111/j.1365-2249.2006.03242.x; Chan WP, 2013, MOL CELL BIOL, V33, P429, DOI 10.1128/MCB.00850-12; Che TJ, 2004, J BIOL CHEM, V279, P15870, DOI 10.1074/jbc.M310599200; Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Dong GH, 2011, CLIN CANCER RES, V17, P1440, DOI 10.1158/1078-0432.CCR-10-1859; Dubois SM, 2014, BLOOD, V123, P2199, DOI 10.1182/blood-2013-05-504019; Duwel M, 2010, SUBCELL BIOCHEM, V54, P88, DOI 10.1007/978-1-4419-6676-6_7; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Gaide O, 2001, FEBS LETT, V496, P121, DOI 10.1016/S0014-5793(01)02414-0; Geahlen RL, 2009, BBA-MOL CELL RES, V1793, P1115, DOI 10.1016/j.bbamcr.2009.03.004; Greil J, 2013, J ALLERGY CLIN IMMUN, V131, P1376, DOI 10.1016/j.jaci.2013.02.012; Hailfinger S, 2011, P NATL ACAD SCI USA, V108, P14596, DOI 10.1073/pnas.1105020108; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Jabara HH, 2013, J ALLERGY CLIN IMMUN, V132, P151, DOI 10.1016/j.jaci.2013.04.047; Jiang CY, 2012, IMMUNOL REV, V246, P141, DOI 10.1111/j.1600-065X.2012.01110.x; Kirchhofer Daniel, 2012, Biochem J, V444, pe3, DOI 10.1042/BJ20120414; Kong KF, 2013, TRENDS IMMUNOL, V34, P234, DOI 10.1016/j.it.2013.01.002; Lamason RL, 2010, MOL CELL, V40, P798, DOI 10.1016/j.molcel.2010.11.007; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Love PE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002485; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; McDonald DR, 2006, MICROBES INFECT, V8, P1151, DOI 10.1016/j.micinf.2005.10.030; McKinnon ML, 2014, J ALLERGY CLIN IMMUN, V133, P1458, DOI 10.1016/j.jaci.2013.10.045; Molinero LL, 2009, J IMMUNOL, V182, P6736, DOI 10.4049/jimmunol.0900498; Montesinos-Rongen M, 2010, ACTA NEUROPATHOL, V120, P529, DOI 10.1007/s00401-010-0709-7; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Notarangelo LD, 2013, ANNU REV IMMUNOL, V31, P195, DOI 10.1146/annurev-immunol-032712-095927; Oeckinghaus A, 2007, EMBO J, V26, P4634, DOI 10.1038/sj.emboj.7601897; Pannicke U, 2013, NEW ENGL J MED, V369, P2504, DOI 10.1056/NEJMoa1309199; Platt C, 2014, J ALLERGY CLIN IMMUN, V134, P262, DOI 10.1016/j.jaci.2013.08.021; Qiao Q, 2013, MOL CELL, V51, P766, DOI 10.1016/j.molcel.2013.08.032; Readinger JA, 2009, IMMUNOL REV, V228, P93, DOI 10.1111/j.1600-065X.2008.00757.x; Rebeaud F, 2008, NAT IMMUNOL, V9, P272, DOI 10.1038/ni1568; Roche MI, 2013, CRIT REV IMMUNOL, V33, P219, DOI 10.1615/CritRevImmunol.2013007056; Roifman CM, 2012, J ALLERGY CLIN IMMUN, V130, P177, DOI 10.1016/j.jaci.2012.04.029; Rosebeck S, 2011, CELL CYCLE, V10, P2485, DOI 10.4161/cc.10.15.16923; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Schulze-Luehrmann J, 2006, IMMUNITY, V25, P701, DOI 10.1016/j.immuni.2006.10.010; Shaffer AL, 2012, ANNU REV IMMUNOL, V30, P565, DOI 10.1146/annurev-immunol-020711-075027; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P1092, DOI 10.1016/j.jaci.2013.09.044; Shinohara H, 2005, J EXP MED, V202, P1423, DOI 10.1084/jem.20051591; Snow AL, 2012, J EXP MED, V209, P2247, DOI 10.1084/jem.20120831; Sommer K, 2005, IMMUNITY, V23, P561, DOI 10.1016/j.immuni.2005.09.014; Staal J, 2011, EMBO J, V30, P1742, DOI 10.1038/emboj.2011.85; Stepensky P, 2013, J ALLERGY CLIN IMMUN, V131, P477, DOI 10.1016/j.jaci.2012.11.050; Thome M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003004; Tsang P, 2005, PEDIATR DENT, V27, P68; Uehata T, 2013, CELL, V153, P1036, DOI 10.1016/j.cell.2013.04.034; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(00)00094-0; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Xue LQ, 2003, NAT IMMUNOL, V4, P857, DOI 10.1038/ni963; Yang YB, 2014, CANCER DISCOV, V4, P480, DOI 10.1158/2159-8290.CD-13-0915; Young RM, 2012, CANCER CELL, V22, P706, DOI 10.1016/j.ccr.2012.11.011; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	65	91	93	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					276	284		10.1016/j.jaci.2014.06.015	http://dx.doi.org/10.1016/j.jaci.2014.06.015			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	25087226	Green Accepted			2022-12-18	WOS:000341370800005
J	Apter, AJ; Wan, F; Reisine, S; Bender, B; Rand, C; Bogen, DK; Bennett, IM; Bryant-Stephens, T; Roy, J; Gonzalez, R; Priolo, C; Ten Have, T; Morales, KH				Apter, Andrea J.; Wan, Fei; Reisine, Susan; Bender, Bruce; Rand, Cynthia; Bogen, Daniel K.; Bennett, Ian M.; Bryant-Stephens, Tyra; Roy, Jason; Gonzalez, Rodalyn; Priolo, Chantel; Ten Have, Thomas; Morales, Knashawn H.			The association of health literacy with adherence and outcomes in moderate-severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Health literacy; numeracy; print literacy; asthma; adherence; adults; inner-city asthma; inhaled corticosteroids; asthma-related quality of life; asthma control	DOSE INHALER ADHERENCE; MEDICATION ADHERENCE; MANAGEMENT PROGRAM; CORTICOSTEROIDS; QUESTIONNAIRE; VALIDATION; ADULTS; STEROIDS; FAILURE; TRIAL	Background: Low health literacy is associated with poor outcomes in asthma and other diseases, but the mechanisms governing this relationship are not well defined. Objective: We sought to assess whether literacy is related to subsequent asthma self-management, measured as adherence to inhaled steroids, and asthma outcomes. Methods: In a prospective longitudinal cohort study, numeric (Asthma Numeracy Questionnaire) and print literacy (Short Test of Functional Health Literacy in Adults) were assessed at baseline in adults with moderate or severe asthma for their impact on subsequent electronically monitored adherence and asthma outcomes (asthma control, asthma-related quality of life, and FEV1) over 26 weeks, using mixed-effects linear regression models. Results: A total of 284 adults participated: age, 48 6 14 years, 71% females, 70% African American, 6% Latino, mean FEV1 66% +/- 19%, 86 (30%) with hospitalizations, and 148 (52%) with emergency department visits for asthma in the prior year. Mean Asthma Numeracy Questionnaire score was 2.3 +/- 1.2 (range, 04); mean Short Test of Functional Health Literacy in Adults score was 31 6 8 (range, 0-36). In unadjusted analyses, numeric and print literacy were associated with better adherence (P = .01 and P = .08, respectively), asthma control (P = .005 and P < .001, respectively), and quality of life (P < .001 and P < .001, respectively). After controlling for age, sex, and race/ethnicity, the associations diminished and only quality of life (numeric P = .03, print P = .006) and asthma control (print P = .005) remained significantly associated with literacy. Race/ethnicity, income, and educational attainment were correlated (P < .001). Conclusion: While the relationship between literacy and health is complex, interventions that account for and address the literacy needs of patients may improve asthma outcomes.	[Apter, Andrea J.; Gonzalez, Rodalyn; Priolo, Chantel] Univ Penn, Div Pulm Allergy & Crit Care Med, Sect Allergy & Immunol, Philadelphia, PA 19104 USA; [Apter, Andrea J.; Gonzalez, Rodalyn; Priolo, Chantel] Univ Penn, Dept Med, Philadelphia, PA 19104 USA; [Wan, Fei; Roy, Jason; Ten Have, Thomas; Morales, Knashawn H.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Bogen, Daniel K.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Bennett, Ian M.] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA; [Apter, Andrea J.; Wan, Fei; Bogen, Daniel K.; Bennett, Ian M.; Bryant-Stephens, Tyra; Roy, Jason; Gonzalez, Rodalyn; Priolo, Chantel; Ten Have, Thomas; Morales, Knashawn H.] Univ Penn, Philadelphia, PA 19104 USA; [Reisine, Susan] Univ Connecticut, Ctr Hlth, Dept Oral Hlth & Diagnost Sci, Div Behav Sci & Community Hlth, Farmington, CT USA; [Bender, Bruce] Natl Jewish Hlth, Denver, CO USA; [Rand, Cynthia] Johns Hopkins Univ, Baltimore, MD USA; [Bryant-Stephens, Tyra] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Connecticut; National Jewish Health; Johns Hopkins University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Apter, AJ (corresponding author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.	apter@mail.med.upenn.edu	Bennett, Ian/AAH-6133-2019	Ten Have, Thomas/0000-0003-0026-3073; Bennett, Ian/0000-0002-7139-9456	National Institutes of Health (NIH)/National Heart, Lung and Blood Institute (NHLBI); AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; NIH/NHLBI; NIH [RC1 HL09612]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073932, RC1HL099612, K02HL088469] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Heart, Lung and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AstraZeneca(AstraZeneca); Bristol-Myers Squibb(Bristol-Myers Squibb); GlaxoSmithKline(GlaxoSmithKline); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	A. J. Apter has been supported by one or more grants from the National Institutes of Health (NIH)/National Heart, Lung and Blood Institute (NHLBI); is a Board member for the American Academy of Allergy, Asthma & Immunology; has been supported by AstraZeneca and Bristol-Myers Squibb; and has had consultancy arrangements with UpToDate. B. Bender has received one or more grants from or has one or more grants pending with GlaxoSmithKline and has received one or more payments for lecturing from or is on the speakers' bureau for and has received one or more payments for travel/accommodations/meeting expenses from Merck. D. K. Bogen has been supported by one or more grants from the NIH. T. Bryant-Stephens has received one or more grants from or has one or more grants pending with the Merck Childhood Asthma Network; Region 3, Environmental Protection Agency; National Cancer Institute; and Pennsylvania Department of Health; has received one or more payments for lecturing from or is on the speakers' bureau for Xavier University; and has received one or more payments for travel/accommodations/ meeting expenses from the Children's Health Protection Advisory Board, the US EPA, and Xavier University. Rodalyn Gonzalez and Chantel Priolo have been supported by one or more grants from the NIH/NHLBI. J. Roy has been supported by one or more grants from the NIH (grant no. RC1 HL09612). The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 2007, 3 US DEP HLTH HUM SE; [Anonymous], HLTH PEOPL 2010 HLTH; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; APTER AJ, 2003, AM REV RESP CRIT CAR, V167, pA155; Apter AJ, 2006, J ASTHMA, V43, P705, DOI 10.1080/02770900600925585; Apter AJ, 2011, J ALLERGY CLIN IMMUN, V128, P516, DOI 10.1016/j.jaci.2011.05.010; Apter AJ, 2009, PATIENT EDUC COUNS, V75, P386, DOI 10.1016/j.pec.2009.01.003; Baker DW, 2006, J GEN INTERN MED, V21, P878, DOI 10.1111/j.1525-1497.2006.00540.x; Baker DW, 2000, J GERONTOL B-PSYCHOL, V55, pS368, DOI 10.1093/geronb/55.6.S368; Baker DW, 1999, PATIENT EDUC COUNS, V38, P33, DOI 10.1016/S0738-3991(98)00116-5; Bender B, 2000, ANN ALLERG ASTHMA IM, V85, P416, DOI 10.1016/S1081-1206(10)62557-4; Berg J, 1998, ANN BEHAV MED, V20, P36, DOI 10.1007/BF02893807; BERKMAN N, 2004, AHRQ PUBLICATION; Berkman ND, 2011, ANN INTERN MED, V155, P97, DOI 10.7326/0003-4819-155-2-201107190-00005; Bogen D, 2004, J ALLERGY CLIN IMMUN, V114, P863, DOI 10.1016/j.jaci.2004.07.017; DeWalt DA, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-30; ERNST P, 1992, JAMA-J AM MED ASSOC, V268, P3462, DOI 10.1001/jama.268.24.3462; French JRP, 1950, EXPT SOCIAL PROCESS, P82; Gamble J, 2009, AM J RESP CRIT CARE, V180, P817, DOI 10.1164/rccm.200902-0166OC; HALL JA, 1988, MED CARE, V26, P657, DOI 10.1097/00005650-198807000-00002; Haynes RB, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub3; Institute of Medicine, 2011, HLTH LIT IMPL HLTH C; Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, 2003, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330, DOI 10.1164/ajrccm.162.4.9912138; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Juniper EF, 2001, RESP MED, V95, P319, DOI 10.1053/rmed.2001.1034; Krishnan JA, 2012, J ALLERGY CLIN IMMUN, V129, P112, DOI 10.1016/j.jaci.2011.10.030; Kutner M, 2006, 2006483 NCES US DEP; Le TT, 2008, J ASTHMA, V45, P33, DOI 10.1080/02770900701815552; Leidy NK, 1998, AM J RESP CRIT CARE, V158, P1082, DOI 10.1164/ajrccm.158.4.9708130; Martin LT, 2011, JAMA-J AM MED ASSOC, V306, P874, DOI 10.1001/jama.2011.1212; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; National Center for Education Statistics, 2003, NAT ASS AD LIT; National Toxicology Program, 2007, Natl Toxicol Program Tech Rep Ser, P1; NIDES MA, 1993, CHEST, V104, P501, DOI 10.1378/chest.104.2.501; Nielson-Bohlman L, 2004, HLTH LITERACY PRESCR; Nurss JR, 1995, TEST FUNCTIONAL HLTH; Osborn CY, 2007, AM J PREV MED, V33, P374, DOI 10.1016/j.amepre.2007.07.022; PARKER RM, 1995, J GEN INTERN MED, V10, P537, DOI 10.1007/BF02640361; RAND CS, 1995, AM J RESP CRIT CARE, V152, P580, DOI 10.1164/ajrccm.152.2.7633711; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; Riekert KA, 2002, J CLIN PSYCHOL MED S, V9, P25, DOI 10.1023/A:1014131928789; Rosenfeld L, 2011, PATIENT EDUC COUNS, V82, P110, DOI 10.1016/j.pec.2010.02.023; Schillinger D, 2002, JAMA-J AM MED ASSOC, V288, P475, DOI 10.1001/jama.288.4.475; Schillinger D, 2003, ARCH INTERN MED, V163, P83, DOI 10.1001/archinte.163.1.83; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; US Department of Health and Human Services Office of Disease Prevention and Health Promotion, HLTH PEOPL 2020 HLTH; Williams LK, 2007, J ALLERGY CLIN IMMUN, V120, P1153, DOI 10.1016/j.jaci.2007.08.020; Williams LK, 2010, J ALLERGY CLIN IMMUN, V126, P225, DOI 10.1016/j.jaci.2010.03.034; Williams MV, 1998, CHEST, V114, P1008, DOI 10.1378/chest.114.4.1008	56	91	91	1	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					321	327		10.1016/j.jaci.2013.02.014	http://dx.doi.org/10.1016/j.jaci.2013.02.014			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	194KL	23591273	Green Accepted			2022-12-18	WOS:000322631700008
J	Shi, YX; Aledia, AS; Galant, SP; George, SC				Shi, Yixin; Aledia, Anna S.; Galant, Stanley P.; George, Steven C.			Peripheral airway impairment measured by oscillometry predicts loss of asthma control in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Impulse oscillometry; pediatric; lung function; longitudinal	IMPULSE OSCILLOMETRY; CHILDHOOD ASTHMA; REFERENCE VALUES; OBESITY; INFLAMMATION; ASSOCIATION; GUIDELINES; MANAGEMENT; SEVERITY	Background: We previously showed that impulse oscillometry (IOS) indices of peripheral airway function are associated with asthma control in children. However, little data exist on whether dysfunction in the peripheral airways can predict loss of asthma control. Objective: We sought to determine the utility of peripheral airway impairment, as measured by IOS, in predicting loss of asthma control in children. Methods: Fifty-four children (age, 7-17 years) with controlled asthma were enrolled in the study. Spirometric and IOS indices of airway function were obtained at baseline and at a follow-up visit 8 to 12 weeks later. Physicians who were blinded to the IOS measurements assessed asthma control (National Asthma Education and Prevention Program guidelines) on both visits and prescribed no medication change between visits. Results: Thirty-eight (70%) patients maintained asthma control between 2 visits (group C-C), and 16 patients had asthma that became uncontrolled on the follow-up visit (group C-UC). There was no difference in baseline spirometric results between the C-C and C-UC groups, except for FEV1/forced vital capacity ratio (86% vs 82%, respectively; P < .01). Baseline IOS results, including resistance of the respiratory system at 5 Hz (R5; 6.4 vs 4.3 cm H2O . L-1 . s), frequency dependence of resistance (difference of R5 and resistance of the respiratory system at 20 Hz [R5-20]; 2.0 vs 0.7 cm H2O . L-1 . s), and reactance area (13.1 vs 4.1 cm H2O . L 21), of group C-UC were significantly higher than those of group C-C (P < .01). Receiver operating characteristic analysis showed baseline R5-20 and reactance area effectively predicted asthma control status at the follow-up visit (area under the curve, 0.91 and 0.90). Conclusion: Children with controlled asthma who have increased peripheral airway IOS indices are at risk of losing asthma control. (J Allergy Clin Immunol 2013;131:718-23.)	[Shi, Yixin; Aledia, Anna S.; George, Steven C.] Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92697 USA; [George, Steven C.] Univ Calif Irvine, Dept Chem Engn & Mat Sci, Irvine, CA 92697 USA; [Aledia, Anna S.; George, Steven C.] Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; [Galant, Stanley P.] Univ Calif Irvine, Dept Pediat, Irvine, CA 92717 USA; [George, Steven C.] Univ Calif Irvine, Edwards Lifesci Ctr Adv Cardiovasc Technol, Irvine, CA 92697 USA; [Galant, Stanley P.] Childrens Hosp Orange Cty, Orange, CA 92668 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; Childrens Hospital of Orange County	George, SC (corresponding author), Univ Calif Irvine, 2420 Engn Hall, Irvine, CA 92697 USA.	scgeorge@uci.edu	George, Steven/K-9359-2015	George, Steven/0000-0003-2263-1914	National Institutes of Health [HL070645]; University of California, Irvine; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070645] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of California, Irvine(University of California System); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grant HL070645.; S. P. Galant has received research support from the University of California, Irvine. The rest of the authors declare that they have no relevant conflicts of interest.	Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Boulet LP, 2007, RESP MED, V101, P2240, DOI 10.1016/j.rmed.2007.06.031; Cabral ALB, 2009, ANN ALLERG ASTHMA IM, V103, P206, DOI 10.1016/S1081-1206(10)60183-4; Carroll WD, 2012, EUR RESPIR J, V39, P90, DOI 10.1183/09031936.00048911; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Davis KJ, 2011, PEDIAT ALLERG IMM-UK, V22, P31, DOI 10.1111/j.1399-3038.2010.01016.x; Farah CS, 2012, J ALLERGY CLIN IMMUN, V130, P61, DOI 10.1016/j.jaci.2012.02.015; Farah CS, 2012, J ALLERGY CLIN IMMUN, V129, P381, DOI 10.1016/j.jaci.2011.11.017; Farah CS, 2011, CHEST, V140, P659, DOI 10.1378/chest.11-0027; Frei J, 2005, CHEST, V128, P1266, DOI 10.1378/chest.128.3.1266; Fritz GK, 2010, AM J RESP CRIT CARE, V182, P12, DOI 10.1164/rccm.200906-0836OC; Fuhlbrigge AL, 2006, PEDIATRICS, V118, pE347, DOI 10.1542/peds.2005-2962; Global Initiative for Asthma (GINA), 2011, GLOB STRAT ASTHM MAN; Goldman MD, 2005, RESP PHYSIOL NEUROBI, V148, P179, DOI 10.1016/j.resp.2005.05.026; Goldman MD, 2002, PEDIATR PULM, V34, P312, DOI 10.1002/ppul.10168; Goldman MD, 2001, PULM PHARMACOL THER, V14, P341, DOI 10.1006/pupt.2001.0310; GRIMBY G, 1968, J CLIN INVEST, V47, P1455, DOI 10.1172/JCI105837; Gruchalla RS, 2009, J ALLERGY CLIN IMMUN, V124, P213, DOI 10.1016/j.jaci.2009.05.036; Hammer SC, 2008, PEDIATR ALLERGY IMMU, V19, P626, DOI 10.1111/j.1399-3038.2007.00705.x; Kendig EL, 1986, DISORDERS RESP TRACT; Kroegel C, 2009, EXPERT REV CLIN IMMU, V5, P239, DOI 10.1586/ECI.09.1; Larsen GL, 2009, J ALLERGY CLIN IMMUN, V123, P861, DOI 10.1016/j.jaci.2008.10.036; Liao O, 2006, J SCHOOL HEALTH, V76, P313, DOI 10.1111/j.1746-1561.2006.00119.x; Martin RJ, 2002, J ALLERGY CLIN IMMUN, V109, pS447, DOI 10.1067/mai.2002.121409; Meraz EG, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-21; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Nowowiejska B, 2008, PEDIATR PULM, V43, P1193, DOI 10.1002/ppul.20926; Quinto KB, 2011, J ALLERGY CLIN IMMUN, V128, P964, DOI 10.1016/j.jaci.2011.06.031; Robroeks CMHHT, 2012, CLIN EXP ALLERGY, V42, P792, DOI 10.1111/j.1365-2222.2012.03992.x; Scott L, 2011, J ALLERGY CLIN IMMUN, V128, P56, DOI 10.1016/j.jaci.2011.03.020; Shi YX, 2012, J ALLERGY CLIN IMMUN, V129, P671, DOI 10.1016/j.jaci.2011.11.002; Song TW, 2008, PEDIAT ALLERG IMM-UK, V19, P763, DOI 10.1111/j.1399-3038.2008.00734.x; Takeda T, 2010, RESPIRATION, V80, P120, DOI 10.1159/000242113; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036	35	91	98	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					718	723		10.1016/j.jaci.2012.09.022	http://dx.doi.org/10.1016/j.jaci.2012.09.022			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23146376				2022-12-18	WOS:000315587800012
J	Miyata, J; Fukunaga, K; Iwamoto, R; Isobe, Y; Niimi, K; Takamiya, R; Takihara, T; Tomomatsu, K; Suzuki, Y; Oguma, T; Sayama, K; Arai, H; Betsuyaku, T; Arita, M; Asano, K				Miyata, Jun; Fukunaga, Koichi; Iwamoto, Ryo; Isobe, Yosuke; Niimi, Kyoko; Takamiya, Rina; Takihara, Takahisa; Tomomatsu, Katsuyoshi; Suzuki, Yusuke; Oguma, Tsuyoshi; Sayama, Koichi; Arai, Hiroyuki; Betsuyaku, Tomoko; Arita, Makoto; Asano, Koichiro			Dysregulated synthesis of protectin D1 in eosinophils from patients with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; CCL11; docosahexaenoic acid; 15-lipoxygenase; 5-oxo-eicosatetraenoic acid; IL-5; lipid mediator; platelet-activating factor	DOCOSAHEXAENOIC ACID; LEUKOTRIENE B-4; POLYMORPHONUCLEAR CELLS; ARACHIDONIC-ACID; LIPOXIN A(4); TRANSFORMATION; INFLAMMATION; GENERATION; CHILDREN; 5-LIPOXYGENASE	Background: Protectin D1 (PD1) is an anti-inflammatory and proresolving lipid mediator biosynthesized from the omega-3 fatty acid docosahexaenoic acid (DHA). Exogenous PD1 conferred protection against eosinophilic inflammation in animals with experimental asthma, although its endogenous cellular source and functions in human airways are of interest. Objective: We sought to investigate the synthesizing capacity of PD1 in eosinophils from healthy subjects and patients with severe asthma and its direct effects on eosinophil functions. Methods: Human eosinophil-derived metabolites of arachidonic acid and DHA were analyzed with liquid chromatography-tandem mass spectrometry-based lipidomic analysis. The biological activities of PD1 on the function of human eosinophils, including chemotaxis, adhesion molecule expressions, degranulation, superoxide anion generation, or survival, were examined. Results: We identified PD1 as one of the main anti-inflammatory and proresolving molecules synthesized in human eosinophils. PD1, in nanomolar concentrations, suppressed the chemotaxis induced by CCL11/eotaxin-1 or 5-oxo-eicosatetraenoic acid and modulated the expression of the adhesion molecules CD11b and L-selectin, although it had no effects on the degranulation, superoxide anion generation, or survival of the eosinophils. Compared with the cells harvested from healthy subjects, we observed a prominent decrease in the biosynthesis of PD1 by eosinophils from patients with severe asthma, even in presence of DHA. Conclusion: These observations are a first indication that activated human eosinophils represent a major source of PD1, which can act as a self-resolving machinery in eosinophilic inflammation, whereas the production of PD1 is impaired in patients with severe asthma. (J Allergy Clin Immunol 2013;131:353-60.)	[Miyata, Jun; Fukunaga, Koichi; Niimi, Kyoko; Takamiya, Rina; Takihara, Takahisa; Tomomatsu, Katsuyoshi; Suzuki, Yusuke; Oguma, Tsuyoshi; Sayama, Koichi; Betsuyaku, Tomoko; Asano, Koichiro] Keio Univ, Sch Med, Dept Med, Div Pulm Med, Tokyo 160, Japan; [Iwamoto, Ryo; Isobe, Yosuke] Univ Tokyo, Grad Sch Pharmaceut Sci, Business Acad Collaborat Lab, Tokyo 1138654, Japan; [Isobe, Yosuke; Arai, Hiroyuki; Arita, Makoto] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Tokyo 1138654, Japan; [Tomomatsu, Katsuyoshi; Oguma, Tsuyoshi; Asano, Koichiro] Tokai Univ, Sch Med, Dept Med, Div Pulm Med, Isehara, Kanagawa 2591193, Japan	Keio University; University of Tokyo; University of Tokyo; Tokai University	Asano, K (corresponding author), Tokai Univ, Sch Med, Dept Med, Div Pulm Med, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	ko-asano@tokai-u.jp	Fukunaga, Koichi/R-5338-2019; Miyata, Jun/CAH-9822-2022	Miyata, Jun/0000-0002-3189-1702; Arita, Makoto/0000-0001-9902-0463	Ministry of Health, Labor, and Welfare; Ministry of Education, Culture, Sports, Science, and Technology of Japan; Japan Science and Technology Agency Precursory Research for Embryonic Science and Technology (PRESTO); GlaxoSmithKline	Ministry of Health, Labor, and Welfare(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Science and Technology Agency Precursory Research for Embryonic Science and Technology (PRESTO); GlaxoSmithKline(GlaxoSmithKline)	Supported by a grant-in-aid for research on allergic disease and immunology from the Ministry of Health, Labor, and Welfare (to K. A.); grants-in-aid for scientific research (to K. A. and M. A.) and for the Global COE Program (Center for Human Metabolomic Systems Biology; to J.M.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; a grant-in-aid from the Japan Science and Technology Agency Precursory Research for Embryonic Science and Technology (PRESTO; to M. A.); and a grant-in-aid from GlaxoSmithKline.	[Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Antova T, 2003, THORAX, V58, P231, DOI 10.1136/thorax.58.3.231; Bartemes KR, 1999, J IMMUNOL, V162, P2982; Bhavsar PK, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-71; Bilal S, 2011, BBA-MOL BASIS DIS, V1812, P1164, DOI 10.1016/j.bbadis.2011.05.002; BORGEAT P, 1979, J BIOL CHEM, V254, P2643; Brinckmann R, 1998, BLOOD, V91, P64, DOI 10.1182/blood.V91.1.64.64_64_74; Chavis C, 1996, J EXP MED, V183, P1633, DOI 10.1084/jem.183.4.1633; FIORE S, 1990, J EXP MED, V172, P1451, DOI 10.1084/jem.172.5.1451; Gervais FG, 2001, J ALLERGY CLIN IMMUN, V108, P982, DOI 10.1067/mai.2001.119919; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Isobe Y, 2012, J BIOL CHEM, V287, P10525, DOI 10.1074/jbc.M112.340612; Kikuchi S, 1998, PROSTAG LEUKOTR ESS, V58, P243, DOI 10.1016/S0952-3278(98)90121-1; LEE TH, 1990, AM REV RESPIR DIS, V141, P1453, DOI 10.1164/ajrccm/141.6.1453; Levy BD, 2005, AM J RESP CRIT CARE, V172, P824, DOI 10.1164/rccm.200410-1413OC; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Levy BD, 2007, J IMMUNOL, V178, P496, DOI 10.4049/jimmunol.178.1.496; Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420; Mathur SK, 2008, CHEST, V133, P412, DOI 10.1378/chest.07-2114; Nagakura T, 2000, EUR RESPIR J, V16, P861, DOI 10.1183/09031936.00.16586100; Nagata M, 1998, AM J RESP CELL MOL, V19, P158, DOI 10.1165/ajrcmb.19.1.3001; NAGATA M, 1995, J IMMUNOL, V155, P2194; NICHOLS RC, 1991, BIOCHIM BIOPHYS ACTA, V1085, P77, DOI 10.1016/0005-2760(91)90234-9; Niimi K, 2007, J IMMUNOL, V178, P489, DOI 10.4049/jimmunol.178.1.489; OFLaherty JT, 1996, J IMMUNOL, V157, P336; PARSONS WG, 1988, J IMMUNOL, V141, P2413; Peacock CD, 1999, J ALLERGY CLIN IMMUN, V104, P153, DOI 10.1016/S0091-6749(99)70127-2; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Planaguma A, 2008, AM J RESP CRIT CARE, V178, P574, DOI 10.1164/rccm.200801-061OC; Powell WS, 2001, J ALLERGY CLIN IMMUN, V107, P272, DOI 10.1067/mai.2001.112847; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Sala A, 1996, J BIOL CHEM, V271, P17944, DOI 10.1074/jbc.271.30.17944; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan CN, 2006, J IMMUNOL, V176, P1848, DOI 10.4049/jimmunol.176.3.1848; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; THOMAS E, 1995, INFLAMM RES, V44, P121, DOI 10.1007/BF01782022; Vachier I, 2005, J ALLERGY CLIN IMMUN, V115, P55, DOI 10.1016/j.jaci.2004.09.038; Vachier I, 2001, J ALLERGY CLIN IMMUN, V107, P824, DOI 10.1067/mai.2001.113868; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WELLER PF, 1994, CURR OPIN IMMUNOL, V6, P85, DOI 10.1016/0952-7915(94)90038-8; Yamada T, 2011, FASEB J, V25, P561, DOI 10.1096/fj.10-170027; Yokoyama A, 2000, INT ARCH ALLERGY IMM, V123, P327, DOI 10.1159/000053645	44	91	95	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					353	+		10.1016/j.jaci.2012.07.048	http://dx.doi.org/10.1016/j.jaci.2012.07.048			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23006546				2022-12-18	WOS:000314661500011
J	Sherrill, JD; Rothenberg, ME				Sherrill, Joseph D.; Rothenberg, Marc E.			Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; genetics; candidate gene; genome-wide association; polymorphism	THYMIC STROMAL LYMPHOPOIETIN; PROMOTER POLYMORPHISM C-509T; HUMAN EPITHELIAL-CELLS; EXPRESSION PROFILE; ATOPIC-DERMATITIS; COMMON VARIANTS; DENDRITIC CELLS; RISK VARIANTS; PERIOSTIN; FILAGGRIN	Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder of the esophagus that is compounded by both genetic predisposition and aberrant responses to environmental antigens, particularly those that are food derived. Data have indicated a unique transcriptional response in vivo that defines EoE and that appears to be partially attributable to the T(H)2 cytokine IL-13. Moreover, a number of genetic risk variants in proinflammatory and epithelial cell genes associate with EoE susceptibility, demonstrating novel heritable mechanisms that contribute to disease risk. Here we discuss recent advances in our understanding of the intrinsic (genetic) and extrinsic (environmental) components that illustrate the complex nature of EoE. (J Allergy Clin Immunol 2011; 128: 23-32.)	[Sherrill, Joseph D.; Rothenberg, Marc E.] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol, MLC 7028,3333 Burnet Ave, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org	Sherrill, Joseph/B-6662-2014		National Institutes of Health (NIH) [2U19 AI066738, U19 AI070235, R01 DK076893, R37 AI1045898, HL091805]; PHS [P30 DK078392]; Department of Defense; Food Allergy Project; Buckeye Foundation; Campaign Urging Research for Eosinophilic Disease (CURED) Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL091805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI045898, U19AI070235, U19AI066738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076893, P30DK078392] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PHS(United States Department of Health & Human ServicesUnited States Public Health Service); Department of Defense(United States Department of Defense); Food Allergy Project; Buckeye Foundation; Campaign Urging Research for Eosinophilic Disease (CURED) Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported in part by National Institutes of Health (NIH) grants 2U19 AI066738, U19 AI070235, R01 DK076893, and R37 AI1045898; PHS Grant P30 DK078392; the Department of Defense; the Food Allergy Project; the Buckeye Foundation; and the Campaign Urging Research for Eosinophilic Disease (CURED) Foundation. J.D.S. is supported by a T32 NIH training grant (HL091805).	Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Aceves SS, 2010, ALLERGY, V65, P109, DOI 10.1111/j.1398-9995.2009.02142.x; Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; Atkins D, 2009, NAT REV GASTRO HEPAT, V6, P267, DOI 10.1038/nrgastro.2009.45; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Blanchard C, 2006, J ALLERGY CLIN IMMUN, V118, P1054, DOI 10.1016/j.jaci.2006.07.038; Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, P208, DOI 10.1016/j.jaci.2010.10.039; Blanchard C, 2010, J IMMUNOL, V184, P4033, DOI 10.4049/jimmunol.0903069; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373, DOI 10.4049/jimmunol.178.6.3373; Brown-Whitehorn TF, 2010, EXPERT REV CLIN IMMU, V6, P101, DOI [10.1586/eci.09.74, 10.1586/ECI.09.74]; Chae SC, 2004, BIOCHEM BIOPH RES CO, V320, P131, DOI 10.1016/j.bbrc.2004.05.136; Chehade M, 2010, CURR OPIN ALLERGY CL, V10, P231, DOI 10.1097/ACI.0b013e328338cbab; Collins MH, 2008, CLIN GASTROENTEROL H, V6, P621, DOI 10.1016/j.cgh.2008.01.004; Conway SJ, 2008, CURR GENOMICS, V9, P548, DOI 10.2174/138920208786847917; DeBrosse CW, 2010, J ALLERGY CLIN IMMUN, V126, P112, DOI 10.1016/j.jaci.2010.05.027; Dellon ES, 2009, CLIN GASTROENTEROL H, V7, P1305, DOI 10.1016/j.cgh.2009.08.030; Dubois PCA, 2010, NAT GENET, V42, P295, DOI 10.1038/ng.543; El-Serag HB, 2009, SCAND J GASTROENTERO, V44, P787, DOI 10.1080/00365520902898127; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Franciosi JP, 2009, CLIN GASTROENTEROL H, V7, P415, DOI 10.1016/j.cgh.2008.10.006; Franke A, 2008, NAT GENET, V40, P713, DOI 10.1038/ng.148; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Fuentebella J, 2010, J PEDIATR GASTR NUTR, V51, P283, DOI 10.1097/MPG.0b013e3181e0817b; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Gallenberger M, 2011, HUM MOL GENET, V20, P422, DOI 10.1093/hmg/ddq478; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Harada M, 2009, AM J RESP CELL MOL, V40, P368, DOI 10.1165/rcmb.2008-0041OC; Ho SM, 2010, J ALLERGY CLIN IMMUN, V126, P453, DOI 10.1016/j.jaci.2010.07.030; Hunt DM, 2001, EUR J HUM GENET, V9, P197, DOI 10.1038/sj.ejhg.5200605; Hunt KA, 2008, NAT GENET, V40, P395, DOI 10.1038/ng.102; Ichimiya Makoto, 1998, Journal of Dermatology (Tokyo), V25, P195; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Kainu K, 2009, EXP DERMATOL, V18, P109, DOI 10.1111/j.1600-0625.2008.00769.x; Kottke MD, 2006, J CELL SCI, V119, P797, DOI 10.1242/jcs.02888; Li-Kim-Moy JP, 2011, J PEDIATR GASTR NUTR, V52, P147, DOI 10.1097/MPG.0b013e3181ef37a1; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lim EJ, 2011, J BIOL CHEM, V286, P13193, DOI 10.1074/jbc.M110.210724; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Lucendo AJ, 2008, AM J GASTROENTEROL, V103, P2184, DOI 10.1111/j.1572-0241.2008.01937.x; Mao M, 2004, GENOMICS, V83, P989, DOI 10.1016/j.ygeno.2003.12.019; Maruhashi T, 2010, J BIOL CHEM, V285, P13294, DOI 10.1074/jbc.M109.088864; McLean WHI, 2008, J ALLERGY CLIN IMMUN, V121, P1294, DOI 10.1016/j.jaci.2008.02.039; Monemi S, 2005, HUM MOL GENET, V14, P725, DOI 10.1093/hmg/ddi068; Noel RJ, 2005, CURR OPIN PEDIATR, V17, P690, DOI 10.1097/01.mop.0000184291.34654.be; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; O'Regan GM, 2009, J ALLERGY CLIN IMMUN, V124, pR2, DOI 10.1016/j.jaci.2009.07.013; Odze RD, 2009, AM J GASTROENTEROL, V104, P485, DOI 10.1038/ajg.2008.40; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, P976, DOI 10.1016/j.jaci.2010.08.041; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Ronkainen J, 2007, GUT, V56, P615, DOI 10.1136/gut.2006.107714; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; SCHREIBER MH, 1962, GASTROENTEROLOGY, V43, P206; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Sidhu SS, 2010, P NATL ACAD SCI USA, V107, P14170, DOI 10.1073/pnas.1009426107; Silverman ES, 2004, AM J RESP CRIT CARE, V169, P214, DOI 10.1164/rccm.200307-973OC; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Smelter DF, 2010, J IMMUNOL, V185, P3035, DOI 10.4049/jimmunol.1000252; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Snider P, 2008, CIRC RES, V102, P752, DOI 10.1161/CIRCRESAHA.107.159517; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; South AP, 1999, J INVEST DERMATOL, V112, P910, DOI 10.1046/j.1523-1747.1999.00613.x; Spergel JM, 2011, J PEDIATR GASTR NUTR, V52, P300, DOI 10.1097/MPG.0b013e3181eb5a9f; Spergel JM, 2009, J PEDIATR GASTR NUTR, V48, P30, DOI 10.1097/MPG.0b013e3181788282; Stingl C, 2011, J PROTEOME RES, V10, P288, DOI 10.1021/pr100709b; Straumann A, 2005, J ALLERGY CLIN IMMUN, V115, P418, DOI 10.1016/j.jaci.2004.11.006; Togias A, 2010, J ALLERGY CLIN IMMUN, V125, P540, DOI 10.1016/j.jaci.2010.01.040; Tonozuka Y, 2001, CYTOGENET CELL GENET, V93, P23, DOI 10.1159/000056941; Ueda T, 2008, J ALLERGY CLIN IMMUN, V121, P659, DOI 10.1016/j.jaci.2007.10.005; van Heel DA, 2007, NAT GENET, V39, P827, DOI 10.1038/ng2058; Vicario M, 2010, GUT, V59, P12, DOI 10.1136/gut.2009.178020; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Wong CK, 2010, AM J RESP CELL MOL, V43, P305, DOI 10.1165/rcmb.2009-0168OC; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Ziegler SF, 2010, CURR OPIN IMMUNOL, V22, P795, DOI 10.1016/j.coi.2010.10.020; Zuo L, 2010, J IMMUNOL, V185, P660, DOI 10.4049/jimmunol.1000471	82	91	94	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					23	32		10.1016/j.jaci.2011.03.046	http://dx.doi.org/10.1016/j.jaci.2011.03.046			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21570716	Green Accepted			2022-12-18	WOS:000292245600002
J	Young, MC; Munoz-Furlong, A; Sicherer, SH				Young, Michael C.; Munoz-Furlong, Anne; Sicherer, Scott H.			Management of food allergies in schools: A perspective for allergists	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Food allergy; school; anaphylaxis	TREE-NUT-ALLERGY; ANAPHYLACTIC REACTIONS; EPINEPHRINE AUTOINJECTOR; COPING STRATEGIES; YOUNG-CHILDREN; PEANUT ALLERGY; RISK; EPIDEMIOLOGY; PREVALENCE; GUIDELINES	Epidemiologic studies indicate that food allergy has increased among school-aged children and now affects approximately I in 25. Food allergy and other triggers of anaphylaxis pose considerable challenges in the school setting. The cornerstones of management include methods to prevent relevant exposure to allergens and plans to recognize and treat allergic reactions and anaphylaxis. Numerous studies have identified gaps in the implementation of procedures to address these simple tenets. Guidelines and policies have been proposed front various stakeholders to improve the safety and management of schoolchildren with food allergy and anaphylaxis. However, there remain knowledge gaps that preclude suggesting definitive evidence-based guidelines to approach all aspects of management. The allergist plays a key role in guiding families, schools, administrators, and policymakers in developing meaningful plans to improve the safety of the school setting for children with food allergies and anaphylaxis. We review literature that is relevant to key elements that can assist the allergist in addressing patient- and school-specific issues. We additionally focus on areas of current controversy, provide information about available resources, and highlight areas in need of further study. (J Allergy Clin Immunol 2009;124:175-82.)	[Young, Michael C.] Harvard Univ, Div Allergy & Immunol, Sch Med, Childrens Hosp Boston, Boston, MA 02115 USA; [Munoz-Furlong, Anne] Food Allergy & Anaphylaxis Network, Fairfax, VA USA; [Sicherer, Scott H.] Mt Sinai Sch Med, Div Allergy & Immunol, Elliot & Roslyn Jaffe Food Allergy Inst, New York, NY USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Icahn School of Medicine at Mount Sinai	Young, MC (corresponding author), Harvard Univ, Div Allergy & Immunol, Sch Med, Childrens Hosp Boston, Fegan 6,300 Longwood Ave, Boston, MA 02115 USA.	michael.young@childrens.harvard.edu						AAAI Board Directors, 1998, J ALLERGY CLIN IMMUN, V102, P173; *AM AC ALL ASTHM I, 2005, J ALLERGY CLIN IMMUN, V115, pS483; [Anonymous], 2008, ADV SCH CAMPS; Avery NJ, 2003, PEDIAT ALLERG IMM-UK, V14, P378, DOI 10.1034/j.1399-3038.2003.00072.x; Banerjee DK, 2007, ARCH DIS CHILD, V92, P980, DOI 10.1136/adc.2006.113118; Ben-Shoshan M, 2008, ANN ALLERG ASTHMA IM, V100, P570, DOI 10.1016/S1081-1206(10)60056-7; Bischoff S. C., 2003, FOOD ALLERGY ADVERSE, P14; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Bollinger ME, 2006, ANN ALLERG ASTHMA IM, V96, P415, DOI 10.1016/S1081-1206(10)60908-8; Brisman J, 2002, OCCUP ENVIRON MED, V59, P498, DOI 10.1136/oem.59.7.498; *CAN SCH BOARDS AS, 2001, AN HDB SCH BOARDS; de Silva IL, 2008, ALLERGY, V63, P1071, DOI 10.1111/j.1398-9995.2008.01719.x; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Estelle F, 2008, J ALLERGY CLIN IMMUN, V121, pS402, DOI 10.1016/j.jaci.2007.08.061; *FOOD ALL AN NETW, 2009, FOOD ALL ACT PLAN; Furlong TJ, 2001, J ALLERGY CLIN IMMUN, V108, P867, DOI 10.1067/mai.2001.119157; Gold MS, 2000, J ALLERGY CLIN IMMUN, V106, P171, DOI 10.1067/mai.2000.106041; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Jarvinen KM, 2008, J ALLERGY CLIN IMMUN, V122, P133, DOI 10.1016/j.jaci.2008.04.031; Jeebhay MF, 2001, OCCUP ENVIRON MED, V58, P553, DOI 10.1136/oem.58.9.553; Kelso JM, 2006, J ALLERGY CLIN IMMUN, V117, P464, DOI 10.1016/j.jaci.2005.11.015; Kemp SF, 2008, ALLERGY, V63, P1061, DOI 10.1111/j.1398-9995.2008.01733.x; Korenblat P, 1999, ALLERGY ASTHMA PROC, V20, P383, DOI 10.2500/108854199778251834; LEOPOLD D, 1992, OTOLARYNGOLOGY HEAD, P770; Lieberman P, 2005, ANN ALLERG ASTHMA IM, V95, P217, DOI 10.1016/S1081-1206(10)61217-3; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; MAGA JA, 1973, J AGR FOOD CHEM, V21, P22, DOI 10.1021/jf60185a006; Massachusetts Department of Education, 2002, MAN LIF THREAT FOOD; McIntyre CL, 2005, PEDIATRICS, V116, P1134, DOI 10.1542/peds.2004-1475; Mehl A, 2005, ALLERGY, V60, P1440, DOI 10.1111/j.1398-9995.2005.00909.x; Moneret-Vautrin DA, 2001, ALLERGY, V56, P1071, DOI 10.1034/j.1398-9995.2001.00047.x; Munoz-Furlong A, 2004, ANN ALLERG ASTHMA IM, V93, pS47, DOI 10.1016/S1081-1206(10)61732-2; Munoz-Furlong A, 2003, PEDIATRICS, V111, P1654; MUNOZFURLONG A, 1995, SCH FOOD ALLERGY PRO; Norton L, 2008, J ALLERGY CLIN IMMUN, V122, P209, DOI 10.1016/j.jaci.2008.04.020; Novembre E, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.4.e8; Nowak-Wegrzyn A, 2001, ARCH PEDIAT ADOL MED, V155, P790, DOI 10.1001/archpedi.155.7.790; Nurmatov U, 2008, J ALLERGY CLIN IMMUN, V122, P353, DOI 10.1016/j.jaci.2008.05.028; Oren E, 2007, ANN ALLERG ASTHMA IM, V99, P429, DOI 10.1016/S1081-1206(10)60568-6; Perry TT, 2004, J ALLERGY CLIN IMMUN, V113, P973, DOI 10.1016/j.jaci.2004.02.035; Pouessel G, 2006, PEDIAT ALLERG IMM-UK, V17, P221, DOI 10.1111/j.1399-3038.2006.00391.x; Powers Jill, 2007, J Sch Nurs, V23, P252; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Rhim GS, 2001, ANN ALLERG ASTHMA IM, V86, P172, DOI 10.1016/S1081-1206(10)62687-7; Roberts G, 2002, ALLERGY, V57, P713, DOI 10.1034/j.1398-9995.2002.03366.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sampson MA, 2006, J ALLERGY CLIN IMMUN, V117, P1440, DOI 10.1016/j.jaci.2006.03.009; Sheetz AH, 2004, J SCHOOL HEALTH, V74, P155, DOI 10.1111/j.1746-1561.2004.tb08212.x; Sheikh A, 2009, ALLERGY, V64, P204, DOI 10.1111/j.1398-9995.2008.01926.x; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, P1419, DOI 10.1016/j.jaci.2006.01.051; Sicherer SH, 2001, J PEDIATR-US, V138, P560, DOI 10.1067/mpd.2001.111821; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P575, DOI 10.1016/j.jaci.2004.12.1122; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461, DOI 10.1016/S1081-1206(10)62258-2; Sicherer SH, 2002, ANN ALLERG ASTHMA IM, V88, P350, DOI 10.1016/S1081-1206(10)62363-0; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, P186, DOI 10.1016/S0091-6749(99)70133-8; Simons FER, 2008, BMJ-BRIT MED J, V336, P1141, DOI 10.1136/bmj.39547.452153.80; Simons FER, 2007, IMMUNOL ALLERGY CLIN, V27, P231, DOI 10.1016/j.iac.2007.03.007; Simons FER, 2008, J ALLERGY CLIN IMMUN, V122, P1166, DOI 10.1016/j.jaci.2008.10.019; Simons FER, 2002, J ALLERGY CLIN IMMUN, V109, P171, DOI 10.1067/mai.2002.120758; Simonte SJ, 2003, J ALLERGY CLIN IMMUN, V112, P180, DOI 10.1067/mai.2003.1486; Tan BM, 2001, ANN ALLERG ASTHMA IM, V86, P583, DOI 10.1016/S1081-1206(10)62908-0; Uguz A, 2005, CLIN EXP ALLERGY, V35, P746, DOI 10.1111/j.1365-2222.2005.02257.x; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Wainstein BK, 2007, CLIN EXP ALLERGY, V37, P839, DOI 10.1111/j.1365-2222.2007.02726.x; Watura JC, 2002, ARCH DIS CHILD, V86, P240, DOI 10.1136/adc.86.4.240; Weiss Christopher, 2004, J Sch Nurs, V20, P268, DOI 10.1177/10598405040200050501; Wu F, 1998, ALLERGY ASTHMA PROC, V19, P307, DOI 10.2500/108854198778557719; Wuthrich B, 2000, J INVEST ALLERG CLIN, V10, P59; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	74	91	94	1	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					175	182		10.1016/j.jaci.2009.04.004	http://dx.doi.org/10.1016/j.jaci.2009.04.004			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19493563				2022-12-18	WOS:000268860400001
J	Dykewicz, MS				Dykewicz, Mark S.			Occupational asthma: Current concepts in pathogenesis, diagnosis, and management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Occupational asthma; irritant-induced asthma; sensitizer-induced asthma diagnosis; isocyanates; management; guidelines; RADS	DIISOCYANATE-INDUCED ASTHMA; NATURAL-RUBBER LATEX; MONOCYTE CHEMOATTRACTANT PROTEIN-1; EXHALED NITRIC-OXIDE; RED CEDAR ASTHMA; TOLUENE DIISOCYANATE; BAKERS ASTHMA; AIRWAY INFLAMMATION; INDUCED SPUTUM; ONSET ASTHMA	Occupational asthma (OA) may account for 25% or more of de novo adult asthma. The nomenclature has now better defined categories of OA caused by sensitizing agents and irritants, the latter best typified by the reactive airways dysfunction syndrome. Selecting the most appropriate diagnostic testing and management is driven by assessing whether a sensitizer is involved, and if so, identifying whether the sensitizing agent is a high-molecular-weight agent such as a protein or a low-molecular-weight: reactive chemical such as an isocyanate. Increased understanding of the pathogenesis of OA from reactive chemical sensitizers is leading to development of better diagnostic testing and also an understanding of why testing for sensitization to such agents can be problematic. Risk factors for OA including possible genetic factors are being delineated better. Recently published guidelines for the diagnosis and management of occupational asthma are summarized; these reflect an increasingly robust evidence basis for recommendations. The utility of diagnostic tests for OA is being better defined by evidence, including sputum analysis performed in relation to work exposure with suspected sensitizers. Preventive and management approaches are reviewed. Longitudinal studies of patients with OA continue to show that timely removal from exposure leads to the best prognosis. (J Allergy Clin Immunol 2009;123:519-28.)	[Dykewicz, Mark S.] Wake Forest Univ, Bowman Gray Sch Med, Allergy & Immunol Serv, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC 27109 USA	Wake Forest University; Wake Forest Baptist Medical Center	Dykewicz, MS (corresponding author), Wake Forest Univ Hlth Sci, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dykewicz@wfubmc.edu						Allmers H, 2000, INT ARCH OCC ENV HEA, V73, P181, DOI 10.1007/s004200050025; Allmers H, 2002, J ALLERGY CLIN IMMUN, V110, P318, DOI 10.1067/mai.2002.126461; Andersson E, 2003, AM J IND MED, V43, P532, DOI 10.1002/ajim.10203; Anees W, 2002, THORAX, V57, P231, DOI 10.1136/thorax.57.3.231; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; Banauch GI, 2005, CURR OPIN PULM MED, V11, P160, DOI 10.1097/01.mcp.0000151716.96241.0a; BANKS DE, 1990, CHEST, V97, P121, DOI 10.1378/chest.97.1.121; BANKS DE, 1986, CHEST, V89, P389, DOI 10.1378/chest.89.3.389; Bardana EJ, 2008, J ALLERGY CLIN IMMUN, V121, pS408, DOI 10.1016/j.jaci.2007.08.005; BEACH J, 2005, PUBLICATION DEP HLTH; Becklake M, 2003, AM J RESP CRIT CARE, V167, P466; Bernstein DI, 2002, AM J RESP CRIT CARE, V166, P445, DOI 10.1164/rccm.2109018; Bernstein JA, 1997, J ALLERGY CLIN IMMUN, V99, P245, DOI 10.1016/S0091-6749(97)70104-0; Bernstein JA, 2002, J ALLERGY CLIN IMMUN, V110, P35, DOI 10.1067/mai.2002.124891; Boulet LP, 2007, CURR OPIN ALLERGY CL, V7, P96, DOI 10.1097/ACI.0b013e328013ccd8; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; Campo P, 2007, CLIN EXP ALLERGY, V37, P1095, DOI 10.1111/j.1365-2222.2007.02745.x; Chan-Yeung M, 1999, AM J RESP CRIT CARE, V159, P1434, DOI 10.1164/ajrccm.159.5.9807007; Christiani DC, 2008, OCCUP ENVIRON MED, V65, P430, DOI 10.1136/oem.2007.033977; Constantin C, 2008, J IMMUNOL, V180, P7451, DOI 10.4049/jimmunol.180.11.7451; Cristaudo A, 2005, ALLERGY, V60, P159, DOI 10.1111/j.1398-9995.2004.00521.x; ENARSON DA, 1987, AM REV RESPIR DIS, V136, P613, DOI 10.1164/ajrccm/136.3.613; Gautrin D, 2006, ASTHMA WORK PLACE, P581; Girard F, 2004, AM J RESP CRIT CARE, V170, P845, DOI 10.1164/rccm.200403-380OC; Grammer LC, 2002, J OCCUP ENVIRON MED, V44, P1179, DOI 10.1097/00043764-200212000-00013; Grammer LC, 2002, CHEST, V121, P1317, DOI 10.1378/chest.121.4.1317; Herrick CA, 2002, J ALLERGY CLIN IMMUN, V109, P873, DOI 10.1067/mai.2002.123533; Jeal H, 2003, J ALLERGY CLIN IMMUN, V111, P795, DOI 10.1067/mai.2003.176; Jones MG, 2006, J ALLERGY CLIN IMMUN, V117, P663, DOI 10.1016/j.jaci.2005.09.053; Karjalainen A, 2003, CHEST, V123, P283, DOI 10.1378/chest.123.1.283; Kim SH, 2006, ALLERGY, V61, P891, DOI 10.1111/j.1398-9995.2006.01023.x; Kogevinas M, 2007, LANCET, V370, P336, DOI 10.1016/S0140-6736(07)61164-7; Lemiere C, 2002, J ALLERGY CLIN IMMUN, V110, P641, DOI 10.1067/mai.2002.128806; Lemiere C, 2001, J ALLERGY CLIN IMMUN, V107, P1063, DOI 10.1067/mai.2001.115486; Lutz Waldemar, 2004, Int J Occup Med Environ Health, V17, P417; Malo JL, 2007, LANCET, V370, P295, DOI 10.1016/S0140-6736(07)61137-4; Malo JL, 2006, J ALLERGY CLIN IMMUN, V118, P530, DOI 10.1016/j.jaci.2006.04.022; MALO JL, 1991, AM REV RESPIR DIS, V143, P528, DOI 10.1164/ajrccm/143.3.528; Malo JL, 2004, CURR OPIN PULM MED, V10, P57, DOI 10.1097/00063198-200401000-00010; MALO JL, 1993, THORAX, V48, P1211, DOI 10.1136/thx.48.12.1211; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; Mapp CE, 2000, CLIN EXP ALLERGY, V30, P651; Mapp CE, 2005, CURR OPIN ALLERGY CL, V5, P113, DOI 10.1097/01.all.0000162301.74610.21; MAPP CE, 1986, EUR J RESPIR DIS, V68, P89; Mapp CE, 2005, AM J RESP CRIT CARE, V172, P280, DOI 10.1164/rccm.200311-1575SO; Mapp Cristina E, 2005, Acta Biomed, V76 Suppl 2, P15; MARABINI A, 1993, CHEST, V104, P821, DOI 10.1378/chest.104.3.821; Matheson JM, 2005, TOXICOL SCI, V84, P99, DOI 10.1093/toxsci/kfi051; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Newman Taylor Anthony, 2002, Ann Occup Hyg, V46, P563, DOI 10.1093/annhyg/mef079; Nicholson PJ, 2005, OCCUP ENVIRON MED, V62, P290, DOI 10.1136/oem.2004.016287; Padoan M, 2003, EUR RESPIR J, V21, P637, DOI 10.1183/09031936.03.00060703; Palacin A, 2007, J ALLERGY CLIN IMMUN, V120, P1132, DOI 10.1016/j.jaci.2007.07.008; Park HS, 2003, CLIN EXP ALLERGY, V33, P113, DOI 10.1046/j.1365-2222.2003.01563.x; PATTERSON R, 1982, J ALLERGY CLIN IMMUN, V70, P19, DOI 10.1016/0091-6749(82)90196-8; Quirce S, 2000, J ASTHMA, V37, P267, DOI 10.3109/02770900009055449; Quirce S, 2004, CURR OPIN ALLERGY CL, V4, P87, DOI 10.1097/01.all.0000123963.96233.92; Rachiotis G, 2007, THORAX, V62, P147, DOI 10.1136/thx.2006.061952; Rihs HP, 1997, AM J IND MED, V32, P522, DOI 10.1002/(SICI)1097-0274(199711)32:5<522::AID-AJIM13>3.0.CO;2-4; Rioux JP, 2008, EUR RESPIR J, V32, P997, DOI 10.1183/09031936.00100207; Sastre J, 2006, CURR OPIN ALLERGY CL, V6, P96, DOI 10.1097/01.all.0000216851.10571.64; Siracusa A, 2006, CLIN EXP ALLERGY, V36, P577, DOI 10.1111/j.1365-2222.2006.02486.x; Tarlo SM, 2006, EUR RESPIR J, V27, P607, DOI 10.1183/09031936.06.00062105; Tarlo SM, 2005, OCCUP MED-OXFORD, V55, P588, DOI 10.1093/occmed/kqi182; Tarlo SM, 2002, OCCUP ENVIRON MED, V59, P58, DOI 10.1136/oem.59.1.58; Tarlo SM, 2008, CHEST, V134, p1S, DOI 10.1378/chest.08-0201; Taylor AJN, 2003, ANN ALLERG ASTHMA IM, V90, P24; Thulin H, 2002, ANN OCCUP HYG, V46, P61, DOI 10.1093/annhyg/mef022; Vandenplas O, 2005, EUR RESPIR J, V26, P1056, DOI 10.1183/09031936.05.00024705; Vandenplas O, 2001, J ALLERGY CLIN IMMUN, V107, P542, DOI 10.1067/mai.2001.113519; Weichel M, 2006, J ALLERGY CLIN IMMUN, V117, P676, DOI 10.1016/j.jaci.2005.11.040; Wisnewski AV, 2007, CURR OPIN ALLERGY CL, V7, P138, DOI 10.1097/ACI.0b013e3280895d22; Ye YM, 2006, J ALLERGY CLIN IMMUN, V118, P885, DOI 10.1016/j.jaci.2006.06.026	73	91	93	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					519	528		10.1016/j.jaci.2009.01.061	http://dx.doi.org/10.1016/j.jaci.2009.01.061			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19281900				2022-12-18	WOS:000264731200007
J	Malo, JL; Chan-Yeung, M				Malo, Jean-Luc; Chan-Yeung, Moira			Agents causing occupational asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma in the workplace; occupational asthma; irritant-induced asthma	NESTED CASE-CONTROL; PROCESSING WORKERS; SENSITIZATION; DETERMINANTS; APPRENTICES; PREVENTION; EXPOSURE; SALTS	The workplace is a significant contributor to the burden of asthma. Although the majority of cases probably represent what is labeled work-exacerbated asthma, in a significant number of subjects, asthma is actually caused by 1 or more agents present in the workplace; this is occupational asthma. Two types of occupational asthma are distinguished, according to whether the asthma appears after a latency period. This article discusses (1) two types of agents causing asthma with a latency period and acting through an apparently immunologic mechanism (high-molecular-weight agents and low-molecular-weight agents) and (2) agents causing asthma without a latency period. (J Allergy Clin Immunol 2009;123:545-50.)	[Malo, Jean-Luc] Univ Montreal, Montreal, PQ H3C 3J7, Canada; [Malo, Jean-Luc] Hop Sacre Coeur, Montreal, PQ, Canada; [Chan-Yeung, Moira] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	Universite de Montreal; Universite de Montreal; University of British Columbia	Malo, JL (corresponding author), 5400 Gouin Blvd W, Montreal, PQ H4J 1C5, Canada.	malojl@meddir.umontreal.ca						ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; Bernstein I. L., 2006, ASTHMA WORKPLACE, V3, P1; Blanc PD, 1999, AM J MED, V107, P580, DOI 10.1016/S0002-9343(99)00307-1; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; BURGE PS, 1981, THORAX, V36, P828, DOI 10.1136/thx.36.11.828; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; Chan-Yeung M, 2006, ASTHMA WORKPLACE, P641; Chan-Yeung M, 2006, ASTHMA WORKPLACE, P505; Gautrin D, 2000, AM J RESP CRIT CARE, V162, P1222, DOI 10.1164/ajrccm.162.4.2001023; Gautrin D, 2002, ALLERGY, V57, P913, DOI 10.1034/j.1398-9995.2002.23636.x; Gautrin D, 2006, ASTHMA WORKPLACE, P579; Gautrin D, 2008, AM J RESP CRIT CARE, V177, P871, DOI 10.1164/rccm.200707-991OC; Gordon S, 2006, ASTHMA WORKPLACE, P415; HEEDERIK D, 2006, ASTHMA WORKPLACE, P393; Henneberger PK, 2007, CURR OPIN ALLERGY CL, V7, P146, DOI 10.1097/ACI.0b013e328054c640; Houba R, 1998, AM J RESP CRIT CARE, V158, P1499, DOI 10.1164/ajrccm.158.5.9803055; Howse D, 2006, ENVIRON RES, V101, P163, DOI 10.1016/j.envres.2005.06.008; Jarvis J, 2005, OCCUP ENVIRON MED, V62, P243, DOI 10.1136/oem.2004.016402; Jeebhay MF, 2004, OCCUP ENVIRON MED, V61, P471, DOI 10.1136/oem.2002.001099; JUNIPER CP, 1977, J SOC OCCUP MED, V27, P3; Kogevinas M, 2007, LANCET, V370, P336, DOI 10.1016/S0140-6736(07)61164-7; KONGERUD J, 1994, EUR RESPIR J, V7, P165, DOI 10.1183/09031936.94.07010165; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; Medina-Ramon M, 2005, OCCUP ENVIRON MED, V62, P598, DOI 10.1136/oem.2004.017640; Merget R, 2001, J ALLERGY CLIN IMMUN, V107, P707; Monso E, 2004, CURR OPIN PULM MED, V10, P147, DOI 10.1097/00063198-200403000-00010; PATTERSON R, 1982, J ALLERGY CLIN IMMUN, V70, P19, DOI 10.1016/0091-6749(82)90196-8; PEPYS J, 1984, CLIN IMMUNOL ALLERGY, V4, P131; PEPYS J, 2006, ASTHMA WORKPLACE, P9; Piipari R, 2005, CLIN EXP ALLERGY, V35, P1632, DOI 10.1111/j.1365-2222.2005.02386.x; Tarlo SM, 2005, OCCUP MED-OXFORD, V55, P588, DOI 10.1093/occmed/kqi182; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201	33	91	92	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					545	550		10.1016/j.jaci.2008.09.010	http://dx.doi.org/10.1016/j.jaci.2008.09.010			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	18951622				2022-12-18	WOS:000264731200009
J	Stensballe, LG; Simonsen, JB; Thomsen, SF; Larsen, AMH; Lysdal, SH; Aaby, P; Kyvik, KO; Skytthe, A; Backer, V; Bisgaard, H				Stensballe, Lone Graff; Simonsen, Jacob Brunbjerg; Thomsen, Simon Francis; Larsen, Anne-Marie Hellesoe; Lysdal, Susan Hovmand; Aaby, Peter; Kyvik, Kirsten Ohm; Skytthe, Axel; Backer, Vibeke; Bisgaard, Hans			The causal direction in the association between respiratory syncytial virus hospitalization and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; child; epidemiology; respiratory syncytial virus; twins	INFECTION REQUIRING HOSPITALIZATION; EARLY-LIFE; LUNG-FUNCTION; AGE 13; CHILDREN; BRONCHIOLITIS; RISK; EPIDEMIOLOGY; SYMPTOMS; INFANTS	Background: Earlier studies have reported an increased risk of asthma after respiratory syncytial virus (RSV) hospitalization. Other studies found that asthmatic disposition and propensity to wheeze increase the risk of RSV hospitalization. Objective: The current study examined the causal direction of the associations between RSV hospitalization and asthma in a population-based cohort of twins. Methods: We conducted a prospective cohort study examining the associations between RSV hospitalization and asthma by using registry information on RSV hospitalization and asthma among 18,614 Danish twins born 1994 to 2003. The associations between RSV and asthma were examined in both directions: we examined the risk of asthma after RSV hospitalization, and the risk of RSV hospitalization in children with asthma in the same population-based cohort. Results: Asthma hospitalization after RSV hospitalization was increased as much as 6-fold to 8-fold during the first 2 months after RSV hospitalization but was no longer increased 1 year later. Asthma increased the risk of RSV hospitalization by 3-fold, and the risk was not time-dependent. Analyzing these associations on the basis of asthma defined from use of inhaled corticosteroid did not materially change the risk estimates. Conclusion: There is a bidirectional association between severe RSV infection and asthma. Severe RSV infection is associated with a short-term increase in the risk of subsequent asthma, suggesting that RSV induce bronchial hyperresponsiveness; and asthma is associated with a long-term increased susceptibility for severe RSV disease, suggesting a host factor being responsible for the severe response to RSV infection. This suggests that severe RSV infection and asthma may share a common genetic predisposition and/or environmental exposure. (J Allergy Clin Immunol 2009;123:131-7.)	[Stensballe, Lone Graff; Aaby, Peter] Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen S, Denmark; [Simonsen, Jacob Brunbjerg] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark; [Kyvik, Kirsten Ohm; Skytthe, Axel] Univ So Denmark, Inst Publ Hlth, Danish Twin Registry, Odense, Denmark; [Stensballe, Lone Graff; Larsen, Anne-Marie Hellesoe; Lysdal, Susan Hovmand; Bisgaard, Hans] Univ Hosp Gentofte, Danish Pediat Asthma Ctr, Copenhagen, Denmark; [Thomsen, Simon Francis; Backer, Vibeke] Bispebjerg Hosp, Dept Resp Med, DK-2400 Copenhagen, Denmark; [Kyvik, Kirsten Ohm] Univ So Denmark, Inst Reg Hlth Res, Odense, Denmark	Statens Serum Institut; Statens Serum Institut; University of Southern Denmark; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Bispebjerg Hospital; University of Southern Denmark	Stensballe, LG (corresponding author), Statens Serum Inst, Bandim Hlth Project, Artillerivej 5, DK-2300 Copenhagen S, Denmark.	LGN@ssi.dk	Skytthe, Axel E/G-4820-2019; Bisgaard, Hans/N-4761-2016; Kronow, Joern/B-1054-2011; Stensballe, Lone Graff/AAS-4137-2020; Backer, Vibeke/AAQ-9379-2021; Backer, Vibeke/I-9573-2014; Kyvik, Kirsten O/K-5680-2016	Skytthe, Axel E/0000-0002-8629-4913; Bisgaard, Hans/0000-0003-4131-7592; Stensballe, Lone Graff/0000-0003-1569-153X; Backer, Vibeke/0000-0002-7806-7219; Kyvik, Kirsten O/0000-0003-2981-0245; Aaby, Peter/0000-0001-8331-1389; Simonsen, Jacob/0000-0002-8700-4826	Lundbeck Foundation; Augustinus Foundation; MedImmune	Lundbeck Foundation(Lundbeckfonden); Augustinus Foundation; MedImmune(AstraZenecaMedimmune)	supported by the Lundbeck Foundation, the Augustinus Foundation, and an unrestricted institutional grant from MedImmune.	Andersen TF, 1999, DAN MED BULL, V46, P263; Bloomfield P., 1976, FOURIER ANAL TIME SE; Castro-Rodriguez JA, 1999, AM J RESP CRIT CARE, V159, P1891, DOI 10.1164/ajrccm.159.6.9811035; Christiansen L, 2003, TWIN RES, V6, P275, DOI 10.1375/136905203322296610; COLLINS PL, 2001, FIELDS VIROLOGY, P1443; *DIV HLTH PROM DIS, 1985, NEW VACCINE DEV, V1, P397; Eriksson M, 2000, PEDIAT ALLERG IMM-UK, V11, P193, DOI 10.1034/j.1399-3038.2000.00076.x; Figueras-Aloy J, 2004, PEDIATR INFECT DIS J, V23, P815, DOI 10.1097/01.inf.0000136869.21397.6b; GLEZEN WP, 1973, NEW ENGL J MED, V288, P498, DOI 10.1056/NEJM197303082881005; Goetghebuer T, 2004, PEDIATR PULM, V38, P321, DOI 10.1002/ppul.20069; Kristensen K, 1998, PEDIATR INFECT DIS J, V17, P996, DOI 10.1097/00006454-199811000-00006; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; LANE DJ, 1996, OXFORD TXB MED, P2729; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McBride JT, 1999, J PEDIATR-US, V135, pS28; MEISSNER HC, 1994, J PEDIATR-US, V124, pS17, DOI 10.1016/S0022-3476(94)70186-5; Murray CS, 2002, THORAX, V57, P388, DOI 10.1136/thorax.57.5.388; Pedersen CB, 2006, DAN MED BULL, V53, P441; PLOVSING J, 2006, FRAM ACT STAT DENM S; SELWYN BJ, 1990, REV INFECT DIS, V12, pS870; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; SIGURS N, 1995, PEDIATRICS, V95, P500; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stensballe LG, 2005, SCAND J INFECT DIS, V37, P747, DOI 10.1080/00365540510012107; Stensballe LG, 2006, PEDIATRICS, V118, pE1360, DOI 10.1542/peds.2006-0907; Thomsen SF, 2008, PEDIATRICS, V121, P493, DOI 10.1542/peds.2007-1889; Trefny P, 2000, PEDIATR PULM, V30, P302, DOI 10.1002/1099-0496(200010)30:4<302::AID-PPUL5>3.0.CO;2-R; Turner SW, 2002, ARCH DIS CHILD, V87, P417, DOI 10.1136/adc.87.5.417; Warren P, 2006, LANCET, V368, P1416, DOI 10.1016/S0140-6736(06)69596-2; Young S, 2000, EUR RESPIR J, V15, P151, DOI 10.1034/j.1399-3003.2000.15a28.x	31	91	97	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					131	137		10.1016/j.jaci.2008.10.042	http://dx.doi.org/10.1016/j.jaci.2008.10.042			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19130934				2022-12-18	WOS:000262793900022
J	Wu, Y; Farrell, J; Pirmohmed, M; Park, BK; Naisbitt, DJ				Wu, Ying; Farrell, John; Pirmohmed, Munir; Park, B. Kevin; Naisbitt, Dean J.			Generation and characterization of antigen-specific CD4(+), CD8(+), and CD4(+)CD8(+) T-cell clones from patients with carbamazopine hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						drug allergy; T cells; anticonvulsant hypersensitivity syndrome	TOXIC EPIDERMAL NECROLYSIS; DRUG-SPECIFIC CD4(+); IMMUNE SURVEILLANCE; CROSS-REACTIVITY; SKIN; CARBAMAZEPINE; RECOGNITION; LYMPHOCYTES; INVOLVEMENT; ACTIVATION	Background: Hypersensitivity is a serious manifestation of anticonvulsant therapy characterized by infiltration of the epidermis and dermis by activated CD8(+) and CD4(+) T-cells, respectively. Attempts to characterize drug-specific CD8(+) T cells have been largely unsuccessful. Objectives: The aim of these studies was to generate and characterize CD4(+), CD8(+), and CD4(+)CD8(+) T cells in patients with carbamazepine hypersensitivity. Methods: Carbamazepine-specific T-cell clones were generated from 5 patients by using modified cloning methodologies. Cell surface receptor phenotype, functionality, and mechanisms of antigen presentation were then compared. Results: Ninety CD4(+), 23 CD8(+), and 14 CD4(+)CD8(+) carbamazepine-specific T-cell clones were generated. CD4(+) T-cell clones proliferated vigorously with carbamazepine associated with MHC class II but exhibited little cytotoxic activity. In contrast, most CD8(+) T cells proliferated weakly but effectively killed target cells via an MHC class I or MHC class II restricted, perforin-dependent pathway. CD4(+)CD8(+) T cells displayed characteristics similar to those of CD4(+) T cells; however? drug stimulation was demonstrable in the absence of antigen-presenting cells. Carbamazepine was presented to CD4(+), CD8(+), and CD4+CD8+ T cells in the absence of antigen processing. Drug stimulation resulted in the secretion of IFN-gamma and IL-5. A panel of CD11a(+)CD27(-) clones differentially expressed the receptors CXCR4, CCR4, CCR5, CCR8, CCR9. and CCR10. Conclusion: Carbamazepine-specific CD4+, CD8+, and CD4(+)CD8(+) T cells exist in the peripheral circulation of hyersensitive patients, often many years after the. P resolution of clinical manifestations. Clinical implications: Carbamazepine-specific CD4(+), CD8(+), and CD4(+)CD8(+) T cells displaying different effector functions and homing characteristics persist in hypersensitive patients' blood for many, years after resolution of clinical symptoms.	Univ Liverpool, Dept Pharmacol, Liverpool L69 3GE, Merseyside, England	University of Liverpool	Naisbitt, DJ (corresponding author), Univ Liverpool, Dept Pharmacol, Sherrington Bldg,Ashton St, Liverpool L69 3GE, Merseyside, England.	dnes@liv.ac.uk	Pirmohamed, Munir/H-6004-2011	Pirmohamed, Munir/0000-0002-7534-7266; Farrell, John/0000-0002-8726-5997; Naisbitt, Dean/0000-0003-4107-7832	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bang K, 2001, BRIT J DERMATOL, V144, P1140, DOI 10.1046/j.1365-2133.2001.04223.x; Beeler A, 2006, J ALLERGY CLIN IMMUN, V117, P455, DOI 10.1016/j.jaci.2005.10.030; Britschgi M, 2001, J CLIN INVEST, V107, P1433, DOI 10.1172/JCI12118; Clark RA, 2006, J IMMUNOL, V176, P4431, DOI 10.4049/jimmunol.176.7.4431; DEMARIA A, 1987, EUR J IMMUNOL, V17, P1815, DOI 10.1002/eji.1830171221; Depta JPH, 2004, J ALLERGY CLIN IMMUN, V113, P519, DOI 10.1016/j.jaci.2003.11.030; FRIEDMANN PS, 1994, ARCH DERMATOL, V130, P598, DOI 10.1001/archderm.130.5.598; Gogtay Nithya J, 2005, Expert Opin Drug Saf, V4, P571; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Hari Y, 2001, CLIN EXP ALLERGY, V31, P1398, DOI 10.1046/j.1365-2222.2001.01164.x; Hashizume H, 2005, ACTA DERM-VENEREOL, V85, P47, DOI 10.1080/00015550410024094; Hashizume H, 2002, J IMMUNOL, V168, P5359, DOI 10.4049/jimmunol.168.10.5359; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Hudak S, 2002, J IMMUNOL, V169, P1189, DOI 10.4049/jimmunol.169.3.1189; Kuechler PC, 2004, ALLERGY, V59, P613, DOI 10.1111/j.1398-9995.2004.00460.x; LANG F, 1995, J IMMUNOL, V154, P5986; Leyva L, 2000, J ALLERGY CLIN IMMUN, V105, P157, DOI 10.1016/S0091-6749(00)90191-X; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; Moed H, 2004, J PATHOL, V204, P39, DOI 10.1002/path.1619; MORITA CT, 1995, IMMUNITY, V3, P495, DOI 10.1016/1074-7613(95)90178-7; Morita CT, 2001, IMMUNITY, V14, P331, DOI 10.1016/S1074-7613(01)00113-3; Naisbitt DJ, 2004, TOXICOLOGY, V194, P179, DOI 10.1016/j.tox.2003.09.004; Naisbitt DJ, 2003, J ALLERGY CLIN IMMUN, V111, P1393, DOI 10.1067/mai.2003.1507; Naisbitt DJ, 2003, MOL PHARMACOL, V63, P732, DOI 10.1124/mol.63.3.732; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; PALIARD X, 1988, NATURE, V335, P642, DOI 10.1038/335642a0; Pichler WJ, 2002, CURR OPIN ALLERGY CL, V2, P301, DOI 10.1097/00130832-200208000-00003; Pichler Werner J, 2002, Am J Clin Dermatol, V3, P229, DOI 10.2165/00128071-200203040-00001; Pichler WJ, 2004, ALLERGY, V59, P809, DOI 10.1111/j.1398-9995.2004.00547.x; Schaerli P, 2004, J EXP MED, V199, P1265, DOI 10.1084/jem.20032177; Schmid DA, 2006, MOL PHARMACOL, V70, P356, DOI 10.1124/mol.105.021576; Schnyder B, 1997, J CLIN INVEST, V100, P136, DOI 10.1172/JCI119505; Schnyder B, 2000, J IMMUNOL, V164, P6647, DOI 10.4049/jimmunol.164.12.6647; Sieben S, 2002, J ALLERGY CLIN IMMUN, V109, P1005, DOI 10.1067/mai.2002.123872; Soler D, 2003, BLOOD, V101, P1677, DOI 10.1182/blood-2002-07-2348; Tapia B, 2004, J ALLERGY CLIN IMMUN, V114, P335, DOI 10.1016/j.jaci.2004.04.034; Vestergaard C, 2003, BRIT J DERMATOL, V149, P457, DOI 10.1046/j.1365-2133.2003.05505.x; Wu Y, 2006, J ALLERGY CLIN IMMUN, V118, P233, DOI 10.1016/j.jaci.2006.03.005; Zanni MP, 1997, J IMMUNOL, V158, P1139	39	91	96	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					973	981		10.1016/j.jaci.2006.12.617	http://dx.doi.org/10.1016/j.jaci.2006.12.617			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17320939				2022-12-18	WOS:000245729500029
J	Vonakis, BM; Vasagar, K; Gibbons, SP; Gober, L; Sterba, PM; Chang, HY; Saini, SS				Vonakis, Becky M.; Vasagar, Kavitha; Gibbons, Scott P., Jr.; Gober, Laura; Sterba, Patricia M.; Chang, Hyeyoun; Saini, Sarbjit S.			Basophil Fc epsilon RI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophils; SHIP-1; SHIP-2; CIU; Fc epsilon RI	ANTI-IGE AUTOANTIBODIES; IN-VIVO; DISEASE SEVERITY; SHIP; RECEPTOR; ALPHA; CELLS; IDENTIFICATION; RELEASABILITY; MACROPHAGES	Background: Basophils are implicated in the pathogenesis of chronic idiopathic urticaria (CIU). Autoantibodies to the IgE receptor (Fc epsilon RI) and serum histamine releasing activity have been detected in some subjects with CIU, although their role in vivo is unclear. Basophils of patients with CIU have altered Fc epsilon RI-mediated histamine release (HR); however, the mechanism is unknown. In the basophil Fc epsilon RI signaling pathway, protein levels of Src-homology 2-containing-5'-inositol phosphatase (SHIP)-1 are inversely correlated with the release of mediators or releasability. A related phosphatase, SHIP-2, is a negative regulator of monocyte IgG receptor (Fc gamma R) signaling. We hypothesized that SHIP levels are altered in CIU basophils. Methods: Blood basophils were isolated from cold urticaria, CIU, or normal donors, and Fc epsilon RI-dependent and independent HR were quantified. Protein levels of SHIP-1, SHIP-2, spleen tyrosine kinase, and phosphorylated Akt were determined by Western blotting. Subjects' serum was tested for serum histamine releasing activity and anti-Fc epsilon RI alpha antibodies. Results: CIU basophils displayed a bimodal response to anti-IgE activation. One half of CIU subjects' basophils had reductions in anti-IgE-induced HR and were designated nonresponders (CIU NR). CIU NR basophil HR remained diminished at 10-fold to 30-fold higher doses of anti-IgE. CIU anti-IgE responder basophils had HR similar to normal subjects. SHIP-1 and SHIP-2 proteins were increased in CIU NR basophils and were linked to reduced phosphoAkt after anti-IgE stimulation. CIU basophil anti-IgE response was not related to the presence of serologic factors. Conclusion: In CIU basophils, the observed changes in Fc epsilon RI signaling pathway molecule expression may underlie changes in releasability. Clinical implications: Patients with CIU can be segregated on the basis of basophil functional phenotype.	Johns Hopkins Univ, Med Ctr, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD 21218 USA	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Saini, SS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	ssaini@jhmi.edu	Vonakis, Becky/GSN-7958-2022	Vonakis, Becky/0000-0003-4174-6514	NIAID NIH HHS [AI49288, AI01564, K08 AI001564-05] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001564, K22AI049288] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ai J, 2006, BLOOD, V107, P813, DOI 10.1182/blood-2005-05-1841; Baker R, 2006, J ALLERGY CLIN IMMUN, V117, pS123, DOI 10.1016/j.jaci.2005.12.494; Caproni M, 2005, CLIN IMMUNOL, V114, P284, DOI 10.1016/j.clim.2004.10.007; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; GILBERT HS, 1975, BLOOD, V46, P279; Grattan CEH, 1997, CLIN EXP ALLERGY, V27, P1417, DOI 10.1111/j.1365-2222.1997.tb02986.x; Grattan CEH, 2001, J INVEST DERM SYMP P, V6, P139, DOI 10.1046/j.0022-202x.2001.00027.x; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; Kaplan AP, 2004, J ALLERGY CLIN IMMUN, V114, P465, DOI 10.1016/j.jaci.2004.02.049; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; Kikuchi Y, 2002, J ALLERGY CLIN IMMUN, V109, P114, DOI 10.1067/mai.2002.120954; Lavens-Phillips SE, 2000, AM J RESP CELL MOL, V23, P566, DOI 10.1165/ajrcmb.23.4.4123; Lu Yiling, 2003, Rev Clin Exp Hematol, V7, P205; MACDONALD SM, 1995, SCIENCE, V269, P688, DOI 10.1126/science.7542803; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MACGLASHAN DW, 2007, IN PRESS J ALLERGY C; Miescher Sylvia M., 2001, Human Antibodies, V10, P119; Miura K, 2001, J IMMUNOL, V167, P7027, DOI 10.4049/jimmunol.167.12.7027; Pengal RA, 2003, J BIOL CHEM, V278, P22657, DOI 10.1074/jbc.M302907200; Rauh MJ, 2002, CLIN INVEST MED, V25, P68; Rohrschneider LR, 2000, GENE DEV, V14, P505; Sabroe RA, 1999, J ALLERGY CLIN IMMUN, V103, P484, DOI 10.1016/S0091-6749(99)70475-6; Sabroe RA, 2002, J ALLERGY CLIN IMMUN, V110, P492, DOI 10.1067/mai.2002.126782; Sabroe RA, 1998, J ALLERGY CLIN IMMUN, V102, P651, DOI 10.1016/S0091-6749(98)70283-0; Saini S. S., 2004, Journal of Allergy and Clinical Immunology, V113, pS89, DOI 10.1016/j.jaci.2003.12.302; Saini SS, 2001, J ALLERGY CLIN IMMUN, V107, P832, DOI 10.1067/mai.2001.114653; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; Sly LM, 2004, IMMUNITY, V21, P227, DOI 10.1016/j.immuni.2004.07.010; Sly LM, 2003, EXP HEMATOL, V31, P1170, DOI 10.1016/j.exphem.2003.09.011; Soundararajan S, 2005, J ALLERGY CLIN IMMUN, V115, P815, DOI 10.1016/j.jaci.2004.12.1120; Valderrama-Carvajal H, 2002, NAT CELL BIOL, V4, P963, DOI 10.1038/ncb885; Vasagar K, 2006, CLIN EXP ALLERGY, V36, P770, DOI 10.1111/j.1365-2222.2006.02494.x; Vonakis BM, 2005, J IMMUNOL, V175, P4543, DOI 10.4049/jimmunol.175.7.4543; Vonakis BM, 2001, J ALLERGY CLIN IMMUN, V108, P822, DOI 10.1067/mai.2001.119159; Wofsy C, 1999, P NATL ACAD SCI USA, V96, P8615, DOI 10.1073/pnas.96.15.8615; Ying S, 2002, J ALLERGY CLIN IMMUN, V109, P694, DOI 10.1067/mai.2002.123236	43	91	94	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					441	448		10.1016/j.jaci.2006.09.035	http://dx.doi.org/10.1016/j.jaci.2006.09.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17125820				2022-12-18	WOS:000244327900024
J	van Schalkwyk, E; Strydom, K; Williams, Z; Venter, L; Leichtl, S; Schmid-Wirlitsch, C; Bredenbroker, D; Bardin, PG				van Schalkwyk, E; Strydom, K; Williams, Z; Venter, L; Leichtl, S; Schmid-Wirlitsch, C; Bredenbroker, D; Bardin, PG			Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; roflumilast; phosphodiesterase type 4; allergen provocation; inflammation; late phase	BRONCHIAL-ASTHMA; INHALED ALLERGEN; PDE4 INHIBITOR; CHALLENGE; RESPONSES; INFLAMMATION; SALMETEROL; MONTELUKAST; AIRWAYS; MODEL	Background: Asthma is a chronic inflammatory disease with increasing incidence worldwide. Roflumilast is an oral, once-daily inhibitor of phosphodiesterase type 4 that prevents the breakdown of cyclic adenosine monophosphate levels, leading to inhibition of proinflammatory signaling. Objective: The objective of this study was to investigate the effects of repeated doses of 250 or 500 mu g of roflumilast on asthmatic airway responses to allergen. Methods: Twenty-three patients with mild asthma with an FEV1 of 70% of predicted value or greater were enrolled in a randomized, double-blind, placebo-controlled, 3-period crossover study. Patients participated in 3 treatment periods (7-10 days) separated by washout periods (2-5 weeks). Patients received 250 jig of oral roflumilast, 500 mu g of roflumilast, or placebo once daily. Allergen challenge was performed at the end of each treatment period, followed by FEV1 measurements over the ensuing 24 hours. Results: Late asthmatic reactions (LARs) were reduced by 27% (P = .0110) and 43 % (P = .0009) in patients treated with 250 and 500 mu g of roflumilast, respectively, versus placebo. Roflumilast, 250 and 500 mu g, also attenuated early asthmatic reactions by 25 % (P = .0038) and 28 % (P = .0046), although not to the same extent as LAR attenuation. Roflumilast was well tolerated. No serious adverse events or discontinuations caused by adverse events were reported. Conclusion: Once-daily oral roflumilast modestly attenuated early asthmatic reactions and, to a greater extent, LARs to allergen in patients with mild allergic asthma. Pronounced suppression of late responses in an allergen challenge model suggests that roflumilast might have anti-inflammatory activity, which could provide clinical efficacy in chronic inflammatory pulmonary diseases, such as asthma.	Monash Med Ctr, Melbourne, Vic 3168, Australia; Monash Univ, Monash Ctr Inflammatory Dis, Melbourne, Vic 3168, Australia; Univ Stellenbosch, Dept Internal Med, Cape Town, South Africa; ALTANA Madaus Ltd, Rivonia, Germany; ALTANA Pharma AG, Constance, Germany	Monash University; Monash University; Stellenbosch University; Altana	Bardin, PG (corresponding author), Monash Med Ctr, 246 Clayton Rd, Melbourne, Vic 3168, Australia.	p.bardin@southemhealth.org.au						Adams BK, 2003, EMERG MED CLIN N AM, V21, P315, DOI 10.1016/S0733-8627(03)00015-4; Adcock IM, 2003, J ENDOCRINOL, V178, P347, DOI 10.1677/joe.0.1780347; American Lung Association Epidemiology and Statistics Unit, TRENDS ASTHM MORB MO; Bardin PG, 1998, BRIT J CLIN PHARMACO, V45, P387, DOI 10.1046/j.1365-2125.1998.00689.x; Bundschuh DS, 2001, J PHARMACOL EXP THER, V297, P280; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1988, J ALLERGY CLIN IMMUN, V81, P111, DOI 10.1016/0091-6749(88)90229-1; Dente FL, 2004, PULM PHARMACOL THER, V17, P147, DOI 10.1016/j.pupt.2004.01.005; Dykewicz MS, 2001, ALLERGY ASTHMA PROC, V22, P11, DOI 10.2500/108854101778249230; ENGELSTATTER R, 2004, 2004 ACAAI M NOV 12; Essayan DM, 1999, BIOCHEM PHARMACOL, V57, P965, DOI 10.1016/S0006-2952(98)00331-1; Hatzelmann A, 2001, J PHARMACOL EXP THER, V297, P267; Hofstra WB, 1997, THORAX, V52, P739, DOI 10.1136/thx.52.8.739; IZQUIERDO JL, 2003, AM J RESP CRIT CARE, V167, pA765; Kidney JC, 1997, J ALLERGY CLIN IMMUN, V100, P65, DOI 10.1016/S0091-6749(97)70196-9; Larsen BB, 2003, ALLERGY, V58, P207, DOI 10.1034/j.1398-9995.2003.00052.x; LARSEN GL, 1987, FASEB J, V46, P105; LEICHTL S, 2002, EUR RESP J S38, V20, pS303; Leigh R, 2002, AM J RESP CRIT CARE, V166, P1212, DOI 10.1164/rccm.200206-509OC; *NAT I HLTH NAT HE, GLOB STRAT ASTHM MAN; NELL H, 2000, AM J RESP CRIT CARE, V161, pA200; Neri M, 2000, THORAX, V55, pS57, DOI 10.1136/thorax.55.suppl_2.S57; Niimi A, 1996, J ALLERGY CLIN IMMUN, V97, P1308, DOI 10.1016/S0091-6749(96)70200-2; Palmqvist M, 2005, ALLERGY, V60, P65, DOI 10.1111/j.1398-9995.2005.00633.x; Pizzichini MMM, 1996, EUR RESPIR J, V9, P449, DOI 10.1183/09031936.96.09030449; ROSSI GA, 1991, AM REV RESPIR DIS, V144, P379, DOI 10.1164/ajrccm/144.2.379; Spector S, 2000, J ASTHMA, V37, P381, DOI 10.3109/02770900009055463; Timmer W, 2002, J CLIN PHARMACOL, V42, P297, DOI 10.1177/00912700222011328; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; WEERSINK EJM, 1994, AM J RESP CRIT CARE, V150, P1262, DOI 10.1164/ajrccm.150.5.7952550; *WHO, 206 WHO	31	91	92	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					292	298		10.1016/j.jaci.2005.04.023	http://dx.doi.org/10.1016/j.jaci.2005.04.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083782				2022-12-18	WOS:000235686400008
J	Novak, N; Kruse, S; Potreck, J; Maintz, L; Jenneck, C; Weidinger, S; Fimmers, R; Bieber, T				Novak, N; Kruse, S; Potreck, J; Maintz, L; Jenneck, C; Weidinger, S; Fimmers, R; Bieber, T			Single nucleotide polymorphisms of the IL18 gene are associated with atopic eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-18; IgE; atopic eczema; allergy; polymorphism	IFN-GAMMA; T-CELLS; IL-18; INTERLEUKIN-18; DERMATITIS; ASTHMA; TH1; ORGANIZATION; EXPRESSION; CYTOKINE	Background: Human IL-18 is an inflammatory cytokine that plays a role in atopic diseases, such as atopic eczema (AE), by enhancing IL-4 and IL-13 production and stimulating the synthesis of IgE. Objective: To evaluate associations of polymorphisms in the 11,18 gene on chromosome 11q22 with AE, we performed genotyping for single nucleotide polymorphisms (SNPs) in the IL18 gene in 225 patients with AE and 175 healthy control volunteers. Methods: Genotyping was performed by means of restriction fragment length polymorphism analysis. Results: Analyses revealed significant associations of SNPs +113[t/g] and +127[c/t] in exon 1, -137[g/c] in promoter region 1, and - t33[c/g] in promoter region 2 with AE. These associations were not directly dependent on a specific subtype of AE or the concomitant manifestation of allergic rhinitis or asthma. On the functional level, the amount of IL-18 in the supernatants of PBMCs of patients with AE stimulated with Staphylococcus aureus enterotoxin B was significantly higher than that in healthy control subjects. In parallel, the amount of active IL-18 in the sera of patients with AE was enhanced at the exacerbation of their disease. Conclusion: In conclusion, our data suggest that SNPs in the IL18 gene might be involved in the development of AE by contributing to a functional dysregulation of the IL-18 production in vivo.	Univ Bonn, Dept Dermatol, D-53105 Bonn, Germany; Univ Bonn, Dept Med Biometry Informat & Epidemiol, D-53105 Bonn, Germany; Hannover Med Sch, D-3000 Hannover, Germany; Tech Univ Munich, Dept Dermatol, D-8000 Munich, Germany	University of Bonn; University of Bonn; Hannover Medical School; Technical University of Munich	Novak, N (corresponding author), Univ Bonn, Dept Dermatol, Sigmund Freud Str 25, D-53105 Bonn, Germany.	Natalija.Novak@ukb.uni-bonn.de	Weidinger, Stephan/C-8461-2011	Weidinger, Stephan/0000-0003-3944-252X				Diepgen TL, 1996, J CLIN EPIDEMIOL, V49, P1031, DOI 10.1016/0895-4356(96)00119-9; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; El-Mezzein REH, 2001, CLIN EXP IMMUNOL, V126, P193, DOI 10.1046/j.1365-2249.2001.01664.x; Giedraitis V, 2001, J NEUROIMMUNOL, V112, P146, DOI 10.1016/S0165-5728(00)00407-0; Hanifin JM, 1999, ARCH DERMATOL, V135, P1551, DOI 10.1001/archderm.135.12.1551; Heinzmann A, 2004, ALLERGY, V59, P845, DOI 10.1111/j.1398-9995.2004.00538.x; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kalina U, 2000, SCAND J IMMUNOL, V52, P525, DOI 10.1046/j.1365-3083.2000.00836.x; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Kretowski A, 2002, DIABETES, V51, P3347, DOI 10.2337/diabetes.51.11.3347; Kruse S, 2003, J ALLERGY CLIN IMMUN, V111, P117, DOI 10.1067/mai.2003.43; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Nakanishi K, 2001, CYTOKINE GROWTH F R, V12, P53, DOI 10.1016/S1359-6101(00)00015-0; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Novak N, 2002, J INVEST DERMATOL, V119, P870, DOI 10.1046/j.1523-1747.2002.00191.x; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, pS128, DOI DOI 10.1016/j.jaci.2003.09.032; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; Slager SL, 2001, HUM HERED, V52, P149, DOI 10.1159/000053370; Sohn MH, 2004, ALLERGY ASTHMA PROC, V25, P181; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Stoll S, 1997, J IMMUNOL, V159, P298; Tamura K, 2002, J GASTROENTEROL, V37, P111, DOI 10.1007/BF03326428; Tanaka H, 2001, J ALLERGY CLIN IMMUN, V107, P331, DOI 10.1067/mai.2001.112275; Verhaeghe B, 2002, ALLERGY, V57, P825, DOI 10.1034/j.1398-9995.2002.23539.x; Wong CK, 2001, CLIN EXP IMMUNOL, V125, P177, DOI 10.1046/j.1365-2249.2001.01602.x; Yoshimoto T, 1999, P NATL ACAD SCI USA, V96, P13962, DOI 10.1073/pnas.96.24.13962; Yoshimoto T, 2000, NAT IMMUNOL, V1, P132, DOI 10.1038/77811; Yoshimoto T, 1998, J IMMUNOL, V161, P3400	30	91	96	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					828	833		10.1016/j.jaci.2005.01.030	http://dx.doi.org/10.1016/j.jaci.2005.01.030			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15806006				2022-12-18	WOS:000228373400025
J	Fukakusa, M; Bergeron, C; Tulic, MK; Fiset, PO; Al Dewachi, O; Laviolette, M; Hamid, Q; Chakir, J				Fukakusa, M; Bergeron, C; Tulic, MK; Fiset, PO; Al Dewachi, O; Laviolette, M; Hamid, Q; Chakir, J			Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-gamma-inducible protein 10 expression in asthmatic airway mucosa	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; chemokines; IL-8; eotaxin; bronchial epithelial cell; corticosteroids	BRONCHIAL BIOPSIES; MESSENGER-RNA; EOTAXIN; INFLAMMATION; MCP-3; GLUCOCORTICOIDS; MODULATION; CYTOKINES; RANTES; CELLS	Background: Cytokines and chemokines have been implicated in the pathogenesis of asthma. Inhaled corticosteroids have been shown to decrease the number of eosinophils and to downregulate T(H)2 cytokines but to increase neutrophils. The effect of corticosteroids on chemokine expression in asthma has not yet been investigated. Objective: We sought to investigate the effect of a 2-week course of oral corticosteroid (methylprednisolone, 40 mg/d) on the expression of CXC chemokines (IL-8 and IFN-gamma-inducible protein 10 [IP-10]) and CC chemokines (eotaxin and monocyte chemotactic proteins [MCPs] 1-4) in endoscopic biopsy specimens of 13 patients with moderate-to-severe asthma. Methods: CD3, major basic protein, and elastase immunoreactivities were monitored before and after treatment by using immunocytochemistry. Eotaxin, IL-8, IP-10, MCP-1, MCP-2, MCP-3, and MCP-4 mRNA expression in epithelium and submucosa were studied by using in situ hybridization. Results: Corticosteroids reduced the number of CD3-positive T cells and major basic protein-positive eosinophils (P < .05), whereas the number of neutrophils were increased (P < .05). Corticosteroids also reduced the number of eotaxin (P < .05), MCP-3, and MCP-4 mRNA-positive cells (P < .001) in the epithelium and subepithelium. However, corticosteroids caused a significant increase in the epithelial expression of IL-8 (P < .001), IP-10 (P < .05), and MCP-2 mRNAs (P < .01). Corticosteroids had no effects on MCP-1 mRNA expression. Conclusion: Our results demonstrate the dual nature of corticosteroids. Although corticosteroids can downregulate the expression of some asthma-associated chemokines, such as eotaxin, MCP-3, and MCP-4, they can also upregulate the expression of other chemokines, including IL-8, IP-10, and MCP-2. The failure of oral corticosteroids to inhibit IL-8 mRNA expression might contribute to persistent airway neutrophilia observed in patients with moderate-to-severe asthma, despite treatment with corticosteroids.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Hop Laval, Inst Univ Carciol & Pneumol, Unite Rech Pneumol, Ste Foy, PQ, Canada	McGill University; Laval University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	qutayba.hamid@mcgill.ca	Tulic, Meri/P-6613-2016; Tulic, Meri K/ABB-5138-2020	Tulic, Meri/0000-0002-2661-2369; Tulic, Meri K/0000-0002-2661-2369				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; Chakir J, 2002, CLIN EXP ALLERGY, V32, P578, DOI 10.1046/j.0954-7894.2002.01323.x; Christodoulopoulos P, 1999, J ALLERGY CLIN IMMUN, V103, P1036, DOI 10.1016/S0091-6749(99)70176-4; Gangur V, 2002, VET IMMUNOL IMMUNOP, V86, P127, DOI 10.1016/S0165-2427(02)00018-1; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; Greiff L, 2001, CLIN EXP ALLERGY, V31, P1321, DOI 10.1046/j.1365-2222.2001.01029.x; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hauber HP, 2003, J ALLERGY CLIN IMMUN, V112, P58, DOI 10.1067/mai.2003.1612; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; KWON OJ, 1994, IMMUNOLOGY, V81, P389; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; Meagher LC, 1996, J IMMUNOL, V156, P4422; Meyer-Hoffert U, 2003, INT ARCH ALLERGY IMM, V131, P264, DOI 10.1159/000072138; Miotto D, 2001, J ALLERGY CLIN IMMUN, V107, P664, DOI 10.1067/mai.2001.113524; Miyamasu M, 1998, J ALLERGY CLIN IMMUN, V101, P75, DOI 10.1016/S0091-6749(98)70196-4; Pype JL, 1999, AM J RESP CELL MOL, V21, P528, DOI 10.1165/ajrcmb.21.4.3660; Rose CE, 2003, MICROCIRCULATION, V10, P273, DOI 10.1038/sj.mn.7800193; Sousa AR, 2000, J ALLERGY CLIN IMMUN, V105, P943, DOI 10.1067/mai.2000.106486; SOUSA AR, 1994, AM J RESP CELL MOL, V10, P142, DOI 10.1165/ajrcmb.10.2.8110469; Stirling RG, 2001, ALLERGY, V56, P825, DOI 10.1034/j.1398-9995.2001.00143.x; Wilson SJ, 2001, AM J RESP CRIT CARE, V164, P1047, DOI 10.1164/ajrccm.164.6.2010045; Ying S, 1999, J IMMUNOL, V163, P6321	27	91	98	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					280	286		10.1016/j.jaci.2004.10.036	http://dx.doi.org/10.1016/j.jaci.2004.10.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696082				2022-12-18	WOS:000227043600011
J	Niehues, T; Reichenbach, J; Neubert, J; Gudowius, S; Puel, A; Horneff, G; Lainka, E; Dirksen, U; Schroten, H; Doffinger, R; Casanova, JL; Wahn, V				Niehues, T; Reichenbach, J; Neubert, J; Gudowius, S; Puel, A; Horneff, G; Lainka, E; Dirksen, U; Schroten, H; Doffinger, R; Casanova, JL; Wahn, V			Nuclear factor kappa B essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						children; hyper-IgM; immunodeficiency; ectodermal dysplasia; mycobacteria	INCONTINENTIA PIGMENTI; LYMPHOCYTE SUBPOPULATIONS; NEMO; MUTATIONS; EXPRESSION; INFECTION; IMMUNITY; SUBSETS; CELLS; AGE	Background: Amorphic mutations in the X-linked nuclear factor kappaB essential modulator (NEMO) gene cause Incontinentia pigmenti, which is lethal in hemizygous male patients. Hypomorphic NEMO mutations in male patients lead to anhidrotic ectodermal dysplasia (EDA) with immunodeficiency. Objective: To report the clinical features of a child bearing a NEMO mutation who displayed an immunodeficiency without EDA. Methods: Documentation of clinical care, chart review, standard immunologic and microbiological laboratory techniques, mutation analysis of the NEMO gene. Results: Since the age of 15 months, the patient had Mycobacterium avium disease, beginning with multiple adenitis, later followed by disseminated osteomyelitis and dermatitis. In addition, Haemophilus influenzae and Streptococcus pneumoniae infections led to bronchiectasis. An immunologic work-up revealed a low production of IFN-gamma by PBMCs associated with a hyper-IgM phenotype. Despite treatment using repeated cycles of a 4-drug antimycobacterial regimen, continuous subcutaneous IFN-gamma, repeated antibiotic treatment, and intravenous immunoglobulin substitution, the boy remained chronically ill. At the age of 12 years, the disease was complicated by severe autoimmune hemolytic anemia and eventually fatal herpes simplex virus I encephalitis despite high-dose acyclovir therapy. Although he did not present any sign of EDA, a novel type of disease-causing hypomorphic NEMO mutation (110-111insC in exon 2) was identified. Conclusion: This case demonstrates that patients hemizygous for NEMO mutations can present with an immunodeficiency without EDA. An investigation of NEMO should thus be undertaken in selected children with immunodeficiency despite the lack of EDA.	Univ Dusseldorf, Pediat Immunol & Rheumatol Unit, Dept Pediat Oncol Hematol & Immunol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Pediat Immunol & Rheumatol Unit, Dept Gen Pediat, D-40225 Dusseldorf, Germany; Univ Paris Rene Descartes, INSERM, U550,Lab Genet Humaine Malad Infect, Unite Immunol & Hematol Pediat,Fac Med Necker Enf, Paris, France; Childrens Hosp Schwedt Oder, Schwedt, Germany; Univ Halle Wittenberg, Dept Pediat, Halle Saale, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Martin Luther University Halle Wittenberg	Niehues, T (corresponding author), Univ Dusseldorf, Pediat Immunol & Rheumatol Unit, Dept Pediat Oncol Hematol & Immunol, Moorenstr 5, D-40225 Dusseldorf, Germany.	niehues@uni-duesseldorf.de	Reichenbach, Janine/U-2171-2018; Puel, Anne/H-7305-2017; Dirksen, Uta/AGX-8472-2022; Casanova, Jean-Laurent/I-3418-2017	Reichenbach, Janine/0000-0002-9008-1312; Puel, Anne/0000-0003-2603-0323; Casanova, Jean-Laurent/0000-0002-7782-4169				Agematsu K, 1997, EUR J IMMUNOL, V27, P2073, DOI 10.1002/eji.1830270835; Aradhya S, 2001, HUM MOL GENET, V10, P2171, DOI 10.1093/hmg/10.19.2171; Carrol ED, 2003, ARCH DIS CHILD, V88, P340, DOI 10.1136/adc.88.4.340; Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Dupuis-Girod S, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e97; ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5; Gulino AV, 2003, CURR OPIN RHEUMATOL, V15, P422, DOI 10.1097/00002281-200307000-00009; HORNEFF G, 1993, CLIN IMMUNOL IMMUNOP, V66, P80, DOI 10.1006/clin.1993.1011; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Mansour S, 2001, AM J MED GENET, V99, P172, DOI 10.1002/1096-8628(2001)9999:9999<::AID-AJMG1155>3.0.CO;2-Y; MASSE JF, 1994, ARCH DIS CHILD, V71, P1, DOI 10.1136/adc.71.1.1; Niehues T, 1998, PEDIATR RES, V44, P265, DOI 10.1203/00006450-199808000-00021; Niehues T, 2001, CLIN DIAGN LAB IMMUN, V8, P74, DOI 10.1128/CDLI.8.1.74-78.2001; Orange JS, 2004, J ALLERGY CLIN IMMUN, V114, P650, DOI 10.1016/j.jaci.2004.06.052; Orange JS, 2004, J ALLERGY CLIN IMMUN, V113, P725, DOI 10.1016/j.jaci.2004.01.762; Orange JS, 2002, J CLIN INVEST, V109, P1501, DOI 10.1172/JCI200214858; Priolo M, 2001, J MED GENET, V38, P579, DOI 10.1136/jmg.38.9.579; Puel A, 2004, CURR OPIN IMMUNOL, V16, P34, DOI 10.1016/j.coi.2003.11.013; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Smahi A, 2000, NATURE, V405, P466; Soler P, 1999, CLIN EXP IMMUNOL, V116, P332; WAHN V, 1991, J IMMUNOL, V147, P2934; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	26	91	95	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1456	1462		10.1016/j.jaci.2004.08.047	http://dx.doi.org/10.1016/j.jaci.2004.08.047			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577852				2022-12-18	WOS:000225577400031
J	Allmers, H; Schmengler, J; John, SM				Allmers, H; Schmengler, J; John, SM			Decreasing incidence of occupational contact urticaria caused by natural rubber latex allergy in German health care workers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						contact urticaria; natural rubber latex allergy; powder-free latex gloves; latex allergens; primary prevention	GLOVES	Background: The development of allergy to natural rubber latex (NRL) is a risk for health care workers. A regulation banning powdered NRL gloves was implemented in Germany in 1998. Objective: This study assesses the effects of this regulation on the development of occupational skin disease caused by NRL in health care personnel working in facilities insured by the German statutory accident insurance company, covering some 1.8 million insured health care workers. Methods: We reviewed the annual numbers of reported suspected cases of NRL-induced occupational allergies (mainly contact urticaria) from 1996 through 2002, as well as the number and type of gloves purchased in acute-care hospitals from 1986 through 2002. Results: The number of purchased nonsterile examination gloves increased by 1387% between 1986 and 2002. The purchase of powder-free NRL examination gloves exceeded that of powdered gloves in 1998. The incidence of suspected cases increased until 1998 and has since decreased by 79.9%. Most suspected cases (67.9%) were identified as occupationally caused. Conclusions: Reducing the purchase of powdered NRL gloves is associated with a decrease in suspected and proved cases of occupational contact urticaria caused by NRL. Development of occupationally caused contact urticaria by NRL can be reduced by banning the use of powdered NRL gloves.	Univ Osnabruck, Dept Dermatol Environm Med & Hlth Sci, D-49090 Osnabruck, Germany; Berufsgenossenschaft Gesundheitsdienst & Wohlfahr, Delmenhorst, Germany	University Osnabruck	Allmers, H (corresponding author), Univ Osnabruck, Dept Dermatol Environm Med & Hlth Sci, Sedanstr 115, D-49090 Osnabruck, Germany.	hallmers@uos.de						Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; Allmers H, 2002, J ALLERGY CLIN IMMUN, V110, P318, DOI 10.1067/mai.2002.126461; Baur X, 1998, J ALLERGY CLIN IMMUN, V101, P24, DOI 10.1016/S0091-6749(98)70188-5; HEESE A, 1991, J AM ACAD DERMATOL, V25, P831, DOI 10.1016/S0190-9622(08)80977-2; Levy DA, 1999, JAMA-J AM MED ASSOC, V281, P988, DOI 10.1001/jama.281.11.988; Liss GM, 2001, AM J IND MED, V40, P347, DOI 10.1002/ajim.1108; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; Ownby DR, 2002, J ALLERGY CLIN IMMUN, V110, pS27, DOI 10.1067/mai.2002.125336; Roy A, 1997, J Can Dent Assoc, V63, P297; Shoup AJ, 1997, AORN J, V66, P729; Sommer S, 2002, BRIT J DERMATOL, V146, P114, DOI 10.1046/j.1365-2133.2002.04565.x; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V102, P333, DOI 10.1016/S0091-6749(98)70110-1; Tarlo S M, 2001, Curr Opin Pulm Med, V7, P27, DOI 10.1097/00063198-200101000-00005; Tarlo SM, 2001, J ALLERGY CLIN IMMUN, V108, P628, DOI 10.1067/mai.2001.118792; Turjanmaa K, 2000, J ALLERGY CLIN IMMUN, V105, pS373, DOI 10.1016/S0091-6749(00)91520-3; WITT S, 1999, TECHNICAL INFORMATIO	16	91	94	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					347	351		10.1016/j.jaci.2004.05.054	http://dx.doi.org/10.1016/j.jaci.2004.05.054			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316514				2022-12-18	WOS:000223405600021
J	van Rift, LS; Vos, N; Willart, M; KleinJan, A; Coyle, AJ; Hoogsteden, HC; Lambrecht, BN				van Rift, LS; Vos, N; Willart, M; KleinJan, A; Coyle, AJ; Hoogsteden, HC; Lambrecht, BN			Essential role of dendritic cell CD80/86 costimulation in the induction, but not reactivation, of T(H)2 effector responses in a mouse model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EOSINOPHILIC AIRWAY INFLAMMATION; ANTIGEN-PRESENTING CELLS; NAIVE T-CELLS; CO-STIMULATION; IN-VIVO; PERIPHERAL TOLERANCE; INHALED ANTIGEN; IMMUNE-RESPONSE; TH2 RESPONSES; MURINE MODEL	Background: Airway dendritic cells (DCs) are crucial for the generation of T(H)2 cells from naive T cells during sensitization and for reactivation of primed T(H)2 cells on allergen challenge in mouse models of asthma. It is unknown whether CD80/CD86 costimulation is necessary during both phases of the response because primed T cells rely less on costimulatory molecules compared with naive T cells. Objective: We sought to study the contribution of CD80/CD86 costimulatory molecules on DCs during sensitization or challenge in a mouse model of asthma. Methods: Naive BALB/c mice received an intratracheal injection of ovalbumin (OVA)-pulsed DCs obtained from the bone marrow of wild-type (WT) or CD80/CD86(-/-) mice and were subsequently challenged with OVA aerosol to address the role of costimulation during sensitization. OVA-sensitized mice received OVA-pulsed WT or CD80/CD86(-/-) DCs without OVA aerosol to address the role of costimulation during challenge. Results: WT DCs induced the proliferation and effector T(H)2 differentiation of naive OVA-specific T cells, whereas CD80/ CD86(-/-) DCs induced only proliferation. Not surprisingly, WT DCs but not CD80/CD86(-/-) DCs induced sensitization to OVA in naive mice. In contrast, in OVA-sensitized mice intratracheal injection of CD80/CD86(-/-) OVA-pulsed DCs led to eosinophilic airway inflammation, goblet cell hyperplasia, and effector T(H)2 cytokine production that was not different from that seen after injection with WT OVA-DCs, even when the inducible costimulator ICOS was blocked or cytotoxic T lymphocyte-associated antigen 4 immunoglobulin was given. Conclusion: CD80/CD86 costimulation on DCs is only necessary during priming of naive T cells into T(H)2 cells but not during restimulation of previously primed T(H)2 cells in the challenge phase.	Erasmus Univ, Med Ctr, Dept Pulm & Crit Care Med, NL-3015 GE Rotterdam, Netherlands; Millennium Pharmaceut, Inflammat Div, Boston, MA USA	Erasmus University Rotterdam; Erasmus MC; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	van Rift, LS (corresponding author), Erasmus Univ, Dept Pulm Med, Room Ee2257a,Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.	L.vanrijt@erasmusmc.nl	Lambrecht, Bart N/K-2484-2014	Lambrecht, Bart N/0000-0003-4376-6834				Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Alegre ML, 2001, NAT REV IMMUNOL, V1, P220, DOI 10.1038/35105024; Bertolino P, 1999, INT IMMUNOL, V11, P1225, DOI 10.1093/intimm/11.8.1225; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7; Brimnes MK, 2003, J EXP MED, V198, P133, DOI 10.1084/jem.20030266; Christensen JE, 2002, INT IMMUNOL, V14, P701, DOI 10.1093/intimm/dxf037; Constant SL, 2002, J CLIN INVEST, V110, P1441, DOI 10.1172/JCI200216109; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; Deurloo DT, 2003, CLIN EXP ALLERGY, V33, P1297, DOI 10.1046/j.1365-2222.2003.01757.x; Gause WC, 1996, EXP PARASITOL, V84, P264, DOI 10.1006/expr.1996.0112; Gett AV, 2003, NAT IMMUNOL, V4, P355, DOI 10.1038/ni908; Gonzalo JA, 2001, NAT IMMUNOL, V2, P597, DOI 10.1038/89739; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; Harris N, 1997, EUR J IMMUNOL, V27, P155, DOI 10.1002/eji.1830270123; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; KeaneMyers A, 1997, J IMMUNOL, V158, P2042; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Lakkis FG, 1997, J IMMUNOL, V158, P2443; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lambrecht BN, 2001, CLIN EXP ALLERGY, V31, P206, DOI 10.1046/j.1365-2222.2001.01061.x; Lambrecht BN, 2000, J IMMUNOL, V164, P2937, DOI 10.4049/jimmunol.164.6.2937; Lanzavecchia A, 2002, NAT REV IMMUNOL, V2, P982, DOI 10.1038/nri959; London CA, 2000, J IMMUNOL, V164, P265, DOI 10.4049/jimmunol.164.1.265; LUCAS PJ, 1995, J IMMUNOL, V154, P5757; Padrid PA, 1998, AM J RESP CELL MOL, V18, P453, DOI 10.1165/ajrcmb.18.4.3055; Robinson DS, 1998, CLIN EXP ALLERGY, V28, P788; Salek-Ardakani S, 2003, J EXP MED, V198, P315, DOI 10.1084/jem.20021937; Schweitzer AN, 1998, J IMMUNOL, V161, P2762; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Smith A, 2000, IMMUNITY, V13, P783, DOI 10.1016/S1074-7613(00)00076-5; Speiser DE, 1997, TRANSPLANTATION, V63, P1042, DOI 10.1097/00007890-199704150-00028; Sperling AI, 1996, J IMMUNOL, V157, P3909; Storni T, 2003, J IMMUNOL, V171, P795, DOI 10.4049/jimmunol.171.2.795; Tang AM, 1996, J IMMUNOL, V157, P117; Tang QZ, 2003, J IMMUNOL, V170, P1510, DOI 10.4049/jimmunol.170.3.1510; van Rijt LS, 2003, J IMMUNOL, V171, P3372, DOI 10.4049/jimmunol.171.7.3372; van Rijt LS, 2002, BLOOD, V100, P3663, DOI 10.1182/blood-2002-03-0673; VanOosterhout AJM, 1997, AM J RESP CELL MOL, V17, P386, DOI 10.1165/ajrcmb.17.3.2679; Vella AT, 1997, J IMMUNOL, V158, P4714; Vermaelen K, 2003, AM J RESP CELL MOL, V29, P405, DOI 10.1165/rcmb.2003-0008OC; Watts TH, 1999, CURR OPIN IMMUNOL, V11, P286, DOI 10.1016/S0952-7915(99)80046-6; Yamada A, 2001, J IMMUNOL, V167, P140, DOI 10.4049/jimmunol.167.1.140	46	91	97	2	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					166	173		10.1016/j.jaci.2004.03.044	http://dx.doi.org/10.1016/j.jaci.2004.03.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241361				2022-12-18	WOS:000222534300025
J	Beyer, M; Bartz, H; Horner, K; Doths, S; Koerner-Rettberg, C; Schwarze, J				Beyer, M; Bartz, H; Horner, K; Doths, S; Koerner-Rettberg, C; Schwarze, J			Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						respiratory syncytial virus; antigen-presenting cells; dendritic cells; CD11c antigen; airway inflammation; mice; virus-induced asthma	T-CELLS; AIRWAY SENSITIZATION; ALLERGIC SENSITIZATION; IMMUNE-RESPONSE; MACROPHAGE; EXPRESSION; RISK; BRONCHIOLITIS; INFLAMMATION; INDUCTION	Background: Respiratory syncytial virus (RSV) bronchiolitis in infants can lead to wheezing and early allergic sensitization. In mice, RSV infection enhances allergic airway inflammation and airway hyperresponsiveness. Dendritic cells are critical in inducing T-cell responses to both viruses and allergens and could be pivotal in regulating interactions between these. Objective: This study addresses the effects of RSV infection on phenotype and function of pulmonary dendritic cells. Methods: BALB/c mice were infected with RSV, and expression of CD11c, MHC II, and CD86 on lung and spleen cells was monitored by flow cytometry for 21 days after infection. CD11c(+) cells were isolated to assess their phagocytic capacity and their ability to induce proliferation in allogenic T cells. Results: Numbers of pulmonary CD11c(+) MHC IIhi cells increased 13-fold starting from day 6 after RSV infection. This was associated with increased CD86 expression, reduced phagocytosis, and increased allogenic T-cell stimulatory capacity in CD11c(+) cells. These changes in the lung outlasted acute infection and were not observed in spleens. Conclusion: RSV infection results in sustained increases in numbers of mature dendritic cells in the lung. These might well contribute to the development of intense airway inflammation and airway hyperresponsiveness after RSV infection and to enhancement of subsequent responses to allergen exposure.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Dept Resp Med, London W2 1PG, England; Ruhr Univ Bochum, St Josef Hosp, Klin Kinder & Jugendmed, D-4630 Bochum, Germany	Imperial College London; Ruhr University Bochum	Schwarze, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Dept Resp Med, Norfolk Pl, London W2 1PG, England.		Koerner-Rettberg, Cordula/AGI-3532-2022; Schwarze, Jürgen/F-7396-2011	Koerner-Rettberg, Cordula/0000-0003-0946-1009; Schwarze, Jurgen/0000-0002-6899-748X				ANDERSON JJ, 1990, J GEN VIROL, V71, P1561, DOI 10.1099/0022-1317-71-7-1561; Brimnes MK, 2003, J EXP MED, V198, P133, DOI 10.1084/jem.20030266; Bukreyev A, 2001, J VIROL, V75, P12128, DOI 10.1128/JVI.75.24.12128-12140.2001; CHRISTENSEN PJ, 1995, AM J RESP CELL MOL, V13, P426, DOI 10.1165/ajrcmb.13.4.7546772; Cochand L, 1999, AM J RESP CELL MOL, V21, P547, DOI 10.1165/ajrcmb.21.5.3785; Constant SL, 2002, J CLIN INVEST, V110, P1441, DOI 10.1172/JCI200216109; Foster S, 2003, IMMUNOLOGY, V108, P109, DOI 10.1046/j.1365-2567.2003.01539.x; Gajewska BU, 2001, AM J RESP CELL MOL, V25, P326, DOI 10.1165/ajrcmb.25.3.4482; GRAHAM BS, 1991, J CLIN INVEST, V88, P1026, DOI 10.1172/JCI115362; HOLT PG, 1988, J EXP MED, V167, P262, DOI 10.1084/jem.167.2.262; Julia V, 2002, IMMUNITY, V16, P271, DOI 10.1016/S1074-7613(02)00276-5; KEIZER GD, 1987, J IMMUNOL, V138, P3130; Lin YL, 2003, EUR J IMMUNOL, V33, P2736, DOI 10.1002/eji.200324087; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Masten BJ, 1999, J IMMUNOL, V162, P1310; Masten BJ, 1997, AM J RESP CELL MOL, V16, P335, DOI 10.1165/ajrcmb.16.3.9070619; Matsuse H, 2000, J IMMUNOL, V164, P6583, DOI 10.4049/jimmunol.164.12.6583; McWilliam AS, 1996, J EXP MED, V184, P2429, DOI 10.1084/jem.184.6.2429; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1111/j.1365-2222.1996.tb00571.x; NOAH TL, 1993, AM J PHYSIOL, V265, pL472, DOI 10.1152/ajplung.1993.265.5.L472; OPENSHAW PJM, 1995, AM J RESP CRIT CARE, V152, pS59, DOI 10.1164/ajrccm/152.4_Pt_2.S59; Ruedl C, 1996, EUR J IMMUNOL, V26, P1801, DOI 10.1002/eji.1830260821; Schauer U, 2002, EUR RESPIR J, V20, P1277, DOI 10.1183/09031936.02.00019902; Schwarze J, 1999, J IMMUNOL, V163, P5729; Schwarze J, 1999, J IMMUNOL, V162, P4207; Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Smyth RL, 1999, LANCET, V354, P1997, DOI 10.1016/S0140-6736(05)76769-6; Spender LC, 1998, J GEN VIROL, V79, P1751, DOI 10.1099/0022-1317-79-7-1751; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Vremec D, 2000, J IMMUNOL, V164, P2978, DOI 10.4049/jimmunol.164.6.2978; Vremec D, 1997, J IMMUNOL, V159, P565; Ward C, 2001, J HEART LUNG TRANSPL, V20, P1064, DOI 10.1016/S1053-2498(01)00319-9; Yamamoto N, 2000, EUR J IMMUNOL, V30, P316, DOI 10.1002/1521-4141(200001)30:1<316::AID-IMMU316>3.0.CO;2-0; Yamamoto N, 2001, J VIROL, V75, P499, DOI 10.1128/JVI.75.1.499-505.2001	37	91	100	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					127	133		10.1016/j.jaci.2003.10.057	http://dx.doi.org/10.1016/j.jaci.2003.10.057			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	760MP	14713917				2022-12-18	WOS:000187837900017
J	Habib, T; Nelson, A; Kaushansky, K				Habib, T; Nelson, A; Kaushansky, K			IL-21: A novel IL-2-family lymphokine that modulates B,T, and natural killer cell responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						interleukins; cytotoxicity; (X-linked severe combined); immunodeficiency; inflammation; interferon-gamma; lymphoma; apoptosis; proliferation	COMMON GAMMA-CHAIN; CYTOKINE RECEPTOR; TRANSCRIPTIONAL CONTROL; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; STAT PROTEINS; CUTTING EDGE; GENE; GROWTH; ACTIVATION	IL-21 is a recently described type I cytokine produced by activated CD4(+) T cells that profoundly affects the growth, survival, and functional activation of B, T, and natural killer lymphocytes in concert with other cytokines or activating stimuli. Structurally, IL-21 is predicted to display a 4-helix-bundle-type fold with significant homology to IL-2, IL-4, and IL-15 and mediates its biologic effects through a novel type I cytokine receptor, IL-21R, in conjunction with the common cytokine receptor gamma chain (gammac) of the IL-2, IL-4, IL-7, IL-9, and IL-15 receptors. As a new member of the 7c-dependent cytokine family, there is significant interest in IL-21, in part because of its potential to provide new insights into the immunologic phenotype caused by gammac deficiency. IL-21R knockout mice have been generated that have normal lymphoid cell development yet exhibit impaired production of the immunoglobulin IgG(1) and increased IgE responses after immunization. As expected for cytokines that use gammac, recent studies indicate that IL-21 induces Janus kinase 1 (JAK1) and JAK3 activation to initiate signal transduction, but unlike these other gammac-dependent cytokines, which predominantly activate signal transducer and activator of transcription 5 (STAT5), IL-21 preferentially activates STAT1 and STAT3. IL-21 potently enhances primary antigen responses and the effector functions of T and natural killer cells and stimulates IFN-gamma production alone or in concert with other cytokines. Thus, on the basis of primary structure, receptor composition, and biologic activities, IL-21 is a new IL-2-family cytokine that participates in both innate and adaptive immunity and might be important for the development of a T(H)1 immune response.	Univ Calif San Diego, Sch Med, Dept Med, San Diego, CA 92103 USA; LAB Preclin Res Int Inc, Laval, PQ, Canada	University of California System; University of California San Diego	Kaushansky, K (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, 402 Dickinson St,Suite 380, San Diego, CA 92103 USA.							Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Asao H, 2001, J IMMUNOL, V167, P1, DOI 10.4049/jimmunol.167.1.1; Bennett F, 2003, J IMMUNOL, V170, P711, DOI 10.4049/jimmunol.170.2.711; Brenne AT, 2002, BLOOD, V99, P3756, DOI 10.1182/blood.V99.10.3756; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Chang TLY, 2000, J BIOL CHEM, V275, P10212, DOI 10.1074/jbc.275.14.10212; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; DiSanto JP, 1995, IMMUNOL REV, V148, P19; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; Fallarino F, 1999, J IMMUNOL, V163, P4109; Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14; Habib T, 2002, BIOCHEMISTRY-US, V41, P8725, DOI 10.1021/bi0202023; He YW, 1998, CRIT REV IMMUNOL, V18, P503, DOI 10.1615/CritRevImmunol.v18.i6.20; Henderson WR, 2000, J IMMUNOL, V164, P1086, DOI 10.4049/jimmunol.164.2.1086; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Josephson K, 2001, IMMUNITY, V15, P35, DOI 10.1016/S1074-7613(01)00169-8; Kasaian MT, 2002, IMMUNITY, V16, P559, DOI 10.1016/S1074-7613(02)00295-9; KAUSHANSKY K, 1993, BLOOD, V82, P3229; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Lee CK, 2000, J IMMUNOL, V164, P1286, DOI 10.4049/jimmunol.164.3.1286; Leonard WJ, 2001, NAT REV IMMUNOL, V1, P200, DOI 10.1038/35105066; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Levy DE, 1999, CELL MOL LIFE SCI, V55, P1559, DOI 10.1007/s000180050395; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Lodolce JP, 2001, J EXP MED, V194, P1187, DOI 10.1084/jem.194.8.1187; Ma A, 2000, J EXP MED, V191, P753, DOI 10.1084/jem.191.5.753; Ma HL, 2003, J IMMUNOL, V171, P608, DOI 10.4049/jimmunol.171.2.608; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Mehta DS, 2003, J IMMUNOL, V170, P4111, DOI 10.4049/jimmunol.170.8.4111; Mogensen KE, 1999, J INTERF CYTOK RES, V19, P1069, DOI 10.1089/107999099313019; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; Mui ALF, 1999, CELL MOL LIFE SCI, V55, P1547, DOI 10.1007/s000180050394; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nelson A, 2002, BLOOD, V100, p158A; NELSON A, 2003, AM ASS CANC RES ANN; NELSON A, 2003, AM SOC CLIN ON ANN M; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Ozaki K, 2002, J BIOL CHEM, V277, P29355, DOI 10.1074/jbc.R200003200; Ozaki K, 2000, P NATL ACAD SCI USA, V97, P11439, DOI 10.1073/pnas.200360997; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; Parrish-Novak J, 2002, J LEUKOCYTE BIOL, V72, P856; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; Sprent J, 2001, CURR OPIN IMMUNOL, V13, P248, DOI 10.1016/S0952-7915(00)00211-9; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Strengeil M, 2002, J IMMUNOL, V169, P3600, DOI 10.4049/jimmunol.169.7.3600; Strengell M, 2003, J IMMUNOL, V170, P5464, DOI 10.4049/jimmunol.170.11.5464; Suto A, 2002, BLOOD, V100, P4565, DOI 10.1182/blood-2002-04-1115; Takeda K, 2000, CYTOKINE GROWTH F R, V11, P199, DOI 10.1016/S1359-6101(00)00005-8; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; Ueda C, 2002, ONCOGENE, V21, P368, DOI 10.1038/sj.onc.1205099; Ugai S, 2003, CANCER GENE THER, V10, P187, DOI 10.1038/sj.cgt.7700552; Uribe L, 1998, SEMIN HEMATOL, V35, P299; van Leeuwen EM, 2002, J IMMUNOL, V169, P5838, DOI 10.4049/jimmunol.169.10.5838; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; Wang KS, 1999, J IMMUNOL, V162, P299; Weng NP, 2002, ANN NY ACAD SCI, V975, P46, DOI 10.1111/j.1749-6632.2002.tb05940.x; Yu CR, 1999, J IMMUNOL, V162, P2785; Zhang JL, 2003, BIOCHEM BIOPH RES CO, V300, P291, DOI 10.1016/S0006-291X(02)02836-X	76	91	100	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1033	1045		10.1016/j.jaci.2003.08.039	http://dx.doi.org/10.1016/j.jaci.2003.08.039			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657853				2022-12-18	WOS:000187154200002
J	Anderson, SD; Fitch, K; Perry, CP; Sue-Chu, M; Crapo, R; McKenzie, D; Magnussen, H				Anderson, SD; Fitch, K; Perry, CP; Sue-Chu, M; Crapo, R; McKenzie, D; Magnussen, H			Responses to bronchial challenge submitted for approval to use inhaled beta(2)-agonists before an event at the 2002 Winter Olympics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beta(2)-agonists; sport; elite athletes; exercise-induced asthma; asthma; Olympic Games	EUCAPNIC VOLUNTARY HYPERVENTILATION; EXERCISE-INDUCED ASTHMA; WORKING PARTY STANDARDIZATION; RESPIRATORY HEALTH SURVEY; TESTS EUROPEAN-COMMUNITY; CROSS-COUNTRY SKIERS; BRONCHOPROVOCATION TECHNIQUE; AIRWAY HYPERRESPONSIVENESS; CORTICOSTEROID BUDESONIDE; INDUCED BRONCHOSPASM	Background: There has been an increase in the number and percentage of athletes competing in Olympic Games notifying Use Of beta(2)-agonists, from 1.7% at Los Angeles (1984) to 5.5% at Sydney (2000). For Salt Lake City (2002), the International Olympic Committee requested objective evidence to use beta(2)-agonists for asthma or exercise-induced asthma (EIA). Objective: The objective of this study was to evaluate the evidence submitted for approval to use a beta(2)-agonist. Methods: Objective evidence for asthma or EIA included (1) an increase of 12% or more of the predicted FEV1 in response to bronchodilator, (2) a reduction in FEV1 of 10% or greater from baseline in response to exercise or eucapnic voluntary hyperpnea, (3) a PD20 FEV1 to methacholine or histamine at a dose of less than 200 mug (2 mg/mL) or less than 1320 mug (13.2 mg/mL) for those taking inhaled corticosteroids for 3 months. Results: There were 165 applications. Of these, 147 (89%) included evidence of a challenge, bronchodilator response, or both, and 163 test results were submitted. One hundred thirty (5.2%) applications were approved. For those with positive responses, the median value (1) was 16.2% of predicted FEV1 for response to a bronchodilator (n = 13), (2) was a 15.9% decrease in FEV1 for response to a physical challenge (n = 36), and, (3) for PD20 FEV1 was 173 mug for response to a pharmacologic challenge (n = 45). Conclusion: The analysis demonstrated that it is feasible to request objective evidence to justify use of beta(2)-agonists on the medical grounds of asthma or EIA.	Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW 2050, Australia; Univ Western Australia, Dept Human Movement & Exercise Sci, Nedlands, WA 6009, Australia; Univ Trondheim Hosp, Dept Lung Med, N-7006 Trondheim, Norway; LDS Hosp, Div Pulm, Salt Lake City, UT USA; Univ British Columbia, Div Sports Med, Vancouver, BC V5Z 1M9, Canada	University of Sydney; University of Western Australia; Norwegian University of Science & Technology (NTNU); University of British Columbia	Anderson, SD (corresponding author), Royal Prince Alfred Hosp, Dept Resp Med, E11S, Camperdown, NSW 2050, Australia.		Sue-Chu, Malcolm/D-8671-2016	Sue-Chu, Malcolm/0000-0002-3301-1983; Anderson, Sandra/0000-0002-6308-8770				Altman DG, 1990, PRACTICAL STAT MED R; Anderson SD, 2001, MED SCI SPORT EXER, V33, P893, DOI 10.1097/00005768-200106000-00007; Anderson SD, 2001, BRIT J SPORT MED, V35, P344, DOI 10.1136/bjsm.35.5.344; Anderson SD, 1997, ALLERGY ALLERGIC DIS, P692; Argyros GJ, 1996, CHEST, V109, P1520, DOI 10.1378/chest.109.6.1520; BACKER V, 1991, J ALLERGY CLIN IMMUN, V88, P68, DOI 10.1016/0091-6749(91)90302-5; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Brannan JD, 1998, AM J RESP CRIT CARE, V158, P1120, DOI 10.1164/ajrccm.158.4.9802087; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; COCKCROFT DW, 1992, J ALLERGY CLIN IMMUN, V89, P23, DOI 10.1016/S0091-6749(05)80037-5; Collomp K, 2000, J APPL PHYSIOL, V89, P430, DOI 10.1152/jappl.2000.89.2.430; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; ELIASSON AH, 1992, CHEST, V102, P347, DOI 10.1378/chest.102.2.347; HABY MM, 1995, EUR RESPIR J, V8, P729; Holzer K, 2002, J ALLERGY CLIN IMMUN, V110, P374, DOI 10.1067/mai.2002.127784; HURWITZ KM, 1995, CHEST, V108, P1240, DOI 10.1378/chest.108.5.1240; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; LARSSON K, 1993, BRIT MED J, V307, P1326, DOI 10.1136/bmj.307.6915.1326; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; MARTINEAU L, 1992, CLIN SCI, V83, P615, DOI 10.1042/cs0830615; MCKENZIE DC, 2000, ASTHMA EXERCISE, P237; *MED AUSTR PTY LTD, 1999, 1999 MIMS ANN; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Reddel HK, 2000, EUR RESPIR J, V16, P226, DOI 10.1034/j.1399-3003.2000.16b08.x; ROACH JM, 1994, CHEST, V105, P667, DOI 10.1378/chest.105.3.667; Rundell KW, 2000, MED SCI SPORT EXER, V32, P309, DOI 10.1097/00005768-200002000-00010; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; SALOME CM, 1980, CLIN ALLERGY, V10, P541, DOI 10.1111/j.1365-2222.1980.tb02135.x; Sandsund M, 1998, EUR J APPL PHYSIOL O, V77, P297, DOI 10.1007/s004210050337; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Stewart IB, 2002, MED SCI SPORT EXER, V34, P213, DOI 10.1097/00005768-200202000-00005; Sue-Chu M, 1999, EUR RESPIR J, V13, P626, DOI 10.1183/09031936.99.13362699; Sue-Chu M, 1998, AM J RESP CRIT CARE, V158, P597, DOI 10.1164/ajrccm.158.2.9711012; Sue-Chu M, 1999, RESP MED, V93, P719, DOI 10.1016/S0954-6111(99)90039-2; Sue-Chu M, 2002, EUR RESP J S38, V20, p410s; VOY RO, 1984, MED SCI SPORTS EXERC, V18, P328; WAALKENS JH, 1993, EUR RESPIR J, V6, P652; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; WEILER JM, 1986, CHEST, V90, P23, DOI 10.1378/chest.90.1.23; Wilber RL, 2000, MED SCI SPORT EXER, V32, P732, DOI 10.1097/00005768-200004000-00003; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; WOOLCOCK AJ, 1983, AIRWAY RESPONSIVENES, P80	46	91	94	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					45	50		10.1067/mai.2003.1	http://dx.doi.org/10.1067/mai.2003.1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532095				2022-12-18	WOS:000180465500007
J	Eigenmann, PA				Eigenmann, PA			Anaphylactic reactions to raw eggs after negative challenges with cooked eggs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						anaphylaxis; eggs; ovomucoid; ovalbumin	NATURAL-HISTORY; CHILDREN		Univ Geneva, Sch Med, Dept Pediat, CH-1211 Geneva, Switzerland; Univ Geneva, Sch Med, Dept Med, Div Immunol & Allergy, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Eigenmann, PA (corresponding author), Univ Hosp Geneva, Allergy Unit, 24 rue Micheli du Crest, CH-1211 Geneva 14, Switzerland.		Eigenmann, Philippe/A-6569-2017	Eigenmann, Philippe/0000-0003-1738-1826				BERNHISELBROADBENT J, 1994, J ALLERGY CLIN IMMUN, V93, P1047, DOI 10.1016/S0091-6749(94)70054-0; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; Cooke SK, 1997, J IMMUNOL, V159, P2026; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3	6	91	93	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					587	588		10.1067/mai.2000.104255	http://dx.doi.org/10.1067/mai.2000.104255			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719312				2022-12-18	WOS:000088946700029
J	Valenta, R; Seiberler, S; Natter, S; Mahler, V; Mossabeb, R; Ring, J; Stingl, G				Valenta, R; Seiberler, S; Natter, S; Mahler, V; Mossabeb, R; Ring, J; Stingl, G			Autoallergy: A pathogenetic factor in atopic dermatitis?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						autoallergy; IgE autoreactivity; atopic dermatitis; cross-reactivity; complementary DNA cloning; allergy; immune responses; eczema; molecular biology	HISTAMINE-RELEASING FACTOR; IGE-REACTIVE AUTOANTIGENS; MOLECULAR CHARACTERIZATION; ALLERGIC DISEASES; SERUM IGE; POLLEN; IDENTIFICATION; AUTOREACTIVITY; PROFILIN	Long before the discovery of IgE it was reported that human dander extract can elicit immediate-type skin reactions in patients with severe atopy and that this skin sensitivity can be passively transferred with serum, Several recent findings have rekindled the interest in this phenomenon and led to the concept that IgE autoreactivity may play a pathogenetic role in severe and chronic forms of atopy, The elucidation of the nature of several environmental allergens has revealed striking structural and immunologic similarities with human proteins. It was also reported that patients predominantly with severe and chronic manifestations of atopy (eg, atopic dermatitis) contain IgE autoantibodies against a wide variety of proteins expressed in histogenetically unrelated human cell types and tissue specimens, Last, complementary DNAs coding for autoallergens were isolated from human expression complementary DNA libraries and recombinant autoallergens were produced. The autoallergens characterized to date represent mainly intracellular proteins, but some of them could be detected as IgE immune complexes in sera of sensitized patients. We suggest that at least two pathomechanisms could play a role in autoallergy, First, autoallergens may cross-link effector cell-bound IgE autoantibodies and, by release of inflammatory mediators, lead to immediate-type symptoms. Second, IgE-mediated presentation of autoallergens may activate autoreactive T cells to release proinflammatory cytokines, contributing to the magnitude of the allergic tissue reaction.	Univ Vienna, Sch Med,Vienna Gen Hosp, Dept Dermatol,Div Allergy Immunol & Infect Dis, Inst Gen & Expt Pathol,Mol Immunopathol Grp, A-1090 Vienna, Austria; Tech Univ Munich, GSF, Inst Gen & Expt Pathol, Dept Dermatol & Allergy, D-8000 Munich, Germany; Tech Univ Munich, GSF, Div Environm Dermatol & Allergol, Dept Dermatol & Allergy, D-8000 Munich, Germany	University of Vienna; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich	Valenta, R (corresponding author), Univ Vienna, Sch Med,Vienna Gen Hosp, Dept Dermatol,Div Allergy Immunol & Infect Dis, Inst Gen & Expt Pathol,Mol Immunopathol Grp, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152; Valenta, Rudolf/0000-0001-5944-3365				Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; DARSOW U, 1995, J ALLERGY CLIN IMMUN, V95, P677, DOI 10.1016/S0091-6749(95)70172-9; De Marino S, 1999, STRUCT FOLD DES, V7, P943; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; HAMPTON STANLEY F., 1941, JOUR ALLERGY, V13, P63, DOI 10.1016/S0021-8707(41)90008-4; HASHEM N, 1963, LANCET, V2, P269; HENDERSON LL, 1975, J ALLERGY CLIN IMMUN, V55, P10, DOI 10.1016/S0091-6749(75)80003-0; Keller P, 1924, ARCH DERMATOL SYPH-G, V148, P82, DOI 10.1007/BF01827500; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; LEUNG DYM, 1993, CURR OPIN IMMUNOL, V5, P956, DOI 10.1016/0952-7915(93)90112-6; LEUNG DYM, 1993, DERMATOLOGY GEN MED, P1385; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MACDONALD SM, 1995, SCIENCE, V269, P688, DOI 10.1126/science.7542803; MATTHEWS PA, 1988, MOL IMMUNOL, V25, P63, DOI 10.1016/0161-5890(88)90091-0; Mayer C, 1999, J EXP MED, V189, P1507, DOI 10.1084/jem.189.9.1507; Natter S, 1998, FASEB J, V12, P1559, DOI 10.1096/fasebj.12.14.1559; RUZICKA T, 1991, HDB ATOPIC ECZEMA; Seiberler S, 1999, INT ARCH ALLERGY IMM, V120, P117, DOI 10.1159/000024229; Seiberler S, 1999, INT ARCH ALLERGY IMM, V120, P108, DOI 10.1159/000024228; Simon F, 1944, J ALLERGY, V15, P338, DOI DOI 10.1016/S0021-8707(44)90143-7; Simon F. A., 1944, JOUR AMER MED ASSOC, V125, P350; SIMON FA, 1947, J ALLERGY, V18, P186, DOI 10.1016/0021-8707(47)90106-8; SIMON FA, 1947, J INVEST DERMATOL, V9, P329, DOI 10.1038/jid.1947.106; SPITZAUER S, 1994, J ALLERGY CLIN IMMUN, V93, P614, DOI 10.1016/S0091-6749(94)70073-7; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24, DOI 10.1159/000237499; Storm van Leuwen W., 1926, KLIN WOCHENSCHR, V5, P1023, DOI DOI 10.1007/BF01717944; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; Valenta R, 1998, J INVEST DERMATOL, V111, P1178, DOI 10.1046/j.1523-1747.1998.00413.x; Valenta R, 1996, J INVEST DERMATOL, V107, P203, DOI 10.1111/1523-1747.ep12329617; Valenta R, 1998, INT ARCH ALLERGY IMM, V117, P160, DOI 10.1159/000024005; Wantke F, 1999, J ALLERGY CLIN IMMUN, V103, P642, DOI 10.1016/S0091-6749(99)70237-X	34	91	103	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					432	437		10.1067/mai.2000.104783	http://dx.doi.org/10.1067/mai.2000.104783			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719290				2022-12-18	WOS:000088946700006
J	Devouassoux, G; Foster, B; Scott, LM; Metcalfe, DD; Prussin, C				Devouassoux, G; Foster, B; Scott, LM; Metcalfe, DD; Prussin, C			Frequency and characterization of antigen-specific IL-4-and IL-13-producing basophils and T cells in peripheral blood of healthy and asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophils; T cell; cytokines; flow cytometry; human; allergy; asthma	HUMAN B-CELLS; MIXED LEUKOCYTE-CULTURES; FLOW CYTOMETRIC ANALYSIS; LATE-PHASE RESPONSE; HUMAN IGE SYNTHESIS; HUMAN MAST-CELLS; FC-EPSILON-RI; INTRACELLULAR INTERLEUKIN-4; CYTOKINE PRODUCTION; HISTAMINE-RELEASE	Background: Both basophils and T cells are known to secrete IL-4 and IL-13 after activation with either nonspecific stimuli or specific antigen, but the relative contribution of these 2 cell types to overall cytokine production is unclear. Objectives: To further characterize basophil cytokine production and compare it with that of T cells, we examined the frequency of IL-4- and IL-13-producing basophils and T cells in human PBMCs by means of flow cytometry after activation in allergic asthmatic and normal subjects. Methods: PBMCs obtained from whole blood after Percoll gradient were activated with specific antigen or ionomycin and fixed. PBMCs were made permeable; stained with antibodies to IgE, CD3, and either IL-4 or IL-13; and analyzed by means of flow cytometry, Results: Preformed cytokines were not detected in unactivated basophils, After ionomycin activation, 60% to 90% of basophils from both control and allergic asthmatic subjects expressed IL-4 and IL-13, Specific antigen induced cytokine expression by 10% to 20% of basophils from the asthmatic group only. After specific antigen activation, basophils accounted for 4 times more IL-4-producing cells than did T cells, IL-4 and IL-13 production at 2 hours was exclusively from basophils, After allergen activation, CD40 ligand was upregulated on a subset of peripheral blood basophils, Conclusions: These data demonstrate that basophils are the predominant peripheral blood cells that express IL-4 and IL-13 in the first 6 hours after antigen activation and strengthen the putative role of basophils both in IgE production and in the generation of allergic inflammation.	NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA	Devouassoux, G (corresponding author), NIAID, Lab Allerg Dis, NIH, Bldg 10,Rm 11C209,10 Ctr Dr,MSC 1881, Bethesda, MD 20892 USA.			Prussin, Calman/0000-0002-3917-3326	NIAID NIH HHS [201-AI-00709-05] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000709] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEHSIRAAMAR O, 1992, J IMMUNOL, V148, P3820; ANDERSSON U, 1988, J IMMUNOL METHODS, V112, P139, DOI 10.1016/0022-1759(88)90044-0; AROCK M, 1993, J IMMUNOL, V151, P1441; BOCHNER BS, 1989, J IMMUNOL METHODS, V125, P265, DOI 10.1016/0022-1759(89)90102-6; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BRADDING P, 1995, J IMMUNOL, V155, P297; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; DEVRIES JE, 1995, INT ARCH ALLERGY IMM, V106, P175, DOI 10.1159/000236842; ELSON LH, 1995, J IMMUNOL, V154, P4294; Falcone FH, 1996, EUR J IMMUNOL, V26, P1147, DOI 10.1002/eji.1830260528; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GAUCHAT JF, 1992, INT IMMUNOL, V4, P397, DOI 10.1093/intimm/4.3.397; Gibbs BF, 1996, EUR J IMMUNOL, V26, P2493, DOI 10.1002/eji.1830261033; Gopinath R, 1997, CYTOMETRY, V30, P313; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; Grattan CEH, 1997, CLIN EXP ALLERGY, V27, P1417, DOI 10.1111/j.1365-2222.1997.tb02986.x; GUO CB, 1994, AM J RESP CELL MOL, V10, P384, DOI 10.1165/ajrcmb.10.4.7510984; IMADA M, 1995, IMMUNOLOGY, V85, P373; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; Komanduri KV, 1998, NAT MED, V4, P953, DOI 10.1038/nm0898-953; Kon OM, 1998, ALLERGY, V53, P891, DOI 10.1111/j.1398-9995.1998.tb03997.x; Li HM, 1996, J IMMUNOL, V156, P4833; Maurer D, 1996, J IMMUNOL, V157, P607; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; MUELLER R, 1994, EUR J IMMUNOL, V24, P2935, DOI 10.1002/eji.1830241203; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; NONAKA M, 1995, J IMMUNOL, V155, P3234; Ochensberger B, 1996, BLOOD, V88, P3028, DOI 10.1182/blood.V88.8.3028.bloodjournal8883028; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; PAUL WE, 1992, NATURE, V357, P16, DOI 10.1038/357016a0; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Prussin C, 1997, J CLIN IMMUNOL, V17, P195, DOI 10.1023/A:1027350226435; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Redrup AC, 1998, J IMMUNOL, V160, P1957; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; TAKAHASHI K, 1993, J IMMUNOL METHODS, V162, P17, DOI 10.1016/0022-1759(93)90402-S; Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338; WARNER JA, 1987, J IMMUNOL METHODS, V105, P107, DOI 10.1016/0022-1759(87)90419-4; Yanagihara Y, 1997, CLIN EXP IMMUNOL, V108, P295, DOI 10.1046/j.1365-2249.1997.d01-1001.x; Zhu FG, 1998, J IMMUNOL, V161, P2541; Zhu XD, 1998, J IMMUNOL, V161, P2574	46	91	93	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				811	819		10.1016/S0091-6749(99)70292-7	http://dx.doi.org/10.1016/S0091-6749(99)70292-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518826	Bronze			2022-12-18	WOS:000083281200013
J	Schatz, M				Schatz, M			Interrelationships between asthma and pregnancy: A literature review	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							BRONCHIAL-ASTHMA; PRETERM LABOR; WOMEN; PREECLAMPSIA; THEOPHYLLINE; PREDNISONE; DELIVERY; ALLERGY; MOTHERS; GROWTH	Pregnancy can affect the course of asthma, and asthma can affect pregnancy outcomes. Asthma course may improve, worsen, or remain unchanged during pregnancy. The mechanisms involved have not been defined, and the course in an individual woman is largely unpredictable. Therefore pregnant women with asthma must be followed up particularly closely so that any change in course can be matched by an appropriate change in therapy. The data also suggest that asthma is associated with increased frequencies of adverse pregnancy outcomes. The mechanisms of this are not totally clear either, but some data support the hypothesis that improved pregnancy outcomes are associated with well-controlled disease, The risk of using medications to control asthma during pregnancy appears to be much less than the risk of adverse outcomes related to severe uncontrolled asthma.	Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA 92111 USA	Kaiser Permanente	Schatz, M (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.							Alexander S, 1998, OBSTET GYNECOL, V92, P435, DOI 10.1016/S0029-7844(98)00191-4; BAHNA SL, 1972, ACTA ALLERGOL, V27, P397, DOI 10.1111/j.1398-9995.1972.tb01439.x; BERTRAND JM, 1985, NEW ENGL J MED, V312, P742, DOI 10.1056/NEJM198503213121202; Briggs GG., 2008, DRUGS PREGNANCY LACT, P431; COUSINS L, 1998, ASTHMA IMMUNOLOGIC D, P27; Demissie K, 1998, PEDIATRICS, V102, P84, DOI 10.1542/peds.102.1.84; Demissie K, 1998, AM J RESP CRIT CARE, V158, P1091, DOI 10.1164/ajrccm.158.4.9802053; Dombrowski M P, 1996, J Matern Fetal Med, V5, P310; DOMBROWSKI MP, 1986, AM J OBSTET GYNECOL, V155, P265, DOI 10.1016/0002-9378(86)90804-5; DOUCETTE JT, 1993, EPIDEMIOLOGY, V4, P143, DOI 10.1097/00001648-199303000-00010; GLUCK JC, 1976, ANN ALLERGY, V37, P164; GORDON M, 1970, AM J OBSTET GYNECOL, V106, P421, DOI 10.1016/0002-9378(70)90371-6; GREENBERGER PA, 1983, ANN INTERN MED, V98, P478, DOI 10.7326/0003-4819-98-4-478; GREENBERGER PA, 1988, NEW ENGL REG ALLERGY, V9, P539, DOI 10.2500/108854188778965555; HEINONEN OP, BIRTH DEFECTS DRUGS, P77; Jana N, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P227; Juniper E, 1993, ASTHMA IMMUNOLOGICAL, P401; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; KRAMER MS, 1995, AM J EPIDEMIOL, V142, P1078, DOI 10.1093/oxfordjournals.aje.a117561; LAO TT, 1990, EUR J OBSTET GYN R B, V35, P183, DOI 10.1016/0028-2243(90)90160-3; LARSSON K, 1985, EUR J RESPIR DIS, V66, P1; LEE F, 1982, OBSTET GYNECOL, V60, P314; LEHRER S, 1993, AM J OBSTET GYNECOL, V168, P1463, DOI 10.1016/S0002-9378(11)90782-0; LEVIN ER, 1995, NEW ENGL J MED, V333, P356, DOI 10.1056/NEJM199508103330607; MABIE WC, 1992, J MATERNAL FETAL MED, V1, P45; MILLAR E, 1995, EUR RESPIR J, V8, P1838, DOI 10.1183/09031936.95.08111838; Minerbi-Codish I, 1998, RESPIRATION, V65, P130, DOI 10.1159/000029244; PERLOW JH, 1992, AM J OBSTET GYNECOL, V167, P963, DOI 10.1016/S0002-9378(12)80020-2; REINISCH JM, 1978, SCIENCE, V202, P436, DOI 10.1126/science.705336; SCHAEFER G, 1961, AM J OBSTET GYNECOL, V82, P182, DOI 10.1016/S0002-9378(16)36114-2; SCHATZ M, 1991, AM J DIS CHILD, V145, P156, DOI 10.1001/archpedi.1991.02160020046013; SCHATZ M, 1990, CHEST, V98, P389, DOI 10.1378/chest.98.2.389; SCHATZ M, 1988, Journal of Allergy and Clinical Immunology, V81, P509, DOI 10.1016/0091-6749(88)90187-X; SCHATZ M, 1995, AM J RESP CRIT CARE, V151, P1170; Schatz M, 1997, J ALLERGY CLIN IMMUN, V100, P301, DOI 10.1016/S0091-6749(97)70241-0; SMITH KD, 1979, SCIENCE, V206, P96, DOI 10.1126/science.482933; STENIUSAARNIALA B, 1988, THORAX, V43, P12, DOI 10.1136/thx.43.1.12; STENIUSAARNIALA B, 1995, CHEST, V107, P642, DOI 10.1378/chest.107.3.642; SteniusAarniala BSM, 1996, THORAX, V51, P411, DOI 10.1136/thx.51.4.411; VINATIER D, 1995, EUR J OBSTET GYN R B, V61, P85, DOI 10.1016/0301-2115(95)02106-H; Wendel PJ, 1996, AM J OBSTET GYNECOL, V175, P150, DOI 10.1016/S0002-9378(96)70265-X; WILLIAMS DA, 1967, ACTA ALLERGOL, V22, P311, DOI 10.1111/j.1398-9995.1967.tb03228.x; WILSON J, 1982, ACTA THERAPEUTICA S, V8, P4551	43	91	93	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	2	S			S330	S336		10.1016/S0091-6749(99)70258-7	http://dx.doi.org/10.1016/S0091-6749(99)70258-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	171KA	9949333				2022-12-18	WOS:000078861500002
J	Batanero, E; Crespo, JF; Monsalve, RI; Martin-Esteban, M; Villalba, M; Rodriguez, R				Batanero, E; Crespo, JF; Monsalve, RI; Martin-Esteban, M; Villalba, M; Rodriguez, R			IgE-binding and histamine-release capabilities of the main carbohydrate component isolated from the major allergen of olive tree pollen, Ole e 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; olive pollen allergy; Ole e 1; N-linked carbohydrate; carbohydrate epitope; histamine release; cross-reactivity	CRYPTOMERIA-JAPONICA POLLEN; ASPARAGINE-LINKED GLYCANS; CRY-J-I; AMINO-ACID-SEQUENCE; CROSS-REACTIVITY; HONEYBEE VENOM; STRUCTURAL-ANALYSIS; PHOSPHOLIPASE A(2); GLYCOPROTEINS; ANTIBODIES	Background: Pollen from olive trees (Olea europaea) is a cause of pollinosis and an aggravating of asthma in Mediterranean regions. Recently, Ole e 1, the major allergen from olive tree pollen, has been isolated and its amino acid sequence has been elucidated. It is a glycoprotein whose carbohydrate moiety is involved in an IgE-binding epitope responsible for cross-reactivity among plant glycoproteins. However, the allergenicity of the free carbohydrate side chains remains to be clarified. Objective: The purpose of this study was to isolate the main carbohydrate component of Ole e 1 allergen and analyze its IgE-binding and histamine-release capabilities. Methods: Deglycosylation treatment of Ole e 1 with PNGase F and gel exclusion chromatography were used to isolate the main sugar component of the allergen. Sera of patients who are allergic to olive pollen and sera sensitive to Ole e 1 have been used in dot blotting assays of IgE binding to the isolated carbohydrate. Heparinized whole blood obtained from patients sensitive to Ole e 1 were stimulated by the free carbohydrate; the resulting histamine release was measured. Results: The main sugar component of Ole el has been isolated. Free carbohydrate was able to bind IgE from sera of patients allergic to olive pollen; the sera of 65% of these patients contained anticarbohydrate reacting IgE, and 100% of those patients were sensitive to Ole e 1. The free carbohydrate promoted in vitro histamine release from basophils of sensitized patients. Conclusion: The carbohydrate moieties of allergenic glycoproteins can constitute significant determinants on the binding to IgE of the sera from patients who are hypersensitive and can be responsible for inducing histamine release from blood cells.	Univ Complutense Madrid, Fac Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain; Hosp Univ 12 Octubre, Serv Alergia, Madrid, Spain; Hosp Infantil La Paz, Serv Alergia, Madrid, Spain	Complutense University of Madrid; Hospital Universitario 12 de Octubre; Hospital Universitario La Paz	Rodriguez, R (corresponding author), Univ Complutense Madrid, Fac Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain.		Villalba, Mayte/K-5365-2014; RODRIGUEZ, ROSALIA/K-4993-2014; Villalba, María Teresa/AAW-1067-2020	RODRIGUEZ, ROSALIA/0000-0002-4280-3691; Villalba, María Teresa/0000-0002-0042-9953; Monsalve, Rafael/0000-0002-6838-4472				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; BATANERO E, 1994, MOL IMMUNOL, V31, P31, DOI 10.1016/0161-5890(94)90135-X; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; BOUSQUET J, 1985, CLIN ALLERGY, V15, P439, DOI 10.1111/j.1365-2222.1985.tb02293.x; CARDOT E, 1995, J ALLERGY CLIN IMMUN, V95, P1, DOI 10.1016/S0091-6749(95)70145-1; DIDIER A, 1987, J ALLERGY CLIN IMMUN, V79, P578, DOI 10.1016/S0091-6749(87)80152-5; DUNN MJ, 1993, GEL ELECTROPHORESIS, P113; FAYE L, 1993, ANAL BIOCHEM, V209, P104, DOI 10.1006/abio.1993.1088; FAYE L, 1988, GLYCOCONJUGATE J, V5, P245, DOI 10.1007/BF01049085; FEIZI T, 1985, BIOCHEM J, V245, P1; FORSTER E, 1995, J ALLERGY CLIN IMMUN, V95, P1229, DOI 10.1016/S0091-6749(95)70080-3; GarciaCasado G, 1996, GLYCOBIOLOGY, V6, P471, DOI 10.1093/glycob/6.4.471; HIJIKATA A, 1994, INT ARCH ALLERGY IMM, V105, P198, DOI 10.1159/000236826; IGEA JM, 1992, ANN ALLERGY, V68, P515; KNUDSEN JD, 1992, SCAND J INFECT DIS, V24, P395, DOI 10.3109/00365549209061350; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIERE M, 1989, PLANT PHYSIOL, V90, P1182, DOI 10.1104/pp.90.3.1182; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; MULLER UR, 1995, J ALLERGY CLIN IMMUN, V96, P395, DOI 10.1016/S0091-6749(95)70059-5; NILSEN BM, 1991, J BIOL CHEM, V266, P2660; Ogawa H, 1996, GLYCOCONJUGATE J, V13, P555, DOI 10.1007/BF00731443; OHTA M, 1989, ARCH BIOCHEM BIOPHYS, V275, P151, DOI 10.1016/0003-9861(89)90359-7; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; Petersen A, 1996, J ALLERGY CLIN IMMUN, V98, P805, DOI 10.1016/S0091-6749(96)70130-6; PIENKOWSKI MM, 1988, J ALLERGY CLIN IMMUN, V82, P171, DOI 10.1016/0091-6749(88)90996-7; TANIAI M, 1993, MOL IMMUNOL, V30, P183; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P970, DOI 10.1016/S0091-6749(95)70097-8; VILLALBA M, 1990, BIOCHEM BIOPH RES CO, V172, P523, DOI 10.1016/0006-291X(90)90704-Q; VILLALBA M, 1994, J BIOL CHEM, V269, P15217; VILLALBA M, 1993, EUR J BIOCHEM, V216, P863, DOI 10.1111/j.1432-1033.1993.tb18208.x; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x; WOODWARD JR, 1992, GLYCOBIOLOGY, V2, P241, DOI 10.1093/glycob/2.3.241; YASUDA Y, 1970, BIOCHEMISTRY-US, V9, P25, DOI 10.1021/bi00803a004	38	91	92	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				147	153		10.1016/S0091-6749(99)70538-5	http://dx.doi.org/10.1016/S0091-6749(99)70538-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893198				2022-12-18	WOS:000078112300022
J	Corren, J				Corren, J			The impact of allergic rhinitis on bronchial asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	21st Century Management of Upper Respiratory Allergic Diseases - a Focus on Allergy and Asthma	JAN 13-14, 1997	CHICAGO, IL				SEASONAL INCREASE; NASAL PROVOCATION; CONTROLLED TRIAL; FOLLOW-UP; TERFENADINE; HYPERRESPONSIVENESS; RESPONSIVENESS; CETIRIZINE; ANTAGONIST; ASPIRATION		Univ Calif Los Angeles, Sch Med, Allergy Res Fdn Inc, Los Angeles, CA 90025 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Corren, J (corresponding author), Univ Calif Los Angeles, Sch Med, Allergy Res Fdn Inc, 11620 Wilshire Blvd,Suite 200, Los Angeles, CA 90025 USA.							ARSDEL PP, 1959, ACTA GENET, V9, P101; BARDIN PG, 1990, J ALLERGY CLIN IMMUN, V86, P82, DOI 10.1016/S0091-6749(05)80126-5; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BRAMAN SS, 1987, CHEST, V91, P671, DOI 10.1378/chest.91.5.671; BRUTTMANN G, 1990, ANN ALLERGY, V64, P224; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; DIJKMAN JH, 1990, CLIN EXP ALLERGY, V20, P483, DOI 10.1111/j.1365-2222.1990.tb03140.x; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; Fontanari P, 1996, J APPL PHYSIOL, V81, P1739, DOI 10.1152/jappl.1996.81.4.1739; GRANT JA, 1995, J ALLERGY CLIN IMMUN, V95, P923, DOI 10.1016/S0091-6749(95)70090-0; GRIFFIN MP, 1982, J ALLERGY CLIN IMMUN, V69, P354, DOI 10.1016/0091-6749(82)90145-2; HALPERN M, 1996, AM J RESP CRIT CARE, V153, pA860; HENRIKSEN JM, 1984, AM REV RESPIR DIS, V130, P1014; HOEHNE JH, 1971, J ALLERGY CLIN IMMUN, V48, P36, DOI 10.1016/0091-6749(71)90053-4; Huse D., 1996, AM J RESP CRIT CARE, V153, pA860; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; Kapsali T, 1997, J ALLERGY CLIN IMMUN, V99, P556; KARLIN JM, 1972, ANN ALLERGY, V30, P342; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; KAUFMAN J, 1970, AM REV RESPIR DIS, V101, P768; LITTELL NT, 1990, AM REV RESPIR DIS, V141, P580, DOI 10.1164/ajrccm/141.3.580; MADONINI E, 1987, J ALLERGY CLIN IMMUN, V79, P358, DOI 10.1016/0091-6749(87)90156-4; MATERNOWSKI CJ, 1962, J ALLERGY, V33, P130; MCLAURIN JG, 1932, ANN OTO RHINOL LARYN, V41, P780; Mullen WV, 1920, AM REV TUBERC, V4, P6840; PEDERSEN PA, 1983, ALLERGY, V38, P25, DOI 10.1111/j.1398-9995.1983.tb00852.x; RAFFERTY P, 1990, BRIT J CLIN PHARMACO, V30, P229, DOI 10.1111/j.1365-2125.1990.tb03769.x; RAMSDALE EH, 1985, J ALLERGY CLIN IMMUN, V75, P573; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V78, P30, DOI 10.1016/0091-6749(86)90111-9; SETTIPANE GA, 1986, OTOLARYNG HEAD NECK, V94, P470, DOI 10.1177/019459988609400411; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; SHTURMANELLSTEIN R, 1978, AM REV RESPIR DIS, V118, P65; Small P., 1989, AM J RHINOL, V3, P17, DOI [10.2500/105065889782024384, DOI 10.2500/105065889782024384]; SMITH JM, 1988, ALLERGY PRINCIPLES P; SPECTOR S, 1992, ANN ALLERGY, V69, P212; TAYTARD A, 1987, BRIT J CLIN PHARMACO, V24, P743, DOI 10.1111/j.1365-2125.1987.tb03240.x; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; WOODBAKER R, 1995, BRIT J CLIN PHARMACO, V39, P671, DOI 10.1111/j.1365-2125.1995.tb05727.x; YAN K, 1983, EUR J RESPIR DIS, V64, P105	44	91	94	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	2	S			S352	S356		10.1016/S0091-6749(98)70218-0	http://dx.doi.org/10.1016/S0091-6749(98)70218-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	ZA245	9500726				2022-12-18	WOS:000072343900002
J	Foster, CA				Foster, CA			VCAM-1/alpha 4-integrin adhesion pathway: Therapeutic target for allergic inflammatory disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adhesion molecules; endothelial cells; inhibitors; VCAM-1; VLA-4; review	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; ENDOTHELIAL-CELL ACTIVATION; NONOBESE DIABETIC MICE; LEUKOCYTE ADHESION; E-SELECTIN; MOLECULE-1 EXPRESSION; MONOCLONAL-ANTIBODIES; CARDIAC ALLOGRAFTS; IN-VIVO	Lymphocyte recirculation and leukocyte extravasation involve a multistep process that is central to immune surveillance and the rapid response of white blood cells to sites of injury or infection. Interaction of vascular adhesion molecules (VCAM-1, ICAM-1, and selectins) with ligands on the leukocyte surface (integrins, carbohydrates, and mucin-like molecules) regulate diapedesis. The nature of an inflammatory stimulus ultimately determines the pattern of endothelial adhesion molecule expression and the avidity state of their counterreceptors, thus dictating to a large extent whether a subclass of leukocytes will play a dominant role in the immune response. Immunoglobulin superfamily member VCAM-1 recognizes alpha 4 beta 1 integrin, expressed on all leukocytes except neutrophils. Blockade or inhibition of VCAM-1/alpha 4 beta 1 interaction is expected to have therapeutic potential in treating various inflammatory disorders and autoimmune diseases since this adhesion pathway has a major influence on eosinophil, lymphocyte, and monocyte trafficking. This review summarizes some of the strategies that are currently used to selectively inhibit the VCAM-1/alpha 4 integrin pathway, including soluble VCAM-Ig fusion protein, peptide antagonists, antisense oligonucleotides, natural products, and neutralizing antibodies to VCAM-1 or alpha 4 integrin.			Foster, CA (corresponding author), SANDOZ GMBH, RES INST, DEPT GEN DERMATOL, BRUNNER STR 59, A-1235 VIENNA, AUSTRIA.							AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BACCHI CE, 1993, AM J PATHOL, V142, P579; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BARON JL, 1994, J CLIN INVEST, V93, P1700, DOI 10.1172/JCI117153; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BENNETT CF, 1994, J IMMUNOL, V152, P3530; BENTLEY AM, 1993, J ALLERGY CLIN IMMUN, V92, P857, DOI 10.1016/0091-6749(93)90064-M; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BEVILACQUA MP, 1994, ANNU REV MED, V45, P361, DOI 10.1146/annurev.med.45.1.361; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BOSCHELLI DH, 1995, J MED CHEM, V38, P4597, DOI 10.1021/jm00022a026; Boschelli Diane H., 1995, Drugs of the Future, V20, P805; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRASCH J, 1992, DERMATOLOGY, V185, P12, DOI 10.1159/000247395; BRISCOE DM, 1991, TRANSPLANTATION, V51, P537; BRISCOE DM, 1992, J IMMUNOL, V149, P2954; CARLOS TM, 1994, BLOOD, V84, P2068; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CHEN CC, 1995, J IMMUNOL, V155, P3538; CHEN SJ, 1995, GENE THER, V2, P469; CHISHOLM PL, 1993, EUR J IMMUNOL, V23, P682, DOI 10.1002/eji.1830230317; ELICES MJ, 1994, J CLIN INVEST, V93, P405, DOI 10.1172/JCI116975; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FERRAN C, 1995, BIOCHEM BIOPH RES CO, V214, P212, DOI 10.1006/bbrc.1995.2277; FOSTER CA, 1994, JOURNAL OF DERMATOLOGY, VOL 21, NO 11, NOVEMBER 1994, P847, DOI 10.1111/j.1346-8138.1994.tb03300.x; FOSTER CA, 1996, SKIN PHARMACOL, V9, P149; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; GOSSET P, 1995, INT ARCH ALLERGY IMM, V106, P69, DOI 10.1159/000236892; GROVES RW, 1993, J AM ACAD DERMATOL, V29, P67, DOI 10.1016/0190-9622(93)70154-L; GROVES RW, 1995, BRIT J DERMATOL, V132, P345, DOI 10.1111/j.1365-2133.1995.tb08666.x; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; GURTNER GC, 1995, GENE DEV, V9, P1, DOI 10.1101/gad.9.1.1; HARDING CV, 1995, J IMMUNOL, V155, P1767; HARLAN JM, 1992, ADHESION ITS ROLE IN, P117; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Henseleit U, 1994, Exp Dermatol, V3, P249, DOI 10.1111/j.1600-0625.1994.tb00286.x; Hommel U, 1996, FEBS LETT, V379, P69, DOI 10.1016/0014-5793(95)01453-5; IADEMARCO MF, 1995, J CLIN INVEST, V95, P264, DOI 10.1172/JCI117650; ISOBE M, 1994, J IMMUNOL, V153, P5810; JAKUBOWSKI A, 1995, J IMMUNOL, V155, P938; KAWAI M, 1995, J IMMUNOL, V154, P2333; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KWEE L, 1995, DEVELOPMENT, V121, P489; LI HM, 1993, AM J PATHOL, V143, P1551; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; MARLOR CW, 1992, AM J PATHOL, V140, P1055; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MCCARTY JM, 1995, FEBS LETT, V372, P194, DOI 10.1016/0014-5793(95)00976-G; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MILNE AAY, 1995, EUR J PHARMACOL, V282, P243, DOI 10.1016/0014-2999(95)00340-Q; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MOLOSSI S, 1995, J CLIN INVEST, V95, P2601, DOI 10.1172/JCI117962; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393, DOI 10.1165/ajrcmb/7.4.393; NAKAJIMA H, 1994, J EXP MED, V179, P1145, DOI 10.1084/jem.179.4.1145; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; OROSZ CG, 1993, TRANSPLANTATION, V56, P453, DOI 10.1097/00007890-199308000-00039; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PELLETIER RP, 1992, J IMMUNOL, V149, P2473; PRETOLANI M, 1994, J EXP MED, V180, P795, DOI 10.1084/jem.180.3.795; READ MA, 1995, IMMUNITY, V2, P493, DOI 10.1016/1074-7613(95)90030-6; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; RICE GE, 1991, AM J PATHOL, V138, P385; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHLEGEL PG, 1995, J IMMUNOL, V155, P3856; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHARAR SR, 1991, SURGERY, V110, P213; SHEPPARD AM, 1994, CELL ADHES COMMUN, V2, P27, DOI 10.3109/15419069409014200; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SILBER A, 1994, J CLIN INVEST, V93, P1554, DOI 10.1172/JCI117134; SIMMONS PJ, 1992, BLOOD, V80, P388; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SWERLICK RA, 1992, J IMMUNOL, V149, P698; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THORNHILL MH, 1990, J IMMUNOL, V145, P865; TSUKAMOTO K, 1995, CELL IMMUNOL, V165, P193, DOI 10.1006/cimm.1995.1205; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013; YANG JT, 1995, DEVELOPMENT, V121, P549; YANG XD, 1993, P NATL ACAD SCI USA, V90, P10494, DOI 10.1073/pnas.90.22.10494; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	86	91	102	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	2	S			S270	S277		10.1016/S0091-6749(96)70075-1	http://dx.doi.org/10.1016/S0091-6749(96)70075-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WC447	8977536				2022-12-18	WOS:A1996WC44700013
J	CHAROUS, BL; HAMILTON, RG; YUNGINGER, JW				CHAROUS, BL; HAMILTON, RG; YUNGINGER, JW			OCCUPATIONAL LATEX EXPOSURE - CHARACTERISTICS OF CONTACT AND SYSTEMIC REACTIONS IN 47 WORKERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CONTACT URTICARIA; LATEX; OCCUPATIONAL ASTHMA; ALLERGIC CONTACT DERMATITIS	SURGICAL GLOVE POWDER; NATURAL-HISTORY; RUBBER GLOVES; URTICARIA; ALLERGY; ANAPHYLAXIS; DERMATITIS; PREVALENCE; ANTIGENS; PERSONNEL	Background: Recent reports have noted an apparent increase in the prevalence of natural rubber latex (NRL) allergy among workers with occupational latex exposure (OLE). The risk factors for and the natural history of NRL allergy in this population are not well delineated, and the utility and comparability of immunoassays as confirmatory testing are unclear. Methods: Serum samples and medical histories were obtained from 47 symptomatic workers with OLE, from nine other individuals with a history consistent with NRL allergy, and from 10 atopic asymptomatic NRL-exposed control subjects. Sera were coded and analyzed in a blinded manner for latex-specific IgE, using a variety of antigen sources, including ammoniated and nonammoniated raw latex preparations and three finished glove preparations. Results: Risk factors for the latex allergy in workers with OLE appear to include a history of atopy or preexisting dermatitis involving the hands. In this population, NRL allergy is commonly preceded by latex glove-associated contact dermatitis. Serologic testing confirmed the suspected diagnosis in 62% of workers (15 of 24) with systemic symptoms but was only positive in 27% of workers (4 of 15) with symptoms limited to contact urticaria. Conclusions: The appearance of a latex glove-associated contact rash may precede the development of NRL allergy, particularly in atopic persons. Workers at risk should be advised to use alternate types and brands of latex gloves or to switch to nonlatex gloves entirely.	JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR,BALTIMORE,MD; MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55905	Johns Hopkins University; Johns Hopkins Medicine; Mayo Clinic	CHAROUS, BL (corresponding author), MILWAUKEE MED CLIN,DIV ALLERGY IMMUNOL,3003 W GOOD HOPE RD,MILWAUKEE,WI, USA.							ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BAUR X, 1990, LANCET, V335, P912, DOI 10.1016/0140-6736(90)90508-3; BEEZHOLD D, 1992, ARCH SURG-CHICAGO, V127, P1354; BERKY ZT, 1992, JAMA-J AM MED ASSOC, V268, P2695; BOSQUET J, 1991, CLIN REV ALLERG, V9, P357; CARILLO T, 1986, CONTACT DERMATITIS, V15, P69; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P443; DALRYMPLE S. J., 1992, RUBBER DEV, V45, P51; ESTLANDER T, 1986, CONTACT DERMATITIS, V14, P20, DOI 10.1111/j.1600-0536.1986.tb01147.x; FISHER AA, 1987, CONTACT DERMATITIS, V16, P224, DOI 10.1111/j.1600-0536.1987.tb01430.x; FRANSWAY A, 1992, INT LAT C SENS LAT M, P43; FUCHS T, 1992, ALLERGY PROC, V13, P61, DOI 10.2500/108854192778878881; HAMILTON RG, 1994, J LAB CLIN MED, V123, P594; IACOBELLI AM, 1993, J ALLERGY CLIN IMMUN, V91, P216; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; KROGH G, 1981, J AM ACAD DERMATOL, V5, P328; KURUP V, 1993, J ALLERGY CLIN IMMUN, V91, P11228; LAGIER F, 1990, LANCET, V336, P516, DOI 10.1016/0140-6736(90)92076-T; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; PECQUET C, 1990, J AM ACAD DERMATOL, V22, P631, DOI 10.1016/0190-9622(90)70086-W; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; RICH P, 1991, J AM ACAD DERMATOL, V24, P37, DOI 10.1016/0190-9622(91)70006-N; SAVLIWALA MN, 1987, J ALLERGY CLIN IMMUN, V80, P741, DOI 10.1016/0091-6749(87)90296-X; SEGGEV JS, 1990, ANN ALLERGY, V65, P152; SHMUNES E, 1984, CONTACT DERMATITIS, V10, P240, DOI 10.1111/j.1600-0536.1984.tb00107.x; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; VANDERMEEREN HLM, 1986, CONTACT DERMATITIS, V14, P190, DOI 10.1111/j.1600-0536.1986.tb01213.x; VANKETEL WG, 1984, CONTACT DERMATITIS, V11, P323, DOI 10.1111/j.1600-0536.1984.tb01026.x; VOELKER R, 1992, AMA NEWS        1216; WRANGSJO K, 1986, CONTACT DERMATITIS, V15, P79, DOI 10.1111/j.1600-0536.1986.tb01281.x; WRANGSJO K, 1988, CONTACT DERMATITIS, V19, P264, DOI 10.1111/j.1600-0536.1988.tb02925.x	39	91	94	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					12	18		10.1016/0091-6749(94)90065-5	http://dx.doi.org/10.1016/0091-6749(94)90065-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	8027489	Bronze			2022-12-18	WOS:A1994NX39300002
J	BERNSTEIN, DI; KORBEE, L; STAUDER, T; BERNSTEIN, JA; SCINTO, J; HERD, ZL; BERNSTEIN, IL				BERNSTEIN, DI; KORBEE, L; STAUDER, T; BERNSTEIN, JA; SCINTO, J; HERD, ZL; BERNSTEIN, IL			THE LOW-PREVALENCE OF OCCUPATIONAL ASTHMA AND ANTIBODY-DEPENDENT SENSITIZATION TO DIPHENYLMETHANE DIISOCYANATE IN A PLANT ENGINEERED FOR MINIMAL EXPOSURE TO DIISOCYANATES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DIISOCYANATES; OCCUPATIONAL ASTHMA; DIPHENYLMETHANE DIISOCYANATE; URETHANE; MOLDING, QUESTIONNAIRE; SENSITIZATION, DIAGNOSIS	TOLUENE DIISOCYANATE; FOUNDRY WORKERS; PULMONARY; MDI	Background: Diisocyanate chemicals are leading causes of occupational asthma (OA). Methods: We conducted a cross-sectional study of 243 workers exposed to diphenylmethane diisocyanate (MDI) in a urethane mold plant that had been designed to minimize MDI exposure (levels were maintained below 0.005 ppm and were continuously monitored). All participants were screened by questionnaire and tests for serum antibodies to MDI-human serum albumin (HSA). On the basis of questionnaire responses, diagnoses were derived that included OA; non-OA; work-related and non-work-related rhinitis; and lower respiratory irritant responses. Serial peak expiratory flow rate studies were performed for 2 weeks in 43 workers with and in 23 workers without lower respiratory symptoms. Results: Results of serial peak expiratory flow rate studies were abnormal in 3 (33%) of 9 workers with OA, in 2 (50%) of 4 with non-OA, and in 2 (9%) of 23 case control subjects. A significant association was found between peak flow rate variability and a questionnaire asthma diagnosis (chi2 p < 0.002). Physicians confirmed three cases of OA, one of which occurred in a control worker who was free of symptoms. In all three cases asthma symptoms remitted after the worker left the workplace. Serum specific IgE and IgG levels were elevated in 2 of 243 workers, one of whom was prick test positive to MDI-HSA and had had cutaneous anaphylaxis after MDI exposure. Conclusions: On the basis of these cases, specific work activities associated with exposure to MDI were identified and corrective measures were instituted. Strict control and monitoring of ambient MDI exposure was associated with a low prevalence of specific sensitization to MDI and a lower than expected prevalence of OA.			BERNSTEIN, DI (corresponding author), UNIV CINCINNATI,MED CTR,DIV IMMUNOL,ML 563,231 BETHESDA AVE,CINCINNATI,OH 45267, USA.			Bernstein, Jonathan/0000-0002-3476-1196				ADAMS WGF, 1975, BRIT J IND MED, V32, P72; BAUR X, 1990, LUNG, V168, P606, DOI 10.1007/BF02718184; BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P24, DOI 10.1016/0091-6749(82)90197-X; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; BURGE PS, 1987, BRIT J DIS CHEST, V81, P105; BUTCHER BT, 1977, AM REV RESPIR DIS, V116, P411, DOI 10.1164/arrd.1977.116.3.411; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; DIEM JE, 1982, AM REV RESPIR DIS, V126, P420; GALLAGHER JS, 1981, J OCCUP ENVIRON MED, V23, P610, DOI 10.1097/00043764-198109000-00009; HIGGINS BG, 1989, AM REV RESPIR DIS, V140, P1368, DOI 10.1164/ajrccm/140.5.1368; LISS GM, 1988, J ALLERGY CLIN IMMUN, V82, P55, DOI 10.1016/0091-6749(88)90051-6; LUSHNIAK BD, 1990, J ALLERGY CLIN IMMUN, V85, P252; MOLLER DR, 1986, AM REV RESPIR DIS, V134, P175; PETERS J M, 1975, Environmental Health Perspectives, V11, P97, DOI 10.2307/3428330; PETERS J M, 1970, Archives of Environmental Health, V20, P364; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SMITH AB, 1987, AM J IND MED, V12, P205, DOI 10.1002/ajim.4700120209; TANSER AR, 1973, THORAX, V28, P596, DOI 10.1136/thx.28.5.596; ZAMMITTABONA M, 1983, AM REV RESPIR DIS, V128, P226; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0	20	91	92	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1993	92	3					387	396		10.1016/0091-6749(93)90117-X	http://dx.doi.org/10.1016/0091-6749(93)90117-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LX309	8360389				2022-12-18	WOS:A1993LX30900004
J	MALO, JL; GHEZZO, H; DAQUINO, C; LARCHEVEQUE, J; CARTIER, A; CHANYEUNG, M				MALO, JL; GHEZZO, H; DAQUINO, C; LARCHEVEQUE, J; CARTIER, A; CHANYEUNG, M			NATURAL-HISTORY OF OCCUPATIONAL ASTHMA - RELEVANCE OF TYPE OF AGENT AND OTHER FACTORS IN THE RATE OF DEVELOPMENT OF SYMPTOMS IN AFFECTED SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						OBSTRUCTIVE LUNG DISEASES; BRONCHI; AIRWAY OBSTRUCTION	CEDAR THUJA-PLICATA; BRONCHIAL REACTIVITY; WORKERS; VOLUME	It is unknown whether factors such as the nature of the agent, gender, age, atopy, smoking habits, continuous or noncontinuous exposure, and pattern of asthmatic reaction can influence the rate of development of symptoms in subjects with occupational asthma. We compared several clinical and functional parameters among three groups of subjects with occupational asthma caused by Western red cedar (group 1, n = 433), isocyanates (group 2, n = 107), and high molecular weight agents acting through an IgE-mediated mechanism (group 3, n = 121). Survival analysis showed that the three curves relating years of exposure before onset of symptoms to the proportion of subjects without symptoms were significantly different in two respects: (1) almost 40% of subjects in groups 1 and 2 as compared with 20% of subjects in group 3 became symptomatic within 1 year of exposure; (2) after 5 years of exposure, the rate of sensitization was slower for subjects in groups 2 and 3 as compared with those in group 1. Having a nonimmediate reaction at the time of specific inhalation challenges, being continuously exposed and being younger slightly increased the risk at each time point on the curve of developing symptoms in subjects with occupational asthma. These data suggest that the natural history for onset of occupational asthma is different depending on the sensitizing agent. Factors such as age, type of exposure, and pattern of reaction on exposure to the agent also modulate the rate of development of this condition.	VANCOUVER GEN HOSP, DEPT MED, VANCOUVER V5Z 1M9, BC, CANADA	University of British Columbia	MALO, JL (corresponding author), HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA.							AGIUS RM, 1991, ANN OCCUP HYG, V35, P129, DOI 10.1093/annhyg/35.2.129; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; BURGE PS, 1981, THORAX, V36, P828, DOI 10.1136/thx.36.11.828; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CHANYEUNG M, 1982, J ALLERGY CLIN IMMUN, V70, P32, DOI 10.1016/0091-6749(82)90198-1; CHANYEUNG M, 1977, AM REV RESPIR DIS, V116, P1023; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; CLOUTIER Y, 1989, EUR RESPIR J, V2, P769; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COREY PN, 1979, J OCCUP ENVIRON MED, V21, P395; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LAM S, 1987, J ALLERGY CLIN IMMUN, V80, P44, DOI 10.1016/S0091-6749(87)80189-6; MALO JL, 1988, AM REV RESPIR DIS, V138, P807, DOI 10.1164/ajrccm/138.4.807; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MANNING PJ, 1990, J ALLERGY CLIN IMMUN, V86, P211, DOI 10.1016/S0091-6749(05)80068-5; MAPP CE, 1987, B EUR PHYSIOPATH RES, V23, P583; MATTE TD, 1990, CHEST, V98, pS173, DOI 10.1378/chest.98.5_Supplement.173S; MEREDITH SK, 1991, BRIT J IND MED, V48, P292; MOIRA CY, 1990, CLIN EXP ALLERGY, V20, P1; MUSK AW, 1989, BRIT J IND MED, V46, P636; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; VANDENPLAS O, 1992, AM REV RESPIR DIS, V145, P582, DOI 10.1164/ajrccm/145.3.582; VEDAL S, 1986, ARCH ENVIRON HEALTH, V41, P179, DOI 10.1080/00039896.1986.9935774; VENABLES KM, 1987, BRIT J IND MED, V44, P73; VENABLES KM, 1989, RESP MED, V83, P437, DOI 10.1016/S0954-6111(89)80078-2	27	91	93	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	1				937	944		10.1016/0091-6749(92)90466-F	http://dx.doi.org/10.1016/0091-6749(92)90466-F			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD190	1460199	Bronze			2022-12-18	WOS:A1992KD19000010
J	HEPNER, MJ; OWNBY, DR; ANDERSON, JA; ROWE, MS; SEARSEWALD, D; BROWN, EB				HEPNER, MJ; OWNBY, DR; ANDERSON, JA; ROWE, MS; SEARSEWALD, D; BROWN, EB			RISK OF SYSTEMIC REACTIONS IN PATIENTS TAKING BETA-BLOCKER DRUGS RECEIVING ALLERGEN IMMUNOTHERAPY INJECTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HENRY FORD HOSP,DEPT INTERNAL MED & PEDIAT,DIV ALLERGY & CLIN IMMUNOL,DETROIT,MI 48202; HENRY FORD HOSP,DIV BIOSTAT & RES EPIDEMIOL,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital								BICKELL WH, 1984, ANN EMERG MED, V13, P189, DOI 10.1016/S0196-0644(84)80611-3; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; HANNAWAY PJ, 1983, NEW ENGL J MED, V308, P1536; HEPNER M, 1987, J ALLERGY CLIN IMMUN, V79, P135; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; LEVINE MI, 1979, J ALLERGY CLIN IMMUN, V63, P209; NEWMAN BR, 1981, ANN ALLERGY, V47, P35; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3	10	91	94	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1990	86	3	1				407	411		10.1016/S0091-6749(05)80105-8	http://dx.doi.org/10.1016/S0091-6749(05)80105-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA859	1976666	Bronze			2022-12-18	WOS:A1990EA85900016
J	DIDIER, A; CADOR, D; BONGRAND, P; FURSTOSS, R; FOURNERON, P; SENFT, M; PHILIPJOET, F; CHARPIN, D; CHARPIN, J; VERVLOET, D				DIDIER, A; CADOR, D; BONGRAND, P; FURSTOSS, R; FOURNERON, P; SENFT, M; PHILIPJOET, F; CHARPIN, D; CHARPIN, J; VERVLOET, D			ROLE OF THE QUATERNARY AMMONIUM ION DETERMINANTS IN ALLERGY TO MUSCLE-RELAXANTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP STE MARGUERITE,DEPT CHEST DIS & ALLERGOL,BP 29,F-13277 MARSEILLE 9,FRANCE; HOP STE MARGUERITE,INSERM,F-13277 MARSEILLE 9,FRANCE; FAC STE MARGUERITE,DEPT IMMUNOL,F-13277 MARSEILLE 9,FRANCE; FAC SCI LUMINY,DEPT CHEM,F-13288 MARSEILLE 9,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite			Bongrand, Pierre/C-4456-2013	Bongrand, Pierre/0000-0001-6185-6572				Baldo B A, 1985, Ann Fr Anesth Reanim, V4, P139, DOI 10.1016/S0750-7658(85)80189-1; BALDO BA, 1983, NATURE, V306, P262, DOI 10.1038/306262a0; BALDO BA, 1983, ANAESTH INTENS CARE, V11, P194, DOI 10.1177/0310057X8301100302; Boileau S, 1985, Ann Fr Anesth Reanim, V4, P195, DOI 10.1016/S0750-7658(85)80200-8; FISHER MM, 1979, ANAESTH INTENS CARE, V7, P58, DOI 10.1177/0310057X7900700110; HARLE DG, 1985, BRIT J ANAESTH, V57, P1073, DOI 10.1093/bja/57.11.1073; HARLE DG, 1984, LANCET, V1, P930; LAXENAIRE M C, 1985, Annales Francaises d'Anesthesie et de Reanimation, V4, P30, DOI 10.1016/S0750-7658(85)80220-3; LEVINE BB, 1986, J CLIN INVEST, V47, P55; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SIRAGANIAN RP, 1975, IMMUNOCHEMISTRY, V12, P149, DOI 10.1016/0019-2791(75)90111-1; SOMMER HZ, 1971, J ORG CHEM, V36, P824, DOI 10.1021/jo00805a021; VERVLOET D, 1983, J ALLERGY CLIN IMMUN, V71, P552, DOI 10.1016/0091-6749(83)90436-0; VERVLOET D, 1985, J ALLERGY CLIN IMMUN, V75, P338, DOI 10.1016/0091-6749(85)90069-7; VERVLOET D, 1985, J ALLERGY CLIN IMMUN, V76, P222, DOI 10.1016/0091-6749(85)90705-5	16	91	92	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1987	79	4					578	584		10.1016/S0091-6749(87)80152-5	http://dx.doi.org/10.1016/S0091-6749(87)80152-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G9720	2435775				2022-12-18	WOS:A1987G972000005
J	MAPP, CE; POLATO, R; MAESTRELLI, P; HENDRICK, DJ; FABBRI, LM				MAPP, CE; POLATO, R; MAESTRELLI, P; HENDRICK, DJ; FABBRI, LM			TIME COURSE OF THE INCREASE IN AIRWAY RESPONSIVENESS ASSOCIATED WITH LATE ASTHMATIC REACTIONS TO TOLUENE DIISOCYANATE IN SENSITIZED SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PADUA,INST OCCUPAT MED,I-35100 PADUA,ITALY; NEWCASTLE GEN HOSP,SCH MED,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	University of Padua; Newcastle General Hospital			Fabbri, Leonardo M/I-4055-2012	Fabbri, Leonardo M/0000-0001-8894-1689				BENSON MK, 1975, BRIT J DIS CHEST, V69, P227, DOI 10.1016/0007-0971(75)90090-X; BOUSHEY HA, 1975, PHYSIOLOGIST, V18, P148; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1979, AM REV RESPIR DIS, V119, P505; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, CAN MED ASSOC J, V121, P602; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FABBRI LM, 1984, AM REV RESPIR DIS, V129, P288; FABBRI LM, 1984, 1984 ANN M AM THOR S, V129, P159; FISH JE, 1978, J ALLERGY CLIN IMMUN, V61, P140, DOI 10.1016/0091-6749(78)90277-4; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; HOLTZMAN MJ, 1979, AM REV RESPIR DIS, V120, P1059; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; MALO JL, 1983, J ALLERGY CLIN IMMUN, V72, P413, DOI 10.1016/0091-6749(83)90508-0; Mapp C, 1979, Med Lav, V70, P203; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; RUBINFELD AR, 1977, AM REV RESPIR DIS, V115, P381; SIRACUSA A, 1978, CLIN ALLERGY, V8, P195, DOI 10.1111/j.1365-2222.1978.tb00464.x; VALLIERES M, 1977, AM REV RESPIR DIS, V115, P867; ZAMMITTABONA M, 1983, AM REV RESPIR DIS, V128, P226; 1971, TABLES REFERENCE EXA	24	91	91	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	5					568	572		10.1016/0091-6749(85)90031-4	http://dx.doi.org/10.1016/0091-6749(85)90031-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AHV07	2985677	Bronze			2022-12-18	WOS:A1985AHV0700005
J	SHEFFER, AL; AUSTEN, KF				SHEFFER, AL; AUSTEN, KF			EXERCISE-INDUCED ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL IMMUNOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital	SHEFFER, AL (corresponding author), HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115, USA.				NHLBI NIH HHS [HL-17382] Funding Source: Medline; NIAID NIH HHS [AI-10356, AI-07722] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAER RL, 1971, IMMUNOLOGICAL DISEAS, P973; HARBER LC, 1963, J INVEST DERMATOL, V41, P439, DOI 10.1038/jid.1963.138; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; ILLIG L, 1967, ARCH KLIN EXP DERM, V229, P360, DOI 10.1007/BF00509213; JAMES LP, 1964, NEW ENGL J MED, V270, P597, DOI 10.1056/NEJM196403192701202; JUHLIN L, 1961, JAMA-J AM MED ASSOC, V177, P371, DOI 10.1001/jama.1961.73040320001004; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P319, DOI 10.1016/0091-6749(81)90158-5; KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KIDD J, 1982, Journal of Allergy and Clinical Immunology, V69, P103; LEWIS J, 1981, J ALLERGY CLIN IMMUN, V68, P432, DOI 10.1016/0091-6749(81)90197-4; MATTHEWS CNA, 1973, BR J DERMATOL, V99, P279; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; NEWCOMB RW, 1973, AM J MED, V54, P174, DOI 10.1016/0002-9343(73)90221-0; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SHEFFER AL, 1983, J ALLERGY CLIN IMMUN, V71, P311, DOI 10.1016/0091-6749(83)90085-4; SHEFFER AL, 1979, SCI PRACTICE CLIN ME, V4, P468; SHERMAN WB, 1950, J ALLERGY, V21, P414, DOI 10.1016/0021-8707(50)90017-7; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; SOTER NA, 1979, J INVEST DERMATOL, V72, P282; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; SOTER NA, 1977, FED P, V26, P1736; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P366, DOI 10.1016/0091-6749(71)90083-2; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756	24	91	93	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					699	703		10.1016/0091-6749(84)90309-9	http://dx.doi.org/10.1016/0091-6749(84)90309-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS046	6715733				2022-12-18	WOS:A1984SS04600016
J	LYBARGER, JA; GALLAGHER, JS; PULVER, DW; LITWIN, A; BROOKS, S; BERNSTEIN, IL				LYBARGER, JA; GALLAGHER, JS; PULVER, DW; LITWIN, A; BROOKS, S; BERNSTEIN, IL			OCCUPATIONAL ASTHMA INDUCED BY INHALATION AND INGESTION OF GARLIC	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,MED CTR,DEPT INTERNAL MED,CINCINNATI,OH 45267; UNIV CINCINNATI,MED CTR,DEPT ENVIRONM HLTH,CINCINNATI,OH 45267; UNIV CINCINNATI,MED CTR,DEPT IMMUNOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati					NCRR NIH HHS [MOL-RR-00068] Funding Source: Medline; NHLBI NIH HHS [HL 22415] Funding Source: Medline; NIEHS NIH HHS [ES 00159] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000159] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAUR X, 1979, CLIN ALLERGY, V9, P443, DOI 10.1111/j.1365-2222.1979.tb02507.x; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; BERNSTEIN IL, 1981, CLIN CHEST MED, P255; BROOKS SM, 1981, ENV OCCUPATIONAL MED; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; FALLERONI AE, 1981, J ALLERGY CLIN IMMUN, V68, P156, DOI 10.1016/0091-6749(81)90173-1; HENDRICK DJ, 1976, CLIN ALLERGY, V6, P241, DOI 10.1111/j.1365-2222.1976.tb01903.x; HENSON G. E., 1940, JOUR FLORIDA MED ASSOC, V27, P86; Hjorth N, 1976, Contact Dermatitis, V2, P28, DOI 10.1111/j.1600-0536.1976.tb02975.x; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P147, DOI 10.1016/0091-6749(77)90217-2; KARR RM, 1979, J ALLERGY CLIN IMMUN, V64, P650, DOI 10.1016/0091-6749(79)90030-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKAMURA S, 1972, ASTHMA RES, V10, P37	13	91	91	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	5					448	454		10.1016/0091-6749(82)90120-8	http://dx.doi.org/10.1016/0091-6749(82)90120-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NP934	7076985				2022-12-18	WOS:A1982NP93400007
J	SUSSMAN, GL; HARVEY, RP; SCHOCKET, AL				SUSSMAN, GL; HARVEY, RP; SCHOCKET, AL			DELAYED PRESSURE URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,SCH MED,DIV CLIN IMMUNOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								EBKEN RK, 1968, J ALLERGY, V41, P338, DOI 10.1016/0021-8707(68)90076-2; ESTES SA, 1981, J AM ACAD DERMATOL, V5, P25, DOI 10.1016/S0190-9622(81)70073-2; GREAVES MW, 1970, ARCH DERMATOL, V101, P418, DOI 10.1001/archderm.101.4.418; KALZ F, 1950, ARCH DERMATOL SYPH, V61, P772, DOI 10.1001/archderm.1950.01530120063005; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KOHLER PF, 1981, N ENGL SOC ALLERGY P, V2, P136; NEWCOMB RW, 1973, AM J MED, V54, P174, DOI 10.1016/0002-9343(73)90221-0; OERTEL H, 1981, J ALLERGY CLIN IMMUN, V68, P238, DOI 10.1016/0091-6749(81)90190-1; OERTEL HL, 1981, J IMMUNOL, V127, P1398; OSTROV MR, 1967, ANN ALLERGY, V25, P591; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P436, DOI 10.1016/0091-6749(80)90237-7; RYAN TJ, 1968, BRIT J DERMATOL, V80, P485, DOI 10.1111/j.1365-2133.1968.tb12334.x; SOTER NA, 1977, FED PROC, V36, P1736; Wadsworth A, 1938, J IMMUNOL, V35, P217; WARIN RP, 1974, MAJOR PROBLEMS DERMA, P120; YECIES LD, 1980, CLIN IMMUNOLOGY, P1294	16	91	91	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	5					337	342		10.1016/0091-6749(82)90022-7	http://dx.doi.org/10.1016/0091-6749(82)90022-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PQ105	6127359				2022-12-18	WOS:A1982PQ10500004
J	HARVEY, RP; SCHOCKET, AL				HARVEY, RP; SCHOCKET, AL			EFFECT OF H-1 AND H-2 BLOCKADE ON CUTANEOUS HISTAMINE RESPONSE IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO, MED CTR, DEPT MED, DIV CLIN IMMUNOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								ASH ASF, 1966, BRIT J PHARM CHEMOTH, V27, P427, DOI 10.1111/j.1476-5381.1966.tb01674.x; BARAF CS, 1976, CURR THER RES CLIN E, V19, P32; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; CHAKRIN LW, 1974, AGENTS ACTIONS, V4, P297, DOI 10.1007/BF01964930; CLAYMAN CB, 1977, JAMA-J AM MED ASSOC, V238, P1289, DOI 10.1001/jama.238.12.1289; CODE CF, 1976, NEW ENGL J MED, V295, P1160; COMMENS CA, 1978, BRIT J DERMATOL, V99, P675, DOI 10.1111/j.1365-2133.1978.tb07062.x; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; GREEN JP, 1977, NATURE, V269, P163, DOI 10.1038/269163a0; HUTCHCROFT BJ, 1978, J ALLERGY CLIN IMMUN, V61, P192, DOI 10.1016/0091-6749(78)90451-7; LICHTENSTEIN LM, 1973, NATURE, V244, P287, DOI 10.1038/244287a0; MARKS R, 1977, BRIT J CLIN PHARMACO, V4, P367, DOI 10.1111/j.1365-2125.1977.tb00725.x; MCCARTHY DM, 1977, ANN INTERN MED, V87, P668, DOI 10.7326/0003-4819-87-6-668; PHANUPHAK P, 1978, CLIN ALLERGY, V8, P429, DOI 10.1111/j.1365-2222.1978.tb01493.x; POWELL JR, 1976, J PHARMACOL EXP THER, V196, P1; REGAN PT, 1978, MAYO CLIN PROC, V53, P79; ROBERTS LJ, 1979, NEW ENGL J MED, V300, P236, DOI 10.1056/NEJM197902013000506; ROBERTSON I, 1978, BRIT J CLIN PHARMACO, V5, P319, DOI 10.1111/j.1365-2125.1978.tb01714.x; WARIN RP, 1974, URTICARIA, P100	20	91	93	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	2					136	139		10.1016/0091-6749(80)90198-0	http://dx.doi.org/10.1016/0091-6749(80)90198-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JF199	6101337				2022-12-18	WOS:A1980JF19900009
J	BUTCHER, BT; KARR, RM; ONEIL, CE; WILSON, MR; DHARMARAJAN, V; SALVAGGIO, JE; WEILL, H				BUTCHER, BT; KARR, RM; ONEIL, CE; WILSON, MR; DHARMARAJAN, V; SALVAGGIO, JE; WEILL, H			INHALATION CHALLENGE AND PHARMACOLOGIC STUDIES OF TOLUENE DIISOCYANATE (TDI) SENSITIVE WORKERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,MED CTR,DEPT MED,NEW ORLEANS,LA 70118	Tulane University								ARROYAVE CM, 1976, J IMMUNOL METHODS, V13, P101, DOI 10.1016/0022-1759(76)90148-4; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BUTCHER BT, 1977, J ALLERGY CLIN IMMUN, V59, P223, DOI 10.1016/0091-6749(77)90153-1; BUTCHER BT, 1977, AM REV RESPIR DIS, V116, P411, DOI 10.1164/arrd.1977.116.3.411; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; DAVIES RJ, 1977, J ALLERGY CLIN IMMUN, V60, P233; FINE DP, 1977, CLIN RES, V25, pA357; HARGREAVE FE, 1972, J ALLERGY CLIN IMMUN, V50, P157, DOI 10.1016/0091-6749(72)90047-4; KARR RM, 1978, J ALLERGY CLIN IMMUN, V61, P54, DOI 10.1016/0091-6749(78)90474-8; KARR RM, UNPUBLISHED; Mayer M. M., 1964, EXPT IMMUNOCHEMISTRY, P133; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PLATTSMI.TA, 1974, J IMMUNOL, V113, P348; SVENTIVANYI A, 1968, J ALLERGY, V42, P203; Weill H, 1975, Environ Health Perspect, V11, P101	16	91	91	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	2					146	152		10.1016/0091-6749(79)90049-6	http://dx.doi.org/10.1016/0091-6749(79)90049-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG426	222827				2022-12-18	WOS:A1979HG42600009
J	SCHATZ, M; PATTERSON, R; FINK, J				SCHATZ, M; PATTERSON, R; FINK, J			IMMUNOPATHOGENESIS OF HYPERSENSITIVITY PNEUMONITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review									USN,REG MED CTR,SAN DIEGO,CA 92134; USN,REG MED CTR,DEPT INTERNAL MED,SAN DIEGO,CA 92134; USN,CTR CLIN INVEST,SAN DIEGO,CA 92134; NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60614; MED COLL WISCONSIN,MILWAUKEE,WI 53233; WOOD VET ADM HOSP,MILWAUKEE,WI	United States Department of Defense; United States Navy; United States Department of Defense; United States Navy; United States Department of Defense; United States Navy; Northwestern University; Medical College of Wisconsin								ALLEN DH, 1975, AM J MED, V59, P505, DOI 10.1016/0002-9343(75)90258-2; ALLEN DH, 1976, CHEST, V69, P283, DOI 10.1378/chest.69.2.283; ALLEN DH, 1977, MONOGR ALLERGY, V11, P7; BACH FH, 1976, NEW ENGL J MED, V295, P927, DOI 10.1056/NEJM197610212951705; BANASZAK EF, 1974, AM REV RESPIR DIS, V110, P585; BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; BARBORIAK JJ, 1973, J LAB CLIN MED, V82, P372; BARBORIAK JJ, 1976, CLIN EXP IMMUNOL, V24, P542; BARROWCLIFF DF, 1968, THORAX, V23, P490, DOI 10.1136/thx.23.5.490; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BERRENS L, 1974, ANN NY ACAD SCI, V221, P153, DOI 10.1111/j.1749-6632.1974.tb28213.x; BERRENS L, 1972, INT ARCH ALLER A IMM, V43, P347, DOI 10.1159/000230850; BERRILL WT, 1975, LANCET, V2, P1006; BICE DE, 1976, J ALLERGY CLIN IMMUN, V58, P250, DOI 10.1016/0091-6749(76)90130-5; BICE DE, 1976, J ALLERGY CLIN IMMUN, V57, P207; BOROS DL, 1973, IMMUNOLOGY, V24, P511; BRENTJENS JR, 1974, J EXP MED, V140, P105, DOI 10.1084/jem.140.1.105; CALDWELL JR, 1973, J ALLERGY CLIN IMMUN, V52, P225, DOI 10.1016/0091-6749(73)90060-2; CAMPBELL JM, 1932, BRIT MED J, V2, P1143; CHANNELL S, 1969, Q J MED, V38, P351; CHEMLIK F, 1974, J ALLERGY CLIN IMMUN, V54, P180; CRYSTAL RG, 1976, ANN INTERN MED, V85, P769, DOI 10.7326/0003-4819-85-6-769; DOPICO GA, 1976, AM REV RESPIR DIS, V113, P451; DUBOCZY BO, 1965, AM REV RESPIR DIS, V92, P55; EDWARDS C, 1974, BRIT J DIS CHEST, V68, P57, DOI 10.1016/0007-0971(74)90010-2; EDWARDS J H, 1974, Clinical Allergy, V4, P379, DOI 10.1111/j.1365-2222.1974.tb01399.x; EDWARDS JH, 1976, CLIN ALLERGY, V6, P19, DOI 10.1111/j.1365-2222.1976.tb01408.x; EDWARDS JH, 1970, IMMUNOLOGY, V19, P729; ELGEFORS B, 1971, SCAND J RESPIR DIS, V52, P167; ELMAN AJ, 1968, ARCH ENVIRON HEALTH, V17, P98, DOI 10.1080/00039896.1968.10665196; EMANUEL DA, 1964, AM J MED, V37, P392, DOI 10.1016/0002-9343(64)90195-0; Fasske E, 1974, Pneumonologie, V150, P49; FAUX J A, 1971, Clinical Allergy, V1, P149, DOI 10.1111/j.1365-2222.1971.tb03014.x; FINK JN, 1970, J ALLERGY, V46, P156, DOI 10.1016/0021-8707(70)90094-8; FINK JN, 1971, J ALLERGY CLIN IMMUN, V48, P179, DOI 10.1016/0091-6749(71)90014-5; FINK JN, 1968, J LAB CLIN MED, V71, P20; FINK JN, 1967, J ALLERGY, V39, P214, DOI 10.1016/0021-8707(67)90013-5; FINK JN, 1975, INT ARCH ALLER A IMM, V49, P831, DOI 10.1159/000231466; FINK JN, 1969, J IMMUNOL, V103, P244; FINK JN, 1969, J LAB CLIN MED, V74, P325; FINK JN, 1973, J ALLERGY CLIN IMMUN, V52, P309, DOI 10.1016/0091-6749(73)90051-1; FINK JN, 1968, ANN INTERN MED, V68, P1205, DOI 10.7326/0003-4819-68-6-1205; FINK JN, 1972, CHEST, V62, P277, DOI 10.1378/chest.62.3.277; FINK JN, 1976, J ALLERGY CLIN IMMUN, V57, P226; FINK JN, 1974, MED CLIN N AM, V58, P157, DOI 10.1016/S0025-7125(16)32185-X; FLAHERTY DK, 1975, LANCET, V2, P507; FLAHERTY DK, 1974, J ALLERGY CLIN IMMUN, V53, P329, DOI 10.1016/0091-6749(74)90116-X; GELL PGH, 1969, CLINICAL ASPECTS IMM; GERMUTH FG, 1961, AM REV RESPIR DIS, V84, P84; GHOSE T, 1974, CLIN ALLERGY, V4, P119, DOI 10.1111/j.1365-2222.1974.tb01369.x; HANSEN P, 1974, MED J AUSTRALIA, V1, P984, DOI 10.5694/j.1326-5377.1974.tb93491.x; HANSEN PJ, 1974, INT ARCH ALLER A IMM, V47, P498, DOI 10.1159/000231244; HARGREAVE FE, 1972, J ALLERGY CLIN IMMUN, V50, P157, DOI 10.1016/0091-6749(72)90047-4; HARRIS JO, 1976, CHEST, V69, P287; HENNEY CS, 1970, SCIENCE, V169, P696, DOI 10.1126/science.169.3946.696; HENSLEY GT, 1974, ARCH PATHOL, V97, P33; HENSON P, 1969, CELLULAR HUMORAL MEC, P124; HOLLINGDALE MR, 1974, J HYG-CAMBRIDGE, V72, P79, DOI 10.1017/S002217240002324X; JOHNSON KJ, 1974, J CLIN INVEST, V54, P349, DOI 10.1172/JCI107770; JOUBERT JR, 1976, AM REV RESPIR DIS, V113, P503; KABE J, 1971, J ALLERGY, V47, P59, DOI 10.1016/S0091-6749(71)80372-X; KALTREIDER HB, 1976, AM REV RESPIR DIS, V113, P347; KAWAI T, 1973, CLIN EXP IMMUNOL, V15, P123; KAWAI T, 1972, J ALLERGY CLIN IMMUN, V50, P276, DOI 10.1016/0091-6749(72)90026-7; Kochman S, 1972, Clin Allergy, V2, P307, DOI 10.1111/j.1365-2222.1972.tb01295.x; MARX JJ, 1976, J ALLERGY CLIN IMMUN, V57, P328, DOI 10.1016/0091-6749(76)90089-0; MIYAMOTO T, 1971, AM REV RESPIR DIS, V103, P509; MIYAMOTO T, 1975, J ALLERGY CLIN IMMUN, V56, P464, DOI 10.1016/0091-6749(75)90064-0; MIYAMOTO T, 1971, J ALLERGY, V47, P181, DOI 10.1016/S0091-6749(71)80296-8; MOORE VL, 1975, J LAB CLIN MED, V85, P540; MOORE VL, 1973, FED PROC, V32, P1038; MOORE VL, 1976, J ALLERGY CLIN IMMUN, V57, P225; MOORE VL, 1974, J ALLERGY CLIN IMMUN, V53, P319, DOI 10.1016/0091-6749(74)90115-8; MOORE VL, 1975, P SOC EXP BIOL MED, V149, P307; MOORE VL, 1975, J CLIN INVEST, V56, P937, DOI 10.1172/JCI108173; NICHOLSON DP, 1972, AM J MED, V53, P131, DOI 10.1016/0002-9343(72)90123-4; NIELSEN KH, 1974, INT ARCH ALLER A IMM, V47, P339, DOI 10.1159/000231227; OLENCHOCK SA, 1976, J ALLERGY CLIN IMMUN, V58, P76, DOI 10.1016/0091-6749(76)90109-3; PARRATT D, 1975, CLIN EXP IMMUNOL, V20, P217; PARRISH WE, 1970, LANCET, V2, P591; PATTERSON R, 1976, AM J MED, V60, P144, DOI 10.1016/0002-9343(76)90543-X; PEPYS J, 1965, THORAX, V20, P21, DOI 10.1136/thx.20.1.21; PEPYS J, 1969, MONOGRAPHS ALLERGY; PURTILO DT, 1975, J PEDIATR-US, V86, P569, DOI 10.1016/S0022-3476(75)80150-8; REDMOND AOB, 1975, IRISH MED J, V68, P381; REED CE, 1974, PROGR IMMUNOLOGY 2, V4, P277; REISS JS, 1974, ANN ALLERGY, V32, P208; REYNOLDS HY, 1977, J CLIN INVEST, V59, P165, DOI 10.1172/JCI108615; RICHERSON HB, 1972, J LAB CLIN MED, V79, P745; RITTNER C, 1975, LANCET, V2, P1303; ROBERTS RC, 1976, J ALLERGY CLIN IMMUN, V57, P518, DOI 10.1016/0091-6749(76)90002-6; ROBERTS RC, 1973, J ALLERGY CLIN IMMUN, V52, P297, DOI 10.1016/0091-6749(73)90048-1; ROBINSON TJ, 1976, BRIT MED J, V1, P745, DOI 10.1136/bmj.1.6012.745; SALVAGGIO J, 1975, J ALLERGY CLIN IMMUN, V56, P364, DOI 10.1016/0091-6749(75)90130-X; SALVAGGIO J, 1969, AM J MED, V46, P538, DOI 10.1016/0002-9343(69)90073-4; SALVAGGIO J, 1973, CHEST, V63, P51; SALVAGGIO JE, 1975, MAR SCI P AM ASS PAT; SANTIVES T, 1976, J ALLERGY CLIN IMMUN, V57, P582, DOI 10.1016/0091-6749(76)90010-5; SCHATZ M, 1976, CLIN ALLERGY, V6, P7, DOI 10.1111/j.1365-2222.1976.tb01407.x; SCHATZ M, 1976, CLIN EXP IMMUNOL, V24, P33; SEABURY J, 1969, P SOC EXP BIOL MED, V129, P351; SEAL RME, 1968, THORAX, V23, P468; SPECTOR WG, 1969, J PATHOL, V98, P31, DOI 10.1002/path.1710980105; STANDFORD RE, 1976, CHEST, V69, P288; STEINBERG P, 1973, J ALLERGY CLIN IMMUN, V51, P109, DOI 10.1016/S0091-6749(73)80067-3; STIEHM ER, 1967, PEDIATRICS, V39, P904; TEWKSBURY D A, 1968, Clinical and Experimental Immunology, V3, P857; TUFT DS, 1972, J ALLERGY CLIN IMMUN, V49, P103; Turner-Warwick M, 1971, Clin Allergy, V1, P209; UNANUE ER, 1973, AM J PATHOL, V71, P349; VANTOORN DW, 1970, THORAX, V25, P399, DOI 10.1136/thx.25.4.399; WALDMAN RH, 1973, J IMMUNOL, V111, P38; WALDMAN RH, 1971, J EXP MED, V134, P482, DOI 10.1084/jem.134.2.482; WARREN CPW, 1974, AM REV RESPIR DIS, V109, P672; WARREN P, 1973, J ALLERGY CLIN IMMUN, V51, P104, DOI 10.1016/S0091-6749(73)80056-9; WARREN WP, 1972, CAN MED ASSOC J, V107, P1196; WENZEL FJ, 1967, ARCH ENVIRON HEALTH, V14, P385, DOI 10.1080/00039896.1967.10664759; WENZEL FJ, 1971, J ALLERGY CLIN IMMUN, V48, P244; WILKIE B, 1973, PATHOL MICROBIOL, V39, P393, DOI 10.1159/000162686; WILLOUGHBY WF, 1976, CHEST, V69, P290	120	91	91	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	1					27	37		10.1016/0091-6749(77)90079-3	http://dx.doi.org/10.1016/0091-6749(77)90079-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	DN224	141470				2022-12-18	WOS:A1977DN22400004
J	FARAH, FS; SHBAKLU, Z				FARAH, FS; SHBAKLU, Z			AUTOIMMUNE PROGESTERONE URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		FARAH FS, 1960, J EXP MED, V112, P1211, DOI 10.1084/jem.112.6.1211; GUY WH, 1951, AMA ARCH DERM SYPH, V63, P377, DOI 10.1001/archderm.1951.01570030091012; HOISCHEN W, 1966, DEUT MED WOCHENSCHR, V91, P398, DOI 10.1055/s-0028-1110586; JONES WN, 1969, ARCH DERMATOL, V99, P57, DOI 10.1001/archderm.99.1.57; SHELLEY WB, 1964, JAMA-J AM MED ASSOC, V120, P147; TROMOVITCH TA, 1967, CALIF MED, V106, P211; ZONDEK B, 1945, J ALLERGY, V16, P1, DOI 10.1016/0021-8707(45)90035-9	7	91	91	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	5					257	&		10.1016/0091-6749(71)90025-X	http://dx.doi.org/10.1016/0091-6749(71)90025-X			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K7978	4398434				2022-12-18	WOS:A1971K797800001
J	Wopereis, H; Sim, K; Shaw, A; Warner, JO; Knol, J; Kroll, JS				Wopereis, Harm; Sim, Kathleen; Shaw, Alexander; Warner, John O.; Knol, Jan; Kroll, J. Simon			Intestinal microbiota in infants at high risk for allergy: Effects of prebiotics and role in eczema development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; eczema; gastrointestinal; microbiome; microbiota; short-chain fatty acids; butyrate; lactate; prebiotics; infants	BUTYRATE-PRODUCING BACTERIA; GALACTO-OLIGOSACCHARIDES; ATOPIC-DERMATITIS; GUT MICROBIOME; HUMAN FECES; FORMULA; LACTATE; LIFE; BIFIDOBACTERIA; METABOLITES	Background: Development of the gut microbiota in infancy is important in maturation of the immune system. Deviations in colonization patterns have been associated with allergic manifestations such as eczema, but exact microbiome dysfunctions underlying allergies remain unclear. We studied the gut microbiota of 138 infants at increased risk of allergy, participating in a clinical trial investigating the effectiveness of a partially hydrolyzed protein formula supplemented with nondigestible oligosaccharides on the prevention of eczema. Objective: The effects of interventions and breast-feeding on fecal microbiota were investigated. Additionally, we aimed to identify microbial patterns associated with the onset of eczema. Methods: Bacterial taxonomic compositions in the first 26 weeks of life were analyzed by using 16SrRNA gene sequencing. Additionally, fecal pH and microbial metabolite levels were measured. Results: Fecal microbial composition, metabolites, and pH of infants receiving partially hydrolyzed protein formula supplemented with nondigestible oligosaccharides was closer to that of breast-fed infants than that of infants receiving standard cow's milk formula. Infants with eczema by 18 months showed discordant development of bacterial genera of Enterobacteriaceae and Parabacteroides species in the first 26 weeks, as well as decreased acquisition of lactate-utilizing bacteria producing butyrate, namely Eubacterium and Anaerostipes species, supported by increased lactate and decreased butyrate levels. Conclusions: We showed that a partially hydrolyzed protein infant formula with specific prebiotics modulated the gut microbiota closer to that of breast-fed infants. Additionally, we identified a potential link between microbial activity and onset of eczema, which might reflect a suboptimal implementation of gut microbiota at specific developmental stages in infants at high risk for allergy.	[Wopereis, Harm; Knol, Jan] Danone Nutricia Res, Uppsalalaan 12, NL-3584 CT Utrecht, Netherlands; [Wopereis, Harm; Knol, Jan] Wageningen Univ, Lab Microbiol, Wageningen, Netherlands; [Sim, Kathleen; Shaw, Alexander; Warner, John O.; Kroll, J. Simon] Imperial Coll London, Dept Med, Sect Paediat, London, England	Danone Nutricia; Wageningen University & Research; Imperial College London	Wopereis, H (corresponding author), Danone Nutricia Res, Uppsalalaan 12, NL-3584 CT Utrecht, Netherlands.	harm.wopereis@danone.com	Warner, John/AAF-9587-2020; Shaw, Alex/GWC-7464-2022; Knol, Jan/A-2178-2010; Knol, Jan/AAL-6487-2020	Knol, Jan/0000-0002-2103-5961; Knol, Jan/0000-0002-2103-5961; Shaw, Alex/0000-0002-3166-872X	Danone Nutricia Research; National Institute for Health Research (NIHR) Biomedical Research Centre; Imperial College London	Danone Nutricia Research(Danone Nutricia); National Institute for Health Research (NIHR) Biomedical Research Centre(National Institute for Health Research (NIHR)); Imperial College London(General Electric)	This study was funded by Danone Nutricia Research. Work in the Kroll laboratory was supported by funding from the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial Healthcare NHS Trust and Imperial College London.	Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Arslanoglu S, 2012, J Biol Regul Homeost Agents, V26, P49; Backhed F, 2015, CELL HOST MICROBE, V17, P690, DOI [10.1016/j.chom.2015.05.012, 10.1016/j.chom.2015.04.004]; Bakker-Zierikzee AM, 2005, BRIT J NUTR, V94, P783, DOI 10.1079/BJN20051451; Belenguer A, 2011, FEMS MICROBIOL ECOL, V77, P107, DOI 10.1111/j.1574-6941.2011.01086.x; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bindels LB, 2015, NAT REV GASTRO HEPAT, V12, P303, DOI 10.1038/nrgastro.2015.47; Borcard D, 2011, USE R, P1, DOI 10.1007/978-1-4419-7976-6; Boyle RJ, 2016, ALLERGY, V71, P701, DOI 10.1111/all.12848; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Duncan SH, 2004, APPL ENVIRON MICROB, V70, P5810, DOI 10.1128/AEM.70.10.5810-5817.2004; FAITH DP, 1992, BIOL CONSERV, V61, P1, DOI 10.1016/0006-3207(92)91201-3; Flint HJ, 2015, P NUTR SOC, V74, P13, DOI 10.1017/S0029665114001463; Fukuda S, 2011, NATURE, V469, P543, DOI 10.1038/nature09646; GIBSON GR, 1995, J NUTR, V125, P1401, DOI 10.1093/jn/125.6.1401; Gruber C, 2010, J ALLERGY CLIN IMMUN, V126, P791, DOI 10.1016/j.jaci.2010.07.022; HOVE H, 1994, SCAND J GASTROENTERO, V29, P255, DOI 10.3109/00365529409090473; Ip Stanley, 2007, Evid Rep Technol Assess (Full Rep), P1; Kanauchi O, 1999, INT J MOL MED, V3, P175; Knol J, 2005, ACTA PAEDIATR, V94, P31, DOI 10.1080/08035320510043529; Knol J, 2005, J PEDIATR GASTR NUTR, V40, P36, DOI 10.1097/00005176-200501000-00007; Leps J, 2014, MULTIVARIATE ANAL EC; Li RW, 2014, PEDIATRICS, V134, pS13, DOI 10.1542/peds.2014-0646D; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Martin R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158498; Matsuki T, 2004, APPL ENVIRON MICROB, V70, P167, DOI 10.1128/AEM.70.1.167-173.2004; Moro G, 2006, ARCH DIS CHILD, V91, P814, DOI 10.1136/adc.2006.098251; Nylund L, 2015, ALLERGY, V70, P241, DOI 10.1111/all.12549; Oozeer R, 2013, AM J CLIN NUTR, V98, p561S, DOI 10.3945/ajcn.112.038893; Paulson JN, 2013, NAT METHODS, V10, P1200, DOI [10.1038/NMETH.2658, 10.1038/nmeth.2658]; Prescott SL, 2008, J ALLERGY CLIN IMMUN, V122, P391, DOI 10.1016/j.jaci.2008.04.042; Pruesse E, 2007, NUCLEIC ACIDS RES, V35, P7188, DOI 10.1093/nar/gkm864; Sato T, 2008, FEMS MICROBIOL ECOL, V66, P528, DOI 10.1111/j.1574-6941.2008.00528.x; Shanahan F, 2012, NAT REV GASTRO HEPAT, V9, P609, DOI 10.1038/nrgastro.2012.145; Sim K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032543; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Steinmeyer S, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0524-2; TERBRAAK CJF, 1986, ECOLOGY, V67, P1167; Tulic MK, 2011, J ALLERGY CLIN IMMUN, V127, P470, DOI 10.1016/j.jaci.2010.09.020; van den Brink PJ, 2009, ENVIRON MONIT ASSESS, V152, P271, DOI 10.1007/s10661-008-0314-6; Verhasselt V, 2010, MUCOSAL IMMUNOL, V3, P326, DOI 10.1038/mi.2010.25; VERNIA P, 1988, GASTROENTEROLOGY, V95, P1564, DOI 10.1016/S0016-5085(88)80078-7; West CE, 2015, CLIN EXP ALLERGY, V45, P1419, DOI 10.1111/cea.12566; Wopereis H, 2014, PEDIAT ALLERG IMM-UK, V25, P428, DOI 10.1111/pai.12232	45	90	99	6	58	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1334	+		10.1016/j.jaci.2017.05.054	http://dx.doi.org/10.1016/j.jaci.2017.05.054			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	28866384	hybrid, Green Published			2022-12-18	WOS:000429197800019
J	Marciano, BE; Zerbe, CS; Falcone, EL; Ding, L; DeRavin, SS; Daub, J; Kreuzburg, S; Yockey, L; Hunsberger, S; Foruraghi, L; Barnhart, LA; Matharu, K; Anderson, V; Darnell, DN; Frein, C; Fink, DL; Lau, KP; Priel, DAL; Gallin, JI; Malech, HL; Uzel, G; Freeman, AF; Kuhns, DB; Rosenzweig, SD; Holland, SM				Marciano, Beatriz E.; Zerbe, Christa S.; Falcone, E. Liana; Ding, Li; DeRavin, Suk See; Daub, Janine; Kreuzburg, Samantha; Yockey, Lynne; Hunsberger, Sally; Foruraghi, Ladan; Barnhart, Lisa A.; Matharu, Kabir; Anderson, Victoria; Darnell, Dirk N.; Frein, Cathleen; Fink, Danielle L.; Lau, Karen P.; Priel, Debra A. Long; Gallin, John I.; Malech, Harry L.; Uzel, Gulbu; Freeman, Alexandra F.; Kuhns, Douglas B.; Rosenzweig, Sergio D.; Holland, Steven M.			X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stability	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Superoxide; X inactivation; dihydrorhodamine flow cytometry test; autoimmunity; lyonization	DISCOID LUPUS-ERYTHEMATOSUS; ORNITHINE TRANSCARBAMYLASE DEFICIENCY; CHROMOSOME-INACTIVATION; CLINICAL-FEATURES; AGE; MANIFESTATIONS; INFECTION; PATTERNS; FEMALES; RISK	BACKGROUND: Chronic granulomatous disease (CGD) is characterized by recurrent life-threatening bacterial and fungal infections and aberrant inflammation. Mutations in CYBB cause X-linked CGD and account for 65% to 70% of cases in Western countries. OBJECTIVE: We sought to understand the clinical manifestations associated with the X-linked CGD carrier state. METHODS: We undertook a comprehensive retrospective study of 162 affected female subjects. We examined dihydrorhodamine 123 (DHR) oxidation data for percentage of X-chromosome inactivation. We correlated lyonization (%DHR+) with clinical features. Where possible, we followed %DHR+ values over time. RESULTS: Clinical data were available for 93 female subjects: %DHR+ values were 46% (mean) and 47% (median; SD, 24). Using the %DHR+ value as the criterion for X inactivation, 78% of patients had levels of inactivation of 20% to 80%, suggesting random inactivation that was independent of age. In contrast, carriers with CGD-type infections had median %DHR+ values of 8% (n = 14; range, 0.06% to 48%), and those with only autoimmune or inflammatory manifestations had median %DHR+ values of 39% (n = 31; range, 7.4% to 74%). Those with both infections and autoimmunity had low %DHR+ values (n = 6; range, 3% to 14%). A %DHR+ value of less than 10% was strongly associated with infections (odds ratio, 99). Strong association persisted when %DHR+ values were less than 20% (odds ratio, 12). Autoimmunity was not associated with %DHR+ values. In 2 sets of identical twins, the %DHR+ populations tracked closely over time. Although the %DHR+ populations were very similar between sisters, those between mothers and daughters were unrelated. CONCLUSIONS: A low %DHR+ value strongly predicts infection risk in X-linked CGD carriers, and the carrier state itself is associated with autoimmunity.	[Marciano, Beatriz E.; Zerbe, Christa S.; Falcone, E. Liana; Ding, Li; Daub, Janine; Kreuzburg, Samantha; Yockey, Lynne; Foruraghi, Ladan; Barnhart, Lisa A.; Anderson, Victoria; Darnell, Dirk N.; Frein, Cathleen; Uzel, Gulbu; Freeman, Alexandra F.; Holland, Steven M.] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [DeRavin, Suk See; Gallin, John I.; Malech, Harry L.] NIAID, Lab Host Def, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Hunsberger, Sally] NIAID, Biostat Branch, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Fink, Danielle L.; Lau, Karen P.; Priel, Debra A. Long; Kuhns, Douglas B.] Frederick Natl Lab Canc Res, Neutrophil Monitoring Lab, Appl Dev Res Directorate, Leidos Biomed Res, Frederick, MD USA; [Rosenzweig, Sergio D.] NIH, Dept Lab Med, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Holland, SM (corresponding author), Bldg 10-11N248,MSC 1960, Bethesda, MD 20892 USA.	smh@nih.gov		Kreuzburg, Samantha/0000-0002-5295-4047; De Ravin, Suk See/0000-0002-9800-774X; Malech, Harry/0000-0001-5874-5775	National Cancer Institute, National Institutes of Health [HHSN261200800001E]; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000988, ZIAAI000645, ZIAAI000155, ZIAAI001247, ZIAAI001122, ZIAAI000991, ZIAAI000646, ZIAAI001216, ZIAAI000644] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL010304] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER	Supported in part by federal funds from the National Cancer Institute, National Institutes of Health, under contract no. HHSN261200800001E. Additional support was provided by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.	Agrelo R, 2010, SEMIN CELL DEV BIOL, V21, P194, DOI 10.1016/j.semcdb.2009.09.017; Almyroudis NG, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00045; Amos-Landgraf JM, 2006, AM J HUM GENET, V79, P493, DOI 10.1086/507565; Barton L L, 1986, Pediatr Dermatol, V3, P376, DOI 10.1111/j.1525-1470.1986.tb00544.x; Battersby AC, 2013, J CLIN IMMUNOL, V33, P1276, DOI 10.1007/s10875-013-9939-5; Busque L, 1996, BLOOD, V88, P59; Cale CM, 2007, CLIN EXP IMMUNOL, V148, P79, DOI 10.1111/j.1365-2249.2007.03321.x; Chabchoub G, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2759; Coman D, 2010, MOL GENET METAB, V99, P329, DOI 10.1016/j.ymgme.2009.11.006; CUNY JF, 1990, ANN DERMATOL VENER, V117, P713; De Ravin SS, 2008, J ALLERGY CLIN IMMUN, V122, P1097, DOI 10.1016/j.jaci.2008.07.050; Durosaro O, 2009, ARCH DERMATOL, V145, P249, DOI 10.1001/archdermatol.2009.21; FRANCKE U, 1984, CYTOGENET CELL GENET, V38, P298, DOI 10.1159/000132078; Gardiner GJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00295; Hatakeyama C, 2004, CLIN GENET, V66, P327, DOI 10.1111/j.1399-0004.2004.00310.x; Ishihara H, 2001, J NEUROL, V248, P856, DOI 10.1007/s004150170069; Kuhn A, 2014, J AUTOIMMUN, V48-49, P14, DOI 10.1016/j.jaut.2014.01.021; Kuhns DB, 2010, NEW ENGL J MED, V363, P2600, DOI 10.1056/NEJMoa1007097; Kyriakis KP, 2007, J EUR ACAD DERMATOL, V21, P1108, DOI 10.1111/j.1468-3083.2007.02095.x; LANDING BH, 1957, PEDIATRICS, V20, P431; LINDSKOV R, 1983, DERMATOLOGICA, V167, P231, DOI 10.1159/000249788; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Minks J, 2008, J CLIN INVEST, V118, P20, DOI 10.1172/JCI34470; Renault NKE, 2013, EUR J HUM GENET, V21, P1396, DOI 10.1038/ejhg.2013.84; Roesler J, 2009, CLIN IMMUNOL, V130, P233, DOI 10.1016/j.clim.2008.09.013; Rosen-Wolff A, 2001, ANN HEMATOL, V80, P113, DOI 10.1007/s002770000230; Rosenzweig SD, 2008, J CLIN IMMUNOL, V28, pS67, DOI 10.1007/s10875-007-9160-5; Rupec RA, 2000, EUR J DERMATOL, V10, P184; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Soltanzadeh P, 2010, NEUROMUSCULAR DISORD, V20, P499, DOI 10.1016/j.nmd.2010.05.010; YEAMAN GR, 1992, BRIT J DERMATOL, V126, P60, DOI 10.1111/j.1365-2133.1992.tb08405.x	31	90	94	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					365	371		10.1016/j.jaci.2017.04.035	http://dx.doi.org/10.1016/j.jaci.2017.04.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28528201	Bronze			2022-12-18	WOS:000419312200041
J	Yang, IV; Lozupone, CA; Schwartz, DA				Yang, Ivana V.; Lozupone, Catherine A.; Schwartz, David A.			The environment, epigenome, and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; DNA methylation; epigenetics; nasal epithelium; microbiome; air pollution; allergens	POLYCYCLIC AROMATIC-HYDROCARBONS; GENOME-WIDE ASSOCIATION; INNER-CITY CHILDREN; DIFFERENTIAL DNA METHYLATION; CHILDHOOD ALLERGIC DISEASES; DIESEL EXHAUST PARTICLES; TOBACCO-SMOKE EXPOSURE; OUTDOOR AIR-POLLUTION; CPG ISLAND SHORES; T-CELLS	Asthma prevalence has been on the increase, especially in North America compared with other continents. However, the prevalence of asthma differs worldwide, and in many countries the prevalence is stable or decreasing. This highlights the influence of environmental exposures, such as allergens, air pollution, and the environmental microbiome, on disease etiology and pathogenesis. The epigenome might provide the unifying mechanism that translates the influence of environmental exposures to changes in gene expression, respiratory epithelial function, and immune cell skewing that are hallmarks of asthma. In this review we will introduce the concept of the environmental epigenome in asthmatic patients, summarize previous publications of relevance to this field, and discuss future directions.	[Yang, Ivana V.; Lozupone, Catherine A.; Schwartz, David A.] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA; [Yang, Ivana V.; Schwartz, David A.] Natl Jewish Hlth, Denver, CO USA; [Yang, Ivana V.] Univ Colorado, Dept Epidemiol, Colorado Sch Publ Hlth, Aurora, CO USA; [Schwartz, David A.] Univ Colorado, Dept Immunol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; National Jewish Health; Colorado School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Boulder	Yang, IV (corresponding author), Univ Colorado, Sch Med, 12700 East 19th Ave,8611, Aurora, CO 80045 USA.	ivana.yang@ucdenver.edu	Lozupone, Catherine/AAD-9317-2020; Yang, Ivana V/P-3059-2018	Yang, Ivana V/0000-0002-1018-489X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL101251] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL101251] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahluwalia SK, 2013, J ALLERGY CLIN IMMUN, V132, P830, DOI 10.1016/j.jaci.2013.05.005; Ahluwalia SK, 2011, CURR OPIN ALLERGY CL, V11, P137, DOI 10.1097/ACI.0b013e3283445921; Alegria-Torres JA, 2013, CHEMOSPHERE, V91, P475, DOI 10.1016/j.chemosphere.2012.11.077; Allis CD, 2009, EPIGENETICS; Avci FY, 2010, ANNU REV IMMUNOL, V28, P107, DOI 10.1146/annurev-immunol-030409-101159; Baccarelli A, 2012, EPIGENOMICS-UK, V4, P91, DOI [10.2217/EPI.11.106, 10.2217/epi.11.106]; Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC; Baldacci S, 2015, RESP MED, V109, P1089, DOI 10.1016/j.rmed.2015.05.017; Bellavia A, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000212; Bind MA, 2014, EPIGENETICS-US, V9, P448, DOI 10.4161/epi.27584; Bind MA, 2012, EPIDEMIOLOGY, V23, P332, DOI 10.1097/EDE.0b013e31824523f0; Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877; Bonnelykke K, 2013, NAT GENET, V45, P902, DOI 10.1038/ng.2694; Bonner JC, 1998, AM J RESP CELL MOL, V19, P672, DOI 10.1165/ajrcmb.19.4.3176; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080; Brand S, 2012, J ALLERGY CLIN IMMUN, V129, P1602, DOI 10.1016/j.jaci.2011.12.963; Brandt HCA, 2003, ANN OCCUP HYG, V47, P349, DOI 10.1093/annhyg/meg052; Breton CV, 2011, AM J RESP CRIT CARE, V184, P191, DOI 10.1164/rccm.201012-2029OC; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Brock MV, 2008, NEW ENGL J MED, V358, P1118, DOI 10.1056/NEJMoa0706550; Bunyavanich S, 2015, J ALLERGY CLIN IMMUN, V135, P31, DOI 10.1016/j.jaci.2014.10.015; Buro-Auriemma LJ, 2013, HUM MOL GENET, V22, P4726, DOI 10.1093/hmg/ddt326; Castro-Nallar E, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0121-1; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; Chen P, 2017, DIABETOLOGIA, V60, P645, DOI 10.1007/s00125-016-4203-1; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Clark NA, 2010, ENVIRON HEALTH PERSP, V118, P284, DOI 10.1289/ehp.0900916; Clifford RL, 2017, J ALLERGY CLIN IMMUN, V139, P112, DOI 10.1016/j.jaci.2016.03.046; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; Cortese R, 2016, EPIGENETICS-US, V11, P205, DOI 10.1080/15592294.2016.1155011; De Prins S, 2013, ENVIRON INT, V59, P418, DOI 10.1016/j.envint.2013.07.007; Di Ruscio A, 2013, NATURE, V503, P371, DOI 10.1038/nature12598; Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Fitzsimon N, 2007, Ir Med J, V100, P27; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708, DOI 10.1164/ajrccm.157.6.9707163; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Fretzayas A, 2013, WORLD J PEDIATR, V9, P112, DOI 10.1007/s12519-013-0412-6; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gandhi VD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00147; Gandhi VD, 2013, CURR ALLERGY ASTHM R, V13, P262, DOI 10.1007/s11882-013-0349-9; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Guarnieri M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; Guo LQ, 2014, ENVIRON MOL MUTAGEN, V55, P322, DOI 10.1002/em.21838; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Henderson AJ, 2010, THORAX, V65, P897, DOI 10.1136/thx.2009.125856; Hew KM, 2015, CLIN EXP ALLERGY, V45, P238, DOI 10.1111/cea.12377; Heyn H, 2012, P NATL ACAD SCI USA, V109, P10522, DOI 10.1073/pnas.1120658109; Ho SM, 2010, J ALLERGY CLIN IMMUN, V126, P453, DOI 10.1016/j.jaci.2010.07.030; Hou LF, 2014, ENVIRON MOL MUTAGEN, V55, P256, DOI 10.1002/em.21829; Hylkema Machteld N, 2009, Proc Am Thorac Soc, V6, P660, DOI 10.1513/pats.200907-065DP; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367; Jiang RW, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/s12989-014-0071-3; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Jones B, 2006, EMBO J, V25, P2443, DOI 10.1038/sj.emboj.7601148; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Joubert BR, 2012, ENVIRON HEALTH PERSP, V120, P1425, DOI 10.1289/ehp.1205412; Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214; Kaminskas E, 2005, ONCOLOGIST, V10, P176, DOI 10.1634/theoncologist.10-3-176; Kasowski M, 2013, SCIENCE, V342, P750, DOI 10.1126/science.1242510; Kilpinen H, 2013, SCIENCE, V342, P744, DOI 10.1126/science.1242463; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Kim ST, 2007, P NATL ACAD SCI USA, V104, P17052, DOI 10.1073/pnas.0708293104; Kohli A, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-17; Kulis M, 2012, NAT GENET, V44, P1236, DOI 10.1038/ng.2443; Kumar H, 2014, MBIO, V5, DOI 10.1128/mBio.02113-14; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Kuo CH, 2013, J MICROBIOL IMMUNOL, V46, P320, DOI 10.1016/j.jmii.2013.04.005; Kuriakose J, 2012, AM J RESP CRIT CARE, V185, P460, DOI 10.1164/ajrccm.185.4.460; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Lawson HA, 2013, NAT REV GENET, V14, P608, DOI 10.1038/nrg3543; Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X; Lee GR, 2006, IMMUNITY, V24, P369, DOI 10.1016/j.immuni.2006.03.007; Levy BD, 2015, AM J RESP CRIT CARE, V192, P1366, DOI 10.1164/rccm.201505-0963WS; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Liang L, 2015, NATURE, V520, P4; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Liu AH, 2016, J ALLERGY CLIN IMMUN, V138, P1042, DOI 10.1016/j.jaci.2016.06.060; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Los H, 2001, Twin Res, V4, P81, DOI 10.1375/twin.4.2.81; Mallol J, 2013, ALLERGOL IMMUNOPATH, V41, P73, DOI 10.1016/j.aller.2012.03.001; Mann JK, 2010, ENVIRON HEALTH PERSP, V118, P1497, DOI 10.1289/ehp.0901292; March ME, 2011, DISCOV MED, V11, P35; Mathias RA, 2010, J ALLERGY CLIN IMMUN, V125, P336, DOI 10.1016/j.jaci.2009.08.031; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mazmanian SK, 2006, NAT REV IMMUNOL, V6, P849, DOI 10.1038/nri1956; McVicker G, 2013, SCIENCE, V342, P747, DOI 10.1126/science.1242429; Meng YY, 2010, J EPIDEMIOL COMMUN H, V64, P142, DOI 10.1136/jech.2009.083576; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Moffatt MF, 1998, CLIN EXP ALLERGY, V28, P56; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Morales E, 2012, AM J RESP CRIT CARE, V185, P937, DOI 10.1164/rccm.201105-0870OC; Muc M, 2013, ADV EXP MED BIOL, V788, P393, DOI 10.1007/978-94-007-6627-3_53; Munthe-Kaas MC, 2012, PEDIAT ALLERG IMM-UK, V23, P747, DOI 10.1111/pai.12021; Nagy-Szakal D, 2011, GUT MICROBES, V2, P178, DOI 10.4161/gmic.2.3.16107; Neff CP, 2016, CELL HOST MICROBE, V20, P535, DOI 10.1016/j.chom.2016.09.002; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775, DOI 10.1016/S0091-6749(99)70287-3; Nestor CE, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004059; Nicole W, 2012, ENVIRON HEALTH PERSP, V120, pA402, DOI 10.1289/ehp.120-a402a; Oh SS, 2012, J ALLERGY CLIN IMMUN, V129, P1478, DOI 10.1016/j.jaci.2012.03.017; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Pakarinen J, 2008, ENVIRON MICROBIOL, V10, P3317, DOI 10.1111/j.1462-2920.2008.01723.x; Peden D B, 2001, Curr Allergy Asthma Rep, V1, P242, DOI 10.1007/s11882-001-0011-9; Perez-Losada M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131819; Pidsley R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1066-1; Pongracic JA, 2016, J ALLERGY CLIN IMMUN, V138, P1030, DOI 10.1016/j.jaci.2016.06.059; Poole A, 2014, J ALLERGY CLIN IMMUN, V133, P670, DOI 10.1016/j.jaci.2013.11.025; Pua HH, 2015, CURR OPIN IMMUNOL, V36, P101, DOI 10.1016/j.coi.2015.07.006; Ramasamy A, 2011, J ALLERGY CLIN IMMUN, V128, P996, DOI 10.1016/j.jaci.2011.08.030; Reynolds SD, 2016, AM J RESP CELL MOL, V55, P323, DOI 10.1165/rcmb.2015-0274MA; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Rossi M, 2011, NUTRIENTS, V3, P118, DOI 10.3390/nu3010118; Roy SR, 2003, J ALLERGY CLIN IMMUN, V112, P571, DOI 10.1067/mai.2003.1711; Rullo VEV, 2002, J ALLERGY CLIN IMMUN, V110, P582, DOI 10.1067/mai.2002.127511; SAMET JM, 1991, ENVIRON HEALTH PERSP, V95, P71, DOI 10.2307/3431109; Santangelo S, 2002, J IMMUNOL, V169, P1893, DOI 10.4049/jimmunol.169.4.1893; Santos FPS, 2010, EXPERT REV ANTICANC, V10, P9, DOI [10.1586/era.09.164, 10.1586/ERA.09.164]; Schultz MD, 2015, NATURE, V523, P212, DOI 10.1038/nature14465; Schwartz DA, 2001, RESP PHYSIOL, V128, P47, DOI 10.1016/S0034-5687(01)00264-X; Seumois G, 2014, NAT IMMUNOL, V15, P777, DOI 10.1038/ni.2937; Sharma S, 2014, THORAX, V69, P481, DOI 10.1136/thoraxjnl-2014-205166; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Slaats GGG, 2012, ALLERGY, V67, P895, DOI 10.1111/j.1398-9995.2012.02831.x; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Sofer T, 2013, EPIGENOMICS-UK, V5, P147, DOI [10.2217/epi.13.16, 10.2217/EPI.13.16]; Somers CM, 2002, P NATL ACAD SCI USA, V99, P15904, DOI 10.1073/pnas.252499499; Sordillo JE, 2013, INT ARCH ALLERGY IMM, V161, P37, DOI 10.1159/000343004; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stingele F, 2004, J IMMUNOL, V172, P1483, DOI 10.4049/jimmunol.172.3.1483; Takahashi K, 2011, J BIOL CHEM, V286, P35755, DOI 10.1074/jbc.M111.271007; Tang WY, 2012, ENVIRON HEALTH PERSP, V120, P1195, DOI 10.1289/ehp.1103744; Tarantini L, 2013, OCCUP ENVIRON MED, V70, P418, DOI 10.1136/oemed-2012-101079; Thomsen SF, 2006, CLIN EXP ALLERGY, V36, P1382, DOI 10.1111/j.1365-2222.2006.02512.x; Thomsen SF, 2011, RESP MED, V105, P1147, DOI 10.1016/j.rmed.2011.03.007; Tollanes MC, 2008, J PEDIATR-US, V153, P112, DOI 10.1016/j.jpeds.2008.01.029; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Tsien A, 1997, TOXICOL APPL PHARM, V142, P256, DOI 10.1006/taap.1996.8063; TZIANABOS AO, 1993, SCIENCE, V262, P416, DOI 10.1126/science.8211161; United States Environmental Protection Agency, 2003, NAT AIR QUAL EM TREN; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Villarreal-Calderon A, 2002, ARCH ENVIRON HEALTH, V57, P450, DOI 10.1080/00039890209601437; von Mutius E, 2002, J ALLERGY CLIN IMMUN, V109, pS525, DOI 10.1067/mai.2002.124565; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; von Mutius Erika, 2007, Proc Am Thorac Soc, V4, P212, DOI 10.1513/pats.200701-028AW; Wahl S, 2017, NATURE, V541, P81, DOI 10.1038/nature20784; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Wan ES, 2012, HUM MOL GENET, V21, P3073, DOI 10.1093/hmg/dds135; Wang JY, 2013, INT J EPIDEMIOL, V42, P1087, DOI 10.1093/ije/dyt121; Wang Lei, 2007, Birth Defects Research, V81, P144, DOI 10.1002/bdrc.20097; Webster RB, 2007, J BIOL CHEM, V282, P700, DOI 10.1074/jbc.M609501200; Weiss ST, 2012, J ALLERGY CLIN IMMUN, V129, P327, DOI 10.1016/j.jaci.2011.12.971; Weiss ST, 2011, AM J RESP CRIT CARE, V184, P631, DOI 10.1164/rccm.201103-0485ED; White GP, 2006, PEDIAT ALLERG IMM-UK, V17, P557, DOI 10.1111/j.1399-3038.2006.00465.x; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yan ML, 2013, CELL HOST MICROBE, V14, P631, DOI 10.1016/j.chom.2013.11.005; Yang IV, 2017, J ALLERGY CLIN IMMUN, V139, P1478, DOI 10.1016/j.jaci.2016.07.036; Yang IV, 2017, AM J RESP CRIT CARE, V195, P829, DOI 10.1164/rccm.201608-1558LE; Yang IV, 2015, J ALLERGY CLIN IMMUN, V136, P69, DOI 10.1016/j.jaci.2015.01.025; Yang IV, 2012, J ALLERGY CLIN IMMUN, V130, P1243, DOI 10.1016/j.jaci.2012.07.052; Yang IV, 2012, AM J RESP CRIT CARE, V185, P620, DOI 10.1164/rccm.201108-1503OC; Yu DH, 2014, J CLIN INVEST, V124, P3708, DOI 10.1172/JCI76507; Zhou VW, 2011, NAT REV GENET, V12, P7, DOI 10.1038/nrg2905; Zipperer A, 2016, NATURE, V535, P511, DOI 10.1038/nature18634	178	90	95	0	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					14	23		10.1016/j.jaci.2017.05.011	http://dx.doi.org/10.1016/j.jaci.2017.05.011			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28673400	Green Accepted, Bronze			2022-12-18	WOS:000404542000002
J	Yang, IV; Pedersen, BS; Liu, AH; O'Connor, GT; Pillai, D; Kattan, M; Misiak, RT; Gruchalla, R; Szefler, SJ; Hershey, GKK; Kercsmar, C; Richards, A; Stevens, AD; Kolakowski, CA; Makhija, M; Sorkness, CA; Krouse, RZ; Visness, C; Davidson, EJ; Hennessy, CE; Martin, RJ; Togias, A; Busse, WW; Schwartz, DA				Yang, Ivana V.; Pedersen, Brent S.; Liu, Andrew H.; O'Connor, George T.; Pillai, Dinesh; Kattan, Meyer; Misiak, Rana Tawil; Gruchalla, Rebecca; Szefler, Stanley J.; Hershey, Gurjit K. Khurana; Kercsmar, Carolyn; Richards, Adam; Stevens, Allen D.; Kolakowski, Christena A.; Makhija, Melanie; Sorkness, Christine A.; Krouse, Rebecca Z.; Visness, Cynthia; Davidson, Elizabeth J.; Hennessy, Corinne E.; Martin, Richard J.; Togias, Alkis; Busse, William W.; Schwartz, David A.			The nasal methylome and childhood atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DNA methylation; gene expression; microarray; atopic asthma; respiratory epithelia; epigenetic regulation; inner city	EPIGENOME-WIDE ASSOCIATION; DNA METHYLATION PATTERNS; AIRWAY EPITHELIUM; GENE-EXPRESSION; CELLS; DISEASE; HYPOMETHYLATION; SUBPHENOTYPES; INFLAMMATION; EXPOSURE	Background: Given the strong environmental influence on both epigenetic marks and allergic asthma in children, the epigenetic alterations in respiratory epithelia might provide insight into allergic asthma. Objective: We sought to identify DNA methylation and gene expression changes associated with childhood allergic persistent asthma. Methods: We compared genomic DNA methylation patterns and gene expression in African American children with persistent atopic asthma (n = 36) versus healthy control subjects (n = 36). Results were validated in an independent population of asthmatic children (n = 30) by using a shared healthy control population (n = 36) and in an independent population of white adult atopic asthmatic patients (n = 12) and control subjects (n = 12). Results: We identified 186 genes with significant methylation changes, differentially methylated regions or differentially methylated probes, after adjustment for age, sex, race/ethnicity, batch effects, inflation, and multiple comparisons. Genes differentially methylated included those with established roles in asthma and atopy and genes related to extracellular matrix, immunity, cell adhesion, epigenetic regulation, and airflow obstruction. The methylation changes were substantial (median, 9.5%; range, 2.6% to 29.5%). Hypomethylated and hypermethylated genes were associated with increased and decreased gene expression, respectively (P < 2.8 x 10(-6) for differentially methylated regions and P < 7.8 x 10(-10) for differentially methylated probes). Quantitative analysis in 53 differentially expressed genes demonstrated that 32 (60%) have significant methylation-expression relationships within 5 kb of the gene. Ten loci selected based on the relevance to asthma, magnitude of methylation change, and methylation-expression relationships were validated in an independent cohort of children with atopic asthma. Sixty-seven of 186 genes also have significant asthma-associated methylation changes in nasal epithelia of adult white asthmatic patients. Conclusions: Epigenetic marks in respiratory epithelia are associated with allergic asthma and gene expression changes in inner-city children.	[Yang, Ivana V.; Pedersen, Brent S.; Richards, Adam; Davidson, Elizabeth J.; Hennessy, Corinne E.; Schwartz, David A.] Dept Med, Aurora, CO USA; [Yang, Ivana V.; Pedersen, Brent S.; Szefler, Stanley J.; Richards, Adam; Davidson, Elizabeth J.; Hennessy, Corinne E.; Schwartz, David A.] Univ Colorado, Sch Med, 12700 E 19th Ave,8611, Aurora, CO 80045 USA; [Yang, Ivana V.; Liu, Andrew H.; Stevens, Allen D.; Kolakowski, Christena A.; Martin, Richard J.; Schwartz, David A.] Natl Jewish Hlth, Denver, CO USA; [Yang, Ivana V.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA; [Schwartz, David A.] Univ Colorado, Dept Immunol, Aurora, CO USA; [O'Connor, George T.] Boston Univ, Sch Med, Dept Med, Boston, MA 02215 USA; [Pillai, Dinesh] Childrens Natl Hlth Syst, Washington, DC USA; [Kattan, Meyer] Columbia Univ, Med Ctr, New York, NY USA; [Misiak, Rana Tawil] Henry Ford Hosp, Dept Med, Detroit, MI 48202 USA; [Gruchalla, Rebecca] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Szefler, Stanley J.] Childrens Hosp Colorado, Dept Pediat, Aurora, CO USA; [Hershey, Gurjit K. Khurana; Kercsmar, Carolyn] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Makhija, Melanie] Childrens Hosp Chicago, Chicago, IL USA; [Sorkness, Christine A.; Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA; [Krouse, Rebecca Z.; Visness, Cynthia] Rho Fed Syst Div, Chapel Hill, NC USA; [Togias, Alkis] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Togias, Alkis] Univ Colorado, 12631 E 17th Ave,B178, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; National Jewish Health; Colorado School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Boston University; Children's National Health System; Columbia University; Henry Ford Health System; Henry Ford Hospital; University of Texas System; University of Texas Southwestern Medical Center Dallas; Children's Hospital Colorado; Cincinnati Children's Hospital Medical Center; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Colorado System; University of Colorado Anschutz Medical Campus	Yang, IV (corresponding author), Univ Colorado, Sch Med, 12700 E 19th Ave,8611, Aurora, CO 80045 USA.; Schwartz, DA (corresponding author), Univ Colorado, 12631 E 17th Ave,B178, Aurora, CO 80045 USA.	ivana.yang@ucdenver.edu; david.schwartz@ucdenver.edu	Yang, Ivana V/P-3059-2018	Yang, Ivana V/0000-0002-1018-489X; Szefler, Stanley/0000-0002-6911-3199	National Institute of Allergy and Infectious Diseases [N01-AI90052]; National Heart, Lung, and Blood Institute [R01-HL101251]; National Institute for Environmental Health Sciences [P01-ES18181]; National Center for Advancing Translational Sciences [UL1TR000075]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL101251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI114271, UM2AI117870, N01AI025496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES018181] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute for Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the National Institute of Allergy and Infectious Diseases (N01-AI90052); the National Heart, Lung, and Blood Institute (R01-HL101251); the National Institute for Environmental Health Sciences (P01-ES18181); and the National Center for Advancing Translational Sciences (UL1TR000075).	Baccarelli A, 2012, EPIGENOMICS-UK, V4, P91, DOI [10.2217/EPI.11.106, 10.2217/epi.11.106]; Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC; Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533; Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Benoist C, 2012, NAT REV IMMUNOL, V12, P734, DOI 10.1038/nri3300; Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080; Brock MV, 2008, NEW ENGL J MED, V358, P1118, DOI 10.1056/NEJMoa0706550; Buro-Auriemma LJ, 2013, HUM MOL GENET, V22, P4726, DOI 10.1093/hmg/ddt326; Candiano G, 2005, AM J RESP CRIT CARE, V172, P1090, DOI 10.1164/rccm.200409-1185OC; Dolzhenko E, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-215; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Fraser HB, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-2-r8; Galanter JM, 2014, J ALLERGY CLIN IMMUN, V134, P295, DOI 10.1016/j.jaci.2013.08.055; Gandhi VD, 2013, CURR ALLERGY ASTHM R, V13, P262, DOI 10.1007/s11882-013-0349-9; Gerstein M, 2012, NATURE, V489, P208, DOI 10.1038/489208b; Goh FY, 2013, J IMMUNOL, V191, P2691, DOI 10.4049/jimmunol.1202416; Han HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085085; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Imaoka H, 2011, AM J RESP CRIT CARE, V184, P771, DOI 10.1164/rccm.201102-0272OC; Imoto Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067057; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214; Kaminskas E, 2005, CLIN CANCER RES, V11, P3604, DOI 10.1158/1078-0432.CCR-04-2135; Kim ST, 2007, P NATL ACAD SCI USA, V104, P17052, DOI 10.1073/pnas.0708293104; Kulis M, 2012, NAT GENET, V44, P1236, DOI 10.1038/ng.2443; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Lampe WR, 2012, PULM PHARMACOL THER, V25, P427, DOI 10.1016/j.pupt.2012.06.003; Lee GR, 2006, IMMUNITY, V24, P369, DOI 10.1016/j.immuni.2006.03.007; Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109; Liang LM, 2015, NATURE, V520, P670, DOI 10.1038/nature14125; Lindley AR, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/727305; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Liu Y, 2013, NAT BIOTECHNOL, V31, P142, DOI 10.1038/nbt.2487; Lockett GA, 2013, CURR OPIN ALLERGY CL, V13, P463, DOI 10.1097/ACI.0b013e328364ea5f; Lovinsky-Desir S, 2014, CLIN EPIGENETICS, V6, DOI 10.1186/1868-7083-6-9; Mabbott NA, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-632; Maksimovic J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r44; Marcucci G, 2014, J CLIN ONCOL, V32, P548, DOI 10.1200/JCO.2013.50.6337; McErlean P, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-37; Michel S, 2013, ALLERGY, V68, P355, DOI 10.1111/all.12097; Moffatt MF, 1998, CLIN EXP ALLERGY, V28, P56; Morales E, 2012, AM J RESP CRIT CARE, V185, P937, DOI 10.1164/rccm.201105-0870OC; Nachbur U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7442; Nassenstein C, 2003, J EXP MED, V198, P455, DOI 10.1084/jem.20010897; Nicodemus-Johnson J, 2016, AM J RESP CRIT CARE, V193, P376, DOI 10.1164/rccm.201506-1243OC; Pedersen BS, 2012, BIOINFORMATICS, V28, P2986, DOI 10.1093/bioinformatics/bts545; Poole A, 2014, J ALLERGY CLIN IMMUN, V133, P670, DOI 10.1016/j.jaci.2013.11.025; Qiu WL, 2012, AM J RESP CRIT CARE, V185, P373, DOI 10.1164/rccm.201108-1382OC; Rastogi D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02164; Santos FPS, 2010, EXPERT REV ANTICANC, V10, P9, DOI [10.1586/era.09.164, 10.1586/ERA.09.164]; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Stegle O, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000770; Timp W, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0061-y; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Vergara C, 2013, GENET EPIDEMIOL, V37, P393, DOI 10.1002/gepi.21702; Wan ES, 2012, HUM MOL GENET, V21, P3073, DOI 10.1093/hmg/dds135; Webster RB, 2007, J BIOL CHEM, V282, P700, DOI 10.1074/jbc.M609501200; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Xia JG, 2014, NUCLEIC ACIDS RES, V42, pW167, DOI 10.1093/nar/gku443; Yang IV, 2015, J ALLERGY CLIN IMMUN, V136, P69, DOI 10.1016/j.jaci.2015.01.025; Yang IV, 2014, AM J RESP CRIT CARE, V190, P1263, DOI 10.1164/rccm.201408-1452OC; Yang IV, 2012, AM J RESP CRIT CARE, V185, P620, DOI 10.1164/rccm.201108-1503OC; Yu DH, 2014, J CLIN INVEST, V124, P3708, DOI 10.1172/JCI76507; Zhang DD, 2010, AM J HUM GENET, V86, P411, DOI 10.1016/j.ajhg.2010.02.005	70	90	96	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1478	1488		10.1016/j.jaci.2016.07.036	http://dx.doi.org/10.1016/j.jaci.2016.07.036			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27745942	Green Accepted, Bronze			2022-12-18	WOS:000400465300008
J	Tordesillas, L; Mondoulet, L; Blazquez, AB; Benhamou, PH; Sampson, HA; Berin, MC				Tordesillas, Leticia; Mondoulet, Lucie; Blazquez, Ana Belen; Benhamou, Pierre-Henri; Sampson, Hugh A.; Berin, M. Cecilia			Epicutaneous immunotherapy induces gastrointestinal LAP(+) regulatory T cells and prevents food-induced anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epicutaneous immunotherapy; oral immunotherapy; food allergy; regulatory T cells; mast cells	PEANUT ORAL IMMUNOTHERAPY; LATENCY-ASSOCIATED PEPTIDE; TGF-BETA; DENDRITIC CELLS; AUTOIMMUNE ENCEPHALOMYELITIS; MUCOSAL LYMPHOCYTES; COLORECTAL-CANCER; DELIVERY-SYSTEM; SENSITIZED MICE; INTACT SKIN	Background: The attempt to induce oral tolerance as a treatment for food allergy has been hampered by a lack of sustained clinical protection. Immunotherapy by nonoral routes, such as the skin, may be more effective for the development of maintained tolerance to food allergens. Objective: We sought to determine the efficacy and mechanism of tolerance induced by epicutaneous immunotherapy (EPIT) in a model of food-induced anaphylaxis. Methods: C3H/ HeJ mice were sensitized to ovalbumin (OVA) orally or through the skin and treated with EPIT using OVA-Viaskin patches or oral immunotherapy using OVA. Mice were orally challenged with OVA to induce anaphylaxis. Antigen-specific regulatory T (Treg)-cell induction was assessed by flow cytometry using a transgenic T-cell transfer model. Results: By using an adjuvant-free model of food allergy generated by epicutaneous sensitization and reactions triggered by oral allergen challenge, we found that EPIT induced sustained protection against anaphylaxis. We show that the gastrointestinal tract is deficient in de novo generation of Treg cells in allergic mice. This defect was tissue-specific, and epicutaneous application of antigen generated a population of gastrointestinal-homing LAP(+) Foxp3(-) Treg cells. The mechanism of protection was found to be a novel pathway of direct TGF-beta-dependent Treg-cell suppression of mast cell activation, in the absence of modulation of T-or B-cell responses. Conclusions: Our data highlight the immune communication between skin and gastrointestinal tract, and identifies novel mechanisms by which epicutaneous tolerance can suppress food-induced anaphylaxis.	[Tordesillas, Leticia; Blazquez, Ana Belen; Sampson, Hugh A.; Berin, M. Cecilia] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA; [Tordesillas, Leticia; Blazquez, Ana Belen; Sampson, Hugh A.; Berin, M. Cecilia] Icahn Sch Med Mt Sinai, Inst Immunol, New York, NY 10029 USA; [Mondoulet, Lucie; Benhamou, Pierre-Henri] DBV Technol, Bagneux, France; [Sampson, Hugh A.; Berin, M. Cecilia] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA; [Berin, M. Cecilia] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Berin, MC (corresponding author), Icahn Sch Med Mt Sinai, Pediat Allergy & Immunol, Box 1198,One Gustave L Levy Pl, New York, NY 10029 USA.	cecilia.berin@mssm.edu		Mondoulet, Lucie/0000-0003-0110-0321; berin, cecilia/0000-0002-9051-9249	National Institutes of Health [AI093577]; David H. and Julia Koch Research Program in Food Allergy Therapeutics; Robin Chemers Neustein Fellowship; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI093577] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); David H. and Julia Koch Research Program in Food Allergy Therapeutics; Robin Chemers Neustein Fellowship; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the National Institutes of Health (grant no. AI093577 to M.C.B.), David H. and Julia Koch Research Program in Food Allergy Therapeutics (to H. A.S.), and Robin Chemers Neustein Fellowship (to L.T.).	Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Berin MC, 2013, J ALLERGY CLIN IMMUN, V131, P14, DOI 10.1016/j.jaci.2012.10.058; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P707, DOI 10.1067/mai.2002.122503; Blazquez AB, 2010, GASTROENTEROLOGY, V139, P1301, DOI 10.1053/j.gastro.2010.06.055; Boswell S, 2013, IMMUNOBIOLOGY, V218, P427, DOI 10.1016/j.imbio.2012.05.028; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Burton OT, 2014, IMMUNITY, V41, P141, DOI 10.1016/j.immuni.2014.05.017; Campbell DJ, 2002, J EXP MED, V195, P135, DOI 10.1084/jem.20011502; Carrier Y, 2007, J IMMUNOL, V178, P179, DOI 10.4049/jimmunol.178.1.179; Chaillous L, 2000, LANCET, V356, P545, DOI 10.1016/S0140-6736(00)02579-4; Chen ML, 2008, J IMMUNOL, V180, P7327, DOI 10.4049/jimmunol.180.11.7327; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Ciabattini A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019346; Dioszeghy V, 2014, CLIN EXP ALLERGY, V44, P867, DOI 10.1111/cea.12312; Dioszeghy V, 2011, J IMMUNOL, V186, P5629, DOI 10.4049/jimmunol.1003134; Duan W, 2011, J IMMUNOL, V187, P6499, DOI 10.4049/jimmunol.1101398; Dudda JC, 2004, J IMMUNOL, V172, P857, DOI 10.4049/jimmunol.172.2.857; Ekoff M, 2007, J IMMUNOL, V178, P4177, DOI 10.4049/jimmunol.178.7.4177; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; Fukaura H, 1996, J CLIN INVEST, V98, P70, DOI 10.1172/JCI118779; Gandhi R, 2010, J IMMUNOL, V184, P4620, DOI 10.4049/jimmunol.0903329; Ganeshan K, 2012, J IMMUNOL, V188, P594, DOI 10.4049/jimmunol.1102389; Gomez G, 2005, J IMMUNOL, V174, P5987, DOI 10.4049/jimmunol.174.10.5987; Gri G, 2008, IMMUNITY, V29, P771, DOI 10.1016/j.immuni.2008.08.018; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Han YM, 2009, J IMMUNOL, V182, P111, DOI 10.4049/jimmunol.182.1.111; Ishikawa H, 2007, DIABETES, V56, P2103, DOI 10.2337/db06-1632; Ito T, 2011, EXP CELL RES, V317, P613, DOI 10.1016/j.yexcr.2010.12.018; Jawdat DM, 2004, J IMMUNOL, V173, P5275, DOI 10.4049/jimmunol.173.8.5275; Kashyap M, 2008, J IMMUNOL, V180, P2039, DOI 10.4049/jimmunol.180.4.2039; Keet CA, 2013, J ALLERGY CLIN IMMUN, V132, P737, DOI 10.1016/j.jaci.2013.05.006; Kuehn Hye Sun, 2010, Curr Protoc Immunol, VChapter 7, DOI 10.1002/0471142735.im0738s91; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V129, P1579, DOI 10.1016/j.jaci.2012.04.009; Mahalingam J, 2012, CLIN CANCER RES, V18, P5224, DOI 10.1158/1078-0432.CCR-12-0211; McLachlan JB, 2008, NAT MED, V14, P536, DOI 10.1038/nm1757; Mondoulet L, 2010, CLIN EXP ALLERGY, V40, P659, DOI 10.1111/j.1365-2222.2009.03430.x; Mondoulet L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031967; Mondoulet L, 2011, INT ARCH ALLERGY IMM, V154, P299, DOI 10.1159/000321822; Mora JR, 2003, NATURE, V424, P88, DOI 10.1038/nature01726; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Neurath MF, 1996, J EXP MED, V183, P2605, DOI 10.1084/jem.183.6.2605; Ochi H, 2006, NAT MED, V12, P627, DOI 10.1038/nm1408; Oida T, 2003, J IMMUNOL, V170, P2516, DOI 10.4049/jimmunol.170.5.2516; Pabst O, 2012, MUCOSAL IMMUNOL, V5, P232, DOI 10.1038/mi.2012.4; Perez-Machado MA, 2003, EUR J IMMUNOL, V33, P2307, DOI 10.1002/eji.200323308; Ruane D, 2013, J EXP MED, V210, P1871, DOI 10.1084/jem.20122762; Scurr M, 2014, MUCOSAL IMMUNOL, V7, P428, DOI 10.1038/mi.2013.62; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Soler D, 2003, BLOOD, V101, P1677, DOI 10.1182/blood-2002-07-2348; Stagg AJ, 2002, EUR J IMMUNOL, V32, P1445, DOI 10.1002/1521-4141(200205)32:5<1445::AID-IMMU1445>3.0.CO;2-E; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Wu HY, 2008, J IMMUNOL, V181, P6038, DOI 10.4049/jimmunol.181.9.6038; Zabel BA, 1999, J EXP MED, V190, P1241, DOI 10.1084/jem.190.9.1241; Zhao W, 2008, J IMMUNOL, V181, P7263, DOI 10.4049/jimmunol.181.10.7263; Zheng SG, 2002, J IMMUNOL, V169, P4183, DOI 10.4049/jimmunol.169.8.4183	60	90	92	2	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					189	+		10.1016/j.jaci.2016.03.057	http://dx.doi.org/10.1016/j.jaci.2016.03.057			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27417020	Bronze, Green Accepted			2022-12-18	WOS:000393996800021
J	Fischer, J; Hebsaker, J; Caponetto, P; Platts-Mills, TAE; Biedermann, T				Fischer, Joerg; Hebsaker, Johanna; Caponetto, Patricia; Platts-Mills, Thomas A. E.; Biedermann, Tilo			Galactose-alpha-1,3-galactose sensitization is a prerequisite for pork-kidney allergy and cofactor-related mammalian meat anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RED MEAT		[Fischer, Joerg; Hebsaker, Johanna; Caponetto, Patricia; Biedermann, Tilo] Univ Tubingen, Fac Med, Dept Dermatol, Allergy Unit, Tubingen, Germany; [Biedermann, Tilo] Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Munich, Germany; [Platts-Mills, Thomas A. E.] Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Technical University of Munich; University of Virginia	Fischer, J (corresponding author), Univ Tubingen, Fac Med, Dept Dermatol, Allergy Unit, Tubingen, Germany.	tilo.biedermann@lrz.tum.de		Platts-Mills, Thomas/0000-0002-1263-329X; Biedermann, Tilo/0000-0002-5352-5105	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Caponetto P, 2013, J ALLER CL IMM-PRACT, V1, P302, DOI 10.1016/j.jaip.2013.01.007; Commins SP, 2013, CURR ALLERGY ASTHM R, V13, P72, DOI 10.1007/s11882-012-0315-y; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Hamsten C, 2013, ALLERGY, V68, P549, DOI 10.1111/all.12128; Morisset M, 2012, ALLERGY, V67, P609, DOI 10.1111/j.1398-9995.2012.02799.x; Mullins RJ, 2012, J ALLERGY CLIN IMMUN, V129, P1334, DOI 10.1016/j.jaci.2012.02.038; RING J, 1977, LANCET, V1, P466; Wolbing F, 2013, ALLERGY, V68, P1085, DOI 10.1111/all.12193	9	90	90	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					755	759		10.1016/j.jaci.2014.05.051	http://dx.doi.org/10.1016/j.jaci.2014.05.051			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	25171869				2022-12-18	WOS:000341372400040
J	Undem, BJ; Taylor-Clark, T				Undem, Bradley J.; Taylor-Clark, Thomas			Mechanisms underlying the neuronal-based symptoms of allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; allergen; mast cell; IgE; degranulation; nerve; afferent; efferent; autonomic; sensory; nociceptor; C-fiber; parasympathetic; sympathetic; enteric; myenteric; nucleus tractus solitarious; ion channel; depolarization; action potential; cough; itch; pain; reflex; motility; bronchospasm; dysfunction; inflammation; skin; lungs; airways; gut; eye; hypersecretion; anti-inflammatory; steroids; vagal; dorsal root; trigeminal; nodose; jugular; ganglia; mast cell-nerve interactions; symptoms; transient receptor potential channels; mast cell mediators; histamine; prostaglandin; leukotriene; cytokine; irritant; receptor; innervation; plasticity; critical periods; phenotypic switch	IRRITABLE-BOWEL-SYNDROME; SUPERIOR CERVICAL-GANGLION; HISTAMINE EXCITES NEURONS; CELL-ADHESION MOLECULE-1; PULMONARY C-FIBERS; MAST-CELLS; SENSORY NEURONS; SYNERGISTIC INTERACTIONS; NEUROIMMUNE INTERACTIONS; FUNCTIONAL-SIGNIFICANCE	Persons with allergies present with symptoms that often are the result of alterations in the nervous system. Neuronally based symptoms depend on the organ in which the allergic reaction occurs but can include red itchy eyes, sneezing, nasal congestion, rhinorrhea, coughing, bronchoconstriction, airway mucus secretion, dysphagia, altered gastrointestinal motility, and itchy swollen skin. These symptoms occur because mediators released during an allergic reaction can interact with sensory nerves, change processing in the central nervous system, and alter transmission in sympathetic, parasympathetic, and enteric autonomic nerves. In addition, evidence supports the idea that in some subjects this neuromodulation is, for reasons poorly understood, upregulated such that the same degree of nerve stimulus causes a larger effect than seen in healthy subjects. There are distinctions in the mechanisms and nerve types involved in allergen-induced neuromodulation among different organ systems, but general principles have emerged. The products of activated mast cells, other inflammatory cells, and resident cells can overtly stimulate nerve endings, cause long-lasting changes in neuronal excitability, increase synaptic efficacy, and also change gene expression in nerves, resulting in phenotypically altered neurons. A better understanding of these processes might lead to novel therapeutic strategies aimed at limiting the suffering of those with allergies.	[Undem, Bradley J.] Johns Hopkins Sch Med, Div Allergy & Clin Immunol, Baltimore, MD 21224 USA; [Taylor-Clark, Thomas] Univ S Florida, Morsani Coll Med, Dept Mol Pharmacol & Physiol, Tampa, FL USA	Johns Hopkins University; Johns Hopkins Medicine; State University System of Florida; University of South Florida	Undem, BJ (corresponding author), Johns Hopkins Sch Med, Div Allergy & Clin Immunol, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	bundem@jhmi.edu			National Institutes of Health; GlaxoSmithKline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL119802] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline(GlaxoSmithKline); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Disclosure of potential conflict of interest: B. Undem has received grants from the National Institutes of Health and GlaxoSmithKline; is on the scientific advisory board for Afferent Pharmaceuticals; and has consultant arrangements with GlaxoSmithKline. T. Taylor-Clark declares that he has no relevant conflicts of interest.	Al-Chaer ED, 2000, GASTROENTEROLOGY, V119, P1276, DOI 10.1053/gast.2000.19576; ALVING K, 1991, CELL TISSUE RES, V264, P529, DOI 10.1007/BF00319042; ARIZONO N, 1990, LAB INVEST, V62, P626; BALUK P, 1997, J INVEST DERMATOL S, V2, P76; Barbara G, 2007, GASTROENTEROLOGY, V132, P26, DOI 10.1053/j.gastro.2006.11.039; Berardi N, 2000, CURR OPIN NEUROBIOL, V10, P138, DOI 10.1016/S0959-4388(99)00047-1; Bischoff SC, 2006, ADV EXP MED BIOL, V579, P177; Blackshaw LA, 2007, NEUROGASTROENT MOTIL, V19, P1, DOI 10.1111/j.1365-2982.2006.00871.x; Bonini S, 1999, INT ARCH ALLERGY IMM, V118, P159, DOI 10.1159/000024055; Breunig E, 2007, J PHYSIOL-LONDON, V583, P731, DOI 10.1113/jphysiol.2007.139352; Buhner S, 2012, NEUROGASTROENT MOTIL, V24, P1134, DOI 10.1111/nmo.12011; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chen CY, 2001, J ALLERGY CLIN IMMUN, V108, P557; CHRISTIAN EP, 1989, J PHYSIOL-LONDON, V409, P297, DOI 10.1113/jphysiol.1989.sp017498; Chuaychoo B, 2005, J ALLERGY CLIN IMMUN, V116, P325, DOI 10.1016/j.jaci.2005.04.005; Coldwell JR, 2007, J PHYSIOL-LONDON, V579, P203, DOI 10.1113/jphysiol.2006.123158; COLERIDGE JCG, 1984, REV PHYSIOL BIOCH P, V99, P1, DOI 10.1007/BFb0027715; Costello RW, 1999, AM J PHYSIOL-LUNG C, V276, pL709, DOI 10.1152/ajplung.1999.276.5.L709; Cremon C, 2011, AM J GASTROENTEROL, V106, P1290, DOI 10.1038/ajg.2011.86; Cyphert JM, 2009, J IMMUNOL, V182, P7430, DOI 10.4049/jimmunol.0900039; D'Andrea MR, 2005, AM J PHYSIOL-REG I, V288, pR491, DOI 10.1152/ajpregu.00452.2004; Ding-Pfennigdorff D, 2004, NEUROREPORT, V15, P2071, DOI 10.1097/00001756-200409150-00015; EGLEZOS A, 1992, ARCH INT PHARMACOD T, V315, P96; Fischer A, 1996, J CLIN INVEST, V98, P2284, DOI 10.1172/JCI119039; Forsythe P, 2012, CHEM IMMUNOL ALLERGY, V98, P196, DOI 10.1159/000336523; FRIELING T, 1994, AM J PHYSIOL-GASTR L, V267, pG1087, DOI 10.1152/ajpgi.1994.267.6.G1087; FRYER AD, 1991, J APPL PHYSIOL, V71, P2255, DOI 10.1152/jappl.1991.71.6.2255; Furuno T, 2012, J NEUROIMMUNOL, V250, P50, DOI 10.1016/j.jneuroim.2012.05.016; GREENE R, 1988, J APPL PHYSIOL, V64, P2249, DOI 10.1152/jappl.1988.64.5.2249; Gu QH, 2009, AM J PHYSIOL-LUNG C, V296, pL453, DOI 10.1152/ajplung.90467.2008; Hagiyama M, 2011, J IMMUNOL, V186, P5983, DOI 10.4049/jimmunol.1002244; Hong JL, 1998, J PHYSIOL-LONDON, V508, P109, DOI 10.1111/j.1469-7793.1998.109br.x; Hunter DD, 2011, AM J RESP CELL MOL, V45, P359, DOI 10.1165/rcmb.2010-0345OC; Jiang W, 2000, GASTROENTEROLOGY, V119, P1267, DOI 10.1053/gast.2000.19461; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Kajekar R, 2003, AM J PHYSIOL-LUNG C, V284, pL581, DOI 10.1152/ajplung.00332.2002; Kakurai M, 2006, AM J PATHOL, V169, P1713, DOI 10.2353/ajpath.2006.060602; KEITH IM, 1995, J COMP NEUROL, V363, P28, DOI 10.1002/cne.903630104; Kirkup AJ, 2003, J PHYSIOL-LONDON, V552, P589, DOI 10.1113/jphysiol.2003.049387; Kreis ME, 2000, NEUROSCI LETT, V289, P45, DOI 10.1016/S0304-3940(00)01265-9; LEE LY, 1993, RESP PHYSIOL, V93, P83, DOI 10.1016/0034-5687(93)90070-Q; Lieu TM, 2012, AM J PHYSIOL-LUNG C, V302, pL941, DOI 10.1152/ajplung.00366.2011; Lieu T, 2011, AM J PHYSIOL-LUNG C, V300, pL790, DOI 10.1152/ajplung.00449.2010; Liu SM, 2003, AM J PHYSIOL-GASTR L, V284, pG154, DOI 10.1152/ajpgi.00241.2002; LYNN B, 1975, ANNU REV PHYSIOL, V37, P105, DOI 10.1146/annurev.ph.37.030175.000541; MAWE GM, 1995, J PHYSIOL-LONDON, V485, P513, DOI 10.1113/jphysiol.1995.sp020747; Mazzone SB, 2005, J PHYSIOL-LONDON, V569, P559, DOI 10.1113/jphysiol.2005.093153; Mazzone SB, 2002, AM J PHYSIOL-REG I, V283, pR86, DOI 10.1152/ajpregu.00007.2002; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Moon TC, 2010, MUCOSAL IMMUNOL, V3, P111, DOI 10.1038/mi.2009.136; MYERS AC, 1993, J PHYSIOL-LONDON, V470, P665, DOI 10.1113/jphysiol.1993.sp019881; Myers AC, 2002, AM J PHYSIOL-LUNG C, V282, pL775, DOI 10.1152/ajplung.00353.2001; MYERS AC, 1991, J APPL PHYSIOL, V71, P970, DOI 10.1152/jappl.1991.71.3.970; Neumann S, 1996, NATURE, V384, P360, DOI 10.1038/384360a0; Nockher WA, 2006, J ALLERGY CLIN IMMUN, V117, P67, DOI 10.1016/j.jaci.2005.08.029; Omori Y, 2009, NEUROREPORT, V20, P478, DOI 10.1097/WNR.0b013e3283293725; Pan J, 2010, AM J RESP CELL MOL, V43, P452, DOI 10.1165/rcmb.2009-0130OC; Pelleg A, 1996, J PHYSIOL-LONDON, V490, P265, DOI 10.1113/jphysiol.1996.sp021142; Potenzieri C, 2012, J PHYSIOL-LONDON, V590, P5449, DOI 10.1113/jphysiol.2012.237115; Revicki DA, 1998, QUAL LIFE RES, V7, P693, DOI 10.1023/A:1008860113818; Riccio MM, 1996, J PHYSIOL-LONDON, V491, P499, DOI 10.1113/jphysiol.1996.sp021234; Ruda MA, 2000, SCIENCE, V289, P628, DOI 10.1126/science.289.5479.628; Sanico AM, 1997, J ALLERGY CLIN IMMUN, V100, P632, DOI 10.1016/S0091-6749(97)70167-2; Sarin S, 2006, J ALLERGY CLIN IMMUN, V118, P999, DOI 10.1016/j.jaci.2006.09.013; Sawatzky DA, 2002, AM J PHYSIOL-LUNG C, V282, pL1279, DOI 10.1152/ajplung.00279.2001; Schemann M, 2005, NEUROGASTROENT MOTIL, V17, P281, DOI 10.1111/j.1365-2982.2004.00591.x; Schemann M, 2013, GASTROENTEROLOGY, V144, P698, DOI 10.1053/j.gastro.2013.01.040; Sherrington CS., 1906, INTEGRATIVE ACTION N; Shim WS, 2007, J NEUROSCI, V27, P2331, DOI 10.1523/JNEUROSCI.4643-06.2007; Shusterman DJ, 1998, J ALLERGY CLIN IMMUN, V101, P732, DOI 10.1016/S0091-6749(98)70302-1; Silver R, 1996, TRENDS NEUROSCI, V19, P25, DOI 10.1016/0166-2236(96)81863-7; Silver RB, 2004, P NATL ACAD SCI USA, V101, P13607, DOI 10.1073/pnas.0403208101; STEAD RH, 1989, GASTROENTEROLOGY, V97, P575, DOI 10.1016/0016-5085(89)90627-6; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; Suh YG, 2005, CURR PHARM DESIGN, V11, P2687, DOI 10.2174/1381612054546789; Surdenikova L, 2012, NEUROGASTROENT MOTIL, V24, pe517, DOI 10.1111/nmo.12002; Tatar M, 2009, PULM PHARMACOL THER, V22, P121, DOI 10.1016/j.pupt.2008.11.014; Taylor-Clark TE, 2008, BRIT J PHARMACOL, V154, P1359, DOI 10.1038/bjp.2008.196; Taylor-Clark TE, 2008, MOL PHARMACOL, V73, P274, DOI 10.1124/mol.107.040832; Taylor-Clark TE, 2011, RESP PHYSIOL NEUROBI, V178, P406, DOI 10.1016/j.resp.2011.05.003; Thornton MA, 2013, CLIN IMMUNOL, V147, P50, DOI 10.1016/j.clim.2013.02.008; UNDEM BJ, 1990, J AUTONOM NERV SYST, V30, P75, DOI 10.1016/0165-1838(90)90164-E; UNDEM BJ, 1991, INT ARCH ALLER A IMM, V94, P319, DOI 10.1159/000235394; UNDEM BJ, 1993, J AUTONOM NERV SYST, V44, P35, DOI 10.1016/0165-1838(93)90376-6; Van Nassauw L, 2007, AUTON NEUROSCI-BASIC, V133, P91, DOI 10.1016/j.autneu.2006.10.003; Weigand LA, 2009, J PHYSIOL-LONDON, V587, P3355, DOI 10.1113/jphysiol.2009.173054; WEINREICH D, 1992, ANN NY ACAD SCI, V664, P293, DOI 10.1111/j.1749-6632.1992.tb39769.x; WEINREICH D, 1987, J CLIN INVEST, V79, P1529, DOI 10.1172/JCI112984; WIESEL TN, 1965, J NEUROPHYSIOL, V28, P1060, DOI 10.1152/jn.1965.28.6.1060; Williams RM, 1997, NEUROIMMUNOMODULAT, V4, P266, DOI 10.1159/000097346; Wood JD, 2012, J ANIM SCI, V90, P1213, DOI 10.2527/jas.2011-4787; Wood JD, 2004, GASTROENTEROLOGY, V127, P635, DOI 10.1053/j.gastro.2004.02.017; Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030; Wu ZX, 2009, ENVIRON HEALTH PERSP, V117, P1434, DOI 10.1289/ehp.0800511; Yu S, 2007, AM J PHYSIOL-GASTR L, V293, pG850, DOI 10.1152/ajpgi.00277.2007; Zhang GF, 2008, J APPL PHYSIOL, V105, P128, DOI 10.1152/japplphysiol.01367.2007; Zhang GF, 2008, J PHYSIOL-LONDON, V586, P5771, DOI 10.1113/jphysiol.2008.161042; Zweifel LS, 2005, NAT REV NEUROSCI, V6, P615, DOI 10.1038/nrn1727	98	90	100	2	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1521	1534		10.1016/j.jaci.2013.11.027	http://dx.doi.org/10.1016/j.jaci.2013.11.027			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24433703	Green Accepted, Bronze			2022-12-18	WOS:000336672500003
J	Wildfire, JJ; Gergen, PJ; Sorkness, CA; Mitchell, HE; Calatroni, A; Kattan, M; Szefler, SJ; Teach, SJ; Bloomberg, GR; Wood, RA; Liu, AH; Pongracic, JA; Chmiel, JF; Conroy, K; Rivera-Sanchez, Y; Busse, WW; Morgan, WJ				Wildfire, Jeremy J.; Gergen, Peter J.; Sorkness, Christine A.; Mitchell, Herman E.; Calatroni, Agustin; Kattan, Meyer; Szefler, Stanley J.; Teach, Stephen J.; Bloomberg, Gordon R.; Wood, Robert A.; Liu, Andrew H.; Pongracic, Jacqueline A.; Chmiel, James F.; Conroy, Kathleen; Rivera-Sanchez, Yadira; Busse, William W.; Morgan, Wayne J.			Development and validation of the Composite Asthma Severity Index-an outcome measure for use in children and adolescents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; composite score; morbidity; treatment; exacerbations; symptoms; severity	INNER-CITY CHILDREN; CLINICAL-TRIAL; END-POINTS; EXACERBATIONS; MANAGEMENT	Background: Asthma severity is reflected in many aspects of the disease, including impairment and future risks, particularly for exacerbations. According to the Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, however, to assess more comprehensively the severity of asthma the level of current treatment needed to maintain a level of control should be included. Objective: Development and validation of a new instrument, the Composite Asthma Severity Index (CASI), which can quantify disease severity by taking into account impairment, risk, and the amount of medication needed to maintain control. At present, there is no instrument available to measure and assess the multidimensional nature of asthma. Methods: Twenty-six established asthma investigators, who are part of the National Institutes of Health-supported Inner City Asthma Consortium, participated in a modified Delphi consensus process to identify and weight the dimensions of asthma. Factor analysis was performed to identify independent domains of asthma by using the Asthma Control Evaluation trial. CASI was validated by using the Inner City Anti-IgE Therapy for Asthma trial. Results: CASI scores include 5 domains: day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations. At Asthma Control Evaluation trial enrollment, CASI ranged from 0 to 17, with a mean of 6.2. CASI was stable, with minimal change in variance after 1 year of treatment. In external validation, CASI detected a 32% larger improvement than did symptoms alone. Conclusion: CASI retained its discriminatory ability even with low levels of symptoms reported after months of guidelines-directed care. Thus, CASI has the ability to determine the level of asthma severity and provide a composite clinical characterization of asthma. (J Allergy Clin Immunol 2012; 129: 694-701.)	[Wildfire, Jeremy J.; Mitchell, Herman E.; Calatroni, Agustin] Rho Fed Syst Div Inc, Chapel Hill, NC 27517 USA; [Gergen, Peter J.] NIAID, Bethesda, MD 20892 USA; [Sorkness, Christine A.; Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Kattan, Meyer] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Szefler, Stanley J.; Liu, Andrew H.] Natl Jewish Hlth, Denver, CO USA; [Szefler, Stanley J.; Liu, Andrew H.] Univ Colorado, Sch Med, Denver, CO USA; [Teach, Stephen J.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Bloomberg, Gordon R.] Washington Univ, St Louis, MO USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Pongracic, Jacqueline A.] Childrens Mem Hosp, Chicago, IL 60614 USA; [Chmiel, James F.] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Conroy, Kathleen] Boston Univ, Sch Med, Boston, MA 02118 USA; [Rivera-Sanchez, Yadira] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Morgan, Wayne J.] Univ Arizona, Coll Med, Tucson, AZ USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Wisconsin System; University of Wisconsin Madison; Columbia University; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's National Health System; Washington University (WUSTL); Johns Hopkins University; Ann & Robert H. Lurie Children's Hospital of Chicago; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Boston University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Arizona	Wildfire, JJ (corresponding author), Rho Fed Syst Div Inc, 6330 Quadrangle Dr, Chapel Hill, NC 27517 USA.	jeremy_wildfire@rhoworld.com		Szefler, Stanley/0000-0002-6911-3199	National Institute of Allergy and Infectious Diseases, National Institutes of Health [NO1-AI-25496, NO1-JAI-25482]; National Center for Research Resources, National Institutes of Health [RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, 5UL1RR024992-02, 5M01RR020359-04]; GlaxoSmithKline; National Heart, Lung, and Blood Institute (NHLBI); National Institute of Environmental Health Sciences (NIEHS; NIAID; NIH; Environmental Protection Agency; Novartis; NIAID/NHLBI/NIH; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025771, M01RR000533, UL1RR024156, UL1RR024992, M01RR020359, M01RR000052, M01RR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025496] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); GlaxoSmithKline(GlaxoSmithKline); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Environmental Health Sciences (NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Environmental Protection Agency(United States Environmental Protection Agency); Novartis(Novartis); NIAID/NHLBI/NIH; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project was funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under contract nos. NO1-AI-25496 and NO1-JAI-25482. Additional funds were provided by the National Center for Research Resources, National Institutes of Health, under grants RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, 5UL1RR024992-02, and 5M01RR020359-04.; M. Kattan and G. R. Bloomberg have received research support from the National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH). S. J. Szefer has consulted for GlaxoSmithKline, Genentech, Merck, Boehringer-Ingelheim, Novartis, and Schering-Plough and has received research support from GlaxoSmithKline, the National Heart, Lung, and Blood Institute (NHLBI), the National Institute of Environmental Health Sciences (NIEHS), the NIAID, the NIH, and the Environmental Protection Agency. R. A. Wood has consulted for the Asthma and Allergy Foundation of America, received research support from the NIH, and served on the medical advisory board for the Food Allergy and Anaphylaxis Network. A. H. Liu has received a speaker honorarium from Merck. J. A. Pongracic has received research support from the NIAID. J. F. Chmiel has received research support from the NIH. W. J. Morgan has consulted for the Cystic Fibrosis Foundation, Genentech, and Novartis and has received research support from the NIH and Novartis. W. W. Busse has served on advisory boards for Centocor and Merck; has consulted for Amgen, AstraZeneca, Novartis, GlaxoSmithKline, Med-Immune, and Genentech; and has received research support from the NIAID/NHLBI/NIH. The rest of the authors declare that they have no relevant conflicts of interest.	ADELROTH E, 2000, EUR RESPIR REV, V10, P36; APTER AJ, 1994, J ALLERGY CLIN IMMUN, V94, P732, DOI 10.1016/0091-6749(94)90181-3; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Covar RA, 2008, J ALLERGY CLIN IMMUN, V122, P741, DOI 10.1016/j.jaci.2008.08.021; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Guttmann A, 2006, PEDIATRICS, V118, P114, DOI 10.1542/peds.2005-3029; Harding G, 2009, CURR MED RES OPIN, V25, P1563, DOI 10.1185/03007990902914403; Jones CA, 2007, J ALLERGY CLIN IMMUN, V119, P1445, DOI 10.1016/j.jaci.2007.02.031; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Miller MK, 2007, RESP MED, V101, P481, DOI 10.1016/j.rmed.2006.07.005; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; National Heart Lung and Blood Institute, 2007, EPR3 NAT HEART LUNG; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Taylor DR, 2008, EUR RESPIR J, V32, P545, DOI 10.1183/09031936.00155307; van Belle G., 2002, STAT RULES THUMB; Zhang J, 2002, EUR RESPIR J, V20, P1102, DOI 10.1183/09031936.02.02402001	22	90	92	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					694	701		10.1016/j.jaci.2011.12.962	http://dx.doi.org/10.1016/j.jaci.2011.12.962			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22244599	Green Accepted			2022-12-18	WOS:000301189300013
J	Hamilton, MJ; Hornick, JL; Akin, C; Castells, MC; Greenberger, NJ				Hamilton, Matthew J.; Hornick, Jason L.; Akin, Cem; Castells, Mariana C.; Greenberger, Norton J.			Mast cell activation syndrome: A newly recognized disorder with systemic clinical manifestations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Diarrhea; mast cell; abdominal pain; histamine; tryptase; flushing; mast cell activation	MASTOCYTOSIS	Background: Diagnostic criteria for mast cell (MC) activation syndrome have been recently proposed, but clinical studies to validate these criteria are lacking. Objective: We sought to determine the clinical manifestations of this newly recognized syndrome in a cohort of patients. Methods: We prospectively evaluated 18 patients seen at our institution with MC activation syndrome from 2006 to 2009. Patients enrolled had at least 4 of the signs and symptoms of abdominal pain, diarrhea, flushing, dermatographism, memory and concentration difficulties, or headache. Response to treatment with anti-MC mediator medications was assessed based on established criteria. Laboratory tests indicating MC mediator release and histopathology and immunohistochemical studies on gastrointestinal biopsy samples were performed. Results: Ninety-four percent of the patients had abdominal pain, 89% had dermatographism, 89% had flushing, and 72% had the constellation of all 3 symptoms. Patients additionally had headache, diarrhea, and memory and concentration difficulties. All patients had at least 1 positive laboratory test result for an increased MC mediator level. On the basis of the response to treatment criteria, 67% of the patients in the cohort had either a complete or major regression in symptoms while taking medications targeting MC mediators. There was no significant difference in the numbers of intestinal mucosal MCs between our patients and healthy control subjects. Conclusion: MC activation syndrome might be the underlying cause of unexplained symptoms when several organ systems are involved, such as the gastrointestinal tract and the skin. It is especially important to be able to recognize the constellation of clinical features because response to anti-MC mediator medications is often excellent. (J Allergy Clin Immunol 2011; 128: 147-52.)	[Hamilton, Matthew J.] Brigham & Womens Hosp, Gastroenterol Clin ASBII, Dept Med, Boston, MA 02115 USA; [Hornick, Jason L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Hornick, Jason L.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University	Hamilton, MJ (corresponding author), Brigham & Womens Hosp, Gastroenterol Clin ASBII, Dept Med, 45 Francis St, Boston, MA 02115 USA.	mjhamilton@partners.org		Akin, Cem/0000-0001-6301-4520; Hornick, Jason/0000-0001-6475-8345	Ovations for the Cure; Mastocytosis Society	Ovations for the Cure; Mastocytosis Society	Disclosure of potential conflict of interest: C. Akin is a consultant for Novartis and is on the Medical Advisory Board for the Mastocytosis Society. M. C. Castells is a consultant for Merck, receives research support from Ovations for the Cure, and has received funds from the Mastocytosis Society. The rest of the authors have declared that they have no conflict of interest.	Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Akin C, 2010, J ALLERGY CLIN IMMUN, V126, P1099, DOI 10.1016/j.jaci.2010.08.035; Alvarez-Twose I, 2010, J ALLERGY CLIN IMMUN, V125, P1269, DOI 10.1016/j.jaci.2010.02.019; Barbara G, 2006, NEUROGASTROENT MOTIL, V18, P6, DOI 10.1111/j.1365-2982.2005.00685.x; Bhute D, 2008, INDIAN J DERMATOL VE, V74, P177, DOI 10.4103/0378-6323.39724; Buhner S, 2009, GASTROENTEROLOGY, V137, P1425, DOI 10.1053/j.gastro.2009.07.005; Butterfield JH, 2008, INT ARCH ALLERGY IMM, V147, P338, DOI 10.1159/000144042; Castells M, 2002, INT ARCH ALLERGY IMM, V127, P147, DOI 10.1159/000048188; CHERNER JA, 1988, GASTROENTEROLOGY, V95, P657, DOI 10.1016/S0016-5085(88)80012-X; FRIERI M, 1985, AM J MED, V78, P9, DOI 10.1016/0002-9343(85)90454-1; Hahn HP, 2007, AM J SURG PATHOL, V31, P1669, DOI 10.1097/PAS.0b013e318078ce7a; He SH, 2004, WORLD J GASTROENTERO, V10, P309; Jakate S, 2006, ARCH PATHOL LAB MED, V130, P362; Nakajima S, 2004, ALIMENT PHARM THER, V20, P165, DOI 10.1111/j.1365-2036.2004.01974.x; O'Sullivan M, 2000, NEUROGASTROENT MOTIL, V12, P449; Park JH, 2006, J GASTROEN HEPATOL, V21, P71, DOI 10.1111/j.1440-1746.2005.04143.x; Pothoulakis C, 2001, AM J PHYSIOL-GASTR L, V280, pG178, DOI 10.1152/ajpgi.2001.280.2.G178; Spiegel B, 2009, GASTROENTEROLOGY, V137, P1944, DOI 10.1053/j.gastro.2009.08.047; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Wang SH, 2007, WORLD J GASTROENTERO, V13, P6041, DOI 10.3748/wjg.13.6041; WESTON AP, 1993, DIGEST DIS SCI, V38, P1590, DOI 10.1007/BF01303164	22	90	95	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					147	U228		10.1016/j.jaci.2011.04.037	http://dx.doi.org/10.1016/j.jaci.2011.04.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21621255				2022-12-18	WOS:000292245600019
J	Dolhnikoff, M; da Silva, LFF; de Araujo, BB; Gomes, HAP; Fernezlian, S; Mulder, A; Lindeman, JH; Mauad, T				Dolhnikoff, Marisa; da Silva, Luiz F. F.; de Araujo, Bianca B.; Gomes, Higor A. P.; Fernezlian, Sandra; Mulder, Adri; Lindeman, Jan H.; Mauad, Thais			The outer wall of small airways is a major site of remodeling in fatal asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Collagen; fatal asthma; extracellular matrix; distal lung; remodeling	BRONCHIAL SUBEPITHELIAL FIBROSIS; BRONCHOALVEOLAR LAVAGE FLUID; RETICULAR BASEMENT-MEMBRANE; MATRIX METALLOPROTEINASES; PERIPHERAL AIRWAYS; RESPIRATORY-TRACT; TISSUE INHIBITORS; INFLAMMATION; COLLAGEN; LUNG	Background: Structural and inflammatory changes in asthma involve both the large and small airways, with involvement of the distal lung being related to disease severity. We have previously shown that changes in the extracellular matrix (ECM) composition of the distal lung are associated with loss of alveolar attachments in patients with fatal asthma. However, major ECM elements, such as collagen I and fibronectin and their regulators, have not been addressed at the distal level. Objective: We sought to evaluate ECM remodeling in the distal lungs of asthmatic patients. Methods: Using immunohistochemistry and image analysis, we determined the content of collagen I and III, fibronectin, and matrix metalloproteinases; (MMPs) 1, 2, and 9 and tissue inhibitors of metalloproteinase (MMPs) 1 and 2 in the large and small airways and lung parenchyma of 24 patients with fatal asthma and compared the results with those of 11 nonasthmatic control subjects. Protein content was defined as the area of positive staining divided by basement membrane or septum length. Results: We observed increased collagen I and decreased collagen III content in the small airways of asthmatic patients compared with that seen in control subjects. Greater fibronectin and MMP-1, MMP-2, and MMP-9 content was observed at the outer area of the small airways in asthmatic patients. NIMP content was also increased in the peribronchiolar parenchyma in asthmatic patients. In contrast, TIMP expression was only increased in the large airways of asthmatic patients compared with that seen in control subjects. Conclusions: The outer area of the small airways is a major site of ECM remodeling in fatal asthma, potentially contributing to functional changes and the loss of airway-parenchyma interdependence observed in patients with fatal asthma. (J Allergy Clin Immunol 2009;123:1090-7.)	[Dolhnikoff, Marisa] Univ Sao Paulo, Fac Med, Dept Patol, Sch Med, BR-01246903 Sao Paulo, Brazil; [Mulder, Adri; Lindeman, Jan H.] Leiden Univ, Dept Vasc Surg, Med Ctr, Leiden, Netherlands	Universidade de Sao Paulo; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Dolhnikoff, M (corresponding author), Univ Sao Paulo, Fac Med, Dept Patol, Sch Med, Av Dr Arnaldo,455 Sala 1155, BR-01246903 Sao Paulo, Brazil.	maridol@usp.br	Silva, Luiz/D-2760-2012; Mauad, Thais/G-1254-2012; ambiental, Inct Risco/H-9808-2013; Dolhnikoff, Marisa/B-9019-2013	Silva, Luiz/0000-0002-0181-6357; Mauad, Thais/0000-0002-3354-1466; Dolhnikoff, Marisa/0000-0002-9073-9989	Fundacao de Amparo Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Laboratorio de Investigacao Medica do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo [LIM-05 HCFMUSP]	Fundacao de Amparo Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Laboratorio de Investigacao Medica do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo	Supported by Fundacao de Amparo Pesquisa do Estado de Sao Paulo (FAPESP), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), and Laboratorio de Investigacao Medica do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (LIM-05 HCFMUSP).	Araujo BB, 2008, EUR RESPIR J, V32, P61, DOI 10.1183/09031936.00147807; Bergeron C, 2006, CHEST, V129, P1068, DOI 10.1378/chest.129.4.1068; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P983, DOI 10.1016/j.jaci.2005.07.029; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; Cataldo DD, 2004, LAB INVEST, V84, P418, DOI 10.1038/labinvest.3700063; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; Culpitt SV, 2005, RESP MED, V99, P703, DOI 10.1016/j.rmed.2004.10.022; de Kluijver J, 2005, CLIN EXP ALLERGY, V35, P1361, DOI 10.1111/j.1365-2222.2005.02334.x; Dolhnikoff M, 1999, AM J RESP CRIT CARE, V160, P1750, DOI 10.1164/ajrccm.160.5.9812040; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; GAY S, 1983, ULTRASTRUCT PATHOL, V4, P365, DOI 10.3109/01913128309140589; Gueders MM, 2006, EUR J PHARMACOL, V533, P133, DOI 10.1016/j.ejphar.2005.12.082; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Hocking DC, 2002, CHEST, V122, p275S, DOI 10.1378/chest.122.6_suppl.275S; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; James A, 2005, CURR OPIN PULM MED, V11, P1, DOI 10.1097/01.mcp.0000146779.26339.d8; James Alan L, 2002, Curr Allergy Asthma Rep, V2, P166, DOI 10.1007/s11882-002-0012-3; Kelly EA, 2003, CURR OPIN PULM MED, V9, P28, DOI 10.1097/00063198-200301000-00005; Lahzami S, 2008, EUR RESPIR J, V31, P1145, DOI 10.1183/09031936.00045608; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; LIMPER AH, 1992, CHEST, V101, P1663, DOI 10.1378/chest.101.6.1663; Maisi P, 2002, APMIS, V110, P771, DOI 10.1034/j.1600-0463.2002.1101102.x; Matsushita MD, 2005, J PATHOL, V207, P102, DOI 10.1002/path.1818; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; Mauad T, 2008, REV PANAM SALUD PUBL, V23, P418, DOI 10.1590/S1020-49892008000600007; Mauad T, 2007, J ALLERGY CLIN IMMUN, V120, P997, DOI 10.1016/j.jaci.2007.06.031; Mautino G, 1999, AM J RESP CRIT CARE, V160, P324, DOI 10.1164/ajrccm.160.1.9808087; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; ROCHE WR, 1989, LANCET, V1, P520; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138, DOI 10.1164/ajrccm/143.1.138; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Simoes SD, 2005, CLIN EXP ALLERGY, V35, P602, DOI 10.1111/j.1365-2222.2005.02235.x; Suki B, 2008, RESP PHYSIOL NEUROBI, V163, P33, DOI 10.1016/j.resp.2008.03.015; Vanacker NJ, 2002, CLIN EXP ALLERGY, V32, P914, DOI 10.1046/j.1365-2222.2002.01394.x; Vignola AM, 2003, CHEST, V123, p417S, DOI 10.1378/chest.123.3_suppl.417S; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Wilson JW, 1997, CLIN EXP ALLERGY, V27, P363	42	90	93	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1090	1097		10.1016/j.jaci.2009.02.032	http://dx.doi.org/10.1016/j.jaci.2009.02.032			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19361849	Bronze			2022-12-18	WOS:000266309400017
J	Ben-Shoshan, M; Kagan, RS; Alizadehfar, R; Joseph, L; Turnbull, E; St Pierre, Y; Clarke, AE				Ben-Shoshan, Moshe; Kagan, Rhoda S.; Alizadehfar, Reza; Joseph, Lawrence; Turnbull, Elizabeth; St Pierre, Yvan; Clarke, Ann E.			Is the prevalence of peanut allergy increasing? A 5-year follow-up study in children in Montreal	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; prevalence; skin prick test; peanut-specific IgE; food challenge; epidemiology	DIAL TELEPHONE SURVEY; TREE NUT ALLERGY; FOOD ALLERGY; IGE CONCENTRATIONS; UNITED-STATES; VITAMIN-D; ASTHMA; INFANTS; DISEASE; DIAGNOSIS	Background: Studies suggest that peanut allergy prevalence might be increasing, but these results have not yet been substantiated. Objective: We conducted a follow-up study to determine whether peanut allergy prevalence in Montreal is increasing. Methods: Questionnaires regarding peanut ingestion were administered to parents of children in randomly selected kindergarten through grade 3 classrooms between December 2000 and September 2002 and between October 2005 and December 2007. Respondents were stratified as (1) peanut tolerant, (2) never/rarely ingest peanut, (3) convincing history of peanut allergy, or (4) uncertain history of peanut allergy. Children in group 3 with positive skin prick test responses were considered to have peanut allergy. Children in groups 2 and 4 with positive skin prick test responses had peanut-specific IgE levels measured, and if the value was less than 15 kU/L, an oral peanut challenge was performed. Multiple imputation was used to generate prevalence estimates that incorporated respondents providing incomplete data and nonrespondents. Results: Of 8,039 children surveyed in 2005-2007, 64.2% of parents responded. Among those providing complete data, the prevalence was 1.63% (95% CI, 1.30% to 2.02%) in 2005-2007 versus 1.50% (95% CI, 1.16% to 1.92%) in 2000-2002. After adjustment for missing data, the prevalence was 1.62% (95% credible interval, 1.31% to 1.98%) versus 1.34% (95% credible interval, 1.08% to 1.64%), respectively. The differences between the prevalences in 2005-2007 and 2000-2002 were 0.13% (95% credible interval, 20.38% to 0.63%) among those providing complete data and 0.28% (95% credible interval, 20.15 % to 0.70 %) after adjustment for missing data. Conclusions: This is the first North American study to document temporal trends in peanut allergy prevalence by corroborating history with confirmatory tests. The results suggest a stable prevalence, but wide CIs preclude definitive conclusions. (J Allergy Clin Immunol 2009;123:783-8.)	[Ben-Shoshan, Moshe; Alizadehfar, Reza] McGill Univ, Hlth Ctr, Division of Clin Immunol Allergy & Rheumatol, Dept Pediat, Montreal, PQ H3A 2T5, Canada; [Kagan, Rhoda S.] Univ Toronto, N York Gen Hosp, Dept Pediat, Toronto, ON, Canada; [Joseph, Lawrence; Turnbull, Elizabeth; St Pierre, Yvan] McGill Univ, Hlth Ctr, Dept Med, Div Clin Epidemiol, Montreal, PQ H3A 2T5, Canada; [Joseph, Lawrence; Clarke, Ann E.] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ H3A 2T5, Canada; [Joseph, Lawrence; Clarke, Ann E.] McGill Univ, Hlth Ctr, Div Clin Epidemiol & Clin Immunol Allergy, Dept Med, Montreal, PQ H3A 2T5, Canada	McGill University; University of Toronto; University Toronto Affiliates; North York General Hospital; McGill University; McGill University; McGill University	Clarke, AE (corresponding author), McGill Univ, Hlth Ctr, 687 Pine Ave West, V Building, Montreal, PQ H3A 2T5, Canada.	Ann.Clarke@mcgill.ca			Canadian Institutes of Health Research [MOP-77584]; Allergy, Genes and Environment Network Centres of Excellence (AllerGen NCE); Anaphylaxis Canada; Canadian Allergy, Asthma and Immunology Foundation; Novartis Pharmaceuticals; National Scholars of Fonds de la recherche en sante du Quebec	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Allergy, Genes and Environment Network Centres of Excellence (AllerGen NCE); Anaphylaxis Canada; Canadian Allergy, Asthma and Immunology Foundation; Novartis Pharmaceuticals(Novartis); National Scholars of Fonds de la recherche en sante du Quebec(Fonds de la Recherche en Sante du Quebec)	Supported by the Canadian Institutes of Health Research (MOP-77584); the Allergy, Genes and Environment Network Centres of Excellence (AllerGen NCE); Anaphylaxis Canada; the Canadian Allergy, Asthma and Immunology Foundation; and Novartis Pharmaceuticals. Dr Clarke received a $2500 unrestricted grant from Novartis Pharmaceuticals. Drs Joseph and Clarke are National Scholars of Fonds de la recherche en sante du Quebec.	*AAP, 2008, AAP NEWS, V29, P12; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Baker SS, 2000, PEDIATRICS, V106, P346; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Cohen JE, 2003, SCIENCE, V302, P1172, DOI 10.1126/science.1088665; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Eigenmann PA, 1998, PEDIAT ALLERG IMM-UK, V9, P186, DOI 10.1111/j.1399-3038.1998.tb00371.x; Ginde AA, 2008, J ALLERGY CLIN IMMUN, V122, P313, DOI 10.1016/j.jaci.2008.04.024; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Guarner F, 2007, CURR OPIN GASTROEN, V23, P667, DOI 10.1097/MOG.0b013e3282eeb43b; Hayes CE, 2003, CELL MOL BIOL, V49, P277; Host A, 2008, PEDIAT ALLERG IMM-UK, V19, P1, DOI 10.1111/j.1399-3038.2007.00680.x; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Kmetic A, 2002, EPIDEMIOLOGY, V13, P437, DOI 10.1097/00001648-200207000-00012; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Maloney JM, 2008, J ALLERGY CLIN IMMUN, V122, P145, DOI 10.1016/j.jaci.2008.04.014; Milner JD, 2004, PEDIATRICS, V114, P27, DOI 10.1542/peds.114.1.27; RAM B, 1988, J BIOSOC SCI, V20, P19, DOI 10.1017/S0021932000017211; Rangaraj S, 2004, PEDIAT ALLERG IMM-UK, V15, P449, DOI 10.1111/j.1399-3038.2004.00174.x; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; RUDIN D, 1987, MULTI IMPUTAT NONRES; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Tarini BA, 2006, ARCH PEDIAT ADOL MED, V160, P502, DOI 10.1001/archpedi.160.5.502; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; Vadas P, 2001, JAMA-J AM MED ASSOC, V285, P1746, DOI 10.1001/jama.285.13.1746; Williams H, 2008, J ALLERGY CLIN IMMUN, V121, P947, DOI 10.1016/j.jaci.2007.11.004; 1997, COCHRANE W SAMPLING	40	90	90	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					783	788		10.1016/j.jaci.2009.02.004	http://dx.doi.org/10.1016/j.jaci.2009.02.004			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19348918	Bronze			2022-12-18	WOS:000265058600039
J	Stern, DA; Guerra, S; Halonen, M; Wright, AL; Martinez, FD				Stern, Debra A.; Guerra, Stefano; Halonen, Marilyn; Wright, Anne L.; Martinez, Fernando D.			Low IFN-gamma production in the first year of life as a predictor of wheeze during childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; wheeze; IFN-gamma; IL-2; cytokine; infancy	LONGITUDINAL DATA-ANALYSIS; 1ST YEAR; ASTHMA PREVENTION; IMMUNE-RESPONSES; INTERFERON; RISK; EXPOSURE; INTERLEUKIN-2; ASSOCIATION; DISEASE	Background: Diminished cytokine production in infancy has been associated with an increased risk for allergen sensitization and early-life wheeze. Objective: We sought to assess the effect of low cytokine production in the first year of life on the development of wheeze through age 13 years. Methods: Cytokine production (IFN-gamma and IL-2) by mitogen-stimulated mononuclear cells was determined from peripheral blood samples (9.4 months, n = 118) in a subset of healthy infants enrolled in the Tucson Children's Respiratory Study. The occurrence of wheeze during the previous year was ascertained at ages 2, 3, 6, 8, 11, and 13 years by means of questionnaire. Relative risk for wheeze was computed with generalized estimating equations. Results: The risk of wheezing between 2 and 13 years was significantly higher for subjects with low 9-month IFN-,gamma production (relative risk, 2.29; 95% Cl, 1.35-3.89) and borderline significant for those with intermediate IFN-,gamma production (relative risk, 1.59; 95% Cl, 0.95-2.68) compared with those who produced high levels of IFN-gamma (P value for linear association =.002). Nine-month IL-2 production was unrelated to wheeze. In relation to complex wheezing phenotypes, 9-month IFN-,gamma production was inversely related to toddler wheeze (occurring only before age 6 years, P =.03) and chronic wheeze (occurring before and after age 6 years, P =.007) but not school-age wheeze (occurring only after age 6 years, P =.06). Conclusion: The results suggest that characteristics of the immune system present during the first year of life can anticipate the likelihood of development of episodes of airway obstruction characterized by wheezing. Clinical implications: Immune susceptibility to asthma is established very early during postnatal life.	Univ Arizona, Hlth Sci Ctr, Arizona Resp Ctr, Tucson, AZ 85721 USA; Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85721 USA; Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85721 USA; Univ Arizona, Coll Med, Dept Pediat, Tucson, AZ 85721 USA; Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ 85721 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona; University of Arizona; University of Arizona	Martinez, FD (corresponding author), Univ Arizona, Hlth Sci Ctr, Arizona Resp Ctr, Tucson, AZ 85721 USA.	fernando@arc.arizona.edu		Halonen, Marilyn/0000-0001-9606-935X	NHLBI NIH HHS [HL-56177, HL-14136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056177, P50HL014136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Ballinger GA, 2004, ORGAN RES METHODS, V7, P127, DOI 10.1177/1094428104263672; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Guerra S, 2004, AM J RESP CRIT CARE, V169, P70, DOI 10.1164/rccm.200304-499OC; Hardin J.W., 2002, GEN ESTIMATING EQUAT; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; Holt PG, 2005, J ALLERGY CLIN IMMUN, V116, P16, DOI 10.1016/j.jaci.2005.04.017; JONES JF, 1983, J CLIN IMMUNOL, V3, P14, DOI 10.1007/BF00919134; KIBLER R, 1985, J CLIN IMMUNOL, V5, P46, DOI 10.1007/BF00915168; KIBLER R, 1986, DIAGN CLIN IMMUNOL, V4, P201; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; Martinez FD, 2003, NEW ENGL J MED, V349, P1473, DOI 10.1056/NEJMe030041; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Oberle D, 2003, ALLERGY, V58, P1033, DOI 10.1034/j.1398-9995.2003.00285.x; Pan W, 2001, BIOMETRICS, V57, P120, DOI 10.1111/j.0006-341X.2001.00120.x; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P39; Prescott SL, 2003, ALLERGY, V58, P1187, DOI 10.1034/j.1398-9995.2003.00263.x; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	26	90	91	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					835	841		10.1016/j.jaci.2007.05.050	http://dx.doi.org/10.1016/j.jaci.2007.05.050			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17689598				2022-12-18	WOS:000250157700017
J	Kemeny, ME; Rosenwasser, LJ; Panettieri, RA; Rose, RM; Berg-Smith, SM; Kline, JN				Kemeny, Margaret E.; Rosenwasser, Lanny J.; Panettieri, Reynold A.; Rose, Robert M.; Berg-Smith, Steve M.; Kline, Joel N.			Placebo response in asthma: A robust and objective phenomenon	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; placebo; mind-body; psychology; bronchial hyperresponsiveness; central nervous system	FUNCTIONAL NEUROANATOMY; BRAIN; EXPECTATIONS; MEDIATORS; CHILDREN; RECOVERY; EMOTION; DISEASE; CORTEX	Background: Placebos are hypothesized to exert positive effects on medical conditions by enhancing patient expectancies. Recent reviews suggest that placebo benefits are restricted to subjective responses, like pain, but might be ineffective for objective physiologic outcomes. Nevertheless, mind-body links and placebo responsivity in asthma are widely believed to exist. Objective: We carried out a randomized, double-blind investigation to (1) determine whether placebo can suppress airway hyperreactivity in asthmatic subjects, (2) quantify the placebo effect, (3) identify predictors of the placebo response, and (4) determine whether physician interventions modify the placebo response. Methods: In a double-blind, crossover design investigation, 55 subjects with mild intermittent and persistent asthma with stable airway hyperreactivity were randomized to placebo or salmeterol before serial methacholine challenges. Subjects were additionally randomized to physician interactions that communicated either positive or neutral expectancies regarding drug effect. Results: Placebo bronchodilator administration significantly reduced bronchial hyperreactivity compared with baseline (the calculated concentration of methacholine required to induce a 20% decrease in FEV1 nearly doubled); 18% of subjects were placebo responders by using conservative definitions. Experimental manipulation of physician behavior altered perceptions of the physician but not the magnitude or frequency of the placebo response. Conclusions: Objective placebo effects exist in asthma. These responses are of significant magnitude and likely to be meaningful clinically. The placebo response was not modulated by alterations in physician behavior in this study. Clinical implications: The placebo response in patients with asthma is important in understanding the limitations of clinical research studies and in maximizing safe and effective therapies. This article confirms the existence of a strong placebo response in an objective and clinically relevant measure of disease activity.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Missouri, Kansas City, MO 64110 USA; Univ Penn, Philadelphia, PA 19104 USA; Univ Texas, Med Branch, Galveston, TX 77550 USA; Univ Iowa, Iowa City, IA USA	University of California System; University of California San Francisco; University of Missouri System; University of Missouri Kansas City; University of Pennsylvania; University of Texas System; University of Texas Medical Branch Galveston; University of Iowa	Kline, JN (corresponding author), Univ Iowa Hosp & Clin, C33GH,200 Hawkins Dr, Iowa City, IA 52242 USA.	joel-kline@uiowa.edu	panettieri, reynold/AAG-9485-2019	kline, joel/0000-0002-5523-8855	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020645] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR000592, P20 RR020645, RR020645, RR00059] Funding Source: Medline; NIEHS NIH HHS [P30 ES005605, ES05605] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; Brown RH, 2006, J APPL PHYSIOL, V101, P30, DOI 10.1152/japplphysiol.01190.2005; Chen E, 2006, J ALLERGY CLIN IMMUN, V117, P1014, DOI 10.1016/j.jaci.2006.01.036; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Crow R., 1999, HEALTH TECHNOL ASSES, V3, P1, DOI [DOI 10.3310/HTA3030, DOI 10.3310/hta3030]; CUFF P, 2004, BOARD NEUROSCIENCE B; Damasio AR, 1999, SCI AM, V281, P112, DOI 10.1038/scientificamerican1299-112; Davidson RJ, 1999, TRENDS COGN SCI, V3, P11, DOI 10.1016/S1364-6613(98)01265-0; de la Fuente-Fernandez R, 2001, ANN NEUROL, V49, P298; Deng YM, 2005, ACTA PHARMACOL SIN, V26, P353, DOI 10.1111/j.1745-7254.2005.00043.x; Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6; Helgeson VS, 2003, HEALTH PSYCHOL, V22, P30, DOI 10.1037/0278-6133.22.1.30; HOOPER R, 1843, HOOPERS MED DICT; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; ICHINOSE M, 1987, J APPL PHYSIOL, V63, P923, DOI 10.1152/jappl.1987.63.3.923; Leuchter AF, 2002, AM J PSYCHIAT, V159, P122, DOI 10.1176/appi.ajp.159.1.122; Liu LY, 2002, AM J RESP CRIT CARE, V165, P1062, DOI 10.1164/ajrccm.165.8.2109065; Maarsingh H, 2006, EUR J PHARMACOL, V546, P171, DOI 10.1016/j.ejphar.2006.07.041; Mayberg HS, 2002, AM J PSYCHIAT, V159, P728, DOI 10.1176/appi.ajp.159.5.728; McQuaid EL, 2000, J PSYCHOSOM RES, V49, P239, DOI 10.1016/S0022-3999(00)00173-2; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Mondloch MV, 2001, CAN MED ASSOC J, V165, P174; *NIH, 1997, NIH PUBL; On LS, 2001, AM J RESP CRIT CARE, V163, P1320, DOI 10.1164/ajrccm.163.6.2002129; Price DD, 1999, PAIN, V83, P147, DOI 10.1016/S0304-3959(99)00081-0; Reed GM, 1999, HEALTH PSYCHOL, V18, P354, DOI 10.1037/0278-6133.18.4.354; REED GM, 1994, HEALTH PSYCHOL, V13, P299, DOI 10.1037/0278-6133.13.4.299; RICHARDSON J, 1976, J APPL PHYSIOL, V41, P764, DOI 10.1152/jappl.1976.41.5.764; Rosenkranz MA, 2005, P NATL ACAD SCI USA, V102, P13319, DOI 10.1073/pnas.0504365102; ROSS M, 1981, PSYCHOL REV, V88, P408, DOI 10.1037/0033-295X.88.5.408; Sandberg S, 2004, THORAX, V59, P1046, DOI 10.1136/thx.2004.024604; SCHEIER MF, 1989, J PERS SOC PSYCHOL, V57, P1024, DOI 10.1037/0022-3514.57.6.1024; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wager TD, 2005, PAIN, V115, P225, DOI 10.1016/j.pain.2005.03.018; Wager TD, 2005, BRAIN BEHAV IMMUN, V19, P281, DOI 10.1016/j.bbi.2005.04.009; WARD JK, 1995, AM J RESP CELL MOL, V13, P175, DOI 10.1165/ajrcmb.13.2.7542897	37	90	90	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1375	1381		10.1016/j.jaci.2007.03.016	http://dx.doi.org/10.1016/j.jaci.2007.03.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17451796	Green Published, Bronze			2022-12-18	WOS:000247232800012
J	von Gunten, S; Vogel, M; Schaub, A; Stadler, BM; Miescher, S; Crocker, PR; Simon, HU				von Gunten, Stephan; Vogel, Monique; Schaub, Alexander; Stadler, Beda M.; Miescher, Sylvia; Crocker, Paul R.; Simon, Hans-Uwe			Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						apoptosis; autoantibodies; eosinophils; inflammation; IVIg; Siglec-8	HUMAN-EOSINOPHIL APOPTOSIS; CHURG-STRAUSS-SYNDROME; NEUTROPHILS; MECHANISM; SIGLEC-8; INFLAMMATION; INDUCTION; SURVIVIN; PATHWAY; IVIG	Background: Human intravenous immunoglobulin (IVIg) preparations are used for the treatment of autoimmune and allergic diseases. Natural autoantibodies are believed to contribute to IVIg-mediated anti-inflammatory effects. Objective: To address the question of whether IVIg preparations contain anti-sialic acid-binding Ig-like lectin-8 (anti-Siglec-8) autoantibodies. Methods: The presence of possible anti-Siglec-8 autoantibodies in IVIg preparations was first examined by functional eosinophil death and apoptosis assays. Specificity of IVIg effects was shown by depleting anti-Siglec-8 autoantibodies from IVIg. Binding of purified anti-Siglec-8 autoantibodies to recombinant Siglec-8 was demonstrated by an immunodot assay. Results: IVIg exerts cytotoxic effects on purified human blood eosinophils. Both potency and efficacy of the IVIg-mediated eosinophil killing effect was enhanced by IL-5, granulocyte/ macrophage colony-stimulating factor, IFN-gamma, TNF-alpha, and leptin. Similarly, inflammatory eosinophils obtained from patients suffering from the hypereosinophilic syndrome (HES) demonstrated increased Siglec-8 cytotoxic responses when compared with normal blood eosinophils. Pharmacologic blocking experiments indicated that the IVIg-mediated additional eosinophil death in the presence of cytokines is largely caspase-independent, but it depends on reactive oxygen species. Anti-Siglec-8 autoantibody-depleted IVIg failed to induce caspase-independent eosinophil death. Conclusion: IVIg preparations contain natural anti-Siglec-8 autoantibodies. Clinical implications: Anti-Siglec-8 autoantibodies present in IVIg preparations may have therapeutic relevance in autoimmune and allergic diseases, respectively, such as Churg-Strauss syndrome.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Bern, Dept Immunol, Bern, Switzerland; ZLB Behring AG, Bern, Switzerland; Univ Dundee, Sch Life Sci, Div Cell Biol & Immunol, Dundee, Scotland	University of Bern; University of Bern; University of Dundee	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736; von Gunten, Stephan/0000-0002-2753-8738; Crocker, Paul/0000-0001-6230-0293				Altznauer F, 2003, J ALLERGY CLIN IMMUN, V112, P1185, DOI 10.1016/j.jaci.2003.09.045; Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; Baumann R, 2003, FASEB J, V17, P2221, DOI 10.1096/fj.03-0110com; Bochner BS, 2005, J BIOL CHEM, V280, P4307, DOI 10.1074/jbc.M412378200; Conus S, 2005, J ALLERGY CLIN IMMUN, V116, P1228, DOI 10.1016/j.jaci.2005.09.003; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; Jolles S, 2005, CLIN EXP IMMUNOL, V142, P1, DOI 10.1111/j.1365-2249.2005.02834.X; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Klion AD, 2006, J ALLERGY CLIN IMMUN, V117, P1292, DOI 10.1016/j.jaci.2006.02.042; Mollnes TE, 2002, BLOOD, V100, P1869; Nutku E, 2005, BIOCHEM BIOPH RES CO, V336, P918, DOI 10.1016/j.bbrc.2005.08.202; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; Prasad NKA, 1998, J IMMUNOL, V161, P3781; Simon HU, 2000, J IMMUNOL, V165, P4069, DOI 10.4049/jimmunol.165.7.4069; Simon HU, 2006, CHEM IMMUNOL ALLERGY, V91, P49; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Simon HU, 2003, ALLERGY, V58, P543, DOI 10.1034/j.1398-9995.2003.00239.x; Simon HU, 2003, EUR J IMMUNOL, V33, P834, DOI 10.1002/eji.200323727; Takigawa N, 2005, J ASTHMA, V42, P639, DOI 10.1080/02770900500263822; Tsurikisawa N, 2004, ANN ALLERG ASTHMA IM, V92, P80, DOI 10.1016/S1081-1206(10)61714-0; Vassina EM, 2006, EUR J IMMUNOL, V36, P1975, DOI 10.1002/eji.200635943; von Gunten S, 2005, BLOOD, V106, P1423, DOI 10.1182/blood-2004-10-4112; von Gunten S, 2006, BLOOD, V108, P4255, DOI 10.1182/blood-2006-05-021568; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482	26	90	96	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					1005	1011		10.1016/j.jaci.2007.01.023	http://dx.doi.org/10.1016/j.jaci.2007.01.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17337295				2022-12-18	WOS:000245729500033
J	Moore, WC; Peters, SP				Moore, WC; Peters, SP			Severe asthma: An overview	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						severe asthma; definition; phenotype; eosinophils; sputum; exhaled nitric oxide	EXHALED NITRIC-OXIDE; MUCOSAL EOSINOPHILIC INFLAMMATION; AIR-FLOW OBSTRUCTION; CLINICAL CHARACTERISTICS; PHYSICIAN ESTIMATE; DIFFICULT ASTHMA; LUNG-FUNCTION; SPUTUM; CHILDREN; SYMPTOMS	Severe asthma represents less than 10% of all asthma, but these patients are responsible for a disproportionate share of the health care costs and morbidity associated with the disease. A significant challenge in the diagnosis and management of severe asthma is the ability to identify accurately the patients most at risk for adverse outcomes, such as medication side effects, emergency department visits, hospitalization, near-fatal events, or disability from persistent symptoms or chronic lung function abnormalities. To improve the treatment of these patients, we must improve our understanding of the mechanisms responsible for severe disease. To achieve this goal, it is imperative to develop a common definition of severe asthma to allow adequate characterization of the disease clinically and provide the opportunity to compare results from many studies. Several severe asthma phenotypes have been described in the literature on the basis of the age of patients, age of disease onset, corticosteroid resistance, chronic airflow obstruction, and evidence for eosinophilic airway inflammation on biopsy. These phenotypes have led to an emerging interest in the use or noninvasive methods to monitor airway inflammation in severe asthma. Treatment algorithms based on markers of airway inflammation may decrease measures of health care utilization in severe asthma.	Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Moore, WC (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.	wmoore@wfubmc.edu			NHLBI NIH HHS [HL067663, HL074225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL067663, U10HL074225, P01HL067663] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; *AM LUNG ASS EP ST, 2005, TRENDS ASTHM MORB MO; Antonicelli L, 2004, EUR RESPIR J, V23, P723, DOI 10.1183/09031936.04.00004904; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Barnes PJ, 2005, IMMUNOL ALLERGY CLIN, V25, P451, DOI 10.1016/j.iac.2005.05.003; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; Boulet Louis-Philippe, 2002, Can Respir J, V9, P417; Bousquet J, 2005, B WORLD HEALTH ORGAN, V83, P548; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; Cisternas MG, 2003, J ALLERGY CLIN IMMUN, V111, P1212, DOI 10.1067/mai.2003.1449; Colice Gene L, 2004, Clin Med Res, V2, P155; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Delgado-Corcoran Claudia, 2004, Pediatr Crit Care Med, V5, P48, DOI 10.1097/01.CCM.0000105310.00799.51; Diette GB, 2004, ANN ALLERG ASTHMA IM, V93, P546, DOI 10.1016/S1081-1206(10)61261-6; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Djukanovic R, 2000, J ALLERGY CLIN IMMUN, V105, pS522, DOI 10.1016/S0091-6749(00)90055-1; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Gibson PG, 2000, J ALLERGY CLIN IMMUN, V105, P752, DOI 10.1067/mai.2000.105319; Godard P, 2002, EUR RESPIR J, V19, P61, DOI 10.1183/09031936.02.00232001; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Horak E, 2003, BRIT MED J, V326, P422, DOI 10.1136/bmj.326.7386.422; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Lim S, 2000, THORAX, V55, P184, DOI 10.1136/thorax.55.3.184; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; *NAT ASTHM ED PREV, 1997, 2 NAT I HLTH NAT HEA; *NIH NAT HEART LUN, 1995, 953659 NIH NAT HEART; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pascual RM, 2005, J ALLERGY CLIN IMMUN, V116, P477, DOI 10.1016/j.jaci.2005.07.011; Paull K, 2005, PEDIATR PULM, V39, P311, DOI 10.1002/ppul.20161; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Pizzichini MMM, 1999, EUR RESPIR J, V13, P15, DOI 10.1183/09031936.99.13101599; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Romagnoli M, 2002, EUR RESPIR J, V20, P1370, DOI 10.1183/09031936.02.00029202; Rosi E, 2002, RESP MED, V96, P745, DOI 10.1053/rmed.2002.1343; Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322; Silkoff PE, 2005, J ALLERGY CLIN IMMUN, V116, P1249, DOI 10.1016/j.jaci.2005.09.029; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Stirling RG, 1998, THORAX, V53, P1030, DOI 10.1136/thx.53.12.1030; Teeter JG, 1998, CHEST, V113, P272, DOI 10.1378/chest.113.2.272; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; TURNERWARWICK M, 1977, BRIT J DIS CHEST, V71, P73, DOI 10.1016/0007-0971(77)90086-9; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Wolfenden LL, 2003, ARCH INTERN MED, V163, P231, DOI 10.1001/archinte.163.2.231	57	90	96	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					487	494		10.1016/j.jaci.2006.01.033	http://dx.doi.org/10.1016/j.jaci.2006.01.033			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522445				2022-12-18	WOS:000236263100001
J	Rabinovitch, N; Liu, AH; Zhang, LN; Rodes, CE; Foarde, K; Dutton, SJ; Murphy, JR; Gelfand, EW				Rabinovitch, N; Liu, AH; Zhang, LN; Rodes, CE; Foarde, K; Dutton, SJ; Murphy, JR; Gelfand, EW			Importance of the personal endotoxin cloud in school-age children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; asthma; children; personal monitoring	HOUSE-DUST ENDOTOXIN; AIRBORNE ENDOTOXIN; EXPOSURE; SYMPTOMS; INHALATION; SEVERITY	Background: A number of studies have observed associations between the amount of endotoxin in urban dust and chronic asthma severity, but a direct relationship between personal exposure to household endotoxin and acute asthma worsening has not yet been defined. Objective: We sought to investigate the relationship between day-to-day changes in personal endotoxin exposure and asthma severity. Methods: In the winter and spring of 1999 through 2000, endotoxin exposures were monitored in asthmatic schoolchildren by using portable, as opposed to stationary, monitors designed to measure inhalable and respirable particulate matter less than or equal to 2.5 and 10 mu m in diameter. Children were followed with daily measurements of FEV1 and asthma symptoms. Results: Over a 24-hour period, median daily personal endotoxin exposures ranged from 0.08 EU/m(3) (measured at a particulate matter size range <= 2.5 mu m in diameter) to 0.37 EU/m(3) (measured at a particulate matter size range <= 10 mu m in diameter). Personal exposures were significantly (P <.001) higher than endotoxin measurements from either indoor or outdoor stationary monitors. Moreover, individual exposures did not correlate with stationary measurements, suggesting that exposures derived front sources in close proximity to the children's personal activities might be better correlated with disease severity. Increases in personal endotoxin exposures were associated with decreased FEV1 values and increased symptoms. Conclusions: These findings demonstrate the importance of using personal monitoring to both measure and correlate endotoxin exposure with asthma severity.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Biostat, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Occupat Med, Denver, CO 80206 USA; Res Triangle Inst Int, Res Triangle Pk, NC USA	National Jewish Health; National Jewish Health; National Jewish Health; Research Triangle Institute	Rabinovitch, N (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	rabinovitchn@njc.org	Dutton, Steven J/C-5912-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004272] Funding Source: NIH RePORTER; NHLBI NIH HHS [K23-HL-04272] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 2001, AEROSOL MEASUREMENT; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; CHATBUM RL, 1990, HDB RESP CARE, P42; Foarde K, 2004, J EXPO ANAL ENV EPID, V14, pS41, DOI 10.1038/sj.jea.7500357; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; HEEDERIK D, 1991, INT ARCH OCC ENV HEA, V62, P595, DOI 10.1007/BF00381114; Hines CJ, 2000, INDOOR AIR, V10, P2, DOI 10.1034/j.1600-0668.2000.010001002.x; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297, DOI 10.1164/ajrccm.160.1.9808144; Lawless PA, 1999, J AIR WASTE MANAGE, V49, P1039, DOI 10.1080/10473289.1999.10463877; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352, DOI 10.1164/ajrccm/146.2.352; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Michel O, 2001, J ALLERGY CLIN IMMUN, V107, P797, DOI 10.1067/mai.2001.114249; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; Pacheco KA, 2003, AM J RESP CRIT CARE, V167, P983, DOI 10.1164/rccm.2112062; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Rizzo MC, 1997, PEDIAT ALLERG IMM-UK, V8, P121; Rodes CE, 2001, J EXPO ANAL ENV EPID, V11, P103, DOI 10.1038/sj.jea.7500155; Rylander R, 2002, J ENDOTOXIN RES, V8, P241, DOI 10.1179/096805102125000452; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; RYLANDER R, 1989, AM REV RESPIR DIS, V140, P981, DOI 10.1164/ajrccm/140.4.981; SMID T, 1992, AM REV RESPIR DIS, V146, P1474, DOI 10.1164/ajrccm/146.6.1474	22	90	91	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1053	1057		10.1016/j.jaci.2005.08.045	http://dx.doi.org/10.1016/j.jaci.2005.08.045			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275375				2022-12-18	WOS:000235686700016
J	Tabar, AI; Echechipia, S; Garcia, BE; Olaguibel, JM; Lizaso, MT; Gomez, B; Aldunate, MT; Martin, S; Marcotegui, F				Tabar, AI; Echechipia, S; Garcia, BE; Olaguibel, JM; Lizaso, MT; Gomez, B; Aldunate, MT; Martin, S; Marcotegui, F			Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cluster immunotherapy; conventional immunotherapy; double-blind study; clinical efficacy; safety; children; adults; skin prick test; specific immunoglobulins; kinetics	PLACEBO-CONTROLLED IMMUNOTHERAPY; ALLERGEN-SPECIFIC IMMUNOTHERAPY; BRONCHIAL-ASTHMA; CONTROLLED-TRIAL; IN-VIVO; EFFICACY; EXTRACT; RUSH; RHINITIS; SAFETY	Background: The conventional schedule for subcutaneous immunotherapy with allergen extracts, although efficacious and safe, is slow during the dose-increase phase. Objective: We sought to compare the efficacy and safety of subcutaneous immunotherapy with Dermatophagoides pteronyssinus standardized extract given in a 6-week cluster period and a conventional 12-week schedule during the incremental-dose phase. Methods: Of 239 patients with rhinitis, allergic bronchial asthma, or both caused by D pteronyssinus, 120 were randomly assigned to the cluster schedule, and 119 were randomly assigned to the conventional schedule. A biologically standardized D pteronyssinus depot extract (ALK-Abello S.A., Madrid, Spain) was administered in a placebo-controlled, double-blind fashion during the initial phase of cluster or conventional treatment. We recorded adverse reactions, clinical efficacy, cutaneous reactivity, and serum specific immunoglobulins to D pteronyssinus before immunotherapy, when the maximum dose was reached in the cluster and conventional schedules, and after I year of treatment. Results: The cluster schedule reduced the time to maintenance dose by 46% and caused systemic adverse reactions (all mild) after only 0.15% of injections, with no differences in comparison with the conventional schedule. Cluster immunotherapy led to decreases in asthma and rhinitis symptoms, reduced the cutaneous reactivity, and produced the increase in specific IgE and IgG(4) levels on reaching the maintenance dose in the sixth week, 6 weeks earlier than with the conventional schedule. Conclusion: The cluster schedule for the initial phase of immunotherapy with incremental doses of D pteronyssinus is a safe alternative to conventional immunotherapy and offers the further advantage of achieving clinical and immunologic improvements sooner.	Hosp Virgen Camino, Allergol Sect, Pamplona, Spain; Hosp Virgen Camino, Serv Pharm, Pamplona, Navarra, Spain; ALK Abello, Dept Clin Res, Madrid, Spain	Hospital Virgen del Camino; Servicio Navarro de Salud - Osasunbidea; Hospital Virgen del Camino; Servicio Navarro de Salud - Osasunbidea; ALK-Abello AS	Echechipia, S (corresponding author), CS Conde Oliveto, Paz S-N, Pamplona 31002, Navarra, Spain.	sechechipiam@meditex.es	RIVERA, JOSE MARIA OLAGUIBEL/AAK-3845-2020	RIVERA, JOSE MARIA OLAGUIBEL/0000-0002-9126-4559				AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; ADAMS NP, 2000, COCHRANE DB SYST REV; ANTONICELLI L, 1994, J INVEST ALLERG CLIN, V4, P57; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; Bousquet J, 1998, ALLERGY, V53, P4; Bray GA, 1999, DIABETES CARE, V22, P623; Busse WW, 1998, J ALLERGY CLIN IMMUN, V101, P457, DOI 10.1016/S0091-6749(98)70353-7; CHOWIENCZYK PJ, 1994, BRIT MED J, V309, P1618, DOI 10.1136/bmj.309.6969.1618; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Drebotg S, 1989, ALLERGY S10, V44, P22; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Ebner C, 1999, INT ARCH ALLERGY IMM, V119, P1, DOI 10.1159/000024168; Echechipia S, 1995, J INVEST ALLERG CLIN, V5, P325; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; FERNANDEZTAVORA L, 1991, REV ESP ALERGOL I S1, V6, P68; GARCIA BE, 1988, ALLERGOL IMMUNOPATH, V16, P379; GARCIAORTEGA P, 1993, CHEST, V103, P183, DOI 10.1378/chest.103.1.183; GERN JE, 1994, J ALLERGY CLIN IMMUN, V93, P706, DOI 10.1016/0091-6749(94)90250-X; Gershman NH, 2000, EUR RESPIR J, V15, P11, DOI 10.1183/09031936.00.15101100; *IMM SUBC EAACI, 1993, ALLERGY          S14, V48, P1; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; Malling HJ, 1998, ALLERGY, V53, P461; Martin S, 1997, ALLERGY, V52, P97, DOI 10.1111/j.1398-9995.1997.tb02552.x; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; Mellerup MT, 2000, CLIN EXP ALLERGY, V30, P1423, DOI 10.1046/j.1365-2222.2000.00910.x; MELTZER EO, 1988, J ALLERGY CLIN IMMUN, V82, P900, DOI 10.1016/0091-6749(88)90032-2; MORENO C, 2001, ALERGOL INMUNOL CLIN, V16, P95; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; MUNOZ D, 1991, REV ESP ALERGOL I S1, V6, P57; Muro MD, 1999, J INVEST ALLERG CLIN, V9, P146; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Olaguibel JM, 1999, J INVEST ALLERG CLIN, V9, P110; Olaguibel JM, 1997, ALLERGY, V52, P168, DOI 10.1111/j.1398-9995.1997.tb00971.x; Paranos S, 1997, J INVEST ALLERG CLIN, V7, P588; QUACKENBOSS JJ, 1991, AM REV RESPIR DIS, V143, P323, DOI 10.1164/ajrccm/143.2.323; REBUCK AS, 1990, J ALLERGY CLIN IMMUN, V85, P612, DOI 10.1016/0091-6749(90)90101-9; RICO P, 1998, REV ESP ALERGOL IMMU, V13, P280; SANCHEZ I, 2001, INVEST ALLERGOL CLIN, V11, P167; STEVENS WJ, 1985, ALLERGY, V40, P447, DOI 10.1111/j.1398-9995.1985.tb02684.x; Tabar A. I., 2001, Allergy (Copenhagen), V56, P91; TABAR AI, 1993, ALLERGY, V48, P450, DOI 10.1111/j.1398-9995.1993.tb00743.x; Tabar AI, 1999, J INVEST ALLERG CLIN, V9, P155; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; VENTAS P, 1998, REV ESP ALERGOL IMMU, V13, P280; VIDAL C, 1997, REV ESP ALERGOL IMMU, V12, P351; Virchow JC, 2000, AM J RESP CRIT CARE, V162, P578; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624	50	90	102	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					109	118		10.1016/j.jaci.2005.05.005	http://dx.doi.org/10.1016/j.jaci.2005.05.005			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990782	Bronze			2022-12-18	WOS:000235686300017
J	Peng, ZK; Beckett, AN; Engler, RJ; Hoffman, DR; Ott, NL; Simons, FER				Peng, ZK; Beckett, AN; Engler, RJ; Hoffman, DR; Ott, NL; Simons, FER			Immune responses to mosquito saliva in 14 individuals with acute systemic allergic reactions to mosquito bites	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						acute systemic allergic reaction; aedes aegypti; Aedes albopictus; Aedes vexans; Anopheles sinensis; anaphylaxis; angioedema; Culex quinquefasciatus; mosquito allergy; mosquito salivaspecific IgE	IGG BINDING ANTIGENS; AEDES-AEGYPTI; IMMUNOBLOT ANALYSIS; ANTIBODIES; SKIN; SENSITIZATION; PROTEINS; HYPERSENSITIVITY; IMMUNOTHERAPY; CHIRONOMIDS	Background: Mosquito bite-induced acute systemic allergic reactions are an increasing clinical concern and have not been optimally characterized immunologically. Objective: We wanted to study the immunologic basis of these reactions. Methods: Sera were received from 14 individuals with a history of acute systemic allergic reactions to mosquito bites, defined as the presence of one or more of the following: urticaria, angioedema, wheezing, dyspnea, hypotension, and decrease or loss of consciousness. Ten individuals were from the United States and one each was from Canada, Germany, Japan, and Switzerland. An indirect ELISA was developed to measure specific IgE and IgG antibodies to saliva from 5 common mosquito species with different geographic distributions: Aedes aegypti, Aedes vexans, Aedes albopictus, Anopheles sinensis, and Culex quinquefasciatus. Twenty-nine individuals with negative bite test results from laboratory-reared mosquitoes served as control subjects. Results: Mosquito saliva-specific IgE levels to all 5 species were significantly increased in the individuals with systemic allergic reactions compared with the control subjects (P < .061 for Aedes vexans and P < .008 for the remaining 4 species). By using the mean of the control subjects plus 1 SD as a cut-off level, 11 individuals had positive results to Aedes albopictus and up to 4 additional species; 3 individuals had positive results to only one species. Saliva-specific IgG levels were not significantly increased in the individuals with systemic allergic reactions compared with levels seen in the control subjects (P > .05). Conclusion: Acute systemic allergic reactions to mosquito bites involve mosquito saliva-specific IgE and can be characterized immunologically. Aedes albopictus is the most common species associated with systemic allergic reactions to mosquito bites.	Univ Manitoba, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB R3E 3P4, Canada; Walter Reed Army Med Ctr, Washington, DC 20307 USA; E Carolina Univ, Dept Pathol & Lab Med, Greenville, NC 27858 USA; Southdale Pediat Associates, Edina, MN USA	University of Manitoba; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; University of North Carolina; East Carolina University	Peng, ZK (corresponding author), Univ Manitoba, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, 532-715 McDermot Ave, Winnipeg, MB R3E 3P4, Canada.	zpeng@ms.umanitoba.ca						BALDO BA, 1988, INT ARCH ALLER A IMM, V85, P278, DOI 10.1159/000234518; Beckett A. N., 2004, Journal of Allergy and Clinical Immunology, V113, pS74, DOI 10.1016/j.jaci.2003.12.239; BENAIMPINTO C, 1990, INT J DERMATOL, V29, P600, DOI 10.1111/j.1365-4362.1990.tb03479.x; Engler RJM, 2001, CURR OPIN ALLERGY CL, V1, P349; ERIKSSON NE, 1989, ALLERGY, V44, P305, DOI 10.1111/j.1398-9995.1989.tb00451.x; Galindo P A, 1998, Allergol Immunopathol (Madr), V26, P251; Galindo PA, 1999, J INVEST ALLERG CLIN, V9, P117; GARCIA ORTIZ JC, 1994, MED CLIN, V102, P157; Gluck J, 2000, Wiad Lek, V53, P175; GLUCK JC, 1986, ANN ALLERGY, V56, P492; Hassoun S, 1999, Allerg Immunol (Paris), V31, P285; LI C, 2003, J WORLD ALLERGY O S1, V1, P195; MCCORMACK DR, 1995, ANN ALLERG ASTHMA IM, V74, P39; MELLANBY K, 1946, NATURE, V158, P554, DOI 10.1038/158554c0; OKA K, 1989, Journal of Dermatology (Tokyo), V16, P341; Panzani RC, 2001, ALLERGY, V56, P1, DOI 10.1111/j.1398-9995.2001.tb04419.x; Peng, 1998, J ALLERGY CLIN IMMUN, V101, P746; Peng Z., 2003, Journal of Allergy and Clinical Immunology, V111, pS207, DOI 10.1016/S0091-6749(03)80715-7; Peng Z, 1998, J ALLERGY CLIN IMMUN, V101, pS32; Peng ZK, 1996, ANN ALLERG ASTHMA IM, V77, P238, DOI 10.1016/S1081-1206(10)63262-0; Peng ZK, 1998, J ALLERGY CLIN IMMUN, V101, P284, DOI 10.1016/S0091-6749(98)70395-1; Peng ZK, 1998, J ALLERGY CLIN IMMUN, V101, P498, DOI 10.1016/S0091-6749(98)70357-4; Peng ZK, 2004, INT ARCH ALLERGY IMM, V133, P198, DOI 10.1159/000076787; PENG ZK, 1995, ANN ALLERG ASTHMA IM, V74, P259; Peng ZK, 1997, J ALLERGY CLIN IMMUN, V100, P192, DOI 10.1016/S0091-6749(97)70224-0; Peng ZK, 1996, ANN ALLERG ASTHMA IM, V77, P371, DOI 10.1016/S1081-1206(10)63335-2; Peng ZK, 2001, INT IMMUNOL, V13, P1445, DOI 10.1093/intimm/13.12.1445; Peng ZK, 1996, INT ARCH ALLERGY IMM, V110, P46, DOI 10.1159/000237309; RACIOPPI JV, 1987, INSECT BIOCHEM, V17, P503, DOI 10.1016/0020-1790(87)90010-2; REUNALA T, 1994, J ALLERGY CLIN IMMUN, V94, P902, DOI 10.1016/0091-6749(94)90158-9; Sabbah A, 1999, Allerg Immunol (Paris), V31, P175; SHEN HD, 1989, ANN ALLERGY, V63, P143; Simons FER, 2001, INT ARCH ALLERGY IMM, V124, P403, DOI 10.1159/000053771; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P705, DOI 10.1016/S0091-6749(99)70348-9; SIMONS FER, 2003, MOSQUITO ALLERGY, P175; SUZUKI S, 1976, ACTA ALLERGOL, V31, P428, DOI 10.1111/j.1398-9995.1976.tb01493.x; Valenzuela JG, 2002, INSECT BIOCHEM MOLEC, V32, P1101, DOI 10.1016/S0965-1748(02)00047-4; Xu W, 1998, J ALLERGY CLIN IMMUN, V101, pS203	38	90	96	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1189	1194		10.1016/j.jaci.2004.08.014	http://dx.doi.org/10.1016/j.jaci.2004.08.014			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536430				2022-12-18	WOS:000225047800030
J	Tiemessen, MM; Van Leperen-Van Dijk, AG; Bruijnzeel-Koomen, CAFM; Garssen, J; Knol, EF; Van Hoffen, E				Tiemessen, MM; Van Leperen-Van Dijk, AG; Bruijnzeel-Koomen, CAFM; Garssen, J; Knol, EF; Van Hoffen, E			Cow's milk-specific T-cell reactivity of children with and without persistent cow's milk allergy: Key role for IL-10	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						antigen-specific T cells; cow's milk; food allergy; tolerance; IL-10	HOUSE-DUST MITE; LYMPHOCYTE-RESPONSES; PERIPHERAL-BLOOD; INTERLEUKIN-10; EXPRESSION; TOLERANCE; OVALBUMIN; EPITOPES; ANTIGEN; CLONES	Background: The role of antigen-specific T cells in the mechanism of food allergy or maintenance of tolerance toward an innocuous antigen, such as cow's milk, is not yet fully understood. Objective: The cow's milk-specific T-cell response of donors with various allergic backgrounds was investigated. Methods: Cow's milk-specific T-cell clones (TCCs) were generated from the blood of children with persistent cow's milk allergy (CMA) and the blood of cow's milk-tolerant allergic and nonallergic control subjects. The TCCs were characterized by their antigen-specific proliferation, cytokine production, and activation status. Results: Cow's milk-specific TCCs of children with persistent CMA were T(H)2 skewed, and the production of IL-4 and IL-13 was significantly correlated with the expression of the activation marker CD25. TCCs of the allergic control subjects were characterized by a high production of IL-10, which was positively correlated with the production of IL-4 and IFN-gamma and with the expression of CD25. TCCs derived from nonallergic control subjects had an attenuated response toward cow's milk in that they did not produce high levels of cytokines nor did they express high levels of surface markers. As in the allergic control subjects, in the nonallergic control subjects IL-10 production was positively correlated with the expression of CD25. Conclusion: The activation status of T cells derived from persistent donors with CMA was associated with the production of IL-4 and IL-13, whereas activated TCCs of cow's milk-tolerant control subjects were characterized by the production of IL-10 and, to a lesser extent, IFN-gamma. These findings suggest that activated CD4(+) T cells (characterized by a high CD25 expression) might contribute to the tolerogenic immune response toward an antigen, such as cow's milk, through the production of IL-10.	Univ Utrecht, Med Ctr, Dept Dermatol Allergol, NL-3508 GA Utrecht, Netherlands; Numico Res, Wageningen, Netherlands	Utrecht University; Danone Nutricia; Royal Numico N.V.	Tiemessen, MM (corresponding author), Univ Utrecht, Med Ctr, Dept Dermatol Allergol, G02-124,POB 85-500, NL-3508 GA Utrecht, Netherlands.	e.vanhoffen@azu.nl	garssen, johan/I-7159-2016	Knol, Edward/0000-0001-7368-9820				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Bashir MEH, 2002, J IMMUNOL, V169, P3284, DOI 10.4049/jimmunol.169.6.3284; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; deJong EC, 1996, J ALLERGY CLIN IMMUN, V98, P73, DOI 10.1016/S0091-6749(96)70228-2; GURKA G, 1989, J ALLERGY CLIN IMMUN, V83, P945, DOI 10.1016/0091-6749(89)90110-3; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HIGGINS JA, 1995, IMMUNOLOGY, V84, P91; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Katsuki T, 1996, INT ARCH ALLERGY IMM, V109, P344, DOI 10.1159/000237261; Kitani A, 2003, J EXP MED, V198, P1179, DOI 10.1084/jem.20030917; Lagging E, 1998, IMMUNOL LETT, V60, P45, DOI 10.1016/S0165-2478(97)00130-2; Nagata S, 2000, J IMMUNOL, V165, P5315, DOI 10.4049/jimmunol.165.9.5315; Neumann C, 1996, J MOL MED, V74, P401, DOI 10.1007/BF00210634; Ng TW, 2002, ALLERGY, V57, P207, DOI 10.1034/j.1398-9995.2002.1o3369.x; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Perez-Machado MA, 2003, EUR J IMMUNOL, V33, P2307, DOI 10.1002/eji.200323308; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Schade RP, 2003, CLIN EXP ALLERGY, V33, P725, DOI 10.1046/j.1365-2222.2003.01655.x; Schade RP, 2000, J ALLERGY CLIN IMMUN, V106, P1155, DOI 10.1067/mai.2000.110802; Schade RR, 2002, J ALLERGY CLIN IMMUN, V109, P357, DOI 10.1067/mai.2002.121457; Sicherer SH, 1999, CLIN EXP ALLERGY, V29, P507, DOI 10.1046/j.1365-2222.1999.00520.x; Smart V, 2003, J IMMUNOL, V171, P2116, DOI 10.4049/jimmunol.171.4.2116; Torres MJ, 2003, BLOOD CELL MOL DIS, V30, P124, DOI 10.1016/S1079-9796(03)00004-4; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Vila L, 2001, CLIN EXP ALLERGY, V31, P1599, DOI 10.1046/j.1365-2222.2001.01218.x; Werfel T, 1996, CLIN EXP ALLERGY, V26, P1380, DOI 10.1111/j.1365-2222.1996.tb00539.x; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2; Zemann B, 2003, J ALLERGY CLIN IMMUN, V111, P1069, DOI [10.1067/mai.2003.1411, 10.1067/mai.2003/1411]	30	90	94	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					932	939		10.1016/j.jaci.2003.12.016	http://dx.doi.org/10.1016/j.jaci.2003.12.016			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131577	Green Submitted, Bronze			2022-12-18	WOS:000221269000017
J	Yang, M; Hogan, SP; Mahalingam, S; Pope, SM; Zimmermann, N; Fulkerson, P; Dent, LA; Young, IG; Matthaei, KI; Rothenberg, ME; Foster, PS				Yang, M; Hogan, SP; Mahalingam, S; Pope, SM; Zimmermann, N; Fulkerson, P; Dent, LA; Young, IG; Matthaei, KI; Rothenberg, ME; Foster, PS			Eotaxin-2 and 165 cooperate in the lung to regulate IL-13 production and airway eosinophilia and hyperreactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway hyperreactivity; eosinophils; eotaxin-2; interleukins-5 and-13; mouse model; cell recruitment	C-C CHEMOKINES; TISSUE EOSINOPHILIA; INTERLEUKIN-5; RECEPTOR; CELLS; ACTIVATION; MECHANISMS; EXPRESSION; PROTEIN; MODEL	Background: Eotaxin-2 is a member of the eotaxin subfamily of CC chemokines that display eosinophil-specific, chemotactic properties and has been associated with allergic disorders. However, the contribution of eotaxin-2 to the development of defined pathogenic features of allergic disease remains to be defined. Objective: We sought to determine whether eotaxin-2 was a cofactor with IL-5 for the regulation of pulmonary eosinophilia and to identify the combined role of these molecules in the induction of phenotypic characteristics of allergic lung disease. Methods: We instilled recombinant eotaxin-2 into the airways of wild-type mice that had been treated systemically with IL-5 or into IL-5-transgenic mice and characterized pulmonary eosinophil numbers, IL-13 production, and airway hyperreactivity (AHR) to methacholine. Mice deficient in the IL-4 receptor alpha-chain, IL-13, and signal transducers and activators of transcription 6 or mice treated with anti-CCR3 monoclonal antibody were also used. Results: Eotaxin-2.and IL-5 cooperatively promoted eosinophil accumulation, IL-13 production, and AHR to methacholine. Neither eotaxin-2 nor IL-5 alone induced these features of allergic disease. IL-13 production was critically dependent on eotaxin-2- and IL-5-regulated eosinophilia, which predisposed to the development of AHR. AHR was dependent on IL-13 and signaling through the IL-4R alpha-chain and signal transducers and activators of transcription 6 pathways and the presence of eosinophils in the lung.	Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 0200, Australia; Univ Adelaide, Dept Mol Biosci, Microbiol & Immunol Sect, Adelaide, SA, Australia; Childrens Hosp, Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45229 USA	Australian National University; John Curtin School of Medical Research; University of Adelaide; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Foster, PS (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 0200, Australia.		Klaus, Matthaei/D-8691-2011; Foster, Paul/G-5057-2013	Pope, Sam/0000-0002-7724-9141; , Paul/0000-0002-0827-8299	NIAID NIH HHS [R01 AI42242-02, R01 AI45898-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042242, R01AI045898] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Campbell EM, 1998, J IMMUNOL, V161, P7047; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Elsner J, 1998, EUR J IMMUNOL, V28, P2152, DOI 10.1002/(SICI)1521-4141(199807)28:07<2152::AID-IMMU2152>3.3.CO;2-7; Elsner J, 2001, INT ARCH ALLERGY IMM, V124, P227, DOI 10.1159/000053719; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; INGLEY E, 1991, EUR J BIOCHEM, V196, P623, DOI 10.1111/j.1432-1033.1991.tb15858.x; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Luster AD, 1997, J LEUKOCYTE BIOL, V62, P620, DOI 10.1002/jlb.62.5.620; Matsukura S, 2001, AM J RESP CELL MOL, V24, P755, DOI 10.1165/ajrcmb.24.6.4351; Matsukura S, 1999, J IMMUNOL, V163, P6876; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; NobenTrauth N, 1997, P NATL ACAD SCI USA, V94, P10838, DOI 10.1073/pnas.94.20.10838; Patel VP, 1997, J EXP MED, V185, P1163, DOI 10.1084/jem.185.7.1163; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rothenberg ME, 1999, J CLIN IMMUNOL, V19, P250, DOI 10.1023/A:1020531322556; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Shinkai A, 1999, J IMMUNOL, V163, P1602; Tachimoto H, 2002, AM J RESP CELL MOL, V26, P645, DOI 10.1165/ajrcmb.26.6.4741; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; Ying S, 1999, J IMMUNOL, V163, P3976; Yoshie O, 1997, J LEUKOCYTE BIOL, V62, P634, DOI 10.1002/jlb.62.5.634; Zimmermann N, 2000, J IMMUNOL, V165, P5839, DOI 10.4049/jimmunol.165.10.5839; Zimmermann N, 1999, J BIOL CHEM, V274, P12611, DOI 10.1074/jbc.274.18.12611	32	90	94	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					935	943		10.1016/j.jaci.2003.08.010	http://dx.doi.org/10.1016/j.jaci.2003.08.010			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610483				2022-12-18	WOS:000186553300016
J	Kikuchi, Y; Fann, T; Kaplan, AP				Kikuchi, Y; Fann, T; Kaplan, AP			Antithyroid antibodies in chronic urticaria and angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HISTAMINE-RELEASE; THYROID AUTOIMMUNITY; AUTOANTIBODIES; PREVALENCE; BASOPHILS		Med Univ S Carolina, Div Pulm & Crit Care Med & Allergy & Clin Immunol, Charleston, SC 29425 USA	Medical University of South Carolina	Kikuchi, Y (corresponding author), Med Univ S Carolina, Div Pulm & Crit Care Med & Allergy & Clin Immunol, 96 Jonathan Lucas St, Charleston, SC 29425 USA.							AJJAN RA, 2001, SAMTERS IMMUNOLOGIC, V2, P605; Bjoro T, 2000, EUR J ENDOCRINOL, V143, P639, DOI 10.1530/eje.0.1430639; Ferrer M, 1999, J ALLERGY CLIN IMMUN, V104, P169, DOI 10.1016/S0091-6749(99)70129-6; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; Kikuchi Y, 2002, J ALLERGY CLIN IMMUN, V109, P114, DOI 10.1067/mai.2002.120954; LEZNOFF A, 1989, J ALLERGY CLIN IMMUN, V84, P66, DOI 10.1016/0091-6749(89)90180-2; LEZNOFF A, 1983, ARCH DERMATOL, V119, P636, DOI 10.1001/archderm.119.8.636	10	90	90	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					218	218		10.1067/mai.2003.1605	http://dx.doi.org/10.1067/mai.2003.1605			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847508	Bronze			2022-12-18	WOS:000184010600039
J	Asai, K; Kanazawa, H; Otani, K; Shiraishi, S; Hirata, K; Yoshikawa, J				Asai, K; Kanazawa, H; Otani, K; Shiraishi, S; Hirata, K; Yoshikawa, J			Imbalance between vascular endothelial growth factor and endostatin levels in induced sputum from asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial asthma; vascular endothelial growth factor; endostatin; induced sputum; beclomethasone dipropionate	BRONCHIAL-MUCOSA; ANGIOGENESIS; EXPRESSION; AIRWAYS; INHIBITOR; CANCER; VEGF	Background: Angiogenesis has recently attracted considerable attention as a component of airway remodeling in bronchial asthma. Vascular endothelial growth factor (VEGF) is highly expressed in asthmatic airways, and its contribution to airway remodeling has been reported. Although angiogenesis is regulated by a balance of angiogenic and antiangiogenic factors, the relative levels of antiangiogenic factors in asthmatic airways have not been evaluated. Objective: We sought to determine whether an imbalance between angiogenic and antiangiogenic factors exists in asthmatic airways. Methods: We simultaneously measured VEGF and endostatin levels and evaluated their correlation and balance in induced sputum from 18 steroid-naive asthmatic subjects and 11 healthy control subjects. After initial sputum induction, asthmatic subjects underwent 8 weeks of inhaled beclomethasone dipropionate (BDP; 800 mug/d) therapy, and sputum induction was then repeated. Results: VEGF and endostatin levels in induced sputum were significantly higher in asthmatic subjects than in control subjects (P < .001). There was a significant correlation between VEGF and endostatin levels in both control subjects (r = 0.995, P < .001) and asthmatic subjects (r = 0.923, P < .001). Moreover, the VEGF/endostatin level ratio in asthmatic subjects was significantly higher than that in control subjects (P < .0001). After 8 weeks of inhaled BDP therapy, the VEGF level in induced sputum in asthmatic subjects was significantly decreased (P < .001), whereas the endostatin level was not. A correlation between VEGF and endostatin levels existed even after BDP therapy (r = 0.861, P < .001). Moreover, the VEGF/endostatin level ratio was significantly decreased to the same level as in the control subjects after BDP therapy (P < .0001). Conclusion: There was an imbalance between VEGF and endostatin levels in induced sputum from asthmatic subjects. This imbalance might play an important role in the pathogenesis of bronchial asthma through its effects on angiogenesis.	Osaka City Univ, Grad Sch Med, Dept Resp Med, Abeno Ku, Osaka 5458585, Japan	Osaka Metropolitan University	Asai, K (corresponding author), Osaka City Univ, Grad Sch Med, Dept Resp Med, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Bandi N, 2001, EUR J PHARMACOL, V425, P109, DOI 10.1016/S0014-2999(01)01192-X; Feldman AL, 2000, CLIN CANCER RES, V6, P4628; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Funatsu H, 2001, JPN J OPHTHALMOL, V45, P577, DOI 10.1016/S0021-5155(01)00420-8; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hoshino M, 2001, CLIN EXP ALLERGY, V31, P722, DOI 10.1046/j.1365-2222.2001.01071.x; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Maniscalco WM, 1997, AM J RESP CELL MOL, V16, P557, DOI 10.1165/ajrcmb.16.5.9160838; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Orsida BE, 1999, THORAX, V54, P289, DOI 10.1136/thx.54.4.289; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; Salvato G, 2001, THORAX, V56, P902, DOI 10.1136/thorax.56.12.902; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; YONG CL, 2001, J ALLERGY CLIN IMMUN, V107, P1106; Yoshikawa T, 1998, EUR RESPIR J, V12, P879, DOI 10.1183/09031936.98.12040879	20	90	95	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2002	110	4					571	575		10.1067/mai.2002.127797	http://dx.doi.org/10.1067/mai.2002.127797			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	602JJ	12373263	Bronze			2022-12-18	WOS:000178501900005
J	Vally, H; de Klerk, N; Thompson, PJ				Vally, H; de Klerk, N; Thompson, PJ			Alcoholic drinks: Important triggers for asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; alcoholic drinks; sulfite additives; questionnaire; allergy	WINE	Background: Although anecdotally alcoholic drinks seem to be common triggers for asthma, little is known of the prevalence, the characteristics, or the mechanisms underlying these reactions. Objectives: The primary aim of this study was to determine the frequency and characteristics of asthmatic reactions triggered by alcoholic drinks in a community-based cohort of asthmatic subjects, Investigations of other food sensitivities were also completed to explore some of the possible components of alcoholic drinks that may be responsible for these asthmatic responses, Methods: A validated food allergy questionnaire was used to assess the characteristics of alcoholic drink-induced asthma in 366 adult patients recruited from the Asthma Foundation of Western Australia, The food allergy questionnaire was sent out by mail and self-administered by recipients. Results: Thirty-three percent of respondents indicated that alcoholic drinks had been associated with the triggering of asthma on at least 2 occasions. Wines were the most frequent triggers, with responses being rapid in onset (<1 hour) and of mild to moderate severity. Logistic regression analysis indicated that wine-induced asthmatic reactions were reported more often by women (P = .032), by those taking oral steroids (P = .021), by individuals who had reported their first asthma attack at a younger age (P < .001), and by those who had previously visited an alternative health practitioner for asthma (P = .041). A significant association between wine-induced asthma and asthma triggered by sulfite-containing foods (P < .001) and by aspirin and nonsteroidal anti-inflammatory medicines (P = .01) was also observed. Conclusion: Alcoholic drinks, and particularly wines, appear to be important triggers for asthmatic responses. Sensitivity to the sulfite additives in wines seems likely to play an important role in many of these reactions. Sensitivities of individuals to salicylates present in wines may also play a role.	Univ Western Australia, Dept Med, Nedlands, WA 6009, Australia; Univ Western Australia, Asthma & Allergy Res Inst, Nedlands, WA 6009, Australia; Univ Western Australia, Dept Publ Hlth, Nedlands, WA 6009, Australia	University of Western Australia; University of Western Australia; University of Western Australia	Thompson, PJ (corresponding author), Sir Charles Gairdner Hosp, Asthma & Allergy Res Inst, Ground Floor,E Block, Nedlands, WA 6009, Australia.		Vally, Hassan/AAG-1307-2022; Vally, Hassan/AFK-2936-2022; de Klerk, Nicholas H/D-8388-2016	Vally, Hassan/0000-0001-5281-7459; Vally, Hassan/0000-0001-5281-7459; de Klerk, Nicholas H/0000-0001-9223-0767				AYRES JG, 1983, BRIT J DIS CHEST, V77, P370, DOI 10.1016/0007-0971(83)90072-4; BRESLIN A B X, 1973, Clinical Allergy, V3, P71, DOI 10.1111/j.1365-2222.1973.tb01311.x; DAHL R, 1986, J ALLERGY CLIN IMMUN, V78, P1126, DOI 10.1016/0091-6749(86)90261-7; DAWSON KP, 1990, NEW ZEAL MED J, V103, P239; Emery NL, 1996, WESTERN J NURS RES, V18, P643, DOI 10.1177/019394599601800603; FORD R, 1969, MED J AUSTRALIA, V74, P279; GERSHWIN ME, 1985, J ALLERGY CLIN IMMUN, V75, P411, DOI 10.1016/0091-6749(85)90080-6; HALPERN GM, 1985, ANN ALLERGY, V55, P686; *HLTH PROM SER RES, 1986, ALC HLTH W AUSTR RES; Klatsky A L, 1987, Alcohol Alcohol Suppl, V1, P117; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; Larsen K, 1996, ALLERGY ASTHMA PROC, V17, P243, DOI 10.2500/108854196778662255; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; NASSER SMS, 1995, CLIN EXP ALLERGY, V25, P1; Perry CA, 1996, NUTR REV, V54, P225, DOI 10.1111/j.1753-4887.1996.tb03940.x; Seitz HK, 1998, RECENT DEV ALCOHOL, V14, P67, DOI 10.1007/0-306-47148-5_4; Shimoda T, 1996, J ALLERGY CLIN IMMUN, V97, P74, DOI 10.1016/S0091-6749(96)70285-3; SIMON RA, 1986, ANN ALLERGY, V56, P281; Vally H, 1999, J ALLERGY CLIN IMMUN, V103, P41, DOI 10.1016/S0091-6749(99)70523-3; Vally H, 1999, AUST NZ J PUBL HEAL, V23, P590, DOI 10.1111/j.1467-842X.1999.tb01542.x; WANTKE F, 1994, ALLERGY PROC, V15, P27, DOI 10.2500/108854194778816599; Woods RK, 1996, AUST NZ J MED, V26, P504, DOI 10.1111/j.1445-5994.1996.tb00596.x	22	90	91	2	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					462	467		10.1067/mai.2000.104548	http://dx.doi.org/10.1067/mai.2000.104548			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719294				2022-12-18	WOS:000088946700010
J	Corren, J				Corren, J			Intranasal corticosteroids for allergic rhinitis: How do different agents compare?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						intranasal steroids; potency; lipophilicity; systemic bioavailability; onset of action	AQUEOUS NASAL SPRAY; PITUITARY-ADRENAL-AXIS; DAILY BECLOMETHASONE DIPROPIONATE; FLUTICASONE PROPIONATE; PERENNIAL RHINITIS; ADRENOCORTICAL FUNCTION; ORAL PREDNISONE; PLACEBO; GLUCOCORTICOSTEROIDS; CHILDREN	Intranasal steroids have proved to be an effective and safe form of therapy for allergic rhinitis, However, as the number of new glucocorticoid compounds has increased over the past decade, it has become important to consider whether significant differences exist between these agents. Pharmacologically, newer drugs such as mometasone furoate and fluticasone propionate appear to have substantially higher topical potencies and lipid solubilities and lower systemic bioavailabilities than do older compounds. In clinical use, however, all the available drugs appear to be equally effective in controlling symptoms of seasonal and perennial allergic rhinitis. With respect to adverse effects, emerging data suggest that mometasone furoate and fluticasone propionate may have less potential for systemic effects during prolonged use, particularly in children. Newer intranasal steroids appear to have practical advantages over older agents that mag favor their use in some groups of patients with allergic rhinitis.	Univ Calif Los Angeles, Allergy Res Fdn, Los Angeles, CA 90025 USA	University of California System; University of California Los Angeles	Corren, J (corresponding author), Univ Calif Los Angeles, Allergy Res Fdn, 11620 Wilshire Blvd,Suite 200, Los Angeles, CA 90025 USA.							Andersson Morgan, 1995, Rhinology (Utrecht), V33, P18; Berkowitz R. B., 1997, Journal of Allergy and Clinical Immunology, V99, pS441; BRANNAN MD, 1995, CLIN THER, V17, P637, DOI 10.1016/0149-2918(95)80040-9; Brattsand R., 1992, NEW DRUGS ASTHMA, V2, P193; Day J, 1998, J ALLERGY CLIN IMMUN, V102, P902, DOI 10.1016/S0091-6749(98)70326-4; Drouin M, 1996, ANN ALLERG ASTHMA IM, V77, P153, DOI 10.1016/S1081-1206(10)63502-8; ENGLISH AF, 1994, AM J RESP CRIT CAR S, V149, pA212; Fokkens WJ, 1999, ALLERGY, V54, P158, DOI 10.1034/j.1398-9995.1999.00747.x; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; Haye R., 1993, Rhinology (Utrecht), V31, P169; Hebert JR, 1996, ALLERGY, V51, P569; HOGGER P, 1994, STEROIDS, V59, P597, DOI 10.1016/0039-128X(94)90054-X; Holm AF, 1998, CLIN OTOLARYNGOL, V23, P69; Howland WC, 1996, J ALLERGY CLIN IMMUN, V98, P32, DOI 10.1016/S0091-6749(96)70223-3; Johnson M, 1998, J ALLERGY CLIN IMMUN, V101, pS434, DOI 10.1016/S0091-6749(98)70155-1; JUNIPER EF, 1993, J ALLERGY CLIN IMMUN, V92, P66, DOI 10.1016/0091-6749(93)90039-I; KNUTSSON U, 1995, J ENDOCRINOL, V144, P301, DOI 10.1677/joe.0.1440301; Mandl M, 1997, ANN ALLERG ASTHMA IM, V79, P237; MCKENZIE AW, 1962, ARCH DERMATOL, V86, P611, DOI 10.1001/archderm.1962.01590110047006; Minshall E, 1998, OTOLARYNG HEAD NECK, V118, P648, DOI 10.1016/S0194-5998(98)70235-9; MYGIND N, 1993, ALLERGY, V48, P476, DOI 10.1111/j.1398-9995.1993.tb01103.x; Nayak AS, 1998, J ALLERGY CLIN IMMUN, V101, P157, DOI 10.1016/S0091-6749(98)70379-3; Rachelefsky GS, 1998, J ALLERGY CLIN IMMUN, V101, pS236; RATNER PH, 1992, J ALLERGY CLIN IMMUN, V90, P285, DOI 10.1016/S0091-6749(05)80005-3; SCADDING GK, 1995, CLIN EXP ALLERGY, V25, P737, DOI 10.1111/j.1365-2222.1995.tb00011.x; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; Small P, 1997, J ALLERGY CLIN IMMUN, V100, P592, DOI 10.1016/S0091-6749(97)70160-X; Smith CL, 1998, ARZNEIMITTEL-FORSCH, V48, P957; Stern MA, 1997, AM J RHINOL, V11, P323, DOI 10.2500/105065897781446658; Umland SP, 1997, J ALLERGY CLIN IMMUN, V100, P511, DOI 10.1016/S0091-6749(97)70144-1; VANAS A, 1993, J ALLERGY CLIN IMMUN, V91, P1146, DOI 10.1016/0091-6749(93)90317-9; VANCENASE AQ, 1999, PHYSICIANS DESK REF, P2890; Vargas R, 1998, J ALLERGY CLIN IMMUN, V102, P191, DOI 10.1016/S0091-6749(98)70085-5; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; Wihl JA, 1997, ALLERGY, V52, P620, DOI 10.1111/j.1398-9995.1997.tb01040.x; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V102, P598, DOI 10.1016/S0091-6749(98)70275-1; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V101, P470, DOI 10.1016/S0091-6749(98)70354-9; 1999, PHYSICIANS DESK REF, P591; 1998, PHYSICIANS DESK REF, P2956; 1999, PHYSICIANS DESK REF, P2861; 1998, PHYSICIANS DESK REF, P955	42	90	96	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				S144	S149		10.1016/S0091-6749(99)70310-6	http://dx.doi.org/10.1016/S0091-6749(99)70310-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518811				2022-12-18	WOS:000083281200031
J	Martinez, FD				Martinez, FD			Maturation of immune responses at the beginning of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; respiratory syncytial virus; allergen	RESPIRATORY SYNCYTIAL-VIRUS; BLOOD MONONUCLEAR-CELLS; T-LYMPHOCYTE SUBSETS; DENDRITIC CELLS; CD14-DEPENDENT PATHWAY; ALVEOLAR MACROPHAGES; SUCCESSFUL PREGNANCY; INTERFERON-GAMMA; WHEEZY INFANTS; INFECTION	The prevalence of childhood asthma appears to be increasing worldwide. A critical element in the development of childhood asthma is maturation of the child's immune system. Most asthmatic children have a history of recurrent lower respiratory tract illnesses associated with airway obstruction during the first year of life, Most infants and young children who will go on to have persistent wheezing and asthma show high IgE production and eosinophilic immune responses at the time of their first viral lower respiratory tract illness, Understanding the genetic and environmental factors that regulate the maturation of the immune response during early life will greatly enhance the development of strategies for the primary and secondary prevention of asthma.	Univ Arizona, Tucson, AZ 85724 USA	University of Arizona	Martinez, FD (corresponding author), Univ Arizona, POB 245030, Tucson, AZ 85724 USA.							ALWAN WH, 1993, J IMMUNOL, V150, P5211; Azevedo I, 1997, EUR RESPIR J, V10, P1767, DOI 10.1183/09031936.97.10081767; AZEVEDO I, 1995, AM J RESP CRIT CARE, V152, P1208, DOI 10.1164/ajrccm.152.4.7551372; BALDINI M, 1998, IN PRESS AM J CELL M; BASS DA, 1980, J CLIN INVEST, V65, P1265, DOI 10.1172/JCI109789; CAUX C, 1995, IMMUNOL TODAY, V16, P2, DOI 10.1016/0167-5699(95)80061-1; Cleveland MG, 1996, INFECT IMMUN, V64, P1906, DOI 10.1128/IAI.64.6.1906-1912.1996; DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413; EVERARD ML, 1995, ARCH DIS CHILD, V72, P64, DOI 10.1136/adc.72.1.64; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; HAZIOT A, 1988, J IMMUNOL, V141, P547; Hilkens CMU, 1997, BLOOD, V90, P1920, DOI 10.1182/blood.V90.5.1920; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Holt PG, 1997, CIBA F SYMP, V206, P35; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Hussell T, 1998, J GEN VIROL, V79, P2593, DOI 10.1099/0022-1317-79-11-2593; Hussell T, 1997, EUR J IMMUNOL, V27, P3341, DOI 10.1002/eji.1830271233; Landmann R, 1996, INFECT IMMUN, V64, P1762, DOI 10.1128/IAI.64.5.1762-1769.1996; Lee SM, 1996, BLOOD, V88, P945; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; Martinez FD, 1998, AM J RESP CRIT CARE, V158, P1739, DOI 10.1164/ajrccm.158.6.9712040; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 1998, J ALLERGY CLIN IMMUN, V102, P915, DOI 10.1016/S0091-6749(98)70328-8; Martinez FD, 1997, PEDIATR PULM, P84; MARTINEZ FD, 1997, ASTHMA, V1, P121; Michie C, 1998, IMMUNOL TODAY, V19, P333, DOI 10.1016/S0167-5699(98)01260-2; OPENSHAW PJM, 1995, AM J RESP CRIT CARE, V152, pS59, DOI 10.1164/ajrccm/152.4_Pt_2.S59; Peritt D, 1998, J IMMUNOL, V161, P5821; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Prescott SL, 1998, J IMMUNOL, V160, P4730; Raghupathy R, 1997, IMMUNOL TODAY, V18, P478, DOI 10.1016/S0167-5699(97)01127-4; Ridgway GL, 1996, INT J STD AIDS, V7, P1, DOI 10.1258/0956462961917195; Roman M, 1997, AM J RESP CRIT CARE, V156, P190, DOI 10.1164/ajrccm.156.1.9611050; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SIGURS N, 1995, PEDIATRICS, V95, P500; Srikiatkhachorn A, 1997, J EXP MED, V186, P421, DOI 10.1084/jem.186.3.421; Stanciu LA, 1997, J ALLERGY CLIN IMMUN, V100, P373, DOI 10.1016/S0091-6749(97)70251-3; Stevenson EC, 1997, CLIN EXP ALLERGY, V27, P1027, DOI 10.1111/j.1365-2222.1997.tb01254.x; Suri RM, 1998, J IMMUNOL METHODS, V214, P149, DOI 10.1016/S0022-1759(98)00048-9; TAYLOR G, 1995, J VIROL, V69, P6658, DOI 10.1128/JVI.69.11.6658-6664.1995; Thomas LH, 1996, RES VET SCI, V61, P38, DOI 10.1016/S0034-5288(96)90108-3; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Verhasselt V, 1997, J IMMUNOL, V158, P2919; Walker C, 1998, J IMMUNOL, V161, P1962; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Woolcock AJ, 1997, CIBA F SYMP, V206, P122; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243; Yoshida A, 1997, INFECT IMMUN, V65, P1953, DOI 10.1128/IAI.65.5.1953-1955.1997; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	51	90	93	2	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				355	361		10.1016/S0091-6749(99)70456-2	http://dx.doi.org/10.1016/S0091-6749(99)70456-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069865				2022-12-18	WOS:000079175700001
J	Volovitz, B; Bentur, L; Finkelstein, Y; Mansour, Y; Shalitin, S; Nussinovitch, M; Varsano, I				Volovitz, B; Bentur, L; Finkelstein, Y; Mansour, Y; Shalitin, S; Nussinovitch, M; Varsano, I			Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department: A controlled comparative study with oral prednisolone	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						corticosteroids; budesonide turbohaler; asthma; acute asthmatic attack; children; efficacy; safety	BUDESONIDE; THERAPY; METHYLPREDNISOLONE; TRIAL	Background: Inhaled corticosteroids have a greater antiinflammatory potency and fewer systemic effects than intravenous, intramuscular, or oral corticosteroids. However, their role in acute asthma has not been established, We prospectively investigated the efficacy and safety of inhaled corticosteroids in controlling moderately severe acute asthma attacks in children who were treated in the emergency department. Methods: Children who were treated in the emergency department with moderately severe asthma attacks after receiving treatment with inhaled terbutaline were allocated by double-blind design to receive 1 dose of either 1600 mu g budesonide turbohaler or 2 mg/kg prednisolone, The pulmonary index score and peak expiratory flow rate were measured hourly for the first 4 hours. After discharge the children were treated with the same initial doses given 4 times daily, followed by a 25% reduction in dose every second day for 1 week. Parents recorded asthma symptoms and use of beta-2 agonists on a daily diary card, Serum cortisol concentration was measured at the end of weeks 1 and 3. Results: Twenty-two children (11 in each group) with similar baseline parameters completed the study. There was a similar improvement in pulmonary index score and peak expiratory flow rate in the 2 groups. Children treated with budesonide showed an earlier clinical response than those given prednisolone, who also showed a decrease in serum cortisol concentration. Conclusion: In children with moderately severe asthma attacks who were treated in the emergency department, a short-term dose schedule of inhaled budesonide turbohaler, starting with a high dose and followed by a decrease over 1 week, is at Least as effective as oral prednisolone, without suppressing serum cortisol concentration.	Schneider Childrens Med Ctr Israel, Dept Pediat C, Asthma Clin, IL-49202 Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Technion Israel Inst Technol, Rambam Hosp, Pediat Pulm Unit, Fac Med, Haifa, Israel	Tel Aviv University; Sackler Faculty of Medicine; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Volovitz, B (corresponding author), Schneider Childrens Med Ctr Israel, Dept Pediat C, Asthma Clin, 14 Kaplan St, IL-49202 Petah Tiqwa, Israel.							[Anonymous], 1991, NIH PUBLICATION; Barnett PLJ, 1997, ANN EMERG MED, V29, P212, DOI 10.1016/S0196-0644(97)70270-1; CONNETT G, 1993, ARCH DIS CHILD, V68, P85, DOI 10.1136/adc.68.1.85; ENGEL T, 1991, ALLERGY, V46, P547, DOI 10.1111/j.1398-9995.1991.tb00619.x; ENGEL T, 1991, EUR RESPIR J, V4, P881; HASKELL RJ, 1983, ARCH INTERN MED, V143, P1324, DOI 10.1001/archinte.143.7.1324; LITTENBERG B, 1986, NEW ENGL J MED, V314, P150, DOI 10.1056/NEJM198601163140304; MCFADDEN ER, 1976, AM J MED, V60, P52, DOI 10.1016/0002-9343(76)90533-7; ROWE BH, 1992, AM J EMERG MED, V10, P301, DOI 10.1016/0735-6757(92)90007-K; SCARFONE RJ, 1993, PEDIATRICS, V92, P513; STEIN LM, 1990, ANN INTERN MED, V112, P822, DOI 10.7326/0003-4819-112-11-822; STORR J, 1987, LANCET, V1, P879; SVERDYMYR J, 1995, ACTA PAEDIATR, V84, P884; TAL A, 1990, PEDIATRICS, V86, P350; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; Volovitz B, 1998, J ALLERGY CLIN IMMUN, V101, P464, DOI 10.1016/S0091-6749(98)70405-1; VOLOVITZ B, 1993, NEW ENGL J MED, V329, P1703, DOI 10.1056/NEJM199312023292305; WILSON NM, 1990, ARCH DIS CHILD, V65, P407, DOI 10.1136/adc.65.4.407; ZORA JA, 1986, J ALLERGY CLIN IMMUN, V77, P9, DOI 10.1016/0091-6749(86)90315-5; 1997, THORAX S, V52, pS1	20	90	94	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				605	609		10.1016/S0091-6749(98)70276-3	http://dx.doi.org/10.1016/S0091-6749(98)70276-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802368				2022-12-18	WOS:000076600400010
J	Rosenwasser, LJ				Rosenwasser, LJ			Biologic activities of IL-1 and its role in human disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INTERLEUKIN-1 RECEPTOR ANTAGONIST; TUMOR-NECROSIS-FACTOR; ASTHMATIC BRONCHIAL EPITHELIUM; GENE-EXPRESSION; CIRCULATING INTERLEUKIN-1; MONONUCLEAR PHAGOCYTES; CYTOKINE PRODUCTION; SMOOTH-MUSCLE; FACTOR-ALPHA; GUINEA-PIGS	The role of the polypeptide proinflammatory cytokine IL-1 family represents a group of proteins that have contrasting and synergistic biologic responses. IL-1 alpha and beta and their precursor forms are heavily involved in the enhancement of inflammation and host defense. Within this family of gene products, there is also a naturally occurring receptor antagonist, IL-1ra, as well as a family of receptor proteins that have differential signaling functions and activities. The study of these proteins in human disease, including allergic disease and type 1 hypersensitivity responses, has led to a better understanding of the underlying general inflammation associated with these syndromes and has provided opportunities to look at new forms of intervention in allergic disease and asthma.	Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Div Clin Immunol & Allergy, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Rosenwasser, LJ (corresponding author), Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Div Clin Immunol & Allergy, 1400 Jackson St,Room K261B, Denver, CO 80206 USA.							ACKERMAN V, 1995, J ALLERGY CLIN IMMUN, V96, P618, DOI 10.1016/S0091-6749(95)70260-1; ANDERSSON CE, 1991, GASTROENTEROLOGY, V100, P938, DOI 10.1016/0016-5085(91)90267-O; AREND WP, 1990, ARTHRITIS RHEUM-US, V33, P305, DOI 10.1002/art.1780330302; AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; AURON PE, 1992, BIOCHEMISTRY-US, V31, P6632, DOI 10.1021/bi00144a002; AURON PE, 1994, EUR CYTOKINE NETW, V5, P573; BLACK RA, 1988, J BIOL CHEM, V263, P9437; BOCHNER BS, 1990, J ALLERGY CLIN IMMUN, V86, P830, DOI 10.1016/S0091-6749(05)80143-5; BORISH L, 1992, J IMMUNOL, V149, P3078; BORISH L, 1991, J IMMUNOL, V146, P63; BRODY JI, 1992, AM J CLIN PATHOL, V97, P8, DOI 10.1093/ajcp/97.1.8; BURAS JA, 1995, MOL IMMUNOL, V32, P541, DOI 10.1016/0161-5890(95)00018-A; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; FERRETTI M, 1994, J CLIN INVEST, V94, P449, DOI 10.1172/JCI117345; GEHRKE L, 1990, J BIOL CHEM, V265, P5922; GERSHENWALD JE, 1990, P NATL ACAD SCI USA, V87, P4966, DOI 10.1073/pnas.87.13.4966; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; Hakonarson H, 1997, J CLIN INVEST, V99, P117, DOI 10.1172/JCI119122; Hastie AT, 1996, CYTOKINE, V8, P730, DOI 10.1006/cyto.1996.0097; HAWRYLOWICZ CM, 1991, J EXP MED, V174, P785, DOI 10.1084/jem.174.4.785; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; MANDRUPPOULSEN T, 1995, CRIT CARE MED, V23, P26, DOI 10.1097/00003246-199501000-00008; MANETTI R, 1994, RES IMMUNOL, V145, P93, DOI 10.1016/S0923-2494(94)80019-7; NETA R, 1994, J IMMUNOL, V153, P1536; OHISSON K, 1990, NATURE, V348, P550; OKADA S, 1995, J ALLERGY CLIN IMMUN, V95, P1236, DOI 10.1016/S0091-6749(95)70081-1; PEARCE WH, 1992, J VASC SURG, V16, P784; RE F, 1994, J EXP MED, V179, P739, DOI 10.1084/jem.179.2.739; SHIRAKAWA F, 1989, CANCER RES, V49, P1143; Shornick LP, 1996, J EXP MED, V183, P1427, DOI 10.1084/jem.183.4.1427; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SMITH JW, 1993, NEW ENGL J MED, V328, P756, DOI 10.1056/NEJM199303183281103; Sousa AR, 1997, THORAX, V52, P407, DOI 10.1136/thx.52.5.407; Sousa AR, 1996, AM J RESP CRIT CARE, V154, P1061, DOI 10.1164/ajrccm.154.4.8887608; VANNIER E, 1991, J EXP MED, V174, P281, DOI 10.1084/jem.174.1.281; VANNIER E, 1991, J CLIN INVEST, V87, P1936, DOI 10.1172/JCI115219; VANNIER E, 1992, P NATL ACAD SCI USA, V89, P4076, DOI 10.1073/pnas.89.9.4076; VANNIER E, 1994, J BIOL CHEM, V269, P9952; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WARNER SJC, 1987, J EXP MED, V165, P1316, DOI 10.1084/jem.165.5.1316; WARNER SJC, 1987, J IMMUNOL, V139, P1911; WILLIAMS J, 1992, J IMMUNOL, V149, P2823; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0	47	90	97	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					344	350						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768571				2022-12-18	WOS:000076212800002
J	Soldatova, LN; Crameri, R; Gmachl, M; Kemeny, DM; Schmidt, M; Weber, M; Mueller, UR				Soldatova, LN; Crameri, R; Gmachl, M; Kemeny, DM; Schmidt, M; Weber, M; Mueller, UR			Superior biologic activity of the recombinant bee venom allergen hyaluronidase expressed in baculovirus-infected insect cells as compared with Escherichia coli	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bee venom allergy; hyaluronidase; recombinant allergens; baculovirus; enzymatic activity; specific IgE	HONEY-BEE; GLYCOSYLATION; PURIFICATION; INTERFERON; ENZYMES; PROTEIN; PHOSPHOLIPASE-A2; SECRETION; CDNA; BETA	Background: Hyaluronidase (Hya) is one of several allergens in honeybee venom. Its cDNA sequence was recently described. Objective: We sought to express recombinant Hya in prokaryotic and eukaryotic systems and to compare it with natural (n)Hya for biologic activity. Methods: In Escherichia coli Hya was produced as inclusion body 6xHis-fusion protein. In baculovirus-infected insect cells expression was obtained by cotransfection of linearized Bac-N-Blue DNA and pMelBac transfer vector into Spodoptera frugiperda cells. Results: Enzymatic activity of Hya from the baculovirus system was equal to nHya, and that of the enzyme expressed in E. coli was only 20% to 30% of nHya. In vitro IgE binding was similar in nHya and the enzyme from baculovirus but markedly lower in Hya expressed in E. coli. Conclusions: Biologic activity of Hya expressed in baculovirus-infected insect cells,vas comparable with that of the natural enzyme, indicating a native-like conformation of the recombinant protein. In contrast, the enzyme expressed in a coli as an inclusion-body protein and reconstituted in vitro reached only 20% to 30% of the activity of nHya.	Zieglerspital, Div Med, CH-3007 Bern, Switzerland; Univ Bern, Inst Biochem, CH-3012 Bern, Switzerland; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Austrian Acad Sci, Inst Mol Biol, A-5020 Salzburg, Austria; Univ London Kings Coll, Sch Med & Dent, London, England; E Carolina Univ, Dept Biol, Greenville, NC 27858 USA	University of Bern; Swiss Institute of Allergy & Asthma Research; Austrian Academy of Sciences; University of London; King's College London; University of North Carolina; East Carolina University	Mueller, UR (corresponding author), Zieglerspital, Div Med, CH-3007 Bern, Switzerland.							CHAI H, 1993, BIOTECHNOL APPL BIOC, V18, P259; DARBRE A, 1986, PRACTICAL PROTEIN CH, P227; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P5584, DOI 10.1021/bi00475a024; DAVIS TR, 1992, BIO-TECHNOL, V10, P1148, DOI 10.1038/nbt1092-1148; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; EINARSSON R, 1987, INT ARCH ALLER A IMM, V83, P217, DOI 10.1159/000234360; FAROOQUI AA, 1980, J CHROMATOGR, V184, P335, DOI 10.1016/S0021-9673(00)89004-4; FORSTER E, 1995, J ALLERGY CLIN IMMUN, V95, P1229, DOI 10.1016/S0091-6749(95)70080-3; GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569; GREIF RL, 1952, J BIOL CHEM, V194, P619; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; HOFFMAN DR, 1986, J ALLERGY CLIN IMMUN, V78, P337, DOI 10.1016/S0091-6749(86)80086-0; KEMENY DM, 1984, EUR J BIOCHEM, V139, P217, DOI 10.1111/j.1432-1033.1984.tb07997.x; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KREIL G, 1995, PROTEIN SCI, V4, P1666, DOI 10.1002/pro.5560040902; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; LU G, 1995, J BIOL CHEM, V270, P4457, DOI 10.1074/jbc.270.9.4457; MANNEBERG M, 1994, PROTEIN SCI, V3, P30; Meyer K., 1971, ENZYMES, V5, P307; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V67, P290, DOI 10.1016/0091-6749(81)90024-5; MUELLER UR, 1995, J ALLERGY CLIN IMMUN, V96, P395; MUELLER UR, 1990, INSECT STING ALLERGY, P46; OREILLY DR, 1994, BACULOVIRUS EXPRESSI, P216; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; SCHEINER O, 1992, ADVANCES IN ALLERGOLOGY AND CLINICAL IMMUNOLOGY, P115; Schmidt M, 1996, J ALLERGY CLIN IMMUN, V98, P82, DOI 10.1016/S0091-6749(96)70229-4; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555, P29; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; VALENTA R, 1995, PROGR ALLERGY CLIN I, P226; VOSS T, 1993, EUR J BIOCHEM, V217, P913, DOI 10.1111/j.1432-1033.1993.tb18321.x; Wang CQ, 1996, BIOCHEMISTRY-US, V35, P7299, DOI 10.1021/bi9517704; YEH JC, 1993, BIOCHEMISTRY-US, V32, P11087, DOI 10.1021/bi00092a019; ZAMENHOF PJ, 1972, J BACTERIOL, V110, P171, DOI 10.1128/JB.110.1.171-178.1972	38	90	102	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					691	698		10.1016/S0091-6749(98)70179-4	http://dx.doi.org/10.1016/S0091-6749(98)70179-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600508	Bronze			2022-12-18	WOS:000073697400019
J	Calpin, C; Macarthur, C; Stephens, D; Feldman, W; Parkin, PC				Calpin, C; Macarthur, C; Stephens, D; Feldman, W; Parkin, PC			Effectiveness of prophylactic inhaled steroids in childhood asthma: A systematic review of the literature	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; drug therapy; glucocorticoid; inhaled corticosteroid; inhaled steroid; clinical trial; randomized controlled trial	LONG-TERM TREATMENT; NEBULIZED BECLOMETHASONE DIPROPIONATE; FLUNISOLIDE AEROSOL; MILD ASTHMA; CORTICOSTEROID BUDESONIDE; PRESCHOOL ASTHMA; CHILDREN; GROWTH; RESPONSIVENESS; SUSPENSION	Background: There has been no systematic appraisal of the evidence regarding the effectiveness of prophylactic inhaled steroids in childhood asthma, Objective: We sought to evaluate the effectiveness of prophylactic inhaled steroids in childhood asthma. Methods: A MEDLINE search from January-1966 through December 1996 was used to identify pertinent English-language publications, All randomized, double-blind, placebo-controlled trials of prophylactic inhaled steroid therapy for childhood asthma that included data on clinical outcomes (symptom scores and concomitant drug use) or laboratory outcomes (peak expiratory how rate) were included. Results: In total, 24 of 93 studies retrieved met the inclusion criteria, The overall weighted relative improvement in mean total symptom score (inhaled steroid vs placebo) was 50% (95% confidence interval [CI]: 49%, 51%), the overall weighted relative decrease in mean concomitant beta(2)-agonist use (inhaled steroid vs placebo) was 37% (95% CI: 36%, 38%), and the overall weighted relative decrease in mean concomitant oral steroid use (inhaled steroid vs placebo) was 68% (95% CI: 66%, 70%). The overall weighted absolute improvement in mean peak expiratory flow rate (inhaled steroid vs placebo) was 38 L/min (95% CI: 34.3 L/min, 41.7 L/min). Conclusions: Prophylactic inhaled steroids are effective, compared with placebo, in improving both clinical and laboratory outcomes in childhood asthma.	HOSP SICK CHILDREN,DIV GEN PEDIAT,PEDIAT OUTCOMES RES TEAM,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT PEDIAT,TORONTO,ON M5S 1A1,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BARNES PJ, 1991, MED INT, V89, P3694; BENNATI D, 1989, J ASTHMA, V26, P359, DOI 10.3109/02770908909073279; BISGAARD H, 1990, LANCET, V336, P649, DOI 10.1016/0140-6736(90)92147-A; BROWN H, 1976, PRACTITIONER, V31, P309; CARLSEN K, 1988, ARCH DIS CHILD, V63, P1428, DOI 10.1136/adc.63.12.1428; CONNETT GJ, 1993, ARCH DIS CHILD, V69, P351, DOI 10.1136/adc.69.3.351; DEBLIC J, 1996, EFFICACY NEBULIZED B, V98, P14; DOUGHERTY G, 1994, ARCH PEDIAT ADOLESC, V148, P66; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; EFFRON B, 1993, JACKKNIFE INTRO BOOT, P141; FLEISS JL, 1986, DESIGN ANAL CLIN EXP, P149; FREARS JF, 1973, ARCH DIS CHILD, V48, P856, DOI 10.1136/adc.48.11.856; GLEESON J, 1988, BRIT MED J, V298, P163; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; GODFREY S, 1974, CLIN ALLERGY, V4, P325; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HILLER EJ, 1981, PROGR RESPIRATORY RE, V17, P285; HOWARD K, 1974, POSTGRAD MED J, V50, P41; ILANGOVAN P, 1993, ARCH DIS CHILD, V68, P356, DOI 10.1136/adc.68.3.356; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KATZ RM, 1986, J ASTHMA, V23, P1, DOI 10.3109/02770908609077462; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KLEIN R, 1977, PEDIATRICS, V60, P7; KONIG P, 1993, J PEDIATR-US, V122, P219, DOI 10.1016/S0022-3476(06)80116-2; KRAMER MS, 1988, CLIN EPIDEMIOLOGY BI, P159; LORENTZSON S, 1990, THORAX, V45, P733, DOI 10.1136/thx.45.10.733; LOVERA J, 1975, POSTGRAD MED J S4, V51, P94; Macarthur C, 1996, J ALLERGY CLIN IMMUN, V98, P992, DOI 10.1016/S0091-6749(96)80017-0; MACKENZIE CA, 1993, EUR J PEDIATR, V152, P856, DOI 10.1007/BF02073387; MELTZER EO, 1982, PEDIATRICS, V69, P340; NINAN TK, 1992, ARCH DIS CHILD, V67, P703, DOI 10.1136/adc.67.6.703; NOBLE V, 1992, ARCH DIS CHILD, V67, P285, DOI 10.1136/adc.67.3.285; ORGEL HA, 1983, ANN ALLERGY, V51, P21; PEARCE N, 1993, EUR RESPIR J, V6, P1455; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; PHILLIP M, 1992, PEDIATR PULM, V12, P84, DOI 10.1002/ppul.1950120205; PIACENTINI GL, 1990, ALLERGY, V45, P612, DOI 10.1111/j.1398-9995.1990.tb00947.x; REED CE, 1991, NEW ENGL J MED, V325, P425, DOI 10.1056/NEJM199108083250610; RICHARDS W, 1978, ANN ALLERGY, V41, P274; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; SHAPIRO GG, 1981, CHEST, V80, P671, DOI 10.1378/chest.80.6.671; Sly PD, 1996, J ASTHMA, V33, P277, DOI 10.3109/02770909609055369; STORR J, 1986, ARCH DIS CHILD, V61, P270, DOI 10.1136/adc.61.3.270; Strachan DP, 1996, BRIT MED J, V312, P1195; TAYLOR B, 1974, POSTGRAD MED J, V50, P44; TAYLOR WR, 1992, PEDIATRICS, V90, P657; VANBEVER HP, 1990, PEDIATR PULM, V9, P177, DOI 10.1002/ppul.1950090310; VANESSENZANDVLIET EE, 1994, EUR RESPIR J, V7, P63, DOI 10.1183/09031936.94.07010063; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VOLOVITZ B, 1993, NEW ENGL J MED, V329, P1703, DOI 10.1056/NEJM199312023292305; WARNER JO, 1992, ARCH DIS CHILD, V67, P240; WEBB MSC, 1986, ARCH DIS CHILD, V61, P1108, DOI 10.1136/adc.61.11.1108; WILKINS K, 1993, CAN MED ASSOC J, V148, P185; WOLTHERS OD, 1993, PEDIATR PULM, V16, P341, DOI 10.1002/ppul.1950160604	57	90	94	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					452	457		10.1016/S0091-6749(97)70134-9	http://dx.doi.org/10.1016/S0091-6749(97)70134-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338536	Bronze			2022-12-18	WOS:A1997YA52900004
J	Fritsche, R; Pahud, JJ; Pecquet, S; Pfeifer, A				Fritsche, R; Pahud, JJ; Pecquet, S; Pfeifer, A			Induction of systemic immunologic tolerance to beta-lactoglobulin by oral administration of a whey protein hydrolysate	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						oral tolerance; beta-lactoglobulin; whey protein; hydrolysate; IgE; mast cells	DELAYED-TYPE HYPERSENSITIVITY; SUPPRESSOR T-CELLS; BYSTANDER SUPPRESSION; IMMUNE-RESPONSES; FED OVALBUMIN; ANTIGEN; MICE; ANERGY; HUMANS; IGE	Background: Oral administration of an antigen has been shown to suppress the specific immune response to this antigen. This approach, called oral tolerance, has been demonstrated with intact proteins in animal models for prevention of allergy and autoimmune diseases, Objective: The purpose of this study was to determine whether oral tolerance can be induced, with protein peptides, Partially hydrolyzed and extensively hydrolyzed cow's milk formulas were compared for their capacity to induce tolerance to cow's milk proteins. Methods: Five-week-old Sprague-Dawley rats were fed cow's milk formulas ad libitum from day 1 to day 19. All animals were immunized with beta-lactoglobulin and ovalbumin on day 5 and bled on day 19. Sera were analyzed for specific IgE and IgG antibodies by ELISA and for functional IgE response by in vitro mast cell mediator (tritiated serotonin) release, In vivo modulation of intestinal mast cells was analyzed by the specific release of the rat mast cell protease II, and T-cell response was determined by tritiated thymidine incorporation into lymph node lymphocytes. Results: Oral administration of a partially hydrolyzed cow's milk formula suppresses specific serum IgE and Ige anti-beta-lactoglobulin antibodies, as well as mediator release from rat mast cells and T-lymphocyte response, This suppression was shown to be antigen-specific and dose-dependent. An extensively hydrolyzed formula was unable to achieve the induction of such an oral tolerance, Conclusion: These results support the view that partially hydrolyzed proteins are able to induce specific oral tolerance, whereas extensively hydrolyzed proteins are not.			Fritsche, R (corresponding author), NESTEC LTD,NESTLE RES CTR,VERS CHEZ LES BLANC,POB 44,CH-1000 LAUSANNE 26,SWITZERLAND.							BALDO BA, 1984, AUSTR J DAIRY TECHNO, V40, P120; DAHLMANHOGLUND A, 1995, IMMUNOLOGY, V86, P128; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; FRITSCHE R, 1994, J ALLERGY CLIN IMMUN, V93, P778, DOI 10.1016/0091-6749(94)90258-5; FRITSCHE R, 1990, INT ARCH ALLER A IMM, V93, P289, DOI 10.1159/000235256; HACHIMURA S, 1993, BIOSCI BIOTECH BIOCH, V57, P1674, DOI 10.1271/bbb.57.1674; HANSON DG, 1977, INT ARCH ALLER A IMM, V55, P526, DOI 10.1159/000231966; HUSBY S, 1994, J IMMUNOL, V152, P4663; LAMONT AG, 1989, IMMUNOLOGY, V66, P595; MELAMED D, 1993, EUR J IMMUNOL, V23, P935, DOI 10.1002/eji.1830230426; MICHAEL JG, 1989, IMMUNOL INVEST, V18, P1049, DOI 10.3109/08820138909030606; MILLER A, 1991, J EXP MED, V174, P791, DOI 10.1084/jem.174.4.791; MOWAT AM, 1985, IMMUNOLOGY, V56, P253; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; MOWAT AM, 1986, IMMUNOLOGY, V58, P179; NGAN J, 1978, J IMMUNOL, V120, P861; Pollard C., 1996, Journal of Allergy and Clinical Immunology, V97, P240, DOI 10.1016/S0091-6749(96)80449-0; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; TAYLOR SL, 1986, J FOOD PROTECT, V49, P239, DOI 10.4315/0362-028X-49.3.239; THOMAS HC, 1974, IMMUNOLOGY, V27, P631; TURNER MW, 1990, CLIN EXP ALLERGY, V20, P421, DOI 10.1111/j.1365-2222.1990.tb02804.x; Wells HG, 1911, J INFECT DIS, V8, P66, DOI 10.1093/infdis/8.1.66; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	24	90	101	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					266	273		10.1016/S0091-6749(97)70235-5	http://dx.doi.org/10.1016/S0091-6749(97)70235-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275151				2022-12-18	WOS:A1997XR35100020
J	deBlay, F; Sanchez, J; Hedelin, G; PerezInfante, A; Verot, A; Chapman, M; Pauli, G				deBlay, F; Sanchez, J; Hedelin, G; PerezInfante, A; Verot, A; Chapman, M; Pauli, G			Dust and airborne exposure to allergens derived from cockroach (Blattella germanica) in low-cost public housing in Strasbourg (France)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cockroach allergens; asthma; aeroallergen; environmental exposure; immediate hypersensitivity	FEL-D-I; CAT-ALLERGEN; RISK-FACTORS; F-I; ASTHMA; MITE; HYPERSENSITIVITY; ELISA	Background: Although a strong association between allergy to cockroach (CR) and asthma has been observed in the United States and Asia, there are little data about the extent of exposure to CR allergen in Europe. Objective: To deter-mine the levels of CR allergens in dust samples from apartments in strasbourg and to determine the concentration and size of CR allergens in the air. Methods: Nine apartments in a public housing complex were chosen on the basis of visual evidence of CR infestation. Levels of CR allergens (Bla g 1 and Bla g 2) in kitchen and mattress dust samples were measured by immunoassay with the use of monoclonal antibodies. Air was sampled for 3 to 8 hours in the kitchen under undisturbed conditions, during artificial disturbance and during normal domestic activity by using an impinger and a parallel glass fiber filter and at flow rates of 2 to 20 L/min. Airborne CR and mite allergens were measured concurrently in the bedroom of one apartment before, during, and after artificial disturbance. Results: High levels of Bla g 1 and Bla g 2 were found in kitchen dust from the nine apartments (geometric means of 3919 U/gm [range 530 to 14306 U/gm] and 497 U/gm [range 73 to 1946 U/gm], respectively). Under undisturbed conditions, airborne CR allergens were not detectable in any of the apartments. During vigorous artificial disturbance, Bin g I and Bla g 2 were detectable in ab samples front seven apartments (geometric means of 4.5 U/m(3) [range 0.7 to 17.2 U/m(3)] and 1.0 U/m(3) [range 0.4 to 3.4 U/m(3)], respectively). Both allergens were predominantly collected on the first stage of the impinger; and 76% to 80% of the airborne allergen was associated with particles greater than 10 mu m in diameter. The levels were significantly higher than those collected on the second or third stages of the impinger (p < 0.001). A comparison of the levels of mite and CR allergens showed that the airborne properties of these allergens were similar; that is, measurable only during disturbance and not detectable 30 minutes after disturbance. Conclusion: Levels of CR allergen in low-cost public housing in Strasbourg can be as high as ol higher than the levels measured in towns in the United States. CR allergens become airborne during disturbance and are primarily associated with particles greater than 10 mu m in diameter. Patients with asthma living in urban areas of Europe in housing prone to CR infestation should be evaluated for sensitization and exposure to CR allergens.	UNIV STRASBOURG 1, FAC MED, INST EPIDEMIOL, STRASBOURG, FRANCE; UNIV VIRGINIA, DEPT MED, ASTHMA & ALLERGIC DIS CTR, CHARLOTTESVILLE, VA USA	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Virginia	deBlay, F (corresponding author), HOP UNIV STRASBOURG, HOP CIVIL, UNITE INSERM U425 PAVILLON LAENNEC, BP 426, F-67091 STRASBOURG, FRANCE.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032557, U01AI034607, U19AI034607] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32557, AI 34607] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aitchison J., 1986, MONOGRAPHS STAT APPL; [Anonymous], 1966, HEALTH PHYS, V12, P173; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; BIRNBAUM J, 1991, LANCET, V337, P249, DOI 10.1016/0140-6736(91)92225-Q; BRAIN JD, 1979, AM REV RESPIR DIS, V120, P1325; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHOOVIVATHANAVANICH P, 1970, LANCET, V2, P1362; CUSTOVIC A, 1996, IN PRESS AM J CRIT C; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; DEBLAY F, 1992, PRESSE MED, V21, P1685; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; IHRE E, 1993, CLIN EXP ALLERGY, V23, P298, DOI 10.1111/j.1365-2222.1993.tb00326.x; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V87, P574, DOI 10.1016/0091-6749(91)90017-I; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MAY KR, 1966, BACTERIOL REV, V30, P559, DOI 10.1128/MMBR.30.3.559-570.1966; MOSIMANN B, 1992, SCHWEIZ MED WSCHR, V122, P1245; *NF AFNOR, 1993, 43404 NF AFNOR X; POLA J, 1988, ALLERGOL IMMUNOPATH, V16, P105; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; SAKAGUCHI M, 1993, J ALLERGY CLIN IMMUN, V92, P797, DOI 10.1016/0091-6749(93)90056-L; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; SWARTENGREN M, 1987, EXP LUNG RES, V12, P75; TANDON N, 1990, ANN ALLERGY, V64, P155; WOOD RA, 1993, CLIN EXP ALLERGY, V23, P733, DOI 10.1111/j.1365-2222.1993.tb00360.x; ZWICK H, 1991, J ALLERGY CLIN IMMUN, V87, P626, DOI 10.1016/0091-6749(91)90380-7	29	90	92	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				107	112		10.1016/S0091-6749(97)81051-2	http://dx.doi.org/10.1016/S0091-6749(97)81051-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003218	Bronze			2022-12-18	WOS:A1997WD06100015
J	Beck, LA; Stellato, C; Beall, LD; Schall, TJ; Leopold, D; Bickel, CA; Baroody, F; Bochner, BS; Schleimer, RP				Beck, LA; Stellato, C; Beall, LD; Schall, TJ; Leopold, D; Bickel, CA; Baroody, F; Bochner, BS; Schleimer, RP			Detection of the chemokine RANTES and endothelial adhesion molecules in nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chemotactic factors; RANTES; VCAM-1; E-selectin; eosinophil; nasal polyps; endothelial adhesion molecules; eosinophils; epithelium	INFLAMMATORY PROTEIN 1-ALPHA; COLONY-STIMULATING FACTOR; LATE ACTIVATION ANTIGEN-4; LEUKOCYTE ADHESION; HUMAN EOSINOPHILS; E-SELECTIN; AIRWAY HYPERRESPONSIVENESS; BRONCHIAL-ASTHMA; EPITHELIAL-CELLS; CYTOKINE RANTES	Background: To better understand the mechanisms of eosinophil recruitment into the upper airways, we examined human nasal polyps for the expression of the chemotactic cytokine RANTES and the endothelial adhesion molecules E-selectin and vascular cell adhesion molecule-1 (VCAM-1). Methods: Routine histologic examination and immunostaining with antibodies to RANTES, E-selectin, and VCAM-1 were performed on three types of tissues: nasal polyps, sinus mucosa, or turbinates from patients undergoing other elective procedures (S/T), and nasal biopsy specimens from nonallergic volunteers (NA). To further quantify the expression of endothelial adhesion molecules, some tissue samples were homogenized and the resulting supernatants were assayed with sandwich ELISAs for VCAM-1 and E-selectin. Results: Polyp eosinophil counts ranged from 19/mm(2) to 1818/mm(2) (763 +/- 120/mm(2), mean +/- SEM) and were significantly higher than those found in the control tissues (5 +/- 2 in S/T samples and 20 +/- 9 in NA samples, p < 0.002). Immunochemical staining for RANTES was observed in 11 of 14 polyps; intense staining for RANTES (grade 3) was observed in six of 14 polyps. None of nine S/T samples of five NA samples demonstrated grade 3 staining. Staining with anti-RANTES was largely localized to airway and glandular epithelium. There was no significant correlation between counts of eosinophils or the combined total of eosinophils plus mononuclear cells and the intensity of epithelial RANTES staining in all nasal tissues. Staining for VCAM-1, as well as for E-selectin, was detected in 11 of 14 polyps and eight of 13 control tissues. VCAM-1 detected by ELISA in polyp tissues (6.8 +/- 1.3 mu g/gm) was higher than that found in six S/T samples (1.2 +/- 0.3 mu g/gm, p < 0.005) and in two NA samples (1.8 +/- 0.02 mu g/gm, p = 0.08). E-selectin values in polyps (1.4 +/- 0.3 mu g/gm) were not statistically different from those detected in six S/T samples (0.5 +/- 0.2 mu g/gm) or two NA samples (1.6 +/- 0.4 mu g/gm). Counts of eosinophils and eosinophils plus mononuclear cells displayed a strong correlation with VCAM-1 ELISA values (p < 0.005 and p < 0.004, respectively) but not with VCAM-1 staining. VCAM-1 staining correlated with EG2-positive eosinophils in nasal polyp tissues (p < 0.01). E-selectin staining did not correlate with either neutrophil or eosinophil counts. Conclusions: These studies demonstrate that the chemokine RANTES is produced in vivo and is localized predominantly to nasal epithelium. Endothelial activation, as indicated by adhesion molecule expression, occurs in human nasal polyp tissues and in control tissues.	JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR,DEPT MED,DIV IMMUNOL,BALTIMORE,MD; OTSUKA AMER PHARMACEUT INC,ROCKVILLE,MD; DNAX RES INST MOL & CELLULAR BIOL INC,PALO ALTO,CA 94304; JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR,DEPT OTOLARYNGOL HEAD & NECK SURG,BALTIMORE,MD	Johns Hopkins University; Johns Hopkins Medicine; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Johns Hopkins University; Johns Hopkins Medicine			Stellato, Cristiana/P-3001-2015	Stellato, Cristiana/0000-0002-1294-8355	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM031891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI001226] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 31891] Funding Source: Medline; NIAID NIH HHS [AI 01226, AI 21037] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM WM, 1994, J CLIN INVEST, V93, P776, DOI 10.1172/JCI117032; BARON JL, 1994, J CLIN INVEST, V93, P1700, DOI 10.1172/JCI117153; BECK L, 1995, FASEB J, V9, pA804; BENTLEY AM, 1993, J ALLERGY CLIN IMMUN, V92, P857, DOI 10.1016/0091-6749(93)90064-M; BOCHNER BS, 1994, J IMMUNOL, V152, P774; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADDING P, 1993, J IMMUNOL, V151, P3853; COX G, 1991, AM J RESP CELL MOL, V4, P525, DOI 10.1165/ajrcmb/4.6.525; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; DENBURG JA, 1991, INT ARCH ALLER A IMM, V94, P127, DOI 10.1159/000235343; DEVERGNE O, 1994, J EXP MED, V179, P1689, DOI 10.1084/jem.179.5.1689; DOBRINA A, 1991, J CLIN INVEST, V88, P22; DURHAM SR, 1992, J IMMUNOL, V148, P2390; EBISAWA M, 1994, J IMMUNOL, V153, P2153; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FINOTTO S, 1994, J IMMUNOL, V153, P2278; GEORAS SN, 1992, AM J RESP CELL MOL, V7, P261, DOI 10.1165/ajrcmb/7.3.261; GILAT D, 1994, J IMMUNOL, V153, P4899; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GUNDEL RH, 1991, J CLIN INVEST, V88, P1407, DOI 10.1172/JCI115447; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KAKOI H, 1987, ACTA OTO-LARYNGOL, V103, P137, DOI 10.3109/00016488709134709; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KANAI N, 1994, AM J RESP CRIT CARE, V150, P1094, DOI 10.1164/ajrccm.150.4.7921442; KAY AB, 1991, NEW ENGL J MED, V324, P1514; KENNEY JS, 1994, J ALLERGY CLIN IMMUN, V93, P1060, DOI 10.1016/S0091-6749(94)70055-9; KOBAYASHI T, 1994, CLIN EXP IMMUNOL, V96, P110; KYANAUNG U, 1991, J IMMUNOL, V146, P521; LEE BJ, 1994, J ALLERGY CLIN IMMUN, V94, P1006, DOI 10.1016/0091-6749(94)90119-8; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; NAKAJIMA H, 1994, J EXP MED, V179, P1145, DOI 10.1084/jem.179.4.1145; NEWMAN W, 1993, J IMMUNOL, V150, P644; RAND TH, 1991, J EXP MED, V173, P1521, DOI 10.1084/jem.173.6.1521; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; RICE GE, 1991, AM J PATHOL, V138, P385; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; Schleimer R P, 1991, J Immunol, V147, P380; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SELVAN RS, 1994, J BIOL CHEM, V269, P13893; SOUSA AR, 1994, AM J RESP CELL MOL, V10, P142, DOI 10.1165/ajrcmb.10.2.8110469; Stellato C., 1995, Journal of Allergy and Clinical Immunology, V95, P299; STELLATO C, 1995, J IMMUNOL, V155, P308; STOOP AE, 1993, J ALLERGY CLIN IMMUN, V91, P616, DOI 10.1016/0091-6749(93)90267-J; SYMON FA, 1994, J EXP MED, V180, P371, DOI 10.1084/jem.180.1.371; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; TERADA N, 1994, J ALLERGY CLIN IMMUN, V94, P629, DOI 10.1016/0091-6749(94)90140-6; THORNHILL MH, 1990, J IMMUNOL, V144, P3060; WAKITA H, 1994, J CUTAN PATHOL, V21, P33, DOI 10.1111/j.1600-0560.1994.tb00688.x; WALSH GM, 1991, J IMMUNOL, V146, P3419; WARRINGA RAJ, 1991, BLOOD, V77, P2694; WEG VB, 1993, J EXP MED, V177, P561, DOI 10.1084/jem.177.2.561; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; WLADISLAVOSKYWASERMAN P, 1984, CLIN ALLERGY, V14, P241, DOI 10.1111/j.1365-2222.1984.tb02203.x	63	90	91	2	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1996	98	4					766	780		10.1016/S0091-6749(96)70126-4	http://dx.doi.org/10.1016/S0091-6749(96)70126-4			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VM665	8876553	hybrid			2022-12-18	WOS:A1996VM66500010
J	Venge, J; Lampinen, M; Hakansson, L; Rak, S; Venge, P				Venge, J; Lampinen, M; Hakansson, L; Rak, S; Venge, P			Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-5; RANTES; eosinophils; asthma; lungs	NEUTROPHIL CHEMOTACTIC ACTIVITY; POLLEN SEASON; ACTIVATING FACTOR; IMMUNOTHERAPY; INTERLEUKIN-8; MIGRATION	The study was carried out to identify those molecules that are important in vivo in the attraction of eosinophil granulocytes to the lungs of patients with asthma. Asthmatic patients with birch pollen allergy had lavages performed before and during the pollen season, and the chemotactic activity of the bronchoalveolar lavage fluid was tested against normal eosinophils. The activity was significantly increased during the pollen season as compared with the activity before the pollen season (p < 0.01). Neutralizing antibodies to IL-2, IL-5 and IL-8, leukemia inhibitory factor, and to RANTES were added to the bronchoalveolar lavage fluid. Antibodies to IL-5 and RANTES, but not to IL-2 and IL-8 or leukemia inhibitory factor, significantly inhibited the chemotactic activity for eosinophils (p < 0.001). It is concluded that IL-5 and RANTES are important chemoattractants in the lungs of patients with allergic asthma. The effect of IL-5 may be that of a cofactor to the chemotactic molecules, of which RANTES may be one of the most important in allergic asthma.	UNIV UPPSALA HOSP, DEPT CLIN CHEM, ASTHMA RES CTR, S-75185 UPPSALA, SWEDEN	Uppsala University; Uppsala University Hospital			Lampinen, Maria/L-3389-2019	Lampinen, Maria/0000-0002-0396-2147				ALAM R, 1993, J IMMUNOL, V150, P3442; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BALDWIN ET, 1990, J BIOL CHEM, V265, P6851; BARNES PJ, 1992, ASTHMA BASIC MECH CL; BONER AL, 1993, CLIN EXP ALLERGY, V23, P1021, DOI 10.1111/j.1365-2222.1993.tb00294.x; CLARK RAF, 1975, J EXP MED, V142, P1462, DOI 10.1084/jem.142.6.1462; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; DAHL R, 1992, ASTHMA BASIC MECHANI, P111; DESREUMAUX P, 1993, BLOOD, V82, P1553; DUBUCQUOI S, 1994, J EXP MED, V179, P703, DOI 10.1084/jem.179.2.703; HAKANSSON L, 1989, J ALLERGY CLIN IMMUN, V83, P933, DOI 10.1016/0091-6749(89)90108-5; HAKANSSON L, 1980, SCAND J IMMUNOL, V11, P271, DOI 10.1111/j.1365-3083.1980.tb00235.x; HAKANSSON L, 1987, J LEUKOCYTE BIOL, V42, P689, DOI 10.1002/jlb.42.6.689; HAKANSSON L, 1994, APMIS, V102, P308, DOI 10.1111/j.1699-0463.1994.tb04880.x; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; NOURSHARGH S, 1993, AM REV RESPIR DIS, V148, pS60, DOI 10.1164/ajrccm/148.6_Pt_2.S60; RAK S, 1987, INT ARCH ALLER A IMM, V82, P349, DOI 10.1159/000234224; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; RAK S, 1990, J ALLERGY CLIN IMMUN, V86, P706, DOI 10.1016/S0091-6749(05)80174-5; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROBINSON DS, 1993, THORAX, V48, P845, DOI 10.1136/thx.48.8.845; SCHMEKEL B, 1993, ALLERGY, V48, P94, DOI 10.1111/j.1398-9995.1993.tb04708.x; SEHMI R, 1993, CLIN EXP ALLERGY, V23, P1027, DOI 10.1111/j.1365-2222.1993.tb00295.x; SIGAL CE, 1987, J CLIN IMMUNOL, V7, P179, DOI 10.1007/BF00916012; SMITH CH, 1993, AM REV RESPIR DIS, V148, pS75, DOI 10.1164/ajrccm/148.6_Pt_2.S75; SPADA CS, 1994, J LEUKOCYTE BIOL, V55, P183, DOI 10.1002/jlb.55.2.183; VENGE P, 1990, CL IMMUNOL, V2, P105; VENGE P, 1987, J ALLERGY CLIN IMMUN, V80, P679, DOI 10.1016/0091-6749(87)90287-9; VENGE P, 1991, ASTHMA ITS PATHOLOGY, P477; VENGE P, 1990, INFLAMMATORY INDICES, P219; WARRINGA RAJ, 1993, J ALLERGY CLIN IMMUN, V91, P1198, DOI 10.1016/0091-6749(93)90323-8; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	34	90	94	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1110	1115		10.1016/S0091-6749(96)70265-8	http://dx.doi.org/10.1016/S0091-6749(96)70265-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626989				2022-12-18	WOS:A1996UL26100012
J	Gustafson, LM; Proud, D; Hendley, JO; Hayden, FG; Gwaltney, JM				Gustafson, LM; Proud, D; Hendley, JO; Hayden, FG; Gwaltney, JM			Oral prednisone therapy in experimental rhinovirus infections	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						prednisone; corticosteroids; rhinovirus; kinins; viral titers	ALLERGIC INDIVIDUALS; ANTIGEN CHALLENGE; MEDIATOR RELEASE; NASAL SECRETIONS; RHINITIS; KININS	This study was designed to test the effects of oral steroid therapy on the kinin levels and symptoms of experimental rhinoviral colds. Forty-seven men were randomized to receive prednisone (20 mg) or placebo. Therapy was administered three times a day for 5 days, after one dose was given 11 hours before inoculation with rhinovirus. Viral titers, symptom scores, and kinin and albumin concentrations in nasal washes were monitored. The mean kinin levels were lower in the steroid group (287 vs 449 pg/ml, p = 0.005) with significant differences in kinin levels on days 3 and 4 (p < 0.01). No significant difference in total symptom scores was seen between the two groups. Except for increased sneezing (p < 0.01) and mucus weights (p < 0.05) on day 1 in patients treated with prednisone, there were no significant differences in individual symptom scores. Headache tended to be less prominent in steroid recipients. Mean viral titers were higher in the steroid group (1.13 vs 0.79, p = 0.03) with significant differences in the daily viral titers on days 3 (p < 0.05) and 4 (p < 0.01). Steroids reduced kinin levels in rhinoviral infections, but that reduction was not associated with a significant reduction in symptoms. This study also provides evidence for the enhancement of viral growth in steroid recipients.	UNIV VIRGINIA,CTR HLTH SCI,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,CTR HLTH SCI,DEPT PEDIAT,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,CTR HLTH SCI,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD	University of Virginia; University of Virginia; University of Virginia; Johns Hopkins University								BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; BEISEL WR, 1969, NEW ENGL J MED, V280, P596, DOI 10.1056/NEJM196903132801106; CLINE MJ, 1966, SCIENCE, V153, P1135, DOI 10.1126/science.153.3740.1135; DOUGLAS RG, 1968, ANTIMICROBIAL AGENTS, P340; FARR BM, 1990, J INFECT DIS, V162, P1173, DOI 10.1093/infdis/162.5.1173; GWALTNEY JM, 1980, J INFECT DIS, V142, P811, DOI 10.1093/infdis/142.6.811; GWALTNEY JM, 1994, 34 INT C ANT AG CHEM; HAMORY BH, 1977, P SOC EXP BIOL MED, V155, P577, DOI 10.3181/00379727-155-39854; Haparian V. V., 1979, DIAGNOSTIC PROCEDURE, P535; HAYDEN FG, 1982, ANTIMICROB AGENTS CH, V21, P892, DOI 10.1128/AAC.21.6.892; HO M, 1970, ARCH INTERN MED, V126, P135, DOI 10.1001/archinte.126.1.135; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; KILBOURNE E, 1961, NATURE, V190, P650, DOI 10.1038/190650a0; NACLERIO RM, 1988, J INFECT DIS, V157, P132; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PIPKORN U, 1986, J ALLERGY CLIN IMMUN, V77, P180; PROUD D, 1990, J INFECT DIS, V161, P120, DOI 10.1093/infdis/161.1.120; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; PROUD D, 1988, AM REV RESPIR DIS, V137, P613, DOI 10.1164/ajrccm/137.3.613; SCHLEIMER RP, 1988, ALLERGY PRINCIPLES P, P739; WINTHER B, 1982, S CELL NEUR MECH NOS	21	90	90	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1996	97	4					1009	1014		10.1016/S0091-6749(96)80077-7	http://dx.doi.org/10.1016/S0091-6749(96)80077-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UG086	8655877				2022-12-18	WOS:A1996UG08600017
J	MCFADDEN, ER				MCFADDEN, ER			IMPROPER PATIENT TECHNIQUES WITH METERED-DOSE INHALERS - CLINICAL CONSEQUENCES AND SOLUTIONS TO MISUSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PRESSURIZED AEROSOL INHALERS; BREATH-ACTUATED INHALER; INHALATION TECHNIQUE; CANISTER NEBULIZERS; ASTHMATIC-CHILDREN; DELIVERY SYSTEMS; TUBE SPACER; BRONCHODILATOR; THERAPY; DRUGS				MCFADDEN, ER (corresponding author), CASE WESTERN RESERVE UNIV HOSP, SCH MED, DIV PULM & CRIT CARE MED, CLEVELAND, OH 44106 USA.							AGUSTI AGN, 1985, CHEST, V88, P159, DOI 10.1378/chest.88.1.159-b; ALLEN SC, 1986, BRIT J DIS CHEST, V80, P45, DOI 10.1016/0007-0971(86)90008-2; APPEL D, 1982, J FAM PRACTICE, V14, P1135; ARMITAGE JM, 1988, AGE AGEING, V17, P275, DOI 10.1093/ageing/17.4.275; BASSETT MF, 1869, MED SURG REP, V20, P23; BENTON G, 1989, AM J DIS CHILD, V143, P678, DOI 10.1001/archpedi.1989.02150180056020; BLOOMFIELD P, 1979, BRIT MED J, V2, P1479, DOI 10.1136/bmj.2.6203.1479; BOWTON DL, 1992, CHEST, V101, P305, DOI 10.1378/chest.101.2.305; CHRISTIE T, 1911, EDINBURGH MED SURG J, V7, P153; COADY TJ, 1976, PRACTITIONER, V217, P273; COMPTON GK, 1982, EUR J RESPIR DIS, V63, P489; CONNOLLY CK, 1975, BRIT MED J, V3, P21, DOI 10.1136/bmj.3.5974.21; CROMPTON G, 1989, PRACTITIONER, V233, P268; CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P101; CROMPTON GK, 1988, EUR RESPIR J, V1, P679; DEBLAQUIERE P, 1989, AM REV RESPIR DIS, V140, P910, DOI 10.1164/ajrccm/140.4.910; DIGGORY P, 1991, AGE AGEING, V20, P379, DOI 10.1093/ageing/20.5.379; DOLOVICH M, 1981, CHEST, V80, P911; DOLOVICH M, 1983, CHEST, V84, P36, DOI 10.1378/chest.84.1.36; EARL JE, 1978, BRIT MED J, V1, P1554; EPSTEIN SW, 1979, CAN MED ASSOC J, V120, P813; FERGUSSON RJ, 1991, EUR RESPIR J, V4, P172; FUGLSANG G, 1986, EUR J RESPIR DIS, V69, P109; GANDEVIA B, 1975, POSTGRAD MED J, V51, P13; GAYRARD P, 1980, RESPIRATION, V40, P47, DOI 10.1159/000194250; GOMM SA, 1980, THORAX, V35, P552, DOI 10.1136/thx.35.7.552; Graeser JB, 1935, J ALLERGY, V6, P415; GUIDRY GG, 1992, CHEST, V101, P31, DOI 10.1378/chest.101.1.31; GURWITZ D, 1983, ANN ALLERGY, V50, P166; HARRISON BA, 1983, AUST NZ J MED, V13, P29, DOI 10.1111/j.1445-5994.1983.tb04543.x; HILTON S, 1990, BRIT J GEN PRACT, V40, P505; KELLING JS, 1983, CHEST, V83, P612, DOI 10.1378/chest.83.4.612; KING D, 1991, BJCP, V45, P10; LAWFORD P, 1982, BRIT J DIS CHEST, V76, P229, DOI 10.1016/0007-0971(82)90046-8; LEE HS, 1983, CLIN PEDIATR, V22, P440; LEVINE ER, 1959, INHALE THER, V4, P14; LINDGREN S, 1987, EUR J RESPIR DIS, V70, P93; LINDGREN SB, 1980, EUR J RESPIR DIS, V61, P56; LULLING J, 1983, EUR J RESPIR DIS, V64, P33; MANZELLA BA, 1989, J ASTHMA, V26, P223, DOI 10.3109/02770908909073253; MCFADDEN ER, 1986, INHALED AEROSOL BRON, P1; NEWMAN SP, 1984, CHEST, V86, P342, DOI 10.1378/chest.86.3.342; NEWMAN SP, 1981, THORAX, V36, P52, DOI 10.1136/thx.36.1.52; NEWMAN SP, 1981, EUR J RESPIR DIS, V62, P3; NEWMAN SP, 1991, THORAX, V46, P712, DOI 10.1136/thx.46.10.712; NEWMAN SP, 1983, PRACT CARDIOL, V9, P84; OREHEK J, 1976, BRIT MED J, V1, P76, DOI 10.1136/bmj.1.6001.76; PATERSON IC, 1976, BRIT MED J, V1, P76, DOI 10.1136/bmj.1.6001.76-a; PEDERSEN S, 1983, NEW ENGL J MED, V308, P1328, DOI 10.1056/NEJM198306023082205; PEDERSEN S, 1986, ALLERGY, V41, P118, DOI 10.1111/j.1398-9995.1986.tb00287.x; POPPIUS H, 1980, RESPIRATION, V40, P278, DOI 10.1159/000194290; RILEY DJ, 1979, CHEST, V76, P501, DOI 10.1378/chest.76.5.501; RILEY DJ, 1976, AM REV RESPIR DIS, V114, P509; SAUNDERS KB, 1965, BRIT MED J, V1, P1037, DOI 10.1136/bmj.1.5441.1037; SCHULTZ PD, 1919, NY MED J, V109, P768; SHIM C, 1980, AM J MED, V69, P891, DOI 10.1016/S0002-9343(80)80016-7; SHIM CS, 1984, J ALLERGY CLIN IMMUN, V73, P387, DOI 10.1016/0091-6749(84)90413-5; THOMPSON A, 1982, AM REV RESPIR DIS, V125, P140; TOBIN MJ, 1985, ARCH INTERN MED, V145, P1659, DOI 10.1001/archinte.145.9.1659; TOBIN MJ, 1982, AM REV RESPIR DIS, V126, P670	60	90	95	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					278	283		10.1016/S0091-6749(95)70206-7	http://dx.doi.org/10.1016/S0091-6749(95)70206-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636071				2022-12-18	WOS:A1995RQ00100026
J	BOULET, LP; DESCHESNES, F; TURCOTTE, H; GIGNAC, F				BOULET, LP; DESCHESNES, F; TURCOTTE, H; GIGNAC, F			NEAR-FATAL ASTHMA - CLINICAL AND PHYSIOLOGICAL FEATURES, PERCEPTION OF BRONCHOCONSTRICTION, AND PSYCHOLOGIC PROFILE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NEAR-FATAL ASTHMA; PERCEPTION OF DYSPNEA; SEVERE ASTHMA	DEATHS; MORTALITY; IDENTIFICATION; CHILDHOOD; WORKSHOP; CHILDREN; PATIENT	We studied 19 subjects with asthma (11 men and eight women, aged 20 to 66 years), 6 months to 5 years after a near-fatal (NF) episode of asthma (NF group). Mean duration of asthma was 16.3 +/- 2.4 years. On reevaluation, all subjects were using an inhaled beta-2-agonist and inhaled steroids (mean daily dose of budesonide, 1070-mu-g [N = 5], and beclomethasone, 1079-mu-g [N = 14]). Two subjects were taking prednisone, 10 and 15 mg/day. Subjects were matched for age, sex, atopic status, baseline FEV1, and medication use to a control group (C group) of subjects with asthma who had never experienced an NF asthma episode. All subjects had the following evaluation: (1) questionnaire on the characteristics of their asthma, (2) spirometry, (3) morning and evening measurements of peak expiratory flow rates (PEFR) with daily recordings of asthma symptoms for 4 weeks, and (4) psychometric evaluation with the Minnesota Multiphasic Personality Inventory. Ten subjects of the NF group and 13 of the C group had a methacholine challenge with scoring of dyspnea on a modified Borg scale. Mean percent predicted (+/- SEM), FEV1, FVC, and PEFR were similar for the NF and C groups with respective values of 63.4 (4.4), 61.3 (5.6), 81.1 (4.5), 79.1 (3.8), 61.3 (5.6), and 62.4 (6.1). Geometric mean of the provocative concentration of methacholine causing a 20% drop in FEV1 (milligrams per milliliter) was 0.61 for the NF group (N = 10) and 1.18 for the C group (N = 13). In comparison to the C group, subjects of the NF group had an increased diurnal variations of PEFR (p less-than-or-equal-to 0.0002), and more subjects had poor asthma control (NF = 13; C = 5) or a poor treatment compliance (NF = 11; C = 4). No particular psychologic profile could be found on analysis of the Minnesota Multiphasic Personality Inventory in either group. However, analysis of individual profiles revealed more frequent personality disturbances with reduced adaptative personality characteristics in the NF group than in the C group. In conclusion, subjects with asthma who experienced NF asthma have (1) increased diurnal variations of PEFR, (2) an increased prevalence of poorly controlled asthma and reduced compliance to treatment, and (3) less adaptative personality characteristics and more psychologic disturbances that can affect asthma control. However, they do not differ significantly from a C group for perception of dyspnea.			BOULET, LP (corresponding author), UNIV LAVAL,HOP LAVAL,CTR PNEUMOL,UNITE RECH,2725 CHEMIN STE FOY,ST FOY C1V 4G5,QUEBEC,CANADA.							BARON C, 1986, J ASTHMA, V23, P69, DOI 10.3109/02770908609077477; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BURDON JGW, 1982, AM REV RESPIR DIS, V126, P825; COLLINSWILLIAMS C, 1981, CAN MED ASSOC J, V125, P341; COTE J, 1987, AM REV RESPIR DIS, V135, P321; CREER TL, 1986, J ASTHMA, V23, P261, DOI 10.3109/02770908609073170; DIRKS JF, 1982, J ASTHMA, V19, P177, DOI 10.3109/02770908209104755; DIRKS JF, 1977, PSYCHOSOM MED, V39, P120, DOI 10.1097/00006842-197703000-00006; DRAZEN JM, 1987, J ALLERGY CLIN IMMUN, V80, P428, DOI 10.1016/0091-6749(87)90069-8; FRIEDMAN MS, 1984, J ASTHMA, V21, P97, DOI 10.3109/02770908409077408; Graham J.R., 1987, MMPI PRACTICAL GUIDE; JUNIPER EF, 1982, THORAX, V37, P288, DOI 10.1136/thx.37.4.288; MACDONALD JB, 1976, BRIT MED J, V1, P1493, DOI 10.1136/bmj.1.6024.1493; MACFADDEN ER, 1973, NEW ENGL J MED, V288, P221; MARQUETTE C, 1990, J ALLERGY CLIN IMMUN, V85, P236; MASCIA A, 1989, ANN ALLERGY, V62, P311; NEWCOMB RW, 1988, AM J DIS CHILD, V142, P1041, DOI 10.1001/archpedi.1988.02150100035020; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; RUBENFIELD AR, 1976, LANCET, V24, P882; RUFFIN RE, 1991, CHEST, V99, P77, DOI 10.1378/chest.99.1.77; SAETTA M, 1989, EUR RESPIR J, V2, P1008; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P477, DOI 10.1016/0091-6749(87)90079-0; SEARS MR, 1988, J ALLERGY CLIN IMMUN, V82, P957, DOI 10.1016/0091-6749(88)90130-3; SLY RM, 1984, ANN ALLERGY, V53, P20; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; STRUNK RC, 1989, J ALLERGY CLIN IMMUN, V83, P477, DOI 10.1016/0091-6749(89)90137-1; STRUNK RC, 1987, J ALLERGY CLIN IMMUN, V80, P455, DOI 10.1016/0091-6749(87)90073-X; TIETZ W, 1975, Journal of Asthma Research, V12, P199, DOI 10.3109/02770907509098947; TURCOTTE H, 1990, THORAX, V45, P914, DOI 10.1136/thx.45.12.914; YELLOWLEES PM, 1989, CHEST, V95, P1298, DOI 10.1378/chest.95.6.1298; 1987, AM REV RESPIR DIS, V136, P225	31	90	90	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1991	88	6					838	846		10.1016/0091-6749(91)90239-K	http://dx.doi.org/10.1016/0091-6749(91)90239-K			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GW262	1744354				2022-12-18	WOS:A1991GW26200003
J	SETTIPANE, RA; STEVENSON, DD				SETTIPANE, RA; STEVENSON, DD			CROSS SENSITIVITY WITH ACETAMINOPHEN IN ASPIRIN-SENSITIVE SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN,10666 N TORREY PINES RD,LA JOLLA,CA 92037	Scripps Research Institute				Settipane, Russell/0000-0002-6328-8780	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00833] Funding Source: Medline; NIAID NIH HHS [AI-10386] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOUGHTONSMITH NK, 1983, BRIT J PHARMACOL, V78, P173, DOI 10.1111/j.1476-5381.1983.tb09378.x; BRUNE K, 1980, EUR J PHARMACOL, V68, P365, DOI 10.1016/0014-2999(80)90534-8; CHAFEE FH, 1967, J ALLERGY, V40, P65, DOI 10.1016/0021-8707(67)90099-8; DELANEY J C, 1975, Clinical Allergy, V5, P234; DELANEY JC, 1976, CLIN ALLERGY, V6, P177, DOI 10.1111/j.1365-2222.1976.tb01896.x; DELANEY JC, 1983, CLIN ALLERGY, V13, P247, DOI 10.1111/j.1365-2222.1983.tb02595.x; DUNIEC Z, 1983, BIOCHEM PHARMACOL, V32, P2283, DOI 10.1016/0006-2952(83)90239-3; ESPEY LL, 1983, PROSTAGLANDINS, V26, P71, DOI 10.1016/0090-6980(83)90075-8; FALLIERS CJ, 1983, J ASTHMA, V20, P39, DOI 10.3109/02770908309078051; FELDBERG W, 1972, BRIT J PHARMACOL, V46, P550; FISCHER TJ, 1983, PEDIATRICS, V71, P313; FISHERMAN EW, 1973, ANN ALLERGY, V31, P476; FITZPATRICK FA, 1976, PROSTAGLANDINS, V12, P1037, DOI 10.1016/0090-6980(76)90137-4; FLOWER R, 1972, NATURE-NEW BIOL, V238, P104, DOI 10.1038/newbio238104a0; FLOWER RJ, 1972, NATURE, V240, P410, DOI 10.1038/240410a0; GLENN EM, 1977, AGENTS ACTIONS, V7, P513, DOI 10.1007/BF02111123; GREAVES MW, 1972, BRIT MED J, V3, P527, DOI 10.1136/bmj.3.5825.527-b; HENOCHOWICZ S, 1986, IMMUNOL ALLERGY PRAC, V8, P43; KONTUREK SJ, 1982, GUT, V23, P536, DOI 10.1136/gut.23.6.536; KONTUREK SJ, 1981, GUT, V22, P283, DOI 10.1136/gut.22.4.283; LIGUMSKY M, 1986, ISRAEL J MED SCI, V22, P807; MATTAMMAL MB, 1979, J PHARMACOL EXP THER, V210, P405; MCDONALDGIBSON WJ, 1979, EUR J PHARMACOL, V58, P497, DOI 10.1016/0014-2999(79)90324-8; MILLER L, 1981, J PHARM PHARMACOL, V33, P188, DOI 10.1111/j.2042-7158.1981.tb13751.x; MILTON AS, 1973, SUPPLEMENTUM ADV BIO, V9, P495; PALMER MA, 1973, BRIT J PHARMACOL, V49, P226, DOI 10.1111/j.1476-5381.1973.tb08368.x; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; ROBAK J, 1978, BIOCHEM PHARMACOL, V27, P393, DOI 10.1016/0006-2952(78)90367-2; ROBAK J, 1980, BIOCHEM PHARMACOL, V29, P1863, DOI 10.1016/0006-2952(80)90155-0; ROTH GJ, 1975, J CLIN INVEST, V56, P624, DOI 10.1172/JCI108132; ROTH GJ, 1975, P NATL ACAD SCI USA, V72, P3073, DOI 10.1073/pnas.72.8.3073; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SEWELL RDE, 1984, ARCH INT PHARMACOD T, V268, P325; SHAFFER JE, 1981, EUR J PHARMACOL, V72, P57, DOI 10.1016/0014-2999(81)90296-X; SMITH AP, 1971, BRIT MED J, V2, P494, DOI 10.1136/bmj.2.5760.494; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; STEVENSON DD, 1988, NEW ENGL REG ALLERGY, V9, P135; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; STEVENSON DD, 1986, NEW ENGL REG ALLERGY, V7, P101; STEVENSON DD, 1982, PSEUDOALLERGIC REACT, V3, P133; SZCZEKLIK A, 1986, DRUGS, V32, P148, DOI 10.2165/00003495-198600324-00011; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; TOLMAN EL, 1983, PROSTA LEUKOTR MED, V12, P347, DOI 10.1016/0262-1746(83)90025-2; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANKOFSCHOTEN AA, 1982, EUR J PHARMACOL, V84, P123, DOI 10.1016/0014-2999(82)90168-6; VANKOLFSCHOTEN AA, 1981, J PHARM PHARMACOL, V33, P462; VARGAFTIG BB, 1973, EUR J PHARMACOL, V24, P283, DOI 10.1016/0014-2999(73)90151-9; WILLIS AL, 1972, PROSTAGLANDINS CELLU, P227; WOLFE LS, 1976, ADV PROSTAG THROMB R, V1, P345; YUNIGER JW, 1983, J PEDIATR, V82, P218; ZENSER TV, 1978, BIOCHIM BIOPHYS ACTA, V542, P486, DOI 10.1016/0304-4165(78)90378-1	52	90	91	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1989	84	1					26	33		10.1016/0091-6749(89)90174-7	http://dx.doi.org/10.1016/0091-6749(89)90174-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG120	2666482				2022-12-18	WOS:A1989AG12000005
J	FERGUSON, AC				FERGUSON, AC			PERSISTING AIRWAY-OBSTRUCTION IN ASYMPTOMATIC CHILDREN WITH ASTHMA WITH NORMAL PEAK EXPIRATORY FLOW-RATES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV BRITISH COLUMBIA,DEPT PAEDIAT,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia				Ferguson, Alexander C./0000-0002-3143-5619				BURR ML, 1974, ARCH DIS CHILD, V49, P923, DOI 10.1136/adc.49.12.923; CHAI H, 1968, J ALLERGY, V41, P23, DOI 10.1016/0021-8707(68)90005-1; COOPER DM, 1977, CHEST, V71, P361, DOI 10.1378/chest.71.3.361; FERGUSON AC, 1986, CAN MED ASSOC J, V134, P1365; GELB AF, 1973, NEW ENGL J MED, V288, P395, DOI 10.1056/NEJM197302222880805; GODFREY S, 1983, ASTHMA, P432; GREAVES IA, 1985, AUST NZ J MED, V15, P427, DOI 10.1111/j.1445-5994.1985.tb02765.x; Ho T F, 1981, J Singapore Paediatr Soc, V23, P42; HORE PM, 1982, NEW ZEAL MED J, V95, P458; ISENBERG PD, 1973, AM J DIS CHILD, V125, P341, DOI 10.1001/archpedi.1973.04160030021004; JOHNSTON IDA, 1984, THORAX, V39, P583, DOI 10.1136/thx.39.8.583; KRAEMER R, 1983, J PEDIATR-US, V102, P347, DOI 10.1016/S0022-3476(83)80646-5; MACKLEM PT, 1967, J APPL PHYSIOL, V22, P395, DOI 10.1152/jappl.1967.22.3.395; MARTIN AJ, 1980, AM REV RESPIR DIS, V122, P609; MCFADDEN ER, 1972, AM J MED, V52, P725, DOI 10.1016/0002-9343(72)90078-2; MOK JYQ, 1983, EUR J RESPIR DIS, V64, P487; MURRAY AB, 1981, CLIN ALLERGY, V11, P87, DOI 10.1111/j.1365-2222.1981.tb01570.x; MURRAY AB, 1977, LANCET, V1, P708; PAULI G, 1985, EUR J RESPIR DIS, V67, P369; Polgar G, 1971, PULMONARY FUNCTION T, P170; SLY PD, 1985, AM J DIS CHILD, V139, P479, DOI 10.1001/archpedi.1985.02140070053032; WENG TR, 1969, AM REV RESPIR DIS, V99, P719; 1983, CAN MED ASS J, V129, P828; 1986, DHHS NIH862107 PUBL	24	90	93	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1988	82	1					19	22		10.1016/0091-6749(88)90045-0	http://dx.doi.org/10.1016/0091-6749(88)90045-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P4004	3392366				2022-12-18	WOS:A1988P400400004
J	FALTHMAGNUSSON, K; KJELLMAN, NIM				FALTHMAGNUSSON, K; KJELLMAN, NIM			DEVELOPMENT OF ATOPIC DISEASE IN BABIES WHOSE MOTHERS WERE RECEIVING EXCLUSION DIET DURING PREGNANCY - A RANDOMIZED STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FALTHMAGNUSSON, K (corresponding author), LINKOPING UNIV HOSP, DEPT PEDIAT, S-58185 LINKOPING, SWEDEN.							BJORKSTEN F, 1976, CLIN ALLERGY, V6, P165, DOI 10.1111/j.1365-2222.1976.tb01894.x; BUSINCO L, 1983, CLIN ALLERGY, V13, P505; CHANDRA RK, 1986, CLIN ALLERGY, V16, P563, DOI 10.1111/j.1365-2222.1986.tb01995.x; CHANDRA RK, 1985, CLIN ALLERGY, V15, P517, DOI 10.1111/j.1365-2222.1985.tb02304.x; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; DANNAEUS A, 1978, ACTA PAEDIATR SCAND, V67, P497, DOI 10.1111/j.1651-2227.1978.tb16360.x; FALTHMAGNUSSON K, 1987, ALLERGY, V42, P64, DOI 10.1111/j.1398-9995.1987.tb02189.x; FORD RPK, 1982, ARCH DIS CHILD, V57, P649, DOI 10.1136/adc.57.9.649; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; GERRARD JW, 1986, ANN ALLERGY, V56, P351; GLASER J, 1953, JAMA-J AM MED ASSOC, V153, P620, DOI 10.1001/jama.1953.02940240012003; HAMBURGER RN, 1983, ANN ALLERGY, V51, P281; HANIFIN JM, 1977, ARCH DERMATOL, V113, P663, DOI 10.1001/archderm.113.5.663; JAKOBSSON I, 1985, ACTA PAEDIATR SCAND, V74, P342, DOI 10.1111/j.1651-2227.1985.tb10981.x; JARRETT EEE, 1984, IMMUNOLOGY, V53, P365; KAUFMAN H S, 1971, Clinical Allergy, V1, P363, DOI 10.1111/j.1365-2222.1971.tb00787.x; KILSHAW PJ, 1984, INT ARCH ALLER A IMM, V75, P8, DOI 10.1159/000233582; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P601, DOI 10.1111/j.1651-2227.1976.tb04939.x; MELLANDER L, 1986, CLIN EXP IMMUNOL, V63, P555; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; MILLER DL, 1973, J ALLERGY CLIN IMMUN, V52, P182, DOI 10.1016/0091-6749(73)90035-3; SAARINEN UM, 1979, LANCET, V2, P163; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x; VANASPEREN PP, 1984, CLIN ALLERGY, V14, P525; VANASPEREN PP, 1984, ACTA PAEDIATR SCAND, V73, P80; WITTIG HJ, 1978, ANN ALLERGY, V41, P84; ZEIGER RS, 1985, J ALLERGY CLIN IMMUN, V75, P633, DOI 10.1016/0091-6749(85)90086-7	27	90	91	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1987	80	6					868	875		10.1016/S0091-6749(87)80279-8	http://dx.doi.org/10.1016/S0091-6749(87)80279-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L5020	3693764	Bronze			2022-12-18	WOS:A1987L502000016
J	WITT, C; STUCKEY, MS; WOOLCOCK, AJ; DAWKINS, RL				WITT, C; STUCKEY, MS; WOOLCOCK, AJ; DAWKINS, RL			POSITIVE ALLERGY PRICK TESTS ASSOCIATED WITH BRONCHIAL HISTAMINE RESPONSIVENESS IN AN UNSELECTED POPULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SYDNEY,DEPT MED,SYDNEY,NSW 2006,AUSTRALIA; STATE HLTH SEROL LABS,PERTH,WA,AUSTRALIA	University of Sydney								BEER DJ, 1982, NEW ENGL J MED, V306, P454, DOI 10.1056/NEJM198202253060804; BERGMAN RK, 1966, P SOC EXP BIOL MED, V122, P428; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BRYANT DH, 1976, CLIN ALLERGY, V6, P373, DOI 10.1111/j.1365-2222.1976.tb01919.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; COOKSON DU, 1963, AM REV RESPIR DIS, V88, P636; Laitinen L A, 1974, Scand J Respir Dis Suppl, V86, P1; MAKINO S, 1966, J ALLERGY, V38, P127, DOI 10.1016/0021-8707(66)90036-0; PAUWELS R, 1980, INT ARCH ALLER A IMM, V61, P347, DOI 10.1159/000232458; Pepys J, 1975, CLIN ASPECTS IMMUNOL, P55; REED CE, 1972, J ALLERGY CLIN IMMUN, V49, P174, DOI 10.1016/0091-6749(72)90111-X; SHELHAMER JH, 1980, J ALLERGY CLIN IMMUN, V66, P52, DOI 10.1016/0091-6749(80)90138-4; STUCKEY MS, 1985, J ALLERGY CLIN IMMUN, V75, P373, DOI 10.1016/0091-6749(85)90074-0; TOWNLEY RG, 1967, J ALLERGY, V39, P177, DOI 10.1016/0021-8707(67)90036-6; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	16	90	90	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1986	77	5					698	702		10.1016/0091-6749(86)90413-6	http://dx.doi.org/10.1016/0091-6749(86)90413-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C3903	3700894				2022-12-18	WOS:A1986C390300011
J	GREENBERGER, PA				GREENBERGER, PA			CONTRAST-MEDIA REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GREENBERGER, PA (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611, USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NIAID NIH HHS [AI 11759] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMEN T, 1973, Acta Radiologica Supplementum, V335, P233; ALMENT T, 1980, INVEST RADIOL, V15, pS1; ANSELL G, 1970, INVEST RADIOL, V5, P374, DOI 10.1097/00004424-197011000-00002; ANSELL G, 1980, INVEST RADIOL, V15, pS32, DOI 10.1097/00004424-198011001-00010; ARROYAVE CM, 1976, J IMMUNOL, V117, P1866; AUSMAN J I, 1964, J Surg Res, V4, P349, DOI 10.1016/S0022-4804(64)80082-2; BRASCH RC, 1980, INVEST RADIOL, V15, pS29, DOI 10.1097/00004424-198011001-00009; COGEN FC, 1979, J ALLERGY CLIN IMMUN, V64, P229; COLEMAN WP, 1964, SOUTHERN MED J, V57, P1401, DOI 10.1097/00007611-196412000-00004; FISCHER HW, 1972, RADIOLOGY, V103, P497, DOI 10.1148/103.3.497; FREYRIA AM, 1982, J ALLERGY CLIN IMMUN, V69, P397, DOI 10.1016/0091-6749(82)90152-X; GOLMAN K, 1980, INVEST RADIOL, V15, pS61, DOI 10.1097/00004424-198011001-00015; GONSETTE RE, 1980, INVEST RADIOL, V15, pS26, DOI 10.1097/00004424-198011001-00008; GREENBERGER PA, J ALLERGY CLIN IMMUN; KELLY JF, 1978, J ALLERGY CLIN IMMUN, V62, P181, DOI 10.1016/0091-6749(78)90104-5; LASSER EC, 1979, J ALLERGY CLIN IMMUN, V64, P105, DOI 10.1016/0091-6749(79)90043-5; LASSER EC, 1977, RADIOLOGY, V125, P1; LASSER EC, 1968, RADIOLOGY, V91, P63, DOI 10.1148/91.1.63; LASSER EC, 1970, INVEST RADIOL, V5, P446; LASSER EC, 1979, AM J ROENTGENOL, V132, P171, DOI 10.2214/ajr.132.2.171; LASSER EC, 1981, RADIOLOGY, V140, P11, DOI 10.1148/radiology.140.1.6166025; LASSER EC, 1980, INVEST RADIOL, V15, pS6, DOI 10.1097/00004424-198011001-00004; LEPOW IRWIN H., 1965, CIBA FOUND SYMP, P74, DOI 10.1002/9780470719381.ch4; LORENZ W, 1980, AGENTS ACTIONS, V10, P114, DOI 10.1007/BF02024192; PFISTER RC, 1980, INVEST RADIOL, V15, pS239, DOI 10.1097/00004424-198011001-00050; RAPOPORT S, 1982, RADIOLOGY, V143, P321, DOI 10.1148/radiology.143.2.7071332; RING J, 1978, CLIN EXP IMMUNOL, V34, P302; SCHATZ M, 1975, J ALLERGY CLIN IMMUN, V55, P358, DOI 10.1016/0091-6749(75)90007-X; SHEHADI WH, 1982, RADIOLOGY, V143, P11, DOI 10.1148/radiology.143.1.7063711; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; SIEGLE RL, 1976, INVEST RADIOL, V11, P93; SIMON RA, 1979, J ALLERGY CLIN IMMUN, V63, P281, DOI 10.1016/0091-6749(79)90114-3; SMALL P, 1982, CLIN ALLERGY, V12, P289, DOI 10.1111/j.1365-2222.1982.tb02530.x; SWARTZ RD, 1978, AM J MED, V65, P31, DOI 10.1016/0002-9343(78)90689-7; TURNER E, 1982, RADIOLOGY, V143, P327, DOI 10.1148/radiology.143.2.7071333; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832, DOI 10.2214/ajr.119.4.832; WITTEN DM, 1975, JAMA-J AM MED ASSOC, V231, P974; ZWEIMAN B, 1975, ANN INTERN MED, V83, P159, DOI 10.7326/0003-4819-83-2-159	38	90	91	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					600	605		10.1016/0091-6749(84)90113-1	http://dx.doi.org/10.1016/0091-6749(84)90113-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ163	6491107				2022-12-18	WOS:A1984TQ16300010
J	NADEL, JA				NADEL, JA			INFLAMMATION AND ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NADEL, JA (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; GOETZL EJ, 1983, J EXP MED, V158, P731, DOI 10.1084/jem.158.3.731; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; HOLTZMAN MJ, 1983, BIOCHEM BIOPH RES CO, V114, P1071, DOI 10.1016/0006-291X(83)90671-X; HOLTZMAN MJ, 1983, J APPL PHYSIOL, V55, P1232, DOI 10.1152/jappl.1983.55.4.1232; LEE LY, 1977, J APPL PHYSIOL, V43, P626, DOI 10.1152/jappl.1977.43.4.626; NADEL JA, ASTHMA PHYSL IMMUNOP	7	90	92	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					651	653		10.1016/0091-6749(84)90299-9	http://dx.doi.org/10.1016/0091-6749(84)90299-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS046	6325524				2022-12-18	WOS:A1984SS04600006
J	VANASPEREN, PP; KEMP, AS; MELLIS, CM				VANASPEREN, PP; KEMP, AS; MELLIS, CM			SKIN-TEST REACTIVITY AND CLINICAL ALLERGEN SENSITIVITY IN INFANCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL ALEXANDRA HOSP CHILDREN,DEPT IMMUNOL,CAMPERDOWN,NSW 2050,AUSTRALIA; ROYAL ALEXANDRA HOSP CHILDREN,DEPT RESP MED,CAMPERDOWN,NSW 2050,AUSTRALIA									ADKINSON NF, 1980, J ALLERGY CLIN IMMUN, V65, P1, DOI 10.1016/0091-6749(80)90169-4; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; CHANDRA RK, 1979, ACTA PAEDIATR SCAND, V68, P691, DOI 10.1111/j.1651-2227.1979.tb18439.x; CHIPPS BE, 1978, ANN ALLERGY, V41, P211; COGSWELL JJ, 1982, BRIT MED J, V284, P1011, DOI 10.1136/bmj.284.6321.1011; DANNAEUS A, 1978, ACTA PAEDIATR SCAND, V67, P497, DOI 10.1111/j.1651-2227.1978.tb16360.x; FOUCARD T, 1973, ACTA PAEDIATR SCAND, V62, P633, DOI 10.1111/j.1651-2227.1973.tb17078.x; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; HANIFIN JM, 1982, J AM ACAD DERMATOL, V6, P1, DOI 10.1016/S0190-9622(82)70001-5; JARRETT EEE, 1977, LANCET, V2, P233; JOHNSTONE DE, 1977, ANN ALLERGY, V38, P387; KAUFMAN H S, 1971, Clinical Allergy, V1, P363, DOI 10.1111/j.1365-2222.1971.tb00787.x; KAUFMAN HS, 1981, CLIN ALLERGY, V11, P549, DOI 10.1111/j.1365-2222.1981.tb02173.x; KJELLMAN NIM, 1979, CLIN ALLERGY, V9, P347, DOI 10.1111/j.1365-2222.1979.tb02493.x; MATTHEW DJ, 1977, LANCET, V1, P321; MAY CD, 1978, ALLERGY, V33, P166, DOI 10.1111/j.1398-9995.1978.tb01532.x; MITCHELL EB, 1982, LANCET, V1, P127; Mygind N, 1978, NASAL ALLERGY, P140; ORGEL HA, 1977, ANN ALLERGY, V39, P161; PEPYS J, 1972, P ROY SOC MED, V65, P271, DOI 10.1177/003591577206500320; SOOTHILL JF, 1976, CLIN ALLERGY, V6, P305, DOI 10.1111/j.1365-2222.1976.tb01911.x; STEVENSON DD, 1971, J ALLERGY CLIN IMMUN, V48, P61, DOI 10.1016/0091-6749(71)90088-1; Sulzberger MB, 1940, ARCH DERMATOL SYPH, V41, P1029, DOI 10.1001/archderm.1940.01490120031004; VANASPEREN PP, 1980, MED J AUSTRALIA, V2, P266; WOOLCOCK AJ, 1976, AUST NZ J MED, V6, P158, DOI 10.1111/j.1445-5994.1976.tb03313.x	26	90	91	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	3					381	386		10.1016/0091-6749(84)90412-3	http://dx.doi.org/10.1016/0091-6749(84)90412-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SK155	6699318				2022-12-18	WOS:A1984SK15500013
J	HIGBEE, MD; KUMAR, M; GALANT, SP				HIGBEE, MD; KUMAR, M; GALANT, SP			STIMULATION OF ENDOGENOUS CATECHOLAMINE RELEASE BY THEOPHYLLINE - A PROPOSED ADDITIONAL MECHANISM OF ACTION FOR THEOPHYLLINE EFFECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WARNER LAMBERT PARKE DAVIS, DIV CLIN RES, ANN ARBOR, MI 48105 USA; UNIV CALIF IRVINE, DEPT PEDIAT, IRVINE, CA 92717 USA; MEMORIAL HOSP, MED CTR, LONG BEACH, CA 90801 USA	Pfizer; University of California System; University of California Irvine	HIGBEE, MD (corresponding author), UNIV UTAH, COLL PHARM, SALT LAKE CITY, UT 84112 USA.							ATUK NO, 1967, CIRCULATION, V35, P745, DOI 10.1161/01.CIR.35.4.745; BELLET S, 1969, METABOLIS, V18, P288, DOI 10.1016/0026-0495(69)90049-3; BERGSTRAND H, 1980, EUR J RESPIR DIS, V61, P37; BERKOWITZ BA, 1971, EUR J PHARMACOL, V13, P193, DOI 10.1016/0014-2999(71)90150-6; COFFEY RG, 1977, COMPREHENSIVE IMMUNO, V3, P203; FREDHOLM BB, 1980, EUR J RESPIR DIS, V61, P29; HORROBIN DF, 1977, PROSTAGLANDINS, V13, P33, DOI 10.1016/0090-6980(77)90040-5; JAMES GWL, 1967, J PHARM PHARMACOL, V19, P797, DOI 10.1111/j.2042-7158.1967.tb09546.x; KOLBECK RC, 1977, LUNG, V156, P178; LEVI L, 1967, ACTA MED SCAND, V181, P431; PEACH MJ, 1972, P NATL ACAD SCI USA, V69, P834, DOI 10.1073/pnas.69.4.834; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; POISNER AM, 1973, BIOCHEM PHARMACOL, V22, P469, DOI 10.1016/0006-2952(73)90288-8; POLSON JB, 1979, BIOCHEM PHARMACOL, V28, P1319; RALL TW, 1981, PHARMACOL BASIS THER, P592; ROBERTSON D, 1978, NEW ENGL J MED, V298, P181, DOI 10.1056/NEJM197801262980403; ROBERTSON D, 1979, CIRCULATION, V59, P637, DOI 10.1161/01.CIR.59.4.637; STRUBELT O, 1969, ARCH INT PHARMACOD T, V179, P215; VANDENBERG W, 1980, ANN ALLERGY, V44, P235; VESTAL RE, 1981, CLIN RES, V29, pA23	20	90	91	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	5					377	382		10.1016/0091-6749(82)90028-8	http://dx.doi.org/10.1016/0091-6749(82)90028-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PQ105	7130553				2022-12-18	WOS:A1982PQ10500010
J	VERVLOET, D; ARNAUD, A; VELLIEUX, P; KAPLANSKI, S; CHARPIN, J				VERVLOET, D; ARNAUD, A; VELLIEUX, P; KAPLANSKI, S; CHARPIN, J			ANAPHYLACTIC REACTIONS TO MUSCLE-RELAXANTS UNDER GENERAL-ANESTHESIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											VERVLOET, D (corresponding author), HOP ST MARGUERITE,DEPT CHEST DIS,PHYSIOLPATHOL ASTHMA & OBSTRUCT SYNDROMES UNIT,CTR,F-13274 MARSEILLE 2,FRANCE.							BERNSTEIN IL, 1977, INT ARCH ALLER A IMM, V55, P215, DOI 10.1159/000231929; CHAN CS, 1972, BRIT J ANAESTH, V44, P103, DOI 10.1093/bja/44.1.103; CLARK RM, 1973, BRIT J ANAESTH, V45, P997, DOI 10.1093/bja/45.9.997; COMROE JH, 1946, ANESTHESIOLOGY, V7, P260, DOI 10.1097/00000542-194605000-00003; EVANS JM, 1977, BRIT MED J, V2, P735, DOI 10.1136/bmj.2.6089.735; EVANS R, 1972, J ALLERGY CLIN IMMUN, V49, P285, DOI 10.1016/0091-6749(72)90096-6; HAINSWORTH AM, 1970, ANAESTHESIA, V25, P105, DOI 10.1111/j.1365-2044.1970.tb00163.x; LICHTENSTEIN LM, 1977, ASTHMA PHYSL IMMUNOP, P97; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MONERETVAUTRIN DA, 1975, REV FR ALLERGOL, V15, P93, DOI 10.1016/S0335-7457(75)80019-0; MONGAR JL, 1953, J PHYSIOL-LONDON, V120, P146, DOI 10.1113/jphysiol.1953.sp004881; REMACLEBONNET MM, 1976, J IMMUNOL, V117, P1145; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SIRAGANIAN RP, 1977, J IMMUNOL, V119, P2078; WESTGATE HD, 1961, ANESTHESIOLOGY, V22, P286, DOI 10.1097/00000542-196103000-00019	15	90	90	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	5					348	353		10.1016/0091-6749(79)90130-1	http://dx.doi.org/10.1016/0091-6749(79)90130-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GU943	85651	Bronze			2022-12-18	WOS:A1979GU94300009
J	SCHWARTZ, HJ; CITRON, KM; CHESTER, EH; KAIMAL, J; BARLOW, PB; BAUM, GL; SCHUYLER, MR				SCHWARTZ, HJ; CITRON, KM; CHESTER, EH; KAIMAL, J; BARLOW, PB; BAUM, GL; SCHUYLER, MR			COMPARISON OF PREVALENCE OF SENSITIZATION TO ASPERGILLUS ANTIGENS AMONG ASTHMATICS IN CLEVELAND AND LONDON	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM HOSP, DEPT MED, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT MED, CLEVELAND, OH 44106 USA; BROMPTON HOSP, DEPT MED, LONDON SW3 6HP, ENGLAND	Case Western Reserve University; Royal Brompton Hospital								Dixon WJ, 1969, INTRO STATISTICAL AN, P237; FERRIS BG, 1965, AM REV RESPIR DIS, V91, P252; HENDERSON AH, 1968, THORAX, V23, P513, DOI 10.1136/thx.23.5.513; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; HOEHNE J, 1971, J LAB CLIN MED, V78, P1007; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; HYDE H A, 1972, Clinical Allergy, V2, P153, DOI 10.1111/j.1365-2222.1972.tb01280.x; LONGBOTTOM JL, 1964, J PATHOL BACTERIOL, V88, P141, DOI 10.1002/path.1700880119; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; NEWTON ANNA, 1948, ANN ALLERGY, V6, P260; NOBLE WC, 1963, J GEN MICROBIOL, V32, P397, DOI 10.1099/00221287-32-3-397; PEPYS J, 1972, P ROY SOC MED, V65, P271, DOI 10.1177/003591577206500320; SOLOMON WR, 1976, J ALLERGY CLIN IMMUN, V57, P46, DOI 10.1016/0091-6749(76)90078-6	15	90	92	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	1					9	14		10.1016/0091-6749(78)90065-9	http://dx.doi.org/10.1016/0091-6749(78)90065-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG870	350936				2022-12-18	WOS:A1978FG87000003
J	Phillips, EJ; Bigliardi, P; Bircher, AJ; Broyles, A; Chang, YS; Chung, WH; Lehloenya, R; Mockenhaupt, M; Peter, J; Pirmohamed, M; Roujeau, JC; Shear, NH; Tanno, LK; Trubiano, J; Valluzzi, R; Barbaud, A				Phillips, Elizabeth J.; Bigliardi, Paul; Bircher, Andreas J.; Broyles, Ana; Chang, Yoon-Seok; Chung, Wen-Hung; Lehloenya, Rannakoe; Mockenhaupt, Maja; Peter, Jonny; Pirmohamed, Munir; Roujeau, Jean-Claude; Shear, Neil H.; Tanno, Luciana Kase; Trubiano, Jason; Valluzzi, Rocco; Barbaud, Annick			Controversies in drug allergy: Testing for delayed reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Delayed; intradermal; prick; patch; oral challenge; HLA; acute generalized exanthematous pustulosis; fixed drug eruption; drug reaction with eosinophilia and systemic symptoms; Stevens-Johnson syndrome/toxic epidermal necrolysis	SKIN-TEST CONCENTRATIONS; HYPERSENSITIVITY; CARBAMAZEPINE; SENSITIVITY; GENOTYPE; SCIENCE; MARKER	Controversies exist with regard to in vivo approaches to delayed immunologically mediated adverse drug reactions, such as exanthem (maculopapular eruption), drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, Stevens-Johnson syndrome/toxic epidermal necrolysis, and fixed drug eruptions. In particular, widespread differences exist between regions and practice on the availability and use of intradermal and patch testing, the standard drug concentrations used, the use of additional drugs in intradermal and patch testing to help determine cross-reactivity, the timing of testing in relation to the occurrence of the adverse drug reaction, the use of testing in specific phenotypes, and the use of oral challenge in conjunction with delayed intradermal and patch testing to ascertain drug tolerance. It was noted that there have been advances in the science of delayed T cell-mediated reactions that have shed light on immunopathogenesis and provided a mechanism of preprescription screening in the case of HLA-B*57:01 and abacavir hypersensitivity and HLA-B*15:02 and carbamazepine Stevens-Johnson syndrome/toxic epidermal necrolysis in Southeast Asian subjects. Future directions should include the collaboration of large international networks to develop and standardize in vivo diagnostic approaches, such as skin testing and patch testing, combined with ex vivo and in vitro laboratory approaches.	[Phillips, Elizabeth J.] Vanderbilt Univ, Med Ctr, 1161 21st Ave South,A-2200 Med Ctr North, Nashville, TN 37332 USA; [Phillips, Elizabeth J.] Inst Immunol & Infect Dis, Murdoch, WA, Australia; [Bigliardi, Paul] Univ Minnesota, Dept Dermatol, Dermatoallergy Div, Minneapolis, MN 55455 USA; [Bircher, Andreas J.] Univ Basel, Univ Hosp, Dept Dermatol, Allergy Unit, Basel, Switzerland; [Broyles, Ana] Boston Childrens Hosp, Boston, MA USA; [Broyles, Ana] Harvard Med Sch, Boston, MA USA; [Chang, Yoon-Seok] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Internal Med, Seongnam, South Korea; [Chung, Wen-Hung] Chang Gung Mem Hosp, Drug Hypersensit Clin & Res Ctr, Dept Dermatol, Taipei, Taiwan; [Chung, Wen-Hung] Chang Gung Mem Hosp, Drug Hypersensit Clin & Res Ctr, Dept Dermatol, Linkou, Taiwan; [Chung, Wen-Hung] Chang Gung Mem Hosp, Drug Hypersensit Clin & Res Ctr, Dept Dermatol, Keelung, Taiwan; [Lehloenya, Rannakoe; Peter, Jonny] Univ Cape Town, Dept Med, Div Dermatol, Rondebosch, South Africa; [Lehloenya, Rannakoe; Peter, Jonny] Univ Cape Town, Dept Med, Combined Drug Allergy Clin, Rondebosch, South Africa; [Mockenhaupt, Maja] Univ Freiburg, Med Ctr, Dept Dermatol, Dokumentat Zentrum Schwerer Hautreaktionen DZh, Freiburg, Germany; [Mockenhaupt, Maja] Univ Freiburg, Fac Med, Freiburg, Germany; [Pirmohamed, Munir] Univ Liverpool, Dept Mol & Clin Pharmacol, Ctr Drug Safety Sci, Liverpool, Merseyside, England; [Roujeau, Jean-Claude] Univ ~ Paris Est Creteil, Creteil, France; [Shear, Neil H.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Div Dermatol, Toronto, ON, Canada; [Tanno, Luciana Kase] Univ Hosp Montpellier, Montpellier, France; [Tanno, Luciana Kase] Sorbonne Univ, INSERM, Paris, France; [Tanno, Luciana Kase] Hosp Sirio Libanes, Sao Paulo, Brazil; [Trubiano, Jason] Univ Melbourne, Austin Hlth, Dept Infect Dis, Heidelberg, Vic, Australia; [Trubiano, Jason] Univ Melbourne, Austin Hlth, Ctr Antibiot Allergy & Res, Heidelberg, Vic, Australia; [Trubiano, Jason] Peter MacCallum Canc Ctr, Dept Infect Dis, Natl Ctr Infect Canc, Parkville, Vic, Australia; [Valluzzi, Rocco] Pediat Hosp Bambino Gesu, Dept Allergy, Vatican City, Vatican; [Barbaud, Annick] Sorbonne Univ, Tenon Hosp, Dermatol & Allergy Dept, Paris, France; [Barbaud, Annick] AP HP, Paris, France	Vanderbilt University; University of Minnesota System; University of Minnesota Twin Cities; University of Basel; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Seoul National University (SNU); Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; University of Cape Town; University of Cape Town; University of Freiburg; University of Freiburg; University of Liverpool; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Hospital Sirio Libanes; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Peter Maccallum Cancer Center; IRCCS Bambino Gesu; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP)	Phillips, EJ (corresponding author), Vanderbilt Univ, Med Ctr, 1161 21st Ave South,A-2200 Med Ctr North, Nashville, TN 37332 USA.	elizabeth.j.phillips@vanderbilt.edu	, barbaud/AAZ-7250-2021; Pirmohamed, Munir/H-6004-2011; Chang, Yoon-Seok/J-5628-2012; Tanno, Luciana Kase/J-9981-2014; Valluzzi, Rocco Luigi/Q-3879-2019	Pirmohamed, Munir/0000-0002-7534-7266; Chang, Yoon-Seok/0000-0003-3157-0447; Tanno, Luciana Kase/0000-0003-3236-1225; Valluzzi, Rocco Luigi/0000-0003-0029-6254; Bigliardi, Paul Lorenz/0000-0003-4567-9080; Peter, Jonathan/0000-0002-2658-0723; Trubiano, Jason/0000-0002-5111-6367; Hung, Shuen-Iu/0000-0001-6531-5538	MRC [MR/L006758/1] Funding Source: UKRI; FOGARTY INTERNATIONAL CENTER [K43TW011178] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI110527, R34AI136815, R21AI139021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM115305] Funding Source: NIH RePORTER; FIC NIH HHS [K43 TW011178] Funding Source: Medline; Medical Research Council [MR/L006758/1] Funding Source: Medline; NIAID NIH HHS [P30 AI110527, R34 AI136815, R21 AI139021] Funding Source: Medline; NIGMS NIH HHS [P50 GM115305] Funding Source: Medline; Department of Health Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Department of Health		Abana CO, 2017, J IMMUNOL, V199, P3187, DOI 10.4049/jimmunol.1700851; Assier H, 2017, CONTACT DERMATITIS, V77, P297, DOI 10.1111/cod.12842; Azimi E, 2017, BRIEF COMMUNICATION, V2; Barbaud A, 2001, CONTACT DERMATITIS, V45, P321, DOI 10.1034/j.1600-0536.2001.450601.x; Barbaud A, 2013, BRIT J DERMATOL, V168, P555, DOI 10.1111/bjd.12125; Barbaud A, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0442-8; Barbaud A, 2009, IMMUNOL ALLERGY CLIN, V29, P517, DOI 10.1016/j.iac.2009.04.010; Brajon D, 2014, CONTACT DERMATITIS, V71, P170, DOI 10.1111/cod.12269; Brockow K, 2013, ALLERGY, V68, P702, DOI 10.1111/all.12142; Brockow K, 2002, ALLERGY, V57, P45; Chen DY, 2015, ANN RHEUM DIS, V74, DOI 10.1136/annrheumdis-2013-203893; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379; Demoly P, 2010, ALLERGY, V65, P327, DOI 10.1111/j.1398-9995.2009.02228.x; Derrick MI, 2018, J ALLER CL IMM-PRACT, V6, P302, DOI 10.1016/j.jaip.2017.08.003; Empedrad R, 2003, J ALLERGY CLIN IMMUN, V112, P629, DOI 10.1067/mai.2003.1690; Garon SL, 2017, BRIT J CLIN PHARMACO, V83, P1896, DOI 10.1111/bcp.13294; Gomes E., 2005, ALLERGY CLIN IMMUNOL, V17, P9; Illing PT, 2012, NATURE, V486, P554, DOI 10.1038/nature11147; la Tour AT, 2018, J ALLER CL IMM-PRACT, V6, P1321, DOI 10.1016/j.jaip.2017.10.008; Lammintausta K, 2005, ACTA DERM-VENEREOL, V85, P491, DOI 10.1080/00015550510042859; Lin YT, 2013, J EUR ACAD DERMATOL, V27, P356, DOI 10.1111/j.1468-3083.2011.04418.x; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Mayorga C, 2016, ALLERGY, V71, P1103, DOI 10.1111/all.12886; Mayorga C, 2019, J ALLERGY CLIN IMMUN, V143, P56, DOI 10.1016/j.jaci.2018.09.022; McCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Mill C, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0033; Mushiroda T, 2018, JAMA NEUROL, V75, P842, DOI 10.1001/jamaneurol.2018.0278; Ostrov DA, 2012, P NATL ACAD SCI USA, V109, P9959, DOI 10.1073/pnas.1207934109; Pavlos R, 2017, IMMUNOL ALLERGY CLIN, V37, P785, DOI 10.1016/j.iac.2017.07.007; Peter JG, 2017, J ALLER CL IMM-PRACT, V5, P547, DOI 10.1016/j.jaip.2017.01.025; Phillips E, 2001, ALLERGY, V56, P790, DOI 10.1034/j.1398-9995.2001.056008790.x; Phillips EJ, 2002, AIDS, V16, P2223, DOI 10.1097/00002030-200211080-00017; Phillips EJ, 2018, CLIN PHARMACOL THER, V103, P574, DOI 10.1002/cpt.1004; Saag M, 2008, CLIN INFECT DIS, V46, P1111, DOI 10.1086/529382; Solensky R, 2010, ANN ALLERG ASTHMA IM, V105, P259, DOI 10.1016/j.anai.2010.08.002; Trautmann A, 2017, J ALLER CL IMM-PRACT, V5, P1650, DOI 10.1016/j.jaip.2017.03.032; Trubiano JA, 2018, J ALLERGY CLIN IMMUN; Trubiano JA, 2018, J ALLER CL IMM-PRACT, V6, P1287, DOI 10.1016/j.jaip.2017.09.004; Waton J, 2011, ALLERGY, V66, P941, DOI 10.1111/j.1398-9995.2011.02554.x; White KD, 2018, J ALLER CL IMM-PRACT, V6, P38, DOI 10.1016/j.jaip.2017.11.023; White KD, 2015, J ALLERGY CLIN IMMUN, V136, P219, DOI 10.1016/j.jaci.2015.05.050; Zhang FR, 2013, NEW ENGL J MED, V369, P1620, DOI 10.1056/NEJMoa1213096	44	89	89	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					66	73		10.1016/j.jaci.2018.10.030	http://dx.doi.org/10.1016/j.jaci.2018.10.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30573342	Green Accepted, Bronze, Green Published			2022-12-18	WOS:000454918300007
J	Dzidic, M; Abrahamsson, TR; Artacho, A; Bjorksten, B; Collado, MC; Mira, A; Jenmalm, MC				Dzidic, Majda; Abrahamsson, Thomas R.; Artacho, Alejandro; Bjorksten, Bengt; Carmen Collado, Maria; Mira, Alex; Jenmalm, Maria C.			Aberrant IgA responses to the gut microbiota during infancy precede asthma and allergy development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic disease; asthma; secretory IgA; IgA index; IgA recognition patterns; microbiome composition; gut microbiota; childhood	BREAST-MILK; INTESTINAL MICROBIOTA; IMMUNOGLOBULIN-A; ATOPIC ECZEMA; REDUCED DIVERSITY; CONTROLLED-TRIAL; SECRETORY IGA; EARLY-LIFE; 1ST YEAR; IMMUNITY	Background: Although a reduced gut microbiota diversity and low mucosal total IgA levels in infancy have been associated with allergy development, IgA responses to the gut microbiota have not yet been studied. Objective: We sought to determine the proportions of IgA coating together with the characterization of the dominant bacteria, bound to IgA or not, in infant stool samples in relation to allergy development. Methods: A combination of flow cytometric cell sorting and deep sequencing of the 16S rDNA gene was used to characterize the bacterial recognition patterns by IgA in stool samples collected at 1 and 12 months of age from children staying healthy or having allergic symptoms up to 7 years of age. Results: The children with allergic manifestations, particularly asthma, during childhood had a lower proportion of IgA bound to fecal bacteria at 12months of age compared with healthy children. These alterations cannot be attributed to differences in IgA levels or bacterial load between the 2 groups. Moreover, the bacterial targets of early IgA responses (including coating of the Bacteroides genus), as well as IgA recognition patterns, differed between healthy children and children with allergic manifestations. Altered IgA recognition patterns in children with allergy were observed already at 1 month of age, when the IgA antibodies are predominantly maternally derived in breast-fed children. Conclusion: An aberrant IgAresponsiveness to the gutmicrobiota during infancy precedes asthma and allergy development, possibly indicating an impaired mucosal barrier function in allergic children.	[Dzidic, Majda; Jenmalm, Maria C.] Linkoping Univ, Dept Clin & Expt Med, Unit Autoimmun & Immune Regulat, S-58183 Linkoping, Sweden; [Abrahamsson, Thomas R.] Linkoping Univ, Dept Clin & Expt Med, Div Paediat, S-58183 Linkoping, Sweden; [Dzidic, Majda; Artacho, Alejandro; Mira, Alex] FISABIO Fdn, Ctr Adv Res Publ Hlth, Dept Hlth & Genom, Valencia, Spain; [Bjorksten, Bengt] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Dzidic, Majda; Carmen Collado, Maria] Spanish Natl Res Council, CSIC, IATA, Inst Agrochem & Food Technol,Dept Biotechnol,Unit, Valencia, Spain	Linkoping University; Linkoping University; Karolinska Institutet; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA)	Jenmalm, MC (corresponding author), Linkoping Univ, Dept Clin & Expt Med, AIR Clin Immunol, S-58185 Linkoping, Sweden.; Mira, A (corresponding author), Ave Cataluna 21, Valencia 46020, Spain.	mira_ale@gva.es; maria.jenmalm@liu.se	COLLADO, MARIA CARMEN/H-4924-2012; Artacho, Alejandro/Z-4613-2019; Jenmalm, Maria C/C-9679-2009	COLLADO, MARIA CARMEN/0000-0002-6204-4864; Jenmalm, Maria C/0000-0002-2117-5366; Mira, Alex/0000-0002-9127-3877	Swedish Research Council [K2011-56X-21854-01-06]; Swedish Heart-Lung Foundation [20140321]; Ekhaga Foundation [210-53]; Medical Research Council of Southeast Sweden; Olle Engqvist Foundation; Cancer and Allergy Foundation; University Hospital of Linkoping, Sweden; Spanish MINECO [2012-40007]	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Ekhaga Foundation; Medical Research Council of Southeast Sweden(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Olle Engqvist Foundation; Cancer and Allergy Foundation; University Hospital of Linkoping, Sweden; Spanish MINECO(Spanish Government)	Supported by the Swedish Research Council (K2011-56X-21854-01-06); the Swedish Heart-Lung Foundation (20140321); the Ekhaga Foundation (210-53); the Medical Research Council of Southeast Sweden; the Olle Engqvist Foundation; the Cancer and Allergy Foundation; the University Hospital of Linkoping, Sweden; and grant 2012-40007 from Spanish MINECO (to A.M.).	Abrahamsson TR, 2014, CLIN EXP ALLERGY, V44, P842, DOI 10.1111/cea.12253; Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; Abrahamsson TR, 2015, PEDIATR RES, V77, P214, DOI 10.1038/pr.2014.165; Abrahamsson TR, 2013, PEDIAT ALLERG IMM-UK, V24, P556, DOI 10.1111/pai.12104; Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; ACHI R, 1992, J INFECTION, V25, P89, DOI 10.1016/0163-4453(92)93657-C; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Arrieta MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00427; Azad MB, 2015, CLIN EXP ALLERGY, V45, P632, DOI 10.1111/cea.12487; Backhed F, 2015, CELL HOST MICROBE, V17, P852, DOI 10.1016/j.chom.2015.05.012; Benitez-Paez A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057782; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Blankenberg D, 2014, METHODS MOL BIOL, V1150, P21, DOI 10.1007/978-1-4939-0512-6_2; Bridgman SL, 2016, J DEV ORIG HLTH DIS, V7, P68, DOI 10.1017/S2040174415007862; Brix S, 2015, J ALLERGY CLIN IMMUN, V135, P277, DOI 10.1016/j.jaci.2014.09.036; Bunker JJ, 2015, IMMUNITY, V43, P541, DOI 10.1016/j.immuni.2015.08.007; Carrero JC, 2007, PARASITE IMMUNOL, V29, P331, DOI 10.1111/j.1365-3024.2007.00955.x; Chen WHC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039039; Christmann BS, 2015, J ALLERGY CLIN IMMUN, V136, P1378, DOI 10.1016/j.jaci.2015.03.036; Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879; Corthesy B, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00185; Cullender TC, 2013, CELL HOST MICROBE, V14, P571, DOI 10.1016/j.chom.2013.10.009; Dray S, 2007, J STAT SOFTW, V22, P1, DOI 10.18637/jss.v022.i04; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Fageras M, 2011, PEDIATR RES, V70, P572, DOI 10.1203/PDR.0b013e318232169e; Forno Erick, 2008, Clin Mol Allergy, V6, P11, DOI 10.1186/1476-7961-6-11; Fuchs O, 2013, LANCET RESP MED, V1, P743, DOI 10.1016/S2213-2600(13)70145-0; Gustafson CE, 2014, MUCOSAL IMMUNOL, V7, P467, DOI 10.1038/mi.2013.64; Gutzeit C, 2014, IMMUNOL REV, V260, P76, DOI 10.1111/imr.12189; Hansel TT, 2013, LANCET, V381, P861, DOI 10.1016/S0140-6736(12)62202-8; Holt PG, 2012, NAT MED, V18, P726, DOI 10.1038/nm.2768; Ismail IH, 2012, PEDIAT ALLERG IMM-UK, V23, P674, DOI 10.1111/j.1399-3038.2012.01328.x; Jakobsson HE, 2014, GUT, V63, P559, DOI 10.1136/gutjnl-2012-303249; JAYASHREE S, 1988, J MED VIROL, V26, P333, DOI 10.1002/jmv.1890260313; Jenmalm MC, 2013, CLIN EXP ALLERGY, V43, P273, DOI 10.1111/cea.12003; Jenmalm MC, 2011, AM J REPROD IMMUNOL, V66, P75, DOI 10.1111/j.1600-0897.2011.01036.x; Kaiko GE, 2014, TRENDS IMMUNOL, V35, P538, DOI 10.1016/j.it.2014.08.002; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kau AL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4877; Kawamoto S, 2014, IMMUNITY, V41, P152, DOI 10.1016/j.immuni.2014.05.016; Khan MT, 2012, ISME J, V6, P1578, DOI 10.1038/ismej.2012.5; Kim YS, 2007, J NUTR, V137, p2576S, DOI 10.1093/jn/137.11.2576S; Kubinak JL, 2015, CELL HOST MICROBE, V17, P153, DOI 10.1016/j.chom.2014.12.009; Kukkonen K, 2010, PEDIAT ALLERG IMM-UK, V21, P67, DOI 10.1111/j.1399-3038.2009.00907.x; Kverka M, 2011, CLIN EXP IMMUNOL, V163, P250, DOI 10.1111/j.1365-2249.2010.04286.x; Machiels Kathleen, 2014, Gut, V63, P1275, DOI 10.1136/gutjnl-2013-304833; Mantis NJ, 2011, MUCOSAL IMMUNOL, V4, P603, DOI 10.1038/mi.2011.41; Marchesi JR, 2016, GUT, V65, P330, DOI 10.1136/gutjnl-2015-309990; Martens EC, 2008, CELL HOST MICROBE, V4, P447, DOI 10.1016/j.chom.2008.09.007; Maruya M, 2013, GUT MICROBES, V4, P165, DOI 10.4161/gmic.23595; Nava GM, 2011, ISME J, V5, P627, DOI 10.1038/ismej.2010.161; Palm NW, 2014, CELL, V158, P1000, DOI 10.1016/j.cell.2014.08.006; Penders J, 2006, CLIN EXP ALLERGY, V36, P1602, DOI 10.1111/j.1365-2222.2006.02599.x; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Penders J, 2013, J ALLERGY CLIN IMMUN, V132, P601, DOI 10.1016/j.jaci.2013.05.043; Peterson DA, 2007, CELL HOST MICROBE, V2, P328, DOI 10.1016/j.chom.2007.09.013; Rogier EW, 2014, P NATL ACAD SCI USA, V111, P3074, DOI 10.1073/pnas.1315792111; Sandin A, 2011, PEDIAT ALLERG IMM-UK, V22, P477, DOI 10.1111/j.1399-3038.2010.01106.x; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Sim K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032543; Simon-Soro A, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0456-y; Sjogren YM, 2009, CLIN EXP ALLERGY, V39, P518, DOI 10.1111/j.1365-2222.2008.03156.x; Tourneur E, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/270301; Tsuruta T, 2010, BIOSCI BIOTECH BIOCH, V74, P968, DOI 10.1271/bbb.90801; Turfkruyer M, 2015, CURR OPIN INFECT DIS, V28, P199, DOI 10.1097/QCO.0000000000000165; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; West CE, 2015, CLIN EXP ALLERGY, V45, P43, DOI 10.1111/cea.12332; Zhu QC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090849	70	89	91	4	48	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					1017	+		10.1016/j.jaci.2016.06.047	http://dx.doi.org/10.1016/j.jaci.2016.06.047			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27531072	Bronze, Green Submitted			2022-12-18	WOS:000397295800033
J	Zoratti, EM; Krouse, RZ; Babineau, DC; Pongracic, JA; O'Connor, GT; Wood, RA; Hershey, GKK; Kercsmar, CM; Gruchalla, RS; Kattan, M; Teach, SJ; Sigelman, SM; Gergen, PJ; Togias, A; Visness, CM; Busse, WW; Liu, AH				Zoratti, Edward M.; Krouse, Rebecca Z.; Babineau, Denise C.; Pongracic, Jacqueline A.; O'Connor, George T.; Wood, Robert A.; Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.; Gruchalla, Rebecca S.; Kattan, Meyer; Teach, Stephen J.; Sigelman, Steven M.; Gergen, Peter J.; Togias, Alkis; Visness, Cynthia M.; Busse, William W.; Liu, Andrew H.			Asthma phenotypes in inner-city children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen sensitization; allergy; airway inflammation; bronchial hyperresponsiveness; asthma phenotypes; asthma severity; IgE; hierarchical cluster; inner-city asthma; rhinitis	ALLERGIC SENSITIZATION; CLUSTER-ANALYSIS; MORBIDITY; SEVERITY; CLASSIFICATION; EXPOSURE; RHINITIS; VIOLENCE; DISEASE; HEALTH	Background: Children with asthma in low-income urban areas have high morbidity. Phenotypic analysis in these children is lacking, but may identify characteristics to inform successful tailored management approaches. Objective: We sought to identify distinct asthma phenotypes among inner-city children receiving guidelines-based management. Methods: Nine inner-city asthma consortium centers enrolled 717 children aged 6 to 17 years. Data were collected at baseline and prospectively every 2 months for 1 year. Participants' asthma and rhinitis were optimally managed by study physicians on the basis of guidelines. Cluster analysis using 50 baseline and 12 longitudinal variables was performed in 616 participants completing 4 or more follow-up visits. Results: Five clusters (designated A through E) were distinguished by indicators of asthma and rhinitis severity, pulmonary physiology, allergy (sensitization and total serum IgE), and allergic inflammation. In comparison to other clusters, cluster A was distinguished by lower allergy/inflammation, minimally symptomatic asthma and rhinitis, and normal pulmonary physiology. Cluster B had highly symptomatic asthma despite high step-level treatment, lower allergy and inflammation, and mildly altered pulmonary physiology. Cluster C had minimally symptomatic asthma and rhinitis, intermediate allergy and inflammation, and mildly impaired pulmonary physiology. Clusters D and E exhibited progressively higher asthma and rhinitis symptoms and allergy/inflammation. Cluster E had the most symptomatic asthma while receiving high step-level treatment and had the highest total serum IgE level (median, 733 kU/L), blood eosinophil count (median, 400 cells/mm(3)), and allergen sensitizations (15 of 22 tested). Conclusions: Allergy distinguishes asthma phenotypes in urban children. Severe asthma often coclusters with highly allergic children. However, a symptomatic phenotype with little allergy or allergic inflammation was identified.	[Zoratti, Edward M.] Henry Ford Hlth Syst, Detroit, MI USA; [Zoratti, Edward M.] Wayne State Univ, Sch Med, Detroit, MI USA; [Krouse, Rebecca Z.; Babineau, Denise C.; Visness, Cynthia M.] Rho Fed Syst Div, Chapel Hill, NC USA; [Pongracic, Jacqueline A.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [O'Connor, George T.] Boston Univ, Sch Med, Boston, MA 02215 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.] Cincinnati Childrens Hosp, Cincinnati, OH USA; [Gruchalla, Rebecca S.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Kattan, Meyer] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Teach, Stephen J.] Childrens Natl Hlth Syst, Washington, DC USA; [Teach, Stephen J.] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA; [Sigelman, Steven M.; Gergen, Peter J.; Togias, Alkis] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Liu, Andrew H.] Natl Jewish Hlth, Denver, CO USA; [Liu, Andrew H.] Childrens Hosp Colorado, Aurora, CO USA; [Liu, Andrew H.] Univ Colorado, Sch Med, Aurora, CO USA	Henry Ford Health System; Henry Ford Hospital; Wayne State University; Ann & Robert H. Lurie Children's Hospital of Chicago; Boston University; Johns Hopkins University; Cincinnati Children's Hospital Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; Columbia University; Children's National Health System; George Washington University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Wisconsin System; University of Wisconsin Madison; National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Zoratti, EM (corresponding author), Henry Ford Hosp, Dept Internal Med, Div Allergy & Immunol, 4B69 One Ford Pl, Detroit, MI 48202 USA.	ezoratt1@hfhs.org			National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services [HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01]; National Center for Research Resources (NCRR); National Center for Advancing Translational Sciences (NCATS), NIH [NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075, NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077 04, UL1TR000040, UL1TR000150, UL1TR001105]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082, UL1TR001105, UL1TR000150, UL1TR000075, UL1TR000077, UL1TR001422, UL1TR000154, UL1TR000451, UL1TR000040] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI114271, UM2AI117870] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services; National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences (NCATS), NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (under contract nos., HHSN272200900052C and HHSN272201000052I, and 1UM1AI114271-01). Additional support was provided by the National Center for Research Resources (NCRR), and the National Center for Advancing Translational Sciences (NCATS), NIH ( under grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075 and NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077 04, UL1TR000040, UL1TR000150, and UL1TR001105). GlaxoSmithKline (GSK) provided Ventolin, Flovent, Advair, and Flonase under a clinical trial agreement with NIH-NIAID; GSK did not have a role in the development or approval of the protocol, conduct of the trial, data analysis, decision to submit the manuscript for publication.	Bourdin A, 2014, J ALLERGY CLIN IMMUN, V134, P1043, DOI 10.1016/j.jaci.2014.04.038; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2012, J ALLERGY CLIN IMMUN, V130, P1049, DOI 10.1016/j.jaci.2012.07.053; Buttrey SE, 2015, R J, V7, P227; Carroll WD, 2006, ARCH DIS CHILD, V91, P405, DOI 10.1136/adc.2005.088278; Chang TS, 2014, J ALLERGY CLIN IMMUN, V133, P363, DOI 10.1016/j.jaci.2013.09.002; de Marco R, 2006, J ALLERGY CLIN IMMUN, V117, P1249, DOI 10.1016/j.jaci.2006.03.019; Depner M, 2014, AM J RESP CRIT CARE, V189, P129, DOI 10.1164/rccm.201307-1198OC; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Hamilton RG, 2014, J ALLERGY CLIN IMMUN, V134, P360, DOI 10.1016/j.jaci.2014.02.022; Hastie T., 2009, ELEMENTS STAT LEARNI, P520, DOI DOI 10.1007/978-0-387-84858-7; Hens G, 2008, ALLERGY, V63, P261, DOI 10.1111/j.1398-9995.2007.01545.x; Howrylak JA, 2014, J ALLERGY CLIN IMMUN, V133, P1289, DOI 10.1016/j.jaci.2014.02.006; Just J, 2012, EUR RESPIR J, V40, P55, DOI 10.1183/09031936.00123411; Kursa MB, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i11; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Lynch SK, 2014, THESIS; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Pongracic JA, 2016, J ALLERGY CLIN IMMUN, V138, P1030, DOI 10.1016/j.jaci.2016.06.059; Prosperi MCF, 2013, AM J RESP CRIT CARE, V188, P1303, DOI 10.1164/rccm.201304-0694OC; Ramsey CD, 2005, PEDIATR PULM, V39, P268, DOI 10.1002/ppul.20177; Rand CS, 2012, J ALLERGY CLIN IMMUN, V129, pS136, DOI 10.1016/j.jaci.2011.12.987; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Salo PM, 2014, J ALLERGY CLIN IMMUN, V134, P350, DOI 10.1016/j.jaci.2013.12.1071; Sandberg S, 2004, THORAX, V59, P1046, DOI 10.1136/thx.2004.024604; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Schatz M, 2014, J ALLERGY CLIN IMMUN, V133, P1549, DOI 10.1016/j.jaci.2013.10.006; Schwindt CD, 2006, J ASTHMA, V43, P439, DOI 10.1080/02770900600758234; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Togias A, 2010, J ALLERGY CLIN IMMUN, V125, P540, DOI 10.1016/j.jaci.2010.01.040; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2001, ENVIRON HEALTH PERSP, V109, P1085, DOI 10.2307/3454965; Wu W, 2014, J ALLERGY CLIN IMMUN, V133, P1280, DOI 10.1016/j.jaci.2013.11.042	35	89	90	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1016	1029		10.1016/j.jaci.2016.06.061	http://dx.doi.org/10.1016/j.jaci.2016.06.061			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27720016	Green Accepted, Bronze			2022-12-18	WOS:000385499400007
J	Czarnowicki, T; Malajian, D; Khattri, S; da Rosa, JC; Dutt, R; Finney, R; Dhingra, N; Peng, XY; Xu, H; Estrada, YD; Zheng, XZ; Gilleaudeau, P; Sullivan-Whalen, M; Suarez-Farinas, M; Shemer, A; Krueger, JG; Guttman-Yassky, E				Czarnowicki, Tali; Malajian, Dana; Khattri, Saakshi; da Rosa, Joel Correa; Dutt, Riana; Finney, Robert; Dhingra, Nikhil; Peng Xiangyu; Xu, Hui; Estrada, Yeriel D.; Zheng, Xiuzhong; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Suarez-Farinas, Mayte; Shemer, Avner; Krueger, James G.; Guttman-Yassky, Emma			Petrolatum: Barrier repair and antimicrobial responses underlying this "inert" moisturizer	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Petrolatum; moisturizer; occlusion; patch tests; antimicrobial peptides; innate immunity; atopic dermatitis; barrier; skin surgeries	SEVERE ATOPIC-DERMATITIS; ALLERGY CLIN IMMUNOL; T-CELL POPULATION; SKIN BARRIER; BACITRACIN OINTMENT; PERMEABILITY BARRIER; HUMAN KERATINOCYTES; PSORIASIN S100A7; CONTROLLED-TRIAL; DENDRITIC CELLS	Background: Petrolatum is a common moisturizer often used in the prevention of skin infections after ambulatory surgeries and as a maintenance therapy of atopic dermatitis (AD). However, the molecular responses induced by petrolatum in the skin have never been assessed. Objective: We sought to define the cutaneous molecular and structural effects induced by petrolatum. Methods: Thirty-six healthy subjects and 13 patients with moderate AD (mean SCORAD score, 39) were studied by using RT-PCR, gene arrays, immunohistochemistry, and immunofluorescence performed on control skin, petrolatum-occluded skin, and skin occluded with a Finn chamber only. Results: Significant upregulations of antimicrobial peptides (S100A8/fold change [FCH], 13.04; S100A9/FCH, 11.28; CCL20/FCH, 8.36; PI3 [elafin]/FCH, 15.40; lipocalin 2/FCH, 6.94, human beta-defensin 2 [DEFB4A]/FCH, 4.96; P < .001 for all) and innate immune genes (IL6, IL8, and IL1B; P < .01) were observed in petrolatum-occluded skin compared with expression in both control and occluded-only skin. Application of petrolatum also induced expression of key barrier differentiation markers (filaggrin and loricrin), increased stratum corneum thickness, and significantly reduced T-cell infiltrates in the setting of "normal-appearing" or nonlesional AD skin, which is known to harbor barrier and immune defects. Conclusions: Petrolatum robustly modulates antimicrobials and epidermal differentiation barrier measures. These data shed light on the beneficial molecular responses of petrolatum in barrier-defective states, such as AD and postoperative wound care.	[Czarnowicki, Tali; Malajian, Dana; Khattri, Saakshi; da Rosa, Joel Correa; Dutt, Riana; Peng Xiangyu; Xu, Hui; Zheng, Xiuzhong; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Suarez-Farinas, Mayte; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA; [da Rosa, Joel Correa] Rockefeller Univ, Ctr Clin & Translat Sci, 1230 York Ave, New York, NY 10021 USA; [Malajian, Dana] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA; [Khattri, Saakshi; Dutt, Riana; Dhingra, Nikhil; Peng Xiangyu; Xu, Hui; Estrada, Yeriel D.; Suarez-Farinas, Mayte; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, 5 E 98th St, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, 5 E 98th St, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, 5 E 98th St, New York, NY 10029 USA; [Finney, Robert] Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol, Philadelphia, PA 19107 USA; [Shemer, Avner] Tel Hashomer Hosp, Dept Dermatol, Tel Aviv, Israel	Rockefeller University; Rockefeller University; Columbia University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Jefferson University	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	eguttman@rockefeller.edu	Correa da Rosa, Joel/Q-4753-2017; Da Rosa, Joel/AAU-1238-2020	Correa da Rosa, Joel/0000-0003-4221-1976; Da Rosa, Joel/0000-0003-4221-1976; Sanyal, Riana/0000-0002-6638-9026	Center for Basic and Translational Research on Disorders of the Digestive System through the generosity of the Leona M. and Harry B. Helmsley Charitable Trust; American Dermatological Association's Medical Student Fellowship; National Center for Research Resources (NCRR), National Institutes of Health (NIH) [5UL1RR024143-02]; NIH Roadmap for Medical Research; Dermatology Foundation Physician Scientist Career Development Award; CTSA grant from the Rockefeller University; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER	Center for Basic and Translational Research on Disorders of the Digestive System through the generosity of the Leona M. and Harry B. Helmsley Charitable Trust; American Dermatological Association's Medical Student Fellowship; National Center for Research Resources (NCRR), National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dermatology Foundation Physician Scientist Career Development Award; CTSA grant from the Rockefeller University; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	T.C. was cosponsored by the Center for Basic and Translational Research on Disorders of the Digestive System through the generosity of the Leona M. and Harry B. Helmsley Charitable Trust. D.M. was supported by the American Dermatological Association's Medical Student Fellowship. J.G.K. was supported by grant no. 5UL1RR024143-02 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. E.G.-Y. was supported by the Dermatology Foundation Physician Scientist Career Development Award and by a CTSA grant from the Rockefeller University.	Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bin LH, 2014, J ALLERGY CLIN IMMUN, V134, P848, DOI 10.1016/j.jaci.2014.07.018; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Bose F, 2013, AM J PATHOL, V183, P413, DOI 10.1016/j.ajpath.2013.04.021; Bowdish DME, 2005, J ENDOTOXIN RES, V11, P230, DOI 10.1179/096805105X37394; Braff MH, 2006, CURR TOP MICROBIOL, V306, P91; BRANDTZAEG P, 1995, ADV EXP MED BIOL, V371, P201; Burton MJ, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004461.PUB2; Chesebrough RA., 1872, US Patent, Patent No. [127,568, 127568, US127568]; Cho JS, 2010, J CLIN INVEST, V120, P1762, DOI 10.1172/JCI40891; CHRISTOPHERS E, 1987, ARCH DERMATOL RES, V279, pS48, DOI 10.1007/BF00585919; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P104, DOI 10.1016/j.jaci.2015.01.020; Czarnowicki T, 2014, J ALLER CL IMM-PRACT, V2, P371, DOI 10.1016/j.jaip.2014.03.006; da Rosa JC, 2015, J ALLERGY CLIN IMMUN, V135, P712, DOI 10.1016/j.jaci.2014.11.017; Dhingra N, 2014, J ALLERGY CLIN IMMUN, V134, P362, DOI 10.1016/j.jaci.2014.03.009; Dhingra N, 2013, J INVEST DERMATOL, V133, P2311, DOI 10.1038/jid.2013.239; Dhingra N, 2013, J ALLERGY CLIN IMMUN, V132, P498, DOI 10.1016/j.jaci.2013.04.043; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Elias PM, 2014, J ALLERGY CLIN IMMUN, V134, P781, DOI 10.1016/j.jaci.2014.05.048; Eyerich S, 2010, TRENDS IMMUNOL, V31, P354, DOI 10.1016/j.it.2010.06.004; Fleischer AB, 1997, J AM ACAD DERMATOL, V37, P719, DOI 10.1016/S0190-9622(97)70107-5; Flores GE, 2014, J DRUGS DERMATOL, V13, P1365; FRAKI JE, 1979, CONTACT DERMATITIS, V5, P97, DOI 10.1111/j.1600-0536.1979.tb04806.x; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Fujita H, 2013, J DERMATOL SCI, V72, P3, DOI 10.1016/j.jdermsci.2013.04.028; GETTE MT, 1992, ARCH DERMATOL, V128, P365, DOI 10.1001/archderm.128.3.365; GHADIALLY R, 1992, J AM ACAD DERMATOL, V26, P387, DOI 10.1016/0190-9622(92)70060-S; GHADIALLY R, 1995, J CLIN INVEST, V95, P2281, DOI 10.1172/JCI117919; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Glatz M, 2015, J INVEST DERMATOL, V135, pS31; Goupil M, 2014, BMC IMMUNOL, V15, DOI 10.1186/s12865-014-0049-9; Greenberg K, 2007, AM J EMERG MED, V25, P95, DOI 10.1016/j.ajem.2006.04.010; Gros E, 2011, J ALLERGY CLIN IMMUN, V128, P1015, DOI 10.1016/j.jaci.2011.05.043; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Hegyi Z, 2012, J INVEST DERMATOL, V132, P1416, DOI 10.1038/jid.2011.486; Holm EA, 2006, J AM ACAD DERMATOL, V55, P772, DOI 10.1016/j.jaad.2006.03.036; Hoover DM, 2000, J BIOL CHEM, V275, P32911, DOI 10.1074/jbc.M006098200; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Isailovic N, 2015, J AUTOIMMUN, V60, P1, DOI 10.1016/j.jaut.2015.04.006; Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009; Jakasa I, 2007, J INVEST DERMATOL, V127, P129, DOI 10.1038/sj.jid.5700582; Jakasa I, 2015, TOXICOL LETT, V235, P123, DOI 10.1016/j.toxlet.2015.03.012; James WD, 2006, J AM ACAD DERMATOL, V55, P915, DOI 10.1016/j.jaad.2006.02.060; Janssens M, 2012, J LIPID RES, V53, P2755, DOI 10.1194/jlr.P030338; Jenssen H, 2006, CLIN MICROBIOL REV, V19, P491, DOI 10.1128/CMR.00056-05; Krishna S, 2012, SEMIN IMMUNOPATHOL, V34, P261, DOI 10.1007/s00281-011-0292-6; Li CW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091950; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Liu SY, 2012, P NATL ACAD SCI USA, V109, P4239, DOI 10.1073/pnas.1114981109; LODEN M, 1992, ACTA DERM-VENEREOL, V72, P327; Loden M, 2000, ACTA DERM-VENEREOL, V80, P412; Lusitani D, 2003, INFECT IMMUN, V71, P4711, DOI 10.1128/IAI.71.8.4711-4716.2003; MACHARIA WM, 1991, TROP DOCT, V21, P104, DOI 10.1177/004947559102100305; Malajian D, 2013, J AM ACAD DERMATOL, V69, P232, DOI 10.1016/j.jaad.2013.03.012; Mathias RA, 2013, BRIT J DERMATOL, V169, P700, DOI 10.1111/bjd.12382; Matsumoto T, 2007, J DERMATOL, V34, P447, DOI 10.1111/j.1346-8138.2007.00308.x; Miller DW, 2011, J DRUGS DERMATOL, V10, P531; MIYASAKI KT, 1993, J DENT RES, V72, P517, DOI 10.1177/00220345930720020801; MURTHY ARK, 1993, J IMMUNOL, V151, P6291; Niebuhr M, 2011, INT ARCH ALLERGY IMM, V156, P412, DOI 10.1159/000323905; Nijhawan RI, 2013, DERMATOL SURG, V39, P1260, DOI 10.1111/dsu.12245; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Park HY, 2013, ANN DERMATOL, V25, P410, DOI 10.5021/ad.2013.25.4.410; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Pennick G., 2010, International Journal of Cosmetic Science, V32, P304, DOI 10.1111/j.1468-2494.2010.00604.x; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Rawlings A V, 2004, Dermatol Ther, V17 Suppl 1, P49, DOI 10.1111/j.1396-0296.2004.04S1006.x; Reynolds JM, 2010, CYTOKINE GROWTH F R, V21, P413, DOI 10.1016/j.cytogfr.2010.10.002; Ryu S, 2014, INT J MOL SCI, V15, P8753, DOI 10.3390/ijms15058753; Sa SM, 2007, J IMMUNOL, V178, P2229, DOI 10.4049/jimmunol.178.4.2229; Saryan JA, 1998, AM J EMERG MED, V16, P512, DOI 10.1016/S0735-6757(98)90005-5; Schauber J, 2009, J ALLERGY CLIN IMMUN, V124, pR13, DOI 10.1016/j.jaci.2009.07.014; SCHECHTER JF, 1984, ARCH DERMATOL, V120, P909, DOI 10.1001/archderm.120.7.909; Seltmann J, 2015, J ALLERGY CLIN IMMUN, V135, P1659, DOI 10.1016/j.jaci.2015.01.048; Shen F, 2006, J BIOL CHEM, V281, P24138, DOI 10.1074/jbc.M604597200; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Simpson EL, 2010, J AM ACAD DERMATOL, V63, P587, DOI 10.1016/j.jaad.2009.11.011; Slutsky JB, 2010, J DRUGS DERMATOL, V9, P1258; Smack DP, 1996, JAMA-J AM MED ASSOC, V276, P972, DOI 10.1001/jama.276.12.972; Sonnenberg GF, 2011, NAT IMMUNOL, V12, P383, DOI 10.1038/ni.2025; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; VALE MA, 1978, ARCH DERMATOL, V114, P800, DOI 10.1001/archderm.1978.01640170094034; van den Bogaard EH, 2013, J CLIN INVEST, V123, P917, DOI 10.1172/JCI65642; van Smeden J, 2014, BBA-MOL CELL BIOL L, V1841, P295, DOI 10.1016/j.bbalip.2013.11.006; van Smeden J, 2014, EXP DERMATOL, V23, P45, DOI 10.1111/exd.12293; Warner JA, 2009, BRIT J DERMATOL, V160, P183, DOI 10.1111/j.1365-2133.2008.08905.x; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; Winge MCG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028254; Wolk K, 2014, CLIN CANCER RES, V20, P5507, DOI 10.1158/1078-0432.CCR-14-0707; Yin XY, 2014, IMMUNOGENETICS, V66, P215, DOI 10.1007/s00251-013-0756-z; Zhang LJ, 2015, SCIENCE, V347, P67, DOI 10.1126/science.1260972; Zug KA, 2014, DERMATITIS, V25, P345, DOI 10.1097/DER.0000000000000083	105	89	90	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1091	+		10.1016/j.jaci.2015.08.013	http://dx.doi.org/10.1016/j.jaci.2015.08.013			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26431582	Bronze			2022-12-18	WOS:000373351200015
J	Alkhairy, OK; Perez-Becker, R; Driessen, GJ; Abolhassani, H; van Montfrans, J; Borte, S; Choo, S; Wang, N; Tesselaar, K; Fang, MY; Bienemann, K; Boztug, K; Daneva, A; Mechinaud, F; Wiesel, T; Becker, C; Duckers, G; Siepermann, K; van Zelm, MC; Rezaei, N; van der Burg, M; Aghamohammadi, A; Seidel, MG; Niehues, T; Hammarstrom, L				Alkhairy, Omar K.; Perez-Becker, Ruy; Driessen, Gertjan J.; Abolhassani, Hassan; van Montfrans, Joris; Borte, Stephan; Choo, Sharon; Wang, Ning; Tesselaar, Kiki; Fang, Mingyan; Bienemann, Kirsten; Boztug, Kaan; Daneva, Ana; Mechinaud, Francoise; Wiesel, Thomas; Becker, Christian; Duckers, Gregor; Siepermann, Kathrin; van Zelm, Menno C.; Rezaei, Nima; van der Burg, Mirjam; Aghamohammadi, Asghar; Seidel, Markus G.; Niehues, Tim; Hammarstrom, Lennart			Novel mutations in TNFRSF7/CD27: Clinical, immunologic, and genetic characterization of human CD27 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD27 deficiency; EBV-induced lymphoproliferation; Hodgkin lymphoma; hypogammaglobulinemia; hemophagocytic lymphohistiocytosis	EPSTEIN-BARR-VIRUS; COMMON VARIABLE IMMUNODEFICIENCY; NATURAL-KILLER-CELLS; T-CELLS; LYMPHOPROLIFERATIVE DISORDER; CD27-CD70 INTERACTIONS; READ ALIGNMENT; EBV INFECTION; SCID MICE; NK CELLS	Background: The clinical and immunologic features of CD27 deficiency remain obscure because only a few patients have been identified to date. Objective: We sought to identify novel mutations in TNFRSF7/CD27 and to provide an overview of clinical, immunologic, and laboratory phenotypes in patients with CD27 deficiency. Methods: Review of the medical records and molecular, genetic, and flow cytometric analyses of the patients and family members were performed. Treatment outcomes of previously described patients were followed up. Results: In addition to the previously reported homozygous mutations c.G24A/p.W8X (n = 2) and c.G158A/p.C53Y (n = 8), 4 novel mutations were identified: homozygous missense c.G287A/p.C96Y (n = 4), homozygous missense c.C232T/p.R78W (n = 1), heterozygous nonsense c.C30A/p.C10X (n = 1), and compound heterozygous c.C319T/p.R107C-c.G24A/p. W8X (n = 1). EBV-associated lymphoproliferative disease/hemophagocytic lymphohistiocytosis, Hodgkin lymphoma, uveitis, and recurrent infections were the predominant clinical features. Expression of cell-surface and solubleCD27 was significantly reduced in patients and heterozygous family members. Immunoglobulin substitution therapy was administered in 5 of the newly diagnosed cases. Conclusion: CD27 deficiency is potentially fatal and should be excluded in all cases of severe EBV infections to minimize diagnostic delay. Flow cytometric immunophenotyping offers a reliable initial test for CD27 deficiency. Determining the precise role of CD27 in immunity against EBV might provide a framework for new therapeutic concepts.	[Alkhairy, Omar K.; Abolhassani, Hassan; Borte, Stephan; Wang, Ning; Hammarstrom, Lennart] Karolinska Univ Hosp, Div Clin Immunol, Dept Lab Med, Karolinska Inst, Huddinge, Sweden; [Alkhairy, Omar K.] King Abdul Aziz Med City, Dept Pathol & Lab Med, Riyadh, Saudi Arabia; [Perez-Becker, Ruy; Duckers, Gregor; Siepermann, Kathrin; Niehues, Tim] HELIOS Clin Krefeld, Ctr Child & Adolescent Hlth, Krefeld, Germany; [Becker, Christian] HELIOS Clin Krefeld, Inst Hyg & Lab Med, Krefeld, Germany; [Driessen, Gertjan J.; Daneva, Ana] Erasmus MC, Dept Pediat, Subdept Pediat Infect Dis & Immunol, Rotterdam, Netherlands; [Abolhassani, Hassan; Rezaei, Nima; Aghamohammadi, Asghar] Univ Tehran Med Sci, Res Ctr Immunodeficiencies, Pediat Ctr Excellence, Childrens Med Ctr, Tehran, Iran; [Rezaei, Nima] Univ Tehran Med Sci, Dept Immunol, Sch Med & Mol Immunol, Sch Med, Tehran, Iran; [Rezaei, Nima] Univ Tehran Med Sci, Mol Immunol Res Ctr, Tehran, Iran; [van Montfrans, Joris; Tesselaar, Kiki] Univ Med Ctr Utrecht, Dept Pediat Immunol, Wilhelmina Childrens Hosp, Utrecht, Netherlands; [van Montfrans, Joris; Tesselaar, Kiki] Univ Med Ctr Utrecht, Dept Infect Dis, Wilhelmina Childrens Hosp, Utrecht, Netherlands; [Borte, Stephan] Univ Leipzig, Translat Ctr Regenerat Med TRM, D-04109 Leipzig, Germany; [Choo, Sharon] Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia; [Fang, Mingyan] BGI Shenzhen, Shenzhen, Peoples R China; [Bienemann, Kirsten] Univ Dusseldorf, Pediat Oncol Hematol & Clin Immunol, Fac Med, Dusseldorf, Germany; [Boztug, Kaan] Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1010 Vienna, Austria; [Boztug, Kaan] Med Univ Vienna, Div Neonatal Med & Intens Care, Dept Pediat & Adolescent Med, Vienna, Austria; [Seidel, Markus G.] Med Univ Vienna, St Anna Childrens Hosp, Div Pediat Hematol Oncol, Dept Pediat & Adolescent Med, Vienna, Austria; [Mechinaud, Francoise] Royal Childrens Hosp, Childrens Canc Ctr, Melbourne, Vic, Australia; [Wiesel, Thomas] Univ Witten Herdecke, Childrens Hosp, Vest Youth Hosp, Datteln, Germany; [van Zelm, Menno C.; van der Burg, Mirjam] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [van Montfrans, Joris; Tesselaar, Kiki] Med Univ Graz, Div Pediat Hematol Oncol, Dept Pediat & Adolescent Med, Graz, Austria	Karolinska Institutet; Karolinska University Hospital; King Abdulaziz Medical City; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Riyadh; Erasmus University Rotterdam; Erasmus MC; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Leipzig University; Royal Children's Hospital Melbourne; Beijing Genomics Institute (BGI); Heinrich Heine University Dusseldorf; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Medical University of Vienna; Medical University of Vienna; Saint Anna Children's Hospital; Royal Children's Hospital Melbourne; Witten Herdecke University; Erasmus University Rotterdam; Erasmus MC; Medical University of Graz	Hammarstrom, L (corresponding author), Karolinska Univ Hosp, Dept Lab Med, Div Clin Immunol & Transfus Med, SE-14186 Stockholm, Sweden.	markus.seidel@medunigraz.at; tim.niehues@helios-kliniken.de; lennart.hammarstrom@ki.se	van Zelm, Menno C/O-4404-2015; Fang, Mingyan/B-8505-2017; Fang, Mingyan/M-9171-2019; Boztug, Kaan/AAM-4161-2021; Rezaei, Nima/B-4245-2008; Abolhassani, Hassan/B-3465-2014; Driessen, Gertjan/AAI-9711-2020; Seidel, Markus G/N-9951-2017	van Zelm, Menno C/0000-0003-4161-1919; Fang, Mingyan/0000-0001-7185-6445; Boztug, Kaan/0000-0001-8387-9185; Rezaei, Nima/0000-0002-3836-1827; Abolhassani, Hassan/0000-0002-4838-0407; Seidel, Markus G/0000-0003-0981-8661; Tesselaar, Kiki/0000-0002-9847-0814; Aghamohammadi, Asghar/0000-0002-9454-1603	Jeffrey Modell Foundation; Swedish Research Council; German Federal Ministry of Education and Research (BMBF) [1315883]; Karolinska Institutet	Jeffrey Modell Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Karolinska Institutet(Karolinska Institutet)	Supported by the Jeffrey Modell Foundation, the Swedish Research Council, the German Federal Ministry of Education and Research (BMBF 1315883), and funds from the Karolinska Institutet.	ABEDI MR, 1993, INT J CANCER, V55, P824, DOI 10.1002/ijc.2910550522; Abedi MR, 1997, INT J CANCER, V71, P624, DOI 10.1002/(SICI)1097-0215(19970516)71:4<624::AID-IJC19>3.0.CO;2-B; Abolhassani H, 2014, J ALLERGY CLIN IMMUN, V134, P1375, DOI 10.1016/j.jaci.2014.04.042; Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Beillard E, 2003, LEUKEMIA, V17, P2474, DOI 10.1038/sj.leu.2403136; BIREK C, 1989, ORAL SURG ORAL MED O, V68, P612, DOI 10.1016/0030-4220(89)90249-1; Boldt A, 2014, CYTOM PART B-CLIN CY, V86, P191, DOI 10.1002/cyto.b.21162; Chan A, 2007, J IMMUNOL, V179, P89, DOI 10.4049/jimmunol.179.1.89; Cheng J, 2005, NUCLEIC ACIDS RES, V33, pW72, DOI 10.1093/nar/gki396; Chijioke O, 2013, CELL REP, V5, P1489, DOI 10.1016/j.celrep.2013.11.041; Cho HI, 2006, INT J HEMATOL, V83, P66, DOI 10.1532/IJH97.A30505; Chung BK, 2013, BLOOD, V122, P2600, DOI 10.1182/blood-2013-01-480665; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Denoeud J, 2011, J LEUKOCYTE BIOL, V89, P195, DOI 10.1189/jlb.0610351; Frenzel K, 2014, MED MICROBIOL IMMUN, V203, P115, DOI 10.1007/s00430-013-0321-2; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Helminen ME, 2001, J INFECT DIS, V184, P777, DOI 10.1086/322987; Hendriks J, 2000, NAT IMMUNOL, V1, P433, DOI 10.1038/80877; Hendriks J, 2005, J IMMUNOL, V175, P1665, DOI 10.4049/jimmunol.175.3.1665; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Hislop AD, 2001, J IMMUNOL, V167, P2019, DOI 10.4049/jimmunol.167.4.2019; Hjalgrim H, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P929; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Huck K, 2009, J CLIN INVEST, V119, P1350, DOI 10.1172/JCI37901; Jang YS, 2013, CLIN IMMUNOL, V149, P379, DOI 10.1016/j.clim.2013.09.007; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kimura H, 2001, BLOOD, V98, P280, DOI 10.1182/blood.V98.2.280; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; KOBATA T, 1995, P NATL ACAD SCI USA, V92, P11249, DOI 10.1073/pnas.92.24.11249; Lemaitre C, 2004, INVEST OPHTH VIS SCI, V45, pU600; Li FY, 2011, NATURE, V475, P471, DOI 10.1038/nature10246; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li RQ, 2009, BIOINFORMATICS, V25, P1966, DOI 10.1093/bioinformatics/btp336; Li RQ, 2009, GENOME RES, V19, P1124, DOI 10.1101/gr.088013.108; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Merlo A, 2010, HAEMATOL-HEMATOL J, V95, P1769, DOI 10.3324/haematol.2010.023689; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Moshous D, 2003, J CLIN INVEST, V111, P381, DOI 10.1172/JCI200316774; Moshous D, 2013, J ALLERGY CLIN IMMUN, V131, P1594, DOI 10.1016/j.jaci.2013.01.042; Nehme NT, 2012, BLOOD, V119, P3458, DOI 10.1182/blood-2011-09-378364; Nolte MA, 2009, IMMUNOL REV, V229, P216, DOI 10.1111/j.1600-065X.2009.00774.x; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Okano M, 2002, CRIT REV ONCOL HEMAT, V44, P273, DOI 10.1016/S1040-8428(02)00118-X; Peperzak V, 2010, J IMMUNOL, V185, P6670, DOI 10.4049/jimmunol.1000159; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; Rigaud S, 2006, NATURE, V444, P110, DOI 10.1038/nature05257; Rozen S, 2000, Methods Mol Biol, V132, P365; Salzer E, 2013, HAEMATOLOGICA, V98, P473, DOI 10.3324/haematol.2012.068791; Schildknecht A, 2007, EUR J IMMUNOL, V37, P716, DOI 10.1002/eji.200636824; Seidel MG, 2012, J ALLERGY CLIN IMMUN, V129, P1175, DOI 10.1016/j.jaci.2012.01.053; Strowig T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040027; Takeda K, 2000, J IMMUNOL, V164, P1741, DOI 10.4049/jimmunol.164.4.1741; Tchang VSY, 2013, MOL IMMUNOL, V56, P683, DOI 10.1016/j.molimm.2013.05.003; USUI M, 1990, INT OPHTHALMOL, V14, P371, DOI 10.1007/BF00163559; van der Burg M, 2006, J CLIN INVEST, V116, P137, DOI 10.1172/JCI26121; van Montfrans JM, 2012, J ALLERGY CLIN IMMUN, V129, P787, DOI 10.1016/j.jaci.2011.11.013; van Zelm MC, 2007, J EXP MED, V204, P645, DOI 10.1084/jem.20060964; van Zelm MC, 2010, J CLIN INVEST, V120, P1265, DOI 10.1172/JCI39748; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744	60	89	89	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					703	+		10.1016/j.jaci.2015.02.022	http://dx.doi.org/10.1016/j.jaci.2015.02.022			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25843314				2022-12-18	WOS:000360913300023
J	Seltmann, J; Roesner, LM; von Hesler, FW; Wittmann, M; Weifel, T				Seltmann, Jenny; Roesner, Lennart M.; von Hesler, Friedrich-Wilhelm; Wittmann, Miriam; Weifel, Thomas			IL-33 impacts on the skin barrier by down-regulating the expression of filaggrin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ATOPIC-DERMATITIS; GENE; KERATINOCYTES; INFLAMMATION; DYSFUNCTION; MECHANISM; CYTOKINE; IL-25; AP-1		[Seltmann, Jenny; Roesner, Lennart M.; Weifel, Thomas] Hannover Med Sch, Dept Dermatol & Allergy, Div Immunodermatol & Allergy Res, Hannover, Germany; [von Hesler, Friedrich-Wilhelm] Plast Surg Kropcke, Hannover, Germany; [Wittmann, Miriam] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England; [Wittmann, Miriam] Chapel Allerton Hosp, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England; [Wittmann, Miriam] Univ Bradford, Ctr Skin Sci, Bradford BD7 1DP, W Yorkshire, England	Hannover Medical School; University of Leeds; Chapel Allerton Hospital; Leeds Biomedical Research Centre; University of Bradford	Seltmann, J (corresponding author), Hannover Med Sch, Dept Dermatol & Allergy, Div Immunodermatol & Allergy Res, Hannover, Germany.	roesner.lennart@mh-hannover.de	Roesner, Lennart/K-1074-2019	Roesner, Lennart/0000-0001-6651-0458; Wittmann, Miriam/0000-0003-2328-4926				Alase A, 2012, BRIT J DERMATOL, V167, P1386, DOI 10.1111/j.1365-2133.2012.11140.x; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Cornelissen C, 2012, J ALLERGY CLIN IMMUN, V129, P426, DOI 10.1016/j.jaci.2011.10.042; Deleuran M, 2012, CHEM IMMUNOL ALLERGY, V96, P45, DOI 10.1159/000331871; Denecker G, 2008, J CELL BIOL, V180, P451, DOI 10.1083/jcb.200709098; Dickel H, 2010, CONTACT DERMATITIS, V63, P215, DOI 10.1111/j.1600-0536.2010.01769.x; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fujioka S, 2004, MOL CELL BIOL, V24, P7806, DOI 10.1128/MCB.24.17.7806-7819.2004; Gutowska-Owsiak D, 2012, EXP DERMATOL, V21, P104, DOI 10.1111/j.1600-0625.2011.01412.x; Haraldsen G, 2009, TRENDS IMMUNOL, V30, P227, DOI 10.1016/j.it.2009.03.003; Houben E, 2007, SKIN PHARMACOL PHYS, V20, P122, DOI 10.1159/000098163; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Hvid M, 2011, J INVEST DERMATOL, V131, P150, DOI 10.1038/jid.2010.277; Jang SI, 2000, J BIOL CHEM, V275, P15295, DOI 10.1074/jbc.275.20.15295; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; MACK JW, 1993, J MOL BIOL, V232, P50, DOI 10.1006/jmbi.1993.1369; Miajlovic H, 2010, J ALLERGY CLIN IMMUN, V126, P1184, DOI 10.1016/j.jaci.2010.09.015; Mildner M, 2006, BIOCHEM BIOPH RES CO, V348, P76, DOI 10.1016/j.bbrc.2006.07.035; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Seltmann J, 2013, EXP DERMATOL, V22, P102, DOI 10.1111/exd.12076; Wang D, 2008, ARTHRITIS RHEUM, V58, P3205, DOI 10.1002/art.23868; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004	25	89	96	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1659	+		10.1016/j.jaci.2015.01.048	http://dx.doi.org/10.1016/j.jaci.2015.01.048			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25863977	Green Accepted			2022-12-18	WOS:000355933400036
J	Bublin, M; Eiwegger, T; Breiteneder, H				Bublin, Merima; Eiwegger, Thomas; Breiteneder, Heimo			Do lipids influence the allergic sensitization process?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; food allergens; immunomodulatory lipids; lipid-binding allergens; microbial lipids; pollen allergens; pollen associated lipid mediators; pollen lipids	KILLER T-CELLS; BET V 1; MAJOR BIRCH ALLERGEN; CRYSTAL-STRUCTURE; TRANSFER PROTEINS; IMMUNE-RESPONSES; DENDRITIC CELLS; POLLEN; BINDING; PEANUT	Allergic sensitization is a multifactorial process that is not only influenced by the allergen and its biological function per se but also by other small molecular compounds, such as lipids, that are directly bound as ligands by the allergen or are present in the allergen source. Several members of major allergen families bind lipid ligands through hydrophobic cavities or electrostatic or hydrophobic interactions. These allergens include certain seed storage proteins, Bet v 1-like and nonspecific lipid transfer proteins from pollens and fruits, certain inhalant allergens from house dust mites and cockroaches, and lipocalins. Lipids from the pollen coat and furry animals and the so-called pollen-associated lipid mediators are codelivered with the allergens and can modulate the immune responses of predisposed subjects by interacting with the innate immune system and invariant natural killer T cells. In addition, lipids originating from bacterial members of the pollen microbiome contribute to the outcome of the sensitization process. Dietary lipids act as adjuvants and might skew the immune response toward a T(H)2-dominated phenotype. In addition, the association with lipids protects food allergens from gastrointestinal degradation and facilitates their uptake by intestinal cells. These findings will have a major influence on how allergic sensitization will be viewed and studied in the future.	[Bublin, Merima; Breiteneder, Heimo] Med Univ Vienna, Dept Pathophysiol & Allergy Res, A-1090 Vienna, Austria; [Eiwegger, Thomas] Med Univ Vienna, Dept Pediat Adolescent Med, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna	Breiteneder, H (corresponding author), Med Univ Vienna, Dept Pathophysiol & Allergy Res, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	heimo.breiteneder@meduniwien.ac.at		Eiwegger, Thomas/0000-0002-2914-7829; Breiteneder, Heimo/0000-0003-2022-8689; Bublin, Merima/0000-0002-7191-9431	Austrian Science Fund [SFB F4608]	Austrian Science Fund(Austrian Science Fund (FWF))	H.B. was supported by the Austrian Science Fund (grant SFB F4608).	Abos-Gracia B, 2013, J ALLERGY CLIN IMMUN, V131, P1393, DOI 10.1016/j.jaci.2012.11.014; Agati G, 2013, PLANT PHYSIOL BIOCH, V72, P35, DOI 10.1016/j.plaphy.2013.03.014; Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; Akkerdaas JH, 2006, MOL NUTR FOOD RES, V50, P18, DOI 10.1002/mnfr.200500147; Alcocer M, 2012, BIOTECHNOL LETT, V34, P597, DOI 10.1007/s10529-011-0831-1; Anderson KE, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0058425, 10.1371/journal.pone.0083125]; Asarnoj A, 2012, J ALLERGY CLIN IMMUN, V130, P468, DOI 10.1016/j.jaci.2012.05.019; Bashir MEH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057566; Bogh KL, 2013, INT ARCH ALLERGY IMM, V161, P21, DOI 10.1159/000343042; Bonura A, 2013, IMMUNOBIOLOGY, V218, P995, DOI 10.1016/j.imbio.2012.11.006; Bonura A, 2013, ALLERGY, V68, P297, DOI 10.1111/all.12086; Bossios Apostolos, 2011, Clin Transl Allergy, V1, P6, DOI 10.1186/2045-7022-1-6; Brennan PJ, 2013, NAT REV IMMUNOL, V13, P101, DOI 10.1038/nri3369; Bulgarelli D, 2013, ANNU REV PLANT BIOL, V64, P807, DOI 10.1146/annurev-arplant-050312-120106; Burnett GR, 2002, J COLLOID INTERF SCI, V247, P177, DOI 10.1006/jcis.2001.8093; Chapman LA, 2010, J EXP BOT, V61, P1987, DOI 10.1093/jxb/erq021; Dearman RJ, 2007, CLIN EXP ALLERGY, V37, P582, DOI 10.1111/j.1365-2222.2007.02689.x; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fahy E, 2009, J LIPID RES, V50, pS9, DOI 10.1194/jlr.R800095-JLR200; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Gilles S, 2010, CLIN EXP ALLERGY, V40, P269, DOI 10.1111/j.1365-2222.2009.03369.x; Gilles S, 2012, CURR PHARM DESIGN, V18, P2314, DOI 10.2174/138161212800166040; Gilles S, 2009, J IMMUNOL, V182, P6653, DOI 10.4049/jimmunol.0802613; Gunawan H, 2008, INT ARCH ALLERGY IMM, V147, P276, DOI 10.1159/000144035; Herre J, 2013, J IMMUNOL, V191, P1529, DOI 10.4049/jimmunol.1300284; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Heydenreich B, 2012, CLIN EXP ALLERGY, V42, P76, DOI 10.1111/j.1365-2222.2011.03888.x; Hilger C, 2012, CURR ALLERGY ASTHM R, V12, P438, DOI 10.1007/s11882-012-0283-2; Hsieh K, 2004, PLANT PHYSIOL, V136, P3427, DOI 10.1104/pp.104.051060; Huang SR, 2012, J LIPID RES, V53, P2002, DOI 10.1194/jlr.D029546; Ichikawa S, 2009, GENES CELLS, V14, P1055, DOI 10.1111/j.1365-2443.2009.01334.x; Jia HP, 2004, AM J PHYSIOL-LUNG C, V287, pL428, DOI 10.1152/ajplung.00377.2003; Jyonouchi S, 2014, CLIN EXP ALLERGY, V44, P58, DOI 10.1111/cea.12201; Jyonouchi S, 2011, J ALLERGY CLIN IMMUN, V128, P102, DOI 10.1016/j.jaci.2011.02.026; Kamijo S, 2009, J IMMUNOL, V183, P6087, DOI 10.4049/jimmunol.0901039; Kim JO, 2004, J ALLERGY CLIN IMMUN, V114, P1332, DOI 10.1016/j.jaci.2004.09.004; Leduc V, 2006, ALLERGY, V61, P349, DOI 10.1111/j.1398-9995.2006.01013.x; Li JN, 2013, J ALLERGY CLIN IMMUN, V131, P442, DOI 10.1016/j.jaci.2012.10.011; Liu CF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075983; Mariani V, 2007, J IMMUNOL, V178, P7623, DOI 10.4049/jimmunol.178.12.7623; Markovic-Housley Z, 2003, J MOL BIOL, V325, P123, DOI 10.1016/S0022-2836(02)01197-X; Mattila K, 2009, SCAND J IMMUNOL, V70, P116, DOI 10.1111/j.1365-3083.2009.02277.x; Mirotti L, 2013, ALLERGY, V68, P74, DOI 10.1111/all.12057; Mittag D, 2004, J ALLERGY CLIN IMMUN, V114, P1410, DOI 10.1016/j.jaci.2004.09.014; Mittag D, 2013, EUR J IMMUNOL, V43, P723, DOI 10.1002/eji.201242747; Mogensen JE, 2002, J BIOL CHEM, V277, P23684, DOI 10.1074/jbc.M202065200; Mogensen JE, 2007, BIOCHEMISTRY-US, V46, P3356, DOI 10.1021/bi062058h; Moreno FJ, 2005, J AGR FOOD CHEM, V53, P9810, DOI 10.1021/jf0515227; Mueller GA, 2013, J ALLERGY CLIN IMMUN, V132, P1420, DOI 10.1016/j.jaci.2013.06.014; Mueller GA, 2010, J BIOL CHEM, V285, P25394, DOI 10.1074/jbc.M110.128306; Mueller GA, 2010, J ALLERGY CLIN IMMUN, V125, P909, DOI 10.1016/j.jaci.2009.12.016; ONADERRA M, 1994, EUR J BIOCHEM, V225, P609, DOI 10.1111/j.1432-1033.1994.00609.x; Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830; Parviainen S, 2013, SCAND J IMMUNOL, V77, P171, DOI 10.1111/sji.12023; Pasquato N, 2006, J MOL BIOL, V356, P684, DOI 10.1016/j.jmb.2005.11.063; Petersen A, 2014, BIOL CHEM, V395, P239, DOI 10.1515/hsz-2013-0206; Plotz SG, 2004, J ALLERGY CLIN IMMUN, V113, P1152, DOI 10.1016/j.jaci.2004.03.011; Pons L, 2002, ALLERGY, V57, P88, DOI 10.1034/j.1398-9995.57.s72.16.x; Rundqvist L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046435; Russano AM, 2006, J ALLERGY CLIN IMMUN, V117, P1178, DOI 10.1016/j.jaci.2006.01.001; Salcedo G, 2007, BBA-MOL CELL BIOL L, V1771, P781, DOI 10.1016/j.bbalip.2007.01.001; Sancho AI, 2011, MOL NUTR FOOD RES, V55, P1690, DOI 10.1002/mnfr.201100025; Scanlon ST, 2011, J EXP MED, V208, P2113, DOI 10.1084/jem.20110522; Seutter von Loetzen C, 2014, BIOCHEM J, V457, P379, DOI 10.1042/BJ20130413; Tan KW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044850; Thomas WR, 2013, CLIN EXP ALLERGY, V43, P152, DOI 10.1111/j.1365-2222.2012.04059.x; Tordesillas L., 2013, BJU International, V112, P1374, DOI 10.1111/cea.12202; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Traidl-Hoffmann C, 2002, J ALLERGY CLIN IMMUN, V109, P831, DOI 10.1067/mai.2002.124655; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Vassilopoulou E, 2006, J ALLERGY CLIN IMMUN, V118, P473, DOI 10.1016/j.jaci.2006.04.057; Wang TY, 2013, EUR J CLIN INVEST, V43, P1203, DOI 10.1111/eci.12161; Weangsripanaval T, 2005, J NUTR, V135, P1738, DOI 10.1093/jn/135.7.1738; Yeats TH, 2008, PROTEIN SCI, V17, P191, DOI 10.1110/ps.073300108; Zhang XQ, 2006, BIOCHEMISTRY-US, V45, P8444, DOI 10.1021/bi0602967; Zhao LP, 2013, J AGR FOOD CHEM, V61, P9727, DOI 10.1021/jf403327e	77	89	90	2	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					521	529		10.1016/j.jaci.2014.04.015	http://dx.doi.org/10.1016/j.jaci.2014.04.015			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24880633	hybrid, Green Published			2022-12-18	WOS:000341372400003
J	Lyons, JJ; Sun, GP; Stone, KD; Nelson, C; Wisch, L; O'Brien, M; Jones, N; Lindsley, A; Komarow, HD; Bai, Y; Scott, LM; Cantave, D; Maric, I; Abonia, JP; Rothenberg, ME; Schwartz, LB; Milner, JD; Wilson, TM				Lyons, Jonathan J.; Sun, Guangping; Stone, Kelly D.; Nelson, Celeste; Wisch, Laura; O'Brien, Michelle; Jones, Nina; Lindsley, Andrew; Komarow, Hirsh D.; Bai, Yun; Scott, Linda M.; Cantave, Daly; Maric, Irina; Abonia, J. Pablo; Rothenberg, Marc E.; Schwartz, Lawrence B.; Milner, Joshua D.; Wilson, Todd M.			Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MUTATIONS; KIT		[Lyons, Jonathan J.; Sun, Guangping; Stone, Kelly D.; Nelson, Celeste; Wisch, Laura; O'Brien, Michelle; Komarow, Hirsh D.; Bai, Yun; Scott, Linda M.; Milner, Joshua D.; Wilson, Todd M.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Jones, Nina] Frederick Natl Lab Canc Res, Leidos Biomed Res SAIC Frederick, Clin Res Directorate CMRP, Frederick, MD USA; [Lindsley, Andrew; Abonia, J. Pablo; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Cantave, Daly] NIH, Ctr Clin, Bethesda, MD 20892 USA; [Maric, Irina] NIH, Dept Lab Med, Bethesda, MD 20892 USA; [Schwartz, Lawrence B.] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; Virginia Commonwealth University	Lyons, JJ (corresponding author), NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	jdmilner@niaid.nih.gov; twilson@mail.nih.gov		Abonia, Juan/0000-0003-3788-6485; Lyons, Jonathan/0000-0002-2346-8189	Intramural NIH HHS [ZIA AI001183-01] Funding Source: Medline; NCI NIH HHS [HHSN261200800001E] Funding Source: Medline; NIAID NIH HHS [U19AI77435, T32 AI060515] Funding Source: Medline; NICHD NIH HHS [K12 HD028827] Funding Source: Medline; NIDDK NIH HHS [P30 DK090971] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD028827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001091, ZIAAI001192, U19AI077435, ZIAAI001183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090971] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL080005] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); CLINICAL CENTER		Abonia JP, 2013, J ALLERGY CLIN IMMUN, V132, P378, DOI 10.1016/j.jaci.2013.02.030; Chavanas S, 2000, AM J HUM GENET, V66, P914, DOI 10.1086/302824; Chirumbolo S, 2009, INFLAMM RES, V58, P755, DOI 10.1007/s00011-009-0044-4; Frischmeyer-Guerrerio PA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006448; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Ombrello MJ, 2012, NEW ENGL J MED, V366, P330, DOI 10.1056/NEJMoa1102140; Tang X, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015156; Valent P, 2012, INT ARCH ALLERGY IMM, V157, P215, DOI 10.1159/000328760; Zanotti R, 2013, J ALLERGY CLIN IMMUN, V131, P605, DOI 10.1016/j.jaci.2012.11.040	9	89	90	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1471	+		10.1016/j.jaci.2013.11.039	http://dx.doi.org/10.1016/j.jaci.2013.11.039			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24472624	Green Accepted			2022-12-18	WOS:000335450700034
J	Wang, XW; Wang, WY; Lin, ZM; Wang, XL; Li, T; Yu, J; Liu, W; Tong, ZS; Xu, YH; Zhang, JL; Guan, LP; Dai, LL; Yang, Y; Han, WL; Li, RY				Wang, Xiaowen; Wang, Wenyan; Lin, Zhimiao; Wang, Xiaolin; Li, Ting; Yu, Jin; Liu, Wei; Tong, Zhongsheng; Xu, Yonghao; Zhang, Junling; Guan, Liping; Dai, Lanlan; Yang, Yong; Han, Wenling; Li, Ruoyu			CARD9 mutations linked to subcutaneous phaeohyphomycosis and T(H)17 cell deficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SUSCEPTIBILITY		[Wang, Xiaowen; Lin, Zhimiao; Yu, Jin; Liu, Wei; Yang, Yong; Li, Ruoyu] Peking Univ, Hosp 1, Dept Dermatol, Beijing 100871, Peoples R China; [Wang, Xiaowen; Yu, Jin; Liu, Wei; Li, Ruoyu] Peking Univ, Res Ctr Med Mycol, Beijing 100871, Peoples R China; [Wang, Xiaowen; Lin, Zhimiao; Yu, Jin; Liu, Wei; Yang, Yong; Li, Ruoyu] Peking Univ, Hlth Sci Ctr, Beijing Key Lab Mol Diag Dermatoses, Beijing 100871, Peoples R China; [Wang, Wenyan; Wang, Xiaolin; Li, Ting; Han, Wenling] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Immunol, Beijing 100871, Peoples R China; [Wang, Wenyan; Wang, Xiaolin; Li, Ting; Han, Wenling] Peking Univ, Ctr Human Dis Genom, Beijing 100871, Peoples R China; [Wang, Wenyan; Wang, Xiaolin; Li, Ting; Han, Wenling] Minist Hlth, Key Lab Med Immunol, Beijing, Peoples R China; [Tong, Zhongsheng] Wuhan First Hosp, Ctr Infect Skin Dis, Dept Dermatol, Wuhan, Peoples R China; [Xu, Yonghao] Shandong Univ, Dept Dermatol, Qilu Hosp, Jinan 250100, Peoples R China; [Zhang, Junling] Tianjin Changzheng Hosp, Dept Dermatol, Tianjin, Peoples R China; [Guan, Liping; Dai, Lanlan] BGI Shenzhen, Shenzhen, Peoples R China; [Yang, Yong] Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China	Peking University; Peking University; Peking University; Peking University; Peking University; Shandong University; Beijing Genomics Institute (BGI)	Wang, XW (corresponding author), Peking Univ, Hosp 1, Dept Dermatol, Beijing 100871, Peoples R China.	hanwl@bjmu.edu.cn						Bertin J, 2000, J BIOL CHEM, V275, P41082, DOI 10.1074/jbc.C000726200; Drummond RA, 2011, EUR J IMMUNOL, V41, P276, DOI 10.1002/eji.201041252; Engelhardt KR, 2012, J ALLERGY CLIN IMMUN, V129, P294, DOI [10.1016/j.jaci.2011.12.966, 10.1016/j.jaci.2011.12.972]; Gao LJ, 2013, MYCOPATHOLOGIA, V175, P165, DOI 10.1007/s11046-012-9602-3; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; Li RuoYu, 1996, Japanese Journal of Medical Mycology, V37, P135; Romani L, 2011, NAT REV IMMUNOL, V11, P275, DOI 10.1038/nri2939; Wang XW, 2013, J ALLERGY CLIN IMMUN, V131, P1242, DOI 10.1016/j.jaci.2012.11.005	9	89	95	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					905	+		10.1016/j.jaci.2013.09.033	http://dx.doi.org/10.1016/j.jaci.2013.09.033			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24231284				2022-12-18	WOS:000332397600043
J	Alvarez-Twose, I; Zanotti, R; Gonzalez-de-Olano, D; Bonadonna, P; Vega, A; Matito, A; Sanchez-Munoz, L; Morgado, JM; Perbellini, O; Garcia-Montero, A; De Matteis, G; Teodosio, C; Rossini, M; Jara-Acevedo, M; Schena, D; Mayado, A; Zamo, A; Mollejo, M; Sanchez-Lopez, P; Cabanes, N; Orfao, A; Escribano, L				Alvarez-Twose, Ivan; Zanotti, Roberta; Gonzalez-de-Olano, David; Bonadonna, Patrizia; Vega, Arantza; Matito, Almudena; Sanchez-Munoz, Laura; Mario Morgado, Jose; Perbellini, Omar; Garcia-Montero, Andres; De Matteis, Giovanna; Teodosio, Cristina; Rossini, Maurizio; Jara-Acevedo, Maria; Schena, Donatella; Mayado, Andrea; Zamo, Alberto; Mollejo, Manuela; Sanchez-Lopez, Paula; Cabanes, Nieves; Orfao, Alberto; Escribano, Luis		Spanish Network Mastocytosis REMA; Italian Network Mastocytosis RIMA	Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; mastocytosis; anaphylaxis; insect; Hymenoptera; insect sting anaphylaxis	MAST-CELL DISORDERS; C-KIT; SPANISH NETWORK; IMMUNOPHENOTYPIC CHARACTERIZATION; CATALYTIC DOMAIN; SERUM TRYPTASE; VENOM; HYMENOPTERA; DIAGNOSIS; MUTATION	Background: Indolent systemic mastocytosis (ISM) without skin lesions (ISMs-) shows a higher prevalence in males, lower serum baseline tryptase levels, and KIT mutation more frequently restricted to bone marrow (BM) mast cells (MCs) than ISM with skin lesions (ISMs+). Interestingly, in almost one-half of ISMs- patients, MC-mediator release episodes are triggered exclusively by insects. Objective: We aimed to determine the clinical and laboratory features of ISMs- associated with insect-induced anaphylaxis (insectISMs(-)) versus other patients with ISM. Methods: A total of 335 patients presenting with MC activation syndrome, including 143 insectISMs(-), 72 ISMs- triggered by other factors (otherISMs(-)), 56 ISMs+, and 64 nonclonal MC activation syndrome, were studied. Results: Compared with otherISMs(-) and ISMs+ patients, insectISMs(-) cases showed marked male predominance (78% vs 53% and 46%; P < .001), a distinct pattern of MC-related symptoms, and significantly lower median serum baseline tryptase levels (22.4 vs 28.7 and 45.8 mu g/L; P <= .009). Moreover, insectISMs(-) less frequently presented BM MC aggregates (46% vs 70% and 81%; P <= .001), and they systematically showed MC-restricted KIT mutation. Conclusions: ISMs- patients with anaphylaxis triggered exclusively by insects display clinical and laboratory features that are significantly different from other ISM cases, including other ISMs- and ISMs+ patients, suggesting that they represent a unique subgroup of ISM with a particularly low BM MC burden in the absence of adverse prognostic factors.	[Alvarez-Twose, Ivan; Matito, Almudena; Sanchez-Munoz, Laura; Mario Morgado, Jose] Hosp Virgen del Valle, Inst Estudios Mastocitosis Castilla La Mancha CLM, Toledo 45071, Spain; [Alvarez-Twose, Ivan; Gonzalez-de-Olano, David; Matito, Almudena; Sanchez-Munoz, Laura; Mario Morgado, Jose; Garcia-Montero, Andres; Teodosio, Cristina; Jara-Acevedo, Maria; Mayado, Andrea; Mollejo, Manuela; Orfao, Alberto; Escribano, Luis] Spanish Network Mastocytosis REMA, Toledo, Spain; [Alvarez-Twose, Ivan; Gonzalez-de-Olano, David; Matito, Almudena; Sanchez-Munoz, Laura; Mario Morgado, Jose; Garcia-Montero, Andres; Teodosio, Cristina; Jara-Acevedo, Maria; Mayado, Andrea; Mollejo, Manuela; Orfao, Alberto; Escribano, Luis] Spanish Network Mastocytosis REMA, Salamanca, Spain; [Zanotti, Roberta; Perbellini, Omar] Univ Verona, Dept Med, Sect Haematol, I-37100 Verona, Italy; [Zanotti, Roberta; Bonadonna, Patrizia; Perbellini, Omar; De Matteis, Giovanna; Rossini, Maurizio; Schena, Donatella; Zamo, Alberto] Multidisciplinary Outpatients Clin Mastocytosis, Verona, Italy; [Gonzalez-de-Olano, David] Hosp Fuenlabrada, Allergy Unit, Madrid, Spain; [Bonadonna, Patrizia] Azienda Osped Univ Integrata, Allergy Unit, Verona, Italy; [Vega, Arantza] Hosp Guadalajara, Dept Allergy, Guadalajara, Spain; [Garcia-Montero, Andres; Teodosio, Cristina; Jara-Acevedo, Maria; Mayado, Andrea; Orfao, Alberto] Univ Salamanca, Ctr Invest Canc IBMCC USAL CSIC, E-37008 Salamanca, Spain; [Garcia-Montero, Andres; Teodosio, Cristina; Jara-Acevedo, Maria; Mayado, Andrea; Orfao, Alberto] Univ Salamanca, IBSAL, Dept Med, E-37008 Salamanca, Spain; [Garcia-Montero, Andres; Teodosio, Cristina; Jara-Acevedo, Maria; Mayado, Andrea; Orfao, Alberto] Univ Salamanca, Serv Gen Citometria, E-37008 Salamanca, Spain; [De Matteis, Giovanna] Azienda Osped Univ Integrata, Verona, Italy; [Rossini, Maurizio] Azienda Osped Univ Integrata, Dept Med, Rheumatol Sect, Verona, Italy; [Schena, Donatella] Azienda Osped Univ Integrata, Dept Med, Dermatol Sect, Verona, Italy; [Zamo, Alberto] Azienda Osped Univ Integrata, Dept Pathol, Verona, Italy; [Mollejo, Manuela] Hosp Virgen de la Salud, Pathol Dept, Toledo, Spain; [Sanchez-Lopez, Paula; Cabanes, Nieves] Hosp Virgen del Valle, Allergy Unit, Toledo 45071, Spain	Complejo Hospitalario de Toledo; University of Verona; Hospital Universitario Fuenlabrada; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Salamanca; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; Complejo Hospitalario de Toledo; Complejo Hospitalario de Toledo	Alvarez-Twose, I (corresponding author), Hosp Virgen del Valle, Inst Estudios Mastocitosis Castilla La Mancha CLM, Carretera Cobisa S-N, Toledo 45071, Spain.	ivana@sescam.jccm.es	Garcia-Montero, Andres C/B-6558-2017; Orfao, Alberto/B-5801-2017; rossini, maurizio/D-6610-2011; Zamò, Alberto/ABF-4436-2020; Montero, Andres/HGA-9093-2022	Garcia-Montero, Andres C/0000-0003-4360-1386; Matito, Almudena/0000-0002-9547-4844; PERBELLINI, Omar/0000-0002-8278-8916; Jara-Acevedo, Maria/0000-0001-7965-7512; Sanchez-Munoz, Laura/0000-0003-1757-7255; Zamo, Alberto/0000-0001-6203-7966; Rossini, Maurizio/0000-0001-9692-2293; Mollejo, Manuela/0000-0001-5658-0532; Alvarez-Twose, Ivan/0000-0002-1190-4473; Teodosio, Cristina/0000-0002-2097-7199	Fondo de Investigaciones Sanitarias - FIS-of the Instituto de Salud Carlos III, Ministery of Economy and Competitivity, Madrid, Spain [PS09/00032]; Fundacion Sociosanitaria de Castilla-La Mancha [2010/008, G-2010/C-002]; Fundacion Espanola de Mastocitosis [FEM 2011]; RETICS (Redes Tematicas de Investigacion Cooperativa en Salud) (Toledo, Spain) [RD09/00760074]; RTICC (Red Tematica de Investigacion Cooperativa en Cancer) [RD09/0076/00133, RD12/0036/0048]; FIS; FEDER, Ministery of Economy and Competitivity, Madrid, Spain [PI11/02399]; Fundacion Ramon Areces, Madrid, Spain [CIVP16A1806]; Associazione Italiana Leucemie e Linfomi of Verona (AIL-Verona); ASIMAS (Associazione Italiana Mastocitosi)	Fondo de Investigaciones Sanitarias - FIS-of the Instituto de Salud Carlos III, Ministery of Economy and Competitivity, Madrid, Spain; Fundacion Sociosanitaria de Castilla-La Mancha; Fundacion Espanola de Mastocitosis; RETICS (Redes Tematicas de Investigacion Cooperativa en Salud) (Toledo, Spain); RTICC (Red Tematica de Investigacion Cooperativa en Cancer); FIS(Instituto de Salud Carlos III); FEDER, Ministery of Economy and Competitivity, Madrid, Spain; Fundacion Ramon Areces, Madrid, Spain; Associazione Italiana Leucemie e Linfomi of Verona (AIL-Verona); ASIMAS (Associazione Italiana Mastocitosi)	Supported by Fondo de Investigaciones Sanitarias - FIS-of the Instituto de Salud Carlos III, Ministery of Economy and Competitivity, Madrid, Spain grant PS09/00032; Fundacion Sociosanitaria de Castilla-La Mancha grants 2010/008 and G-2010/C-002; Fundacion Espanola de Mastocitosis grant FEM 2011; BioB-HVS is supported by grant RETICS (Redes Tematicas de Investigacion Cooperativa en Salud) RD09/00760074 (Toledo, Spain); RTICC (Red Tematica de Investigacion Cooperativa en Cancer) grants RD09/0076/00133, RD12/0036/0048; FIS; FEDER, Ministery of Economy and Competitivity, Madrid, Spain grant PI11/02399; and Fundacion Ramon Areces, Madrid, Spain grant CIVP16A1806; and by Associazione Italiana Leucemie e Linfomi of Verona (AIL-Verona) and ASIMAS (Associazione Italiana Mastocitosi).	Alvarez-Twose I, 2012, INT J LAB HEMATOL, V34, P445, DOI 10.1111/j.1751-553X.2012.01427.x; Alvarez-Twose I, 2012, ALLERGY, V67, P1190, DOI 10.1111/j.1398-9995.2012.02850.x; Alvarez-Twose I, 2012, INT ARCH ALLERGY IMM, V157, P275, DOI 10.1159/000329856; Alvarez-Twose I, 2009, J ALLERGY CLIN IMMUN, V123, pS141, DOI 10.1016/j.jaci.2008.12.524; Alvarez-Twose I, 2010, J ALLERGY CLIN IMMUN, V125, P1269, DOI 10.1016/j.jaci.2010.02.019; Bonadonna P, 2012, ALLERGY, V67, P962, DOI 10.1111/j.1398-9995.2012.02849.x; Bonadonna P, 2008, J ALLERGY CLIN IMMUN, V121, P256, DOI 10.1016/j.jaci.2007.10.014; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; de Olano DG, 2007, CLIN EXP ALLERGY, V37, P1547, DOI 10.1111/j.1365-2222.2007.02804.x; De Olano DG, 2008, J ALLERGY CLIN IMMUN, V121, P519, DOI 10.1016/j.jaci.2007.11.010; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Dubois AEJ, 2004, CURR OPIN ALLERGY CL, V4, P291, DOI 10.1097/01.all.0000136756.20701.f8; Escribano L, 1998, BLOOD, V91, P2731, DOI 10.1182/blood.V91.8.2731.2731_2731_2736; Escribano L, 2004, CYTOM PART B-CLIN CY, V58B, P1, DOI 10.1002/cyto.b.10072; Escribano L, 2012, LAB HEMATOLOGY PRACT, P388; Escribano L, 2009, J ALLERGY CLIN IMMUN, V124, P514, DOI 10.1016/j.jaci.2009.05.003; Garcia-Montero AC, 2006, BLOOD, V108, P2366, DOI 10.1182/blood-2006-04-015545; Golden DBK, 2003, J ALLERGY CLIN IMMUN, V112, P495, DOI [10.1067/mai.2003.1606, 10.1016/S0091-6749(03)01537-9]; Gonzalez-de-Olano D, 2011, CYTOM PART B-CLIN CY, V80B, P167, DOI 10.1002/cyto.b.20577; Gonzalez-de-Olano D, 2011, IMMUNOTHERAPY-UK, V3, P637, DOI [10.2217/IMT.11.44, 10.2217/imt.11.44]; Hermann K, 1997, INT ARCH ALLERGY IMM, V112, P251, DOI 10.1159/000237462; Horny HP, 1998, AM J SURG PATHOL, V22, P1132, DOI 10.1097/00000478-199809000-00013; Horny HP, 2001, LEUKEMIA RES, V25, P543, DOI 10.1016/S0145-2126(01)00021-2; Horny HP, 2008, WHO CLASSIFICATION T, P54; Kawabata Y, 2000, SHOCK, V14, P572, DOI 10.1097/00024382-200014050-00013; Kosnik M, 2000, ALLERGY, V55, P676, DOI 10.1034/j.1398-9995.2000.00691.x; Kranke B, 2004, J ALLERGY CLIN IMMUN, V113, P180, DOI 10.1016/j.jaci.2003.10.013; Krokowski M, 2005, AM J CLIN PATHOL, V124, P560, DOI 10.1309/CX45R79PCU9HCV6V; Lawley W, 2005, MUTAT RES-FUND MOL M, V572, P1, DOI 10.1016/j.mrfmmm.2004.08.015; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Monsalve RI, 2012, ALLERGY, V67, P528, DOI 10.1111/j.1398-9995.2011.02781.x; Muller UR, 2009, CLIN EXP ALLERGY, V39, P620, DOI 10.1111/j.1365-2222.2009.03251.x; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Niedoszytko M, 2009, ALLERGY, V64, P1237, DOI 10.1111/j.1398-9995.2009.02118.x; Niedoszytko M, 2010, INT ARCH ALLERGY IMM, V153, P166, DOI 10.1159/000312634; Pardanani A, 2003, LEUKEMIA RES, V27, P883, DOI 10.1016/S0145-2126(03)00065-1; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sanchez-Munoz L, 2011, MODERN PATHOL, V24, P1157, DOI 10.1038/modpathol.2011.84; Sanchez-Munoz L, 2011, METHOD CELL BIOL, V103, P333, DOI 10.1016/B978-0-12-385493-3.00014-0; Sotlar K, 2003, AM J PATHOL, V162, P737, DOI 10.1016/S0002-9440(10)63870-9; Sperr WR, 2001, LEUKEMIA RES, V25, P529, DOI 10.1016/S0145-2126(01)00041-8; Teodosio C, 2012, LEUKEMIA, V26, P951, DOI 10.1038/leu.2011.293; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Valent P, 2004, J ALLERGY CLIN IMMUN, V114, P3, DOI 10.1016/j.jaci.2004.02.045; VANDERLINDEN PWG, 1990, LANCET, V336, P904, DOI 10.1016/0140-6736(90)92272-J; Volcheck GW, 1998, J ALLERGY CLIN IMMUN, V102, P149, DOI 10.1016/S0091-6749(98)70068-5; Wagner N, 2008, INT ARCH ALLERGY IMM, V146, P162, DOI 10.1159/000113520; Yavuz AS, 2002, BLOOD, V100, P661, DOI 10.1182/blood-2002-01-0203; Zanotti R, 2011, HAEMATOL-HEMATOL J, V96, P482, DOI 10.3324/haematol.2010.034553	50	89	89	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					520	+		10.1016/j.jaci.2013.06.020	http://dx.doi.org/10.1016/j.jaci.2013.06.020			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	23921094				2022-12-18	WOS:000332397100028
J	Hylander, T; Latif, L; Petersson-Westin, U; Cardell, LO				Hylander, Terese; Latif, Leith; Petersson-Westin, Ulla; Cardell, Lars Olaf			Intralymphatic allergen-specific immunotherapy: An effective and safe alternative treatment route for pollen-induced allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen-specific immunotherapy; allergic rhinitis; intralymphatic immunotherapy; seasonal allergic rhinitis	LOCALIZATION; MECHANISMS; DISEASES; MARKERS; DIFFERENTIATION; IMMUNOLOGY; INJECTION; ANTIGENS; VACCINES; UPDATE	Background: Allergen-specific immunotherapy is the only causative treatment of IgE-mediated allergic disorders. The most common administration route is subcutaneous, which may necessitate more than 50 allergen injections during 3 to 5 years. Recent evidence suggests that direct intralymphatic injections could yield faster beneficial results with considerably lower allergen doses and markedly reduced numbers of injections. Objective: To evaluate the effects of intralymphatic allergen-specific immunotherapy in pollen-allergic patients. Methods: In an open pilot investigation followed by a double-blind, placebo-controlled study, patients with allergic rhinitis were treated with 3 intralymphatic inguinal injections of ALK Alutard (containing 1000 SQ-U birch pollen or grass pollen) or placebo (ALK diluent). Clinical pre- and posttreatment parameters were assessed, the inflammatory cell content in nasal lavage fluids estimated, and the activation pattern of peripheral T cells described. Results: All patients tolerated the intralymphatic immunotherapy (ILIT) treatment well, and the injections did not elicit any severe adverse event. Patients receiving active treatment displayed an initial increase in allergen-specific IgE level and peripheral T-cell activation. A clinical improvement in nasal allergic symptoms upon challenge was recorded along with a decreased inflammatory response in the nose. In addition, these patients reported an improvement in their seasonal allergic disease. No such changes were seen in the placebo group. Conclusions: Although this study is based on a limited number of patients, ILIT with grass-pollen or birch-pollen extracts appears to reduce nasal allergic symptoms without causing any safety problems. Hence, ILIT might constitute a less time-consuming and more cost-effective alternative to conventional subcutaneous allergen-specific immunotherapy. (J Allergy Clin Immunol 2013;131:412-20.)	[Hylander, Terese; Cardell, Lars Olaf] Karolinska Inst, Div ENT Dis, Dept Clin Sci Intervent & Technol, SE-14186 Stockholm, Sweden; [Latif, Leith; Petersson-Westin, Ulla; Cardell, Lars Olaf] Lund Univ, Skane Univ Hosp, Dept Otorhinolaryngol Malmo, Malmo, Sweden	Karolinska Institutet; Lund University; Skane University Hospital	Cardell, LO (corresponding author), Karolinska Inst, Div ENT Dis, Dept Clin Sci Intervent & Technol CLINTEC, SE-14186 Stockholm, Sweden.	lars-olaf.cardell@ki.se			Swedish Medical Research Council	Swedish Medical Research Council(Swedish Medical Research Council (SMRC))	L. O. Cardell has received grants from the Swedish Medical Research Council. The rest of the authors declare that they have no relevant conflicts of interest.	Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Casale TB, 2004, J ALLERGY CLIN IMMUN, V113, P1036, DOI 10.1016/j.jaci.2004.04.017; Cevit O, 2007, J INVEST ALLERG CLIN, V17, P286; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Dorfman DM, 2002, HUM PATHOL, V33, P330, DOI 10.1053/hupa.2002.32215; Eifan AO, 2011, CURR OPIN ALLERGY CL, V11, P586, DOI 10.1097/ACI.0b013e32834cb994; Ekman AK, 2012, INT ARCH ALLERGY IMM, V159, P6, DOI 10.1159/000335196; Fransson M, 2004, ACTA OTO-LARYNGOL, V124, P616, DOI 10.1080/00016480310015173; Frew Anthony J., 2003, Journal of Allergy and Clinical Immunology, V111, pS712; Frew AJ, 2010, J ALLERGY CLIN IMMUN, V125, pS306, DOI 10.1016/j.jaci.2009.10.064; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; Hellgren J, 2010, ALLERGY, V65, P776, DOI 10.1111/j.1398-9995.2009.02269.x; Holgate ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262; James LK, 2008, CLIN EXP ALLERGY, V38, P1074, DOI 10.1111/j.1365-2222.2008.02976.x; Johansen P, 2005, EUR J IMMUNOL, V35, P568, DOI 10.1002/eji.200425599; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kay AB, 2001, NEW ENGL J MED, V344, P109, DOI 10.1056/NEJM200101113440206; Kundig TM, 2011, ALLERGY, V66, P60, DOI 10.1111/j.1398-9995.2011.02643.x; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Larenas-Linnemann D, 2008, ANN ALLERG ASTHMA IM, V100, P137, DOI 10.1016/S1081-1206(10)60422-X; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Malling HJ, 1998, ALLERGY, V53, P461; Maloy KJ, 2001, P NATL ACAD SCI USA, V98, P3299, DOI 10.1073/pnas.051630798; Mansson A, 2010, J INVEST ALLERG CLIN, V20, P476; Mansson A, 2009, ALLERGY, V64, P1292, DOI 10.1111/j.1398-9995.2009.02012.x; Martinez-Gomez JM, 2009, INT ARCH ALLERGY IMM, V150, P59, DOI 10.1159/000210381; Pfaar O, 2011, IMMUNOL ALLERGY CLIN, V31, P289, DOI 10.1016/j.iac.2011.02.004; POPPER P, 1988, PEPTIDES, V9, P257, DOI 10.1016/0196-9781(88)90258-6; Ragusa V Franco, 2004, Eur Ann Allergy Clin Immunol, V36, P52; Senna G, 2009, CURR OPIN ALLERGY CL, V9, P544, DOI 10.1097/ACI.0b013e328332b8df; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P1290, DOI 10.1016/j.jaci.2012.02.026; Senti G, 2009, CURR OPIN ALLERGY CL, V9, P537, DOI 10.1097/ACI.0b013e3283310ff7; Senti G, 2008, P NATL ACAD SCI USA, V105, P17908, DOI 10.1073/pnas.0803725105; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Storms WW, 2003, ANN ALLERG ASTHMA IM, V91, P131, DOI 10.1016/S1081-1206(10)62167-9; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; von Beust BR, 2005, EUR J IMMUNOL, V35, P1869, DOI 10.1002/eji.200526124; ZIEGLER SF, 1994, STEM CELLS, V12, P456, DOI 10.1002/stem.5530120502; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x; Zinkernagel RM, 2000, SEMIN IMMUNOL, V12, P163, DOI 10.1006/smim.2000.0253; Zola H, 2000, J BIOL REG HOMEOS AG, V14, P218	42	89	98	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					412	420		10.1016/j.jaci.2012.10.056	http://dx.doi.org/10.1016/j.jaci.2012.10.056			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23374268				2022-12-18	WOS:000314661500019
J	Mobs, C; Ipsen, H; Mayer, L; Slotosch, C; Petersen, A; Wurtzen, PA; Hertl, M; Pfutzner, W				Moebs, Christian; Ipsen, Henrik; Mayer, Lea; Slotosch, Caroline; Petersen, Arnd; Wurtzen, Peter A.; Hertl, Michael; Pfuetzner, Wolfgang			Birch pollen immunotherapy results in long-term loss of Bet v 1-specific T(H)2 responses, transient T(R)1 activation, and synthesis of IgE-blocking antibodies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Respiratory allergy; specific immunotherapy; allergen tolerance; Bet v 1; IgE; IgG; blocking antibodies; regulatory T cells	REGULATORY T-CELLS; ALLERGEN-SPECIFIC IMMUNOTHERAPY; MEMORY B-CELLS; FOLLOW-UP; SUBLINGUAL IMMUNOTHERAPY; ANTIVIRAL IMMUNITY; CLINICAL-EFFICACY; HISTAMINE-RELEASE; INHIBITION; EXPANSION	Background: Early events of specific immunotherapy (SIT) are induction of allergen-specific IL-10-producing T(R)1 cells and production of IgG antibodies, but there is little knowledge about the long-term immune mechanisms responsible for sustained allergen tolerance. Objective: Bet v 1-specific immune responses of 16 patients with birch pollen allergy were characterized up to 54 months at defined time points before, during, and after a 3-year period of SIT. Methods: We sought to analyze allergen-specific T- and B-cell responses. Bet v 1-specific IL-5-, IFN-gamma-, and IL-10-secreting T cells were quantified in peripheral blood, and birch pollenspecific IgE and IgG antibody levels were determined in serum. Furthermore, the inhibitory capacity of SIT-induced IgG was evaluated by blocking allergen binding to IgE and inhibition of facilitated allergen presentation. Results: Seasonal increases in Bet v 1-specific T(H)2 cell numbers ceased to appear after the first year of SIT without deviation to a TH1-dominated immune response. Furthermore, the frequency of IL-10-producing TR1 cells, which had increased during the first year of SIT, returned to pretreatment levels in the second year. In contrast, allergen-specific IgG antibody concentrations continuously increased during SIT but started to decrease after cessation of treatment. Functional analysis confirmed the ability of the IgG antibodies to inhibit IgE-allergen interactions, which peaked at the end of SIT but then slowly started to decrease. Conclusion: Long-term allergen tolerance achieved by SIT is associated with the development of peripheral T-cell tolerance characterized by decreased reactivity of Bet v 1-specific TH2 cells and enriched allergen-specific IgG competing with IgE antibodies for allergen binding. (J Allergy Clin Immunol 2012; 130: 1108-16.)	[Moebs, Christian; Mayer, Lea; Slotosch, Caroline; Hertl, Michael; Pfuetzner, Wolfgang] Univ Marburg, Dept Dermatol & Allergol, D-35043 Marburg, Germany; [Ipsen, Henrik; Wurtzen, Peter A.] ALK Abello, Vaccine Res & Discovery, Horsholm, Denmark	Philipps University Marburg; ALK-Abello AS	Pfutzner, W (corresponding author), Univ Marburg, Dept Dermatol & Allergol, Baldingerstr, D-35043 Marburg, Germany.	wpfuetzn@med.uni-marburg.de		Mobs, Christian/0000-0002-5197-7669	Deutsche Forschungsgemeinschaft [HE 1602/10-1, SFB/TR22 A20, Z1]; ALK-Scherax, Horsholm, Denmark	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); ALK-Scherax, Horsholm, Denmark	Supported by grants from the Deutsche Forschungsgemeinschaft (HE 1602/10-1 and SFB/TR22 A20 and Z1) and a grant from ALK-Scherax, Horsholm, Denmark.	Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Anderson AE, 2009, CLIN EXP ALLERGY, V39, P1693, DOI 10.1111/j.1365-2222.2009.03320.x; Antunez C, 2008, PEDIAT ALLERG IMM-UK, V19, P210, DOI 10.1111/j.1399-3038.2007.00604.x; Bacchetta R, 2002, EUR J IMMUNOL, V32, P2237, DOI 10.1002/1521-4141(200208)32:8<2237::AID-IMMU2237>3.0.CO;2-2; Batard T, 2005, INT ARCH ALLERGY IMM, V136, P239, DOI 10.1159/000083950; Benjaponpitak S, 1999, J ALLERGY CLIN IMMUN, V103, P468, DOI 10.1016/S0091-6749(99)70473-2; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Dormann D, 1997, INT ARCH ALLERGY IMM, V114, P272, DOI 10.1159/000237679; Durham SR, 2011, ALLERGY, V66, P50, DOI 10.1111/j.1398-9995.2011.02639.x; Durham S R, 1991, Clin Exp Allergy, V21 Suppl 1, P206, DOI 10.1111/j.1365-2222.1991.tb01729.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Ejrnaes AM, 2006, CLIN EXP ALLERGY, V36, P273, DOI 10.1111/j.1365-2222.2006.02442.x; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; Gadermaier E, 2011, ALLERGY, V66, P1174, DOI 10.1111/j.1398-9995.2011.02592.x; Gardner LM, 2004, INT ARCH ALLERGY IMM, V133, P1, DOI 10.1159/000075248; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; Geroldinger-Simic M, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Geroldinger-Simic M, 2011, J ALLERGY CLIN IMMUN, V127, P616, DOI 10.1016/j.jaci.2010.10.027; Grindebacke H, 2009, J CLIN IMMUNOL, V29, P752, DOI 10.1007/s10875-009-9312-x; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Guerra F, 2001, J ALLERGY CLIN IMMUN, V107, P647, DOI 10.1067/mai.2001.112263; Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917; Hammarlund E, 2010, J VIROL, V84, P12754, DOI 10.1128/JVI.01763-10; Hebeis BJ, 2004, J EXP MED, V199, P593, DOI 10.1084/jem.20030091; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Jeannin P, 1998, J IMMUNOL, V160, P3555; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Karamloo F, 1999, J ALLERGY CLIN IMMUN, V104, P991, DOI 10.1016/S0091-6749(99)70080-1; Keles S, 2011, J ALLERGY CLIN IMMUN, V128, P808, DOI 10.1016/j.jaci.2011.04.033; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; Linhart B, 2012, CURR OPIN IMMUNOL, V24, P354, DOI 10.1016/j.coi.2012.03.006; Mobs C, 2010, J IMMUNOL, V184, P2194, DOI 10.4049/jimmunol.0901379; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Nieminen K, 2009, INT ARCH ALLERGY IMM, V150, P370, DOI 10.1159/000226238; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; O'Hehir RE, 2009, AM J RESP CRIT CARE, V180, P936, DOI 10.1164/rccm.200905-0686OC; Ott H, 2009, ALLERGY, V64, P1394, DOI [10.1111/j.1398-9995.2008.01875.x, 10.1111/j.1398-9995.2009.02194.x]; Petersen AB, 2004, CLIN BIOCHEM, V37, P882, DOI 10.1016/j.clinbiochem.2004.06.010; Pilette C, 2007, J IMMUNOL, V178, P4658, DOI 10.4049/jimmunol.178.7.4658; Pree I, 2010, CLIN EXP ALLERGY, V40, P1346, DOI 10.1111/j.1365-2222.2010.03548.x; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; Rolland JM, 2010, CURR OPIN ALLERGY CL, V10, P559, DOI 10.1097/ACI.0b013e32833ff2b2; Roncarolo MG, 2006, IMMUNOL REV, V212, P28; Rueff F, 2011, Pneumologie, V65, P484, DOI 10.1055/s-0030-1256476; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Sparholt SH, 1997, CLIN EXP ALLERGY, V27, P932; Tsai YG, 2005, PEDIAT ALLERG IMM-UK, V16, P602, DOI 10.1111/j.1399-3038.2005.00313.x; Van Overtvelt L, 2008, J IMMUNOL, V180, P4514, DOI 10.4049/jimmunol.180.7.4514; VanRee R, 1997, CLIN EXP ALLERGY, V27, P68, DOI 10.1046/j.1365-2222.1997.d01-416.x; VIEIRA P, 1990, INT IMMUNOL, V2, P487, DOI 10.1093/intimm/2.6.487; Vieira PL, 2004, J IMMUNOL, V172, P5986, DOI 10.4049/jimmunol.172.10.5986; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, P544, DOI 10.1016/j.jaci.2011.08.034; Wurtzen PA, 2008, CLIN EXP ALLERGY, V38, P1290, DOI 10.1111/j.1365-2222.2008.03020.x; Yamanaka Kei-ichi, 2011, Allergology International, V60, P45, DOI 10.2332/allergolint.10-OA-0198; Yamanaka K, 2009, J ALLERGY CLIN IMMUN, V124, P842, DOI 10.1016/j.jaci.2009.06.020	71	89	92	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1108	+		10.1016/j.jaci.2012.07.056	http://dx.doi.org/10.1016/j.jaci.2012.07.056			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	23021882				2022-12-18	WOS:000310571400011
J	Wasserman, RL; Melamed, I; Stein, MR; Gupta, S; Puck, J; Engl, W; Leibl, H; McCoy, B; Empson, VG; Gelmont, D; Schiff, RI				Wasserman, Richard L.; Melamed, Isaac; Stein, Mark R.; Gupta, Sudhir; Puck, Jennifer; Engl, Werner; Leibl, Heinz; McCoy, Barbara; Empson, Victoria G.; Gelmont, David; Schiff, Richard I.		IGSC; Grp, WRS	Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Facilitated subcutaneous immunoglobulin; intravenous immunoglobulin; recombinant human hyaluronidase; primary immunodeficiency; efficacy; tolerability; bioavailability	PRIMARY ANTIBODY DEFICIENCIES; QUALITY-OF-LIFE; REPLACEMENT THERAPY; INTERNATIONAL-UNION; SAFETY; EFFICACY; PHARMACOKINETICS; DISEASES; CLASSIFICATION; CHILDREN	Background: Subcutaneous immunoglobulin (IGSC) replacement therapy for primary immunodeficiency (PI) is equally efficacious to intravenous immunoglobulin (IGIV), induces fewer systemic reactions, and may be self-infused. Limited SC infusion volumes and reduced bioavailability, however, necessitate multiple infusion sites, more frequent treatment, and dose adjustment to achieve pharmacokinetic equivalence. Recombinant human hyaluronidase (rHuPH20) increases SC tissue permeability and facilitates dispersion and absorption, enabling administration of monthly doses in one site. Objective: This study investigated the efficacy and tolerability of rHuPH20-facilitated IGSC (IGHy) in patients with PI. Methods: In this open-label, multicenter phase III study, 87 patients with PI aged >= 2 years received 10% IGIV for 3 months, then IGHy (n = 83) for approximately 14 to 18 months at 108% of the IGIV dose. IGHy infusions began weekly, increasing to 3- or 4-week intervals. Results: The majority (94.0%) of IGHy infusions were administered every 3 or 4 weeks, using one site (median, 1.09/month), with a mean volume of 292.2 mL. The bioavailability of IGHy measured by area under the concentration versus time curve was 93.3% of IGIV, which is pharmacokinetically equivalent. Systemic reactions were less frequent with IGHy than with IGIV (8.3% vs 25.0% of infusions). Local reactions to IGHy were generally mild to moderate, with a rate of 0.203 per infusion. The acute serious bacterial infection rate per subject-year for IGHy was low (0.025; upper 99% CI limit, 0.046). Overall infection rates per subject-year were 2.97 for IGHy and 4.51 for IGIV. Conclusion: IGHy was effective, safe, and pharmacokinetically equivalent to IGIV at the same administration intervals, but it caused fewer systemic reactions. Tolerability was good despite high infusion volumes and rates. (J Allergy Clin Immunol 2012; 130:951-7.)	[Gelmont, David; Schiff, Richard I.] Baxter Healthcare Corp, Westlake Village, CA 91362 USA; [Wasserman, Richard L.] Allergy Immunol Res Ctr N Texas, Dallas, TX USA; [Stein, Mark R.] Allergy Associates Palm Beaches, N Palm Beach, FL USA; [Gupta, Sudhir] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; [Puck, Jennifer] Univ Calif San Francisco, Dept Pediat & Clin, San Francisco, CA 94143 USA; [Puck, Jennifer] Univ Calif San Francisco, Translat Sci Inst, San Francisco, CA 94143 USA; [Engl, Werner; Leibl, Heinz; McCoy, Barbara; Empson, Victoria G.] Baxter Innovat GmbH, Vienna, Austria	Baxter International Inc; University of California System; University of California Irvine; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Baxter International Inc; Baxter Innovations GmbH	Schiff, RI (corresponding author), Baxter Healthcare Corp, 1 Baxter Way, Westlake Village, CA 91362 USA.	richard_schiff@baxter.com		Engl, Werner/0000-0002-1705-7850; Empson, Victoria/0000-0003-3819-2370	Baxter Healthcare Corporation; National Institutes of Health [UL1 RR024131]; Clinical and Translational Service Awards [UL1RR025750, TL1RR025748, KL2RR025749, UL1TR000086, TL1TR000087, KL2TR000088]; Baxter International; CSL Behring; Baxter; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR000087, KL2TR000088, UL1TR000086] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025750, KL2RR025749, TL1RR025748, UL1RR024131] Funding Source: NIH RePORTER	Baxter Healthcare Corporation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Clinical and Translational Service Awards; Baxter International; CSL Behring; Baxter; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by Baxter Healthcare Corporation; conducted in part at the pediatric research center at the University of California, San Francisco (UCSF; study site J. Puck) supported by the National Institutes of Health (NIH grant UL1 RR024131) to the UCSF Clinical and Translational Science Institute; and conducted in part in facilities (study site A. Rubenstein) supported by Clinical and Translational Service Awards (grants UL1RR025750, TL1RR025748, and KL2RR025749; and UL1TR000086, TL1TR000087, and KL2TR000088).; R.L. Wasserman has served as a consultant and/or speaker for Baxter International, CSL Behring, and Grifols; has served as an investigator for Baxter, CSL Behring, the Korean Green Cross, and Biotest; and has served as a consultant for Biotest. I. Melamed has received one or more payments for speaking from Baxter and has served as a principal investigator for Baxter, CSL Behring, Biotest, Octapharma, and Gammaplex. M.R. Stein has received funding from Baxter International and from CSL Behring and has consultancy arrangements with and/or has provided expert testimony for Baxter International, CSL Behring, and Grifols. S. Gupta has received one or more payments for speaking from Baxter. J. Puck has received funding from Baxter for an immunoglobin clinical trial. H. Leibl is a shareholder and holds stock options in Baxter. B. McCoy is a shareholder in Baxter. The rest of the authors declare that they have no relevant conflicts of interest.	Al-Herz W, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00054; Allen CH, 2009, PEDIATRICS, V124, pE858, DOI 10.1542/peds.2008-3588; [Anonymous], 2010, VIV IMM GLOB SUBC HU; Berger M, 2004, CLIN IMMUNOL, V112, P1, DOI 10.1016/j.clim.2004.02.002; Berger M, 2010, SOUTH MED J, V103, P856, DOI 10.1097/SMJ.0b013e3181eba6ea; Bonilla FA, 2008, J ALLERGY CLIN IMMUN, V122, P1238, DOI 10.1016/j.jaci.2008.08.033; Bookbinder LH, 2006, J CONTROL RELEASE, V114, P230, DOI 10.1016/j.jconrel.2006.05.027; CHURCH JD, 2006, CONSUM REP, V71, P10; Food and Drug Administration, 2008, GUID IND SAF EFF PHA; Frost GI, 2007, EXPERT OPIN DRUG DEL, V4, P427, DOI 10.1517/17425247.4.4.427; Gardulf A, 2004, J ALLERGY CLIN IMMUN, V114, P936, DOI 10.1016/j.jaci.2004.06.053; Gardulf A, 2007, BIODRUGS, V21, P105, DOI 10.2165/00063030-200721020-00005; Gardulf A, 2006, J CLIN IMMUNOL, V26, P177, DOI 10.1007/s10875-006-9002-x; Geha RS, 2007, J ALLERGY CLIN IMMUN, V120, P776, DOI 10.1016/j.jaci.2007.08.053; Gustafson R, 2008, CLIN EXP IMMUNOL, V152, P274, DOI 10.1111/j.1365-2249.2008.03620.x; Hagan JB, 2010, J CLIN IMMUNOL, V30, P734, DOI 10.1007/s10875-010-9423-4; Harb G, 2010, CURR MED RES OPIN, V26, P279, DOI 10.1185/03007990903432900; Jolles S, 2011, CLIN IMMUNOL, V141, P90, DOI 10.1016/j.clim.2011.06.002; Jolles S, 2011, ADV THER, V28, P521, DOI 10.1007/s12325-011-0036-y; Melamed I, 2011, J ALLERGY CLIN IM S1, V127; Meth MJ, 2010, ANN ALLERG ASTHMA IM, V105, P187, DOI 10.1016/j.anai.2010.06.012; Misbah S, 2009, CLIN EXP IMMUNOL, V158, P51, DOI [10.1111/j.1365-2249.2009.04027.X, 10.1111/j.1365-2249.2009.04027.x]; Moore ML, 2008, ANN ALLERG ASTHMA IM, V101, P114, DOI 10.1016/S1081-1206(10)60197-4; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Ochs HD, 2006, J CLIN IMMUNOL, V26, P265, DOI 10.1007/s10875-006-9021-7; Orange JS, 2010, CLIN IMMUNOL, V137, P21, DOI 10.1016/j.clim.2010.06.012; Quinti I, 2011, J CLIN IMMUNOL, V31, P315, DOI 10.1007/s10875-011-9511-0; Skoda-Smith S, 2010, THER CLIN RISK MANAG, V6, P1; Thomas JR, 2007, J PALLIAT MED, V10, P1312, DOI 10.1089/jpm.2007.0126; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; Wasserman RL, 2010, CLIN EXP IMMUNOL, V161, P518, DOI 10.1111/j.1365-2249.2010.04195.x; Wasserman RL, 2011, J CLIN IMMUNOL, V31, P323, DOI 10.1007/s10875-011-9512-z; Wasserman RL, 2011, CLIN PHARMACOKINET, V50, P405, DOI 10.2165/11587030-000000000-00000; Wynne C, 2012, J CLIN PHARM; Yocum RC, 2007, J INFUS MURS, V30, P293, DOI 10.1097/01.NAN.0000292572.70387.17	35	89	90	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					951	+		10.1016/j.jaci.2012.06.021	http://dx.doi.org/10.1016/j.jaci.2012.06.021			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22846381	Bronze			2022-12-18	WOS:000309594800017
J	Thyagarajan, A; Varshney, P; Jones, SM; Sicherer, S; Wood, R; Vickery, BP; Sampson, H; Burks, AW				Thyagarajan, Ananth; Varshney, Pooja; Jones, Stacie M.; Sicherer, Scott; Wood, Robert; Vickery, Brian P.; Sampson, Hugh; Burks, A. Wesley			Peanut oral immunotherapy is not ready for clinical use	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Peanut allergy; oral immunotherapy; desensitization	TOLERANCE INDUCTION; FOOD ALLERGY; CHILDREN; FEATURES		[Thyagarajan, Ananth; Varshney, Pooja; Vickery, Brian P.; Burks, A. Wesley] Duke Univ, Med Ctr, Div Allergy & Immunol, Dept Pediat, Durham, NC 27710 USA; [Jones, Stacie M.] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Dept Pediat, Div Allergy & Immunol, Little Rock, AR 72205 USA; [Sicherer, Scott; Sampson, Hugh] Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Elliot & Roslyn Jaffe Food Allergy Inst, New York, NY USA; [Wood, Robert] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA	Duke University; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; Icahn School of Medicine at Mount Sinai; Johns Hopkins University	Burks, AW (corresponding author), Duke Univ, Med Ctr, Div Allergy & Immunol, Dept Pediat, Box 2898, Durham, NC 27710 USA.	wesley.burks@duke.edu		Vickery, Brian/0000-0002-7243-5543	NCCIH NIH HHS [R21 AT002557-03, R21 AT002557] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT002557] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Ben-Shoshan M, 2009, J ALLERGY CLIN IMMUN, V123, P783, DOI 10.1016/j.jaci.2009.02.004; Bird A, 2010, J ALLERGY CLIN IMMUN, V125, pAB22, DOI 10.1016/j.jaci.2009.12.117; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; Clark AT, 2008, J ALLERGY CLIN IMMUN, V122, P286, DOI 10.1016/j.jaci.2008.05.015; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Mullins RJ, 2009, J ALLERGY CLIN IMMUN, V123, P689, DOI 10.1016/j.jaci.2008.12.1116; Narisety SD, 2009, J ALLERGY CLIN IMMUN, V124, P610, DOI 10.1016/j.jaci.2009.06.025; Rolinck-Werninghaus C, 2005, ALLERGY, V60, P1320, DOI 10.1111/j.1398-9995.2005.00882.x; Scurlock AM, 2009, CURR ALLERGY ASTHM R, V9, P186, DOI 10.1007/s11882-009-0028-z; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2009, ANNU REV MED, V60, P261, DOI 10.1146/annurev.med.60.042407.205711; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Varshney P, 2009, J ALLERGY CLIN IMMUN, V124, P1351, DOI 10.1016/j.jaci.2009.09.042	21	89	91	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					31	32		10.1016/j.jaci.2010.05.012	http://dx.doi.org/10.1016/j.jaci.2010.05.012			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20620564	Green Accepted			2022-12-18	WOS:000280061800005
J	Haselkorn, T; Zeiger, RS; Chipps, BE; Mink, DR; Szefler, SJ; Simons, FER; Massanari, M; Fish, JE				Haselkorn, Tmirah; Zeiger, Robert S.; Chipps, Bradley E.; Mink, David R.; Szefler, Stanley J.; Simons, F. Estelle R.; Massanari, Marc; Fish, James E.			Recent asthma exacerbations predict future exacerbations in children with severe or difficult-to-treat asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; pediatric asthma; exacerbation; predictor of exacerbation; corticosteroid burst; long-term control	CLINICAL CHARACTERISTICS; CHILDHOOD ASTHMA; MORBIDITY; REGIMENS; DESIGN; COHORT; ADULTS; TRIAL; ATOPY; MILD	Background: Children with severe/difficult-to-treat asthma experience high morbidity including frequent severe exacerbations. More knowledge is required to identify predictors of these exacerbations to reduce their occurrence. Objective: To investigate the risk of future severe exacerbations (FSEs) in children with severe/difficult-to-treat asthma and recent severe exacerbations (RSEs). Methods: We analyzed the occurrence and association of RSE (defined as I or more corticosteroid bursts during the 3 months before each of 3 annual visits) and FSE (defined as I or more corticosteroid bursts 6 or 12 months later) in children age 6 to 11 years in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens 3-year observational study. Repeated measures logistic regression analysis assessed the risk of FSE adjusted for demographics and clinical variables. Results: In a multivariable model, FSE at 6 months was most strongly predicted by RSE (odds ratio [OR], 3.08; 95% CI, 2.21-4.28) and having 3 to 4 allergic triggers (OR, 2.05; 95% CI, 1.31-3.20). Race (OR, 1.77; 95% CI, 1.25-2.51) and being very poorly controlled according to the impairment component of the National Heart, Lung, and Blood Institute guidelines (OR, 1.59; 95% CI, 1.14-2.23) also significantly predicted FSE. Conclusion: Recent severe asthma exacerbations are an important independent predictor of FSE in children with severe/difficult-to-treat asthma and should be considered when establishing asthma management plans. (J Allergy Clin Immunol 2009;124:921-7.)	[Haselkorn, Tmirah; Fish, James E.] Genentech Inc, San Francisco, CA 94080 USA; [Zeiger, Robert S.] Kaiser Permanente Med Ctr, San Diego, CA USA; [Chipps, Bradley E.] Capital Allergy & Resp Dis Ctr, Sacramento, CA USA; [Mink, David R.] ICON Clin Res, San Francisco, CA USA; [Szefler, Stanley J.] Natl Jewish Hlth, Denver, CO USA; [Simons, F. Estelle R.] Univ Manitoba, Winnipeg, MB R3T 2N2, Canada; [Massanari, Marc] Novartis Pharmaceut, E Hanover, NJ USA	Roche Holding; Genentech; Kaiser Permanente; ICON plc; National Jewish Health; University of Manitoba; Novartis	Haselkorn, T (corresponding author), Genentech Inc, 1 DNA Way,MS 58B, San Francisco, CA 94080 USA.	haselkorn.tmirah@gene.com		Zeiger, Robert/0000-0001-5788-5063				Antonicelli L, 2004, EUR RESPIR J, V23, P723, DOI 10.1183/09031936.04.00004904; BLOOM B, 2005, VITAL HLTH STAT, V10, P1; Bousquet J, 2005, B WORLD HEALTH ORGAN, V83, P548; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; Chipps BE, 2007, J ALLERGY CLIN IMMUN, V119, P1156, DOI 10.1016/j.jaci.2006.12.668; Covar RA, 2008, J ALLERGY CLIN IMMUN, V122, P741, DOI 10.1016/j.jaci.2008.08.021; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939, DOI 10.1289/ehp.02110939; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Fuhlbrigge AL, 2006, PEDIATRICS, V118, pE347, DOI 10.1542/peds.2005-2962; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P895, DOI 10.1016/j.jaci.2009.07.035; Herjavecz I, 2003, J ASTHMA, V40, P673, DOI 10.1081/JAS-120021100; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Kwong KYC, 2008, ANN ALLERG ASTHMA IM, V101, P144, DOI 10.1016/S1081-1206(10)60202-5; LOZANO P, 1995, JAMA-J AM MED ASSOC, V274, P469, DOI 10.1001/jama.274.6.469; McCoy K, 2006, J ALLERGY CLIN IMMUN, V118, P1226, DOI 10.1016/j.jaci.2006.09.006; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; Miller PE, 2007, VET OPHTHALMOL, V10, P1, DOI 10.1111/j.1463-5224.2007.00587.x; Moore WC, 2006, J ALLERGY CLIN IMMUN, V117, P487, DOI 10.1016/j.jaci.2006.01.033; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; *NAT HEART LUNG BL, 2007, 3 NAT HEART LUNG BLO, P2991; *NAT HEART LUNG BL, 1997, 2 NAT HEART LUNG BLO, P2991; ROBERTSON CF, 1992, PEDIATR PULM, V13, P95, DOI 10.1002/ppul.1950130207; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Stoloff SW, 2006, J ALLERGY CLIN IMMUN, V117, P544, DOI 10.1016/j.jaci.2006.01.005; Sullivan Sean D, 2003, J Manag Care Pharm, V9, P3; Ungar WJ, 2001, PEDIATR PULM, V32, P101, DOI 10.1002/ppul.1095; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Walker S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub3; Weinmann S, 2003, PEDIAT ALLERG IMM-UK, V14, P18, DOI 10.1034/j.1399-3038.2003.02085.x; Wenzel S, 2006, J ALLERGY CLIN IMMUN, V117, P508, DOI 10.1016/j.jaci.2005.12.1316; Wever-Hess J, 2000, PEDIATR PULM, V29, P250, DOI 10.1002/(SICI)1099-0496(200004)29:4<250::AID-PPUL3>3.0.CO;2-4; Zeiger RS, 2009, J ALLERGY CLIN IMMUN, V124, P1106, DOI 10.1016/j.jaci.2009.07.052	35	89	90	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					921	927		10.1016/j.jaci.2009.09.006	http://dx.doi.org/10.1016/j.jaci.2009.09.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19895984				2022-12-18	WOS:000272108000007
J	Scholtens, S; Wijga, AH; Seidell, JC; Brunekreef, B; de Jongste, JC; Gehring, U; Postma, DS; Kerkhof, M; Smit, HA				Scholtens, Salome; Wijga, Alet H.; Seidell, Jacob C.; Brunekreef, Bert; de Jongste, Johan C.; Gehring, Ulrike; Postma, Dirkje S.; Kerkhof, Marjan; Smit, Henriette A.			Overweight and changes in weight status during childhood in relation to asthma symptoms at 8 years of age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Obesity; body mass index; asthma; child; cohort study	BODY-MASS INDEX; BIRTH COHORT; CHILDREN; OBESITY; ALLERGY; RISK; ATOPY; INFLAMMATION; ASSOCIATION; ADOLESCENTS	Background: Asthma may be more prevalent in overweight children. However, how early overweight and changes in weight status during childhood affect the asthma risk is unclear. Objectives: To investigate overweight and changes in overweight status in children age 1 to 8 years in relation to asthma symptoms in childhood. Methods: We studied 3756 children who participated in a large birth cohort study. The parents reported their children's weight and height, and wheeze, dyspnea, and prescription of inhaled corticosteroids in yearly questionnaires. Sensitization to inhalant allergens and bronchial hyperresponsiveness (BHR) were determined at 8 years. Results: At 8 years, 275 children (7.3%) wheezed, 361 (9.6%) had dyspnea, and 268 (7.1%) had a prescription of inhaled corticosteroids in the preceding year. Children who had a persistent high body mass index (BMI, weight/height(2)) during childhood or a high BMI at 6 to 7 years had a significantly increased risk of dyspnea (adjusted odds ratio, 1.68; 95% CI, 1.18-2.39, for a high BMI at 6-7 years) and measured BHR (adjusted odds ratio, 1.66; 95% CI, 1.10-2.52) at 8 years. Children with a high BMI at a young age, but who developed a normal BMI at 6 to 7 years, did not have an increased risk of dyspnea or BHR at 8 years. BMI was not associated with sensitization. Conclusion: Children with a current high BMI are at increased risk to have dyspnea and BHR at 8 years. A high BMI at an earlier age is not related to an increased risk if the child has become normal weight at 6 to 7 years. (J Allergy Clin Immunol 2009;123:1312-8.)	[Scholtens, Salome; Brunekreef, Bert; Gehring, Ulrike] Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands; [Wijga, Alet H.; Smit, Henriette A.] Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands; [Seidell, Jacob C.] Vrije Univ Amsterdam, Inst Hlth Sci, Amsterdam, Netherlands; [Brunekreef, Bert; Smit, Henriette A.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [de Jongste, Johan C.] Erasmus Med Ctr Sophia, Div Resp Med, Dept Pediat, Rotterdam, Netherlands; [Postma, Dirkje S.] Univ Med Ctr Groningen, Dept Pulmonol, Groningen, Netherlands; [Kerkhof, Marjan] Univ Groningen, Dept Epidemiol & Bioinformat, NL-9700 AB Groningen, Netherlands	Utrecht University; Netherlands National Institute for Public Health & the Environment; Vrije Universiteit Amsterdam; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC; University of Groningen; University of Groningen	Scholtens, S (corresponding author), Natl Inst Publ Hlth & Environm RIVM, Ctr Prevent & Hlth Serv Res Pb 101, POB 1, NL-3720 BA Bilthoven, Netherlands.	salome.scholtens@rivm.nl	seidell, jacob c/N-7427-2013; seidell, jacob/AAF-5362-2019	seidell, jacob/0000-0002-9262-9062; brunekreef, bert/0000-0001-9908-0060; Gehring, Ulrike/0000-0003-3612-5780; Scholtens, Salome/0000-0002-0651-5203	Netherlands Organization for Health Research and Development; Netherlands Asthma Foundation; Netherlands Ministry of Health, Welfare and Sport and Numico Research, The Netherlands	Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); Netherlands Asthma Foundation; Netherlands Ministry of Health, Welfare and Sport and Numico Research, The Netherlands	Supported by the Netherlands Organization for Health Research and Development; the Netherlands Asthma Foundation the Netherlands Ministry of Health, Welfare and Sport and Numico Research, The Netherlands.	Beuther DA, 2006, AM J RESP CRIT CARE, V174, P112, DOI 10.1164/rccm.200602-231PP; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Burgess JA, 2007, EUR RESPIR J, V29, P668, DOI 10.1183/09031936.00080906; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Carroll CL, 2007, PEDIATRICS, V120, P734, DOI 10.1542/peds.2007-0409; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; Chinn S, 2006, PAEDIATR RESPIR REV, V7, P223, DOI 10.1016/j.prrv.2006.04.007; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Flaherman V, 2006, ARCH DIS CHILD, V91, P334, DOI 10.1136/adc.2005.080390; Fredriks AM, 2000, PEDIATR RES, V47, P316, DOI 10.1203/00006450-200003000-00006; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; Gold DR, 2003, PEDIATR PULM, V36, P514, DOI 10.1002/ppul.10376; Guida B, 2008, NUTR METAB CARDIOVAS, V18, P133, DOI 10.1016/j.numecd.2006.08.008; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; Hersoug LG, 2007, ALLERGY, V62, P1205, DOI 10.1111/j.1398-9995.2007.01506.x; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323, DOI 10.1046/j.1365-2222.1999.00455.x; Kerkhof M, 2000, CLIN EXP ALLERGY, V30, P1387, DOI 10.1046/j.1365-2222.2000.00907.x; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Lakwijk N, 1998, CLIN EXP ALLERGY, V28, P454; Litonjua AA, 2008, J ALLERGY CLIN IMMUN, V121, P1075, DOI 10.1016/j.jaci.2008.03.005; Mai XM, 2007, ALLERGY, V62, P1295, DOI 10.1111/j.1398-9995.2007.01491.x; Mai XM, 2003, ACTA PAEDIATR, V92, P1144, DOI 10.1080/08035250310005666; Mamun AA, 2007, INT J OBESITY, V31, P578, DOI 10.1038/sj.ijo.0803571; Mannino DM, 2006, INT J OBESITY, V30, P6, DOI 10.1038/sj.ijo.0803145; Pietrobelli A, 1998, J PEDIATR-US, V132, P204, DOI 10.1016/S0022-3476(98)70433-0; Rubin DB, 2004, MULTIPLE IMPUTATION; Schafer JL., 1997, ANAL INCOMPLETE MULT, DOI 10.1201/9781439821862; Scholtens S, 2007, EUR J PUBLIC HEALTH, V17, P369, DOI 10.1093/eurpub/ckl253; Schwarzenberg SJ, 2006, PAEDIATR RESPIR REV, V7, P239, DOI 10.1016/j.prrv.2006.08.002; Tantisira KG, 2001, THORAX, V56, P64; VANBUUREN S, 2005, MICE MULTIVARIATE IM; Visser M, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.1.e13; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; *WHO MULT GROWTH R, 2006, WHO CHILD GROWTH ST; Xu BZ, 2002, EUR J PUBLIC HEALTH, V12, P166, DOI 10.1093/eurpub/12.3.166	35	89	90	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1312	1318		10.1016/j.jaci.2009.02.029	http://dx.doi.org/10.1016/j.jaci.2009.02.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19409606				2022-12-18	WOS:000266799100022
J	Murphy, KR; Zeiger, RS; Kosinski, M; Chipps, B; Mellon, M; Schatz, M; Lampl, K; Hanlon, JT; Ramachandran, S				Murphy, Kevin R.; Zeiger, Robert S.; Kosinski, Mark; Chipps, Bradley; Mellon, Michael; Schatz, Michael; Lampl, Kathy; Hanlon, Jennifer T.; Ramachandran, Sulabha			Test for Respiratory and Asthma Control in Kids (TRACK): A caregiver-completed questionnaire for preschool-aged children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; respiratory symptoms; asthma control; TRACK; validated questionnaire; asthma guidelines; Young children	VALIDATION; TRENDS	Background: A validated questionnaire is needed to monitor respiratory control in preschool-aged children. Objective: We sought to develop and validate a caregiver-completed questionnaire that measures respiratory control in young children. Methods: A 33-item questionnaire that included asthma impairment and risk items was administered to 486 caregivers of children aged younger than 5 years with a current, recent, or past history of respiratory symptoms. Stepwise regression was used to select a subset of items with the greatest discriminant validity in relation to guidelines-defined asthma control in a random two-thirds development sample. Reliability, validity, and ability to screen for respiratory control problems were tested in development and validation samples (remaining one-third sample). Results: The content of the 5 items selected, the Test for Respiratory and Asthma Control in Kids (TRACK), included frequency of respiratory symptoms (wheeze, cough, shortness of breath), activity limitation, and nighttime awakenings in the past 4 weeks; rescue medication use in the past 3 months; and oral corticosteroid use in the previous year. Reliability was greater than 0.70 in both samples. ANOVA showed that mean scores differed significantly (P < .001) in the expected direction across both samples for 3 levels of guidelines-based respiratory control, physician-recommended change in therapy, and symptom status. In the development and validation samples, screening analyses revealed areas under the receiver operating characteristic curve of 0.88 and 0.82, respectively; control status was correctly classified in 81% and 78% of cases. Conclusion: TRACK is a valid, easy-to-administer, caregiver-completed questionnaire of respiratory control in preschool-aged children with symptoms consistent with asthma. (J Allergy Clin Immunol 2009;123:833-39.)	[Murphy, Kevin R.] Boys Town Natl Res Hosp, Omaha, NE 68010 USA; [Zeiger, Robert S.; Mellon, Michael; Schatz, Michael] So Calif Permanente Med Grp, San Diego, CA 92120 USA; [Kosinski, Mark; Hanlon, Jennifer T.] QualityMetric Inc, Lincoln, RI USA; [Chipps, Bradley] Capital Allergy & Resp Dis Ctr, Sacramento, CA USA; [Lampl, Kathy; Ramachandran, Sulabha] AstraZeneca LP, Wilmington, DE USA	Boys Town National Research Hospital; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; AstraZeneca	Murphy, KR (corresponding author), Boys Town Natl Res Hosp, 14080 Hosp Rd, Omaha, NE 68010 USA.	murphyk@boystown.org		Zeiger, Robert/0000-0001-5788-5063	AstraZeneca LP	AstraZeneca LP(AstraZeneca)	Supported by AstraZeneca LP.	*AM LUNG ASS EP ST, 2005, TRENDS ASTHM MORB MO; BOULET LP, 2002, CAN RESPIR J, V9, P377; *CDCP, 2004, MMWR-MORBID MORTAL W, V53, P145; *CDCP, 1996, JAMA-J AM MED ASSOC, V275, P1535; *GINA, 2007, GLOB STRAT ASTHM MAN; Halterman JS, 2003, AMBUL PEDIATR, V3, P102, DOI 10.1367/1539-4409(2003)003<0102:APPIPA>2.0.CO;2; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330, DOI 10.1164/ajrccm.162.4.9912138; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kerlinger FN, 1973, FDN BEHAV RES, V2nd; Lara M, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.6.e68; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Newacheck PW, 2000, ARCH PEDIAT ADOL MED, V154, P287, DOI 10.1001/archpedi.154.3.287; *NHLBI NAEPP, 2007, PUBL NHLBI NAEPP; Nunnally J., 1994, PSYCHOMETRIC THEORY, DOI DOI 10.1037/018882; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Skinner Elizabeth A, 2004, Dis Manag, V7, P305, DOI 10.1089/dis.2004.7.305; Sullivan Sean D, 2003, J Manag Care Pharm, V9, P3; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; Zorc JJ, 2006, J ASTHMA, V43, P753, DOI 10.1080/02770900601031615	24	89	95	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					833	839		10.1016/j.jaci.2009.01.058	http://dx.doi.org/10.1016/j.jaci.2009.01.058			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19348922				2022-12-18	WOS:000265058600008
J	Hope, AP; Woessner, KA; Simon, RA; Stevenson, DD				Hope, Andrew P.; Woessner, Katharine A.; Simon, Ronald A.; Stevenson, Donald D.			Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin; asthma; aspirin-exacerbated respiratory disease; sinusitis; polyps; oral challenge; drug allergy; drug desensitization	LEUKOTRIENE-MODIFIER DRUGS; INDUCED ASTHMA; SENSITIVITY; DIAGNOSIS; SEVERITY	Background: Aspirin desensitization improves clinical outcomes in most patients with aspirin-exacerbated respiratory disease. Most protocols for desensitization are time-consuming. Objective: Our objective was to use historical information about the course of aspirin desensitization to enhance the efficiency of the desensitization protocol. Methods: Four hundred twenty subjects with suspected aspirin-exacerbated respiratory disease underwent oral aspirin challenges. Their clinical characteristics were analyzed in relation to features of reactions during aspirin challenges. Results: Large (FEV1 decrease >30%) and moderate (FEV1 decrease 21% to 30%) bronchial reactions occurred in 9% and 20% of subjects, respectively. Multivariate analysis identified risk factors associated with these larger reactions, including lack of leukotriene modifier use, baseline FEV1 of less than 80% of predicted value, and previous asthma-related emergency department visits. Seventy-five percent of patients reacted to a provoking dose of either 45 or 60 mg. Only 3% of initial reactions occurred after 150- or 325-mg provoking doses, and none occurred after the 650-mg dose. Conclusions: Most bronchial and naso-ocular reactions during oral aspirin challenges occurred within a narrow dosing range (45-100 mg). Only 1 of 26 patients without risk factors had a moderate reaction. (J Allergy Clin Immunol 2009;123:406-10.)	[Hope, Andrew P.] Kaiser Permanente Santa Clara, Dept Allergy, Santa Clara, CA 95051 USA; [Hope, Andrew P.; Woessner, Katharine A.; Simon, Ronald A.; Stevenson, Donald D.] Scripps Clin, Div Allergy Asthma & Immunol, La Jolla, CA 92037 USA; [Hope, Andrew P.; Woessner, Katharine A.; Simon, Ronald A.; Stevenson, Donald D.] Scripps Res Inst, La Jolla, CA 92037 USA	Kaiser Permanente; Scripps Research Institute; Scripps Research Institute	Hope, AP (corresponding author), Kaiser Permanente Santa Clara, Dept Allergy, 2885 Kaiser Dr,Bldg B, Santa Clara, CA 95051 USA.	andrew.hope@yahoo.com						Berges-Gimeno MP, 2003, J ALLERGY CLIN IMMUN, V111, P180, DOI 10.1067/mai.2003.7; Berges-Gimeno MP, 2002, CLIN EXP ALLERGY, V32, P1491, DOI 10.1046/j.1365-2745.2002.01501.x; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; Daffern PJ, 1999, J ALLERGY CLIN IMMUN, V104, P559, DOI 10.1016/S0091-6749(99)70324-6; Lee JY, 2007, J ALLERGY CLIN IMMUN, V119, P157, DOI 10.1016/j.jaci.2006.09.011; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; Nizankowska-Mogilnicka E, 2007, ALLERGY, V62, P1111, DOI 10.1111/j.1398-9995.2007.01409.x; Ogata N, 2007, J LARYNGOL OTOL, V121, P1156, DOI 10.1017/S0022215107000515; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; STEVENSON DD, 1988, NEW ENGL REG ALLERGY, V9, P135; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; Stevenson DD, 2003, CLIN REV ALLERG IMMU, V24, P159, DOI 10.1385/CRIAI:24:2:159; Stevenson DD, 2003, MIDDLETONS ALLERGY P, V2, P1695; STEVENSON DD, 1998, ALLERGY PRINCIPLES P, P1225; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; White AA, 2005, ANN ALLERG ASTHMA IM, V95, P330, DOI 10.1016/S1081-1206(10)61150-7; White A, 2006, ANN ALLERG ASTHMA IM, V97, P688, DOI 10.1016/S1081-1206(10)61101-5; Williams AN, 2007, J ALLERGY CLIN IMMUN, V120, P273, DOI 10.1016/j.jaci.2007.03.020; Wong JT, 2000, J ALLERGY CLIN IMMUN, V105, P997, DOI 10.1067/mai.2000.104571	19	89	90	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					406	410		10.1016/j.jaci.2008.09.048	http://dx.doi.org/10.1016/j.jaci.2008.09.048			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19056109				2022-12-18	WOS:000263495000018
J	Stensballe, LG; Ravn, H; Kristensen, K; Agerskov, K; Meakins, T; Aaby, P; Simoes, EAF				Stensballe, Lone Graff; Ravn, Henrik; Kristensen, Kim; Agerskov, Kenneth; Meakins, Tiffany; Aaby, Peter; Simoes, Eric A. F.			Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cord blood; maternally derived antibodies; neutralizing; respiratory syncytial virus; recurrent wheeze	1ST 6 YEARS; MATERNAL ANTIBODY; AIRWAY HYPERRESPONSIVENESS; RISK-FACTORS; ASTHMA; INFECTION; INFANTS; COHORT; TRACT; AGE	Background: Respiratory syncytial virus (RSV) hospitalization is associated with wheeze. Objective: To examine the influence of maternally derived RSV neutralizing antibodies in cord blood on RSV hospitalization and recurrent wheeze in infancy. Methods: Among children from the Danish National Birth Cohort, we selected a subcohort of 459 randomly selected children, 408 children with RSV hospitalization, 408 children with recurrent wheeze, and all 289 children who experienced both RSV hospitalization and recurrent wheeze. The influence of cord blood RSV neutralizing antibodies was examined as predictors for (1) RSV hospitalization, (2) RSV hospitalization after recurrent wheeze, (3) recurrent wheeze, and (4) recurrent wheeze after RSV hospitalization. Results: Neutralizing antibody levels were inversely associated with RSV hospitalization in infants below 6 months of age (adjusted incidence rate ratio [IRR], 0.74; 95% CI, 0.62-0.87), and also inversely associated with RSV hospitalization in infants with recurrent wheeze (IRR, 0.83; 0.71-0.97). In contrast, neutralizing antibody levels were directly associated with an increased risk of recurrent wheeze in infants below 6 months of age (IRR, 1.28; 1.04-1.57) and with an increased risk of recurrent wheeze after RSV hospitalization in infants below 6 months of age (IRR, 1.44; 1.10-1.90). Conclusion: Maternally derived RSV neutralizing antibodies protect infants against RSV hospitalization, and also when the infant has recurrent wheeze. However, high maternally derived RSV neutralizing antibody levels were associated with an increased risk of recurrent wheeze. (J Allergy Clin Immunol 2009;123:398-403.)	[Stensballe, Lone Graff; Ravn, Henrik; Agerskov, Kenneth; Aaby, Peter] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark; [Stensballe, Lone Graff; Ravn, Henrik; Agerskov, Kenneth; Aaby, Peter] Bandim Hlth Project, Bissau, Guinea Bissau; [Kristensen, Kim] Rigshosp, Pediat Clin 2, DK-2100 Copenhagen, Denmark; [Meakins, Tiffany; Simoes, Eric A. F.] Univ Colorado, Sch Med, Dept Pediat, Boulder, CO 80309 USA; [Meakins, Tiffany; Simoes, Eric A. F.] Childrens Hosp, Boston, MA USA	Statens Serum Institut; Rigshospitalet; University of Copenhagen; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; Harvard University; Boston Children's Hospital	Simoes, EAF (corresponding author), Childrens Hosp, Infect Dis Sect, 13123 E 16th Ave B055, Aurora, CO 80045 USA.	eric.simoes@uchsc.edu	Stensballe, Lone Graff/AAS-4137-2020	Stensballe, Lone Graff/0000-0003-1569-153X; Aaby, Peter/0000-0001-8331-1389	Lundbeck Foundation; Novo Nordisk Foundation; Danish National Research Foundation; Augustinus Foundation; Pharmacy Foundation; Egmont Foundation; March of Dimes Birth Defects Foundation; Health Foundation	Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish National Research Foundation(Danmarks Grundforskningsfond); Augustinus Foundation; Pharmacy Foundation; Egmont Foundation; March of Dimes Birth Defects Foundation(March of Dimes); Health Foundation	Supported by the Lundbeck Foundation, the Novo Nordisk Foundation, the Danish National Research Foundation, and the Augustinus Foundation. The Danish Epidemiology Science Center was established by a grant from the Danish National Research Foundation, and the center initiated and created the Danish National Birth Cohort. The cohort is furthermore a result of a major grant from the Danish National Research Foundation. Additional support for the Danish National Birth Cohort was obtained from the Pharmacy Foundation, the Egmont Foundation, the March of Dimes Birth Defects Foundation, the Augustinus Foundation, and the Health Foundation.	Andersen TF, 1999, DAN MED BULL, V46, P263; ANDERSON LJ, 1988, PEDIATRICS, V82, P300; ANDERSON LJ, 1985, J CLIN MICROBIOL, V22, P1050, DOI 10.1128/JCM.22.6.1050-1052.1985; Apelberg BJ, 2001, J ALLERGY CLIN IMMUN, V107, P455, DOI 10.1067/mai.2001.113240; Barlow WE, 1999, J CLIN EPIDEMIOL, V52, P1165, DOI 10.1016/S0895-4356(99)00102-X; Benn CS, 2001, CLIN EXP ALLERGY, V31, P1862, DOI 10.1046/j.1365-2222.2001.01128.x; Bermejo-Martin JF, 2008, INTERVIROLOGY, V51, P112, DOI 10.1159/000134268; BRUHN FW, 1977, AM J DIS CHILD, V131, P145, DOI 10.1001/archpedi.1977.02120150027004; Connor E, 1997, PEDIATRICS, V99, P93; DESIERRA TM, 1993, J PEDIATR-US, V122, P787, DOI 10.1016/S0022-3476(06)80027-2; Dik N, 2004, CHEST, V126, P1147, DOI 10.1378/chest.126.4.1147; Englund J, 1998, VACCINE, V16, P1456, DOI 10.1016/S0264-410X(98)00108-X; Eriksson M, 2000, PEDIAT ALLERG IMM-UK, V11, P193, DOI 10.1034/j.1399-3038.2000.00076.x; Fischer JE, 2000, J INFECT DIS, V182, P1029, DOI 10.1086/315806; Foster SB, 2008, J ALLERGY CLIN IMMUN, V122, P159, DOI 10.1016/j.jaci.2008.04.043; GLEZEN WP, 1981, J PEDIATR-US, V98, P708, DOI 10.1016/S0022-3476(81)80829-3; GRAHAM BS, 1993, J IMMUNOL, V151, P2032; GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102; HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135, DOI 10.1093/oxfordjournals.aje.a115826; Infante-Rivard C, 2001, AM J EPIDEMIOL, V153, P653, DOI 10.1093/aje/153.7.653; LAMPRECHT CL, 1976, J INFECT DIS, V134, P211, DOI 10.1093/infdis/134.3.211; Legg JP, 2002, ARCH DIS CHILD, V86, P431, DOI 10.1136/adc.86.6.431; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; OGILVIE MM, 1981, J MED VIROL, V7, P263, DOI 10.1002/jmv.1890070403; Olsen J, 2001, SCAND J PUBLIC HEALT, V29, P300, DOI 10.1177/14034948010290040201; Pedersen CB, 2006, DAN MED BULL, V53, P441; Peebles RS, 2000, J INFECT DIS, V182, P671; Peebles RS, 1999, J MED VIROL, V57, P186, DOI 10.1002/(SICI)1096-9071(199902)57:2<186::AID-JMV17>3.0.CO;2-Q; Petersen L, 2003, STAT MED, V22, P3795, DOI 10.1002/sim.1672; Piedra PA, 2003, VACCINE, V21, P3479, DOI 10.1016/S0264-410X(03)00355-4; Roca A, 2002, J MED VIROL, V67, P616, DOI 10.1002/jmv.10148; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Simoes EAF, 2007, J PEDIATR-US, V151, P34, DOI 10.1016/j.jpeds.2007.02.032; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stensballe LG, 2005, SCAND J INFECT DIS, V37, P747, DOI 10.1080/00365540510012107; Stensballe LG, 2003, PEDIATR INFECT DIS J, V22, pS21, DOI 10.1097/00006454-200302001-00004; Stensballe LG, 2006, PEDIATRICS, V118, pE1360, DOI 10.1542/peds.2006-0907; WARD KA, 1983, J GEN VIROL, V64, P1867, DOI 10.1099/0022-1317-64-9-1867; Wickens K, 2001, AUST NZ J PUBL HEAL, V25, P44, DOI 10.1111/j.1467-842X.2001.tb00549.x; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	41	89	91	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					398	403		10.1016/j.jaci.2008.10.043	http://dx.doi.org/10.1016/j.jaci.2008.10.043			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19101023	Bronze			2022-12-18	WOS:000263495000016
J	Chan, RCF; Wang, MY; Li, N; Yanagawa, Y; Onoe, K; Lee, JJ; Nel, AE				Chan, Ray Chun-Fai; Wang, Meiying; Li, Ning; Yanagawa, Yoshiki; Onoe, Kazunori; Lee, James J.; Nel, Andre E.			Pro-oxidative diesel exhaust particle chemicals inhibit LPS-induced dendritic cell responses involved in T-helper differentiation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; T(H)1/T(H)2 cells; LPS; cell differentiation	NF-KAPPA-B; ANTIGEN-PRESENTING CELLS; AIRWAY INFLAMMATION; EPITHELIAL-CELLS; DEPOSITION PATTERNS; HEME OXYGENASE-1; INHALED ANTIGEN; TH2 RESPONSES; MURINE MODEL; ACTIVATION	Background: Epidemiologic studies show that exposure to ambient particulate matter leads to asthma exacerbation. Diesel exhaust particles (DEPs), a model pollutant, act as an adjuvant for allergic sensitization. Increasing evidence shows that this effect could be mediated by an effect on dendritic cells (DCs). Objective: Our aim was to elucidate the mechanism by which pro-oxidative DEP chemicals change DC function so that these antigen-presenting cells strengthen the immune response to an experimental allergen. Methods: We exposed murine bone marrow-derived DCs and a homogeneous myeloid DC line, BC1, to DEPs and organic extracts made from these particles to determine how the induction of oxidative stress affects cellular maturation, cytokine production, and activation of antigen-specific T cells. Results: DEP extracts induced oxidative stress in DCs. This change in redox equilibrium interfered in the ability of Toll-like receptor agonists to induce the expression of maturation receptors (eg, CD86, CD54, and I-A(d)) and IL-12 production. This perturbation of DC function was accompanied by decreased IFN-gamma and increased IL-10 induction in antigen-specific T cells. The molecular basis for the perturbation of DC function is the activation of a nuclear factor-erythroid 2 (NF-E2)-related factor 2-mediated signaling pathway that suppresses IL-12 production. NF-E2-related factor 2 deficiency abrogates the perturbation of DC function by DEPs. Conclusion: These data provide the first report that prooxidative DEP chemicals can interfere in T(H)1-promoting response pathways in a homogeneous DC population and provide a novel explanation for the adjuvant effect of DEPs on allergic inflammation.	Univ Calif Los Angeles, Div Clin Immunol & Allergy, Dept Med, Los Angeles, CA 90095 USA; Hokkaido Univ, Div Immunobiol, Inst Med Genet, Sapporo, Hokkaido, Japan; Mayo Clin, Div Pulm Med, Scottsdale, AZ USA	University of California System; University of California Los Angeles; Hokkaido University; Mayo Clinic; Mayo Clinic Phoenix	Nel, AE (corresponding author), Univ Calif Los Angeles, Div Clin Immunol & Allergy, Dept Med, Los Angeles, CA 90095 USA.	anel@mednet.ucla.edu	Nel, Andre E/J-2808-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010553, R01ES013432, R01ES012053] Funding Source: NIH RePORTER; NIAID NIH HHS [U19 AI 070453] Funding Source: Medline; NIEHS NIH HHS [R01 ES 10553, R01 ES 12053, R01 ES 013432] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akdis M, 2006, CHEM IMMUNOL ALLERGY, V91, P159; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; An HZ, 2002, IMMUNOLOGY, V106, P38, DOI 10.1046/j.1365-2567.2002.01401.x; Balashazy I, 2000, HEALTH PHYS, V78, P147, DOI 10.1097/00004032-200002000-00004; Banning A, 2005, ANTIOXID REDOX SIGN, V7, P889, DOI 10.1089/ars.2005.7.889; Bengtsson A, 2001, CLIN EXP IMMUNOL, V123, P350, DOI 10.1046/j.1365-2249.2001.01453.x; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan RCF, 2004, BRIT J CANCER, V90, P1636, DOI 10.1038/sj.bjc.6601706; Chapman TJ, 2005, VIROLOGY, V340, P296, DOI 10.1016/j.virol.2005.06.023; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Chvatchko Y, 1996, J EXP MED, V184, P2353, DOI 10.1084/jem.184.6.2353; Devouassoux G, 2002, J ALLERGY CLIN IMMUN, V109, P847, DOI 10.1067/mai.2002.122843; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Finkelman FD, 2004, J IMMUNOL, V172, P3808, DOI 10.4049/jimmunol.172.6.3808; Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101; Geiser M, 2005, ENVIRON HEALTH PERSP, V113, P1555, DOI 10.1289/ehp.8006; Hao MQ, 2003, J ALLERGY CLIN IMMUN, V112, P905, DOI 10.1016/j.jaci.2003.07.005; Hiura TS, 1999, J IMMUNOL, V163, P5582; Hoshino A, 2003, EUR J IMMUNOL, V33, P861, DOI 10.1002/eji.200323455; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; Justice JP, 2001, AM J PHYSIOL-LUNG C, V280, pL363, DOI 10.1152/ajplung.2001.280.2.L363; Kantengwa S, 2003, AM J RESP CRIT CARE, V167, P431, DOI 10.1164/rccm.200205-425OC; Kaye SR, 2000, J AEROSOL SCI, V31, P849, DOI 10.1016/S0021-8502(99)00565-0; Khoshnan A, 1999, J IMMUNOL, V163, P5444; Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2005, ALLERGY, V60, P271, DOI 10.1111/j.1398-9995.2005.00708.x; Laouini D, 2003, J CLIN INVEST, V112, P1058, DOI 10.1172/JCI200318246; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Li N, 2002, J IMMUNOL, V169, P4531, DOI 10.4049/jimmunol.169.8.4531; Miyabara Y, 1998, J ALLERGY CLIN IMMUN, V102, P805, DOI 10.1016/S0091-6749(98)70021-1; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Ohtani T, 2005, J IMMUNOL, V174, P2412, DOI 10.4049/jimmunol.174.4.2412; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; Phalen RF, 2006, TOXICOL SCI, V92, P126, DOI 10.1093/toxsci/kfj182; Reider N, 2002, J ALLERGY CLIN IMMUN, V109, P89, DOI 10.1067/mai.2002.120556; Soares MP, 2004, J IMMUNOL, V172, P3553, DOI 10.4049/jimmunol.172.6.3553; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; Xiao GG, 2003, J BIOL CHEM, V278, P50781, DOI 10.1074/jbc.M306423200; Yanagawa Y, 2002, J LEUKOCYTE BIOL, V71, P125	45	89	91	1	12	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					455	465		10.1016/j.jaci.2006.06.006	http://dx.doi.org/10.1016/j.jaci.2006.06.006			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890772				2022-12-18	WOS:000239877700023
J	Perkins, C; Wills-Karp, M; Finkelman, FD				Perkins, Charles; Wills-Karp, Marsha; Finkelman, Fred D.			IL-4 induces IL-13-independent allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airways hyperresponsiveness; eosinophil; goblet cell; IL-4; IL-4 receptor; IL-13; mouse; mucus	MUCUS PRODUCTION; INTERLEUKIN-13 RECEPTOR; TH2 CELLS; PROTECTIVE IMMUNITY; BINDING SUBUNIT; GAMMA-CHAIN; MAST-CELL; RESPONSES; MICE; ASTHMA	Background: The related T(H)2 cytokines IL-4 and IL-13 are produced during allergic responses, signal through receptors that contain IL-4 receptor (IL-4R) alpha, and promote allergic inflammation by activating signal transducer and activator of transcription 6. IL-4 promotes T(H)2 response induction, and IL-13 is necessary and sufficient to induce airways hyperresponsiveness (AHR) and goblet cell hyperplasia in some mouse models of asthma. The nonredundant role of IL-13 could reflect unique IL-13 activation of a signaling pathway, inhibitory effects induced by IL-4 but not IL-13, or greater production-potency of IL-13 than IL-4. Objectives: We sought to distinguish among these possibilities by determining whether IL-4 inhalation can induce acute allergic airways disease in the absence of IL-13. Methods: Mice were inoculated intratracheally with IL-13 or a long-acting formulation of IL-4. Responses of IL-13-deficient and IL-13-sufficient mice were compared, as were responses in mice treated with a potent IL-13 antagonist, anti-IL-4R alpha antibody, or control reagents. Results: IL-4 inhalation stimulated bronchoalveolar lavage fluid eosinophilia, AHR, and goblet cell hyperplasia. These responses were similar in IL-13-deficient and IL-13-sufficient mice and were not inhibited by an IL-13 antagonist but were blocked by anti-IL-4R alpha antibody. Conclusion: IL-4 can induce IL-13-independent AHR and goblet cell hyperplasia. Thus the greater role for IL-13 than IL-4 in the induction of these acute allergy-related changes reflects increased production, potency, or both of IL-13 relative to IL-4 rather than a unique IL-13-signaling pathway or a suppressive effect of IL-4. Clinical implications: Dual IL-4/IL-13 inhibition might be more effective than selective IL-13 inhibition at suppressing allergic inflammation in some circumstances.	Univ Cincinnati, Coll Med, Div Immunol, Cincinnati, OH 45267 USA; Cincinnati Childrens Hosp, Ctr Med, Div Immunobiol, Cincinnati, OH USA; Cincinnati Vet Adm Med Ctr, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Finkelman, FD (corresponding author), Univ Cincinnati, Coll Med, Div Immunol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	ffinkelman@pol.net			NHLBI NIH HHS [P01 HL 076383, R01 HL 072987] Funding Source: Medline; NIAID NIH HHS [R01 AI 55848] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL076383, R01HL072987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055848] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS JS, 1992, IMMUNOL REV, V127, P5, DOI 10.1111/j.1600-065X.1992.tb01406.x; BECKMANN MP, 1990, J IMMUNOL, V144, P4212; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903; CHILTON PM, 1993, J IMMUNOL, V151, P5907; Chomarat P, 1998, Int Rev Immunol, V17, P1, DOI 10.3109/08830189809084486; Cohn L, 2002, NOVART FDN SYMP, V248, P201; Cohn L, 1999, J IMMUNOL, V162, P6178; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Doucet C, 1998, INT IMMUNOL, V10, P1421, DOI 10.1093/intimm/10.10.1421; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Finkelman F., 2001, SAMTERS IMMUNOLOGIC, P111; Finkelman FD, 1999, CURR OPIN IMMUNOL, V11, P420, DOI 10.1016/S0952-7915(99)80070-3; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; Finkelman FD, 2000, J IMMUNOL, V164, P2303, DOI 10.4049/jimmunol.164.5.2303; Finkelman FD, 2005, J IMMUNOL, V174, P4630, DOI 10.4049/jimmunol.174.8.4630; FINKELMAN FD, 2001, SAMTERS IMMUNOLOGICA; Gauchat JF, 1997, EUR J IMMUNOL, V27, P971, DOI 10.1002/eji.1830270425; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; HE YW, 1995, J IMMUNOL, V155, P9; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Lutz MB, 2002, J IMMUNOL, V169, P3574, DOI 10.4049/jimmunol.169.7.3574; Marshall MA, 2001, MICROBES INFECT, V3, P1051, DOI 10.1016/S1286-4579(01)01499-X; McKenzie GJ, 1998, CURR BIOL, V8, P339, DOI 10.1016/S0960-9822(98)70134-4; McKenzie GJ, 1999, J EXP MED, V189, P1565, DOI 10.1084/jem.189.10.1565; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Obiri NI, 1997, J IMMUNOL, V158, P756; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; Ruetten H, 1997, SHOCK, V8, P409, DOI 10.1097/00024382-199712000-00003; Schnyder B, 1996, BLOOD, V87, P4286, DOI 10.1182/blood.V87.10.4286.bloodjournal87104286; Shim JJ, 2001, AM J PHYSIOL-LUNG C, V280, pL134, DOI 10.1152/ajplung.2001.280.1.L134; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Suzuki K, 2000, BLOOD, V96, P2172, DOI 10.1182/blood.V96.6.2172.h8002172_2172_2180; Terabe M, 2000, NAT IMMUNOL, V1, P515, DOI 10.1038/82771; Tomkinson A, 2001, J IMMUNOL, V166, P5792, DOI 10.4049/jimmunol.166.9.5792; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; Urban JF, 2000, J IMMUNOL, V164, P2046, DOI 10.4049/jimmunol.164.4.2046; Venkayya R, 2002, AM J RESP CELL MOL, V26, P202, DOI 10.1165/ajrcmb.26.2.4600; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; WANG LM, 1995, BLOOD, V86, P4218, DOI 10.1182/blood.V86.11.4218.bloodjournal86114218; Whittaker L, 2002, AM J RESP CELL MOL, V27, P593, DOI 10.1165/rcmb.4838; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 2003, CURR OPIN PULM MED, V9, P21, DOI 10.1097/00063198-200301000-00004; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wood N, 2003, J EXP MED, V197, P703, DOI 10.1084/jem.20020906; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	58	89	97	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					410	419		10.1016/j.jaci.2006.06.004	http://dx.doi.org/10.1016/j.jaci.2006.06.004			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890766				2022-12-18	WOS:000239877700017
J	Pajno, GB; Vita, D; Caminiti, L; Arrigo, T; Lombardo, F; Incorvaia, C; Barberio, G				Pajno, GB; Vita, D; Caminiti, L; Arrigo, T; Lombardo, F; Incorvaia, C; Barberio, G			Children's compliance with allergen immunotherapy according to administration routes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Univ Messina, Dept Pediat, Allergy Unit, I-98125 Messina, Italy; ICP Hosp, Allergy Rheumatol Unit, Milan, Italy	University of Messina	Pajno, GB (corresponding author), Univ Messina, Dept Pediat, Allergy Unit, Via Consolare Valeria, I-98125 Messina, Italy.							Bousquet J, 1998, ALLERGY, V53, P4; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Lombardi C, 2004, J ALLERGY CLIN IMMUN, V113, P1219, DOI 10.1016/j.jaci.2004.03.013; More DR, 2002, ANN ALLERG ASTHMA IM, V88, P391, DOI 10.1016/S1081-1206(10)62370-8; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Rhodes BJ, 1999, ANN ALLERG ASTHMA IM, V82, P281, DOI 10.1016/S1081-1206(10)62609-9	8	89	93	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1380	1381		10.1016/j.jaci.2005.07.034	http://dx.doi.org/10.1016/j.jaci.2005.07.034			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337474				2022-12-18	WOS:000235687000033
J	Bergeron, C; Hauber, HP; Gotfried, M; Newman, K; Dhanda, R; Servi, RJ; Ludwig, MS; Hamid, Q				Bergeron, C; Hauber, HP; Gotfried, M; Newman, K; Dhanda, R; Servi, RJ; Ludwig, MS; Hamid, Q			Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: Effect of hydrofluoroalkane-flunisolide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; flunisolide; hydrofluoroalkane; inhaled corticosteroids; remodeling; small airway; peripheral airways	GROWTH-FACTOR-BETA; MESSENGER-RNA EXPRESSION; SUBEPITHELIAL COLLAGEN DEPOSITION; RETICULAR BASEMENT-MEMBRANE; SMOOTH-MUSCLE-CELLS; INHALED CORTICOSTEROIDS; BRONCHIAL-ASTHMA; INTERFERON-GAMMA; MUCOSAL BIOPSIES; LUNG FIBROBLASTS	Background: We have shown previously that inflammation in asthma is not restricted to central airways but can also be demonstrated in peripheral airways. It is not clear whether inflammation of the peripheral airways is associated with structural changes and whether this remodeling process can be modulated by deposition of inhaled corticosteroids (ICSs). Objectives: To compare remodeling in peripheral and central airways and to investigate the effects of hydrofluoroalkane (HFA)-ICS on remodeling at these sites. Methods: Transbronchial and endobronchial biopsies were obtained from 12 patients with mild to moderate asthma before and after a 6-week course of HFA-ICS (flunisolide). Total collagen deposition, expression of collagen III, TGF-beta, and alpha-smooth muscle actin were examined by using Van Gieson staining and immunocytochemistry, respectively Results: Total collagen occupied 37.7% of the wall area of peripheral airways, compared with 54.5% of the wall area of central airways (P =.04). There was no significant difference in central versus peripheral airways for collagen III or alpha-smooth muscle actin immunoreactivity and in the number of TGF-beta(+) cells in the submucosa. The only significant effect of HFA-flunisolide was a decrease in alpha-smooth muscle actin area in peripheral airways (13.4% vs 4.6%; P =.01) that correlated with the percentage increase in forced expiratory How at 25% to 75% of vital capacity (r(s) = -1.00; P =.00). Conclusion: Our data show that there is a considerable degree of airway remodeling in peripheral airways in patients with asthma and confirm the inability of ICS to modulate collagen deposition and TGF-beta expression. Treatment with HFA-flunisolide is associated with a significant decrease in the expression of alpha-smooth muscle actin in peripheral airways, which correlated with improvement in peripheral airway function.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Pulm Associates, Phoenix, AZ USA; Forest Labs Inc, New York, NY USA	McGill University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	qutayba.hamid@mcgill.ca						Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308, DOI 10.1164/ajrccm.162.4.9910051; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; EBINA M, 1993, AM REV RESPIR DIS, V148, P720, DOI 10.1164/ajrccm/148.3.720; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; FINE A, 1987, J BIOL CHEM, V262, P3897; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Hakonarson H, 1999, J CLIN INVEST, V103, P1077, DOI 10.1172/JCI5809; Hauber HP, 2003, J ALLERGY CLIN IMMUN, V112, P58, DOI 10.1067/mai.2003.1612; Hoshino M, 1998, THORAX, V53, P21, DOI 10.1136/thx.53.1.21; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Huang J, 1999, AM J RESP CRIT CARE, V160, P725, DOI 10.1164/ajrccm.160.2.9809040; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; James A, 2000, EUR RESPIR J, V15, P782, DOI 10.1034/j.1399-3003.2000.15d25.x; James AL, 2002, AM J RESP CRIT CARE, V166, P1590, DOI 10.1164/rccm.2108069; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JEFFERY PK, 1992, BRIT MED BULL, V48, P23, DOI 10.1093/oxfordjournals.bmb.a072537; Karjalainen EM, 2003, RESP MED, V97, P1045, DOI 10.1016/S0954-6111(03)00136-7; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Minshall EM, 1998, J ALLERGY CLIN IMMUN, V101, P386, DOI 10.1016/S0091-6749(98)70252-0; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; Panettieri Reynold A. Jr., 2002, Journal of Allergy and Clinical Immunology, V110, pS269, DOI 10.1067/mai.2002.129429; Quadrelli SA, 1996, RESPIRATION, V63, P131; Richards J, 2001, J AEROSOL MED, V14, P197, DOI 10.1089/08942680152484126; ROCHE WR, 1989, LANCET, V1, P520; Roth M, 2004, NEW ENGL J MED, V351, P560, DOI 10.1056/NEJMoa021660; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Stewart AG, 1995, BRIT J PHARMACOL, V116, P3219, DOI 10.1111/j.1476-5381.1995.tb15127.x; Synek M, 1996, AM J RESP CRIT CARE, V154, P224, DOI 10.1164/ajrccm.154.1.8680684; Taha RA, 1999, J ALLERGY CLIN IMMUN, V103, P476, DOI 10.1016/S0091-6749(99)70474-4; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; Venkatesan N, 2002, AM J PHYSIOL-LUNG C, V283, pL806, DOI 10.1152/ajplung.00061.2002; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; Wilson JW, 1997, CLIN EXP ALLERGY, V27, P363; YOUNG PG, 1995, EUR J PHARMACOL, V273, P137, DOI 10.1016/0014-2999(94)00679-2	46	89	91	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					983	989		10.1016/j.jaci.2005.07.029	http://dx.doi.org/10.1016/j.jaci.2005.07.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275364				2022-12-18	WOS:000235686700005
J	Bakhireva, LN; Jones, KL; Schatz, M; Johnson, D; Chambers, CD				Bakhireva, LN; Jones, KL; Schatz, M; Johnson, D; Chambers, CD		Org Teratology Information Service	Asthma medication use in pregnancy and fetal growth	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; asthma medications; beta(2)-agonists; inhaled corticosteroids; systemic corticosteroids; pregnancy; fetal growth	INTRAUTERINE GROWTH; MATERNAL ASTHMA; WOMEN; OUTCOMES; SEVERITY; SYMPTOMS; SAFETY; ASSOCIATION; PREVALENCE; DIAGNOSIS	Background: Given the high prevalence of asthma in pregnancy, it is important to understand the relationship between asthma medications and fetal growth in the context of appropriate treatment. Objective: This study examines the effect of inhaled corticosteroids, systemic corticosteroids, and beta(2)-agonists on fetal growth in 654 infants born to women with asthma compared with 303 infants born to controls without asthma. Methods: Subjects for this prospective study were enrolled throughout North America between 1998 and 2003 and followed up by the Organization of Teratology Information Services. Incidence of small for gestational age (SGA) infants and mean birth size measures were compared among groups. Results: Mean birth weight of full-term infants born to mothers who used systemic corticosteroids (3373 g) was lower than in the beta(2)-agonist group (3552 g) and controls without asthma (3540 g; P < .05) after adjustment for other risk factors. However, no differences in the incidence of SGA for weight were observed among groups. Adjusted mean birth length was slightly shorter in the systemic steroid group compared with controls (P = .02). Incidence of SGA for length and head circumference and mean head circumference did not vary among groups (P > .05). Conclusion: The treatment of asthma with systemic corticosteroids resulted in a deficit of about 200 g in birth weight compared with controls and exclusive beta(2)-agonist users and no increased incidence of SGA. These results suggest that asthma management with beta(2)-agonists and/or inhaled corticosteroids during pregnancy does not impair fetal growth, whereas systemic corticosteroids have a minimal effect which should be weighed against the necessity to control severe asthma.	Univ Calif San Diego, Med Ctr, Dept Pediat, San Diego, CA 92103 USA; Kaiser Permanente Med Ctr, Dept Allergy Immunol, San Diego, CA USA; Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA	University of California System; University of California San Diego; Kaiser Permanente; University of California System; University of California San Diego	Chambers, CD (corresponding author), Univ Calif San Diego, Med Ctr, Dept Pediat, MC8446,200 W Arbor Dr, San Diego, CA 92103 USA.	chchambers@ucsd.edu	Jones, Kenneth/GXF-4945-2022	Chambers, Christina D/0000-0003-4675-7722				Allen DB, 2002, PEDIATRICS, V109, P373; Bracken MB, 1999, J ALLERGY CLIN IMMUN, V103, pS354, DOI 10.1016/S0091-6749(99)70262-9; Bracken MB, 2003, OBSTET GYNECOL, V102, P739, DOI 10.1016/S0029-7844(03)00621-5; Demissie K, 1998, AM J RESP CRIT CARE, V158, P1091, DOI 10.1164/ajrccm.158.4.9802053; *EUR SURV CONG AN, 2003, WHO COLL CTR EP SURV; Fortk E, 2000, J Pediatr (Rio J), V76, P263; *GLOB IN ASTHM, 2004, NIH PUBL; Jana N, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P227; Johnson KA, 2001, TERATOLOGY, V64, P79, DOI 10.1002/tera.1048; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; Kuczmarski RJ, 2000, ADV DATA, V314, P1; Kwon HL, 2003, ANN EPIDEMIOL, V13, P317, DOI 10.1016/S1047-2797(03)00008-5; LARSSON K, 1985, EUR J RESPIR DIS, V66, P1; LECK I, 1995, J EPIDEMIOL COMMUN H, V49, P171, DOI 10.1136/jech.49.2.171; Levy-Marchal Claire, 2004, Semin Neonatol, V9, P67, DOI 10.1016/j.siny.2003.08.001; Liu SL, 2001, AM J OBSTET GYNECOL, V184, P90, DOI 10.1067/mob.2001.108073; LUBCHENCO LO, 1966, PEDIATRICS, V37, P403; Luskin AT, 1999, J ALLERGY CLIN IMMUN, V103, pS350, DOI 10.1016/S0091-6749(99)70261-7; MILLER HC, 1971, PEDIATRICS, V48, P511; Namazy J, 2004, J ALLERGY CLIN IMMUN, V113, P427, DOI 10.1016/j.jaci.2003.11.046; *NAT ASTHM ED PROG, 1993, NIH PUBL; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Norjavaara E, 2003, J ALLERGY CLIN IMMUN, V111, P736, DOI 10.1067/mai.2003.1340; Olesen C, 2001, EPIDEMIOLOGY, V12, P497, DOI 10.1097/00001648-200109000-00006; Park-Wyllie L, 2000, TERATOLOGY, V62, P385, DOI 10.1002/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z; PERLOW JH, 1992, AM J OBSTET GYNECOL, V167, P963, DOI 10.1016/S0002-9378(12)80020-2; SCHATZ M, 1992, ANN ALLERGY, V68, P123; SCHATZ M, 1990, CHEST, V98, P389, DOI 10.1378/chest.98.2.389; Schatz M, 2004, J ALLERGY CLIN IMMUN, V113, P1040, DOI 10.1016/j.jaci.2004.03.017; SCHATZ M, 1988, J ALLERGY CLIN IMMUN, V82, P686, DOI 10.1016/0091-6749(88)90984-0; Schatz M, 1997, J ALLERGY CLIN IMMUN, V100, P301, DOI 10.1016/S0091-6749(97)70241-0; Schatz M, 2001, SEMIN PERINATOL, V25, P145, DOI 10.1053/sper.2001.24569; Scialli AR, 1999, J ALLERGY CLIN IMMUN, V103, pS373, DOI 10.1016/S0091-6749(99)70267-8; Sorensen TK, 2003, ANN EPIDEMIOL, V13, P267, DOI 10.1016/S1047-2797(02)00413-1; Tan KS, 2000, AM J MED, V109, P727, DOI 10.1016/S0002-9343(00)00615-X; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Triche EW, 2004, OBSTET GYNECOL, V104, P585, DOI 10.1097/01.AOG.0000136481.05983.91; Van den Berg LTWDJ, 1999, TERATOLOGY, V60, P33; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098	40	89	91	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					503	509		10.1016/j.jaci.2005.05.027	http://dx.doi.org/10.1016/j.jaci.2005.05.027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159616				2022-12-18	WOS:000235686500005
J	Robotham, JM; Wang, F; Seamon, V; Teuber, SS; Sathe, SK; Sampson, HA; Beyer, K; Seavy, M; Roux, KH				Robotham, JM; Wang, F; Seamon, V; Teuber, SS; Sathe, SK; Sampson, HA; Beyer, K; Seavy, M; Roux, KH			Ana o 3, an important cashew nut (Anacardium occidentale L.) allergen of the 2S albumin family	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ana o 3; food allergy; cashew allergy; tree nut allergy; 2S albumin; epitope mapping; seed storage proteins	WALNUT JUGLANS-REGIA; MAJOR ALLERGEN; STORAGE PROTEIN; PISTACHIO NUT; MUSTARD SEEDS; IDENTIFICATION; SESAME; ANAPHYLAXIS; PRECURSOR; PEANUT	Background: Cashew nut allergy is the second most commonly reported tree nut allergy in the United States. We have previously cloned and characterized major cashew allergens belonging to the vicilin and legumin families of seed storage proteins. Objective: Here we set out to describe a third major cashew allergen, a 2S albumin. Methods: The recombinant cashew 2S albumin was amplified from a cDNA library by means of PCR, sequenced, and expressed in Escherichia coli. Immunoblotting was used to screen for reactivity with patients' sera, and inhibition immunoblotting was used to identify the corresponding native cashew nut proteins. The mass of affinity-purified native allergen was determined by means of matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectroscopy. Patients' sera were used to probe solid-phase 2S albumin peptides to identify linear epitopes. Results: The cloned allergen, designated Ana o 3, was identified as 2S albumin. MALDI-TOF mass spectroscopy of native Ana o 3 yielded a molecular mass of 12,598 d. Immunoblot analysis showed 21 (81%) of 26 sera from patients with cashew allergy were reactive. Three native Ana o 3 large-subunit isoforms with molecular weights ranging front approximately 6 to 10 kd were identified. Probing of overlapping synthetic Ana o 3 peptides with patients' sera identified 16 reactive peptides, 4 of which gave strong signals and one of which positionally overlaps linear epitopes in mustard and walnut allergenic 2S albumins. The overlapping cashew and walnut epitopes also share considerable homology. Conclusions: We conclude that this 2S albumin protein is a major allergen in cashew nut and demonstrates a possible basis for cross-reactivity with walnut 2S albumin.	Florida State Univ, Dept Biol Sci, Biol Unit 1, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA; Florida State Univ, Dept Nutr Food & Exercise Sci, Tallahassee, FL 32306 USA; Univ Calif Davis, Sch Med, Dept Internal Med, Davis, CA 95616 USA; Vet Affairs No Calif Hlth Care Syst, Pleasant Hill, CA USA; Mt Sinai Sch Med, Dept Pediat Allergy, New York, NY USA; Humboldt Univ, Childrens Hosp Charite, Dept Pneumol & Immunol, Berlin, Germany	State University System of Florida; Florida State University; State University System of Florida; Florida State University; State University System of Florida; Florida State University; University of California System; University of California Davis; Icahn School of Medicine at Mount Sinai; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Roux, KH (corresponding author), Florida State Univ, Dept Biol Sci, Biol Unit 1, Tallahassee, FL 32306 USA.	roux@bio.fsu.edu			NIAID NIH HHS [K23 AI 01604-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI001604] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alcocer MJC, 2002, J MOL BIOL, V324, P165, DOI 10.1016/S0022-2836(02)01061-6; BANNON G, 2001, J ALLERGY CLIN IMM S, V107; Bashir MEH, 1998, INT ARCH ALLERGY IMM, V115, P73, DOI 10.1159/000023833; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P154, DOI 10.1067/mai.2002.125487; Bredehorst R, 2001, J CHROMATOGR B, V756, P33, DOI 10.1016/S0378-4347(01)00069-X; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; DECASTRO LAB, 1987, MOL GEN GENET, V206, P338, DOI 10.1007/BF00333592; DELAPENA MAG, 1991, INT ARCH ALLER A IMM, V96, P263, DOI 10.1159/000235505; Fernandez C, 1995, CLIN EXP ALLERGY, V25, P1254, DOI 10.1111/j.1365-2222.1995.tb03050.x; GANDER ES, 1991, PLANT MOL BIOL, V16, P437, DOI 10.1007/BF00023994; Garcia F, 2000, J INVEST ALLERG CLIN, V10, P173; Kelly JD, 2000, INT ARCH ALLERGY IMM, V121, P19, DOI 10.1159/000024293; MENENDEZARIAS L, 1988, EUR J BIOCHEM, V177, P159, DOI 10.1111/j.1432-1033.1988.tb14357.x; MENENDEZARIAS L, 1990, MOL IMMUNOL, V27, P143, DOI 10.1016/0161-5890(90)90109-D; MONSALVE RI, 1993, BIOCHEM J, V293, P625, DOI 10.1042/bj2930625; Monsalve RI, 1997, CLIN EXP ALLERGY, V27, P833, DOI 10.1046/j.1365-2222.1997.660843.x; PARRA FM, 1993, CLIN EXP ALLERGY, V23, P996, DOI 10.1111/j.1365-2222.1993.tb00290.x; Pastorello EA, 2001, J CHROMATOGR B, V756, P85, DOI 10.1016/S0378-4347(01)00073-1; Poltronieri P, 2002, INT ARCH ALLERGY IMM, V128, P97, DOI 10.1159/000059399; Quercia O, 1999, ALLERGY, V54, P895, DOI 10.1034/j.1398-9995.1999.00264.x; Robotham JM, 2002, J ALLERGY CLIN IMMUN, V109, P143, DOI 10.1067/mai.2002.120558; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sathe SK, 1997, J AGR FOOD CHEM, V45, P2854, DOI 10.1021/jf970153e; Shewry PR, 1999, SEED PROTEINS, P563; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Teuber SS, 2002, J AGR FOOD CHEM, V50, P6543, DOI 10.1021/jf025757j; Teuber SS, 1998, J ALLERGY CLIN IMMUN, V101, P807, DOI 10.1016/S0091-6749(98)70308-2; THORPE SC, 1988, J ALLERGY CLIN IMMUN, V82, P67, DOI 10.1016/0091-6749(88)90053-X; Wang F, 2002, J ALLERGY CLIN IMMUN, V110, P160, DOI 10.1067/mai.2002.125208; Wang Q, 2002, ANN CHIM-SCI MAT, V27, P19, DOI 10.1016/S0151-9107(02)80041-1; Wolff N, 2003, FOOD CHEM TOXICOL, V41, P1165, DOI 10.1016/S0278-6915(03)00107-8; YOULE RJ, 1979, J AGR FOOD CHEM, V27, P500, DOI 10.1021/jf60223a017	34	89	97	1	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1284	1290		10.1016/j.jaci.2005.02.028	http://dx.doi.org/10.1016/j.jaci.2005.02.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940148				2022-12-18	WOS:000229815400028
J	de Blic, J; Tillie-Leblond, I; Tonnel, AB; Jaubert, F; Scheinmann, P; Gosset, P				de Blic, J; Tillie-Leblond, I; Tonnel, AB; Jaubert, F; Scheinmann, P; Gosset, P			Difficult asthma in children: An analysis of airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						difficult asthma; child; bronchoalveolar lavage; bronchial biopsy; interferon gamma; eosinophils; neutrophils; reticular basement membrane	INDUCED CYTOKINE RESPONSES; INTERFERON-GAMMA; IFN-GAMMA; EOSINOPHILIC INFLAMMATION; RESISTANT ASTHMA; BRONCHIAL LAVAGE; GENE-EXPRESSION; INTERLEUKIN-5; BRONCHOSCOPY; NEUTROPHILS	Background: Difficult asthma in children displays distinct clinical patterns, and its physiopathology remains poorly understood. Objective: To determine the characteristics of the bronchial inflammatory profile in children with difficult asthma. Methods: We performed endobronchial biopsy and bronchoalveolar lavage in 28 children with persistent bronchial obstruction despite high doses of inhaled corticosteroids and regular treatment with long-acting beta(2)-agonists: 13 had persistent symptoms and 15 had few or no symptoms. Results: The number of eosinophils (P =.03) and neutrophils (P =.04) in the epithelium was significantly higher in symptomatic children than in children with few symptoms. Reticular basement membrane thicknening was similar in both groups. IFNgamma levels (P =.03) and IFNgamma/IL-4 ratio (P =.01) were significantly higher in children with few symptoms. Conclusions: In symptomatic children, T(H)2-type inflammation was associated with the presence of activated eosinophils in the epithelium, whereas asthma in children with few symptoms was associated with an increase in T(H)1 cytokine levels. The high levels of IFNgamma suggest that this T(H)1 cytokine may modulate the local inflammatory response.	Hop Necker Enfants Malad, Serv Pneumol & Allergol Pediat, F-75015 Paris, France; Inst Pasteur, INSERM, U416, F-59019 Lille, France; Hop Necker Enfants Malad, Serv Anatomopathol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	de Blic, J (corresponding author), Hop Necker Enfants Malad, Serv Pneumol & Allergol Pediat, 149 Rue Sevres, F-75015 Paris, France.		Gosset, Philippe/C-6174-2018	Gosset, Philippe/0000-0002-4043-6429				ADELROTH E, 2000, EUR RESPIR REV, V10, P36; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; Chung KF, 1999, EUR RESPIR J, V13, P1198; CORRIGAN CJ, 1991, INT ARCH ALLER A IMM, V94, P270, DOI 10.1159/000235380; COX G, 1995, J IMMUNOL, V154, P4719; de Blic J, 2000, EUR RESPIR J, V15, P217; de Blic J, 2002, EUR RESPIR J, V20, P1271, DOI 10.1183/09031936.02.02072001; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Fregonese L, 2000, EUR RESPIR J, V15, P1128, DOI 10.1034/j.1399-3003.2000.01524.x; Grunig G, 2002, CHEST, V121, p88S, DOI 10.1378/chest.121.3_suppl.88S; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Jeffery PK, 2002, EUR RESPIR J, V20, P1378, DOI 10.1183/09031936.02.00542001; Just J, 2002, J ALLERGY CLIN IMMUN, V110, P42, DOI 10.1067/mai.2002.123304; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; Lee YC, 2001, J ASTHMA, V38, P665, DOI 10.1081/JAS-100107544; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; Magnan AO, 2000, AM J RESP CRIT CARE, V161, P1790, DOI 10.1164/ajrccm.161.6.9906130; Marguet C, 2000, AM J RESP CRIT CARE, V162, P1016, DOI 10.1164/ajrccm.162.3.9902101; Marguet C, 1999, AM J RESP CRIT CARE, V159, P1533, DOI 10.1164/ajrccm.159.5.9805028; MCKENZIE SA, 2000, EUR RESPIR REV, V10, P18; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; National cholesterol education program National heart lung and blood institute National institutes of health, 2002, 3 REP NAT CHOL ED PR; Payne D, 2001, ARCH DIS CHILD, V84, P423, DOI 10.1136/adc.84.5.423; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; POSTON RN, 1992, AM REV RESPIR DIS, V145, P918, DOI 10.1164/ajrccm/145.4_Pt_1.918; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Saetta M, 1998, EUR RESPIR J, V11, p20S; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; Smart JM, 2002, CLIN EXP ALLERGY, V32, P796, DOI 10.1046/j.1365-2222.2002.01391.x; Smart JM, 2002, J ALLERGY CLIN IMMUN, V110, P450, DOI 10.1067/mai.2002.127283; So EY, 2000, J IMMUNOL, V165, P5472, DOI 10.4049/jimmunol.165.10.5472; Spahn JD, 2002, J ALLERGY CLIN IMMUN, V109, P3, DOI 10.1067/mai.2002.120756; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; Tillie-Leblond I, 1999, AM J RESP CRIT CARE, V159, P487, DOI 10.1164/ajrccm.159.2.9805115; Tillie-Leblond I, 2000, AM J RESP CRIT CARE, V162, P586, DOI 10.1164/ajrccm.162.2.9907014; Venkataraman C, 1999, J IMMUNOL, V162, P4053; Vignola AM, 1998, AM J RESP CRIT CARE, V157, pS184, DOI 10.1164/ajrccm.157.5.rsaa-3; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	43	89	90	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					94	100		10.1016/j.jaci.2003.10.045	http://dx.doi.org/10.1016/j.jaci.2003.10.045			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	760MP	14713913	Bronze			2022-12-18	WOS:000187837900012
J	Matsui, EC; Wood, RA; Rand, C; Kanchanaraksa, S; Swartz, L; Curtin-Brosnan, J; Eggleston, PA				Matsui, EC; Wood, RA; Rand, C; Kanchanaraksa, S; Swartz, L; Curtin-Brosnan, J; Eggleston, PA			Cockroach allergen exposure and sensitization in suburban middle-class children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cockroach allergen; childhood asthma; cockroach sensitization; allergen exposure	HOUSE-DUST MITE; INNER-CITY ASTHMA; MANAGEMENT PROGRAM; INDOOR ALLERGENS; CROSS-REACTIVITY; RISK-FACTORS; HOMES; CHILDHOOD; CAT; ENVIRONMENT	Background: Exposure to cockroach allergen is prevalent in inner-city homes and is associated with an increased risk of cockroach sensitization. Objective: We sought to determine the prevalence of cockroach allergen exposure in suburban middle-class homes and to study its relationship to cockroach sensitization. Methods: Children with asthma, 6 to 17 years of age, were recruited from 3 pediatric practices located in counties surrounding Baltimore city and from 1 practice located within Baltimore city limits. Participants underwent skin prick testing and completed baseline questionnaires. In addition, their homes were inspected, and settled dust samples were collected for allergen analysis. Results: Forty-one percent of the total study population (n = 339) had kitchen Bla g 1 levels of greater than 1 U/g. Forty-nine percent were white, 53% had annual incomes of greater than $50,000, and 48% of mothers had college degrees. Seventy-seven percent of the study population resided in a suburban or rural location, and 30% of kitchens in these homes had Bla g 1 levels of greater than 1 U/g. Among the suburban-rural subgroup, 21% were sensitized to cockroach compared with 35% of the city group. In multivariate analysis, exposure to kitchen Bla g 1 levels of greater than 1 U/g was associated with cockroach sensitization for both the total study population (odds ratio, 2.29; 95% CI, 1.28-4.11) and the suburban-rural subgroup (odds ratio, 2.37; 95% CI, 1.23-4.57). Conclusions: Cockroach allergen exposure might be more common in suburban middle-class homes of asthmatic children than previously thought. Moreover, the data suggest that low-level cockroach exposure is a risk factor for cockroach sensitization.	Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Med, Baltimore, MD USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Matsui, EC (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102, 600 N Wolfe St, Baltimore, MD 21287 USA.			Matsui, Elizabeth/0000-0001-8134-5593	NHLBI NIH HHS [R18-HL058942] Funding Source: Medline; NIAID NIH HHS [T32 AI07007] Funding Source: Medline; NIEHS NIH HHS [P01 ES09606] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R18HL058942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009606] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Ayuso R, 2002, INT ARCH ALLERGY IMM, V129, P38, DOI 10.1159/000065172; Berge M, 1998, PEDIATR ALLERGY IMMU, V9, P25, DOI 10.1111/j.1399-3038.1998.tb00296.x; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842, DOI 10.1016/S0091-6749(99)70296-4; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; GARCIA DP, 1994, ANN ALLERGY, V72, P203; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Kaleyias J, 2002, PEDIAT ALLERG IMM-UK, V13, P368, DOI 10.1034/j.1399-3038.2002.02077.x; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419, DOI 10.1289/ehp.02110419; Mitchell H, 1997, PEDIATR PULM, V24, P237; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; Wilson NW, 1999, ANN ALLERG ASTHMA IM, V83, P27, DOI 10.1016/S1081-1206(10)63509-0; WITTEMAN AM, 1995, INT ARCH ALLERGY IMM, V108, P165, DOI 10.1159/000237134; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358	23	89	90	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					87	92		10.1067/mai.2003.1588	http://dx.doi.org/10.1067/mai.2003.1588			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847484	Bronze			2022-12-18	WOS:000184010600015
J	Saxena, S; Madan, T; Shah, A; Muralidhar, K; Sarma, PU				Saxena, S; Madan, T; Shah, A; Muralidhar, K; Sarma, PU			Association of polymorphisms in the collagen region of SP-A2 with increased levels of total IgE antibodies and eosinophilia in patients with allergic bronchopulmonary aspergillosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SP-A1; SP-A2; collagen; ABPA; single nucleotide polymorphism; association; IgE; eosinophilia	SURFACTANT-PROTEIN-A; CYSTIC-FIBROSIS; PULMONARY SURFACTANT; SP-B; MEXICAN POPULATION; MARKER ALLELES; GENE-MUTATIONS; FUMIGATUS; MICE; TUBERCULOSIS	Background: Studies from our group have shown a protective role of pulmonary surfactant protein A (SP-A) against lung allergy and infections caused by Aspergillus fumigatus. Objective: Present study investigated the association of polymorphisms in the collagen region of SP-A1 and SP-A2 (genes encoding SP-A) with allergic bronchopulmonary aspergillosis (ABPA) and its clinical markers. Methods: Genomic DNA was extracted from blood samples of patients with ABPA and age-matched, unrelated control subjects. The polymorphisms were detected by means of PCR amplification and sequencing of the collagen region of SP-A1 and SP-A2. Results: Two exonic (SP-A2 G1649C and SP-A2 A1660G, 10 patients and 11 control subjects) and 2 intronic (SP-A2 T1492C, 8 patients and 8 control subjects; SP-A1 C1416T, 5 patients and 7 control subjects) polymorphisms in the collagen region of SP-A2 and SP-A1 showed significant association with patients with ABPA. A significantly higher frequency of the AGA allele (A1660G) of SP-A2 was observed in patients with ABPA in comparison with control subjects (P = .0156, odds ratio [OR] = 4.78, 95% CI = 1.23 < OR < 18.52). This polymorphism, when existing along with a nonredundant polymorphism, SP-A2 G1649C (Ala91Pro) resulted in a stronger association with ABPA (A166OG and G1649C: P = .0079, OR = 10.4, 95 % CI = 1.62 < OR < 66.90). Patients with ABPA with GCT and AGG alleles showed significantly high levels of total IgE and percentage eosinophilia versus patients with ABPA with CCT and AGA alleles. Conclusion: The results indicated that SP-A2 G1649C and SP-A2 A1660G, polymorphisms in the collagen region of SP-A2, might be one of the contributing factors to genetic predisposition and severity of clinical markers of ABPA.	Inst Genom & Integrat Biol, Delhi 110007, India; Univ Delhi, Dept Zool, Delhi 110007, India; Vallabhbhai Patel Chest Inst, Delhi, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); University of Delhi	Sarma, PU (corresponding author), Inst Genom & Integrat Biol, Mall Rd, Delhi 110007, India.			, shweta/0000-0001-8171-4264				Al-Amoudi OS, 2001, SAUDI MED J, V22, P708; Behera D, 1994, Indian J Chest Dis Allied Sci, V36, P173; Chauhan B, 1997, J IMMUNOL, V159, P4072; Chauhan B, 2000, J ALLERGY CLIN IMMUN, V106, P723, DOI 10.1067/mai.2000.109913; Chauhan B, 1996, J CLIN INVEST, V97, P2324, DOI 10.1172/JCI118675; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; DiAngelo S, 1999, DIS MARKERS, V15, P269, DOI 10.1155/1999/961430; Dobbeling U, 1997, BIOTECHNIQUES, V22, P88, DOI 10.2144/97221bm19; Floros J, 2000, J INFECT DIS, V182, P1473, DOI 10.1086/315866; Griese M, 1999, EUR RESPIR J, V13, P1455, DOI 10.1183/09031936.99.13614779; Guo XX, 2000, CHEST, V117, p249S, DOI 10.1378/chest.117.5_suppl_1.249S-a; Hoover RR, 1998, AM J RESP CELL MOL, V18, P353, DOI 10.1165/ajrcmb.18.3.3035; Improta R, 2001, J AM CHEM SOC, V123, P12568, DOI 10.1021/ja010599i; Judson M A, 2001, Expert Opin Pharmacother, V2, P1065, DOI 10.1517/14656566.2.7.1065; Kala P, 1998, PEDIATR RES, V43, P169, DOI 10.1203/00006450-199802000-00003; Karinch AM, 1997, BIOCHEM J, V321, P39, DOI 10.1042/bj3210039; KNUTSEN AP, 1994, J ALLERGY CLIN IMMUN, V94, P215, DOI 10.1016/0091-6749(94)90043-4; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; Kothari K, 2000, J Assoc Physicians India, V48, P445; Kumar AR, 1998, AM J PHYSIOL-LUNG C, V274, pL177, DOI 10.1152/ajplung.1998.274.2.L177; Kumar R, 2000, ASIAN PAC J ALLERGY, V18, P181; LeVine AM, 1997, J IMMUNOL, V158, P4336; LeVine AM, 1999, J CLIN INVEST, V103, P1015, DOI 10.1172/JCI5849; Lin Z, 2000, CLIN GENET, V58, P181, DOI 10.1034/j.1399-0004.2000.580305.x; Madan T, 1997, CLIN EXP IMMUNOL, V110, P241; Madan T, 2002, CLIN CHEM LAB MED, V40, P1002, DOI 10.1515/CCLM.2002.174; Madan T, 1997, INFECT IMMUN, V65, P3171, DOI 10.1128/IAI.65.8.3171-3179.1997; Madan T, 2001, J CLIN INVEST, V107, P467, DOI 10.1172/JCI10124; MANNES GPM, 1993, LANCET, V341, P492, DOI 10.1016/0140-6736(93)90244-B; Marchand E, 2001, CHEST, V119, P762, DOI 10.1378/chest.119.3.762; Miller PW, 1996, AM J HUM GENET, V59, P45; Mussaffi H, 2000, PEDIATR PULM, V29, P155, DOI 10.1002/(SICI)1099-0496(200002)29:2<155::AID-PPUL11>3.0.CO;2-H; Ramet M, 2000, DIS MARKERS, V16, P119; ROSENBERG M, 1978, AM J MED, V64, P599, DOI 10.1016/0002-9343(78)90579-X; SHAH A, 1990, ANN ALLERGY, V64, P507; Shah A, 2001, CLIN EXP ALLERGY, V31, P1896, DOI 10.1046/j.1365-2222.2001.01159.x; Shah A, 2002, J ASTHMA, V39, P273, DOI 10.1081/JAS-120002284; STARKE ID, 1985, BRIT J DIS CHEST, V79, P295, DOI 10.1016/S0007-0971(85)80033-4; Vlahakis NE, 2001, MAYO CLIN PROC, V76, P930; Wang GR, 2002, ENVIRON HEALTH PERSP, V110, P79, DOI 10.1289/ehp.0211079; Weikert LF, 1997, AM J PHYSIOL-LUNG C, V272, pL989, DOI 10.1152/ajplung.1997.272.5.L989	41	89	96	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1001	1007		10.1067/mai.2003.1395	http://dx.doi.org/10.1067/mai.2003.1395			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743564	Bronze			2022-12-18	WOS:000182904500014
J	Hawrylowicz, C; Richards, D; Loke, TK; Corrigan, C; Lee, T				Hawrylowicz, C; Richards, D; Loke, TK; Corrigan, C; Lee, T			A defect in corticosteroid-induced IL-10 production in T lymphocytes from corticosteroid-resistant asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INTERLEUKIN-10		Guys Kings & St Thomas Sch Med, Dept Resp Med & Allergy, London, England	University of London; King's College London	Hawrylowicz, C (corresponding author), Guys Kings & St Thomas Sch Med, Dept Resp Med & Allergy, London, England.		Hawrylowicz, Catherine/Q-8483-2017	Hawrylowicz, Catherine/0000-0002-2337-7463; Corrigan, Chris/0000-0002-0706-6534; Lee, Tak/0000-0002-7554-4059; Loke, Tuck-Kay/0000-0002-4608-2756				Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Richards DF, 2000, EUR J IMMUNOL, V30, P2344, DOI 10.1002/1521-4141(2000)30:8<2344::AID-IMMU2344>3.0.CO;2-7	5	89	101	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					369	370		10.1067/mai.2002.121455	http://dx.doi.org/10.1067/mai.2002.121455			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842311				2022-12-18	WOS:000174232600026
J	Wilson, DR; Nouri-Aria, KT; Walker, SM; Pajno, GB; O'Brien, F; Jacobson, MR; Mackay, IS; Durham, SR				Wilson, DR; Nouri-Aria, KT; Walker, SM; Pajno, GB; O'Brien, F; Jacobson, MR; Mackay, IS; Durham, SR			Grass pollen immunotherapy: Symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; eosinophils; IL-5; immunotherapy	RECOMBINANT HUMAN INTERLEUKIN-5; NATURAL ALLERGEN EXPOSURE; COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; MAST-CELLS; TISSUE EOSINOPHILIA; INDUCED RHINITIS; HAY-FEVER; ASTHMA; INFLAMMATION	Background: Tissue eosinophilia and infiltration by T(H)2-type T tells are characteristic features of allergic rhinitis both after allergen challenge and during natural allergen exposure. Specific immunotherapy inhibits allergen-induced nasal eosinophilia. Objectives: We sought to assess, in the context of a randomized trial, the relationships between symptomatic improvement after immunotherapy and eosinophil numbers and IL-5 expression in the nasal mucosa during the pollen season. Methods: Nasal biopsy specimens were taken from 37 adults with severe summer hay fever at baseline (out of season) and at peak season after 2 years of treatment with a depot grass pollen extract or placebo. Biopsy specimens were processed for immunohistochemistry by using mAbs against eosinophils (EG2), T cells (CD3), and IL-2 receptor-positive cells (CD25), as well as for in situ hybridization by using a sulfur 35-labeled antisense riboprobe directed against IL-5. Results: Immunotherapy significantly reduced symptoms (49%, P = .01) and medication requirements (80%, P = .007) compared with placebo. There was a 400% increase (P = .004) in eosinophils during the pollen season in placebo-treated patients, which was inhibited in the immunotherapy group (20% increase, P = .04 between groups). Seasonal increases were also observed for CD25(+) cells (P = .002), CD3(+) cells (P = .02), and IL-5 mRNA-expressing cells (P = .03) in the placebo group but not in the immunotherapy group. A significant correlation was observed between eosinophils and IL-5 expression (r = 0.5, P < .05). Both eosinophils (r = 0.6, P < .02) and IL-5 (r = 0.6, P < .02) correlated with symptoms after immunotherapy. Conclusion: Improvement in symptoms after grass pollen immunotherapy may result, at least in part, from inhibition of IL-5-dependent tissue eosinophilia during the pollen season. Conclusion: Improvement in symptoms after grass pollen immunotherapy may result, at least in part, from inhibition of IL-5-dependent tissue eosinophilia during the pollen season.	Natl Heart & Lung Inst, Imperial Coll, Sch Med, Dept Upper Resp Med, London SW3 6LY, England	Imperial College London	Durham, SR (corresponding author), Natl Heart & Lung Inst, Imperial Coll, Sch Med, Dept Upper Resp Med, Dovehouse St, London SW3 6LY, England.		Walker, Samantha/B-9740-2013	Walker, Samantha/0000-0001-5503-8258; Jacobson, Mikila/0000-0002-2921-6169				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; Cameron L, 2000, J IMMUNOL, V164, P1538, DOI 10.4049/jimmunol.164.3.1538; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; DJURUP R, 1984, ALLERGY, V39, P472; Durham SR, 1999, CLIN EXP ALLERGY, V29, P1490; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; FOKKENS W J, 1988, Rhinology (Utrecht), V26, P293; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Fujisawa T, 1997, INT ARCH ALLERGY IMM, V114, P81, DOI 10.1159/000237726; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; Ishihara K, 2000, INT ARCH ALLERGY IMM, V122, P36, DOI 10.1159/000053630; Kaminuma O, 1997, INT ARCH ALLERGY IMM, V114, P10, DOI 10.1159/000237709; Kita H, 2000, J ALLERGY CLIN IMMUN, V106, P521, DOI 10.1067/mai.2000.108430; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; Masuyama K, 1998, J ALLERGY CLIN IMMUN, V102, P610, DOI 10.1016/S0091-6749(98)70277-5; MOQBEL R, 1995, J IMMUNOL, V155, P4939; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Robinson DS, 1999, INT ARCH ALLERGY IMM, V118, P98, DOI 10.1159/000024039; Robinson DS, 1999, AM J RESP CELL MOL, V20, P9, DOI 10.1165/ajrcmb.20.1.3449; Roboz G J, 1999, Curr Opin Hematol, V6, P164, DOI 10.1097/00062752-199905000-00007; Romagnani S, 1998, ALLERGY, V53, P12, DOI 10.1111/j.1398-9995.1998.tb04951.x; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; TERADA N, 1992, J ALLERGY CLIN IMMUN, V90, P160, DOI 10.1016/0091-6749(92)90067-C; VALENT P, 1994, J ALLERGY CLIN IMMUN, V94, P1177, DOI 10.1016/0091-6749(94)90329-8; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; Walker C, 1998, J IMMUNOL, V161, P1962; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356	41	89	92	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					971	976		10.1067/mai.2001.115483	http://dx.doi.org/10.1067/mai.2001.115483			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398073				2022-12-18	WOS:000169454800006
J	Blomqvist, EH; Lundblad, L; Anggard, A; Haraldsson, PO; Stjame, P				Blomqvist, EH; Lundblad, L; Anggard, A; Haraldsson, PO; Stjame, P			A randomized controlled study evaluating medical treatment versus surgical treatment in addition to medical treatment of nasal polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyposis; olfaction; sinus surgery; medical treatment; surgical treatment; corticosteroids; scoring; staging; endoscopy; symptoms	ENDOSCOPIC SINUS SURGERY; OLFACTORY DYSFUNCTION; ANOSMIA; DISEASE	Background: Controlled prospective studies are needed to determine whether surgical treatment in fact has an effect additive to that of medical treatment of nasal polyposis. Objective: We sought to compare the effect of medical treatment versus combined surgical and medical treatment on olfaction, polyp score, and symptoms in nasal polyposis. Methods: Thirty-two patients with nasal polyposis and symmetrical nasal airways were randomized to unilateral endoscopic sinus surgery after pretreatment with oral prednisolone for 10 days and local nasal budesonide bilaterally for 1 month, Postoperatively, patients were given local nasal steroids (budesonide). Patients were evaluated with nasal endoscopy, symptom scores, and olfactory thresholds, They were followed for 12 months. Results: The sense of smell was improved by the combination of local and oral steroids. Surgery had no additional effect, Symptom scores improved significantly with medical treatment alone, but surgery had additional beneficial effects on nasal obstruction and secretion. After surgery, the polyp score decreased significantly on the operated side but remained the same on the unoperated side. Twenty-five percent of the patients were willing to undergo an operation also on the unoperated side at the end of the study. Conclusions: Medical treatment seems to be sufficient to treat most symptoms of nasal polyposis. When hyposmia is the primary symptom, no additional benefit seems to be gained from surgical treatment. If nasal obstruction is the main problem after steroid treatment, surgical treatment is indicated. Selection of those who will benefit from surgery should be based on the patient's symptoms and not on the examiner's polyp score.	Karolinska Hosp, Dept Otorhinolaryngol, S-17176 Stockholm, Sweden; Huddinge Hosp, Dept Otorhinolaryngol, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Blomqvist, EH (corresponding author), Karolinska Hosp, Dept Otorhinolaryngol, S-17176 Stockholm, Sweden.							BERNSTEIN JM, 1997, IMMUNOHISTOPATHOLOGY; CAIN WS, 1988, LARYNGOSCOPE, V98, P83; Downey LL, 1996, OTOLARYNG HEAD NECK, V115, P24, DOI 10.1016/S0194-5998(96)70131-6; GOODSPEED RB, 1986, CLIN MEASUREMENT TAS, P514; Hinriksdottir I, 1997, ORL J OTO-RHINO-LARY, V59, P36, DOI 10.1159/000276902; HOSEMANN W, 1994, AM J OTOLARYNG, V15, P85, DOI 10.1016/0196-0709(94)90056-6; HOSEMANN W, 1993, AM J RHINOL, V7, P11, DOI 10.2500/105065893781976564; JAFEK B W, 1989, Ear Nose and Throat Journal, V68, P402; JAFEK BW, 1987, ARCH OTOLARYNGOL, V113, P547; JAFEK BW, 1989, ENT-EAR NOSE THROAT, V68, P402; JAFEK BW, 1989, ENT-EAR NOSE THROAT, V68, P400; Johansson L, 2000, ACTA OTO-LARYNGOL, V120, P72; Klimek L, 1997, J ALLERGY CLIN IMMUN, V100, P158, DOI 10.1016/S0091-6749(97)70218-5; Klimek L, 1998, Pneumologie, V52, P196; LILDHOLDT T, 1988, ACTA OTO-LARYNGOL, V105, P140, DOI 10.3109/00016488809119457; LILDHOLDT T, 1995, CLIN OTOLARYNGOL, V20, P26, DOI 10.1111/j.1365-2273.1995.tb00007.x; LILDHOLDT T, 1994, RHINOLOGY, V32, P126; LUND VJ, 1995, ANN OTO RHINOL LARYN, V104, P17, DOI 10.1177/000348949510410s02; LUND VJ, 1994, J ROY SOC MED, V87, P70; MAW AR, 1986, LANCET, V1, P1399; Mott AE, 1997, ARCH OTOLARYNGOL, V123, P367; MOTT AE, 1991, SMELL TASTE HLTH DIS, P553; Radenne F, 1999, J ALLERGY CLIN IMMUN, V104, P79, DOI 10.1016/S0091-6749(99)70117-X; SCOTT AE, 1989, ARCH OTOLARYNGOL, V115, P109; Shin SH, 1999, AM J RHINOL, V13, P63, DOI 10.2500/105065899781389894; STAMMBERGER H, 1990, EUR ARCH OTO-RHINO-L, V247, P63; Stammberger H, 1999, ALLERGY, V54, P7, DOI 10.1111/j.1398-9995.1999.tb05031.x; TOS M, 1997, EALRY STAGES POLYP F	28	89	93	2	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					224	228		10.1067/mai.2001.112124	http://dx.doi.org/10.1067/mai.2001.112124			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174186				2022-12-18	WOS:000167071400006
J	Mitakakis, TZ; Barnes, C; Tovey, ER				Mitakakis, TZ; Barnes, C; Tovey, ER			Spore germination increases allergen release from Alternaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						allergen; Alt a 1; Alternaria; germination; Halogen; immunoassay	ASPERGILLUS-FUMIGATUS	Allergen released from individual spores of the fungus Alternaria has not been investigated. Germination of spores has been suggested to increase allergen release. This study examined allergen released from individual spores and the effect of germination on allergen availability. Allergen release was determined with the Halogen (Inhalix, Sydney, Australia) immunoassay, by use of serum IgE from Alternaria-sensitized subjects and 3 Alt a 1-specific antibodies. Not all spores released allergen. Germination of the spores significantly increased the proportion that released allergen (P < .0001 for all antibodies). Alt a 1 may be a minor contributor to the total allergen released from spores except when spores have germinated. How these results reflect the allergen content of spores in the air that we breathe requires investigation.	Univ Sydney, Sch Biol Sci, Inst Resp Med, Allergen Unit, Sydney, NSW 2006, Australia; Royal Prince Alfred Hosp, Inst Resp Med, Sydney, NSW, Australia; Childrens Mercy Hosp, Kansas City, MO 64108 USA	University of Sydney; University of Sydney; Children's Mercy Hospital	Mitakakis, TZ (corresponding author), Univ Sydney, Sch Biol Sci, Inst Resp Med, Allergen Unit, Room 461,Blackburn Bldg D06, Sydney, NSW 2006, Australia.		Tovey, Euan R/G-8604-2017	Tovey, Euan R/0000-0002-1802-7266				DeVouge MW, 1996, INT ARCH ALLERGY IMM, V111, P385, DOI 10.1159/000237397; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; MORRISON VA, 1993, CLIN INFECT DIS, V16, P265, DOI 10.1093/clind/16.2.265; PORTNOY J, 1993, J ALLERGY CLIN IMMUN, V91, P930, DOI 10.1016/0091-6749(93)90351-F; Razmovski V, 2000, J ALLERGY CLIN IMMUN, V105, P725, DOI 10.1067/mai.2000.105222; REIJULA KE, 1991, J ALLERGY CLIN IMMUN, V87, P683, DOI 10.1016/0091-6749(91)90389-6; SALVAGGIO JE, 1994, J ALLERGY CLIN IMMUN, V94, P304, DOI 10.1053/ai.1994.v94.a56009; SPORIK RB, 1993, CLIN EXP ALLERGY, V23, P326, DOI 10.1111/j.1365-2222.1993.tb00330.x; VIJAY HM, 1993, J ALLERGY CLIN IMMUN, V91, P826, DOI 10.1016/0091-6749(93)90338-G	9	89	93	0	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					388	390		10.1067/mai.2001.112602	http://dx.doi.org/10.1067/mai.2001.112602			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174210	Bronze			2022-12-18	WOS:000167071400030
J	Platts-Mills, TAE; Vaughan, JW; Carter, MC; Woodfolk, JA				Platts-Mills, TAE; Vaughan, JW; Carter, MC; Woodfolk, JA			The role of intervention in established allergy: Avoidance of indoor allergens in the treatment of chronic allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; indoor allergens; intervention	HOUSE-DUST MITE; FEL-D-I; PARTICLE-SIZE DISTRIBUTION; PLACEBO-CONTROLLED TRIAL; COCKROACH ALLERGEN; REDUCE ALLERGEN; CAT ALLERGEN; RISK-FACTOR; BRONCHIAL HYPERREACTIVITY; PROLIFERATIVE RESPONSES	Avoidance of exposure to indoor allergens is an important element in the treatment of allergic disease. The results of several studies provide strong evidence in support of a role for allergen avoidance; however, strategies that optimize allergen reduction in houses have not been determined. Complex issues regarding the efficacy of physical and chemical measures that target house dust mite, pet, and cockroach allergens in the home are discussed. The greatest challenge is to educate allergic patients so that they can play an important role in controlling their own disease.	Univ Virginia, Dept Med, Div Asthma Allergy & Immunol, Charlottesville, VA 22908 USA	University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, Dept Med, Div Asthma Allergy & Immunol, POB 801355, Charlottesville, VA 22908 USA.			Platts-Mills, Thomas/0000-0002-1263-329X				AALBERSE RC, 1983, J IMMUNOL, V130, P722; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; ARLIAN LG, 1992, EXP APPL ACAROL, V16, P15, DOI 10.1007/BF01201490; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; Arlian LG, 1999, J MED ENTOMOL, V36, P457, DOI 10.1093/jmedent/36.4.457; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; Avner DB, 1997, J ALLERGY CLIN IMMUN, V100, P307, DOI 10.1016/S0091-6749(97)70242-2; BERMAN AR, 1995, J APPL PHYSIOL, V78, P1844, DOI 10.1152/jappl.1995.78.5.1844; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BONER AL, 1993, ALLERGY, V48, P119, DOI 10.1111/j.1398-9995.1993.tb04713.x; BRUYNZEELKOOMEN C, 1986, ARCH DERMATOL RES, V278, P199, DOI 10.1007/BF00412924; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; Butland BK, 1997, THORAX, V52, P618, DOI 10.1136/thx.52.7.618; Butland BK, 1997, BRIT MED J, V315, P717, DOI 10.1136/bmj.315.7110.717; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Carter M, 1998, J ALLERGY CLIN IMMUN, V101, pS5; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHARPIN C, 1991, J ALLERGY CLIN IMMUN, V88, P77, DOI 10.1016/0091-6749(91)90303-6; COCHRAN DG, 1995, EXPERIENTIA, V51, P561, DOI 10.1007/BF02128743; Colloff M. J., 1990, Pesticide Outlook, V1, P3; COLLOFF MJ, 1986, CLIN ALLERGY, V16, P41, DOI 10.1111/j.1365-2222.1986.tb01952.x; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53, DOI 10.1046/j.1365-2222.1998.00183.x; Custovic A, 1999, CLIN EXP ALLERGY, V29, P144; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; DANA H, 1986, 2 YEARS MAST; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DIETEMANN A, 1993, J ALLERGY CLIN IMMUN, V91, P738, DOI 10.1016/0091-6749(93)90193-J; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842, DOI 10.1016/S0091-6749(99)70296-4; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Fitzharris P, 1999, CLIN EXP ALLERGY, V29, P429; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Gotzsche PC, 1998, BRIT MED J, V317, P1105, DOI 10.1136/bmj.317.7166.1105; GREEN WF, 1984, LANCET, V2, P160; GREEN WF, 1989, CLIN EXP ALLERGY, V19, P203, DOI 10.1111/j.1365-2222.1989.tb02365.x; HANLEY JT, 1994, INDOOR AIR, V4, P169, DOI 10.1111/j.1600-0668.1994.t01-1-00005.x; HAYDEN ML, 1992, J ALLERGY CLIN IMMUN, V89, P536, DOI 10.1016/0091-6749(92)90320-2; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hodson T, 1999, J ALLERGY CLIN IMMUN, V103, P581, DOI 10.1016/S0091-6749(99)70227-7; Horak F, 1995, Wien Med Wochenschr, V145, P1; Horsfield M., 1997, BITING DUST JOYS HOU; Hughes, 1976, MITES STORED FOOD HO; HULETT AC, 1979, ANN ALLERGY, V42, P160; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; KANG BC, 1988, J ASTHMA, V25, P205, DOI 10.3109/02770908809071367; Kern RA., 1921, MED CLIN N AM, V5, P751; KERREBIJN KF, 1970, BRONCHITIS, V3, P38; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; KLUCKA CV, 1995, J ALLERGY CLIN IMMUN, V95, P1164, DOI 10.1016/S0091-6749(95)70072-2; KORSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; KORSGAARD J, 1982, J ALLERGY CLIN IMMUN, V38, P93; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; Mason K, 1999, J ALLERGY CLIN IMMUN, V104, P499, DOI 10.1016/S0091-6749(99)70400-8; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; MCGREGOR PG, 1996, P NZ SOC PAR C 25 JU; Miller JD, 1996, J ALLERGY CLIN IMMUN, V97, P962; MITCHELL EB, 1982, LANCET, V1, P127; MITCHELL EB, 1985, CLIN ALLERGY, V15, P235, DOI 10.1111/j.1365-2222.1985.tb02280.x; MITCHELL EB, 1984, J INVEST DERMATOL, V83, P290, DOI 10.1111/1523-1747.ep12340423; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Munir A K, 1994, Pediatr Allergy Immunol, V5, P32, DOI 10.1111/j.1399-3038.1994.tb00216.x; MURRAY AB, 1983, PEDIATRICS, V71, P418; NELSON HS, 1988, J ALLERGY CLIN IMMUN, V82, P661, DOI 10.1016/0091-6749(88)90980-3; *NIH, 1997, NIH PUBLICATION; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 1997, J ALLERGY CLIN IMMUN, V100, P428, DOI 10.1016/S0091-6749(97)70261-6; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P441; Platts-Mills TAE, 1999, BRIT MED J, V318, P870; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V105, pS503, DOI 10.1016/S0091-6749(00)90051-4; Platts-Mills TAE, 1984, ASTHMA PHYSL IMMUNOP, P297; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P505, DOI 10.1016/0091-6749(87)90369-1; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; Prescott SL, 1998, J IMMUNOL, V160, P4730; RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0; Ransom JH, 1996, J ALLERGY CLIN IMMUN, V97, P164; Ronmark E, 1998, RESP MED, V92, P316, DOI 10.1016/S0954-6111(98)90115-9; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; ROST GA, 1932, ARCH DERMATOL SYPHIL, V155, P297; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; Shaver JR, 1997, AM J RESP CRIT CARE, V155, P442, DOI 10.1164/ajrccm.155.2.9032176; SHAW J, 1991, OVERWORKED AM UNEXPE, P83; SIMON HU, 1994, PEDIATR PULM, V17, P304, DOI 10.1002/ppul.1950170507; SLY RM, 1985, ANN ALLERGY, V54, P209; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; Spivacke CA, 1925, J IMMUNOL, V10, P465; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; Valles SM, 1999, COMP BIOCHEM PHYS C, V124, P227, DOI 10.1016/S0742-8413(99)00076-6; Van Leeuwen WS, 1927, LANCET, V1, P1287; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V103, P227, DOI 10.1016/S0091-6749(99)70495-1; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V104, P1079, DOI 10.1016/S0091-6749(99)70092-8; VOORHORST R, 1969, DERMATOPHAGOIDES PTE; VYSZENSKIMOHER DL, 2000, ANN ALLERG ASTHMA IM, V84, P136; WALSHAW MJ, 1986, Q J MED, V58, P199; Wharton Edith, 1984, HOUSE MIRTH; WHARTON GW, 1997, ACAROLOGY, V19, P112; WICKMAN M, 1993, AM REV RESPIR DIS, V148, P58, DOI 10.1164/ajrccm/148.1.58; Williams LW, 1999, J ALLERGY CLIN IMMUN, V104, P702, DOI 10.1016/S0091-6749(99)70346-5; Wood RA, 1998, AM J RESP CRIT CARE, V158, P115, DOI 10.1164/ajrccm.158.1.9712110; WOODFOLK JA, 1995, J ALLERGY CLIN IMMUN, V96, P325, DOI 10.1016/S0091-6749(95)70051-X; WOODFOLK JA, 1994, J ALLERGY CLIN IMMUN, V94, P19, DOI 10.1016/0091-6749(94)90066-3; WOODFOLK JA, 1993, J ALLERGY CLIN IMMUN, V91, P829, DOI 10.1016/0091-6749(93)90339-H; YASUEDA H, 1989, INT ARCH ALLER A IMM, V90, P182, DOI 10.1159/000235021	117	89	96	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					787	804		10.1067/mai.2000.110548	http://dx.doi.org/10.1067/mai.2000.110548			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080699				2022-12-18	WOS:000167865200001
J	Warner, JA; Jones, CA; Jones, AC; Warner, JO				Warner, JA; Jones, CA; Jones, AC; Warner, JO			Prenatal origins of allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pregnancy; cytokines; allergens; placenta	NECROSIS-FACTOR-ALPHA; EPITHELIAL-CELLS; PARENTAL SMOKING; HUMAN-PLACENTA; MESSENGER-RNA; NK CELLS; T-CELLS; PREGNANCY; IGE; INTERLEUKIN-10	The prevalence of asthma and related allergic disorders has increased considerably over the last 25 years. Because genetic stock has not changed, environmental factors must have influenced the phenotype, Infants who experience the development of allergy already have an altered immune response at birth, We have investigated the development of immune responses during gestation and the effect of maternal allergen exposure during pregnancy and infant exposure in the first month of Life on the development of allergy and disease, There was higher specific peripheral blood mononuclear cell proliferation to house dust mite and birch pollen in the third trimester compared with the second trimester, with the first positive responses seen at 22 weeks gestation. Maternal exposure to birch pollen after 22 weeks resulted in higher infant peripheral blood mononuclear cell responses to birch pollen at birth. Infants born at term, with at least 1 atopic parent with asthma, who experienced the development of allergic symptoms and positive skin prick test by 1 year of age had raised proliferative responses to house dust mite at birth compared with those infants with no symptoms. In genetically predisposed individuals, antenatal factors including maternal and thereby fetal exposure to allergens and materno-placental-fetal immunologic interactions are active in determining whether an allergic predisposition is manifested as disease.	Univ Southampton, Southampton, Hants, England	University of Southampton	Warner, JA (corresponding author), Univ Southampton, Southampton Gen Hosp, Level G,Ctr Block,Tremona Rd, Southampton SO16 6YD, Hants, England.		Warner, John/AAF-9587-2020					ABBAS A, 1993, AM J OBSTET GYNECOL, V168, P1414, DOI 10.1016/S0002-9378(11)90774-1; Barker DJP, 1992, FETAL INFANT ORIGINS; BOEHM KD, 1989, P NATL ACAD SCI USA, V86, P656, DOI 10.1073/pnas.86.2.656; CADET P, 1995, AM J OBSTET GYNECOL, V173, P25, DOI 10.1016/0002-9378(95)90164-7; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; deMoraesPinto MI, 1997, IMMUNOLOGY, V90, P87, DOI 10.1046/j.1365-2567.1997.00139.x; GRABOWSKA A, 1990, PLACENTA, V11, P301, DOI 10.1016/S0143-4004(05)80221-8; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Holt PG, 1997, CIBA F SYMP, V206, P35; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; JONES CA, 1995, BIOL REPROD, V52, P839, DOI 10.1095/biolreprod52.4.839; KING A, 1990, CELL IMMUNOL, V129, P435, DOI 10.1016/0008-8749(90)90219-H; KJELLMAN NIM, 1981, LANCET, V1, P993; MAGNUSSON CGM, 1986, J ALLERGY CLIN IMMUN, V78, P898, DOI 10.1016/0091-6749(86)90237-X; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; PAGANIN C, 1994, CYTOKINE, V6, P135, DOI 10.1016/1043-4666(94)90034-5; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; ROBERTSON SA, 1992, BIOL REPROD, V46, P1069, DOI 10.1095/biolreprod46.6.1069; Roth I, 1996, J EXP MED, V184, P539, DOI 10.1084/jem.184.2.539; RUIZ RGG, 1991, CLIN EXP ALLERGY, V21, P467, DOI 10.1111/j.1365-2222.1991.tb01687.x; RUPPERT J, 1991, IMMUNOBIOLOGY, V182, P449, DOI 10.1016/S0171-2985(11)80209-3; SAITO S, 1994, IMMUNOL LETT, V40, P193, DOI 10.1016/0165-2478(93)00019-A; SHOHAT B, 1993, BIOL NEONATE, V63, P281; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; Warner JA, 1997, PEDIAT ALLERG IMM-UK, V8, P5; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; YELAVARTHI KK, 1991, J IMMUNOL, V146, P3840; Zeiger R, 1992, PEDIAT ALLERG IMM-UK, V3, P110, DOI [DOI 10.1111/J.1399-3038.1992.TB00035.X, 10.1111/j.1399-3038.1992.tb00035.x]	32	89	92	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	2	S			S493	S496		10.1016/S0091-6749(00)90049-6	http://dx.doi.org/10.1016/S0091-6749(00)90049-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286JG	10669530				2022-12-18	WOS:000085439600007
J	Ohta, K; Yamashita, N; Tajima, M; Miyasaka, T; Nakano, J; Nakajima, M; Ishii, A; Horiuchi, T; Mano, K; Miyamoto, T				Ohta, K; Yamashita, N; Tajima, M; Miyasaka, T; Nakano, J; Nakajima, M; Ishii, A; Horiuchi, T; Mano, K; Miyamoto, T			Diesel exhaust particulate induces airway hyperresponsiveness in a murine model: Essential role of GM-CSF	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway hyperresponsiveness; GM-CSF; diesel exhaust particulate; acetylcholine; bronchial epithelial cells	BRONCHIAL EPITHELIAL-CELLS; HEMATOPOIETIC GROWTH-FACTORS; COLONY-STIMULATING FACTOR; ADJUVANT ACTIVITY; IGE PRODUCTION; MESSENGER-RNA; SHORT-TERM; IN-VITRO; INFLAMMATION; EXPRESSION	Background: Inhaled pollutants were recently shown to be responsible for an increased incidence of airway allergic diseases, including asthma. A common feature of all forms of asthma is airway hyperresponsiveness. Objective: Our purpose was to elucidate the effects of diesel exhaust particulate (DEP), one of the most prevalent inhaled pollutants, on airway responsiveness. Methods: A/J and C57Bl/6 mice were used; the former are genetically predisposed to be hyperresponsive to acetylcholine, whereas the latter are not. DEP was administered intranasally for 2 weeks, after which pulmonary function was analyzed by whole-body plethysmography. Results: Intranasal administration of DEP increased airway responsiveness to acetylcholine in both A/J and C57Bl/6 mice and induced displacement of ciliated epithelial cells by mucus-secreting Clara cells. The effect was mediated by M-3 muscarinic receptors. Acetylcholine-evoked bronchial constriction was reversed by administration of terbutaline, a beta(2)-adrenergic antagonist, which is also characteristic of human asthma. Intranasal administration of antibody raised against GM-CSF abolished DEP-evoked increases in airway responsiveness and Clara cell hyperplasia. The antibody raised against IL-4 also inhibited DEP-evoked increases in airway responsiveness. However, it was to a lesser extent compared with antibody against GM-CSF In addition, DEP stimulated GM-CSF messenger RNA expression in the lung. Conclusion DEP induces airway hyperresponsiveness by stimulating GM-CSF synthesis.	Teikyo Univ, Sch Med, Dept Med, Itabashi Ku, Tokyo 173, Japan; Univ Tokyo, Fac Med, Dept Med, Tokyo 113, Japan; Univ Tokyo, Fac Med, Dept Phys Therapy, Tokyo 113, Japan; Kanto Chyuo Hosp, Tokyo, Japan; Japan Clin Allergy Inst, Tokyo, Japan	Teikyo University; University of Tokyo; University of Tokyo	Ohta, K (corresponding author), Teikyo Univ, Sch Med, Dept Med, Itabashi Ku, 2-11-1 Kaga, Tokyo 173, Japan.		Yamashita, Naomi/F-5045-2011					ANTONIADES HN, 1990, J CLIN INVEST, V86, P1055, DOI 10.1172/JCI114808; Bayram H, 1998, AM J RESP CELL MOL, V18, P441, DOI 10.1165/ajrcmb.18.3.2882; BRICHANT JF, 1990, AM J PHYSIOL, V258, pL349, DOI 10.1152/ajplung.1990.258.6.L349; BYLIN G, 1985, EUR J RESPIR DIS, V66, P205; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; DESANCTIS GT, 1997, AM J RESP CRIT CARE, V156, P582; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; FUJIMAKI H, 1995, INT ARCH ALLERGY IMM, V108, P268, DOI 10.1159/000237163; GASSON JC, 1991, BLOOD, V77, P131; GAVETT SH, 1993, AM J PHYSIOL, V265, pL493, DOI 10.1152/ajplung.1993.265.5.L493; GLEICH GJ, 1992, INFLAMMATION BASIC P, P663; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HIRAI K, 1988, J IMMUNOL, V141, P3958; HIRANO T, 1989, J IMMUNOL METHODS, V119, P145, DOI 10.1016/0022-1759(89)90391-8; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KOYAMA S, 1989, AM J PHYSIOL, V257, pL130, DOI 10.1152/ajplung.1989.257.2.L130; LEVITT RC, 1990, AM J PHYSIOL, V258, pL157, DOI 10.1152/ajplung.1990.258.4.L157; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MARINI M, 1991, AM J RESP CELL MOL, V4, P519, DOI 10.1165/ajrcmb/4.6.519; MATOLI S, 1991, AM REV RESPIR DIS, V143, pA144; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; Miyamoto T, 1997, ALLERGY, V52, P30, DOI 10.1111/j.1398-9995.1997.tb04867.x; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; OHTOSHI T, 1991, AM J RESP CELL MOL, V4, P255, DOI 10.1165/ajrcmb/4.3.255; Ohtoshi T, 1998, J ALLERGY CLIN IMMUN, V101, P778, DOI 10.1016/S0091-6749(98)70307-0; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; OSTER W, 1989, EUR J IMMUNOL, V19, P543, DOI 10.1002/eji.1830190320; OWEN S, 1991, NEW ENGL J MED, V325, P586; SACCO O, 1992, J CLIN INVEST, V90, P1379, DOI 10.1172/JCI116004; SHOJI S, 1990, AM REV RESPIR DIS, V141, P218, DOI 10.1164/ajrccm/141.1.218; SPRIGGS DR, 1988, J CLIN INVEST, V81, P455, DOI 10.1172/JCI113341; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; Takano H, 1997, AM J RESP CRIT CARE, V156, P36, DOI 10.1164/ajrccm.156.1.9610054; TAKIZAWA H, 1992, BIOCHEM BIOPH RES CO, V187, P596, DOI 10.1016/0006-291X(92)91236-J; TOMIOKA K, 1993, J IMMUNOL, V151, P4989; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Xing Z, 1996, J LEUKOCYTE BIOL, V59, P481, DOI 10.1002/jlb.59.4.481; YAMAGUCHI M, 1992, INT ARCH ALLERGY IMM, V97, P322, DOI 10.1159/000236140; YAMAGUCHI M, 1992, CLIN EXP ALLERGY, V22, P379, DOI 10.1111/j.1365-2222.1992.tb03099.x	44	89	98	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					1024	1030		10.1016/S0091-6749(99)70084-9	http://dx.doi.org/10.1016/S0091-6749(99)70084-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550748				2022-12-18	WOS:000083778400026
J	Gawchik, SM; Saccar, CL; Noonan, M; Reasner, DS; DeGraw, SS				Gawchik, SM; Saccar, CL; Noonan, M; Reasner, DS; DeGraw, SS			The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						levalbuterol; pediatric; asthma; FEV1; racemic albuterol; bronchodilator; beta(2)-agonist; inhalation solution; S-albuterol; R-albuterol	PERFORMANCE LIQUID-CHROMATOGRAPHY; AIRWAY SMOOTH-MUSCLE; S-ALBUTEROL; CHILDHOOD ASTHMA; RS-ALBUTEROL; SALBUTAMOL; ENANTIOMERS; CHILDREN; DISPOSITION; RESPONSES	Background: Limited dose-response information is available for nebulized beta(2)-agonists, especially in young children. Objective: The purpose of this study was to determine the safety and efficacy of increasing doses of nebulized levalbuterol (Xopenex; the pure R-isomer of racemic albuterol) and racemic albuterol compared with placebo in the treatment of asthma in pediatric patients. Methods: In this randomized, double-blind, crossover study, children (aged 3 to 11 years) with asthma (resting FEV1 50% to 80% of predicted normal [Polgar's] values) were treated with either levalbuterol, racemic albuterol, or placebo. Eligible subjects underwent a screening visit followed by 4 treatment visits. At each treatment visit, serial pulmonary function tests were completed before and after the treatment; plasma was collected to determine enantiomer levels, and safety was evaluated. Results: Five 3- to 5-year-old patients and twenty-eight 6- to 11-year-old patients completed the study, and a total of 87 doses of levalbuterol were administered. In the 6- to 11-year-old group, all doses of levalbuterol were significantly greater than placebo in peak change and percent peak change in FEV1 and area under the FEV1 versus time curve (P < .05). The FEV1 values over the 8-hour study period were similar for levalbuterol 0.31 and 0.63 mg and racemic albuterol 2.5 mg and were greatest after levalbuterol 1.25 mg. Median plasma levels of R-albuterol depended on dose and were 0.4, 0.7, 1.2, and 1.0 after levalbuterol 0.31 mg, 0.63 mg, and 1.25 mg and racemic albuterol 2.5 mg, respectively. All patients in the 2.5-mg racemic albuterol arm had measurable plasma levels of S-albuterol, although S-albuterol levels were undetectable in most patients in the levalbuterol arms. In a few patients who received levalbuterol, S-albuterol levels were detected, which was likely because of the use of racemic albuterol as a concomitant medication. Ail active treatments were well tolerated. beta-Mediated changes in heart rate, potassium, and glucose mere dose dependent for all active treatment groups. Conclusion: Levalbuterol caused a significantly greater increase in FEV1 than placebo, and FEV1 values were comparable with or better than those observed with racemic albuterol. beta-Mediated side effects were lower for an equipotent dose of levalbuterol when compared with racemic albuterol. Treatment with levalbuterol resulted in plasma levels that were dose dependent and had an approximate correlation with pharmacodynamic parameters.	Asthma & Allergy Res Associates, Chester, PA 19013 USA; Allergy Associates PC, Portland, OR USA; Sepracor Inc, Marlborough, MA USA	Dainippon Sumitomo Pharmaceutical Company; Sunovion Pharmaceuticals Inc.	Gawchik, SM (corresponding author), Asthma & Allergy Res Associates, Presidents House,1 Med Ctr Blvd, Chester, PA 19013 USA.							Auclair B, 1998, FASEB J, V12, pA142; Bakale RP, 1996, CLIN REV ALLERG IMMU, V14, P7, DOI 10.1007/BF02772200; Bannister O M, 1980, Physiotherapy, V66, P144; BLACKHALL MI, 1976, MED J AUSTRALIA, V2, P439, DOI 10.5694/j.1326-5377.1976.tb130323.x; Boulton DW, 1996, BRIT J CLIN PHARMACO, V41, P35, DOI 10.1111/j.1365-2125.1996.tb00156.x; CRAPO RO, 1995, AM J RESP CRIT CARE, V152, P1107, DOI DOI 10.1164/AJRCCM.152.3.7663792; Fried KM, 1998, CHIRALITY, V10, P484, DOI 10.1002/(SICI)1520-636X(1998)10:5<484::AID-CHIR11>3.0.CO;2-W; GROGGINS RC, 1981, ARCH DIS CHILD, V56, P342, DOI 10.1136/adc.56.5.342; GUMBHIRSHAH K, 1998, IN PRESS J CLIN PHAR; HARTLEY D, 1971, J MED CHEM, V14, P895, DOI 10.1021/jm00291a036; HUGHES D, 1982, ANN ALLERGY, V48, P6; Johansson F, 1996, CLIN REV ALLERG IMMU, V14, P57, DOI 10.1007/BF02772203; JONES B, 1990, DESIGN ANAL 3 MORE T, P189; KEMP JP, 1989, J ALLERGY CLIN IMMUN, V83, P697, DOI 10.1016/0091-6749(89)90085-7; Mitra S, 1998, MOL PHARMACOL, V53, P347, DOI 10.1124/mol.53.3.347; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V102, P943, DOI 10.1016/S0091-6749(98)70332-X; OBERKLAID F, 1993, MED J AUSTRALIA, V158, P751, DOI 10.5694/j.1326-5377.1993.tb121956.x; Penn RB, 1996, CLIN REV ALLERG IMMU, V14, P37, DOI 10.1007/BF02772201; PENNA AC, 1993, J ASTHMA, V30, P105, DOI 10.3109/02770909309054504; PerrinFayolle M, 1996, CLIN REV ALLERG IMMU, V14, P139, DOI 10.1007/BF02772208; POLGAR G, 1971, PULMONARY FUNCTION T, P272; SCHUH S, 1990, PEDIATRICS, V86, P509; SCHUH S, 1989, PEDIATRICS, V83, P513; TAN YK, 1987, J CHROMATOGR-BIOMED, V422, P187, DOI 10.1016/0378-4347(87)80451-6; Wall CE, 1996, LIBR HI TECH, V14, P1; WOLFE JD, 1991, PEDIATRICS, V88, P312; Yamaguchi H, 1996, CLIN REV ALLERG IMMU, V14, P47, DOI 10.1007/BF02772202	27	89	89	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					615	621		10.1016/S0091-6749(99)70233-2	http://dx.doi.org/10.1016/S0091-6749(99)70233-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200010				2022-12-18	WOS:000079723900013
J	Day, JH; Briscoe, M; Widlitz, MD				Day, JH; Briscoe, M; Widlitz, MD			Cetirizine, Ioratadine, or placebo in subjects with seasonal allergic rhinitis: Effects after controlled ragweed pollen challenge in an environmental exposure unit	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; cetirizine; environmental exposure unit; loratadine; placebo; pollen challenge; seasonal allergic rhinitis	DOUBLE-BLIND; HAY-FEVER; EFFICACY; TERFENADINE; ASTEMIZOLE; MULTICENTER; THERAPY; SAFETY; ANTIHISTAMINE; LORATADINE	Background: Allergic rhinitis affects nearly one in 10 Americans. Cetirizine is a newer once-daily selective H-1-antagonist. In traditional clinical trials, cetirizine has been shown to be safe and effective for the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria. Objective: To better characterize the efficacy and onset of action of cetirizine in a more controlled but clinically relevant setting, this agent was compared with loratadine and placebo in patients with symptomatic seasonal allergic rhinitis undergoing controlled pollen challenge in an environmental exposure unit (EEU). Methods: This was a double-blind, randomized, parallel-group study. After screening, patients were exposed to rag-weed pollen (primed) in the EEU (up to six exposures), and those with qualifying symptom scores were randomized to controlled pollen exposure (two periods of 5.5 to 6.5 hours over 2 days) and once-daily treatment with 10 mg cetirizine (n = 67), 10 mg loratadine (n = 67), or placebo (n = 68). The mean ragweed pollen level was 3480 +/- 350 grains/m(3) (standard deviation). The primary efficacy variables were the total symptom complex (TSC) and the major symptom complex (MSC) scores. Symptoms were evaluated every half hour in the EEU throughout the study. Results: Cetirizine produced a 36.7% mean reduction in TSC scores overall versus 15.4% with loratadine and 12.0% with placebo (p less than or equal to 0.01), Cetirizine also produced a 37.4% mean reduction in MSC scores overall versus 14.7% with loratadine and 6.7% with placebo (p less than or equal to 0.01). Onset of action as assessed by reductions in TSC and MSC scores versus placebo was evident within 1 hour with cetirizine (p less than or equal to 0.02) and 3 hours with loratadine (p less than or equal to 0.03). The incidence of treatment-related side effects was similar among groups, with headache reported most commonly in each group. Conclusion: Cetirizine is well tolerated and effective in reducing symptoms of seasonal allergic rhinitis in patients undergoing controlled pollen challenge.	Queens Univ, Dept Med, Div Allergy & Immunol, Kingston, ON K7L 2V7, Canada; Pfizer Inc, US Pharmaceut Grp, New York, NY USA	Queens University - Canada; Pfizer	Day, JH (corresponding author), Queens Univ, Dept Med, Div Allergy & Immunol, 76 Stuart St, Kingston, ON K7L 2V7, Canada.							ARBESMAN CE, 1955, REGIONAL ALLERGY US, P31; BACKHOUSE CI, 1990, BRIT J CLIN PRACT, V44, P88; Berkowitz RB, 1996, ANN ALLERG ASTHMA IM, V76, P363, DOI 10.1016/S1081-1206(10)60039-7; BRAUN JJ, 1992, C R THER PHARM CLIN, V10, P19; BUCK P, 1982, ANN ALLERGY, V49, P272; CAIAFFA MF, 1992, J INVEST ALLERG CLIN, V2, P162; CAVE JP, 1991, IMMUNOLOGIE MED, V8, P87; *CDCP, 1995, DHHS PUBL PHS, P82; *CDCP, 1994, DHHS PUBL PHS, P24; CONNELL JT, 1979, ANN ALLERGY, V42, P278; Day JH, 1997, ANN ALLERG ASTHMA IM, V79, P163, DOI 10.1016/S1081-1206(10)63104-3; Day JH, 1996, J ALLERGY CLIN IMMUN, V97, P1050, DOI 10.1016/S0091-6749(96)70257-9; DOCKHORN RJ, 1987, ANN ALLERGY, V58, P407; Donovan JP, 1996, ANN ALLERG ASTHMA IM, V77, P74, DOI 10.1016/S1081-1206(10)63483-7; DRIESSEN MNBM, 1991, EUR RESPIR J, V4, P359; FLEISS JL, 1973, STATISTICAL METHODS, P14; FRENZ DA, 1995, ANN ALLERG ASTHMA IM, V75, P417; HABENICHT HA, 1984, J ALLERGY CLIN IMMUN, V74, P64, DOI 10.1016/0091-6749(84)90088-5; HARCUP JW, 1993, BRIT J CLIN PRACT, V47, P131; Herman D, 1992, Allerg Immunol (Paris), V24, P270; KALIVAS J, 1990, J ALLERGY CLIN IMMUN, V86, P1014, DOI 10.1016/S0091-6749(05)80246-5; Lockey RF, 1996, ANN ALLERG ASTHMA IM, V76, P448, DOI 10.1016/S1081-1206(10)63462-X; LOCKEY RF, 1993, ANN ALLERGY, V70, P311; MANSMANN HC, 1992, ANN ALLERGY, V68, P348; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCMENAMIN P, 1994, ANN ALLERGY, V73, P35; MELTZER EO, 1996, J ALLERGY CLIN IMMUN, V97, P17; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; OGDEN EC, 1969, AM J BOT, V56, P16, DOI 10.2307/2440389; RIJNTJES E, 1990, J INT MED RES, V18, P219, DOI 10.1177/030006059001800306; *SAS I INC, SAS PROC GUID VERS 6, V2; *SAS I INC, SAS PROC GUID VERS 6, V1; SHEFFER AL, 1990, J ALLERGY CLIN IMMUN, V86, P1040, DOI 10.1016/S0091-6749(05)80251-9; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540; SNYDER SH, 1987, ANN ALLERGY, V59, P4; Solomon W. R., 1983, ALLERGY PRINCIPLES P, P1143; SOLOMON WR, 1984, J ALLERGY CLIN IMMUN, V74, P449, DOI 10.1016/0091-6749(84)90376-2; SOLOMON WR, 1976, J ALLERGY CLIN IMMUN, V57, P318, DOI 10.1016/0091-6749(76)90088-9; SPENCER CM, 1993, DRUGS, V46, P1055, DOI 10.2165/00003495-199346060-00008; TACHALSKAKRYNSK.B, 1994, PNEUMONOL ALERGOL PO, V62, P573; WINER BJ, 1971, STATISTICAL PRINCIPL, P205; WOOD SG, 1987, ANN ALLERGY, V59, P31	42	89	93	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					638	645		10.1016/S0091-6749(98)70172-1	http://dx.doi.org/10.1016/S0091-6749(98)70172-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600501				2022-12-18	WOS:000073697400012
J	Nelson, HS; Lahr, J; Buchmeier, A; McCormick, D				Nelson, HS; Lahr, J; Buchmeier, A; McCormick, D			Evaluation of devices for skin prick testing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						skin testing; skin test devices	PERFORMANCE	Background: Previous comparisons of devices for percutaneous skin testing have revealed statistically and clinically significant differences, from one device to another, in the size of reactions to histamine and allergen extracts and at negative control sites. Objective: The objective of this study was to compare the performance of several skin test devices which are either new, modified, or used with a modified technique. Methods: Twenty subjects were tested five to eight times with each of the devices both to glycerol-saline and to 10 mg/ml histamine base. The devices tested were the MultiTest II, Duo Tip-Test (prick and scarification), Quintest, DermaPik (prick and scarification), and small pox needle. Results: There were highly significant differences among the devices for the size of the reaction to histamine.(mean wheal diameter 4.28 to 8.59 mm, p < 0.0001), the standard errors of the wheals to histamine (0.82 to 1.45 mm, p < 0.05) and in the mean wheal size with glycerol-saline (0.00 to 2.48 mm, p < 0.0001). Conclusions: Devices for performing skin prick testing vary greatly in several characteristics, including the size of reactions at both positive and negative test sites. Each skin test technician should be tested with the device used in that skin testing laboratory to establish criteria for positive and negative tests.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	National Jewish Health	Nelson, HS (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.							ADINOFF AD, 1989, J ALLERGY CLIN IMMUN, V84, P168, DOI 10.1016/0091-6749(89)90321-7; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P750, DOI 10.1016/0091-6749(93)90019-C; NELSON SH, 1989, PROVOCATIVE CHALLENG	3	89	93	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				153	156		10.1016/S0091-6749(98)70409-9	http://dx.doi.org/10.1016/S0091-6749(98)70409-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500746				2022-12-18	WOS:000072244800002
J	Punnonen, J; Yssel, H; de Vries, JE				Punnonen, J; Yssel, H; de Vries, JE			The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4(+) or CB8(+) T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B lymphocytes; allergy; cytokines; isotype switching; T helper cells	HUMAN B-CELLS; NECROSIS-FACTOR-ALPHA; CD40 LIGAND; HYPER-IGM; IFN-GAMMA; INTERLEUKIN-4-DEFICIENT MICE; INTERLEUKIN-13 RECEPTOR; STIMULATION PROVIDES; HUMAN-LYMPHOCYTES; INTERFERON-GAMMA	The relative contribution of IL-4 and IL-13 to the regulation of IgE synthesis has remained relatively poorly characterized, partially because of lack of suitable animal models. We have studied the roles of IL-4 and IL-13 in human IgE synthesis induced by supernatants derived from activated CD4(+) or CD8(+) T cell clones. Neutralizing anti-IL-4 and anti-IL-13 monoclonal antibodies (mAbs) inhibited IgE synthesis induced by anti-CD40 mAbs and supernatants from CD4(+) T cells by an average 61% and 42%, respectively (n = 25). Recombinant IL-13 had additive effects on IL-4-induced IgE synthesis, but only when IL-4 was present at low concentrations. Accordingly, IL-4 was the dominant IgE synthesis-inducing cytokine derived from highly polarized T helper (TH)(2) cells. However, anti-IL-13 mAbs also significantly inhibited IgE synthesis induced by two of three supernatants derived from allergen-specific T-H2-like cell lines generated from the skin of patients with atopic dermatitis. Furthermore, anti-IL-13 mAbs almost completely inhibited IgE synthesis induced by supernatants from T-H1 cells or CD8(+) T cell clones. Taken together, these data indicate that IL-13, in addition to IL-4, contributes to IgE synthesis induced by all T helper cell subsets, including allergen-specific T-H2 cells. Moreover, IL-13 appears to be the major IgE synthesis-inducing cytokine derived from T-H1 cells or CD8(+) T cells.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Human Immunol, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	de Vries, JE (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Human Immunol, 901 Calif Ave, Palo Alto, CA 94304 USA.		Yssel, Hans/AFV-2907-2022; Yssel, Hans/C-6406-2009	Yssel, Hans/0000-0001-7454-1836; Yssel, Hans/0000-0001-7454-1836				ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; AVERSA G, 1993, J EXP MED, V177, P1575, DOI 10.1084/jem.177.6.1575; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; BRINKMANN V, 1995, J IMMUNOL, V154, P3078; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; CHRETIEN I, 1989, J IMMUNOL METHODS, V117, P6781; CLAASSEN JL, 1990, J IMMUNOL, V144, P2123; CRONIN DC, 1995, J IMMUNOL, V154, P3118; DIAZSANCHEZ D, 1994, J IMMUNOL, V153, P10; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; HUANG SK, 1995, J IMMUNOL, V155, P2688; Jung T, 1996, EUR J IMMUNOL, V26, P571, DOI 10.1002/eji.1830260311; KEALTOFT K, 1995, CANC GENET CYTOGENET, V85, P68; KEMENY DM, 1994, IMMUNOL TODAY, V15, P107, DOI 10.1016/0167-5699(94)90152-X; KIMATA H, 1994, J EXP MED, V180, P727, DOI 10.1084/jem.180.2.727; KIMATA H, 1995, EUR J IMMUNOL, V25, P1497, DOI 10.1002/eji.1830250604; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LIFE P, 1994, J EXP MED, V180, P1775, DOI 10.1084/jem.180.5.1775; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; MACCHIA D, 1993, NATURE, V363, P464, DOI 10.1038/363464a0; MAGGI E, 1994, J EXP MED, V180, P489, DOI 10.1084/jem.180.2.489; MALEFYT RD, 1995, INT IMMUNOL, V7, P1405, DOI 10.1093/intimm/7.9.1405; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MARSHALL JD, 1995, J IMMUNOL, V155, P111; MATTHEWS DJ, 1995, BLOOD, V85, P38, DOI 10.1182/blood.V85.1.38.bloodjournal85138; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; NobenTrauth N, 1996, SCIENCE, V271, P987, DOI 10.1126/science.271.5251.987; PAGANELLI R, 1995, J EXP MED, V181, P423, DOI 10.1084/jem.181.1.423; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; PUNNONEN J, 1994, J IMMUNOL, V152, P1094; PUNNONEN J, 1995, J IMMUNOL, V155, P4248; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SMIRNOV DV, 1995, GENE, V155, P277, DOI 10.1016/0378-1119(94)00720-D; Sornasse T, 1996, J EXP MED, V184, P473, DOI 10.1084/jem.184.2.473; SPITS H, 1983, HYBRIDOMA, V2, P423, DOI 10.1089/hyb.1983.2.423; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; THYPHRONITIS G, 1989, P NATL ACAD SCI USA, V86, P5580, DOI 10.1073/pnas.86.14.5580; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; VONDERWEID T, 1994, EUR J IMMUNOL, V24, P2285, DOI 10.1002/eji.1830241004; XU LX, 1994, INT IMMUNOL, V6, P515, DOI 10.1093/intimm/6.4.515; YSSEL H, 1992, J IMMUNOL, V148, P738; ZHANG K, 1991, J IMMUNOL, V146, P1836; ZHANG XH, 1992, EUR J IMMUNOL, V22, P829, DOI 10.1002/eji.1830220330; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	58	89	96	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				792	801		10.1016/S0091-6749(97)70276-8	http://dx.doi.org/10.1016/S0091-6749(97)70276-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438489				2022-12-18	WOS:000071353600013
J	Essayan, DM; KageySobotka, A; Colarusso, PJ; Lichtenstein, LM; Ozols, RF; King, ED				Essayan, DM; KageySobotka, A; Colarusso, PJ; Lichtenstein, LM; Ozols, RF; King, ED			Successful parenteral desensitization to paclitaxel	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						paclitaxel; desensitization; histamine release	CREMOPHOR-EL; HISTAMINE-RELEASE; HYPERSENSITIVITY REACTIONS; HUMAN BASOPHILS; TAXOL	Background: Paclitaxel, a member of a new class of antineoplastic agents called die taxanes, has been associated with anaphylactoid reactions. Objective: We report a case of successful parental desensitization to paclitaxel. Methods: Desensitization was performed with serial 10-fold dilutions (up to 1:100,000) of paclitaxel in sufficient volume to administer successive doses of 1, 2, 4 and 8 ml. Basophil histamine release tests were performed with paclitaxel alone, vehicle alone, and paclitaxel and vehicle combined to determine which agent was responsible for the anaphylactoid reactions. Results: After parental desensitization was performed, the patient was able to tolerate infusion of paclitaxel without complications or. need for antihistamines or steroids. Basophil histamine release occurred only with paclitaxel and not with the vehicle. Conclusions: Successful parenteral desensitization to paclitaxel can be achieved, it is paclitaxel, and not its vehicle, that is most likely responsible for anaphylactoid reactions inpatients undergoing treatment.	FOX CHASE CANC CTR,AMER ONCOL HOSP,PHILADELPHIA,PA 19111	Fox Chase Cancer Center	Essayan, DM (corresponding author), JOHNS HOPKINS ASTHMA & ALLERGY CTR,DIV CLIN IMMUNOL,5501 HOPKINS BAYVIEW CIRCLE,BALTIMORE,MD 21224, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI008270, R01AI008270] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 08270, AI 07290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P800; ARBUCK SG, 1993, J NATL CANCER I, V15, P155; ARBUCK SG, 1993, JNCI-J NATL CANCER I, V15, P131; DYE D, 1980, BRIT MED J, V280, P1353, DOI 10.1136/bmj.280.6228.1353; FINDLAY SR, 1981, J CLIN INVEST, V67, P1604, DOI 10.1172/JCI110195; FOSSELLA FV, 1994, J CLIN ONCOL, V12, P1238, DOI 10.1200/JCO.1994.12.6.1238; HOWRIE DL, 1985, DRUG INTEL CLIN PHAR, V19, P425, DOI 10.1177/106002808501900603; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LASKIN MS, 1993, J CLIN ONCOL, V11, P2456, DOI 10.1200/JCO.1993.11.12.2456; LORENZ W, 1975, AGENTS ACTIONS, V5, P402, DOI 10.1007/BF01972656; LORENZ W, 1977, AGENTS ACTIONS, V7, P63, DOI 10.1007/BF01964882; NOLTE H, 1988, AM J PEDIAT HEMATOL, V10, P308; PEEREBOOM DM, 1993, J CLIN ONCOL, V11, P885, DOI 10.1200/JCO.1993.11.5.885; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SOBOTKA AK, 1979, J IMMUNOL, V122, P511; Sullivan TJ, 1993, ALLERGY PRINCIPLES P, P1726; WEISS RB, 1990, J CLIN ONCOL, V8, P1263, DOI 10.1200/JCO.1990.8.7.1263; WOODCOCK DM, 1990, CANCER RES, V50, P4199	18	89	99	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	1				42	46		10.1016/S0091-6749(96)70281-6	http://dx.doi.org/10.1016/S0091-6749(96)70281-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TR947	8568136	hybrid			2022-12-18	WOS:A1996TR94700006
J	Vaarala, O; Saukkonen, T; Savilahti, E; Klemola, T; Akerblom, HK				Vaarala, O; Saukkonen, T; Savilahti, E; Klemola, T; Akerblom, HK			Development of immune response to cow's milk proteins in infants receiving cow's milk or hydrolyzed formula	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						oral tolerance; beta-lactoglobulin; bovine serum albumin; casein; insulin-dependent diabetes mellitus; cow's milk allergy; formula	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; ORAL TOLERIZATION; II COLLAGEN; SUPPRESSION; ANTIGENS; ANTIBODIES; TOLERANCE; ARTHRITIS; CHILDREN	Background: Development of humoral and cellular immune responses to orally administered antigens in human beings is poorly understood, although antigen administration has been suggested as a treatment for hypersensitivity disorders and autoimmune diseases. Objective: The purpose of the study was to investigate the development of systemic immune response in infants fed with formula containing whole cow's milk proteins or hydrolyzed formula containing casein peptides. Methods: In a double-blind trial, 10 infants received cow's milk-based formula, and 10 infants received a casein hydrolysate formula until the age of 9 months. Blood samples were taken at the age of 6, 9, and 12 months. Cellular responses were assessed by proliferation assay of peripheral blood mononuclear cells to cow's milk proteins (beta-lactoglobulin, bovine serum albumin, and alpha-casein). Humoral responses to the same proteins were measured by ELISA for IgG antibodies. Results: Feeding infants with cow's milk-based formula induced systemic humoral and cellular responses to cow's milk proteins. T-cell response later declined, supporting the concept of oral tolerization. Exposure to cow's milk proteins after the age of 9 months resulted in depressed cellular and humoral responsiveness to these proteins. Conclusion: Our results support the view that induction of oral tolerance in human beings is an age-dependent phenomenon.	UNIV HELSINKI,CHILDRENS HOSP,DEPT PEDIAT 2,SF-00290 HELSINKI,FINLAND	University of Helsinki	Vaarala, O (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,DEPT PEDIAT 1,RES LAB,STENBACKINKATU 11,SF-00290 HELSINKI,FINLAND.							BITAR DM, 1988, CELL IMMUNOL, V112, P364, DOI 10.1016/0008-8749(88)90305-X; GUNTHER M, 1960, IMMUNOLOGY, V3, P296; HIGGINS PJ, 1988, J IMMUNOL, V140, P440; HUSBY S, 1994, J IMMUNOL, V152, P4663; JAKOBSSON I, 1986, GUT, V27, P1029, DOI 10.1136/gut.27.9.1029; KARJALAINEN J, 1992, NEW ENGL J MED, V327, P302, DOI 10.1056/NEJM199207303270502; KLETTER B, 1971, INT ARCH ALLER A IMM, V40, P656, DOI 10.1159/000230447; KORENBLAT PE, 1968, J ALLERGY, V41, P226, DOI 10.1016/0021-8707(68)90046-4; KUITUNEN M, 1994, ALLERGY, V49, P354, DOI 10.1111/j.1398-9995.1994.tb02281.x; KUITUNEN M, 1995, IN PRESS PEDIATR ALL; KUITUNEN OOM, 1994, PEDIATR RES, V35, P344, DOI 10.1203/00006450-199403000-00014; MELAMED D, 1993, EUR J IMMUNOL, V23, P935, DOI 10.1002/eji.1830230426; MILLER A, 1991, J EXP MED, V174, P791, DOI 10.1084/jem.174.4.791; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; PIETROPAOLO M, 1993, J CLIN INVEST, V92, P359, DOI 10.1172/JCI116574; SAMPSON HA, 1991, J PEDIATR-US, V118, P520, DOI 10.1016/S0022-3476(05)90001-2; SAUKKONEN T, 1994, DIABETES CARE, V17, P970, DOI 10.2337/diacare.17.9.970; SAVILAHTI E, 1993, DIABETES CARE, V16, P984, DOI 10.2337/diacare.16.7.984; SAYLOR JD, 1991, J PEDIATR-US, V118, P71, DOI 10.1016/S0022-3476(05)81848-7; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; TAINIO VM, 1988, ACTA PAEDIATR SCAND, V77, P807, DOI 10.1111/j.1651-2227.1988.tb10760.x; THOMPSON HSG, 1990, IMMUNOL TODAY, V11, P396; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; WAHN U, 1992, J PEDIATR-US, V121, pS80, DOI 10.1016/S0022-3476(05)81412-X; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252; ZHANG ZYJ, 1990, J IMMUNOL, V145, P2489	28	89	92	1	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				917	923		10.1016/S0091-6749(95)70229-6	http://dx.doi.org/10.1016/S0091-6749(95)70229-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543750				2022-12-18	WOS:A1995TN12400009
J	ABSAR, N; DANESHVAR, H; BEALL, G				ABSAR, N; DANESHVAR, H; BEALL, G			DESENSITIZATION TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN HIV-INFECTED PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TRIMETHOPRIM SULFAMETHOXAZOLE; DESENSITIZATION; RIDS; HIV/1 INFECTION; DRUG REACTIONS	PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; BLOOD-INSTITUTE WORKSHOP; TRIMETHOPRIM-SULFAMETHOXAZOLE; PULMONARY COMPLICATIONS; AEROSOLIZED PENTAMIDINE; SECONDARY PROPHYLAXIS; ORAL DESENSITIZATION; NATIONAL-HEART; CO-TRIMOXAZOLE	Background: Trimethoprim-sulfamethoxazole (T/S) is art effective and important prophylactic medication for HIV-infected patients that must frequently be discontinued because of allergic reactions. Objective: Out objective was to assess the safety, the frequency of success, and the duration of desensitization to T/S in HIV-infected patients. Method: We studied oral desensitization with T/S of patients with a history of allergy to the medication and longitudinal follow-up. Twenty-eight men with a history of T/S-induced skin rashes were studied. Mean age was 35 years (range, 26 to 50 years). Mean CD4 count was 89 cells/mm(3) (range, 0/mm(3) to 210/mm(3)). patients were seen every 4 to 6 weeks. Mean follow-up was 19.07 week (range 2 to 81 weeks). Results: After 32 weeks, 23 of 28 (82%) patients were successfully desensitized (four had rashes develop, and one could not continue for personal reasons). Of the 23 patients who were successfully desensitized, six were known to have subsequently discontinued T/S (four had rashes; two discontinued on the advice of their personal primary physicians). Six patients were lost to follow-up. One patient died of pulmonary Kaposi's sarcoma. ren patients are taking the medication regularly without any problems. Conclusion: T/S desensitization is a simple, safe and effective means to provide it for most patients with a history of ''allergic'' rashes.	UNIV CALIF LOS ANGELES,HARBOR MED CTR,DEPT MED,DIV CLIN IMMUNOL & ALLERGY,TORRANCE,CA 90509	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center			Daneshvar, Hamid/AAG-9175-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027660] Funding Source: NIH RePORTER; NIAID NIH HHS [NIAID AI27660] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CASTELLANO AR, 1991, JAMA-J AM MED ASSOC, V266, P820, DOI 10.1001/jama.266.6.820; FINEGOLD I, 1985, J ALLERGY CLIN IMMUN, V75, P137, DOI 10.1016/0091-6749(85)90264-7; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FRASER IS, 1993, 9 INT C AIDS BERL; GRUCHALLA RS, 1991, J ALLERGY CLIN IMMUN, V88, P784, DOI 10.1016/0091-6749(91)90186-R; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HUGHES TE, 1986, ANN INTERN MED, V105, P148, DOI 10.7326/0003-4819-105-1-148; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; JAFFE HS, 1983, LANCET, V2, P1109; JICK H, 1982, REV INFECT DIS, V4, P426; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MARTIN MA, 1992, ARCH INTERN MED, V152, P523, DOI 10.1001/archinte.152.3.523; MITSUYASU R, 1983, NEW ENGL J MED, V308, P1535, DOI 10.1056/NEJM198306233082512; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; MURRAY JF, 1987, AM REV RESPIR DIS, V135, P504; RIEDER MJ, 1988, J PHARMACOL EXP THER, V244, P724; RIEDER MJ, 1989, ANN INTERN MED, V110, P286, DOI 10.7326/0003-4819-110-4-286; SHEAR NH, 1986, ANN INTERN MED, V105, P179, DOI 10.7326/0003-4819-105-2-179; SHER MR, 1986, J ALLERGY CLIN IMMUN, V77, P133; SMITH RM, 1987, ANN INTERN MED, V106, P335, DOI 10.7326/0003-4819-106-2-335_1; TAFFET SL, 1982, AM J MED, V73, P520, DOI 10.1016/0002-9343(82)90330-8; TORGOVNICK J, 1990, AM J MED, V88, P548, DOI 10.1016/0002-9343(90)90443-H; WALZER PD, 1974, ANN INTERN MED, V80, P83, DOI 10.7326/0003-4819-80-1-83; WHITE MV, 1989, ANN ALLERGY, V62, P177; 1989, MMWR S5, V38, P1	25	89	90	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1994	93	6					1001	1005		10.1016/S0091-6749(94)70048-6	http://dx.doi.org/10.1016/S0091-6749(94)70048-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT172	8006304				2022-12-18	WOS:A1994NT17200008
J	OHEHIR, RE; VERHOEF, A; PANAGIOTOPOULOU, E; KESWANI, S; HAYBALL, JD; THOMAS, WR; LAMB, JR				OHEHIR, RE; VERHOEF, A; PANAGIOTOPOULOU, E; KESWANI, S; HAYBALL, JD; THOMAS, WR; LAMB, JR			ANALYSIS OF HUMAN T-CELL RESPONSES TO THE GROUP-II ALLERGEN OF DERMATOPHAGOIDES SPECIES - LOCALIZATION OF MAJOR ANTIGENIC SITES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PEPTIDES; T-CELLS; DERMATOPHAGOIDES SPECIES; HOUSE DUST MITE; DER P-II; DESENSITIZATION	HOUSE-DUST MITE; DER-P-I; INFLUENZA HEMAGGLUTININ; LYMPHOKINE PRODUCTION; PEPTIC FRAGMENTS; IMMUNE-RESPONSE; LYMPHOCYTE-T; PTERONYSSINUS; IGE; RESPONSIVENESS	Background: IgE antibodies reactive with the group II allergens of Dermatophagoides species (house dust mite [HDM]) are a major component of the allergic immune response in HDM-allergic atopic individuals. Methods: Here we demonstrate, with the use of overlapping synthetic peptides of the group H allergen of Dermatophagoides pteronyssinus (Der p II), that polyclonal T cells isolated from the majority of atopic HDM-allergic individuals and healthy nonatopic control subjects respond to Der p II and that T-cell epitopes are present in all regions of the protein. Results: From comparison of peptide-specific T-cell proliferation in both groups of individuals, it appears that together peptides 61-86 and 78-104 are the most frequently recognized (16 of 18 individuals). We also observed that nine of the 18 individuals responded to T-cell epitopes in the region 11-50, and with Der p II-reactive T-cell clones, three distinct T-cell epitopes were mapped within the sequence 11-35. Also, with the use of T-cell clones, two additional epitopes were identified at residues 81-96 and 91-101. Conclusions: These results suggest that T-cell epitopes located in these regions (11-50 and 61-104) are immunodominant. The value of this information in the potential application of Der p II peptides to desensitize HDM allergic responses is discussed.	PRINCESS MARGARET HOSP CHILDREN,WESTERN AUSTRALIAN RES INST CHILD HLTH,PERTH,WA,AUSTRALIA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,LONDON SW7 2AZ,ENGLAND	Telethon Kids Institute; University of Western Australia; Imperial College London	OHEHIR, RE (corresponding author), ST MARYS HOSP,SCH MED,DEPT IMMUNOL,NORFOLK PL,LONDON W2 1PG,ENGLAND.		O'Hehir, Robyn E/H-3627-2011; Hayball, John D/F-4137-2013	O'Hehir, Robyn E/0000-0002-3489-7595; Hayball, John D/0000-0002-3089-4506	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALDO BA, 1990, MONOGR ALLERGY, V28, P138; BURT DS, 1989, J EXP MED, V170, P383, DOI 10.1084/jem.170.2.383; CHAPMAN MD, 1988, ALLERGY, V43, P7, DOI 10.1111/j.1398-9995.1988.tb05042.x; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P124, DOI 10.1159/000235102; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; DRIEDIJK WV, 1992, MOL IMMUNOL, V28, P1225; GAMMON G, 1989, NATURE, V342, P183, DOI 10.1038/342183a0; HAENEY M, 1985, J ROY COLL PHYS LOND, V19, P147; HAYGLASS KT, 1991, J EXP MED, V173, P279, DOI 10.1084/jem.173.2.279; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; HIGGINS JA, 1992, J ALLERGY CLIN IMMUN, V90, P749, DOI 10.1016/0091-6749(92)90098-M; ISHIZAKA K, 1984, ANNU REV IMMUNOL, V2, P159, DOI 10.1146/annurev.immunol.2.1.159; KAY AB, 1988, ALLERGIC BASIS ASTHM, P1; LAMB JR, 1983, IMMUNOLOGY, V50, P659; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; Lett-Brown M A, 1989, Year Immunol, V5, P195; LITWIN A, 1991, CLIN EXP ALLERGY, V21, P457, DOI 10.1111/j.1365-2222.1991.tb01686.x; LITWIN A, 1988, INT ARCH ALLER A IMM, V87, P361, DOI 10.1159/000234701; OBRIEN RM, 1992, J ALLERGY CLIN IMMUN, V89, P1021, DOI 10.1016/0091-6749(92)90225-Q; OHEHIR RE, 1991, INT IMMUNOL, V3, P819, DOI 10.1093/intimm/3.8.819; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; OHEHIR RE, 1987, IMMUNOLOGY, V62, P635; Pepys J., 1975, BR J HOSP MED, V14, P412; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROTHBARD JB, 1988, CELL, V52, P515, DOI 10.1016/0092-8674(88)90464-3; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STEWART GA, 1989, LANCET, V2, P154, DOI 10.1016/S0140-6736(89)90203-1; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; WITT C, 1986, J ALLERGY CLIN IMMUN, V77, P698, DOI 10.1016/0091-6749(86)90413-6; YSSEL H, 1992, J IMMUNOL, V148, P738; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	32	89	92	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	1				105	113		10.1016/0091-6749(93)90044-G	http://dx.doi.org/10.1016/0091-6749(93)90044-G			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ353	8335846	Bronze			2022-12-18	WOS:A1993LQ35300016
J	BREITENEDER, H; FERREIRA, F; REIKERSTORFER, A; DUCHENE, M; VALENTA, R; HOFFMANNSOMMERGRUBER, K; EBNER, C; BREITENBACH, M; KRAFT, D; SCHEINER, O				BREITENEDER, H; FERREIRA, F; REIKERSTORFER, A; DUCHENE, M; VALENTA, R; HOFFMANNSOMMERGRUBER, K; EBNER, C; BREITENBACH, M; KRAFT, D; SCHEINER, O			COMPLEMENTARY-DNA CLONING AND EXPRESSION IN ESCHERICHIA-COLI OF ALN G-I, THE MAJOR ALLERGEN IN POLLEN OF ALDER (ALNUS-GLUTINOSA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALDER POLLEN; MAJOR ALLERGEN; ALN G-I; CDNA CLONING; EXPRESSION; RECOMBINANT NONFUSION PROTEIN; IGE-BINDING; EPITOPES	AMINO-ACID-SEQUENCE; BET-V-I; BIRCH-POLLEN; MITE ALLERGEN; PROTEINS; GENE; TRANSCRIPTS; ANTIBODIES; VERRUCOSA; HOMOLOGY	Previous data showed that the major pollen allergens from trees of the order Fagales, in particular alder, birch, hazel, and hornbeam, are highly interrelated. As only the complete amino acid sequence of Bet v I, the major allergen from birch, has been known, it was of interest to obtain the primary structure of other major allergens of this group, to attribute IgE-binding properties to certain features of the amino acid sequences of those allergens. cDNA was synthesized from alder pollen mRNA, sequence-specifically amplified by polymerase chain reaction and cloned into plasmid bluescript. Comparison of the deduced amino acid sequences of Aln g I and Bet v I revealed a 86.8% homology. The Aln g I encoding cDNA was subcloned into pKK223-3 and expressed in Escherichia coli as a full-length nonfusion protein. The recombinant Aln g I bound IgE from tree pollen-allergic patients and was shown to share IgE-epitopes with Bet v I by inhibition studies with recombinant Bet v I. Computer-aided calculations predicted epitopes in both Aln g I and Bet v I at the same position; the Bet v I molecule was predicted to possess two additional epitopes near the N-terminus of the molecule.	UNIV VIENNA,INST GEN & EXPTL PATHOL,AKH EBO WAHRINGER GURTEL 18-20,A-1090 VIENNA,AUSTRIA; SALZBURG UNIV,DEPT GENET & DEV BIOL,A-5020 SALZBURG,AUSTRIA	University of Vienna; Salzburg University			Ferreira, Fatima/AAB-4321-2019; Ferreira, Fatima/E-4889-2011; Duchêne, Michael/G-6659-2019	Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Duchêne, Michael/0000-0003-1232-3600; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X; Valenta, Rudolf/0000-0001-5944-3365				BREITENBACH M, 1992, IN PRESS TREE POLLEN; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; FRISTENSKY B, 1988, PLANT MOL BIOL, V11, P713, DOI 10.1007/BF00017470; GHOSH B, 1991, GENE, V101, P2; GRIFFITH IJ, 1991, FEBS LETT, V279, P210, DOI 10.1016/0014-5793(91)80151-R; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; IPSEN H, 1991, MOL IMMUNOL, V28, P1279, DOI 10.1016/0161-5890(91)90015-C; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; KUNKEL AT, 1987, METHOD ENZYMOL, V154, P369; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTON DP, 1989, MOL PLANT MICROBE IN, V2, P325, DOI 10.1094/MPMI-2-325; PEREZ M, 1990, J BIOL CHEM, V265, P16210; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; ROHAC M, 1991, MOL IMMUNOL, V28, P897, DOI 10.1016/0161-5890(91)90054-N; SAMBROOK J, 1908, MOL CLONING LABORATO; SILVANOVICH A, 1991, J BIOL CHEM, V266, P1204; SOMSSICH IE, 1988, MOL GEN GENET, V213, P93, DOI 10.1007/BF00333403; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUDINGER M, 1991, CLIN EXP ALLERGY, V21, P33, DOI 10.1111/j.1365-2222.1991.tb00801.x; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V87, P677, DOI 10.1016/0091-6749(91)90388-5; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; WALTER MH, 1990, MOL GEN GENET, V222, P353, DOI 10.1007/BF00633840	30	89	98	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	1				909	917		10.1016/0091-6749(92)90463-C	http://dx.doi.org/10.1016/0091-6749(92)90463-C			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD190	1460197				2022-12-18	WOS:A1992KD19000007
J	HIGGINS, JA; LAMB, JR; MARSH, SGE; TONKS, S; HAYBALL, JD; ROSENBRONSON, S; BODMER, JG; OHEHIR, RE				HIGGINS, JA; LAMB, JR; MARSH, SGE; TONKS, S; HAYBALL, JD; ROSENBRONSON, S; BODMER, JG; OHEHIR, RE			PEPTIDE-INDUCED NONRESPONSIVENESS OF HLA-DP RESTRICTED HUMAN T-CELLS REACTIVE WITH DERMATOPHAGOIDES SPP	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PEPTIDE; T-CELLS; MHC; HLA-DP; DERMATOPHAGOIDES SPP; HOUSE DUST MITE; DER P-I; DESENSITIZATION	HOUSE DUST MITE; MAJOR HISTOCOMPATIBILITY COMPLEX; HUMAN IMMUNE-RESPONSE; RAGWEED POLLEN; LYMPHOCYTES-T; ANTIGEN RECOGNITION; GENE-PRODUCTS; ALLERGEN; RESPONSIVENESS; SPECIFICITY	The activation of CD4+ T lymphocytes, which play a central role in allergic inflammation, depends on the recognition of allergen-derived peptides in association with major histocompatibility complex class II gene products. In this report we demonstrate, at a clonal level, that a component of the T-cell repertoire reactive with Dermatophagoides spp. (house dust mite) in atopic individuals, is restricted by HLA-DP class II molecules. This supports the recent results emerging from genetic epidemiologic studies that indicate positive associations between the HLA-DP phenotype and immune responsiveness to a variety of common allergens. Our findings also reveal that the T cells restricted by HLA-DP recognize a species-specific epitope located in the group I allergen of Dermatophagoides pteronyssinus (residues 101-119). Furthermore, we report that the pretreatment of the T cells restricted by HLA-DP with the Der p I peptide renders them nonresponsive to an immunogenic challenge with house dust mite allergen, and the loss of antigen-dependent proliferation is associated with downregulation of membrane expression of the T-cell antigen receptor. The ability to functionally inactivate T cells restricted by HLA-DP, as well as those that recognize allergen in association with HLA-DR class II molecules, suggests that desensitization with allergen-derived peptides may have therapeutic potential in the management of allergic diseases irrespective of their HLA class II association.	IMPERIAL CANC RES FUND,TISSUE ANTIGEN LAB,LONDON WC2A 3PX,ENGLAND; GEORGETOWN UNIV,IMMUNOGENET GRP,WASHINGTON,DC 20057	Cancer Research UK; Georgetown University	HIGGINS, JA (corresponding author), IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT IMMUNOL,NORFOLK PL,LONDON W2 1PG,ENGLAND.		Hayball, John D/F-4137-2013; O'Hehir, Robyn E/H-3627-2011	Hayball, John D/0000-0002-3089-4506; O'Hehir, Robyn E/0000-0002-3489-7595	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANSARI AA, 1989, HUM IMMUNOL, V25, P59, DOI 10.1016/0198-8859(89)90070-0; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEKOSTER HS, 1989, J EXP MED, V169, P1191, DOI 10.1084/jem.169.3.1191; ECKELS DD, 1983, NATURE, V301, P716, DOI 10.1038/301716a0; EURA M, 1991, P HLA INT S YOKUHAMA, P235; FREIDHOFF LR, 1988, TISSUE ANTIGENS, V31, P211, DOI 10.1111/j.1399-0039.1988.tb02083.x; GASTON JSH, 1991, INT IMMUNOL, V3, P965, DOI 10.1093/intimm/3.10.965; HUANG SK, 1991, IMMUNOLOGY, V73, P363; ISHIZAKA K, 1984, ANNU REV IMMUNOL, V2, P159, DOI 10.1146/annurev.immunol.2.1.159; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; KNIGHT SC, 1989, CLIN EXP IMMUNOL, V78, P19; LAMB JR, 1984, NATURE, V308, P72, DOI 10.1038/308072a0; LAMB JR, 1983, J EXP MED, V157, P397; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LANZAVECCHIA A, 1983, CLIN EXP IMMUNOL, V52, P21; Lett-Brown M A, 1989, Year Immunol, V5, P195; MARSH DG, 1989, COLD SPRING HARB SYM, V54, P459; MARSH DG, 1987, IMMUNOGENETICS, V26, P230, DOI 10.1007/BF00346517; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; Moller G., 1987, IMMUNOL REV, V98, P1; OHEHIR RE, 1991, INT IMMUNOL, V3, P819, DOI 10.1093/intimm/3.8.819; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; OHEHIR RE, 1988, IMMUNOLOGY, V64, P627; OHEHIR RE, 1987, IMMUNOLOGY, V62, P635; OHEHIR RE, 1990, INT IMMUNOL, V2, P885, DOI 10.1093/intimm/2.9.885; ROEBBER M, 1985, J IMMUNOL, V134, P3062; ROTHBARD JB, 1988, CELL, V52, P515, DOI 10.1016/0092-8674(88)90464-3; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; WATSON AJ, 1983, NATURE, V304, P358, DOI 10.1038/304358a0; YOUNG RP, 1992, 15TH P EUR C ALL CLI; ZWOLLO P, 1991, IMMUNOGENETICS, V33, P141	31	89	94	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1992	90	5					749	756		10.1016/0091-6749(92)90098-M	http://dx.doi.org/10.1016/0091-6749(92)90098-M			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ319	1385507				2022-12-18	WOS:A1992JZ31900004
J	VALENTA, R; BREITENEDER, H; PETTENBURGER, K; BREITENBACH, M; RUMPOLD, H; KRAFT, D; SCHEINER, O				VALENTA, R; BREITENEDER, H; PETTENBURGER, K; BREITENBACH, M; RUMPOLD, H; KRAFT, D; SCHEINER, O			HOMOLOGY OF THE MAJOR BIRCH-POLLEN ALLERGEN, BET VI, WITH THE MAJOR POLLEN ALLERGENS OF ALDER, HAZEL, AND HORNBEAM AT THE NUCLEIC-ACID LEVEL AS DETERMINED BY CROSS-HYBRIDIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							3-YEAR DOUBLE-BLIND; GEL-ELECTROPHORESIS; EXTRACTS; IMMUNOTHERAPY; FRAGMENTS; RNA; COMBINATIONS; SEQUENCES; GENE	To investigate the relationship of the major allergens of birch (Bet v I), alder (Aln g I), hazel (Cor a I), and hornbeam (Car b I) at the nucleic acid level, a cDNA clone coding for the complete Bet v I protein was used for Northern and Southern blot experiments. RNAs were isolated from pollen of birch (Betula verrucosa), alder (Alnus glutinosa), hazel (Corylus avellana), and hornbeam (Carpinus betulus). Hybridization was performed at different stringencies. At high stringency, comparable binding of the complete Bet v I cDNA probe to pollen RNAs from birch, alder, and hazel could be observed, indicating high homology of the mRNAs coding for these allergens. With the 3' and 5' half fragments of the Bet v I cDNA, both probes bound to transcripts of all four tree pollens, but most strongly to birch RNA. In Southern blots, distinct binding patterns of genomic DNA digests of birch, alder, hazel, and hornbeam were observed. Most bands were observed with birch DNA digests and less with alder, whereas in genomic DNA digests of hornbeam and hazel, only one band was observed. The result of these cross-hybridization experiments indicate a high homology at the nucleic acid level of the four major allergens of trees belonging to the order Fagales. The sequence similarity presented here further corroborates earlier observations of immunologic cross-reactivity at the protein level. Therefore, in the case of the major allergens of the Betulaceae, an extract with only one major allergen, preferentially Bet v I, instead of all four major allergens, should be sufficient for diagnostic and therapeutic purposes.	UNIV VIENNA,INST GEN & EXPTL PATHOL,WAHRINGERGUERTEL 18-20,AKH EB OST,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST MICROBIOL & GENET,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST CLIN CHEM & LAB DIAGNOST,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna; University of Vienna				Valenta, Rudolf/0000-0001-5944-3365				Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BREITENEDER H, 1988, INT ARCH ALLER A IMM, V87, P19, DOI 10.1159/000234643; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Dellaporta S.L., 1983, PLANT MOL BIOL REPOR, V1, P19, DOI [10.1007/BF02712670, DOI 10.1007/BF02712670]; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRISTENSKY B, 1988, PLANT MOL BIOL, V11, P713, DOI 10.1007/BF00017470; IPSEN H, 1988, ALLERGY, V43, P370, DOI 10.1111/j.1398-9995.1988.tb00431.x; IPSEN H, 1985, ALLERGY, V40, P510, DOI 10.1111/j.1398-9995.1985.tb00259.x; IPSEN H, 1988, ALLERGY S7, V43, pB11; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Maniatis T., 1982, MOL CLONING; PETERSEN BN, 1988, ALLERGY, V43, P353, DOI 10.1111/j.1398-9995.1988.tb00429.x; RUMPOLD H, 1990, EPITOPES ATOPIC ALLE, P26; SOMSSICH IE, 1988, MOL GEN GENET, V213, P93, DOI 10.1007/BF00333403; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VALENTA R, 1989, ALLERGOLOGIE; VIK H, 1989, ALLRGOLOGIE; WIHL JA, 1988, ALLERGY, V43, P363, DOI 10.1111/j.1398-9995.1988.tb00430.x; YMAN L, 1982, BOTANICAL RELATIONS	21	89	94	2	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1991	87	3					677	682		10.1016/0091-6749(91)90388-5	http://dx.doi.org/10.1016/0091-6749(91)90388-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FB801	2005320				2022-12-18	WOS:A1991FB80100012
J	SCHOU, C; LIND, P; FERNANDEZCALDAS, E; LOCKEY, RF; LOWENSTEIN, H				SCHOU, C; LIND, P; FERNANDEZCALDAS, E; LOCKEY, RF; LOWENSTEIN, H			IDENTIFICATION AND PURIFICATION OF AN IMPORTANT CROSS-REACTIVE ALLERGEN FROM AMERICAN (PERIPLANETA-AMERICANA) AND GERMAN (BLATTELLA-GERMANICA) COCKROACH	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HYPERSENSITIVITY; IGE; IMMUNOELECTROPHORESIS; ANTIBODIES; ANTIGENS	Aqueous whole body extracts from two major domiciliary cockroaches, the American, Periplaneta americana, and the German, Blattella germanica, were analyzed in crossed immunoelectrophoresis and immunoblotting. Forty-five antigens were found in P. americana and 29 in B. germanica. IgE-binding antigens were identified by crossed radioimmunoelectrophoresis with sera from 30 cockroach allergic patients. Seven and three precipitates from P. americana and B. germanica bound significant amounts of IgE. A cross-reactivre, apparently homologous allergen, from P. america and B. germanica bound IgE from 100% and 70%, respectively, of the patients. These important allergens were tentatively named Per a I and Bla g I. The allergens were purified by sequential ion exchange, gel filtration, and isoelectric focusing. Both allergens had a molecular size of 33 to 37 kd in Sephadex G-75 gel filtration, and 28 kd in high-performance liquid chromatography gel filtration. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed a minor band at approximately 25 kd, and most of the protein of 6 kd. The isoelectric point of both allergens was found to be 3.5. In amino acid analysis, the allergens were highly similar. Skin test revealed the allergens to be important in vivo sensitizing agents. The allergens may be used for environmental assays for cockroach exposure in the homes of allergic subjects.	UNIV S FLORIDA, TAMPA, FL 33620 USA	State University System of Florida; University of South Florida	SCHOU, C (corresponding author), ALK RES, BOGE ALLE 10-12, DK-2970 HORSHOLM, DENMARK.							BALDO BA, 1988, INT ARCH ALLER A IMM, V85, P278, DOI 10.1159/000234518; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; BERNTON HS, 1970, ANN ALLERGY, V28, P543; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; HELM RM, 1988, INT ARCH ALLER A IMM, V87, P230, DOI 10.1159/000234678; KANG B, 1978, ANN ALLERGY, V41, P333; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONK BE, 1987, BRIT MED J, V294, P935, DOI 10.1136/bmj.294.6577.935; OSTERBALLE O, 1983, J ALLERGY CLIN IMMUN, V71, P40, DOI 10.1016/0091-6749(83)90545-6; RICHMAN PG, 1984, J ALLERGY CLIN IMMUN, V73, P590, DOI 10.1016/0091-6749(84)90516-5; SCHAL C, 1984, BIOL REV, V59, P209, DOI 10.1111/j.1469-185X.1984.tb00408.x; SKJODT K, 1984, J IMMUNOL METHODS, V72, P243, DOI 10.1016/0022-1759(84)90452-6; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V81, P548, DOI 10.1016/0091-6749(88)90195-9; STEINBERG DR, 1987, J ALLERGY CLIN IMMUN, V80, P586, DOI 10.1016/0091-6749(87)90012-1; SVENDSEN PJ, 1973, SCAND J IMMUNOL, V2, P69, DOI 10.1111/j.1365-3083.1973.tb03781.x; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; WEEKE B, 1973, SCAND J IMMUNOL, V2, P37, DOI 10.1111/j.1365-3083.1973.tb03777.x; WEEKE B, 1983, SCAND J IMMUNOL S10, V17, P265; WU CH, 1988, J ALLERGY CLIN IMMUN, V82, P727, DOI 10.1016/0091-6749(88)90071-1	20	89	89	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	1				935	946		10.1016/S0091-6749(05)80157-5	http://dx.doi.org/10.1016/S0091-6749(05)80157-5			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EQ045	2262648				2022-12-18	WOS:A1990EQ04500015
J	CRETICOS, PS; MARSH, DG; PROUD, D; KAGEYSOBOTKA, A; ADKINSON, NF; FRIEDHOFF, L; NACLERIO, RM; LICHTENSTEIN, LM; NORMAN, PS				CRETICOS, PS; MARSH, DG; PROUD, D; KAGEYSOBOTKA, A; ADKINSON, NF; FRIEDHOFF, L; NACLERIO, RM; LICHTENSTEIN, LM; NORMAN, PS			RESPONSES TO RAGWEED-POLLEN NASAL CHALLENGE BEFORE AND AFTER IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CRETICOS, PS (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,DEPT MED,DIV CLIN IMMUNOL,5601 LOCH RAVEN BLVD,BALTIMORE,MD 21239, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI008270, R37AI004866, R01AI008270, R01AI004866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022488] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 08270, AI 04866] Funding Source: Medline; NINDS NIH HHS [NS 22488] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; CRETICOS PS, 1987, J ALLERGY CLIN IMMUN, V79, P216; CRETICOS PS, 1987, JAMA-J AM MED ASSOC, V258, P2874, DOI 10.1001/jama.258.20.2874; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; HANSEL FRENCH K., 1941, JOUR ALLERGY, V12, P457, DOI 10.1016/S0021-8707(41)90222-8; HEDLIN G, IN PRESS J ALLERGY C; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; HUNT KJ, 1978, NEW ENGL J MED, V299, P257; IMANARI T, 1974, DHEW NIH76791 PUBL; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; MOSS RB, 1987, J ALLERGY CLIN IMMUN, V79, P387, DOI 10.1016/0091-6749(87)90160-6; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NAGOYA H, 1985, J ALLERGY CLIN IMMUN, V75, P388; Norman P, 1986, MANUAL CLIN LABORATO, P660; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P384, DOI 10.1016/0091-6749(78)90118-5; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OSTERBALLE O, 1982, ALLERGY, V37, P379, DOI 10.1111/j.1398-9995.1982.tb02316.x; PIENKOWSKI MM, 1985, J ALLERGY CLIN IMMUN, V76, P729, DOI 10.1016/0091-6749(85)90679-7; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; RINKEL HJ, 1963, ARCHIV OTOLARYNGOL, V77, P205; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; ROCKLIN RE, 1974, J CLIN INVEST, V53, P735, DOI 10.1172/JCI107612; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; Snedecor G.W., 1980, STAT METHODS, V7; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; TAMIR R, 1987, J ALLERGY CLIN IMMUN, V79, P591, DOI 10.1016/S0091-6749(87)80154-9; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; VAUGHAN WT, 1932, J ALLERGY, V3, P542; WARNER JO, 1978, LANCET, V2, P912; WILLOUGHBY JW, 1974, OTOLARYNG CLIN N AM, V7, P579	45	89	91	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1989	84	2					197	205		10.1016/0091-6749(89)90325-4	http://dx.doi.org/10.1016/0091-6749(89)90325-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL836	2668381				2022-12-18	WOS:A1989AL83600010
J	SALZMAN, GA; PYSZCZYNSKI, DR				SALZMAN, GA; PYSZCZYNSKI, DR			OROPHARYNGEAL CANDIDIASIS IN PATIENTS TREATED WITH BECLOMETHASONE DIPROPIONATE DELIVERED BY METERED-DOSE INHALER ALONE AND WITH AEROCHAMBER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SALZMAN, GA (corresponding author), UNIV MISSOURI,SCH MED,DEPT MED,PULM DIS SECT,2411 HOLMES,KANSAS CITY,MO 64108, USA.							BACAL E, 1978, J ALLERGY CLIN IMMUN, V62, P72, DOI 10.1016/0091-6749(78)90081-7; BROWN HM, 1972, BRIT MED J, V1, P585, DOI 10.1136/bmj.1.5800.585; CAYTON RM, 1974, LANCET, V2, P303; CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P101; DAVIES G, 1977, ANN INTERN MED, V86, P549, DOI 10.7326/0003-4819-86-5-549; DOLOVICH M, 1983, CHEST, V83, P36; EPSTEIN SW, 1979, CAN MED ASSOC J, V120, P813; GERGAIS P, 1977, NOUV PRESSE MED, V15, P1329; GODDEN DJ, 1981, BRIT J DIS CHEST, V75, P165, DOI 10.1016/0007-0971(81)90049-8; HIDINGER KG, 1981, EUR J CLIN PHARMACOL, V20, P109, DOI 10.1007/BF00607145; KNIGHT L, 1971, J INFECT DIS, V123, P371, DOI 10.1093/infdis/123.4.371; KONIG P, 1985, CHEST, V88, P276, DOI 10.1378/chest.88.2.276; MOREN F, 1978, INT J PHARM, V1, P205, DOI 10.1016/0378-5173(78)90009-1; NEWMAN SP, 1981, AM REV RESPIR DIS, V124, P317; NEWMAN SP, 1981, THORAX, V36, P52, DOI 10.1136/thx.36.1.52; PATERSON IC, 1976, BRIT MED J, V1, P76, DOI 10.1136/bmj.1.6001.76-a; PEDERSEN S, 1983, NEW ENGL J MED, V308, P1328, DOI 10.1056/NEJM198306023082205; REISER J, 1986, PEDIATR PULM, V2, P237, DOI 10.1002/ppul.1950020412; SHIM C, 1980, AM J MED, V69, P891, DOI 10.1016/S0002-9343(80)80016-7; SMITH MJ, 1983, LANCET, V1, P265, DOI 10.1016/S0140-6736(83)91686-0; TOOGOOD JH, 1980, J ALLERGY CLIN IMMUN, V65, P145, DOI 10.1016/0091-6749(80)90200-6; TOOGOOD JH, 1982, J ALLERGY CLIN IMMUN, V70, P288, DOI 10.1016/0091-6749(82)90065-3; TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; TOOGOOD JH, 1978, J ALLERGY CLIN IMMUN, V62, P72; VOGT FC, 1979, ANN ALLERGY, V43, P205; WANGAARD C, 1977, ANN ALLERGY, V39, P73; WILLEY RF, 1976, BRIT J DIS CHEST, V70, P32, DOI 10.1016/0007-0971(76)90004-8; WILLIAMS MH, 1981, ANN INTERN MED, V95, P464, DOI 10.7326/0003-4819-95-4-464; 1976, BR J DIS CHEST, V70, P95; 1981, STATISTICAL ANAL SYS	31	89	90	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1988	81	2					424	428		10.1016/0091-6749(88)90911-6	http://dx.doi.org/10.1016/0091-6749(88)90911-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0993	3339197				2022-12-18	WOS:A1988M099300009
J	SCHWARTZ, LB; ATKINS, PC; BRADFORD, TR; FLEEKOP, P; SHALIT, M; ZWEIMAN, B				SCHWARTZ, LB; ATKINS, PC; BRADFORD, TR; FLEEKOP, P; SHALIT, M; ZWEIMAN, B			RELEASE OF TRYPTASE TOGETHER WITH HISTAMINE DURING THE IMMEDIATE CUTANEOUS RESPONSE TO ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104	University of Pennsylvania	SCHWARTZ, LB (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298, USA.				NIAID NIH HHS [R01-AI-14532, R01-AI-20987] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS PC, 1982, J ALLERGY CLIN IMMUN, V69, P39, DOI 10.1016/0091-6749(82)90085-9; BEDARD PM, 1983, J ALLERGY CLIN IMMUN, V71, P394, DOI 10.1016/0091-6749(83)90068-4; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; CRAIG SS, 1986, AM J PATHOL, V124, P427; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MCGLASHAN DW, 1980, J IMMUNOL, V124, P2519; SCHECHTER NM, 1983, J BIOL CHEM, V258, P2973; SCHECHTER NM, 1986, J IMMUNOL, V137, P962; SCHWARTZ LB, 1981, J IMMUNOL, V126, P1290; SCHWARTZ LB, 1985, J IMMUNOL, V134, P526; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SMITH TJ, 1984, J BIOL CHEM, V259, P1046; SNYDER SH, 1976, METHODS IMMUNOLOGY I, P135; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018; TALBOT SF, 1984, J ALLERGY CLIN IMMUN, V74, P819, DOI 10.1016/0091-6749(84)90185-4; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0; WENZEL S, 1986, J IMMUNOL METHODS, V86, P139, DOI 10.1016/0022-1759(86)90277-2	21	89	92	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1987	80	6					850	855		10.1016/S0091-6749(87)80276-2	http://dx.doi.org/10.1016/S0091-6749(87)80276-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L5020	2447144				2022-12-18	WOS:A1987L502000013
J	OTSUKA, H; DOLOVICH, J; BEFUS, AD; TELIZYN, S; BIENENSTOCK, J; DENBURG, JA				OTSUKA, H; DOLOVICH, J; BEFUS, AD; TELIZYN, S; BIENENSTOCK, J; DENBURG, JA			BASOPHILIC CELL PROGENITORS, NASAL METACHROMATIC CELLS, AND PERIPHERAL-BLOOD BASOPHILS IN RAGWEED-ALLERGIC PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,HLTH SCI CTR,DEPT MED,ROOM 4H21,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,DEPT PATHOL,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,DEPT PEDIAT,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; McMaster University			Befus, Dean/C-5561-2009	Befus, Dean/0000-0002-1611-2897				BOETCHER DA, 1973, IMMUNOL COMMUN, V2, P421, DOI 10.3109/08820137309022813; CRAPPER RM, 1983, J IMMUNOL, V131, P923; CRAPPER RM, 1984, J IMMUNOL, V133, P2174; DENBURG JA, 1980, IMMUNOLOGY, V41, P195; DENBURG JA, 1980, J CLIN INVEST, V65, P390, DOI 10.1172/JCI109682; DENBURG JA, 1983, BLOOD, V61, P775; DENBURG JA, 1985, J ALLERGY CLIN IMMUN, V76, P466, DOI 10.1016/0091-6749(85)90728-6; DENBURG JA, 1986, MAST CELL HETEROGENE; DENBURG JA, UNPUB LYMPHOKINE RES; DENBURG JA, 1985, CLIN RES, V33, P160; GUYGRAND D, 1984, J EXP MED, V160, P12, DOI 10.1084/jem.160.1.12; HAGY GW, 1971, J ALLERGY CLIN IMMUN, V48, P200, DOI 10.1016/0091-6749(71)90066-2; HIRSCH SR, 1976, J ALLERGY CLIN IMMUN, V58, P676, DOI 10.1016/0091-6749(76)90179-2; KAY AB, 1972, CLIN EXP IMMUNOL, V11, P557; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; LETTBROWN MA, 1976, J IMMUNOL, V117, P246; MAYRHOFER G, 1981, INT ARCH ALLER A IMM, V64, P320, DOI 10.1159/000232710; MITCHELL EB, 1983, CLIN REV ALLERG, V1, P427; OGAWA M, 1983, P NATL ACAD SCI-BIOL, V80, P4494, DOI 10.1073/pnas.80.14.4494; OKUDA M, 1979, WAKAYAMA MED REP, V22, P15; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; OTSUKA H, CLIN ALLERGY; OTSUKA H, 1980, JAP J OTOL TOKYO, V83, P543; OTSUKA H, AM REV RESPIR DIS; SCHRADER JW, 1981, P NATL ACAD SCI-BIOL, V78, P323, DOI 10.1073/pnas.78.1.323; SCHRADER JW, 1983, J IMMUNOL, V130, P558; SIRAGANIAN RP, 1976, J ALLERGY CLIN IMMUN, V57, P525, DOI 10.1016/0091-6749(76)90003-8; TANNO Y, UNPUB EXP HEMATOL; WARD PA, 1975, J IMMUNOL, V114, P1523	29	89	89	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1986	78	2					365	371		10.1016/S0091-6749(86)80091-4	http://dx.doi.org/10.1016/S0091-6749(86)80091-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D7261	3734290				2022-12-18	WOS:A1986D726100021
J	ATKINS, FM; STEINBERG, SS; METCALFE, DD				ATKINS, FM; STEINBERG, SS; METCALFE, DD			EVALUATION OF IMMEDIATE ADVERSE REACTIONS TO FOODS IN ADULT PATIENTS .2. A DETAILED ANALYSIS OF REACTION PATTERNS DURING ORAL FOOD CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ATKINS, FM (corresponding author), NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BLG 10,RM 11C-209,BETHESDA,MD 20205, USA.							ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; BELLANTI JA, 1981, ANN ALLERGY, V47, P260; BERNSTEIN M, 1982, J ALLERGY CLIN IMMUN, V70, P205, DOI 10.1016/0091-6749(82)90043-4; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; ERIKSSON NE, 1978, ALLERGY, V33, P189, DOI 10.1111/j.1398-9995.1978.tb01533.x; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; WARREN K, 1983, J ALLERGY CLIN IMMUN, V71, P206, DOI 10.1016/0091-6749(83)90101-X	9	89	89	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	3					356	363		10.1016/0091-6749(85)90072-7	http://dx.doi.org/10.1016/0091-6749(85)90072-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AEB46	3973310				2022-12-18	WOS:A1985AEB4600006
J	GOSSET, P; TONNEL, AB; JOSEPH, M; PRIN, L; MALLART, A; CHARON, J; CAPRON, A				GOSSET, P; TONNEL, AB; JOSEPH, M; PRIN, L; MALLART, A; CHARON, J; CAPRON, A			SECRETION OF A CHEMOTACTIC FACTOR FOR NEUTROPHILS AND EOSINOPHILS BY ALVEOLAR MACROPHAGES FROM ASTHMATIC-PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GOSSET, P (corresponding author), INST PASTEUR,CTR IMMUNOL & BIOL PARASITAIRE,BP 245,F-59019 LILLE,FRANCE.		Gosset, Philippe/C-6174-2018	Gosset, Philippe/0000-0002-4043-6429				ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CAPRON A, 1975, NATURE, V253, P474, DOI 10.1038/253474a0; DESSAINT JP, 1979, CELL IMMUNOL, V46, P12, DOI 10.1016/0008-8749(79)90241-7; DU JT, 1983, BIOCHIM BIOPHYS ACTA, V753, P159, DOI 10.1016/0005-2760(83)90003-6; FELS AOS, 1982, P NATL ACAD SCI-BIOL, V79, P7866, DOI 10.1073/pnas.79.24.7866; GADEK JE, 1980, AM REV RESPIR DIS, V121, P723; GODARD P, 1982, J ALLERGY CLIN IMMUN, V70, P88, DOI 10.1016/0091-6749(82)90234-2; HANNSON G, 1981, FEBS LETT, V130, P107; HARWARTH L, 1980, J IMMUNOL METHODS, V37, P39; HUNNINGHAKE GW, 1981, J CLIN INVEST, V68, P259, DOI 10.1172/JCI110242; HUNNINGHAKE GW, 1978, AM REV RESPIR DIS, V117, P15; HUNNINGHAKE GW, 1980, J CLIN INVEST, V66, P473, DOI 10.1172/JCI109878; JOSEPH M, 1977, CELL IMMUNOL, V34, P247, DOI 10.1016/0008-8749(77)90247-7; JOSEPH M, 1980, CLIN EXP IMMUNOL, V40, P416; JOSEPH M, 1978, CLIN EXP IMMUNOL, V33, P48; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; KAZMIEROWSKI JA, 1977, J CLIN INVEST, V59, P273, DOI 10.1172/JCI108638; MERRILL WW, 1980, J CLIN INVEST, V65, P268, DOI 10.1172/JCI109668; METZGER WJ, 1983, AM REV RESPIR DIS, V127, P67; NELSON RD, 1978, INFECT IMMUN, V22, P441, DOI 10.1128/IAI.22.2.441-444.1978; ROUZER CA, 1982, P NATL ACAD SCI-BIOL, V79, P5656, DOI 10.1073/pnas.79.18.5656; ROUZER CA, 1982, J EXP MED, V156, P1077, DOI 10.1084/jem.156.4.1077; TONNEL AB, 1983, LANCET, V1, P1406; VADAS MA, 1979, J IMMUNOL, V122, P1228; VALONE FH, 1980, CELL IMMUNOL, V54, P390, DOI 10.1016/0008-8749(80)90219-1; ZWEIMAN B, 1980, ADV ALLERGOLOGY CLIN, P231	28	89	89	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	6					827	834		10.1016/0091-6749(84)90186-6	http://dx.doi.org/10.1016/0091-6749(84)90186-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW418	6334110				2022-12-18	WOS:A1984TW41800011
J	DOLOVICH, J; BELL, B				DOLOVICH, J; BELL, B			ALLERGY TO A PRODUCT(S) OF ETHYLENE-OXIDE GAS - DEMONSTRATION OF IGE AND IGG ANTIBODIES AND HAPTEN SPECIFICITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,DEPT PEDIAT,HAMILTON L8S 4L8,ONTARIO,CANADA	McMaster University								CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; POOTHULLIL J, 1975, ANN INTERN MED, V82, P58, DOI 10.7326/0003-4819-82-1-58	3	89	89	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	1					30	32		10.1016/0091-6749(78)90069-6	http://dx.doi.org/10.1016/0091-6749(78)90069-6			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG870	307011				2022-12-18	WOS:A1978FG87000007
J	ZEIGER, RS; YURDIN, DL; COLTEN, HR				ZEIGER, RS; YURDIN, DL; COLTEN, HR			HISTAMINE METABOLISM .2. CELLULAR AND SUBCELLULAR-LOCALIZATION OF CATABOLIC ENZYMES, HISTAMINASE AND HISTAMINE METHYL TRANSFERASE, IN HUMAN LEUKOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP MED CTR,DEPT MED,DIV ALLERGY,BOSTON,MA 02115; HARVARD UNIV,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University				Zeiger, Robert/0000-0001-5788-5063				ARCHER GT, 1963, J EXP MED, V118, P277, DOI 10.1084/jem.118.2.277; ARGENTOCERU MP, 1973, EUR J BIOCHEM, V34, P375, DOI 10.1111/j.1432-1033.1973.tb02769.x; BACKUS B, 1972, COMP GEN PHARMACOL, V1, P196; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; BROOME J, 1962, NATURE, V193, P446, DOI 10.1038/193446a0; BROWN DD, 1959, J BIOL CHEM, V234, P2948; BUFFONI F, 1966, PHARMACOL REV, V18, P1163; DAY RP, 1970, IMMUNOLOGY, V18, P955; GIERTZ H, 1969, INT ARCH ALLER A IMM, V36, P41, DOI 10.1159/000230719; HONSINGER RW, 1972, J ALLERGY CLIN IMMUN, V49, P142, DOI 10.1016/0091-6749(72)90108-X; HUBSCHER T, 1975, J IMMUNOL, V114, P1389; KATER LA, 1975, ARTHRITIS RHEUM, V18, P408; KOVACS A, 1950, EXPERIENTIA, V6, P349, DOI 10.1007/BF02152872; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL RH, 1970, BIOCHEM J, V116, P209; PAOLUCCI L, 1971, BIOCHIMIE, V53, P735; SCHAYER RW, 1959, PHYSIOL REV, V39, P116, DOI 10.1152/physrev.1959.39.1.116; SNYDER SH, 1966, J PHARMACOL EXP THER, V153, P544; SPEIRS RS, 1970, REGULATION HAEMATOPO, V2, P995; SURIYACHAN D, 1972, BIOCHEM BIOPH RES CO, V48, P1199, DOI 10.1016/0006-291X(72)90838-8; WASSERMAN SI, 1975, J IMMUNOL, V114, P645; ZEIGER RS, 1976, J LAB CLIN MED, V87, P1065	24	89	89	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					172	179		10.1016/0091-6749(76)90152-4	http://dx.doi.org/10.1016/0091-6749(76)90152-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX744	821987	Bronze			2022-12-18	WOS:A1976BX74400006
J	GRUNDBACHER, FJ				GRUNDBACHER, FJ			CAUSES OF VARIATION IN SERUM IGE LEVELS IN NORMAL POPULATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									PEORIA SCH MED,1400 W MAIN ST,PEORIA,IL 61606									BAZARAL M, 1971, J IMMUNOL, V107, P794; BAZARAL M, 1973, CLIN EXP IMMUNOL, V14, P117; Falconer D.S., 1960, INTRO QUANTITATIVE G; GRUNDBACHER FJ, 1972, SCIENCE, V176, P311, DOI 10.1126/science.176.4032.311; GRUNDBACHER FJ, 1972, J MED GENET, V9, P344, DOI 10.1136/jmg.9.3.344; GRUNDBACHER FJ, 1974, AM J HUM GENET, V26, P1; GRUNDBACHER FJ, 1973, SCIENCE, V181, P461, DOI 10.1126/science.181.4098.461; GRUNDBACHER FJ, 1972, HUM HERED, V22, P399, DOI 10.1159/000152516; GRUNDBACHER FJ, 1970, Z IMMUNITATSFORSCH, V141, P20; HAMBURGER RN, 1973, MECHANISMS ALLERGY R, P131; ISHIZAKA K, 1971, ANN NY ACAD SCI, V190, P443; Johansson S G, 1972, Prog Clin Immunol, V1, P157; JOHANSSON SG, 1968, LANCET, V1, P1118; KALFF MW, 1970, CLIN CHIM ACTA, V28, P277, DOI 10.1016/0009-8981(70)90092-6; LICHTMAN MA, 1967, ARTHRITIS RHEUM, V10, P204, DOI 10.1002/art.1780100306; Neel JV, 1954, HUMAN HEREDITY; OPREE W, 1972, ACTA ALLERGOL, V27, P247, DOI 10.1111/j.1398-9995.1972.tb01423.x; ORGEL HA, 1974, J ALLERGY CLIN IMMUN, V53, P213, DOI 10.1016/0091-6749(74)90083-9; PHILLS JA, 1972, NEW ENGL J MED, V286, P965, DOI 10.1056/NEJM197205042861802; POLMAR SH, 1972, AM J PATHOL, V69, P499; TADA T, 1970, Journal of Immunology, V104, P377; TOMASI TB, 1972, NEW ENGL J MED, V287, P500, DOI 10.1056/NEJM197209072871008	22	89	89	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	2					104	111		10.1016/0091-6749(75)90114-1	http://dx.doi.org/10.1016/0091-6749(75)90114-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AM325	807609	Bronze			2022-12-18	WOS:A1975AM32500003
J	GILLESPIE, E; VALENTINE, MD; LICHTENSTEIN, LM				GILLESPIE, E; VALENTINE, MD; LICHTENSTEIN, LM			CYCLIC-AMP METABOLISM IN ASTHMA - STUDIES WITH LEUKOCYTES AND LYMPHOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, GOOD SAMARITAN HOSP, SCH MED, 5601 LOCH RAVEN BLVD, BALTIMORE, MD 21239 USA	Johns Hopkins University								BERNSTEIN RA, 1972, J LAB CLIN MED, V80, P772; BOURNE HR, 1971, SCIENCE, V173, P743, DOI 10.1126/science.173.3998.743; BOURNEHR, 1973, J CLIN INVEST, V52, P698; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; BUSSE W, 1973, J ALLERGY CLIN IMMUN, V51, P89, DOI 10.1016/S0091-6749(73)80026-0; COOKSON DU, 1963, AM REV RESPIR DIS, V88, P636; INOUE S, 1967, J ALLERGY, V40, P337, DOI 10.1016/0021-8707(67)90023-8; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOCKEY SD, 1967, J ALLERGY, V40, P349, DOI 10.1016/0021-8707(67)90024-X; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; Robison G.A., 1971, CYCLIC AMP, DOI [10.1146/annurev.bi.37.070168.001053, DOI 10.1146/ANNUREV.BI.37.070168.001053]; SOLINGER A, 1973, J ALLERGY CLIN IMMUN, V51, P29; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2	16	89	89	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	1					27	33		10.1016/0091-6749(74)90096-7	http://dx.doi.org/10.1016/0091-6749(74)90096-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R8075	4357825				2022-12-18	WOS:A1974R807500004
J	Brandt, EB; Beck, AF; Mersha, TB				Brandt, Eric B.; Beck, Andrew F.; Mersha, Tesfaye B.			Air pollution, racial disparities, and COVID-19 mortality	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						SARS-CoV-2; COVID-19; coronavirus; air pollution; PM2.5; NO2; racial disparity; minorities; African American; black; Latino			[Brandt, Eric B.; Mersha, Tesfaye B.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH USA; [Beck, Andrew F.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Gen & Community Pediat, Cincinnati, OH USA; [Beck, Andrew F.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Hosp Med, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Mersha, TB (corresponding author), Univ Cincinnati, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 7037, Cincinnati, OH 45229 USA.	tesfaye.mersha@cchmc.org			National Institutes of Health [R01HL132344, 2U19AI70235-12]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by the National Institutes of Health (grant nos. R01HL132344 and 2U19AI70235-12).	Cohen AJ, 2017, LANCET, V389, P1907, DOI [10.1016/S0140-6736(17)30505-6, 10.1016/s0140-6736(17)30505-6]; Cui Yan, 2003, Environ Health, V2, P15, DOI 10.1186/1476-069X-2-15; Fattorini D, 2020, ENVIRON POLLUT, V264, DOI 10.1016/j.envpol.2020.114732; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Pansini R, 2020, INITIAL EVIDENCE HIG; Tessum CW, 2019, P NATL ACAD SCI USA, V116, P6001, DOI 10.1073/pnas.1818859116; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Xie C, 2020, PROC ASME CONF SMART; Yao Y, 2020, TEMPORAL ASS PARTICU, DOI [10.1101/2020.04.09.20049924, DOI 10.1101/2020.04.09.20049924]; Yao Y, AMBIENT NITROGEN DIO, DOI [10.1101/2020.03.31, DOI 10.1101/2020.03.31]	10	88	91	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					61	63		10.1016/j.jaci.2020.04.035	http://dx.doi.org/10.1016/j.jaci.2020.04.035			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32389591	Green Published, Bronze			2022-12-18	WOS:000579170500010
J	Paller, AS; Renert-Yuval, Y; Suprun, M; Esaki, H; Oliva, M; Huynh, TN; Ungar, B; Kunjravia, N; Friedland, R; Peng, XY; Zheng, XZ; Estrada, YD; Krueger, JG; Choate, KA; Suarez-Farinas, M; Guttman-Yassky, E				Paller, Amy S.; Renert-Yuval, Yael; Suprun, Maria; Esaki, Hitokazu; Oliva, Margeaux; Thy Nhat Huynh; Ungar, Benjamin; Kunjravia, Norma; Friedland, Rivka; Peng, Xiangyu; Zheng, Xiuzhong; Estrada, Yeriel D.; Krueger, James G.; Choate, Keith A.; Suarez-Farinas, Mayte; Guttman-Yassky, Emma			An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epidermis; ichthyosis; inflammation; autosomal recessive congenital ichthyosis; congenital ichthyosiform erythroderma; lamellar ichthyosis; Netherton syndrome; epidermolytic ichthyosis; skin; IL-17; TNF-alpha	RECESSIVE CONGENITAL ICHTHYOSIS; TO-SEVERE PSORIASIS; SEVERE ATOPIC-DERMATITIS; COMEL-NETHERTON-SYNDROME; LAMELLAR ICHTHYOSIS; BARRIER FUNCTION; PERMEABILITY BARRIER; MONOCLONAL-ANTIBODY; CONTROLLED-TRIAL; STRATUM-CORNEUM	Background: The ichthyoses are rare genetic disorders associated with generalized scaling, erythema, and epidermal barrier impairment. Pathogenesis-basedtherapy is largely lacking because the underlying molecular basis is poorly understood. Objective: We sought to characterize molecularly cutaneous inflammation and its correlation with clinical and barrier characteristics. Methods: We analyzed biopsy specimens from 21 genotyped patients with ichthyosis (congenital ichthyosiform erythroderma, n = 6; lamellar ichthyosis, n = 7; epidermolytic ichthyosis, n = 5; and Netherton syndrome, n = 3) using immunohistochemistry and RT-PCR and compared them with specimens from healthy control subjects, patients with atopic dermatitis (AD), and patients with psoriasis. Clinical measures included the Ichthyosis Area Severity Index (IASI), which integrates erythema (IASI-E) and scaling (IASI-S); transepidermal water loss; and pruritus. Results: Ichthyosis samples showed increased epidermal hyperplasia (increased thickness and keratin 16 expression) and Tcell and dendritic cell infiltrates. Increases of general inflammatory (IL-2), innate (IL-1 beta), and some TH1/interferon (IFN-gamma) markers in patients with ichthyosis were comparable with those in patients with psoriasis or AD. TNF-alpha levels in patients with ichthyosis were increased only in those with Netherton syndrome but were much lower than in patientswith psoriasis and those withAD. Expression of TH2 cytokines (IL-13 and IL-31) was similar to that seen in control subjects. The striking induction of IL-17-related genes or markers synergistically induced by IL-17 and TNF-alpha (IL-17A/C, IL-19, CXCL1, PI3, CCL20, and IL36G; P <.05) in patients with ichthyosis was similar to that seen in patients with psoriasis. IASI and IASI-E scores strongly correlated with IL-17A (r = 0.74, P <.001) and IL-17/TNF-synergistic/additive gene expression. These markers also significantly correlated with transepidermal water loss, suggesting a link between the barrier defect and inflammation in patients with ichthyosis. Conclusion: Our data associate a shared TH17/IL-23 immune fingerprint with the major orphan forms of ichthyosis and raise the possibility of IL-17-targeting strategies.	[Paller, Amy S.; Thy Nhat Huynh; Friedland, Rivka] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA; [Paller, Amy S.; Thy Nhat Huynh; Friedland, Rivka] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Renert-Yuval, Yael; Esaki, Hitokazu; Oliva, Margeaux; Peng, Xiangyu; Estrada, Yeriel D.; Suarez-Farinas, Mayte; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Suprun, Maria; Krueger, James G.; Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA; [Esaki, Hitokazu; Ungar, Benjamin; Kunjravia, Norma; Zheng, Xiuzhong; Suarez-Farinas, Mayte] Rockefeller Univ, Lab Investigat Dermatol, 1230 York Ave, New York, NY 10021 USA; [Choate, Keith A.] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rockefeller University; Yale University	Paller, AS (corresponding author), Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA.; Paller, AS (corresponding author), Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA.	apaller@northwestern.edu	Suprun, Maria/ABE-8323-2020; Suprun, Maria/AAE-5507-2022; Renert-Yuval, Yael/AAP-5414-2020	Suprun, Maria/0000-0001-9161-4021; Esaki, Hitokazu/0000-0002-3716-520X; Ungar, Benjamin/0000-0003-0882-8163; Paller, Amy/0000-0001-6187-6549	Foglia Family Foundation Endowment; National Psoriasis Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR057216] Funding Source: NIH RePORTER	Foglia Family Foundation Endowment; National Psoriasis Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the Foglia Family Foundation Endowment and the National Psoriasis Foundation (RF fellowship).; This research was supported by the Foglia Family Foundation Endowment and the National Psoriasis Foundation (RF fellowship). We acknowledge Core resources provided by the Northwestern University Skin Disease Research Center (NIAMS P30AR057216).	Akagi A, 2013, J DERMATOL, V40, P752, DOI 10.1111/1346-8138.12209; Akiyama T, 2014, J INNATE IMMUN, V6, P739, DOI 10.1159/000362789; Allen A, 2001, ARCH DERMATOL, V137, P747; Aufenvenne K, 2012, J INVEST DERMATOL, V132, P1918, DOI 10.1038/jid.2012.65; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Bonefeld CM, 2016, BR J DERMATOL; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Briot A, 2010, J INVEST DERMATOL, V130, P2736, DOI 10.1038/jid.2010.233; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Cedeno-Laurent F, 2015, CLIN IMMUNOL, V158, P1, DOI 10.1016/j.clim.2015.02.014; Chaudhari U, 2001, LANCET, V357, P1842, DOI 10.1016/S0140-6736(00)04954-0; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Chiricozzi A, 2014, EXPERT OPIN THER TAR, V18, P513, DOI 10.1517/14728222.2014.889686; Chiricozzi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090284; Chiricozzi A, 2013, EXPERT OPIN INV DRUG, V22, P993, DOI 10.1517/13543784.2013.806483; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Cottle DL, 2015, HUM MOL GENET, V24, P436, DOI 10.1093/hmg/ddu459; Craig WY, 2010, PRENATAL DIAG, V30, P893, DOI 10.1002/pd.2588; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, pe5; D'Erme AM, 2015, J INVEST DERMATOL, V135, P1025, DOI 10.1038/jid.2014.532; Damsky WE, 2016, PEDIATR DERMATOL, V33, pE140, DOI 10.1111/pde.12769; de Oliveira GV, 2005, J AM ACAD DERMATOL, V52, P725, DOI 10.1016/j.jaad.2004.11.033; DEMARE S, 1990, ARCH DERMATOL RES, V282, P126, DOI 10.1007/BF00493471; Deraison C, 2007, MOL BIOL CELL, V18, P3607, DOI 10.1091/mbc.E07-02-0124; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; Descargues P, 2006, J INVEST DERMATOL, V126, P1622, DOI 10.1038/sj.jid.5700284; Dhingra N, 2013, J ALLERGY CLIN IMMUN, V132, P498, DOI 10.1016/j.jaci.2013.04.043; DiGiovanna JJ, 2003, AM J CLIN DERMATOL, V4, P81, DOI 10.2165/00128071-200304020-00002; DiGiovanna JJ, 2013, DERMATOL THER, V26, P26, DOI 10.1111/j.1529-8019.2012.01527.x; Dreyfus I, 2015, ACTA DERM-VENEREOL, V95, P326, DOI 10.2340/00015555-1955; Dunbar GC, 2011, J PSYCHOPHARMACOL, V25, P1020, DOI 10.1177/0269881110367727; Eckl KM, 2014, EXP DERMATOL, V23, P286, DOI 10.1111/exd.12366; Eckl KM, 2009, J INVEST DERMATOL, V129, P1421, DOI 10.1038/jid.2008.409; Elias PM, 2008, J LIPID RES, V49, P697, DOI 10.1194/jlr.R800002-JLR200; Elman S, 2010, BRIT J DERMATOL, V162, P587, DOI 10.1111/j.1365-2133.2009.09586.x; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Fischer J, 2009, J INVEST DERMATOL, V129, P1319, DOI 10.1038/jid.2009.57; Fleckman P, 2003, Skin Therapy Lett, V8, P3; Fontao L, 2011, J INVEST DERMATOL, V131, P1947, DOI 10.1038/jid.2011.124; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; Furio L, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005389; Furio L, 2014, J EXP MED, V211, P499, DOI 10.1084/jem.20131797; Gallagher G, 2004, INT IMMUNOPHARMACOL, V4, P615, DOI 10.1016/j.intimp.2004.01.005; Ganemo A, 2003, J ADV NURS, V44, P412, DOI 10.1046/j.0309-2402.2003.02820.x; Gordon KB, 2012, J INVEST DERMATOL, V132, P304, DOI 10.1038/jid.2011.304; Griffiths CEM, 2015, LANCET, V386, P541, DOI 10.1016/S0140-6736(15)60125-8; Griffiths CEM, 2010, NEW ENGL J MED, V362, P118, DOI 10.1056/NEJMoa0810652; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hachem JP, 2006, J INVEST DERMATOL, V126, P1609, DOI 10.1038/sj.jid.5700288; Halverstam CP, 2007, PEDIATR DERMATOL, V24, P42, DOI 10.1111/j.1525-1470.2007.00331.x; Hamilton JD, 2015, IMMUNOTHERAPY-UK, V7, P1043, DOI 10.2217/imt.15.69; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hannula-Jouppi K, 2016, JAMA DERMATOL, V152, P435, DOI 10.1001/jamadermatol.2015.5827; He M, 2010, J IMMUNOL, V184, P1793, DOI 10.4049/jimmunol.0901829; Hernandez-Martin A, 2013, J AM ACAD DERMATOL, V69, P544, DOI 10.1016/j.jaad.2013.05.017; Hewett DR, 2005, HUM MOL GENET, V14, P335, DOI 10.1093/hmg/ddi030; Hosomi N, 2008, BRIT J DERMATOL, V159, P744, DOI [10.1111/j.1365-2133.2008.08706.x, 10.1111/j.1365-2133.2008.08706]; Hsing CH, 2007, NEPHROL DIAL TRANSPL, V22, P2230, DOI 10.1093/ndt/gfm179; Huang F, 2008, J ALLERGY CLIN IMMUN, V121, P1415, DOI 10.1016/j.jaci.2008.04.016; Jensen JM, 2000, J INVEST DERMATOL, V115, P708, DOI 10.1046/j.1523-1747.2000.00103.x; Johnson-Huang LM, 2010, J INVEST DERMATOL, V130, P2654, DOI 10.1038/jid.2010.166; Kamalpour L, 2010, PEDIATR DERMATOL, V27, P148, DOI 10.1111/j.1525-1470.2010.01114.x; Kawashima J, 2005, CLIN EXP DERMATOL, V30, P429, DOI 10.1111/j.1365-2230.2005.01818.x; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kiatsurayanon C, 2014, J INVEST DERMATOL, V134, P2163, DOI 10.1038/jid.2014.143; Konishi T, 2014, J DERMATOL, V41, P258, DOI 10.1111/1346-8138.12410; Krieg P, 2013, J INVEST DERMATOL, V133, P172, DOI 10.1038/jid.2012.250; Krueger JG, 2015, J ALLERGY CLIN IMMUN, V136, P116, DOI 10.1016/j.jaci.2015.01.018; Lacroix M, 2012, J INVEST DERMATOL, V132, P575, DOI 10.1038/jid.2011.366; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Lebwohl M, 2003, LANCET, V361, P1197, DOI 10.1016/S0140-6736(03)12954-6; Lee JS, 2011, CLIN IMMUNOL, V140, P84, DOI 10.1016/j.clim.2011.03.018; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Liao SC, 2004, J IMMUNOL, V173, P6712, DOI 10.4049/jimmunol.173.11.6712; Lopez-Ferrer A, 2015, EXPERT REV CLIN IMMU, V11, P1177, DOI 10.1586/1744666X.2015.1095092; Lorie EP, 2009, ACTA DERM-VENEREOL, V89, P12, DOI 10.2340/00015555-0573; Lowes MA, 2013, TRENDS IMMUNOL, V34, P174, DOI 10.1016/j.it.2012.11.005; Mansouri Y, 2015, J CLIN MED, V4, P858, DOI 10.3390/jcm4050858; Martin DA, 2013, J INVEST DERMATOL, V133, P17, DOI 10.1038/jid.2012.194; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; de Freitas CFNP, 2013, AN BRAS DERMATOL, V88, P627, DOI 10.1590/abd1806-4841.20131854; O'Shaughnessy RFL, 2010, HUM MOL GENET, V19, P2594, DOI 10.1093/hmg/ddq145; Oji V, 2006, EUR J DERMATOL, V16, P349; Oji V, 2010, J AM ACAD DERMATOL, V63, P607, DOI 10.1016/j.jaad.2009.11.020; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Papp KA, 2005, BRIT J DERMATOL, V152, P1304, DOI 10.1111/j.1365-2133.2005.06688.x; Papp KA, 2008, LANCET, V371, P1675, DOI 10.1016/S0140-6736(08)60726-6; Renner ED, 2009, J ALLERGY CLIN IMMUN, V124, P536, DOI 10.1016/j.jaci.2009.06.009; Rice RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075355; Rosenberger S, 2014, BRIT J DERMATOL, V171, P1347, DOI 10.1111/bjd.13308; Roth W, 2012, J CELL SCI, V125, P5269, DOI 10.1242/jcs.116574; Russell CB, 2014, J IMMUNOL, V192, P3828, DOI 10.4049/jimmunol.1301737; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; Sa SM, 2007, J IMMUNOL, V178, P2229, DOI 10.4049/jimmunol.178.4.2229; Samuelov L, 2014, J ALLERGY CLIN IMMUN, V134, P808, DOI 10.1016/j.jaci.2014.07.061; Schopf RE, 2002, J AM ACAD DERMATOL, V46, P886, DOI 10.1067/mjd.2002.120472; Smyth I, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000192; Sofen H, 2014, J ALLERGY CLIN IMMUN, V133, P1032, DOI 10.1016/j.jaci.2014.01.025; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Suarez-Farinas M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010247; Taieb A, 2002, J EUR ACAD DERMATOL, V16, P436, DOI 10.1046/j.1468-3083.2002.00478.x; Takahashi H, 2014, J DERMATOL, V41, P144, DOI 10.1111/1346-8138.12393; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Thyssen JP, 2013, BRIT J DERMATOL, V168, P1155, DOI 10.1111/bjd.12219; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Traupe H, 2014, J DTSCH DERMATOL GES, V12, P109, DOI 10.1111/ddg.12229; Vahlquist A, 2008, ACTA DERM-VENEREOL, V88, P4, DOI 10.2340/00015555-0415; van de Kerkhof PCM, 2016, J AM ACAD DERMATOL, V75, P83, DOI 10.1016/j.jaad.2016.03.024; Van Gysel D, 2002, J EUR ACAD DERMATOL, V16, P472, DOI 10.1046/j.1468-3083.2002.00477.x; Van Gysel D, 2001, DERMATOLOGY, V202, P99, DOI 10.1159/000051607; Vyas NS, 2016, PEDIATR DERMATOL, V33, pE6, DOI 10.1111/pde.12728; Wang CQF, 2014, J INVEST DERMATOL, V134, P2990, DOI 10.1038/jid.2014.268; Wang F, 2006, J INVEST DERMATOL, V126, P1590, DOI 10.1038/sj.jid.5700310; WILLIAMS ML, 1992, PEDIATR DERMATOL, V9, P365, DOI 10.1111/j.1525-1470.1992.tb00632.x; Witte E, 2014, J INVEST DERMATOL, V134, P2757, DOI 10.1038/jid.2014.308; Yalcin AD, 2016, IMMUNOPHARM IMMUNOT, V38, P162, DOI 10.3109/08923973.2015.1115518; Ye L, 2014, J INVEST DERMATOL, V134, P2843, DOI 10.1038/jid.2014.205; Zaba LC, 2009, J ALLERGY CLIN IMMUN, V124, P1022, DOI 10.1016/j.jaci.2009.08.046; Zuo Y, 2008, J BIOL CHEM, V283, P36624, DOI 10.1074/jbc.M807377200	125	88	87	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					152	165		10.1016/j.jaci.2016.07.019	http://dx.doi.org/10.1016/j.jaci.2016.07.019			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27554821	Green Accepted, Bronze			2022-12-18	WOS:000393996800017
J	Chan, TK; Loh, XY; Peh, HY; Tan, WNF; Tan, WSD; Li, N; Tay, IJJ; Wong, WSF; Engelward, BP				Chan, Tze Khee; Loh, Xin Yi; Peh, Hong Yong; Tan, W. N. Felicia; Tan, W. S. Daniel; Li, Na; Tay, Ian J. J.; Wong, W. S. Fred; Engelward, Bevin P.			House dust mite-induced asthma causes oxidative damage and DNA double-strand breaks in the lungs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						House dust mite; asthma; oxidative stress; DNA double-strand breaks; BEAS-2B; cell death; DNA repair; NU7441	DEPENDENT PROTEIN-KINASE; ANTIMALARIAL-DRUG ARTESUNATE; HOMOLOGOUS RECOMBINATION; ATAXIA-TELANGIECTASIA; MOLECULAR-MECHANISMS; IONIZING-RADIATION; MAMMALIAN-CELLS; GENETIC-DISEASE; ALLERGIC-ASTHMA; NITRIC-OXIDE	Background: Asthma is related to airway inflammation and oxidative stress. High levels of reactive oxygen and nitrogen species can induce cytotoxic DNA damage. Nevertheless, little is known about the possible role of allergen-induced DNA damage and DNA repair as modulators of asthma-associated pathology. Objective: We sought to study DNA damage and DNA damage responses induced by house dust mite (HDM) in vivo and in vitro. Methods: We measured DNA double-strand breaks (DSBs), DNA repair proteins, and apoptosis in anHDM-induced allergic asthma model and in lung samples from asthmatic patients. To study DNA repair, we treated mice with the DSB repair inhibitor NU7441. To study the direct DNA-damaging effect of HDM on human bronchial epithelial cells, we exposed BEAS-2B cells to HDM and measured DNA damage and reactive oxygen species levels. Results: HDM challenge increased lung levels of oxidative damage to proteins (3-nitrotyrosine), lipids (8-isoprostane), and nucleic acid (8-oxoguanine). Immunohistochemical evidence for HDM-induced DNA DSBs was revealed by increased levels of the DSB marker gamma Histone 2AX (H2AX) foci in bronchial epithelium. BEAS-2B cells exposed to HDM showed enhanced DNA damage, as measured by using the comet assay and gamma H2AX staining. In lung tissue from human patients with asthma, we observed increased levels of DNA repair proteins and apoptosis, as shown by caspase-3 cleavage, caspase-activated DNase levels, and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling staining. Notably, NU7441 augmented DNA damage and cytokine production in the bronchial epithelium and apoptosis in the allergic airway, implicating DSBs as an underlying driver of asthma pathophysiology. Conclusion: This work calls attention to reactive oxygen and nitrogen species and HDM-induced cytotoxicity and to a potential role for DNA repair as a modulator of asthma-associated pathophysiology.	[Chan, Tze Khee; Loh, Xin Yi; Peh, Hong Yong; Tan, W. N. Felicia; Tan, W. S. Daniel; Wong, W. S. Fred] Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore; [Chan, Tze Khee; Peh, Hong Yong; Tan, W. S. Daniel; Wong, W. S. Fred] Natl Univ Singapore, Program Immunol, Inst Life Sci, Singapore 117548, Singapore; [Chan, Tze Khee; Li, Na; Engelward, Bevin P.] Singapore MIT Alliance Res & Technol SMART, Infect Dis Interdisciplinary Res Grp, Singapore, Singapore; [Tay, Ian J. J.] Agcy Sci Technol & Res, Grad Acad, Singapore, Singapore; [Tay, Ian J. J.; Engelward, Bevin P.] MIT, Cambridge, MA 02139 USA	National University of Singapore; National University of Singapore; Singapore-MIT Alliance for Research & Technology Centre (SMART); Agency for Science Technology & Research (A*STAR); Massachusetts Institute of Technology (MIT)	Wong, WSF (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Block MD3,16 Med Dr,Level 4,04-01, Singapore 117600, Singapore.	phcwongf@nus.edu.sg	Peh, Hong Yong/AFN-7934-2022	Tan, Wan Shun Daniel/0000-0002-5840-5698; Wong, Wai Shiu Fred/0000-0001-7010-3759	National Medical Research Council from the NMRC of Singapore [NMRC/CBRG/0027/2012]; Singapore-MIT Alliance for Research and Technology (SMART)	National Medical Research Council from the NMRC of Singapore(National Medical Research Council, Singapore); Singapore-MIT Alliance for Research and Technology (SMART)(Singapore-MIT Alliance for Research & Technology Centre (SMART))	Supported in part by National Medical Research Council grant NMRC/CBRG/0027/2012 from the NMRC of Singapore and by the Singapore-MIT Alliance for Research and Technology (SMART).	Asher I, 2014, GLOBAL ASTHMA REPORT; Bao Z, 2009, AM J RESP CRIT CARE, V179, P657, DOI 10.1164/rccm.200809-1516OC; Berkun Y, 2010, PEDIATR PULM, V45, P230, DOI 10.1002/ppul.21095; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Brown KD, 2000, J BIOL CHEM, V275, P6651, DOI 10.1074/jbc.275.9.6651; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Caldecott KW, 2008, NAT REV GENET, V9, P619, DOI 10.1038/nrg2380; Campbell C, 1998, NUCLEIC ACIDS RES, V26, P3165, DOI 10.1093/nar/26.13.3165; Chapman AM, 2014, MUTAT RES-FUND MOL M, V769, P100, DOI 10.1016/j.mrfmmm.2014.06.007; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Cheng C, 2013, ALLERGY, V68, P195, DOI 10.1111/all.12077; Cheng C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020932; Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702; Comhair SAA, 2010, ANTIOXID REDOX SIGN, V12, P93, DOI 10.1089/ARS.2008.2425; Davis AJ, 2014, DNA REPAIR, V17, P21, DOI 10.1016/j.dnarep.2014.02.020; De Zio D, 2011, CELL DEATH DIFFER, V18, P516, DOI 10.1038/cdd.2010.125; Fahy John V, 2009, Proc Am Thorac Soc, V6, P256, DOI 10.1513/pats.200808-087RM; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Ghonim MA, 2015, J ALLERGY CLIN IMMUN, V135, P425, DOI 10.1016/j.jaci.2014.09.005; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Gregory LG, 2011, TRENDS IMMUNOL, V32, P402, DOI 10.1016/j.it.2011.06.006; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Ho WE, 2012, FREE RADICAL BIO MED, V53, P498, DOI 10.1016/j.freeradbiomed.2012.05.021; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Kaczmarek A, 2013, IMMUNITY, V38, P209, DOI 10.1016/j.immuni.2013.02.003; Kiziltepe T, 2005, CHEM BIOL, V12, P357, DOI 10.1016/j.chembiol.2004.12.011; Krejci L, 2012, NUCLEIC ACIDS RES, V40, P5795, DOI 10.1093/nar/gks270; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Lambrecht BN, 2014, NAT IMMUNOL, P45; Langelier MF, 2012, SCIENCE, V336, P728, DOI 10.1126/science.1216338; Li JQ, 2014, SCI REP-UK, V4, DOI 10.1038/srep04275; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; McKinnon PJ, 2007, ANNU REV GENOM HUM G, V8, P37, DOI 10.1146/annurev.genom.7.080505.115648; McKinnon PJ, 2012, ANNU REV PATHOL-MECH, V7, P303, DOI 10.1146/annurev-pathol-011811-132509; Mishra A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7224; Montuschi P, 2004, FASEB J, V18, P1791, DOI 10.1096/fj.04-2330rev; Mutamba JT, 2011, DNA REPAIR, V10, P1282, DOI 10.1016/j.dnarep.2011.10.008; Nakamura AJ, 2010, CELL CYCLE, V9, P389, DOI 10.4161/cc.9.2.10475; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Panier S, 2013, NAT REV MOL CELL BIO, V14, P661, DOI 10.1038/nrm3659; Parkin J, 2001, LANCET, V357, P1777, DOI 10.1016/S0140-6736(00)04904-7; Persson C, 2014, CLIN EXP ALLERGY, V44, P173, DOI 10.1111/cea.12255; Shrivastav M, 2009, DNA REPAIR, V8, P920, DOI 10.1016/j.dnarep.2009.05.006; Singh G, 1997, AM J RESP CELL MOL, V17, P141, DOI 10.1165/ajrcmb.17.2.f138; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sugiura H, 2011, NITRIC OXIDE-BIOL CH, V25, P138, DOI 10.1016/j.niox.2011.03.079; Tarsounas M, 2004, PHILOS T R SOC B, V359, P87, DOI 10.1098/rstb.2003.1368; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Weingeist DM, 2013, CELL CYCLE, V12, P907, DOI 10.4161/cc.23880; Weterings E, 2008, CELL RES, V18, P114, DOI 10.1038/cr.2008.3; Wood DK, 2010, P NATL ACAD SCI USA, V107, P10008, DOI 10.1073/pnas.1004056107; Yamada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031494; Zhao Y, 2006, CANCER RES, V66, P5354, DOI 10.1158/0008-5472.CAN-05-4275	58	88	89	2	34	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					84	+		10.1016/j.jaci.2016.02.017	http://dx.doi.org/10.1016/j.jaci.2016.02.017			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	27157131	Green Published, Bronze			2022-12-18	WOS:000379659100009
J	Cetica, V; Sieni, E; Pende, D; Danesino, C; De Fusco, C; Locatelli, F; Micalizzi, C; Putti, MC; Biondi, A; Fagioli, F; Moretta, L; Griffiths, GM; Luzzatto, L; Arico, M				Cetica, Valentina; Sieni, Elena; Pende, Daniela; Danesino, Cesare; De Fusco, Carmen; Locatelli, Franco; Micalizzi, Concetta; Putti, Maria Caterina; Biondi, Andrea; Fagioli, Franca; Moretta, Lorenzo; Griffiths, Gillian M.; Luzzatto, Lucio; Arico, Maurizio			Genetic predisposition to hemophagocytic lymphohistiocytosis: Report on 500 patients from the Italian registry	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hemophagocytic lymphohistiocytosis; PRF1; UNC13D; immunologic tests	MACROPHAGE ACTIVATION SYNDROME; LINKED LYMPHOPROLIFERATIVE DISEASE; JUVENILE IDIOPATHIC ARTHRITIS; STEM-CELL TRANSPLANTATION; BONE-MARROW; CYTOTOXIC LYMPHOCYTES; INTRONIC MUTATIONS; MUNC13-4; EXPRESSION; PATHOGENESIS	Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease affecting mostly children but also adults and characterized by hyperinflammatory features. A subset of patients, referred to as having familial hemophagocytic lymphohistiocytosis (FHL), have various underlying genetic abnormalities, the frequencies of which have not been systematically determined previously. Objective: This work aims to further our understanding of the pathogenic bases of this rare condition based on an analysis of our 25 years of experience. Methods: From our registry, we have analyzed a total of 500 unselected patients with HLH. Results: Biallelic pathogenic mutations defining FHL were found in 171 (34%) patients; the proportion of FHL was much higher (64%) in patients given a diagnosis during the first year of life. Taken together, mutations of the genes PRF1 (FHL2) and UNC13D (FHL3) accounted for 70% of cases of FHL. Overall, a genetic diagnosis was possible in more than 90% of our patients with FHL. Perforin expression and the extent of degranulation have been more useful for diagnosing FHL than hemophagocytosis and the cytotoxicity assay. Of 281 (56%) patients classified as having "sporadic'' HLH, 43 had monoallelic mutations in one of the FHL-defining genes. Given this gene dosage effect, FHL is not strictly recessive. Conclusion: We suggest that the clinical syndrome HLH generally results from the combined effects of an exogenous trigger and genetic predisposition. Within this combination, different weights of exogenous and genetic factors account for the wide disease spectrum that ranges from HLH secondary to severe infection to FHL.	[Cetica, Valentina; Sieni, Elena] Univ Meyer Children Hosp, Azienda Osped, Dept Pediat Hematol Oncol, Florence, Italy; [Pende, Daniela] Univ San Martino, Azienda Osped, Ist Ricovero & Cura Carattere Sci, Ist Nazl Ric Canc, Genoa, Italy; [Danesino, Cesare] Univ Pavia, Med Genet, Dept Mol Med, I-27100 Pavia, Italy; [Danesino, Cesare] Fdn IRCCS Policlin San Matteo, Pavia, Italy; [De Fusco, Carmen] Pausilipon Hosp, Pediat Hematol & Oncol, Naples, Italy; [Locatelli, Franco] IRCCS Osped Pediat Bambino Gesu, Dept Pediat Hematol & Oncol, Rome, Italy; [Locatelli, Franco] Univ Pavia, I-27100 Pavia, Italy; [Micalizzi, Concetta; Moretta, Lorenzo] Ist Giannina Gaslini, I-16148 Genoa, Italy; [Putti, Maria Caterina] Padua Hosp, Clin Pediat Hematol Oncol, Padua, Italy; [Biondi, Andrea] Univ Milano Bicocca, Pediat Clin, San Gerardo Hosp, Fdn MBBM, Monza, Italy; [Fagioli, Franca] Regina Margherita Childrens Hosp, Pediat Oncohematol, Stem Cell Transplantat & Cellular Therapy Div, Turin, Italy; [Griffiths, Gillian M.] Univ Cambridge Biomed Campus, Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge, England; [Luzzatto, Lucio; Arico, Maurizio] ITT, Florence, Italy; [Arico, Maurizio] Azienda Sanit Prov, I-97100 Ragusa, Italy	University of Genoa; IRCCS AOU San Martino IST; University of Pavia; IRCCS Fondazione San Matteo; IRCCS Bambino Gesu; University of Pavia; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Padua; Azienda Ospedaliera - Universita di Padova; San Gerardo Hospital; University of Milano-Bicocca; A.O.U. Citta della Salute e della Scienza di Torino; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Arico, M (corresponding author), Azienda Sanit Prov, Piazza Igea 1, I-97100 Ragusa, Italy.	maurizio.arico@asp.rg.it	Biondi, Andrea/K-9997-2016; Arico, Maurizio/ABI-2155-2020; Biondi, Andrea/AAX-1865-2020; Moretta, Lorenzo/AAA-7239-2020; Cetica, Valentina/J-2885-2018; Sieni, Elena/J-8729-2018; Arico, Maurizio/S-3039-2019; Fagioli, Franca/AAC-2181-2022; Micalizzi, Concetta/ABF-6300-2020; Pende, Daniela/J-7429-2016	Biondi, Andrea/0000-0002-6757-6173; Moretta, Lorenzo/0000-0003-4658-1747; Cetica, Valentina/0000-0001-8549-4158; Sieni, Elena/0000-0002-6192-9812; Arico, Maurizio/0000-0002-1908-6671; Pende, Daniela/0000-0003-1565-451X; Griffiths, Gillian/0000-0003-0434-5842; FAGIOLI, FRANCA/0000-0002-9257-900X	Associazione Italiana Ricerca Istiocitosi (AIRI); Associazione Ciemmeesse-Girotondo per il Meyer, Ministero della Salute (Bando Malattie Rare) [RF-TOS-2008-1219488]; European Commission [306124]	Associazione Italiana Ricerca Istiocitosi (AIRI); Associazione Ciemmeesse-Girotondo per il Meyer, Ministero della Salute (Bando Malattie Rare); European Commission(European CommissionEuropean Commission Joint Research Centre)	Supported by grants from Associazione Italiana Ricerca Istiocitosi (AIRI), Associazione Ciemmeesse-Girotondo per il Meyer, Ministero della Salute (Bando Malattie Rare RF-TOS-2008-1219488), and the Seventh Framework Programme (FP7) of the European Commission ("FIGHT-HLH'' Project no. 306124 to M.A.).	Arico M, 1996, LEUKEMIA, V10, P197; Arico M, 2001, BRIT J HAEMATOL, V114, P761, DOI 10.1046/j.1365-2141.2001.02936.x; Arico M, 2001, BLOOD, V97, P1131, DOI 10.1182/blood.V97.4.1131; Basheer A, 2015, MEDITERR J HEMATOL I, V7, DOI 10.4084/MJHID.2015.008; Bryceson YT, 2012, BLOOD, V119, P2754, DOI 10.1182/blood-2011-08-374199; Canna S, 2014, ARTHRITIS RHEUMATOL, V66, pS203, DOI 10.1002/art.38583; Cesaro S, 2008, HAEMATOL-HEMATOL J, V93, P1694, DOI 10.3324/haematol.13142; CHEDIAK M M, 1952, Rev Hematol, V7, P362; Cichocki F, 2014, J EXP MED, V211, P1079, DOI 10.1084/jem.20131131; Cooper N, 2006, BLOOD, V107, P1233, DOI 10.1182/blood-2005-05-1819; Cote M, 2009, J CLIN INVEST, V119, P3765, DOI 10.1172/JCI40732; FARQUHAR JW, 1952, ARCH DIS CHILD, V27, P519, DOI 10.1136/adc.27.136.519; Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9; FISCHER A, 1986, J PEDIATR-US, V108, P267, DOI 10.1016/S0022-3476(86)81002-2; GRISCELLI C, 1978, AM J MED, V65, P691, DOI 10.1016/0002-9343(78)90858-6; Hackmann Y, 2013, P NATL ACAD SCI USA, V110, pE4482, DOI 10.1073/pnas.1313474110; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Henter JI, 2002, BLOOD, V100, P2367, DOI 10.1182/blood-2002-01-0172; HENTER JI, 1991, ACTA PAEDIATR SCAND, V80, P428, DOI 10.1111/j.1651-2227.1991.tb11878.x; HERMANSKY F, 1959, BLOOD, V14, P162, DOI 10.1182/blood.V14.2.162.162; HIGASHI O, 1954, Tohoku J Exp Med, V59, P315; Janka G, 2005, ASH ED BOOK, V2005, P82, DOI DOI 10.1182/ASHE-DUCATI0N-2005.1.82]; Kaufman KM, 2014, ARTHRITIS RHEUMATOL, V66, P3486, DOI 10.1002/art.38793; Kogawa K, 2002, BLOOD, V99, P61, DOI 10.1182/blood.V99.1.61; Marcenaro S, 2006, BLOOD, V108, P2316, DOI 10.1182/blood-2006-04-015693; Marsh RA, 2010, J IMMUNOL METHODS, V362, P1, DOI 10.1016/j.jim.2010.08.010; Meazza R, 2014, J ALLERGY CLIN IMMUN, V134, P1381, DOI 10.1016/j.jaci.2014.04.043; Meazza R, 2014, EUR J IMMUNOL, V44, P1526, DOI 10.1002/eji.201344312; Nagai K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014173; Qian YP, 2014, PEDIATR BLOOD CANCER, V61, P1034, DOI 10.1002/pbc.24955; Ramos-Casals M, 2014, LANCET, V383, P1503, DOI 10.1016/S0140-6736(13)61048-X; Ravelli A, 2012, GENES IMMUN, V13, P289, DOI 10.1038/gene.2012.3; Santoro A, 2006, J MED GENET, V43, P953, DOI 10.1136/jmg.2006.041863; Santoro A, 2008, HAEMATOL-HEMATOL J, V93, P1086, DOI 10.3324/haematol.12622; Santoro A, 2005, HAEMATOLOGICA, V90, P697; Schmid JP, 2010, IMMUNOL REV, V235, P10, DOI 10.1111/j.0105-2896.2010.00890.x; Scott RB, 1939, LANCET, V2, P194; Seo JY, 2013, ANN HEMATOL, V92, P357, DOI 10.1007/s00277-012-1628-6; Sieni E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00167; Sieni E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044649; Sieni E, 2011, J MED GENET, V48, P343, DOI 10.1136/jmg.2010.085456; Stadt UZ, 2006, HUM MUTAT, V27, P62, DOI 10.1002/humu.20274; Stadt UZ, 2004, BLOOD, V104, P1909, DOI 10.1182/blood-2004-02-0733; Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957; Strippoli R, 2013, J RHEUMATOL, V40, P761, DOI 10.3899/jrheum.121233; Trambas C, 2005, BLOOD, V106, P932, DOI 10.1182/blood-2004-09-3713; Trizzino A, 2008, J MED GENET, V45, P15, DOI 10.1136/jmg.2007.052670; Trottestam H, 2011, BLOOD, V118, P4577, DOI 10.1182/blood-2011-06-356261; Voskoboinik I, 2005, BLOOD, V105, P4700, DOI 10.1182/blood-2004-12-4935; Voskoboinik I, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00441; Zhang KJ, 2011, BLOOD, V118, P5794, DOI 10.1182/blood-2011-07-370148; zur Stadt U, 2005, HUM MOL GENET, V14, P827, DOI 10.1093/hmg/ddi076; zur Stadt U, 2009, AM J HUM GENET, V85, P482, DOI 10.1016/j.ajhg.2009.09.005	53	88	97	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					188	+		10.1016/j.jaci.2015.06.048	http://dx.doi.org/10.1016/j.jaci.2015.06.048			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26342526	Green Published, hybrid			2022-12-18	WOS:000367724300009
J	Peters, SP; Bleecker, ER; Kunselman, SJ; Icitovic, N; Moore, WC; Pascual, R; Ameredes, BT; Boushey, HA; Calhoun, WJ; Castro, M; Cherniack, RM; Craig, T; Denlinger, LC; Engle, LL; DiMango, EA; Israel, E; Kraft, M; Lazarus, SC; Lemanske, RF; Lugogo, N; Martin, RJ; Meyers, DA; Ramsdell, J; Sorkness, CA; Sutherland, ER; Wasserman, SI; Walter, MJ; Wechsler, ME; Chinchilli, VM; Szefler, SJ				Peters, Stephen P.; Bleecker, Eugene R.; Kunselman, Susan J.; Icitovic, Nikolina; Moore, Wendy C.; Pascual, Rodolfo; Ameredes, Bill T.; Boushey, Homer A.; Calhoun, William J.; Castro, Mario; Cherniack, Reuben M.; Craig, Timothy; Denlinger, Loren C.; Engle, Linda L.; DiMango, Emily A.; Israel, Elliot; Kraft, Monica; Lazarus, Stephen C.; Lemanske, Robert F., Jr.; Lugogo, Njira; Martin, Richard J.; Meyers, Deborah A.; Ramsdell, Joe; Sorkness, Christine A.; Sutherland, E. Rand; Wasserman, Stephen I.; Walter, Michael J.; Wechsler, Michael E.; Chinchilli, Vernon M.; Szefler, Stanley J.		Natl Heart Lung Blood Inst	Predictors of response to tiotropium versus salmeterol in asthmatic adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; tiotropium; salmeterol; responder analysis; predictor of response	PERSONALIZED MEDICINE; LUNG-FUNCTION; FLUTICASONE; MONTELUKAST	Background: Tiotropium has activity as an asthma controller. However, predictors of a positive response to tiotropium have not been described. Objective: We sought to describe individual and differential responses of asthmatic patients to salmeterol and tiotropium when added to an inhaled corticosteroid, as well as predictors of a positive clinical response. Methods: Data from the double-blind, 3-way, crossover National Heart, Lung, and Blood Institute's Asthma Clinical Research Network's Tiotropium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (ClinicalTrials.gov number, NCT00565266) trial were analyzed for individual and differential treatment responses to salmeterol and tiotropium and predictors of a positive response to the end points FEV1, morning peak expiratory flow (PEF), and asthma control days (ACDs). Results: Although approximately equal numbers of patients showed a differential response to salmeterol and tiotropium in terms of morning PEF (n = 90 and 78, respectively) and ACDs (n = 49 and 53, respectively), more showed a differential response to tiotropium for FEV1 (n = 104) than salmeterol (n = 62). An acute response to a short-acting bronchodilator, especially albuterol, predicted a positive clinical response to tiotropium for FEV1 (odds ratio, 4.08; 95% CI, 2.00-8.31; P < .001) and morning PEF (odds ratio, 2.12; 95% CI, 1.12-4.01; P = 0.021), as did a decreased FEV1/forced vital capacity ratio (FEV1 response increased 0.39% of baseline for every 1% decrease in FEV1/forced vital capacity ratio). Higher cholinergic tone was also a predictor, whereas ethnicity, sex, atopy, IgE level, sputum eosinophil count, fraction of exhaled nitric oxide, asthma duration, and body mass index were not. Conclusion: Although these results require confirmation, predictors of a positive clinical response to tiotropium include a positive response to albuterol and airway obstruction, factors that could help identify appropriate patients for this therapy.	[Peters, Stephen P.; Bleecker, Eugene R.; Moore, Wendy C.; Pascual, Rodolfo; Meyers, Deborah A.] Wake Forest Sch Med, Winston Salem, NC 27157 USA; [Kunselman, Susan J.; Icitovic, Nikolina; Craig, Timothy; Engle, Linda L.; Chinchilli, Vernon M.] Penn State Coll Med, Dept Publ Hlth Sci, Hershey, PA USA; [Ameredes, Bill T.; Calhoun, William J.] Univ Texas Med Branch, Galveston, TX 77555 USA; [Boushey, Homer A.; Lazarus, Stephen C.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Castro, Mario; Walter, Michael J.] Washington Univ, St Louis, MO USA; [Cherniack, Reuben M.; Martin, Richard J.; Sutherland, E. Rand; Wechsler, Michael E.; Szefler, Stanley J.] Natl Jewish Hlth, Denver, CO USA; [Cherniack, Reuben M.; Martin, Richard J.; Sutherland, E. Rand; Wechsler, Michael E.; Szefler, Stanley J.] Univ Colorado, Sch Med, Denver, CO USA; [Denlinger, Loren C.; Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [DiMango, Emily A.] Columbia Univ, Med Ctr, New York, NY USA; [Israel, Elliot] Brigham & Womens Hosp, Boston, MA 02115 USA; [Israel, Elliot] Harvard Univ, Boston, MA 02115 USA; [Kraft, Monica; Lugogo, Njira] Duke Univ, Durham, NC 27706 USA; [Ramsdell, Joe; Wasserman, Stephen I.] Univ Calif San Diego, San Diego, CA 92103 USA; [Sorkness, Christine A.] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA	Wake Forest University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Texas System; University of Texas Medical Branch Galveston; University of California System; University of California San Francisco; Washington University (WUSTL); National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Wisconsin System; University of Wisconsin Madison; Columbia University; Harvard University; Brigham & Women's Hospital; Harvard University; Duke University; University of California System; University of California San Diego; University of Wisconsin System; University of Wisconsin Madison	Peters, SP (corresponding author), Wake Forest Sch Med, Ctr Genom & Personalized Med Res, Med Ctr Blvd, Winston Salem, NC 27157 USA.	sppeters@wakehealth.edu	Wechsler, Michael/AAC-5506-2019	Szefler, Stanley/0000-0002-6911-3199; Calhoun, William/0000-0001-7075-712X	National Heart, Lung, and Blood Institute [U10 HL074225, U10 HL074227, U10 HL074231, U10 HL074204, U10 HL074212, U10 HL074073, U10 HL074206, U10 HL074208, U10 HL074218]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL074208, U10HL074212, U10HL074206, U10HL074225, U10HL074073, U10HL074204, U10HL074231, U10HL074218, U10HL074227] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants from the National Heart, Lung, and Blood Institute (U10 HL074225, U10 HL074227, U10 HL074231, U10 HL074204, U10 HL074212, U10 HL074073, U10 HL074206, U10 HL074208, and U10 HL074218). Beclomethasone HFA canisters (Qvar) containing either 40 mu g or 80 mu g and rescue albuterol (Pro-Air) were supplied by TEVA Specialty Pharmaceuticals. Tiotropium and matching placebo were supplied by Boehringer Ingelheim Pharmaceuticals, which had the opportunity to comment on the study design.	Bateman ED, 2011, J ALLERGY CLIN IMMUN, V128, P315, DOI 10.1016/j.jaci.2011.06.004; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Greenberger PA, 2010, J ALLERGY CLIN IMMUN, V125, P305, DOI 10.1016/j.jaci.2009.11.038; Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606; Kerstjens HAM, 2011, J ALLERGY CLIN IMMUN, V128, P308, DOI 10.1016/j.jaci.2011.04.039; Knuffman JE, 2009, J ALLERGY CLIN IMMUN, V123, P411, DOI 10.1016/j.jaci.2008.11.016; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; National Asthma Education and Prevention Program, 2007, 3 DEP HLTH HUM SERV; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Sharma S, 2008, J ALLERGY CLIN IMMUN, V122, P921, DOI 10.1016/j.jaci.2008.09.004; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V125, P285, DOI 10.1016/j.jaci.2009.10.026; Weiss ST, 2012, J ALLERGY CLIN IMMUN, V129, P327, DOI 10.1016/j.jaci.2011.12.971; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	15	88	89	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1068	+		10.1016/j.jaci.2013.08.003	http://dx.doi.org/10.1016/j.jaci.2013.08.003			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	24084072	Green Accepted			2022-12-18	WOS:000326235600005
J	Sasaki, T; Shiohama, A; Kubo, A; Kawasaki, H; Ishida-Yamamoto, A; Yamada, T; Hachiya, T; Shimizu, A; Okano, H; Kudoh, J; Amagai, M				Sasaki, Takashi; Shiohama, Aiko; Kubo, Akiharu; Kawasaki, Hiroshi; Ishida-Yamamoto, Akemi; Yamada, Taketo; Hachiya, Takayuki; Shimizu, Atsushi; Okano, Hideyuki; Kudoh, Jun; Amagai, Masayuki			A homozygous nonsense mutation in the gene for Tmem79, a component for the lamellar granule secretory system, produces spontaneous eczema in an experimental model of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; skin barrier; stratum corneum; trans-Golgi network; filaggrin	OF-FUNCTION MUTATIONS; TRANS-GOLGI NETWORK; FLAKY TAIL MICE; STRATUM-CORNEUM; FILAGGRIN MUTATIONS; FUNCTION VARIANTS; HOUSE-MOUSE; BARRIER; PROTEIN; SKIN	Background: Flaky tail (ma/ma Flg(ft/ft)) mice have a frameshift mutation in the filaggrin (Flg(ft)) gene and are widely used as a model of human atopic dermatitis associated with FLG mutations. These mice possess another recessive hair mutation, matted (ma), and develop spontaneous dermatitis under specific pathogen-free conditions, whereas genetically engineered Flg(-/-) mice do not. Objective: We identified and characterized the gene responsible for the matted hair and dermatitis phenotype in flaky tail mice. Methods: We narrowed down the responsible region by backcrossing ma/ma mice with wild-type mice and identified the mutation using next-generation DNA sequencing. We attempted to rescue the matted phenotype by introducing the wild-type matted transgene. We characterized the responsible gene product by using whole-mount immunostaining of epidermal sheets. Results: We demonstrated that ma, but not Flg(ft), was responsible for the dermatitis phenotype and corresponded to a Tmem79 gene nonsense mutation (c.840C>G, p.Y280*), which encoded a 5-transmembrane protein. Exogenous Tmem79 expression rescued the matted hair and dermatitis phenotype of Tmem79(ma/ma) mice. Tmem79 was mainly expressed in the trans-Golgi network in stratum granulosum cells in the epidermis in both mice and humans. The Tmem79(ma/ma) mutation impaired the lamellar granule secretory system, which resulted in altered stratum corneum formation and a subsequent spontaneous dermatitis phenotype. Conclusions: The Tmem79(ma/ma) mutation is responsible for the spontaneous dermatitis phenotype in matted mice, probably as a result of impaired lamellar granule secretory system and altered stratum corneum barrier function.	[Sasaki, Takashi; Kubo, Akiharu; Kawasaki, Hiroshi; Amagai, Masayuki] Keio Univ, Sch Med, Dept Dermatol, Tokyo, Japan; [Yamada, Taketo] Keio Univ, Sch Med, Dept Pathol, Tokyo 160, Japan; [Shimizu, Atsushi] Keio Univ, Sch Med, Dept Mol Biol, Tokyo, Japan; [Okano, Hideyuki] Keio Univ, Sch Med, Dept Physiol, Tokyo 160, Japan; [Sasaki, Takashi; Kubo, Akiharu] Keio Univ, Sch Med, Ctr Integrated Med Res, Tokyo, Japan; [Shiohama, Aiko; Amagai, Masayuki] Keio Univ, Sch Med, MSD Endowed Program Allergy Res, Tokyo, Japan; [Shiohama, Aiko; Kudoh, Jun] Keio Univ, Sch Med, Lab Gene Med, Tokyo, Japan; [Ishida-Yamamoto, Akemi] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Hokkaido, Japan; [Hachiya, Takayuki] Med & Biol Labs Co Ltd, Nagano, Japan	Keio University; Keio University; Keio University; Keio University; Keio University; Keio University; Keio University; Asahikawa Medical College	Amagai, M (corresponding author), Keio Univ, Sch Med, Dept Dermatol, Shinjyuku Ku, 35 Shinanomachi, Tokyo, Japan.	amagai@med.keio.ac.jp	Amagai, Masayuki/K-5325-2013; Okano, Hideyuki/I-7584-2019; Sasaki, Takashi/AAD-1461-2019; Kubo, Akiharu/I-2711-2014	Amagai, Masayuki/0000-0003-3314-7052; Kubo, Akiharu/0000-0003-0902-3586; Sasaki, Takashi/0000-0002-6275-046X	Health Labour Sciences Research Grant for Research on Allergic Disease and Immunology from the Ministry of Health, Labour, and Welfare of Japan; Ministry of Education, Culture, Sports, Science, and Technology of Japan; Global Centre of Excellence (GCOE) program at Keio University from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; Grants-in-Aid for Scientific Research [23390086] Funding Source: KAKEN	Health Labour Sciences Research Grant for Research on Allergic Disease and Immunology from the Ministry of Health, Labour, and Welfare of Japan; Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Global Centre of Excellence (GCOE) program at Keio University from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	M.A. and J.K. are supported by Health Labour Sciences Research Grant for Research on Allergic Disease and Immunology from the Ministry of Health, Labour, and Welfare of Japan. A.K., A.I.-Y., and A.S. are supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. M.A, H.O., J.K., A.S., and T.S. are supported by the Global Centre of Excellence (GCOE) program at Keio University from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Akiyama M, 2005, J CLIN INVEST, V115, P1777, DOI 10.1172/JCI24834; Basel-Vanagaite L, 2007, AM J HUM GENET, V80, P467, DOI 10.1086/512487; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Ishida-Yamamoto A, 2004, J INVEST DERMATOL, V122, P1137, DOI 10.1111/j.0022-202X.2004.22515.x; Ishida-Yamamoto A, 2011, MED MOL MORPHOL, V44, P1, DOI 10.1007/s00795-010-0513-4; Kain R, 1998, J BIOL CHEM, V273, P981, DOI 10.1074/jbc.273.2.981; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kelsell DP, 2005, AM J HUM GENET, V76, P794; Kezic S, 2012, J ALLERGY CLIN IMMUN, V129, P1031, DOI 10.1016/j.jaci.2011.12.989; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; Kubo A, 2009, J EXP MED, V206, P2937, DOI 10.1084/jem.20091527; LANE PW, 1972, J HERED, V63, P135, DOI 10.1093/oxfordjournals.jhered.a108252; LEUNG DYM, 1990, J ALLERGY CLIN IMMUN, V85, P927, DOI 10.1016/0091-6749(90)90079-J; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; LUNDSTROM A, 1994, ARCH DERMATOL RES, V286, P369, DOI 10.1007/BF00371795; MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Moniaga CS, 2013, AM J PATHOL, V182, P841, DOI 10.1016/j.ajpath.2012.11.039; Moniaga Catharina Sagita, 2011, Inflammation & Allergy Drug Targets, V10, P477; Moniaga CS, 2010, AM J PATHOL, V176, P2385, DOI 10.2353/ajpath.2010.090957; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nakai K, 2012, AM J PATHOL, V181, P969, DOI 10.1016/j.ajpath.2012.06.005; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Oji V, 2010, AM J HUM GENET, V87, P274, DOI 10.1016/j.ajhg.2010.07.005; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Presland RB, 2000, J INVEST DERMATOL, V115, P1072, DOI 10.1046/j.1523-1747.2000.00178.x; Rodriguez-Boulan E, 2005, BBA-MOL CELL RES, V1744, P455, DOI 10.1016/j.bbamcr.2005.04.007; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; SEARLE AG, 1957, J EMBRYOL EXP MORPH, V5, P93; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Spergel JM, 2010, ANN ALLERG ASTHMA IM, V105, P99, DOI 10.1016/j.anai.2009.10.002; Sprecher E, 2005, AM J HUM GENET, V77, P242, DOI 10.1086/432556; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Viklund H, 2008, BIOINFORMATICS, V24, P1662, DOI 10.1093/bioinformatics/btn221; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014	43	88	92	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1111	+		10.1016/j.jaci.2013.08.027	http://dx.doi.org/10.1016/j.jaci.2013.08.027			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	24060273				2022-12-18	WOS:000326235600010
J	Philbin, VJ; Dowling, DJ; Gallington, LC; Cortes, G; Tan, Z; Suter, EE; Chi, KW; Shuckett, A; Stoler-Barak, L; Tomai, M; Miller, RL; Mansfield, K; Levy, O				Philbin, Victoria J.; Dowling, David J.; Gallington, Leighanne C.; Cortes, Guadalupe; Tan, Zhen; Suter, Eugenie E.; Chi, Kevin W.; Shuckett, Ariel; Stoler-Barak, Liat; Tomai, Mark; Miller, Richard L.; Mansfield, Keith; Levy, Ofer			Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Toll-like receptor 8; innate immunity; neonate; newborn; alum; adjuvant; adenosine; IL-1 beta; caspase-1; inflammasome	INNATE IMMUNITY; BASIC MECHANISMS; VACCINE ADJUVANTS; ALPHA PRODUCTION; RESPONSES; TLR7; INFLAMMASOME; IMMUNIZATION; EXPRESSION; MAGNITUDE	Background: Newborns have frequent infections and manifest impaired vaccine responses, motivating a search for neonatal vaccine adjuvants. Alum is a neonatal adjuvant but might confer a T(H)2 bias. Toll-like receptor (TLR) agonists are candidate adjuvants, but human neonatal cord blood monocytes demonstrate impaired T(H)1-polarizing responses to many TLR agonists caused by plasma adenosine acting through cyclic AMP. TLR8 agonists, including imidazoquinolines (IMQs), such as the small synthetic 3M-002, induce adult-level TNF from neonatal monocytes, but the scope and mechanisms of IMQ-induced activation of neonatal monocytes and monocyte-derived dendritic cells (MoDCs) have not been reported. Objective: We sought to characterize IMQ-induced activation of neonatal monocytes and MoDCs. Methods: Neonatal cord and adult peripheral blood monocytes and MoDCs were cultured in autologous plasma; levels of alum- and TLR agonist-induced cytokines and costimulatory molecules were measured. TLR8 and inflammasome function were assayed by using small interfering RNA and Western blotting/caspase-1 inhibitory peptide, respectively. The ontogeny of TLR8 agonist-induced cytokine responses was defined in rhesus macaque whole blood ex vivo. Results: IMQs were more potent and effective than alum at inducing TNF and IL-1 beta from monocytes. 3M-002 induced robust TLR pathway transcriptome activation and T(H)1-polarizing cytokine production in neonatal and adult monocytes and MoDCs, signaling through TLR8 in an adenosine/cyclic AMP-refractory manner. Newborn MoDCs displayed impaired LPS/ATP-induced caspase-1-mediated IL-1 beta production but robust 3M-002-induced caspase-1-mediated inflammasome activation independent of exogenous ATP. TLR8 IMQs induced robust TNF and IL-1 beta in whole blood of rhesus macaques at birth and infancy. Conclusions: IMQ TLR8 agonists engage adenosine-refractory TLR8 and inflammasome pathways to induce robust monocyte and MoDC activation and represent promising neonatal adjuvants. (J Allergy Clin Immunol 2012; 130:195-204.)	[Philbin, Victoria J.; Dowling, David J.; Gallington, Leighanne C.; Cortes, Guadalupe; Tan, Zhen; Suter, Eugenie E.; Chi, Kevin W.; Shuckett, Ariel; Stoler-Barak, Liat; Levy, Ofer] Childrens Hosp, Div Infect Dis, Dept Med, Boston, MA 02115 USA; [Philbin, Victoria J.; Dowling, David J.; Cortes, Guadalupe; Tan, Zhen; Mansfield, Keith; Levy, Ofer] Harvard Univ, Sch Med, Boston, MA USA; [Tomai, Mark] 3M Drug Delivery Syst, St Paul, MN USA; [Miller, Richard L.] 3M Pharmaceut, St Paul, MN USA; [Mansfield, Keith] New England Reg Primate Res Ctr, Southborough, MA 01772 USA; [Tan, Zhen] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200030, Peoples R China	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; 3M; 3M; Shanghai Jiao Tong University	Levy, O (corresponding author), Childrens Hosp, Div Infect Dis, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.	ofer.levy@childrens.harvard.edu	Gallington, Leighanne C/G-9341-2011	Gallington, Leighanne C/0000-0002-0383-7522; Levy, Ofer/0000-0002-5859-1945; Dowling, David/0000-0003-1095-6156; Suter, Eugenie/0000-0003-3559-3347; Chi, Kevin/0000-0002-8279-0397	National Institutes of Health [RO1 AI067353-01A1, 3R01AI067353-05S1]; Patterson Trust; Grand Challenges Explorations grant [53278]; Bill & Melinda Gates Foundation [OPPGH5284]; 3M Pharmaceuticals; American Heart Association; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI067353] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Patterson Trust; Grand Challenges Explorations grant; Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); 3M Pharmaceuticals(3M); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants to O.L. from the National Institutes of Health (RO1 AI067353-01A1 and Administrative Supplement 3R01AI067353-05S1), the Patterson Trust and Grand Challenges Explorations grant 53278, and Global Health grant OPPGH5284 from the Bill & Melinda Gates Foundation. Reagent support was provided by 3M Pharmaceuticals. V.J.P. was supported by an American Heart Association Postdoctoral Fellowship.	Adams S, 2008, J IMMUNOL, V181, P776, DOI 10.4049/jimmunol.181.1.776; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Belderbos M, 2009, CURR OPIN PEDIATR, V21, P762, DOI 10.1097/MOP.0b013e3283325e3a; Blasius AL, 2010, IMMUNITY, V32, P305, DOI 10.1016/j.immuni.2010.03.012; Bracci L, 2008, EXPERT REV VACCINES, V7, P373, DOI 10.1586/14760584.7.3.373; Burl S, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0012287, 10.1371/journal.pone.0018185]; Cho MH, 2010, INFECT IMMUN, V78, P387, DOI 10.1128/IAI.00956-09; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Coombs MRP, 2011, EXPERT REV ANTI-INFE, V9, P261, DOI [10.1586/ERI.10.158, 10.1586/eri.10.158]; Darmochwal-Kolarz D, 2004, IMMUNOL LETT, V91, P71, DOI 10.1016/j.imlet.2003.11.006; Davila S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000218; De Wit D, 2004, BLOOD, V103, P1030, DOI 10.1182/blood-2003-04-1216; Demirjian A, 2009, EUR J IMMUNOL, V39, P36, DOI 10.1002/eji.200838620; Desrosiers MD, 2007, J IMMUNOL, V179, P1884, DOI 10.4049/jimmunol.179.3.1884; Du J, 2010, VACCINE, V28, P6273, DOI 10.1016/j.vaccine.2010.06.117; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Flach TL, 2011, NAT MED, V17, P479, DOI 10.1038/nm.2306; Gilles S, 2011, J ALLERGY CLIN IMMUN, V127, P454, DOI 10.1016/j.jaci.2010.12.1082; Gorden KB, 2005, J IMMUNOL, V174, P1259, DOI 10.4049/jimmunol.174.3.1259; Hasko G, 2007, PHARMACOL THERAPEUT, V113, P264, DOI 10.1016/j.pharmthera.2006.08.003; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hoshino K, 2008, CURR OPIN IMMUNOL, V20, P408, DOI 10.1016/j.coi.2008.06.003; Hurst J, 2009, IMMUNOBIOLOGY, V214, P683, DOI 10.1016/j.imbio.2008.12.003; Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517; Kanswal S, 2008, J IMMUNOL, V181, P976, DOI 10.4049/jimmunol.181.2.976; Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737; Ketloy C, 2008, VET IMMUNOL IMMUNOP, V125, P18, DOI 10.1016/j.vetimm.2008.05.001; Kollmann TR, 2009, J IMMUNOL, V183, P7150, DOI 10.4049/jimmunol.0901481; Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755; Krumbiegel D, 2007, HUM IMMUNOL, V68, P813, DOI 10.1016/j.humimm.2007.08.001; Langrish CL, 2002, CLIN EXP IMMUNOL, V128, P118, DOI 10.1046/j.1365-2249.2002.01817.x; Lawn JE, 2008, EARLY HUM DEV, V84, P809, DOI 10.1016/j.earlhumdev.2008.09.009; Levy O, 2004, J IMMUNOL, V173, P4627, DOI 10.4049/jimmunol.173.7.4627; Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075; Levy O, 2006, BLOOD, V108, P1284, DOI 10.1182/blood-2005-12-4821; Levy O, 2006, J IMMUNOL, V177, P1956, DOI 10.4049/jimmunol.177.3.1956; Li HF, 2007, J IMMUNOL, V178, P5271, DOI 10.4049/jimmunol.178.8.5271; Lombardi V, 2009, J IMMUNOL, V182, P3372, DOI 10.4049/jimmunol.0801969; Marodi L, 2002, ACTA PAEDIATR, V91, P117, DOI 10.1080/080352502320764292; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; Miller RL, 2008, DRUG NEWS PERSPECT, V21, P69, DOI 10.1358/dnp.2008.21.2.1188193; Monie TP, 2009, TRENDS BIOCHEM SCI, V34, P553, DOI 10.1016/j.tibs.2009.06.011; Netea MG, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000661; Netea MG, 2009, BLOOD, V113, P2324, DOI 10.1182/blood-2008-03-146720; Nguyen M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010407; Philbin VJ, 2007, BIOCHEM SOC T, V35, P1485, DOI 10.1042/BST0351485; Philbin VJ, 2009, PEDIATR RES, V65, p98R, DOI 10.1203/PDR.0b013e31819f195d; Sanghavi SK, 2004, IMMUNOGENETICS, V56, P667, DOI 10.1007/s00251-004-0734-6; Schon MP, 2006, J INVEST DERMATOL, V126, P1338, DOI 10.1038/sj.jid.5700286; Siegrist CA, 2007, J COMP PATHOL, V137, pS4, DOI 10.1016/j.jcpa.2007.04.004; Tomai MA, 2011, EXPERT REV VACCINES, V10, P405, DOI [10.1586/erv.11.26, 10.1586/ERV.11.26]; UNICEF, 2009, STAT WORLDS CHILDR S; van den Biggelaar AHJ, 2009, VACCINE, V27, P1340, DOI 10.1016/j.vaccine.2008.12.046; van Duin D, 2006, TRENDS IMMUNOL, V27, P49, DOI 10.1016/j.it.2005.11.005; *WHO, 2005, WORLD HLTH REP; Wille-Reece U, 2005, P NATL ACAD SCI USA, V102, P15190, DOI 10.1073/pnas.0507484102; Wille-Reece U, 2006, J EXP MED, V203, P1249, DOI 10.1084/jem.20052433; Willems F, 2009, EUR J IMMUNOL, V39, P26, DOI 10.1002/eji.200838391; Yan SR, 2004, INFECT IMMUN, V72, P1223, DOI 10.1128/IAI.72.3.1223-1229.2004	61	88	91	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					195	+		10.1016/j.jaci.2012.02.042	http://dx.doi.org/10.1016/j.jaci.2012.02.042			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22521247	Green Accepted			2022-12-18	WOS:000306644800028
J	Sugawara, K; Biro, T; Tsuruta, D; Toth, BI; Kromminga, A; Zakany, N; Zimmer, A; Funk, W; Gibbs, BF; Zimmer, A; Paus, R				Sugawara, Koji; Biro, Tamas; Tsuruta, Daisuke; Toth, Balazs I.; Kromminga, Arno; Zakany, Nora; Zimmer, Anne; Funk, Wolfgang; Gibbs, Bernhard F.; Zimmer, Andreas; Paus, Ralf			Endocannabinoids limit excessive mast cell maturation and activation in human skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Endocannabinoid; cannabinoid receptor; skin; hair follicle; mast cell; stem cell factor; tryptase	HUMAN HAIR FOLLICLE; RECEPTOR KNOCKOUT MICE; CANNABINOID RECEPTORS; ORGAN-CULTURE; IN-VIVO; ANANDAMIDE; CB1; EXPRESSION; SYSTEM; GROWTH	Background: Mast cells (MCs) crucially contribute to many inflammatory diseases. However, the physiological controls preventing excessive activities of MCs in human skin are incompletely understood. Objective: Since endocannabinoids are important neuroendocrine MC modifiers, we investigated how stimulation/inhibition of cannabinoid 1 (CB1) receptors affect the biology of human skin MCs in situ. Methods: This was investigated in the MC-rich connective tissue sheath of organ-cultured human scalp hair follicles by quantitative (immuno) histomorphometry, ultrastructural, and quantitative PCR techniques with the use of CB1 agonists or antagonists, CB1 knockdown, or CB1 knockout mice. Results: Kit + MCs within the connective tissue sheath of human hair follicles express functional CB1 receptors, whose pharmacological blockade or gene silencing significantly stimulated both the degranulation and the maturation of MCs from resident progenitor cells in situ (ie, enhanced the number of tryptase+, Fc epsilon RI alpha, or chymase + connective tissue sheath-MCs). This was, at least in part, stem cell factor-dependent. CB1 agonists counteracted the MC-activating effects of classical MC secretagogues. Similar phenomena were observed in CB1 knockout mice, attesting to the in vivo relevance of this novel MC-inhibitory mechanism. Conclusion: By using human hair follicle organ culture as an unconventional, but clinically relevant model system for studying the biology of MCs in situ, we show that normal skin MCs are tightly controlled by the endocannabinoid system. This limits excessive activation and maturation of MCs from resident progenitors via "tonic" CB1 stimulation by locally synthesized endocannabinoids. The excessive numbers and activation of MCs in allergic and other chronic inflammatory skin diseases may partially arise from resident intracutaneous MC progenitors, for example, because of insufficient CB1 stimulation. Therefore, CB1 stimulation is a promising strategy for the future management of allergy and MC-dependent skin diseases. (J Allergy Clin Immunol 2012; 129: 726-38.)	[Sugawara, Koji; Zakany, Nora; Gibbs, Bernhard F.; Paus, Ralf] Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany; [Sugawara, Koji; Tsuruta, Daisuke] Osaka City Univ, Dept Dermatol, Grad Sch Med, Osaka 558, Japan; [Biro, Tamas; Toth, Balazs I.; Zakany, Nora] Univ Debrecen, Dept Physiol, DE MTA Lendulet Cellular Physiol Res Grp, MHSC,RCMM, Debrecen, Hungary; [Kromminga, Arno] Univ Kiel, Inst Immunol, Kiel, Germany; [Kromminga, Arno] IPM Biotech, Hamburg, Germany; [Zimmer, Anne; Zimmer, Andreas] Univ Bonn, Inst Mol Psychiat, Bonn, Germany; [Funk, Wolfgang] Klin Dr Kozlowski & Dr Funk, Munich, Germany; [Gibbs, Bernhard F.] Univ Kent, Medway Sch Pharm, Chatham, England; [Paus, Ralf] Univ Manchester, Sch Translat Med, Manchester, Lancs, England	University of Lubeck; Osaka Metropolitan University; University of Debrecen; University of Kiel; University of Bonn; University of Greenwich; University of Kent; University of Manchester	Paus, R (corresponding author), Univ Lubeck, Dept Dermatol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	ralf.paus@uk-sh.de	Zimmer, Andreas/B-8357-2009; Sumbayev, Vadim/HCH-7696-2022; Paus, Ralf/F-6243-2011; Tóth, Balázs István/K-1214-2013; Paus, Ralf/B-5279-2015	Tóth, Balázs István/0000-0002-4103-4333; Paus, Ralf/0000-0002-3492-9358; Sugawara, Koji/0000-0003-1662-3272	Deutsche Forschungsgemeinschaft (Cluster of Excellence, "Inflammation at interfaces'') [FOR926]	Deutsche Forschungsgemeinschaft (Cluster of Excellence, "Inflammation at interfaces'')(German Research Foundation (DFG))	We gratefully acknowledge Dr Martin Metz (Charite, Berlin), Prof Thomas Tueting (University of Bonn), and Dr Vincenzo Di Marzo (Institute of Biomolecular Chemistry-CNR, Italy) for professional advice as well as Mrs Motoko Sugawara for excellent technical assistance. The generous professional support of Prof Masamitsu Ishii and Prof Hiromi Kobayashi (Osaka City University Graduate School of Medicine) for this work is also appreciated.; R. P. has received grant support from Deutsche Forschungsgemeinschaft (Cluster of Excellence, "Inflammation at interfaces''). A. Z. has received grant support from Deutsche Forschungsgemeinschaft (FOR926).	Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; Arck PC, 2005, J MOL MED, V83, P386, DOI 10.1007/s00109-004-0627-z; Arck PC, 2006, J INVEST DERMATOL, V126, P1697, DOI 10.1038/sj.jid.5700104; Biro T, 2009, TRENDS PHARMACOL SCI, V30, P411, DOI 10.1016/j.tips.2009.05.004; Borbiro I, 2011, J INVEST DERMATOL, V131, P1605, DOI 10.1038/jid.2011.122; Bueb JL, 2001, BBA-MOL CELL RES, V1538, P252, DOI 10.1016/S0167-4889(01)00076-3; Cantarella G, 2011, BIOCHEM PHARMACOL, V82, P380, DOI 10.1016/j.bcp.2011.05.004; Cerrato S, 2010, VET IMMUNOL IMMUNOP, V133, P9, DOI 10.1016/j.vetimm.2009.06.011; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; De Filippis D, 2008, J NEUROENDOCRINOL, V20, P20, DOI 10.1111/j.1365-2826.2008.01674.x; Del Giudice E, 2007, J LEUKOCYTE BIOL, V81, P1512, DOI 10.1189/jlb.1206738; Di Marzo V, 2011, HANDB EXP PHARMACOL, V203, P75, DOI 10.1007/978-3-642-17214-4_4; Dobrosi N, 2008, FASEB J, V22, P3685, DOI 10.1096/fj.07-104877; DVORAK AM, 1988, BLOOD, V71, P76; Eberlein B, 2008, J EUR ACAD DERMATOL, V22, P73, DOI 10.1111/j.1468-3083.2007.02351.x; Ekoff M, 2011, ADV EXP MED BIOL, V716, P47, DOI 10.1007/978-1-4419-9533-9_4; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; Fajardo I, 2003, J IMMUNOL, V171, P1493, DOI 10.4049/jimmunol.171.3.1493; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; Gilfillan AM, 2011, ADV EXP MED BIOL, V716, P2, DOI 10.1007/978-1-4419-9533-9_1; Granberg M, 2001, N-S ARCH PHARMACOL, V364, P66, DOI 10.1007/s002100100424; Ito N, 2010, J INVEST DERMATOL, V130, P995, DOI 10.1038/jid.2009.387; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; Kambe N, 2001, BLOOD, V97, P2045, DOI 10.1182/blood.V97.7.2045; Karsak M, 2007, SCIENCE, V316, P1494, DOI 10.1126/science.1142265; Khasabova IA, 2008, J NEUROSCI, V28, P11141, DOI 10.1523/JNEUROSCI.2847-08.2008; Kloepper JE, 2010, EXP DERMATOL, V19, P305, DOI 10.1111/j.1600-0625.2009.00939.x; Kumamoto T, 2003, BLOOD, V102, P1654, DOI 10.1182/blood-2003-02-0449; Leterrier C, 2004, J BIOL CHEM, V279, P36013, DOI 10.1074/jbc.M403990200; Liu J, 2008, NEUROPHARMACOLOGY, V54, P1, DOI 10.1016/j.neuropharm.2007.05.020; Lu ZF, 2007, EXP DERMATOL, V16, P37, DOI 10.1111/j.1600-0625.2006.00510.x; Marshall Gailen D, 2004, J Am Osteopath Assoc, V104, pS1; Maurer M, 2003, EXP DERMATOL, V12, P886, DOI 10.1111/j.0906-6705.2003.0109a.x; Metz M, 2007, TRENDS IMMUNOL, V28, P234, DOI 10.1016/j.it.2007.03.003; Metz M, 2009, CURR OPIN IMMUNOL, V21, P687, DOI 10.1016/j.coi.2009.09.009; Miettinen M, 2005, APPL IMMUNOHISTO M M, V13, P205, DOI 10.1097/01.pai.0000173054.83414.22; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Papadopoulou N, 2005, J INVEST DERMATOL, V125, P952, DOI 10.1111/j.0022-202X.2005.23913.x; Paus R, 2005, TRENDS IMMUNOL, V26, P32, DOI 10.1016/j.it.2004.09.014; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Pertwee RG, 2010, PHARMACOL REV, V62, P588, DOI 10.1124/pr.110.003004; Peters EMJ, 2003, J INVEST DERMATOL, V121, P976, DOI 10.1046/j.1523-1747.2003.12478.x; Peters EMJ, 2007, AM J PATHOL, V171, P1872, DOI 10.2353/ajpath.2007.061206; Radosa J, 2011, EXP DERMATOL, V20, P677, DOI 10.1111/j.1600-0625.2011.01283.x; Ramot Y, 2010, FASEB J, V24, P1768, DOI 10.1096/fj.09-146415; Rao KN, 2008, ANN NY ACAD SCI, V1143, P83, DOI 10.1196/annals.1443.023; Romana-Souza B, 2010, EXP DERMATOL, V19, P821, DOI 10.1111/j.1600-0625.2010.01113.x; Rudolph MI, 2008, J PHARMACOL SCI, V106, P208, DOI 10.1254/jphs.FP0070736; Samson MT, 2003, J IMMUNOL, V170, P4953, DOI 10.4049/jimmunol.170.10.4953; Schernthaner GH, 2005, ALLERGY, V60, P1248, DOI 10.1111/j.1398-9995.2005.00865.x; SCHIERHORN K, 1995, IN VITRO CELL DEV-AN, V31, P215; Schlosburg JE, 2009, J PHARMACOL EXP THER, V329, P314, DOI 10.1124/jpet.108.150136; Schneider MR, 2009, CURR BIOL, V19, pR132, DOI 10.1016/j.cub.2008.12.005; Seeliger S, 2010, AM J PATHOL, V177, P2563, DOI 10.2353/ajpath.2010.090941; Small-Howard AL, 2005, BIOCHEM J, V388, P465, DOI 10.1042/BJ20041682; Solinas M, 2008, BRIT J PHARMACOL, V154, P369, DOI 10.1038/bjp.2008.130; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; Telek A, 2007, FASEB J, V21, P3534, DOI 10.1096/fj.06-7689com; Valent P, 2010, BEST PRACT RES CL HA, V23, P369, DOI 10.1016/j.beha.2010.07.003; Viscomi MT, 2010, EXP NEUROL, V224, P56, DOI 10.1016/j.expneurol.2010.03.023; Waldmann H, 2006, NATURE, V442, P987, DOI 10.1038/nature05165; Weber A, 2003, BRIT J DERMATOL, V148, P224, DOI 10.1046/j.1365-2133.2003.05090.x; WERSHIL BK, 1988, J IMMUNOL, V140, P2356; Yosipovitch G, 2003, AM J CLIN DERMATOL, V4, P617, DOI 10.2165/00128071-200304090-00004; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780	65	88	89	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					726	U205		10.1016/j.jaci.2011.11.009	http://dx.doi.org/10.1016/j.jaci.2011.11.009			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22226549				2022-12-18	WOS:000301189300018
J	Navarini, AA; French, LE; Hofbauer, GFL				Navarini, Alexander A.; French, Lars E.; Hofbauer, Gunther F. L.			Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							T-CELLS; INTERLEUKIN-6 RECEPTOR; TOCILIZUMAB; ECZEMA		[Navarini, Alexander A.; French, Lars E.; Hofbauer, Gunther F. L.] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Navarini, AA (corresponding author), Univ Zurich Hosp, Dept Dermatol, Gloriastr 31, CH-8091 Zurich, Switzerland.	alexander.navarini@usz.ch	French, Lars/AAL-5977-2020; Hofbauer, Gunther/B-2671-2010; Navarini, Alexander/C-5504-2014	French, Lars/0000-0002-4629-1486; Hofbauer, Gunther/0000-0003-0542-7989; Navarini, Alexander/0000-0001-7059-632X				Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Hirao M, 2009, ANN RHEUM DIS, V68, P654, DOI 10.1136/ard.2008.090068; LEE CE, 1992, J ALLERGY CLIN IMMUN, V89, P1010, DOI 10.1016/0091-6749(92)90224-P; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; Simon D, 2008, J ALLERGY CLIN IMMUN, V122, P423, DOI 10.1016/j.jaci.2008.06.010; Smolen JS, 2008, LANCET, V371, P987, DOI 10.1016/S0140-6736(08)60453-5; TOSHITANI A, 1993, J INVEST DERMATOL, V100, P299, DOI 10.1111/1523-1747.ep12469875; Yokoyama A, 1997, AM J RESP CRIT CARE, V156, P1688, DOI 10.1164/ajrccm.156.5.9610070	9	88	92	2	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1128	1130		10.1016/j.jaci.2011.09.009	http://dx.doi.org/10.1016/j.jaci.2011.09.009			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21962991				2022-12-18	WOS:000296578200037
J	Broccardo, CJ; Mahaffey, S; Schwarz, J; Wruck, L; David, G; Schlievert, PM; Reisdorph, NA; Leung, DYM				Broccardo, Carolyn J.; Mahaffey, Spencer; Schwarz, John; Wruck, Lisa; David, Gloria; Schlievert, Patrick M.; Reisdorph, Nichole A.; Leung, Donald Y. M.			Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and Staphylococcus aureus colonization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; mass spectrometry; proteomics; natural moisturizing factor; eczema herpeticum; tape stripping; skin barrier; filaggrin-2; epidermal fatty acid binding protein; methicillin-resistant Staphylococcus aureus	ACID-BINDING PROTEIN; SKIN BARRIER; STRATUM-CORNEUM; WATER-LOSS; IN-VIVO; FILAGGRIN; DISEASE; RISK; METAANALYSIS; CASPASE-14	Background: Atopic dermatitis (AD) is the most common inflammatory skin disorder in the general population worldwide, and the majority of patients are colonized with Staphylococcus aureus. Eczema herpeticum is a disseminated herpes simplex virus infection that occurs in a small subset of patients. Objectives: The goal was to conduct proteomic profiling of patients with AD based on S aureus colonization status and history of eczema herpeticum. We hoped to identify new biomarkers for improved diagnosis and prediction of eczema herpeticum and S aureus susceptibility and to generate new hypotheses regarding disease pathogenesis. Methods: Skin taping was performed on nonlesional skin of nonatopic control subjects and on lesional and nonlesional skin of patients with AD. Subjects were classified according to the history of eczema herpeticum and S aureus colonization. Proteins were analyzed by using mass spectrometry; diagnostic groups were compared for statistically significant differences in protein expression. Results: Proteins related to the skin barrier (filaggrin-2, corneodesmosin, desmoglein-1, desmocollin-1, and transglutaminase-3) and generation of natural moisturizing factor (arginase-1, caspase-14, and gamma-glutamyl cyclotransferase) were expressed at significantly lower levels in lesional versus nonlesional sites of patients with AD with and without history of eczema herpeticum; epidermal fatty acid-binding protein was expressed at significantly higher levels in patients with methicillin-resistant S aureus. Conclusion: This noninvasive, semiquantitative profiling method has revealed novel proteins likely involved in the pathogenesis of AD. The lower expression of skin barrier proteins and enzymes involved in the generation of the natural moisturizing factor could further exacerbate barrier defects and perpetuate water loss from the skin. The greater expression of epidermal fatty acid-binding protein, especially in patients colonized with methicillin-resistant S aureus, might perpetuate the inflammatory response through eicosanoid signaling. (J Allergy Clin Immunol 2011;127:186-93.)	[Leung, Donald Y. M.] Natl Jewish Hlth, Edelstein Family Chair Pediat Allergy Immunol, Dept Pediat, Denver, CO 80206 USA; [Broccardo, Carolyn J.; Mahaffey, Spencer; Reisdorph, Nichole A.] Natl Jewish Hlth, Dept Immunol, Denver, CO 80206 USA; [Schwarz, John; Wruck, Lisa; David, Gloria] Rho Inc, Chapel Hill, NC USA; [Schlievert, Patrick M.] Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA; [Reisdorph, Nichole A.] Univ Colorado, Dept Immunol, Aurora, CO USA; [Leung, Donald Y. M.] Univ Colorado Denver, Dept Pediat, Aurora, CO USA	National Jewish Health; National Jewish Health; Rho; University of Minnesota System; University of Minnesota Twin Cities; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Leung, DYM (corresponding author), Natl Jewish Hlth, Edelstein Family Chair Pediat Allergy Immunol, Dept Pediat, 1400 Jackson St,Room K926I, Denver, CO 80206 USA.	Leungd@njhealth.org	Reisdorph, Nichole/AAX-8774-2020; Mahaffey, Spencer/AAC-8712-2021	Reisdorph, Nichole/0000-0002-0425-8012; Schlievert, Patrick/0000-0001-8314-9369	National Institutes of Health/National Institute of Allergy and Infectious Diseases [N01-AI-40029, N01 AI-40033, R01 AR41256]; NCRR [S10RR023703]; National Institute of Allergy and Infectious Diseases; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR023703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI140029, N01AI040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases contracts N01-AI-40029, N01 AI-40033, R01 AR41256, and NCRR S10RR023703.; S. Mahaffey is the owner of Laboratory Information Management Solutions. J. Schwarz is employed by Monsanto. L. Wruck and G. David are employed by Rho, Inc, and have received research support from the National Institute of Allergy and Infectious Diseases. The rest of the authors have declared that they have no conflict of interest.	Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Bennaars-Eiden A, 2002, J BIOL CHEM, V277, P50693, DOI 10.1074/jbc.M209493200; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Breuer K, 2002, BRIT J DERMATOL, V147, P55, DOI 10.1046/j.1365-2133.2002.04872.x; Broccardo CJ, 2009, J ALLERGY CLIN IMMUN, V124, P1113, DOI 10.1016/j.jaci.2009.07.057; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; De Benedetto A, 2009, J INVEST DERMATOL, V129, P14, DOI 10.1038/jid.2008.259; Denecker G, 2007, NAT CELL BIOL, V9, P666, DOI 10.1038/ncb1597; Elias PM, 2009, CURR OPIN ALLERGY CL, V9, P437, DOI 10.1097/ACI.0b013e32832e7d36; Fluhr JW, 2006, EXP DERMATOL, V15, P483, DOI 10.1111/j.1600-0625.2006.00437.x; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Kamata Y, 2009, J BIOL CHEM, V284, P12829, DOI 10.1074/jbc.M807908200; Kezic S, 2009, BRIT J DERMATOL, V161, P1098, DOI 10.1111/j.1365-2133.2009.09342.x; Loden M, 2003, AM J CLIN DERMATOL, V4, P771; Makowski L, 2004, J NUTR, V134, p2464S, DOI 10.1093/jn/134.9.2464S; Mikolajczak SA, 2007, INT J PARASITOL, V37, P483, DOI 10.1016/j.ijpara.2007.01.002; Niwa Y, 2003, BRIT J DERMATOL, V149, P248, DOI 10.1046/j.1365-2133.2003.05417.x; Oakley AJ, 2008, J BIOL CHEM, V283, P22031, DOI 10.1074/jbc.M803623200; Omata N, 2001, LIFE SCI, V69, P223, DOI 10.1016/S0024-3205(01)01124-9; Oymar K, 2005, ALLERGY, V60, P86, DOI 10.1111/j.1398-9995.2005.00658.x; Presland RB, 2009, DERMATOL SIN, V27, P1; Proksch E, 2009, J DTSCH DERMATOL GES, V7, P899, DOI 10.1111/j.1610-0387.2009.07157.x; Proksch E, 2008, EXP DERMATOL, V17, P1063, DOI 10.1111/j.1600-0625.2008.00786.x; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Storch J, 2008, ANNU REV NUTR, V28, P73, DOI 10.1146/annurev.nutr.27.061406.093710; Suh L, 2008, PEDIATR DERMATOL, V25, P528, DOI 10.1111/j.1525-1470.2008.00768.x; Tan NS, 2002, MOL CELL BIOL, V22, P5114, DOI 10.1128/MCB.22.14.5114-5127.2002; Toulza E, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-r107; Wang GQ, 2007, MICROBIOL-SGM, V153, P1935, DOI 10.1099/mic.0.2006/003491-0; Watanabe R, 1997, J DERMATOL SCI, V16, P17, DOI 10.1016/S0923-1811(97)00615-4; Wetzel S, 2004, HAUTARZT, V55, P646, DOI 10.1007/s00105-004-0744-1; Wiren K, 2009, J EUR ACAD DERMATOL, V23, P1267, DOI 10.1111/j.1468-3083.2009.03303.x; Wollenberg A, 2003, J AM ACAD DERMATOL, V49, P198, DOI 10.1067/S0190-9622(03)00896-X; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Wu ZH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005227; Yamane Y, 2009, INT ARCH ALLERGY IMM, V150, P89, DOI 10.1159/000210385; Zimmer JSD, 2004, J BIOL CHEM, V279, P7420, DOI 10.1074/jbc.M311404200; Zuberbier T, 2006, J ALLERGY CLIN IMMUN, V118, P226, DOI 10.1016/j.jaci.2006.02.031	42	88	91	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					186	U300		10.1016/j.jaci.2010.10.033	http://dx.doi.org/10.1016/j.jaci.2010.10.033			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211653	Green Accepted			2022-12-18	WOS:000285917300027
J	Hassan, M; Jo, T; Risse, PA; Tolloczko, B; Lemiere, C; Olivenstein, R; Hamid, Q; Martin, JG				Hassan, Muhannad; Jo, Taisuke; Risse, Paul-Andre; Tolloczko, Barbara; Lemiere, Catherine; Olivenstein, Ronald; Hamid, Qutayba; Martin, James G.			Airway smooth muscle remodeling is a dynamic process in severe long-standing asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HB-EGF; PCNA; Ki 67; in situ hybridization; biomarker	EPIDERMAL-GROWTH-FACTOR; CELL-PROLIFERATION; EPITHELIAL-CELLS; HB-EGF; GENE-EXPRESSION; MODERATE ASTHMA; MESSENGER-RNA; IN-VIVO; RAT; HYPERPLASIA	Background: The origin of the excess airway smooth muscle in asthma and when in the course of the disease it is acquired are uncertain. Objectives: We examined the relative sensitivities of 2 markers of proliferation, proliferating cell nuclear antigen (PCNA) and Ki 67, in airway smooth muscle in vivo and in vitro. We then studied whether muscle remodeling is a dynamic process in asthma by quantifying proliferation rate and area. Finally we examined heparin-binding epidermal growth factor as a biomarker of remodeling. Methods: We obtained bronchoscopic biopsies from subjects with moderate or severe asthma and healthy controls (n = 9/group). For in vitro studies, airway smooth muscle cells were cultured from tracheas of transplant donors. The proliferation rate was quantified from PCNA and Ki 67, co-localized to smooth muscle specific alpha-actin cells in vivo. Muscle area was assessed morphometrically. We examined the expression of heparin-binding epidermal growth factor on tissues by in situ hybridization and by immunohistochemistry and in cells in culture by RT-PCR. Results: Proliferating cell nuclear antigen and Ki 67 were highly correlated, but PCNA was a significantly more sensitive marker both in vivo and in vitro. Muscle area was 3.4-fold greater and the fraction of PCNA(+) nuclei in muscle was 5-fold greater in severe asthma than in healthy subjects. Heparin-binding epidermal growth factor was upregulated in proliferating muscle cells in culture and in airway smooth muscle in severe asthmatic tissues. Conclusion: Proliferating cell nuclear antigen is a highly sensitive marker of proliferation and heparin-binding epidermal growth factor is a potential biomarker during active remodeling of ASM in severe asthma. (J Allergy Clin Immunol 2010;125:1037-45.)	[Hassan, Muhannad; Jo, Taisuke; Risse, Paul-Andre; Tolloczko, Barbara; Lemiere, Catherine; Hamid, Qutayba; Martin, James G.] McGill Univ, Meakins Christie Labs, Dept Med, Montreal, PQ H2X 2P2, Canada; [Lemiere, Catherine] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; [Olivenstein, Ronald] Montreal Chest Inst, Montreal, PQ, Canada	McGill University; Universite de Montreal; McGill University	Martin, JG (corresponding author), McGill Univ, Meakins Christie Labs, Dept Med, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	james.martin@mcgill.ca		Martin, James/0000-0001-7574-5363	Richard and Edith Strauss Canada Foundation	Richard and Edith Strauss Canada Foundation	Supported by the Richard and Edith Strauss Canada Foundation.	Allahverdian S, 2008, AM J RESP CELL MOL, V38, P153, DOI 10.1165/rcmb.2007-0173OC; Amishima M, 1998, AM J RESP CRIT CARE, V157, P1907, DOI 10.1164/ajrccm.157.6.9609040; Benayoun L, 2001, AM J RESP CRIT CARE, V164, P1487, DOI 10.1164/ajrccm.164.8.2101070; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Cohen L, 2007, AM J RESP CRIT CARE, V176, P138, DOI 10.1164/rccm.200607-1062OC; EBINA M, 1993, AM REV RESPIR DIS, V148, P720, DOI 10.1164/ajrccm/148.3.720; EIDELMAN DH, 1991, AM REV RESPIR DIS, V144, P792, DOI 10.1164/ajrccm/144.4.792; Govindaraju V, 2006, AM J PHYSIOL-CELL PH, V291, pC957, DOI 10.1152/ajpcell.00451.2005; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hardie WD, 2008, AM J PHYSIOL-LUNG C, V294, pL1217, DOI 10.1152/ajplung.00020.2008; HEARD BE, 1973, J PATHOL, V110, P319, DOI 10.1002/path.1711100406; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Hirst SJ, 2000, AM J RESP CELL MOL, V23, P335, DOI 10.1165/ajrcmb.23.3.3990; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Labonte I, 2009, AM J PHYSIOL-LUNG C, V297, pL698, DOI 10.1152/ajplung.00142.2009; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; LEIKAUF GD, 1990, AM J PHYSIOL, V259, pL255, DOI 10.1152/ajplung.1990.259.4.L255; LEONARDI E, 1992, J CLIN PATHOL, V45, P416, DOI 10.1136/jcp.45.5.416; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83, DOI 10.1164/ajrccm.153.1.8542167; Means AL, 2003, GASTROENTEROLOGY, V124, P1020, DOI 10.1053/gast.2003.50150; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453, DOI 10.1165/ajrcmb.19.3.2999; PANETTIERI RA, 1995, CHEST, V107, pS94, DOI 10.1378/chest.107.3_Supplement.94S; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Polosa R, 2002, J ALLERGY CLIN IMMUN, V109, P75, DOI 10.1067/mai.2002.120274; Ramos-Barbon D, 2005, J CLIN INVEST, V115, P1580, DOI 10.1172/JCI19711; Ravasi S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-42; SAPIENZA S, 1991, AM REV RESPIR DIS, V144, P423, DOI 10.1164/ajrccm/144.2.423; Takeyama K, 2001, AM J RESP CRIT CARE, V163, P511, DOI 10.1164/ajrccm.163.2.2001038; Tamaoka M, 2008, EUR RESPIR J, V32, P1213, DOI 10.1183/09031936.00166907; Tillie-Leblond I, 2008, ALLERGY, V63, P533, DOI 10.1111/j.1398-9995.2008.01656.x; Tormanen KR, 2005, AM J RESP CRIT CARE, V171, P19, DOI 10.1164/rccm.200406-498OC; Tschumperlin DJ, 2004, NATURE, V429, P83, DOI 10.1038/nature02543; Tschumperlin DJ, 2002, AM J PHYSIOL-LUNG C, V282, pL904, DOI 10.1152/ajplung.00270.2001; Ushikoshi H, 2005, LAB INVEST, V85, P862, DOI 10.1038/labinvest.3700282; Vargaftig BB, 2003, AM J PHYSIOL-LUNG C, V285, pL808, DOI 10.1152/ajplung.00377.2002; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Ward JE, 2008, EUR RESPIR J, V32, P362, DOI 10.1183/09031936.00119307; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Yang YW, 2008, J ALLERGY CLIN IMMUN, V121, P1393, DOI 10.1016/j.jaci.2008.02.031; Zacchetti A, 2003, APMIS, V111, P430, DOI 10.1034/j.1600-0463.2003.t01-1-1110208.x; 1987, AM REV RESP DIS, V136, P225	44	88	96	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1037	1045		10.1016/j.jaci.2010.02.031	http://dx.doi.org/10.1016/j.jaci.2010.02.031			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20451038	Bronze			2022-12-18	WOS:000277686700012
J	Fonacier, LS; Dreskin, SC; Leung, DYM				Fonacier, Luz S.; Dreskin, Stephen C.; Leung, Donald Y. M.			Allergic skin diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic contact dermatitis; autoimmune blistering disease; atopic dermatitis; eczema; immune-mediated skin disorders; irritant contact dermatitis; psoriasis; urticaria	PLASMACYTOID DENDRITIC CELLS; ATOPIC-DERMATITIS; CONTACT-DERMATITIS; CHRONIC URTICARIA; EYELID DERMATITIS; THERAPEUTIC ALTERNATIVES; ANTIMICROBIAL PEPTIDES; STAPHYLOCOCCUS-AUREUS; FILAGGRIN MUTATIONS; FECAL MICROBIOTA	The skin is one of the largest immunologic organs and is affected by both external and internal factors, as well as innate and adaptive immune responses. Many skin disorders, such as atopic dermatitis, contact dermatitis, urticaria, angioedema, psoriasis, and autoimmune blistering disorders, are immune mediated. Most of these diseases are chronic, inflammatory, and proliferative, in which both genetic and environmental factors play important roles. These immunologic mechanisms might have implications for potential targets of future therapeutic interventions. (J Allergy Clin Immunol 2010;125:S138-49.)	[Leung, Donald Y. M.] Natl Jewish Hlth, Denver, CO 80206 USA; [Fonacier, Luz S.] Winthrop Univ Hosp, Mineola, NY 11501 USA; [Dreskin, Stephen C.] Univ Colorado Denver, Aurora, CO USA	National Jewish Health; Winthrop University Hospital; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Leung, DYM (corresponding author), Natl Jewish Hlth, 1400 Jackson St,Room K926I, Denver, CO 80206 USA.	leungd@njhealth.org			Novartis Genentech; Dyax; Lev; Allerderm; Alcom; National Institutes of Health	Novartis Genentech(Roche HoldingGenentech); Dyax; Lev; Allerderm; Alcom; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Disclosure of potential conflict of interest: L. S. Fonacier has received research support from Novartis Genentech, Dyax, Lev, Allerderm, and Alcom; is on the Board of Regents of the American College of Allergy, Asthma & Immunology; is President of the Long Island Allergy Society; and is past President of the International Association of Filipino Allergists and Immunologists. S. C. Dreskin has received research support from the National Institutes of Health and has provided expert witness testimony on antibiotic allergy and vaccine allergy. D. Y. M. Leung has declared that he has no conflict of interest.	Akdis M, 2003, FASEB J, V17, P1026, DOI 10.1096/fj.02-1070com; Asero R, 2007, AUTOIMMUN REV, V7, P71, DOI 10.1016/j.autrev.2007.08.002; Ayala Fabio, 2003, Am J Contact Dermat, V14, P69; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Beltrani VS, 2006, ANN ALLERG ASTHMA IM, V97, pS1, DOI 10.1016/S1081-1206(10)60811-3; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Brodell LA, 2008, ANN ALLERG ASTHMA IM, V100, P291, DOI 10.1016/S1081-1206(10)60588-1; Brown SJ, 2008, J ALLERGY CLIN IMMUN, V121, P940, DOI 10.1016/j.jaci.2008.01.013; Cashman AL, 2005, DERMATITIS, V16, P57, DOI 10.2310/6620.2005.05008; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; De Benedetto A, 2009, J INVEST DERMATOL, V129, P14, DOI 10.1038/jid.2008.259; Deleo VA, 2006, DERMATITIS, V17, P53, DOI 10.2310/6620.2006.05054; Duarte I, 1998, Am J Contact Dermat, V9, P216; Ebner S, 2007, J ALLERGY CLIN IMMUN, V119, P982, DOI 10.1016/j.jaci.2007.01.003; EDMAN B, 2000, DERM CLIN BAS SCI, P75; Ehrlich A, 2000, CUTIS, V65, P323; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Ferrer M, 2007, ALLERGOL IMMUNOPATH, V35, P57, DOI 10.1157/13101339; Fitch Erin, 2007, Curr Rheumatol Rep, V9, P461, DOI 10.1007/s11926-007-0075-1; Fonacier Luz, 2002, Am J Contact Dermat, V13, P164, DOI 10.1053/ajcd.2002.36639; Fowler J Jr, 2001, Am J Contact Dermat, V12, P3, DOI 10.1053/ajcd.2001.21472; Fowler Joseph F Jr, 2004, Dermatitis, V15, P3, DOI 10.2310/6620.2004.11744; Gore C, 2008, J ALLERGY CLIN IMMUN, V121, P135, DOI 10.1016/j.jaci.2007.07.061; Grattan CEH, 2007, BRIT J DERMATOL, V157, P1116, DOI 10.1111/j.1365-2133.2007.08283.x; Guin JD, 2002, J AM ACAD DERMATOL, V47, P755, DOI 10.1067/mjd.2002.122736; Gupta J, 2008, J ALLERGY CLIN IMMUN, V121, P725, DOI 10.1016/j.jaci.2007.12.1161; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Hata TR, 2008, J ALLERGY CLIN IMMUN, V122, P829, DOI 10.1016/j.jaci.2008.08.020; Hausermann P, 2004, CONTACT DERMATITIS, V51, P297, DOI 10.1111/j.0105-1873.2004.00445.x; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Higashi N, 2001, J ALLERGY CLIN IMMUN, V108, P607, DOI 10.1067/mai.2001.118601; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Iijima R, 2005, INT J CARDIOL, V104, P319, DOI 10.1016/j.ijcard.2004.12.034; Isaksson M, 2005, DERMATITIS, V16, P3, DOI 10.2310/6620.2005.04042; Isaksson M, 2000, CONTACT DERMATITIS, V42, P27, DOI 10.1034/j.1600-0536.2000.042001027.x; Jacob SE, 2008, DERMATITIS, V19, P9, DOI 10.2310/6620.2008.06069; Jensen CS, 2006, CONTACT DERMATITIS, V54, P79, DOI 10.1111/j.0105-1873.2006.00773.x; Johansen JD, 2003, AM J CLIN DERMATOL, V4, P789, DOI 10.2165/00128071-200304110-00006; Joly P, 2002, NEW ENGL J MED, V346, P321, DOI 10.1056/NEJMoa011592; Jung T, 2008, J ALLERGY CLIN IMMUN, V122, P1074, DOI 10.1016/j.jaci.2008.09.042; Kisich KO, 2008, J ALLERGY CLIN IMMUN, V122, P62, DOI 10.1016/j.jaci.2008.04.022; Kornik R, 2008, DERMATITIS, V19, P3, DOI 10.2310/6620.2008.07082; Koster R, 2000, LANCET, V356, P1895, DOI 10.1016/S0140-6736(00)03262-1; Krasteva M, 2002, EUR J DERMATOL, V12, P322; Kutting B, 2004, EUR J DERMATOL, V14, P80; Lazzarini Rosana, 2004, Dermatitis, V15, P125, DOI 10.2310/6620.2004.03039; Lebre MC, 2008, J ALLERGY CLIN IMMUN, V122, P969, DOI 10.1016/j.jaci.2008.08.028; Lee B, 2008, DERMATITIS, V19, P63, DOI 10.2310/6620.2608.07060; Lee J, 2008, J ALLERGY CLIN IMMUN, V121, P116, DOI 10.1016/j.jaci.2007.10.043; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; LEPOITTEVIN JP, 1995, ARCH DERMATOL, V131, P31, DOI 10.1001/archderm.131.1.31; Lin W, 2005, J ALLERGY CLIN IMMUN, V116, P1106, DOI 10.1016/j.jaci.2005.08.046; Machura E, 2008, PEDIAT ALLERG IMM-UK, V19, P37, DOI 10.1111/j.1399-3038.2007.00586.x; Mihai S, 2007, J CELL MOL MED, V11, P462, DOI 10.1111/j.1582-4934.2007.00033.x; Morgan M, 2008, ANN ALLERG ASTHMA IM, V100, P517, DOI 10.1016/S1081-1206(10)60047-6; Morgan M, 2008, ANN ALLERG ASTHMA IM, V100, P403, DOI 10.1016/S1081-1206(10)60462-0; Mortz CG, 2001, BRIT J DERMATOL, V144, P523, DOI 10.1046/j.1365-2133.2001.04078.x; Mrabet-Dahbi S, 2008, J ALLERGY CLIN IMMUN, V121, P1013, DOI 10.1016/j.jaci.2007.11.029; Nielsen NH, 2001, ACTA DERM-VENEREOL, V81, P31, DOI 10.1080/000155501750208155; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Novak N, 2004, J ALLERGY CLIN IMMUN, V114, P364, DOI 10.1016/j.jaci.2004.05.038; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Novak N, 2007, ADV EXP MED BIOL, V601, P97; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Powell RJ, 2007, CLIN EXP ALLERGY, V37, P631, DOI 10.1111/j.1365-2222.2007.02678.x; Raap U, 2008, J ALLERGY CLIN IMMUN, V122, P421, DOI 10.1016/j.jaci.2008.05.047; Reefer AJ, 2008, J ALLERGY CLIN IMMUN, V121, P415, DOI 10.1016/j.jaci.2007.11.003; Rice NE, 2008, J ALLERGY CLIN IMMUN, V122, P834, DOI 10.1016/j.jaci.2008.07.027; Rietschel RL, 2007, DERMATITIS, V18, P78, DOI 10.2310/6620.2007.06041; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Schroeder JT, 2005, J IMMUNOL, V175, P5724, DOI 10.4049/jimmunol.175.9.5724; Simon D, 2008, J ALLERGY CLIN IMMUN, V122, P423, DOI 10.1016/j.jaci.2008.06.010; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P122, DOI 10.1016/j.jaci.2007.11.016; Simpson EL, 2006, DERMATITIS, V17, P123, DOI 10.2310/6620.2006.06005; Sitaru C, 2005, EXP DERMATOL, V14, P861, DOI 10.1111/j.1600-0625.2005.00367.x; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Storrs FJ, 2007, DERMATITIS, V18, P3, DOI 10.2310/6620.2007.06053; Szegedi A, 2009, BRIT J DERMATOL, V160, P984, DOI 10.1111/j.1365-2133.2009.09035.x; Tversky JR, 2008, CLIN EXP ALLERGY, V38, P781, DOI 10.1111/j.1365-2222.2008.02954.x; VALSECCHI R, 1992, CONTACT DERMATITIS, V27, P143, DOI 10.1111/j.1600-0536.1992.tb05242.x; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; von Berg A, 2008, J ALLERGY CLIN IMMUN, V121, P1442, DOI 10.1016/j.jaci.2008.04.021; Vonakis BM, 2008, CURR OPIN IMMUNOL, V20, P709, DOI 10.1016/j.coi.2008.09.005; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; Warshaw Erin, 2003, Am J Contact Dermat, V14, P119; Warshaw EM, 2008, DERMATITIS, V19, P129, DOI 10.2310/6620.2007.06060; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V122, P560, DOI 10.1016/j.jaci.2008.05.050; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Wickens K, 2008, J ALLERGY CLIN IMMUN, V122, P788, DOI 10.1016/j.jaci.2008.07.011; Wilkinson SM, 2000, CONTACT DERMATITIS, V42, P59, DOI 10.1034/j.1600-0536.2000.042002059.x; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhao G, 2005, J DERMATOL, V32, P91, DOI 10.1111/j.1346-8138.2005.tb00723.x	99	88	93	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S138	S149		10.1016/j.jaci.2009.05.039	http://dx.doi.org/10.1016/j.jaci.2009.05.039			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	19932921				2022-12-18	WOS:000280170600013
J	Jacquenet, S; Moneret-Vautrin, DA; Bihain, BE				Jacquenet, Sandrine; Moneret-Vautrin, Denise-Anne; Bihain, Bernard E.			Mammalian meat-induced anaphylaxis: Clinical relevance of anti-galactose-alpha-1,3-galactose IgE confirmed by means of skin tests to cetuximab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGY		[Jacquenet, Sandrine; Bihain, Bernard E.] Genclis SAS, Vandoeuvre Les Nancy, France; [Moneret-Vautrin, Denise-Anne] Univ Hosp, Dept Internal Med Clin Immunol & Allergol, Nancy, France	CHU de Nancy	Jacquenet, S (corresponding author), Genclis SAS, Vandoeuvre Les Nancy, France.	s.barrat@chu-nancy.fr						Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Drouet M, 2001, Allerg Immunol (Paris), V33, P163; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Hilger C, 1997, ALLERGY, V52, P179, DOI 10.1111/j.1398-9995.1997.tb00972.x; Llatser R, 1998, CLIN EXP ALLERGY, V28, P1021, DOI 10.1046/j.1365-2222.1998.00362.x; Macher BA, 2008, BBA-GEN SUBJECTS, V1780, P75, DOI 10.1016/j.bbagen.2007.11.003; Restani P, 2009, CURR OPIN ALLERGY CL, V9, P265, DOI 10.1097/ACI.0b013e32832aef3d; Spergel JM, 2007, CURR OPIN ALLERGY CL, V7, P274, DOI 10.1097/ACI.0b013e32813aee4a; STRICKER WE, 1986, J ALLERGY CLIN IMMUN, V77, P516, DOI 10.1016/0091-6749(86)90188-0	10	88	89	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					603	605		10.1016/j.jaci.2009.06.014	http://dx.doi.org/10.1016/j.jaci.2009.06.014			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19733301				2022-12-18	WOS:000274315900032
J	Nelson, HS				Nelson, Harold S.			Multiallergen immunotherapy for allergic rhinitis and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen extracts; allergic rhinitis; bronchial asthma; multiallergen; polysensitization; subcutaneous immunotherapy; sublingual immunotherapy	HOUSE-DUST MITE; SUBLINGUAL IMMUNOTHERAPY; HAY-FEVER; DOUBLE-BLIND; BRONCHIAL HYPERREACTIVITY; HYPOSENSITIZATION THERAPY; POLLEN IMMUNOTHERAPY; CHILDREN; SENSITIZATIONS; EFFICACY	The English and non-English language literature on allergen immunotherapy was reviewed for studies simultaneously using 2 or more distinct allergen extracts in either subcutaneous or sublingual immunotherapy. Thirteen studies were identified, 11 using subcutaneous injections, I using sublingual administration, and 1 using both. In studies with adequate information, administration of 2 extracts by means of either subcutaneous immunotherapy or sublingual immunotherapy was effective. In studies using multiple allergens, 3 studies showed clear efficacy, whereas in the other 2 studies, lack of efficacy might have been due to inadequate doses of extract or omission of clinically relevant allergens in the treatment regimen. It is concluded that simultaneous administration of more than 1 allergen extract is clinically effective. However, more studies are needed, particularly with more than 2 allergen extracts and with sublingual administration. (J Allergy Clin Immunol 2009;123:763-9.)	Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA	National Jewish Health	Nelson, HS (corresponding author), Natl Jewish Hlth, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	nelsonh@njc.org			Greer Laboratories, Inc	Greer Laboratories, Inc	Editorial support was funded by Greer Laboratories, Inc.	Abramson MJ, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001186, DOI 10.1002/14651858.CD001186]; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Alvarez-Cuesta E, 2005, CLIN EXP ALLERGY, V35, P572, DOI 10.1111/j.1365-2222.2005.02245.x; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Cirla A M, 2003, Allergol Immunopathol (Madr), V31, P31, DOI 10.1157/13042841; COELLO CVM, 2003, REV ALERG MEX, V50, P170; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; EBNER C, 1994, ALLERGY, V49, P38, DOI 10.1111/j.1398-9995.1994.tb00771.x; Esch RE, 2003, ARB P EHRLICH I BUND, V94, P17; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; Freeman J, 1911, LANCET, V2, P814; FREW AJ, 1993, BRIT MED J, V307, P919, DOI 10.1136/bmj.307.6909.919; Guardia P, 2004, Allergol Immunopathol (Madr), V32, P271, DOI 10.1157/13066304; HAUGAARD L, 1992, ALLERGY, V47, P249, DOI 10.1111/j.1398-9995.1992.tb00658.x; Hedlin G, 1999, J ALLERGY CLIN IMMUN, V103, P609, DOI 10.1016/S0091-6749(99)70232-0; JOHNSTONE D, 1961, PEDIATRICS, V27, P39; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; Marogna M, 2007, ANN ALLERG ASTHMA IM, V98, P274, DOI 10.1016/S1081-1206(10)60718-1; Marogna M, 2007, INT ARCH ALLERGY IMM, V142, P70, DOI 10.1159/000096001; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; Noon L, 1911, LANCET, V1, P1572; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Penagos M, 2008, CHEST, V133, P599, DOI 10.1378/chest.06-1425; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Ross RN, 2000, CLIN THER, V22, P342, DOI 10.1016/S0149-2918(00)80038-7; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	35	88	91	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					763	769		10.1016/j.jaci.2008.12.013	http://dx.doi.org/10.1016/j.jaci.2008.12.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19217653				2022-12-18	WOS:000265058600004
J	Puck, JM				Puck, Jennifer M.		SCID Newborn Screening Working Grp	Population-based newborn screening for severe combined immunodeficiency: Steps toward implementation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference of the SCID-Newborn-Screening-Working-Group	MAY 14-15, 2007	San Francisco, CA	SCID		public health; primary immunodeficiency; newborn screening; severe combined immunodeficiency (SCID); live vaccine; bone marrow transplantation; hematopoietic stem cell transplantation; early diagnosis; genetic disease	CELL TRANSPLANTATION; RECONSTITUTION	Severe combined immune deficiency (SCID) has been identified as a disorder of high priority for population-based newborn screening. Most affected infants are not brought to medical attention until they develop serious infectious complications, and SCID is fatal if untreated. Effective treatment with allogeneic hematopoietic stem cell transplantation is widely established. The best outcome for SCID, as with many other conditions for which newborn screening is now done, is achieved if hematopoietic stem cell transplantation is performed in the first months of life, ideally before clinical presentation with infections and failure to thrive. A meeting in San Francisco in May 2007 brought together experts from newborn screening programs; the pediatric immunology community; pediatric transplant centers; and federal, state, and nongovernmental agencies to consider obstacles to and implications of developing newborn screening for SCID. Development of an appropriate low-cost, high-throughput screening algorithm has been a challenge, although absence of T-cell receptor gene excision circles is a sensitive marker of profound T lymphocytopenia and currently is the most developed screening method. A consensus was reached on several points: SCID newborn screening should be pursued with pilot studies in key locales, test methodologies need to be optimized, screening programs must be integrated with plans for definitive diagnosis and management, centralized specimen banks and registries are required to foster test validation and track outcomes that will guide future treatment, and SCID newborn screening will lead to important knowledge about human immune disorders as well as better care of patients.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Puck, JM (corresponding author), Univ Calif San Francisco, Dept Pediat, Box 0519,513 Parnassus Ave,HSE 301A, San Francisco, CA 94143 USA.	puckj@peds.ucsf.edu			NCRR NIH HHS [UL RR024131-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024131] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Buckley R, 2007, PRIMARY IMMUNODEFICI, P669; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Calado RT, 1999, CYTOMETRY, V38, P133, DOI 10.1002/(SICI)1097-0320(19990615)38:3<133::AID-CYTO8>3.0.CO;2-9; Candotti F, 2007, PRIMARY IMMUNODEFICI, P688; Cavazzana-Calvo M, 2007, J CLIN INVEST, V117, P1456, DOI 10.1172/JCI30953; Cavazzana-Calvo M, 2007, BLOOD, V109, P4575, DOI 10.1182/blood-2006-07-029090; Centers for Disease Control and Prevention (CDC), 2004, MMWR-MORBID MORTAL W, V52, P1; Chan B, 2005, CLIN IMMUNOL, V117, P133, DOI 10.1016/j.clim.2005.07.006; Chan K, 2005, J ALLERGY CLIN IMMUN, V115, P391, DOI 10.1016/j.jaci.2004.10.012; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; Knutsen AP, 2000, J CLIN IMMUNOL, V20, P466, DOI 10.1023/A:1026463900925; LAESSIIG RH, 2007, IN PRESS P 2007 NEWB; Mazzolari E, 2007, J ALLERGY CLIN IMMUN, V120, P892, DOI 10.1016/j.jaci.2007.08.007; McGhee SA, 2005, J PEDIATR-US, V147, P603, DOI 10.1016/j.jpeds.2005.06.001; McGhee SA, 2005, MOL GENET METAB, V86, P427, DOI 10.1016/j.ymgme.2005.09.005; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; O'Reilly RJ, 1994, BONE MARROW TRANSPL, P849; Pass K, 2006, MENT RETARD DEV D R, V12, P293, DOI 10.1002/mrdd.20122; Puck J M, 2007, PRIMARY IMMUNODEFICI, P123; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Smogorzewska Elzbieta M., 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P111; Watson MS, 2006, GENET MED, V8, p1S, DOI 10.1097/01.gim.0000223891.82390.ad	23	88	99	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					760	768		10.1016/j.jaci.2007.08.043	http://dx.doi.org/10.1016/j.jaci.2007.08.043			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	220LH	17931561				2022-12-18	WOS:000250157700008
J	Hunninghake, GM; Soto-Quiros, ME; Avila, L; Su, J; Murphy, A; Demeo, DL; Ly, NP; Liang, C; Sylvia, JS; Klanderman, BJ; Lange, C; Raby, BA; Silverman, EK; Celedon, JC				Hunninghake, Gary M.; Soto-Quiros, Manuel E.; Avila, Lydiana; Su, Jessica; Murphy, Amy; Demeo, Dawn L.; Ly, Ngoc P.; Liang, Catherine; Sylvia, Jody S.; Klanderman, Barbara J.; Lange, Christoph; Raby, Benjamin A.; Silverman, Edwin K.; Celedon, Juan C.			Polymorphisms in IL13, total IgE, eosinophilia, and asthma exacerbations in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL13; asthma; IgE; eosinophil; severity; exacerbations; Costa Rica; CAMP	TOTAL SERUM IGE; SYNCYTIAL VIRUS-INFECTION; INTERLEUKIN-13 GENE; IL-13; ASSOCIATION; ATOPY; CYTOKINE; HYPERRESPONSIVENESS; RISK; SUSCEPTIBILITY	Background: It is unclear whether single nucleotide polymorphisms (SNPs) in the gene for IL-13 (IL13) influence asthma severity and/or asthma morbidity. Objectives: To examine the relation between IL13 SNPs and asthma-related phenotypes in 2 independent populations. Methods: We used family-based methods to test for association between SNPs in IL13 and asthma-related phenotypes in Costa Rican children with asthma. We attempted to reproduce significant findings in white (non-Hispanic) children with asthma in the Childhood Asthma Management Program (CAMP). Results: In Costa Rica and in CAMP, the A allele (Gin) of IL13 coding SNP (rs20541) was significantly associated with increased eosinophil count (P <.011 in both studies) and increased serum total IgE (P <.054 in both studies). The T allele of IL13 promoter SNP (rs1800925) was inversely associated with asthma exacerbations in Costa Rica (P =.069). Although this SNP (rs1800925) was not associated with asthma exacerbations among all white children in CAMP, it was associated with increased risk of asthma exacerbations among children on inhaled corticosteroids (P :=.02). Conclusion: Polymorphisms in IL13 were significantly associated with serum total IgE and eosinophil count in 2 populations. IL13 polymorphisms may also be associated with asthma exacerbations, and this effect may be dependent on medication use. Our study is the first to report a potential negative interaction between a genetic polymorphism and response to inhaled corticosteroids. Clinical implications: Polymorphisms in IL13 are associated with serum total IgE and eosinophil count and may be associated with asthma exacerbations.	Channing Labs, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Hosp Nacl Ninos Dr Carlos Saenz Herrera, Div Pediat Pulmonol, San Jose, CA USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Massachusetts Gen Hosp Children, Dept Educ, Div Pediat Pulm Med, Boston, MA USA; Beth Israel Deaconess Med Ctr, Div Pulm & Crit Care Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center	Celedon, JC (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	juan.celedon@channing.harvard.edu	Avila, Lydiana/D-5638-2015; Raby, Benjamin/AAK-3866-2021	Avila, Lydiana/0000-0002-9579-1591; 	DIVISION OF LUNG DISEASES [N01HR016049] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL083634, R37HL066289, P50HL067664, K01HL004370, T32HL007427, R01HL066289] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07427, HL66289, N01 HR16049, HL04370, F32 HL083634-02, P50 HL67664, F32 HL083634] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1999, NAT GENET, V22, P1; Arima K, 2002, J ALLERGY CLIN IMMUN, V109, P980, DOI 10.1067/mai.2002.124656; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BLEECKER ER, 1995, CLIN EXP ALLERGY, V25, P84, DOI 10.1111/j.1365-2222.1995.tb00430.x; BLUMENTHAL MN, 1995, CLIN EXP ALLERGY, V25, P29, DOI 10.1111/j.1365-2222.1995.tb00416.x; Bogdan C, 1997, J IMMUNOL, V159, P4506; Cameron L, 2006, J IMMUNOL, V177, P8633, DOI 10.4049/jimmunol.177.12.8633; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Celedon JC, 2002, CLIN EXP ALLERGY, V32, P387, DOI 10.1046/j.1365-2222.2002.01348.x; CHATHAM M, 1982, AM REV RESPIR DIS, V126, P235; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; DeMeo DL, 2002, GENET EPIDEMIOL, V23, P335, DOI 10.1002/gepi.10182; Ermers MJJ, 2007, J ALLERGY CLIN IMMUN, V119, P1086, DOI 10.1016/j.jaci.2006.12.655; Eum SY, 2003, J ALLERGY CLIN IMMUN, V111, P1049, DOI 10.1067/mai.2003.1416; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Gessner A, 2005, J IMMUNOL, V174, P1063, DOI 10.4049/jimmunol.174.2.1063; Gibbons FK, 2005, J CLIN IMMUNOL, V25, P437, DOI 10.1007/s10875-005-5625-6; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Hakonarson H, 2001, AM J RESP CRIT CARE, V164, P2036, DOI 10.1164/ajrccm.164.11.2101086; He JQ, 2003, GENES IMMUN, V4, P385, DOI 10.1038/sj.gene.6363985; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; Kabesch M, 2006, J ALLERGY CLIN IMMUN, V117, P269, DOI 10.1016/j.jaci.2005.10.024; Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; Lange C, 2004, AM J HUM GENET, V74, P367, DOI 10.1086/381563; Leung TF, 2001, CLIN EXP ALLERGY, V31, P1515, DOI 10.1046/j.1365-2222.2001.01212.x; Maier LM, 2006, J ALLERGY CLIN IMMUN, V117, P1306, DOI 10.1016/j.jaci.2005.12.1354; Marsh DG, 1997, NAT GENET, V15, P389; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; Moissidis I, 2005, GENET MED, V7, P406, DOI 10.1097/01.GIM.0000170994.24960.48; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Ober C, 1998, CLIN EXP ALLERGY, V28, P101; Park SW, 2005, CHEST, V128, P1921, DOI 10.1378/chest.128.4.1921; Postma DS, 2005, AM J RESP CRIT CARE, V172, P446, DOI 10.1164/rccm.200407-864OC; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Puthothu B, 2006, J INFECT DIS, V193, P438, DOI 10.1086/499316; Sorkness RL, 2002, J ALLERGY CLIN IMMUN, V110, P607, DOI 10.1067/mai.2002.128241; Truyen E, 2006, THORAX, V61, P202, DOI 10.1136/thx.2005.052399; Vladich FD, 2005, J CLIN INVEST, V115, P747, DOI 10.1172/JCI200522818; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhou W, 2006, MICROBES INFECT, V8, P2880, DOI 10.1016/j.micinf.2006.09.007	52	88	92	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					84	90		10.1016/j.jaci.2007.04.032	http://dx.doi.org/10.1016/j.jaci.2007.04.032			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17561245	Bronze			2022-12-18	WOS:000248066400012
J	Roder, E; Berger, MY; Hop, WCJ; Bernsen, RMD; de Groot, H; van Wijk, RG				Roder, Esther; Berger, Marjolein Y.; Hop, Wim C. J.; Bernsen, Roos M. D.; de Groot, Hans; van Wijk, Roy Gerth			Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						immunotherapy; sublingual; grass pollen; allergic rhinitis; child; adolescent; primary care	PLACEBO-CONTROLLED EVALUATION; RANDOMIZED CONTROLLED-TRIAL; HOUSE-DUST MITE; QUALITY-OF-LIFE; DOUBLE-BLIND; ALLERGIC RHINITIS; SWALLOW IMMUNOTHERAPY; PEDIATRIC-PATIENTS; CHILDREN; EFFICACY	Background: Sublingual immunotherapy (SLIT) is considered safer and more convenient than subcutaneous therapy and therefore has been proposed as especially suitable for children and in primary care. Most efficacy studies in children lack power to be conclusive, and all have been performed in referral centers. Objective: To investigate the efficacy of SLIT with grass pollen allergen in children and adolescents with rhinoconjunctivitis in a primary care setting. Methods: Youngsters aged 6-18 years with hay fever were enrolled from general practices and randomly assigned to receive placebo or grass pollen mix for 2 years. The primary outcome was the mean daily total symptom score (scale 0-15) comprising sneezing, itching nose, watery running nose, nasal blockage, and itching eyes during the months May-August of the second treatment year. Results: Out of 204 youngsters randomized, 168 entered the intention-to-treat analysis (91 verum, 77 placebo). The mean daily total symptom score did not differ between participants allocated to verum and those allocated to placebo (difference for verum minus placebo: -0.08, 95% CI, -0.66-0.50; P =.78). No differences were found for rescue medication-free days, disease-specific quality of life, and overall evaluation of the treatment effect. Local side effects were more frequent in the verum group (39% vs 17% of participants; P =.001). Conclusion: Sublingual immunotherapy with grass pollen in a primary care setting is not effective in children and adolescents. Clinical implications: Currently, SLIT cannot be recommended for general practitioners as a therapeutic modality in youngsters with grass pollen allergy.	Erasmus MC Univ, Med Ctr, Sect Allergol, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands; Erasmus MC Univ, Med Ctr, Dept Gen Practice, NL-3000 CA Rotterdam, Netherlands; Erasmus MC Univ, Med Ctr, Dept Epidemiol & Biostat, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	van Wijk, RG (corresponding author), Erasmus MC Univ, Med Ctr, Sect Allergol, Dept Internal Med, POB 2040, NL-3000 CA Rotterdam, Netherlands.	r.gerthvanwijk@erasmusmc.nl						Andre C, 2000, INT ARCH ALLERGY IMM, V121, P229, DOI 10.1159/000024322; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Bodtger U, 2003, CLIN EXP ALLERGY, V33, P496, DOI 10.1046/j.1365-2222.2003.01611.x; Bousquet J, 1998, ALLERGY, V53, P4; Bousquet J, 2006, J ALLERGY CLIN IMMUN, V117, P158, DOI 10.1016/j.jaci.2005.09.047; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V101, P163, DOI 10.1016/S0091-6749(98)70380-X; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Lamberts H., 1987, INT CLASSIFICATION P; Malling HJ, 1998, ALLERGY, V53, P461; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P9; Pajno GB, 2003, CLIN EXP ALLERGY, V33, P1641, DOI 10.1111/j.1365-2222.2003.01809.x; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; Van Hoecke H, 2006, ALLERGY, V61, P705, DOI 10.1111/j.1398-9995.2006.01057.x; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; Wilson DR, 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD002893; Winther L, 2000, ALLERGY, V55, P818, DOI 10.1034/j.1398-9995.2000.00367.x; Yuksel H, 1999, J INVEST ALLERG CLIN, V9, P305	31	88	92	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					892	898		10.1016/j.jaci.2006.12.651	http://dx.doi.org/10.1016/j.jaci.2006.12.651			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17321581				2022-12-18	WOS:000245729500017
J	Kambayashi, T; Koretzky, GA				Kambayashi, Taku; Koretzky, Gary A.			Proximal signaling events in Fc epsilon RI-mediated mast cell activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						mast cell; IgE; Fc epsilon RI; allergy; cell signaling; adapter molecules; Syk	AFFINITY IGE RECEPTOR; BRUTONS TYROSINE KINASE; CYTOSOLIC PHOSPHOLIPASE A(2); IMMUNOGLOBULIN-E RECEPTOR; ADAPTER PROTEIN LAX; N-TERMINAL KINASE; NEGATIVE REGULATION; CYTOKINE PRODUCTION; INHIBITOR R112; LINKER REGION	Mast cells are central mediators of allergic diseases. Their involvement in allergic reactions is largely dependent on activation through the specific receptor for IgE (Fc epsilon RI). Crosslinking of Fc epsilon RI on mast cells initiates a cascade of signaling events that eventually results in degranulation, cytokine/chemokine production, and leukotriene release, contributing to allergic symptomology. Because of the importance of IgE in allergy, much focus has been placed on deciphering the signaling events that take place downstream of Fc epsilon RI. Studies have identified spleen tyrosine kinase as a key proximal regulator of Fc epsilon RI-mediated signaling. In this review, we discuss the multiple pathways that diverge from spleen tyrosine kinase with emphasis on the role of adapter molecules to orchestrate these signaling events. Understanding the molecular mechanisms underlying mast cell activation ideally will provide insights into the development of novel therapeutics to control allergic disease.	Univ Penn, Abramson Family Canc Res Inst, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Div Rheumatol, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Koretzky, GA (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Dept Pathol, 415 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	koretzky@mail.med.upenn.edu	Koretzky, Gary/AAU-5381-2021					Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Barker SA, 1999, J LEUKOCYTE BIOL, V65, P321, DOI 10.1002/jlb.65.3.321; BARKER SA, 1995, MOL BIOL CELL, V6, P1145, DOI 10.1091/mbc.6.9.1145; Berry DM, 2002, CURR BIOL, V12, P1336, DOI 10.1016/S0960-9822(02)01038-2; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; Borsch-Haubold AG, 1999, EUR J BIOCHEM, V265, P195, DOI 10.1046/j.1432-1327.1999.00722.x; Boudreau RTM, 2004, J LEUKOCYTE BIOL, V76, P1075, DOI 10.1189/jlb.1003498; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Costello PS, 1996, ONCOGENE, V13, P2595; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Ebinu JO, 2000, BLOOD, V95, P3199; Fang N, 1999, J BIOL CHEM, V274, P16206, DOI 10.1074/jbc.274.23.16206; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Finkelstein LD, 2004, TRENDS CELL BIOL, V14, P443, DOI 10.1016/j.tcb.2003.07.001; Furumoto Y, 2004, J BIOL CHEM, V279, P49177, DOI 10.1074/jbc.M404730200; Gomez G, 2005, J IMMUNOL, V175, P7602, DOI 10.4049/jimmunol.175.11.7602; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Guyer BJ, 2006, ALLERGY ASTHMA PROC, V27, P208, DOI 10.2500/aap.2006.27.2861; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; Hata D, 1998, J BIOL CHEM, V273, P10979, DOI 10.1074/jbc.273.18.10979; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; Hernandez-Hansen V, 2004, J IMMUNOL, V173, P100, DOI 10.4049/jimmunol.173.1.100; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Hines C, 2002, CLIN REV ALLERG IMMU, V22, P149, DOI 10.1385/CRIAI:22:2:149; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Ishiai M, 2000, J EXP MED, V192, P847, DOI 10.1084/jem.192.6.847; Ishizuka T, 1999, J IMMUNOL, V162, P2087; Ishizuka T, 1997, P NATL ACAD SCI USA, V94, P6358, DOI 10.1073/pnas.94.12.6358; Janssen E, 2004, J IMMUNOL, V172, P6810, DOI 10.4049/jimmunol.172.11.6810; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Jordan MS, 2003, NAT IMMUNOL, V4, P110, DOI 10.1038/ni0203-110; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Kawakami Y, 2000, J IMMUNOL, V165, P1210, DOI 10.4049/jimmunol.165.3.1210; Kawakami Y, 2003, P NATL ACAD SCI USA, V100, P9470, DOI 10.1073/pnas.1633695100; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Kettner A, 2003, MOL CELL BIOL, V23, P2395, DOI 10.1128/MCB.23.7.2395-2406.2003; Kim YJ, 2004, MOL CELL BIOL, V24, P9986, DOI 10.1128/MCB.24.22.9986-9999.2004; Kimura T, 1996, J BIOL CHEM, V271, P27962, DOI 10.1074/jbc.271.44.27962; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Kubo S, 2001, J IMMUNOL, V167, P3427, DOI 10.4049/jimmunol.167.6.3427; Law CL, 1996, MOL CELL BIOL, V16, P1305; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Liu Q, 2003, MOL CELL, V11, P471, DOI 10.1016/S1097-2765(03)00046-7; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Meltzer EO, 2005, J ALLERGY CLIN IMMUN, V115, P791, DOI 10.1016/j.jaci.2005.01.040; Moriya K, 1997, P NATL ACAD SCI USA, V94, P12539, DOI 10.1073/pnas.94.23.12539; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Nishizumi H, 1997, J IMMUNOL, V158, P2350; Odom S, 2004, J EXP MED, V199, P1491, DOI 10.1084/jem.20040382; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Pelletier C, 1998, INFLAMM RES, V47, P493, DOI 10.1007/s000110050364; Pivniouk VI, 1999, J CLIN INVEST, V103, P1737; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; RA C, 1989, J BIOL CHEM, V264, P15323; Rossi AB, 2006, J ALLERGY CLIN IMMUN, V118, P749, DOI 10.1016/j.jaci.2006.05.023; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Saitoh S, 2003, J EXP MED, V198, P831, DOI 10.1084/jem.20030574; Sakurai D, 2004, J IMMUNOL, V172, P2374, DOI 10.4049/jimmunol.172.4.2374; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; Silverman MA, 2006, MOL CELL BIOL, V26, P1826, DOI 10.1128/MCB.26.5.1826-1838.2006; Simon M, 2005, J BIOL CHEM, V280, P4510, DOI 10.1074/jbc.M410326200; Singer AL, 2004, J BIOL CHEM, V279, P15481, DOI 10.1074/jbc.M313339200; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Volna P, 2004, J EXP MED, V200, P1001, DOI 10.1084/jem.20041213; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Wen RR, 2002, J IMMUNOL, V169, P6743, DOI 10.4049/jimmunol.169.12.6743; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Wu JN, 2004, J IMMUNOL, V172, P6768, DOI 10.4049/jimmunol.172.11.6768; Wunderlich L, 1999, EUR J IMMUNOL, V29, P1068, DOI 10.1002/(SICI)1521-4141(199904)29:04<1068::AID-IMMU1068>3.0.CO;2-P; Xiao WB, 2005, J IMMUNOL, V175, P6885, DOI 10.4049/jimmunol.175.10.6885; Xie ZH, 2000, J IMMUNOL, V164, P1521, DOI 10.4049/jimmunol.164.3.1521; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yamamoto N, 2003, J PHARMACOL EXP THER, V306, P1174, DOI 10.1124/jpet.103.052316; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Yu M, 2006, J IMMUNOL, V176, P2421, DOI 10.4049/jimmunol.176.4.2421; Zeng R, 2003, J IMMUNOL, V171, P1360, DOI 10.4049/jimmunol.171.3.1360; Zhang J, 2002, MOL CELL BIOL, V22, P8144, DOI 10.1128/MCB.22.23.8144-8154.2002; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71; Zhu MH, 2004, J EXP MED, V200, P991, DOI 10.1084/jem.20041223; Zhu MH, 2005, J IMMUNOL, V174, P5612, DOI 10.4049/jimmunol.174.9.5612; Zhu MH, 2006, J BIOL CHEM, V281, P18408, DOI 10.1074/jbc.M601535200	96	88	95	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					544	552		10.1016/j.jaci.2007.01.017	http://dx.doi.org/10.1016/j.jaci.2007.01.017			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17336609				2022-12-18	WOS:000244925000002
J	Bae, JS; Kim, SH; Ye, YM; Yoon, HJ; Suh, CH; Nahm, DH; Park, HS				Bae, Jin-Sik; Kim, Seung-Hyun; Ye, Young-Min; Yoon, Ho Joo; Suh, Chang-Hee; Nahm, Dong-Ho; Park, Hae-Sim			Significant association of Fc epsilon RI alpha promoter polymorphisms with aspirin-intolerant chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin; hypersensitivity; chronic urticaria; high-affinity IgE receptor; genetic polymorphism	IMMUNOGLOBULIN-E; MAST-CELLS; CHAIN GENE; IGE; RECEPTOR; EXPRESSION; MAZ; HISTAMINE; SP1; SENSITIVITY	Background: Although the mechanism that underlies aspirin hypersensitivity is not completely understood, an IgE-mediated response was reported for a patient with aspirin-intolerant chronic urticaria (AICU). Objective: We investigated whether genetic polymorphisms on the a-chain of the high-affinity IgE receptor (Fc epsilon RI alpha) gene were associated with the AICU phenotype. Methods: We genotyped 2 promoter polymorphisms (-344C > T and -95T > C) of Fc epsilon RI alpha gene in the Korean population, and the functional effect of the -344C > T polymorphism was analyzed by using a luciferase reporter assay and an electrophoretic mobility shift assay. Results: The rare allele frequency of the -344C > T polymorphism was significantly higher in the patients with AICU compared with the other subjects (P = .008 for AICU vs aspirin-tolerant chronic urticaria; P = .03 for AICU vs controls). This polymorphism was also significantly associated with total serum IgE concentrations and a higher rate of atopy in the patients with AICU (P = .01 and .05, respectively). The reporter plasmid that carried the -344T allele exhibited significantly higher promoter activity in a rat mast cell line (RBL-2H3) compared with the promoter activity of the -344C allele (P < .001). We found that transcription factor Myc-associated zinc finger protein preferentially bound the -344C promoter. Moreover, patients with AICU with the heterozygous CT genotype of the -344C > T polymorphism exhibited greater anti-IgE-mediated histamine release compared with those with the homozygous CC genotype. Conclusion: These results suggest that the -344C > T polymorphism of the Fc epsilon RI alpha promoter may be associated with increased expression of Fc epsilon RI alpha on mast cells and enhanced release of histamine. Clinical implications: The Fc epsilon RI alpha -344C > T polymorphism may contribute to the development of AICU.	Ajou Univ, Dept Allergy & Rheumatol, Sch Med, Suwon 442721, South Korea; Hanyang Univ, Dept Internal Med, Sch Med, Seoul 133791, South Korea	Ajou University; Hanyang University	Park, HS (corresponding author), Ajou Univ, Dept Allergy & Rheumatol, Sch Med, San-5, Suwon 442721, South Korea.	hspark@ajou.ac.kr	Suh, Chang-Hee/H-9723-2019; Park, Hae-Sim/S-7974-2019	Suh, Chang-Hee/0000-0001-6156-393X; Park, Hae-Sim/0000-0003-2614-0303; Ye, Young-Min/0000-0002-7517-1715; Kim, Seung-Hyun/0000-0003-1789-8964				Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; BLANCA M, 1989, ANN ALLERGY, V62, P295; Borkowski TA, 2001, J IMMUNOL, V167, P1290, DOI 10.4049/jimmunol.167.3.1290; CROMWELL O, 1986, APPL IMMUNOLOGICAL M, P127; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; FURUICHI K, 1985, P NATL ACAD SCI USA, V82, P1522, DOI 10.1073/pnas.82.5.1522; Gollapudi RR, 2004, JAMA-J AM MED ASSOC, V292, P3017, DOI 10.1001/jama.292.24.3017; Grattan CEH, 2003, CLIN EXP DERMATOL, V28, P123, DOI 10.1046/j.1365-2230.2003.01228.x; Hasegawa M, 2003, J IMMUNOL, V170, P3732, DOI 10.4049/jimmunol.170.7.3732; Hasegawa M, 2003, J IMMUNOL, V171, P1927, DOI 10.4049/jimmunol.171.4.1927; HEDRICK PW, 1987, GENETICS, V117, P331; Her S, 1999, J BIOL CHEM, V274, P8698, DOI 10.1074/jbc.274.13.8698; HOIGNE RV, 1992, NSAIDS PROFILE ADVER, P157; Hsu C, 1996, IMMUNOL LETT, V52, P129, DOI 10.1016/0165-2478(96)02599-0; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Kim SH, 2006, CLIN EXP ALLERGY, V36, P877, DOI 10.1111/j.1365-2222.2006.02443.x; 예영민, 2005, 천식 및 알레르기, V25, P194; Kim SH, 2005, CLIN EXP ALLERGY, V35, P339, DOI 10.1111/j.1365-2222.2004.02197.x; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; LICHTENSTEIN LM, 1975, J IMMUNOL, V114, P1692; Parks CL, 1996, J BIOL CHEM, V271, P4417; Shikanai T, 2002, J APPL PHYSIOL, V93, P37, DOI 10.1152/japplphysiol.00993.2001; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; Song J, 1998, J BIOL CHEM, V273, P20603, DOI 10.1074/jbc.273.32.20603; Song J, 2001, J BIOL CHEM, V276, P19897, DOI 10.1074/jbc.M010658200; Suzukawa M, 2005, INT IMMUNOL, V17, P1249, DOI 10.1093/intimm/dxh301; Tanaka S, 2002, J EXP MED, V196, P229, DOI 10.1084/jem.20012037; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663	30	88	93	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					449	456		10.1016/j.jaci.2006.10.006	http://dx.doi.org/10.1016/j.jaci.2006.10.006			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17125826	Bronze			2022-12-18	WOS:000244327900025
J	Flohr, C; Tuyen, LN; Lewis, S; Quinnell, R; Minh, TT; Liem, HT; Campbell, J; Pritchard, D; Hien, TT; Farrar, J; Williams, H; Britton, J				Flohr, Carsten; Tuyen, Luc Nguyen; Lewis, Sarah; Quinnell, Rupert; Minh, Truong Tan; Liem, Ho Thanh; Campbell, Jim; Pritchard, David; Hien, Tran Tinh; Farrar, Jeremy; Williams, Hywel; Britton, John			Poor sanitation and helminth infection protect against skin sensitization in Vietnamese children: A cross-sectional study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; helminths; hygiene hypothesis; epidemiology	ATOPIC-DERMATITIS; RURAL AREA; GEOHELMINTH PARASITES; ALLERGIC REACTIVITY; SCHOOL-CHILDREN; RISK-FACTORS; PREVALENCE; SYMPTOMS; ASTHMA; URBAN	Background: Geohelminth infection and poor hygiene may be protective against allergic sensitization. Objective: To determine whether current helminth infection is associated with a reduced prevalence of allergen skin test sensitization in a Southeast Asian population of children with a high prevalence of hookworm infection. Methods: A total of 1742 Vietnamese schoolchildren were invited to take part in a cross-sectional survey. Allergen skin sensitization to house dust mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae) and American cockroach (Periplaneta americana) were measured and stool samples for qualitative and quantitative geohelminth estimation collected. Results: A total of 1601 children age 6 to 18 participated. Sensitization to dust mites was present in 14.4% and to cockroach in 27.6% of children. In a mutually adjusted model, the risk of sensitization to dust mites was reduced in those with higher hookworm burden (adjusted odds ratio [OR] for 350+ vs no eggs per gram, 0.61; 95% CI, 0.39-0.96) and with Ascaris infection (adjusted OR, 0.28; 0.10-0.78), and increased in those using flush toilets (adjusted OR for flush toilet vs none/bush/pit, 2.51; 1.00-6.28). In contrast, sensitization to cockroach was not independently related to geohelminth infection but was increased in those regularly drinking piped or well water rather than from a stream (adjusted OR, 1.33; 1.02-1.75). Conclusion: Geohelminth infection, sanitation, and water supply influence the risk of allergic sensitization in Vietnamese children. This is consistent with a protective effect against allergy by geohelminth or other gastrointestinal infection. Clinical implications: If the inverse relationship between geohelminth infection, poor sanitation, and allergic sensitization proves to be causal, drugs derived from parasite products may help to alleviate clinical allergic disease.	Univ Oxford, Hosp Trop Dis, Clin Res Unit, Ho Chi Minh City, Vietnam; Univ Nottingham, Inst Clin Res, Nottingham NG7 2RD, England; Univ Nottingham, Sch Pharmaceut Sci, Nottingham NG7 2RD, England; Khanh Hoa Provincial Ctr Malaria & Filariasis Con, Nha Trang City, Vietnam; Khanh Hoa Provincial Hlth Serv, Nha Trang City, Vietnam; Khanh Son Dist Hlth Serv, Nha Trang City, Vietnam; Univ Leeds, Fac Biol Sci, Inst Integrat & Comparat Biol, Leeds LS2 9JT, W Yorkshire, England	University of Oxford; University of Nottingham; University of Nottingham; University of Leeds	Flohr, C (corresponding author), Univ Oxford, Hosp Trop Dis, Clin Res Unit, 190 Ben Ham Tu,Dist 5, Ho Chi Minh City, Vietnam.	flohr@dng.vnn.vn	Britton, John R/G-9705-2011	williams, hywel/0000-0002-5646-3093; Farrar, Jeremy/0000-0002-2700-623X				Araujo MIAS, 2004, J INFECT DIS, V190, P1797, DOI 10.1086/425017; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Blumenthal MN, 2004, GENES IMMUN, V5, P226, DOI 10.1038/sj.gene.6364063; Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047; Cooper PJ, 2004, PARASITE IMMUNOL, V26, P455, DOI 10.1111/j.0141-9838.2004.00728.x; Cooper PJ, 2006, LANCET, V367, P1598, DOI 10.1016/S0140-6736(06)68697-2; Cooper PJ, 2004, J INFECT DIS, V190, P1338, DOI 10.1086/423944; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Cooper PJ, 2004, CLIN EXP ALLERGY, V34, P845, DOI 10.1111/j.1365-2222.2004.01958.x; Cooper PJ, 2003, AM J RESP CRIT CARE, V168, P313, DOI 10.1164/rccm.200211-1320OC; Dagoye D, 2003, AM J RESP CRIT CARE, V167, P1369, DOI 10.1164/rccm.200210-1204OC; Flohr C, 2003, BRIT J DERMATOL, V148, P871, DOI 10.1046/j.1365-2133.2003.05403.x; FLOHR C, 2006, IN PRESS AM H TROP M; Fohr C, 2005, BRIT J DERMATOL, V152, P202, DOI [10.1111/J.1365-2133.2005.06436.X, 10.1111/j.1365-2133.2004.06436.x]; HAGEL I, 1993, PARASITE IMMUNOL, V15, P311, DOI 10.1111/j.1365-3024.1993.tb00615.x; Haileamlak A, 2005, J ALLERGY CLIN IMMUN, V115, P370, DOI 10.1016/j.jaci.2004.10.024; *INT STUD ASTHM AL, 2006, CHILD CONT MOD MOD 3; Lell B, 2001, WIEN KLIN WOCHENSCHR, V113, P927; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Nga NN, 2003, PEDIAT ALLERG IMM-UK, V14, P272, DOI 10.1034/j.1399-3038.2003.00043.x; Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x; Pritchard DI, 2001, TRENDS PARASITOL, V17, P169, DOI 10.1016/S1471-4922(01)01941-9; PRITCHARD DI, 1993, INT J PARASITOL, V23, P167, DOI 10.1016/0020-7519(93)90137-N; Riley EM, 2006, PARASITE IMMUNOL, V28, P35, DOI 10.1111/j.1365-3024.2006.00775.x; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yemaneberhan H, 2004, CLIN EXP ALLERGY, V34, P779, DOI 10.1111/j.1365-2222.2004.1946.x; Yobo EODA, 1997, THORAX, V52, P161, DOI 10.1136/thx.52.2.161; 2006, RVC FAO GUIDE VET DI	31	88	92	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1305	1311		10.1016/j.jaci.2006.08.035	http://dx.doi.org/10.1016/j.jaci.2006.08.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157661				2022-12-18	WOS:000242880300015
J	Yasnowsky, KM; Dreskin, SC; Efaw, B; Schoen, D; Vedanthan, PK; Alam, R; Harbeck, RJ				Yasnowsky, Karen M.; Dreskin, Stephen C.; Efaw, Benjamin; Schoen, David; Vedanthan, P. K.; Alam, Rafeul; Harbeck, Ronald J.			Chronic urticaria sera increase basophil CD203c expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic idiopathic urticaria; autoimmunity; autoantibodies; CD203c; basophils; autologous serum skin test; flow cytometry; basophil histamine release	HISTAMINE-RELEASE; ACTIVATION; AUTOANTIBODIES; IDENTIFICATION; MARKER	Background: Approximately 40% of patients with chronic idiopathic urticaria have antibodies to the alpha subunit of the high-affinity IgE receptor. CD203c is a basophil activation marker known to be upregulated by cross-linking of the FccRI alpha receptor and may serve as a useful marker to identify these patients. Objective: The primary objective was to assess the affect of sera from patients with chronic idiopathic urticaria on basophil CD203c expression. Secondary objectives were to correlate CD203c expression with basophil histamine release and size of the autologous; serum skin test and to determine whether the mechanism is mediated by an IgG antibody. Methods: Sera were obtained from patients with chronic idiopathic urticaria and positive autologous serum skin test or negative autologous serum skin test and normal controls. Sera were incubated with donor whole blood. Activated basophils from whole blood were identified by flow cytometry on the basis of the presence of CD203c on high-expressing IgE positive cells. Results: Incubation of donor basophils with sera from patients with chronic idiopathic urticaria and positive autologous serum skin test demonstrated significant upregulation of CD203c. IgG depletion of representative sera from patients with chronic idiopathic urticaria resulted in significant decrease in CD203c expression on donor basophils. CD203c expression correlated with basophil histamine release and the size of the autologous serum skin test. Conclusion: Sera from patients with chronic idiopathic urticaria and positive autologous serum skin test significantly upregulate basophil CD203c and correlate with basophil histamine release. Clinical implications: This article describes an activation marker on basophils whose expression is increased by sera from patients with chronic idiopathic urticaria.	Natl Jewish Med & Res Ctr, Div Allergy & Clin Immunol, Denver, CO 80206 USA; Univ Colorado, Dept Med, Div Allergy & Clin Immunol, Hlth Sci Ctr, Denver, CO 80202 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Harbeck, RJ (corresponding author), Natl Jewish Med & Res Ctr, Div Allergy & Clin Immunol, 1400 Jackson st, Denver, CO 80206 USA.	harbeckr@njc.org						Binder M, 2002, INT ARCH ALLERGY IMM, V129, P160, DOI 10.1159/000065875; Boumiza R, 2003, CLIN EXP ALLERGY, V33, P259, DOI 10.1046/j.1365-2222.2003.01594.x; Buhring HJ, 2004, INT ARCH ALLERGY IMM, V133, P317, DOI 10.1159/000077351; Buhring HJ, 2001, BLOOD, V97, P3303, DOI 10.1182/blood.V97.10.3303; Ebo DG, 2004, CLIN EXP ALLERGY, V34, P332, DOI 10.1111/j.1365-2222.2004.01891.x; Ferrer M, 1999, J ALLERGY CLIN IMMUN, V104, P169, DOI 10.1016/S0091-6749(99)70129-6; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; Ghannadan M, 2002, INT ARCH ALLERGY IMM, V127, P299, DOI 10.1159/000057747; Gyimesi E, 2004, BRIT J DERMATOL, V151, P388, DOI 10.1111/j.1365-2133.2004.06042.x; Hennersdorf F, 2005, CELL RES, V15, P325, DOI 10.1038/sj.cr.7290301; Kaplan AP, 2004, J ALLERGY CLIN IMMUN, V114, P465, DOI 10.1016/j.jaci.2004.02.049; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; Monneret G, 2005, J PHARMACOL EXP THER, V312, P627, DOI 10.1124/jpet.104.074823; Sabroe RA, 1999, BRIT J DERMATOL, V140, P446; VASGAR K, 2003, J ALLERGY CLIN IMMUN, V113, pS257; Wedi B, 2000, J ALLERGY CLIN IMMUN, V105, P552, DOI 10.1067/mai.2000.104939	16	88	91	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1430	1434		10.1016/j.jaci.2006.02.016	http://dx.doi.org/10.1016/j.jaci.2006.02.016			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751009				2022-12-18	WOS:000238332300035
J	von Hertzen, L; Haahtela, T				von Hertzen, L; Haahtela, T			Disconnection of man and the soil: Reason for the asthma and atopy epidemic?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; asthma; atopy; hygiene hypothesis; saprophytes; urbanization	REGULATORY T-CELLS; TOLL-LIKE RECEPTORS; KILLED MYCOBACTERIUM-VACCAE; HAY-FEVER; ALLERGIC DISEASE; SCHOOL-CHILDREN; MACROPHAGE RESPONSE; ENDOTOXIN EXPOSURE; CHILDHOOD ASTHMA; ACID FRACTION	Intense search has been going on to find factors responsible for the asthma and atopy epidemic in Western societies. Attention has increasingly been devoted to environmental saprophytes, which, in addition to gut commensals, might be the major players in the development and fine tuning of immunologic homeostasis. This review outlines current evidence for the role of environmental saprophytes in the development of atopic disease and considers the consequences of urbanization in reducing contacts with soil microorganisms. The major microbial components that have been shown to possess immunomodulatory capacity and their respective Toll-like receptors are also discussed, as are the possible mechanisms underlying the ability of saprophytes to confer protection against atopic disease.	HUCH, Skin & Allergy Hosp, Helsinki 00029, Finland		von Hertzen, L (corresponding author), HUCH, Skin & Allergy Hosp, POB 160, Helsinki 00029, Finland.	leena.vonhertzen@kolumbus.fi						Adams VC, 2004, EUR J IMMUNOL, V34, P631, DOI 10.1002/eji.200324659; Akbari O, 2003, INT ARCH ALLERGY IMM, V130, P108, DOI 10.1159/000069012; Akira S, 2003, SCAND J INFECT DIS, V35, P555, DOI 10.1080/00365540310015683; Andersson AM, 1999, J APPL MICROBIOL, V86, P622, DOI 10.1046/j.1365-2672.1999.00706.x; [Anonymous], 1980, REV MED MICROBIOLOGY; Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V107, P531, DOI 10.1067/mai.2001.113081; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bakken L. R., 1997, Modern soil microbiology., P47; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Bjorksten B, 1998, EUR RESPIR J, V12, P432, DOI 10.1183/09031936.98.12020432; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Bohle B, 2002, INT ARCH ALLERGY IMM, V129, P198, DOI 10.1159/000066771; Boneca IG, 2005, CURR OPIN MICROBIOL, V8, P46, DOI 10.1016/j.mib.2004.12.008; Bottcher MF, 2004, J ALLERGY CLIN IMMUN, V114, P561, DOI 10.1016/j.jaci.2004.04.050; Braback L, 2004, CLIN EXP ALLERGY, V34, P38, DOI 10.1111/j.1365-2222.2004.01841.x; Braun-Fahrlander C, 2003, CURR OPIN ALLERGY CL, V3, P325, DOI 10.1097/01.all.0000092600.10871.e0; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; Brisbon N, 2005, J ALLERGY CLIN IMMUN, V115, P1024, DOI 10.1016/j.jaci.2005.02.020; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Chen Y, 2001, GENE THER, V8, P1024, DOI 10.1038/sj.gt.3301482; Cleveland MG, 1996, INFECT IMMUN, V64, P1906, DOI 10.1128/IAI.64.6.1906-1912.1996; Cooper PJ, 2004, CLIN EXP ALLERGY, V34, P845, DOI 10.1111/j.1365-2222.2004.01958.x; Cottrez F, 2000, J IMMUNOL, V165, P4848, DOI 10.4049/jimmunol.165.9.4848; de Lafaille MAC, 2001, J EXP MED, V194, P1349, DOI 10.1084/jem.194.9.1349; de Lafaille MAC, 2004, SPRINGER SEMIN IMMUN, V25, P295, DOI 10.1007/s00281-003-0144-0; DRUTZ DJ, 1994, BASIC CLIN IMMUNOL, P649; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eder W, 2004, CURR OPIN ALLERGY CL, V4, P113, DOI 10.1097/01.all.0000123970.96233.fc; FRANKLAND AW, 1955, BRIT MED J, V2, P941, DOI 10.1136/bmj.2.4945.941; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Garrity G. M., 2001, BERGEYS MANUAL SYSTE, V2; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; GISI U, 1997, BODENOKOLOGIE; Gruber C, 2002, CLIN EXP ALLERGY, V32, P526, DOI 10.1046/j.0954-7894.2002.01331.x; Haileamlak A, 2005, J ALLERGY CLIN IMMUN, V115, P370, DOI 10.1016/j.jaci.2004.10.024; Hall G, 2003, VACCINE, V21, P549, DOI 10.1016/S0264-410X(02)00394-8; Hauswirth DW, 2004, CURR OPIN ALLERGY CL, V4, P361, DOI 10.1097/00130832-200410000-00006; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; Heine H, 2003, INT ARCH ALLERGY IMM, V130, P180, DOI 10.1159/000069517; Horner AA, 2002, J ALLERGY CLIN IMMUN, V110, P706, DOI 10.1067/mai.2002.129122; Horner AA, 2004, CURR OPIN ALLERGY CL, V4, P555, DOI 10.1097/00130832-200412000-00014; Hussain I, 2004, J INVEST DERM SYMP P, V9, P23, DOI 10.1111/j.1087-0024.2004.00828.x; Isolauri E, 2004, CURR ALLERGY ASTHM R, V4, P270, DOI 10.1007/s11882-004-0070-9; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Kabesch M, 2004, J LEUKOCYTE BIOL, V75, P383, DOI 10.1189/jlb.1003468; Kalliomaki M, 2003, CURR OPIN ALLERGY CL, V3, P15, DOI [10.1097/00130832-200302000-00003, 10.1097/01.all.0000053262.39029.a1]; KALYONCU AF, 1992, ALLERGY, V47, P277, DOI 10.1111/j.1398-9995.1992.tb02053.x; KELLER R, 1992, INFECT IMMUN, V60, P3664, DOI 10.1128/IAI.60.9.3664-3672.1992; KELLER R, 1994, IMMUNOLOGY, V81, P161; Kemp A, 2003, PEDIAT ALLERG IMM-UK, V14, P74, DOI 10.1034/j.1399-3038.2003.00017.x; Kitagaki K, 2002, CLIN DIAGN LAB IMMUN, V9, P1260, DOI 10.1128/CDLI.9.6.1260-1269.2002; Latvala J, 2005, BMJ-BRIT MED J, V330, P1186, DOI 10.1136/bmj.38448.603924.AE; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Le Souef PN, 2000, LANCET, V356, P242; Liesack W., 1997, Modern soil microbiology., P375; Lindstrom ES, 2005, AQUAT SCI, V67, P210, DOI 10.1007/s00027-005-0769-2; Linneberg A, 2005, ALLERGY, V60, P538, DOI 10.1111/j.1398-9995.2005.00721.x; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Liu Y, 2003, SOLID STATE ELECTRON, V47, P1, DOI 10.1016/S0038-1101(02)00310-6; Matricardi PM, 2003, ALLERGY, V58, P461, DOI 10.1034/j.1398-9995.2003.00175.x; Matricardi PM, 2003, CLIN EXP ALLERGY, V33, P717, DOI 10.1046/j.1365-2222.2003.01695.x; McGuirk P, 2002, TRENDS IMMUNOL, V23, P450, DOI 10.1016/S1471-4906(02)02288-3; Mills KHG, 2004, SEMIN IMMUNOL, V16, P107, DOI 10.1016/j.smim.2003.12.006; Netea MG, 2004, J LEUKOCYTE BIOL, V75, P749, DOI 10.1189/jlb.1103543; Netea MG, 2004, J IMMUNOL, V172, P3712, DOI 10.4049/jimmunol.172.6.3712; Netea MG, 2002, TRENDS IMMUNOL, V23, P135, DOI 10.1016/S1471-4906(01)02169-X; Netea MG, 2004, EUR J CLIN MICROBIOL, V23, P672, DOI 10.1007/s10096-004-1192-7; Nilsson L, 1999, ALLERGY, V54, P716, DOI 10.1034/j.1398-9995.1999.00896.x; Ogden NS, 2005, CURR OPIN ALLERGY CL, V5, P179, DOI 10.1097/01.all.0000162312.64308.fc; Perzanowski MS, 2002, J PEDIATR-US, V140, P582, DOI 10.1067/mpd.2002.122937; Pisetsky DS, 2000, CLIN IMMUNOL, V96, P198, DOI 10.1006/clim.2000.4897; Raby BA, 2002, AM J RESP CRIT CARE, V166, P1449, DOI 10.1164/rccm.200207-634OC; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Re F, 2004, J IMMUNOL, V173, P7548, DOI 10.4049/jimmunol.173.12.7548; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Ring J, 2001, CURR OPIN IMMUNOL, V13, P701, DOI 10.1016/S0952-7915(01)00282-5; Ronchetti R, 2001, EUR RESPIR J, V17, P881, DOI 10.1183/09031936.01.17508810; Rook GAW, 2004, SPRINGER SEMIN IMMUN, V25, P237, DOI 10.1007/s00281-003-0148-9; Roy SR, 2003, J ALLERGY CLIN IMMUN, V112, P571, DOI 10.1067/mai.2003.1711; Santamaria J, 2003, INT MICROBIOL, V6, P5, DOI 10.1007/s10123-003-0096-1; Seydel U, 2003, EUR J IMMUNOL, V33, P1586, DOI 10.1002/eji.200323649; Seydel U, 2000, CHEM IMMUNOL, V74, P5; Smit JJ, 2004, CURR OPIN ALLERGY CL, V4, P57, DOI [10.1097/00130832-200402000-00012, 10.1097/01.all.0000113680.18759.17]; Smits HH, 2005, J ALLERGY CLIN IMMUN, V115, P1260, DOI 10.1016/j.jaci.2005.03.036; STANIER RY, 1972, GEN MICROBIOLOGY; SUDA Y, 1995, FEMS IMMUNOL MED MIC, V12, P97, DOI 10.1111/j.1574-695X.1995.tb00181.x; Takabayashi K, 2003, J IMMUNOL, V170, P3898, DOI 10.4049/jimmunol.170.7.3898; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; THOM G, 1997, MODERN SOIL MICROBIO, P63; TOIVOLA M, 2004, THESIS U KUOPIO; TOKUNAGA T, 1984, J NATL CANCER I, V72, P955; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Van Uden J, 1999, J ALLERGY CLIN IMMUN, V104, P902, DOI 10.1016/S0091-6749(99)70066-7; Verlato G, 2003, J ALLERGY CLIN IMMUN, V111, P1232, DOI 10.1067/mai.2003.1484; Viinanen A, 2005, ALLERGY, V60, P1370, DOI 10.1111/j.1398-9995.2005.00877.x; VIINANEN A, 2004, THESIS U TURKU; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Hertzen L, 2006, J ALLERGY CLIN IMMUN, V117, P151, DOI 10.1016/j.jaci.2005.07.028; von Hertzen LC, 2004, ALLERGY, V59, P124, DOI 10.1046/j.1398-9995.2003.00433.x; von Mutius E, 2004, J ALLERGY CLIN IMMUN, V113, P373, DOI 10.1016/j.jaci.2003.12.040; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Waser M, 2005, ALLERGY, V60, P177, DOI 10.1111/j.1398-9995.2004.00645.x; WESTPHAL O, 1954, ANGEW CHEM-GER EDIT, V66, P407, DOI 10.1002/ange.19540661312; Wild JS, 2001, ALLERGY, V56, P365, DOI 10.1034/j.1398-9995.2001.056005365.x; Williams DL, 1997, MEDIAT INFLAMM, V6, P247, DOI 10.1080/09629359791550; YAMAMOTO S, 1992, MICROBIOL IMMUNOL, V36, P983, DOI 10.1111/j.1348-0421.1992.tb02102.x; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; Young IM, 2004, SCIENCE, V304, P1634, DOI 10.1126/science.1097394; Yura A, 2001, BRIT J DERMATOL, V145, P966, DOI 10.1046/j.1365-2133.2001.04506.x; Zuany-Amorim C, 2002, J IMMUNOL, V169, P1492, DOI 10.4049/jimmunol.169.3.1492; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	119	88	91	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					334	344		10.1016/j.jaci.2005.11.013	http://dx.doi.org/10.1016/j.jaci.2005.11.013			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461134				2022-12-18	WOS:000235687300016
J	Romagnani, P; Maggi, L; Mazzinghi, B; Cosmi, L; Lasagni, L; Liotta, F; Lazzeri, E; Angeli, R; Rotondi, M; Fili, L; Parronchi, P; Serio, M; Maggi, E; Romagnani, S; Annunziato, F				Romagnani, P; Maggi, L; Mazzinghi, B; Cosmi, L; Lasagni, L; Liotta, F; Lazzeri, E; Angeli, R; Rotondi, M; Fili, L; Parronchi, P; Serio, M; Maggi, E; Romagnani, S; Annunziato, F			CXCR3-mediated opposite effects of CXCL10 and CXCL4 on T(H)1 or T-H cytokine production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CXCR3; T(H)1; T(H)2; CXCL10; CXCL4; GATA-3; T-bet; immune deviation	CYCLIC-AMP; IFN-GAMMA; CHEMOKINE RECEPTORS; PLATELET ACTIVATION; PROTEIN-KINASE; TH2 CELLS; EXPRESSION; IP-10; CXCR3; LYMPHOCYTES	Background: Two variants of the CXCR3 receptor exist, one (CXCR3-A) reactive with CXCL9, CXCL10, and CXCL11 and the other (CXCR3-B) also reactive with CXCL4. Both variants are contemporarily expressed by human T cells. Objective: We sought to investigate the in vitro effects of CXCL10 and CXCL4 on the production of T(H)1 or T(H)2 cytokines. Methods: The cytokine profile of antigen-specific human CD4(+) T-cell lines obtained in the absence or presence of CXCL10 or CXCL4 was evaluated by means of quantitative RT-PCR, flow cytometry, and ELISA. Results: CXCL10 upregulated IFN-gamma and downregulated IL-4, IL-5, and IL-13 production, whereas CXCL4 downregulated IFN-gamma and upregulated TH2 cytokines. Similar effects were also observed on polyclonally activated pure naive CD4+ T cells. The opposite effects of CXCL10 and CXCL4 on TH1 and TH2 cytokine production were inhibited by an anti-CXCR3 antibody able to neutralize both CXCR3-A and CXCR3-B and were apparently related to the activation of distinct signal transduction pathways. Moreover, CXCL10 upregulated mRNA levels of T-box expressed in T cells and downregulated GATA-3 expression, whereas CXCL4 downregulated T-box expressed in T cells and upregulated GATA-3. Finally, CXCL4, but not CXCL10, induced direct activation of IL-5 and IL-13 promoters. Conclusion: CXCL10 and CXCL4 exert opposite effects on the production of human TH1 and TH2 cytokines, likely through their respective interaction with CXCR3-A or CXCR3-B and the consequent activation of different signal transduction pathways. This might represent an internal regulatory pathway of T-H cell responses and might contribute to the modulation of chronic inflammatory reactions, including allergy.	Univ Florence, Ctr Res Transfer & High Educ DENOthe, Dept Internal Med, I-50134 Florence, Italy	University of Florence	Romagnani, S (corresponding author), Univ Florence, Ctr Res Transfer & High Educ DENOthe, Dept Internal Med, Viale Morgagni 85, I-50134 Florence, Italy.	s.romagnani@dmi.unifi.it	Rotondi, Mario/K-5250-2016; Annunziato, Francesco/C-1155-2013; Maggi, Enrico/AAA-8045-2019; Mazzinghi, Benedetta/K-1120-2018; Lasagni, Laura/J-6856-2018; Parronchi, Paola/AAE-5422-2022; Romagnani, Paola/A-4309-2008; Maggi, Laura/B-6693-2013	Rotondi, Mario/0000-0001-6464-2334; Maggi, Enrico/0000-0002-1824-3583; Mazzinghi, Benedetta/0000-0003-2809-5622; Lasagni, Laura/0000-0001-6553-9160; Parronchi, Paola/0000-0002-9184-5089; Romagnani, Paola/0000-0002-1774-8088; Maggi, Laura/0000-0003-2862-9591; LAZZERI, Elena/0000-0002-9505-2115; Annunziato, Francesco/0000-0001-8798-7589				Annunziato F, 1999, J LEUKOCYTE BIOL, V65, P691, DOI 10.1002/jlb.65.5.691; AVERILL FJ, 1992, AM REV RESPIR DIS, V145, P571, DOI 10.1164/ajrccm/145.3.571; Baggiolini M, 2000, IMMUNOL TODAY, V21, P418, DOI 10.1016/S0167-5699(00)01672-8; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Brugnolo F, 2003, J ALLERGY CLIN IMMUN, V111, P380, DOI 10.1067/mai.2003.102; Bryce PJ, 1999, IMMUNOPHARMACOLOGY, V41, P139, DOI 10.1016/S0162-3109(98)00060-5; Chen CH, 2000, J IMMUNOL, V165, P5597, DOI 10.4049/jimmunol.165.10.5597; Fleischer J, 2002, J IMMUNOL, V169, P770, DOI 10.4049/jimmunol.169.2.770; Gangur V, 1998, FASEB J, V12, P705, DOI 10.1096/fasebj.12.9.705; Inngjerdingen M, 2001, BLOOD, V97, P367, DOI 10.1182/blood.V97.2.367; Lantelme E, 2001, IMMUNOLOGY, V102, P123, DOI 10.1046/j.1365-2567.2001.01168.x; Lasagni L, 2003, J EXP MED, V197, P1537, DOI 10.1084/jem.20021897; LUSTER AD, 1987, MOL CELL BIOL, V7, P3723, DOI 10.1128/MCB.7.10.3723; MCLAREN KM, 1980, THROMB RES, V19, P293, DOI 10.1016/0049-3848(80)90431-4; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; Romagnani P, 1999, J AM SOC NEPHROL, V10, P2518; Romagnani P, 2001, J CLIN INVEST, V107, P53, DOI 10.1172/JCI9775; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Wang JH, 2003, J BIOL CHEM, V278, P37622, DOI 10.1074/jbc.M301224200; YAMAMOTO H, 1993, J ALLERGY CLIN IMMUN, V91, P79, DOI 10.1016/0091-6749(93)90299-U; Zhang Y, 2004, FASEB J, V18, pA232; Zhu H, 2001, J IMMUNOL, V167, P855, DOI 10.4049/jimmunol.167.2.855; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128	23	88	97	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1372	1379		10.1016/j.jaci.2005.09.035	http://dx.doi.org/10.1016/j.jaci.2005.09.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337473				2022-12-18	WOS:000235687000032
J	Gomes, I; Mathur, SK; Espenshade, BM; Mori, Y; Varga, J; Ackerman, SJ				Gomes, I; Mathur, SK; Espenshade, BM; Mori, Y; Varga, J; Ackerman, SJ			Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: Implications in fibrogenesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; fibrosis; IL-1 alpha; IL-1 beta; IL-5; IL-6; TGF-beta; fibionectin; PAI-1; TIMP-1	GROWTH-FACTOR-BETA; AIRWAY INFLAMMATION; PULMONARY-FIBROSIS; TRANSGENIC MICE; LUNG INJURY; TGF-BETA; INTERLEUKIN-6; SKIN; TRANSCRIPTION; STIMULATION	Background: Eosinophils are frequently associated with tissue remodeling and fibrosis in allergic and other diseases and animal models. Their close physical proximity to fibroblasts at sites of tissue remodeling strongly implicates them in fibrogenesis, including subepithelial fibrosis and airway remodeling characteristic of asthma. Objective: To identify the mediators and characterize the mechanisms underlying the fibrogenic activities of eosinophils. Methods: A coculture system of blood eosinophils or eosinophil cell lines with normal fibroblasts was used to assess their ability to induce a fibrogenic fibroblast phenotype, including IL-6 secretion and mRNA expression, and induction of genes involved in extracellular matrix production and homeostasis. The mediators of these responses were identified by using transwell barrier cocultures, eosinophil-conditioned media, and cytokine-specific antibody neutralization. Results: Eosinophil-fibroblast coculture induced potent fibroblast IL-6 secretion and mRNA expression, responses further enhanced by IL-5. The soluble nature of the eosinophilderived mediators was demonstrated by using eosinophil-fibroblast coculture in the presence of permeable transwell barriers, and fibroblast culture in eosinophil-conditioned media, indicating that cell contact was not required. Induction of fibroblast IL-6 expression was accompanied by increased expression of fibronectin and the extracellular matrix regulatory genes plasminogen activator inhibitor 1 and tissue inhibitor of metalloproteinase 1. Antibody neutralization identified the principal eosinophil-derived mediator of fibroblast IL-6 expression as IL-1 beta (> 60%), with lesser contributions from IL-1 alpha, IL-4, and TGF-beta (10% to 20%). Conclusion: Eosinophils express at least 2 potent mediators (IL-1 beta and TGF-beta) that induce a fibrogenie fibroblast phenotype, strongly supporting a role for the eosinophil in the dysregulation of extracellular matrix homeostasis and consequent tissue remodeling and fibrosis in eosinophilassociated diseases.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Med, Rheumatol Sect, Chicago, IL 60607 USA; Univ Wisconsin, Sect Allergy & Immunol, Dept Med, Madison, WI 53706 USA; St Joseph Reg Med Ctr, South Bend, IN USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Wisconsin System; University of Wisconsin Madison	Ackerman, SJ (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, MC669,Mol Biol Res Bldg,Rm 2074,900 S Ashland Ave, Chicago, IL 60607 USA.	sackerma@uic.edu	Varga, John/AAK-6472-2021		NCRR NIH HHS [M01-RR-13987] Funding Source: Medline; NIAID NIH HHS [AI25230] Funding Source: Medline; NIAMS NIH HHS [AR42309] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR013987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042309] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baumann MA, 1998, STEM CELLS, V16, P16, DOI 10.1002/stem.160016; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; DICOSMO B, 1995, CHEST, V107, pS131, DOI 10.1378/chest.107.3_Supplement.131S; Du J, 2000, J BIOL CHEM, V275, P33167, DOI 10.1074/jbc.M003655200; Eddy AA, 2000, PEDIATR NEPHROL, V15, P290, DOI 10.1007/s004670000461; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; FRIES KM, 1994, AM J RESP CELL MOL, V11, P552, DOI 10.1165/ajrcmb.11.5.7946384; Gharaee-Kermani M, 1998, INT J MOL MED, V1, P43; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Kayano K, 2000, J GASTROENTEROL, V35, P250, DOI 10.1007/s005350050339; Kolb M, 2001, J CLIN INVEST, V107, P1529, DOI 10.1172/JCI12568; Kuhn C, 2000, AM J RESP CELL MOL, V22, P289, DOI 10.1165/ajrcmb.22.3.3690; Lacy P, 2000, CHEM IMMUNOL, V76, P134; Lacy P, 2001, CURR OPIN ALLERGY CL, V1, P79, DOI 10.1097/01.all.0000010989.39379.49; Levi-Schaffer F, 1999, P NATL ACAD SCI USA, V96, P9660, DOI 10.1073/pnas.96.17.9660; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Loskutoff DJ, 2000, J CLIN INVEST, V106, P1441, DOI 10.1172/JCI11765; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Natsume M, 1999, J LEUKOCYTE BIOL, V66, P601, DOI 10.1002/jlb.66.4.601; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; Pawluczyk IZA, 1998, KIDNEY INT, V54, P62, DOI 10.1046/j.1523-1755.1998.00965.x; Phipps S, 2002, J IMMUNOL, V169, P4604, DOI 10.4049/jimmunol.169.8.4604; Rochester CL, 1996, J IMMUNOL, V156, P4449; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Roy SG, 2001, INT J BIOCHEM CELL B, V33, P723, DOI 10.1016/S1357-2725(01)00041-3; Sato S, 2001, J DERMATOL SCI, V27, P140, DOI 10.1016/S0923-1811(01)00128-1; Smith RE, 1998, J LEUKOCYTE BIOL, V64, P528, DOI 10.1002/jlb.64.4.528; TAI PC, 1987, LANCET, V1, P643; VARGA J, 1995, ANN INTERN MED, V122, P60, DOI 10.7326/0003-4819-122-1-199501010-00010; Varga John, 1997, Current Opinion in Rheumatology, V9, P562, DOI 10.1097/00002281-199711000-00013; Vesey DA, 2002, J LAB CLIN MED, V140, P342, DOI 10.1067/mlc.2002.128468; Zhang HY, 1997, J IMMUNOL, V158, P1392; Zhang HY, 1999, AM J RESP CELL MOL, V21, P658, DOI 10.1165/ajrcmb.21.6.3720	35	88	94	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					796	804		10.1016/j.jaci.2005.06.031	http://dx.doi.org/10.1016/j.jaci.2005.06.031			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210053				2022-12-18	WOS:000235686600013
J	Ponikau, JU; Sherris, DA; Kephart, GM; Kern, EB; Congdon, DJ; Adolphson, CR; Springett, MJ; Gleich, GJ; Kita, H				Ponikau, JU; Sherris, DA; Kephart, GM; Kern, EB; Congdon, DJ; Adolphson, CR; Springett, MJ; Gleich, GJ; Kita, H			Striking deposition of toxic eosinophil major basic protein in mucus: Implications for chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; chronic rhinosinusitis; mucus; degranulation; major basic protein	SINUSITIS; LOCALIZATION; INFLAMMATION; NEUTROPHIL	Background: The mechanisms by which eosinophilic inflammation damages the epithelium and contributes to recurrent acute exacerbations in chronic rhinosinusitis (CRS) have not been fully elucidated. Objective: We tested the hypotheses that eosinophils deposit toxic major basic protein (MBP) in the mucus and that MBP reaches concentrations able to damage the sinonasal epithelium. Methods: Tissue specimens with mucus attached to the tissue were carefully collected from 22 patients with CRS and examined by using immuninfluorescence staining for MBP. This immuninfluorescence was digitally analyzed to determine the area covered by MBP and the intensity of the staining (estimating MBP concentration). Levels of MBP in extracts from nasal mucus were quantitated by means of RIA. Results: Heterogeneous eosinophilia was evident within tissue and mucus specimens. All tissue specimens showed intact eosinophils, but diffuse extracellular MBP deposition, as a marker of eosinophil degranulation, was rare. In contrast, all mucus specimens showed diffuse MBP throughout and abundant diffuse extracellular MBP deposition within clusters of eosinophils. Digitized analyses of MBP immunofluorescence revealed increased area coverage (P < .0001) in mucus compared with that seen in tissue. Estimated concentrations of MBP within the clusters suggested toxic levels. MBP concentrations in mucus extract reached 11.7 mu g/mL; MBP was not detectable in healthy control subjects. Conclusion: In patients with CRS, eosinophils form clusters in the mucus where they release MBP, which is diffusely deposited on the epithelium, a process not observed in the tissue. Estimated MBP levels far exceed those needed to damage epithelium from the luminal side and could predispose patients with CRS to secondary bacterial infections.	Mayo Clin & Mayo Fdn, Dept Otorhinolaryngol, Dept Otorhinolaryngol Head & Neck Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Div Allerg Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; SUNY Buffalo, Dept Otorhinolaryngol, Buffalo, NY 14260 USA; Univ Utah, Dept Dermatol, Salt Lake City, UT USA; Univ Utah, Dept Med, Salt Lake City, UT USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Ponikau, JU (corresponding author), Mayo Clin & Mayo Fdn, Dept Otorhinolaryngol, Dept Otorhinolaryngol Head & Neck Surg, 200 1st St SW, Rochester, MN 55905 USA.	ponikau.jens@imyo.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009728, R56AI049235, R01AI049235, R37AI009728] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 49235, AI09728] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; Braun H, 2003, LARYNGOSCOPE, V113, P264, DOI 10.1097/00005537-200302000-00013; DUNNETTE SL, 1986, J ALLERGY CLIN IMMUN, V78, P102, DOI 10.1016/0091-6749(86)90121-1; Erjefalt JS, 2000, AM J RESP CRIT CARE, V161, P2074, DOI 10.1164/ajrccm.161.6.9906085; FILLEY WV, 1982, LANCET, V2, P11; FILLEY WV, 1981, J IMMUNOL METHODS, V47, P227, DOI 10.1016/0022-1759(81)90123-X; FRIGAS E, 1980, LAB INVEST, V42, P35; FUJISAWA T, 1990, AM REV RESPIR DIS, V141, P689, DOI 10.1164/ajrccm/141.3.689; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.me.44.020193.000505; GLIKLICH RE, 1995, OTOLARYNG HEAD NECK, V113, P104, DOI 10.1016/S0194-5998(95)70152-4; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; Kalcioglu MT, 2003, AM J RHINOL, V17, P143, DOI 10.1177/194589240301700306; Kaliner MA, 1997, OTOLARYNG HEAD NECK, V116, pS1; KEPHART GM, 1984, LAB INVEST, V50, P51; KITA H, 2003, MIDDLETONS ALLERGY P, P305; LETHBRIDGECEJKU.M, 2004, VITAL HLTH STAT, V10, P23; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Nadel DM, 1998, AM J RHINOL, V12, P233, DOI 10.2500/105065898781390000; OTT NL, 1994, J ALLERGY CLIN IMMUN, V94, P120, DOI 10.1016/0091-6749(94)90078-7; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; Ponikau JU, 2003, J ALLERGY CLIN IMMUN, V112, P877, DOI 10.1016/j.jaci.2003.08.009; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; Popken-Harris P, 1998, BLOOD, V92, P623, DOI 10.1182/blood.V92.2.623.414k32_623_631; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P408, DOI 10.1016/S0091-6749(99)70464-1; WAGNER JM, 1993, PLACENTA, V14, P671, DOI 10.1016/S0143-4004(05)80384-4	26	88	98	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					362	369		10.1016/j.jaci.2005.03.049	http://dx.doi.org/10.1016/j.jaci.2005.03.049			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083791				2022-12-18	WOS:000235686400019
J	Ebeling, C; Forsythe, P; Ng, J; Gordon, JR; Hollenberg, M; Vliagoftis, H				Ebeling, C; Forsythe, P; Ng, J; Gordon, JR; Hollenberg, M; Vliagoftis, H			Proteinase-activated receptor 2 activation in the airways enhances antigen-mediated airway inflammation and airway hyperresponsiveness through different pathways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						proteinase-activated receptor 2; allergy; rodent; airway inflammation; eosinophils; IL-13	MICROVASCULAR ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; MITE ALLERGENS; MAST-CELLS; ASTHMA; HYPERREACTIVITY; TRYPTASE; RELEASE; SENSITIZATION; INDUCTION	Background: Serine proteinases such as mast cell tryptase, trypsin-like enzymes, and certain allergens are important in the pathogenesis of asthma. These proteinases can activate the proteinase-activated receptor (PAR)-2, which has been shown to be upregulated in the airways of patients with asthma. Objective: The purpose of this study was to investigate PAR-2 activation in the airways during allergen challenge and its effects on the 2 principle features of asthma, airway inflammation and airway hyperresponsiveness (AHR). Methods: Proteinase-activated receptor 2 activating peptide SLIGRL-NH2 (PAR-2 activating peptide [ap]) or control peptide LSIGRL-NH2 (PAR-2 control peptide [cp]) was administered alone or in conjunction with ovalbumin intranasally to mice, and AHR and airway inflammation were evaluated. Results: PAR2ap did not induce AHR or airway inflammation in ovalbumin-sensitized mice that had not been challenged with ovalbumin. When administered with ovalbumin, PAR-2ap enhanced AHR and airway inflammation compared with ovalbumin administered alone or with PAR-2cp. The enhanced AHR persisted for 5 days, whereas the enhancement to airway inflammation dissipated. Mice administered PAR-2ap alone during the 5 days after the final antigen challenge demonstrated an additional enhancement to airway inflammation compared with the control animals. PAR-2ap administered with allergen increased TNF and IL-5 mRNA in lung tissue and IL-13 and TNF in bronchoalveolar lavage fluid. Conclusion: Exogenous PAR-2 activation in parallel with allergen challenge enhances allergen-mediated AHR and airway inflammation through distinct mechanisms. PAR-2 activation can also enhance established airway inflammation even when dissociated from exposure to allergen. Therefore, PAR-2 activation may play a pathogenic role in the development of AHR and airway inflammation.	Univ Alberta, Pulm Res Grp, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Saskatchewan, Immunol Res Grp, Saskatoon, SK, Canada; Univ Calgary, Dept Therapeut & Pharmacol, Calgary, AB, Canada	University of Alberta; University of Saskatchewan; University of Calgary	Vliagoftis, H (corresponding author), Univ Alberta, Pulm Res Grp, Dept Med, 550 HMRC, Edmonton, AB T6G 2S2, Canada.	harissios.vliagoftis@ualberta.ca	Hollenberg, Morley/AFV-6966-2022; Gordon, John/D-7621-2013; Vliagoftis, Harissis/C-6480-2013	Vliagoftis, Harissis/0000-0002-5029-855X; Gordon, John/0000-0003-3830-8070				Al-Ani B, 1999, J PHARMACOL EXP THER, V290, P753; Asokananthan N, 2002, J IMMUNOL, V169, P4572, DOI 10.4049/jimmunol.169.8.4572; Barrios VE, 2003, BIOCHEM PHARMACOL, V66, P519, DOI 10.1016/S0006-2952(03)00292-2; Berger P, 1999, CLIN EXP ALLERGY, V29, P804; Cenac N, 2002, AM J PATHOL, V161, P1903, DOI 10.1016/S0002-9440(10)64466-5; Chow JM, 2000, BRIT J PHARMACOL, V131, P1584, DOI 10.1038/sj.bjp.0703738; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Compton SJ, 2001, BRIT J PHARMACOL, V134, P705, DOI 10.1038/sj.bjp.0704303; Forsythe P, 2004, AM J RESP CRIT CARE, V169, P220, DOI 10.1164/rccm.200307-979OC; Gordon JR, 2000, CELL IMMUNOL, V205, P128, DOI 10.1006/cimm.2000.1714; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Haraldsen G, 1996, J IMMUNOL, V156, P2558; Hewitt CRA, 1998, ALLERGY, V53, P60, DOI 10.1111/j.1398-9995.1998.tb05000.x; Kauffman HF, 2003, CURR ALLERGY ASTHM R, V3, P430, DOI 10.1007/s11882-003-0080-z; Klarenbach SW, 2003, CIRC RES, V92, P272, DOI 10.1161/01.RES.0000057386.15390.A3; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797, DOI 10.1067/mai.2001.119025; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Miike S, 2001, J IMMUNOL, V167, P6615, DOI 10.4049/jimmunol.167.11.6615; Ricciardolo FLM, 2000, AM J RESP CRIT CARE, V161, P1672, DOI 10.1164/ajrccm.161.5.9907133; Schmidlin F, 2002, J IMMUNOL, V169, P5315, DOI 10.4049/jimmunol.169.9.5315; Schneider AM, 2001, CELL IMMUNOL, V212, P101, DOI 10.1006/cimm.2001.1854; SCHWARTZ LB, 1990, J ALLERGY CLIN IMMUN, V86, P594, DOI 10.1016/S0091-6749(05)80222-2; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; Shen HD, 1999, INT ARCH ALLERGY IMM, V119, P259, DOI 10.1159/000024202; Shpacovitch VM, 2002, J INVEST DERMATOL, V118, P380, DOI 10.1046/j.0022-202x.2001.01658.x; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Sun G, 2001, J IMMUNOL, V167, P1014, DOI 10.4049/jimmunol.167.2.1014; Vergnolle N, 1999, BRIT J PHARMACOL, V127, P1083, DOI 10.1038/sj.bjp.0702634; Vergnolle N, 2001, NAT MED, V7, P821, DOI 10.1038/89945; Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058; Vliagoftis H, 2001, J ALLERGY CLIN IMMUN, V107, P679, DOI 10.1067/mai.2001.114245; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Yang M, 2001, AM J RESP CELL MOL, V25, P522, DOI 10.1165/ajrcmb.25.4.4620; Yawn BP, 1999, J ALLERGY CLIN IMMUN, V103, P54, DOI 10.1016/S0091-6749(99)70525-7	36	88	91	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					623	630		10.1016/j.jaci.2004.11.042	http://dx.doi.org/10.1016/j.jaci.2004.11.042			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753914	Bronze			2022-12-18	WOS:000227687000029
J	Page, K; Strunk, VS; Hershenson, MB				Page, K; Strunk, VS; Hershenson, MB			Cockroach proteases increase IL-8 expression in human bronchial epithelial cells via activation of protease-activated receptor (PAR)-2 and extracellular-signal-regulated kinase	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Blattella germanica; mitogen-activated protein kinase; serine protease; tumor necrosis factor-alpha	RESPIRATORY SYNCYTIAL VIRUS; TRANSCRIPTION FACTOR; THROMBIN RECEPTOR; INTERLEUKIN-8 GENE; MOLECULAR-CLONING; AIRWAY EPITHELIUM; SMOOTH-MUSCLE; MAP KINASES; MECHANISM; RELEASE	Background: We have shown that serine proteases in German cockroach extract increase TNF-alpha-induced expression of IL-8 in human bronchial epithelial cells. The mechanism by which cockroach proteases regulate cytokine expression is unknown; however, protease-activated receptors (PARs) might play a role. Objective: We sought to determine the role of PARs and extra cellular-signal-regulated kinase (ERK) in cockroach-induced regulation of IL-8 expression. Methods: 16HBE14o- human bronchial epithelial cells were treated with the specific PAR-1 and PAR-2 agonists, TFRIFD and SLIGKV, respectively. IL-8 transcription was assessed by transiently transfecting cells with a luciferase-tagged IL-8 promoter construct, and in some cases, dominant-negative expression vectors. To block PAR cleavage, antibodies against the cleavage region of PAR-1 and PAR-2 were used. ERK phosphorylation was determined by Western blot. Results: Although both PAR-1 and PAR-2 were endogenously expressed in 16HBE14o- cells, selective activation of PAR-2 but not PAR-1 mimicked the effect of cockroach extract on IL-8 expression. Using a blocking antibody against cleavage of PAR-2 but not PAR-1 attenuated cockroach-extract-induced responses, suggesting that cockroach proteases cleave PAR-2. Treatment of cells with cockroach extract and SLIGKV each increased phosphorylation of ERK. Chemical or genetic inhibition of Ras and mitogen-activated protein kinase/ERK (MEK), upstream activators of ERK, each attenuated cockroach- and PAR-2-induced IL-8 transcription. Conclusion: Cockroach proteases and PAR-2 activation synergistically increase TNF-alpha-induced IL-8 transcription via activation of ERK. These data suggest an important role for PAR-2 and ERK activation in the regulation of cytokine expression in airway epithelium in response to cockroach proteases.	Childrens Hosp, Div Crit Care Med, Dept Pediat, Cincinnati, OH 45229 USA; Univ Michigan, Dept Pediat & Communicable Dis, Div Pediat Pulmonol, Ann Arbor, MI 48109 USA	Cincinnati Children's Hospital Medical Center; University of Michigan System; University of Michigan	Page, K (corresponding author), Childrens Hosp, Div Crit Care Med, Dept Pediat, 3333 Burnet Ave,ML2005, Cincinnati, OH 45229 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056399] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56399] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akers IA, 2000, AM J PHYSIOL-LUNG C, V278, pL193, DOI 10.1152/ajplung.2000.278.1.L193; Asokananthan N, 2002, J IMMUNOL, V168, P3577, DOI 10.4049/jimmunol.168.7.3577; Belham CL, 1996, BIOCHEM J, V320, P939, DOI 10.1042/bj3200939; Berger P, 2001, J APPL PHYSIOL, V91, P1372, DOI 10.1152/jappl.2001.91.3.1372; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; Bhat RK, 2003, CLIN EXP ALLERGY, V33, P35, DOI 10.1046/j.1365-2222.2002.01481.x; Borger P, 1999, J INFECT DIS, V180, P1267, DOI 10.1086/315027; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; Chambers LS, 2001, AM J PHYSIOL-LUNG C, V281, pL1369, DOI 10.1152/ajplung.2001.281.6.L1369; Chen WZ, 2000, EXP LUNG RES, V26, P13, DOI 10.1080/019021400269934; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; D'Andrea MR, 2000, BIOTECH HISTOCHEM, V75, P85, DOI 10.3109/10520290009064152; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; FEIG LA, 1988, MOL CELL BIOL, V8, P5750; Garofalo R, 1996, J VIROL, V70, P8773, DOI 10.1128/JVI.70.12.8773-8781.1996; Graness A, 2002, J BIOL CHEM, V277, P18440, DOI 10.1074/jbc.M200468200; Hou L, 1998, IMMUNOLOGY, V94, P356, DOI 10.1046/j.1365-2567.1998.00528.x; Howells GL, 1997, J CELL SCI, V110, P881; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; King C, 1998, J IMMUNOL, V161, P3645; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797, DOI 10.1067/mai.2001.119025; Lan RS, 2002, PHARMACOL THERAPEUT, V95, P239, DOI 10.1016/S0163-7258(02)00237-1; Li J, 2002, AM J PHYSIOL-LUNG C, V283, pL690, DOI 10.1152/ajplung.00060.2002; Mastronarde JG, 1996, J INFECT DIS, V174, P262, DOI 10.1093/infdis/174.2.262; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; Miike S, 2001, J IMMUNOL, V167, P6615, DOI 10.4049/jimmunol.167.11.6615; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Ricciardolo FLM, 2000, AM J RESP CRIT CARE, V161, P1672, DOI 10.1164/ajrccm.161.5.9907133; Ring PC, 2000, CLIN EXP ALLERGY, V30, P1085; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Schmidlin F, 2001, AM J RESP CRIT CARE, V164, P1276, DOI 10.1164/ajrccm.164.7.2101157; Sun G, 2001, J IMMUNOL, V167, P1014, DOI 10.4049/jimmunol.167.2.1014; Vliagoftis H, 2001, J ALLERGY CLIN IMMUN, V107, P679, DOI 10.1067/mai.2001.114245; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	43	88	91	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1112	1118		10.1016/j.jaci.2003.08.050	http://dx.doi.org/10.1016/j.jaci.2003.08.050			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657869				2022-12-18	WOS:000187154200013
J	Perry, T; Matsui, E; Merriman, B; Duong, T; Eggleston, P				Perry, T; Matsui, E; Merriman, B; Duong, T; Eggleston, P			The prevalence of rat allergen in inner-city homes and its relationship to sensitization and asthma morbidity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rat allergen; indoor allergens; inner-city asthma; sensitization; asthma morbidity	LABORATORY-ANIMAL ALLERGY; MOUSE ALLERGEN; CHILDREN; EXPOSURE	Background: Rat allergen has proved to be an important cause of IgE-mediated hypersensitivity in the occupational setting. The prevalence and significance of rat allergen in homes has not been studied. Objective: The purpose of this study was to determine the prevalence of rat allergen in the homes of inner-city children with asthma and to examine the relationship between rat allergen exposure, sensitization, and asthma morbidity. Methods: We developed a new monoclonal-based ELISA to determine the prevalence of rat allergen in dust samples from inner-city homes of the National Cooperative Inner-City Asthma Study population. Home characteristics were evaluated to detect variables that were associated with the presence of rat allergen. Data were also analyzed to assess the relationship between the presence of rat allergen, sensitization, and asthma morbidity. Results: Thirty-three percent of inner-city homes had detectable rat allergen (Rat n 1). The presence of rat allergen was associated with reported rat and mouse infestation, as well as evidence of mouse infestation on home inspection. Twenty-one percent of the participants were sensitized to rat allergen; however, sensitization was not more common when rat allergen was found in the home. The number of hospitalizations, unscheduled medical visits, and days with slowed activity because of asthma were significantly increased in those individuals who were both sensitized and exposed to rat allergen. Conclusions: Rat allergen sensitization and exposure are associated with increased asthma morbidity in inner-city children.	Johns Hopkins Univ, Dept Pediat, Div Allergy & Immunol, Sch Med, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Internal Med, Div Pulmonol, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Eggleston, P (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.			Matsui, Elizabeth/0000-0001-8134-5593				AOYAMA K, 1992, BRIT J IND MED, V49, P41; Bayard C, 1996, BBA-GEN SUBJECTS, V1290, P129, DOI 10.1016/0304-4165(96)00006-2; BENNETT GW, 1988, TRUMANS SCI GUIDE PE, P307; Bush RK, 1998, J ALLERGY CLIN IMMUN, V102, P99, DOI 10.1016/S0091-6749(98)70060-0; CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; Chen P, 2001, CLIN EXP ALLERGY, V31, P1086, DOI 10.1046/j.1365-2222.2001.01127.x; CLARK AJ, 1984, EMBO J, V3, P1045, DOI 10.1002/j.1460-2075.1984.tb01925.x; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; EGGLESTON PA, 1995, AM J RESP CRIT CARE, V151, P640; Heederik D, 1999, J ALLERGY CLIN IMMUN, V103, P678, DOI 10.1016/S0091-6749(99)70242-3; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; LONGBOTTOM JL, 1980, ADV ALLERGOLOGY APPL, P483; Mitchell H, 1997, PEDIATR PULM, V24, P237; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; Renstrom A, 1997, J ALLERGY CLIN IMMUN, V100, P649, DOI 10.1016/S0091-6749(97)70169-6; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358	20	88	92	2	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					346	352		10.1067/mai.2003.1640	http://dx.doi.org/10.1067/mai.2003.1640			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897741				2022-12-18	WOS:000184650600019
J	Howard, TD; Postma, DS; Hawkins, GA; Koppelman, GH; Zheng, SL; Wysong, AKS; Xu, JF; Meyers, DA; Bleecker, ER				Howard, TD; Postma, DS; Hawkins, GA; Koppelman, GH; Zheng, SL; Wysong, AKS; Xu, JF; Meyers, DA; Bleecker, ER			Fine mapping of an IgE-controlling gene on chromosome 2q: Analysis of CTLA4 and CD28	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CTLA4; CD28; chromosome 2; IgE; asthma; atopy; bronchial hyperresponsiveness	SERUM IGE; MULTIPLE-SCLEROSIS; DIABETES-MELLITUS; GENOMEWIDE SCREEN; CELIAC-DISEASE; GRAVES-DISEASE; ASTHMA; SUSCEPTIBILITY; POLYMORPHISM; IDENTIFICATION	Background: Several genomic regions have been identified that might contain genes contributing to the development of asthma and atopy. These include chromosome 2q33, where we have observed evidence for linkage for variation in total serum IgE levels in a Dutch asthma population. Two candidate genes, CTLA4 and CD28, important homeostatic regulators of T-cell activation and subsequent IgE production, map within this candidate region. Objective: We sought to fine-map the chromosome 2q33 region and evaluate CTLA4 and CD28 as candidate genes for the regulation of total serum IgE levels and related phenotypes. Methods: The coding regions of CTLA4 and CD28 were resequenced in 96 individuals; 4 novel SNPs in CTLA4 and 10 in CD28 were identified. Polymorphisms in both genes were analyzed in 200 asthmatic probands and their spouses (n = 201). Results: Subsequent fine-mapping in this region has resulted in an increased log of the odds (lod) score (1.96 to 3.16) for total serum IgE levels. For CTLA4, the +49 A/G single nucleotide polymorphism (SNP) in exon 1 and the 3' untranslated region microsatellite were significantly associated with total serum IgE levels (P = .0005 and .006, respectively). For the combined +49 A/G and 3' untranslated region genotypes, individuals homozygous for the risk allele for both polymorphisms (AA and 86/86) had the highest total serum IgE values (87.1 IU/mL), whereas those individuals with the GG and XX/XX genotypes (anything but the 86-bp allele) had the lowest IgE values (29.3 IU/mL). Significant association was also observed for the CTLA4-1147 C/T SNP with bronchial hyper-responsiveness (BHR) and asthma (P = .008 and .012, respectively, but not for allergy-related phenotypes. Promoter luciferase assays examining the -1147 polymorphism suggested that the T allele, which was associated with increased BHR susceptibility, was expressed at half the level of the C allele. Individuals with the risk genotypes for both BHR (-1147 CT or TT) and elevated IgE levels (+49 AA) were 4.5 times more likely to have asthma than individuals with both nonrisk genotypes (P = .0009). No significant associations were observed for SNPs in CD28. Conclusion: These data suggest that the costimulatory pathway, specifically CTLA4, is important in the development of atopy and asthma.	Wake Forest Univ, Sch Med, Ctr Human Genom, Dept Pediat, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Ctr Human Genom, Dept Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Ctr Human Genom, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Univ Groningen Hosp, Dept Pulmonol, Groningen, Netherlands; Beatrixoord, Dept Pulm Rehabil, Haren, Netherlands	Wake Forest University; Wake Forest University; Wake Forest University; University of Groningen; University of Groningen	Bleecker, ER (corresponding author), Wake Forest Univ, Sch Med, Ctr Human Genom, Dept Pediat, Med Ctr Blvd, Winston Salem, NC 27157 USA.		Koppelman, Gerard/AAG-9187-2020	Koppelman, Gerard/0000-0001-8567-3252	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066393, R01HL048341] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL/48341, R01HL/66393] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe T, 1999, DIABETES RES CLIN PR, V46, P169, DOI 10.1016/S0168-8227(99)00084-4; Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844; Badenhoop K, 2000, CLIN ENDOCRINOL, V52, P139, DOI 10.1046/j.1365-2265.2000.00953.x; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BURROWS B, 1995, J ALLERGY CLIN IMMUN, V95, P548, DOI 10.1016/S0091-6749(95)70317-9; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Deichmann K, 1996, BIOCHEM BIOPH RES CO, V225, P817, DOI 10.1006/bbrc.1996.1256; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; Djilali-Saiah I, 1998, GUT, V43, P187, DOI 10.1136/gut.43.2.187; Donner H, 1997, J CLIN ENDOCR METAB, V82, P143, DOI 10.1210/jc.82.1.143; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866, DOI 10.1164/ajrccm/146.4.866; Harbo HF, 1999, TISSUE ANTIGENS, V53, P106; Heinzmann A, 2000, EUR J IMMUNOGENET, V27, P57, DOI 10.1046/j.1365-2370.2000.00198.x; Hizawa N, 2001, J ALLERGY CLIN IMMUN, V108, P74, DOI 10.1067/mai.2001.116119; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Kouki T, 2000, J IMMUNOL, V165, P6606, DOI 10.4049/jimmunol.165.11.6606; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; Lee YJ, 2000, CLIN ENDOCRINOL, V52, P153, DOI 10.1046/j.1365-2265.2000.00929.x; Ligers A, 1999, J NEUROIMMUNOL, V97, P182, DOI 10.1016/S0165-5728(99)00072-7; Marron MP, 1997, HUM MOL GENET, V6, P1275, DOI 10.1093/hmg/6.8.1275; Marsh DG, 1997, NAT GENET, V15, P389; Nakao F, 2000, EXP CLIN IMMUNOGENET, V17, P179, DOI 10.1159/000019137; Naluai AT, 2000, TISSUE ANTIGENS, V56, P350; Nistico L, 1996, HUM MOL GENET, V5, P1075, DOI 10.1093/hmg/5.7.1075; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734, DOI 10.1164/ajrccm.157.6.9606088; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P4018, DOI 10.1093/nar/19.14.4018-a; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Snyder SR, 2001, J BIOL CHEM, V276, P5323, DOI 10.1074/jbc.M009454200; Tsai AF, 1998, J REPROD IMMUNOL, V40, P147, DOI 10.1016/S0165-0378(98)00073-4; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; ZAYKIN D, 1995, GENETICA, V96, P169, DOI 10.1007/BF01441162	37	88	90	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2002	110	5					743	751		10.1067/mai.2002.128723	http://dx.doi.org/10.1067/mai.2002.128723			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	612NN	12417883				2022-12-18	WOS:000179082500009
J	Yip, E; Cacioli, P				Yip, E; Cacioli, P			The manufacture of gloves from natural rubber latex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on Natural Rubber Latex Sensitivity	FEB 09-10, 2001	SAN FRANCISCO, CA	Malaysian Rubber Res Inst		latex products; dry rubber products; residual extractable proteins; allergenicity; powdered and powder-free gloves; barrier protection	CONTACT URTICARIA; ALLERGENS; PRODUCTS	Gloves that will provide a barrier of protection from infectious organisms are an essential feature of medical practice for the protection of both patients and medical personnel. Natural rubber latex has consistently been the most satisfactory raw material for the manufacture of gloves. Certain latex proteins, carried over into the finished product by inadequate manufacturing processes, may pose a risk of provoking allergic reactions in some patients and medical workers. As with any allergy, the risk depends on the route of exposure and dose. Hence, the method of manufacture, including the means used to coat gloves to make donning easy, can influence the eventual exposure of sensitive people to latex allergens. In this article, we describe the several processes in use and their effects on latex protein content.	Malaysian Rubber Export Promot Council, Kuala Lumpur, Malaysia; Ansell Healthcare Prod Inc, Massillon, OH USA		Yip, E (corresponding author), Malaysian Rubber Export Promot Council, 3516 Int Court NW, Washington, DC 20008 USA.							ALOMAR A, 1986, CONTACT DERMATITIS, V15, P44, DOI 10.1111/j.1600-0536.1986.tb01267.x; AMIRHASHIM MY, 1994, EFFECT LEACHING EXTR, P51; ANSELL CW, 1993, Patent No. 5272771; ANSELL CW, 1992, Patent No. 5088125; Blackley D.C., 1997, POLYM LATICES SCI TE, V2, P1; BLACKLEY DC, 1977, POLYM LATICES SCI TE, V2, P548; BLACKLEY DC, 1997, POLYM LATICES, V3, P544; BLACKLEY DC, 1997, POLYM LATICES, V3, P220; Brehler R, 1996, CONTACT DERMATITIS, V34, P296, DOI 10.1111/j.1600-0536.1996.tb02206.x; CALVERT KO, 1982, POLYM LATTICES THEIR, P188; CALVERT KO, 1982, POLYM LATTICES THEIR, P184; DALRYMPLE S. J., 1992, RUBBER DEV, V45, P51; ELVING N, 1992, P INT LAT C SENS LAT, P34; ENG AH, 1993, NATURAL RUBBER CURRE, P101; ESLANDER T, 1986, CONTACT DERMATITIS, V14, P20; HAFSAH G, 1994, J NAT RUBBER RES, V9, P96; Hasma H., 1998, Journal of Rubber Research, V1, P146; HASMA H, 1997, J RUBBER RES, V12, P21; HAYAKAWA R, 2000, ENV DERMATOL, V7, P48; HEFMANN W, 1967, VULCANIZATION VULCAN; *JAP MIN HLTH WELF, 2000, US PVC GLOV FOOD HAN; KLEIN RC, 1990, BIOTECHNIQUES, V9, P196; KOMIEWICZ DM, 1990, J CLIN MICROBIOL, V28, P787; KOMIEWICZ DM, 1998, NURS RES, V38, P144; KORNIEWICZ DM, 1993, AM IND HYG ASSOC J, V54, P22, DOI 10.1080/15298669391354261; KORNIEWICZ DM, 1994, AM J INFECT CONTROL, V22, P12, DOI 10.1016/0196-6553(94)90085-X; KURUP VP, 1994, ALLERGY PROC, V15, P211, DOI 10.2500/108854194778702711; LAHTI A, 1992, CONTACT DERMATITIS, V27, P188, DOI 10.1111/j.1600-0536.1992.tb05252.x; Liss GM, 1999, AM J IND MED, V35, P196, DOI 10.1002/(SICI)1097-0274(199902)35:2<196::AID-AJIM12>3.0.CO;2-Y; LOW FC, 1992, J RUBBER RES, V7, P195; MASOUDI ML, 1987, CONTACT DERMATITIS, V16, P290; MAUSSER RF, 1987, VANDERBILT LATEX HDB, P201; MAUSSER RF, 1987, VANDERBILT LATEX HDB, P199; MAZAM MS, 1999, P INT LAT C AKR OH 2, P3; Miguel AG, 1996, ENVIRON HEALTH PERSP, V104, P1180, DOI 10.2307/3432911; MOIR GFJ, 1959, NATURE, V184, P1626, DOI 10.1038/1841626a0; MONMA S, 1999, ENV DERMATOL S1, V6, P84; MORRIS MD, 1994, J RUBBER RES, V9, P121; *MS, 1998, 139298 MS; Newsom S W, 1998, Ann R Coll Surg Engl, V80, P288; Ng K.P., 1994, J RUBBER RES, V9, P87; Nieto A, 1998, J ALLERGY CLIN IMMUN, V101, pS207; NILE J. G., 2000, US patent No, Patent No. [6,075,081, 6075081]; NILE JG, 1996, Patent No. 5570475; NORAISAH AA, 1994, CHLORINATION GLOVES, P59; OLSEN RJ, 1993, JAMA-J AM MED ASSOC, V270, P350, DOI 10.1001/jama.270.3.350; ONG EL, 1998, MONOGRAPH, V1; ONG EL, 2000, MAL GLOV SEM HELD CO; OSMUNDSEN PE, 1980, CONTACT DERMATITIS, V6, P452, DOI 10.1111/j.1600-0536.1980.tb05564.x; PALOSUO T, P INT C LAT PROT ALL, P11; PENDLE T, 1995, DIPPING NATURAL RUBB, P1; PERRELLA F, 1998, P INT LAT C AKR OH 2, P1; Podell HI, 1986, United States Patent, US, Patent No. 4575476; REGO A, 1999, AM J INFECT CONTROL, V27, P1; Sugiura K, 2000, CONTACT DERMATITIS, V43, P237; TATA SJ, 1980, J RUBBER RES I MALAY, V28, P77; TOMAZIC VJ, 1994, J ALLERGY CLIN IMMUN, V93, P751, DOI 10.1016/0091-6749(94)90255-0; TSUCHII A, 1990, APPL ENVIRON MICROB, V56, P269, DOI 10.1128/AEM.56.1.269-274.1990; Tung R C, 1998, Am J Contact Dermat, V9, P234; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; Yeang H.Y., 1993, J NAT RUBB RES, V8, P154; Yip E., 1994, J RUBBER RES, V9, P79; Yip E., 1997, J RUBBER RES, V12, P120; YIP E, 2000, J RUBBER RES, V3, P129; YIP E, 1995, RUBBER DEV, V48, P48; YIP E, 1997, J NAT RUBBER RES, V12, P166; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3; 1999, FED REG, V64, P41709; [No title captured]	70	88	90	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2		S			S3	S14		10.1067/mai.2002.124499	http://dx.doi.org/10.1067/mai.2002.124499			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	586ET	12170237				2022-12-18	WOS:000177572200002
J	Joshi, P; Mofidi, S; Sicherer, SH				Joshi, P; Mofidi, S; Sicherer, SH			Interpretation of commercial food ingredient labels by parents of food-allergic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; labels; commercial foods	ANAPHYLACTIC REACTIONS; OIL	Background: To avoid allergic reactions, food-allergic consumers depend on the ingredient labels of commercial products. Complex ingredient terminology (eg, casein and whey for milk) and label ambiguities (eg, natural flavor and may contain peanut) might compromise the ability of patients/parents to determine the safety of particular products. Objective: The purpose of this investigation was to determine the accuracy of label reading among parents of food-allergic children. Methods: Parents of children on restricted diets attending our referral center were asked to review a group of 23 food labels taken from widely available commercial products. For each label, each parent/parent pair was asked to indicate whether the product was safe for the allergic child and, if it was not, which foods restricted from the child's diet were in the product. Results: There were 91 participants. Peanut was the most commonly restricted food (82 children), followed by milk, egg, soy, and wheat (60, 45, 27 and 16 children, respectively). Identification of milk and soy was the most problematic: only 4 (7%) of 60 parents correctly identified all 14 labels that indicated milk, and only 6 (22%) of 27 parents correctly identified soy protein in 7 products, Peanut was correctly identified in 5 products by 44 (54%) of the 82 parents restricting peanut. Wheat (10 labels) and egg (7 labels) were correctly identified by most parents (14/16 and 42/45, respectively). Correct label identification was associated with prior instruction by a dietitian. Conclusions: With current labeling practices, most parents are unable to identify common allergenic food ingredients. These results strongly support the need for improved labeling with plain-English terminology and allergen warnings as well as the need for diligent education of patients about reading labels.	Mt Sinai Hosp, Jaffe Food Allergy Inst, Div Allergy Immunol, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Sicherer, SH (corresponding author), Mt Sinai Hosp, Jaffe Food Allergy Inst, Div Allergy Immunol, Dept Pediat, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.				NIAID NIH HHS [P01 AI44236, K23 AI 01709-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI001709, P01AI044236] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul AS, 2001, J ALLERGY CLIN IMMUN, V108, P468, DOI 10.1067/mai.2001.117794; Awazuhara H, 1998, CLIN EXP ALLERGY, V28, P1559, DOI 10.1046/j.1365-2222.1998.00431.x; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1987, PEDIATRICS, V79, P683; BUSH RK, 1985, J ALLERGY CLIN IMMUN, V76, P242, DOI 10.1016/0091-6749(85)90709-2; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; *US FDA, 2001, FOOD ALL PARTN; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	10	88	95	0	18	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					1019	1021		10.1067/mai.2002.123305	http://dx.doi.org/10.1067/mai.2002.123305			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063534	Bronze			2022-12-18	WOS:000176442700020
J	Remitz, A; Kyllonen, H; Granlund, H; Reitamo, S				Remitz, A; Kyllonen, H; Granlund, H; Reitamo, S			Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Univ Helsinki, Hosp Skin & Allerg Dis, Dept Dermatol, Helsinki 00250, Finland	University of Helsinki	Remitz, A (corresponding author), Univ Helsinki, Hosp Skin & Allerg Dis, Dept Dermatol, Helsinki 00250, Finland.							ALY R, 1980, ACTA DERM-VENEREOL, V92, P16; KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Reitamo S, 2000, ARCH DERMATOL, V136, P999, DOI 10.1001/archderm.136.8.999; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Ruzicka T, 1998, NEW ENGL J MED, V339, P1788; STALDER JF, 1994, BRIT J DERMATOL, V131, P536	7	88	94	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					196	197		10.1067/mai.2001.112131	http://dx.doi.org/10.1067/mai.2001.112131			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11150013				2022-12-18	WOS:000166533300033
J	Shiomori, T; Yoshida, S; Miyamoto, H; Makishima, K				Shiomori, T; Yoshida, S; Miyamoto, H; Makishima, K			Relationship of nasal carriage of Staphylococcus aureus to pathogenesis of perennial allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						perennial allergic rhinitis; Staphylococcus aureus colonization; superantigen; T-H2 type cytokine	BLOOD MONONUCLEAR-CELLS; SHOCK SYNDROME TOXIN-1; ATOPIC-DERMATITIS; IFN-GAMMA; MESSENGER-RNA; IGE SYNTHESIS; IL-4; ASSOCIATION; EPIDEMIOLOGY; SUPERANTIGEN	Background: Several studies bare previously shown some factors that modify the pathogenesis of perennial allergic rhinitis (PAR), However, the association between bacterial colonization and PAR has not been well understood. Objective: We sought to study the association between super-antigen-producing Staphylococcus aureus and PAR. Methods: S aureus colonization in the nasal cavity and its superantigen production were studied in 65 patients with FAR and 45 nonallergic control subjects. The nasal symptom scores of the patients were evaluated, Furthermore, we examined the response to staphylococcal enterotoxin B or toxic shock syndrome toxin I of peripheral blood lymphocytes from both patients and control subjects by measuring proliferative responses and production of cytokines (IFN-gamma, IL-3, and IL-5). Results: The rate of nasal carriage of S aureus in the patients (44%) was significantly higher than that of the control subjects (20%, P < .01). Moreover, the rate of nasal carriage of super-antigen-producing S aureus in the patients (22%) was significantly higher than that of the control subjects (6.7%, P < .05), The nasal symptom scores of the S aureus-positive patients,I pre significantly higher than those of the S aureus-negative patients (P < .05), although there was no significant association between symptom scores and superantigen production. Peripheral blood lymphocytes from the patients showed significantly higher proliferative responses and were more likely to produce T-H2 type cytokines in response to superantigens (P < .01), but the responses were not different among the patients with S aureus carriage and superantigen production. Conclusion: This study suggests that PAR leads to a higher carriage rate of S aureus, and nasal carriage of S aureus may aggravate PAR.	Univ Occupat & Environm Hlth, Sch Med, Dept Otorhinolaryngol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Microbiol, Kitakyushu, Fukuoka 8078555, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Bacteriol, Fukuoka 812, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; Kyushu University	Shiomori, T (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Otorhinolaryngol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan.							BIBEL DJ, 1983, J INVEST DERMATOL, V80, P494, DOI 10.1111/1523-1747.ep12535001; BRANGER C, 1994, EPIDEMIOL INFECT, V112, P489, DOI 10.1017/S0950268800051190; Campbell DE, 1997, CLIN EXP IMMUNOL, V107, P392, DOI 10.1111/j.1365-2249.1997.278-ce1172.x; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; ELLIOTT ST, 1979, ARCH DERMATOL, V115, P1424, DOI 10.1001/archderm.115.12.1424; Ezepchuk YV, 1996, J INVEST DERMATOL, V107, P603, DOI 10.1111/1523-1747.ep12583377; FALANGA V, 1985, J CLIN MICROBIOL, V22, P452, DOI 10.1128/JCM.22.3.452-454.1985; HAHN DL, 1991, JAMA-J AM MED ASSOC, V266, P225, DOI 10.1001/jama.266.2.225; HANIFIN JM, 1986, J ALLERGY CLIN IMMUN, V78, P563, DOI 10.1016/0091-6749(86)90071-0; Hofer MF, 1995, CLIN EXP ALLERGY, V25, P1218, DOI 10.1111/j.1365-2222.1995.tb03046.x; IMADA M, 1995, IMMUNOLOGY, V85, P373; Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505, DOI 10.1128/CMR.10.3.505; KONIG B, 1995, INT ARCH ALLERGY IMM, V106, P124, DOI 10.1159/000236832; Lee CH, 1997, ANN OTO RHINOL LARYN, V106, P215, DOI 10.1177/000348949710600306; LESTER MR, 1995, CLIN IMMUNOL IMMUNOP, V77, P332, DOI 10.1006/clin.1995.1160; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LOPES JD, 1985, SCIENCE, V229, P275, DOI 10.1126/science.3160113; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MCFADDEN JP, 1993, BRIT J DERMATOL, V128, P631, DOI 10.1111/j.1365-2133.1993.tb00257.x; MOTALA C, 1986, J ALLERGY CLIN IMMUN, V78, P583, DOI 10.1016/0091-6749(86)90075-8; OKUDA M, 1983, ANN ALLERGY, V50, P116; PENE J, 1988, J IMMUNOL, V141, P1218; Peterson B, 1996, ANN ALLERG ASTHMA IM, V77, P263, DOI 10.1016/S1081-1206(10)63318-2; Saito H, 1997, INT ARCH ALLERGY IMM, V114, P81, DOI 10.1159/000237647; Shinogi J, 1998, LARYNGOSCOPE, V108, P703, DOI 10.1097/00005537-199805000-00014; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SORRI M, 1980, Rhinology (Utrecht), V18, P83; Takeuchi S, 1998, VET MICROBIOL, V59, P251, DOI 10.1016/S0378-1135(96)01253-9; Terada N, 1995, J ALLERGY CLIN IMMUN, V96, P1161, DOI 10.1016/S0091-6749(95)70201-6; Till S, 1997, IMMUNOLOGY, V91, P53, DOI 10.1046/j.1365-2567.1997.00218.x; WIENEKE AA, 1988, INT J FOOD MICROBIOL, V7, P25, DOI 10.1016/S0168-1605(00)00216-6; WILSON SZ, 1977, ANTIMICROB AGENTS CH, V11, P407, DOI 10.1128/AAC.11.3.407	32	88	101	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					449	454		10.1067/mai.2000.104256	http://dx.doi.org/10.1067/mai.2000.104256			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719292				2022-12-18	WOS:000088946700008
J	Marcotte, GV; Braun, CM; Norman, PS; Nicodemus, CF; Kagey-Sobotka, A; Lichtenstein, LM; Essayan, DW				Marcotte, GV; Braun, CM; Norman, PS; Nicodemus, CF; Kagey-Sobotka, A; Lichtenstein, LM; Essayan, DW			Effects of peptide therapy on ex vivo T-cell responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; IL-4; T cell; allergen; peptide	MESSENGER-RNA EXPRESSION; ALLERGEN INHALATION CHALLENGE; ATOPIC ASTHMA; BRONCHOALVEOLAR LAVAGE; RAGWEED IMMUNOTHERAPY; BRONCHIAL BIOPSIES; HAY-FEVER; ACID; INTERLEUKIN-5; ACTIVATION	Background: Peptide therapy targets T cells directly with short peptides containing multiple T-cell receptor epitopes. Murine studies suggest T cell anergy as the mechanism of action; however, changes in T-cell cytokine profiles may be more relevant in human beings. Objective: We sought to study the effects of peptide therapy on ex rivet antigen specific T-cell responses. Methods: Antigen-specific T cell lines were generated from subjects enrolled in a double-blind, placebo controlled, two-dose study of the ALLERVAX CAT therapeutic, containing Fel d 1 peptide (ImmuLogic Pharmaceutical Corp., Waltham, Mass.) (n = 7, 8, and 7, respectively, for groups receiving placebo, 75 mu g, or 750 mu g). Each subject had three lines propagated before and after receiving peptide therapy; antigens used were cat hair extract, Fel d I peptides, and tetanus toroid (negative control), Proliferative responses and cytokine generation from each line were assessed after two restimulations with antigen and autologous antigen-presenting cells. Results: The Fel d 1 peptide lines showed a dose-dependent decrease of IL-4 production (p = 0.02 and 0.025, respectively, for the 750 mu g group vs both the 75 mu g and placebo groups), IL-4 production from the cat hair allergen extract lines and interferon-gamma production from both the Fel d 1 peptide lines and cat hair allergen extract lines showed no statistically significant changes. The control tetanus toroid lines showed no changes in cytokine production; there were no significant changes in proliferation with any of the antigens in any of the treatment groups. In the clinical arm of the trial, only the 750 mu g dose of peptides produced a significant response. Conclusions: Peptide therapy indices a significant, dose-dependent decrease in peptide-stimulated IL-4 production, consistent with either a shift in T-cell phenotype or peptide-specific T-cell tolerance.	Johns Hopkins Univ, Sch Med, Div Clin Immunol, Baltimore, MD USA; Immunol Inc, Waltham, MA USA	Johns Hopkins University	Essayan, DW (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Ctr, Baltimore, MD 21224 USA.				NIAID NIH HHS [AI07290-32, AI07056-22] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007056] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P719, DOI 10.1016/S0091-6749(96)80146-1; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; ESSAYAN DM, 1994, J IMMUNOL, V153, P3408; Essayan DM, 1996, J ALLERGY CLIN IMMUN, V98, P1035, DOI 10.1016/S0091-6749(96)80188-6; Essayan DM, 1997, J ALLERGY CLIN IMMUN, V99, P28, DOI 10.1016/S0091-6749(97)81041-X; FASLER S, 1995, J IMMUNOL, V155, P4199; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; FRANKLAND AW, 1954, LANCET, V1, P1055; GREENSTEIN JL, 1992, J ALLERGY CLIN IMMUN, V89, P322; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HUANG SK, 1995, J IMMUNOL, V155, P2688; JUTEL M, 1995, J IMMUNOL, V154, P4187; Lack G, 1997, J ALLERGY CLIN IMMUN, V99, P530, DOI 10.1016/S0091-6749(97)70081-2; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; MERINEY DK, 1986, ANN ALLERGY, V56, P34; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1993, CURR OPIN IMMUNOL, V5, P968, DOI 10.1016/0952-7915(93)90114-8; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; NORMAN PS, 1997, J ALLERGY CLIN IMMUN, V99, P127; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Simons FER, 1996, INT IMMUNOL, V8, P1937, DOI 10.1093/intimm/8.12.1937; SMILEK DE, 1991, P NATL ACAD SCI USA, V88, P9633, DOI 10.1073/pnas.88.21.9633; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012	33	88	95	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				506	513		10.1016/S0091-6749(98)70358-6	http://dx.doi.org/10.1016/S0091-6749(98)70358-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564804	hybrid			2022-12-18	WOS:000073113500013
J	Hoover, GE; Newman, LJ; PlattsMills, TAE; Phillips, CD; Gross, CW; Wheatley, LM				Hoover, GE; Newman, LJ; PlattsMills, TAE; Phillips, CD; Gross, CW; Wheatley, LM			Chronic sinusitis: Risk factors for extensive disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; immunoglobulins; age; asthma; computed tomography	COLONY-STIMULATING FACTOR; LINKED IMMUNOSORBENT-ASSAY; NASAL POLYPS; CAPSULAR POLYSACCHARIDE; FUNCTIONAL-PROPERTIES; SUBCLASS DEFICIENCY; EOSINOPHIL; CHILDREN; INTERLEUKIN-3; INVITRO	Background: Chronic sinus disease is one of the most common diseases in the United States, and little is understood about its pathogenesis. Objective: To characterize prospectively the immunologic parameters that accompany extensive chronic sinusitis. Methods: Eighty adult patients with chronic sinus symptoms had a complete blood count with differential, coronal computed tomographic (CT) scan of the sinuses, and serum assays for total IgE, specific IgE, IgA, Igc, Ige subclasses, and pneumococcal titers. Results: Thirty-seven (46%) patients had extensive sinusitis, defined as a CT score greater than or equal to 12. A highly significant correlation was noted between the extent of disease and the peripheral eosinophil count (r = 0.53, p < 0.0001), In keeping with this finding, an eosinophil count greater than or equal to 200/mu l was strongly associated with extensive disease (odds ratio [OR] = 19.2, 95% confidence interval [CI] = 5.4 to 72.7), Asthma (OR = 6.8, 95% CI = 2.2 to 22.0), atopy (OR = 4.3, 95% CI, 1.5 to 12.8), and age greater than or equal to 50 years (OR = 6.5, 95% CI = 2.0 to 22.2) were also associated with extensive disease. However, the association of eosinophils with extent of disease was independent of asthma, atopy, or age, Levels of IgG1, IgG2, and IgG3 subclasses did not correlate with extent of disease seen on CT scan. Although total IgE and IgG4 levels did correlate with disease, on multiple stepwise regression they did not add to the predictive value of the eosinophil count in identifying patients with extensive disease. Conclusions: The association of asthma, atopy, eosinophilia, and elevated levels of IgE and IgG4 with extensive disease on CT scan is compatible with the hypothesis that chronic sinusitis may be a disease of immune activation of the T-H2 type.	UNIV VIRGINIA,HLTH SCI CTR,CTR ASTHMA & ALLERG DIS,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT RADIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT OTOLARYNGOL,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia; University of Virginia				Platts-Mills, Thomas/0000-0002-1263-329X	NIAID NIH HHS [AI-30840, AI-34607, AI-01416] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034607, R01AI030840, U19AI034607, K08AI001416] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMENAKA M, 1994, ANN ALLERGY, V72, P507; BEAUVAIS F, 1990, J IMMUNOL, V144, P3881; BERMAN SZ, 1974, J ALLERGY CLIN IMMUN, V53, P311, DOI 10.1016/0091-6749(74)90111-0; FERRANTE A, 1986, J IMMUNOL METHODS, V93, P207, DOI 10.1016/0022-1759(86)90190-0; Gottlieb MJ, 1925, J AMER MED ASSOC, V85, P105, DOI 10.1001/jama.1925.02670020025013; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P37; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; KEITH PK, 1994, J ALLERGY CLIN IMMUN, V93, P567, DOI 10.1016/S0091-6749(94)70068-0; MESSINA JP, 1985, J CLIN MICROBIOL, V21, P390, DOI 10.1128/JCM.21.3.390-394.1985; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; OHNISHI M, 1988, AM REV RESPIR DIS, V138, P560, DOI 10.1164/ajrccm/138.3.560; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; OXELIUS VA, 1974, CLIN EXP IMMUNOL, V17, P19; PELIKAN Z, 1990, J ALLERGY CLIN IMMUN, V86, P484, DOI 10.1016/S0091-6749(05)80203-9; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; ROTHENBERG ME, 1987, SCIENCE, V237, P645, DOI 10.1126/science.3110954; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SCHWARTZ HJ, 1987, ARCH INTERN MED, V147, P2194, DOI 10.1001/archinte.147.12.2194; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; SHACKELFORD PG, 1986, J PEDIATR-US, V108, P647, DOI 10.1016/S0022-3476(86)81035-6; SHAPIRO GG, 1992, J ALLERGY CLIN IMMUN, V90, P417, DOI 10.1016/0091-6749(92)90160-4; SLAVIN RG, 1982, ANN ALLERGY, V49, P123; SONODA Y, 1989, LEUKEMIA, V3, P14; STOOP AE, 1991, J ALLERGY CLIN IMMUN, V87, P470, DOI 10.1016/0091-6749(91)90004-8; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; WALKER C, 1991, J IMMUNOL, V146, P1829; ZETTERSTROM O, 1981, ALLERGY, V36, P537, DOI 10.1111/j.1398-9995.1981.tb01871.x	30	88	93	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					185	191		10.1016/S0091-6749(97)70223-9	http://dx.doi.org/10.1016/S0091-6749(97)70223-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275139				2022-12-18	WOS:A1997XR35100008
J	Fireman, P				Fireman, P			Otitis media and eustachian tube dysfunction: Connection to allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						otitis media; otitis media with effusion; eustachian tube dysfunction/obstruction; allergic rhinitis; upper respiratory infection	INFLUENZA-A VIRUS; MIDDLE-EAR EFFUSIONS; POLYMORPHONUCLEAR LEUKOCYTE DYSFUNCTION; EXPERIMENTAL RHINOVIRUS INFECTION; INTRANASAL HISTAMINE CHALLENGE; RESPIRATORY SYNCYTIAL VIRUS; INFLAMMATORY MEDIATORS; NONALLERGIC SUBJECTS; BACTERIAL ADHERENCE; PRESCHOOL-CHILDREN	Otitis media and otitis media with effusion are among the most common childhood illnesses and contribute a great deal to health care costs. The cause of otitis media is multifactorial. Eustachian tube dysfunction, bacterial or viral infection of the middle ear, and nasal inflammation resulting from allergic rhinitis or upper respiratory infection are acknowledged contributing factors. Data from epidemiology studies indicate that 25% to 40% of upper respiratory infections in children younger than 3 years are accompanied by an episode of otitis media; 40% to 50% of children older than 3 years with chronic otitis media have confirmed allergic rhinitis. Studies of the pathogenesis of otitis media have identified interactions among infection, allergic reactions, and eustachian tube dysfunction. Nasal inflammation due to allergen challenge results in classic signs and symptoms of allergic rhinitis and eustachian tube dysfunction. Eustachian tube dysfunction leads to increased negative pressure in the middle ear and improper ventilation. Both viral upper respiratory infection and nasal allergic reaction provoke nasal inflammation, eustachian tube dysfunction, and enhanced nasal protein transudation and secretion, which is likely to be sustained and modulated by inflammatory mediators and cytokines. In a study of experimental infection with influenza A virus, histamine release increased from peripheral blood basophils of patients with allergic rhinitis. These data support an interaction between viral infection and nasal allergy in enhancing certain pathophysiologic responses. Viral upper respiratory infections may promote secondary bacterial infections by altering bacterial adherence, modulating host immune and inflammatory responses, and impairing eustachian tube function. In acute otitis media, bacteria are cultured from approximately 70% of middle ear effusions, with Streptococcus pneumoniae being the most common organism. Initial management of otitis media consists of appropriate antimicrobial therapy. In the presence of allergic rhinitis, antiallergic therapies may be used to augment symptom resolution and therapeutic response. Surgical insertion of tympanostomy or ventilation tubes to promote drainage of unresolved effusions has become common. Further delineation of the pathogenesis of otitis media and otitis media with effusion will guide appropriate medical management and may decrease the need and frequency of surgical procedures.			Fireman, P (corresponding author), UNIV PITTSBURGH,CHILDRENS HOSP PITTSBURGH,SCH MED,DEPT PEDIAT,3705 5TH AVE,PITTSBURGH,PA 15213, USA.							ABRAMSON JS, 1982, INFECT IMMUN, V36, P289, DOI 10.1128/IAI.36.1.289-296.1982; ABRAMSON JS, 1992, INFECT IMMUNOL, V36, P289; ACKERMAN MN, 1984, J ALLERGY CLIN IMMUN, V73, P604, DOI 10.1016/0091-6749(84)90519-0; ADLINGTON P, 1980, J LARYNGOL OTOL, V94, P191, DOI 10.1017/S0022215100088666; AROLA M, 1988, J PEDIATR-US, V113, P693, DOI 10.1016/S0022-3476(88)80380-9; AROLA M, 1990, PEDIATRICS, V86, P848; BAKALETZ LO, 1993, J INFECT DIS, V168, P865, DOI 10.1093/infdis/168.4.865; BAKELETZ LO, 1988, AM J OTOLARYNG, V9, P127; BALLENGER JJ, 1988, ANN OTO RHINOL LARYN, V97, P253, DOI 10.1177/000348948809700308; BARNETT JC, 1993, P 5 INT S REC ADV OT, P462; BEERY QC, 1979, LARYNGOSCOPE, V89, P1446, DOI 10.1002/lary.5540890910; BERNSTEIN JM, 1983, AM J OTOL, V5, P66; BERNSTEIN JM, 1985, OTOLARYNG HEAD NECK, V93, P611, DOI 10.1177/019459988509300508; BERNSTEIN JM, 1988, J ALLERGY CLIN IMMUN, V81, P1004, DOI 10.1016/0091-6749(88)90169-8; BERNSTEIN L, 1994, ANN OTOLRHINOL LAR S, V163, P15; Bluestone, 1990, PEDIATRIC OTOLARYNGO, P320; BLUESTONE CD, 1971, ANN OTO RHINOL LARYN, V80, P1; Bluestone CD, 1985, ANN OTOL RHINOL S120, V94, P48, DOI 10.1177/00034894850945S235; BUCHMAN CA, 1994, LARYNGOSCOPE, V104, P1295; BUSSE WW, 1988, J ALLERGY CLIN IMMUN, V81, P770, DOI 10.1016/0091-6749(88)90930-X; BYLANDER A, 1984, ACTA OTOLARYNGOL STO, V97, P342; CANTEKIN EI, 1983, NEW ENGL J MED, V308, P297, DOI 10.1056/NEJM198302103080601; CASSELBRANT ML, 1985, LARYNGOSCOPE, V95, P428; CASSELBRANT ML, 1988, ACTA OTO-LARYNGOL, V106, P178, DOI 10.3109/00016488809106423; CASSELBRANT ML, 1986, RECENT ADV OTITIS ME, P16; CLEMENTS DA, 1993, P 5 INT S REC ADV OT, P323; CRAFT AW, 1976, BRIT MED J, V1, P1570, DOI 10.1136/bmj.1.6025.1570; Doyle W. J., 1988, AM J RHINOL, V2, P149, DOI DOI 10.2500/105065888781692961; DOYLE WJ, 1985, ARCH OTOLARYNGOL, V111, P502; DOYLE WJ, 1993, AM J RHINOL, V7, P227, DOI 10.2500/105065893781976311; DOYLE WJ, 1990, J ALLERGY CLIN IMMUN, V86, P924, DOI 10.1016/S0091-6749(05)80156-3; DOYLE WJ, 1994, ANN OTO RHINOL LARYN, V103, P59, DOI 10.1177/000348949410300111; DOYLE WJ, 1992, J ALLERGY CLIN IMMUN, V89, P968, DOI 10.1016/0091-6749(92)90219-R; DOYLE WJ, 1984, ARCH OTOLARYNGOL, V110, P508; DOYLE WJ, 1985, J ALLERGY CLIN IMMUN, V76, P551, DOI 10.1016/0091-6749(85)90774-2; DOYLE WJ, 1994, J ALLERGY CLIN IMMUN, V92, P534; FAINSTEIN V, 1980, J INFECT DIS, V141, P172, DOI 10.1093/infdis/141.2.172; FIREMAN P, 1985, J ALLERGY CLIN IMMUN, V76, P137, DOI 10.1016/0091-6749(85)90690-6; FIREMAN P, 1994, J ALLERGY CLIN IMMUN, V93, P194; FRIEDMAN RA, 1993, J ALLERGY CLIN IMMUN, V71, P442; GATES GA, 1987, NEW ENGL J MED, V317, P1444, DOI 10.1056/NEJM198712033172305; GIEBINK GS, 1987, ANN OTO RHINOL LARYN, V96, P199, DOI 10.1177/000348948709600212; GIEBINK GS, 1980, INFECT IMMUN, V30, P445; GIEBINK GS, 1979, J PEDIATR-US, V94, P13, DOI 10.1016/S0022-3476(79)80342-X; GIEBINK GS, 1989, PEDIATR INFECT DIS J, V8, P218; GWALTNEY JM, 1966, AM REV RESPIR DIS, V93, P362; HEALY GB, 1977, LARYNGOSCOPE, V87, P1472, DOI 10.1288/00005537-197709000-00007; HEIKKINEN T, 1991, AM J DIS CHILD, V145, P445, DOI 10.1001/archpedi.1991.02160040103017; HENDERSON FW, 1982, NEW ENGL J MED, V306, P1377, DOI 10.1056/NEJM198206103062301; HSIA J, 1990, J INFECT DIS, V162, P591, DOI 10.1093/infdis/162.3.591; ISHII T, 1980, ANN OTO RHINOL LARYN, V89, P83, DOI 10.1177/00034894800890S323; KLEIN JO, 1976, ANN OTO RHINOL LARYN, V85, P140, DOI 10.1177/00034894760850S226; KRAEMER MJ, 1983, JAMA-J AM MED ASSOC, V249, P1022, DOI 10.1001/jama.249.8.1022; LARSON HE, 1976, LANCET, V7, P285; LEHMANN MD, 1979, INT J PEDIATR OTORHI, V1, P137, DOI 10.1016/0165-5876(79)90005-3; MANDEL EM, 1989, ARCH OTOLARYNGOL, V115, P1217; MCBRIDE TP, 1989, ARCH OTOLARYNGOL, V115, P1054; NACLERIO RM, 1993, AM REV RESPIR DIS, V112, P597; Niederman LG, 1984, RECENT ADV OTITIS ME, P273; NSOULI TM, 1994, ANN ALLERGY, V73, P215; OKAMOTO Y, 1993, J INFECT DIS, V168, P1277, DOI 10.1093/infdis/168.5.1277; OKAMOTO Y, 1992, ANN OTO RHINOL LARYN, V101, P7, DOI 10.1177/0003489492101S1003; OSUR SL, 1987, J ALLERGY CLIN IMMUN, V79, P259; PARADISE JL, 1969, PEDIATRICS, V44, P35; POST JC, 1995, JAMA-J AM MED ASSOC, V273, P1598, DOI 10.1001/jama.273.20.1598; PROUD D, 1990, J INFECT DIS, V161, P120, DOI 10.1093/infdis/161.1.120; Pukander J., 1988, RECENT ADV OTITIS ME, P8; PUKANDER JS, 1985, ACTA OTOLARYNGOL, V100, P19; REUMAN PD, 1993, P 5 INT S REC ADV OT, P323; RIDING KH, 1978, J PEDIATR-US, V93, P739, DOI 10.1016/S0022-3476(78)81069-5; ROCKLEY TJ, 1988, RECENT ADV OTITIS ME, P22; RUNTER T, 1971, ACTA PATHOL MIC SC, V79, P67; SANFORD BA, 1987, P SOC EXP BIOL MED, V185, P120; SANUYAL MA, 1980, J PEDIATR, V97, P11; SARKKINEN H, 1985, J INFECT DIS, V151, P444, DOI 10.1093/infdis/151.3.444; SAWYER WD, 1969, J INFECT DIS, V119, P541, DOI 10.1093/infdis/119.6.541; SKONER DP, 1986, ARCH OTOLARYNGOL, V112, P840; SKONER DP, 1990, ANN ALLERGY, V65, P206; SKONER DP, 1987, J ALLERGY CLIN IMMUN, V79, P27, DOI 10.1016/S0091-6749(87)80012-X; SKONER DP, 1991, ANN ALLERGY, V67, P619; SKONER DP, 1988, AM J RHINOL, V2, P155; SKONER DP, 1995, ANN ALLERG ASTHMA IM, V74, P171; STIEHM ER, 1992, IMMUNOLOGIC DISORDER, P201; STRANGERT K, 1976, PEDIATRICS, V57, P191; TAN TQ, 1995, CONT PEDIAT, V12, P107; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; TEELE DW, 1980, ANN OTO RHINOL LARYN, V89, P5, DOI 10.1177/00034894800890S304; TEELE DW, 1983, JAMA-J AM MED ASSOC, V249, P1026, DOI 10.1001/jama.249.8.1026; TEELE DW, 1980, PEDIATR RES, V14, P94; THOMSEN J, 1984, RECENT ADV OTITIS ME, P278; TOGIAS A, 1988, J ALLERGY CLIN IMMUN, V81, P782, DOI 10.1016/0091-6749(88)90932-3; TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113; TOS M, 1986, ACUTE SECRETORY OTIT; WALD ER, 1991, PEDIATRICS, V87, P129; WARSHAUER D, 1977, AM REV RESPIR DIS, V115, P269	95	88	94	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					S787	S797		10.1016/S0091-6749(97)70130-1	http://dx.doi.org/10.1016/S0091-6749(97)70130-1			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042072				2022-12-18	WOS:A1997WH83100040
J	Barnes, PJ				Barnes, PJ			Molecular mechanisms of steroid action in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							GLUCOCORTICOID RECEPTOR CHARACTERISTICS; RESISTANT BRONCHIAL-ASTHMA; TRANSCRIPTION FACTORS; PROTEIN-INTERACTION; HORMONE RECEPTORS; DNA-BINDING; NF-AT; INHIBITION; GENE; INTERFERENCE				Barnes, PJ (corresponding author), NATL HEART & LUNG INST,DEPT THORAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.			Barnes, Peter/0000-0002-5122-4018				ABBINANTENISSEN JM, 1995, AM J PHYSIOL, V12, pL601; ADCOCK I M, 1991, American Review of Respiratory Disease, V143, pA628; ADCOCK IM, 1994, LIFE SCI, V55, P1147, DOI 10.1016/0024-3205(94)00243-6; ADCOCK IM, 1994, EUR RESPIR J, V7, P2117, DOI 10.1183/09031936.94.07122117; ADCOCK IM, 1993, J MOL ENDOCRINOL, V11, P1, DOI 10.1677/jme.0.0110001; ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; ADCOCK IM, 1995, J IMMUNOL, V154, P3000; ADCOCK IM, IN PRESS J EXP MED; ADCOCK IM, 1995, AM J PHYSIOL, V37, pC331; ADCOCK IM, 1995, AM J RESP CRIT CARE, V161, pA195; ALVAREZ J, 1992, J ALLERGY CLIN IMMUN, V89, P714, DOI 10.1016/0091-6749(92)90379-G; BAMES PJ, 1995, IMMUNOL TODAY, V16, P128; BARNES PJ, 1992, TRENDS PHARMACOL SCI, V13, P20, DOI 10.1016/0165-6147(92)90011-T; BARNES PJ, 1995, QJM-MON J ASSOC PHYS, V88, P455; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; BOSCHETTO P, 1991, AM REV RESPIR DIS, V143, P605, DOI 10.1164/ajrccm/143.3.605; BROWN PH, 1991, LANCET, V337, P576, DOI 10.1016/0140-6736(91)91639-C; CARNUCCIO R, 1987, BRIT J PHARMACOL, V90, P443, DOI 10.1111/j.1476-5381.1987.tb11193.x; CHUNG KF, 1991, RESPIR MED, V95, P121; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; CRONSTEIN BN, 1992, P NATL ACAD SCI USA, V89, P9999; CYPCAR D, 1993, J ALLERGY CLIN IMMUN, V92, P362, DOI 10.1016/0091-6749(93)90114-U; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953, DOI 10.1164/ajrccm.149.4.8143061; FLOWER RJ, 1994, TRENDS PHARMACOL SCI, V15, P71, DOI 10.1016/0165-6147(94)90281-X; GOULDING NJ, 1989, ANN RHEUM DIS, V48, P843, DOI 10.1136/ard.48.10.843; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HIRATA F, 1981, P NATL ACAD SCI-BIOL, V78, P3190, DOI 10.1073/pnas.78.5.3190; IMAI E, 1993, J BIOL CHEM, V268, P5353; KAM JC, 1993, J IMMUNOL, V151, P3460; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHARITONOV SA, IN PRESS AM J RESPIR; KWON OJ, 1995, AM J RESP CELL MOL, V12, P488, DOI 10.1165/ajrcmb.12.5.7537968; KWON OJ, 1994, AM J PHYSIOL-LUNG C, V267, pL398, DOI 10.1152/ajplung.1994.267.4.L398; LAMBERTS SWJ, 1992, J STEROID BIOCH MOL, V43, P285; LANE SJ, 1991, AM REV RESPIR DIS, V143, P1020, DOI 10.1164/ajrccm/143.5_Pt_1.1020; LANE SJ, 1994, AM J RESP CELL MOL, V11, P42, DOI 10.1165/ajrcmb.11.1.8018337; MAK JCW, 1995, J CLIN INVEST, V96, P99, DOI 10.1172/JCI118084; MAK JCW, 1995, AM J PHYSIOL, V12, pL41; MALCHOFF DM, 1993, J CLIN INVEST, V91, P1918, DOI 10.1172/JCI116410; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MULLER M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P171, DOI 10.1016/0167-4781(91)90052-N; NELSON PJ, 1993, J IMMUNOL, V151, P2601; NEWTON R, 1995, AM J RESP CRIT CARE, V151, pA165; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKRET S, 1991, BIOCHIMIE, V73, P51, DOI 10.1016/0300-9084(91)90074-B; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PALIOGIANNI F, 1993, J CLIN INVEST, V91, P1481, DOI 10.1172/JCI116353; Peters M. J., 1993, Thorax, V48, P1066; PETERS MJ, 1995, EUR J PHARM-MOLEC PH, V289, P275, DOI 10.1016/0922-4106(95)90104-3; PETERS MJ, 1993, AM REV RESPIR DIS, V147, pA772; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; POZNANSKY MC, 1984, CLIN SCI, V67, P639, DOI 10.1042/cs0670639; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V203, P209, DOI 10.1006/bbrc.1994.2169; ROSEWICZ S, 1988, J BIOL CHEM, V263, P2581; SCHLEIMER RP, 1990, AM REV RESPIR DIS, V141, pS59; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; STEVENS DA, 1995, AM J RESP CRIT CARE, V151, pA195; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; VACRA A, 1989, MOL ENDOCRINOL, V3, P1659; VANDESTOLPE A, 1993, AM J RESP CELL MOL, V8, P340, DOI 10.1165/ajrcmb/8.3.340; VITTORI E, 1992, AM REV RESPIR DIS, V146, P1320, DOI 10.1164/ajrccm/146.5_Pt_1.1320; WILKINSON JRW, 1990, CLIN EXP ALLERGY, V20, P189, DOI 10.1111/j.1365-2222.1990.tb02666.x; WILKINSON JRW, 1989, J CLIN INVEST, V84, P1930, DOI 10.1172/JCI114381; WONG CS, 1994, AM J RESP CRIT CARE, V150, P1268, DOI 10.1164/ajrccm.150.5.7952551; WOOLCOCK AJ, 1993, EUR RESPIR J, V6, P743; XIE QW, 1994, J BIOL CHEM, V269, P4705; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892, DOI 10.1164/ajrccm.152.3.7663801	74	88	92	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	2	S			159	168		10.1016/S0091-6749(96)80216-8	http://dx.doi.org/10.1016/S0091-6749(96)80216-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TT805	8568147				2022-12-18	WOS:A1996TT80500003
J	VANREE, R; HOFFMAN, DR; VANDIJK, W; BRODARD, V; MAHIEU, K; KOELEMAN, CAM; GRANDE, M; VANLEEUWEN, WA; AALBERSE, RC				VANREE, R; HOFFMAN, DR; VANDIJK, W; BRODARD, V; MAHIEU, K; KOELEMAN, CAM; GRANDE, M; VANLEEUWEN, WA; AALBERSE, RC			LOL-P-XI, A NEW MAJOR GRASS-POLLEN ALLERGEN, IS A MEMBER OF A FAMILY OF SOYBEAN TRYPSIN INHIBITOR-RELATED PROTEINS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LOL P XI; MONOSACCHARIDE COMPOSITION; AMINO ACID SEQUENCE; ANTICARBOHYDRATE	AMINO-ACID-SEQUENCES; HYMENOPTERA VENOM; VEGETABLE FOODS; ANTIBODIES; EXPRESSION; EPITOPE; IGE	Background: Monoclonal antibodies were obtained against an unknown allergen from Lolium perenne grass pollen. The allergen had an apparent molecular mass of 18 kd on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Earlier immunoblotting studies had shown that carbohydrate-specific IgG antibodies recognize an antigen of similar size. Objective: We sought to characterize the allergen biochemically and immunologically. Methods: The amino acid sequence of the allergen was determined by automated. Edman degradation, and its monosaccharide composition was determined by gas chromatographic analysis. A panel of 270 grass pollen-positive sera was assessed in a RAST with the purified allergen. Protease digestion (proteinase K) and chemical deglycosylation (trifluoromethane sulfonic acid) were used to distinguish between carbohydrate and peptide epitopes for IgE antibodies. Results: The allergen was shown to be a glycoprotein with a molecular mass of 16 kd, of which 8% is carbohydrate. Its amino acid sequence shares 32% homology with soybean trypsin inhibitor (Kunitz) but lacks its active site. No homology was found with known grass pollen allergens hence it was designated Lol p XI. A high degree of homology (44%) was found with a tree pollen allergen, Ole e I, the major allergen of olive pollen. More than 65% of grass pollen-positive sera had IgE against Lol p XI IgE reactivity was demonstrated both with the carbohydrate moiety and the peptide backbone. Conclusions: Lol p XI is a new major grass pollen allergen carrying an IgE-binding carbohydrate determinant Lol p XI is structurally related to the major allergen from olive pollen.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS; E CAROLINA UNIV,SCH MED,DEPT PATHOL,GREENVILLE,NC 27834; FREE UNIV AMSTERDAM,FAC MED,DEPT MED CHEM,AMSTERDAM,NETHERLANDS; INST PASTEUR,UNITE IMMUNOALLERGIE,PARIS,FRANCE	University of Amsterdam; University of North Carolina; East Carolina University; Vrije Universiteit Amsterdam; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; AALBERSE RC, 1983, EXCERPTA MED, P17; ANSARI AA, 1989, BIOCHEMISTRY-US, V28, P8665, DOI 10.1021/bi00447a058; ANSARI AA, 1989, J BIOL CHEM, V264, P11181; ANSARI AA, 1987, J IMMUNOL, V139, P4034; ANSARI AA, 1987, J ALLERGY CLIN IMMUN, V80, P229, DOI 10.1016/0091-6749(87)90134-5; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRODARD V, 1993, INT ARCH ALLERGY IMM, V102, P72, DOI 10.1159/000236553; DANDREA G, 1988, GLYCOCONJUGATE J, V5, P151, DOI 10.1007/BF01061204; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; EKRAMODDOULLAH AKM, 1983, MOL IMMUNOL, V20, P465, DOI 10.1016/0161-5890(83)90027-5; HANSON DD, 1989, PLANT CELL, V1, P173, DOI 10.1105/tpc.1.2.173; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P71, DOI 10.1016/0091-6749(93)90298-T; HOWLETT BJ, 1981, BIOCHEM J, V197, P695, DOI 10.1042/bj1970695; JOHNSON P, 1965, EUR POLYM J, V1, P63; KIM SH, 1985, J BIOCHEM, V98, P435, DOI 10.1093/oxfordjournals.jbchem.a135298; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; McCormick S, 1991, Symp Soc Exp Biol, V45, P229; PEREZ M, 1990, J BIOL CHEM, V265, P16210; RICHARDSON M, 1977, PHYTOCHEMISTRY, V16, P159, DOI 10.1016/S0031-9422(00)86777-1; SAVAGE AV, 1986, EUR J BIOCHEM, V160, P123, DOI 10.1111/j.1432-1033.1986.tb09948.x; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; TWELL D, 1989, MOL GEN GENET, V217, P240, DOI 10.1007/BF02464887; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VANREE R, 1989, J ALLERGY CLIN IMMUN, V83, P144, DOI 10.1016/0091-6749(89)90489-2; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VANREE R, 1991, J ALLERGY CLIN IMMUN, V87, P188; VILLALBA M, 1993, EUR J BIOCHEM, V216, P863, DOI 10.1111/j.1432-1033.1993.tb18208.x; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x	31	88	93	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	1				970	978		10.1016/S0091-6749(95)70097-8	http://dx.doi.org/10.1016/S0091-6749(95)70097-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY917	7751518				2022-12-18	WOS:A1995QY91700008
J	TSICOPOULOS, A; HAMID, Q; HACZKU, A; JACOBSON, MR; DURHAM, SR; NORTH, J; BARKANS, J; CORRIGAN, CJ; MENG, Q; MOQBEL, R; KAY, AB				TSICOPOULOS, A; HAMID, Q; HACZKU, A; JACOBSON, MR; DURHAM, SR; NORTH, J; BARKANS, J; CORRIGAN, CJ; MENG, Q; MOQBEL, R; KAY, AB			KINETICS OF CELL INFILTRATION AND CYTOKINE MESSENGER-RNA EXPRESSION AFTER INTRADERMAL CHALLENGE WITH ALLERGEN AND TUBERCULIN IN THE SAME ATOPIC INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IMMUNOCYTOCHEMISTRY; KINETICS; LATE-PHASE RESPONSE; LYMPHOCYTE; EOSINOPHIL; CYTOKINE	DELAYED-TYPE HYPERSENSITIVITY; EOSINOPHIL CATIONIC PROTEIN; COLONY-STIMULATING FACTOR; LYMPHOCYTE-T; MONOCLONAL-ANTIBODIES; CD4+ LYMPHOCYTES; HUMAN-SKIN; INTERLEUKIN-5; RESPONSES; SUBSETS	Background: Previous studies, in which one time point was used, have shown that cells infiltrating skin biopsy specimens taken during allergen-induced late-phase responses (LPR) had a T-H2-like (interleukin-4 [IL]-4 and IL-5 mRNA(+)) cytokine profile, whereas in delayed-type hypersensitivity (DTH) there was a predominant T-H1-type pattern. Objective: The study was designed to examine the kinetics of accumulation of inflammatory cells and cells expressing mRNA for T-H2- or T-H1-type cytokines in LPR and DTH elicited simultaneously in the same subjects. Methods: Immunocytochemistry (alkaline phosphatase anti-alkaline phosphatase technique) and in situ hybridization were used to analyze skin biopsy specimens taken during allergen-induced LPR. Results: In LPR elevated numbers of CD3(+) and CD4(+) cells, eosinophils, neutrophils, and IL-4 and IL-5 mRNA(+) cells were detected as early as 1 hour after allergen challenge, with a peak at 6 hours, which was maintained for rtp to 96 hours. A small bur significant delayed increase in macrophages, CD8(+) and CD25(+) cells, and IL-2 and interferon-gamma mRNA(+) cells was also observed, but only at the 48-hour and 96-hour time points. In contrast, in DTH the numbers of CD3(+), CD4(+), and mRNA(+) cells for IL-2 and interferon-gamma were not elevated until 24 hours after challenge and peaked at 48 hours after injection. At 48 hours there was an additional small but significant increase in IL-4 and IL-5 mRNA(+) cells. For both LPR and DTH the kinetics of the increases in inflammatory cells and cytokine mRNA-expressing cells paralleled the clinical response. Conclusions: In LPR accumulation of T cells and granulocytes, together with cells expressing mRNA encoding for T-H2-type cytokines, is relatively rapid (i.e., within 1 to 6 hours), whereas in DTH the T cell/macrophage infiltration and appearance of cells expressing T-H1-type cytokines are nor apparent until 24 to 48 hours. In LPR there is a T-H1-type (or possibly T-H0) component at 48 to 96 hours, and in DTH there is an additional T-H2/T-H0 response.	NATL HEART & LUNG INST,DEPT ALLERGY & CLIN IMMUNOL,LONDON SW3 6LY,ENGLAND; ROYAL BROMPTON NATL HEART & LUNG INST,DEPT LUNG PATHOL,LONDON,ENGLAND	Imperial College London; Imperial College London			Tsicopoulos, Anne/C-2260-2019; HACZKU, ANGELA/A-8486-2013	Tsicopoulos, Anne/0000-0002-1579-2763; HACZKU, ANGELA/0000-0002-1301-4941; Jacobson, Mikila/0000-0002-2921-6169	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BROD SA, 1991, J IMMUNOL, V147, P810; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; DESREUMAUX P, 1992, J EXP MED, V175, P293, DOI 10.1084/jem.175.1.293; FREW AJ, 1988, J IMMUNOL, V141, P4158; GAGA M, 1991, J IMMUNOL, V147, P816; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; HAENEN JBA, 1991, J EXP MED, V174, P583; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; MOQBEL R, 1992, CLIN EXP ALLERGY, V22, P265, DOI 10.1111/j.1365-2222.1992.tb03082.x; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PLATT JL, 1983, J EXP MED, V158, P1227, DOI 10.1084/jem.158.4.1227; POULTER LW, 1982, CELL IMMUNOL, V74, P358, DOI 10.1016/0008-8749(82)90036-3; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; SCHEYNIUS A, 1982, CLIN EXP IMMUNOL, V49, P325; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; STREET NE, 1991, FASEB J, V5, P171, DOI 10.1096/fasebj.5.2.1825981; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; TSICOPOULOS A, 1992, J IMMUNOL, V148, P2058; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356	25	88	88	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					764	772		10.1016/0091-6749(94)90185-6	http://dx.doi.org/10.1016/0091-6749(94)90185-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PM273	7930311				2022-12-18	WOS:A1994PM27300016
J	LINTNER, TJ; BRAME, KA				LINTNER, TJ; BRAME, KA			THE EFFECTS OF SEASON, CLIMATE, AND AIR-CONDITIONING ON THE PREVALENCE OF DERMATOPHAGOIDES MITE ALLERGENS IN HOUSEHOLD DUST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DERMATOPHAGOIDES; DUST MITES; ALLERGEN EXPOSURE	D-FARINAE; D-PTERONYSSINUS; MAJOR ALLERGEN; D-MICROCERAS; RADIOIMMUNOASSAY; ANTIGENS; EXTRACTS; HOMES; CAT	Background: Clinical evidence reveals a strong relationship between dust mite allergen levels and asthma. This study suggests the relative importance and interactions among factors that influence mite allergen levels in human dwellings. Methods: Dermatophagoides pteronyssinus allergen (Der p I) and D. farinae allergen (Der f I) were measured in 536 dust samples collected from 424 homes across the United States. Results: There were distinct seasonal fluctuations of Der p I and Der f I. Der p I rapidly increased to peak in July then gradually decreased through October. Der f I slowly rose to peak later, around September, before declining. Different climates in regions of the United States had no significant affect on the quantity of Der p I or Der f I. However, regional climate differences seemed to influence the prevalence of either D. pteronyssinus or D. farinae. Air-conditioning significantly reduced (p < 0.001) Der I mite allergens detected in the dust samples, and a tendency existed for Der f I to be higher than Der p I in air-conditioned homes. There was a significant (p < 0.01) interaction between air-conditioning and seasons. The most dramatic affect was observed during the summer months, the cooling season, from approximately May to September. Conclusions: These findings show that distinct seasonal fluctuations exist of D. pteronyssinus and D. farinae mite populations, and suggest that differences in the microclimate within homes may have a dramatic affect on Dermatophagoides mite populations.			LINTNER, TJ (corresponding author), VESPA LABS INC,RD 1,BOX 29,SPRING MILLS,PA 16875, USA.							[Anonymous], 1989, J ALLERGY CLIN IMMUN, V83, P416; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; CARPENTER GB, 1985, J ALLERGY CLIN IMMUN, V75, P121, DOI 10.1016/0091-6749(85)90201-5; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; Kern RA., 1921, MED CLIN N AM, V5, P751; LANG JD, 1978, ENVIRON ENTOMOL, V7, P281, DOI 10.1093/ee/7.2.281; LARSON DG, 1969, J MED ENTOMOL, V6, P295, DOI 10.1093/jmedent/6.3.295; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LIND P, 1986, ALLERGY, V41, P442, DOI 10.1111/j.1398-9995.1986.tb00325.x; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; LIND P, 1986, INT ARCH ALLER A IMM, V79, P60, DOI 10.1159/000233943; MURRAY AB, 1980, ANN ALLERGY, V45, P347; PLATTSMILLS TAE, 1985, INT ARCH ALLER A IMM, V77, P163; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V78, P398, DOI 10.1016/0091-6749(86)90024-2; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; SPIEKSMA FTM, 1967, THESIS LEIDEN; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; Waki S., 1973, Japanese J Sanit Zool, V23, P159; WHARTON GW, 1976, J MED ENTOMOL, V12, P577, DOI 10.1093/jmedent/12.6.577; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; [No title captured]	25	88	91	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1993	91	4					862	867		10.1016/0091-6749(93)90343-E	http://dx.doi.org/10.1016/0091-6749(93)90343-E			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KY251	8473674				2022-12-18	WOS:A1993KY25100006
J	SORVA, R; TURPEINEN, M; JUNTUNENBACKMAN, K; KARONEN, SL; SORVA, A				SORVA, R; TURPEINEN, M; JUNTUNENBACKMAN, K; KARONEN, SL; SORVA, A			EFFECTS OF INHALED BUDESONIDE ON SERUM MARKERS OF BONE METABOLISM IN CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; BONE METABOLISM; CALCIUM; CHILDREN; GLUCOCORTICOIDS; GROWTH; OSTEOCALCIN; PROCOLLAGENS	III PROCOLLAGEN PROPEPTIDES; GROWTH FACTOR-I; GLA-PROTEIN; ALKALINE-PHOSPHATASE; BIOCHEMICAL MARKERS; ORAL PREDNISOLONE; OSTEOCALCIN; DISEASE; CORTICOSTEROIDS; TURNOVER	The effects of inhaled glucocorticoids on serum markers of bone formation were evaluated in asthmatic children. Serum total alkaline phosphatase (AP), bone alkaline phosphatase (BAP), osteocalcin, and the novel marker of bone formation, carboxypropeptide of type I procollagen (PICP), were measured. In the cross-sectional part, long-term glucocorticoid users were compared with sodium cromoglycate (SCG) users. In the boys (n = 16), but not in the girls (n = 11), PICP was significantly lower in the glucocorticoid users than in the SCG users. PICP correlated positively with BAP (n = 54; groups combined, r = 0.29, p < 0.05). In the longitudinal part, the effects of inhaled budesonide or SCG, both used for the first time, were evaluated before and after 1 and 5 months of treatment. The budesonide dose was 800 mug/m2/day for 1 month and thereafter half of that. The SCG dose was 30 mg/day throughout the study. Only during budesonide use did osteocalcin and PICP decrease, the median osteocalcin by 8% at 1 month (p < 0.05) and by 6% at 5 months (n = 15), and PICP by 5% at 1 month (p < 0.05) and by 28% at 5 months (n = 7, p < 0.01). AP and BAP did not change significantly. Decreased PICP suggests decreased bone formation rate. PICP might be clinically useful as a marker of early adverse effects of glucocarticoids on bone.	UNIV HELSINKI,CENT HOSP,DEPT ALLERG DIS,SF-00290 HELSINKI 29,FINLAND; UNIV HELSINKI,CENT HOSP,CLIN LAB,SF-00290 HELSINKI 29,FINLAND	University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital								ALI N, 1991, BRIT MED J, V302, P1080, DOI 10.1136/bmj.302.6784.1080; BROWN JP, 1984, LANCET, V1, P1091; COLE DEC, 1985, J PEDIATR-US, V106, P770, DOI 10.1016/S0022-3476(85)80351-6; DAVIE MWJ, 1991, ANN CLIN BIOCHEM, V28, P194, DOI 10.1177/000456329102800216; DELMAS PD, 1990, ENDOCRIN METAB CLIN, V19, P1; DELMAS PD, 1986, J BONE MINER RES, V1, P333; DELMAS PD, 1985, BONE, V6, P339, DOI 10.1016/8756-3282(85)90326-6; DUDA RJ, 1988, J CLIN ENDOCR METAB, V66, P951, DOI 10.1210/jcem-66-5-951; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HODSMAN AB, 1991, J CLIN ENDOCR METAB, V72, P530, DOI 10.1210/jcem-72-3-530; HYAMS JS, 1988, J PEDIATR-US, V113, P249, DOI 10.1016/S0022-3476(88)80260-9; HYAMS JS, 1989, J PEDIATR GASTR NUTR, V8, P68, DOI 10.1097/00005176-198901000-00013; JENNINGS BH, 1991, EUR J CLIN PHARMACOL, V40, P77, DOI 10.1007/BF00315143; JENSEN LT, 1991, ACTA ENDOCRINOL-COP, V124, P278, DOI 10.1530/acta.0.1240278; JOHANSEN JS, 1988, J CLIN ENDOCR METAB, V67, P273, DOI 10.1210/jcem-67-2-273; KRUSE K, 1986, EUR J PEDIATR, V145, P27, DOI 10.1007/BF00441848; LITTLEWOOD JM, 1988, LANCET, V1, P115; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; MELKKO J, 1990, CLIN CHEM, V36, P1328; OIKARINEN A, 1990, 3RD INT S OST CONS D, P1644; PARFITT AM, 1987, J BONE MINER RES, V2, P427; REID DM, 1986, BMJ-BRIT MED J, V293, P1463, DOI 10.1136/bmj.293.6560.1463; Risteli J, 1991, J BONE MINER RES  S1, V6, pS251; ROSALKI SB, 1984, CLIN CHEM, V30, P1182; SCHMID C, 1989, ENDOCRINOLOGY, V125, P1575, DOI 10.1210/endo-125-3-1575; SIMON LS, 1984, J CLIN ENDOCR METAB, V58, P110, DOI 10.1210/jcem-58-1-110; SLOVIK DM, 1984, J CLIN ENDOCR METAB, V59, P228, DOI 10.1210/jcem-59-2-228; SMITH R, 1990, THORAX, V45, P573, DOI 10.1136/thx.45.8.573; SORVA R, 1984, ACTA PAEDIATR SCAND, V73, P527, DOI 10.1111/j.1651-2227.1984.tb09965.x; TARALLO P, 1990, SCAND J CLIN LAB INV, V50, P649, DOI 10.3109/00365519009089183; TEELUCKSINGH S, 1991, LANCET, V338, P60, DOI 10.1016/0140-6736(91)90058-W; TOOGOOD JH, 1991, J ALLERGY CLIN IMMUN, V88, P572, DOI 10.1016/0091-6749(91)90150-M; TRIVEDI P, 1991, PEDIATR RES, V30, P276, DOI 10.1203/00006450-199109000-00016; TURPEINEN M, 1991, J ALLERGY CLIN IMMUN, V88, P384, DOI 10.1016/0091-6749(91)90101-S; WOLTHERS OD, BMJ, V203, P163; WOOLSON RF, 1987, STATISTICAL METHODS, P274	36	88	88	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1992	90	5					808	815		10.1016/0091-6749(92)90106-C	http://dx.doi.org/10.1016/0091-6749(92)90106-C			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ319	1430706				2022-12-18	WOS:A1992JZ31900012
J	REDIER, H; CHANEZ, P; DEVOS, C; RIFAI, N; CLAUZEL, AM; MICHEL, FB; GODARD, P				REDIER, H; CHANEZ, P; DEVOS, C; RIFAI, N; CLAUZEL, AM; MICHEL, FB; GODARD, P			INHIBITORY EFFECT OF CETIRIZINE ON THE BRONCHIAL EOSINOPHIL RECRUITMENT INDUCED BY ALLERGEN INHALATION CHALLENGE IN ALLERGIC PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; EOSINOPHILS; BRONCHOALVEOLAR LAVAGE; ALLERGEN INHALATION CHALLENGE; CETIRIZINE	BRONCHOALVEOLAR LAVAGE; MAST-CELLS; INFLAMMATORY CELLS; INDUCED INCREASE; MILD ASTHMA; RESPONSIVENESS; HISTAMINE; TESTS; BRONCHOCONSTRICTION; BRONCHOPROVOCATION	In patients with asthma there is a recruitment of eosinophils in bronchoalveolar lavage fluid (BALF) after the late asthmatic reaction (LAR). Cetirizine is a selective H-1 antagonist that inhibits the eosinophil recruitment induced by allergen in the skin. The aim of this study was to evaluate whether cetirizine was able to inhibit the LAR-induced inflammatory reaction. Twelve allergic asymptomatic subjects with asthma (aged 18 to 58 years) without any treatment were enrolled in the study; FEV1 was >83% predicted in each case. An allergen inhalation-challenge test was performed to assess the presence of an LAR. In a double-blind, randomized, placebo-controlled study, the patients were treated for 8 days with either cetirizine, 15 mg twice a day (six patients, group 1), or placebo (six patients, group 2). On day 8, a second allergen inhalation-challenge test with the same allergen was performed, and BAL was realized 24 hours later; as usual 250 ml of saline was instilled by 50 ml aliquots, and the first recovery was analyzed separately. In each case, the LAR observed after treatment was similar to the first one. In placebo-treated patients, an increased number of cells, mainly eosinophils, was observed in the first recovery of BALF compared with the number in subsequent recoveries. These numbers were significantly higher than numbers observed in cetirizine-treated patients. Cetirizine did not modify significantly the allergen inhalation-challenge test, but it inhibited the recruitment of inflammatory cells, mainly eosinophils.	HOP UNIV AIGUELONGUE,AVE MAJOR FLANDRE,F-34059 MONTPELLIER,FRANCE; UNIV CLIN BRUSSELS,BRUSSELS,BELGIUM	Universite Libre de Bruxelles				chanez, pascal/0000-0003-4059-0917				AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; ADVENIER C, 1991, J ALLERGY CLIN IMMUN, V88, P104, DOI 10.1016/0091-6749(91)90307-A; BALZANO G, 1982, 4TH C INT SOC AER ME; BESLAY R, 1989, AM REV RESPIR DIS, V139, P806; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRIK A, 1987, J ALLERGY CLIN IMMUN, V80, P51, DOI 10.1016/S0091-6749(87)80190-2; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; COOKSON WOCM, 1989, AM REV RESPIR DIS, V139, P458, DOI 10.1164/ajrccm/139.2.458; CRIMI E, 1986, J ALLERGY CLIN IMMUN, V78, P908, DOI 10.1016/0091-6749(86)90239-3; CRIMI E, 1991, AM REV RESPIR DIS, V144, P1282, DOI 10.1164/ajrccm/144.6.1282; CRYSTAL RG, 1986, CHEST, V90, P122, DOI 10.1378/chest.90.1.122; CUTZ E, 1978, HISTOPATHOLOGY, V2, P407, DOI 10.1111/j.1365-2559.1978.tb01735.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; DIAZ P, 1984, J ALLERGY CLIN IMMUN, V74, P42; DIJKMAN JH, 1990, CLIN EXP ALLERGY, V20, P483, DOI 10.1111/j.1365-2222.1990.tb03140.x; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FADEL R, 1990, J ALLERGY CLIN IMMUN, V86, P314, DOI 10.1016/S0091-6749(05)80093-4; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; FICK RB, 1987, AM REV RESPIR DIS, V135, P1204; FILLEY WV, 1982, LANCET, V2, P11; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; GHOSH SK, 1991, J ALLERGY CLIN IMMUN, V87, P1010, DOI 10.1016/0091-6749(91)90424-M; GODARD P, 1987, B EUR PHYSIOPATH RES, V23, P73; GODARD P, 1981, NOUV PRESSE MED, V10, P3141; HENOCQ E, 1990, CLIN EXP ALLERGY, V20, P269, DOI 10.1111/j.1365-2222.1990.tb02682.x; KELLY C, 1988, THORAX, V43, P684, DOI 10.1136/thx.43.9.684; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; KLEMENTSSON H, 1990, J ALLERGY CLIN IMMUN, V86, P466, DOI 10.1016/S0091-6749(05)80201-5; KONTOUFILI K, 1990, ANN ALLERGY, V65, P517; KOPFERSCHMITT MC, 1990, EUR RESPIR J, V3, pS229; KOPFERSCHMITTKUBLER MC, 1987, J ALLERGY CLIN IMMUN, V80, P730, DOI 10.1016/0091-6749(87)90295-8; KURZEJA A, 1989, LANCET, V8637, P556; LAI CKW, 1989, CLIN EXP ALLERGY, V19, P209, DOI 10.1111/j.1365-2222.1989.tb02366.x; LAM S, 1987, J ALLERGY CLIN IMMUN, V80, P44, DOI 10.1016/S0091-6749(87)80189-6; LEPREVOST C, 1988, INT ARCH ALLER A IMM, V87, P9, DOI 10.1159/000234641; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P214; REED CE, 1986, J ALLERGY CLIN IMMUN, V77, P537, DOI 10.1016/0091-6749(86)90342-8; RIFAI E, 1989, AM REV RESPIR DIS, V142, P592; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; TERRAL C, 1983, B EUR PHYSIOPATH RES, V19, P51; TONNEL AB, 1983, LANCET, V1, P406; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; VANSCHAYCK CP, 1991, AM REV RESPIR DIS, V143, P145; VANVYVE T, 1991, AM REV RESPIR DIS, V143, P26; VENGE P, 1988, AM REV RESPIR DIS, V138, pS54, DOI 10.1164/ajrccm/138.6_Pt_2.S54; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WASSERFALLEN JB, 1991, ALLERGY CLIN IMMUN S, V1, P185; 1987, AM REV RESPIR DIS, V136, P225; 1980, ATS NEWS, P11; 1990, AM REV RESPIR DIS, V142, P481	59	88	89	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1992	90	2					215	224		10.1016/0091-6749(92)90074-C	http://dx.doi.org/10.1016/0091-6749(92)90074-C			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ423	1354225				2022-12-18	WOS:A1992JJ42300011
J	PELIKAN, Z; PELIKANFILIPEK, M				PELIKAN, Z; PELIKANFILIPEK, M			ROLE OF NASAL ALLERGY IN CHRONIC MAXILLARY SINUSITIS - DIAGNOSTIC-VALUE OF NASAL CHALLENGE WITH ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PELIKAN, Z (corresponding author), INST MED SCI DE KLOKKENBERG,DEPT ALLERGOLOGY & IMMUNOL,GALDERSEWEG 81,4836 AE BREDA,NETHERLANDS.							AUST R, 1976, Rhinology (Utrecht), V14, P43; AUST R, 1974, RHINOLOGY, V2, P25; ENGLISH GM, 1983, ALLERGY PRINCIPLES P, P1215; FRIEDMAN WH, 1984, CLIN REV ALLERG, V2, P409; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; JENEY E, 1989, J ALLERGY CLIN IMMUN, V83, P214; KUHN JP, 1986, J ALLERGY CLIN IMMUN, V77, P6, DOI 10.1016/0091-6749(86)90314-3; LOBER P, 1983, OTOLARYNGOLOGY, V1, P551; MIDDLETON E, 1988, J ALLERGY CLIN IMMUN, V81, P971, DOI 10.1016/0091-6749(88)90163-7; PEARLMAN DS, 1988, J ALLERGY CLIN IMMUN, V81, P962, DOI 10.1016/0091-6749(88)90161-3; Pelikan Z, 1988, Ned Tijdschr Geneeskd, V132, P329; PELIKAN Z, 1989, J ALLERGY CLIN IMMUN, V83, P243; PELIKAN Z, 1989, J ALLERGY CLIN IMMUN, V83, P214; PELIKAN Z, 1986, J ALLERGY CLIN IMMUN, V77, P245; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PELIKAN Z, 1982, ANN ALLERGY, V49, P200; PELIKAN Z, 1982, ANN ALLERGY, V49, P283; PELIKAN Z, 1977, ANN ALLERGY, V38, P263; PELIKAN Z, 1988, J ALLERGY CLIN IMMUN, V82, P1103, DOI 10.1016/0091-6749(88)90150-9; PELIKAN Z, 1989, J ALLERGY CLIN IMMUN, V83, P1068, DOI 10.1016/0091-6749(89)90448-X; PELIKAN Z, 1988, NEW ENGL REG ALLERGY, V9, P253; PELIKAN Z, 1983, ANN ALLERGY, V50, P395; RACHELEFSKY GS, 1982, J ALLERGY CLIN IMMUN, V69, P382, DOI 10.1016/0091-6749(82)90150-6; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; ROHR AS, 1984, CLIN REV ALLERG, V2, P387; SACHA RF, 1985, ANN ALLERGY, V54, P195; SHAPIRO GG, 1986, J ALLERGY CLIN IMMUN, V77, P59, DOI 10.1016/0091-6749(86)90324-6; SHAPIRO GG, 1988, J ALLERGY CLIN IMMUN, V81, P1025, DOI 10.1016/0091-6749(88)90173-X; SLAVIN RG, 1982, ANN ALLERGY, V49, P123; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V81, P1028, DOI 10.1016/0091-6749(88)90174-1; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; SLAVIN RG, 1988, NEW ENGL REG ALLERGY, V9, P253; STEINER D, 1989, J ALLERGY CLIN IMMUN, V83, P276; WILLIAMS HL, 1983, OTOLARYNGOLGOY, V3, P27; ZIZMOR J, 1983, OTOLARYNGOLOGY, V1, P1043	35	88	91	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	1				484	491		10.1016/S0091-6749(05)80203-9	http://dx.doi.org/10.1016/S0091-6749(05)80203-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EG454	2229810				2022-12-18	WOS:A1990EG45400007
J	RONCHETTI, R; MACRI, F; CIOFETTA, G; INDINNIMEO, L; CUTRERA, R; BONCI, E; ANTOGNONI, G; MARTINEZ, FD				RONCHETTI, R; MACRI, F; CIOFETTA, G; INDINNIMEO, L; CUTRERA, R; BONCI, E; ANTOGNONI, G; MARTINEZ, FD			INCREASED SERUM IGE AND INCREASED PREVALENCE OF EOSINOPHILIA IN 9-YEAR-OLD CHILDREN OF SMOKING PARENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											RONCHETTI, R (corresponding author), UNIV LA SAPIENZA,CATTEDRA CLIN PEDIAT 4,VIALE REGINA ELENA 324,I-00164 ROME,ITALY.		Cutrera, Renato/E-9894-2012	Cutrera, Renato/0000-0001-7711-5672; Bonci, Enea/0000-0003-3325-1124				BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P919, DOI 10.1016/0091-6749(87)90241-7; BEHRMAN RE, 1987, NELSON TXB PEDIATRIC, P1549; BONINI S, 1982, BRIT MED J, V284, P512, DOI 10.1136/bmj.284.6314.512-b; BURROWS B, 1980, AM REV RESPIR DIS, V122, P709, DOI 10.1164/arrd.1980.122.5.709; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; COSTABEL U, 1986, CHEST, V90, P39, DOI 10.1378/chest.90.1.39; DANIELE RP, 1977, AM REV RESPIR DIS, V116, P997; GERRARD JW, 1980, ANN ALLERGY, V44, P261; HALONEN M, 1982, J ALLERGY CLIN IMMUN, V69, P221, DOI 10.1016/0091-6749(82)90103-8; JONES JG, 1980, LANCET, V1, P66; KAUFFMANN F, 1986, AM REV RESPIR DIS, V134, P1172; LEHRER SB, 1980, AM REV RESPIR DIS, V121, P168; LEITCH AG, 1981, CLIN ALLERGY, V11, P257, DOI 10.1111/j.1365-2222.1981.tb01592.x; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; NORUSIS MJ, 1986, SPSS PC PLUS ADV STA; OSAKA F, 1985, Japanese Journal of Hygiene, V40, P789; OWNBY DR, 1988, J ALLERGY CLIN IMMUN, V82, P634, DOI 10.1016/0091-6749(88)90976-1; PETERSEN BH, 1983, CLIN IMMUNOL IMMUNOP, V27, P135, DOI 10.1016/0090-1229(83)90062-4; RIZK NW, 1984, J APPL PHYSIOL, V56, P723, DOI 10.1152/jappl.1984.56.3.723; Rothman K, 1986, MODERN EPIDEMIOLOGY; SILVERMAN NA, 1975, CLIN EXP IMMUNOL, V22, P285; SOPORI ML, 1985, CLIN IMMUNOL IMMUNOP, V36, P338, DOI 10.1016/0090-1229(85)90054-6; TAYLOR RG, 1985, THORAX, V40, P17, DOI 10.1136/thx.40.1.17; Wagner V, 1987, Czech Med, V10, P70; WARREN CPW, 1982, J ALLERGY CLIN IMMUN, V69, P370, DOI 10.1016/0091-6749(82)90148-8; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573, DOI 10.1164/arrd.1985.131.4.573; WITTEN ML, 1985, AM REV RESPIR DIS, V132, P321; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215; 1986, DHHS CDC878398 PUBL	29	88	90	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1990	86	3	1				400	407		10.1016/S0091-6749(05)80104-6	http://dx.doi.org/10.1016/S0091-6749(05)80104-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA859	2212412	Bronze			2022-12-18	WOS:A1990EA85900015
J	WANDERER, AA				WANDERER, AA			COLD URTICARIA SYNDROMES - HISTORICAL BACKGROUND, DIAGNOSTIC CLASSIFICATION, CLINICAL AND LABORATORY CHARACTERISTICS, PATHOGENESIS, AND MANAGEMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review									UNIV COLORADO, HLTH SCI CTR, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								AKIYAMA T, 1981, Journal of Dermatology (Tokyo), V8, P139; AMBROSINO SV, 1971, NEW YORK STATE J MED, V71, P1223; Anderson P C, 1967, Mo Med, V64, P916; Anderson R H, 1983, Va Med, V110, P549; AOKI T, 1982, CLIN EXP DERMATOL, V7, P377, DOI 10.1111/j.1365-2230.1982.tb02445.x; BACK O, 1978, ACTA DERM-VENEREOL, V58, P369; BEALL GN, 1963, J ALLERGY, V34, P8, DOI 10.1016/0021-8707(63)90080-7; BECKER RM, 1948, ARCH INTERN MED, V81, P630, DOI 10.1001/archinte.1948.00220230028004; BENCHETRIT E, 1982, ACTA HAEMATOL-BASEL, V68, P343; BENTLEYPHILLIPS CB, 1978, J INVEST DERMATOL, V71, P266, DOI 10.1111/1523-1747.ep12515101; BENTLEYPHILLIPS CB, 1976, LANCET, V2, P63; BJORKNER B, 1981, CONTACT DERMATITIS, V7, P338, DOI 10.1111/j.1600-0536.1981.tb04099.x; BLACKFORD LM, 1931, JAMA-J AM MED ASSOC, V96, P525; BONNETBLANC JM, 1983, PRESSE MED, V12, P1174; Bourdon H, 1866, B MEM SOC MED HOP P, V3, P259; BURNS MR, 1983, ANN INTERN MED, V98, P1025, DOI 10.7326/0003-4819-98-6-1025_3; CASALE TB, 1988, J ALLERGY CLIN IMMUN, V82, P758, DOI 10.1016/0091-6749(88)90076-0; CENTER DM, 1979, CLIN EXP IMMUNOL, V35, P112; CHANG TW, 1965, J AMER MED ASSOC, V193, P848, DOI 10.1001/jama.1965.03090100094041; CHODIRKER WB, 1985, J ALLERGY CLIN IMMUN, V76, P745, DOI 10.1016/0091-6749(85)90681-5; CLARKE GHV, 1969, ARCH DERMATOL, V100, P121, DOI 10.1001/archderm.1969.01610250127038; Costanzi J J, 1967, Clin Exp Immunol, V2, P167; COSTANZI JJ, 1969, J LAB CLIN MED, V74, P902; CURNOW JSH, 1978, MED BIOL ENG COMPUT, V16, P215, DOI 10.1007/BF02451925; CZARNETZKI BM, 1981, BRIT J DERMATOL, V104, P83, DOI 10.1111/j.1365-2133.1981.tb01716.x; DEFEO CP, 1962, ARCH DERMATOL, V85, P784; DOEGLAS HMG, 1974, ARCH DERMATOL, V110, P382, DOI 10.1001/archderm.110.3.382; DOEGLAS HMG, 1986, BRIT J DERMATOL, V114, P311, DOI 10.1111/j.1365-2133.1986.tb02822.x; DOEGLAS HMG, 1985, BRIT J DERMATOL, V112, P381, DOI 10.1111/j.1365-2133.1985.tb02309.x; DOEGLAS HMG, 1975, ARCH DERMATOL, V111, P979, DOI 10.1001/archderm.111.8.979; DUBBS AW, 1935, JAMA-J AM MED ASSOC, V104, P116; DUC J, 1986, ANN ALLERGY, V56, P355; DUCK H-J, 1971, Dermatologische Monatsschrift, V157, P491; Duke WW, 1924, J AMER MED ASSOC, V83, P3, DOI 10.1001/jama.1924.02660010007002; DUKE WW, 1932, J ALLERGY, V3, P408; DUNER HANS, 1960, ACTA ALLERGOL, V15, P417, DOI 10.1111/j.1398-9995.1960.tb02869.x; Dutta A K, 1976, J Indian Med Assoc, V66, P234; EADY RAJ, 1981, CLIN EXP DERMATOL, V6, P355, DOI 10.1111/j.1365-2230.1981.tb02318.x; EADY RAJ, 1978, LANCET, V1, P336; EHRLICH M, 1936, J MED SOC N J, V33, P477; FELDAKER M, 1956, ARCH DERMATOL, V73, P325, DOI 10.1001/archderm.1956.01550040019004; FITZMAURICE BT, 1935, NORTHWEST MED, V34, P443; FITZPATRICK TB, 1963, ARCH DERMATOL, V87, P495; FRANK D E, 1947, Ann Allergy, V5, P574; Gay M W, 1970, Cutis, V6, P1104; GOLDBERG EE, 1959, ANN INTERN MED, V50, P505, DOI 10.7326/0003-4819-50-2-505; GOREVIC PD, 1980, INT J DERMATOL, V19, P417, DOI 10.1111/j.1365-4362.1980.tb05893.x; GRANDEL KE, 1985, NEW ENGL J MED, V313, P405, DOI 10.1056/NEJM198508153130702; GREAVES MW, 1979, J INVEST DERMATOL, V73, P310; GREY HM, 1973, SEMIN HEMATOL, V10, P87; GRIEM S F, 1956, Am Pract Dig Treat, V7, P1335; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; Harris KE, 1929, HEART-J STUD CIRC, V14, P305; HAUPTMANN G, 1975, SCAND J HAEMATOL, V15, P22; HEAVEY DJ, 1986, J ALLERGY CLIN IMMUN, V78, P458, DOI 10.1016/0091-6749(86)90033-3; HENDERSON LL, 1958, J ALLERGY, V29, P122, DOI 10.1016/0021-8707(58)90097-2; HERLITZ G, 1953, INT ARCH ALLER A IMM, V4, P10, DOI 10.1159/000228003; HIGHET AS, 1979, BRIT J DERMATOL, V101, P51, DOI 10.1111/j.1365-2133.1979.tb15292.x; Horton BT, 1936, J AMER MED ASSOC, V107, P1263, DOI 10.1001/jama.1936.02770420001001; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; HUSTON DP, 1986, ANN INTERN MED, V104, P507, DOI 10.7326/0003-4819-104-4-507; ILLIG L, 1980, ACTA DERM-VENEREOL, V60, P373; ILLIG L, 1967, GERM MED MTH, V12, P392; INGANAS M, 1981, INT ARCH ALLER A IMM, V65, P51, DOI 10.1159/000232737; INOUE S, 1980, J ALLERGY CLIN IMMUN, V66, P299, DOI 10.1016/0091-6749(80)90025-1; JOHNSTON WE, 1982, NEW ENGL J MED, V306, P219, DOI 10.1056/NEJM198201283060406; JORGENSEN M, 1984, EUR J CLIN INVEST, V14, P135, DOI 10.1111/j.1365-2362.1984.tb02102.x; JUHLIN L, 1981, BRIT J DERMATOL, V104, P705, DOI 10.1111/j.1365-2133.1981.tb00759.x; JUHLIN L, 1961, JAMA-J AM MED ASSOC, V177, P371, DOI 10.1001/jama.1961.73040320001004; KALINER M, 1989, J ALLERGY CLIN IMMUN, V83, P510, DOI 10.1016/0091-6749(89)90031-6; KAPLAN AP, 1977, J ALLERGY CLIN IMMUN, V60, P324, DOI 10.1016/0091-6749(77)90113-0; KAPLAN AP, 1984, J ALLERGY CLIN IMMUN, V73, P453, DOI 10.1016/0091-6749(84)90354-3; KAPLAN AP, 1981, NEW ENGL J MED, V305, P1074, DOI 10.1056/NEJM198110293051808; KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P438; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KATAYAMA I, 1984, Journal of Dermatology (Tokyo), V11, P259; KATAYAMA I, 1983, Journal of Dermatology (Tokyo), V10, P377; KEAHEY TM, 1988, J ALLERGY CLIN IMMUN, V82, P256, DOI 10.1016/0091-6749(88)91008-1; KEAHEY TM, 1980, ARCH DERMATOL, V116, P174, DOI 10.1001/archderm.116.2.174; KELLY FJ, 1953, AM J MED, V15, P431, DOI 10.1016/0002-9343(53)90132-6; Kile RL., 1940, J AM MED ASS, V114, P1067, DOI [10.1001/jama.1940.62810120003010b, DOI 10.1001/JAMA.1940.62810120003010B]; KIVITY S, 1990, J ALLERGY CLIN IMMUN, V85, P52, DOI 10.1016/0091-6749(90)90220-X; KOBACKER JL, 1935, JAMA-J AM MED ASSOC, V105, P662; Kobza Black A, 1981, BR J CLIN PHARM, V12, P327; KOBZABLACK A, 1979, LANCET, V2, P964; KODA H, 1978, ARCH DERMATOL, V114, P784, DOI 10.1001/archderm.114.5.784; KRAMER DAVID W., 1951, ANGIOLOGY, V2, P283, DOI 10.1177/000331975100200406; LASS N, 1978, J ALLERGY CLIN IMMUN, V61, P195, DOI 10.1016/0091-6749(78)90461-X; LEIGH IM, 1974, T ST JOHNS HOSP DERM, V60, P40; LEMANSKE RF, 1982, JAMA-J AM MED ASSOC, V247, P1604, DOI 10.1001/jama.247.11.1604; LERNER AB, 1947, AM J MED SCI, V214, P410, DOI 10.1097/00000441-194710000-00009; LEWIS J, 1981, J ALLERGY CLIN IMMUN, V68, P432, DOI 10.1016/0091-6749(81)90197-4; LINDELL SE, 1961, J INVEST DERMATOL, V36, P17, DOI 10.1038/jid.1961.6; LOCKHART CH, 1973, ANESTHESIOLOGY, V38, P96, DOI 10.1097/00000542-197301000-00025; MANDEL EH, 1961, ARCH DERMATOL, V84, P880; MARTENS BPM, 1975, ACTA DERM-VENEREOL, V55, P121; MARTIN S, 1981, CUTIS, V27, P173; MATHEWS K P, 1970, Algerie Medicale, V72, P241; MATHEWS KP, 1981, NEW ENGL J MED, V305, P1090, DOI 10.1056/NEJM198110293051814; MATTHEWS CN, 1970, BRIT J DERMATOL, V82, P91; MATTHEWS CNA, 1977, BRIT J DERMATOL, V97, P32, DOI 10.1111/j.1365-2133.1977.tb14313.x; MCGOVERN JP, 1948, J ALLERGY, V19, P408, DOI 10.1016/0021-8707(48)90038-0; MILLER DA, 1968, AM J MED, V44, P68, DOI 10.1016/0002-9343(68)90238-6; MISCH K, 1983, ACTA DERM-VENEREOL, V63, P163; MOROZ LA, 1971, IMMUNOLOGICAL DISEAS, P459; MORRISON JGL, 1977, BRIT J DERMATOL, V97, P99, DOI 10.1111/j.1365-2133.1977.tb15435.x; MULLER SA, 1961, ARCH DERMATOL, V83, P930, DOI 10.1001/archderm.1961.01580120042009; NEITTAANMAKI H, 1984, J AM ACAD DERMATOL, V11, P483, DOI 10.1016/S0190-9622(84)70196-4; NEITTAANMAKI H, 1985, J AM ACAD DERMATOL, V13, P636, DOI 10.1016/S0190-9622(85)70208-3; NILSSON T, 1984, ACTA DERM-VENEREOL, V64, P197; NOTIER VA, 1946, P STAFF M MAYO CLIN, V21, P170; OBERMAYER ME, 1963, ARCH DERMATOL, V87, P269, DOI 10.1001/archderm.1963.01590140131023; ORMEROD AD, 1988, J ALLERGY CLIN IMMUN, V82, P586, DOI 10.1016/0091-6749(88)90968-2; OSBORNE ED, 1947, ARCH DERMATOL SYPH, V55, P309, DOI 10.1001/archderm.1947.01520030002001; PERRY EL, 1947, AM J MED SCI, V214, P553, DOI 10.1097/00000441-194711000-00014; RAPAPORT J, 1957, ARCH DERMATOL, V75, P607; RAWNSLEY HM, 1968, ARCH DERMATOL, V98, P12, DOI 10.1001/archderm.98.1.12; RITZMANN SE, 1961, ARCH INTERN MED, V107, P754, DOI 10.1001/archinte.1961.03620050120014; ROEPETERSEN J, 1978, CONTACT DERMATITIS, V4, P59; ROLLINGS RC, 1985, FACTS FORMULAS; ROSE B, 1954, J ALLERGY, V25, P168, DOI 10.1016/0021-8707(54)90155-0; ROSE B, 1947, AM J MED, V3, P545, DOI 10.1016/0002-9343(47)90200-3; ROSE BRAM, 1941, JOUR ALLERGY, V12, P327, DOI 10.1016/S0021-8707(41)90260-5; Roszkiewicz J, 1985, Przegl Dermatol, V72, P536; ROTHSCHILD JE, 1949, J ALLERGY, V20, P62, DOI 10.1016/0021-8707(49)90084-2; SAMSOE-JENSEN T, 1955, Acta Derm Venereol, V35, P107; SARKANY I, 1965, P ROY SOC MED, V58, P622, DOI 10.1177/003591576505800826; SARKANY I, 1971, BRIT J DERMATOL, V85, P46; SATTLER TA, 1979, J INVEST DERMATOL, V72, P269; Saylor LL, 1936, AM J MED SCI, V192, P388, DOI 10.1097/00000441-193609000-00011; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SEROPIAN E, 1984, ALLERGOL IMMUNOPATH, V12, P303; SHAFAR J, 1965, LANCET, V2, P431; SHERMAN WB, 1950, J ALLERGY, V21, P414, DOI 10.1016/0021-8707(50)90017-7; SIBBALD RG, 1984, DERMATOL CLIN, V3, P62; SIGLER RW, 1979, J ALLERGY CLIN IMMUN, V63, P35, DOI 10.1016/0091-6749(79)90159-3; SIGLER RW, 1980, J ALLERGY CLIN IMMUN, V65, P309, DOI 10.1016/0091-6749(80)90161-X; SOLOMON LM, 1966, ARCH DERMATOL, V94, P156, DOI 10.1001/archderm.94.2.156; SOTER NA, 1975, CLIN RES, V23, pA386; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; SOTER NA, 1977, J ALLERGY CLIN IMMUN, V59, P294, DOI 10.1016/0091-6749(77)90050-1; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; STEINHARDT MJ, 1953, J ALLERGY, V24, P335, DOI 10.1016/0021-8707(53)90178-6; STPIERRE JP, 1985, ANN ALLERGY, V55, P840; TENNENBA.JI, 1973, J ALLERGY CLIN IMMUN, V51, P57, DOI 10.1016/0091-6749(73)90009-2; TINDALL JP, 1969, ARCH INTERN MED, V124, P129, DOI 10.1001/archinte.124.2.129; TING S, 1984, PEDIATRICS, V73, P105; TING S, 1985, J ALLERGY CLIN IMMUN, V75, P421, DOI 10.1016/0091-6749(85)90081-8; TONNESEN MG, 1985, CLIN RES, V33, pA690; TOTHKASA I, 1981, ARCH DERMATOL RES, V271, P447, DOI 10.1007/BF00406691; TOTHKASA I, 1983, J INVEST DERMATOL, V80, P34, DOI 10.1111/1523-1747.ep12530993; Urbach E, 1939, ARCH DERMATOL SYPH, V39, P987, DOI 10.1001/archderm.1939.01480240035003; Urback E, 1941, ARCH DERMATOL SYPH, V43, P366, DOI 10.1001/archderm.1941.01490200148014; VELOU A, 1964, J Indian Med Assoc, V43, P401; VILLACORTE GV, 1970, J ALLERGY, V45, P122; WANDERER AA, 1979, HOSP PRACT, V14, P136, DOI 10.1080/21548331.1979.11707566; WANDERER AA, 1977, ARCH DERMATOL, V113, P1375, DOI 10.1001/archderm.113.10.1375; WANDERER AA, 1986, J ALLERGY CLIN IMMUN, V78, P417, DOI 10.1016/0091-6749(86)90027-8; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P366, DOI 10.1016/0091-6749(71)90083-2; WANDERER AA, 1983, ARCH DERMATOL, V119, P145, DOI 10.1001/archderm.119.2.145; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P13, DOI 10.1016/0091-6749(71)90050-9; WANDERER AA, IN PRESS J ALLERGY C; WASSERMAN SI, 1988, HOSP PRACT, V23, P49; WASSERMAN SI, 1982, CLIN EXP IMMUNOL, V47, P570; WASSERMAN SI, 1984, J ALLERGY CLIN IMMUN, V74, P275, DOI 10.1016/0091-6749(84)90258-6; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756; Weiss E, 1932, ARCH DERMATOL SYPH, V25, P823, DOI 10.1001/archderm.1932.01450020849005; WINKELMANN RK, 1985, ARCH DERMATOL RES, V278, P37, DOI 10.1007/BF00412493; WOZEL VG, 1981, DERMATOL MONATSSCHR, V167, P30; WU LYF, 1983, ANN ALLERGY, V50, P271	171	88	89	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1990	85	6					965	981		10.1016/0091-6749(90)90037-5	http://dx.doi.org/10.1016/0091-6749(90)90037-5			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DK509	2191995				2022-12-18	WOS:A1990DK50900001
J	HOFFMAN, DR; DOVE, DE; JACOBSON, RS				HOFFMAN, DR; DOVE, DE; JACOBSON, RS			ALLERGENS IN HYMENOPTERA VENOM .20. ISOLATION OF 4 ALLERGENS FROM IMPORTED FIRE ANT (SOLENOPSIS-INVICTA) VENOM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HOFFMAN, DR (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PATHOL,GREENVILLE,NC 27858, USA.							AUKRUST L, 1982, ALLERGY, V37, P265, DOI 10.1111/j.1398-9995.1982.tb01909.x; BAER H, 1977, ANN ALLERGY, V38, P378; BAER H, 1979, TOXICON, V17, P397, DOI 10.1016/0041-0101(79)90267-8; BRAND JM, 1972, TOXICON, V10, P259, DOI 10.1016/0041-0101(72)90011-6; BUTCHER BT, 1985, J ALLERGY CLIN IMMUN, V75, P147, DOI 10.1016/0091-6749(85)90306-9; EINARSSON R, 1982, ALLERGY, V37, P273, DOI 10.1111/j.1398-9995.1982.tb01910.x; HABERMANN E, 1972, ANAL BIOCHEM, V50, P163, DOI 10.1016/0003-2697(72)90495-2; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P828, DOI 10.1016/0091-6749(88)90085-1; HOFFMAN DR, 1983, J ALLERGY CLIN IMMUN, V71, P481, DOI 10.1016/0091-6749(83)90465-7; HOFFMAN DR, 1984, ANN ALLERGY, V52, P276; HOFFMAN DR, 1986, J ALLERGY CLIN IMMUN, V78, P337, DOI 10.1016/S0091-6749(86)80086-0; HOFFMAN DR, 1984, J ALLERGY CLIN IMMUN, V74, P93, DOI 10.1016/0091-6749(84)90094-0; HOFFMAN DR, 1987, CLIN REV ALLERG, V5, P75; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P364, DOI 10.1016/0091-6749(77)90019-7; HOFFMAN DR, 1987, J ALLERGY CLIN IMMUN, V80, P300, DOI 10.1016/0091-6749(87)90035-2; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P599, DOI 10.1016/0091-6749(85)90036-3; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P606, DOI 10.1016/0091-6749(85)90037-5; JOHANSSON SGO, 1985, J ALLERGY CLIN IMMUN, V75, P208, DOI 10.1016/0091-6749(85)90551-2; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V71, P505, DOI 10.1016/0091-6749(83)90469-4; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1984, ARCH BIOCHEM BIOPHYS, V230, P1, DOI 10.1016/0003-9861(84)90080-8; MARSH DG, 1986, B WORLD HEALTH ORGAN, V64, P767; NORDVALL SL, 1985, J ALLERGY CLIN IMMUN, V75, P122, DOI 10.1016/0091-6749(85)90207-6; SHIPOLIN.RA, 1974, EUR J BIOCHEM, V48, P465, DOI 10.1111/j.1432-1033.1974.tb03787.x; STABLEIN JJ, 1987, CLIN REV ALLERG, V5, P161; WATKINS DJ, 1987, J ALLERGY CLIN IMMUN, V79, P217; WOOD CL, 1983, TOXICON, V21, P291, DOI 10.1016/0041-0101(83)90014-4	28	88	92	1	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				818	827		10.1016/0091-6749(88)90084-X	http://dx.doi.org/10.1016/0091-6749(88)90084-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	3192865				2022-12-18	WOS:A1988R170800016
J	AGARWAL, MK; SWANSON, MC; REED, CE; YUNGINGER, JW				AGARWAL, MK; SWANSON, MC; REED, CE; YUNGINGER, JW			AIRBORNE RAGWEED ALLERGENS - ASSOCIATION WITH VARIOUS PARTICLE SIZES AND SHORT RAGWEED PLANT-PARTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901; MAYO MED SCH,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO MED SCH,DEPT INTERNAL MED,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic					NIAID NIH HHS [AI-16791] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016791] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL MK, 1983, J ALLERGY CLIN IMMUN, V72, P40, DOI 10.1016/0091-6749(83)90050-7; AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; BURTON RM, 1973, JAPCA J AIR WASTE MA, V23, P277, DOI 10.1080/00022470.1973.10469774; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; EATON WC, 1973, CALIBRATION ANDERSEN; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; HUSSAIN R, 1981, J ALLERGY CLIN IMMUN, V67, P217, DOI 10.1016/0091-6749(81)90064-6; LARSON JB, 1975, J ALLERGY CLIN IMMUN, V56, P112, DOI 10.1016/0091-6749(75)90115-3; LOWELL FC, 1973, J ALLERGY CLIN IMMUN, V51, P187, DOI 10.1016/0091-6749(73)90024-9; MARSH DG, 1981, J ALLERGY CLIN IMMUN, V67, P206, DOI 10.1016/0091-6749(81)90063-4; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P789; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; REBHUN J, 1954, J ALLERGY, V25, P407, DOI 10.1016/0021-8707(54)90005-2; SHAFIEE A, 1973, J PHARM SCI, V62, P1654, DOI 10.1002/jps.2600621015; SHAFIEE A, 1973, IN VITRO CELL DEV B, V9, P19; SOLOMON WR, 1983, J ALLERGY CLIN IMMUN, V72, P443, DOI 10.1016/0091-6749(83)90579-1; SWANSON MC, 1984, AM REV RESPIR DIS, V129, P844, DOI 10.1164/arrd.1984.129.5.844; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN, V69, P522, DOI 10.1016/0091-6749(82)90177-4; Yunginger J. W., 1980, MANUAL CLIN IMMUNOLO, P778	20	88	88	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	5					687	693		10.1016/0091-6749(84)90231-8	http://dx.doi.org/10.1016/0091-6749(84)90231-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TT169	6501741				2022-12-18	WOS:A1984TT16900006
J	NOVEY, HS; FAIRSHTER, RD; SALNESS, K; SIMON, RA; CURD, JG				NOVEY, HS; FAIRSHTER, RD; SALNESS, K; SIMON, RA; CURD, JG			POSTPRANDIAL EXERCISE-INDUCED ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF IRVINE,DEPT MED,ORANGE,CA 92668; UNIV CALIF IRVINE,DEPT CLIN RES,ORANGE,CA 92668	University of California System; University of California Irvine; University of California System; University of California Irvine					PHS HHS [00529-01A2] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CAMPBELL IT, 1981, ANESTHESIOLOGY, V55, P46, DOI 10.1097/00000542-198107000-00010; CODES JE, 1975, LUNG FUNCTION ASSESS, P35; DENO NS, 1979, J APPL PHYSIOL, V46, P1196, DOI 10.1152/jappl.1979.46.6.1196; FELIG P, 1982, NEW ENGL J MED, V306, P895, DOI 10.1056/NEJM198204153061503; GRANT A, 1982, J ALLERGY CLIN IMMUN, V69, P103; HARRIES MG, 1979, CLIN ALLERGY, V9, P437, DOI 10.1111/j.1365-2222.1979.tb02506.x; HOFFMAN JR, 1980, ANN EMERG MED, V9, P419, DOI 10.1016/S0196-0644(80)80155-7; JONES NL, 1975, NEW ENGL J MED, V293, P541; Judy WV, 1976, PHYSIOLOGY; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P319, DOI 10.1016/0091-6749(81)90158-5; KIDD J, 1982, Journal of Allergy and Clinical Immunology, V69, P103; KOHLER PF, 1967, J IMMUNOL, V99, P1211; LIEBERMAN P, 1981, 37TH P ANN M AM AC A, P51; LONGLEY S, 1982, Journal of Allergy and Clinical Immunology, V69, P103; MATHEWS K P, 1970, Algerie Medicale, V72, P241; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; NITSCHE JF, 1981, AM J CLIN PATHOL, V76, P679; NORMAN W, 1980, PHARM BASIS THERAPEU, pCH8; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; Shields J M, 1981, J Kans Med Soc, V82, P412; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SOBOL BJ, 1976, AM J MED, V60, P619, DOI 10.1016/0002-9343(76)90495-2; SOTER N A, 1982, Journal of Allergy and Clinical Immunology, V69, P103; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; TSUTSUMI E, 1979, BRIT MED J, V2, P1480, DOI 10.1136/bmj.2.6203.1480; WASSERMAN K, 1975, AM REV RESPIR DIS, V112, P219	27	88	89	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	5					498	504		10.1016/0091-6749(83)90468-2	http://dx.doi.org/10.1016/0091-6749(83)90468-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QQ742	6841829				2022-12-18	WOS:A1983QQ74200011
J	SHIBASAKI, M; SUZUKI, S; NEMOTO, H; KUROUME, T				SHIBASAKI, M; SUZUKI, S; NEMOTO, H; KUROUME, T			ALLERGENICITY AND LYMPHOCYTE-STIMULATING PROPERTY OF RICE PROTEIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SHIBASAKI, M (corresponding author), GUMMA UNIV,SCH MED,DEPT PEDIAT,MAEBASHI,GUMMA 371,JAPAN.								0	88	93	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	4					259	265		10.1016/0091-6749(79)90141-6	http://dx.doi.org/10.1016/0091-6749(79)90141-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HQ469	479477				2022-12-18	WOS:A1979HQ46900005
J	NORMAN, PS; WINKENWERDER, WL; LICHTENSTEIN, LM				NORMAN, PS; WINKENWERDER, WL; LICHTENSTEIN, LM			TRIALS OF ALUM-PRECIPITATED POLLEN EXTRACTS IN TREATMENT OF HAY-FEVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; GARRISON WT, 1934, PUBLIC HEALTH REP, V49, P462; LEVY DA, 1967, J IMMUNOL, V99, P1068; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN, 1971, ANN INTERN MED, V75, P663; LICHTENSTEIN LM, 1968, J ALLERGY, V41, P49, DOI 10.1016/0021-8707(68)90007-5; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P169; MARSH DG, 1970, IMMUNOLOGY, V18, P703; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SHERMAN WB, PERSONAL COMMUNICATI; Sledge RF, 1938, US NAVAL MED B, V36, P18; STULL ARTHUR, 1940, JOUR ALLERGY, V11, P439, DOI 10.1016/S0021-8707(40)90456-7	18	88	88	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	1					31	+		10.1016/0091-6749(72)90077-2	http://dx.doi.org/10.1016/0091-6749(72)90077-2			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M9284	4113507				2022-12-18	WOS:A1972M928400004
J	Sims, JT; Krishnan, V; Chang, CY; Engle, SM; Casalini, G; Rodgers, GH; Bivi, N; Nickoloff, BJ; Konrad, RJ; de Bono, S; Higgs, RE; Benschop, RJ; Ottaviani, S; Cardoso, A; Nirula, A; Corbellino, M; Stebbing, J				Sims, Jonathan T.; Krishnan, Venkatesh; Chang, Ching-Yun; Engle, Sarah M.; Casalini, Giacomo; Rodgers, George H.; Bivi, Nicoletta; Nickoloff, Brian J.; Konrad, Robert J.; de Bono, Stephanie; Higgs, Richard E.; Benschop, Robert J.; Ottaviani, Silvia; Cardoso, Anabela; Nirula, Ajay; Corbellino, Mario; Stebbing, Justin			Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COVID-19; biomarkers; cardiovascular; inflammation; Ordinal Scale; baricitinib	LIGAND; PTX3	Background: Physicians treating patients with coronavirus disease 2019 (COVID-19) increasingly believe that the hyperinflammatory acute stage of COVID-19 results in a cytokine storm. The circulating biomarkers seen across the spectrum of COVID-19 have not been characterized compared with healthy controls, but such analyses are likely to yield insights into the pursuit of interventions that adequately reduce the burden of these cytokine storms. Objective: To identify and characterize the host inflammatory response to severe acute respiratory syndrome coronavirus 2 infection, we assessed levels of proteins related to immune responses and cardiovascular disease in patients stratified as mild, moderate, and severe versus matched healthy controls. Methods: Blood samples from adult patients hospitalized with COVID-19 were analyzed using high-throughput and ultrasensitive proteomic platforms and compared with ageand sex-matched healthy controls to provide insights into differential regulation of 185 markers. Results: Results indicate a dominant hyperinflammatory milieu in the circulation and vascular endothelial damage markers within patients with COVID-19, and strong biomarker association with patient response as measured by Ordinal Scale. As patients progress, we observe statistically significant dysregulation of IFN-g, IL-1RA, IL-6, IL-10, IL-19, monocyte chemoattractant protein (MCP)-1, MCP-2, MCP-3, CXCL9, CXCL10, CXCL5, ENRAGE, and poly (ADP-ribose) polymerase 1. Furthermore, in a limited series of patients who were sampled frequently, confirming reliability and reproducibility of our assays, we demonstrate that intervention with baricitinib attenuates these circulating biomarkers associated with the cytokine storm. Conclusions: These wide-ranging circulating biomarkers show an association with increased disease severity and may help stratify patients and selection of therapeutic options. They also provide insights into mechanisms of severe acute respiratory syndrome coronavirus 2 pathogenesis and the host response.	[Sims, Jonathan T.; Krishnan, Venkatesh; Chang, Ching-Yun; Engle, Sarah M.; Rodgers, George H.; Bivi, Nicoletta; Nickoloff, Brian J.; Konrad, Robert J.; de Bono, Stephanie; Higgs, Richard E.; Benschop, Robert J.; Cardoso, Anabela; Nirula, Ajay] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Casalini, Giacomo] Univ Milan, Luigi Sacco Dept Clin & Biomed Sci, Milan, Italy; [Ottaviani, Silvia; Stebbing, Justin] Imperial Coll, Dept Surg & Canc, London, England; [Corbellino, Mario] ASST Fatebenefratelli Sacco, Div Infect Dis, Milan, Italy	Eli Lilly; University of Milan; Imperial College London	Stebbing, J (corresponding author), Imperial Coll, Hammersmith Hosp, ICTEM Bldg,Du Cane Rd, London W12 0NN, England.; Krishnan, V (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA.	j.stebbing@imperial.ac.uk; krishnan_gary@lilly.com; j.stebbing@imperial.ac.uk		Krishnan, Venkatesh/0000-0002-3295-6598; Stebbing, Justin/0000-0002-1117-6947; Casalini, Giacomo/0000-0003-0740-5361				Assarsson E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095192; Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830; El-Shahhat N, 2011, EGYPT HEART J, V63, P131, DOI 10.1016/j.ehj.2011.08.024; Fazzini F, 2001, ARTHRITIS RHEUM, V44, P2841, DOI 10.1002/1529-0131(200112)44:12<2841::AID-ART472>3.0.CO;2-6; Folkersen L, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006706; Kitamura T, 2015, NAT REV IMMUNOL, V15, P73, DOI 10.1038/nri3789; Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727; Konrad RJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41609-z; Lau-Kilby AW, 2011, P NATL ACAD SCI USA, V108, P2408, DOI 10.1073/pnas.1009738108; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Morine KJ, 2018, CIRCULATION, V138, P513, DOI 10.1161/CIRCULATIONAHA.117.031635; Muller B, 2001, CRIT CARE MED, V29, P1404, DOI 10.1097/00003246-200107000-00017; Pacher P, 2007, CARDIOVASC DRUG REV, V25, P235, DOI 10.1111/j.1527-3466.2007.00018.x; Pechkovsky DV, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-75; Peterson RL, 2019, CONT CLIN TRIAL COMM, V15, DOI 10.1016/j.conctc.2019.100401; Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; van de Veerdonk FL, 2020, 20200523 MEDRXIV; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; Wilk AJ, 2020, NAT MED, V26, P1070, DOI [10.1038/s41591-020-0944-y, 10.1101/2020.04.17.20069930]; Yang Y, 2020, 2020030220029975 MED; Zhao J, 2020022320026690 MED	22	87	90	2	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					107	111		10.1016/j.jaci.2020.08.031	http://dx.doi.org/10.1016/j.jaci.2020.08.031		JAN 2021	5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	32920092	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000613645900014
J	Kim, BS; Howell, MD; Sun, K; Papp, K; Nasir, A; Kuligowski, ME				Kim, Brian S.; Howell, Michael D.; Sun, Kang; Papp, Kim; Nasir, Adnan; Kuligowski, Michael E.		INCB 18424-206 Study Investigators	Treatment of atopic dermatitis with ruxolitinib cream (JAKI/JAK2 inhibitor) or triamcinolone cream	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; CCL17; IgE; itch; JAK inhibitor; Janus kinase; ruxolitinib; topical	JANUS KINASE INHIBITOR; INNATE LYMPHOID-CELLS; INFLAMMATION; MODERATE; DISEASE; ECZEMA; ADULTS; ACTIVATION; GUIDELINES; MANAGEMENT	Background: Atopic dermatitis (AD) is a highly pruritic chronic inflammatory skin disorder. Ruxolitinib, a selective inhibitor of Janus kinase 1 and Janus kinase 2, potently suppresses cytokine signaling involved in AD pathogenesis. Objective: We sought to evaluate the efficacy and safety of ruxolitinib (RUX) cream in adults with AD. Methods: In this phase 2 study (NCT03011892), 307 adult patients with AD, an Investigator's Global Assessment score of 2 or 3 (mild or moderate), and 3% to 20% affected body surface area were equally randomized for 8 weeks of double-blind treatment to RUX (1.5% twice daily [BID], 1.5% once daily [QD], 0.5% QD, 0.15% QD), vehicle, or triamcinolone cream (0.1% BID for 4 weeks, then vehicle for 4 weeks). Subsequently, patients could apply 1.5% RUX BID for 4 additional weeks of open-label treatment. The primary end point was the comparison between 1.5% RUX cream BID and vehicle in mean percentage change from baseline in Eczema Area and Severity Index at week 4. Results: All RUX regimens demonstrated therapeutic benefit at week 4; 1.5% BID provided the greatest improvement in Eczema Area and Severity Index (71.6% vs 15.5%; P <.0001) and Investigator's Global Assessment responses (38.0% vs 7.7%; P <.001) versus vehicle. Rapid reductions in the itch numerical rating scale score occurred within 36 hours (1.5% BID vs vehicle, 1.8 vs 0.2; P <.0001) and were sustained through 12 weeks. Patients who transitioned to 1.5% RUX BID improved in all measures. RUX was not associated with clinically significant application-site reactions. Conclusions: RUX cream provided rapid and sustained improvements in AD symptoms and was well tolerated.	[Kim, Brian S.] Washington Univ, Sch Med, St Louis, MO 63130 USA; [Howell, Michael D.; Sun, Kang; Kuligowski, Michael E.] Incyte Corp, Wilmington, DE USA; [Papp, Kim] K Papp Clin Res & Prob Med Res, Waterloo, ON, Canada; [Nasir, Adnan] Wake Res Associates LLC, Raleigh, NC USA	Washington University (WUSTL); Incyte	Kim, BS (corresponding author), Washington Univ, Sch Med, Dept Med, 660 South Euclid Ave,Box 8123, St Louis, MO 63110 USA.	briankim@wustl.edu	Kim, Brian/GZK-6649-2022	Kim, Brian/0000-0002-8100-7161	Incyte Corporation	Incyte Corporation	Writing assistance was provided by Tania Iqbal, PhD, at Complete Healthcare Communications, LLC (NorthWales, Pa), a CHC Group company, and was funded by Incyte Corporation. We acknowledge Beth Rumberger and Sherry Owens for their assistance in the analysis of exploratory biomarkers and May Venturanza for her contribution in writing the study protocol and review of the manuscript.	Amano W, 2015, J ALLERGY CLIN IMMUN, V136, P667, DOI 10.1016/j.jaci.2015.03.051; Bao Lei, 2013, JAKSTAT, V2, pe24137, DOI 10.4161/jkst.24137; Bissonnette R, 2016, BRIT J DERMATOL, V175, P902, DOI 10.1111/bjd.14871; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Cotter DG, 2018, J AM ACAD DERMATOL, V78, pS53, DOI 10.1016/j.jaad.2017.12.019; Damsky W, 2017, J AM ACAD DERMATOL, V76, P736, DOI 10.1016/j.jaad.2016.12.005; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Drucker AM, 2017, J INVEST DERMATOL, V137, P26, DOI 10.1016/j.jid.2016.07.012; Eichenfield LF, 2014, J AM ACAD DERMATOL, V71, P116, DOI 10.1016/j.jaad.2014.03.023; Fridman JS, 2011, J INVEST DERMATOL, V131, P1838, DOI 10.1038/jid.2011.140; Gandhi NA, 2016, NAT REV DRUG DISCOV, V15, P35, DOI 10.1038/nrd4624; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Guttman-Yassky E, 2019, J AM ACAD DERMATOL, V80, P913, DOI 10.1016/j.jaad.2018.01.018; GuttmanYassky E, 2018, EUR AC DERM VEN ANN; Hay RJ, 2014, J INVEST DERMATOL, V134, P1527, DOI 10.1038/jid.2013.446; Imai Y, 2013, P NATL ACAD SCI USA, V110, P13921, DOI 10.1073/pnas.1307321110; Jacob SE, 2006, J AM ACAD DERMATOL, V54, P723, DOI 10.1016/j.jaad.2005.12.028; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Kaufman BP, 2018, EXP DERMATOL, V27, P340, DOI 10.1111/exd.13514; Kim BS, 2014, J IMMUNOL, V193, P3717, DOI 10.4049/jimmunol.1401307; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Lima H, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-017-0210-0; Mashiko S, 2015, J ALLERGY CLIN IMMUN, V136, P351, DOI 10.1016/j.jaci.2015.01.033; Nakagawa H, 2018, BRIT J DERMATOL, V178, P424, DOI 10.1111/bjd.16014; Oetjen LK, 2017, CELL, V171, P217, DOI 10.1016/j.cell.2017.08.006; Ott H, 2009, ACTA DERM-VENEREOL, V89, P257, DOI 10.2340/00015555-0627; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Quintas-Cardama A, 2010, BLOOD, V115, P3109, DOI 10.1182/blood-2009-04-214957; Rochman Y, 2010, P NATL ACAD SCI USA, V107, P19455, DOI 10.1073/pnas.1008271107; Roediger B, 2013, NAT IMMUNOL, V14, P564, DOI 10.1038/ni.2584; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Schuttelaar MLA, 2008, J EUR ACAD DERMATOL, V22, P1076, DOI 10.1111/j.1468-3083.2008.02716.x; Schwartz DM, 2017, NAT REV DRUG DISCOV, V16, P843, DOI 10.1038/nrd.2017.201; Silverberg JI, 2018, ANN ALLERG ASTHMA IM, V121, P340, DOI 10.1016/j.anai.2018.07.006; Silverberg JI, 2015, J INVEST DERMATOL, V135, P56, DOI 10.1038/jid.2014.325; Tokura Y, 2010, J DERMATOL SCI, V58, P1, DOI 10.1016/j.jdermsci.2010.02.008; Trier AM, 2018, CURR OPIN IMMUNOL, V54, P7, DOI 10.1016/j.coi.2018.05.005; Wang J, 2017, CLIN EXP ALLERGY, V47, P1456, DOI 10.1111/cea.12979; Wei WH, 2018, J DERMATOL, V45, P150, DOI 10.1111/1346-8138.14116; Welsch K, 2017, EUR J IMMUNOL, V47, P1096, DOI 10.1002/eji.201646680; Wollenberg A, 2018, J EUR ACAD DERMATOL, V32, P657, DOI 10.1111/jdv.14891; Woo Taylor Evart, 2019, Skin Therapy Lett, V24, P4; Zuberbier T, 2006, J ALLERGY CLIN IMMUN, V118, P226, DOI 10.1016/j.jaci.2006.02.031	43	87	91	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2020	145	2					572	582		10.1016/j.jaci.2019.08.042	http://dx.doi.org/10.1016/j.jaci.2019.08.042			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK6ZG	31629805	Green Published, hybrid			2022-12-18	WOS:000512887400020
J	Kohanski, MA; Workman, AD; Patel, NN; Hung, LY; Shtraks, JP; Chen, B; Blasetti, M; Doghramji, L; Kennedy, DW; Adappa, ND; Palmer, JN; Herbert, DR; Cohen, NA				Kohanski, Michael A.; Workman, Alan D.; Patel, Neil N.; Hung, Li -Yin; Shtraks, Julie P.; Chen, Bei; Blasetti, Marie; Doghramji, Laurel; Kennedy, David W.; Adappa, Nithin D.; Palmer, James N.; Herbert, De'Broski R.; Cohen, Noam A.			Solitary chemosensory cells are a primary epithelial source of IL-25 in patients with chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-25; IL-13; solitary chemosensory cells; chronic rhinosinusitis with nasal polyps; type 2 inflammation; gustducin; doublecortin-like kinase 1	INTERLEUKIN 33; TUFT CELLS; INFLAMMATION; IMMUNITY; DIFFERENTIATION; EPIDEMIOLOGY; EXPRESSION; CYTOKINES; IL-13	Background: IL-25 can function as an early signal for the respiratory type 2 response characteristic of allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). In the mouse gut, tuft cells are the epithelial source of IL-25. However, the source of human airway epithelial IL-25 has remained elusive. Objective: In this study we sought to determine whether the solitary chemosensory cell (SCC) is the predominant source of IL-25 in the sinonasal epithelium. Method: Flow cytometry and immunofluorescence for SCCs and IL-25 were used to interrogate polyp and turbinate tissue from patients with CRSwNP. Mucus was collected during acute inflammatory exacerbations from patients with CRSwNP or chronic rhinosinusitis without nasal polyps and IL-25 levels determined by using ELISA. Lastly, sinonasal epithelial cultures derived from polyp and turbinate tissue were stimulated with IL-13 and analyzed for SCC proliferation and IL-25 production. Results: This study demonstrates that a discrete cell type, likely an SCC, characterized by expression of the taste-associated G protein gustducin and the intestinal tuft cell marker doublecortin-like kinase 1, is the predominant source of IL-25 in the human upper airway. Additionally, we show that patients with CRSwNP have increased numbers of SCCs in nasal polyp tissue and that in vitro IL-13 exposure both increased proliferation and induced apical secretion of IL-25 into the mucosal layer. Conclusions: Inflammatory sinus polyps but not adjacent turbinate tissue show expansion of the SCC population, which is the source of epithelial IL-25.	[Kohanski, Michael A.; Workman, Alan D.; Patel, Neil N.; Chen, Bei; Blasetti, Marie; Doghramji, Laurel; Kennedy, David W.; Adappa, Nithin D.; Palmer, James N.; Cohen, Noam A.] Univ Penn, Perelman Sch Med, Div Rhinol, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA; [Hung, Li -Yin; Herbert, De'Broski R.; Cohen, Noam A.] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA; [Shtraks, Julie P.] Temple Univ, Lewis Katz Sch Med, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19122 USA; [Chen, Bei] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA; [Cohen, Noam A.] Monell Chem Senses Ctr, 3500 Market St, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Monell Chemical Senses Center	Cohen, NA (corresponding author), Univ Penn, Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Div Rhinol, 5th Floor Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.	Noam.Cohen@uphs.upenn.edu	Hung, Li-Yin/L-6758-2019; Herbert, DeBroski/AAD-3035-2019	Herbert, DeBroski/0000-0002-2449-5365; Hung, Li-Yin/0000-0001-7623-1946	National Institutes of Health [R01DC013588, GM083204-08A1, UO1AI125940, R01AI095289, TL1R001880]; University of Pennsylvania Department of Otorhinolaryngology-Head and Neck Surgery; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI125940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC013588] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Pennsylvania Department of Otorhinolaryngology-Head and Neck Surgery; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Supported by National Institutes of Health grants R01DC013588 (to N.A.C.); GM083204-08A1, UO1AI125940, and R01AI095289 (to D.R.H.); and TL1R001880 (to N.N.P.). Also supported by a pilot grant from the University of Pennsylvania Department of Otorhinolaryngology-Head and Neck Surgery (to N.A.C. and D.R.H.) and a philanthropic donation from the R.L.G. Foundation (to N.A.C.).	Boita M, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/2643297; Daines SM, 2010, CURR OPIN OTOLARYNGO, V18, P187, DOI 10.1097/MOO.0b013e328338206a; Dames P, 2015, J PHYSIOL-LONDON, V593, P5269, DOI 10.1113/JP271156; DeConde AS, 2016, AM J RHINOL ALLERGY, V30, P134, DOI 10.2500/ajra.2016.30.4297; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gerbe F, 2016, NATURE, V529, P226, DOI 10.1038/nature16527; Gerbe F, 2009, GASTROENTEROLOGY, V137, P2179, DOI 10.1053/j.gastro.2009.06.072; Halawi AM, 2013, ALLERGY ASTHMA PROC, V34, P328, DOI 10.2500/aap.2013.34.3675; Howitt MR, 2016, SCIENCE, V351, P1329, DOI 10.1126/science.aaf1648; Iinuma T, 2015, ANN ALLERG ASTHMA IM, V114, P289, DOI 10.1016/j.anai.2015.01.013; Jarvis D, 2012, ALLERGY, V67, P91, DOI 10.1111/j.1398-9995.2011.02709.x; Kondo M, 2002, AM J RESP CELL MOL, V27, P536, DOI 10.1165/rcmb.4682; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lai YY, 2011, J ALLERGY CLIN IMMUN, V128, P1207, DOI 10.1016/j.jaci.2011.09.001; Lam M, 2015, AM J RHINOL ALLERGY, V29, P175, DOI 10.2500/ajra.2015.29.4176; Laoukili J, 2001, J CLIN INVEST, V108, P1817, DOI 10.1172/JCI13557; Larsen K, 1996, ALLERGY ASTHMA PROC, V17, P243, DOI 10.2500/108854196778662255; Larsen PL, 2004, LARYNGOSCOPE, V114, P710, DOI 10.1097/00005537-200404000-00022; Lee RJ, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aam7703; Lee RJ, 2014, J CLIN INVEST, V124, P1393, DOI 10.1172/JCI72094; Martin NT, 2016, NAT IMMUNOL, V17, P122, DOI 10.1038/ni.3370; Nakanishi Y, 2013, NAT GENET, V45, P98, DOI 10.1038/ng.2481; Orlandi RR, 2016, INT FORUM ALLERGY RH, V6, pS22, DOI 10.1002/alr.21695; Otto BA, 2008, CURR OPIN OTOLARYNGO, V16, P270, DOI 10.1097/MOO.0b013e3282fb2885; Ramanathan M, 2007, AM J RHINOL, V21, P373, DOI 10.2500/ajr.2007.21.3034; Ramezanpour M, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9798206; Reh DD, 2010, AM J RHINOL ALLERGY, V24, P105, DOI 10.2500/ajra.2010.24.3446; Salter BM, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0321-z; Schwartz C, 2016, EUR J IMMUNOL, V46, P1091, DOI 10.1002/eji.201545780; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Shin HW, 2015, J ALLERGY CLIN IMMUN, V135, P1476, DOI 10.1016/j.jaci.2015.01.003; Stevens WW, 2015, AM J RESP CRIT CARE, V192, P682, DOI 10.1164/rccm.201412-2278OC; Sureban SM, 2011, CANCER RES, V71, P2328, DOI 10.1158/0008-5472.CAN-10-2738; Suzukawa M, 2012, J IMMUNOL, V189, P3641, DOI 10.4049/jimmunol.1200461; Tao H, 2017, J CANCER RES CLIN, V143, P1449, DOI 10.1007/s00432-017-2405-7; Tizzano M, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-3; von Moltke J, 2016, NATURE, V529, P221, DOI 10.1038/nature16161; Walford HH, 2014, CLIN IMMUNOL, V155, P126, DOI 10.1016/j.clim.2014.09.007; Wise SK, 2014, INT FORUM ALLERGY RH, V4, P361, DOI 10.1002/alr.21298	39	87	89	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					460	+		10.1016/j.jaci.2018.03.019	http://dx.doi.org/10.1016/j.jaci.2018.03.019			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29778504	Green Accepted, Bronze			2022-12-18	WOS:000440664400015
J	Zhang, Y; Gevaert, E; Lou, HF; Wang, XD; Zhang, L; Bachert, C; Zhang, N				Zhang, Yuan; Gevaert, Elien; Lou, Hongfei; Wang, Xiangdong; Zhang, Luo; Bachert, Claus; Zhang, Nan			Chronic rhinosinusitis in Asia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; nasal polyps; phenotype; endotype; asthma comorbidity; type 2 inflammation; eosinophilic extra-cellular traps	ENDOSCOPIC SINUS SURGERY; ADULT CHRONIC RHINOSINUSITIS; KOREAN NATIONAL-HEALTH; NASAL POLYPS; RESPIRATORY-DISEASE; ALLERGIC RHINITIS; STAPHYLOCOCCUS-AUREUS; INCREASED PREVALENCE; GENE POLYMORPHISMS; RISK-FACTORS	Chronic rhinosinusitis (CRS), although possibly overdiagnosed, is associated with a high burden of disease and is often difficult to treat in those truly affected. Recent research has demonstrated that inflammatory signatures of CRS vary around the world, with less eosinophilic and more neutrophilic inflammation found in Asia compared with Europe and North America. Although in the Western world about 80% of nasal polyps carry a type 2 signature, this might be between 20% and 60% in China and Korea or Thailand, respectively. These differences are associated with a lower asthma comorbidity and risk of disease recurrence after surgery in the Asian population. As a hallmark of severe type 2 inflammation, eosinophils attacking Staphylococcus aureus at the epithelial barrier have been described recently; they also can be found in a subgroup of Asian patients with nasal polyps. Furthermore, the percentage of type 2 signature disease in patients with CRS is dramatically increasing ("eosinophilic shift'') in several Asian countries over the last 20 years. Establishing an accurate diagnosis along with considering the current and shifting patterns of inflammation seen in Asia will enable more effective selection of appropriate pharmacotherapy, surgical therapy, and eventually biotherapy. Determining the causes and pathophysiology for this eosinophilic shift will require additional research.	[Zhang, Yuan; Lou, Hongfei; Wang, Xiangdong; Zhang, Luo] Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Zhang, Yuan; Lou, Hongfei; Wang, Xiangdong; Zhang, Luo] Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing, Peoples R China; [Gevaert, Elien; Bachert, Claus; Zhang, Nan] Univ Ghent, Upper Airways Res Lab, De Pintelaan 185, B-9000 Ghent, Belgium; [Gevaert, Elien; Bachert, Claus; Zhang, Nan] Univ Ghent, Dept Otorhinolaryngol, De Pintelaan 185, B-9000 Ghent, Belgium; [Gevaert, Elien; Bachert, Claus; Zhang, Nan] Ghent Univ Hosp, De Pintelaan 185, B-9000 Ghent, Belgium; [Bachert, Claus] Univ Stockholm, Karolinska Inst, CLINTEC, Div ENT Dis, Stockholm, Sweden	Capital Medical University; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Karolinska Institutet; Stockholm University	Bachert, C (corresponding author), Univ Ghent, Upper Airways Res Lab, De Pintelaan 185, B-9000 Ghent, Belgium.; Bachert, C (corresponding author), Univ Ghent, Dept Otorhinolaryngol, De Pintelaan 185, B-9000 Ghent, Belgium.; Bachert, C (corresponding author), Ghent Univ Hosp, De Pintelaan 185, B-9000 Ghent, Belgium.; Zhang, L (corresponding author), Beijing TongRen Hosp, Beijing Key Lab Nasal Dis, Beijing Inst Otolaryngol, Dept Otolaryngol Head & Neck Surg, 17 HouGouHuTong, Beijing 100005, Peoples R China.	dr.luozhang@139.com; Claus.Bachert@ugent.be	wang, xiao/HGB-7081-2022; Bachert, Claus/J-8825-2012; Zhang, Nan/AAQ-3944-2020	wang, xiao/0000-0002-4088-3341; Zhang, Luo/0000-0002-0910-9884				Ahn JC, 2016, JAMA OTOLARYNGOL, V142, P162, DOI 10.1001/jamaoto.2015.3142; Bachert C, 2008, CURR OPIN ALLERGY CL, V8, P34, DOI 10.1097/ACI.0b013e3282f4178f; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Bachert C, 2017, J ALLERGY CLIN IMMUN, V140, P1024, DOI 10.1016/j.jaci.2017.05.044; Bachert C, 2016, J ALLER CL IMM-PRACT, V4, P621, DOI 10.1016/j.jaip.2016.05.004; Bachert C, 2016, J ALLER CL IMM-PRACT, V4, P629, DOI 10.1016/j.jaip.2015.12.008; Bachert C, 2015, J ALLERGY CLIN IMMUN, V136, P1431, DOI 10.1016/j.jaci.2015.10.010; Bachert C, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-25; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Bhattacharyya N, 2011, OTOLARYNG HEAD NECK, V144, P440, DOI 10.1177/0194599810391852; Bosse Y, 2009, HUM GENET, V125, P305, DOI 10.1007/s00439-009-0626-9; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Chen BY, 2012, AM J EPIDEMIOL, V175, P764, DOI 10.1093/aje/kwr380; Cheng YK, 2006, ARCH OTOLARYNGOL, V132, P285, DOI 10.1001/archotol.132.3.285; Cheong HS, 2011, ALLERGY, V66, P637, DOI 10.1111/j.1398-9995.2010.02514.x; Cho SH, 2016, ALLERGY ASTHMA PROC, V37, P131, DOI 10.2500/aap.2016.37.3925; DeConde AS, 2017, LARYNGOSCOPE, V127, P550, DOI 10.1002/lary.26391; Erbek SS, 2009, AM J RHINOL ALLERGY, V23, P568, DOI 10.2500/ajra.2009.23.3371; Fan Y, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Fan YP, 2012, AM J RHINOL ALLERGY, V26, pE20, DOI 10.2500/ajra.2012.26.3738; Fan YP, 2011, J ALLERGY CLIN IMMUN, V127, P520, DOI 10.1016/j.jaci.2010.09.023; Fu QL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126881; Gevaert E, 2017, J ALLERGY CLIN IMMUN, V139, P1849, DOI 10.1016/j.jaci.2017.01.019; Govindaraj S, 2010, J LARYNGOL OTOL, V124, P242, DOI 10.1017/S0022215109991368; Hamilos DL, 2011, J ALLERGY CLIN IMMUN, V128, P693, DOI 10.1016/j.jaci.2011.08.004; Han DH, 2009, ALLERGY, V64, P118, DOI 10.1111/j.1398-9995.2008.01841.x; Hastan D, 2011, ALLERGY, V66, P1216, DOI 10.1111/j.1398-9995.2011.02646.x; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Hirsch AG, 2017, ALLERGY, V72, P274, DOI 10.1111/all.13042; Hosemann W., 1993, Acta Oto-Rhino-Laryngologica Belgica, V47, P73; Jankowski R, 2006, Rev Laryngol Otol Rhinol (Bord), V127, P131; Johansson L, 2003, ANN OTO RHINOL LARYN, V112, P625, DOI 10.1177/000348940311200709; Katotomichelakis M, 2013, AM J RHINOL ALLERGY, V27, P354, DOI 10.2500/ajra.2013.27.3922; Kim SH, 2007, RESP MED, V101, P490, DOI 10.1016/j.rmed.2006.07.002; Kim SJ, 2013, OTOLARYNG HEAD NECK, V149, P431, DOI 10.1177/0194599813495363; Kim YS, 2011, AM J RHINOL ALLERGY, V25, pE117, DOI 10.2500/ajra.2011.25.3630; Klossek JM, 2005, ALLERGY, V60, P233, DOI 10.1111/j.1398-9995.2005.00688.x; Lee TJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171047; LIN HC, 2016, MEDICINE BALTIMORE, V95; Lou HF, 2016, RHINOLOGY, V54, P150, DOI [10.4193/Rhin15.271, 10.4193/Rhino15.271]; Lou HF, 2015, AM J RHINOL ALLERGY, V29, P350, DOI 10.2500/ajra.2015.29.4231; Ma ZX, 2015, INFLAMM RES, V64, P885, DOI 10.1007/s00011-015-0870-5; Maher B, 2008, NATURE, V456, P18, DOI 10.1038/456018a; Marambaia PP, 2013, BRAZ J OTORHINOLAR, V79, P54, DOI 10.5935/1808-8694.20130010; Mfuna-Endam L, 2011, CURR ALLERGY ASTHM R, V11, P236, DOI 10.1007/s11882-011-0189-4; Morrissey DK, 2016, INT FORUM ALLERGY RH, V6, P820, DOI 10.1002/alr.21739; Morshed M, 2012, ALLERGY, V67, P1127, DOI 10.1111/j.1398-9995.2012.02868.x; Mygind N, 2000, THORAX, V55, pS79, DOI 10.1136/thorax.55.suppl_2.S79; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Nakayama T, 2012, AM J RHINOL ALLERGY, V26, P172, DOI 10.2500/ajra.2012.26.3749; Park CS, 2011, OTOLARYNG HEAD NECK, V144, P96, DOI 10.1177/0194599810390881; Rudmik L, 2014, LARYNGOSCOPE, V124, P2007, DOI 10.1002/lary.24630; Rudmik L, 2011, CURR ALLERGY ASTHM R, V11, P247, DOI 10.1007/s11882-010-0175-2; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; Shi JB, 2015, ALLERGY, V70, P533, DOI 10.1111/all.12577; Shin SH, 2014, AM J RHINOL ALLERGY, V28, P95, DOI 10.2500/ajra.2014.28.4003; Smith KA, 2015, LARYNGOSCOPE, V125, P1547, DOI 10.1002/lary.25180; STAMMBERGER H, 1990, EUR ARCH OTO-RHINO-L, V247, P63; Tanakau S, 2014, ALLERGOL INT, V63, P27, DOI 10.2332/allergolint.13-OA-0579; Teufelberger AR, 2017, J ALLERGY CLIN IMMUN; Thanaviratananich S, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004090; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Ueki S, 2016, J ALLERGY CLIN IMMUN, V137, P258, DOI 10.1016/j.jaci.2015.04.041; van Agthoven M, 2002, RHINOLOGY, V40, P69; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Van Zele T, 2014, AM J RHINOL ALLERGY, V28, P192, DOI 10.2500/ajra.2014.28.4033; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Wang De Yun, 2016, Value Health Reg Issues, V9, P72, DOI 10.1016/j.vhri.2015.11.004; Wang LF, 2008, ARCH OTOLARYNGOL, V134, P852, DOI 10.1001/archotol.134.8.852; Wang LF, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-85; Wang W, 2016, SCI REP, V6; Wang XD, 2016, ALLERGY, V71, P1170, DOI 10.1111/all.12874; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; Wang XJ, 2000, JAMA-J AM MED ASSOC, V284, P1814, DOI 10.1001/jama.284.14.1814; We J, 2015, AM J RHINOL ALLERGY, V29, pE24, DOI 10.2500/ajra.2015.29.4131; Wen WP, 2012, J ALLERGY CLIN IMMUN, V129, P1522, DOI 10.1016/j.jaci.2012.01.079; Yea SS, 2006, AM J RHINOL, V20, P550, DOI 10.2500/ajr.2006.20.2936; Yoo KH, 2016, ALLERGY ASTHMA IMMUN, V8, P527, DOI 10.4168/aair.2016.8.6.527; Yousefi S, 2008, NAT MED, V14, P949, DOI 10.1038/nm.1855; Zhai LJ, 2007, ANN OTO RHINOL LARYN, V116, P66, DOI 10.1177/000348940711600111; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008; Zhang N, 2006, AM J RHINOL, V20, P445, DOI 10.2500/ajr.2006.20.2887; Zhang XH, 2012, AM J RESP CRIT CARE, V185, P140, DOI 10.1164/rccm.201103-0456OC; Zhang Y, 2013, AM J RHINOL ALLERGY, V27, P91, DOI 10.2500/ajra.2013.27.3851; Zhang Y, 2013, HUM IMMUNOL, V74, P241, DOI 10.1016/j.humimm.2012.11.004; Zhang YC, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0044465, 10.1155/2012/583417]; Zheng YB, 2015, RHINOLOGY, V53, P345, DOI [10.4193/Rhin14.086, 10.4193/Rhino14.086]	87	87	102	2	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1230	1239		10.1016/j.jaci.2017.09.009	http://dx.doi.org/10.1016/j.jaci.2017.09.009			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28987810				2022-12-18	WOS:000414304300002
J	Kepert, I; Fonseca, J; Muller, C; Milger, K; Hochwind, K; Kostric, M; Fedoseeva, M; Ohnmacht, C; Dehmel, S; Nathan, P; Bartel, S; Eickelberg, O; Schloter, M; Hartmann, A; Schmitt-Kopplin, P; Krauss-Etschmann, S				Kepert, Inge; Fonseca, Juliano; Mueller, Constanze; Milger, Katrin; Hochwind, Kerstin; Kostric, Matea; Fedoseeva, Maria; Ohnmacht, Caspar; Dehmel, Stefan; Nathan, Petra; Bartel, Sabine; Eickelberg, Oliver; Schloter, Michael; Hartmann, Anton; Schmitt-Kopplin, Philippe; Krauss-Etschmann, Susanne			D-tryptophan from probiotic bacteria influences the gut microbiome and allergic airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						D-tryptophan; probiotic bacteria; bacterial substance; screening; immune modulation; allergic airway disease; gut microbiota	PLACEBO-CONTROLLED TRIAL; D-AMINO ACIDS; MOLECULE N-(3-OXODODECANOYL)-L-HOMOSERINE LACTONE; RANDOMIZED CONTROLLED-TRIAL; 1ST 6 MONTHS; DOUBLE-BLIND; DENDRITIC CELLS; PRIMARY PREVENTION; IN-VIVO; ATOPIC-DERMATITIS	Background: Chronic immune diseases, such as asthma, are highly prevalent. Currently available pharmaceuticals improve symptoms but cannot cure the disease. This prompted demands for alternatives to pharmaceuticals, such as probiotics, for the prevention of allergic disease. However, clinical trials have produced inconsistent results. This is at least partly explained by the highly complex crosstalk among probiotic bacteria, the host's microbiota, and immune cells. The identification of a bioactive substance from probiotic bacteria could circumvent this difficulty. Objective: We sought to identify and characterize a bioactive probiotic metabolite for potential prevention of allergic airway disease. Methods: Probiotic supernatants were screened for their ability to concordantly decrease the constitutive CCL17 secretion of a human Hodgkin lymphoma cell line and prevent upregulation of costimulatory molecules of LPS-stimulated human dendritic cells. Results: Supernatants from 13 of 37 tested probiotic strains showed immunoactivity. Bioassay-guided chromatographic fractionation of 2 supernatants according to polarity, followed by total ion chromatography and mass spectrometry, yielded C11H12N2O2 as the molecular formula of a bioactive substance. Proton nuclear magnetic resonance and enantiomeric separation identified D-tryptophan. In contrast, L-tryptophan and 11 other D-amino acids were inactive. Feeding D-tryptophan to mice before experimental asthma induction increased numbers of lung and gut regulatory T cells, decreased lung TH2 responses, and ameliorated allergic airway inflammation and hyperresponsiveness. Allergic airway inflammation reduced gut microbial diversity, which was increased by D-tryptophan. Conclusions: D-tryptophan is a newly identified product from probiotic bacteria. Our findings support the concept that defined bacterial products can be exploited in novel preventative strategies for chronic immune diseases.	[Kepert, Inge; Milger, Katrin; Dehmel, Stefan; Nathan, Petra; Bartel, Sabine; Eickelberg, Oliver; Krauss-Etschmann, Susanne] Ludwig Maximilians Univ Hosp, Comprehens Pneumol Ctr, German Ctr Lung Res DZL, Munich, Germany; [Kepert, Inge; Milger, Katrin; Dehmel, Stefan; Nathan, Petra; Bartel, Sabine; Eickelberg, Oliver; Krauss-Etschmann, Susanne] Helmholtz Zentrum Munchen, Munich, Germany; [Fonseca, Juliano; Mueller, Constanze; Schmitt-Kopplin, Philippe] Helmholtz Zentrum Munchen, Res Unit Analyt BioGeoChem BGC, Oberschleissheim, Germany; [Hochwind, Kerstin; Hartmann, Anton] Helmholtz Zentrum Munchen, Res Unit Microbe Plant Interact, Oberschleissheim, Germany; [Kostric, Matea; Schloter, Michael] Helmholtz Zentrum Munchen, Res Unit Environm Genom, Oberschleissheim, Germany; [Fedoseeva, Maria; Ohnmacht, Caspar] Tech Univ, Ctr Allergy & Environm ZAUM, Oberschleissheim, Germany; [Fedoseeva, Maria; Ohnmacht, Caspar] German Ctr Lung Res DZL, Helmholtz Zentrum Munchen, Oberschleissheim, Germany; [Schmitt-Kopplin, Philippe] Tech Univ Muenchen, Analyt Food Chem, Freising Weihenstephan, Germany; [Bartel, Sabine; Krauss-Etschmann, Susanne] German Ctr Lung Res DZL, Div Expt Asthma Res, Res Ctr Borstel, Leibniz Ctr Med & Biosci, Borstel, Germany; [Krauss-Etschmann, Susanne] Christian Albrechts Univ Kiel, Inst Expt Med, Kiel, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Forschungszentrum Borstel; University of Kiel	Krauss-Etschmann, S (corresponding author), Leibniz Ctr Med & Biosci, Res Ctr Borstel, Pk Allee 1-40, D-23845 Borstel, Germany.	skrauss-etschmann@fz-borstel.de	Hartmann, Anton/AAN-8922-2020; Ohnmacht, Caspar/M-8033-2013; Krauss-Etschmann, Susanne/H-5198-2018; Bartel, Sabine/P-9463-2019; Dehmel, Stefan/GPF-7907-2022; Schloter, 1Michael/H-9151-2013; Schmitt-Kopplin, Philippe/H-6271-2011; Milger, Katrin/AFI-3881-2022	Krauss-Etschmann, Susanne/0000-0001-5945-5702; Bartel, Sabine/0000-0002-9163-795X; Schmitt-Kopplin, Philippe/0000-0003-0824-2664; Milger, Katrin/0000-0003-2914-8773	Helmholtz Center Munich; German Research Center for Environmental Health, and Research Center Borstel; Leibniz Center for Medicine and Biosciences	Helmholtz Center Munich(Helmholtz Association); German Research Center for Environmental Health, and Research Center Borstel; Leibniz Center for Medicine and Biosciences	Supported by intramural grants provided by the Helmholtz Center Munich, the German Research Center for Environmental Health, and Research Center Borstel, the Leibniz Center for Medicine and Biosciences. Probiotic bacteria were provided by Winclove Bioindustry BV, The Netherlands; Chr. Hansen, Horsholm, Denmark; Daniscom Niebull, Germany; and Ardeypharm GMbH, Herdecke, Germany. None of the providers had any influence on the design, analyses, or interpretation of the study.	Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; Allen SJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003048.pub3; [Anonymous], SEARCH LACT; [Anonymous], 2001, PROBIOTICS FOOD INCL; Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bertelsen RJ, 2014, J ALLERGY CLIN IMMUN, V133, P165, DOI 10.1016/j.jaci.2013.07.032; Borthakur A, 2010, AM J PHYSIOL-GASTR L, V299, pG928, DOI 10.1152/ajpgi.00279.2010; Boyle RJ, 2011, ALLERGY, V66, P509, DOI 10.1111/j.1398-9995.2010.02507.x; Brouwer ML, 2006, CLIN EXP ALLERGY, V36, P899, DOI 10.1111/j.1365-2222.2006.02513.x; Butterworth AD, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006634.pub2; Candela M, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-95; Cava F, 2011, EMBO J, V30, P3442, DOI 10.1038/emboj.2011.246; CHAO A, 1984, SCAND J STAT, V11, P265; Chhabra SR, 2003, J MED CHEM, V46, P97, DOI 10.1021/jm020909n; Cuello-Garcia CA, 2015, J ALLERGY CLIN IMMUN, V136, P952, DOI [10.1016/j.jaci.2015.07.021, 10.1016/j.jaci.2015.04.031]; Dotterud CK, 2010, BRIT J DERMATOL, V163, P616, DOI 10.1111/j.1365-2133.2010.09889.x; European Food Safety Authority, 2010, EFSA NEWS STORY EFSA; Fanning S, 2012, P NATL ACAD SCI USA, V109, P2108, DOI 10.1073/pnas.1115621109; Fiocchi A, 2012, WORLD ALLERGY ORGAN, V5, P148, DOI 10.1097/WOX.0b013e3182784ee0; Friedman M, 2010, CHEM BIODIVERS, V7, P1491, DOI 10.1002/cbdv.200900225; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; HASHIMOTO A, 1993, J NEUROCHEM, V61, P348, DOI 10.1111/j.1471-4159.1993.tb03575.x; Hatanaka T, 2002, BIOCHEM BIOPH RES CO, V291, P291, DOI 10.1006/bbrc.2002.6441; Heuvelin E, 2010, J NUTR, V140, P7, DOI 10.3945/jn.109.114553; Hooi DSW, 2004, INFECT IMMUN, V72, P6463, DOI 10.1128/IAI.72.11.6463-6470.2004; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Irukayama-Tomobe Y, 2009, P NATL ACAD SCI USA, V106, P3930, DOI 10.1073/pnas.0811844106; Jackson Daniel J, 2014, Ann Am Thorac Soc, V11 Suppl 3, pS139, DOI 10.1513/AnnalsATS.201312-448LD; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kicic A, 2010, AM J RESP CRIT CARE, V181, P889, DOI 10.1164/rccm.200907-1071OC; Klindworth A, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks808; Kolodkin-Gal I, 2010, SCIENCE, V328, P627, DOI 10.1126/science.1188628; Kopp MV, 2008, PEDIATRICS, V121, pE850, DOI 10.1542/peds.2007-1492; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Kwon HK, 2010, P NATL ACAD SCI USA, V107, P2159, DOI 10.1073/pnas.0904055107; Lam H, 2009, SCIENCE, V325, P1552, DOI 10.1126/science.1178123; LANGNER RALPH R., 1955, JOUR BIOL CHEM, V214, P699; Lob S, 2008, BLOOD, V111, P2152, DOI 10.1182/blood-2007-10-116111; LOPEZBURILLO S, 1985, BIOCHIM BIOPHYS ACTA, V820, P85, DOI 10.1016/0005-2736(85)90218-4; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; McDonald D, 2012, ISME J, V6, P610, DOI 10.1038/ismej.2011.139; Mileti E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007056; Munn DH, 2013, TRENDS IMMUNOL, V34, P137, DOI 10.1016/j.it.2012.10.001; Pantouris G, 2014, AMINO ACIDS, V46, P2155, DOI 10.1007/s00726-014-1766-3; Probst HC, 2014, EUR J IMMUNOL, V44, P927, DOI 10.1002/eji.201343862; Ritchie AJ, 2003, INFECT IMMUN, V71, P4421, DOI 10.1128/IAI.71.8.4421-4431.2003; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Smith RS, 2002, J IMMUNOL, V169, P2636, DOI 10.4049/jimmunol.169.5.2636; Soh SE, 2009, CLIN EXP ALLERGY, V39, P571, DOI 10.1111/j.1365-2222.2008.03133.x; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Szajewska H, 2015, J ALLERGY CLIN IMMUN, V136, P1422, DOI 10.1016/j.jaci.2015.07.022; Taylor AL, 2007, J ALLERGY CLIN IMMUN, V119, P184, DOI 10.1016/j.jaci.2006.08.036; Thomas CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031951; TRIEBWASSER KC, 1976, J NUTR, V106, P642, DOI 10.1093/jn/106.5.642; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; van Baarlen P, 2011, P NATL ACAD SCI USA, V108, P4562, DOI 10.1073/pnas.1000079107; Visser WF, 2011, J CHROMATOGR A, V1218, P7130, DOI 10.1016/j.chroma.2011.07.087; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Wickens K, 2008, J ALLERGY CLIN IMMUN, V122, P788, DOI 10.1016/j.jaci.2008.07.011; Wise A, 2003, J BIOL CHEM, V278, P9869, DOI 10.1074/jbc.M210695200; World Health Organization, GLOBAL STATUS REPORT; Xu H, 2008, P NATL ACAD SCI USA, V105, P6690, DOI 10.1073/pnas.0708809105; Yan F, 2011, J CLIN INVEST, V121, P2242, DOI 10.1172/JCI44031; Yanofsky C, 2007, RNA, V13, P1141, DOI 10.1261/rna.620507	65	87	91	9	90	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1525	1535		10.1016/j.jaci.2016.09.003	http://dx.doi.org/10.1016/j.jaci.2016.09.003			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27670239	Bronze			2022-12-18	WOS:000400465300013
J	Wehr, C; Gennery, AR; Lindemans, C; Schulz, A; Hoenig, M; Marks, R; Recher, M; Gruhn, B; Holbro, A; Heijnen, I; Meyer, D; Grigoleit, G; Einsele, H; Baumann, U; Witte, T; Sykora, KW; Goldacker, S; Regairaz, L; Aksoylar, S; Ardeniz, O; Zecca, M; Zdziarski, P; Meyts, I; Matthes-Martin, S; Imai, K; Kamae, C; Fielding, A; Seneviratne, S; Mahlaoui, N; Slatter, MA; Gungor, T; Arkwright, PD; van Montfrans, J; Sullivan, KE; Grimbacher, B; Cant, A; Peter, HH; Finke, J; Gaspar, HB; Warnatz, K; Rizzi, M				Wehr, Claudia; Gennery, Andrew R.; Lindemans, Caroline; Schulz, Ansgar; Hoenig, Manfred; Marks, Reinhard; Recher, Mike; Gruhn, Bernd; Holbro, Andreas; Heijnen, Ingmar; Meyer, Deborah; Grigoleit, Goetz; Einsele, Hermann; Baumann, Ulrich; Witte, Thorsten; Sykora, Karl-Walter; Goldacker, Sigune; Regairaz, Lorena; Aksoylar, Serap; Ardeniz, Omur; Zecca, Marco; Zdziarski, Przemyslaw; Meyts, Isabelle; Matthes-Martin, Susanne; Imai, Kohsuke; Kamae, Chikako; Fielding, Adele; Seneviratne, Suranjith; Mahlaoui, Nizar; Slatter, Mary A.; Gungor, Tayfun; Arkwright, Peter D.; van Montfrans, Joris; Sullivan, Kathleen E.; Grimbacher, Bodo; Cant, Andrew; Peter, Hans-Hartmut; Finke, Juergen; Gaspar, H. Bobby; Warnatz, Klaus; Rizzi, Marta		European Soc Blood Marrow; European Soc Immunodeficiency	Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Common variable immunodeficiency; hypogammaglobulinemia; hematopoietic stem cell transplantation; immunologic reconstitution; immunoglobulin substitution/replacement; outcome; mortality; survival	SEVERE APLASTIC-ANEMIA; VERSUS-HOST-DISEASE; BONE-MARROW; B-CELL; EUROPEAN GROUP; WORKING PARTY; ACUTE GVHD; BLOOD; ABNORMALITIES; DISORDERS	Background: Common variable immunodeficiency (CVID) is usually well controlled with immunoglobulin substitution and immunomodulatory drugs. A subgroup of patients has a complicated disease course with high mortality. For these patients, investigation of more invasive, potentially curative treatments, such as allogeneic hematopoietic stem cell transplantation (HSCT), is warranted. Objective: We sought to define the outcomes of HSCT for patients with CVID. Methods: Retrospective data were collected from 14 centers worldwide on patients with CVID receiving HSCT between 1993 and 2012. Results: Twenty-five patients with CVID, which was defined according to international criteria, aged 8 to 50 years at the time of transplantation were included in the study. The indication for HSCT was immunologic dysregulation in the majority of patients. The overall survival rate was 48%, and the survival rate for patients undergoing transplantation for lymphoma was 83%. The major causes of death were treatment-refractory graft-versus-host disease accompanied by poor immune reconstitution and infectious complications. Immunoglobulin substitution was stopped in 50% of surviving patients. In 92% of surviving patients, the condition constituting the indication for HSCT resolved. Conclusion: This multicenter study demonstrated that HSCT in patients with CVID was beneficial in most surviving patients; however, there was a high mortality associated with the procedure. Therefore this therapeutic approach should only be considered in carefully selected patients in whom there has been extensive characterization of the immunologic and/or genetic defect underlying the CVID diagnosis. Criteria for patient selection, refinement of the transplantation protocol, and timing are needed for an improved outcome.	[Wehr, Claudia; Goldacker, Sigune; Grimbacher, Bodo; Peter, Hans-Hartmut; Warnatz, Klaus; Rizzi, Marta] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, D-79108 Freiburg, Germany; [Wehr, Claudia; Goldacker, Sigune; Grimbacher, Bodo; Peter, Hans-Hartmut; Warnatz, Klaus; Rizzi, Marta] Univ Freiburg, Freiburg, Germany; [Gennery, Andrew R.] Newcastle Upon Tyne Hosp Fdn Trust, Dept Paediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England; [Lindemans, Caroline] UMC Utrecht, Pediat Blood & Bone Marrow Transplantat Program, Utrecht, Netherlands; [Schulz, Ansgar; Hoenig, Manfred] Univ Med Ctr Ulm, Dept Pediat, Ulm, Germany; [Marks, Reinhard] Univ Med Ctr Freiburg, Dept Hematol & Oncol, D-79108 Freiburg, Germany; [Recher, Mike] Univ Basel Hosp, Med Outpatient Clin, Clin Primary Immunodeficiency, CH-4031 Basel, Switzerland; [Recher, Mike] Univ Basel Hosp, Dept Biomed, Immunodeficiency Lab, CH-4031 Basel, Switzerland; [Gruhn, Bernd] Univ Jena, Univ Klinikum Jena, Klin Kinder & Jugendmed, D-07745 Jena, Germany; [Holbro, Andreas] Univ Basel Hosp, Div Hematol, CH-4031 Basel, Switzerland; [Holbro, Andreas] Univ Basel Hosp, Stem Cell Transplant Team, CH-4031 Basel, Switzerland; [Heijnen, Ingmar] Univ Basel Hosp, Lab Med, Med Immunol, CH-4031 Basel, Switzerland; [Meyer, Deborah] Univ Childrens Hosp, Zurich, Switzerland; [Grigoleit, Goetz; Einsele, Hermann] Univ Med Ctr Wurzburg, Dept Hematol Oncol, Wurzburg, Germany; [Baumann, Ulrich] Hannover Med Sch, Paediat Pulmonol Allergy & Neonatol, Hannover, Germany; [Witte, Thorsten] Hannover Med Sch, Clin Immunol & Rheumatol, Hannover, Germany; [Sykora, Karl-Walter] Univ Hosp Hannover, Dept Pediat Hematol & Oncol, Hannover, Germany; [Regairaz, Lorena] Hosp Ninos Sor Maria Ludov La Plata, Unidad Immunol, Buenos Aires, DF, Argentina; [Aksoylar, Serap] Ege Univ, Dept Pediat Hematol & Oncol, Bornova, Turkey; [Aksoylar, Serap] Ege Univ, BMT Ctr, Bornova, Turkey; [Ardeniz, Omur] Ege Univ, Fac Med, Div Allergy & Clin Immunol, Izmir, Turkey; [Zecca, Marco] Fdn IRCCS Policlin San Matteo, Oncoematol Pediat, Pavia, Italy; [Zdziarski, Przemyslaw] Lower Silesian Ctr Cellular Transplantat, Wroclaw, Poland; [Meyts, Isabelle] Univ Hosp Leuven, Dept Paediat, Leuven, Belgium	University of Freiburg; University of Freiburg; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Utrecht University; Utrecht University Medical Center; Ulm University; University of Freiburg; University of Basel; University of Basel; Friedrich Schiller University of Jena; University of Basel; University of Basel; University of Basel; University Children's Hospital Zurich; University of Wurzburg; Hannover Medical School; Hannover Medical School; Ege University; Ege University; Ege University; IRCCS Fondazione San Matteo; KU Leuven; University Hospital Leuven	Rizzi, M (corresponding author), Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Engesserstr 4, D-79108 Freiburg, Germany.	klaus.warnatz@uniklinik-freiburg.de; klaus.warnatz@uniklinik-freiburg.de	Witte, Torsten/B-5783-2016; Meyts, Isabelle/Z-3295-2019; Mahlaoui, Nizar/J-7928-2017; Fielding, Adele/AFM-9369-2022; Zecca, Marco/K-3309-2018; Wehr, Claudia/AAZ-5758-2021; Warnatz, Klaus/AAD-3464-2022; Imai, Kohsuke/Q-2602-2015; MAHLAOUI, Nizar/AAH-6103-2020; Zdziarski, Przemyslaw/D-4213-2018; Güngör, Tayfun/ABF-4256-2020; Grigoleit, Goetz U/K-4555-2016; aksoylar, serap/AAB-6343-2022; Rizzi, Marta/ABE-7264-2020	Mahlaoui, Nizar/0000-0002-0030-8094; Zecca, Marco/0000-0002-8818-1744; Wehr, Claudia/0000-0002-5037-6175; Imai, Kohsuke/0000-0003-2132-8403; MAHLAOUI, Nizar/0000-0002-0030-8094; Zdziarski, Przemyslaw/0000-0002-5692-4734; Güngör, Tayfun/0000-0002-3261-1186; Arkwright, Peter/0000-0002-7411-5375; Recher, Mike/0000-0002-9121-6936; Rizzi, Marta/0000-0002-5153-6089	German Federal Ministry of Education and Research (BMBF) [01 EO 0803]; Dutch Cancer Society [2013-5883]; Medical Research Council [G0501468] Funding Source: researchfish; MRC [G0501468] Funding Source: UKRI	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Dutch Cancer Society(KWF Kankerbestrijding); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the German Federal Ministry of Education and Research (BMBF 01 EO 0803). C.L. is supported by a clinical fellowship from the Dutch Cancer Society (2013-5883).	Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Aukrust P, 1996, BLOOD, V87, P674, DOI 10.1182/blood.V87.2.674.bloodjournal872674; Avanzini MA, 2005, EXP HEMATOL, V33, P480, DOI 10.1016/j.exphem.2005.01.005; Ball LM, 2008, BONE MARROW TRANSPL, V41, pS58, DOI 10.1038/bmt.2008.56; Bensinger WI, 2001, NEW ENGL J MED, V344, P175, DOI 10.1056/NEJM200101183440303; Cavazzana-Calvo M, 2009, CURR OPIN IMMUNOL, V21, P544, DOI 10.1016/j.coi.2009.08.001; Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; Chapel H, 2012, J ALLERGY CLIN IMMUN, V130, P1197, DOI 10.1016/j.jaci.2012.05.046; Chapel H, 2009, BRIT J HAEMATOL, V145, P709, DOI 10.1111/j.1365-2141.2009.07669.x; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Driessen GJ, 2011, BLOOD, V118, P6814, DOI 10.1182/blood-2011-06-361881; Dufour C, 2014, HAEMATOLOGICA, V99, P1574, DOI 10.3324/haematol.2014.106096; Filipovich AH, 2005, BIOL BLOOD MARROW TR, V11, P945, DOI 10.1016/j.bbmt.2005.09.004; Geddes M, 2007, BEST PRACT RES CL HA, V20, P329, DOI 10.1016/j.beha.2006.09.009; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Gennery AR, 2004, BLOOD, V103, P1152, DOI 10.1182/blood-2003-06-2014; Giovannetti A, 2007, J IMMUNOL, V178, P3932, DOI 10.4049/jimmunol.178.6.3932; Glauzy S, 2014, BLOOD, V124, P2459, DOI 10.1182/blood-2014-05-573303; Gregersen S, 2010, ANN ALLERG ASTHMA IM, V104, P503, DOI 10.1016/j.anai.2010.04.015; HOLLER E, 1990, BLOOD, V75, P1011; Hussein AA, 2014, BIOL BLOOD MARROW TR, V20, P1448, DOI 10.1016/j.bbmt.2014.05.028; Isgro A, 2005, J IMMUNOL, V174, P5074, DOI 10.4049/jimmunol.174.8.5074; Kamae C, 2013, J ALLERGY CLIN IMMUN, V131, P1437, DOI 10.1016/j.jaci.2012.10.059; Malphettes M, 2009, CLIN INFECT DIS, V49, P1329, DOI 10.1086/606059; Moratto D, 2006, CLIN IMMUNOL, V121, P203, DOI 10.1016/j.clim.2006.07.003; Mouillot G, 2010, J CLIN IMMUNOL, V30, P746, DOI 10.1007/s10875-010-9424-3; Ochtrop MLG, 2011, BLOOD, V118, P309, DOI 10.1182/blood-2010-11-321695; Passweg JR, 2004, BRIT J HAEMATOL, V125, P613, DOI 10.1111/j.1365-2141.2004.04955.x; Peinemann F, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005039; Perreau M, 2014, J EXP MED, V211, P2033, DOI 10.1084/jem.20140039; Petropoulou AD, 2012, TRANSPLANTATION, V94, P879, DOI 10.1097/TP.0b013e3182664042; Piqueras B, 2003, J CLIN IMMUNOL, V23, P385, DOI 10.1023/A:1025373601374; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Quinti I, 2012, BLOOD, V120, P1953, DOI 10.1182/blood-2012-05-431064; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Rizzi M, 2011, J ALLERGY CLIN IMMUN, V128, P1371, DOI 10.1016/j.jaci.2011.07.055; Roifman CM, 2012, J ALLERGY CLIN IMMUN, V130, P177, DOI 10.1016/j.jaci.2012.04.029; Schots R, 2003, LEUKEMIA, V17, P1150, DOI 10.1038/sj.leu.2402946; Sorror ML, 2004, BLOOD, V104, P961, DOI 10.1182/blood-2004-02-0545; Sorror M, 2008, CANCER-AM CANCER SOC, V112, P1992, DOI 10.1002/cncr.23375; Sorror ML, 2013, BLOOD, V121, P2854, DOI 10.1182/blood-2012-09-455063; Sorror ML, 2010, HEMATOL-AM SOC HEMAT, P237, DOI 10.1182/asheducation-2010.1.237; Ueland T, 2001, EUR J CLIN INVEST, V31, P72, DOI 10.1046/j.1365-2362.2001.00768.x; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744	44	87	90	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					988	+		10.1016/j.jaci.2014.11.029	http://dx.doi.org/10.1016/j.jaci.2014.11.029			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25595268	Green Published			2022-12-18	WOS:000352238600022
J	Hartwig, IRV; Sly, PD; Schmidt, LA; van Lieshout, RJ; Bienenstock, J; Holt, PG; Arck, PC				Hartwig, Isabel R. V.; Sly, Peter D.; Schmidt, Louis A.; van Lieshout, Ryan J.; Bienenstock, John; Holt, Patrick G.; Arck, Petra C.			Prenatal adverse life events increase the risk for atopic diseases in children, which is enhanced in the absence of a maternal atopic predisposition	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic disease; eczema; asthma; allergic rhinitis; negative life events; prenatal programming; child; pregnancy	BRONCHIAL RESPONSIVENESS; PARENTAL STRESS; ASTHMA; PREGNANCY; PROLIFERATION; EPIDEMIOLOGY; EXPOSURE; ALLERGEN; COHORT; SCALE	Background: There is evidence to suggest an association between prenatal maternal stress and the development of asthma or other atopic diseases in offspring. Yet, insights on the lasting effect of multiple, common prenatal stressors are rare, and the effects of prenatal timing are poorly understood. Further, it remains elusive if prenatal life events modify the risk for atopic diseases in the context of a parental predisposition to atopy. Objective: We tested whether women's experiences of common, adverse life events during the first or second half of pregnancy predicted the risk of developing atopic diseases in their children and whether a reported parental atopic disease moderated this association. Methods: We calculated the odds of a child developing asthma, eczema, and/or allergic rhinitis at ages 6 or 14 years, depending on maternal prenatal exposure to negative life events in a sample of 1587 children from the Western Australian Pregnancy Cohort (Raine) Study by using multivariable logistic regression. Results: We observed that the likelihood of asthma and eczema at age 14 years was significantly increased in children of mothers who had experienced adverse life events during the second half of gestation (1 life event: adjusted odds ratio for asthma, 2.08 [95% CI, 1.22-3.54]). A stronger increase in the odds to develop asthma upon prenatal life events was present in children of mothers without asthma compared with mothers with asthma. Conclusions: Maternal adverse life events during the second half of gestation are linked to an increased risk for the development of atopic disorders, asthma, and eczema, in the case of asthma, particularly in the absence of a maternal asthma.	[Hartwig, Isabel R. V.; Arck, Petra C.] Univ Med Ctr Hamburg Eppendorf, Dept Obstet & Fetal Med, D-20246 Hamburg, Germany; [Sly, Peter D.] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia; [Schmidt, Louis A.] McMaster Univ, Dept Psychol Neurosci & Behav, Hamilton, ON, Canada; [van Lieshout, Ryan J.] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; [Bienenstock, John] McMaster Univ, Dept Pathol, Brain Body Inst, Hamilton, ON, Canada; [Holt, Patrick G.] Univ Western Australia, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Queensland; McMaster University; McMaster University; McMaster University; Telethon Kids Institute; University of Western Australia	Arck, PC (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Obstet & Fetal Med, Lab Expt Fetomaternal Med, Martinistr 52, D-20246 Hamburg, Germany.	i.hartwig@uke.de; p.arck@uke.de	Sly, Peter D/F-1486-2010; Holt, Patrick G/H-1548-2011; Van Lieshout, Ryan/AAI-1316-2021	Sly, Peter D/0000-0001-6305-2201; Holt, Patrick G/0000-0003-1193-0935; Arck, Petra/0000-0002-2932-926X	Alexander von Humboldt Foundation; Excellence Initiative of the Hamburg Foundation for Research; Association for Prevention and Information for Allergy and Asthma (Praeventions- und Informationsnetzwerk Allergie/Asthma eingetragener Verein [Pina])	Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); Excellence Initiative of the Hamburg Foundation for Research; Association for Prevention and Information for Allergy and Asthma (Praeventions- und Informationsnetzwerk Allergie/Asthma eingetragener Verein [Pina])	Financial support to address the statistical analyses presented herein was provided by the Alexander von Humboldt Foundation, the Excellence Initiative of the Hamburg Foundation for Research and the Association for Prevention and Information for Allergy and Asthma (Praeventions- und Informationsnetzwerk Allergie/Asthma eingetragener Verein [Pina]).	[Anonymous], 2010, R LANG ENV STAT COMP; Asher M. Innes, 2006, Lancet (North American Edition), V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Chida Y, 2008, PSYCHOSOM MED, V70, P102, DOI 10.1097/PSY.0b013e31815c1b71; Chiu YHM, 2012, AM J RESP CRIT CARE, V186, P147, DOI 10.1164/rccm.201201-0162OC; Cookson H, 2009, J ALLERGY CLIN IMMUN, V123, P847, DOI 10.1016/j.jaci.2009.01.042; Diepenbruck I, 2013, J MOL MED, V91, P1293, DOI 10.1007/s00109-013-1069-2; Dom S, 2010, CLIN EXP ALLERGY, V40, P1378, DOI 10.1111/j.1365-2222.2010.03538.x; Drever N, 2010, CURR ALLERGY ASTHM R, V10, P453, DOI 10.1007/s11882-010-0136-9; Fang F, 2011, PLOS ONE, V6, P1, DOI DOI 10.1371/JOURNAL.PONE.0027202; Garcia-Marcos L, 2011, CURR OPIN ALLERGY CL, V11, P162, DOI 10.1097/ACI.0b013e3283464c28; Hosmer W., 2000, APPL LOGISTIC REGRES, V2nd ed.; Imai K, 2010, PSYCHOL METHODS, V15, P309, DOI 10.1037/a0020761; Joseph-Bowen J, 2004, J ALLERGY CLIN IMMUN, V114, P1040, DOI 10.1016/j.jaci.2004.07.051; Joseph-Bowen J, 2004, AM J RESP CRIT CARE, V169, P850, DOI 10.1164/rccm.200304-556OC; Kavelaars A, 1999, PEDIATR RES, V45, P306, DOI 10.1203/00006450-199903000-00003; Kozyrskyj AL, 2011, CURR OPIN ALLERGY CL, V11, P400, DOI 10.1097/ACI.0b013e328349b166; Kozyrskyj AL, 2010, AM J PUBLIC HEALTH, V100, P540, DOI 10.2105/AJPH.2008.150771; Lange NE, 2011, J ALLERGY CLIN IMMUN, V127, P734, DOI 10.1016/j.jaci.2010.11.010; Lim RH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010134; Lim RH, 2009, AM J REPROD IMMUNOL, V61, P1, DOI 10.1111/j.1600-0897.2008.00671.x; Martino D, 2011, CHEST, V139, P640, DOI 10.1378/chest.10-1800; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H; Obel C, 2005, PSYCHONEUROENDOCRINO, V30, P647, DOI 10.1016/j.psyneuen.2004.11.006; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Peters JL, 2012, ALLERGY, V67, P545, DOI 10.1111/j.1398-9995.2012.02791.x; Pincus M, 2012, CHEM IMMUNOL ALLERGY, V98, P70, DOI 10.1159/000336499; Pincus M, 2010, J ALLERGY CLIN IMMUN, V125, P273, DOI 10.1016/j.jaci.2009.10.057; Robinson M, 2008, J CHILD PSYCHOL PSYC, V49, P1118, DOI 10.1111/j.1469-7610.2008.01955.x; Roduit C, 2011, J ALLERGY CLIN IMMUN, V127, P179, DOI 10.1016/j.jaci.2010.10.010; Shankardass K, 2009, P NATL ACAD SCI USA, V106, P12406, DOI 10.1073/pnas.0812910106; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; TENNANT C, 1976, AUST NZ J PSYCHIAT, V10, P27, DOI 10.3109/00048677609159482; Thornton CA, 2010, CURR ALLERGY ASTHM R, V10, P444, DOI 10.1007/s11882-010-0148-5; TURNER RJ, 1995, AM SOCIOL REV, V60, P104, DOI 10.2307/2096348; von Hertzen LC, 2002, J ALLERGY CLIN IMMUN, V109, P923, DOI 10.1067/mai.2002.124776; von Mutius E, 2008, J ALLERGY CLIN IMMUN, V122, P99, DOI 10.1016/j.jaci.2008.05.017; Willers SM, 2008, AM J RESP CRIT CARE, V178, P124, DOI 10.1164/rccm.200710-1544OC; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; Wright RJ, 2011, IMMUNOL ALLERGY CLIN, V31, P19, DOI 10.1016/j.iac.2010.09.011; Wright RJ, 2010, AM J RESP CRIT CARE, V182, P25, DOI 10.1164/rccm.200904-0637OC; Yonas MA, 2012, CURR OPIN ALLERGY CL, V12, P202, DOI 10.1097/ACI.0b013e32835090c9; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704	44	87	88	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					160	+		10.1016/j.jaci.2014.01.033	http://dx.doi.org/10.1016/j.jaci.2014.01.033			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	25117802				2022-12-18	WOS:000338930300021
J	Ahluwalia, SK; Peng, RD; Breysse, PN; Diette, GB; Curtin-Brosnan, J; Aloe, C; Matsui, EC				Ahluwalia, Sharon K.; Peng, Roger D.; Breysse, Patrick N.; Diette, Gregory B.; Curtin-Brosnan, Jean; Aloe, Charles; Matsui, Elizabeth C.			Mouse allergen is the major allergen of public health relevance in Baltimore City	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inner-city asthma; childhood asthma; mouse allergen; cockroach allergen; indoor allergens	COCKROACH ALLERGEN; ASTHMA MORBIDITY; DUST-MITE; EXPOSURE; CHILDREN; SENSITIZATION; CAT	Background: Cockroach and mouse allergens have both been implicated as causes in inner-city asthma morbidity in multicenter studies, but whether both allergens are clinically relevant within specific inner-city communities is unclear. Objective: Our study aimed to identify relevant allergens in Baltimore City. Methods: One hundred forty-four children (5-17 years old) with asthma underwent skin prick tests at baseline and had clinical data collected at baseline and 3, 6, 9, and 12 months. Home settled dust samples were collected at the same time points for quantification of indoor allergens. Participants were grouped based on their sensitization and exposure status to each allergen. All analyses were adjusted for age, sex, and serum total IgE level. Results: Forty-one percent were mouse sensitized/exposed, and 41% were cockroach sensitized/exposed based on bedroom floor exposure data. Mouse sensitization/exposure was associated with acute care visits, decreased FEV1/forced vital capacity percentage values, fraction of exhaled nitric oxide levels, and bronchodilator reversibility. Cockroach sensitization/exposure was only associated with acute care visits and bronchodilator reversibility when exposure was defined by using bedroom floor allergen levels. Mouse-specific IgE levels were associated with poor asthma health across a range of outcomes, whereas cockroach-specific IgE levels were not. The relationships between asthma outcomes and mouse allergen were independent of cockroach allergen. Although sensitization/exposure to both mouse and cockroach was generally associated with worse asthma, mouse sensitization/exposure was the primary contributor to these relationships. Conclusions: In a community with high levels of both mouse and cockroach allergens, mouse allergen appears to be more strongly and consistently associated with poor asthma outcomes than cockroach allergen. Community-level asthma interventions in Baltimore should prioritize reducing mouse allergen exposure.	[Ahluwalia, Sharon K.; Curtin-Brosnan, Jean; Aloe, Charles; Matsui, Elizabeth C.] Johns Hopkins Sch Med, Div Pediat Allergy & Immunol, Baltimore, MD USA; [Diette, Gregory B.] Johns Hopkins Sch Med, Div Pulm & Crit Care Med, Baltimore, MD USA; [Peng, Roger D.] Johns Hopkins Bloomberg Sch Publ Health, Dept Biostat, Baltimore, MD USA; [Breysse, Patrick N.] Johns Hopkins Bloomberg Sch Publ Health, Dept Environm Hlth Sci, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Matsui, EC (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.	ematsui@jhmi.edu		Matsui, Elizabeth/0000-0001-8134-5593	National Institute of Environmental Health Sciences [P50ES015903, P01ES018176]; Environmental Protection Agency [R832139]; National Institute of Allergy and Infectious Diseases [R01AI070630, U01AI083238]; Johns Hopkins University School of Medicine General Clinical Research Center, National Center for Research Resources/National Institutes of Health [M01-RR00052]; Springer Publishing; National Institutes of Health (NIH)/National Institute of Environmental Health Sciences/Environmental Protection Agency; NIH; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070630, U01AI083238, R34AI074928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K24ES021098, P50ES015903, P01ES018176] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Environmental Protection Agency(United States Environmental Protection Agency); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Johns Hopkins University School of Medicine General Clinical Research Center, National Center for Research Resources/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Springer Publishing; National Institutes of Health (NIH)/National Institute of Environmental Health Sciences/Environmental Protection Agency; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the National Institute of Environmental Health Sciences (P50ES015903, P01ES018176), the Environmental Protection Agency (R832139), the National Institute of Allergy and Infectious Diseases (R01AI070630 and U01AI083238), and the Johns Hopkins University School of Medicine General Clinical Research Center (grant no. M01-RR00052) from the National Center for Research Resources/National Institutes of Health.; Disclosure of potential conflict of interest: R. D. Peng has received royalties from Springer Publishing. G. B. Diette has been supported by one or more grants from the National Institutes of Health (NIH)/National Institute of Environmental Health Sciences/Environmental Protection Agency and has consultancy arrangements with GlaxoSmithKline and Fenzian. E. C. Matsui has been supported by one or more grants from the NIH and has received a Phadia Research Form Award. The rest of the authors declare that they have no relevant conflicts of interest.	Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Almqvist C, 2001, AM J RESP CRIT CARE, V163, P694, DOI 10.1164/ajrccm.163.3.2006114; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; Donohue KM, 2008, J ALLERGY CLIN IMMUN, V122, P914, DOI 10.1016/j.jaci.2008.08.034; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Institute of Medicine (US) Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; Matsui EC, 2003, J ALLERGY CLIN IMMUN, V112, P87, DOI 10.1067/mai.2003.1588; Matsui EC, 2006, ANN ALLERG ASTHMA IM, V97, P514, DOI 10.1016/S1081-1206(10)60943-X; Moorman JE., 2011, MMWR SURVEILL SUMM S, V60, P84; Olmedo O, 2011, J ALLERGY CLIN IMMUN, V128, P284, DOI 10.1016/j.jaci.2011.02.044; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; Pongracic JA, 2008, ANN ALLERG ASTHMA IM, V101, P35, DOI 10.1016/S1081-1206(10)60832-0; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sheehan WJ, 2010, J ALLERGY CLIN IMMUN, V125, P575, DOI 10.1016/j.jaci.2010.01.023; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026; Torjusen EN, 2010, J ALLERGY CLIN IMMUN, V125, pAB125, DOI 10.1016/j.jaci.2009.12.493; Torjusen EN, 2012, INDOOR AIR; Wang J, 2009, CLIN EXP ALLERGY, V39, P1381, DOI 10.1111/j.1365-2222.2009.03225.x; Zahran Hatice S., 2011, Morbidity and Mortality Weekly Report, V60, P547	22	87	87	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					830	+		10.1016/j.jaci.2013.05.005	http://dx.doi.org/10.1016/j.jaci.2013.05.005			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23810154	Green Accepted			2022-12-18	WOS:000325096500008
J	Yang, IV; Schwartz, DA				Yang, Ivana V.; Schwartz, David A.			Epigenetic mechanisms and the development of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopy; epigenetics; gene expression; DNA methylation; histone marks; noncoding RNAs	MICRORNA-MEDIATED REGULATION; INTRAGENIC DNA METHYLATION; OXIDE SYNTHASE PROMOTER; FOLIC-ACID SUPPLEMENTS; TOBACCO-SMOKE EXPOSURE; EXHALED NITRIC-OXIDE; TH2 CYTOKINE GENES; CD4(+) T-CELLS; LUNG-FUNCTION; HYPERSENSITIVE SITE	Asthma is heritable, influenced by the environment, and modified by in utero exposures and aging; all of these features are also common to epigenetic regulation. Furthermore, the transcription factors that are involved in the development of mature T cells that are critical to the TH2 immune phenotype in asthmatic patients are regulated by epigenetic mechanisms. Epigenetic marks (DNA methylation, modifications of histone tails, and noncoding RNAs) work in concert with other components of the cellular regulatory machinery to control the spatial and temporal levels of expressed genes. Technology to measure epigenetic marks on a genomic scale and comprehensive approaches to data analysis have recently emerged and continue to improve. Alterations in epigenetic marks have been associated with exposures relevant to asthma, particularly air pollution and tobacco smoke, as well as asthma phenotypes, in a few population-based studies. On the other hand, animal studies have begun to decipher the role of epigenetic regulation of gene expression associated with the development of allergic airway disease. Epigenetic mechanisms represent a promising line of inquiry that might, in part, explain the inheritance and immunobiology of asthma. (J Allergy Clin Immunol 2012;130:1243-55.)	[Yang, Ivana V.; Schwartz, David A.] Univ Colorado, Sch Med, Dept Med, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Schwartz, DA (corresponding author), Univ Colorado, Sch Med, Dept Med, 12631 E 17th Ave,B178, Aurora, CO 80045 USA.	david.schwartz@ucdenver.edu	Yang, Ivana V/P-3059-2018	Yang, Ivana V/0000-0002-1018-489X	National Heart, Lung, and Blood Institute [RO1-HL101251, RC2-HL101715]; National Institute of Allergy and Infectious Diseases [N01-AI90052]; National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL101251, RC2HL101715] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the National Heart, Lung, and Blood Institute (RO1-HL101251 and RC2-HL101715) and the National Institute of Allergy and Infectious Diseases (N01-AI90052).; I. V. Yang has received research support from the National Institutes of Health. D. A. Schwartz has received research support from the National Heart, Lung, and Blood Institute and the National Institute of Allergy and Infectious Diseases.	Akinbami Lara J, 2011, Natl Health Stat Report, P1; Allen JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029348; Allis CD, 2009, EPIGENETICS; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Ariel D, 2012, CURR OPIN ALLERGY CL, V12, P49, DOI 10.1097/ACI.0b013e32834ecb7f; Asher MI, 2012, ALLERGOL IMMUNOPATHO; Baccarelli A, 2012, EPIGENOMICS-UK, V4, P91, DOI [10.2217/EPI.11.106, 10.2217/epi.11.106]; Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC; Barnes Peter J, 2009, Proc Am Thorac Soc, V6, P693, DOI 10.1513/pats.200907-071DP; Bekkers MBM, 2012, EUR RESPIR J, V39, P1468, DOI 10.1183/09031936.00094511; Bell JT, 2011, TRENDS GENET, V27, P116, DOI 10.1016/j.tig.2010.12.005; Berlivet S, 2012, HUM GENET, V131, P1161, DOI 10.1007/s00439-012-1142-x; Bloom B, 2011, SUMMARY HLTH STATE U; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080; Brand S, 2012, J ALLERGY CLIN IMMUN, V129, P1602, DOI 10.1016/j.jaci.2011.12.963; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Breton CV, 2011, AM J RESP CRIT CARE, V184, P191, DOI 10.1164/rccm.201012-2029OC; Breton CV, 2011, EPIGENETICS-US, V6, P895, DOI 10.4161/epi.6.7.15768; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Brinkman AB, 2012, GENOME RES, V22, P1128, DOI 10.1101/gr.133728.111; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Chodavarapu RK, 2010, NATURE, V466, P388, DOI 10.1038/nature09147; Clark NA, 2010, ENVIRON HEALTH PERSP, V118, P284, DOI 10.1289/ehp.0900916; Cobb BS, 2006, J EXP MED, V203, P2519, DOI 10.1084/jem.20061692; Cohen RT, 2010, J ALLERGY CLIN IMMUN, V126, P491, DOI 10.1016/j.jaci.2010.06.016; Collison A, 2011, J ALLERGY CLIN IMMUN, V128, P160, DOI 10.1016/j.jaci.2011.04.005; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Espadaa J, 2010, SEMIN CELL DEV BIOL, V21, P238, DOI 10.1016/j.semcdb.2009.10.006; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Fang F, 2012, P NATL ACAD SCI USA, V109, P7332, DOI 10.1073/pnas.1201310109; Fedulov AV, 2011, AM J RESP CELL MOL, V44, P285, DOI 10.1165/rcmb.2009-0400OC; Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Fitzsimon N, 2007, Ir Med J, V100, P27; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Flom JD, 2011, CANCER EPIDEM BIOMAR, V20, P2518, DOI 10.1158/1055-9965.EPI-11-0553; Flynt AS, 2008, NAT REV GENET, V9, P831, DOI 10.1038/nrg2455; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708, DOI 10.1164/ajrccm.157.6.9707163; Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Fraser HB, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-2-r8; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gaulton KJ, 2010, NAT GENET, V42, P255, DOI 10.1038/ng.530; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Guerrero-Preston R, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12378; Haberg SE, 2009, ARCH DIS CHILD, V94, P180, DOI 10.1136/adc.2008.142448; Harris RA, 2010, NAT BIOTECHNOL, V28, P1097, DOI 10.1038/nbt.1682; Henderson AJ, 2010, THORAX, V65, P897, DOI 10.1136/thx.2009.125856; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Holt PG, 1999, NATURE, V402, pB12; Hu JL, 2009, P NATL ACAD SCI USA, V106, P22187, DOI 10.1073/pnas.0905767106; Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474; Hylkema Machteld N, 2009, Proc Am Thorac Soc, V6, P660, DOI 10.1513/pats.200907-065DP; Ito K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/pnas.132556899; Izzotti A, 2009, FASEB J, V23, P3243, DOI 10.1096/fj.09-135251; Izzotti A, 2009, FASEB J, V23, P806, DOI 10.1096/fj.08-121384; Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Jones B, 2006, EMBO J, V25, P2443, DOI 10.1038/sj.emboj.7601148; Jopling CL, 2012, RNA BIOL, V9, DOI 10.4161/rna.18827; Kang HP, 2012, DIABETOLOGIA, V55, P2205, DOI 10.1007/s00125-012-2568-3; Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006; Kechris KJ, 2010, STAT APPL GENET MOL, V9, DOI 10.2202/1544-6115.1434; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109; Kim ST, 2007, P NATL ACAD SCI USA, V104, P17052, DOI 10.1073/pnas.0708293104; Knight JC, 2012, J INTERN MED, V271, P379, DOI 10.1111/j.1365-2796.2011.02508.x; Koh BH, 2010, P NATL ACAD SCI USA, V107, P10614, DOI 10.1073/pnas.1005383107; Ku CS, 2011, J MED GENET, V48, P721, DOI 10.1136/jmedgenet-2011-100242; Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034; Kuriakose J, 2012, AM J RESP CRIT CARE, V185, P460, DOI 10.1164/ajrccm.185.4.460; Ladd-Acosta Christine, 2010, Curr Protoc Hum Genet, VChapter 20, DOI 10.1002/0471142905.hg2001s65; Lal G, 2009, BLOOD, V114, P3727, DOI 10.1182/blood-2009-05-219584; Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X; Lee GR, 2006, IMMUNITY, V24, P369, DOI 10.1016/j.immuni.2006.03.007; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Li YR, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000533; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Liu CG, 2008, METHODS, V44, P22, DOI 10.1016/j.ymeth.2007.10.010; Liu F, 2010, ONCOGENE, V29, P3650, DOI 10.1038/onc.2010.129; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Lu TX, 2011, J IMMUNOL, V187, P3362, DOI 10.4049/jimmunol.1101235; Ma F, 2011, NAT IMMUNOL, V12, P861, DOI 10.1038/ni.2073; Maccani MA, 2010, EPIGENETICS-US, V5, P583, DOI 10.4161/epi.5.7.12762; Magdelijns FJH, 2011, PEDIATRICS, V128, pE135, DOI 10.1542/peds.2010-1690; March ME, 2011, DISCOV MED, V11, P35; Martinussen MP, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2011.07.033; Mathias RA, 2010, J ALLERGY CLIN IMMUN, V125, P336, DOI 10.1016/j.jaci.2009.08.031; Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165; Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626; Milosavljevic A, 2011, TRENDS GENET, V27, P242, DOI 10.1016/j.tig.2011.03.001; Moffatt MF, 1998, CLIN EXP ALLERGY, V28, P56; Montgomery SB, 2011, NAT REV GENET, V12, P277, DOI 10.1038/nrg2969; Morales E, 2012, AM J RESP CRIT CARE, V185, P937, DOI 10.1164/rccm.201105-0870OC; Murphy SK, 2012, GENE, V494, P36, DOI 10.1016/j.gene.2011.11.062; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Nakamura T, 2007, NAT CELL BIOL, V9, P64, DOI 10.1038/ncb1519; Nana-Sinkam SP, 2009, AM J RESP CRIT CARE, V179, P4, DOI 10.1164/rccm.200807-1042PP; Oh SS, 2012, J ALLERGY CLIN IMMUN, V129, P1478, DOI 10.1016/j.jaci.2012.03.017; Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987; Pan W, 2010, J IMMUNOL, V184, P6773, DOI 10.4049/jimmunol.0904060; Papageorgiou N, 2012, CURR MED CHEM, V19, P2605, DOI 10.2174/092986712800493048; Polikepahad S, 2010, J BIOL CHEM, V285, P30139, DOI 10.1074/jbc.M110.145698; Qin H, 2007, J IMMUNOL, V179, P5966, DOI 10.4049/jimmunol.179.9.5966; Relton CL, 2012, INT J EPIDEMIOL, V41, P161, DOI 10.1093/ije/dyr233; Robertson AB, 2012, NAT PROTOC, V7, P340, DOI 10.1038/nprot.2011.443; Salam MT, 2012, J ALLERGY CLIN IMMUN, V129, P232, DOI 10.1016/j.jaci.2011.09.037; SAMET JM, 1991, ENVIRON HEALTH PERSP, V95, P71, DOI 10.2307/3431109; Santangelo S, 2002, J IMMUNOL, V169, P1893, DOI 10.4049/jimmunol.169.4.1893; Schembri F, 2009, P NATL ACAD SCI USA, V106, P2319, DOI 10.1073/pnas.0806383106; Schones DE, 2008, NAT REV GENET, V9, P179, DOI 10.1038/nrg2270; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V151, P47, DOI 10.1164/ajrccm.151.1.7812571; Shenker N, 2012, BRIT J CANCER, V106, P248, DOI 10.1038/bjc.2011.550; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Smallwood SA, 2012, TRENDS GENET, V28, P33, DOI 10.1016/j.tig.2011.09.004; Song CX, 2012, NAT METHODS, V9, P75, DOI [10.1038/NMETH.1779, 10.1038/nmeth.1779]; Sonkoly E, 2010, J ALLERGY CLIN IMMUN, V126, P581, DOI 10.1016/j.jaci.2010.05.045; Sood A, 2012, CHEST; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Statham AL, 2012, GENOME RES, V22, P1120, DOI 10.1101/gr.132076.111; Steiner DF, 2011, IMMUNITY, V35, P169, DOI 10.1016/j.immuni.2011.07.009; Szulwach KE, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002154; Tanaka S, 2011, NAT IMMUNOL, V12, P77, DOI 10.1038/ni.1966; Tang WY, 2012, ENVIRON HEALTH PERSP, V120, P1195, DOI 10.1289/ehp.1103744; Tanizawa H, 2012, SEMIN CELL DEV BIOL, V23, P213, DOI 10.1016/j.semcdb.2011.11.003; Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314; Tsitsiou E, 2012, J ALLERGY CLIN IMMUN, V129, P95, DOI 10.1016/j.jaci.2011.08.011; Tycko B, 2010, HUM MOL GENET, V19, pR210, DOI 10.1093/hmg/ddq376; Van Stry M, 2011, NAT IMMUNOL, V12, P16, DOI 10.1038/ni0111-16; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Wan ES, 2012, HUM MOL GENET, V21, P3073, DOI 10.1093/hmg/dds135; Wang Lei, 2007, Birth Defects Research, V81, P144, DOI 10.1002/bdrc.20097; Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Webster RB, 2007, J BIOL CHEM, V282, P700, DOI 10.1074/jbc.M609501200; White GP, 2006, PEDIAT ALLERG IMM-UK, V17, P557, DOI 10.1111/j.1399-3038.2006.00465.x; Whitrow MJ, 2009, AM J EPIDEMIOL, V170, P1486, DOI 10.1093/aje/kwp315; Williams AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005889; Xiao CC, 2009, CELL, V136, P26, DOI 10.1016/j.cell.2008.12.027; Yang IV, 2011, AM J RESP CRIT CARE, V183, P1295, DOI 10.1164/rccm.201010-1579PP; Yang YW, 2012, AM J RESP CELL MOL, V46, P633, DOI 10.1165/rcmb.2011-0030OC	153	87	91	0	57	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1243	1255		10.1016/j.jaci.2012.07.052	http://dx.doi.org/10.1016/j.jaci.2012.07.052			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	23026498	Green Accepted			2022-12-18	WOS:000311641100002
J	Krishnan, JA; Bender, BG; Wamboldt, FS; Szefler, SJ; Adkinson, NF; Zeiger, RS; Wise, RA; Bilderback, AL; Rand, CS				Krishnan, Jerry A.; Bender, Bruce G.; Wamboldt, Frederick S.; Szefler, Stanley J.; Adkinson, N. Franklin, Jr.; Zeiger, Robert S.; Wise, Robert A.; Bilderback, Andrew L.; Rand, Cynthia S.		Adherence Ancillary Study Grp	Adherence to inhaled corticosteroids: An ancillary study of the Childhood Asthma Management Program clinical trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; adherence; compliance; children; lung growth; inhaled corticosteroids; budesonide; clinical trial	MILD PERSISTENT ASTHMA; EARLY INTERVENTION; HIGH-RISK; CHILDREN; BUDESONIDE; MEDICATION	Background: Information comparing subjective and objective measurements of adherence to study medications and the effects of adherence on treatment-related differences in asthma clinical trials are limited. Objective: We sought to compare subjective and objective measurements of children's adherence to inhaled corticosteroids or placebo and to determine whether adherence to study medications modified treatment-related differences in outcomes. Methods: In an ancillary study conducted in 3 of 8 Childhood Asthma Management Program Clinical Centers, adherence was assessed by using self-reported and objective data in 5- to 12-year-old children with mild or moderate asthma who were randomly assigned to 200 mu g of inhaled budesonide twice per day (n = 84) or placebo (n = 56) for 4 years. The kappa statistic was used to evaluate agreement between self-reported adherence (daily diary cards) and objectively measured adherence (number of doses left in study inhalers). Multivariable analyses were used to determine whether adherence to study treatment modified treatment-related differences in outcomes. Results: Adherence of less than 80% was seen in 75% of 140 children when adherence was measured objectively but only in 6% of children when measured by means of self-report. There was poor agreement between objective and subjective measurements of adherence of at least 80% (kappa = 0.00; 95% CI, -0.05 to 0.04); self-reported adherence over the 4-year period generally overestimated objectively measured adherence (93.6% vs 60.8%, P < .0001). There was little evidence to indicate that adherence modified treatment-related differences in outcomes. Conclusion: Researchers should use objective rather than self-reported adherence data to identify clinical trial participants with low levels of adherence to study treatment. (J Allergy Clin Immunol 2012; 129: 112-8.)	[Krishnan, Jerry A.] Univ Illinois, Dept Med, Sect Pulm Crit Care Sleep & Allergy, Chicago, IL 60612 USA; [Bender, Bruce G.; Wamboldt, Frederick S.; Szefler, Stanley J.] Natl Jewish Hlth, Denver, CO USA; [Adkinson, N. Franklin, Jr.; Wise, Robert A.; Bilderback, Andrew L.; Rand, Cynthia S.] Johns Hopkins Univ, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD USA; [Zeiger, Robert S.] Univ Calif San Diego, La Jolla, CA 92093 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Jewish Health; Johns Hopkins University; University of California System; University of California San Diego	Krishnan, JA (corresponding author), Univ Illinois, Dept Med, Sect Pulm Crit Care Sleep & Allergy, 840 S Wood St,M-C 719, Chicago, IL 60612 USA.	jakris@uic.edu		Szefler, Stanley/0000-0002-6911-3199; Zeiger, Robert/0000-0001-5788-5063; Wise, Robert/0000-0002-8353-2349	National Heart, Lung, and Blood Institute (NHLBI) [NO1-HR-16044, NO1-HR-16045, NO1-HR-16046, NO1-HR-16047, NO1-HR-16048, NO1-HR-16049, NO1-HR-16050, NO1-HR-16051, NO1-HR-16052, HL048999]; National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI); NHLBI's Childhood Asthma Research and Education; NIH/NHLBI's Asthma Clinical Research Network; NIH/National Institute of Allergy and Infectious Diseases's Inner City Asthma Consortium; GlaxoSmithKline; National Jewish Health/NHLBI Asthma Net; National Institute of Environmental Health Sciences/US Environmental Protection Agency's Children's Environmental Health Center; Aerocrine; Genentech; Merck and Co; DIVISION OF LUNG DISEASES [N01HR016044] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL048999, K23HL067850] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI's Childhood Asthma Research and Education(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NHLBI's Asthma Clinical Research Network(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/National Institute of Allergy and Infectious Diseases's Inner City Asthma Consortium; GlaxoSmithKline(GlaxoSmithKline); National Jewish Health/NHLBI Asthma Net; National Institute of Environmental Health Sciences/US Environmental Protection Agency's Children's Environmental Health Center; Aerocrine; Genentech(Roche HoldingGenentech); Merck and Co(Merck & Company); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The Childhood Asthma Management Program is supported by the National Heart, Lung, and Blood Institute (NHLBI; contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052). The adherence ancillary study was supported by the NHLBI (HL048999).; J. A. Krishnan receives research support from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI). S. J. Szefler has consultant arrangements with GlaxoSmithKline, Genentech, Merck, Boehringer-Ingelheim, Novartis, and Schering-Plough and receives research support from the NIH/NHLBI's Childhood Asthma Management Program, the NHLBI's Childhood Asthma Research and Education, the NIH/NHLBI's Asthma Clinical Research Network, the NIH/National Institute of Allergy and Infectious Diseases's Inner City Asthma Consortium, GlaxoSmithKline, National Jewish Health/NHLBI Asthma Net, and the National Institute of Environmental Health Sciences/US Environmental Protection Agency's Children's Environmental Health Center grant. R. S. Zeiger has consultant arrangements with AstraZeneca, Aerocrine, Genentech, Merck and Co, Schering-Plough, MedImmune, Sunovion, and Centocor and receives research support from Aerocrine, Genentech, Merck and Co, and GlaxoSmithKline. R. A. Wise has consultant arrangements with AstraZeneca. C. S. Rand is an advisor for the Merck Foundation/MCAN and has consultant arrangements with TEVA. The rest of the authors declare that they have no relevant conflicts of interest.	Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; CANNER PL, 1980, NEW ENGL J MED, V303, P1038; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; COUTTS JAP, 1992, ARCH DIS CHILD, V67, P332, DOI 10.1136/adc.67.3.332; Dixon AE, 2005, CURR OPIN PULM MED, V11, P51, DOI 10.1097/01.mcp.0000148663.53798.72; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Huber PJ, 1980, P 5 BERK S MATH STAT, P221; Jonasson G, 2000, ARCH DIS CHILD, V83, P330, DOI 10.1136/adc.83.4.330; Jones CA, 2007, J ALLERGY CLIN IMMUN, V119, P1445, DOI 10.1016/j.jaci.2007.02.031; Krishnan JA, 2004, AM J RESP CRIT CARE, V170, P1281, DOI 10.1164/rccm.200403-409OC; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V104, pS169, DOI 10.1016/S0091-6749(99)70058-8; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; RAND CS, 1994, AM J RESP CRIT CARE, V149, pS69, DOI 10.1164/ajrccm/149.2_Pt_2.S69; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; Rand C, 2007, J ALLERGY CLIN IMMUN, V119, P916, DOI 10.1016/j.jaci.2006.12.664; Simmons MS, 1996, CHEST, V109, P963, DOI 10.1378/chest.109.4.963; Simmons MS, 2000, CHEST, V118, P290, DOI 10.1378/chest.118.2.290; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	25	87	90	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					112	118		10.1016/j.jaci.2011.10.030	http://dx.doi.org/10.1016/j.jaci.2011.10.030			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22104610	Bronze, Green Accepted			2022-12-18	WOS:000298634000014
J	Lodge, CJ; Lowe, AJ; Gurrin, LC; Hill, DJ; Hosking, CS; Khalafzai, RU; Hopper, JL; Matheson, MC; Abramson, MJ; Allen, KJ; Dharmage, SC				Lodge, Caroline J.; Lowe, Adrian J.; Gurrin, Lyle C.; Hill, David J.; Hosking, Clifford S.; Khalafzai, Rida U.; Hopper, John L.; Matheson, Melanie C.; Abramson, Michael J.; Allen, Katrina J.; Dharmage, Shyamali C.			House dust mite sensitization in toddlers predicts current wheeze at age 12 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Birth cohort; asthma; wheeze; eczema; sensitization; house dust mite	ALLERGEN EXPOSURE; ATOPIC SENSITIZATION; EARLY-CHILDHOOD; ASTHMA; CHILDREN; DISEASE; RISK; ASSOCIATION; RATIONALE; INFANTS	Background: Identification of children at risk of developing asthma provides a window of opportunity for risk-reducing interventions. Allergen sensitization might identify high-risk children. Objective: We sought to determine whether skin prick tests (SPTs) to individual allergens up to age 2 years predict wheeze at age 12 years. Methods: In a birth cohort of 620 children oversampled for familial allergy, sensitization was assessed by using SPTs (monosensitized, polysensitized, or either) to 6 allergens at ages 6, 12, and 24 months. Wheeze and eczema were recorded 18 times during the first 2 years. Current wheeze was recorded at age 12 years. Adjusted associations were evaluated by multiple logistic regression. Results: A positive SPT to house dust mite (HDM) at age 1 or 2 years predicted wheeze at age 12 years (adjusted odds ratio: 1 year, 3.31 [95% CI 1.59-6.91]; 2 years, 6.37 [95% CI, 3.48-11.66]). Among wheezy 1-year-olds, those who were HDM sensitized had a 75% (95% CI, 51% to 91%) probability of wheeze at age 12 years compared with a 36% (95% CI, 23% to 50%) probability among those not sensitized. Among eczematous 1-year-olds, those who were HDM sensitized had a 67% (95% CI, 45% to 84%) probability of wheeze at age 12 years compared with a 35% (95% CI, 25% to 45%) probability among those not sensitized. Among 1-year-old children with both eczema and wheeze, the probability of wheeze at age 12 years was 64% (95% CI, 35% to 87%) if HDM sensitized and 50% (95% CI, 26% to 74%) if not. Conclusion: HDM sensitization at age 1 or 2 years in wheezing and eczematous children at increased familial allergy risk predicts asthma and may inform management of these high-risk groups. (J Allergy Clin Immunol 2011;128:782-8.)	[Lodge, Caroline J.] Univ Melbourne, Sch Populat Hlth, Fac Med Dent & Hlth Sci, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic 3010, Australia; [Allen, Katrina J.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia; [Lodge, Caroline J.; Lowe, Adrian J.; Hill, David J.; Allen, Katrina J.; Dharmage, Shyamali C.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy, Melbourne, Vic, Australia; [Hosking, Clifford S.] John Hunter Childrens Hosp, Newcastle, NSW, Australia; [Abramson, Michael J.] Monash Univ, Melbourne, Vic, Australia	University of Melbourne; University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Monash University	Lodge, CJ (corresponding author), Univ Melbourne, Sch Populat Hlth, Fac Med Dent & Hlth Sci, Ctr Mol Environm Genet & Analyt Epidemiol, Level 3,207 Bouverie St, Melbourne, Vic 3010, Australia.	clodge@unimelb.edu.au	Matheson, Melanie C/O-4721-2015; Allen, Katrina/I-4361-2018; Lodge, Caroline J/E-9688-2014; Abramson, Michael/AAQ-2671-2020	Matheson, Melanie C/0000-0002-5822-3499; Allen, Katrina/0000-0002-1921-4493; Abramson, Michael/0000-0002-9954-0538; Lodge, Caroline/0000-0002-2342-3888; Gurrin, Lyle/0000-0001-7052-1969; Lowe, Adrian/0000-0002-4691-8162	Nestle Australia; Asthma Foundation of Victoria; Sidney Myer Health Fund; National Health and Medical Research Council of Australia (NHMRC); Charles and Sylvia Viertel Charitable Foundation; Reckitts Benckiser; Nutricia; SHS International; Nestle	Nestle Australia(Nestle SA); Asthma Foundation of Victoria; Sidney Myer Health Fund; National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Charles and Sylvia Viertel Charitable Foundation; Reckitts Benckiser; Nutricia(Danone Nutricia); SHS International; Nestle(Nestle SA)	Initial support for the study was from Nestle Australia, and the 12-year follow-up was supported by the Asthma Foundation of Victoria. C.J.L. is supported by the Sidney Myer Health Fund and the National Health and Medical Research Council of Australia (NHMRC). A.J.L., L. C. G., J.L.H., M. C. M., and S. C. D. are supported by the NHMRC. K.J.A. is supported by the Charles and Sylvia Viertel Charitable Foundation.; M. J. Abramson was part of the Landmark Symposium for GlaxoSmithKline and receives research support from Reckitts Benckiser. D. Hill has received past support from Nutricia, SHS International, and Nestle for research, and has presented lectures at sponsored meetings. The rest of the authors have declared that they have no conflict of interest.	Almqvist C, 2007, CLIN EXP ALLERGY, V37, P1296, DOI 10.1111/j.1365-2222.2007.02796.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, P1127, DOI 10.1016/j.jaci.2008.09.029; Backlund AB, 2006, ALLERGY, V61, P549, DOI 10.1111/j.1398-9995.2006.01027.x; Brockow I, 2009, J INVEST ALLERG CLIN, V19, P180; Cullinan P, 2004, THORAX, V59, P855, DOI 10.1136/thx.2003.019877; de Bilderling G, 2008, CLIN EXP ALLERGY, V38, P643, DOI 10.1111/j.1365-2222.2008.02938.x; Fasce L, 2004, IMMUNOL LETT, V93, P45, DOI 10.1016/j.imlet.2004.01.016; Fasce L, 2007, ALLERGY ASTHMA PROC, V28, P449, DOI 10.2500/aap.2007.28.2966; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Ghunaim N, 2006, CLIN EXP ALLERGY, V36, P722, DOI 10.1111/j.1365-2222.2006.02489.x; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P421, DOI 10.1111/j.1399-3038.2004.00178.x; Holgate Stephen T, 2009, Proc Am Thorac Soc, V6, P655, DOI 10.1513/pats.200907-072DP; Holgate ST, 2010, CURR OPIN ALLERGY CL, V10, P48, DOI 10.1097/ACI.0b013e3283347be5; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Kurukulaaratchy RJ, 2005, ALLERGY, V60, P1280, DOI 10.1111/j.1398-9995.2005.00890.x; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P1624, DOI 10.1111/j.1365-2222.2007.02822.x; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P536, DOI 10.1111/j.1365-2222.2007.02691.x; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Matricardi PM, 2009, CLIN EXP ALLERGY, V39, P1551, DOI 10.1111/j.1365-2222.2009.03348.x; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Platts-Mills TAE, 2009, AM J RESP CRIT CARE, V180, P109, DOI 10.1164/rccm.200811-1756PR; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; Sporik R, 2001, THORAX, V56, P58; Stein Renato T, 2004, Paediatr Respir Rev, V5, P155, DOI 10.1016/j.prrv.2004.01.007; Stern DA, 2004, CLIN EXP ALLERGY, V34, P1563, DOI 10.1111/j.1365-2222.2004.02088.x; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Tovey ER, 2008, J ALLERGY CLIN IMMUN, V122, P114, DOI 10.1016/j.jaci.2008.05.010; von Hertzen L, 2009, AM J RESP CRIT CARE, V180, P113, DOI 10.1164/rccm.200807-1001CO; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7	42	87	91	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					782	U456		10.1016/j.jaci.2011.06.038	http://dx.doi.org/10.1016/j.jaci.2011.06.038			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21820717				2022-12-18	WOS:000296538100013
J	Senna, G; Lombardi, C; Canonica, GW; Passalacqua, G				Senna, Gianenrico; Lombardi, Carlo; Canonica, Giorgio Walter; Passalacqua, Giovanni			How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							VISUAL ANALOG SCALES; ALLERGIC RHINITIS; IMPLEMENTATION; GUIDELINES; SEVERITY		[Senna, Gianenrico] Verona Gen Hosp, Allergy Unit, Verona, Italy; [Lombardi, Carlo] St Orsola Hosp, Dept Internal Med, Allergy Unit, Brescia, Italy; [Canonica, Giorgio Walter; Passalacqua, Giovanni] Univ Genoa, DIMI, Allergy & Resp Dis, I-16126 Genoa, Italy	University of Genoa	Senna, G (corresponding author), Verona Gen Hosp, Allergy Unit, Verona, Italy.	passalacqua@unige.it	canonica, giorgio walter/ABF-2037-2020; Senna, Gianenrico/AAC-5201-2022	canonica, giorgio walter/0000-0001-8467-2557; Senna, Gianenrico/0000-0003-4172-3216				Bousquet J, 2003, ALLERGY, V58, P733, DOI 10.1034/j.1398-9995.2003.00076.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet J, 2009, INT ARCH ALLERGY IMM, V150, P75, DOI 10.1159/000210383; Bousquet PJ, 2007, INT ARCH ALLERGY IMM, V143, P163, DOI 10.1159/000099307; Bousquet PJ, 2007, ALLERGY, V62, P367, DOI 10.1111/j.1398-9995.2006.01276.x; Bousquet PJ, 2009, J ALLERGY CLIN IMMUN, V123, P1349, DOI 10.1016/j.jaci.2009.02.033; Canonica GW, 2007, ALLERGY, V62, P17, DOI 10.1111/j.1398-9995.2007.01549.x; GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; Juniper EF, 1999, J ALLERGY CLIN IMMUN, V104, P364, DOI 10.1016/S0091-6749(99)70380-5; LANGLEY GB, 1985, RHEUMATOL INT, V5, P145, DOI 10.1007/BF00541514; Lombardi C, 2004, J ALLERGY CLIN IMMUN, V113, P1219, DOI 10.1016/j.jaci.2004.03.013; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Passalacqua G, 2009, ALLERGY, V64, P1796, DOI 10.1111/j.1398-9995.2009.02136.x; REILLY MC, 1993, PHARMACOECONOMICS, V4, P353, DOI 10.2165/00019053-199304050-00006; Senna G, 2009, CURR OPIN ALLERGY CL, V9, P544, DOI 10.1097/ACI.0b013e328332b8df; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; Vita D, 2010, ALLERGY, V65, P668, DOI 10.1111/j.1398-9995.2009.02223.x; WEWERS ME, 1990, RES NURS HEALTH, V13, P227, DOI 10.1002/nur.4770130405	18	87	92	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					668	669		10.1016/j.jaci.2010.06.045	http://dx.doi.org/10.1016/j.jaci.2010.06.045			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20816199				2022-12-18	WOS:000281512500041
J	Sonnappa, S; Bastardo, CM; Wade, A; Saglani, S; McKenzie, SA; Bush, A; Aurora, P				Sonnappa, Samatha; Bastardo, Cristina M.; Wade, Angela; Saglani, Sejal; McKenzie, Sheila A.; Bush, Andrew; Aurora, Paul			Symptom-pattern phenotype and pulmonary function in preschool wheezers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Children; episodic (viral) wheeze; multiple-trigger wheeze; phenotype; preschool wheeze; pulmonary function; symptom-pattern	1ST 6 YEARS; METERED-DOSE INHALER; LUNG-FUNCTION; VENTILATION HETEROGENEITY; WHEEZING PHENOTYPES; AIRWAY INVOLVEMENT; BIRTH-WEIGHT; ASTHMA; CHILDREN; LIFE	Background: Pulmonary function in preschool wheezing phenotypes based on wheeze onset and duration and atopic status has been extensively described but has not been studied in symptom-pattern phenotypes of episodic (viral) and multiple-trigger wheeze. Objective: We investigated whether multiple-trigger wheezers were more likely to have abnormal pulmonary function and increased fraction of exhaled nitric oxide (FeNO) than episodic (viral) wheezers and whether multiple-breath wash-out was more sensitive at detecting abnormal pulmonary function than specific airways resistance (sR(aw)) in preschool wheezers. Methods: FeNO, multiple-breath wash-out indices (lung clearance index [LCI] and conductive airways ventilation inhomogeneity [S-cond]) and s(Raw) were measured in healthy children and those with recurrent wheeze aged 4 to 6 years. Subgroup analysis was performed according to current symptom-pattern (multiple-trigger vs episodic [viral]), atopic status (atopic vs nonatopic), and wheeze status (currently symptomatic vs asymptomatic). Results:Seventy-two control subjects and 62 wheezers were tested. Multiple-trigger wheezers were associated with an average increase of 11% (95% CI, 7% to 18%; P <.001) in LCI, 211% (95% CI, 70% to 470%; P <.001) in Scond, and 15% (95% CI, 3% to 28%; P =.01) in s(Raw) compared with episodic (viral) wheezers. Pulmonary function in episodic (viral) wheezers did not differ significantly from control subjects. The presence of current atopy or wheeze was associated with higher FeNO (P =.05) but did not influence pulmonary function significantly. On average, LCI was abnormal in 39% (95% CI, 32% to 45%), Scond was abnormal in 68% (95% CI, 61% to 74%), and s(Raw) was abnormal in 26% (95% CI, 16% to 35%) of multiple-trigger wheezers. Conclusions: Multiple-trigger wheeze is associated with pulmonary function abnormalities independent of atopic and current wheeze status. Scond is the most sensitive indicator of abnormal pulmonary function in preschool wheezers. (J Allergy Clin Immunol 2010;126:519-26.)	[Sonnappa, Samatha; Bastardo, Cristina M.; Aurora, Paul] UCL Inst Child Hlth, Portex Unit Resp Med & Physiol, London WC1N 1EH, England; [Wade, Angela] UCL Inst Child Hlth, Dept Epidemiol & Biostat, London WC1N 1EH, England; [Sonnappa, Samatha; Aurora, Paul] Great Ormond St Hosp Sick Children, Dept Resp Med, London WC1N 1EH, England; [Saglani, Sejal; Bush, Andrew] Royal Brompton Hosp, Dept Paediat Resp Med, London SW3 6LY, England; [Saglani, Sejal; Bush, Andrew] Univ London Imperial Coll Sci Technol & Med, London, England; [McKenzie, Sheila A.] Royal London Hosp, Dept Paediat Resp Med, London E1 1BB, England	University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Royal Brompton Hospital; Imperial College London; Barts Health NHS Trust; Royal London Hospital	Sonnappa, S (corresponding author), UCL Inst Child Hlth, Portex Unit Resp Med & Physiol, 30 Guilford St, London WC1N 1EH, England.	s.sonnappa@ich.ucl.ac.uk	Sonnappa, Samatha/C-1590-2008; Saglani, Sejal/AAE-5072-2019	Saglani, Sejal/0000-0001-5192-6418	Asthma UK; European Respiratory Society; Smiths Medical	Asthma UK; European Respiratory Society; Smiths Medical	Supported by Asthma UK, the European Respiratory Society, and Smiths Medical.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Aurora P, 2005, RESP PHYSIOL NEUROBI, V148, P125, DOI 10.1016/j.resp.2005.05.027; Aurora P, 2005, AM J RESP CRIT CARE, V171, P249, DOI 10.1164/rccm.200407-895OC; AURORA P, 2005, THESIS U COLL LONDON; Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Brussee JE, 2005, EUR RESPIR J, V25, P455, DOI 10.1183/09031936.05.00079604; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327; Castro-Rodriguez JA, 2009, PEDIATRICS, V123, pe519, DOI 10.1542/peds.2008-2867; Cohen J., 1988, STAT POWER ANAL BEHA; Downie SR, 2007, THORAX, V62, P684, DOI 10.1136/thx.2006.069682; Fish JE, 1999, J ALLERGY CLIN IMMUN, V104, P509, DOI 10.1016/S0091-6749(99)70315-5; Frey U, 2009, NEW ENGL J MED, V360, P2130, DOI 10.1056/NEJMe0902242; Goleva E, 2007, J ALLERGY CLIN IMMUN, V120, P1065, DOI 10.1016/j.jaci.2007.07.042; Gustafsson PM, 2007, PEDIATR PULM, V42, P168, DOI 10.1002/ppul.20554; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Hoo AF, 2004, AM J RESP CRIT CARE, V170, P527, DOI 10.1164/rccm.200311-1552OC; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; JOHNSTON IDA, 1987, THORAX, V42, P542, DOI 10.1136/thx.42.7.542; Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242; KEMP JP, 1989, J ALLERGY CLIN IMMUN, V83, P697, DOI 10.1016/0091-6749(89)90085-7; Kurukulaaratchy RJ, 2004, THORAX, V59, P563, DOI 10.1136/thx.2003.010462; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; Lau S, 2003, EUR RESPIR J, V21, P834, DOI 10.1183/09031936.03.00037203; Lofdahl CG, 1997, EUR RESPIR J, V10, P2474, DOI 10.1183/09031936.97.10112474; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; Lum S, 2001, AM J RESP CRIT CARE, V164, P2078, DOI 10.1164/ajrccm.164.11.2104053; Macleod KA, 2009, THORAX, V64, P33, DOI 10.1136/thx.2007.095018; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Michel G, 2006, EUR RESPIR J, V28, P1124, DOI 10.1183/09031936.06.00008406; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Payne DNR, 2004, THORAX, V59, P862, DOI 10.1136/thx.2003.017244; Razzouk H, 1999, INT J PHARM, V180, P169, DOI 10.1016/S0378-5173(98)00399-8; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Spycher BD, 2008, EUR RESPIR J, V31, P974, DOI 10.1183/09031936.00153507; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Tgavalekos NT, 2007, EUR RESPIR J, V29, P1174, DOI 10.1183/09031936.00113606; Turato G, 2008, AM J RESP CRIT CARE, V178, P476, DOI 10.1164/rccm.200712-1818OC; Venegas JG, 2005, NATURE, V434, P777, DOI 10.1038/nature03490; Verbanck S, 1999, AM J RESP CRIT CARE, V159, P1545, DOI 10.1164/ajrccm.159.5.9809017; Verbanck S, 2003, J APPL PHYSIOL, V94, P1380, DOI 10.1152/japplphysiol.00588.2002; Whittaker AL, 2005, ARCH DIS CHILD-FETAL, V90, pF423, DOI 10.1136/adc.2004.062497	43	87	88	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					519	U201		10.1016/j.jaci.2010.04.018	http://dx.doi.org/10.1016/j.jaci.2010.04.018			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20579717				2022-12-18	WOS:000281512500017
J	Eckman, JA; Sterba, PM; Kelly, D; Alexander, V; Liu, MC; Bochner, BS; MacGlashan, DW; Saini, SS				Eckman, John A.; Sterba, Patricia M.; Kelly, Denise; Alexander, Val; Liu, Mark C.; Bochner, Bruce S.; MacGlashan, Donald W., Jr.; Saini, Sarbjit S.			Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; IgE receptors; omalizumab; basophils; mast cells; basophil histamine release; skin prick test titration; nasal allergen challenge; cat allergy	FC-EPSILON-RI; DOWN-REGULATION; EXPRESSION; IGE; HISTAMINE; ANTIBODY; RELEASE; DECREASES; ALPHA	Background: Omalizumab treatment suppresses Fc is an element of RI expression faster on blood basophils than skin mast cells. Objective: We used omalizumab to elucidate the relative contributions of basophil versus mast cell Fc is an element of RI activation in a nasal allergen challenge (NAC) model. Methods: Eighteen subjects with cat allergy were enrolled in a 3.5-month, double-blind, randomized (3.5:1), placebo-controlled trial of omalizumab using standard dosing. At baseline, subjects underwent NAC with lavage for prostaglandin D-2 measurement, skin prick test titration (SPTT), and blood sampling for basophil histamine release (BHR) and basophil IgE/Fc is an element of RI measurements. Basophil studies were repeated at day 3 and then weekly until cat allergen induced BHR was <20% of baseline or until day 45. Baseline visit procedures were repeated after the BHR reduction (midstudy NAC) and at the treatment period's completion (final NAC). Results: Subjects treated with omalizumab who completed all NACs (n = 12) demonstrated significant mean reduction in BHR to an optimal dose of cat allergen by midstudy NAC compared with baseline (74% decrease; P=.001). In addition, these subjects demonstrated significant decreases in mean combined nasal symptom scores (50% decrease; P=.007) and total sneeze counts (59% decrease; P=.01) by midstudy NAC relative to baseline NAC. In contrast, measures of mast cell response (SPTT and nasal lavage prostaglandin D2) were only significantly reduced by the final NAC. Subjects on placebo (n = 4) did not experience a shift in basophil, NAG symptom, or mast cell measures. Conclusion: Reduction in nasal symptom scores occurred when the basophil, but not mast cell, response was reduced on omalizumab, implicating a role for basophils in the acute NAG response. (J Allergy Clin Immunol 2010;125:889-95.)	[Eckman, John A.; Sterba, Patricia M.; Kelly, Denise; Alexander, Val; Liu, Mark C.; Bochner, Bruce S.; MacGlashan, Donald W., Jr.; Saini, Sarbjit S.] Johns Hopkins Univ, Sch Med, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD 21205 USA	Johns Hopkins University	Saini, SS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	ssaini@jhmi.edu			Johns Hopkins University; National Institutes of Health [U19A1070345]; Genentech; Novartis; Novartis Advisory Board; Pfizer; Centocor; National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070345] Funding Source: NIH RePORTER	Johns Hopkins University(Johns Hopkins University); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genentech(Roche HoldingGenentech); Novartis(Novartis); Novartis Advisory Board; Pfizer(Pfizer); Centocor; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	S.S.S. and B.S.B. received support as Cosner Scholars in Translational Research from Johns Hopkins University. This work was supported by Asthma and Allergic Disease Research Centers grant U19A1070345 front the National Institutes of Health.; Disclosure of potential conflict of interest: S. S. Saini has served as a consultant for and has received research support front Genentech and Novartis. M. C. Liu has served as a consultant for the Novartis Advisory Board and has received research support from Pfizer, Centocor, and Novartis. D. W. MacGlashan Jr has received research support front the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.	Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Corren J, 2004, ANN ALLERG ASTHMA IM, V93, P243, DOI 10.1016/S1081-1206(10)61495-0; Hanf G, 2004, EUR RESPIR J, V23, P414, DOI 10.1183/09031936.04.00024504; HAYES EC, 1983, J IMMUNOL, V131, P429; Karasuyama H, 2009, NAT REV IMMUNOL, V9, P9, DOI 10.1038/nri2458; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; LINDER A, 1988, CLIN ALLERGY, V18, P29, DOI 10.1111/j.1365-2222.1988.tb02840.x; MacGlashan D, 2009, J ALLERGY CLIN IMMUN, V123, P114, DOI 10.1016/j.jaci.2008.10.053; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; Nathan RA, 2005, J ALLERGY CLIN IMMUN, V116, P463, DOI 10.1016/j.jaci.2005.03.045; Noga O, 2008, INT ARCH ALLERGY IMM, V146, P66, DOI 10.1159/000112504; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; PRESTA LG, 1993, J IMMUNOL, V151, P2623; PROUD D, 1992, J ALLERGY CLIN IMMUN, V89, P1098, DOI 10.1016/0091-6749(92)90293-B; Saini SS, 1999, J IMMUNOL, V162, P5624; Saini SS, 2001, J ALLERGY CLIN IMMUN, V107, P832, DOI 10.1067/mai.2001.114653; Schulman ES, 2001, AM J RESP CRIT CARE, V164, pS6, DOI 10.1164/ajrccm.164.supplement_1.2103025; Strunk RC, 2006, NEW ENGL J MED, V354, P2689, DOI 10.1056/NEJMct055184; Vonakis BM, 2007, J ALLERGY CLIN IMMUN, V119, P441, DOI 10.1016/j.jaci.2006.09.035	20	87	89	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					889	895		10.1016/j.jaci.2009.09.012	http://dx.doi.org/10.1016/j.jaci.2009.09.012			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	19962744	Green Accepted			2022-12-18	WOS:000276787900015
J	Wise, RA; Bartlett, SJ; Brown, ED; Castro, M; Cohen, R; Holbrook, JT; Irvin, CG; Rand, CS; Sockrider, MM; Sugar, EA				Wise, Robert A.; Bartlett, Susan J.; Brown, Ellen D.; Castro, Mario; Cohen, Rubin; Holbrook, Janet T.; Irvin, Charles G.; Rand, Cynthia S.; Sockrider, Marianna M.; Sugar, Elizabeth A.		Amer Lung Assoc Asthma	Randomized trial of the effect of drug presentation on asthma outcomes: The American Lung Association Asthma Clinical Research Centers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; placebo effect; montelukast; efficacy; factorial design	PLACEBO ANALGESIA; INFORMED CONSENT; QUESTIONNAIRE; EXPECTANCY; SUGGESTION; VALIDATION; COLOR	Background: Information that enhances expectations about drug effectiveness improves the response to placebos for pain. Although asthma symptoms often improve with placebo, it is not known whether the response to placebo or active treatment can be augmented by increasing expectation of benefit. Objective: The study objective was to determine whether response to placebo or a leukotriene antagonist (montelukast) can be augmented by messages that increase expectation of benefit. Methods: A randomized 20-center controlled trial enrolled 601 asthmatic patients with poor symptom control who were assigned to one of 5 study groups. Participants were randomly assigned to one of 4 treatment groups in a factorial design (ie, placebo with enhanced messages, placebo with neutral messages, montelukast with enhanced messages, or montelukast with neutral messages) or to usual care. Assignment to study drug was double masked, assignment to message content was single masked, and usual care was not masked. The enhanced message aimed to increase expectation of benefit from the drug. The primary outcome was mean change in daily peak flow over 4 weeks. Secondary outcomes included lung function and asthma symptom control. Results: Peak flow and other lung function measures were not improved in participants assigned to the enhanced message groups versus the neutral messages groups for either montelukast or placebo; no differences were noted between the neutral placebo and usual care groups. Placebo-treated participants had improved asthma control with the enhanced message but not montelukast-treated participants; the neutral placebo group did have improved asthma control compared with the usual care group after adjusting for baseline difference. Headaches were more common in participants provided messages that mentioned headache as a montelukast side effect. Conclusions: Optimistic drug presentation augments the placebo effect for patient-reported outcomes (asthma control) but not lung function. However, the effect of montelukast was not enhanced by optimistic messages regarding treatment effectiveness. (J Allergy Clin Immunol 2009;124:436-44.)	[Wise, Robert A.; Rand, Cynthia S.] Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; [Wise, Robert A.; Brown, Ellen D.; Holbrook, Janet T.; Sugar, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Bartlett, Susan J.] McGill Univ, Dept Med, Sch Occupat & Phys Therapy, Montreal, PQ, Canada; [Castro, Mario] Washington Univ, Sch Med, Div Pulm & Crit Care Med, St Louis, MO USA; [Cohen, Rubin] Albert Einstein Coll Med, New Hyde Pk, NY USA; [Cohen, Rubin] N Shore Long Isl Jewish Hlth Syst, Div Pulm Crit Care & Sleep Med, New Hyde Pk, NY USA; [Irvin, Charles G.] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA; [Irvin, Charles G.] Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT USA; [Sockrider, Marianna M.] Baylor Coll Med, Dept Pediat, Sect Pediat Pulmonol, Houston, TX 77030 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; McGill University; Washington University (WUSTL); Yeshiva University; Northwell Health; University of Vermont; University of Vermont; Baylor College of Medicine	Wise, RA (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	rwise@jhmi.edu	Bartlett, Susan Joan/AAD-4103-2020; Bartlett, Susan J./J-9864-2012; Cohen, Rubin I/ABC-2650-2021; silkoff, philip/S-9037-2016	Bartlett, Susan Joan/0000-0001-9755-2490; Schraufnagel, Dean/0000-0003-0063-7223; Wise, Robert/0000-0002-8353-2349; silkoff, philip/0000-0001-6018-5199; , Rubin/0000-0002-1257-391X	National Institutes of Health-National Heart, Lung, and Blood Institute [R01HL073494]; American Lung Association; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024992] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073494] Funding Source: NIH RePORTER	National Institutes of Health-National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Lung Association; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants from National Institutes of Health-National Heart, Lung, and Blood Institute grant R01HL073494 and the American Lung Association.	Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; BERGMANN JF, 1994, CLIN TRIAL META-ANAL, V29, P41; BRANTHWAITE A, 1981, BRIT MED J, V282, P1576, DOI 10.1136/bmj.282.6276.1576; Brodwater BK, 2000, PEDIATR SURG INT, V16, P216, DOI 10.1007/s003830050728; BUCKALEW LW, 1982, PERCEPT MOTOR SKILL, V55, P915, DOI 10.2466/pms.1982.55.3.915; BUCKALEW LW, 1982, J CLIN PSYCHOPHARM, V2, P245; Ciccone DS, 2007, J NERV MENT DIS, V195, P119, DOI 10.1097/01.nmd.0000254731.68430.a9; DAHAN R, 1986, BRIT MED J, V293, P363, DOI 10.1136/bmj.293.6543.363; De Pascalis V, 2002, PAIN, V96, P393, DOI 10.1016/S0304-3959(01)00485-7; deCraen AJM, 1996, BRIT MED J, V313, P1624, DOI 10.1136/bmj.313.7072.1624; Diggle P., 1994, ANAL LONGITUDINAL DA, V13; ELASHOFF JN, 2000, QUERY ADVISOR USER G; Goebel MU, 2002, FASEB J, V16, P1869, DOI 10.1096/fj.02-0389com; Green MW, 2001, BRIT J NUTR, V86, P173, DOI 10.1079/BJN2001398; GRYLL SL, 1978, PSYCHOPHARMACOLOGY, V57, P253, DOI 10.1007/BF00426747; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hosmer D.W, 1998, APPL LOGISTIC REGRES; Joyce DP, 2000, J ASTHMA, V37, P303, DOI 10.3109/02770900009055454; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kemeny ME, 2007, J ALLERGY CLIN IMMUN, V119, P1375, DOI 10.1016/j.jaci.2007.03.016; KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8; LEVINE JD, 1984, NATURE, V312, P755, DOI 10.1038/312755a0; LUPARELLO T, 1968, PSYCHOSOM MED, V30, P819, DOI 10.1097/00006842-196811000-00002; Mahler DA, 2002, AM J RESP CRIT CARE, V166, P1084, DOI 10.1164/rccm.2112055; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; MARLATT GA, 1980, ADV SUBSTANC ABUSE, V1, P159; MCFADDEN ER, 1969, PSYCHOSOM MED, V31, P134, DOI 10.1097/00006842-196903000-00007; Mikalsen A, 2001, PSYCHOPHARMACOLOGY, V157, P373, DOI 10.1007/s002130100841; *NIH, 1997, NIH PUBL; Price DD, 1999, PAIN, V83, P147, DOI 10.1016/S0304-3959(99)00081-0; Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; Rose DA, 2001, J GEN PSYCHOL, V128, P401, DOI 10.1080/00221300109598918; *SAS I, 1999, SAS STAT US GUID VER; SPECTOR S, 1976, AM REV RESPIR DIS, V113, P43; WIGAL JK, 1993, CHEST, V104, P1144, DOI 10.1378/chest.104.4.1144	38	87	87	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					436	U76		10.1016/j.jaci.2009.05.041	http://dx.doi.org/10.1016/j.jaci.2009.05.041			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19632710	Green Accepted			2022-12-18	WOS:000274315900006
J	Knuffman, JE; Sorkness, CA; Lemanske, RF; Mauger, DT; Boehmer, SJ; Martinez, FD; Bacharier, LB; Strunk, RC; Szefler, SJ; Zeiger, RS; Taussig, LM				Knuffman, Jason E.; Sorkness, Christine A.; Lemanske, Robert F., Jr.; Mauger, David T.; Boehmer, Susan J.; Martinez, Fernando D.; Bacharier, Leonard B.; Strunk, Robert C.; Szefler, Stanley J.; Zeiger, Robert S.; Taussig, Lynn M.		Natl Heart Lung Blood Inst	Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; biomarkers; exhaled nitric oxide; fluticasone propionate; inhaled corticosteroids; montelukast; pulmonary response	CHILDREN AGED 2; CLINICAL-RESPONSE; MONTELUKAST; FLUTICASONE; BECLOMETHASONE; RESPONSIVENESS; IMPROVEMENT; RISK	Background: In children with mild-to-moderate persistent asthma, identification of phenotypic predictors to guide selection of a controller regimen is essential. Objective: We sought to identify phenotypic characteristics having predictive value for the difference in treatment responses between twice-daily fluticasone and once-daily montelukast. Methods: Data from the Pediatric Asthma Controller Trial were assessed with multivariate analysis. Outcomes included the change in asthma control days (ACDs), FEV1, peak expiratory flow, and time to first asthma exacerbation measured over a 1-year treatment period. Results: The mean age was 9.6 +/- 2.1 years, 60% were male, 50% had a parental history of asthma, and 78% had positive aeroallergen skin prick test responses. The mean percent predicted prebronchodilator FEV1 was 97.8% +/- 12.9%, the median PC20 value was 0.93 mg/mL, and the median exhaled nitric oxide (eNO) level was 25.2 ppb. A history of parental asthma best predicted the expected treatment benefit with fluticasone compared with montelukast in terms of gain in ACDs (adjusted P = .02) and time to first exacerbation (adjusted P = .05). Increased baseline eNO levels predicted the differential treatment response for fluticasone regarding the gain in ACDs (adjusted P = .01). Prior Inhaled corticosteroid (ICS) use (adjusted P = .01) and low PC20 values (adjusted P = .03) each predicted the expected treatment benefit with fluticasone over montelukast regarding time to first exacerbation. No phenotypic characteristics predicted treatment benefits for montelukast over fluticasone for either outcome. Conclusions: Physicians treating children with a parental history of asthma, increased eNO levels, low PC20 values, or a history of ICS use can expect the best long-term outcomes with ICS therapy compared with treatment with leukotriene receptor antagonists. (J Allergy Clin Immunol 2009;123:411-6.)	[Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Knuffman, Jason E.; Sorkness, Christine A.; Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med, Madison, WI USA; [Knuffman, Jason E.; Sorkness, Christine A.; Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; [Szefler, Stanley J.; Taussig, Lynn M.] Natl Jewish & Res Ctr, Dept Pediat, Denver, CO USA; [Szefler, Stanley J.; Taussig, Lynn M.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA; [Zeiger, Robert S.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Zeiger, Robert S.] Kaiser Permanente, Dept Allergy, San Diego, CA USA; [Bacharier, Leonard B.; Strunk, Robert C.] Washington Univ, Dept Pediat, St Louis, MO 63130 USA; [Mauger, David T.; Boehmer, Susan J.] Penn State Univ, Dept Publ Hlth Sci, Hershey, PA USA	University of Arizona; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California San Diego; Kaiser Permanente; Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Knuffman, JE (corresponding author), Gunderson Lutheran Med Ctr, Dept Allergy & Immunol, 1900 South Ave,MS FB2-008, La Crosse, WI 54601 USA.	JEKnuffm@gundluth.org		Zeiger, Robert/0000-0001-5788-5063; Bacharier, Leonard/0000-0003-0432-2704	National Heart, Lung, and Blood Institute [HL064307, HL64288, HL064295, HL64287, HL064305]; General Clinical Research Centers at Washington University School of Medicine [M01 RR00036]; National Jewish Medical and Research Center [M01 RR00051]; University of Wisconsin [M01 RR03186]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051, M01RR000036, M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064288, U10HL064295, U10HL064287, U10HL064307, U10HL064305, U10HL064313] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); General Clinical Research Centers at Washington University School of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Jewish Medical and Research Center; University of Wisconsin; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants HL064307, HL64288, HL064295, HL64287, and HL064305 from the National Heart, Lung, and Blood Institute. This study was carried out in part by the General Clinical Research Centers at Washington University School of Medicine (M01 RR00036), National Jewish Medical and Research Center (M01 RR00051), and the University of Wisconsin (M01 RR03186).	Becker A, 2000, PEDIATR PULM, V30, P183, DOI 10.1002/1099-0496(200008)30:2<183::AID-PPUL17>3.0.CO;2-M; Brightling Christopher E, 2005, Treat Respir Med, V4, P309, DOI 10.2165/00151829-200504050-00002; Cai C, 2007, LUNG, V185, P105, DOI 10.1007/s00408-006-0001-8; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Crestani E, 2004, J ALLERGY CLIN IMMUN, V113, P284, DOI 10.1016/j.jaci.2003.11.009; Hargreave FE, 1998, J ALLERGY CLIN IMMUN, V102, pS102, DOI 10.1016/S0091-6749(98)70040-5; Israel E, 2002, J ALLERGY CLIN IMMUN, V110, P847, DOI 10.1067/mai.2002.129413; KERSTJENS HAM, 1995, AM J RESP CRIT CARE, V151, P360, DOI 10.1164/ajrccm.151.2.7842192; Klotsman M, 2007, PHARMACOGENET GENOM, V17, P189, DOI 10.1097/FPC.0b013e3280120043; Knorr B, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.3.e48; Lima JJ, 2007, MOL DIAGN THER, V11, P97, DOI 10.1007/BF03256228; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Meijer RJ, 2002, CLIN EXP ALLERGY, V32, P1096, DOI 10.1046/j.1365-2222.2002.01412.x; Meyer KA, 2003, J ALLERGY CLIN IMMUN, V111, P757, DOI 10.1067/mai.2003.1391; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Raby BA, 2005, AM J RESP CRIT CARE, V172, P552, DOI 10.1164/rccm.200501-010OC; Roorda RJ, 2001, J ALLERGY CLIN IMMUN, V108, P540, DOI 10.1067/mai.2001.118789; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Stoloff SW, 2006, J ALLERGY CLIN IMMUN, V117, P544, DOI 10.1016/j.jaci.2006.01.005; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Villaran C, 1999, J ALLERGY CLIN IMMUN, V104, P547, DOI 10.1016/S0091-6749(99)70322-2; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	26	87	95	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					411	416		10.1016/j.jaci.2008.11.016	http://dx.doi.org/10.1016/j.jaci.2008.11.016			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19121860	Green Accepted			2022-12-18	WOS:000263495000019
J	Rundell, KW; Slee, JB				Rundell, Kenneth W.; Slee, Joshua B.			Exercise and other indirect challenges to demonstrate asthma or exercise-induced bronchoconstriction in athletes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						athlete; bronchoconstriction; diagnosis; EVH; exercise-induced asthma; hypertonic saline; mannitol	EUCAPNIC VOLUNTARY HYPERVENTILATION; HYPERTONIC SALINE CHALLENGE; CROSS-COUNTRY SKIERS; EXHALED NITRIC-OXIDE; ADENOSINE 5'-MONOPHOSPHATE; INDUCED BRONCHOSPASM; BRONCHIAL HYPERRESPONSIVENESS; AIRWAY INFLAMMATION; IMPULSE OSCILLOMETRY; DRY POWDER	The prevalence of exercise-induced bronchoconstriction is reported to be high among recreational and elite athletes, yet diagnosis is often symptom-based. Indirect challenges such as the laboratory exercise challenge provide objective criteria for proper diagnosis and treatment. However, a standardized protocol using appropriate exercise intensity, duration, and dry air inhalation is often not implemented, and thus a false-negative test may result. This article reviews and describes the symptom-based diagnosis, the exercise challenge, and other indirect challenges such as eucapnic voluntary hyperpnea, hypertonic saline inhalation, and inhaled powdered mannitol as methods to diagnose and evaluate exercise-induced bronchoconstriction. Advantages and disadvantages of each diagnostic procedure are presented.	[Rundell, Kenneth W.; Slee, Joshua B.] Marywood Univ, Human Physiol Lab, Keith J O Neill Ctr Healthy Families, Scranton, PA 18509 USA		Rundell, KW (corresponding author), Marywood Univ, Human Physiol Lab, Keith J O Neill Ctr Healthy Families, Scranton, PA 18509 USA.	Rundell@marywood.edu						Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P419, DOI 10.1067/mai.2000.108914; Anderson SD, 1997, AM J RESP CRIT CARE, V156, P758, DOI 10.1164/ajrccm.156.3.9701113; Anderson SD, 2006, J ALLERGY CLIN IMMUN, V117, P767, DOI 10.1016/j.jaci.2005.12.1355; Anderson SD, 2003, CLIN REV ALLERG IMMU, V24, P27, DOI 10.1385/CRIAI:24:1:27; Anderson SD, 2003, J ALLERGY CLIN IMMUN, V111, P45, DOI 10.1067/mai.2003.1; Anderson SD, 2002, J AEROSOL MED, V15, P313, DOI 10.1089/089426802760292663; ANDERSON SD, 1971, BMJ-BRIT MED J, V4, P814, DOI 10.1136/bmj.4.5790.814-c; ANDERSON SD, 1971, THORAX, V26, P396, DOI 10.1136/thx.26.4.396; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P472; Anderson SD, 2001, BRIT J SPORT MED, V35, P344, DOI 10.1136/bjsm.35.5.344; Argyros GJ, 1996, CHEST, V109, P1520, DOI 10.1378/chest.109.6.1520; Avital A, 2003, PEDIATR PULM, V36, P433, DOI 10.1002/ppul.10377; AVRAHAM A, 2000, PEDIAT PULMONOL, V30, P207; BECK KC, 1994, AM J RESP CRIT CARE, V149, P352, DOI 10.1164/ajrccm.149.2.8306029; Benckhuijsen J, 1996, PEDIATR PULM, V22, P147, DOI 10.1002/(SICI)1099-0496(199609)22:3<147::AID-PPUL2>3.0.CO;2-M; Beuther DA, 2006, CHEST, V129, P1188, DOI 10.1378/chest.129.5.1188; Boulet LP, 1999, CAN MED ASSOC J, V161, pS1; Brannan JD, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-144; Brannan JD, 1998, AM J RESP CRIT CARE, V158, P1120, DOI 10.1164/ajrccm.158.4.9802087; BYE MR, 1992, AM J DIS CHILD, V146, P977, DOI 10.1001/archpedi.1992.02160200099037; Carlsen KH, 2008, ALLERGY, V63, P387, DOI 10.1111/j.1398-9995.2008.01662.x; Carlsen KH, 2000, RESP MED, V94, P750, DOI 10.1053/rmed.2000.0809; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Currie GP, 2003, CLIN EXP ALLERGY, V33, P783, DOI 10.1046/j.1365-2222.2003.01688.x; Currie GP, 2004, J ASTHMA, V41, P247, DOI 10.1081/JAS-120028582; DAVISKAS E, 1990, J APPL PHYSIOL, V69, P362, DOI 10.1152/jappl.1990.69.1.362; DAVISKAS E, 1991, RESP PHYSIOL, V84, P115, DOI 10.1016/0034-5687(91)90023-C; Dickinson JW, 2006, BRIT J SPORT MED, V40, P179, DOI 10.1136/bjsm.2005.022764; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; Evans TM, 2006, J ASTHMA, V43, P49, DOI 10.1080/02770900500448555; Evans TM, 2005, CHEST, V128, P2412, DOI 10.1378/chest.128.4.2412; Evans TM, 2005, MED SCI SPORT EXER, V37, P544, DOI 10.1249/01.MSS.0000158186.32450.EC; FINNERTY JP, 1989, AM REV RESPIR DIS, V140, P593, DOI 10.1164/ajrccm/140.3.593; FITCH KD, 1971, BRIT MED J, V4, P577, DOI 10.1136/bmj.4.5787.577; GODFREY S, 1975, PEDIATRICS, V56, P893; HABY MM, 1994, EUR RESPIR J, V7, P43, DOI 10.1183/09031936.94.07010043; Helenius I, 2000, J ALLERGY CLIN IMMUN, V106, P444, DOI 10.1067/mai.2000.107749; Helenius IJ, 1997, THORAX, V52, P157, DOI 10.1136/thx.52.2.157; Henriksen AH, 2002, PEDIATR ALLERGY IMMU, V13, P203, DOI 10.1034/j.1399-3038.2002.01034.x; Jones SL, 2002, EUR RESPIR J, V20, P601, DOI 10.1183/09031936.02.00285302; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086, DOI 10.1164/ajrccm.161.6.9907025; KONIG P, 1989, ALLERGY PROC, V10, P345, DOI 10.2500/108854189778959830; MAHLER DA, 1993, MED SCI SPORT EXER, V25, P554; Mannix ET, 1996, CHEST, V109, P312, DOI 10.1378/chest.109.2.312; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; Mohsenin A, 2006, CURR OPIN PULM MED, V12, P54, DOI 10.1097/01.mcp.0000199002.46038.cb; *NAT ASTHM ED PREV, 1997, EXP PAN 2 GUID DIAGN, P146; NEWMAN KB, 1995, AM J RESP CRIT CARE, V152, P1382, DOI 10.1164/ajrccm.152.4.7551399; Ogston J, 2002, CLIN J SPORT MED, V12, P291, DOI 10.1097/00042752-200209000-00006; Parsons JP, 2007, MED SCI SPORT EXER, V39, P1487, DOI 10.1249/mss.0b013e3180986e45; ProvostCraig MA, 1996, J ASTHMA, V33, P67, DOI 10.3109/02770909609077764; Rabone SJ, 1996, OCCUP MED-OXFORD, V46, P177, DOI 10.1093/occmed/46.3.177; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632, DOI 10.1164/ajrccm.150.6.7952626; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; Rorke S, 2002, THORAX, V57, P323, DOI 10.1136/thorax.57.4.323; Rundell Kenneth W, 2005, Can Respir J, V12, P257; Rundell KW, 2004, INHAL TOXICOL, V16, P117, DOI 10.1080/08958370490270918; Rundell KW, 2004, CHEST, V125, P909, DOI 10.1378/chest.125.3.909; Rundell KW, 2004, MED SCI SPORT EXER, V36, P405, DOI 10.1249/01.MSS.0000117118.77267.BF; Rundell KW, 2000, MED SCI SPORT EXER, V32, P309, DOI 10.1097/00005768-200002000-00010; Rundell KW, 2003, INHAL TOXICOL, V15, P237, DOI 10.1080/08958370304502; Rundell KW, 2003, CHEST, V123, P468, DOI 10.1378/chest.123.2.468; Rundell KW, 2003, MED SCI SPORT EXER, V35, P18, DOI 10.1097/00005768-200301000-00004; Rundell KW, 2002, SPORTS MED, V32, P583, DOI 10.2165/00007256-200232090-00004; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; Spiering BA, 2004, J ASTHMA, V41, P745, DOI 10.1081/JAS-200028004; Stensrud T, 2006, RESP MED, V100, P1633, DOI 10.1016/j.rmed.2005.12.001; STERLING GM, 1968, CLIN SCI, V34, P277; Sue-Chu M, 1999, EUR RESPIR J, V13, P626, DOI 10.1183/09031936.99.13362699; Sue-Chu M, 1999, RESP MED, V93, P719, DOI 10.1016/S0954-6111(99)90039-2; Suman OE, 1999, J APPL PHYSIOL, V87, P1107, DOI 10.1152/jappl.1999.87.3.1107; van den Berge M, 2004, CLIN EXP ALLERGY, V34, P71, DOI 10.1111/j.1365-2222.2004.01832.x; van den Toorn LM, 2000, AM J RESP CRIT CARE, V162, P953, DOI 10.1164/ajrccm.162.3.9909033; Van dn Berge M, 2001, AM J RESP CRIT CARE, V163, P1546, DOI 10.1164/ajrccm.163.7.2010145; WARREN JB, 1984, CLIN SCI, V66, P79, DOI 10.1042/cs0660079; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; Weiler JM, 2000, J ALLERGY CLIN IMMUN, V106, P267, DOI 10.1067/mai.2000.108605; Weiler JM, 2007, J ALLERGY CLIN IMMUN, V119, P1349, DOI 10.1016/j.jaci.2007.02.041; Wilber RL, 2000, MED SCI SPORT EXER, V32, P732, DOI 10.1097/00005768-200004000-00003	79	87	89	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					238	246		10.1016/j.jaci.2008.06.014	http://dx.doi.org/10.1016/j.jaci.2008.06.014			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18678339	Bronze			2022-12-18	WOS:000258426300002
J	Razafindratsita, A; Saint-Lu, N; Mascarell, L; Berjont, N; Bardon, T; Betbeder, D; Van Overtvelt, L; Moingeon, P				Razafindratsita, Alain; Saint-Lu, Nathalie; Mascarell, Laurent; Berjont, Nathalie; Bardon, Thierry; Betbeder, Didier; Van Overtvelt, Laurence; Moingeon, Philippe			Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy vaccines; mucosal formulation; sublingual immunotherapy	GRASS-POLLEN IMMUNOTHERAPY; REGULATORY T-CELLS; HOUSE-DUST MITES; IMMUNOLOGICAL MECHANISMS; IGE PRODUCTION; INDUCTION; CHILDREN; RHINITIS; ANTIGEN; ASTHMA	Background: Sublingual immunotherapy is a noninvasive and efficacious treatment of type I respiratory allergies. A murine model of sublingual immunotherapy is needed to understand better the immune mechanisms involved in successful immunotherapy and to assess second-generation candidate vaccines. Objective: Herein, we developed a therapeutic murine model of sublingual immunotherapy in which we document the value of mucoadhesive formulations to enhance treatment efficacy. Methods: BALB/c mice were sublingually treated with soluble or formulated ovalbumin before or after sensitization with ovalbumin. Airways hyperresponsiveness and lung inflammation were assessed by whole-body plethysmography and lung histology, respectively. Humoral and cellular immune responses were monitored by ELISA and ELISPOT techniques. Results: Prophylactic sublingual administration of ovalbumin completely prevents airways hyperresponsiveness as well as IL-5 secretion and IgE induction. Therapeutic administration of ovalbumin as a solution via either the sublingual or oral route has a limited efficacy. In contrast, sublingual application of ovalbumin formulated with maltodextrin to enhance mucosal adhesion results in a major reduction of established airways hyperresponsiveness, lung inflammation, and IL-5 production in splenocytes. This mucoadhesive formulation significantly enhances ovalbumin-specific T-cell proliferation in cervical but not mesenteric lymph nodes, and IgA production in the lungs. Conclusion: A mucoadhesive maltodextrin formulation of ovalbumin enhances priming of the local mucosal immune system and tolerance induction via the sublingual route. Clinical implications: Mucoadhesive formulations offer the opportunity to improve dramatically sublingual immunotherapy in human beings, most particularly by simplifying immunization schemes.	Res & Dev, F-92160 Antony, France; CEVA Sante Animale, Libourne, France; IMPRT, Fac Sci Jean Perrin, Lab Barriere Hemato Encephal, EA 2465,IFR 114, Lens, France	Ceva Sante Animale	Moingeon, P (corresponding author), Res & Dev, 6 Rue Alexis Tocqueville, F-92160 Antony, France.	pmoingeon@stallergenes.fr	BETBEDER, Didier/A-7558-2015	BETBEDER, Didier/0000-0002-2405-392X				Akdis CA, 2006, ALLERGY, V61, P11, DOI 10.1111/j.1398-9995.2006.01159.x; Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122, DOI 10.1016/S0091-6749(97)70203-3; Bagnasco M, 2005, INT ARCH ALLERGY IMM, V138, P197, DOI 10.1159/000088719; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Baudner BC, 2002, INFECT IMMUN, V70, P4785, DOI 10.1128/IAI.70.9.4785-4790.2002; Brimnes J, 2007, CLIN EXP ALLERGY, V37, P488, DOI 10.1111/j.1365-2222.2006.02624.x; Canonica GW, 2006, ALLERGY, V61, P20, DOI 10.1111/j.1398-9995.2006.01161.x; Ciprandi G, 2005, ANN ALLERG ASTHMA IM, V95, P38, DOI 10.1016/S1081-1206(10)61186-6; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; El Mir S, 2001, EUR J CANCER, V37, P1053, DOI 10.1016/S0959-8049(01)00084-3; Epstein MM, 2004, INT ARCH ALLERGY IMM, V133, P84, DOI 10.1159/000076131; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; HOLT PG, 1988, CLIN ALLERGY, V18, P229, DOI 10.1111/j.1365-2222.1988.tb02864.x; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Jutel M, 2006, ALLERGY, V61, P796, DOI 10.1111/j.1398-9995.2006.01175.x; Kline JN, 2002, AM J PHYSIOL-LUNG C, V283, pL170, DOI 10.1152/ajplung.00402.2001; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Liu YH, 2003, J ALLERGY CLIN IMMUN, V112, P301, DOI 10.1067/mai.2003.1619; Malling HJ, 2006, ALLERGY, V61, P24, DOI 10.1111/j.1398-9995.2006.01158.x; Mamessier E, 2006, CLIN EXP ALLERGY, V36, P704, DOI 10.1111/j.1365-2222.2006.02487.x; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Naito S, 2002, INT ARCH ALLERGY IMM, V129, P314, DOI 10.1159/000067588; Novak N, 2006, IMMUNOL ALLERGY CLIN, V26, P307, DOI 10.1016/j.iac.2006.02.010; Omata N, 2005, J ALLERGY CLIN IMMUN, V115, P822, DOI 10.1016/j.jaci.2004.12.1121; Passalacqua G, 2006, CURR ALLERGY ASTHM R, V6, P407, DOI 10.1007/s11882-996-0014-7; Romagnani S, 2006, ALLERGY, V61, P3, DOI 10.1111/j.1398-9995.2006.01005; Savolainen J, 2006, ALLERGY, V61, P1184, DOI 10.1111/j.1398-9995.2006.01206.x; Sun JB, 2006, SCAND J IMMUNOL, V64, P251, DOI 10.1111/j.1365-3083.2006.01823.x; Taube C, 2004, INT ARCH ALLERGY IMM, V135, P173, DOI 10.1159/000080899; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	34	87	90	2	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					278	285		10.1016/j.jaci.2007.04.009	http://dx.doi.org/10.1016/j.jaci.2007.04.009			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17531296				2022-12-18	WOS:000248654900008
J	Kim, JS; Sinacore, JM; Pongracic, JA				Kim, JS; Sinacore, JM; Pongracic, JA			Parental use of EpiPen for children with food allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; anaphylaxis; self-injectable epinephrine; adrenaline; EpiPen; training; empowerment; comfort	QUALITY-OF-LIFE; PEANUT ALLERGY; ANAPHYLAXIS; EPINEPHRINE; EMPOWERMENT; MANAGEMENT; IMPACT	Background: EpiPen is often underused in children with food allergy experiencing anaphylaxis. Objective: We explored whether underuse of EpiPen might be attributed to parental discomfort with administration, as measured by a lack of parental empowerment and knowledge of proper administration. Methods: A written survey was mailed to parents of children with food allergy. Those children with physician-diagnosed food allergy who had been prescribed EpiPen were included in the analysis. Parents were recruited from a local food-allergy support group and private allergy practice. Perceived comfort with administering EpiPen was measured by using a 10-cm visual analog scale. Knowledge of EpiPen use and anaphylaxis was tested by using a series of multiple-choice questions. Empowerment was measured with a 16-item instrument that included statements from the Family Empowerment Scale. Multiple regression analysis was used to determine how much of the variance in the comfort ratings could be explained by knowledge, empowerment, and other factors assessed in the survey. Results: Of 360 mailed surveys, 165 (46%) completed surveys met the inclusion criteria and were analyzed. Anaphylaxis was reported in 42% of children (n = 70); 8% of parents (n = 14) had administered EpiPen to their child. Factors correlating with comfort included prior administration of EpiPen (P = .009), EpiPen training (P = .005), and empowerment (P < .0005). Neither a history of anaphylaxis nor knowledge correlated with an increased level of comfort with administration. Conclusions: Empowerment directly correlated with increased comfort with EpiPen use, but knowledge did not. Physicians should continue to instruct all parents on EpiPen administration because this correlated significantly with comfort. Other psychological factors beyond empowerment might contribute to underuse of EpiPen.	Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; Loyola Univ, Dept Prevent Med & Epidemiol, Stritch Sch Med, Maywood, IL 60153 USA	Northwestern University; Feinberg School of Medicine; Loyola University Chicago	Kim, JS (corresponding author), 2300 Childrens Plaza,60, Chicago, IL 60614 USA.	jskim@childrensmemotial.org						Avery NJ, 2003, PEDIAT ALLERG IMM-UK, V14, P378, DOI 10.1034/j.1399-3038.2003.00072.x; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Florian V, 1998, J PEDIATR PSYCHOL, V23, P239, DOI 10.1093/jpepsy/23.4.239; Gold MS, 2000, J ALLERGY CLIN IMMUN, V106, P171, DOI 10.1067/mai.2000.106041; Grouhi M, 1999, J ALLERGY CLIN IMMUN, V104, P190, DOI 10.1016/S0091-6749(99)70134-X; Huang SW, 1998, J ALLERGY CLIN IMMUN, V102, P525, DOI 10.1016/S0091-6749(98)70145-9; Kapoor S, 2004, ALLERGY, V59, P185, DOI 10.1046/j.1398-9995.2003.00365.x; KOREN PE, 1992, REHABIL PSYCHOL, V37, P305, DOI 10.1037/0090-5550.37.4.305; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Sicherer SH, 2000, PEDIATRICS, V105, P359, DOI 10.1542/peds.105.2.359; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461, DOI 10.1016/S1081-1206(10)62258-2; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P837, DOI 10.1016/j.jaci.2004.01.079; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	15	87	87	1	11	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					164	168		10.1016/j.jaci.2005.03.039	http://dx.doi.org/10.1016/j.jaci.2005.03.039			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990790	Bronze			2022-12-18	WOS:000235686300025
J	Fonacier, L; Spergel, J; Charlesworth, EN; Weldon, D; Beltrani, V; Bernhisel-Broadbent, J; Boguniewicz, M; Leung, DYM				Fonacier, L; Spergel, J; Charlesworth, EN; Weldon, D; Beltrani, V; Bernhisel-Broadbent, J; Boguniewicz, M; Leung, DYM			Report of the topical calcineurin inhibitor task force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; topical corticosteroids; pimecrolimus; tacrolimus	PIMECROLIMUS CREAM 1-PERCENT; NONMELANOMA SKIN-CANCER; LONG-TERM MANAGEMENT; NON-HODGKIN-LYMPHOMA; ATOPIC-DERMATITIS; TACROLIMUS OINTMENT; CYCLOSPORINE-A; UNITED-STATES; INFANTS; CHILDREN		Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Winthrop Univ Hosp, Mineola, NY 11501 USA; Shannon Clin, San Angelo, TX USA; Scott & White Mem Hosp & Clin, College Stn, TX USA; Columbia Univ, Poughkeepsie, NY USA; Intermountain Healthcare, Salt Lake City, UT USA	National Jewish Health; Winthrop University Hospital; Scott & White Medical Center; Columbia University; Intermountain Healthcare; Intermountain Medical Center	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.	leungd@njc.org		Spergel, Jonathan/0000-0002-4658-5353				AaltoKorte K, 1997, BRIT J DERMATOL, V136, P172; Akhavan A, 2003, CLIN DERMATOL, V21, P225, DOI 10.1016/S0738-081X(02)00362-0; Boguniewicz Mark, 2003, Journal of Allergy and Clinical Immunology, V112, pS140, DOI 10.1016/j.jaci.2003.09.031; Bos JD, 2002, BRIT J DERMATOL, V146, P342, DOI 10.1046/j.1365-2133.2002.4653_13.x; CHUANG TY, 1992, J AM ACAD DERMATOL, V26, P173, DOI 10.1016/0190-9622(92)70021-7; COOK D, 2005, NONPRESCRIPTION DRUG; Cover RA, 2000, J ALLERGY CLIN IMMUN, V106, P651; Dantal J, 1998, LANCET, V351, P623, DOI 10.1016/S0140-6736(97)08496-1; Ellison JA, 2000, PEDIATRICS, V105, P794, DOI 10.1542/peds.105.4.794; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Harper J, 2001, BRIT J DERMATOL, V144, P781, DOI 10.1046/j.1365-2133.2001.04133.x; Herman M, 2001, J LAB CLIN MED, V137, P14, DOI 10.1067/mlc.2001.111469; Ho VC, 2003, J PEDIATR-US, V142, P155, DOI 10.1067/mpd.2003.65; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Kang S, 2001, J AM ACAD DERMATOL, V44, pS58, DOI 10.1067/mjd.2001.109812; Kapp A, 2002, J ALLERGY CLIN IMMUN, V110, P277, DOI 10.1067/mai.2002.126500; Karagas MR, 2001, BRIT J CANCER, V85, P683, DOI 10.1054/bjoc.2001.1931; Kirby B, 2002, J AM ACAD DERMATOL, V47, pS165, DOI 10.1067/mjd.2002.106357; Korting HC, 2002, SKIN PHARMACOL APPL, V15, P85, DOI 10.1159/000049394; Lebwohl M, 2001, J AM ACAD DERMATOL, V45, P487, DOI 10.1067/mjd.2001.117046; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Lim JL, 2005, J INVEST DERMATOL, V124, P505, DOI 10.1111/j.0022-202X.2005.23618.x; Lucky AW, 1997, CUTIS, V59, P151; Matsuda K, 2000, ANN ALLERG ASTHMA IM, V85, P35, DOI 10.1016/S1081-1206(10)62431-3; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Momtaz K, 1998, DERMATOL CLIN, V16, P227; Papp KA, 2005, J AM ACAD DERMATOL, V52, P240, DOI 10.1016/j.jaad.2004.09.016; Papp KA, 2005, J AM ACAD DERMATOL, V52, P247, DOI 10.1016/j.jaad.2004.08.046; Reitamo S, 2000, ARCH DERMATOL, V136, P999, DOI 10.1001/archderm.136.8.999; Reitamo S, 1998, J INVEST DERMATOL, V111, P396, DOI 10.1046/j.1523-1747.1998.00323.x; Ries L, 1975, SEER CANC STAT REV; SERUP J, 1985, DERMATOLOGICA, V170, P189, DOI 10.1159/000249529; SHEEHAN MP, 1993, BRIT J DERMATOL, V129, P431, DOI 10.1111/j.1365-2133.1993.tb03171.x; SIBURY R, 2000, CLIN EXP DERMATOL, V25, P559; Sinha A, 2004, ACTA DERM-VENEREOL, V84, P327, DOI 10.1080/00015550410025967; Sorensen HT, 2004, JNCI-J NATL CANCER I, V96, P709, DOI 10.1093/jnci/djh118; STEM RS, 1997, CANCER, V73, P2759; STEM RS, 1997, NEW ENGL J MED, V336, P1041; Stern RS, 2001, J AM ACAD DERMATOL, V44, P755, DOI 10.1067/mjd.2001.114576; STIEHM E, 2005, IN PRESS J AM ACAD D; TURPEINEN M, 1986, BRIT J DERMATOL, V115, P475, DOI 10.1111/j.1365-2133.1986.tb06242.x; Van Leent EJM, 2002, DERMATOLOGY, V204, P63, DOI 10.1159/000051813; VANPRAAG MCG, 1993, DRUG SAFETY, V8, P340, DOI 10.2165/00002018-199308050-00002; Vitko S, 2004, TRANSPL P, V36, p243S, DOI 10.1016/j.transproceed.2004.01.033; Wahn U, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e2; Zhang YW, 2004, CANCER CAUSE CONTROL, V15, P419, DOI 10.1023/B:CACO.0000027506.55846.5d; Zonneveld IM, 1996, BRIT J DERMATOL, V135, P15, DOI 10.1111/j.1365-2133.1996.tb00704.x	48	87	92	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1249	1253		10.1016/j.jaci.2005.04.006	http://dx.doi.org/10.1016/j.jaci.2005.04.006			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940142				2022-12-18	WOS:000229815400022
J	Giustizieri, ML; Albanesi, C; Fluhr, J; Gisondi, P; Norgauer, J; Girolomoni, G				Giustizieri, ML; Albanesi, C; Fluhr, J; Gisondi, P; Norgauer, J; Girolomoni, G			H1 histamine receptor mediates inflammatory responses in human keratinocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						keratinocytes; histamine receptors; chemokines; GM-CSF; adhesion molecules	H-1-RECEPTOR ANTAGONISTS; CHEMOKINE PRODUCTION; ICAM-1 EXPRESSION; ATOPIC-DERMATITIS; T-LYMPHOCYTES; IFN-GAMMA; SKIN; CETIRIZINE; PROTEIN; ALPHA	Background: Keratinocytes participate in initiation and. amplification of T-cell-mediated skin diseases. During these disorders, histamine can be released from both residents skin cells and immigrating leukocytes, and can affect the functions of dendritic cells, monocytes, and lymphocytes. Little information is available on the effects of histamine on keratinocytes. Objective: To examine the presence of functional H1 receptors on human keratinocytes and the capacity of histamine to modulate the expression of inflammatory molecules in these cells. Methods: Primary cultures of resting and cytokine-activated keratinocytes from healthy subjects were analyzed for histamine H1 receptor expression and the production of inflammatory mediators after exposure to histamine receptor agonists and antagonists. Results: Cultured keratinocytes constitutively expressed the H1 receptor mRNA and protein, which was not influenced by IFN-gamma, TNF-alpha, or IL-4. H1 but not H2 agonists induced calcium fluxes in keratinocytes. Treatment of keratinocytes with histamine (10(-7) to 10(-4) mol/L) or beta-histine increased the IFN-gamma-induced expression of membrane intercellular adhesion molecule 1 and MHC class I but not MHC class II molecules. Moreover, H1 stimulation promoted basal CC chemokine ligand (CCL)-5/RANTES and GM-CSF secretion and augmented IFN-gamma-induced release of the chemokines CCL2/monocyte chemoattractant protein 1, CCL5/RANTES, CCL20/macrophage inflammatory protein 3alpha, and CXC chemokine ligand 10/IFN-induced protein of 10 kd, as well as GM-CSF. Administration of the H1 antihistamine levocetirizine, but not of the H2 antihistamine cimetidine, abolished histamine-dependent expression of all of the investigated proinflammatory molecules in a dose-dependent manner (0.01-10 mumol/L). Levocetirizine at higher doses also reduced intercellular adhesion molecule 1, CCL5/RANTES, and GM-CSF release induced solely by IFN-gamma. Conclusion: Histamine exerts proinflammatory effects on keratinocytes via the H1 receptor, and these effects are efficiently inhibited by levocetrizine.	Ist Dermopat Immacolata, Ist Ricovero Cura Caraterre Sci, I-00167 Rome, Italy; Univ Jena, Dept Dermatol, D-6900 Jena, Germany	IRCCS Istituto Dermopatico dell'Immacolata (IDI); Friedrich Schiller University of Jena	Girolomoni, G (corresponding author), Ist Dermopat Immacolata, Ist Ricovero Cura Caraterre Sci, Via dei Monti di Creta 104, I-00167 Rome, Italy.	giro@idi.it	GIROLOMONI, Giampiero/AAC-3405-2022; Gisondi, Paolo/AGI-4840-2022; Albanesi, Cristina/K-4699-2016	Gisondi, Paolo/0000-0002-1777-9001; Albanesi, Cristina/0000-0002-7537-6833				Akdis CA, 2003, J ALLERGY CLIN IMMUN, V112, P15, DOI 10.1067/mai.2003.1585; Albanesi C, 2000, J IMMUNOL, V165, P1395, DOI 10.4049/jimmunol.165.3.1395; Albanesi C, 1998, CLIN EXP ALLERGY, V28, P101; Albanesi C, 1999, J IMMUNOL, V162, P494; Albanesi C, 2001, J LEUKOCYTE BIOL, V70, P617; Bakker Remko A, 2002, Clin Allergy Immunol, V17, P27; Benedetti MS, 2001, EUR J CLIN PHARMACOL, V57, P571; Conti P, 1997, BLOOD, V89, P4120, DOI 10.1182/blood.V89.11.4120; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; DVORAK AM, 1976, J IMMUNOL, V116, P687; Federici M, 2002, J IMMUNOL, V169, P434, DOI 10.4049/jimmunol.169.1.434; Giustizieri ML, 2001, J ALLERGY CLIN IMMUN, V107, P871, DOI 10.1067/mai.2001.114707; Homey B, 2000, J IMMUNOL, V164, P6621, DOI 10.4049/jimmunol.164.12.6621; Idzko M, 2002, J ALLERGY CLIN IMMUN, V109, P839, DOI 10.1067/mai.2002.124044; JUHLIN L, 1967, ACTA DERM-VENEREOL, V47, P383; Kanda N, 2004, J INVEST DERMATOL, V122, P863, DOI 10.1111/j.0022-202X.2004.22432.x; Kanda N, 2003, J INVEST DERMATOL, V121, P570, DOI 10.1046/j.1523-1747.2003.12428.x; Kanda N, 2002, J INVEST DERMATOL, V119, P1411, DOI 10.1046/j.1523-1747.2002.19627.x; Kohda F, 2002, J DERMATOL SCI, V28, P34, DOI 10.1016/S0923-1811(01)00147-5; Krogstad AL, 1997, J INVEST DERMATOL, V109, P632, DOI 10.1111/1523-1747.ep12337620; Leung DYM, 2003, CURR OPIN PEDIATR, V15, P399, DOI 10.1097/00008480-200308000-00008; Malaviya R, 1996, J INVEST DERMATOL, V106, P785, DOI 10.1111/1523-1747.ep12346356; Mascia F, 2003, AM J PATHOL, V163, P303, DOI 10.1016/S0002-9440(10)63654-1; MITRA RS, 1993, J CELL PHYSIOL, V156, P348, DOI 10.1002/jcp.1041560218; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Petersen LJ, 1999, ALLERGY, V54, P607, DOI 10.1034/j.1398-9995.1999.00038.x; Schneider E, 2002, TRENDS IMMUNOL, V23, P255, DOI 10.1016/S1471-4906(02)02215-9; SIMONS FER, 1995, J ALLERGY CLIN IMMUN, V95, P759, DOI 10.1016/S0091-6749(95)70183-4; Tillement JP, 2003, BIOCHEM PHARMACOL, V66, P1123, DOI 10.1016/S0006-2952(03)00558-6; Traidl C, 2000, J IMMUNOL, V165, P3058, DOI 10.4049/jimmunol.165.6.3058	30	87	95	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1176	1182		10.1016/j.jaci.2004.07.054	http://dx.doi.org/10.1016/j.jaci.2004.07.054			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536428				2022-12-18	WOS:000225047800028
J	Smith, H; White, P; Annila, L; Poole, J; Andre, C; Frew, A				Smith, H; White, P; Annila, L; Poole, J; Andre, C; Frew, A			Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sublingual immunotherapy; immunotherapy; seasonal allergic rhinitis; grass pollen; hay fever	PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; SWALLOW IMMUNOTHERAPY; CLINICAL-EFFICACY; GENERAL-PRACTICE; POLLEN EXTRACT; HAY-FEVER; ASTHMA; CHILDREN; MITE	Background: Seasonal allergic rhinitis is common and troublesome. Sublingual immunotherapy (SLIT) has been proposed as an alternative to injection immunotherapy and might offer some advantages if it were effective and practical in a community setting. Objectives: To assess the efficacy and side-effect profile of SLIT in patients with summer hay fever uncontrolled on current standard medication. To assess the feasibility of delivering SLIT in a United Kingdom general practice setting. Methods: Double-blind, placebo-controlled study in 186 patients with severe summer hay fever identified from 16 United Kingdom general practices. After a baseline year to ensure balanced groups, subjects were randomized, and SLIT was given for 1 or 2 years and compared with placebo. The principal outcome measure was symptoms as recorded on diary cards. Secondary criteria were skin and conjunctival reactivity, allergen-specific IgE and IgG(4), and the frequency and severity of adverse effects. Results: One hundred thirty-six subjects completed the study. After 1 year, DO significant differences were found between actively treated subjects and the placebo group. After the second year of therapy, subjects who had received 2 years treatment were 6.8 times more likely to show a reduction in nose running (P < .001) and 2.4 times more likely to have reduced sneezing (P < .05) compared with subjects in the placebo group. Benefits for nasal blockage were found at the peak pollen season and were similar in both actively treated groups. Conclusion: Sublingual immunotherapy can be given successfully and safely in the community. High-dose SLIT has beneficial effects on nasal symptoms during the peak pollen season in patients with severe seasonal allergic rhinitis. At least 2 years of treatment with SLIT is required to show a benefit.	Univ Southampton, Wessex Res Network, Southampton, Hants, England; Univ Southampton, MRC, Environm & Epidemiol Unit, Southampton, Hants, England; Nightingale Surg, Romsey, Hants, England; Univ Tampere, FIN-33101 Tampere, Finland; Stallergenes SA, Sci & Med Dept, Antony, France	University of Southampton; University of Southampton; Stallergenes Greer	Frew, A (corresponding author), Southampton Gen Hosp, RCMB Div, MP810, Southampton SO16 6YD, Hants, England.	A.J.Frew@soton.ac.uk	Kelly, Frank J/C-6125-2009; Smith, Helen E/M-2449-2016	Kelly, Frank J/0000-0003-2558-8392; Smith, Helen E/0000-0003-1883-6124				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Andre C, 2000, INT ARCH ALLERGY IMM, V121, P229, DOI 10.1159/000024322; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; CASANOVAS M, 1994, J INVEST ALLERG CLIN, V4, P305; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; Committee on the Safety of Medicines (CSM), 1986, BMJ-BRIT MED J, V293, P948; CRETICOS P S, 1990, Journal of Allergy and Clinical Immunology, V85, P165; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Frew AJ, 1999, J ALLERGY CLIN IMMUN, V104, P267, DOI 10.1016/S0091-6749(99)70362-3; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; MALLING HJ, 1993, ALLERGY          S14, V48, P7; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; ROSS AM, 1994, BRIT MED J, V308, P897, DOI 10.1136/bmj.308.6933.897; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; VANNIEKERK CH, 1987, CLIN ALLERGY, V17, P507; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; White P, 1998, CLIN EXP ALLERGY, V28, P266	25	87	92	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					831	837		10.1016/j.jaci.2004.06.058	http://dx.doi.org/10.1016/j.jaci.2004.06.058			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480323				2022-12-18	WOS:000224439100017
J	Woo, JG; Assa'ad, A; Heizer, AB; Bernstein, JA; Hershey, GKK				Woo, JG; Assa'ad, A; Heizer, AB; Bernstein, JA; Hershey, GKK			The-159 C -> T polymorphism of CD14 is associated with nonatopic asthma and food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; genetics; food hypersensitivity; toll receptors; CD14; LPS	SERUM IGE LEVELS; PROMOTER POLYMORPHISM; GENE; SUSCEPTIBILITY; ENVIRONMENT; ENDOTOXIN; RESPONSES; AFFINITY; ATOPY	Background: CD14, the receptor for LPS, plays an important role in innate immunity. A polymorphism in the promotor for CD14, -159 C-->T, has been implicated in atopy. Objective: We explored the relationship of this polymorphism with both atopic and nonatopic asthma, as well as with food allergy. Methods: Patients with asthma and food allergy were recruited along with nonatopic, nonasthmatic control subjects. The -159 C-->T polymorphism was genotyped by using the PCR-based RFLP assay. Results: The -159 T allele was more common among patients with nonatopic asthma and food allergy than among control subjects (chi(2) = 6.03, P = .01 and chi2 = 4.94; P = .03, respectively). Patients with food allergy had a 4-fold increased odds of having the TT genotype versus carriers of the C allele compared with control subjects (odds ratio [OR] = 3.9, 95% CI 1.5-10.3), whereas patients with nonatopic asthma had a 3-fold increased odds of having the TT genotype (OR = 3.1 [95% CI = 1.1-9.1]). Controlling for sex differences between groups did not alter this relationship, which remained significant for patients with food allergy (OR = 3.7 [95% CI = 1.4-10.1]) or nonatopic asthma (OR = 2.7 [95% CI = 0.9-8.0]). We performed a stratified analysis, limited to white patients, to reduce population stratification. The relationship with the TT genotype was stronger in white patients with nonatopic asthma (OR = 4.4 [95% CI = 1.3-14.8]) and patients with food allergy (OR = 5.1 [95% CI = 1.6-16.2]), even adjusting for sex differences (OR = 3.9 [95% CI = 1.1-13.5] and OR = 4.6 [95% CI = 1.4-14.8], respectively). Conclusions: The TT genotype of -159 C-->T CD14 is associated with nonatopic asthma and food allergy, particularly in white subjects. Thus CD14 is a candidate gene specifically for nonatopic asthma and not for asthma in general. This indicates that atopic and nonatopic asthma might be distinct conditions in their genetic predisposition, despite the fact that they are very similar once they have been established.	Childrens Hosp, Med Ctr, Div Allergy & Immunol, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Med Ctr, Dept Internal Med, Div Immunol, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Dept Environm Hlth, Div Epidemiol & Biostat, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Hershey, GKK (corresponding author), Childrens Hosp, Med Ctr, Div Allergy & Immunol, Dept Pediat, 333 Burnet Ave, Cincinnati, OH 45229 USA.			Bernstein, Jonathan/0000-0002-3476-1196; Khurana Hershey, Gurjit/0000-0001-6663-977X	NIAID NIH HHS [R01AI46652-01A1] Funding Source: Medline; NIEHS NIH HHS [T32-ES 10957] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES010957] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Baldini M, 2002, ALLERGY, V57, P188, DOI 10.1034/j.1398-9995.2002.1r152.x; Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Gao PS, 1999, CLIN GENET, V56, P164; Gawronska-Szklarz B, 2001, CLIN PHARMACOL THER, V69, P372, DOI 10.1067/mcp.2001.115541; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Haagerup A, 2002, ALLERGY, V57, P680, DOI 10.1034/j.1398-9995.2002.23523.x; Harris JR, 1997, AM J RESP CRIT CARE, V156, P43, DOI 10.1164/ajrccm.156.1.9609094; Karhukorpi J, 2002, CLIN EXP IMMUNOL, V128, P326, DOI 10.1046/j.1365-2249.2002.01837.x; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; Kusunoki T, 2002, AM J RESP CRIT CARE, V165, P551, DOI 10.1164/ajrccm.165.4.correspondenceib; Kusunoki Takashi, 1998, Allergology International, V47, P271; Laitinen T, 1998, AM J RESP CRIT CARE, V157, P1073, DOI 10.1164/ajrccm.157.4.9704041; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Neddenriep D, 1989, Curr Probl Pediatr, V19, P325; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; *NIH, 1997, NIH PUBL; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Silva JRL, 2000, TOXICOLOGY, V152, P31; Sousa CRE, 1999, CURR OPIN IMMUNOL, V11, P392, DOI 10.1016/S0952-7915(99)80066-1; Vercelli D, 2002, J ALLERGY CLIN IMMUN, V109, P14, DOI 10.1067/mai.2002.121015; YOUNG RP, 1994, CLIN EXP ALLERGY, V24, P431, DOI 10.1111/j.1365-2222.1994.tb00931.x; 2003, 2000 CENSUS FIGURES	38	87	92	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					438	444		10.1067/mai.2003.1634	http://dx.doi.org/10.1067/mai.2003.1634			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897754				2022-12-18	WOS:000184650600032
J	Nag, SS; Xu, LJ; Hamid, Q; Renzi, PM				Nag, SS; Xu, LJ; Hamid, Q; Renzi, PM			The effects of IL-5 on airway physiology and inflammation in rats	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						interleukin-5; airway responsiveness; late airway response; lung inflammation	ANTIGEN CHALLENGE; CYTOKINE EXPRESSION; INTERLEUKIN-5; HYPERREACTIVITY; RESPONSES; EOSINOPHILIA; LYMPHOCYTES; ANTI-IL-5; ANTIBODY; ALLERGEN	Background: There is evidence that the cytokine IL-5 is a prominent feature of airway inflammation in asthma. Objective: The aim of this study was to determine whether exogenous IL-5 could cause changes in lung physiology, the early and late airway response after antigen challenge, and airway inflammation in rats that do not have a propensity to develop these changes after sensitization and challenge. Methods and Results: Intratracheal administration of IL-5 to ovalbumin sensitized Brown Norway SSN rats increased the airway responsiveness to methacholine (AHR) 20 hours after administration of IL-5 at the same time as an increase in neutrophils occurred in the lung lavage. This effect was dose dependent and was not caused by endotoxin. Concurrent intratracheal administration of 50 ng of anti-IL-5 monoclonal antibody with 10 mug of recombinant human IL-5 decreased the AHR and neutrophil influx. Pretreatment with 3 mug of IL-5 had no effect on the early and late airway response or on AHR after ovalbumin challenge. However, IL-5 increased lung resistance 20 hours after antigen challenge. Although total lung cells and differential counts did not differ significantly 8 hours after antigen challenge, the blood lymphocyte CD4/CD8 ratio decreased in IL-5 pretreated rats (P <.05). In addition, in situ hybridization showed a significant increase in cells within the airway wall expressing IL-4 and IL-5 mRNA in IL-5 treated/challenged rats compared to controls (P <.05). Conclusion: The intratracheal administration of IL-5 causes only part of the physiologic changes that are associated with asthma. Other factors are necessary to obtain the complete asthma phenotype.	Univ Montreal, CHUM Res Ctr, Montreal, PQ, Canada; McGill Univ, Meakins Christie Labs, Montreal, PQ H3A 2T5, Canada	Universite de Montreal; McGill University	Renzi, PM (corresponding author), Notre Dame Hosp, CHUM Res Ctr, 1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.		Tulic, Meri/P-6613-2016; Tulic, Meri K/ABB-5138-2020	Tulic, Meri/0000-0002-2661-2369; Tulic, Meri K/0000-0002-2661-2369				AKUTSU I, 1995, IMMUNOL LETT, V45, P109, DOI 10.1016/0165-2478(94)00241-I; CHAND N, 1992, EUR J PHARMACOL, V211, P121, DOI 10.1016/0014-2999(92)90273-7; DOLOVICH J, 1981, THORAX, V36, P641, DOI 10.1136/thx.36.9.614; FREOUR P, 1987, CHEST, V91, pS191, DOI 10.1378/chest.91.6.191S; GERBLICH AA, 1991, AM REV RESPIR DIS, V143, P533, DOI 10.1164/ajrccm/143.3.533; Hamelmann E, 1997, AM J RESP CELL MOL, V16, P674, DOI 10.1165/ajrcmb.16.6.9191469; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Herz U, 1996, IMMUNOL CELL BIOL, V74, P209, DOI 10.1038/icb.1996.30; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210, DOI 10.1164/ajrccm.157.1.9702074; Keatings VM, 1997, J ALLERGY CLIN IMMUN, V99, P693, DOI 10.1016/S0091-6749(97)70032-0; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; Nag S, 2002, AM J RESP CRIT CARE, V165, P1540, DOI 10.1164/rccm.2109012; O'Byrne PM, 2001, J ALLERGY CLIN IMMUN, V108, P503, DOI 10.1067/mai.2001.119149; OLIVENSTEIN R, 1993, J CLIN INVEST, V92, P1477, DOI 10.1172/JCI116725; PRETOLANI M, 1994, AM J RESP CRIT CARE, V149, P1167, DOI 10.1164/ajrccm.149.5.8173756; PRETOLANI M, 1992, BRIT J PHARMACOL, V106, P677, DOI 10.1111/j.1476-5381.1992.tb14394.x; RENZI PM, 1993, AM REV RESPIR DIS, V147, P967, DOI 10.1164/ajrccm/147.4.967; Renzi PM, 1996, AM J RESP CELL MOL, V15, P367, DOI 10.1165/ajrcmb.15.3.8810641; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sampson AP, 2000, CLIN EXP ALLERGY, V30, P22; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204, DOI 10.1164/ajrccm.157.1.9703027; TURNER DJ, 1997, AM J RESP CRIT CARE, V155, pA157; VANOOSTERHOUT AJM, 1993, AM REV RESPIR DIS, V147, P548, DOI 10.1164/ajrccm/147.3.548; WASERMAN S, 1992, J ALLERGY CLIN IMMUN, V90, P661, DOI 10.1016/0091-6749(92)90140-W; WATANABE A, 1995, AM J RESP CRIT CARE, V152, P64, DOI 10.1164/ajrccm.152.1.7599864; YANG JP, 1993, J ALLERGY CLIN IMMUN, V91, P792, DOI 10.1016/0091-6749(93)90199-P	27	87	89	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					558	566		10.1067/mai.2003.131	http://dx.doi.org/10.1067/mai.2003.131			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12789257	Bronze			2022-12-18	WOS:000181639500018
J	Israel, E; Chervinsky, PS; Friedman, B; van Bavel, J; Skalky, CS; Ghannam, AF; Bird, SR; Edelman, JM				Israel, E; Chervinsky, PS; Friedman, B; van Bavel, J; Skalky, CS; Ghannam, AF; Bird, SR; Edelman, JM		Montelukast Beclomethasone Compari	Effects of montelukast and beclomethasone on airway function and asthma control	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						montelukast; beclomethasone; asthma	LEUKOTRIENE RECEPTOR ANTAGONIST; INHALED BECLOMETHASONE; COST-EFFECTIVENESS; ORAL MONTELUKAST; CHILDREN; MULTICENTER; CROMOLYN	Background: Maintaining asthma control is a major objective of therapy. Traditionally, the effectiveness of asthma therapy has been judged primarily by its effect on airway function rather than on multiaspect asthma control. Objective: An inhaled corticosteroid and a leukotriene receptor antagonist were compared to determine whether they provided equivalent effects, as judged by days of asthma control. Methods: In a randomized, multicenter, double-blind, placebocontrolled, parallel-group study, asthmatic patients (n = 782) with FEV1 percent predicted values of between 50% and 85% and a weekly average beta-agonist use of more than 2 puffs per day were randomized to receive montelukast (10 mg daily), beclomethasone (200 mug twice daily), or placebo treatment for 6 weeks in a double-dummy fashion. We examined the distribution of the primary end point: percentage of days of asthma control. Secondary end points included FEV1, albuterol use, occurrence of an asthma attack, asthma flare-up, rescue corticosteroid use, sustained asthma control, and adverse experiences. Results: The percentage of days of asthma control was almost identical between the montelukast and beclomethasone groups (98% overlap in the distribution). Montelukast was at least equal to beclomethasone, and both were greater than placebo on the basis of frequency of asthma attacks, asthma flare-ups, and rescue corticosteroid use. Beclomethasone had a greater effect than montelukast and both treatments were better than placebo at improving FEV1. Conclusions: Montelukast was as effective as beclomethasone, as judged by indices of clinical control other than FEV1. When evaluating the outcome of montelukast therapy, FEV1 might underestimate clinical effectiveness.	Brigham & Womens Hosp, Boston, MA 02115 USA; New England Res Ctr Inc, N Dartmouth, NE USA	Harvard University; Brigham & Women's Hospital	Israel, E (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.							[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Bukstein DA, 1996, IMMUNOL ALLERGY CLIN, V16, P859, DOI 10.1016/S0889-8561(05)70276-9; Busse W, 2001, J ALLERGY CLIN IMMUN, V107, P461, DOI 10.1067/mai.2001.114657; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; Cochran WG., 1989, AMES IOWA STATE U PR, V8; DRAZEN JM, 1992, AM REV RESPIR DIS, V146, P104, DOI 10.1164/ajrccm/146.1.104; Edelman JM, 1999, J ALLERGY CLIN IMMUN, V103, pS134; GASTWIRTH JL, 1975, AM STAT, V29, P32, DOI 10.2307/2683677; *GLOB IN ASTHM, 1998, POCK GUID ASTHM MAN; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; KELLOWAY JS, 1994, ARCH INTERN MED, V154, P1349, DOI 10.1001/archinte.154.12.1349; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; Nash DB, 2000, AM J MANAG CARE, V6, pS3; *NAT ASTHM ED PREV, 1997, EXP PAN REP, V2, P57; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; RINGDAL N, 1998, AM J RESP CRIT CARE, V157, pA416; RUTTENVANMOLKEN MPMH, 1993, PHARMACOECONOMICS, V4, P257, DOI 10.2165/00019053-199304040-00004; Santanello NC, 1999, EUR RESPIR J, V14, P23, DOI 10.1034/j.1399-3003.1999.14a06.x; Santanello NC, 1997, EUR RESPIR J, V10, P646; SCULPHER MJ, 1993, PHARMACOECONOMICS, V4, P345, DOI 10.2165/00019053-199304050-00005; SELVIN S, 1991, STAT ANAL EPIDEMIOLO; Silverman ES, 2000, AM J RESP CRIT CARE, V161, pS77, DOI 10.1164/ajrccm.161.supplement_1.ltta-16; Stine RA, 2001, STAT MED, V20, P215, DOI 10.1002/1097-0258(20010130)20:2<215::AID-SIM642>3.0.CO;2-X; Teeter JG, 1998, CHEST, V113, P272, DOI 10.1378/chest.113.2.272; Volovitz B, 2000, CURR THER RES CLIN E, V61, P490, DOI 10.1016/S0011-393X(00)80032-6; Wagener JS, 1998, J PEDIATR-US, V132, P381, DOI 10.1016/S0022-3476(98)70003-4	29	87	93	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2002	110	6					847	854		10.1067/mai.2002.129413	http://dx.doi.org/10.1067/mai.2002.129413			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	624TL	12464949				2022-12-18	WOS:000179777400005
J	Lin, XP; Magnusson, J; Ahlstedt, S; Dahlman-Hoglund, A; Hanson, LA; Magnusson, O; Bengtsson, U; Telemo, E				Lin, XP; Magnusson, J; Ahlstedt, S; Dahlman-Hoglund, A; Hanson, LA; Magnusson, O; Bengtsson, U; Telemo, E			Local allergic reaction in food-hypersensitive adults despite a lack of systemic food-specific IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						duodenal mucosa; food hypersensitivity; eosinophils; eosinophil major basic protein; immunoglobulin E; T lymphocytes	EOSINOPHIL CATIONIC PROTEIN; COWS MILK HYPERSENSITIVITY; IMMUNOGLOBULIN-E; SENSITIVE ENTEROPATHY; INTERFERON-GAMMA; ATOPIC ECZEMA; LAVAGE FLUID; CELLS; DIAGNOSIS; CHILDREN	Background: Objective tools are lacking for the diagnosis of local gastrointestinal inflammatory reactions in skin prick test (SPT)-negative and serum IgE antibody (s-IgE Ab)-negative patients with suspected food allergy. Objective: The purpose of this investigation was to evaluate the presence of eosinophils, T cells, local IgE-bearing cells, IL-4, and IFN-gamma in small intestinal biopsy specimens from adult SPT-negative/s-IgE Ab-negative patients with food allergy during symptomatic and nonsymptomatic periods. Methods: Fourteen patients with food allergy-related gastrointestinal symptoms confirmed by double-blinded, placebo-controlled food challenge (DBPCFC) were investigated. Eleven of the patients were SPT-negative and s-IgE Ab-negative. Sex- and age-matched healthy volunteers were used as controls. Duodenal biopsies were studied with immunostaining through use of a panel of mouse monoclonal antibodies specific for eosinophils, CD3, CD4, CD8, IgE, IL-4, and IFN-gamma. Results: Significant increases in numbers of MBP+ eosinophils, IgE-bearing cells, and T cells were found in the duodenal mucosa of the patients when they were symptomatic in comparison with when they were asymptomatic and in comparison with healthy controls. Numbers of IL-4(+) cells were increased and numbers of IFN-gamma+ cells were reduced in the patients when they were symptomatic in comparison with when they were asymptomatic and in comparison with the controls. There were no differences in total s-IgE levels between any of the groups. Conclusion: A significant correlation was found between the appearance of symptoms of food hypersensitivity and the duodenal presence of IgE-bearing cells, activated eosinophils, and T cells in patients with negative SPT results and negative s-IgE Ab to the offending food. We suggest that a localized IgE-mediated response caused the gastrointestinal symptoms seen in these patients.	Sahlgrens Univ Hosp, Dept Clin Immunol, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Resp Med, Asthma & Allergy Res Grp, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Allergy, Asthma & Allergy Res Grp, S-41345 Gothenburg, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Frolunda Specialist Hosp, Dept Surg, Gothenburg, Sweden	Sahlgrenska University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital; Karolinska Institutet	Telemo, E (corresponding author), Gothenburg Univ, Dept Clin Immunol, Guldhedsgatan 10, S-41346 Gothenburg, Sweden.							AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; Andre F, 1996, ALLERGY, V51, P350; BELUT D, 1980, DIGEST DIS SCI, V25, P323, DOI 10.1007/BF01308055; Bengtsson U, 1996, GUT, V39, P130, DOI 10.1136/gut.39.1.130; BENGTSSON U, 1991, INT ARCH ALLER A IMM, V95, P86, DOI 10.1159/000235459; Bengtsson U, 1997, J ALLERGY CLIN IMMUN, V100, P216, DOI 10.1016/S0091-6749(97)70227-6; Bischoff SC, 1997, DIGEST DIS SCI, V42, P394, DOI 10.1023/A:1018886423475; Bischoff SC, 1997, GUT, V40, P745, DOI 10.1136/gut.40.6.745; Bischoff SC, 1997, INT ARCH ALLERGY IMM, V113, P348, DOI 10.1159/000237598; Bischoff SC, 2000, INT ARCH ALLERGY IMM, V121, P270, DOI 10.1159/000024340; Chung HL, 1999, J ALLERGY CLIN IMMUN, V103, P1195, DOI 10.1016/S0091-6749(99)70199-5; Cohn L, 2001, J IMMUNOL, V166, P2760, DOI 10.4049/jimmunol.166.4.2760; CROWE SE, 1992, GASTROENTEROLOGY, V103, P1075, DOI 10.1016/0016-5085(92)90047-3; Haas H, 1999, INT ARCH ALLERGY IMM, V119, P86, DOI 10.1159/000024182; Hauer AC, 1997, PEDIATR RES, V42, P629, DOI 10.1203/00006450-199711000-00014; HIGGINS JA, 1995, IMMUNOLOGY, V84, P91; KOLMANNSKOG S, 1986, INT ARCH ALLER A IMM, V79, P357, DOI 10.1159/000234002; KOLMANNSKOG S, 1985, INT ARCH ALLER A IMM, V76, P133, DOI 10.1159/000233679; Kosa L, 1996, ALLERGY, V51, P964; Leung DYM, 1998, MOL GENET METAB, V63, P157, DOI 10.1006/mgme.1998.2682; Levy AM, 1997, MAYO CLIN PROC, V72, P117, DOI 10.4065/72.2.117; Majamaa H, 1996, CLIN EXP ALLERGY, V26, P181, DOI 10.1111/j.1365-2222.1996.tb00078.x; MARCUCCI F, 1985, CLIN ALLERGY, V15, P345, DOI 10.1111/j.1365-2222.1985.tb03002.x; Meissner N, 1997, CLIN EXP ALLERGY, V27, P1402, DOI 10.1111/j.1365-2222.1997.tb02984.x; NORGAARD A, 1992, ALLERGY, V47, P503, DOI 10.1111/j.1398-9995.1992.tb00673.x; Ohtsuka Y, 1996, PEDIATR RES, V39, P862, DOI 10.1203/00006450-199605000-00020; RAMASWAMY K, 1994, J EXP MED, V180, P1793, DOI 10.1084/jem.180.5.1793; Romagnani P, 2000, IMMUNOL TODAY, V21, P416, DOI 10.1016/S0167-5699(00)01670-4; Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P9, DOI 10.1016/S1081-1206(10)62426-X; Sampson HA, 1996, ANNU REV NUTR, V16, P161, DOI [10.1146/annurev.nu.16.070196.001113, 10.1146/annurev.nutr.16.1.161]; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 2000, J PEDIATR GASTR NUTR, V30, pS87, DOI 10.1097/00005176-200001001-00013; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Schwab D, 2001, AM J GASTROENTEROL, V96, P508, DOI 10.1111/j.1572-0241.2001.03467.x; SEMINARIO MC, 1994, CURR OPIN IMMUNOL, V6, P860, DOI 10.1016/0952-7915(94)90005-1; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, pS114, DOI 10.1016/S0091-6749(99)70053-9; Ulanova M, 2000, SCAND J IMMUNOL, V52, P609, DOI 10.1046/j.1365-3083.2000.00811.x; Woltmann G, 2000, BLOOD, V95, P3146; Yamashiro Y., 1994, Acta Paediatrica Japonica, V36, P550	39	87	95	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					879	887		10.1067/mai.2002.123238	http://dx.doi.org/10.1067/mai.2002.123238			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994715				2022-12-18	WOS:000175687800021
J	Arkwright, PD; Chase, JM; Babbage, S; Pravica, V; David, TJ; Hutchinson, IV				Arkwright, PD; Chase, JM; Babbage, S; Pravica, V; David, TJ; Hutchinson, IV			Atopic dermatitis is associated with a low-producer transforming growth factor beta(1) cytokine genotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; cytokine gene polymorphisms; transforming growth factor beta(1); IL-10	INDUCED AIRWAY HYPERREACTIVITY; GENE POLYMORPHISMS; IMMUNE-RESPONSES; TNF-ALPHA; TGF-BETA; CELLS; INTERLEUKIN-10; IL-10; INFLAMMATION; DISEASE	Background: Atopic dermatitis (AD) is associated with hyperresponsiveness of lymphocytes to allergens. In acute AD only T(H)2-type lymphocytes are activated, whereas in more chronic forms of AD, the activity of both T(H)1- and T(H)2-type lymphocytes increases. IL-10 and transforming growth factor beta (1) (TGF-beta (1)) are immunosuppressive cytokines that inhibit the activity of both TH cell types in human subjects. Objective: The aim of this study was to determine whether children with moderately severe chronic AD had IL10 or TGFB1 genotypes known to be associated with low cytokine production. Methods: Using amplification refractory mutation screening PCR, we examined TGFB1 and IL10 gene polymorphisms, which are known to affect cytokine production, in 68 children with moderately severe AD and in 50 nonatopic children. Results: The odds ratio of children with AD having a low TGFB1 producer genotype was 4.8 (95% CI, 2.4-9.7) compared with the control subjects (P <.0001). There were no differences in the frequency of IL10 gene polymorphisms between groups. Conclusion: TGFB1 genotype may partly explain the strong genetic predisposition to AD.	Univ Manchester, Booth Hall Childrens Hosp, Acad Unit Child Hlth, Manchester M9 7AA, Lancs, England; Univ Manchester, Sch Biol Sci, Immunol Res Grp, Manchester, Lancs, England	Royal Manchester Children's Hospital; University of Manchester; University of Manchester	Arkwright, PD (corresponding author), Univ Manchester, Booth Hall Childrens Hosp, Acad Unit Child Hlth, Charlestown Rd, Manchester M9 7AA, Lancs, England.		Arkwright, Peter/C-5149-2012	Arkwright, Peter/0000-0002-7411-5375				Andersen R, 1999, HIST TIDSSKR, V78, P48; Awad MR, 1998, TRANSPLANTATION, V66, P1014, DOI 10.1097/00007890-199810270-00009; Borish L, 1998, J ALLERGY CLIN IMMUN, V101, P293, DOI 10.1016/S0091-6749(98)70238-6; Cobbold S, 1998, CURR OPIN IMMUNOL, V10, P518, DOI 10.1016/S0952-7915(98)80217-3; Forrest S, 1999, J ALLERGY CLIN IMMUN, V104, P1066, DOI 10.1016/S0091-6749(99)70090-4; Grainger DJ, 1999, HUM MOL GENET, V8, P93, DOI 10.1093/hmg/8.1.93; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Hobbs K, 1998, AM J RESP CRIT CARE, V158, P1958, DOI 10.1164/ajrccm.158.6.9804011; Inobe J, 1998, EUR J IMMUNOL, V28, P2780, DOI 10.1002/(SICI)1521-4141(199809)28:09<2780::AID-IMMU2780>3.0.CO;2-J; Kalliomaki M, 1999, J ALLERGY CLIN IMMUN, V104, P1251, DOI 10.1016/S0091-6749(99)70021-7; LANING JC, 1997, CELL IMMUNOL, V16, P137; LARSEN FS, 1993, J AM ACAD DERMATOL, V28, P719, DOI 10.1016/0190-9622(93)70099-F; Lee HJ, 2000, ANN ALLERG ASTHMA IM, V84, P553, DOI 10.1016/S1081-1206(10)62522-7; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Li BG, 1999, HYPERTENSION, V33, P271, DOI 10.1161/01.HYP.33.1.271; Lim S, 1998, LANCET, V352, P113, DOI 10.1016/S0140-6736(98)85018-6; MacDonald TT, 1998, CURR OPIN IMMUNOL, V10, P620, DOI 10.1016/S0952-7915(98)80079-4; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Nakao A, 2000, J EXP MED, V192, P151, DOI 10.1084/jem.192.2.151; Ono SJ, 2000, ANNU REV IMMUNOL, V18, P347, DOI 10.1146/annurev.immunol.18.1.347; Perrey C, 1999, TRANSPL IMMUNOL, V7, P127, DOI 10.1016/S0966-3274(99)80030-6; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P1093, DOI 10.1016/S0091-6749(99)70094-1; Sankaran D, 1999, KIDNEY INT, V56, P281, DOI 10.1046/j.1523-1755.1999.00536.x; Tagore A, 1999, TISSUE ANTIGENS, V54, P386, DOI 10.1034/j.1399-0039.1999.540408.x; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x; VANVLASSELAER P, 1992, J IMMUNOL, V148, P2062	29	87	89	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					281	+		10.1067/mai.2001.117259	http://dx.doi.org/10.1067/mai.2001.117259			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496247	Bronze			2022-12-18	WOS:000170584600019
J	Nafstad, P; Magnus, P; Jaakkola, JJK				Nafstad, P; Magnus, P; Jaakkola, JJK			Risk of childhood asthma and allergic rhinitis in relation to pregnancy complications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pregnancy complications; prenatal conditions; asthma; allergic rhinitis; childhood	ATOPIC DISEASE; MATERNAL SMOKING; EARLY-LIFE; INFECTIONS; CHILDREN; ILLNESS; COHORT	Background: Events occurring during Fetal life may affect the development of the immune and respiratory systems and increase the risk of asthma and allergic diseases. Objectives: We sought to elaborate the relations between the occurrence of pregnancy complications and other pregnancy-related conditions and the risk of bronchial obstruction during the first 2 years of life and the occurrence of asthma and allergic rhinitis by the age of 4 years. Pregnancy complications were considered both as predictors of the health outcomes and as possible effects caused by other prenatal factors. Methods: A population-based, l-year, cohort study was carried out involving 2531 children horn in Oslo, Norway. We collected information on maternally related (hyperemesis, hypertension, and preeclampsia) and uterus-related complications in pregnancy (antepartum hemorrhage, preterm contractions, insufficient placenta, and restricted growth of the uterus) and the child's health and environmental exposures at birth and at 6, 12, 18, and 24 months and 4 years of age. The outcomes of interest were bronchial obstruction during the first 2 years and asthma and allergic rhinitis at the age of 4 years. Results: In a logistic regression analysis adjusting for potential confounders, uterus-related, but not other pregnancy-related, complications increased the risk of bronchial obstruction (odds ratio [OR], 2.1; 95% confidence interval [CI], 1,3-3.4), asthma (OR, 3.0; 95% CI, 1.8-5.4), and allergic rhinitis (OR, 2.9; 95% CI, 1.6-5.2). These relations were similar in children of atopic and nonatopic parents. Conclusions: Uterus-related complications in pregnancy increase the risk of having asthma and allergic rhinitis in childhood.	Natl Inst Publ Hlth, Dept Populat Hlth Sci, Epidemiol Sect, N-0403 Oslo, Norway; Nord Sch Publ Hlth, Gothenburg, Sweden		Nafstad, P (corresponding author), Natl Inst Publ Hlth, Dept Populat Hlth Sci, Epidemiol Sect, POB 4404, N-0403 Oslo, Norway.		Jaakkola, Jouni J.K./G-4314-2012	Jaakkola, Jouni/0000-0003-4168-4683				ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; BJORKSTEN B, 1994, ALLERGY, V49, P400, DOI 10.1111/j.1398-9995.1994.tb00831.x; Bjorksten B, 1999, J ALLERGY CLIN IMMUN, V104, P1119; Braback L, 1998, CLIN EXP ALLERGY, V28, P936; Fergusson DM, 1997, CLIN EXP ALLERGY, V27, P1394, DOI 10.1046/j.1365-2222.1997.1430947.x; *ISAAC STEER COMM, 1993, ISAAC INT STUD ASTHM; *ISAAC STEER COMM, 1998, PHASE 2 MODULES INT; Leadbitter P, 1999, THORAX, V54, P905, DOI 10.1136/thx.54.10.905; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; Martinez FD, 1997, CIBA F SYMP, V206, P233; Nafstad P, 1999, PEDIATRICS, V103, P753, DOI 10.1542/peds.103.4.753; Nafstad P, 1996, EUR RESPIR J, V9, P2623, DOI 10.1183/09031936.96.09122623; Nafstad P, 1997, EPIDEMIOLOGY, V8, P293, DOI 10.1097/00001648-199705000-00011; Nafstad P, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e38; NILSSON L, 1997, PEDIATR ALLERGY IMMU, V3, P134; Pekkanen J, 1999, ACTA PAEDIATR, V88, P710, DOI 10.1080/08035259950168964; Ponsonby AL, 1999, THORAX, V54, P664, DOI 10.1136/thx.54.8.664; Sears MR, 1997, LANCET, V350, P1015, DOI 10.1016/S0140-6736(97)01468-2; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Strachan DP, 1996, BRIT MED J, V312, P1195; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Tomeo CA, 1999, EPIDEMIOLOGY, V10, P774, DOI 10.1097/00001648-199911000-00022; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; WEITZMAN M, 1990, PEDIATRICS, V85, P505; Xu B, 1999, ALLERGY, V54, P829, DOI 10.1034/j.1398-9995.1999.00117.x; Xu BZ, 1999, INT J EPIDEMIOL, V28, P723, DOI 10.1093/ije/28.4.723	27	87	88	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					867	873		10.1067/mai.2000.110558	http://dx.doi.org/10.1067/mai.2000.110558			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080708				2022-12-18	WOS:000167865200010
J	Yagami, T; Haishima, Y; Nakamura, A; Osuna, H; Ikezawa, Z				Yagami, T; Haishima, Y; Nakamura, A; Osuna, H; Ikezawa, Z			Digestibility of allergens extracted from natural rubber latex and vegetable foods	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; oral allergy syndrome; cross-reactivity.; defense-related protein; genetically modified plant; allergenicity; simulated gastric fluid; simulated intestinal fluid; sensitization; elicitation	TRANSGENIC TOMATO PLANTS; CROSS-REACTIVITY; IN-VITRO; POTENTIAL PANALLERGENS; POLLEN ALLERGENS; MAJOR ALLERGEN; FRUIT SYNDROME; TREE POLLEN; PROTEINS; DEFENSE	Background: Several cross-reactive allergens are now known to be involved in the defense responses of higher plants. Such proteins are drawing the attention of plant breeders because of their antimicrobial or stress-alleviating activities. Plants genetically modified to express defense-related proteins are being developed. The current concern is focused on the allergenicity of these intentionally expressed proteins. Objective: It is believed that food allergens are proteins resistant to digestion, Digestibility tests have been accepted as an appropriate method for evaluating the allergenicity of newly introduced proteins. In this study we investigated the usefulness of this method for dedtecting allergens from natural rubber latex and vegetable foods, Methods: Proteins were extracted from rubber latex, potato, and 5 kinds of fruits, Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were used for the digestibility test, An aliquot of each digest was periodically withdrawn and analyzed. Allergens were detected with pooled sera from individuals with latex allergy or patients given a diagnosis of oral allergy syndrome, Results: Most latex and vegetable food proteins were digested by the SGF within 4 minutes. Numerous allergens were also decomposed by the SGF within 8 minutes, Although vegetable food allergens were relatively stable in the SIF, kiwi allergens were substantially degraded by the SIF within 16 hours. Conclusion: The pronounced lability of the plant-derived allergens was thought to reflect the discrete sensitization and elicitation processes of patients with latex-fruit syndrome or oral allergy syndrome, These results indicate that the allergenicity of a newly expressed protein should be carefully evaluated according to not only its digestibility but also other important properties.	Natl Inst Hlth Sci, Div Med Devices, Setagaya Ku, Tokyo 1588501, Japan; Yokohama City Univ, Sch Med, Yokohama, Kanagawa 232, Japan	National Institute of Health Sciences - Japan; Yokohama City University	Yagami, T (corresponding author), Natl Inst Hlth Sci, Div Med Devices, Setagaya Ku, Kamiyoga 1-18-1, Tokyo 1588501, Japan.							Aalberse RC, 1997, ENVIRON TOXICOL PHAR, V4, P55, DOI 10.1016/S1382-6689(97)10042-4; ALENIUS H, 1995, CLIN EXP ALLERGY, V25, P659, DOI 10.1111/j.1365-2222.1995.tb01114.x; Astwood JD, 1996, MONOGR ALLERGY, V32, P105; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Baldo BA, 1996, MONOGR ALLERGY, V32, P84; Becker WM, 1997, INT ARCH ALLERGY IMM, V113, P118, DOI 10.1159/000237522; Beezhold DH, 1997, CLIN EXP IMMUNOL, V108, P114, DOI 10.1046/j.1365-2249.1997.d01-983.x; Blanco C, 1999, J ALLERGY CLIN IMMUN, V103, P507, DOI 10.1016/S0091-6749(99)70478-1; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; Breiteneder H, 1998, ALLERGY, V53, P31, DOI 10.1111/j.1398-9995.1998.tb04956.x; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; Fritig B, 1998, CURR OPIN IMMUNOL, V10, P16, DOI 10.1016/S0952-7915(98)80025-3; Fritsch R, 1997, CLIN REV ALLERG IMMU, V15, P397, DOI 10.1007/BF02737735; Gendel SM, 1998, ADV FOOD NUTR RES, V42, P45, DOI 10.1016/S1043-4526(08)60092-3; Hanninen AR, 1999, J ALLERGY CLIN IMMUN, V104, P194, DOI 10.1016/S0091-6749(99)70135-1; Hefle SL, 1996, FOOD TECHNOL-CHICAGO, V50, P86; Hoffmann-Sommergruber K, 1999, J ALLERGY CLIN IMMUN, V104, P478, DOI 10.1016/S0091-6749(99)70397-0; JONGEDIJK E, 1995, EUPHYTICA, V85, P173, DOI 10.1007/BF00023946; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; KESSLER DA, 1992, SCIENCE, V256, P1747, DOI 10.1126/science.1615315; KORTEKANGASSAVOLAINEN O, 1993, CLIN EXP ALLERGY, V23, P587, DOI 10.1111/j.1365-2222.1993.tb00898.x; Kostyal DA, 1998, CLIN EXP IMMUNOL, V112, P355; Lavaud F, 1997, CLIN REV ALLERG IMMU, V15, P429, DOI 10.1007/BF02737738; LEE HI, 1995, BRAZ J MED BIOL RES, V28, P743; Loon L. C. van, 1994, Plant Molecular Biology Reporter, V12, P245, DOI 10.1007/BF02668748; Metcalfe DD, 1996, CRIT REV FOOD SCI, V36, pS165, DOI 10.1080/10408399609527763; Mikkola JH, 1998, J ALLERGY CLIN IMMUN, V102, P1005, DOI 10.1016/S0091-6749(98)70339-2; Nel A, 1998, ANN ALLERG ASTHMA IM, V81, P388, DOI 10.1016/S1081-1206(10)63135-3; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Pastorello EA, 1997, CLIN REV ALLERG IMMU, V15, P415, DOI 10.1007/BF02737737; Posch A, 1999, CLIN EXP ALLERGY, V29, P667, DOI 10.1046/j.1365-2222.1999.00502.x; Posch A, 1998, CLIN EXP ALLERGY, V28, P134; Salcedo G, 1999, CLIN EXP ALLERGY, V29, P1158, DOI 10.1046/j.1365-2222.1999.00629.x; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; Scheiner O, 1997, INT ARCH ALLERGY IMM, V113, P105, DOI 10.1159/000237519; SUNDERASAN E, 1995, J RUBBER RES, V10, P82; Vieths S, 1997, ENVIRON TOXICOL PHAR, V4, P61, DOI 10.1016/S1382-6689(97)10043-6; Vieths S, 1998, ALLERGY, V53, P65, DOI 10.1111/j.1398-9995.1998.tb04965.x; Vieths S, 1999, EUR FOOD RES TECHNOL, V209, P379, DOI 10.1007/s002170050513; Vuitton DA, 1997, CLIN REV ALLERG IMMU, V15, P367, DOI 10.1007/BF02737732; Wal JM, 1999, NAHRUNG, V43, P168, DOI 10.1002/(SICI)1521-3803(19990601)43:3&lt;168::AID-FOOD168&gt;3.0.CO;2-R; Wal JM, 1998, ALLERGY, V53, P98, DOI 10.1111/j.1398-9995.1998.tb04974.x; Wigotzki M., 2000, INTERNET S FOOD ALLE, V2, P1; Yagami T, 1996, FOOD AGR IMMUNOL, V8, P121, DOI 10.1080/09540109609354910; YAGAMI T, 1995, J ALLERGY CLIN IMMUN, V96, P677, DOI 10.1016/S0091-6749(95)70267-9; Yagami T, 1998, J ALLERGY CLIN IMMUN, V101, P379, DOI 10.1016/S0091-6749(98)70251-9; Yagami T., 1998, ENV DERMATOL S2, V5, P31; YAGAMI T, 1995, J RUBBER RES, V10, P100; Yun DJ, 1997, PLANT BREEDING REV, V14, P39	50	87	89	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					752	762		10.1067/mai.2000.109171	http://dx.doi.org/10.1067/mai.2000.109171			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031347				2022-12-18	WOS:000089980600020
J	Leynadier, F; Herman, D; Vervloet, D; Andre, C				Leynadier, F; Herman, D; Vervloet, D; Andre, C			Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex; urticaria; rhinoconjunctivitis; asthma; anaphylactic shock; specific immunotherapy	NATURAL-RUBBER LATEX; CROSS-REACTIVITY; SYSTEMIC REACTIONS; HYPERSENSITIVITY; ANTIBODIES; CHILDREN; ANTIGENS; ASTHMA; BANANA	Background: The prevalence of allergy to natural rubber latex proteins has increased over recent years among healthcare professionals but also in children undergoing multiple operations. Exposure to the antigen mainly occurs through the respiratory mucosa and the percutaneous route. Clinical manifestations range from urticaria to angioedema, rhinoconjunctivitis, bronchial asthma, or anaphylactic shock. Preventive measures have been proposed to reduce the risk of sensitization by using only powder-free or synthetic gloves and latex-free material in operating units, but this is not always possible. Objective: The aim of this study was to investigate the efficacy and safety of specific immunotherapy in sensitized workers. Methods: Seventeen patients with latex skin allergy and rhinitis (9 of whom also had asthma) were included in this randomized, double-blind, placebo-controlled trial (9 in the active group and 8 in the placebo group) for 1 year. Treatment started with a 2-day course of rush immunotherapy in hospital. Treatment efficacy was assessed after 6 and 12 months by means of symptom and medication scores recorded on diary cards. Conjunctival provocation tests were also performed. Results: Patients in the active treatment group had a significantly tower total rhinitis score after 6 (P < .04) and 12 months (P < .05), conjunctivitis score after 6 months (P < .02), and cutaneous score after 12 months (P < .03) than in the placebo group, Asthma symptoms after 6 or 12 months of treatment were not significantly different between the two groups after adjustment for baseline values. The global medication score was markedly decreased in the latex-treated group. A significant difference in conjunctival reactivity was observed in favor of the active group: the number of patients for whom the threshold dose was increased after 12 months of treatment was significantly greater in the active group than in the placebo group (P < .02). Most injections were well tolerated, but several adverse effects, including hypotension, urticaria, wheezing, and pharyngeal edema, were observed. Conclusion: The clinical benefits observed during the present study included a significant improvement of rhinitis, conjunctivitis, and cutaneous symptoms. Immunotherapy also decreased allergen-specific conjunctival reactivity. Latex-specific immunotherapy may allow sensitized personnel to remain at work, but further trials need to be conducted in a larger number of patients.	Stallergenes SA, Sci & Med Dept, F-92183 Antony, France; Hop Rothschild, F-75571 Paris, France; Hop Bichat Claude Bernard, Serv Med Interne, Ctr Allergie, F-75877 Paris, France; Hop St Marguerite, Dept Malad Resp, Marseille, France	Stallergenes Greer; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Andre, C (corresponding author), Stallergenes SA, Sci & Med Dept, 6 Rue Alexis de Tocqueville, F-92183 Antony, France.							AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; ABELSON MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P84, DOI 10.1001/archopht.1990.01070030090035; Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; BAUR X, 1993, LANCET, V342, P1148, DOI 10.1016/0140-6736(93)92127-F; BLANCO C, 1994, ANN ALLERGY, V73, P309; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; Cantani A, 1999, J INVEST ALLERG CLIN, V9, P14; FRANKLAND AW, 1995, CLIN EXP ALLERGY, V25, P199, DOI 10.1111/j.1365-2222.1995.tb01028.x; Gritter M, 1997, Lippincotts Prim Care Pract, V1, P142; KWITTKEN PL, 1995, PEDIATRICS, V95, P693; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; MAKINENKILJUNEN S, 1994, J ALLERGY CLIN IMMUN, V93, P990, DOI 10.1016/S0091-6749(94)70046-X; Malling HJ, 1998, ALLERGY, V53, P461; MATHEW SN, 1993, ANN ALLERGY, V70, P483; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; Nel A, 1998, ANN ALLERG ASTHMA IM, V81, P388, DOI 10.1016/S1081-1206(10)63135-3; Pereira C, 1999, ALLERGY, V54, P291, DOI 10.1034/j.1398-9995.1999.00954.x; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; TURJANMAA K, 1995, IMMUNOL ALLERGY CLIN, V15, P71; Turjanmaa K, 1997, ALLERGY, V52, P41, DOI 10.1111/j.1398-9995.1997.tb02544.x; Valyasevi MA, 1999, ANN ALLERG ASTHMA IM, V83, P132, DOI 10.1016/S1081-1206(10)62624-5	22	87	90	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					585	590		10.1067/mai.2000.109173	http://dx.doi.org/10.1067/mai.2000.109173			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984382				2022-12-18	WOS:000089471900025
J	Levitt, RC; McLane, MP; MacDonald, D; Ferrante, V; Weiss, C; Zhou, TY; Holroyd, KJ; Nicolaides, NC				Levitt, RC; McLane, MP; MacDonald, D; Ferrante, V; Weiss, C; Zhou, TY; Holroyd, KJ; Nicolaides, NC			IL-9 pathway in asthma: New therapeutic targets for allergic inflammatory disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on New Trends in Immunopharmacology 1997	JUL   12, 1997	TOKYO, JAPAN	Novartis Pharma K K Tokyo		asthma; allergy; IL-9; mouse models; IgE; eosinophils	AIRWAY HYPERREACTIVITY; BRONCHIAL REACTIVITY; SERUM IGE; MICE; GENE; HYPERRESPONSIVENESS; SUSCEPTIBILITY; MARKERS; INTERLEUKIN-9; LYMPHOCYTES	Background: Asthma is a complex heritable inflammatory disorder of the airways associated with clinical signs of allergic inflammation and bronchial hyperresponsiveness (BHR), The incidence of asthma continues to rise in industrialized countries despite advances in the identification of cellular and molecular mediators that are associated with the disease. Because of its importance in human health, additional research and alternative therapeutic strategies are justified to create more effective treatments for this debilitating disease. Objective: Studies use recombinant inbred mice to demonstrate that BHR in mouse models of asthma is associated with a genetic alteration at the IL-9 locus, where IL-9 expression in lung is strongly associated with bronchial responsiveness. me have investigated the ability of intratracheal instilled IL-9 to induce asthmatic-like responses in naive C57BL/6 (B6) mice, which express very low levels of IL-9, Methods: IL-9 or vehicle was intratracheal instilled in naive B6 mice for 10 days. Mice were analyzed for effects on BHR, lung eosinophilia, and serum total IgE levels. Results: Phenotypic effects of B6 mice instilled with IL-9 were increased eosinophils in the bronchoalveolar lavage and significantly elevated serum total IgE, Moreover, IL-9 was found to induce IL-5R alpha in vivo and in vitro, suggesting a potential mechanism for the novel actions described for IL-9 on eosinophils. Conclusion: Increased levels of IL-9 in the airway of naive B6 mice induced lung eosinophilia and serum total IgE levels, which are 2 clinical features of asthma. These data support a central role for the IL-9 pathway in the complex pathogenesis of allergic inflammation.	Magainin Pharmaceut, Magainin Inst Mol Med, Plymouth Meeting, PA 19462 USA		Levitt, RC (corresponding author), Magainin Pharmaceut, Magainin Inst Mol Med, 5110 Campus Dr, Plymouth Meeting, PA 19462 USA.			McLane, Michael/0000-0003-2779-5475; Holroyd, Kenneth/0000-0001-6050-3935				Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; DeSanctis GT, 1997, NAT MED, V3, P460, DOI 10.1038/nm0497-460; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; DUGAS B, 1993, EUR J IMMUNOL, V23, P1134; EKLUND KK, 1993, J IMMUNOL, V151, P4266; EWART S, 1995, J APPL PHYSIOL, V79, P560, DOI 10.1152/jappl.1995.79.2.560; GESSNER A, 1993, IMMUNOBIOLOGY, V189, P419, DOI 10.1016/S0171-2985(11)80414-6; GRENCIS RK, 1991, IMMUNOLOGY, V74, P329; HOLGATE ST, 1995, INT ARCH ALLERGY IMM, V107, P29, DOI 10.1159/000236921; HOPP RJ, 1988, ANN ALLERGY, V61, P184; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; HULTNER L, 1990, EXP HEMATOL, V18, P873; KLEEBERGER SR, 1990, AM J PHYSIOL, V258, pL313, DOI 10.1152/ajplung.1990.258.6.L313; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; LEVITT RC, 1989, J APPL PHYSIOL, V67, P1125, DOI 10.1152/jappl.1989.67.3.1125; LEVITT RC, 1991, PHARMACOGENETICS, V1, P94, DOI 10.1097/00008571-199111000-00006; LEVITT RC, 1988, FASEB J, V2, P2605, DOI 10.1096/fasebj.2.10.3384240; LOUAHED J, 1995, J IMMUNOL, V154, P5061; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; NICOLAIDES NC, 1995, GENOMICS, V30, P195, DOI 10.1006/geno.1995.9885; PAUWELS R, 1985, EUR J RESPIR DIS, V66, P98; PETITFRERE C, 1993, IMMUNOLOGY, V79, P146; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; ROBINSON DS, 1992, NEW ENGL J MED, V326, P289; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SVETIC A, 1993, J IMMUNOL, V150, P3434; TOWNLEY RG, 1986, J ALLERGY CLIN IMMUN, V77, P101, DOI 10.1016/0091-6749(86)90330-1	33	87	88	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	2	S			S485	S491		10.1016/S0091-6749(99)70165-X	http://dx.doi.org/10.1016/S0091-6749(99)70165-X			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199TV	10329852				2022-12-18	WOS:000080500200011
J	Laberge, S; Ghaffar, O; Boguniewicz, M; Center, DM; Leung, DY; Hamid, Q				Laberge, S; Ghaffar, O; Boguniewicz, M; Center, DM; Leung, DY; Hamid, Q			Association of increased CD4(+) T-cell infiltration with increased IL-16 gene expression in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; IL-16; allergic inflammation; chemotaxis	LYMPHOCYTE CHEMOATTRACTANT FACTOR; COLONY-STIMULATING FACTOR; CYCLOSPORINE-A; HUMAN-SKIN; INTERLEUKIN-16; KERATINOCYTES; PRODUCE; ASTHMA; MUCOSA; RANTES	Background: The mechanisms involved in the initiation and the maintenance of skin inflammation in atopic dermatitis (AD) are poorly understood. Previous studies have demonstrated increased numbers of infiltrating CD4(+) T cells in acute lesions compared with normal control skin. IL-16 is a cytokine that has selective chemotactic activity for CD4(+) cells. Objective: We sought to examine whether IL-16 expression might be upregulated in acute versus chronic AD. Methods: We investigated the expression of IL-16 mRNA in skin biopsy specimens from acute and chronic skin Lesions, as well as from the uninvolved skin of patients with AD and normal skin. Cryostat sections from 4% paraformaldehyde-fixed skin biopsy specimens were processed for in situ hybridization by using cRNA coding for IL-16 mRNA, Numbers of infiltrating CD4(+) and CD8(+) cells were also determined by immunocytochemistry. Results: There were positive signals for IL-16 mRNA both in the basal layer of the epidermis and in the dermis of AD skin. biopsy specimens from all subjects studied. The numbers of epidermal and dermal IL-16 mRNA(+) cells were significantly increased in acute skin lesions compared with chronic (P<.01) and uninvolved (P<.001) skin lesions and compared with normal skin (P<.001). The number of CD4(+) cells was significantly increased in acute skin lesions compared with chronic (P<.01) skin Lesions and uninvolved skin (P<.01) and compared with normal skin (P<.01). Significant correlations were found between the numbers of CD4+ cells and the numbers of epidermal (r = 0,82, P<.001) and dermal (r = 0.71, P<.001) IL-16 mRNA+ cells. Conclusion: The results demonstrate that upregulation of IL-16 mRNA expression in acute AD is associated with increased numbers of CD4+ cells, suggesting that IL-16 may play a role in the initiation of skin inflammation, presumably through recruitment of CD4+ cells.	McGill Univ, Royal Victoria Hosp, Meakins Christie Labs, Montreal, PQ H3A 2T5, Canada; Univ Montreal, Ste Justine Hosp, Montreal, PQ H3C 3J7, Canada; Natl Jewish Med & Res Ctr, Denver, CO USA; Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02215 USA	McGill University; Royal Victoria Hospital; Universite de Montreal; National Jewish Health; Boston University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.			Center, David/0000-0002-5879-7978				ARAGANE Y, 1994, J IMMUNOL, V153, P5366; ARIMA M, 1996, J ALLERGY CLIN IMMUN, V97, pS443; BERMAN JS, 1985, CELL IMMUNOL, V95, P105, DOI 10.1016/0008-8749(85)90299-0; BOS JD, 1989, ARCH DERMATOL RES, V281, P24, DOI 10.1007/BF00424268; BRATTON DL, 1995, J CLIN INVEST, V95, P211, DOI 10.1172/JCI117642; Center DM, 1996, IMMUNOL TODAY, V17, P476, DOI 10.1016/0167-5699(96)10052-I; CRUIKSHANK WW, 1995, AM J RESP CELL MOL, V13, P738, DOI 10.1165/ajrcmb.13.6.7576712; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; Laberge S, 1997, J ALLERGY CLIN IMMUN, V100, P569, DOI 10.1016/S0091-6749(97)70152-0; Laberge S, 1997, AM J RESP CELL MOL, V17, P193, DOI 10.1165/ajrcmb.17.2.2750; Laberge S, 1998, J ALLERGY CLIN IMMUN, V101, pS235; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; Li J, 1996, J INVEST DERMATOL, V106, P661, DOI 10.1111/1523-1747.ep12345482; Lim KG, 1996, J IMMUNOL, V156, P2566; MUNRO CS, 1991, BRIT J DERMATOL, V124, P43; NICKOLOFF BJ, 1994, J AM ACAD DERMATOL, V30, P535, DOI 10.1016/S0190-9622(94)70059-1; OHMEN JD, 1995, J IMMUNOL, V154, P1956; Pastore S, 1997, J CLIN INVEST, V99, P3009, DOI 10.1172/JCI119496; Rumsaeng V, 1997, J IMMUNOL, V159, P2904; Schleimer RP, 1998, ASTHMA AND ALLERGIC DISEASES, P337, DOI 10.1016/B978-012473340-4/50028-X; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; Su JC, 1997, ARCH DIS CHILD, V76, P159, DOI 10.1136/adc.76.2.159; VANJOOST T, 1992, J AM ACAD DERMATOL, V27, P922, DOI 10.1016/0190-9622(92)70288-Q; WON YH, 1994, BRIT J DERMATOL, V130, P312, DOI 10.1111/j.1365-2133.1994.tb02926.x; YING S, 1994, IMMUNOLOGY, V82, P200; ZACHARY CB, 1985, BRIT J DERMATOL, V112, P149, DOI 10.1111/j.1365-2133.1985.tb00078.x	31	87	88	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				645	650		10.1016/S0091-6749(98)70282-9	http://dx.doi.org/10.1016/S0091-6749(98)70282-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802374	Bronze			2022-12-18	WOS:000076600400016
J	Wilson, AM; Sims, EJ; McFarlane, LC; Lipworth, BJ				Wilson, AM; Sims, EJ; McFarlane, LC; Lipworth, BJ			Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HPA-axis; cortisol; intranasal corticosteroids; mometasone furoate; budesonide; triamcinolone acetonide; rhinitis	AQUEOUS NASAL SPRAY; INHALED FLUTICASONE PROPIONATE; TRIAMCINOLONE ACETONIDE; HEALTHY-VOLUNTEERS; BUDESONIDE; SUPPRESSION; PLACEBO; GLUCOCORTICOSTEROIDS; PREDNISONE	Background: Intranasal corticosteroids are regarded as the first-line treatment for allergic rhinitis, but few studies have directly compared their systemic effects. Objective: The purpose of this study was to compare the systemic bioactivity of aqueous formulations of intranasal burdesonide, mometasone furoate (MF), and triamcinolone acetonide (TAA) in terms of adrenal, bone, and white blood cell markers. Methods: Twenty patients with allergic rhinitis, mean age (SE) 35.7 (3.5) years were studied in a single-blind, randomized, 4-way crossover design, with treatments separated by 7-day washout periods, comparing placebo with budesonide 200 mu g once daily, MF 200 pg once daily, and TAA 220 mu g once daily. After 5 days of treatment at steady-state, serial blood and urine samples were taken for 24 hours. Collective and fractionated measurements (daytime, overnight, and 8 AM) were done on plasma cortisol and urine cortisol/creatinine excretion. plasma osteocalcin and blood eosinophil counts were measured at 8 APII. Results: There was no significant difference between placebo and the active treatments with any of the markers of adrenal suppression. Mean values (SE) for 24-hour area under the curve plasma cortisol (nmol/L.hr) were placebo, 6312.9 (564.4); budesonide, 5908.8 (496.8); MF, 6374.1 (509.9); and TAA, 6239.2 (552.0). Twenty-four hour urinary cortisol/creatinine ratio (nanomoles per millimoles) showed placebo, 9.2 (0.5); budesonide, 8.5 (0.5); MF, 8.6 (0.4); and TAA, 8.6 (0.4), The diurnal circadian rhythm was unaffected, and there mere only occasional patients with abnormally low cortisol values, There was also no suppression in terms of osteocalcin (placebo, 1.27 nmol/L; budesonide, 1.22 nmol/L; MF, 1.33 nmol/L; and TAA, 1.24 nmol/L) and blood eosinophil count (placebo, 0.29 x 10(9)/L; budesonide, 0.27 x 10(9)/L; MF, 0.25 x 10(9)/L; and TAA, 0.24 x 10(9)/L). Conclusion: Neither budesonide, MF, nor TAA produced significant systemic suppression of adrenal, bone, or white blood cell markers at the doses studied. This reflects the good safety profile of these aqueous intranasal formulations when taken at clinically recommended doses.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Resp Med, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Lipworth, BJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland.							AGERTOFT L, 1995, PEDIAT ALLERGY IMMUN, V5, P152; [Anonymous], 1996, Arthritis Rheum, V39, P1791; Bernstein DI, 1996, J ALLERGY CLIN IMMUN, V97, P749, DOI 10.1016/S0091-6749(96)80151-5; Bikle DD, 1997, AM J MED, V103, P427, DOI 10.1016/S0002-9343(97)00137-X; Brannan MD, 1997, CLIN THER, V19, P1330, DOI 10.1016/S0149-2918(97)80008-2; BRANNAN MD, 1997, ANN ALLERG ASTHMA IM, V154, P207; BROIDE J, 1995, J CLIN ENDOCR METAB, V80, P1243, DOI 10.1210/jc.80.4.1243; BROWN PH, 1991, RESP MED, V85, P511, DOI 10.1016/S0954-6111(06)80269-6; Clark DJ, 1997, THORAX, V52, P55, DOI 10.1136/thx.52.1.55; DERENDORF H, 1995, J CLIN PHARMACOL, V35, P302, DOI 10.1002/j.1552-4604.1995.tb04064.x; EDSBACKER S, 1985, EUR J CLIN PHARMACOL, V29, P477, DOI 10.1007/BF00613465; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; HEALD D, 1997, ANN ALLERG ASTHMA IM, V78, P96; HEALD D, 1995, ASTHM 95 C THEOR TRE; HOWARTH PH, 1995, ALLERGY, V50, P4, DOI 10.1111/j.1398-9995.1995.tb02733.x; Howland WC, 1996, J ALLERGY CLIN IMMUN, V98, P32, DOI 10.1016/S0091-6749(96)70223-3; KNUTSSON U, 1995, J ENDOCRINOL, V144, P301, DOI 10.1677/joe.0.1440301; Lipworth BJ, 1998, J ALLERGY CLIN IMMUN, V101, pS8; Lipworth BJ, 1997, THORAX, V52, P476, DOI 10.1136/thx.52.5.476; Lonnebo A, 1996, EUR J CLIN PHARMACOL, V49, P459; MCINTYRE HD, 1995, THORAX, V50, P1280, DOI 10.1136/thx.50.12.1280; MYGIND N, 1993, ALLERGY, V48, P476, DOI 10.1111/j.1398-9995.1993.tb01103.x; NEWMANN PS, 1988, RHINOLOGY, V26, P111; PIPKORN U, 1983, ACTA OTO-LARYNGOL, V95, P167, DOI 10.3109/00016488309130931; RYRDELT A, 1982, EUR J RESP DIS S, V63, P68; SETTIPANE G, 1995, CLIN THER, V17, P252, DOI 10.1016/0149-2918(95)80023-9; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839; Thorsson L, 1997, BRIT J CLIN PHARMACO, V43, P155, DOI 10.1046/j.1365-2125.1997.d01-1425.x; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; Umland SP, 1997, J ALLERGY CLIN IMMUN, V100, P511, DOI 10.1016/S0091-6749(97)70144-1; Wilson AM, 1997, EUR J CLIN PHARMACOL, V53, P33, DOI 10.1007/s002280050333; Wilson AM, 1998, J CLIN ENDOCR METAB, V83, P922, DOI 10.1210/jc.83.3.922; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V101, P470, DOI 10.1016/S0091-6749(98)70354-9; WOLTHERS OD, 1994, ALLERGY, V49, P96, DOI 10.1111/j.1398-9995.1994.tb00807.x; WOLTHERS OD, 1993, ACTA PAEDIATR, V82, P635, DOI 10.1111/j.1651-2227.1993.tb12780.x	35	87	92	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				598	604		10.1016/S0091-6749(98)70275-1	http://dx.doi.org/10.1016/S0091-6749(98)70275-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802367				2022-12-18	WOS:000076600400009
J	Nishioka, K; Yasueda, H; Saito, H				Nishioka, K; Yasueda, H; Saito, H			Preventive effect of bedding encasement with microfine fibers on mite sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; Der p 1; Der f 1; environment control; house dust mite; mite sensitization	ALLERGEN EXPOSURE; DUST MITES; HOUSE; ASTHMA; RISK; CHILDREN; ANTIGEN	Background: The indoor levels of mite allergens are known to determine the thresholds of sensitization and asthma exacerbation. However, the method for preventing mite sensitization by reducing the levels of house dust mites (HDMs) is not well established. Objective: We investigated whether mite-blocking bedding encasing made from microfine fibers can prevent infants from being sensitized to HDMs. Methods: Fifty-seven Japanese infants with atopic dermatitis who had high levels of IgE antibodies against either egg white, cow's milk, or soybean (but not against HDMs) were randomly chosen and divided into two groups. Thirty families of atopic infants (group A) were instructed to decrease HDMs by controlling the indoor environment, including bedding cleaning, whereas 27 families receiving the same instructions (group B) were further guided to use the Allerguard encasing for quilts and mattresses of all family members. We repeatedly examined Der p 1 + Der f 1 in the infants' mattresses and anti-Dermatophagoides farinae (Df) IgE in the infants' sera, and we performed skin prick tests with Df extract for 1 year. Results: The mite-blocking encasing markedly reduced the levels of Der p 1 + Der f 1 (3.0 mu g/g dust for group A vs 0.77 mu g/g dust for B, p < 0.001). It also prevented the increase in serum levels of anti-Df IgE (2.5 U/ml for group A vs 0.7 U/ml for group B, p < 0.05) and positive reactions to skin prick testing with Df extract (63% for group A vs 31% for group B, p < 0.02) over 1 year. Conclusion: The bedding encasement with the mite-blocking fibers was effective for preventing atopic infants from being sensitized to HDMs, and it seems to be beneficial to modern busy housekeepers.	Natl Sagamihara Hosp, Clin Res Ctr Allergy & Rheumatol, Kanagawa 228, Japan; Jikei Univ, Sch Med, Dept Pediat, Tokyo, Japan; Natl Childrens Med Res Ctr, Dept Allergy, Tokyo 154, Japan	Jikei University; National Center for Child Health & Development - Japan	Yasueda, H (corresponding author), Natl Sagamihara Hosp, Clin Res Ctr Allergy & Rheumatol, 18-1 Sakuradai, Kanagawa 228, Japan.			Saito, Hirohisa/0000-0002-6630-8337				CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983, DOI 10.1164/ajrccm/143.5_Pt_1.983; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; COLLOFF MJ, 1989, BRIT J DERMATOL, V121, P199, DOI 10.1111/j.1365-2133.1989.tb01799.x; DUFF AL, 1993, PEDIATRICS, V92, P535; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HOLT PG, 1990, PEDIATR ALLERGY IMMU, V1, P3; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; Maeda Yuji, 1994, Japanese Journal of Allergology, V43, P120; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; SAKAGUCHI M, 1989, INT ARCH ALLER A IMM, V90, P190, DOI 10.1159/000235022; SMITH JM, 1979, CLIN ALLERGY, V9, P153, DOI 10.1111/j.1365-2222.1979.tb01536.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x; YASUEDA H, 1994, CLIN EXP ALLERGY, V24, P1030, DOI 10.1111/j.1365-2222.1994.tb02739.x	19	87	88	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				28	32		10.1016/S0091-6749(98)70189-7	http://dx.doi.org/10.1016/S0091-6749(98)70189-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449497				2022-12-18	WOS:000071539800005
J	Macy, E; Richter, PK; Falkoff, R; Zeiger, R				Macy, E; Richter, PK; Falkoff, R; Zeiger, R			Skin testing with penicilloate and penilloate prepared by an improved method: Amoxicillin oral challenge in patients with negative skin test responses to penicillin reagents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; amoxicillin; challenge; health maintenance organization; minor determinants; penicillin; penicilloate; penilloate; skin test	ALLERGY; DIAGNOSIS	Background: Penicillin skin testing has been limited by the lack of commercial Objective: This project was proposed to produce a stable, well-characterized supply of penicilloate and penilloate for intrastate use by our health maintenance organization and to document clinical safety and efficacy. Methods: An improved method of extraction for penicilloate and penilloate, which changed the solvents used during recrystallization, was developed, With these newly prepared reagents, penicillin skin testing was performed on 348 subjects. Skin testing was immediately followed by an oral challenge of 250 mg of amoxicillin in 215 of 288 (75%) subjects displaying a negative response to a battery of penicillin skin tests. Results: Nuclear magnetic resonance and mass spectrometry of the newly produced penicilloate and penilloate showed no evidence of organic contamination. Penicillin skin testing resulted in 17.2% (60 of 348) positive test results, with 20% of the subjects with positive results only responding to the newly produced minor determinants, The rate of mild adverse reactions to penicillin skin testing was 1.1% (4 of 348). The rate of mild acute adverse reactions was 5.1% (11 of 215), and the delayed reaction rate was 0.9% (2 of 215) with the amoxicillin challenge. Conclusions: This improved penicillin minor determinant extraction method allows for the reproducible production of very pure preparations of penicilloate and penilloate. Large-scale penicillin skin testing, followed by amoxicillin challenge if results are negative is feasible in a large group model health maintenance organization operating within a single state with the use of internally produced penicilloate and penilloate and commercially available penicillin, amoxicillin, and penicilloyl polylysine.	UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, SAN DIEGO, CA 92103 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT PEDIAT, SAN DIEGO, CA 92103 USA; SCRIPPS RES INST, LA JOLLA, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute	Macy, E (corresponding author), KAISER PERMANENTE SAN DIEGO MED CTR, DEPT ALLERGY, 7060 CLAIREMONT MESA BLVD, SAN DIEGO, CA 92111 USA.			Macy, Eric/0000-0002-5857-9444; Zeiger, Robert/0000-0001-5788-5063				CHANDRA RK, 1980, ARCH DIS CHILD, V55, P857, DOI 10.1136/adc.55.11.857; GOLDSCHMIDT BM, 1983, J ANTIBIOT, V36, P709, DOI 10.7164/antibiotics.36.709; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; LEVINE BB, 1969, INT ARCH ALLER A IMM, V35, P445, DOI 10.1159/000230197; MENDELSON LM, 1984, J ALLERGY CLIN IMMUN, V73, P76, DOI 10.1016/0091-6749(84)90487-1; MOZINGO R, 1949, CHEM PENICILLIN, P535; RESSLER C, 1987, ANN ALLERGY, V59, P167; SARTI W, 1985, ANN ALLERGY, V55, P157; SAXON A, 1984, J INFECT DIS, V149, P16, DOI 10.1093/infdis/149.1.16; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; SOGN DD, 1992, ARCH INTERN MED, V152, P1025, DOI 10.1001/archinte.152.5.1025; VANARSDEL PP, 1986, WESTERN J MED, V144, P311	12	87	89	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					586	591		10.1016/S0091-6749(97)70159-3	http://dx.doi.org/10.1016/S0091-6749(97)70159-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389285				2022-12-18	WOS:A1997YG20200002
J	Maruo, K; Akaike, T; Ono, T; Okamoto, T; Maeda, H				Maruo, K; Akaike, T; Ono, T; Okamoto, T; Maeda, H			Generation of anaphylatoxins through proteolytic processing of C3 and C5 by house dust mite protease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dermatophagoides farinae; house dust protease; Df-protease; C3; C5; anaphylatoxins	KALLIKREIN-KININ SYSTEM; MAST-CELLS; DERMATOPHAGOIDES-PTERONYSSINUS; COMPLEMENT-SYSTEM; SERINE PROTEASE; HUMAN PLASMA; HUMAN-SKIN; ACTIVATION; ALLERGENS; INACTIVATION	Background: The group 3 allergen of Dermatophagoides species (Der p 3 and Der f 3) has been identified as a 30 kd trypsin-like protease of the house dust mite. We previously showed that the 30 kd protease from Dermatophagoides farinae (Df-protease) could activate the bradykinin-generating cascade and exacerbate inflammatory reactions. Objective: The purpose of this study was to determine whether Df-protease could enzymatically generate anaphylatoxins from complement components C3 and C5. Methods: Df-protease was incubated with human serum C3 or C5 in a purified system, and the anaphylatoxin activity produced was assayed by measuring enhancement of vascular permeability and release of histamine from mast cells triggered by C3a and by assessing chemotaxis of polymorphonuclear cells caused by C5a. We also attempted to determine whether protease isolated from house dust could cause release of C5a from C5. Results: Df-protease showed strong activation of C3 and C5, producing C3a and Cia by proteolytic cleavage of the complements. An appreciable amount of Df-protease was recovered in the house dust extract, and the house dust protease caused C5a release from C5. Conclusion: Df-protease activated the complement system to produce anaphylatoxins. Thus it is suggested that house dust mite proteases may contribute to the pathogenesis of allergic and inflammatory diseases caused by house dust allergens.	KUMAMOTO UNIV,SCH MED,DEPT MICROBIOL,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT DERMATOL,KUMAMOTO 860,JAPAN	Kumamoto University; Kumamoto University								BOKISCH VA, 1969, J EXP MED, V129, P1109, DOI 10.1084/jem.129.5.1109; CASTRO FFM, 1991, INT ARCH ALLER A IMM, P96305; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; COCHRANE CG, 1968, J EXP MED, V127, P371, DOI 10.1084/jem.127.2.371; EDWARDS J H, 1974, Clinical Allergy, V4, P379, DOI 10.1111/j.1365-2222.1974.tb01399.x; ELLATI SG, 1994, J INVEST DERMATOL, V102, P803, DOI 10.1111/1523-1747.ep12378589; FERNANDEZ HN, 1978, J IMMUNOL, V120, P109; GORSKI JP, 1979, P NATL ACAD SCI USA, V76, P5299, DOI 10.1073/pnas.76.10.5299; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; Hugli T E, 1978, Adv Immunol, V26, P1, DOI 10.1016/S0065-2776(08)60228-X; JACOBSON RS, 1993, J ALLERGY CLIN IMMUN, V91, P187; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; KOHMOTO S, 1991, J CLIN BIOCHEM NUTR, V10, P15; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARUO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P62, DOI 10.1016/0304-4165(91)90040-N; MARUO K, 1993, J BIOL CHEM, V268, P17711; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; NAGATA S, 1987, J ALLERGY CLIN IMMUN, V80, P24, DOI 10.1016/S0091-6749(87)80186-0; ODA T, 1990, INFECT IMMUN, V58, P1269, DOI 10.1128/IAI.58.5.1269-1272.1990; ONEILL GM, 1994, BBA-GENE STRUCT EXPR, V1219, P521, DOI 10.1016/0167-4781(94)90080-9; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; REGAL JF, 1993, J IMMUNOL, V150, P3496; ROBINSON BWS, 1990, J ALLERGY CLIN IMMUN, V86, P726, DOI 10.1016/S0091-6749(05)80176-9; Smith WA, 1996, INT ARCH ALLERGY IMM, V109, P133, DOI 10.1159/000237212; STEWART GA, 1989, LANCET, V2, P154, DOI 10.1016/S0140-6736(89)90203-1; STEWART GA, 1992, IMMUNOLOGY, V75, P29; STEWART GA, 1995, CLIN REV ALLERG IMMU, V13, P135; SULLIVAN TJ, 1975, J IMMUNOL, V114, P1473; SWERLICK RA, 1988, J IMMUNOL, V140, P2376; TAKAHASHI K, 1990, INT ARCH ALLER A IMM, V91, P80, DOI 10.1159/000235094; VANDERZEE JS, 1988, MOL IMMUNOL, V25, P345, DOI 10.1016/0161-5890(88)90029-6; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; WESTEL RA, 1983, J EXP MED, V157, P2029; WHITE MV, 1987, J IMMUNOL, V139, P1624; YASUEDA H, 1991, DUST MITE ALLERGENS, P63	37	87	95	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					253	260		10.1016/S0091-6749(97)70233-1	http://dx.doi.org/10.1016/S0091-6749(97)70233-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275149				2022-12-18	WOS:A1997XR35100018
J	King, C; Simpson, RJ; Moritz, RL; Reed, GE; Thompson, PJ; Stewart, GA				King, C; Simpson, RJ; Moritz, RL; Reed, GE; Thompson, PJ; Stewart, GA			The isolation and characterization of a novel collagenolytic serine protease allergen (Der p 9) from the dust mite Dermatophagoides pteronyssinus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mites; allergy; proteases; allergens; characterization; asthma; trypsin; chymotrypsin	GROUP-III ALLERGEN; SEQUENCE-ANALYSIS; PHYSICOCHEMICAL CHARACTERIZATION; LIQUID-CHROMATOGRAPHY; SUBSTRATE; ENZYMES; HEPATOPANCREAS; PURIFICATION; SPECIFICITY; ELASTASE	Background: Dust mites have been shown to contain a serine protease distinct from the previously reported trypsin and chymotrypsin. The latter enzymes have been shown to be allergens, but the allergenic importance of the former is unknown. Objective: This study was performed to isolate and characterize the novel mite serine protease and determine its allergenicity. Methods: The mire serine protease was isolated from feces-enriched extracts of Dermatophagoides pteronyssinus by ion-exchange chromatography and affinity chromatography, and its physicochemical properties were determined The allergenicity of the protease was assessed by using the RAST. Results: The protease was enzymatically similar to chymotrypsin and cathepsin G-like enzymes from a variety of sources and was shown to cleave collagen. It had a molecular mass of 23,780 d. N-terminal sequence analysis (18 residues) indicated homology with the mite tryptic allergen Der p 3, and the chymotryptic allergen Der p 6. RAST analyses showed that the frequencies of reactivity to the novel allergen and to Der p 1, Der p 2, Der p 3, and Der p 6 were 92%, 97%, 100% 97%, and 65%, respectively (n = 35). RAST inhibition studies showed some cross-reactivity between the protease and Der p 3 but not Der p 6. Conclusions: A novel mite serine protease was isolated from D. pteronyssinus and found to be a major allergen. This allergen has been tentatively designated Der p 9.	UNIV WESTERN AUSTRALIA,DEPT MICROBIOL,NEDLANDS,WA 6907,AUSTRALIA; INST CHILD HLTH,PERTH,WA,AUSTRALIA; LUDWIG INST CANC RES,JOINT PROT STRUCT LAB,PARKVILLE,VIC,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA; UNIV WESTERN AUSTRALIA,DEPT MED,NEDLANDS,WA 6009,AUSTRALIA	University of Western Australia; University of Western Australia; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Western Australia			Moritz, Robert L/B-9222-2011; King, Cecile/Q-9794-2019	King, Cecile/0000-0003-2193-2563; Simpson, Richard/0000-0002-9834-0796				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIETH J, 1974, BIOCHEM MED METAB B, V11, P350, DOI 10.1016/0006-2944(74)90134-3; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHRISTELLER JT, 1990, INSECT BIOCHEM, V20, P157, DOI 10.1016/0020-1790(90)90008-I; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; DELMAR EG, 1980, BIOCHEMISTRY-US, V19, P468, DOI 10.1021/bi00544a011; DELMAR EG, 1979, ANAL BIOCHEM, V99, P316, DOI 10.1016/S0003-2697(79)80013-5; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P217; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369, DOI 10.1165/ajrcmb.12.4.7695916; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; KLIMOVA OA, 1991, DOKL AKAD NAUK SSSR+, V317, P482; KLIMOVA OA, 1990, BIOCHEM BIOPH RES CO, V166, P1411, DOI 10.1016/0006-291X(90)91024-M; KOHMOTO S, 1991, J CLIN BIOCHEM NUTR, V10, P15; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKE FR, 1991, J ALLERGY CLIN IMMUN, V87, P1035, DOI 10.1016/0091-6749(91)92147-S; LECROISEY A, 1985, EUR J BIOCHEM, V152, P123, DOI 10.1111/j.1432-1033.1985.tb09171.x; MORITZ RL, 1992, J CHROMATOGR, V599, P119; MORITZ RL, 1992, J MICROCOLUMN SEP, V4, P485, DOI 10.1002/mcs.1220040604; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; SMITH WA, 1994, CLIN EXP ALLERGY, V24, P220, DOI 10.1111/j.1365-2222.1994.tb00223.x; STEWART GA, 1989, LANCET, V2, P154, DOI 10.1016/S0140-6736(89)90203-1; STEWART GA, 1992, IMMUNOLOGY, V75, P29; STEWART GA, 1991, INT ARCH ALLER A IMM, V95, P248, DOI 10.1159/000235437; STEWART GA, 1992, EXP APPL ACAROL, V16, P165, DOI 10.1007/BF01201499; STEWART GA, 1989, LANCET, V2, P462; STEWART GA, 1994, ALLERGY, V49, P553, DOI 10.1111/j.1398-9995.1994.tb01128.x; TSAI IH, 1991, BIOCHIM BIOPHYS ACTA, V1080, P59, DOI 10.1016/0167-4838(91)90112-D; YASUEDA H, 1993, CLIN EXP ALLERGY, V23, P384, DOI 10.1111/j.1365-2222.1993.tb00343.x	28	87	95	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1996	98	4					739	747		10.1016/S0091-6749(96)70121-5	http://dx.doi.org/10.1016/S0091-6749(96)70121-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VM665	8876548				2022-12-18	WOS:A1996VM66500005
J	Grzybowski, M; Ownby, DR; Peyser, PA; Johnson, CC; Schork, MA				Grzybowski, M; Ownby, DR; Peyser, PA; Johnson, CC; Schork, MA			The prevalence of anti-latex IgE antibodies among registered nurses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; anti-latex IgE antibodies; prevalence; risk factor; epidemiology; nursing population	HOSPITAL PERSONNEL; CONTACT URTICARIA; CROSS-REACTIVITY; ALLERGY; BANANA; HYPERSENSITIVITY; PATIENT; RUBBER; GLOVES	Background: Recent studies have reported that the prevalence of latex allergy among volunteer populations of health care workers ranges from 2% to 25%. To date, no epidemiologic study has investigated the prevalence of latex allergy and its relationship to possible risk factors among nurses. Methods: Registered nurses (n = 741) in a large metropolitan hospital participated in a latex allergy prevalence study. Latex exposure data were obtained through self-administered questionnaires. Blood samples were classified as positive or negative for anti-latex IgE antibodies. Associations between potential risk factors for latex allergy and anti-latex antibodies were assessed. Results: The participation rate was 90.6% among eligible nurses. Sixty-five samples were positive for a prevalence of 8.9% (95% confidence interval 6.7 to 10.8). No differences in latex positivity among five nursing specialties were noted. Logistic regression indicated that after adjusting for age and sex, the following factors were significantly associated with latex seropositivity: nonwhite race (odds ratio [OR] = 4.2), reported histories of penicillin allergy (OR = 2.2), pruritic skin (OR = 2.2), conjunctivitis (OR = 3.0), localized urticaria (OR = 1.8), hay fever (OR = 2.1), avocado allergy (OR = 9.9), and ragweed allergy (OR = 3.4). Conclusions: The prevalence of latex sensitization appeared to be substantial (8.9%) among the nurses studied, and the prevalence did not vary by nursing specialty. The factors associated with latex positivity in the logistic regression model correctly classified 81.3% of the nurses with a sensitivity and specificity of 66.7% and 82.7%, respectively.	HENRY FORD HLTH SCI CTR,DIV BIOSTAT RES EPIDEMIOL & COMP,DETROIT,MI; HENRY FORD HOSP,ALLERGY RES LAB,DETROIT,MI 48202; UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH PUBL HLTH,DEPT BIOSTAT,ANN ARBOR,MI 48109	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Grzybowski, M (corresponding author), HENRY FORD HOSP,DEPT EMERGENCY MED,2799 W GRAND BLVD,DETROIT,MI 48202, USA.			Johnson, Christine Cole/0000-0002-6864-6604				ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; BEAUDOUIN E, 1990, REV FR ALLERGOL, V30, P157, DOI 10.1016/S0335-7457(05)80230-8; *CDC EP PROGR OFF, 1990, EPI INFO VERS 5 01A; CEUPPENS JL, 1992, LANCET, V339, P493, DOI 10.1016/0140-6736(92)91101-D; CRISI G, 1993, CONTACT DERMATITIS, V28, P247, DOI 10.1111/j.1600-0536.1993.tb03415.x; FLACK VF, 1987, AM STAT, V41, P84, DOI 10.2307/2684336; GRIFFITHS WE, 1987, J AM STAT ASSOC, V82, P929, DOI 10.2307/2288807; Hosmer DW, 1989, APPL LOGISTIC REGRES; IACOBELLI AM, 1993, J ALLERGY CLIN IMMUN, V91, P216; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; LAVAUD F, 1992, LANCET, V339, P492, DOI 10.1016/0140-6736(92)91100-M; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; MONERETVAUTRIN DA, 1991, ANESTHESIOLOGY, V74, P391, DOI 10.1097/00000542-199102000-00048; MONERETVAUTRIN DA, 1993, J ALLERGY CLIN IMMUN, V92, P668, DOI 10.1016/0091-6749(93)90009-5; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; Neter J., 1985, APPL LINEAR STAT MOD; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; Ownby DR, 1996, J ALLERGY CLIN IMMUN, V97, P1188, DOI 10.1016/S0091-6749(96)70183-5; OWNBY DR, 1993, J CLIN IMMUNOASSAY, V16, P109; ROSS BD, 1992, J ALLERGY CLIN IMMUN, V90, P409, DOI 10.1016/S0091-6749(05)80023-5; SALKIE ML, 1993, ARCH PATHOL LAB MED, V117, P897; *SAS I INC, 1990, P200 SAS I INC; SAVONIUS B, 1993, ALLERGY, V48, P215, DOI 10.1111/j.1398-9995.1993.tb00718.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1989, CONTACT DERMATITIS, V20, P360, DOI 10.1111/j.1600-0536.1989.tb03173.x; YASSIN MS, 1994, ANN ALLERGY, V72, P245; 1987, MMWR MORB MORTAL S2, V36, pS1	28	87	92	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					535	544		10.1016/S0091-6749(96)70087-8	http://dx.doi.org/10.1016/S0091-6749(96)70087-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828531				2022-12-18	WOS:A1996VJ42800010
J	Pastorello, EA; Pravettoni, V; Ispano, M; Farioli, L; Ansaloni, R; Rotondo, F; Incorvaia, C; Asman, I; Bengtsson, A; Ortolani, C				Pastorello, EA; Pravettoni, V; Ispano, M; Farioli, L; Ansaloni, R; Rotondo, F; Incorvaia, C; Asman, I; Bengtsson, A; Ortolani, C			Identification of the allergenic components of kiwi fruit and evaluation of their cross-reactivity with timothy and birch pollens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						kiwi; oral allergy syndrome; food allergy; cross-allergenicity; immunoblotting; timothy; birch	IGE ANTIBODIES; CYTOCHROMES-C; SENSITIVITY; CELERY; MUGWORT; LATEX	Background: Only a few food allergens have as yet been identified, mainly because of the difficulty of obtaining a sufficient number of patients who are clinically sensitized to a given food. This is more feasible in the case of the oral allergy syndrome (OAS), a common form of food allergy, which is especially prevalent in patients with pollinosis. Objective: We designed a study to identify the allergens of kiwi fruit (Actinidia chinensis) by analyzing the sera of patients with OAS for kiwi and to examine the cross-reactivity of these allergens with timothy and birch pollen. allergens. Methods: Twenty-seven patients with OAS for kiwi, a positive skin prick test response and serum IgE antibody to kiwi, and a positive open kiwi challenge test result and three patients who had OAS with severe systemic symptoms, which excluded a challenge test, were included in this study. The different polypeptide components of an extinct of fresh kiwi were separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis and analyzed by IgE immunoblotting with sera from these patients. Cross-reactivity with the two pollen. extracts was assessed by inhibition of the immunoblots with pooled and individual patients' sera. Results: Twelve IgE-binding components with molecular weights ranging from 12 to 64 kd were identified in the kiwi extract, bur only a 30 kd component acted as major allergen, being recognized by sera of 100% of these patients. Inhibition of kiwi immunoblots with timothy and birch pollen extracts demonstrated strong cross-reactivity with some of the kiwi allergens, suggesting complete identity between certain food and pollen allergens; whereas others, particularly the 30 kd allergen were only partially inhibited suggesting much weaker cross-reactivity. Conclusions: Kiwi fruit contains a large number of allergens widely cross-reacting with allergens in grass and birch pollen extracts. Nevertheless, the major allergen at 30 kd appears to be specific for kiwi.	UNIV MILAN,DIV INTERNAL MED 3,MILAN,ITALY; NIGUARDA CA GRAND HOSP,BIZZOZZERO DIV,MILAN,ITALY; PHARMACIA DIAGNOST AB,S-75182 UPPSALA,SWEDEN	University of Milan; Pfizer; Pharmacia Corporation			PASTORELLO, ELIDE ANNA/E-3897-2017	PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; ALENIUS H, 1992, ALLERGY PROC, V13, P75, DOI 10.2500/108854192778878863; BENGTSSON A, 1986, INT ARCH ALLER A IMM, V80, P383, DOI 10.1159/000234085; CARNE A, 1978, BIOCHEM J, V173, P73, DOI 10.1042/bj1730073; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P61; EKRAMODDOULLAH AKM, 1982, MOL IMMUNOL, V19, P1527, DOI 10.1016/0161-5890(82)90263-2; FALLIERS CJ, 1983, J ASTHMA, V20, P193, DOI 10.3109/02770908309114944; FINE AJ, 1981, J ALLERGY CLIN IMMUN, V68, P235, DOI 10.1016/0091-6749(81)90189-5; Freye HB, 1989, ALLERGOLOGIE, V12, P89; GALL H, 1994, J ALLERGY CLIN IMMUN, V94, P70, DOI 10.1016/0091-6749(94)90073-6; GOODFRIEND L, 1979, FED PROC, V38, P1415; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; IPSEN H, 1993, ALLERGY PRINCIPLES P, P529; LAVAUD F, 1995, J ALLERGY CLIN IMMUN, V95, P557, DOI 10.1016/S0091-6749(95)70318-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; ORTOLANI C, 1993, ANN ALLERGY, V71, P470; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; PAULI G, 1985, CLIN ALLERGY, V15, P273, DOI 10.1111/j.1365-2222.1985.tb02285.x; SABBAH A, 1985, ALLERG IMMUNOL, V17, P524; TOPHAM CM, 1994, PROTEIN ENG, V7, P689; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALLIER P, 1988, CLIN ALLERGY, V18, P491, DOI 10.1111/j.1365-2222.1988.tb02899.x; VOCKS E, 1993, ALLERGY, V48, P168, DOI 10.1111/j.1398-9995.1993.tb00708.x; WADEE AA, 1990, J ALLERGY CLIN IMMUN, V85, P801, DOI 10.1016/0091-6749(90)90202-F; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x	28	87	87	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					601	610		10.1016/S0091-6749(96)70094-5	http://dx.doi.org/10.1016/S0091-6749(96)70094-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828538				2022-12-18	WOS:A1996VJ42800017
J	Batanero, E; Villalba, M; Monsalve, RI; Rodriguez, R				Batanero, E; Villalba, M; Monsalve, RI; Rodriguez, R			Cross-reactivity between the major allergen from olive pollen and unrelated glycoproteins: Evidence of an epitope in the glycan moiety of the allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Olea europaea; major allergen; Ole e 1; glycan epitope; cross-reactivity	OLE-E-I; N-LINKED OLIGOSACCHARIDES; AMINO-ACID-SEQUENCE; CARBOHYDRATE MOIETY; VENOM PHOSPHOLIPASE-A2; OLEACEAE POLLENS; EUROPEA POLLEN; IGE ANTIBODIES; TREE POLLEN; FUCOSE	Ole e 1, the major allergen from olive pollen, is a glycoprotein containing a single Asn-linked glycan moiety. Rabbit antiserum against this protein has been obtained; and its immunologic cross-reactivities in Western blotting with ascorbate oxidase, horseradish peroxidase, bromelain, ovalbumin, and honeybee venom phospholipase A(2) have been studied. Ascorbate oxidase, peroxidase, and bromelain are recognized by the Ole e 1 antiserum. When these three proteins are deglycosylated by periodate treatment, such an immunologic reaction does not occur. The relative affinities of these proteins have been analyzed by direct and inhibition ELISA experiments. A commercially available antibody against horseradish peroxidase has also been considered in these studies. This antibody reacts with Ole e 1 but not with the periodate-deglycosylated allergen. Horseradish peroxidase, bromelain, and ascorbate oxidase are recognized by the IgE of sera from patients who are hypersensitive to olive tree pollen. This binding is also abolished by periodate treatment. The results are interpreted in terms of the presence of an epitope in the carbohydrate moiety of Ole e 1, which would contain a xylose involved in recognition by both IgE and IgG antibodies.	UNIV COMPLUTENSE MADRID,FAC QUIM,DEPT BIOQUIM & BIOL MOL,E-28040 MADRID,SPAIN	Complutense University of Madrid			Villalba, María Teresa/AAW-1067-2020; RODRIGUEZ, ROSALIA/K-4993-2014; Villalba, Mayte/K-5365-2014	Villalba, María Teresa/0000-0002-0042-9953; RODRIGUEZ, ROSALIA/0000-0002-4280-3691; Monsalve, Rafael/0000-0002-6838-4472				AALBERSE RC, 1981, INT ARCH ALLER A IMM, V66, P259, DOI 10.1159/000232913; BALDO BA, 1992, MOL IMMUNOL, V29, P1209, DOI 10.1016/0161-5890(92)90057-5; BATANERO E, 1994, MOL IMMUNOL, V31, P31, DOI 10.1016/0161-5890(94)90135-X; BOUSQUET J, 1985, CLIN ALLERGY, V15, P439, DOI 10.1111/j.1365-2222.1985.tb02293.x; DANDREA G, 1988, GLYCOCONJUGATE J, V5, P151, DOI 10.1007/BF01061204; DUA VK, 1987, ANAL BIOCHEM, V137, P33; FAYE L, 1993, ANAL BIOCHEM, V209, P104, DOI 10.1006/abio.1993.1088; FEIZI T, 1985, BIOCHEM J, V245, P1; HIJIKATA A, 1994, INT ARCH ALLERGY IMM, V105, P198, DOI 10.1159/000236826; KOSHTE VL, 1989, J ALLERGY CLIN IMMUN, V84, P174, DOI 10.1016/0091-6749(89)90322-9; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIERE M, 1989, PLANT PHYSIOL, V90, P1182, DOI 10.1104/pp.90.3.1182; LAUZURICA P, 1988, MOL IMMUNOL, V25, P337, DOI 10.1016/0161-5890(88)90028-4; LOMBARDERO M, 1992, J ALLERGY CLIN IMMUN, V89, P884, DOI 10.1016/0091-6749(92)90445-8; MACCHIA L, 1991, ALLERGENIC POLLEN PO, P87; MARTINOROZCO E, 1994, INT ARCH ALLERGY IMM, V104, P160, DOI 10.1159/000236725; MCMANUS MT, 1988, PLANTA, V175, P506, DOI 10.1007/BF00393072; MENENDEZARIAS L, 1990, MOL IMMUNOL, V27, P143, DOI 10.1016/0161-5890(90)90109-D; OBISPO TM, 1993, CLIN EXP ALLERGY, V23, P311, DOI 10.1111/j.1365-2222.1993.tb00328.x; OHTA M, 1991, ARCH BIOCHEM BIOPHYS, V290, P474, DOI 10.1016/0003-9861(91)90569-5; PRENNER C, 1992, BIOCHEM J, V284, P377, DOI 10.1042/bj2840377; RAMIREZSOTO D, 1991, CARBOHYD RES, V213, P27, DOI 10.1016/S0008-6215(00)90595-0; STURM A, 1991, EUR J BIOCHEM, V199, P169, DOI 10.1111/j.1432-1033.1991.tb16106.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; VANKUIK JA, 1986, GLYCOCONJUGATE J, V3, P27, DOI 10.1007/BF01108609; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; VILLALBA M, 1990, BIOCHEM BIOPH RES CO, V172, P523, DOI 10.1016/0006-291X(90)90704-Q; VILLALBA M, 1994, J BIOL CHEM, V269, P15217; VILLALBA M, 1993, EUR J BIOCHEM, V216, P863, DOI 10.1111/j.1432-1033.1993.tb18208.x; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x; YASUDA Y, 1970, BIOCHEMISTRY-US, V9, P25, DOI 10.1021/bi00803a004	34	87	88	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1264	1271		10.1016/S0091-6749(96)70194-X	http://dx.doi.org/10.1016/S0091-6749(96)70194-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648022				2022-12-18	WOS:A1996VD60700014
J	PLATTSMILLS, TAE; SPORIK, RB; WHEATLEY, LM; HEYMANN, PW				PLATTSMILLS, TAE; SPORIK, RB; WHEATLEY, LM; HEYMANN, PW			IS THERE A DOSE-RESPONSE RELATIONSHIP BETWEEN EXPOSURE TO INDOOR ALLERGENS AND SYMPTOMS OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							HOUSE-DUST MITE; RISK-FACTORS; BRONCHIAL HYPERREACTIVITY; NORTHERN CALIFORNIA; P-I; CHILDREN; SENSITIZATION; ANTIBODY; DERMATOPHAGOIDES; IMMUNOTHERAPY				PLATTSMILLS, TAE (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, DEPT MED, DIV ASTHMA & ALLERG DIS, BOX 225, CHARLOTTESVILLE, VA 22908 USA.			Platts-Mills, Thomas/0000-0002-1263-329X				ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; Blackley C.H, 1959, EXPT RES CAUSES NATU; BOLLINGER ME, 1995, IN PRESS J ALLERGY C; BONER AL, 1993, ALLERGY, V48, P119, DOI 10.1111/j.1398-9995.1993.tb04713.x; BONER AL, 1985, ANN ALLERGY, V54, P42; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CARSWELL F, 1995, CLIN EXP ALLERGY, V25, P99, DOI 10.1111/j.1365-2222.1995.tb01012.x; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983, DOI 10.1164/ajrccm/143.5_Pt_1.983; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1983, LANCET, V2, P253; CRETICOS PS, 1993, J ALLERGY CLIN IMMUN, V91, P227; DEBLAY F, 1992, PRESSE MED, V21, P1685; DUFF AL, 1993, PEDIATRICS, V92, P535; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; KERREBIJN KF, 1970, BRONCHITIS, V3, P38; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MARKS GB, 1995, CLIN EXP ALLERGY, V25, P114, DOI 10.1111/j.1365-2222.1995.tb01015.x; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P224, DOI 10.1016/0091-6749(88)91003-2; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; VERVLOET D, 1991, ALLERGY, V46, P554, DOI 10.1111/j.1398-9995.1991.tb00620.x; VOORHORST R, 1969, HOUSE DUST MITE ATOP	43	87	88	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					435	440		10.1016/S0091-6749(95)70284-9	http://dx.doi.org/10.1016/S0091-6749(95)70284-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560652				2022-12-18	WOS:A1995TA09500001
J	KNUTSEN, AP; MUELLER, KR; LEVINE, AD; CHOUHAN, B; HUTCHESON, PS; SLAVIN, RG				KNUTSEN, AP; MUELLER, KR; LEVINE, AD; CHOUHAN, B; HUTCHESON, PS; SLAVIN, RG			ASP FI CD4+ T-H2-LIKE T-CELL LINES IN ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; ASP F I; INTERLEUKIN-4; CD4+ T-H2 T-CELL LINES	HUMAN B-CELLS; LINKED IMMUNOSORBENT-ASSAY; EPSTEIN-BARR VIRUS; IGE SYNTHESIS; CYSTIC-FIBROSIS; IFN-GAMMA; HUMAN EOSINOPHILS; FUMIGATUS; INVITRO; IL-4	Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease caused by bronchial colonization with Aspergillus fumigatus (Af) characterized by elevated serum total and Af-specific IgE levels and eosinophilia. In order to examine T-cell reactivity to Af antigens, six T-cell lines were established from the peripheral blood of patients with ABPA to Asp f I, an 18 kd protein purified from Af extracts. The Asp f I-specific T-cell lines, analyzed by flow cytometry, were 100% CD3 + CD4 +. Lymphoproliferative responses of the T-cell lines were specific for Asp f I stimulation, 28,999 cpm (stimulation index = 12.2), and showed no response to tetanus toroid stimulation 2178 cpm (stimulation index = 1.1) (p < 0.001). Furthermore, Asp f I-stimulated lymphoproliferation was inhibited in two experiments by monoclonal anti-interleukin (IL)-4 antibody in a dose-response fashion, 78% and 84% inhibition at 5% concentration of anti-IL-4. In contrast, anti-IL-2 antibody did nor inhibit Asp fl-stimulated proliferation. Asp fl-stimulated T-cell lines synthesized predominantly IL-4 (mean, 21.5 ng/ml) after 48 hours of culture, and nondetectable quantities of interferon-gamma and IL-2. In summary Asp f I-specific T-cell lines established from patients with ABPA were characterized as being CD4 + T-H2-like in their cytokine synthesis pattern, and secreted IL-4 behaved in an autocrine fashion, stimulating proliferation.	MONSANTO CORP RES, ST LOUIS, MO USA	Monsanto	KNUTSEN, AP (corresponding author), ST LOUIS UNIV, MED CTR, PEDIAT RES INST, 1465 S GRAND BLVD, ST LOUIS, MO 63104 USA.							ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; ARRUDA LK, 1990, J EXP MED, V172, P1529, DOI 10.1084/jem.172.5.1529; BONNEFOY JY, 1993, IMMUNOL TODAY, V14, P1, DOI 10.1016/0167-5699(93)90313-A; BRUMMUND W, 1987, J CLIN MICROBIOL, V25, P5, DOI 10.1128/JCM.25.1.5-9.1987; CARR C, 1991, BIOCHEMISTRY-US, V30, P1515, DOI 10.1021/bi00220a011; CROMWELL O, 1988, J ALLERGY CLIN IMMUN, V82, P535, DOI 10.1016/0091-6749(88)90962-1; DELPRETE G, 1988, J IMMUNOL, V140, P4193; FORMAN SR, 1978, J ALLERGY CLIN IMMUN, V62, P131, DOI 10.1016/0091-6749(78)90096-9; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; GUTT L, 1986, J ALLERGY CLIN IMMUN, V78, P98, DOI 10.1016/0091-6749(86)90120-X; HIGGINS JA, 1992, J ALLERGY CLIN IMMUN, V90, P749, DOI 10.1016/0091-6749(92)90098-M; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; JABARA HH, 1988, J CLIN IMMUNOL, V8, P437, DOI 10.1007/BF00916948; KAUFFMAN HF, 1989, J ALLERGY CLIN IMMUN, V83, P829, DOI 10.1016/0091-6749(89)90022-5; KAUFFMAN HF, 1984, J ALLERGY CLIN IMMUN, V74, P741, DOI 10.1016/0091-6749(84)90239-2; Knutsen A, 1992, Semin Respir Infect, V7, P179; KNUTSEN AP, 1989, J LAB CLIN MED, V113, P428; KNUTSEN AP, 1990, CLIN IMMUNOL IMMUNOP, V55, P129, DOI 10.1016/0090-1229(90)90074-Z; KURUP VP, 1990, INT ARCH ALLER A IMM, V91, P145, DOI 10.1159/000235106; LAUFER P, 1984, J ALLERGY CLIN IMMUN, V73, P44, DOI 10.1016/0091-6749(84)90482-2; MEARNS M, 1967, LANCET, V1, P538; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PARRONCHI P, 1990, J IMMUNOL, V144, P2102; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; PENE J, 1988, J IMMUNOL, V141, P1218; PENE J, 1989, J CELL BIOCHEM, V39, P253, DOI 10.1002/jcb.240390305; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V81, P718, DOI 10.1016/0091-6749(88)91044-5; SLAVIN RG, 1992, J ALLERGY CLIN IMMUN, V90, P1006, DOI 10.1016/0091-6749(92)90479-L; SLIGH J M, 1991, Journal of Allergy and Clinical Immunology, V87, P288, DOI 10.1016/0091-6749(91)91877-V; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; THORNHILL MH, 1990, J IMMUNOL, V144, P3060; THYPHRONITIS G, 1989, P NATL ACAD SCI USA, V86, P5580, DOI 10.1073/pnas.86.14.5580; VELLA AT, 1992, J IMMUNOL, V149, P1714; VERCELLI D, 1991, J ALLERGY CLIN IMMUN, V88, P285, DOI 10.1016/0091-6749(91)90087-5; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917; ZHANG K, 1991, J IMMUNOL, V146, P1836	38	87	94	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2					215	221		10.1016/0091-6749(94)90043-4	http://dx.doi.org/10.1016/0091-6749(94)90043-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC926	7914901	Bronze			2022-12-18	WOS:A1994PC92600012
J	SPITZAUER, S; SCHWEIGER, C; SPERR, WR; PANDJAITAN, B; VALENT, P; MUHL, S; EBNER, C; SCHEINER, O; KRAFT, D; RUMPOLD, H; VALENTA, R				SPITZAUER, S; SCHWEIGER, C; SPERR, WR; PANDJAITAN, B; VALENT, P; MUHL, S; EBNER, C; SCHEINER, O; KRAFT, D; RUMPOLD, H; VALENTA, R			MOLECULAR CHARACTERIZATION OF DOG ALBUMIN AS A CROSS-REACTIVE ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DOG ALLERGENS; ALBUMIN; CDNA CLONING; IGE	RADIO-IMMUNOELECTROPHORESIS; SERUM-ALBUMIN; BIRCH POLLEN; CAT; PURIFICATION; EXTRACTS; IDENTIFICATION; PROTEINS; HAIR; DANDRUFF	Indoor allergens comprise a group of allergenic proteins that are commonly derived from house dust mite and cat and dog dander. In addition to the two major dog allergens (molecular weights: 19 and 23 kd), dog albumin represents an important allergen for up to 35% of patients who are allergic to dogs. In IgE immunoblot inhibition studies and histamine release tests it has been demonstrated that patients who react to dog albumin exhibit IgE reactivity with purified albumins from cat, mouse, chicken, and rat. The proportion of dog-specific IgE directed against dog albumin was determined for patients allergic to dog albumin, and it ranges from 70% to 90%. By IgE immunoscreening of a lambda gt11 expression library from a dog salivary gland, we identified a number of reactive complementary DNA clones. All patients with IgE reactivity against natural dog albumin displayed IgE reactivity to the beta-galactosidase fusion protein encoded by clone 54c, which was therefore assumed to contain major IgE epitopes of dog albumin. The deduced amino acid sequence of clone 54c was compared with the Swiss-Prot library and significant sequence homologies were found with albumins from different species (human: 82.6%, pig. 81.8%, cattle: 77.3%, sheep: 78.8%, mouse. 75.8%, and rat: 76.2%). Several other IgE-positive clones hybridized with oligonucleotides that were prepared according to this sequence. Partial complementary DNA coding for dog albumin fragments may be considered a useful tool for further characterization of major IgE epitopes of dog albumin.	UNIV VIENNA,AKH,INST GEN & EXPTL PATHOL,WAHRINGERGURTEL 18-20,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,AKH,INST MED,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,AKH,CHEM LAB,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT HEMATOL & HEMOSTASEOL,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna; University of Vienna; University of Vienna			Valent, Peter/B-8533-2016; Gamperl, Susi/V-2715-2019; Sperr, Mast/V-4767-2019; Test, Test/Y-7921-2019; Test, PV/U-9451-2019	Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Sperr, Mast/0000-0002-7778-5219; Sperr, Wolfgang/0000-0003-3288-8027				BLANDS J, 1977, ACTA ALLERGOL, V32, P147, DOI 10.1111/j.1398-9995.1977.tb01346.x; BOUTIN Y, 1988, CLIN ALLERGY, V18, P287, DOI 10.1111/j.1365-2222.1988.tb02871.x; BRANDT R, 1980, INT ARCH ALLER A IMM, V61, P361, DOI 10.1159/000232463; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CHAPMAN MD, 1989, CURR OPIN IMMUNOL, V1, P647, DOI 10.1016/0952-7915(89)90035-6; DEGROOT H, 1991, J ALLERGY CLIN IMMUN, V87, P1056, DOI 10.1016/0091-6749(91)92150-Y; FORD AW, 1992, CLIN EXP ALLERGY, V22, P793, DOI 10.1111/j.1365-2222.1992.tb02820.x; FORD AW, 1989, CLIN EXP ALLERGY, V19, P183, DOI 10.1111/j.1365-2222.1989.tb02362.x; HOFFMAN DR, 1980, ANN ALLERGY, V45, P205; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P50; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN JN, 1988, J ALLERGY CLIN IMMUN, V82, P318, DOI 10.1016/0091-6749(88)90002-4; LAWN RM, 1981, NUCLEIC ACIDS RES, V9, P6103, DOI 10.1093/nar/9.22.6103; LINDGREN S, 1988, J ALLERGY CLIN IMMUN, V82, P196, DOI 10.1016/0091-6749(88)90999-2; LOWENSTEIN H, 1981, ALLERGOLOGIE, V4, P265; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; OHMAN JL, 1976, J ALLERGY CLIN IMMUN, V57, P560, DOI 10.1016/0091-6749(76)90007-5; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOU C, 1991, CLIN EXP ALLERGY, V21, P321, DOI 10.1111/j.1365-2222.1991.tb01663.x; SPITZAUER S, 1993, INT ARCH ALLERGY IMM, V100, P60, DOI 10.1159/000236389; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VIANDER M, 1983, INT ARCH ALLER A IMM, V71, P252, DOI 10.1159/000233399; WUTHRICH B, 1979, CLIN ALLERGY, V9, P191, DOI 10.1111/j.1365-2222.1979.tb01541.x; WUTHRICH B, 1985, CLIN ALLERGY, V15, P87, DOI 10.1111/j.1365-2222.1985.tb02260.x; YMAN L, 1973, INT ARCH ALLER A IMM, V44, P358, DOI 10.1159/000230944	30	87	90	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1994	93	3					614	627		10.1016/S0091-6749(94)70073-7	http://dx.doi.org/10.1016/S0091-6749(94)70073-7			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ND140	7512102	Bronze			2022-12-18	WOS:A1994ND14000008
J	KALIVAS, J; BRENEMAN, D; THARP, M; BRUCE, S; BIGBY, M				KALIVAS, J; BRENEMAN, D; THARP, M; BRUCE, S; BIGBY, M			URTICARIA - CLINICAL EFFICACY OF CETIRIZINE IN COMPARISON WITH HYDROXYZINE AND PLACEBO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	CONF ON ADVANCEMENTS IN ANTIALLERGIC THERAPY : BEYOND CONVENTIONAL ANTIHISTAMINES	OCT 12-15, 1989	NAPLES, FL	PFIZER LAB				Chronic urticaria is a problem for both physician and patient. In an effort to avoid the risks associated with corticosteroid treatment, many first-generation H-1-receptor antagonists have been tried and found to induce undesirable levels of sedation when given in amounts sufficient to control urticaria. Cetirizine, a pharmacologically active oxidized metabolite of hydroxyzine, was developed to provide selective H-1-receptor inhibition without depression of the central nervous system. In a 4-week, multicenter, double-blind, placebo-controlled safety and efficacy study, cetirizine, in a once-a-day dose (5 to 20 mg), was equivalent in efficacy to hydroxyzine in divided doses (25 to 75 mg/day). The incidence of somnolence in the cetirizine group was not significantly different from that of the placebo group. However, in the hydroxyzine group, the incidence of somnolence was significantly higher than that in the placebo group (p = 0.001). The results of this study demonstrate that cetirizine has a greater safety margin over the older parent drug hydroxyzine.	BAYLOR UNIV,HOUSTON,TX 77030; BETH ISRAEL HOSP,BOSTON,MA 02215; UNIV CINCINNATI,MED CTR,CINCINNATI,OH 45267; UNIV TEXAS,HLTH SCI CTR,DALLAS,TX 75235	Baylor University; Harvard University; Beth Israel Deaconess Medical Center; University of Cincinnati; University of Texas System; University of Texas Dallas	KALIVAS, J (corresponding author), UNIV KANSAS,MED CTR,DEPT MED,DIV DERMATOL,39TH & RAINBOW BLVD,KANSAS CITY,KS 66103, USA.							GENGO FM, 1987, ANN ALLERGY, V59, P53; JORIZZO JL, 1985, DERMATOL CLIN, V3, P1; MONROE EW, 1988, J AM ACAD DERMATOL, V19, P842, DOI 10.1016/S0190-9622(88)70243-1; WOODWARD JK, 1988, CUTIS, V42, P5	4	87	87	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	2	S			1014	1018		10.1016/S0091-6749(05)80246-5	http://dx.doi.org/10.1016/S0091-6749(05)80246-5			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER131	1979796				2022-12-18	WOS:A1990ER13100005
J	HENOCQ, E; VARGAFTIG, BB				HENOCQ, E; VARGAFTIG, BB			SKIN EOSINOPHILIA IN ATOPIC PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									INST PASTEUR,INSERM,U285,F-75724 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	HENOCQ, E (corresponding author), HOP NECKER ENFANTS MALAD,SERV IMMUNOL CLIN,161 RUE SEVRES,F-75743 PARIS 15,FRANCE.		Vargaftig, Bernardo Boris B.B.J./C-3323-2013					ARCHER CB, 1985, BRIT J DERMATOL, V112, P285, DOI 10.1111/j.1365-2133.1985.tb04855.x; BOUKILI MA, 1986, BRIT J PHARMACOL, V89, P349, DOI 10.1111/j.1476-5381.1986.tb10267.x; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRUIJNZEEL PLB, 1985, ANN ALLERGY, V55, P250; CAMUSSI G, 1983, AM J PATHOL, V112, P78; CONROY MC, 1985, INT ARCH ALLER A IMM, V77, P222, DOI 10.1159/000233793; DENJEAN A, 1984, American Review of Respiratory Disease, V129, pA3; DESHAZO RD, 1979, J IMMUNOL, V122, P692; FILLEY WV, 1982, LANCET, V2, P11; FITZHARRIS P, 1986, J ALLERGY CLIN IMMUN, V77, P235; FOWLER JW, 1966, J ALLERGY, V37, P19, DOI 10.1016/0021-8707(66)90106-7; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; HAMEL R, 1985, PROSTAGLANDINS, V28, P130; HENOCQ E, 1986, LANCET, V1, P1379; HUMPHREY DM, 1982, LAB INVEST, V47, P227; JOUVINMARCHE E, 1984, FED PROC, V43, P1924; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEFORT J, 1986, British Journal of Pharmacology, V89, p768P; LELLOUCHTUBIANA A, 1985, BRIT J EXP PATHOL, V66, P345; LELLOUCHTUBIANA A, IN PRESS AM REV RESP; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; MCMANUS LM, 1985, AM J PATHOL, V121, P55; METZGER WJ, 1986, J ALLERGY CLIN IMMUN, V78, P282; METZGER WJ, 1985, CHEST, V87, P165; MORLEY J, 1985, INT ARCH ALLER A IMM, V77, P73, DOI 10.1159/000233756; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; REBUCK JW, 1955, ANN NY ACAD SCI, V59, P757, DOI 10.1111/j.1749-6632.1955.tb45983.x; SIRAGANIAN RP, 1977, J IMMUNOL, V119, P2078; SPRY CJF, 1985, IMMUNOL TODAY, V6, P332, DOI 10.1016/0167-5699(85)90130-6; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0; TONNEL B, 1985, TRAITEMENT ASTHME; VARGAFTIG BB, 1980, EUR J PHARMACOL, V65, P185, DOI 10.1016/0014-2999(80)90391-X; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765	34	87	87	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1988	81	4					691	695		10.1016/0091-6749(88)91040-8	http://dx.doi.org/10.1016/0091-6749(88)91040-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N0650	3281998				2022-12-18	WOS:A1988N065000009
J	BUSH, RK; TAYLOR, SL; NORDLEE, JA; BUSSE, WW				BUSH, RK; TAYLOR, SL; NORDLEE, JA; BUSSE, WW			SOYBEAN OIL IS NOT ALLERGENIC TO SOYBEAN-SENSITIVE INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WILLIAM S MIDDLETON MEM VET ADM HOSP,MADISON,WI 53705; UNIV WISCONSIN,INST FOOD RES,DEPT FOOD MICROBIOL & TOXICOL,MADISON,WI 53792; UNIV WISCONSIN,DEPT FOOD SCI,MADISON,WI 53792	US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	BUSH, RK (corresponding author), UNIV WISCONSIN,DEPT MED,ALLERGY SECT,600 HIGHLAND AVE,MADISON,WI 53792, USA.				NIAID NIH HHS [AI-00343] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; MAY CD, 1978, ALLERGY, V33, P166, DOI 10.1111/j.1398-9995.1978.tb01532.x; SACHS MI, 1981, J ALLERGY CLIN IMMUN, V67, P27, DOI 10.1016/0091-6749(81)90041-5; SHIBASAKI M, 1980, INT ARCH ALLER A IMM, V61, P441, DOI 10.1159/000232472; SPEER F, 1978, FOOD ALLERGY, P140; TATTRIE NH, 1973, CAN I FOOD SC TECH J, V6, P289, DOI 10.1016/S0315-5463(73)74041-4; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4; Yunginger J. W., 1980, MANUAL CLIN IMMUNOLO, P778	8	87	87	1	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					242	245		10.1016/0091-6749(85)90709-2	http://dx.doi.org/10.1016/0091-6749(85)90709-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE88	3894482	Green Published			2022-12-18	WOS:A1985APE8800021
J	MOLLER, DR; GALLAGHER, JS; BERNSTEIN, DI; WILCOX, TG; BURROUGHS, HE; BERNSTEIN, IL				MOLLER, DR; GALLAGHER, JS; BERNSTEIN, DI; WILCOX, TG; BURROUGHS, HE; BERNSTEIN, IL			DETECTION OF IGE-MEDIATED RESPIRATORY SENSITIZATION IN WORKERS EXPOSED TO HEXAHYDROPHTHALIC ANHYDRIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,MED CTR,DEPT INTERNAL MED,DIV IMMUNOL,231 BETHESDA AVE,ML 563,CINCINNATI,OH 45267; NIOSH,CTR DIS CONTROL,CINCINNATI,OH 45226	University System of Ohio; University of Cincinnati; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)								BERNSTEIN DI, 1982, J ALLERGY CLIN IMMUN, V69, P311, DOI 10.1016/S0091-6749(82)80009-2; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; BERNSTEIN IL, 1982, 11TH P INT C ALL CLI, P413; BERNSTEIN IL, 1978, CLIN IMMUNOCHEMISTRY, P86; GALLAGHER JS, 1983, J ALLERGY CLIN IMMUN, V71, P157, DOI 10.1016/0091-6749(83)90400-1; GRAMMER LC, 1983, J IMMUNOL METHODS, V58, P49, DOI 10.1016/0022-1759(83)90262-4; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HOWE W, 1983, J ALLERGY CLIN IMMUN, V71, P5, DOI 10.1016/0091-6749(83)90539-0; KERN RICHARD A., 1939, JOUR ALLERGY, V10, P164, DOI 10.1016/S0021-8707(39)90050-X; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1973, J IMMUNOL, V110, P414; ZEISS CR, 1980, INT ARCH ALLERGY APP, V61, P300; ZIMMERMANN EM, 1980, J ALLERGY CLIN IMMUN, V66, P386, DOI 10.1016/0091-6749(80)90118-9; 1982, 1982 AM C GOV IND HY	16	87	87	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	6					663	672		10.1016/0091-6749(85)90091-0	http://dx.doi.org/10.1016/0091-6749(85)90091-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ALA84	4008795				2022-12-18	WOS:A1985ALA8400006
J	GREENBERGER, PA; PATTERSON, R; RADIN, RC				GREENBERGER, PA; PATTERSON, R; RADIN, RC			2 PRETREATMENT REGIMENS FOR HIGH-RISK PATIENTS RECEIVING RADIOGRAPHIC CONTRAST-MEDIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COLEMAN WP, 1964, SOUTHERN MED J, V57, P1401, DOI 10.1097/00007611-196412000-00004; DAVIES P, 1975, BMJ-BRIT MED J, V2, P434, DOI 10.1136/bmj.2.5968.434; DIXON GD, 1982, JAMA-J AM MED ASSOC, V247, P2485; FISCHER HW, 1972, RADIOLOGY, V103, P497, DOI 10.1148/103.3.497; GREENBERGER PA, 1981, J ALLERGY CLIN IMMUN, V67, P185, DOI 10.1016/0091-6749(81)90059-2; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; SAAVEDRADELGADO AMP, 1980, J ALLERGY CLIN IMMUN, V66, P464, DOI 10.1016/0091-6749(80)90007-X; SCHATZ M, 1975, J ALLERGY CLIN IMMUN, V55, P358, DOI 10.1016/0091-6749(75)90007-X; SHEHADI WH, 1982, RADIOLOGY, V143, P11, DOI 10.1148/radiology.143.1.7063711; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; SMALL P, 1982, CLIN ALLERGY, V12, P289, DOI 10.1111/j.1365-2222.1982.tb02530.x; TURNER E, 1982, RADIOLOGY, V143, P327, DOI 10.1148/radiology.143.2.7071333; WEINER N, 1980, PHARM BASIS THERAPEU, P157; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832, DOI 10.2214/ajr.119.4.832; WITTEN DM, 1975, JAMA-J AM MED ASSOC, V231, P974; WOLFROMM R, 1966, J RADIOL ELEC MED N, V47, P346; ZWEIMAN B, 1975, ANN INTERN MED, V83, P158	17	87	90	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					540	543		10.1016/0091-6749(84)90391-9	http://dx.doi.org/10.1016/0091-6749(84)90391-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN620	6491099				2022-12-18	WOS:A1984TN62000013
J	SOLOMON, WR; BURGE, HA; MUILENBERG, ML				SOLOMON, WR; BURGE, HA; MUILENBERG, ML			ALLERGEN CARRIAGE BY ATMOSPHERIC AEROSOL .1. RAGWEED POLLEN DETERMINANTS IN SMALLER MICRONIC FRACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, DIV ALLERGY, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NIAID NIH HHS [AI-10181] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSEN AA, 1958, J BACTERIOL, V76, P471, DOI 10.1128/JB.76.5.471-484.1958; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; DAVIES RR, 1973, CLIN ALLERGY, V3, P477, DOI 10.1111/j.1365-2222.1973.tb01332.x; GOODWIN JE, 1957, FED PROC, V16, P628; Gregory P.H., 1973, MICROBIOLOGY ATMOSPH, V2nd; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; METZGER WJ, 1981, CLIN ALLERGY, V11, P523, DOI 10.1111/j.1365-2222.1981.tb02170.x; MICHEL FB, 1977, AM REV RESPIR DIS, V115, P609; NORMAN PS, 1969, J ALLERGY, V44, P129, DOI 10.1016/0021-8707(69)90137-3; SCHLICHTING HE, 1974, J ALLERGY CLIN IMMUN, V53, P185, DOI 10.1016/0091-6749(74)90006-2; SHAFIEE A, 1973, J PHARM SCI, V62, P1654, DOI 10.1002/jps.2600621015; Sheldon J. M., 1967, MANUAL CLIN ALLERGY; SOLOMON WR, 1969, J ALLERGY, V43, P181; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006	16	87	88	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	5					443	447		10.1016/0091-6749(83)90579-1	http://dx.doi.org/10.1016/0091-6749(83)90579-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RR916	6195205	Bronze			2022-12-18	WOS:A1983RR91600003
J	SZCZEKLIK, A; GRYGLEWSKI, RJ; CZERNIAWSKAMYSIK, G; ZMUDA, A				SZCZEKLIK, A; GRYGLEWSKI, RJ; CZERNIAWSKAMYSIK, G; ZMUDA, A			ASPIRIN-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									COPERNICUS SCH MED,DEPT PHARMACOL,PL-31066 KRAKOW,POLAND; COPERNICUS SCH MED,DEPT ALLERGY & CLIN IMMUNOL,PL-31066 KRAKOW,POLAND	Jagiellonian University; Collegium Medicum Jagiellonian University; Jagiellonian University; Collegium Medicum Jagiellonian University								ALABASTER VA, 1970, BRIT J PHARMACOL CHE, V40, P582; COLLIER HOJ, 1974, PROSTAGLANDINS, V7, P361, DOI 10.1016/0090-6980(74)90100-2; FARR RS, 1970, J ALLERGY, V45, P321, DOI 10.1016/0021-8707(70)90040-7; FLOWER R, 1972, NATURE-NEW BIOL, V238, P104, DOI 10.1038/newbio238104a0; FLOWER RJ, 1974, PHARMACOL RES COMMUN, V26, P33; GILMORE N, 1968, NATURE, V218, P1135, DOI 10.1038/2181135a0; GREEN K, 1974, LANCET, V2, P1419; GREEN K, 1964, J LIPID RES, V5, P117; GRODZINSKA L, 1975, J PHARM PHARMACOL, V27, P88, DOI 10.1111/j.2042-7158.1975.tb09414.x; GRYGLEWSKI RJ, 1975, ANN INTERN MED, V82, P286, DOI 10.7326/0003-4819-82-2-286; GRYLEWSKY RJ, 1974, PROSTAGLANDIN SYNTHE, P33; HO PPK, 1974, PROSTAGLANDINS, V6, P107, DOI 10.1016/0090-6980(74)90022-7; LEIST ER, 1974, NEW ENGL J MED, V291, P710, DOI 10.1056/NEJM197410032911406; LICHTENSTEIN L M, 1973, P91; MALTA E, 1975, EUR J PHARMACOL, V30, P79, DOI 10.1016/0014-2999(75)90206-X; MATHE AA, 1973, BRIT MED J, V1, P193, DOI 10.1136/bmj.1.5847.193; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; MILLER J A JR, 1971, Federation Proceedings, V30, P564; NICKANDER R C, 1971, Federation Proceedings, V30, P563; OREHEK J, 1973, NATURE-NEW BIOL, V245, P84, DOI 10.1038/newbio245084a0; PIPER PJ, 1974, POL J PHARMACOL PHAR, V26, P61; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SAMTER M, 1973, HOSP PRACT, V8, P58; SMITH A P, 1973, P267; STONER J, 1973, P NATL ACAD SCI USA, V70, P3830, DOI 10.1073/pnas.70.12.3830; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; SZCZEKLIK A, 1974, 9 EUR C ALL CLIN IMM, P34; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANESLOW NA, 1967, ANN INTERN MED, V66, P568; WALKER JL, 1973, ADV BIOSCI, V9, P235	30	87	87	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					10	18		10.1016/0091-6749(76)90102-0	http://dx.doi.org/10.1016/0091-6749(76)90102-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX742	820733	Bronze			2022-12-18	WOS:A1976BX74200002
J	Brunner, PM; Pavel, AB; Khattri, S; Leonard, A; Malik, K; Rose, S; On, SJ; Vekaria, AS; Traidl-Hoffmann, C; Singer, GK; Baum, D; Gilleaudeau, P; Sullivan-Whalen, M; Fuentes-Duculan, J; Li, X; Zheng, XZ; Estrada, Y; Garcet, S; Wen, HC; Gonzalez, J; Coats, I; Cueto, I; Neumann, AU; Lebwohl, MG; Krueger, JG; Guttman-Yassky, E				Brunner, Patrick M.; Pavel, Ana B.; Khattri, Saakshi; Leonard, Alexandra; Malik, Kunal; Rose, Sharon; On, Shelbi Jim; Vekaria, Anjali S.; Traidl-Hoffmann, Claudia; Singer, Giselle K.; Baum, Danielle; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Fuentes-Duculan, Judilyn; Li, Xuan; Zheng, Xiuzhong; Estrada, Yeriel; Garcet, Sandra; Wen, Huei-Chi; Gonzalez, Juana; Coats, Israel; Cueto, Inna; Neumann, Avidan U.; Lebwohl, Mark G.; Krueger, James G.; Guttman-Yassky, Emma			Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; moderate-to-severe patients; IL-22; fezakinumab; precision medicine; immune; cytokines; treatment	GENOME-WIDE ASSOCIATION; SKIN; PSORIASIS; IMMUNE; INFLAMMATION; CELLS; BIOMARKERS; CYTOKINES; BARRIER; IL-17	Background: IL-22 is potentially a pathogenic cytokine in patients with atopic dermatitis (AD), but the molecular effects of IL-22 antagonism have not been defined in human subjects. Objective: We sought to evaluate the cellular and molecular effects of IL-22 blockade in tissues from patients with moderate-to-severe AD. Methods: We assessed lesional and nonlesional skin from 59 patients with moderate-to-severe AD treated with anti-IL-22 (fezakinumab) versus placebo (2: 1) using transcriptomic and immunohistochemistry analyses. Results: Greater reversal of the AD genomic profile was seen with fezakinumab versus placebo, namely 25.3% versus 10.5% at 4 weeks (P = 1.7 x 10(-5)) and 65.5% versus 13.9% at 12 weeks (P = 9.5 3 10(-19)), respectively. Because IL-22 blockade showed clinical efficacy only in patients with severe AD, we used baseline median IL-22 mRNA expression to stratify for high (n = 30) and low (n = 29) IL-22 expression groups. Much stronger mean transcriptomic improvements were seen with fezakinumab in the IL-22-high drug-treated group (82.8% and 139.4% at 4 and 12 weeks, respectively) than in the respective IL-22-high placebo-treated group (39.6% and 56.3% at 4 and 12 weeks) or the IL-22-low groups. Significant downregulations of multiple immune pathways, including T(H)1/CXCL9, T(H)2/CCL18/CCL22, T(H)17/CCL20/DEFB4A, and T(H)22/IL22/S100A's, were restricted to the IL-22-high drug group (P <.05). Consistently, tissue predictors of clinical response were mostly genes involved in T-cell and dendritic cell activation and differentiation. Conclusions: This is the first report showing a profound effect of IL-22 blockade on multiple inflammatory pathways in AD. These data, supported by robust effects in patients with high IL-22 baseline expression, suggest a central role for IL-22 in AD, indicating the need for a precision medicine approach for improving therapeutic outcomes in patients with AD.	[Brunner, Patrick M.; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Fuentes-Duculan, Judilyn; Li, Xuan; Zheng, Xiuzhong; Garcet, Sandra; Gonzalez, Juana; Coats, Israel; Cueto, Inna; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Investigat Dermatol, 1230 York Ave, New York, NY 10021 USA; [Pavel, Ana B.; Khattri, Saakshi; Leonard, Alexandra; Malik, Kunal; Rose, Sharon; On, Shelbi Jim; Vekaria, Anjali S.; Singer, Giselle K.; Baum, Danielle; Estrada, Yeriel; Wen, Huei-Chi; Lebwohl, Mark G.; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA; [Traidl-Hoffmann, Claudia; Neumann, Avidan U.] Tech Univ Munich, Klinikum Augsburg, Univ Ctr Hlth Sci, Inst Environm Med, Augsburg, Germany; [Traidl-Hoffmann, Claudia; Neumann, Avidan U.] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Augsburg, Germany; [Traidl-Hoffmann, Claudia] Christine Kuhne Ctr Allergy Res & Educ CK CARE, Davos, Switzerland	Rockefeller University; Icahn School of Medicine at Mount Sinai; Klinikum Augsburg; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	Emma.Guttman@mountsinai.org	Wen, Huei-Chi/ABD-7417-2021	Brunner, Patrick/0000-0002-3488-3345; Garcet, Sandra/0000-0002-4465-8547; , Ana Brandusa/0000-0002-8155-8553	National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [1UM1AR063917]; National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program [UL1 TR0001866]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [UM1AR063917] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) grant no. 1UM1AR063917. P.M.B. was supported in part by grant no. UL1 TR0001866 from the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program. Fezakinumab was provided by Pfizer (New York, NY).	Aujla SJ, 2009, J MOL MED, V87, P451, DOI 10.1007/s00109-009-0448-1; Baurecht H, 2015, AM J HUM GENET, V96, P104, DOI 10.1016/j.ajhg.2014.12.004; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bieber T, 2012, ALLERGY, V67, P1475, DOI 10.1111/all.12049; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Bruggen MC, 2015, J INVEST DERMATOL, V135, P999, DOI 10.1038/jid.2014.489; Bruhn S, 2012, ALLERGY, V67, P33, DOI 10.1111/j.1398-9995.2011.02707.x; Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040; Brunner PM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09207-z; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Brunner PM, 2017, J INVEST DERMATOL, V137, P18, DOI 10.1016/j.jid.2016.08.022; Brunner PM, 2016, J ALLERGY CLIN IMMUN, V138, P169, DOI 10.1016/j.jaci.2015.12.1323; Canonica GW, 2018, CURR OPIN ALLERGY CL, V18, P51, DOI 10.1097/ACI.0000000000000416; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Chung KF, 2018, CURR OPIN PULM MED, V24, P4, DOI 10.1097/MCP.0000000000000434; Damsky W, 2017, J AM ACAD DERMATOL, V76, P736, DOI 10.1016/j.jaad.2016.12.005; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Elias PM, 2014, BBA-MOL CELL BIOL L, V1841, P323, DOI 10.1016/j.bbalip.2013.10.001; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Ewald DA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0133-x; Eyerich K, 2017, EUR J IMMUNOL, V47, P607, DOI 10.1002/eji.201646723; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Flohr C, 2014, ALLERGY, V69, P3, DOI 10.1111/all.12270; Ghosh D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144316; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Golden JB, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0738-z; Gros E, 2009, J ALLERGY CLIN IMMUN, V124, P753, DOI 10.1016/j.jaci.2009.07.004; Guttman-Yassky E, 2018, J AM ACAD DERMATOL, V78, P872, DOI 10.1016/j.jaad.2018.01.016; Guttman-Yassky E, 2017, CURR OPIN IMMUNOL, V48, P68, DOI 10.1016/j.coi.2017.08.008; Halawi A, 2014, J EUR ACAD DERMATOL, V28, P405, DOI 10.1111/jdv.12237; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hawkes JE, 2017, J ALLERGY CLIN IMMUN, V140, P645, DOI 10.1016/j.jaci.2017.07.004; Ito T, 2012, ALLERGOL INT, V61, P35, DOI 10.2332/allergolint.11-RAI-0376; Jones BC, 2008, STRUCTURE, V16, P1333, DOI 10.1016/j.str.2008.06.005; Kabashima K, 2013, J DERMATOL SCI, V70, P3, DOI 10.1016/j.jdermsci.2013.02.001; Kaufman BP, 2018, EXP DERMATOL, V27, P340, DOI 10.1111/exd.13514; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kim J, 2015, DERMATOL CLIN, V33, P13, DOI 10.1016/j.det.2014.09.002; Krueger JG, 2018, EXP DERMATOL, V27, P115, DOI 10.1111/exd.13467; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Li N, 2014, J IMMUNOL, V193, P5140, DOI 10.4049/jimmunol.1302574; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Lou HF, 2017, J IMMUNOL, V198, P2543, DOI 10.4049/jimmunol.1600126; Luo YC, 2014, P NATL ACAD SCI USA, V111, P15178, DOI 10.1073/pnas.1416714111; McAleer JP, 2014, IMMUNOL REV, V260, P129, DOI 10.1111/imr.12183; Moisan J, 2007, J EXP MED, V204, P2825, DOI 10.1084/jem.20070994; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Novak N, 2004, CURR ALLERGY ASTHM R, V4, P263, DOI 10.1007/s11882-004-0069-2; Panzer-Grumayer R, 2017, ONCOTARGET, V8, P96466, DOI 10.18632/oncotarget.22098; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Pennino D, 2010, J IMMUNOL, V184, P4880, DOI 10.4049/jimmunol.0901767; Richmond JM, 2017, J INVEST DERMATOL, V137, P350, DOI 10.1016/j.jid.2016.09.016; Russell L, 2010, CYTOKINE, V51, P217, DOI 10.1016/j.cyto.2010.03.006; Rutz S, 2014, NAT REV IMMUNOL, V14, P783, DOI 10.1038/nri3766; Sabat R, 2014, NAT REV DRUG DISCOV, V13, P21, DOI 10.1038/nrd4176; Sands BE, 2017, GASTROENTEROLOGY, V153, P77, DOI 10.1053/j.gastro.2017.03.049; Silverberg JI, 2017, DERMATOL CLIN, V35, P283, DOI 10.1016/j.det.2017.02.002; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Sonnenberg GF, 2011, NAT IMMUNOL, V12, P383, DOI 10.1038/ni.2025; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V136, P1277, DOI 10.1016/j.jaci.2015.06.032; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Swindell WR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079253; Tamari M, 2014, J DERMATOL, V41, P213, DOI 10.1111/1346-8138.12321; Thijs JL, 2017, J ALLERGY CLIN IMMUN, V140, P730, DOI 10.1016/j.jaci.2017.03.023; Thijs JL, 2017, IMMUNOL ALLERGY CLIN, V37, P51, DOI 10.1016/j.iac.2016.08.008; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Tonini A, 2018, EXPERT OPIN BIOL TH, V18, P135, DOI 10.1080/14712598.2018.1398729; Ungar B, 2017, J INVEST DERMATOL, V137, P603, DOI 10.1016/j.jid.2016.09.037; van Laarhoven AIM, 2015, J INVEST DERMATOL, V135, P1234, DOI 10.1038/jid.2014.522; Wang J, 2017, CLIN EXP ALLERGY, V47, P1456, DOI 10.1111/cea.12979; Wang YM, 2012, J INVEST DERMATOL, V132, P2067, DOI 10.1038/jid.2012.112; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; Zhang J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/450386; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505	84	86	87	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					142	154		10.1016/j.jaci.2018.07.028	http://dx.doi.org/10.1016/j.jaci.2018.07.028			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30121291	Bronze			2022-12-18	WOS:000454918300021
J	Leiding, JW; Okada, S; Hagin, D; Abinun, M; Shcherbina, A; Balashov, DN; Kim, VHD; Ovadia, A; Guthery, SL; Pulsipher, M; Lilic, D; Devlin, LA; Christie, S; Depner, M; Fuchs, S; van Royen-Kerkhof, A; Lindemans, C; Petrovic, A; Sullivan, KE; Bunin, N; Kilic, SS; Arpaci, F; de la Calle-Martin, O; Martinez-Martinez, L; Aldave, JC; Kobayashi, M; Ohkawa, T; Imai, K; Iguchi, A; Roifman, CM; Gennery, AR; Slatter, M; Ochs, HD; Morio, T; Torgerson, TR				Leiding, Jennifer W.; Okada, Satoshi; Hagin, David; Abinun, Mario; Shcherbina, Anna; Balashov, Dmitry N.; Kim, Vy H. D.; Ovadia, Adi; Guthery, Stephen L.; Pulsipher, Michael; Lilic, Desa; Devlin, Lisa A.; Christie, Sharon; Depner, Mark; Fuchs, Sebastian; van Royen-Kerkhof, Annet; Lindemans, Caroline; Petrovic, Aleksandra; Sullivan, Kathleen E.; Bunin, Nancy; Kilic, Sara Sebnem; Arpaci, Fikret; de la Calle-Martin, Oscar; Martinez-Martinez, Laura; Aldave, Juan Carlos; Kobayashi, Masao; Ohkawa, Teppei; Imai, Kohsuke; Iguchi, Akihiro; Roifman, Chaim M.; Gennery, Andrew R.; Slatter, Mary; Ochs, Hans D.; Morio, Tomohiro; Torgerson, Troy R.		Inborn Errors Working Party; European Soc Blood Marrow; Primary Immune Deficiency	Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hematopoietic stem cell transplantation; chronic mucocutaneous candidiasis; signal transducer and activator of transcription; Janus kinase; gain of function; graft-versus-host disease; graft rejection; hemophagocytic lymphohistiocytosis	CHRONIC MUCOCUTANEOUS CANDIDIASIS; BONE-MARROW-TRANSPLANTATION; FUNCTION STAT1 MUTATIONS; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; COMBINED IMMUNODEFICIENCY; CLINICAL PHENOTYPE; DEFICIENCY; RUXOLITINIB; RESPONSES; UNDERLIE	Background: Gain-of-function (GOF) mutations in signal transducer and activator of transcription 1 (STAT1) cause susceptibility to a range of infections, autoimmunity, immune dysregulation, and combined immunodeficiency. Disease manifestations can be mild or severe and life-threatening. Hematopoietic stem cell transplantation (HSCT) has been used in some patients with more severe symptoms to treat and cure the disorder. However, the outcome of HSCT for this disorder is not well established. Objective: We sought to aggregate the worldwide experience of HSCT in patients with GOF-STAT1 mutations and to assess outcomes, including donor engraftment, overall survival, graft-versus-host disease, and transplant-related complications. Methods: Data were collected from an international cohort of 15 patients with GOF-STAT1 mutations who had undergone HSCT-using a variety of conditioning regimens and donor sources. Retrospective data collection allowed the outcome of transplantation to be assessed. In vitro functional testing was performed to confirm that each of the identified STAT1 variants was in fact a GOF mutation. Results: Primary donor engraftment in this cohort of 15 patients with GOF-STAT1 mutations was 74%, and overall survival was only 40%. Secondary graft failure was common (50%), and posttransplantation event-free survival was poor (10% by 100 days). Asubset of patients had hemophagocytic lymphohistiocytosis before transplant, contributing to their poor outcomes. Conclusion: Our data indicate that HSCT for patients with GOF-STAT1 mutations is curative but has significant risk of secondary graft failure and death.	[Leiding, Jennifer W.] Univ South Florida Johns Hopkins, All Childrens Hosp, Dept Pediat, Div Allergy & Immunol, St Petersburg, FL USA; [Okada, Satoshi; Kobayashi, Masao] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pediat, Hiroshima, Japan; [Hagin, David; Petrovic, Aleksandra; Ochs, Hans D.; Torgerson, Troy R.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Hagin, David; Petrovic, Aleksandra; Ochs, Hans D.; Torgerson, Troy R.] Seattle Childrens Res Inst, 1900 9th Ave,JMB 7, Seattle, WA 98101 USA; [Abinun, Mario; Gennery, Andrew R.; Slatter, Mary] Great North Childrens Hosp, RVI, Newcastle Upon Tyne, Tyne & Wear, England; [Abinun, Mario; Lilic, Desa; Gennery, Andrew R.; Slatter, Mary] Newcastle Univ, ICM, Primary Immunodeficiency Grp, Newcastle Upon Tyne, Tyne & Wear, England; [Shcherbina, Anna; Balashov, Dmitry N.] Fed Res & Clin Ctr Pediat Hematol Oncol & Immunol, Moscow, Russia; [Kim, Vy H. D.; Ovadia, Adi; Roifman, Chaim M.] Hosp Sick Children, Canadian Ctr Primary Immunodeficiency, Toronto, ON, Canada; [Guthery, Stephen L.] Univ Utah, Dept Pediat, Div Pediat Gastroenterol Hepatol & Nutr, Salt Lake City, UT USA; [Pulsipher, Michael] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA USA; [Devlin, Lisa A.] Royal Hosp, Reg Immunol Serv, Belfast, Antrim, North Ireland; [Christie, Sharon] Royal Hosp, Dept Pediat, Belfast, Antrim, North Ireland; [Depner, Mark; Fuchs, Sebastian] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Depner, Mark; Fuchs, Sebastian] Univ Freiburg, Freiburg, Germany; [van Royen-Kerkhof, Annet; Lindemans, Caroline] Univ Med Ctr Utrecht, Pediat Blood & Marrow Transplantat Program, Utrecht, Netherlands; [Petrovic, Aleksandra] All Childrens Hosp, Johns Hopkins Med, Blood & Bone Marrow Transplant Program, St Petersburg, FL USA; [Sullivan, Kathleen E.] Univ Penn, Dept Pediat, Perelman Sch Med, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Bunin, Nancy] Univ Penn, Dept Pediat, Perelman Sch Med, Div Oncol, Philadelphia, PA 19104 USA; [Bunin, Nancy] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Kilic, Sara Sebnem] Uludag Univ, Med Fac, Dept Pediat, Div Pediat Immunol, Gorukle, Turkey; [Arpaci, Fikret] GATA Fac, Bone Marrow Transplant Ctr, Ankara, Turkey; [de la Calle-Martin, Oscar; Martinez-Martinez, Laura] Hosp Santa Creu & Sant Pau, Dept Immunol, Barcelona, Spain; [Aldave, Juan Carlos] Hosp Rebagliati, Allergy & Immunol, Lima, Peru; [Ohkawa, Teppei; Imai, Kohsuke; Morio, Tomohiro] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Pediat & Dev Biol, Tokyo, Japan; [Iguchi, Akihiro] Hokkaido Univ, Grad Sch Med, Dept Pediat, Sapporo, Hokkaido, Japan	Hiroshima University; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Newcastle University - UK; Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology & Immunology; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Utah System of Higher Education; University of Utah; Children's Hospital Los Angeles; University of Southern California; University of Freiburg; University of Freiburg; Utrecht University; Utrecht University Medical Center; Johns Hopkins University; Johns Hopkins Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Uludag University; Hospital of Santa Creu i Sant Pau; Seguro Social de Salud del Peru; Tokyo Medical & Dental University (TMDU); Hokkaido University	Torgerson, TR (corresponding author), Seattle Childrens Res Inst, 1900 9th Ave,JMB 7, Seattle, WA 98101 USA.; Morio, T (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, TMDU Med Hosp, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	tmorio.ped@tmd.ac.jp; troy.torgerson@seattlechildrens.org	Kilic, Sara Sebnem/AAH-1658-2021; Balashov, Dmitry/AAW-8132-2020; Imai, Kohsuke/Q-2602-2015; Okada, Satoshi/B-8901-2011; Hagin, David/GRS-3442-2022; de la Calle-Martin, Oscar/Q-3353-2016	Imai, Kohsuke/0000-0003-2132-8403; Okada, Satoshi/0000-0002-4622-5657; de la Calle-Martin, Oscar/0000-0001-9717-053X; kilic, sara sebnem/0000-0001-8571-2581; Morio, Tomohiro/0000-0002-9259-1025; Aldave, Juan/0000-0003-3548-0385	National Institutes of Health (NIH) [R13 AI094943, R01DK091374]; NIH [U54 AI082973]; Japan Society for the Promotion of Science [16H05355, 25713039, 26293244]; Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development (AMED); Jeffrey Modell Foundation; ReumaFonds [LLP-10] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI082973, R13AI094943] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Jeffrey Modell Foundation; ReumaFonds; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Funding from the following grants contributed to this work: National Institutes of Health (NIH) grants R13 AI094943 and R01DK091374 and NIH grant U54 AI082973, Grants in Aid for Scientific Research from the Japan Society for the Promotion of Science (16H05355, 25713039, and 26293244), and the Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development (AMED). The authors were also provided support from the Jeffrey Modell Foundation.	Baris S, 2016, J CLIN IMMUNOL, V36, P641, DOI 10.1007/s10875-016-0312-3; Boisson-Dupuis S, 2012, CURR OPIN IMMUNOL, V24, P364, DOI 10.1016/j.coi.2012.04.011; Aldave JC, 2013, J CLIN IMMUNOL, V33, P1273, DOI 10.1007/s10875-013-9947-5; Das R, 2016, BLOOD, V127, P1666, DOI 10.1182/blood-2015-12-684399; DEEG HJ, 1986, TRANSPLANTATION, V41, P583, DOI 10.1097/00007890-198605000-00006; Depner M, 2016, J CLIN IMMUNOL, V36, P73, DOI 10.1007/s10875-015-0214-9; Faitelson YBA, 2014, LYMPHOSIGN J, V1, P1; Grunebaum E, 2016, J ALLERGY CLIN IMMUN, V138, P612, DOI 10.1016/j.jaci.2016.02.009; Higgins E, 2015, J ALLERGY CLIN IMMUN, V135, P551, DOI 10.1016/j.jaci.2014.12.1867; Hoh MC, 1996, BONE MARROW TRANSPL, V18, P797; Hu H, 2014, NAT BIOTECHNOL, V32, P663, DOI 10.1038/nbt.2895; Jordan M, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.LBA-3.LBA-3; Kataoka S, 2016, J ALLERGY CLIN IMMUN, V137, P619, DOI 10.1016/j.jaci.2015.06.028; Kilic SS, 2015, J CLIN IMMUNOL, V35, P80, DOI 10.1007/s10875-014-0111-7; Kong XF, 2010, BLOOD, V116, P5895, DOI 10.1182/blood-2010-04-280586; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Mizoguchi Y, 2014, J LEUKOCYTE BIOL, V95, P667, DOI 10.1189/jlb.0513250; Mossner R, 2016, CLIN INFECT DIS, V62, DOI 10.1093/cid/ciw020; Ouachee-Chardin M, 2006, PEDIATRICS, V117, pE743, DOI 10.1542/peds.2005-1789; Rao A, 2007, BLOOD, V109, P383, DOI 10.1182/blood-2006-05-025072; Roesler J, 2004, J PEDIATR-US, V145, P806, DOI 10.1016/j.jpeds.2004.08.021; Romberg N, 2013, J ALLERGY CLIN IMMUN, V131, P1691, DOI 10.1016/j.jaci.2013.01.004; Sampaio EP, 2013, J ALLERGY CLIN IMMUN, V131, P1624, DOI 10.1016/j.jaci.2013.01.052; Sharfe N, 2014, J ALLERGY CLIN IMMUN, V133, P807, DOI 10.1016/j.jaci.2013.09.032; Soltesz B, 2013, J MED GENET, V50, P567, DOI 10.1136/jmedgenet-2013-101570; Tabellini G, 2017, J ALLERGY CLIN IMMUN; Tang YM, 2008, BRIT J HAEMATOL, V143, P84, DOI 10.1111/j.1365-2141.2008.07298.x; Toubiana J, 2016, BLOOD, V127, P3154, DOI 10.1182/blood-2015-11-679902; Uzel G, 2013, J ALLERGY CLIN IMMUN, V131, P1611, DOI 10.1016/j.jaci.2012.11.054; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; Vargas-Hernandez A, 2015, J CLIN IMMUNOL, V35, pS16, DOI 10.1007/s10875-015-0199-4; Weinacht KG, 2017, J ALLERGY CLIN IMMUN, V139, P1629, DOI 10.1016/j.jaci.2016.11.022; Wildbaum G, 2013, J ALLERGY CLIN IMMUN, V132, P761, DOI 10.1016/j.jaci.2013.04.018; Yang JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023525	34	86	88	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					704	+		10.1016/j.jaci.2017.03.049	http://dx.doi.org/10.1016/j.jaci.2017.03.049			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28601685	Bronze, Green Accepted			2022-12-18	WOS:000424410800027
J	Mehr, S; Frith, K; Barnes, EH; Campbell, DE				Mehr, Sam; Frith, Katie; Barnes, Elizabeth H.; Campbell, Dianne E.		FPIES Study Grp	Food protein-induced enterocolitis syndrome in Australia: A population-based study, 2012-2014	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food protein-induced enterocolitis syndrome; infants; epidemiology; incidence; allergy	UNIT ANNUAL-REPORT; CLINICAL-FEATURES; SYNDROME FPIES; EXPERIENCE; MANAGEMENT; FISH	Background: Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE-mediated gastrointestinal allergic disorder. Large population-based FPIES studies are lacking. Objective: We sought to determine the incidence and clinical characteristics of FPIES in Australian infants. Methods: An Australia-wide survey (2012-2014) was undertaken through the Australian Paediatric Surveillance Unit, with monthly notification of new cases of acute FPIES in infants aged less than 24 months by 1400 participating pediatricians. Results: Two hundred thirty infants with FPIES were identified. The incidence of FPIES in Australian infants (<24 months) was 15.4/100,000/y. Median age of first episode, diagnosis, and notification were 5, 7, and 10 months, respectively. There was no sex predilection. Seven percent of infants had siblings with a history of FPIES, and 5% reacted during exclusive breast-feeding. Sixty-eight had a single food trigger (20% had 2 and 12% had >= 3 food triggers). The most common FPIES triggers were rice (45%), cow's milk (33%), and egg (12%). Fifty-one percent of infants reacted on their first known exposure. Infants with FPIES to multiple versus single food groups were younger at the initial episode (4.6 vs 5.8 months [ mean], P = .001) and more frequently had FPIES to fruits, vegetables, or both (66% vs 21%, P <.0001). Infants exclusively breast-fed for more than 4 months had a trend toward lower rates of FPIES to multiple food groups (23% vs 36%, P = .06). Sixty-four percent of infants with FPIES to multiple foods, which included cow's milk, had coassociated FPIES to solid foods. Forty-two percent of infants with FPIES to fish reacted to other food groups. Conclusions: FPIES is not rare, with an estimated incidence of 15.4/100,000/y. Rice is the most common food trigger in Australia. Factors associated with FPIES to multiple foods included early-onset disease and FPIES to fruits, vegetables, or both.	[Mehr, Sam; Frith, Katie; Campbell, Dianne E.] Childrens Hosp Westmead, Dept Allergy & Immunol, Hawkesbury Rd, Westmead, NSW 2145, Australia; [Frith, Katie] Sydney Childrens Hosp, Dept Immunol & Infect Dis, Randwick, NSW, Australia; [Barnes, Elizabeth H.] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia; [Campbell, Dianne E.] Univ Sydney, Discipline Child & Adolescent Hlth, Sydney, NSW, Australia	University of Sydney; University of Sydney; University of Sydney	Campbell, DE (corresponding author), Childrens Hosp Westmead, Dept Allergy & Immunol, Hawkesbury Rd, Westmead, NSW 2145, Australia.; Campbell, DE (corresponding author), Univ Sydney, Hawkesbury Rd, Westmead, NSW 2145, Australia.	dianne.campbell1@health.nsw.gov	Allen, Katrina/I-4361-2018	Allen, Katrina/0000-0002-1921-4493; Zurynski, Yvonne/0000-0001-7744-8717; Campbell, Dianne/0000-0002-0907-6963; Mehr, Sam/0000-0003-2483-917X; Peake, Jane/0000-0001-9003-5861; Wainstein, Brynn/0000-0001-5704-650X; Tang, Mimi/0000-0002-3839-5293	Children's Hospital at Westmead Allergy and Immunology Research Fund; Nestle, Australia	Children's Hospital at Westmead Allergy and Immunology Research Fund; Nestle, Australia	Supported by grants from the Children's Hospital at Westmead Allergy and Immunology Research Fund and by Nestle, Australia. Funding from Nestle, Australia was specifically for the administration fees levied by the Australian Paediatric Surveillance Unit, and Nestle, Australia had no involvement in the study design, conduct, or analysis or preparation of the manuscript.	Australian Institute of Health and Welfare, 2011, AUSTR I HLTH WELF AU; Caubet JC, 2014, J ALLERGY CLIN IMMUN, V134, P382, DOI 10.1016/j.jaci.2014.04.008; Deverell M, 2014, COMMUN DIS INTELL, V38, pE343; Deverell M, 2013, COMMUN DIS INTELL, V37, pE394; Deverell M, 2012, COMMUN DIS INTELL, V36, pE263; Gonzalez-Delgado P, 2016, PEDIAT ALLERG IMM-UK, V27, P269, DOI 10.1111/pai.12529; He SW, 2009, J PAEDIATR CHILD H, V45, P498, DOI 10.1111/j.1440-1754.2009.01549.x; Health and Social Care Information Centre, 2012, INF FEED SURV 2010 S; Hsu P, 2013, J ALLERGY CLIN IMMUN, V131, P241, DOI 10.1016/j.jaci.2012.08.045; Hwang JB, 2009, ARCH DIS CHILD, V94, P425, DOI 10.1136/adc.2008.143289; Katz Y, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Katz Y, 2011, J ALLERGY CLIN IMMUN, V127, P647, DOI 10.1016/j.jaci.2010.12.1105; Leonard SA, 2015, PEDIATR CLIN N AM, V62, P1463, DOI 10.1016/j.pcl.2015.07.011; Ludman S, 2014, ANN ALLERG ASTHMA IM, V113, P290, DOI 10.1016/j.anai.2014.06.020; Mehr SS, 2009, ARCH DIS CHILD, V94, P220, DOI 10.1136/adc.2008.145144; Mehr S, 2014, CURR OPIN ALLERGY CL, V14, P208, DOI 10.1097/ACI.0000000000000056; Mehr S, 2009, PEDIATRICS, V123, pe459, DOI 10.1542/peds.2008-2029; Monti G, 2011, J ALLERGY CLIN IMMUN, V127, P679, DOI 10.1016/j.jaci.2010.10.017; Nowak-Wegrzyn A, 2017, J ALLERGY CLIN IMMUN, V139, P1111, DOI 10.1016/j.jaci.2016.12.966; Sandin MDPI, 2014, J INVEST ALLERG CLIN, V24, P354; Rossen LM, 2016, CLIN PEDIATR, V55, P278, DOI 10.1177/0009922815591881; Ruffner MA, 2013, J ALLER CL IMM-PRACT, V1, P343, DOI 10.1016/j.jaip.2013.05.011; Sicherer SH, 1998, J PEDIATR-US, V133, P214, DOI 10.1016/S0022-3476(98)70222-7; Sopo SM, 2013, ALLERGOL IMMUNOPATH, V41, P346, DOI 10.1016/j.aller.2012.06.008; Sopo SM, 2012, CLIN EXP ALLERGY, V42, P1257, DOI 10.1111/j.1365-2222.2012.04027.x; Sopo SM, 2015, PEDIAT ALLERG IMM-UK, V26, P731, DOI 10.1111/pai.12461; Tan J, 2012, J ALLERGY CLIN IMMUN, V129, P873, DOI 10.1016/j.jaci.2011.12.1000	27	86	89	2	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1323	1330		10.1016/j.jaci.2017.03.027	http://dx.doi.org/10.1016/j.jaci.2017.03.027			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28427879	Bronze			2022-12-18	WOS:000414304300012
J	Azimi, E; Reddy, VB; Pereira, PJS; Talbot, S; Woolf, CJ; Lerner, EA				Azimi, Ehsan; Reddy, Vemuri B.; Seadi Pereira, Paula Juliana; Talbot, Sebastien; Woolf, Clifford J.; Lerner, Ethan A.			Substance P activates Mas-related G protein-coupled receptors to induce itch	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Substance P; Mas-related G protein-coupled receptors; dorsal root ganglion neurons; calcium imaging; receptor antagonist; knockout mice	CHRONIC URTICARIA; MRG RECEPTORS; APREPITANT; MOUSE; EXPRESSION; PRURITUS; NEURONS; FAMILY; GPCRS; PAIN	Background: Substance P (SP) is linked to itch and inflammation through activation of receptors on mast cells and sensory neurons. There is increasing evidence that SP functions through Mas-related G protein-coupled receptors (Mrgprs) in addition to its conventional receptor, neurokinin-1. Objective: Because Mrgprs mediate some aspects of inflammation that had been considered mediated by neurokinin-1 receptor (NK-1R), we sought to determine whether itch induced by SP can also be mediated by Mrgprs. Methods: Genetic and pharmacologic approaches were used to evaluate the contribution of Mrgprs to SP-induced scratching behavior and activation of cultured dorsal root ganglion neurons from mice. Results: SP-induced scratching behavior and activation of cultured dorsal root ganglion neurons was dependent on Mrgprs rather than NK-1R. Conclusion: We deduce that SP activates MrgprA1 on sensory neurons rather than NK-1R to induce itch.	[Azimi, Ehsan; Reddy, Vemuri B.; Seadi Pereira, Paula Juliana; Lerner, Ethan A.] Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Charlestown, MA USA; [Azimi, Ehsan; Reddy, Vemuri B.; Seadi Pereira, Paula Juliana; Lerner, Ethan A.] Harvard Med Sch, Charlestown, MA USA; [Talbot, Sebastien; Woolf, Clifford J.] Childrens Hosp Boston, FM Kirby Neurobiol Ctr, Boston, MA USA; [Seadi Pereira, Paula Juliana] Pontificia Univ Catolica Rio Grande do Sul, Programa Posgrad Biol Celular & Mol, Porto Alegre, RS, Brazil	Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Pontificia Universidade Catolica Do Rio Grande Do Sul	Lerner, EA (corresponding author), Harvard Med Sch, Cutaneous Biol Res Ctr, Massachusetts Gen Hosp, Dept Dermatol, Bldg 149,13th St, Charlestown, MA 02129 USA.	elerner@mgh.harvard.edu	Woolf, Clifford/A-9784-2010	Talbot, Sebastien/0000-0001-9932-7174	National Eczema Association; Canadian Institute of Health and Research; National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01AR057744, R21AR067399]; National Institute of Child Health [HD018655]; Human Development and National Institute of Neurological Disorders and Stroke [R37NS039518]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD090255] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR067399, R01AR057744] Funding Source: NIH RePORTER	National Eczema Association; Canadian Institute of Health and Research(Canadian Institutes of Health Research (CIHR)); National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institute of Child Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Human Development and National Institute of Neurological Disorders and Stroke; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	E.A. is the recipient of a grant from the National Eczema Association. S.T. holds postdoctoral fellowships from the Canadian Institute of Health and Research. Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases R01AR057744 and R21AR067399 (to E.A.L.) and the National Institute of Child Health (HD018655) and Human Development and National Institute of Neurological Disorders and Stroke (R37NS039518; to C.J.W.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Andoh T, 1998, J PHARMACOL EXP THER, V286, P1140; Azimi E, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89362; Bader M, 2014, PHARMACOL REV, V66, P1080, DOI 10.1124/pr.113.008136; Borici-Mazi R, 1999, ALLERGY, V54, P46, DOI 10.1034/j.1398-9995.1999.00726.x; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Dong XZ, 2001, CELL, V106, P619, DOI 10.1016/S0092-8674(01)00483-4; Duval A, 2009, NEW ENGL J MED, V361, P1415, DOI 10.1056/NEJMc0906670; Flegel C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128951; Fujisawa D, 2014, J ALLERGY CLIN IMMUN, V134, P622, DOI 10.1016/j.jaci.2014.05.004; Goswami SC, 2014, J PAIN, V15, P1338, DOI 10.1016/j.jpain.2014.09.010; LaMotte RH, 2014, NAT REV NEUROSCI, V15, P19, DOI 10.1038/nrn3641; Liu Q, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001925; Liu Q, 2009, CELL, V139, P1353, DOI 10.1016/j.cell.2009.11.034; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Mishra SK, 2011, EMBO J, V30, P582, DOI 10.1038/emboj.2010.325; O'Donoghue Michael, 2005, Dermatol Ther, V18, P333; Ohmura T, 2004, EUR J PHARMACOL, V491, P191, DOI 10.1016/j.ejphar.2004.03.047; Robas N, 2003, J BIOL CHEM, V278, P44400, DOI 10.1074/jbc.M302456200; Santini D, 2012, LANCET ONCOL, V13, P1020, DOI 10.1016/S1470-2045(12)70373-X; Shimada SG, 2008, PAIN, V139, P681, DOI 10.1016/j.pain.2008.08.002; Solinski HJ, 2014, PHARMACOL REV, V66, P570, DOI 10.1124/pr.113.008425; Stander S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010968; Tatemoto K, 2006, BIOCHEM BIOPH RES CO, V349, P1322, DOI 10.1016/j.bbrc.2006.08.177; Thurmond RL, 2015, HANDB EXP PHARMACOL, V226, P257, DOI 10.1007/978-3-662-44605-8_15; Trivedi M, 2010, ANN HEPATOL, V9, P177, DOI 10.1016/S1665-2681(19)31658-8; Wallengren J, 2014, ARCH DERMATOL RES, V306, P505, DOI 10.1007/s00403-014-1451-0; Wallengren J, 2012, ARCH DERMATOL, V148, P957, DOI 10.1001/archdermatol.2012.1018; Zhang L, 2005, MOL BRAIN RES, V133, P187, DOI 10.1016/j.molbrainres.2004.10.007	29	86	91	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					447	+		10.1016/j.jaci.2016.12.980	http://dx.doi.org/10.1016/j.jaci.2016.12.980			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28219706	Green Accepted, Bronze			2022-12-18	WOS:000406855500017
J	Nolte, H; Bernstein, DI; Nelson, HS; Kleine-Tebbe, J; Sussman, GL; Seitzberg, D; Rehm, D; Kaur, A; Li, ZL; Lu, SS				Nolte, Hendrik; Bernstein, David I.; Nelson, Harold S.; Kleine-Tebbe, Joerg; Sussman, Gordon L.; Seitzberg, Dorthe; Rehm, Dorte; Kaur, Amarjot; Li, Ziliang; Lu, Susan			Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen immunotherapy; allergic rhinoconjunctivitis; house dust mite; sublingual immunotherapy tablet; North America; adolescents	SEASONAL ALLERGIC RHINOCONJUNCTIVITIS; DOUBLE-BLIND; RESPIRATORY ALLERGY; RHINITIS; SAFETY; CHILDREN; PHARMACOTHERAPY; TOLERABILITY; INFLAMMATION; METAANALYSIS	Background: The house dust mite (HDM) sublingual immunotherapy (SLIT) tablet (MK-8237; Merck & Co, Kenilworth, NJ/ALK-Abello, Horsholm, Denmark) has demonstrated beneficial effects on allergic rhinoconjunctivitis and asthma outcomes in European trials. Objective: This is the first trial to assess the efficacy/safety of HDM SLIT-tablets in North American subjects with HDM-induced allergic rhinitis with or without conjunctivitis (AR/C). Methods: In this double-blind, multicenter trial (NCT01700192) 1482 subjects (aged >= 12 years) with HDM-induced AR/C with or without asthma were randomized to a daily SQ HDM SLIT-tablet (12 SQ-HDM dose) or placebo for up to approximately 52 weeks. A rhinitis daily symptom score (DSS; 4 nasal symptoms, maximum score 5 12) of 6 or greater, or 5 or greater with 1 symptom being severe, on 5 of 7 consecutive days before randomization was required. The primary end point was the average total combined rhinitis score, which was defined as the rhinitis DSS plus rhinitis daily medication score (DMS), during the last 8 treatment weeks. Results: Treatment with 12 SQ-HDM improved the total combined rhinitis score by 17% (95% CI, 10% to 25%) versus placebo. Improvements versus placebo in the secondary end points of average rhinitis DSS, rhinitis DMS, total combined rhinoconjunctivitis score, and visual analog scale-assessed AR/C symptoms were 16%, 18%, 17%, and 16%, respectively. All nominal P values were less than .001 versus placebo, except rhinitis DMS (P = 0.15). No treatment-related adverse events meeting the International Council on Harmonization definition of a serious adverse event were reported; 1 nonserious treatment-related systemic allergic reaction occurred (assessed as moderate intensity) at first administration under medical supervision and was treated with epinephrine. Conclusions: In the first North American trial of use of a SLIT-tablet for HDM allergy, 12 SQ-HDM was well tolerated and improved HDM-induced rhinitis symptoms in adults and adolescents.	[Nolte, Hendrik; Kaur, Amarjot; Li, Ziliang; Lu, Susan] Merck & Co Inc, Kenilworth, NJ USA; [Bernstein, David I.] Bernstein Clin Res Ctr, Cincinnati, OH USA; [Bernstein, David I.] Univ Cincinnati, Cincinnati, OH 45221 USA; [Nelson, Harold S.] Natl Jewish Hlth, Denver, CO USA; [Kleine-Tebbe, Joerg] Allergy & Asthma Ctr Westend, Berlin, Germany; [Sussman, Gordon L.] Univ Toronto, Toronto, ON, Canada; [Seitzberg, Dorthe; Rehm, Dorte] ALK Abello, Horsholm, Denmark	Merck & Company; University System of Ohio; University of Cincinnati; National Jewish Health; University of Toronto; ALK-Abello AS	Nolte, H (corresponding author), Merck Res Labs, RY34-A468,126 E Lincoln Ave,POB 2000, Rahway, NJ 07065 USA.	hendrik.nolte@merck.com			Merck & Co, Kenilworth, NJ	Merck & Co, Kenilworth, NJ	Supported by Merck & Co, Kenilworth, NJ.	[Anonymous], 2013, ALL PROD ADV COMM AP; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Bergmann KC, 2014, J ALLERGY CLIN IMMUN, V133, P1608, DOI 10.1016/j.jaci.2013.11.012; Blaiss M, 2011, J ALLERGY CLIN IMMUN, V127, P64, DOI 10.1016/j.jaci.2010.11.034; Bozek A, 2013, CLIN EXP ALLERGY, V43, P242, DOI 10.1111/cea.12039; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Bush RK, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Bush RK, 2011, J ALLERGY CLIN IMMUN, V127, P974, DOI 10.1016/j.jaci.2010.11.045; Calderon MA, 2013, J ALLERGY CLIN IMMUN, V132, P1322, DOI 10.1016/j.jaci.2013.09.004; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; COOK DL, 1962, PHI DELTA KAPPAN, V44, P116; Corzo JL, 2014, J INVEST ALLERG CLIN, V24, P154; Creticos PS, 2013, J ALLERGY CLIN IMMUN, V131, P1342, DOI 10.1016/j.jaci.2013.03.019; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Demoly P, 2016, J ALLERGY CLIN IMMUN, V137, P444, DOI 10.1016/j.jaci.2015.06.036; Devillier P, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-71; Durham SR, 2016, J ALLERGY CLIN IMMUN, V138, P1081, DOI 10.1016/j.jaci.2016.04.061; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Henmar H, 2016, INT ARCH ALLERGY IMM, V169, P23, DOI 10.1159/000444016; Maloney J, 2016, ANN ALLERG ASTHMA IM, V116, P59, DOI 10.1016/j.anai.2015.10.024; Maloney J, 2014, ANN ALLERG ASTHMA IM, V112, P146, DOI 10.1016/j.anai.2013.11.018; Matricardi PM, 2011, J ALLERGY CLIN IMMUN, V128, P791, DOI 10.1016/j.jaci.2011.03.049; Matsuoka T, 2013, ALLERGOL INT, V62, P403, DOI 10.2332/allergolint.13-RAI-0650; Mosbech H, 2014, J ALLERGY CLIN IMMUN, V134, P568, DOI 10.1016/j.jaci.2014.03.019; Nelson HS, 2014, EXPERT REV CLIN IMMU, V10, P1437, DOI 10.1586/1744666X.2014.963556; Nelson HS, 2014, CURR OPIN ALLERGY CL, V14, P542, DOI 10.1097/ACI.0000000000000104; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; Nolte H, 2015, J ALLERGY CLIN IMMUN, V135, P1494, DOI 10.1016/j.jaci.2014.12.1911; Nolte H, 2014, ANN ALLERG ASTHMA IM, V113, P93, DOI 10.1016/j.anai.2014.04.018; Nolte H, 2013, ANN ALLERG ASTHMA IM, V110, P450, DOI 10.1016/j.anai.2013.03.013; Passalacqua G, 2006, ALLERGY, V61, P849, DOI 10.1111/j.1398-9995.2006.01095.x; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Passalacqua G, 2013, J ALLERGY CLIN IMMUN, V132, P93, DOI 10.1016/j.jaci.2013.03.039; Pfaar Oliver, 2015, Curr Treat Options Allergy, V2, P1; Pichler CE, 1997, ALLERGY, V52, P274, DOI 10.1111/j.1398-9995.1997.tb00991.x; Riechelmann H, 2010, AM J RHINOL ALLERGY, V24, pE104, DOI 10.2500/ajra.2010.24.3508; Rodrigo GJ, 2011, CLIN EXP ALLERGY, V41, P160, DOI 10.1111/j.1365-2222.2010.03654.x; Scadding GK, 2000, CLIN OTOLARYNGOL, V25, P551, DOI 10.1046/j.1365-2273.2000.00417.x; Tonnel AB, 2004, ALLERGY, V59, P491, DOI 10.1111/j.1398-9995.2004.00456.x; Virchow JC, 2016, JAMA-J AM MED ASSOC, V315, P1715, DOI 10.1001/jama.2016.3964; Wang DH, 2013, LARYNGOSCOPE, V123, P1334, DOI 10.1002/lary.23935; Wilson AM, 2004, AM J MED, V116, P338, DOI 10.1016/j.amjmed.2003.10.030; Yukselen A, 2013, ASIAN PAC J ALLERGY, V31, P233, DOI 10.12932/AP0276.31.3.2013	43	86	86	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1631	1638		10.1016/j.jaci.2016.06.044	http://dx.doi.org/10.1016/j.jaci.2016.06.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27521719				2022-12-18	WOS:000390019300019
J	Somineni, HK; Zhang, X; Myers, JMB; Kovacic, MB; Ulm, A; Jurcak, N; Ryan, PH; Hershey, GKK; Ji, H				Somineni, Hari K.; Zhang, Xue; Myers, Jocelyn M. Biagini; Kovacic, Melinda Butsch; Ulm, Ashley; Jurcak, Noelle; Ryan, Patrick H.; Hershey, Gurjit K. Khurana; Ji, Hong			Ten-eleven translocation 1 (TET1) methylation is associated with childhood asthma and traffic-related air pollution	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DNA methylation; TET1; 5-hmC; nasal epithelial cells; cross-tissue marker; traffic-related air pollution; asthma	THYMIC STROMAL LYMPHOPOIETIN; DIESEL EXHAUST PARTICLES; DNA METHYLATION; EPITHELIAL-CELLS; PARTICULATE MATTER; ALLERGIC SENSITIZATION; GENE-EXPRESSION; LUNG-FUNCTION; BIRTH COHORT; T-CELLS	Background: Asthma is a complex disorder influenced by genetics and the environment. Recent findings have linked abnormal DNA methylation in T cells with asthma; however, the potential dysregulation of methylation in airway epithelial cells is unknown. Studies of mouse models of asthma have observed greater levels of 5-hydroxymethylcytosine (5-hmC) and ten-eleven translocation 1 (TET1) expression in lungs. TET proteins are known to catalyze methylation through modification of 5-methylcytosine to 5-hmC. Objective: We sought to examine the association of TET1 methylation with asthma and traffic-related air pollution (TRAP). Methods: TET1 methylation levels from DNA derived from nasal airway epithelial cells collected from 12 African American children with physician-diagnosed asthma and their nonasthmatic siblings were measured by using Illumina 450K arrays. Regions of interest were verified by means of locus-specific pyrosequencing in 35 sibling pairs and replicated in an independent population (n = 186). Exposure to TRAP in participants' early life and at current home addresses was estimated by using a land-use regression model. Methylation studies in saliva, PBMCs, and human bronchial epithelial cells were done to support our findings. Results: Loss of methylation at a single CpG site in the TET1 promoter (cg23602092) and increased global 5-hmC levels were significantly associated with asthma. In contrast, TRAP exposure at participants' current homes significantly increased methylation at the same site. Patterns were consistent across tissue sample types. 5-Aza-29-deoxycytidine and diesel exhaust particle exposure in human bronchial epithelial cells was associated with altered TET1 methylation and expression and global 5-hmC levels. Conclusions: Our findings suggest a possible role of TET1 methylation in asthmatic patients and response to TRAP.	[Somineni, Hari K.; Myers, Jocelyn M. Biagini; Kovacic, Melinda Butsch; Ulm, Ashley; Hershey, Gurjit K. Khurana; Ji, Hong] Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, 3333 Burnet Ave,MLC 7037, Cincinnati, OH 45229 USA; [Zhang, Xue] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA; [Kovacic, Melinda Butsch; Ryan, Patrick H.] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Jurcak, Noelle] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Kovacic, Melinda Butsch; Ryan, Patrick H.] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45221 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Johns Hopkins University; University System of Ohio; University of Cincinnati	Ji, H (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, 3333 Burnet Ave,MLC 7037, Cincinnati, OH 45229 USA.	Hong.Ji@cchmc.org	Ryan, Patrick/HDO-1133-2022	Ji, Hong/0000-0002-9558-0620; Biagini, Jocelyn/0000-0002-4378-6133	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [R21AI119236]; NIH/NIAID [R21AI101375]; NIH/National Institute of Environmental Health Sciences (NIEHS) [P30-ES006096]; NIH/NIEHS [ES016830-01A1, 2U19AI70235]; Center for Clinical and Translational Science and Training grant [UL1-RR026314-01]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001425] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR026314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070235, R21AI119236, R21AI101375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES016830, P30ES006096] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Center for Clinical and Translational Science and Training grant; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) grant R21AI119236 (to H.J.), NIH/NIAID grant R21AI101375 (to H.J.), NIH/National Institute of Environmental Health Sciences (NIEHS) grant P30-ES006096 (to H.J.), NIH/NIEHS ES016830-01A1 (to M.B.K.), and 2U19AI70235 (to G.K.K.H.). REDCap was hosted at Cincinnati Children's and supported by the Center for Clinical and Translational Science and Training grant UL1-RR026314-01 (NCRR/NIH).	[Anonymous], 2002, EPA600890057F NAT CT; [Anonymous], 2007, NIH PUBL, V08-5846; Baccarelli A, 2012, EPIGENOMICS-UK, V4, P91, DOI [10.2217/EPI.11.106, 10.2217/epi.11.106]; Barlow SE, 2007, PEDIATRICS, V120, pS164, DOI 10.1542/peds.2007-2329C; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bleck B, 2008, J CLIN IMMUNOL, V28, P147, DOI 10.1007/s10875-007-9149-0; Bleck B, 2010, J IMMUNOL, V185, P6636, DOI 10.4049/jimmunol.1000719; Bowatte G, 2015, ALLERGY, V70, P245, DOI 10.1111/all.12561; Braback L, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-17; Brand S, 2012, J ALLERGY CLIN IMMUN, V129, P1602, DOI 10.1016/j.jaci.2011.12.963; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Breton CV, 2012, ENVIRON HEALTH PERSP, V120, P1320, DOI 10.1289/ehp.1104439; Brunst KJ, 2013, J ALLERGY CLIN IMMUN, V131, P592, DOI 10.1016/j.jaci.2012.10.042; Cheng RYS, 2014, ENVIRON MOL MUTAGEN, V55, P244, DOI 10.1002/em.21851; Cimmino L, 2015, NAT IMMUNOL, V16, P653, DOI 10.1038/ni.3148; Clark NA, 2010, ENVIRON HEALTH PERSP, V118, P284, DOI 10.1289/ehp.0900916; Costa Y, 2013, NATURE, V495, P370, DOI 10.1038/nature11925; Esposito S, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-162; Fu A, 2012, CLIN EXP ALLERGY, V42, P1575, DOI 10.1111/j.1365-2222.2012.04055.x; Gasana J, 2012, ENVIRON RES, V117, P36, DOI 10.1016/j.envres.2012.05.001; Gehring U, 2002, EUR RESPIR J, V19, P690, DOI 10.1183/09031936.02.01182001; Gehring U, 2010, AM J RESP CRIT CARE, V181, P596, DOI 10.1164/rccm.200906-0858OC; Ghio AJ, 2012, CURR OPIN PULM MED, V18, P144, DOI 10.1097/MCP.0b013e32834f0e2a; Gruzieva O, 2013, EPIDEMIOLOGY, V24, P54, DOI 10.1097/EDE.0b013e318276c1ea; Guarnieri M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hartz AMS, 2008, FASEB J, V22, P2723, DOI 10.1096/fj.08-106997; Ho SM, 2010, J ALLERGY CLIN IMMUN, V126, P453, DOI 10.1016/j.jaci.2010.07.030; Holgate ST, 2011, IMMUNOL REV, V242, P205, DOI 10.1111/j.1600-065X.2011.01030.x; Huang H, 2013, P NATL ACAD SCI USA, V110, P11994, DOI 10.1073/pnas.1310656110; Huang Y, 2014, P NATL ACAD SCI USA, V111, P1361, DOI 10.1073/pnas.1322921111; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Iwanaga K, 2013, INHAL TOXICOL, V25, P653, DOI 10.3109/08958378.2013.827283; Jiang RW, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/s12989-014-0071-3; Jones B, 2006, EMBO J, V25, P2443, DOI 10.1038/sj.emboj.7601148; Kaas GA, 2013, NEURON, V79, P1086, DOI 10.1016/j.neuron.2013.08.032; Kabesch M, 2010, EUR RESPIR J, V36, P950, DOI 10.1183/09031936.00019310; Kovacic MB, 2012, PEDIAT ALLER IMM PUL, V25, P104, DOI 10.1089/ped.2011.0116; Krause K, 2012, CURR OPIN ALLERGY CL, V12, P477, DOI 10.1097/ACI.0b013e3283574d0c; Kreiner-Moller E, 2013, CLIN EXP ALLERGY, V43, P1236, DOI 10.1111/cea.12188; Kuhns K, 2015, FASEB J, V29; Kumar RK, 2009, DIS MODEL MECH, V2, P549, DOI 10.1242/dmm.001719; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X; London SJ, 2009, ANNU REV PUBL HEALTH, V30, P55, DOI 10.1146/annurev.publhealth.031308.100151; Maes T, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-7; Mariani CJ, 2014, CELL REP, V7, P1343, DOI 10.1016/j.celrep.2014.04.040; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Nakae S, 2007, J ALLERGY CLIN IMMUN, V120, P48, DOI 10.1016/j.jaci.2007.02.046; Nakano T, 2013, J ALLERGY CLIN IMMUN, V132, P1224, DOI 10.1016/j.jaci.2013.06.041; Pandya RJ, 2002, ENVIRON HEALTH PERSP, V110, P103, DOI 10.1289/ehp.02110s1103; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Putiri EL, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-6-r81; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Rincon M, 2012, INT J BIOL SCI, V8, P1281, DOI 10.7150/ijbs.4874; Rochman Y, 2008, CURR OPIN PHARMACOL, V8, P249, DOI 10.1016/j.coph.2008.03.002; Rudenko A, 2013, NEURON, V79, P1109, DOI 10.1016/j.neuron.2013.08.003; Runyon RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048796; Ryan PH, 2007, ENVIRON HEALTH PERSP, V115, P278, DOI 10.1289/ehp.9480; Ryan PH, 2009, AM J RESP CRIT CARE, V180, P1068, DOI 10.1164/rccm.200808-1307OC; Smargiassi A, 2012, J EXPO SCI ENV EPID, V22, P331, DOI 10.1038/jes.2012.26; Sohni A, 2015, MOL CELL BIOL, V35, P1026, DOI 10.1128/MCB.01172-14; Spira-Cohen A, 2011, ENVIRON HEALTH PERSP, V119, P559, DOI 10.1289/ehp.1002653; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tarantini L, 2009, ENVIRON HEALTH PERSP, V117, P217, DOI 10.1289/ehp.11898; Tsai YP, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0513-0; van Panhuys N, 2008, TISSUE ANTIGENS, V72, P91, DOI 10.1111/j.1399-0039.2008.01068.x; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/ajrccm.164.12.2106126; Vincent JJ, 2013, CELL STEM CELL, V12, P470, DOI 10.1016/j.stem.2013.01.016; Weiss ST, 2009, CURR OPIN GENET DEV, V19, P279, DOI 10.1016/j.gde.2009.05.001; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; White GP, 2002, J IMMUNOL, V168, P2820, DOI 10.4049/jimmunol.168.6.2820; Whitrow MJ, 2009, AM J EPIDEMIOL, V170, P1486, DOI 10.1093/aje/kwp315; Wichmann HE, 2007, INHAL TOXICOL, V19, P241, DOI 10.1080/08958370701498075; Yamaguchi S, 2013, NATURE, V504, P460, DOI 10.1038/nature12805; Zhang RR, 2013, CELL STEM CELL, V13, P237, DOI 10.1016/j.stem.2013.05.006	78	86	90	1	35	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					797	+		10.1016/j.jaci.2015.10.021	http://dx.doi.org/10.1016/j.jaci.2015.10.021			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26684294	Bronze, Green Accepted			2022-12-18	WOS:000371897500023
J	Westman, M; Lupinek, C; Bousquet, J; Andersson, N; Pahr, S; Baar, A; Bergstrom, A; Holmstrom, M; Stjarne, P; Carlsen, KCL; Carlsen, KH; Anto, JM; Valenta, R; van Hage, M; Wickman, M				Westman, Marit; Lupinek, Christian; Bousquet, Jean; Andersson, Niklas; Pahr, Sandra; Baar, Alexandra; Bergstrom, Anna; Holmstrom, Mats; Stjarne, Par; Carlsen, Karin C. Lodrup; Carlsen, Kaj-Hakon; Anto, Josep M.; Valenta, Rudolf; van Hage, Marianne; Wickman, Magnus		Mech Dev Allergies MeDALL Consorti	Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen components; allergic rhinitis; oral allergy syndrome; BAMSE; birch pollen; cohort; cross-reactivity; IgE; MeDALL; microarray	COMPONENT-RESOLVED DIAGNOSIS; PLANT-DERIVED FOOD; NONALLERGIC RHINITIS; POLLEN; SENSITIZATION; CHILDREN; ASTHMA; IMMUNOTHERAPY; SYMPTOMS; DISEASES	Background: Component-resolved diagnosis might improve the prediction of future allergy in young children. Objective: We sought to investigate the association between IgE reactivity to the pathogenesis-related class 10 (PR-10) protein family and allergic rhinitis to birch pollen (AR(bp)) from early childhood up to age 16 years. Method: Questionnaire data and sera obtained at 4, 8, and 16 years of age from the Barn/Children Allergi/Allergy Milieu Stockholm Epidemiologic (BAMSE) study birth cohort were used. Sera from 764 children were analyzed for IgE reactivity to 9 PR-10 allergen proteins at the 3 time points by using an allergen chip based on ISAC technology. ARbp was defined as upper airway symptoms during birch pollen exposure. Results: IgE reactivity to Bet v 1 was found in 12%, 17%, and 25% of children at 4, 8, and 16 years of age. IgE reactivity of PR-10 proteins showed a hierarchic intrarelationship: Bet v 1 > Mal d 1 > Cor a 1.04 > Ara h 8 > Pru p 1 > Aln g 1 > Api g 1 > Act d 8 > Gly m 4. There was an increased risk of incidence and persistence of ARbp up to age 16 years with increasing levels of Bet v 1-specific IgE or increasing numbers of IgE-reactive PR-10 proteins at 4 years. Children with severe ARbp at age 16 years had higher levels of Bet v 1-specific IgE at age 4 years compared with children with mild symptoms. Conclusion: ARbp at age 16 years can be predicted by analysis of IgE reactivity to PR-10 proteins in early childhood.	[Westman, Marit; Holmstrom, Mats; Stjarne, Par] Karolinska Inst, Dept Clin Sci Intervent & Technol, Div Ear Nose & Throat Dis, SE-17177 Stockholm, Sweden; [Andersson, Niklas; Bergstrom, Anna; Wickman, Magnus] Karolinska Inst, Inst Environm Med, SE-17177 Stockholm, Sweden; [Westman, Marit; Holmstrom, Mats; Stjarne, Par] Karolinska Univ Hosp, Dept Ear Nose & Throat Dis, Stockholm, Sweden; [Lupinek, Christian; Pahr, Sandra; Baar, Alexandra; Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Div Immunopathol, Dept Pathophysiol & Allergy Res, Vienna, Austria; [Bousquet, Jean] Univ Hosp Montpellier, Hop Arnaud de Villeneuve, INSERM 1018, Villejuif, France; [Carlsen, Karin C. Lodrup; Carlsen, Kaj-Hakon] Univ Oslo, Oslo Univ Hosp, Dept Pediat, N-0316 Oslo, Norway; Hosp del Mar, Res Inst, IMIM, Barcelona, Spain; [Anto, Josep M.] Univ Pompeu Fabra, Barcelona, Spain; [Anto, Josep M.] CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain; [van Hage, Marianne] Karolinska Inst, Dept Med Solna, Clin Immunol & Allergy Unit, SE-17177 Stockholm, Sweden; [van Hage, Marianne] Univ Hosp, Stockholm, Sweden; [Wickman, Magnus] Sachs Childrens Hosp, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Medical University of Vienna; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Universite de Montpellier; CHU de Montpellier; University of Oslo; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Karolinska Institutet	Westman, M (corresponding author), Karolinska Inst, Inst Environm Med, POB 210, SE-17177 Stockholm, Sweden.	marit.westman@ki.se	Anto, J M/H-2676-2014; Lupinek, Christian/I-3311-2019; Bousquet, Jean/O-4221-2019; Andersson, Niklas/AAN-1633-2020; van Hage, Marianne/A-9678-2017	Anto, J M/0000-0002-4736-8529; Lupinek, Christian/0000-0002-8612-8245; Andersson, Niklas/0000-0001-9785-7462; van Hage, Marianne/0000-0003-3091-1596; Valenta, Rudolf/0000-0001-5944-3365; Wickman, Magnus/0000-0003-2710-8620	Swedish Asthma and Allergy Research Foundation; Frimurare Barnhuset Foundation; Stockholm County Council; Swedish Research Council of Health, Working Life and Welfare; Swedish Heart-Lung Foundation; Swedish Cancer and Allergy Foundation; European Commission's Seventh Framework 29 Program MeDALL [261357]; Austrian Science Fund (FWF) [F4605]; Acta Oto-Laryngologica Foundation; Swedish Research Council	Swedish Asthma and Allergy Research Foundation; Frimurare Barnhuset Foundation; Stockholm County Council(Stockholm County Council); Swedish Research Council of Health, Working Life and Welfare; Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Cancer and Allergy Foundation; European Commission's Seventh Framework 29 Program MeDALL; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Acta Oto-Laryngologica Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission)	Supported by the Swedish Asthma and Allergy Research Foundation; the Frimurare Barnhuset Foundation; the Acta Oto-Laryngologica Foundation; Stockholm County Council; the Swedish Research Council of Health, Working Life and Welfare; the Swedish Research Council, Swedish Heart-Lung Foundation; the Swedish Cancer and Allergy Foundation; the European Commission's Seventh Framework 29 Program MeDALL under grant agreement no. 261357, and in part by grant F4605 of the Austrian Science Fund (FWF).	Andersen MBS, 2011, CLIN REV ALLERG IMMU, V41, P4, DOI 10.1007/s12016-009-8177-3; Asarnoj A, 2010, ALLERGY, V65, P1189, DOI 10.1111/j.1398-9995.2010.02334.x; Bousquet J, 2008, ALLERGY, V63, P842, DOI 10.1111/j.1398-9995.2008.01715.x; Bousquet J, 2006, ALLERGY, V61, P671, DOI 10.1111/j.1398-9995.2006.01048.x; Bousquet J, 2011, ALLERGY, V66, P596, DOI 10.1111/j.1398-9995.2010.02534.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet J, 2014, J ALLERGY CLIN IMMUN, V133, P1535, DOI 10.1016/j.jaci.2014.01.018; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Canonica GW, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-17; D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Geroldinger-Simic M, 2011, J ALLERGY CLIN IMMUN, V127, P616, DOI 10.1016/j.jaci.2010.10.027; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; Kellberger J, 2012, J ALLERGY CLIN IMMUN, V129, P397, DOI 10.1016/j.jaci.2011.08.016; Kilpelainen M, 2001, ALLERGY, V56, P377, DOI 10.1034/j.1398-9995.2001.056005377.x; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Maloney JM, 2008, J ALLERGY CLIN IMMUN, V122, P145, DOI 10.1016/j.jaci.2008.04.014; Masthoff LJN, 2013, J ALLERGY CLIN IMMUN, V132, P393, DOI 10.1016/j.jaci.2013.02.024; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; Panzner P, 2014, INT ARCH ALLERGY IMM, V164, P74, DOI 10.1159/000362760; Rashid RS, 2011, ALLERGY, V66, P1391, DOI 10.1111/j.1398-9995.2011.02618.x; Rondon C, 2010, CURR OPIN ALLERGY CL, V10, P1, DOI 10.1097/ACI.0b013e328334f5fb; Scala E, 2010, CLIN EXP ALLERGY, V40, P911, DOI 10.1111/j.1365-2222.2010.03470.x; Stringari G, 2014, J ALLERGY CLIN IMMUN, V134, P75, DOI 10.1016/j.jaci.2014.01.042; Tillander H, 2014, J ALLERGY CLIN IMMUN, V133, P580, DOI 10.1016/j.jaci.2013.09.009; Valenta R, 1996, IMMUNOL CELL BIOL, V74, P187, DOI 10.1038/icb.1996.26; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; Vieira T, 2014, ALLERGOL IMMUNOPATH, V42, P127, DOI 10.1016/j.aller.2012.09.001; Westman M, 2012, J ALLERGY CLIN IMMUN, V129, P403, DOI 10.1016/j.jaci.2011.09.036; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Yunginger JW, 2000, J ALLERGY CLIN IMMUN, V105, P1077, DOI 10.1067/mai.2000.107041	35	86	88	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1199	U592		10.1016/j.jaci.2014.10.042	http://dx.doi.org/10.1016/j.jaci.2014.10.042			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25528361	Green Accepted			2022-12-18	WOS:000353980700013
J	Siegel, AM; Stone, KD; Cruse, G; Lawrence, MG; Olivera, A; Jung, MY; Barber, JS; Freeman, AF; Holland, SM; O'Brien, M; Jones, N; Wisch, LB; Kong, HH; Desai, A; Farber, O; Gilfillan, AM; Rivera, J; Milner, JD				Siegel, Andrea M.; Stone, Kelly D.; Cruse, Glenn; Lawrence, Monica G.; Olivera, Ana; Jung, Mi-yeon; Barber, John S.; Freeman, Alexandra F.; Holland, Steven M.; O'Brien, Michelle; Jones, Nina; Wisch, Laura B.; Kong, Heidi H.; Desai, Avanti; Farber, Orly; Gilfillan, Alasdair M.; Rivera, Juan; Milner, Joshua D.			Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autosomal dominant hyper-IgE syndrome; Job syndrome; signal transducer and activator of transcription 3; mast cell; degranulation	FC-EPSILON-RI; TRANSCRIPTION FACTOR; IGE; RECEPTOR; GENERATION; BASOPHILS; CHILDREN; BCL6	Background: Severe atopic conditions associated with elevated serum IgE are heterogeneous with few known causes. Nearly every patient with autosomal-dominant hyper-IgE syndrome (AD-HIES) due to signal transducer and activator of transcription 3 (STAT3) mutations has a history of eczematous dermatitis and elevated IgE; however, clinical atopy has never been systematically studied. Objective: Understanding of genetic determinants of allergic disease may lead to novel therapies in controlling allergic disease. Methods: We conducted clinical evaluation of the rates of food allergies and anaphylaxis in patients with AD-HIES, a cohort of patients with no STAT3 mutation but with similar histories of elevated IgE and atopic dermatitis, and healthy volunteers with no history of atopy. Morphine skin prick testing, ImmunoCAP assays for allergen-specific IgE, and basophil activation were measured. A model of systemic anaphylaxis was studied in transgenic mice carrying an AD-HIES mutation. STAT3 was silenced in LAD2 and primary human mast cells to study the role of STAT3 in signaling and degranulation after IgE cross-linking. Results: Food allergies and anaphylaxis were markedly diminished in patients with AD-HIES compared with a cohort of patients with no STAT3 mutation but with similar histories of elevated IgE and atopic dermatitis. Morphine skin prick testing and basophil activation were diminished in patients with AD-HIES, whereas mice carrying an AD-HIES mutation were hyporesponsive to systemic anaphylaxis models. Rapid mast cell STAT3 serine727 phosphorylation was noted after IgE cross-linking, and inhibition of STAT3 signaling in mast cells lead to impaired FceRI-mediated proximal and distal signaling, as well as reduced degranulation. Conclusion: This study serves as an example for how mutations in specific atopic pathways can lead to discrete allergic phenotypes, encompassing increased risk of some phenotypes but a relative protection from others.	[Siegel, Andrea M.; Stone, Kelly D.; Cruse, Glenn; Lawrence, Monica G.; Jung, Mi-yeon; Barber, John S.; O'Brien, Michelle; Jones, Nina; Wisch, Laura B.; Desai, Avanti; Farber, Orly; Gilfillan, Alasdair M.; Milner, Joshua D.] NIAID, Lab Allerg Dis, Bethesda, MD 20892 USA; [Olivera, Ana; Rivera, Juan] NIAMSD, Immunogenet Mol Lab, Bethesda, MD 20892 USA; [Freeman, Alexandra F.; Holland, Steven M.] NIAID, Lab Clin Infect Dis, Bethesda, MD 20892 USA; [Kong, Heidi H.] NIH, Dermatol Branch, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Milner, JD (corresponding author), NIAID, Lab Allerg Dis, Bldg 10,Room 12S236A,10 Ctr Dr, Bethesda, MD 20892 USA.	jdmilner@niaid.nih.gov	Cruse, Glenn/AAZ-1093-2021; Kong, Heidi H/L-4856-2018	Kong, Heidi H/0000-0003-4424-064X; Cruse, Glenn/0000-0002-7511-0082	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases within the National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001098, T32AI007610, ZIAAI001183, ZIAAI000646] Funding Source: NIH RePORTER	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Arthritis and Musculoskeletal and Skin Diseases within the National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases and National Institute of Arthritis and Musculoskeletal and Skin Diseases within the National Institutes of Health.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Avery DT, 2008, BLOOD, V112, P1784, DOI 10.1182/blood-2008-02-142745; Avery DT, 2010, J EXP MED, V207, P155, DOI 10.1084/jem.20091706; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; Buckley RH, 2001, CLIN REV ALLERG IMMU, V20, P139, DOI 10.1385/CRIAI:20:1:139; COHEN RW, 1986, J ALLERGY CLIN IMMUN, V77, P802, DOI 10.1016/0091-6749(86)90377-5; Cruse G, 2013, IMMUNITY, V38, P906, DOI 10.1016/j.immuni.2013.04.007; Drube S, 2010, BLOOD, V115, P3899, DOI 10.1182/blood-2009-10-247411; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Erazo A, 2007, IMMUNITY, V26, P191, DOI 10.1016/j.immuni.2006.12.006; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; Kinoshita T, 1999, BLOOD, V94, P496, DOI 10.1182/blood.V94.2.496.414k19_496_508; Klinker JF, 1997, INFLAMM RES, V46, P46, DOI 10.1007/s000110050058; Kuehn HS, 2010, CURR PROTOC IMMUNOL; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126; Ma CS, 2012, BLOOD, V119, P3997, DOI 10.1182/blood-2011-11-392985; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Nurieva RI, 2008, IMMUNITY, V29, P138, DOI 10.1016/j.immuni.2008.05.009; Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676; Olivera A, 2010, J CLIN INVEST, V120, P1429, DOI 10.1172/JCI40659; Saini SS, 2000, J ALLERGY CLIN IMMUN, V106, P514, DOI 10.1067/mai.2000.108431; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sonnenblick A, 2005, J IMMUNOL, V175, P1450, DOI 10.4049/jimmunol.175.3.1450; Sowerwine KJ, 2012, ANN NY ACAD SCI, V1250, P25, DOI 10.1111/j.1749-6632.2011.06387.x; Speckmann C, 2008, CLIN IMMUNOL, V129, P448, DOI 10.1016/j.clim.2008.08.002; Suzuki Y, 2006, J LEUKOCYTE BIOL, V79, P508, DOI 10.1189/jlb.0705412; Traum D, 2012, J LEUKOCYTE BIOL, V91, P427, DOI 10.1189/jlb.0411209; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Xiong HZ, 2012, J EXP MED, V209, P353, DOI 10.1084/jem.20111941; Yu D, 2009, IMMUNITY, V31, P457, DOI 10.1016/j.immuni.2009.07.002; Zhou Z, 2013, CIRCULATION, V127, P476, DOI 10.1161/CIRCULATIONAHA.112.132126	32	86	89	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1388	+		10.1016/j.jaci.2013.08.045	http://dx.doi.org/10.1016/j.jaci.2013.08.045			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	24184145	Green Accepted			2022-12-18	WOS:000327538200018
J	Zhu, DH; Pan, CY; Li, LM; Bian, Z; Lv, ZY; Shi, L; Zhang, J; Li, DH; Gu, HW; Zhang, CY; Liu, Y; Zen, K				Zhu, Dihan; Pan, Chaoyun; Li, Limin; Bian, Zhen; Lv, Zhiyuan; Shi, Lei; Zhang, Jing; Li, Donghai; Gu, Hongwei; Zhang, Chen-Yu; Liu, Yuan; Zen, Ke			MicroRNA-17/20a/106a modulate macrophage inflammatory responses through targeting signal-regulatory protein alpha	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Signal-regulatory protein alpha; microRNA; macrophage; inflammatory response	TYROSINE-PHOSPHATASE SHP-2; SIRP-ALPHA; NEGATIVE REGULATION; TRANSENDOTHELIAL MIGRATION; MONOCYTE ADHESION; COMPLEX-FORMATION; SHPS-1; PHAGOCYTOSIS; ACTIVATION; EXPRESSION	Background: Signal-regulatory protein alpha (SIRP alpha) is an essential signaling molecule that modulates leukocyte inflammatory responses. However, the regulation of selective SIRPa synthesis and its dynamic changes in leukocytes under inflammatory stimulation remain incompletely understood. Objective: We sought to identify the microRNAs (miRNAs) that posttranscriptionally regulate SIRP alpha synthesis and their roles in modulating macrophage inflammatory responses. Methods: SIRP alpha was induced in SIRP alpha-negative promyelocytic cells by retinoic acid or phorbol 12-myristate 13-acetate, and the differential expression of miRNAs was assessed by means of microarray and quantitative RT-PCR assays. The roles of identified miRNAs in controlling SIRP alpha synthesis in leukocytes and leukocyte inflammatory responses were determined. Results: We identified SIRP alpha as a common target gene of miR17, miR-20a, and miR-106a. During SIRP alpha induction, levels of these 3 miRNAs were all reduced, and their downregulation by retinoic acid or phorbol 12-myristate 13-acetate occurred through suppression of the c-Myc signaling pathway. All miR17, miR-20a, and miR-106a specifically bound to the same seed sequence within the SIRP alpha 39 untranslated region and correlated inversely with SIRP alpha protein levels in various cells. In macrophages upregulation of miR-17, miR-20a, and miR106a by LPS served as the mechanism underlying LPS-induced SIRPa reduction and macrophage activation. Both in vitro and in vivo assays demonstrate that miR-17, miR-20a, and miR-106a regulate macrophage infiltration, phagocytosis, and proinflammatory cytokine secretion through targeting SIRP alpha. Conclusion: These findings demonstrate for the first time that miR-17, miR-20a, and miR-106a regulate SIRP alpha synthesis and SIRPa-mediated macrophage inflammatory responses in a redundant fashion, providing a novel pathway in which a panel of miRNAs can modulate immune polarization through regulation of macrophage activation.	[Zhu, Dihan; Zen, Ke] Nanjing Univ, Sch Med, Jinling Hosp, Res Inst Nephrol, Nanjing 210093, Jiangsu, Peoples R China; [Zhu, Dihan; Pan, Chaoyun; Li, Limin; Lv, Zhiyuan; Shi, Lei; Zhang, Jing; Li, Donghai; Gu, Hongwei; Zhang, Chen-Yu; Zen, Ke] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, JERC MBB, Nanjing 210093, Jiangsu, Peoples R China; [Bian, Zhen; Lv, Zhiyuan; Shi, Lei; Liu, Yuan] Georgia State Univ, Dept Biol, Atlanta, GA USA	Nanjing University; Nanjing University; University System of Georgia; Georgia State University	Zen, K (corresponding author), Nanjing Univ, Sch Life Sci, Hankou Rd 22, Nanjing 210093, Jiangsu, Peoples R China.	cyzhang@nju.edu.cn; yliu@gsu.edu; kzen@nju.edu.cn	Shi, Lei/AAJ-1586-2020	Shi, Lei/0000-0002-6631-6732	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI106839] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI106839] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Barclay AN, 2006, NAT REV IMMUNOL, V6, P457, DOI 10.1038/nri1859; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bode JG, 2012, CELL SIGNAL, V24, P1185, DOI 10.1016/j.cellsig.2012.01.018; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; de Vries HE, 2002, J IMMUNOL, V168, P5832, DOI 10.4049/jimmunol.168.11.5832; Foshay KM, 2009, DEV BIOL, V326, P431, DOI 10.1016/j.ydbio.2008.11.016; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; Ikeda H, 2006, J IMMUNOL, V177, P3123, DOI 10.4049/jimmunol.177.5.3123; Ishikawa-Sekigami T, 2006, BLOOD, V107, P341, DOI 10.1182/blood-2005-05-1896; Janssen WJ, 2008, AM J RESP CRIT CARE, V178, P158, DOI 10.1164/rccm.200711-1661OC; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kim YS, 2012, J PERIODONTAL RES, V47, P719, DOI 10.1111/j.1600-0765.2012.01487.x; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Kong XN, 2007, J EXP MED, V204, P2719, DOI 10.1084/jem.20062611; Kontaridis MI, 2001, J CELL SCI, V114, P2187; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; Liu DQ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003291; Liu SQ, 2005, J BIOL CHEM, V280, P39294, DOI 10.1074/jbc.M503866200; Liu Y, 2002, J BIOL CHEM, V277, P10028, DOI 10.1074/jbc.M109720200; Liu Y, 2007, J MOL BIOL, V365, P680, DOI 10.1016/j.jmb.2006.09.079; Lu Y, 2007, DEV BIOL, V310, P442, DOI 10.1016/j.ydbio.2007.08.007; Matozaki T, 2009, CANCER SCI, V100, P1786, DOI 10.1111/j.1349-7006.2009.01257.x; Matozaki T, 2009, TRENDS CELL BIOL, V19, P72, DOI 10.1016/j.tcb.2008.12.001; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ochi F, 1997, BIOCHEM BIOPH RES CO, V239, P483, DOI 10.1006/bbrc.1997.7489; Oh ES, 1999, MOL CELL BIOL, V19, P3205; OLIVEIRA NL, 1992, BLOOD, V79, P627; Pichiorri F, 2008, P NATL ACAD SCI USA, V105, P12885, DOI 10.1073/pnas.0806202105; Rosseau S, 2000, J IMMUNOL, V164, P427, DOI 10.4049/jimmunol.164.1.427; SOKOLOSKI JA, 1993, BLOOD, V82, P625; Steele C, 2003, J EXP MED, V198, P1677, DOI 10.1084/jem.20030932; Stofega MR, 2000, J BIOL CHEM, V275, P28222; Taguchi A, 2008, CANCER RES, V68, P5540, DOI 10.1158/0008-5472.CAN-07-6460; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; van Beek EM, 2005, J IMMUNOL, V175, P7781, DOI 10.4049/jimmunol.175.12.7781; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Wheeler AP, 2006, J CELL SCI, V119, P2749, DOI 10.1242/jcs.03024; Zuo LS, 2010, GUT, V59, P470, DOI 10.1136/gut.2009.184556	41	86	96	2	42	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					426	+		10.1016/j.jaci.2013.02.005	http://dx.doi.org/10.1016/j.jaci.2013.02.005			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23562609	Green Accepted, Bronze			2022-12-18	WOS:000322631700021
J	Gruzieva, O; Bellander, T; Eneroth, K; Kull, I; Melen, E; Nordling, E; van Hage, M; Wickman, M; Moskalenko, V; Hulchiy, O; Pershagen, G				Gruzieva, Olena; Bellander, Tom; Eneroth, Kristina; Kull, Inger; Melen, Erik; Nordling, Emma; van Hage, Marianne; Wickman, Magnus; Moskalenko, Vitaliy; Hulchiy, Olesya; Pershagen, Goeran			Traffic-related air pollution and development of allergic sensitization in children during the first 8 years of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Air pollution; children; cohort; IgE; long-term exposure; sensitization; traffic	LONG-TERM EXPOSURE; RESPIRATORY SYMPTOMS; ATOPIC SENSITIZATION; BIRCH POLLEN; ASTHMA; PARTICLES; INCREASE; HEALTH; PEANUT; NO	Background: The role of exposure to air pollution in the development of allergic sensitization remains unclear. Objective: We sought to assess the development of sensitization until school age related to longitudinal exposure to air pollution from road traffic. Methods: More than 2500 children in the birth cohort BAMSE (Children, Allergy, Milieu, Stockholm, Epidemiological Survey) from Stockholm, Sweden, were followed with repeated questionnaires and blood sampling until 8 years of age. Outdoor concentrations of nitrogen oxides, as a marker of exhaust particles, and particles with an aerodynamic diameter of less than 10 mu m (PM10), mainly representing road dust, were assigned to residential, day care, and school addresses by using dispersion models. Time-weighted average exposures were linked to levels of IgE against common inhalant and food allergens at 4 and 8 years of age. Results: Air pollution exposure during the first year of life was associated with an increased risk of pollen sensitization at 4 years of age (odds ratio, 1.83; 95% confidence interval, 1.02-3.28) for a 5th to 95th difference in exposure to nitrogen oxides. At 8 years, there was no general increase in the risk of sensitization; however, the risk of food sensitization was increased, particularly among children free of sensitization at 4 years of age (odds ratio, 2.30; 95% confidence interval, 1.10-4.82). Results were similar by using PM10. No associations between air pollution exposure after the first year of life and sensitization were seen. Conclusion: Traffic-related air pollution exposure does not seem to increase the overall risk of sensitization to common inhalant and food allergens up to school age, but sensitization to certain allergens might be related to exposure during infancy. (J Allergy Clin Immunol 2012;129:240-6.)	[Gruzieva, Olena; Bellander, Tom; Kull, Inger; Melen, Erik; Nordling, Emma; Wickman, Magnus; Pershagen, Goeran] Karolinska Inst, Inst Environm Med, SE-17177 Stockholm, Sweden; [Gruzieva, Olena; Moskalenko, Vitaliy] Natl OO Bohomolets Med Univ, Dept Social Med & Hlth Care, Kiev, Ukraine; [Hulchiy, Olesya] Natl OO Bohomolets Med Univ, Social Hyg & Org Hlth Protect Adv Training Manage, Kiev, Ukraine; [Eneroth, Kristina] Environm & Hlth Adm, Stockholm, Sweden; [Kull, Inger] Karolinska Inst, Dept Clin Sci & Educ, SE-17177 Stockholm, Sweden; [Melen, Erik] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [van Hage, Marianne] Karolinska Inst, Clin Immunol & Allergy Unit, Dept Med, SE-17177 Stockholm, Sweden; [van Hage, Marianne] Univ Hosp, Stockholm, Sweden; [Wickman, Magnus] Karolinska Inst, Sachs Childrens Hosp, Dept Paediat, SE-17177 Stockholm, Sweden	Karolinska Institutet; Bogomolets National Medical University; Bogomolets National Medical University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet	Gruzieva, O (corresponding author), Karolinska Inst, Inst Environm Med, Nobels Vag 13,Box 210, SE-17177 Stockholm, Sweden.	olena.gruzieva@ki.se	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Kull, Inger/0000-0001-6096-3771; Hulchiy, Olesya/0000-0001-8283-8672; Gruzieva, Olena/0000-0003-4147-5654; Pershagen, Goran/0000-0002-9701-1130	Swedish Heart-Lung Foundation; Konsul ThC Bergh Foundation; Stockholm County Council; Swedish Asthma and Allergy Association Research Foundation; Swedish Foundation for Health Care Sciences and Allergy Research; Swedish Environmental Protection Agency; Swedish Institute	Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Konsul ThC Bergh Foundation; Stockholm County Council(Stockholm County Council); Swedish Asthma and Allergy Association Research Foundation; Swedish Foundation for Health Care Sciences and Allergy Research; Swedish Environmental Protection Agency; Swedish Institute	Supported by the Swedish Heart-Lung Foundation, the Konsul ThC Bergh Foundation, the Stockholm County Council, the Swedish Asthma and Allergy Association Research Foundation, the Swedish Foundation for Health Care Sciences and Allergy Research, the Swedish Environmental Protection Agency, and the Swedish Institute.	Annesi-Maesano I, 2007, RESP MED, V101, P1721, DOI 10.1016/j.rmed.2007.02.022; Asarnoj A, 2010, ALLERGY, V65, P213, DOI 10.1111/j.1398-9995.2009.02138.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bellander T, 2001, ENVIRON HEALTH PERSP, V109, P633, DOI 10.2307/3455039; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; Eneroth K, 2006, EXPOSURE COMP MEASUR, V2006, P12; Gehring U, 2010, AM J RESP CRIT CARE, V181, P596, DOI 10.1164/rccm.200906-0858OC; Gergen PJ, 2009, J ALLERGY CLIN IMMUN, V124, P447, DOI 10.1016/j.jaci.2009.06.011; Gidhagen L, 2005, ATMOS ENVIRON, V39, P1711, DOI 10.1016/j.atmosenv.2004.11.042; Hammarstrom U, 1994, T150 SWED NAT ROAD T; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Joerink M, 2010, ALLERGY, V65, P1282, DOI 10.1111/j.1398-9995.2010.02328.x; Johansson C, 1999, 698 AQMA SWED NAT RO; Johansson C, 2006, 42006 SLB ENV HLTH A, V4; Johansson C, 2008, EXPOSURE PARTICLES D, P175; Johansson C, 2007, ENVIRON MONIT ASSESS, V127, P477, DOI 10.1007/s10661-006-9296-4; Ketzel M, 2007, ATMOS ENVIRON, V41, P9370, DOI 10.1016/j.atmosenv.2007.09.005; Kramer U, 2009, J DERMATOL SCI, V56, P99, DOI 10.1016/j.jdermsci.2009.07.014; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Laatikainen T, 2011, ALLERGY, V66, P886, DOI 10.1111/j.1398-9995.2010.02533.x; Lannero E, 2008, THORAX, V63, P172, DOI 10.1136/thx.2007.079053; Lannero E, 2002, PEDIAT ALLERG IMM-UK, V13, P182, DOI 10.1034/j.1399-3038.2002.01055.x; Lewne M, 2004, SCI TOTAL ENVIRON, V332, P217, DOI 10.1016/j.scitotenv.2004.04.014; McConnell R, 2010, ENVIRON HEALTH PERSP, V118, P1021, DOI 10.1289/ehp.0901232; Melen E, 2008, ENVIRON HEALTH PERSP, V116, P1077, DOI 10.1289/ehp.11117; Mittag D, 2004, J ALLERGY CLIN IMMUN, V114, P1410, DOI 10.1016/j.jaci.2004.09.014; Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103a; Nordling E, 2008, EPIDEMIOLOGY, V19, P401, DOI 10.1097/EDE.0b013e31816a1ce3; Nyberg F, 2000, EPIDEMIOLOGY, V11, P487, DOI 10.1097/00001648-200009000-00002; Oftedal B, 2007, CLIN EXP ALLERGY, V37, P1632, DOI 10.1111/j.1365-2222.2007.02823.x; Omstedt G, 2005, ATMOS ENVIRON, V39, P6088, DOI 10.1016/j.atmosenv.2005.06.037; Peden DB, 2000, ENVIRON HEALTH PERSP, V108, P475, DOI 10.2307/3454539; Penard-Morand C, 2005, CLIN EXP ALLERGY, V35, P1279, DOI 10.1111/j.1365-2222.2005.02336.x; Penard-Morand C, 2010, EUR RESPIR J, V36, P33, DOI 10.1183/09031936.00116109; Reungoat P, 2005, J EXPO ANAL ENV EPID, V15, P524, DOI 10.1038/sj.jea.7500430; Riedl MA, 2008, CURR ALLERGY ASTHM R, V8, P139, DOI 10.1007/s11882-008-0024-8; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rosenlund H, 2009, PEDIATRICS, V123, P771, DOI 10.1542/peds.2008-0013; Rosenlund M, 2009, THORAX, V64, P573, DOI 10.1136/thx.2007.094953; Rosenlund M, 2006, EPIDEMIOLOGY, V17, P383, DOI 10.1097/01.ede.0000219722.25569.0f; Statistics Sweden, 1989, OCC POP HOUS CENS 19; Zollner IK, 2005, THORAX, V60, P545, DOI 10.1136/thx.2004.029561	45	86	87	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					240	246		10.1016/j.jaci.2011.11.001	http://dx.doi.org/10.1016/j.jaci.2011.11.001			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22104609	Bronze			2022-12-18	WOS:000298634000031
J	Crane, MM; Chang, CM; Kobayashi, MG; Weller, PF				Crane, Martin M.; Chang, Cindy Ma; Kobayashi, Monica G.; Weller, Peter F.			Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Crane, Martin M.; Chang, Cindy Ma; Kobayashi, Monica G.] GlaxoSmithKline, Worldwide Epidemiol, Res Triangle Pk, NC 27709 USA; [Weller, Peter F.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA	GlaxoSmithKline; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Crane, MM (corresponding author), GlaxoSmithKline, Worldwide Epidemiol, Res Triangle Pk, NC 27709 USA.	martin.m.crane@gsk.com	Chang, Cindy/G-4514-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020241] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI020241] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Gotlib J, 2008, LEUKEMIA, V22, P1999, DOI 10.1038/leu.2008.287; Klion AD, 2006, J ALLERGY CLIN IMMUN, V117, P1292, DOI 10.1016/j.jaci.2006.02.042; Klion AD, 2007, IMMUNOL ALLERGY CLIN, V27, P551, DOI 10.1016/j.iac.2007.07.006; Ries LAG, 2007, SEER CANC STAT REV 1; Rollison DE, 2008, BLOOD, V112, P45, DOI 10.1182/blood-2008-01-134858; Sheikh J, 2007, IMMUNOL ALLERGY CLIN, V27, P333, DOI 10.1016/j.iac.2007.07.007; WARDLAW A, 2006, WILLIAMS HEMATOLOGY, P872; Wilkins HJ, 2005, AM J HEMATOL, V80, P148, DOI 10.1002/ajh.20423	9	86	93	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					179	181		10.1016/j.jaci.2010.03.035	http://dx.doi.org/10.1016/j.jaci.2010.03.035			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20639012	Green Accepted			2022-12-18	WOS:000280061800037
J	Prussin, C; Lee, J; Foster, B				Prussin, Calman; Lee, Joohee; Foster, Barbara			Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5(+) and IL-5(-) T(H)2 responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; peanut; T cell; T(H)2; eosinophil-associated gastrointestinal disease; IL-4; IL-5; flow cytometry	T-CELL RESPONSES; PERIPHERAL-BLOOD; CD154 EXPRESSION; ADULT PATIENTS; TH2 CELLS; CYTOKINE; ESOPHAGITIS; VACCINE; IL-4	Background: Both anaphylactic food allergy and eosinophil-associated gastrointestinal disorders are associated with T(H)2 responses and food-specific IgE, yet they have very different clinical presentations. Objective: To determine whether the clinical differences between anaphylactic food allergy and eosinophil-associated gastrointestinal disorders are reflected in different T(H)2 responses to foods. Methods: Subjects with peanut allergy (PA), subjects with allergic eosinophilic gastroenteritis (AEG), and nonatopic subjects were enrolled. Antigen-specific IL-4, IL-5, IFN-gamma, and TNF T-cell responses to peanut, soy, and shrimp were measured by using intracellular cytokine staining and polychromatic flow cytometry. Results: Two distinct subpopulations of T(H)2 cells were found: IL-5(+) T,2 (IL-4(+), IL-5(+)) and IL-5(-) T(H)2 (IL-4(+), IL-5(-)) cells. Peanut-specific IL-5(+) T(H)2 cells were present at a 20-fold greater frequency in AEG versus PA (81 vs 4 per 10(6) CD4 cells; P = .05), whereas there were similar frequencies of IL-5(-) T(H)2 cells (67 vs 41 per 106). For all foods, IL-5(+) T(H)2 cells accounted for a significantly greater fraction of the antigen-specific cells in AEG relative to PA (29% vs 4%; P < .0001). In PA but not AEG, IL-5(-) T(H)2 responses to peanut were highly correlated with peanut-specific IgE (r = 0.87 vs 0.55, respectively). All subject groups elicited similar very low-magnitude T(H)1 responses to food antigens. Conclusion: T(H)2 responses are composed of 2 subpopulations: IL-5(+) T(H)2 and IL-5(-) T(H)2 cells. IL-5(+) T(H)2 food allergen-specific T cells are singularly associated with AEG, whereas PA is associated with a dominant IL-5(-) T(H)2 response. These results suggest heterogeneity within the T(H)2 cytokine response, with different T(H)2 responses alternatively favoring IgE-mediated or eosinophil-dominant immunopathology. (J Allergy Clin Immunol 2009;124:1326-32.)	[Prussin, Calman; Lee, Joohee; Foster, Barbara] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Prussin, C (corresponding author), NIAID, Lab Allerg Dis, NIH, Bldg 10,Room 11C207, Bethesda, MD 20892 USA.	cprussin@niaid.nih.gov		Prussin, Calman/0000-0002-3917-3326	National Institute of Allergy and Infectious Diseases, NIH; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000993] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institute of Allergy and Infectious Diseases, NIH, Intramural Research Program.	Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Blanchard Carine, 2008, Gastrointest Endosc Clin N Am, V18, P133, DOI 10.1016/j.giec.2007.09.016; Branum Amy M, 2008, NCHS Data Brief, P1; Bullock JZ, 2007, J PEDIATR GASTR NUTR, V45, P22, DOI 10.1097/MPG.0b013e318043c097; Campbell JD, 2009, J ALLERGY CLIN IMMUN, V123, pS144, DOI 10.1016/j.jaci.2008.12.539; Casazza JP, 2006, J EXP MED, V203, P2865, DOI 10.1084/jem.20052246; Foroughi S, 2007, J ALLERGY CLIN IMMUN, V120, P594, DOI 10.1016/j.jaci.2007.06.015; Foster B., 2007, CURR PROTOC IMMUNOL; Guo LY, 2005, IMMUNITY, V23, P89, DOI 10.1016/j.immuni.2005.05.008; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; JAFFE JS, 1994, J CLIN IMMUNOL, V14, P299, DOI 10.1007/BF01540983; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Meier S, 2008, CYTOM PART A, V73A, P1035, DOI 10.1002/cyto.a.20640; O'Shea John J, 2008, Nat Immunol, V9, P450, DOI 10.1038/ni0508-450; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Roy-Ghanta S, 2008, CLIN GASTROENTEROL H, V6, P531, DOI 10.1016/j.cgh.2007.12.045; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Sicherer SH, 2009, ANNU REV MED, V60, P261, DOI 10.1146/annurev.med.60.042407.205711; Spergel Jonathan M, 2008, Gastrointest Endosc Clin N Am, V18, P179, DOI 10.1016/j.giec.2007.09.008; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Thottingal TB, 2006, J ALLERGY CLIN IMMUN, V118, P905, DOI 10.1016/j.jaci.2006.06.016; Turcanu V, 2008, CLIN EXP ALLERGY, V38, P1132, DOI 10.1111/j.1365-2222.2008.03016.x; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Woodfolk JA, 2007, J ALLERGY CLIN IMMUN, V119, P280, DOI 10.1016/j.jaci.2006.11.008; Yamazaki K, 2006, DIGEST DIS SCI, V51, P1934, DOI 10.1007/s10620-005-9048-2; Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154	27	86	100	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1326	1332		10.1016/j.jaci.2009.09.048	http://dx.doi.org/10.1016/j.jaci.2009.09.048			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	20004787	Green Accepted			2022-12-18	WOS:000273071500027
J	Al Khatib, S; Keles, S; Garcia-Lioret, M; Koc-Aydiner, EK; Reisli, I; Artac, H; Camcioglu, Y; Cokugras, H; Somer, A; Kutukculer, N; Yilmaz, M; Ikinciogullari, A; Yegin, O; Yuksek, M; Genel, F; Kucukosmanoglu, E; Baki, A; Bahceciler, NN; Rambhatla, A; Nickerson, DW; McGhee, S; Barlan, IB; Chatila, T				Al Khatib, Shadi; Keles, Sevgi; Garcia-Lioret, Maria; Koc-Aydiner, Elif Kara; Reisli, Ismail; Artac, Hasibe; Camcioglu, Yildiz; Cokugras, Haluk; Somer, Ayper; Kutukculer, Necil; Yilmaz, Mustafa; Ikinciogullari, Aydan; Yegin, Olcay; Yueksek, Mutlu; Genel, Ferah; Kucukosmanoglu, Ercan; Baki, Ali; Bahceciler, Nerin N.; Rambhatla, Anupama; Nickerson, Derek W.; McGhee, Sean; Barlan, Isil B.; Chatila, Talal			Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hyper IgE syndrome; STAT3; T(H)17; IL-6; IL-21; ROR gamma t	UNPHOSPHORYLATED STAT3; CELL-DIFFERENTIATION; MUTATIONS; ROLES; PHOSPHORYLATION; DEFICIENCY; GENERATION; DEFENSE; BINDING; INNATE	Background: The hyper IgE syndrome (HIES) is characterized by abscesses, eczema, recurrent infections, skeletal and connective tissue abnormalities, elevated serum IgE, and diminished inflammatory responses. It exists as autosomal-dominant and autosomal-recessive forms that manifest common and distinguishing clinical features. A majority of those with autosomal-dominant HIES have heterozygous mutations in signal transducer and activator of transcription (STAT)-3 and impaired T(H)17 differentiation. Objective: To elucidate mechanisms underlying different forms of HIES. Methods: A cohort of 25 Turkish children diagnosed with HIES were examined for STAT3 mutations by DNA sequencing. Activation of STAT3 by IL-6 and IL-21 and STAT1 by IFN-alpha was assessed by intracellular staining with anti-phospho (p)STAT3 and -pSTAT1 antibodies. T(H)17 and T(H)1 cell differentiation was assessed by measuring the production of IL-17 and IFN-gamma, respectively. Results: Six subjects had STAT3 mutations affecting the DNA binding, Src homology 2, and transactivation domains, including 3 novel ones. Mutation-positive but not mutation-negative subjects with HIES exhibited reduced phosphorylation of STAT3 in response to cytokine stimulation, whereas pSTAT1 activation was unaffected. Both patient groups exhibited impaired TH17 responses, but whereas STAT3 mutations abrogated early steps in TH17 differentiation, the defects in patients with HIES with normal STAT3 affected more distal steps. Conclusion: In this cohort of Turkish children with HIES, a majority had normal STAT3, implicating other targets in disease pathogenesis. Impaired TH17 responses were evident irrespective of the STAT3 mutation status, indicating that different genetic forms of HIES share a common functional outcome. (J Allergy Clin Immunol 2009;124:342-8.)	[Al Khatib, Shadi; Garcia-Lioret, Maria; Rambhatla, Anupama; Nickerson, Derek W.; McGhee, Sean; Chatila, Talal] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Rheumatol Allergy & Immunol, Los Angeles, CA 90095 USA; [Keles, Sevgi; Koc-Aydiner, Elif Kara; Bahceciler, Nerin N.; Barlan, Isil B.] Marmara Univ, Div Pediat Allergy & Immunol, Istanbul, Turkey; [Reisli, Ismail; Artac, Hasibe] Selcuk Univ, Div Pediat Allergy & Immunol, Konya, Turkey; [Camcioglu, Yildiz; Cokugras, Haluk] Istanbul Univ, Cerrahpasa Med Fac, Div Pediat Allergy Immunol & Infect Dis, Istanbul, Turkey; [Reisli, Ismail; Artac, Hasibe] Istanbul Univ, Istanbul Fac Med, Div Infect Dis & Immunol, Istanbul, Turkey; [Kutukculer, Necil] Ege Univ, Fac Med, Dept Pediat, Izmir, Turkey; [Yilmaz, Mustafa] Cukurova Univ, Div Pediat Allergy & Immunol, Adana, Turkey; [Ikinciogullari, Aydan] Ankara Univ, Sch Med, Dept Pediat Immunol Allergy, TR-06100 Ankara, Turkey; [Yegin, Olcay] Akdeniz Univ, Sch Med, Dept Pediat Immunol, TR-07058 Antalya, Turkey; [Yueksek, Mutlu] Zeynep Kamil State Hosp, Div Pediat Immunol, Istanbul, Turkey; [Genel, Ferah] Behcet Uz State Hosp, Div Pediat Immunol, Izmir, Turkey; [Kucukosmanoglu, Ercan] Gaziantep Univ, Div Pediat Allergy, Gaziantep, Turkey; [Baki, Ali] Karadeniz Tech Univ, Div Pediat Allergy, Trabzon, Turkey	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Marmara University; Selcuk University; Istanbul University; Istanbul University - Cerrahpasa; Istanbul University; Ege University; Cukurova University; Ankara University; Akdeniz University; Istanbul Zeynep Kamil Maternity & Children's Diseases Training & Research Hospital; Izmir Dr Behcet Uz Children's Disease & Surgery Training & Research Hospital; Gaziantep University; Karadeniz Technical University	Chatila, T (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Rheumatol Allergy & Immunol, MDCC 12-430,10833 Conte Ave, Los Angeles, CA 90095 USA.	isil.barlan@mannara.edu.tr; tchatila@mednet.ucla.edu	KUCUKOSMANOGLU, ERCAN/AAA-7138-2022; İkinciogullari, Aydan/AAQ-3841-2020; Yılmaz, Mustafa/E-7787-2018; Çokuğraş, Haluk C/D-2598-2019; Somer, Ayper/AAE-5459-2020	KUCUKOSMANOGLU, ERCAN/0000-0002-1824-2038; İkinciogullari, Aydan/0000-0003-1145-0843; cokugras, Haluk Cezmi/0000-0002-0086-3936; Chatila, Talal/0000-0001-7439-2762	National Institutes of Health [5R01AI065617]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065617] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant 5R01AI065617 (T.C.).	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; BASARAN N, 1988, CLIN GENET, V34, P339; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; Chen Z, 2007, ARTHRITIS RHEUM-US, V56, P2936, DOI 10.1002/art.22866; DAVIDSON JW, 1966, J PAC HIST, V1, P5, DOI 10.1080/00223346608572076; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; Hokuto I, 2004, J CLIN INVEST, V113, P28, DOI 10.1172/JCI200419491; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Ivanov II, 2007, SEMIN IMMUNOL, V19, P409, DOI 10.1016/j.smim.2007.10.011; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Krutzik PO, 2004, CLIN IMMUNOL, V110, P206, DOI 10.1016/j.clim.2003.11.009; LeibundGut-Landmann S, 2007, NAT IMMUNOL, V8, P630, DOI 10.1038/ni1460; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Lian XM, 2005, J IMMUNOL, V174, P7250, DOI 10.4049/jimmunol.174.11.7250; Lim CP, 2006, MOL BIOSYST, V2, P536, DOI 10.1039/b606246f; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Palm NW, 2007, NAT IMMUNOL, V8, P549, DOI 10.1038/ni0607-549; Renner ED, 2004, J PEDIATR-US, V144, P93, DOI 10.1016/S0022-3476(03)00449-9; Renner ED, 2008, J ALLERGY CLIN IMMUN, V122, P181, DOI 10.1016/j.jaci.2008.04.037; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Yang J, 2005, CANCER RES, V65, P939; Yang JB, 2007, GENE DEV, V21, P1396, DOI 10.1101/gad.1553707; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	31	86	87	0	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					342	348		10.1016/j.jaci.2009.05.004	http://dx.doi.org/10.1016/j.jaci.2009.05.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19577286	Green Accepted, Bronze			2022-12-18	WOS:000268860400023
J	Bruno, A; Pace, E; Chanez, P; Gras, D; Vachier, I; Chiappara, G; La Guardia, M; Gerbino, S; Profita, M; Gjomarkai, M				Bruno, Andreina; Pace, Elisabetta; Chanez, Pascal; Gras, Delphine; Vachier, Isabelle; Chiappara, Giuseppina; La Guardia, Maurizio; Gerbino, Stefania; Profita, Mirella; Gjomarkai, Mark			Leptin and leptin receptor expression in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Leptin; leptin receptor; severe asthma; epithelium; TGF-beta; remodeling	EPITHELIAL-CELLS; AIRWAY DISEASES; POTENTIAL ROLE; INFLAMMATION; SECRETION; LUNG; RESPONSES; TISSUE; MICE	Background: The adipokine leptin is a potential new mediator for bronchial epithelial homeostasis. Asthma is a chronic inflammatory disease characterized by airway remodeling that might affect disease chronicity and severity. TGF-beta is a tissue growth factor the dysregulation of which is associated with airway remodeling. Objective: We sought to determine whether a bronchial epithelial dysfunction of the leptin/leptin receptor pathway contributes to asthma pathogenesis and severity. Methods: We investigated in vitro the presence of leptin/leptin receptor on human bronchial epithelial cells. Then we studied the effect of TGF-beta and fluticasone propionate on leptin receptor expression. Finally, the role of leptin on TGF-beta release and cell proliferation was analyzed. Ex vivo we investigated the presence of leptin/leptin receptor in the epithelium of bronchial biopsy specimens from subjects with asthma of various severities and from healthy volunteers, and some features of airway remodeling, such as reticular basement membrane (RBM) thickness and TGF-beta expression in the epithelium, were assessed. Results: In vitro bronchial epithelial cells express leptin/leptin receptor. TGF-beta decreased and fluticasone propionate increased leptin receptor expression, and leptin decreased the spontaneous release of TGF-beta and increased cell proliferation. Ex vivo the bronchial epithelium of subjects with mild, uncontrolled, untreated asthma showed a decrease expression of leptin and its receptor and an increased RBM thickness and TGF-beta expression when compared with values seen in healthy volunteers. Furthermore, severe asthma was associated with a reduced expression of leptin and its receptor and an increased RBM thickness with unaltered TGF-beta expression. Conclusions: Decreased expression of leptin/leptin receptor characterizes severe asthma and is associated with airway remodeling features. (J Allergy Clin Immunol 2009;124:230-7.)	[Bruno, Andreina; Pace, Elisabetta; Chiappara, Giuseppina; Gerbino, Stefania; Profita, Mirella; Gjomarkai, Mark] CNR, IBIM, I-90146 Palermo, Italy; [Chanez, Pascal; Gras, Delphine] Univ Aix Marseille 2, CNRS, INSERM, AP HM,Lab Immunol,Dept Malad Resp,U600,UMR6212, Marseille, France; [Vachier, Isabelle] CHU Montpellier, Serv Malad Resp, MED BIO MED, Montpellier, France; [La Guardia, Maurizio; Gerbino, Stefania] Univ Palermo, Dipartimento DIMPEFINU, Sez Fisiol & Nutr Umana, Palermo, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite de Montpellier; CHU de Montpellier; University of Palermo	Bruno, A (corresponding author), CNR, IBIM, Via Ugo Malfa 153, I-90146 Palermo, Italy.	andreina@neomedia.it	Gras, Delphine/AAP-7248-2020; Bruno, Andreina/AAX-8151-2020; Profita, Mirella/AFU-7423-2022; Gras, Delphine/A-7062-2017; Profita, Mirella/D-8957-2018; Profita, Mirella/AAY-3165-2020; Pace, Elisabetta/AAL-2537-2020; Vachier, Isabelle/AAV-5731-2020	Gras, Delphine/0000-0002-6630-2955; Profita, Mirella/0000-0002-7821-8283; Pace, Elisabetta/0000-0003-1141-9010; Vachier, Isabelle/0000-0003-2730-5165; CHIAPPARA, GIUSEPPINA/0000-0002-7226-5660; chanez, pascal/0000-0003-4059-0917	INSERM-CNR	INSERM-CNR	Supported by INSERM-CNR contract.	Balzar S, 2005, J ALLERGY CLIN IMMUN, V115, P110, DOI 10.1016/j.jaci.2004.09.034; Bergen HT, 2002, AM J RESP CELL MOL, V27, P71, DOI 10.1165/ajrcmb.27.1.4540; Bourdin A, 2007, J ALLERGY CLIN IMMUN, V119, P1367, DOI 10.1016/j.jaci.2007.01.055; Bruno A, 2005, EUR RESPIR J, V26, P398, DOI 10.1183/09031936.05.00092404; Bruno A, 2005, J IMMUNOL, V174, P8090, DOI 10.4049/jimmunol.174.12.8090; Burgel PR, 2008, EUR RESPIR J, V32, P1068, DOI 10.1183/09031936.00172007; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588, DOI 10.1164/ajrccm.159.2.9801022; Chanez P, 2005, EUR RESPIR J, V25, P945, DOI 10.1183/09031936.05.00038605; Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702; Chen XL, 1998, OBES RES, V6, P164, DOI 10.1002/j.1550-8528.1998.tb00331.x; Conus S, 2005, J ALLERGY CLIN IMMUN, V116, P1228, DOI 10.1016/j.jaci.2005.09.003; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Feuermann Y, 2006, J ENDOCRINOL, V191, P407, DOI 10.1677/joe.1.06913; Fixman ED, 2007, EUR RESPIR J, V29, P379, DOI 10.1183/09031936.00053506; Goren I, 2003, DIABETES, V52, P2821, DOI 10.2337/diabetes.52.11.2821; Hansen GH, 2008, J HISTOCHEM CYTOCHEM, V56, P677, DOI 10.1369/jhc.2008.950782; Holgate Stephen T, 2008, Allergol Int, V57, P1, DOI 10.2332/allergolint.R-07-154; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Holgate Stephen T., 2003, Journal of Allergy and Clinical Immunology, V111, pS18, DOI 10.1067/mai.2003.25; James AL, 2007, EUR RESPIR J, V30, P134, DOI 10.1183/09031936.00146905; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Karjalainen EM, 2003, RESP MED, V97, P1045, DOI 10.1016/S0954-6111(03)00136-7; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; Lee MJ, 2007, AM J PHYSIOL-ENDOC M, V292, pE858, DOI 10.1152/ajpendo.00439.2006; Matarese G, 2007, CURR PHARM DESIGN, V13, P3676, DOI 10.2174/138161207783018635; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Profita M, 2004, ALLERGY, V59, P927, DOI 10.1111/j.1398-9995.2004.00516.x; ROBERTS CR, 1995, CHEST, V107, pS111, DOI 10.1378/chest.107.3_Supplement.111S; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Torday JS, 2002, AM J PHYSIOL-LUNG C, V282, pL405, DOI 10.1152/ajplung.2002.282.3.L405; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Vignola AM, 2000, J ALLERGY CLIN IMMUN, V105, P1041, DOI 10.1067/mai.2000.107195; Wenzel SE, 2003, J ALLERGY CLIN IMMUN, V111, P1345, DOI 10.1067/mai.2003.1464; Willis BC, 2005, AM J PATHOL, V166, P1321, DOI 10.1016/S0002-9440(10)62351-6; Wolk R, 2005, ATHEROSCLEROSIS, V183, P131, DOI 10.1016/j.atherosclerosis.2005.03.048; Wyrwoll CS, 2005, MOL CELL ENDOCRINOL, V241, P73, DOI 10.1016/j.mce.2005.05.003	37	86	102	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					230	237		10.1016/j.jaci.2009.04.032	http://dx.doi.org/10.1016/j.jaci.2009.04.032			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19539983	Green Submitted			2022-12-18	WOS:000268860400008
J	Mertes, PM; Malinovsky, JM; Mouton-Faivre, C; Bonnet-Boyer, MC; Benhaijoub, A; Lavaud, F; Valfrey, J; O'Brien, J; Pirat, P; Lalourcey, L; Demoly, P				Mertes, Paul Michel; Malinovsky, Jean Marc; Mouton-Faivre, Claudie; Bonnet-Boyer, Marie Caroline; Benhaijoub, Abdelhaouad; Lavaud, Francois; Valfrey, Jocelyne; O'Brien, James; Pirat, Philippe; Lalourcey, Laurent; Demoly, Pascal			Anaphylaxis to dyes during the perioperative period: Reports of 14 clinical cases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Patent Blue; dye; allergy; anaphylaxis; prick test; intradermal test; sentinel lymph node	SENTINEL LYMPH-NODE; ISOSULFAN BLUE-DYE; PATENT-BLUE; BREAST-CANCER; METHYLENE-BLUE; PREOPERATIVE PROPHYLAXIS; ALLERGIC REACTIONS; ADVERSE-REACTIONS; BIOPSY; INJECTION	Background: Vital dyes are widely used for lymphatic mapping and sentinel lymph node biopsy in patients with malignant tumors, and reports of anaphylactic reactions are becoming more frequent. objective: Our aims were to describe specific clinical features of hypersensitivity reactions to Patent Blue (Guerbet, Roissy, France), results of the allergy workup, and their consequences for patient management. Methods: We report a series of 14 clinical cases of dye-induced anaphylaxis recorded between 2004 and 2006 in 4 member centers of a network of French allergoanesthesia outpatient clinics. Results: Reactions appeared to be relatively severe (6/14 grade III reactions). An average 30 +/- 6-minute delay was observed between dye injection and symptom onset. In 9 (65%) patients reactions were sustained for several hours', requiring prolonged continuous epinephrine infusion and transfer to an intensive care unit. Prick test results were positive in 8 patients. In 5 patients prick test results were negative, whereas intradermal test results were positive. Conclusion: Anesthesiologists and allergologists must be aware of this specific risk and of the clinical characteristics of these reactions, which are usually delayed and long lasting.	[Mertes, Paul Michel; Mouton-Faivre, Claudie; Benhaijoub, Abdelhaouad; O'Brien, James] CHU Nancy, Cent Hosp, Serv Anesthesie Reanimat, F-54035 Nancy, France; [Malinovsky, Jean Marc] Hop Maison Blanche, Serv Anesthesie Reanimat, Reims, France; [Lavaud, Francois] Hop Maison Blanche, Serv Allergol, Reims, France; [Bonnet-Boyer, Marie Caroline] Hop Univ Lapeyronie, Serv Anesthesie Reanimat A, Montpellier, France; [Valfrey, Jocelyne] Hospices Civils Strasbourg, Serv Anesthesie, Strasbourg, France; [Pirat, Philippe] Hop Univ Gui Chauliac, Serv Anesthesie Reanimat C, Montpellier, France; [Lalourcey, Laurent] Inst Cancerol Val Aurelle Paul Lamarque Euromed, Dept Anesthesie, Montpellier, France; [Demoly, Pascal] Univ Hosp Montpellier, Hop Arnaud de Villeneuve, INSERM, U657,Allergy Dept, Montpellier, France	CHU de Nancy; CHU de Reims; Universite de Reims Champagne-Ardenne; CHU de Reims; Universite de Montpellier; CHU de Montpellier; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Montpellier; CHU de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Mertes, PM (corresponding author), CHU Nancy, Cent Hosp, Serv Anesthesie Reanimat, 29 Ave Lattre Tassigny, F-54035 Nancy, France.	pm.mertes@chu-nancy.fr	Demoly, Pascal/Y-9938-2019	Demoly, Pascal/0000-0001-7827-7964				AL-FADLY W, 1956, Med Arts Sci, V10, P43; Albo D, 2003, BREAST CANCER RES TR, V77, P9, DOI 10.1023/A:1021173902253; Albo D, 2001, AM J SURG, V182, P393, DOI 10.1016/S0002-9610(01)00734-6; Bilchik AJ, 1998, CANCER J SCI AM, V4, P351; BIRAN S, 1973, RADIOL CLIN, V42, P166; Blessing WD, 2002, AM J SURG, V184, P341, DOI 10.1016/S0002-9610(02)00948-0; Cimmino VM, 2001, SURGERY, V130, P439, DOI 10.1067/msy.2001.116407; Cox CE, 2000, SURG CLIN N AM, V80, P1759, DOI 10.1016/S0039-6109(05)70259-0; Dewachter P, 2005, ANESTH ANALG, V101, P149, DOI 10.1213/01.ANE.0000153497.60047.80; El-Tamer M, 2003, ARCH SURG-CHICAGO, V138, P1257, DOI 10.1001/archsurg.138.11.1257; Fisher MM, 1998, BRIT J ANAESTH, V80, P26, DOI 10.1093/bja/80.1.26; Golshan M, 2006, BREAST J, V12, P428, DOI 10.1111/j.1075-122X.2006.00299.x; Hadar T, 2006, PLAST RECONSTR SURG, V117, P1657, DOI 10.1097/01.prs.0000208867.58053.77; Hoskin RW, 2001, CAN J ANAESTH, V48, P38, DOI 10.1007/BF03019812; Hueter L, 2005, EUR J ANAESTH, V22, P475, DOI 10.1017/S0265021505230818; KALIMO K, 1981, CONTACT DERMATITIS, V7, P171, DOI 10.1111/j.1600-0536.1981.tb04613.x; KALIMO K, 1981, RADIOLOGY, V141, P365, DOI 10.1148/radiology.141.2.7291558; Keller B, 2007, AM J SURG, V193, P122, DOI 10.1016/j.amjsurg.2006.03.013; King TA, 2004, ANN SURG ONCOL, V11, P535, DOI 10.1245/ASO.2004.10.014; Laurie SA, 2002, ANN ALLERG ASTHMA IM, V88, P64, DOI 10.1016/S1081-1206(10)63595-8; Lingam MK, 1997, BRIT J CANCER, V75, P1505, DOI 10.1038/bjc.1997.257; Mertes P M, 2004, Minerva Anestesiol, V70, P285; Mertes PM, 2007, ANESTHESIOLOGY, V107, P245, DOI 10.1097/01.anes.0000270721.27309.b3; Mertes PM, 2005, J INVEST ALLERG CLIN, V15, P91; Mertes PM, 2004, CURR ALLERGY ASTHM R, V4, P7, DOI 10.1007/s11882-004-0036-y; Mertes PM, 2003, ANESTHESIOLOGY, V99, P536, DOI 10.1097/00000542-200309000-00007; Mertes PM, 2002, EUR J ANAESTH, V19, P240, DOI 10.1017/S0265021502000418; Montgomery LL, 2002, ANESTH ANALG, V95, P385, DOI 10.1097/00000539-200208000-00026; Pevny I, 1972, Med Klin, V67, P698; Pinero A, 2004, ARCH SURG-CHICAGO, V139, P1204, DOI 10.1001/archsurg.139.11.1204; Quiliquini A, 1998, DERMATOLOGY, V197, P400, DOI 10.1159/000018045; Raut CP, 2005, CANCER-AM CANCER SOC, V104, P692, DOI 10.1002/cncr.21226; Raut CP, 2004, J CLIN ONCOL, V22, P567, DOI 10.1200/JCO.2004.99.276; Salhab M, 2005, Int Semin Surg Oncol, V2, P26, DOI 10.1186/1477-7800-2-26; Scherer K, 2006, CONTACT DERMATITIS, V54, P231, DOI 10.1111/j.0105-1873.2006.00786.x; Scherer K, 2006, ANN ALLERG ASTHMA IM, V96, P497, DOI 10.1016/S1081-1206(10)60921-0; Simmons R M, 2001, Breast J, V7, P181, DOI 10.1046/j.1524-4741.2001.007003181.x; Singh-Ranger Gurpreet, 2004, Int Semin Surg Oncol, V1, P3, DOI 10.1186/1477-7800-1-3; Stradling B, 2002, AM J SURG, V184, P350, DOI 10.1016/S0002-9610(02)00945-5; Thevarajah S, 2005, AM J SURG, V189, P236, DOI 10.1016/j.amjsurg.2004.06.042; Tsopelas C, 2002, J NUCL MED, V43, P1377; van Zuuren E, 2005, CONTACT DERMATITIS, V53, P171, DOI 10.1111/j.0105-1873.2005.0407c.x; VANVAERENBERGH PM, 1967, J BELG RADIOL, V50, P411; Varghese P, 2007, EJSO-EUR J SURG ONC, V33, P147, DOI 10.1016/j.ejso.2006.09.026; Wohrl S, 2004, BRIT J DERMATOL, V150, P1037, DOI 10.1111/j.1365-2133.2004.05931.x; Woltsche-Kahr I, 2000, EUR J SURG ONCOL, V26, P313, DOI 10.1053/ejso.1999.0888	46	86	88	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					348	352		10.1016/j.jaci.2008.04.040	http://dx.doi.org/10.1016/j.jaci.2008.04.040			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18554702				2022-12-18	WOS:000258426300022
J	Sel, S; Wegmann, M; Dicke, T; Sel, S; Henke, W; Yildirim, AO; Renz, H; Garn, H				Sel, Serdar; Wegmann, Michael; Dicke, Tanja; Sel, Sarper; Henke, Wolfgang; Yildirim, Ali Oe.; Renz, Harald; Garn, Holger			Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic asthma; GATA-3; DNAzymes; T(H)2 cells; antisense DNA; small interference RNA	TRANSCRIPTION FACTOR GATA-3; AIRWAY INFLAMMATION; MURINE MODEL; TH2 CELLS; ANTISENSE OLIGONUCLEOTIDE; BACTERIAL-DNA; EXPRESSION; RESPONSES; GENE; RNA	Background: Allergic bronchial asthma is a chronic inflammatory disease of the airways. The transcription factor GATA-3 was shown to play an important role in T(H)2 cell activation, but also in the regulation of other cell types involved in bronchial asthma including mast cells, eosinophils, and epithelial cells. DNAzymes represent a new class of antisense molecules that combines the specificity of DNA base pairing with an inherent RNA-cleaving enzymatic activity. Objective: To develop a GATA-3 mRNA-specific DNAzyme and analyze its allergy-preventing activity in murine models of experimental allergic asthma. Methods: The most active DNAzyme (termed gd21) was selected by in vitro cleavage assays. Allergic airway inflammation was assessed by inflammatory cell and cytokine analysis within bronchoalveolar lavage. Lung histology, including goblet cell hyperplasia and lung function, was analyzed using head-out body-plethysmography. Results: Intranasal administration of gd21 prevented airway inflammation and mucus production and inhibited development of airway hyperresponsiveness to methacholine in models of acute allergic airway inflammation. Similar effects were also detected in a model of chronic experimental asthma. Interestingly, gd21 was at least as effective as other antisense molecules, and off-target effects were not detected. Further experiments indicated that pulmonary surfactant may facilitate the cellular uptake of gd21 by acting as an endogenous transfectant. Conclusion: These results indicate that topical application of the GATA-3-specific DNAzyme is a promising novel approach for the treatment of allergic bronchial asthma.	[Sel, Serdar; Wegmann, Michael; Dicke, Tanja; Sel, Sarper; Renz, Harald; Garn, Holger] Univ Marburg, Fac Med, Dept Clin Chem & Mol Diagnost, D-35032 Marburg, Germany; [Henke, Wolfgang] Dept Otorhinolaryngol, Mol Biol Res Lab, Marburg, Germany; [Wegmann, Michael; Dicke, Tanja; Renz, Harald; Garn, Holger] Stern Biol GmbH & Co KG, Marburg, Germany; [Yildirim, Ali Oe.] Univ Hosp Giessen, Clin Internal Med Resp Med, Clin Res Grp, Marburg, Germany	Philipps University Marburg	Renz, H (corresponding author), Univ Giessen Klinikum, Dept Clin Chem & Mol Diagnost, Baldingerstr, D-35033 Marburg, Germany.	renzh@med.uni-marburg.de		Wegmann, Michael/0000-0002-1658-1554; Yildirim, Ali Onder/0000-0003-1969-480X; Garn, Holger/0000-0002-5178-4023				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Ali S, 2001, AM J RESP CRIT CARE, V163, P989, DOI 10.1164/ajrccm.163.4.9907078; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Cairns MJ, 2003, NUCLEIC ACIDS RES, V31, P2883, DOI 10.1093/nar/gkg378; Cairns MJ, 1999, NAT BIOTECHNOL, V17, P480, DOI 10.1038/8658; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; DICOSMO BF, 1994, J CLIN INVEST, V94, P2028, DOI 10.1172/JCI117556; Duan W, 2005, AM J RESP CRIT CARE, V171, P571, DOI 10.1164/rccm.200408-1006OC; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; Foster PS, 2000, LAB INVEST, V80, P655, DOI 10.1038/labinvest.3780068; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirasawa R, 2002, J EXP MED, V195, P1379, DOI 10.1084/jem.20020170; Kishikawa H, 2001, J IMMUNOL, V167, P4414, DOI 10.4049/jimmunol.167.8.4414; Klein-Hessling S, 2003, J IMMUNOL, V170, P2956, DOI 10.4049/jimmunol.170.6.2956; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Leaman DW, 2002, VIROLOGY, V292, P70, DOI 10.1006/viro.2001.1213; Neuhaus-Steinmetz U, 2000, INT ARCH ALLERGY IMM, V121, P57, DOI 10.1159/000024298; Nyce J, 2002, CURR OPIN ALLERGY CL, V2, P533, DOI 10.1097/00130832-200212000-00009; Nyce JW, 1997, NATURE, V385, P721, DOI 10.1038/385721a0; Silverman SK, 2005, NUCLEIC ACIDS RES, V33, P6151, DOI 10.1093/nar/gki930; Sparwasser T, 1997, NATURE, V386, P336, DOI 10.1038/386336a0; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Tritz Richard, 2005, Gene Ther Mol Biol, V9A, P89; Usui T, 2006, J EXP MED, V203, P755, DOI 10.1084/jem.20052165; Wegmann M, 2005, CLIN EXP ALLERGY, V35, P1263, DOI 10.1111/j.1365-2222.2005.02306.x; Weibel ER, 2007, J APPL PHYSIOL, V102, P459, DOI 10.1152/japplphysiol.00808.2006; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128; Zhu JF, 2006, CELL RES, V16, P3, DOI 10.1038/sj.cr.7310002; ZON LI, 1993, BLOOD, V81, P3234	32	86	94	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					910	916		10.1016/j.jaci.2007.12.1175	http://dx.doi.org/10.1016/j.jaci.2007.12.1175			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18325571				2022-12-18	WOS:000254884000015
J	Hirota, T; Harada, M; Sakashita, M; Doi, S; Miyatake, A; Fujita, K; Enomoto, T; Ebisawa, M; Yoshihara, S; Noguchi, E; Saito, H; Nakamura, Y; Tamari, M				Hirota, Tomomitsu; Harada, Michishige; Sakashita, Masafumi; Doi, Satoru; Miyatake, Akihiko; Fujita, Kimie; Enomoto, Tadao; Ebisawa, Motohiro; Yoshihara, Shigemi; Noguchi, Emiko; Saito, Hirohisa; Nakamura, Yusuke; Tamari, Mayumi			Genetic polymorphism regulating ORM1-like 3 (Saccharomyces cerevisiae) expression is associated with childhood atopic asthma in a Japanese population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Hirota, Tomomitsu; Harada, Michishige; Sakashita, Masafumi; Tamari, Mayumi] Inst Phys & Chem Res, SNP Res Ctr, Lab Genet Allerg Dis, Yokohama, Kanagawa, Japan; [Doi, Satoru] Osaka Prefectural Med Ctr Resp & Allerg Dis, Habikino, Japan; [Miyatake, Akihiko; Fujita, Kimie] Miyatake Asthma Clin, Osaka, Japan; [Enomoto, Tadao] Wakayama Med Ctr, Japanese Red Cross Soc, Wakayama, Japan; [Ebisawa, Motohiro] Natl Sagamihara Hosp, Sagamihara, Kanagawa, Japan; [Yoshihara, Shigemi] Dokkyo Univ, Sch Med, Tochigi, Japan; [Noguchi, Emiko] Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki, Japan; [Saito, Hirohisa] Natl Res Inst Child Hlth & Dev, Tokyo, Japan; [Nakamura, Yusuke] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo, Japan	RIKEN; Osaka Prefectural Medical Center Respiratory & Allergic Diseases; Dokkyo Medical University; University of Tsukuba; National Center for Child Health & Development - Japan; University of Tokyo	Hirota, T (corresponding author), Inst Phys & Chem Res, SNP Res Ctr, Lab Genet Allerg Dis, Yokohama, Kanagawa, Japan.	tamari@src.riken.jp	Tamari, Mayumi/N-5378-2015	Ebisawa, Motohiro/0000-0003-4117-558X; Saito, Hirohisa/0000-0002-6630-8337				Contoli M, 2005, CLIN EXP ALLERGY, V35, P137, DOI 10.1111/j.1365-2222.2005.02163.x; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Hatsushika K, 2007, CLIN EXP ALLERGY, V37, P1165, DOI 10.1111/j.1365-2222.2007.02768.x; Hirota T, 2005, J ALLERGY CLIN IMMUN, V116, P789, DOI 10.1016/j.jaci.2005.06.010; Hjelmqvist L, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-6-research0027; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Nakashima K, 2006, BIOCHEM BIOPH RES CO, V344, P300, DOI 10.1016/j.bbrc.2006.03.102; National Heart Lung and Blood Institute National Asthma Education Program, 1991, J ALLERGY CLIN IMMUN, V88, P425, DOI DOI 10.1016/0091-6749(91)92135-N; PATTEMORE PK, 2003, EPIDEMIOLOGY DIAGNOS, P43	10	86	100	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					769	770		10.1016/j.jaci.2007.09.038	http://dx.doi.org/10.1016/j.jaci.2007.09.038			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18155279	Bronze			2022-12-18	WOS:000253918900036
J	Gore, C; Munro, K; Lay, C; Bibiloni, R; Morris, J; Woodcock, A; Custovic, A; Tannock, GW				Gore, Claudia; Munro, Karen; Lay, Christophe; Bibiloni, Rodrigo; Morris, Julie; Woodcock, Ashley; Custovic, Adnan; Tannock, Gerald W.			Bifidobacterium pseudocatenulatum is associated with atopic eczema: A nested case-control study investigating the fecal microbiota of infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eczema; atopic dermatitis; atopy; allergy; gastrointestinal; microbiota; microflora; bifidobacteria; fecal bacterial community	16S RIBOSOMAL-RNA; INTESTINAL PERMEABILITY; IDENTIFICATION; PROBES; HYBRIDIZATION; MICROFLORA; DERMATITIS; COUNTRIES; HEALTHY; SAMPLES	Background: Exposure to specific bacterial bowel commensals may increase/reduce the risk of atopic diseases. Objective: To compare fecal bacterial communities of young infants with/without eczema. Methods: Nested case-control study. Infants age 3 to 6 months with eczema (cases, n = 37) and without (controls, n = 24) were matched for sex, age, feeding (breast/bottle/mixed/solids), ethnicity. Information was collected on maternal/infant antibiotic exposure, feeding, gastrointestinal symptoms, family history of allergy. Eczema severity scoring was used (Severity Scoring of Atopic Dermatitis index). Samples were taken for determination of allergen-specific serum IgE (cases) and urinary/fecal eosinophilic protein X. Gastrointestinal permeability was measured. The compositions of fecal bacterial communities were analyzed (culture-independent, nucleic acid-based analyses). Results: There was no difference in overall profiles of fecal bacterial communities between cases and controls. Family history of allergy increased likelihood of bifidobacteria detection (history, 86%; no history, 56%; P =.047); breast-fed infants were more likely to harbor Bifidobacterium bifidum (odds ratio, 5.19; 95% CI, 1.47-18.36; P =.01). Bifidobacterium pseudocatenulatum was detected more commonly in feces of non-breast-fed children (odds ratio, 5.6; 95% CI, 1.3-24.3; P =.02) and children with eczema (eczema, 26%; no eczema, 4%; P =.04). There were no significant associations between clinical measurements and detection of B pseudocatenulatum. Conclusion: Presence of B pseudocatenulatum in feces was associated with eczema and with exclusive formula-feeding; B bifidum was associated with breast-feeding.	[Munro, Karen; Lay, Christophe; Bibiloni, Rodrigo; Tannock, Gerald W.] Univ Otago, Dept Microbiol & Immunol, Dunedin, New Zealand; [Gore, Claudia; Munro, Karen; Lay, Christophe; Bibiloni, Rodrigo; Morris, Julie; Woodcock, Ashley; Custovic, Adnan; Tannock, Gerald W.] Wythenshawe Hosp, NW Lung Res Ctr, Dunedin, New Zealand	University of Otago	Tannock, GW (corresponding author), Univ Otago, Dept Microbiol & Immunol, POB 56, Dunedin, New Zealand.	tannock@stonebow.otago.ac.nz	Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578; Gore, Claudia/0000-0002-3626-5129				Akram S, 1998, DIGEST DIS SCI, V43, P1946, DOI 10.1023/A:1018826307489; AMANN RI, 1990, J BACTERIOL, V172, P762, DOI 10.1128/jb.172.2.762-770.1990; Brandtzaeg P, 2002, ANN NY ACAD SCI, V964, P13; FLEMING SC, 1990, CLIN CHEM, V36, P797; Harmsen HJM, 2000, J PEDIATR GASTR NUTR, V30, P61, DOI 10.1097/00005176-200001000-00019; He F, 2001, FEMS IMMUNOL MED MIC, V30, P43, DOI 10.1016/S0928-8244(00)00232-7; Hopkin JM, 1997, CURR OPIN IMMUNOL, V9, P788, DOI 10.1016/S0952-7915(97)80179-3; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; LANGENDIJK PS, 1995, APPL ENVIRON MICROB, V61, P3069, DOI 10.1128/AEM.61.8.3069-3075.1995; Lay C, 2005, APPL ENVIRON MICROB, V71, P4153, DOI 10.1128/AEM.71.7.4153-4155.2005; Lay C, 2005, ENVIRON MICROBIOL, V7, P933, DOI 10.1111/j.1462-2920.2005.00763.x; Murray CS, 2005, CLIN EXP ALLERGY, V35, P741, DOI 10.1111/j.1365-2222.2005.02259.x; Murray CS, 2002, PROBIOTICS AND PREBIOTICS: WHERE ARE WE GOING?, P239; Ouwehand AC, 2001, J ALLERGY CLIN IMMUN, V108, P144, DOI 10.1067/mai.2001.115754; Peterson CGB, 2002, AM J GASTROENTEROL, V97, P1755; Requena T, 2002, APPL ENVIRON MICROB, V68, P2420, DOI 10.1128/AEM.68.5.2420-2427.2002; SEPP E, 1997, ACTA PEDIAT, V86, P856; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Tannock GW, 2000, APPL ENVIRON MICROB, V66, P2578, DOI 10.1128/AEM.66.6.2578-2588.2000; Tannock GW, 2004, APPL ENVIRON MICROB, V70, P2129, DOI 10.1128/AEM.70.4.2129-2136.2004; WALLNER G, 1993, CYTOMETRY, V14, P136, DOI 10.1002/cyto.990140205; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Young SL, 2004, CLIN DIAGN LAB IMMUN, V11, P686, DOI 10.1128/CDLI.11.4.686-690.2004; Zoetendal EG, 1998, APPL ENVIRON MICROB, V64, P3854	24	86	89	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					135	140		10.1016/j.jaci.2007.07.061	http://dx.doi.org/10.1016/j.jaci.2007.07.061			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17900682				2022-12-18	WOS:000252372000020
J	Devouassoux, G; Levy, P; Rossini, E; Pin, I; Fior-Gozlan, M; Henry, M; Seigneurin, D; Pepin, JL				Devouassoux, Gilles; Levy, Patrick; Rossini, Eliane; Pin, Isabelle; Fior-Gozlan, Michele; Henry, Mireille; Seigneurin, Daniel; Pepin, Jean-Louis			Sleep apnea is associated with bronchial inflammation and continuous positive airway pressure-induced airway hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						obstructive sleep apnea syndrome; bronchial inflammation; neutrophil; IL-8; NO exhalation; airway hyperresponsiveness; continuous positive airway pressure	OBSTRUCTIVE PULMONARY-DISEASE; ENDOTHELIAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; C-REACTIVE PROTEIN; OXIDATIVE STRESS; GASTROESOPHAGEAL-REFLUX; CELL COUNTS; ASTHMA; CYTOKINE; OBESITY	Background: Obstructive sleep apnea syndrome (OSA) is associated with systemic and upper airway inflammation. Pharyngeal inflammation has a potential role in upper airway collapse, whereas systemic inflammation relates to cardiovascular morbidity. However, the presence of an inflammatory involvement of lower airway has been poorly investigated. Objective: The aim of the study was to demonstrate an inflammatory process at the bronchial level in patients with OSA and to analyze effects of continuous positive airway pressure (CPAP) application and humidification on bronchial mucosa. Methods: The study was conducted by using sequential induced sputum for cell analysis and IL-8 production, nitric oxide exhalation measurement, and methacholine challenge before and after CPAP. Results: Bronchial neutrophilia and a high IL-8 concentration were observed in untreated OSA compared with controls (75% +/- 20% vs 43% +/- 12%, P < .05; and 25.02 +/- 9.43 ng/mL vs 8.6 +/- 3.7 ng/mL, P < .001, respectively). IL-8 in sputum supernatant was correlated to apnea hypopnea index (P < .01; r = 0.81). After I month of CPAP, this inflammatory pattern remained unchanged, and an increase in airway hyperresponsiveness (AHR) was observed (P < .001). Conclusion: Obstructive sleep apnea syndrome is associated with bronchial inflammation. Our data demonstrate CPAP effect on the development of AHR, possibly facilitated by the pre-existing inflammation. Both issues should be evaluated during long-term CPAP use. Clinical implications: Results showing a spontaneous bronchial inflammation in OSA and the development of a CPAP-related AHR require a long-term follow-up to evaluate consequences on chronic bronchial obstruction.	Explorat Fonctionnelle Cardioresp Univ Hosp Greno, Sleep Lab, Grenoble, France; Univ Grenoble 1, INSERM ESPRI 0017, Lab HP2, F-38041 Grenoble, France; Univ Hosp Grenoble, Dept Cytol, Grenoble, France; Hospices Civils Lyon, Unit Resp Dis, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Lyon	Pepin, JL (corresponding author), CHU Grenoble, EFCR, Lab Sommeil, BP 217X, F-38043 Grenoble 09, France.	JPepin@chu-grenoble.fr	PEPIN, Jean-Louis/M-6549-2014; PIN, Isabelle/N-3020-2013; LEVY, Patrick/AAX-2802-2020	LEVY, Patrick/0000-0003-3174-7935; Pepin, Jean Louis/0000-0003-3832-2358				BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P1393, DOI 10.1016/j.jaci.2005.10.008; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Boyd JH, 2004, AM J RESP CRIT CARE, V170, P541, DOI 10.1164/rccm.200308-1100OC; Caples SM, 2005, ANN INTERN MED, V142, P187, DOI 10.7326/0003-4819-142-3-200502010-00010; Carpagnano GE, 2002, CHEST, V122, P1162, DOI 10.1378/chest.122.4.1162; Chen LC, 2004, BRAIN BEHAV IMMUN, V18, P390, DOI 10.1016/j.bbi.2003.12.002; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; Ciftci TU, 2004, CYTOKINE, V28, P87, DOI 10.1016/j.cyto.2004.07.003; Constantinidis J, 2000, ACTA OTO-LARYNGOL, V120, P432; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; De A, 2003, BRAIN RES, V981, P133, DOI 10.1016/S0006-8993(03)02997-4; Efthimiadis A, 2002, EUR RESPIR J, V20, p19S, DOI 10.1183/09031936.02.00001902; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Gerritsen WBM, 2005, RESP MED, V99, P84, DOI 10.1016/j.rmed.2004.04.017; Gunnbjomsdottir MI, 2004, EUR RESPIR J, V24, P116, DOI 10.1183/09031936.04.00042603; HOFFSTEIN V, 1992, AM REV RESPIR DIS, V145, P841, DOI 10.1164/ajrccm/145.4_Pt_1.841; Huang TJ, 1999, AM J RESP CRIT CARE, V160, P1717, DOI 10.1164/ajrccm.160.5.9901029; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; Lavie L, 2002, AM J RESP CRIT CARE, V165, P1624, DOI 10.1164/rccm.20110-040OC; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; Lim LHK, 2003, AM J RESP CRIT CARE, V168, P1068, DOI 10.1164/rccm.200207-690OC; Moodie FM, 2004, FASEB J, V18, P1897, DOI 10.1096/fj.04-1506fje; MUNS G, 1995, J OTOLARYNGOL, V24, P105; PAOLETTI P, 1995, AM J RESP CRIT CARE, V151, P1770, DOI 10.1164/ajrccm.151.6.7767519; PEPIN JL, 1995, CHEST, V107, P375, DOI 10.1378/chest.107.2.375; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Richards GN, 1996, AM J RESP CRIT CARE, V154, P182, DOI 10.1164/ajrccm.154.1.8680678; Salerno FG, 2004, RESP MED, V98, P25, DOI 10.1016/j.rmed.2003.08.003; Schrodter S, 2004, RHINOLOGY, V42, P153; Schulz R, 2000, AM J RESP CRIT CARE, V162, P566, DOI 10.1164/ajrccm.162.2.9908091; Sekosan M, 1996, LARYNGOSCOPE, V106, P1018, DOI 10.1097/00005537-199608000-00021; Shamsuzzaman ASM, 2002, CIRCULATION, V105, P2462, DOI 10.1161/01.CIR.0000018948.95175.03; Shamsuzzaman ASM, 2003, JAMA-J AM MED ASSOC, V290, P1906, DOI 10.1001/jama.290.14.1906; Simonini A, 2000, CIRCULATION, V101, P1519, DOI 10.1161/01.CIR.101.13.1519; SULLIVAN CE, 1981, LANCET, V1, P862; Teramoto S, 2003, CHEST, V124, P767, DOI 10.1378/chest.124.2.767; Thalhofer S, 1997, Pneumologie, V51 Suppl 3, P767; THOMPSON AB, 1989, AM REV RESPIR DIS, V140, P1527, DOI 10.1164/ajrccm/140.6.1527; Veale D, 2000, EUR RESPIR J, V15, P326, DOI 10.1034/j.1399-3003.2000.15b18.x; Vgontzas AN, 2000, J CLIN ENDOCR METAB, V85, P1151, DOI 10.1210/jc.85.3.1151; Wenzel U, 1997, KIDNEY INT, V51, P770, DOI 10.1038/ki.1997.108; Woolhouse IS, 2002, THORAX, V57, P709, DOI 10.1136/thorax.57.8.709; Xu W, 2004, NEUROSCIENCE, V126, P313, DOI 10.1016/j.neuroscience.2004.03.055; Yokoe T, 2003, CIRCULATION, V107, P1129, DOI 10.1161/01.CIR.0000052627.99976.18	46	86	92	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					597	603		10.1016/j.jaci.2006.11.638	http://dx.doi.org/10.1016/j.jaci.2006.11.638			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17261329				2022-12-18	WOS:000244925000011
J	Campo, P; Kalra, HK; Levin, L; Reponen, T; Olds, R; Lummus, ZL; Cho, SH; Hershey, GKK; Lockey, J; Villareal, M; Stanforth, S; LeMasters, G; Bernstein, DI				Campo, Paloma; Kalra, Harpinder K.; Levin, Linda; Reponen, Tiina; Olds, Rolanda; Lummus, Zana L.; Cho, Seung-Hyun; Hershey, Gurjit K. Khurana; Lockey, James; Villareal, Manuel; Stanforth, Sherry; LeMasters, Grace; Bernstein, David I.			Influence of dog ownership and high endotoxin on wheezing and atopy during infancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; birth cohort; wheeze; house dust; pet ownership	HOUSE-DUST ENDOTOXIN; HAY-FEVER; WRITTEN QUESTIONNAIRE; DECREASED PREVALENCE; CHILDHOOD ISAAC; TOBACCO-SMOKE; 1ST YEAR; ASTHMA; EXPOSURE; CHILDREN	Background: Increased exposure to microbial products early in life may protect from development of atopic disorders in childhood. Few studies have examined the relationship of endotoxin exposure and pet ownership on atopy and wheezing during infancy. Objective: Evaluate relationships among high endotoxin exposure, pet ownership, atopy, and wheezing in high-risk infants. Methods: Infants (n = 532; mean age, 12.5 +/- 0.8 months) with at least 1 parent with confirmed atopy were recruited. A complete medical history and skin prick testing to foods and aeroallergens were performed at age 1 year. House dust samples were analyzed for endotoxin. Results: Prevalences of wheezing were not independently associated with dog or cat ownership or endotoxin levels. Percutaneous reactivity to at least 1 allergen was observed in 28.6% of infants. Univariate analyses showed significant associations of any wheezing, recurrent wheezing, and recurrent wheezing with an event with daycare attendance, number of siblings, respiratory infections, maternal smoking, and history of parental asthma. Logistic regression adjusting for the latter variables showed that recurrent wheezing (odds ratio, 0.4; 95% CI, 0.1-0.9) as well as 2 other wheeze outcomes were significantly reduced in homes with high endotoxin exposure in the presence of 2 or more dogs. Conclusion: Pet ownership or endotoxin did not independently modify aeroallergen sensitization or wheezing during infancy. However, high endotoxin exposure in the presence of multiple dogs was associated with reduced wheezing in infants. Clinical implications: A home environment with many dogs and high levels of endotoxin may be conducive to reduced wheezing in infancy.	Univ Cincinnati, Dept Internal Med, Div Immunol, Cincinnati, OH 45267 USA; Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Bernstein, DI (corresponding author), Univ Cincinnati, Dept Internal Med, Div Immunol, POB 670563, Cincinnati, OH 45267 USA.	bernstdd@ucmail.uc.edu		Cho, Seung-Hyun/0000-0001-9821-6667; Khurana Hershey, Gurjit/0000-0001-6663-977X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011170] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES011170, 1-R01-ES11170-04, R01 ES011170-04] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adler A, 2005, J ALLERGY CLIN IMMUN, V115, P67, DOI 10.1016/j.jaci.2004.10.008; Almqvist C, 2003, CLIN EXP ALLERGY, V33, P1190, DOI 10.1046/j.1365-2222.2003.01764.x; Arlian LG, 1999, J ALLERGY CLIN IMMUN, V104, P707, DOI 10.1016/S0091-6749(99)70349-0; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bjorksten B, 1999, J ALLERGY CLIN IMMUN, V104, P1119; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Bottcher MF, 2003, CLIN EXP ALLERGY, V33, P295, DOI 10.1046/j.1365-2222.2003.01562.x; Celedon JC, 1999, PEDIATRICS, V104, P495, DOI 10.1542/peds.104.3.495; CHO SH, 2006, IN PRESS ANN ALLERGY; D'Amato G, 2002, Monaldi Arch Chest Dis, V57, P161; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Helsel DR, 2005, ENVIRON SCI TECHNOL, V39, p419A, DOI 10.1021/es053368a; Holt PG, 1997, THORAX, V52, P1, DOI 10.1136/thx.52.1.1; Hopkin JM, 1999, CLIN EXP ALLERGY, V29, P733; *INS CORP, 2000, S PLUS; Jaakkola JJK, 2002, SCAND J WORK ENV HEA, V28, P71; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Kuehni CE, 2001, LANCET, V357, P1821, DOI 10.1016/S0140-6736(00)04958-8; LEMASTERS GK, 2003, AM J RESP CRIT CARE, V167, pA335; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755, DOI 10.1016/S0091-6749(99)70284-8; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Martinez FD, 2001, RESPIR RES, V2, P129, DOI 10.1186/rr48; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Murray CS, 2004, PEDIATR PULM, V37, P492, DOI 10.1002/ppul.20019; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Omran M, 1996, BRIT MED J, V312, P34, DOI 10.1136/bmj.312.7022.34; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Platts-Mills TAE, 2001, MEDIAT INFLAMM, V10, P288, DOI 10.1080/09629350152700902; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.05.014; Schram-Bijkerk D, 2005, CLIN EXP ALLERGY, V35, P1272, DOI 10.1111/j.1365-2222.2005.02339.x; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; SHAW RA, 1992, CLIN EXP ALLERGY, V22, P561, DOI 10.1111/j.1365-2222.1992.tb00166.x; SMITH J M, 1971, Clinical Allergy, V1, P57, DOI 10.1111/j.1365-2222.1971.tb02447.x; SMITH JM, 1976, BRIT J DIS CHEST, V70, P73; Sole D, 1998, J INVEST ALLERG CLIN, V8, P376; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; VANASPEREN PP, 1984, J ALLERGY CLIN IMMUN, V73, P381, DOI 10.1016/0091-6749(84)90412-3; VANTO T, 1983, ACTA PAEDIATR SCAND, V72, P571, DOI 10.1111/j.1651-2227.1983.tb09773.x; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2002, J ALLERGY CLIN IMMUN, V109, pS525, DOI 10.1067/mai.2002.124565; Waser M, 2005, ALLERGY, V60, P177, DOI 10.1111/j.1398-9995.2004.00645.x; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	50	86	87	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1271	1278		10.1016/j.jaci.2006.08.008	http://dx.doi.org/10.1016/j.jaci.2006.08.008			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157656	Green Accepted			2022-12-18	WOS:000242880300010
J	Ogawa, Y; Calhoun, WJ				Ogawa, Yoshiko; Calhoun, William J.			The role of leukotrienes in airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						cysteinyl leukotrienes; asthma; inflammation	SEGMENTAL ANTIGEN CHALLENGE; CYSTEINYL LEUKOTRIENES; RECEPTOR ANTAGONIST; INHALED CORTICOSTEROIDS; ALVEOLAR MACROPHAGES; C-4 SYNTHASE; DOUBLE-BLIND; EOSINOPHILIC INFLAMMATION; 5-LIPOXYGENASE INHIBITOR; FLUTICASONE PROPIONATE	Cysteinyl leukotrienes (cysLTs) are a class of closely structurally related lipid molecules, originally described as slow-reacting substance of anaphylaxis, with a myriad of biologic functions. These activities include producing smooth muscle contraction and mucus secretion, recruiting allergic inflammatory cells, modulating cytokine production, influencing neural transmission, and altering structural changes in the airway. Administration of cysLTs to animals and human subjects reproduces many features of allergic inflammation and asthma. Leukotriene (LT) blockers have independent efficacy in asthma and improve pulmonary function when added to inhaled steroids. Conversely, blockade of this pathway both in animals and in human subjects results in important reductions in inflammation and its consequences and might reduce structural changes of remodeling. These data collectively make a compelling case for an important role of cysLTs in airway inflammation and asthma. However, the magnitude of effect of anti-LTs is smaller than that of corticosteroids, and there is more variability in benefit of LT blockade than is seen with inhaled steroids. In addition, adding anti-LTs to inhaled steroids in asthmatic patients does not appear to produce added anti-inflammatory benefit. Genetic polymorphisms and environmental factors, such as tobacco smoke exposure, might underlie some of the heterogeneity of response to LT blockers.	Univ Texas, Med Branch, Div Allergy Pulm Immunol Crit Care & Sleep, APICS, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Calhoun, WJ (corresponding author), Univ Texas, Med Branch, Div Allergy Pulm Immunol Crit Care & Sleep, APICS, 5-132 JSA,Rt 0561,UTMB 301 Univ Blvd, Galveston, TX 77555 USA.	William.Calhoun@utmb.edu		Calhoun, William/0000-0001-7075-712X				Aronoff DM, 2004, J IMMUNOL, V173, P559, DOI 10.4049/jimmunol.173.1.559; Bailie MB, 1996, J IMMUNOL, V157, P5221; Barnes N, 2005, J ALLERGY CLIN IMMUN, V115, P47, DOI 10.1016/j.jaci.2004.10.011; BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; BENEFRAIM S, 1994, INT J IMMUNOPHARMACO, V16, P397, DOI 10.1016/0192-0561(94)90027-2; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; BRACH MA, 1992, EUR J IMMUNOL, V22, P2705, DOI 10.1002/eji.1830221034; Busse W, 2005, CHEST, V127, P1312, DOI 10.1378/chest.127.4.1312; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Calhoun WJ, 1998, AM J RESP CRIT CARE, V157, pS238, DOI 10.1164/ajrccm.157.6.mar6; Calhoun WJ, 1998, AM J RESP CRIT CARE, V157, P1381, DOI 10.1164/ajrccm.157.5.9609014; CALHOUN WJ, 1988, AM J RESP CRIT CAR S, V157, pS238; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chibana K, 2003, J IMMUNOL, V170, P4290, DOI 10.4049/jimmunol.170.8.4290; Coffey MJ, 1998, J CLIN INVEST, V102, P663, DOI 10.1172/JCI2117; Crimi N, 2003, J ALLERGY CLIN IMMUN, V111, P833, DOI 10.1067/mai.2003.161; Currie GP, 2003, AM J RESP CRIT CARE, V167, P1232, DOI 10.1164/rccm.200209-1116OC; Currie GP, 2005, CHEST, V128, P2954, DOI 10.1378/chest.128.4.2954; DAHLEN SE, 1998, EUR RESPIR REV, V8, P184; Dennis EA, 2000, AM J RESP CRIT CARE, V161, pS32, DOI 10.1164/ajrccm.161.supplement_1.ltta-7; Diamant Z, 1997, AM J RESP CRIT CARE, V155, P1247, DOI 10.1164/ajrccm.155.4.9105062; DIAMANT Z, 1995, J ALLERGY CLIN IMMUN, V95, P42, DOI 10.1016/S0091-6749(95)70151-6; Doull IJM, 1997, BMJ-BRIT MED J, V315, P858, DOI 10.1136/bmj.315.7112.858; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; DUCHARME F, 2006, COCHRANE DATABASE SY; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953, DOI 10.1164/ajrccm.149.4.8143061; Dwyer JH, 2004, NEW ENGL J MED, V350, P29, DOI 10.1056/NEJMoa025079; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; Flamand L, 2004, J INFECT DIS, V189, P2001, DOI 10.1086/386374; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; FRIEDMAN BS, 1993, AM REV RESPIR DIS, V147, P839, DOI 10.1164/ajrccm/147.4.839; Fujii M, 2005, CHEST, V128, P3148, DOI 10.1378/chest.128.5.3148; Hallstrand TS, 2005, AM J RESP CRIT CARE, V172, P679, DOI 10.1164/rccm.200412-1667OC; Hamilton AL, 1997, THORAX, V52, P348, DOI 10.1136/thx.52.4.348; Hasday JD, 2000, AM J RESP CRIT CARE, V161, P1229, DOI 10.1164/ajrccm.161.4.9904026; Henderson WR, 2006, AM J RESP CRIT CARE, V173, P718, DOI 10.1164/rccm.200501-088OC; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Holgate ST, 2000, AM J RESP CRIT CARE, V161, pS147, DOI 10.1164/ajrccm.161.supplement_1.ltta-29; Holgate ST, 1996, J ALLERGY CLIN IMMUN, V98, P1, DOI 10.1016/S0091-6749(96)70220-8; Holgate Stephen T., 2003, Journal of Allergy and Clinical Immunology, V111, pS18, DOI 10.1067/mai.2003.25; Holgate Stephen T., 2003, Journal of Allergy and Clinical Immunology, V111, pS1, DOI 10.1067/mai.2003.107; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; Jakobsson PJ, 2000, AM J RESP CRIT CARE, V161, pS20, DOI 10.1164/ajrccm.161.supplement_1.ltta-5; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; Kane GC, 1996, J ALLERGY CLIN IMMUN, V97, P646, DOI 10.1016/S0091-6749(96)70310-X; KANWAR S, 1995, CIRC RES, V77, P879, DOI 10.1161/01.RES.77.5.879; Korenblat PE, 2001, ANN ALLERG ASTHMA IM, V86, P31, DOI 10.1016/S1081-1206(10)62309-5; KRELL RD, 1994, ANN NY ACAD SCI, V744, P289, DOI 10.1111/j.1749-6632.1994.tb52746.x; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Lam BK, 2000, AM J RESP CRIT CARE, V161, pS16, DOI 10.1164/ajrccm.161.supplement_1.ltta-4; Lazarus SC, 1998, AM J MANAG CARE, V4, P841; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881, DOI 10.1164/ajrccm.161.6.9907054; Leigh R, 2002, AM J RESP CRIT CARE, V166, P1212, DOI 10.1164/rccm.200206-509OC; Lemanske RF, 1997, JAMA-J AM MED ASSOC, V278, P1855, DOI 10.1001/jama.278.22.1855; Levy BD, 2005, AM J RESP CRIT CARE, V172, P824, DOI 10.1164/rccm.200410-1413OC; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; Maeba S, 2005, ANN ALLERG ASTHMA IM, V94, P670, DOI 10.1016/S1081-1206(10)61326-9; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; MANSO G, 1992, EUR RESPIR J, V5, P712; McAlexander MA, 1998, J PHARMACOL EXP THER, V285, P602; Mellor EA, 2002, J EXP MED, V195, P583, DOI 10.1084/jem.20020044; Mellor EA, 2001, P NATL ACAD SCI USA, V98, P7964, DOI 10.1073/pnas.141221498; Meltzer SS, 1996, AM J RESP CRIT CARE, V153, P931, DOI 10.1164/ajrccm.153.3.8630575; Menard G, 2000, AM J RESP CELL MOL, V23, P572, DOI 10.1165/ajrcmb.23.4.4152; Minoguchi K, 2002, CHEST, V121, P732, DOI 10.1378/chest.121.3.732; Mondino C, 2004, J ALLERGY CLIN IMMUN, V114, P761, DOI 10.1016/j.jaci.2004.06.054; Mulder A, 1999, AM J RESP CRIT CARE, V159, P1562, DOI 10.1164/ajrccm.159.5.9810095; Nakamura Y, 1998, THORAX, V53, P835, DOI 10.1136/thx.53.10.835; *NAT ASTHM ED PREV, 1997, GUID DIAGN MAN ASTHM; Nathan RA, 2005, CHEST, V128, P1910, DOI 10.1378/chest.128.4.1910; Nathan RA, 1998, J ALLERGY CLIN IMMUN, V102, P935, DOI 10.1016/S0091-6749(98)70331-8; Nathan RA, 2001, ANN ALLERG ASTHMA IM, V86, P9, DOI 10.1016/S1081-1206(10)62306-X; O'Byrne PM, 2000, AM J RESP CRIT CARE, V161, pS186, DOI 10.1164/ajrccm.161.supplement_2.a1q4-8; O'Byrne PM, 2000, AM J RESP CRIT CARE, V161, pS68, DOI 10.1164/ajrccm.161.supplement_1.ltta-14; Obase Y, 2002, CHEST, V121, P143, DOI 10.1378/chest.121.1.143; OBYRNE PM, 1994, ANN NY ACAD SCI, V744, P251, DOI 10.1111/j.1749-6632.1994.tb52743.x; Oommen A, 2003, LANCET, V362, P1433, DOI 10.1016/S0140-6736(03)14685-5; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1472, DOI 10.1164/ajrccm/147.6_Pt_1.1472; Overbeek SE, 2004, CLIN EXP ALLERGY, V34, P1388, DOI 10.1111/j.1365-2222.2004.02041.x; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453, DOI 10.1165/ajrcmb.19.3.2999; Parker N, 2002, J SUSTAIN AGR, V20, P1; Pavord ID, 1999, AM J RESP CRIT CARE, V160, P1905, DOI 10.1164/ajrccm.160.6.9903114; Pedersen KE, 1997, J PHARMACOL EXP THER, V281, P655; Peters-Golden M, 2002, AM J RESP CRIT CARE, V165, P229, DOI 10.1164/ajrccm.165.2.2104050; Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8; Peters-Golden Marc, 2003, Journal of Allergy and Clinical Immunology, V111, pS37, DOI 10.1067/mai.2003.23; PHAN SH, 1987, J LEUKOCYTE BIOL, V42, P106, DOI 10.1002/jlb.42.2.106; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; Powell WS, 2005, PROG LIPID RES, V44, P154, DOI 10.1016/j.plipres.2005.04.002; Pynaert G, 1999, MOL MED, V5, P685, DOI 10.1007/BF03401987; Radmark OP, 2000, AM J RESP CRIT CARE, V161, pS11, DOI 10.1164/ajrccm.161.supplement_1.ltta-3; Ram FSF, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004403.pub2; Riddick CA, 1997, EUR J BIOCHEM, V246, P112, DOI 10.1111/j.1432-1033.1997.00112.x; Ringdal Nils, 2003, Drugs, V63 Suppl 2, P21, DOI 10.2165/00003495-200363002-00003; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Robinson DS, 2001, LANCET, V357, P2007, DOI 10.1016/S0140-6736(00)05113-8; Rodger IW, 2000, AM J RESP CRIT CARE, V161, pS7, DOI 10.1164/ajrccm.161.supplement_1.ltta-2; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; Sade K, 2005, ISR MED ASSOC J, V7, P792; Sampson Anthony P., 2003, Journal of Allergy and Clinical Immunology, V111, pS49, DOI 10.1067/mai.2003.24; SAMPSON AP, 1995, ARCH DIS CHILD, V73, P221, DOI 10.1136/adc.73.3.221; Samuelsson B, 2000, AM J RESP CRIT CARE, V161, pS2, DOI 10.1164/ajrccm.161.supplement_1.ltta-1; Sandrini A, 2003, CHEST, V124, P1334, DOI 10.1378/chest.124.4.1334; SEBALDT RJ, 1990, P NATL ACAD SCI USA, V87, P6974, DOI 10.1073/pnas.87.18.6974; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; Serezani CHC, 2005, BLOOD, V106, P1067, DOI 10.1182/blood-2004-08-3323; SERHAN CN, 1982, BIOCHEM BIOPH RES CO, V107, P1006, DOI 10.1016/0006-291X(82)90622-2; SHINDO K, 1995, EUR RESPIR J, V8, P605; Shindo K, 1998, EUR RESPIR J, V11, P1098, DOI 10.1183/09031936.98.11051098; Song P, 1998, AM J RESP CRIT CARE, V158, P1809, DOI 10.1164/ajrccm.158.6.9801105; SPADA CS, 1997, J LEUKOCYTE BIOL, V55, P183; Suissa S, 1997, ANN INTERN MED, V126, P177, DOI 10.7326/0003-4819-126-3-199702010-00001; Szczeklik A, 2000, AM J RESP CRIT CARE, V161, pS142, DOI 10.1164/ajrccm.161.supplement_1.ltta-28; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Thivierge M, 2001, J IMMUNOL, V167, P2855, DOI 10.4049/jimmunol.167.5.2855; Van Sambeek R, 2000, J ALLERGY CLIN IMMUN, V106, P72, DOI 10.1067/mai.2000.107603; Volovitz B, 1999, J ALLERGY CLIN IMMUN, V104, P1162, DOI 10.1016/S0091-6749(99)70008-4; Wenzel SE, 1998, AM J MED, V104, P287, DOI 10.1016/S0002-9343(98)00031-X; Woszczek G, 2005, J IMMUNOL, V175, P5152, DOI 10.4049/jimmunol.175.8.5152; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	125	86	93	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					789	798		10.1016/j.jaci.2006.08.009	http://dx.doi.org/10.1016/j.jaci.2006.08.009			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030228				2022-12-18	WOS:000241434200002
J	Rodriguez-Pena, R; Lopez, S; Mayorga, C; Antunez, C; Fernandez, TD; Torres, MJ; Blanca, M				Rodriguez-Pena, Rebeca; Lopez, Soledad; Mayorga, Cristobalina; Antunez, Cristina; Fernandez, Tahia D.; Torres, Maria J.; Blanca, Miguel			Potential involvement of dendritic cells in delayed-type hypersensitivity reactions to beta-lactams	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						delayed-type hypersensitivity; dendritic cells; T cells; cell activation; drug; beta-lactam	CYTOTOXIC T-CELLS; IMMUNE-RESPONSES; CONTACT SENSITIVITY; DRUG-REACTIONS; TNF-ALPHA; EXPRESSION; MATURATION; HAPTENS; ANTIGEN; CD4(+)	Background: Although the involvement of T cells in delayed reactions to drugs has been studied, little is known about the interaction between the drug and the antigen-presenting cells. Dendritic cells (DCs) are professional antigen-presenting cells essential for initiating T-cell responses. Their ability is regulated in a process known as maturation, by which they modulate the effector immune response. Objectives: We studied the role of DCs in subjects who had a delayed-type hypersensitivity reaction to amoxicillin to assess the effect on the pattern of maturation and determine the capacity of DCs to activate T lymphocytes. Methods: We examined the consequences of the interaction between monocyte-derived DCs, lymphocytes, and amoxicillin by means of phenotypic and functional studies, including endocytosis, proliferation, and cytokine production. Results: Amoxicillin drove DCs from hypersensitive subjects to a phenotypic and functional semimature status, inducing a T-cell proliferation response. Conclusions: In delayed reactions to amoxicillin, DCs play a relevant role in inducing the T-cell responses. These results are useful not only to understand the mechanism but potentially as a possible approach to diagnosis. Clinical implications: A better understanding of T-cell and DC involvement in delayed-type hypersensitivity reactions is needed. This in vitro assay might provide clues to the diagnostic evaluation of patients allergic to penicillins.			Rodriguez-Pena, R (corresponding author), Hosp Civil, Res Lab, Pl Hosp Civil,S-N 29009, Malaga, Spain.	rodriguez.exts@juntadeandalucia.es	Fernández, Tahia Diana/J-2404-2012; Mayorga, Lina/FBO-7730-2022; Lopez, Soledad/O-5873-2015; Torres, María José/T-3518-2017; Torres, Maria/GVU-3391-2022; Mayorga, Cristobalina/D-7167-2018	Fernández, Tahia Diana/0000-0003-0625-2156; Lopez, Soledad/0000-0003-3727-1843; Torres, María José/0000-0001-5228-471X; Mayorga, Cristobalina/0000-0001-8852-8077				Aiba S, 1997, EUR J IMMUNOL, V27, P3031, DOI 10.1002/eji.1830271141; Aiba S, 2000, IMMUNOLOGY, V101, P68, DOI 10.1046/j.1365-2567.2000.00087.x; Arrighi JF, 2001, J IMMUNOL, V166, P3837, DOI 10.4049/jimmunol.166.6.3837; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barbaud A, 2001, CONTACT DERMATITIS, V45, P321, DOI 10.1034/j.1600-0536.2001.450601.x; Beeler A, 2006, J ALLERGY CLIN IMMUN, V117, P455, DOI 10.1016/j.jaci.2005.10.030; Boisleve F, 2004, J INVEST DERMATOL, V123, P494, DOI 10.1111/j.0022-202X.2004.23229.x; BRANDER C, 1995, J IMMUNOL, V155, P2670; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Coleman J. W., 1998, Clinical and Experimental Allergy, V28, P79; ENK AH, 1993, J IMMUNOL, V150, P3698; ENK AH, 1992, P NATL ACAD SCI USA, V89, P1398, DOI 10.1073/pnas.89.4.1398; Gorbachev AV, 2004, J IMMUNOL, V172, P2286, DOI 10.4049/jimmunol.172.4.2286; Granucci F, 2001, EUR J IMMUNOL, V31, P2539, DOI 10.1002/1521-4141(200109)31:9<2539::AID-IMMU2539>3.0.CO;2-9; HERTL M, 1995, J INVEST DERMATOL, V105, P95; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hulette BC, 2002, TOXICOL APPL PHARM, V182, P226, DOI 10.1006/taap.2002.9447; Kleindienst P, 2005, J IMMUNOL, V174, P3941, DOI 10.4049/jimmunol.174.7.3941; Lanzavecchia A, 2005, CURR OPIN IMMUNOL, V17, P326, DOI 10.1016/j.coi.2005.04.010; Luque I, 2001, ALLERGY, V56, P611, DOI 10.1034/j.1398-9995.2001.000115.x; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Posadas SJ, 2002, J ALLERGY CLIN IMMUN, V109, P155, DOI 10.1067/mai.2002.120563; Romano A, 2004, ALLERGY, V59, P1153, DOI 10.1111/j.1398-9995.2004.00678.x; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; Rustemeyer T, 2003, EXP DERMATOL, V12, P682, DOI 10.1034/j.1600-0625.2003.00077.x; Ryan CA, 2005, TOXICOL SCI, V88, P4, DOI 10.1093/toxsci/kfi245; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schnyder B, 2000, CLIN EXP ALLERGY, V30, P590; SIRAGANIAN RP, 1988, ALLERGY PRINCIPLES P, P105; Torres MJ, 2006, INT J IMMUNOPATH PH, V19, P119; von Bergwelt-Baildon MS, 2002, BLOOD, V99, P3319, DOI 10.1182/blood.V99.9.3319; Weltzien HU, 1996, TOXICOLOGY, V107, P141, DOI 10.1016/0300-483X(95)03253-C; Yawalkar N, 2000, CLIN EXP ALLERGY, V30, P847	36	86	91	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					949	956		10.1016/j.jaci.2006.07.013	http://dx.doi.org/10.1016/j.jaci.2006.07.013			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030251				2022-12-18	WOS:000241434200026
J	Ying, S; Meng, Q; Scadding, G; Parikh, A; Corrigan, CJ; Lee, TH				Ying, S; Meng, Q; Scadding, G; Parikh, A; Corrigan, CJ; Lee, TH			Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin; rhinosinusitis; prostaglandin E-2; EP receptor; asthma	PROSTAGLANDIN E-2 RECEPTORS; MODULATE TNF-ALPHA; PROSTANOID RECEPTORS; ASTHMATIC SUBJECTS; IL-6 PRODUCTION; IN-VITRO; NEUTROPHILS; CHALLENGE; HISTAMINE; RELEASE	Background: Impaired braking of inflammatory cell cysteinyl leukotriene production by prostaglandin (PG) E-2 has been implicated in the pathogenesis of aspirin exacerbated airways disease, but the mechanism is obscure. PGE(2) acts via G-protein-coupled receptors, E-prostanoid (EP)(1-4), but there is little information on the expression of PGE(2) receptors in this condition. Objective: To address the hypothesis that expression of 1 or more EP receptors on nasal mucosal inflammatory cells is deficient in patients with aspirin-sensitive compared with nonaspirin-sensitive polypoid rhinosinusitis. Methods: By using specific antibodies, immunohistochemistry, and image analysis, we measured the expression of EP1-4 in nasal biopsies from patients with aspirin-sensitive (n = 12) and nonaspirin-sensitive (n = 10) polypoid rhinosinusitis and normal controls (n = 9). Double-staining was used to phenotype inflammatory leukocytes expressing EP1-4. Results: Global mucosal expression of EP1 and EP2, but not EP3 or EP4, immunoreactivity was significantly elevated in aspirin-sensitive and nonaspirin-sensitive rhinosinusitis compared with controls (P < .03). This was attributable principally to elevated expression on tubulin(+) epithelial cells and Mucin 5 subtypes A and B (Muc-5AC(+)) goblet cells. In contrast, the percentages of neutrophils, mast cells, eosinophils, and T cells expressing EP2, but not EP1, EP3, or EP4, were significantly reduced (P <= .04) in the aspirin-sensitive compared with nonaspirin-sensitive patients. Conclusion: The data suggest a possible role for PGE(2) in mediating epithelial repair in rhinitis and asthma. Because PGE(2) exerts a range of inhibitory actions on inflammatory leukocytes via the EP2 receptor, its reduced expression in aspirin-sensitive rhinosinusitis may be partly responsible for the increased inflammatory infiltrate and production of cysteinyl leukotrienes that characterize aspirin-sensitive disease.	Univ London Kings Coll, MRC, London, England; Asthma UK Ctr, Dept Asthma Allergy & Resp Sci, London, England; Royal Natl Throat Nose & Ear Hosp, London, England	University of London; King's College London; University College London Hospitals NHS Foundation Trust; University of London; University College London	Ying, S (corresponding author), Guys Hosp, Guys Kings & St Thomas Sch Med, Dept Asthma Allergy & Resp Sci, 5th Floor Thomas Guy House, London SE1 9RT, England.	ying.sun@kcl.ac.uk	Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059; Corrigan, Chris/0000-0002-0706-6534	MRC [G0400897, G9805965] Funding Source: UKRI; Medical Research Council [G0400897, G9805965] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akaogi J, 2004, J LEUKOCYTE BIOL, V76, P227, DOI 10.1189/jlb.1203627; Burgess JK, 2004, J ALLERGY CLIN IMMUN, V113, P876, DOI 10.1016/j.jaci.2004.02.029; Celik G, 2001, CLIN EXP ALLERGY, V31, P1615, DOI 10.1046/j.1365-2222.2001.01074.x; Chan CL, 2000, BRIT J PHARMACOL, V129, P589, DOI 10.1038/sj.bjp.0703072; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Corrigan C, 2005, J ALLERGY CLIN IMMUN, V115, P316, DOI 10.1016/j.jaci.2004.10.051; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; FISCHER A, 1985, J IMMUNOL, V134, P815; Higashi N, 2002, CLIN EXP ALLERGY, V32, P1484, DOI 10.1046/j.1365-2745.2002.01507.x; Kanamori Y, 1997, LIFE SCI, V60, P1407, DOI 10.1016/S0024-3205(97)00086-6; KANEKO F, 1995, ARCH DERMATOL RES, V287, P539, DOI 10.1007/BF00374073; KONDA Y, 1990, J CLIN INVEST, V86, P1897, DOI 10.1172/JCI114922; Kowalski ML, 2000, AM J RESP CRIT CARE, V161, P391, DOI 10.1164/ajrccm.161.2.9902034; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; Mastalerz L, 2001, CLIN EXP ALLERGY, V31, P1036, DOI 10.1046/j.1365-2222.2001.01105.x; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Nasser SMS, 1996, AM J RESP CRIT CARE, V153, P90, DOI 10.1164/ajrccm.153.1.8542168; NASSER SMS, 1995, AM J RESP CRIT CARE, V151, P1326, DOI 10.1164/ajrccm.151.5.7735581; Nataraj C, 2001, J CLIN INVEST, V108, P1229, DOI 10.1172/JCI13640; ORTOLANI C, 1987, ANN ALLERGY, V59, P106; Peacock CD, 1999, J ALLERGY CLIN IMMUN, V104, P153, DOI 10.1016/S0091-6749(99)70127-2; PEIZCHALSKA M, 2003, J ALLERGY CLIN IMMUN, V111, P1041; Picado Cesar, 2002, Curr Allergy Asthma Rep, V2, P488, DOI 10.1007/s11882-002-0089-8; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; Sousa AR, 1997, THORAX, V52, P940, DOI 10.1136/thx.52.11.940; Sousa AR, 1997, AM J RESP CRIT CARE, V156, P1384, DOI 10.1164/ajrccm.156.5.9702072; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Staples KJ, 2000, BIOCHEM BIOPH RES CO, V273, P811, DOI 10.1006/bbrc.2000.3023; Swierczynska M, 2003, J ALLERGY CLIN IMMUN, V112, P995, DOI 10.1016/S0091-6749(03)02015-3; Szczeklik A, 1999, J ALLERGY CLIN IMMUN, V104, P5, DOI 10.1016/S0091-6749(99)70106-5; Takafuji V, 2000, PROSTAG LEUKOTR ESS, V63, P223, DOI 10.1054/plef.2000.0144; Varga EM, 1999, EUR RESPIR J, V14, P610, DOI 10.1034/j.1399-3003.1999.14c21.x; WHEELDON A, 1993, BRIT J PHARMACOL, V108, P1051, DOI 10.1111/j.1476-5381.1993.tb13504.x; Yamane H, 2000, BIOCHEM BIOPH RES CO, V278, P224, DOI 10.1006/bbrc.2000.3779; Ying S, 2004, J ALLERGY CLIN IMMUN, V114, P1309, DOI 10.1016/j.jaci.2004.08.034	37	86	88	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					312	318		10.1016/j.jaci.2005.10.037	http://dx.doi.org/10.1016/j.jaci.2005.10.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461132	Bronze			2022-12-18	WOS:000235687300013
J	Thorley-Lawson, DA				Thorley-Lawson, DA			EBV the prototypical human tumor virus - just how bad is it?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Epstein-Barr virus; carcinoma; lymphoma; persistent infection; latency; B cell; memory	EPSTEIN-BARR-VIRUS; MEMORY B-CELLS; LINKED LYMPHOPROLIFERATIVE-DISEASE; MUCOSAL IMMUNE-SYSTEM; PERSISTENCE IN-VIVO; BURKITTS-LYMPHOMA; INFECTIOUS-MONONUCLEOSIS; HODGKINS-DISEASE; TERMINAL DIFFERENTIATION; NASOPHARYNGEAL CARCINOMA	EBV was the first candidate human tumor virus. It is found in several human cancers, particularly lymphomas and carcinomas, and has potent transforming activity in vitro. Yet the virus persists benignly for the lifetime of more than 90% of the human population. Thus it seems that EBV has the potential to be highly pathogenic yet rarely manifests this potential. Studies over the last several years show this is because the virus actually persists in resting memory B cells and not proliferating cells. EBV needs its growth-promoting ability to gain access to the memory compartment but has evolved to minimize its oncogenic potential. These studies also reveal that the different EBV-associated tumors apparently arise from different and discrete stages in the life cycle of B cells latently infected with EBV. This raises the question of how actively EBV participates in the development of human tumors. Does the virus cause the disease, or is it simply a passenger? In the case of immunoblastic lymphoma in the immunosuppressed patient, the virus almost certainly plays a causative role, but in other cases, such as Burkitt's lymphoma, the contribution of EBV remains less clear.	Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA	Tufts University	Thorley-Lawson, DA (corresponding author), Tufts Univ, Sch Med, Dept Pathol, Jaharis Bldg,150 Harrison Ave, Boston, MA 02111 USA.	David.Thorley-Lawson@tufts.edu			NCI NIH HHS [R01 CA65883] Funding Source: Medline; PHS HHS [R01 A1062989, R01 A118757] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065883] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; ANDERSSONANVRET M, 1977, INT J CANCER, V20, P486, DOI 10.1002/ijc.2910200403; Arpin C, 1997, J EXP MED, V186, P931, DOI 10.1084/jem.186.6.931; ARPIN C, 1995, SCIENCE, V268, P720, DOI 10.1126/science.7537388; Babcock GJ, 2000, IMMUNITY, V13, P497, DOI 10.1016/S1074-7613(00)00049-2; Babcock GJ, 1999, J EXP MED, V190, P567, DOI 10.1084/jem.190.4.567; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; Brandtzaeg P, 1999, IMMUNOL TODAY, V20, P141, DOI 10.1016/S0167-5699(98)01413-3; Brandtzaeg P, 1999, IMMUNOL TODAY, V20, P267, DOI 10.1016/S0167-5699(99)01468-1; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BURKITT D, 1962, Ann R Coll Surg Engl, V30, P211; Calame KL, 2003, ANNU REV IMMUNOL, V21, P205, DOI 10.1146/annurev.immunol.21.120601.141138; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Casola S, 2004, NAT IMMUNOL, V5, P317, DOI 10.1038/ni1036; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; DEACON EM, 1993, J EXP MED, V177, P339, DOI 10.1084/jem.177.2.339; DETHE G, 1993, BLOOD CELLS, V19, P667; DETHE G, 1985, BURKITTS LYMPHOMA HU, P165; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; Faulkner GC, 1999, J VIROL, V73, P1555, DOI 10.1128/JVI.73.2.1555-1564.1999; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Glaser SL, 2003, CANCER, V98, P300, DOI 10.1002/cncr.11459; Glaser SL, 1997, INT J CANCER, V70, P375, DOI 10.1002/(SICI)1097-0215(19970207)70:4&lt;375::AID-IJC1&gt;3.0.CO;2-T; GOLDEN HD, 1973, J INFECT DIS, V127, P471, DOI 10.1093/infdis/127.4.471; Gottschalk S, 2005, LEUKEMIA LYMPHOMA, V46, P1, DOI 10.1080/10428190400002202; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1987, J IMMUNOL, V139, P313; GULLEY ML, 1992, CANCER, V70, P185, DOI 10.1002/1097-0142(19920701)70:1<185::AID-CNCR2820700129>3.0.CO;2-J; He B, 2003, J IMMUNOL, V171, P5215, DOI 10.4049/jimmunol.171.10.5215; HENLE W, 1967, SCIENCE, V157, P1064, DOI 10.1126/science.157.3792.1064; Henle W., 1979, EPSTEINBARR VIRUS, P61; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; Hochberg D, 2004, J VIROL, V78, P5194, DOI 10.1128/JVI.78.10.5194-5204.2004; Hochberg D, 2004, P NATL ACAD SCI USA, V101, P239, DOI 10.1073/pnas.2237267100; Joseph AM, 2000, J VIROL, V74, P9964, DOI 10.1128/JVI.74.21.9964-9971.2000; Karajannis MA, 1997, BLOOD, V89, P2856, DOI 10.1182/blood.V89.8.2856; Kelly G, 2002, NAT MED, V8, P1098, DOI 10.1038/nm758; Khan G, 1996, IMMUNITY, V5, P173, DOI 10.1016/S1074-7613(00)80493-8; Khanna R, 1999, IMMUNOL REV, V170, P49, DOI 10.1111/j.1600-065X.1999.tb01328.x; Khanna R, 1997, J VIROL, V71, P8340, DOI 10.1128/JVI.71.11.8340-8346.1997; KIEFF E, 2001, VIROLOGY, P2511; KLEIN U, 1995, MOL MED, V1, P495, DOI 10.1007/BF03401587; KLEM G, 1987, ADV VIRAL ONCOL, P207; Kuppers R, 1998, ANNU REV IMMUNOL, V16, P471, DOI 10.1146/annurev.immunol.16.1.471; Kurth J, 2000, IMMUNITY, V13, P485, DOI 10.1016/S1074-7613(00)00048-0; Kurth J, 2003, P NATL ACAD SCI USA, V100, P4730, DOI 10.1073/pnas.2627966100; Kurth J, 2002, EUR J IMMUNOL, V32, P3785, DOI 10.1002/1521-4141(200212)32:12<3785::AID-IMMU3785>3.0.CO;2-E; Laichalk LL, 2005, J VIROL, V79, P1296, DOI 10.1128/JVI.79.2.1296-1307.2005; Lenoir GM, 1987, ADV VIRAL ONCOL, V7, P173; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Liu YJ, 1997, IMMUNOL REV, V156, P111, DOI 10.1111/j.1600-065X.1997.tb00963.x; Miyashita EM, 1997, J VIROL, V71, P4882, DOI 10.1128/JVI.71.7.4882-4891.1997; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Niedobitek G, 1997, BLOOD, V90, P1664, DOI 10.1182/blood.V90.4.1664.1664_1664_1672; Niller HH, 2004, TRENDS MICROBIOL, V12, P495, DOI 10.1016/j.tim.2004.09.006; Oudejans JJ, 1996, J CLIN PATHOL, V49, P897, DOI 10.1136/jcp.49.11.897; Panagopoulos D, 2004, J VIROL, V78, P13253, DOI 10.1128/JVI.78.23.13253-13261.2004; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; Pegtel DM, 2004, J VIROL, V78, P12613, DOI 10.1128/JVI.78.22.12613-12624.2004; Perry M, 1998, IMMUNOL TODAY, V19, P414, DOI 10.1016/S0167-5699(98)01307-3; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; POPE JH, 1968, INT J CANCER, V3, P857, DOI 10.1002/ijc.2910030619; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; SEEMAYER TA, 1995, PEDIATR RES, V38, P471, DOI 10.1203/00006450-199510000-00001; SHIBATA D, 1992, AM J PATHOL, V140, P769; Takada K, 2001, SEMIN CANCER BIOL, V11, P461, DOI 10.1006/scbi.2001.0413; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; Thorley-Lawson DA, 2004, NEW ENGL J MED, V350, P1328, DOI 10.1056/NEJMra032015; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; THORLEYLAWSON DA, 2001, SAMPTERS IMMUNOLOGIC, P970; Timms JM, 2003, LANCET, V361, P217, DOI 10.1016/S0140-6736(03)12271-4; Tugizov SM, 2003, NAT MED, V9, P307, DOI 10.1038/nm830; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; Yu MC, 2002, SEMIN CANCER BIOL, V12, P421, DOI 10.1016/S1044579X02000858	83	86	93	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					251	261		10.1016/j.jaci.2005.05.038	http://dx.doi.org/10.1016/j.jaci.2005.05.038			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083776				2022-12-18	WOS:000235686400002
J	Schatz, M; Mosen, D; Apter, AJ; Zeiger, RS; Vollmer, WM; Stibolt, TB; Leong, A; Johnson, MS; Mendoza, G; Cook, EF				Schatz, M; Mosen, D; Apter, AJ; Zeiger, RS; Vollmer, WM; Stibolt, TB; Leong, A; Johnson, MS; Mendoza, G; Cook, EF			Relationships among quality of life, severity, and control measures in asthma: An evaluation using factor analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; severity; control; exacerbations; quality of life; factor analysis	HEALTH-CARE UTILIZATION; PULMONARY-FUNCTION; QUESTIONNAIRE; ASSOCIATION; VALIDATION; ADULTS	Background: Validated psychometric tools measuring quality of life, asthma control, and asthma severity have been developed, but their relationships with each other and with other important patient-centered outcomes have not been rigorously assessed. Objective: To use factor analysis to evaluate the relationships of these validated tools with each other and with other patient-centered outcomes. Methods: Surveys were completed by a random sample of 2854 Health Maintenance Organization members age 18 to 56 years with persistent asthma. Surveys included demographic information; validated tools measuring generic (Short Form-12; SF-12) and asthma-specific (juniper Mini Asthma Quality of Life Questionnaire; AQLQ) quality of life, asthma control (Asthma Therapy Assessment Questionnaire), and asthma symptom severity (Asthma Outcomes Monitoring System); self-described severity, control, and course over time; and history of acute exacerbations. Results: Principal component analysis suggested a 5-factor model that accounted for approximately 59% of the variability. The most prominent rotated factor reflected asthma symptom frequency (19.4% of variability), was measured by the symptom subscale of the AQLQ, and was the only factor significantly related to the Asthma Therapy Assessment Questionnaire, Asthma Outcomes Monitoring System, or the self-reported assessments of severity, control, or course. Other factors included symptom bother (12.1% of variability), reflected by the environment and emotion AQLQ subscales; activity limitation (13.9% of variability), reflected by the activity AQLQ subscale and the SF-12 physical component scale; mental health (8.3% of variability), reflected by the SF-12 mental component scale; and acute exacerbations (5.0% of variability), not measured by any of the validated scales. Conclusion: Distinct components of patient-reported asthma health status can be identified by factor analysis. Distinct constructs of severity versus control cannot be identified by the use of these tools alone.	Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA 92111 USA; Dept Allergy, Sacramento, CA USA; Dept Allergy, Vacaville, CA USA; Ctr Hlth Res, Portland, OR USA; Kaiser Permanente Med Care Program, Care Management Inst, Oakland, CA USA; Univ Penn, Sch Med, Dept Pulm & Crit Care Med, Div Allergy Immunol, Philadelphia, PA 19104 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Kaiser Permanente; Kaiser Permanente; University of Pennsylvania; Harvard University; Harvard T.H. Chan School of Public Health	Schatz, M (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	michael.x.schatz@kp.org	Leong, Albin/AAF-7215-2019	Zeiger, Robert/0000-0001-5788-5063				Apter AJ, 1999, J ALLERGY CLIN IMMUN, V103, P72, DOI 10.1016/S0091-6749(99)70528-2; BAILEY WC, 1992, AM J MED, V93, P263, DOI 10.1016/0002-9343(92)90231-Y; BAYLISS MS, 1999, ASTHMA OUTCOMES MONI; Cockcroft DW, 1996, J ALLERGY CLIN IMMUN, V98, P1016, DOI 10.1016/S0091-6749(96)80185-0; Eisner MD, 2002, ANN ALLERG ASTHMA IM, V89, P46, DOI 10.1016/S1081-1206(10)61910-2; Fuhlbrigge AL, 2004, CURR OPIN PULM MED, V10, P1, DOI 10.1097/00063198-200401000-00002; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Hatcher L, 2013, STEP BY STEP APPROAC; Juniper EF, 2004, EUR RESPIR J, V23, P287, DOI 10.1183/09031936.04.00064204; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Katz PP, 1999, J CLIN EPIDEMIOL, V52, P667, DOI 10.1016/S0895-4356(99)00026-8; Krommydas GC, 2004, RESP MED, V98, P220, DOI 10.1016/j.rmed.2003.09.018; Moy ML, 2001, AM J RESP CRIT CARE, V163, P924, DOI 10.1164/ajrccm.163.4.2008014; *NIH, 2002, 023659 NIH; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; ten Brinke A, 2001, AM J RESP CRIT CARE, V163, P1093, DOI 10.1164/ajrccm.163.5.2004020; Vollmer WM, 2004, ANN ALLERG ASTHMA IM, V93, P409, DOI 10.1016/S1081-1206(10)61406-8; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Yurk RA, 2004, AM J MANAG CARE, V10, P321; 2004, ASTHMA AM LANDMARK S	24	86	88	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1049	1055		10.1016/j.jaci.2005.02.008	http://dx.doi.org/10.1016/j.jaci.2005.02.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867865				2022-12-18	WOS:000229055100023
J	Liu, X; Beaty, TH; Deindl, P; Huang, SK; Lau, S; Sommerfeld, C; Fallin, D; Kao, WHL; Wahn, U; Nickel, R				Liu, X; Beaty, TH; Deindl, P; Huang, SK; Lau, S; Sommerfeld, C; Fallin, D; Kao, WHL; Wahn, U; Nickel, R			Associations between specific serum IgE response and 6 variants within the genes IL4, IL13, and IL4RA in German children: The German Multicenter Atopy Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sensitization; IL-4; IL-13; IL4RA; single nucleotide polymorphism	MITE-ALLERGEN EXPOSURE; RECEPTOR-ALPHA GENE; HOUSE-DUST MITES; 1ST 3 YEARS; PROMOTER POLYMORPHISM; CHILDHOOD ASTHMA; RISK-FACTOR; SUSCEPTIBILITY ALLELES; COCKROACH EXPOSURE; LINKAGE ANALYSIS	Background: Among many published studies of specific IgE response or atopy, only a few showed positive marginal effects for 6 potentially functional single nucleotide polymorphisms (SNPs; C-590T in the IL4 gene, C-1055T and Arg130Gln in the IL13 gene, and Ile50Val, Ser478Pro, and Gln551Arg in the IL4RA gene). SNPs were commonly considered individually, and therefore the true effect could be masked by other genes or environmental factors. Objective: We tested the relationship between these 6 SNPs and sensitization to food, mite, cat, and outdoor allergens in unrelated German children drawn from the Multicenter Atopy Study. Gene-gene and gene-environment interactions were also evaluated. Methods: Multiple logistic regression models were used for the analyses of 4 sensitization outcomes. Results: The variant C-1055T was significantly associated with increased risk of sensitization to food and outdoor allergens, with odds ratios of 3.49 (95% CI, 1.52-8.02) and 2.27 (95% CI, 1.04-4.94), respectively. The effects of the TT genotype on food sensitization appear to depend on variants in the IL4RA gene, in which marginally significant interaction terms were observed. Significant evidence supported an interaction between exposure to maternal smoking and variant Gln551Arg on risk of cat sensitization. In addition, we found that the effect of variant C-590T on sensitization to mite depended on Der p 1 allergen levels in carpet dust samples. Conclusions: These findings not only suggested that variants in the IL4, IL13, and IL4RA genes play an important role in controlling specific IgE response but also strengthened our understanding of gene-gene and gene-environment interaction on the development of specific sensitization in this study population.	Humboldt Univ, Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Sch Med, Div Clin Immunol, Baltimore, MD USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine	Nickel, R (corresponding author), Humboldt Univ, Charite, Dept Pediat Pneumol & Immunol, Augustenberger Pl 1, D-13353 Berlin, Germany.		Huang, Shau-Ku/F-5509-2010		NIAID NIH HHS [AI-052468] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052468] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bacharier LB, 2000, J ALLERGY CLIN IMMUN, V105, pS547, DOI 10.1016/S0091-6749(00)90059-9; Barnes KC, 1998, IMMUNOL TODAY, V19, P325, DOI 10.1016/S0167-5699(97)01241-3; Braback L, 2001, PEDIAT ALLERG IMM-UK, V12, P4, DOI 10.1034/j.1399-3038.2001.012001004.x; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919, DOI 10.1164/ajrccm.160.3.9812024; CHARPIN D, 1988, CHEST, V93, P758, DOI 10.1378/chest.93.4.758; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983, DOI 10.1164/ajrccm/143.5_Pt_1.983; Deichmann KA, 1998, CLIN EXP ALLERGY, V28, P151; Dewar JC, 1996, MONOGR ALLERGY, V33, P4; Fallin D, 2001, GENOME RES, V11, P143, DOI 10.1101/gr.148401; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Haagerup A, 2002, ALLERGY, V57, P680, DOI 10.1034/j.1398-9995.2002.23523.x; HALKEN S, 1995, ALLERGY, V50, P97; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hijazi Z, 2000, INT ARCH ALLERGY IMM, V122, P190, DOI 10.1159/000024396; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P436, DOI 10.1016/S0091-6749(98)70132-0; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Kawashima T, 1998, J MED GENET, V35, P502, DOI 10.1136/jmg.35.6.502; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; Kruse S, 1999, IMMUNOLOGY, V96, P365; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Kulig M, 1999, ALLERGY, V54, P220, DOI 10.1034/j.1398-9995.1999.00753.x; Kurz T, 2000, J ALLERGY CLIN IMMUN, V106, P925, DOI 10.1067/mai.2000.110557; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167, DOI 10.1067/mai.2000.107935; Liu X, 2003, J ALLERGY CLIN IMMUN, V112, P382, DOI 10.1067/mai.2003.1635; Mitsuyasu H, 1999, J IMMUNOL, V162, P1227; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Noguchi E, 1999, CLIN EXP ALLERGY, V29, P228; Noguchi E, 1999, AM J RESP CRIT CARE, V160, P342, DOI 10.1164/ajrccm.160.1.9807130; Noguchi E, 1998, CLIN EXP ALLERGY, V28, P449; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Ober C, 1999, CLIN EXP ALLERGY, V29, P11; Palmer LJ, 1998, AM J RESP CRIT CARE, V158, P1825, DOI 10.1164/ajrccm.158.6.9804037; Patuzzo C, 2000, J MED GENET, V37, P382, DOI 10.1136/jmg.37.5.382; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Rosa-Rosa L, 1999, J ALLERGY CLIN IMMUN, V104, P1008, DOI 10.1016/S0091-6749(99)70082-5; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135, DOI 10.1067/mai.2000.107926; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; Strachan DP, 1998, THORAX, V53, P117, DOI 10.1136/thx.53.2.117; Ulrik CS, 2000, ANN ALLERG ASTHMA IM, V85, P293, DOI 10.1016/S1081-1206(10)62532-X; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Walley AJ, 1996, J MED GENET, V33, P689, DOI 10.1136/jmg.33.8.689; Walley AJ, 2001, GENOMICS, V72, P15, DOI 10.1006/geno.2000.6435; Wilcox AJ, 1998, AM J EPIDEMIOL, V148, P893; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201; Yokouchi Y, 2002, GENES IMMUN, V3, P9, DOI 10.1038/sj.gene.6363815; Zhu SK, 2000, AM J RESP CRIT CARE, V161, P1655, DOI 10.1164/ajrccm.161.5.9906086	57	86	88	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					489	495		10.1016/j.jaci.2003.12.037	http://dx.doi.org/10.1016/j.jaci.2003.12.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007352				2022-12-18	WOS:000220144200022
J	Higashi, N; Taniguchi, M; Mita, H; Kawagishi, Y; Ishii, T; Higashi, A; Osame, M; Akiyama, K				Higashi, N; Taniguchi, M; Mita, H; Kawagishi, Y; Ishii, T; Higashi, A; Osame, M; Akiyama, K			Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin-intolerant asthma; urinary leukotriene E4; chronic hyperplastic rhinosinusitis with nasal polyposis	SYNTHASE PROMOTER POLYMORPHISM; CHRONIC SINUSITIS; C-4 SYNTHASE; 11-DEHYDROTHROMBOXANE B-2; ASPIRIN; EXPRESSION; ALLERGEN; E-4; INFILTRATION; INFLAMMATION	Background: The urinary leukotriene E4 (U-LTE4) concentration is significantly increased in patients with aspirin-intolerant asthma (AIA). However, the relationship between the clinicopathogenetic factors of asthma and the U-LTE4 concentration remains undetermined. Objective: We sought to examine the clinical features of asthmatic patients with increased excretion levels of U-LTE4 (hyperleukotrienuria). Methods: We measured the U-LTE4 concentrations in 137 asthmatic patients (including 64 patients with AIA) who were in clinically stable condition. A U-LTE4 concentration of 150 pg/mg creatinine or greater (mean U-LTE4 + 3 SDs of normal healthy control subjects) was indicative of hyperleukotrienuria. Results: The basal concentration of U-LTE4 was significantly higher in the patients with AIA than in those with aspirin-tolerant asthma (ATA; median, 227.2 vs 90.3 pg/mg creatinine; P < .01). Compared with normal leukotrienuria in the patients with AIA, hyperleukotrienuria in the patients with AIA was associated with older age and decrease in pulmonary function. On the other hand, compared with normal leukotrienuria in the patients with ATA, hyperleukotrienuria in the patients with ATA was associated with severe asthma and chronic hyperplastic rhinosinusitis with nasal polyposis (CHRS/NP), which are well-known symptoms of the aspirin triad, as well as hypereosinophilia and anosmia. The patients with ATA with CHRS/NP excreted U-LTE4 at significantly high concentrations. There were significant decreases in the U-LTE4 concentrations before and after the sinus surgery in both the AIA and ATA groups (P < .05). Conclusion: Cysteinyl leukotrienes are not strictly associated with aspirin intolerance itself but rather with clinical features, such as CHRS/NP, that are similar to those seen in AIA. CHRS/NP might be involved in cysteinyl leukotriene overproduction in asthmatic patients.	Natl Sagamihara Hosp, Clin Res Ctr, Kanagawa, Japan; Kagoshima Univ, Sch Med, Dept Internal Med 3, Kagoshima 890, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Internal Med 1, Toyama, Japan	Kagoshima University; University of Toyama	Higashi, N (corresponding author), Karolinska Inst, S-17177 Stockholm, Sweden.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; ASANO K, 1995, J ALLERGY CLIN IMMUN, V96, P643, DOI 10.1016/S0091-6749(95)70263-6; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; DRAZEN JM, 1992, AM REV RESPIR DIS, V146, P104, DOI 10.1164/ajrccm/146.1.104; DRAZEN JM, 2000, ASTHMA RHINITIS, P1014; Eichel B S, 1999, Ear Nose Throat J, V78, P262; FAULER J, 1994, ARTHRITIS RHEUM-US, V37, P93, DOI 10.1002/art.1780370114; Ferguson BJ, 2000, LARYNGOSCOPE, V110, P799, DOI 10.1097/00005537-200005000-00010; HACKSHAW KV, 1992, J RHEUMATOL, V19, P252; Hamilos DL, 1996, AM J RESP CELL MOL, V15, P443, DOI 10.1165/ajrcmb.15.4.8879177; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; Higashi N, 2002, CLIN EXP ALLERGY, V32, P1484, DOI 10.1046/j.1365-2745.2002.01507.x; Jantti-Alanko S, 1989, Rhinol Suppl, V8, P59; KALINER MA, 1997, ALLERGY CLIN IMMUN S, V99, pS829; Kawagishi Y, 2002, J ALLERGY CLIN IMMUN, V109, P936, DOI 10.1067/mai.2002.124466; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; Kumlin M, 1996, J CHROMATOGR A, V725, P29, DOI 10.1016/0021-9673(95)01125-0; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MALTBY NH, 1990, J ALLERGY CLIN IMMUN, V85, P3, DOI 10.1016/0091-6749(90)90214-O; MANNING PJ, 1990, J ALLERGY CLIN IMMUN, V86, P211, DOI 10.1016/S0091-6749(05)80068-5; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Mita H, 1997, J CHROMATOGR B, V692, P461, DOI 10.1016/S0378-4347(97)00006-6; Mygind N, 2000, THORAX, V55, pS79, DOI 10.1136/thorax.55.suppl_2.S79; Nasser SMS, 1996, AM J RESP CRIT CARE, V153, P90, DOI 10.1164/ajrccm.153.1.8542168; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; *NIH NAT LUNG LUNG, 2002, NIH PUBL; Oosaki R, 1997, ALLERGY, V52, P470, DOI 10.1111/j.1398-9995.1997.tb01032.x; Oosaki R, 1998, CLIN EXP ALLERGY, V28, P1138; PFISTER R, 1994, J ALLERGY CLIN IMMUN, V94, P804, DOI 10.1016/0091-6749(94)90146-5; Sampson Anthony P., 2003, Journal of Allergy and Clinical Immunology, V111, pS49, DOI 10.1067/mai.2003.24; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Sanak M, 2000, AM J RESP CELL MOL, V23, P290, DOI 10.1165/ajrcmb.23.3.4051; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9; SLADEK K, 1990, AM REV RESPIR DIS, V141, P1441, DOI 10.1164/ajrccm/141.6.1441; Sousa AR, 1997, AM J RESP CRIT CARE, V156, P1384, DOI 10.1164/ajrccm.156.5.9702072; Steinke JW, 2003, J ALLERGY CLIN IMMUN, V111, P342, DOI 10.1067/mai.2003.67; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; Van Sambeek R, 2000, J ALLERGY CLIN IMMUN, V106, P72, DOI 10.1067/mai.2000.107603; VERHAGEN J, 1987, BIOCHEM BIOPH RES CO, V148, P864, DOI 10.1016/0006-291X(87)90955-7; Wald ER, 1998, AM J MED SCI, V316, P13, DOI 10.1097/00000441-199807000-00003	46	86	91	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					277	283		10.1016/j.jaci.2003.10.068	http://dx.doi.org/10.1016/j.jaci.2003.10.068			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767442	Bronze			2022-12-18	WOS:000188885700015
J	Macy, E; Mangat, R; Burchette, RJ				Macy, E; Mangat, R; Burchette, RJ			Penicillin skin testing in advance of need: Multiyear follow-up in 568 test result-negative subjects exposed to oral penicillins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adverse drug reaction; allergy; amoxicillin; antibiotic; outcomes; penicillin; penicillin skin test	AMOXICILLIN; ALLERGY; HYPERSENSITIVITY; CHALLENGE; RESPONSES	Background: There are few published data on adverse drug reactions and/or resensitization associated with oral penicillin use in penicillin allergy history-positive/penicillin skin test-negative individuals during routine clinical care with multiyear follow-up. Objectives: We sought to provide long-term follow-up data on the type, severity, and frequency of adverse reactions associated with oral penicillin use in individuals who have histories of penicillin "allergy" yet also have negative results on penicillin skin tests done in advance of need. We also aimed to repeat testing on individuals with penicillin-associated adverse reactions. Methods: Medical records were reviewed for penicillin use and associated adverse reactions in all 568 penicillin skin test-negative individuals who had received at least 1 course of oral penicillin after testing but before December 31, 2001, during routine care. These individuals were drawn from a group of 1246 penicillin skin test-negative individuals seen initially between November 16, 1994, and August 13, 2001. Results: The mean length of follow-up was 4.26 +/- 1.64 years (range, 0.39-7.12 years). The mean penicillin exposure was 3.94 +/- 3.91 courses (range, 1-22 courses). Only 65 (11.4%) of 568 subjects had any penicillin-associated reactions, and 6 subjects had 2 reactions each. A reaction occurred in 27 subjects (4.8%) with their first penicillin reexposure. There were 71 (3.2%) reactions with 2236 total penicillin courses. There were no serious reactions. Repeated testing was done in 33 subjects older than age 18 years. Only 1 subject was positive on repeated penicillin skin testing. Conclusion: Penicillin use after negative penicillin skin testing done in advance of need is safe, and resensitization is rare.	Kaiser Permanente So Calif, Dept Allergy, San Diego, CA USA; Kaiser Permanente So Calif, Dept Res & Evaluat, San Diego, CA USA; Univ Calif San Diego, Dept Allergy & Immunol, La Jolla, CA 92093 USA	Kaiser Permanente; Kaiser Permanente; University of California System; University of California San Diego	Macy, E (corresponding author), Kaiser Permanente So Calif, Dept Allergy, San Diego, CA USA.			Macy, Eric/0000-0002-5857-9444				GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; GREENBERGER PA, 2002, MANUAL ALLERGY IMMUN, P199; HERMAN R, 1979, CUTIS, V24, P232; LopezSerrano MC, 1996, J INVEST ALLERG CLIN, V6, P30; Macy E, 1998, J ALLERGY CLIN IMMUN, V102, P281, DOI 10.1016/S0091-6749(98)70097-1; Macy E, 1997, J ALLERGY CLIN IMMUN, V100, P586, DOI 10.1016/S0091-6749(97)70159-3; Macy E, 2002, ALLERGY, V57, P1151, DOI 10.1034/j.1398-9995.2002.23700.x; *MED EC CO, 2002, PHYS DESK REF; MENDELSON LM, 1984, J ALLERGY CLIN IMMUN, V73, P76, DOI 10.1016/0091-6749(84)90487-1; PARKER PJ, 1991, J ALLERGY CLIN IMMUN, V88, P213, DOI 10.1016/0091-6749(91)90331-H; Pichichero ME, 1998, J PEDIATR-US, V132, P137, DOI 10.1016/S0022-3476(98)70499-8; ROBERTS J, 1985, J AM DENT ASSOC, V110, P505, DOI 10.14219/jada.archive.1985.0376; Romano A, 1999, J ALLERGY CLIN IMMUN, V103, P1186, DOI 10.1016/S0091-6749(99)70197-1; *SAS I INC, 1999, SAS PROC GUID VERS 8, P451; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; SOGN DD, 1984, J ALLERGY CLIN IMMUN, V74, P589, DOI 10.1016/0091-6749(84)90111-8; SOGN DD, 1992, ARCH INTERN MED, V152, P1025, DOI 10.1001/archinte.152.5.1025; Solensky R, 2002, ARCH INTERN MED, V162, P822, DOI 10.1001/archinte.162.7.822; STOKES ME, 2000, CATEGORICAL DATA ANA, P354	19	86	88	2	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1111	1115		10.1067/mai.2003.1385	http://dx.doi.org/10.1067/mai.2003.1385			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743578				2022-12-18	WOS:000182904500028
J	Sturm, G; Kranke, B; Rudolph, C; Aberer, W				Sturm, G; Kranke, B; Rudolph, C; Aberer, W			Rush Hymenoptera venom immunotherapy: A safe and practical protocol for high-risk patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						honeybee venom; Hymenoptera venom allergy; rush immunotherapy; side effects; yellow jacket venom	PLACEBO-CONTROLLED TRIAL; YELLOW JACKET VENOM; HONEYBEE VENOM; ULTRARUSH IMMUNOTHERAPY; ADVERSE REACTIONS; STING CHALLENGE; WASP VENOM; BEE VENOM; ALLERGY; HYPOSENSITIZATION	Background: Hymenoptera venom immunotherapy in allergic patients is a well-established treatment modality for the prevention of systemic anaphylactic reactions caused by insect stings. A variety of therapy regimens exists, from conventional to rush and ultrarush modalities that operate on continuous or intermittent schedules. Objective: The aim of this study was to report the 8-year experience with our rush venom immunotherapy regimen in predominantly high-risk patients and to compare data on safety and convenience with the results of 26 studies published from 1978 to 2001. Methods: One hundred one patients allergic to bee, yellow jacket, or hornet venom were treated with rush Hymenoptera venom immunotherapy. Diagnosis and selection of patients for venom immunotherapy were carried out according to the recommendations of the European Academy of Allergology and Clinical Immunology. We used a 4-day regimen, and the incidence and nature of systemic reactions (SRs) were documented. Fifty-two patients were treated with honeybee venom, and 49 were treated with yellow jacket venom. Results: One hundred (99%) patients reached the maintenance dose. We observed 8 injection-related SRs (0.47% of all injections given) in 7 (6.9%) patients. The number of SRs was higher in patients treated with bee venom extract (12%) compared with in patients receiving yellow jacket venom extract (2%). There was no significant difference in the risk of SRs between female and male patients. The incidence of SRs was considerably lower than the average of 17.8% reported in the literature. Conclusion: With a rush immunotherapy regimen over a time period of 8 years in predominantly high-risk patients, the incidence of SRs was low, despite the high number of patients with bee venom allergy, who are more likely to have side effects. Epinephrine as rescue medication was never necessary, and the regimen proved to be safe and convenient for both the patients and the medical staff.	Graz Univ, Dept Environm Dermatol & Allergy, A-8036 Graz, Austria	University of Graz	Aberer, W (corresponding author), Graz Univ, Dept Environm Dermatol & Allergy, Auenbruggerpl 8, A-8036 Graz, Austria.							BARSELA S, 1981, ANN ALLERGY, V47, P460; BERCHTOLD E, 1992, CLIN EXP ALLERGY, V22, P59, DOI 10.1111/j.1365-2222.1992.tb00115.x; BERNSTEIN DI, 1989, J ALLERGY CLIN IMMUN, V84, P951, DOI 10.1016/0091-6749(89)90394-1; BERNSTEIN JA, 1994, ANN ALLERGY, V73, P423; BIRNBAUM J, 1993, CLIN EXP ALLERGY, V23, P226, DOI 10.1111/j.1365-2222.1993.tb00886.x; Brehler R, 2000, J ALLERGY CLIN IMMUN, V105, P1231, DOI 10.1067/mai.2000.105708; Brockow K, 1997, J ALLERGY CLIN IMMUN, V100, P458, DOI 10.1016/S0091-6749(97)70135-0; CHIPPS BE, 1980, J PEDIATR-US, V97, P177, DOI 10.1016/S0022-3476(80)80470-7; Elsner J, 2000, ALLERGY, V55, P582, DOI 10.1034/j.1398-9995.2000.00632.x; GILLMAN SA, 1980, ANN ALLERGY, V45, P351; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; Laurent J, 1997, ALLERGY, V52, P94, DOI 10.1111/j.1398-9995.1997.tb02551.x; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; Mosbech H, 2000, ALLERGY, V55, P1005, DOI 10.1034/j.1398-9995.2000.00587.x; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; Muller U, 2001, J ALLERGY CLIN IMMUN, V107, P81, DOI 10.1067/mai.2001.111852; MULLER U, 1993, ALLERGY          S14, V48, P36; Muller UR., 1990, INSECT STING ALLERGY; PRZYBILLA B, 1987, DEUT MED WOCHENSCHR, V112, P416, DOI 10.1055/s-2008-1068068; RAMIREZ DA, 1981, ANN ALLERGY, V47, P435; Reimers A, 2000, ALLERGY, V55, P484, DOI 10.1034/j.1398-9995.2000.00520.x; RING J, 1977, LANCET, V1, P466; Rueff F, 2001, J ALLERGY CLIN IMMUN, V107, P928; RZANY B, 1991, ALLERGY, V46, P251, DOI 10.1111/j.1398-9995.1991.tb00582.x; TARHINI H, 1992, J ALLERGY CLIN IMMUN, V89, P1198, DOI 10.1016/0091-6749(92)90306-M; TEUDLER R, 1997, HAUTARZT, V48, P734; THURNHEER U, 1983, ALLERGY, V38, P465, DOI 10.1111/j.1398-9995.1983.tb02355.x; URBANEK R, 1978, DEUT MED WOCHENSCHR, V103, P1656, DOI 10.1055/s-0028-1129317; van Halteren HK, 1997, J ALLERGY CLIN IMMUN, V100, P767, DOI 10.1016/S0091-6749(97)70271-9; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329, DOI 10.1136/bmj.287.6402.1329; Westall GP, 2001, MED J AUSTRALIA, V174, P227, DOI 10.5694/j.1326-5377.2001.tb143242.x; WYSS M, 1993, ALLERGY, V48, P81, DOI 10.1111/j.1398-9995.1993.tb00690.x; YOULTEN LJF, 1995, CLIN EXP ALLERGY, V25, P159, DOI 10.1111/j.1365-2222.1995.tb01021.x; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P340, DOI 10.1016/0091-6749(79)90129-5	38	86	87	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2002	110	6					928	933		10.1067/mai.2002.129124	http://dx.doi.org/10.1067/mai.2002.129124			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	624TL	12464961				2022-12-18	WOS:000179777400017
J	Oddy, WH; Peat, JK; de Klerk, NH				Oddy, WH; Peat, JK; de Klerk, NH			Maternal asthma, infant feeding, and the risk of asthma in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; maternal asthma; breast-feeding; childhood	HUMAN-MILK; CHILDREN	Controversy surrounds the issue of whether children with asthmatic mothers should be breast-fed. The aim of this study was to investigate whether maternal asthma status alters the association between asthma and breast-feeding. In a cohort study of 2602 West Australian children enrolled before birth and followed prospectively, we collected data on method of infant feeding, maternal asthma (as reported by parental questionnaire), atopy (as measured by skin prick test), and current asthma (defined as a physician's diagnosis of asthma and wheeze in the last year) at 6 years of age. The risk of childhood asthma increased if exclusive breast-feeding was stopped (other milk was introduced) before 4 months (odds ratio, 1.28; 95% CI, 1.01-1.62; P =.038), and this risk was not altered by atopy or maternal asthma status. After adjusting for covariates, exclusive breast-feeding for less than 4 months was a Significant risk factor for current asthma (odds ratio, 1.35; 95% CI, 1.00-1.82; P =.049). There was no formal statistical interaction between breast-feeding and maternal asthma status (P=.970). In this stud), maternal asthma status did not modify the association between asthma and breast-feeding duration. We recommend that infants with or without a maternal history of asthma be exclusively breast-fed for 4 months and beyond.	Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Perth, WA 6872, Australia; Univ Sydney, Dept Pediat & Child Hlth, Sydney, NSW 2006, Australia; Curtin Univ Technol, Sch Publ Hlth, Dept Nutr Dietet & Food Sci, Perth, WA 6001, Australia	Telethon Kids Institute; University of Western Australia; University of Sydney; Curtin University	Oddy, WH (corresponding author), Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, POB 855, Perth, WA 6872, Australia.		Study, Raine/K-4517-2013; de Klerk, Nicholas H/D-8388-2016	de Klerk, Nicholas H/0000-0001-9223-0767				DREBORG S, 1991, ALLERGY PROC, V12, P251, DOI 10.2500/108854191778879278; Garofalo RP, 1999, CLIN PERINATOL, V26, P361, DOI 10.1016/S0095-5108(18)30057-5; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; Hamosh M, 2001, PEDIATR CLIN N AM, V48, P69, DOI 10.1016/S0031-3955(05)70286-8; Infante-Rivard C, 2001, AM J EPIDEMIOL, V153, P653, DOI 10.1093/aje/153.7.653; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617, DOI 10.1164/ajrccm.160.5.9811002; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	10	86	91	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					65	67		10.1067/mai.2002.125296	http://dx.doi.org/10.1067/mai.2002.125296			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110822	Bronze			2022-12-18	WOS:000176870300014
J	Vandenplas, O; Jamart, J; Delwiche, JP; Evrard, G; Larbanois, A				Vandenplas, O; Jamart, J; Delwiche, JP; Evrard, G; Larbanois, A			Occupational asthma caused by natural rubber latex: Outcome according to cessation or reduction of exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; disability; latex; occupational lung disease	HEALTH-CARE WORKERS; BRONCHIAL HYPERRESPONSIVENESS; TOLUENE DIISOCYANATE; GLOVES; DISABILITY; IMPACT	Background: The long-term effects of reducing exposure to latex in subjects with latex-induced asthma remain unknown. Objective: The purpose of this study was to compare the health and socioeconomic outcomes of subjects with latex-induced asthma before and after reduction or cessation of exposure to latex. Methods: Thirty-six subjects with latex-induced asthma as ascertained by specific inhalation challenges were investigated after a median follow-up of 56 months (range, 12 to 92 months). Initial and follow-up visits included use of a detailed questionnaire and measurement of the concentration of histamine causing a 20% fall in FEV1 (PC20). At follow-up, information on employment, financial status, and quality of life was collected. Results: At follow-up, 16 subjects were no longer exposed to latex, whereas 20 subjects had reduced exposure. In the subjects who avoided exposure, asthma severity decreased from a median score of 8.5 to 3.5 (P = .001) and the median histamine PC20 value increased from 0.4 mg/mL to 2.3 mg/mL (P = .002). In the subjects who reduced their exposure, asthma-severity score improved from 6.5 to 2.5 (P < .001) and PC20 values rose from 0.5 mg/mL to 2.4 mg/mL (P < .001). Cessation of exposure to latex was associated with asthma-related work disability (69%) and loss of income (62%) more frequently than was reduction of exposure (35% and 30%, respectively). Conclusion: Reduction of exposure to latex should be considered a reasonably safe alternative that is associated with fewer socioeconomic consequences than removal from exposure.	Catholic Univ Louvain, Clin Univ Mont Godinne, Serv Pneumol, B-5530 Yvoir, Belgium; Catholic Univ Louvain, Clin Univ Mont Godinne, Ctr Biostat & Documentat Med, B-5530 Yvoir, Belgium; Fons Malad Profess, Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain Hospital; Universite Catholique Louvain; Universite Catholique Louvain Hospital	Vandenplas, O (corresponding author), Catholic Univ Louvain, Clin Univ Mont Godinne, Serv Pneumol, B-5530 Yvoir, Belgium.							Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; BLANC PD, 1993, CHEST, V104, P1371, DOI 10.1378/chest.104.5.1371; Blanc PD, 1999, AM J RESP CRIT CARE, V160, P2028, DOI 10.1164/ajrccm.160.6.9901033; CHANYEUNG M, 1995, CHEST, V108, P1084, DOI 10.1378/chest.108.4.1084; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COTE J, 1990, AM REV RESPIR DIS, V141, P373, DOI 10.1164/ajrccm/141.2.373; European Community for Coal and Steel, 1983, B EUR PHYSIOPATHO S5, V19, P45; GRAMMER LC, 1993, AM REV RESPIR DIS, V148, P54, DOI 10.1164/ajrccm/148.1.54; Hamilton RG, 2000, J ALLERGY CLIN IMMUN, V105, P839, DOI 10.1067/mai.2000.105224; Heilman DK, 1996, J ALLERGY CLIN IMMUN, V98, P325, DOI 10.1016/S0091-6749(96)70157-4; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Laoprasert N, 1998, J ALLERGY CLIN IMMUN, V102, P998, DOI 10.1016/S0091-6749(98)70338-0; Lin FJ, 1996, OCCUP ENVIRON MED, V53, P753, DOI 10.1136/oem.53.11.753; Merget R, 1999, INT ARCH OCC ENV HEA, V72, P33, DOI 10.1007/s004200050331; PAGGIARO PL, 1993, CHEST, V103, P1123, DOI 10.1378/chest.103.4.1123; PISATI G, 1993, BRIT J IND MED, V50, P60; Poley GE, 2000, J ALLERGY CLIN IMMUN, V105, P1054, DOI 10.1067/mai.2000.106925; Ross DJ, 1999, CLIN EXP ALLERGY, V29, P750; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V101, P171, DOI 10.1016/S0091-6749(98)70381-1; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; Vandenplas O, 1996, THORAX, V51, P472, DOI 10.1136/thx.51.5.472; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; Vandenplas O, 2001, J ALLERGY CLIN IMMUN, V107, P542, DOI 10.1067/mai.2001.113519; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P887; Vandenplas O, 1999, ASTHMA WORKPLACE, P425	26	86	89	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					125	130		10.1067/mai.2002.120760	http://dx.doi.org/10.1067/mai.2002.120760			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799378	Bronze			2022-12-18	WOS:000173739300021
J	Alexis, N; Eldridge, M; Reed, W; Bromberg, P; Peden, DB				Alexis, N; Eldridge, M; Reed, W; Bromberg, P; Peden, DB			CD14-dependent airway neutrophil response to inhaled LPS: Role of atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD14; LPS; PMN; association with atopy	LIPOPOLYSACCHARIDE RECEPTOR CD14; SOLUBLE CD14; MYOCARDIAL-INFARCTION; EPITHELIAL-CELLS; HUMAN MONOCYTES; INDUCED SPUTUM; ENDOTOXIN; POLYMORPHISM; ASTHMA; EXPRESSION	Background: inhaled endotoxin (LPS) is associated with airway neutrophilic (PMN) Inflammation in both asthmatic and control subjects, with asthmatic subjects demonstrating possibly higher sensitivity. CD14 is the principal receptor mediating LPS responses in vivo. It is unknown whether constitutive CD14 can predict the magnitude of the PMN response after LPS inhalation and whether atopy plays a role in this response. Objective: We sought to examine associations between constitutive airway CD14 expression and LPS-induced PMNs after 5 mug of LPS inhalation and to examine associations between markers of atopy (eosinophils and eosinophil cationic protein) and CD14 expression and LPS-induced PMNs, Methods: Ten atopic asthmatic subjects and 8 healthy control subjects inhaled 0.9% saline and LPS (Escherichia coli 026:B6, 5 mug) separated by 3 weeks. Induced sputum was collected at 24 hours before and 6 hours after inhalation. Induced sputum was analyzed fur total and differential cell counts and soluble markers (soluble [s]CD14, eosinophil cationic protein, IL8, and total protein). Flow cytometry was used to analyze membrane-bound CD14 expression. Results: Significant associations were found between the LPS-induced PR IN response (PMNs per milligram of sputum) and both constitutive sCD14 (R = 0.7, P =.005) and membrane-bound CD14 (R = 0.9, P =.01). Asthmatic subjects demonstrated significantly higher le, els of constitutive sCD14 compared with control subjects, and baseline eosinophils were significantly associated with baseline sCD14 (R = 0.7, P =.01) and LPS-induced PMNs (R = 0.6, P =.03). Conclusion: Constitutive airway CD14 expression can predict the magnitude of the PMN response after inhaled LPS. Atopy appears to play a role in the level of CD14 expression and may contribute to LPS sensitivity in asthmatic subjects.	Univ N Carolina, Ctr Environm Med & Lung Biol, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Environm Med & Lung Biol, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Alexis, N (corresponding author), Univ N Carolina, Ctr Environm Med & Lung Biol, Dept Pediat, 104 Mason Farm Rd,5th Floor, Chapel Hill, NC 27599 USA.			Peden, David/0000-0003-4526-4627	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062624] Funding Source: NIH RePORTER; NHLBI NIH HHS [1-RO1-HL62624] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXIS N, 2000, IN PRESS CLIN IMMUNO; ALEXIS N, 2000, IN PRESS INHAL TOXIC; AntalSzalmas P, 1997, J LEUKOCYTE BIOL, V61, P721, DOI 10.1002/jlb.61.6.721; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; BUFFLER P, 1995, EUR J IMMUNOL, V25, P604; DIMRI R, 1994, LYMPHOKINE CYTOK RES, V13, P239; Doerschug KC, 1999, AM J RESP CRIT CARE, V159, P1735, DOI 10.1164/ajrccm.159.6.9809051; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736, DOI 10.1152/ajplung.1996.270.5.L736; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GOLDBLUM SE, 1994, J CLIN INVEST, V93, P692, DOI 10.1172/JCI117022; HEITBROCK HWZ, 1993, IMMUNOL TODAY, V14, P121; Hubacek JA, 1999, CIRCULATION, V99, P3218, DOI 10.1161/01.CIR.99.25.3218; Kane JP, 1999, CIRCULATION, V99, P3210, DOI 10.1161/01.CIR.99.25.3210; LANDMANN R, 1991, J CELL BIOCHEM, V47, P317, DOI 10.1002/jcb.240470406; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352, DOI 10.1164/ajrccm/146.2.352; MICHEL O, 1992, THORAX, V47, P288, DOI 10.1136/thx.47.4.288; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157, DOI 10.1164/ajrccm.156.4.97-02002; MICHEL O, 1994, AM J IND MED, V25, P129, DOI 10.1002/ajim.4700250135; Nightingale JA, 1998, THORAX, V53, P563, DOI 10.1136/thx.53.7.563; Peden DB, 1999, J ALLERGY CLIN IMMUN, V104, P388, DOI 10.1016/S0091-6749(99)70383-0; Pizzichini E, 1996, EUR RESPIR J, V9, P1174, DOI 10.1183/09031936.96.09061174; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; RYLANDER R, 1989, AM REV RESPIR DIS, V140, P981, DOI 10.1164/ajrccm/140.4.981; Striz I, 1998, IMMUNOL LETT, V62, P177, DOI 10.1016/S0165-2478(98)00046-7; Unkelbach K, 1999, ARTERIOSCL THROM VAS, V19, P932, DOI 10.1161/01.ATV.19.4.932; Virchow JC, 1998, EUR RESPIR J, V11, P317, DOI 10.1183/09031936.98.11020317	29	86	87	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					31	35		10.1067/mai.2001.111594	http://dx.doi.org/10.1067/mai.2001.111594			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11149987				2022-12-18	WOS:000166533300006
J	Jirapongsananuruk, O; Melamed, I; Leung, DYM				Jirapongsananuruk, O; Melamed, I; Leung, DYM			Additive immunosuppressive effects of 1,25-dihydroxyvitamin D-3 and couticosteroids on T(H)1, but not T(H)2, responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						corticosteroid; cytokine; immunosuppression; inflammation; T cells; vitamin D	BLOOD MONONUCLEAR-CELLS; VITAMIN-D ANALOG; IMMUNOGLOBULIN PRODUCTION; HUMAN-LYMPHOCYTES; ACTIVATION; INHIBITION; RECEPTORS; DIFFERENTIATION; PROLIFERATION; CALCITRIOL	Background: The biologic role of the vitamin D analogue 1,25-dihydroxyvitamin D-3, such as antiinflammatory functions, reduction of cytokine production by T cells, and immunoglobulin production by B cells, has been reported, Such immunomodulatory effects may be potentially useful in dealing with autoimmunity and transplantation. However, whether this hormone has an additive immunosuppressive effect when it is used with corticosteroids has not been investigated, although these agents are commonly used together Objective: Our purpose was to investigate the additive immunomodulatory effects of 1,25-dihydroxyvitamin D-3 on lymphocyte proliferation and cytokine production when used with corticosteroids. Methods: To investigate the additive effects of 1,25-dihydroxyvitamin D-3 and dexamethasone on suppression of lymphocyte proliferation, normal PBMCs were cultured in anti-CD3 with or without different concentrations of dexamethasone (0-10(-7) mol/L) plus or minus different concentrations of 1,25-dihydroxyvitamin D-3 (0-10(-6) mol/L), After 3 days, lymphocyte proliferation was assessed by [H-3]-thymidine incorporation. To investigate the additive effects of 1,25-dihydroxyvitamin D, and dexamethasone on cytokine production, PBMCs were cultured for 3 days in the presence of anti-CD3 with or without 10(-6) mol/L dexamethasone plus or minus 10(-6) mol/L, 1,25-dihydroxyvitamin D-3. IFN-gamma IL-5, and IL-13 production in supernatants were measured by ELISA. Results: Our study demonstrated that, at concentrations of 10(-8), 10(-7), and 10(-6) mol/L, 1,25-dihydroxyvitamin D-3 significantly decreased lymphocyte proliferation compared with an ethanol control (P <.05), The IC50 for dexamethasone was 4 x 10(-9) mol/L in culture without 1,25-dihydroxyvitamin D-3. When 10(-9) mol/L of 1,25-dihydroxyvitamin D-3 was added to cultures with dexamethasone, IC50 became 2 x 10(-9) mol/L, Moreover, when 10(-6), 10(-7), and 10(-8) morn of 1,25-dihydroxyvitamin D-3 were added in culture with dexamethasone, IC50 became less than 1 x 10(-9) mol/L, IFN-<gamma> production in culture with either dexamethasone or 1,25-dihydroxyvitamin D-3 was significantly decreased compared with media or ethanol control (P <.0001). Moreover, when both agents were added in the same culture, IFN-<gamma> production was further decreased compared with either agent alone (P <.05), In contrast, 1,25-dihydroxyvitamin D, significantly (P <.0001) increased IL-5 and IL-13, whereas dexamethasone significantly decreased these 2 cytokines (P <.0005), When 1,25-dihydroxyvitamin D-3 was combined with dexamethasone, IL-5 and IL-13 production was increased compared with dexamethasone alone (P <.001). Conclusions: Our results demonstrate that 1,25-dihydroxyvitamin D-3 has significant additive effects on dexamethasone-mediated inhibition of lymphocyte proliferation. This hormone also has additive effects on inhibition of T(H)1 cytokine production when combined with dexamethasone. However, this hormone upregulates T(H)2 cytokines and inhibits steroid-mediated suppression of cytokines, These findings demonstrate the potential use of 1,25-dihydroxyvitamin D-3 as an immunosuppressive agent when combined with corticosteroids in T(H)1, but not T(H)2, immune responses.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Pediat Allergy Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Pediat Allergy Immunol, Room K926,1400 Jackson St, Denver, CO 80206 USA.			Jirapongsananuruk, Orathai/0000-0002-1603-1106	NHLBI NIH HHS [HL37260, HL36577] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL037260, R01HL037260, P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andjelkovic Z, 1999, CLIN EXP RHEUMATOL, V17, P453; Arkachaisri T, 1999, Curr Opin Rheumatol, V11, P384; BHALLA AK, 1986, CELL IMMUNOL, V98, P311, DOI 10.1016/0008-8749(86)90291-1; BHALLA AK, 1983, J CLIN ENDOCR METAB, V57, P1308, DOI 10.1210/jcem-57-6-1308; BHALLA AK, 1984, J IMMUNOL, V133, P1748; Imseis RE, 1999, AM J MED SCI, V318, P61, DOI 10.1097/00000441-199907000-00010; LACEY DL, 1987, J IMMUNOL, V138, P1680; Ledford D, 1998, J ALLERGY CLIN IMMUN, V102, P353, DOI 10.1016/S0091-6749(98)70120-4; LEMIRE JM, 1984, J CLIN INVEST, V74, P657, DOI 10.1172/JCI111465; LEMIRE JM, 1992, TRANSPLANTATION, V54, P762, DOI 10.1097/00007890-199210000-00046; LEMIRE JM, 1985, J IMMUNOL, V134, P3032; LILLEVANG ST, 1992, CLIN EXP IMMUNOL, V88, P301; MATHIASEN IS, 1993, J STEROID BIOCHEM, V46, P365, DOI 10.1016/0960-0760(93)90226-M; MUSCETTOLA M, 1988, IMMUNOL LETT, V17, P121, DOI 10.1016/0165-2478(88)90079-X; NORMAN AW, 1982, ENDOCR REV, V3, P331, DOI 10.1210/edrv-3-4-331; PROVVEDINI DM, 1986, J IMMUNOL, V136, P2734; PROVVEDINI DM, 1983, SCIENCE, V221, P1181, DOI 10.1126/science.6310748; RIGBY WFC, 1984, J CLIN INVEST, V74, P1451, DOI 10.1172/JCI111557; RIGBY WFC, 1987, J CLIN INVEST, V79, P1659, DOI 10.1172/JCI113004; Suzuki S, 1999, INT J MOL MED, V4, P611; ZHOU JY, 1989, BLOOD, V74, P82	21	86	91	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					981	985		10.1067/mai.2000.110101	http://dx.doi.org/10.1067/mai.2000.110101			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080724	Bronze			2022-12-18	WOS:000167865200026
J	Eldridge, MW; Peden, DB				Eldridge, MW; Peden, DB			Allergen provocation augments endotoxin-induced nasal inflammation in subjects with atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; dust mite; antigen; asthma; eosinophils; neutrophils; allergy	AIR-POLLUTION; OZONE; MORTALITY; CHALLENGE; RESPONSES; EXPOSURE; WORKERS; HEALTH	Background: Recent epidemiologic and in vivo studies have suggested that inhaled endotoxin plays an important role in asthma pathogenesis. Objective: The present study examines the effect of nasal allergen provocation on subsequent endotoxin challenge in subjects with atopic asthma. Methods: By using a split-nose randomized crossover design, individual nares of 12 asthmatic subjects underwent challenge and lavage as follows, Immediately after a baseline nasal lavage, one nares received normal saline, and the other received dust mite antigen, Four hours later both nares were exposed to either saline or endotoxin. Dust mite antigen (Dermatophagoides farinae) and endotoxin (Escherichia roll 026:B6) doses were 100 AU and 1000 ng, respectively. Postchallenge lavages were done at 8 and 24 hours after the initial challenge. The subjects then returned a minimum of 3 weeks later for crossover to the study arm. Nasal lavage fluid was analyzed for total and differential cell counts, IL-8, IL-6, intercellular adhesion molecule 1, GM-CSF, eosinophil cationic protein, myeloperoxidase, and soluble CD14. Results: A significant increase in the total inflammatory cell count was seen at 8 hours for the dust mite/endotoxin exposure compared with the saline/saline and saline/endotoxin exposures. Differential cell counts revealed a similar neutrophilic and eosinophilic inflammation for the dust mite/endotoxin exposure at 8 hours. Conclusions: These data demonstrate an interaction between allergen and endotoxin exposure in asthmatic subjects, suggesting that a prior allergen challenge significantly augments the endotoxin-induced inflammation. Moreover, these data provide further evidence that concomitant exposure to allergen and endotoxin may he an important factor in asthma pathogenesis.	Univ N Carolina, Sch Med, Ctr Environm Med & Lung Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pediat, Div Pulm Med & Allergy, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Gen Clin Res Ctr, Chapel Hill, NC 27599 USA; Natl Inst Environm Hlth Sci, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Eldridge, MW (corresponding author), Univ N Carolina, Sch Med, Ctr Environm Med & Lung Biol, 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27599 USA.			Peden, David/0000-0003-4526-4627	NHLBI NIH HHS [1RO1HL62624-01] Funding Source: Medline; NIEHS NIH HHS [N01-ES-35356] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062624] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [N01ES035356] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3, DOI 10.1164/ajrccm.153.1.8542133; BASHA MA, 1994, CHEST, V106, P1757, DOI 10.1378/chest.106.6.1757; COCKCROFT DW, 1987, ANN ALLERGY, V59, P89; Cook DG, 1997, THORAX, V52, P1081, DOI 10.1136/thx.52.12.1081; DONHAM K, 1989, BRIT J IND MED, V46, P31; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736, DOI 10.1152/ajplung.1996.270.5.L736; HALLSWORTH MP, 1994, EUR RESPIR J, V7, P1096; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McFadden ER, 1997, ANN INTERN MED, V127, P142, DOI 10.7326/0003-4819-127-2-199707150-00009; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; MICHELSON PH, 1990, OTOLARYNGOL HEAD NEC, V120, P225; Peden DB, 1996, REGUL TOXICOL PHARM, V24, pS76, DOI 10.1006/rtph.1996.0081; Peden DB, 1997, ALLERGY, V52, P37, DOI 10.1111/j.1398-9995.1997.tb04869.x; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336, DOI 10.1164/ajrccm.151.5.7735583; Peden DB, 1999, J ALLERGY CLIN IMMUN, V104, P388, DOI 10.1016/S0091-6749(99)70383-0; Peden DB, 1996, OTOLARYNG HEAD NECK, V114, P242, DOI 10.1016/S0194-5998(96)70175-4; Richards, 1997, ALLERGY, V52, P57; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; Saitou M, 1997, Fukushima J Med Sci, V43, P75; SALOMONSSON P, 1992, AM REV RESPIR DIS, V146, P1535, DOI 10.1164/ajrccm/146.6.1535; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24, DOI 10.1164/ajrccm.154.1.8680687; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Sunyer Y, 1997, EUR RESPIR J, V10, P2490, DOI 10.1183/09031936.97.10112490; Virchow JC, 1998, EUR RESPIR J, V11, P317, DOI 10.1183/09031936.98.11020317; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683	27	86	88	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					475	481		10.1067/mai.2000.104552	http://dx.doi.org/10.1067/mai.2000.104552			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719296	Bronze			2022-12-18	WOS:000088946700012
J	Holt, PG; Stumbles, PA				Holt, PG; Stumbles, PA			Regulation of immunologic homeostasis in peripheral tissues by dendritic cells: The respiratory tract as a paradigm	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						dendritic cells; immunoregulation; T(H)1/2; T-cell activation; inflammation	COLONY-STIMULATING FACTOR; HUMAN BRONCHOALVEOLAR LAVAGE; PRESUMABLY LANGERHANS CELLS; ANTIGEN-PRESENTING CELLS; MOUSE BONE-MARROW; T-HELPER CELLS; ACCESSORY CELLS; HUMAN-LUNG; AIRWAY EPITHELIUM; IMMUNE-RESPONSE	Dendritic cells are now recognized as the gatekeepers of the immune response, possessing a unique potential for acquisition of antigens at extremely low exposure levels and for efficient presentation of these in an immunogenic form to the naive T-cell system. Dendritic cell populations throughout the body exhibit a wide range of features in common that are associated with their primary functions, and these are considered in the initial section of this review. In addition, it is becoming evident that the properties and functions of these cells are refined by microenvironmental factors unique to their tissues of residence, a prime ex-ample being mucosal microenvironments such as those in respiratory tract tissues, and the latter represents the Focus of the second section of this review.	TVW Telethon Inst Child Hlth Res, Perth, WA 6872, Australia; Univ Western Australia, Dept Microbiol, Perth, WA 6009, Australia; Univ Western Australia, Dept Med, Perth, WA 6009, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia	Holt, PG (corresponding author), TVW Telethon Inst Child Hlth Res, POB 855, Perth, WA 6872, Australia.		Holt, Patrick G/H-1548-2011	Holt, Patrick G/0000-0003-1193-0935				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; ARMSTRONG LR, 1994, AM J RESP CELL MOL, V11, P682, DOI 10.1165/ajrcmb.11.6.7946397; Ban M, 1997, TOXICOL LETT, V93, P185, DOI 10.1016/S0378-4274(97)00091-X; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; BENDER A, 1995, J EXP MED, V182, P1663, DOI 10.1084/jem.182.6.1663; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; BOWERS WE, 1990, IMMUNOBIOLOGY, V180, P362, DOI 10.1016/S0171-2985(11)80299-8; BREEL M, 1988, IMMUNOLOGY, V63, P657; Carbone FR, 1998, IMMUNOL TODAY, V19, P368, DOI 10.1016/S0167-5699(98)01301-2; CASOLARO MA, 1988, AM REV RESPIR DIS, V137, P406, DOI 10.1164/ajrccm/137.2.406; Caux C, 1996, J EXP MED, V184, P695, DOI 10.1084/jem.184.2.695; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; CHRISTENSEN PJ, 1995, AM J RESP CELL MOL, V13, P426, DOI 10.1165/ajrcmb.13.4.7546772; CUMBERBATCH M, 1992, IMMUNOLOGY, V75, P257; de Saint-Vis B, 1998, J IMMUNOL, V160, P1666; Demangel C, 1999, EUR J IMMUNOL, V29, P1972, DOI 10.1002/(SICI)1521-4141(199906)29:06<1972::AID-IMMU1972>3.0.CO;2-1; Fazekas de St Groth B, 1998, IMMUNOL TODAY, V19, P448, DOI 10.1016/S0167-5699(98)01328-0; FOKKENS WJ, 1989, J ALLERGY CLIN IMMUN, V84, P39, DOI 10.1016/0091-6749(89)90176-0; FOKKENS WJ, 1989, ALLERGY, V44, P167, DOI 10.1111/j.1398-9995.1989.tb02257.x; FOSSUM S, 1989, CURR TOP PATHOL, P101; Godthelp T, 1996, CLIN EXP ALLERGY, V26, P677, DOI 10.1046/j.1365-2222.1996.1072451.x; GONG JL, 1994, IMMUNOLOGY, V81, P343; GONG JL, 1992, J EXP MED, V175, P797, DOI 10.1084/jem.175.3.797; GRAEMECOOK F, 1993, AM J PATHOL, V143, P1416; HOLT PG, 1985, CLIN EXP IMMUNOL, V62, P586; HOLT PG, 1989, CLIN EXP ALLERGY, V19, P597, DOI 10.1111/j.1365-2222.1989.tb02752.x; HOLT PG, 1987, IMMUNOLOGY, V62, P349; HOLT PG, 1994, J IMMUNOL, V153, P256; HOLT PG, 1988, J EXP MED, V167, P262, DOI 10.1084/jem.167.2.262; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; Hoogsteden HC, 1999, CLIN EXP ALLERGY, V29, P116, DOI 10.1046/j.1365-2222.1999.00020.x; HOSOI J, 1993, NATURE, V363, P159, DOI 10.1038/363159a0; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; INABA K, 1993, P NATL ACAD SCI USA, V90, P3038, DOI 10.1073/pnas.90.7.3038; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Kalinski P, 1997, J IMMUNOL, V159, P28; Knight SC, 1998, EUR J IMMUNOL, V28, P1636; Kradin R, 1997, AM J PATHOL, V150, P1735; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lambrecht BN, 1999, AM J RESP CELL MOL, V20, P1165, DOI 10.1165/ajrcmb.20.6.3484; Lawrence TE, 1998, J PHARMACOL EXP THER, V284, P222; LAWRENCE TE, 1997, J PHARMACOL EXP THER, V282, P996; LEONARD CT, IN PRESS AM J RESP C; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; MACATONIA SE, 1993, J IMMUNOL, V150, P3755; MACPHERSON GG, 1995, J IMMUNOL, V154, P1317; MACPHERSON GG, 1989, IMMUNOLOGY, V68, P102; Maldonado-Lopez R, 1999, J EXP MED, V189, P587, DOI 10.1084/jem.189.3.587; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; Masten BJ, 1999, J IMMUNOL, V162, P1310; Masten BJ, 1997, AM J RESP CELL MOL, V16, P335, DOI 10.1165/ajrcmb.16.3.9070619; Matsuno K, 1996, J EXP MED, V183, P1865, DOI 10.1084/jem.183.4.1865; MCCARTHY KM, 1992, AM J RESP CELL MOL, V6, P349, DOI 10.1165/ajrcmb/6.3.349; McWilliam AS, 1997, J VIROL, V71, P226, DOI 10.1128/JVI.71.1.226-236.1997; MCWILLIAM AS, 1994, J EXP MED, V179, P1331, DOI 10.1084/jem.179.4.1331; McWilliam AS, 1996, J EXP MED, V184, P2429, DOI 10.1084/jem.184.6.2429; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1111/j.1365-2222.1996.tb00571.x; NELSON DJ, 1995, J IMMUNOL, V155, P3517; NELSON DJ, 1994, J EXP MED, V179, P203, DOI 10.1084/jem.179.1.203; NELSON DJ, 1995, AM J RESP CRIT CARE, V151, P475, DOI 10.1164/ajrccm.151.2.7842209; NICOD LP, 1992, AM J RESP CELL MOL, V7, P207, DOI 10.1165/ajrcmb/7.2.207; NICOD LP, 1989, J LEUKOCYTE BIOL, V45, P458, DOI 10.1002/jlb.45.5.458; NICOD LP, 1990, AM J RESP CELL MOL, V2, P515, DOI 10.1165/ajrcmb/2.6.515; NONACS R, 1992, J EXP MED, V176, P519, DOI 10.1084/jem.176.2.519; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; POLLARD AM, 1990, J EXP MED, V172, P159, DOI 10.1084/jem.172.1.159; POSTON RN, 1992, AM REV RESPIR DIS, V145, P918, DOI 10.1164/ajrccm/145.4_Pt_1.918; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; ROCHESTER CL, 1988, AM REV RESPIR DIS, V138, P121, DOI 10.1164/ajrccm/138.1.121; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Saunders D, 1996, J EXP MED, V184, P2185, DOI 10.1084/jem.184.6.2185; SCHONHEGRAD MA, 1991, J EXP MED, V173, P1345, DOI 10.1084/jem.173.6.1345; SERTL K, 1986, J EXP MED, V163, P436, DOI 10.1084/jem.163.2.436; SIMECKA JW, 1986, IMMUNOLOGY, V57, P93; Smith AL, 1999, J EXP MED, V189, P593, DOI 10.1084/jem.189.3.593; SOLER P, 1989, AM REV RESPIR DIS, V139, P1112, DOI 10.1164/ajrccm/139.5.1112; Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8; SPITERI MA, 1991, CLIN EXP IMMUNOL, V83, P157; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; STEINMAN RM, 1995, J EXP MED, V182, P283, DOI 10.1084/jem.182.2.283; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Suda T, 1998, AM J RESP CELL MOL, V19, P728, DOI 10.1165/ajrcmb.19.5.3214; Suss G, 1996, J EXP MED, V183, P1789, DOI 10.1084/jem.183.4.1789; Svensson M, 1997, J IMMUNOL, V158, P4229; Szabolcs P, 1996, BLOOD, V87, P4520, DOI 10.1182/blood.V87.11.4520.bloodjournal87114520; TAZI A, 1993, J CLIN INVEST, V91, P566, DOI 10.1172/JCI116236; THEPEN T, 1989, J EXP MED, V170, P499, DOI 10.1084/jem.170.2.499; THEPEN T, 1992, CLIN EXP ALLERGY, V22, P1107, DOI 10.1111/j.1365-2222.1992.tb00137.x; Trulock EP, 1997, AM J RESP CRIT CARE, V155, P789, DOI 10.1164/ajrccm.155.3.9117010; TunonDeLara JM, 1996, CLIN EXP ALLERGY, V26, P648, DOI 10.1046/j.1365-2222.1996.1095481.x; Upham JW, 1999, AM J RESP CRIT CARE, V159, pA854; VANHAARST JMW, 1994, AM J RESP CELL MOL, V11, P344, DOI 10.1165/ajrcmb.11.3.8086170; vanHaarst JMW, 1996, AM J RESP CELL MOL, V15, P752, DOI 10.1165/ajrcmb.15.6.8969270; Vieira PL, 1998, J IMMUNOL, V161, P5245; Vremec D, 1997, J IMMUNOL, V159, P565; WARNER AE, 1986, AM J PHYSIOL, V250, pR728, DOI 10.1152/ajpregu.1986.250.4.R728; WINKLER GC, 1989, EXP CELL BIOL, V57, P281; XIA WJ, 1995, J EXP MED, V181, P1275, DOI 10.1084/jem.181.4.1275; XIA WJ, 1991, AM J RESP CELL MOL, V5, P276, DOI 10.1165/ajrcmb/5.3.276; YOUSEM SA, 1990, ANN THORAC SURG, V49, P424, DOI 10.1016/0003-4975(90)90248-5	108	86	92	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					421	429		10.1067/mai.2000.105010	http://dx.doi.org/10.1067/mai.2000.105010			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719288				2022-12-18	WOS:000088946700003
J	Jarvis, D; Chinn, S; Luczynska, C; Burney, P				Jarvis, D; Chinn, S; Luczynska, C; Burney, P		European Community Resp Hlth Surv	The association of smoking with sensitization to common environmental allergens: Results from the European Community Respiratory Health Survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						smoking; specific IgE; total IgE; European Community Respiratory Health Survey	SERUM IGE; CIGARETTE-SMOKING; IMMUNOGLOBULIN-E; LONGITUDINAL CHANGES; MITE ALLERGEN; WORKERS; HYPERSENSITIVITY; REACTIVITY; EXPOSURE; RISK	Background: Smoking is a risk factor for sensitization to some occupational allergens, but its association with sensitization to common environmental allergens remains unclear, Objective: We sought to determine the association of smoking with total IgE levels and with sensitization to 3 common environmental allergens in data from the European Community Respiratory Health Survey Methods: A detailed smoking history and blood sample far determination of serum total IgE and specific IgE levels to house dust mite, grass, and cat allergens was obtained from 13,002 randomly selected young adults Living in the areas served by 34 centers in 14 countries. Associations with smoking status and amount smoked sere determined. Because there was evidence of heterogeneity between centers in the association of age, sex, and smoking with sensitization, odds ratios (ORs) were determined for each center and combined by using random-effects meta-analysis. Results: Compared with lifetime nonsmokers, current smokers were at an increased risk of sensitization to house dust mite allergen (OR, 1.13; 95% confidence interval [CI], 1.02-1.26) but a decreased risk of sensitization to grass (OR, 0.76; 95% CI, 0.67-0.88) and cat allergens (OR, 0.69; 95% CI, 0.59-0.80), Exclusion of those with symptoms suggestive of current asthma strengthened the association of smoking with sensitization to house dust mite allergen (OR, 1.29; 95% CI, 1.11-1.50). The geometric mean total IgE level was higher in smokers and was higher among those who currently smoked the most compared with those who smoked less than 5 cigarettes per day, Conclusion: The association between smoking and sensitization to common environmental allergens is different For different allergens.	Univ London Kings Coll, Guys Hosp, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, London WC2R 2LS, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Jarvis, D (corresponding author), Dept Publ Hlth Med, 5th Floor,Capital House,42 Weston St, London SE1 3QD, England.		Jarvis, Deborah/E-6494-2011	Jarvis, Deborah/0000-0002-1753-3896; Burney, Peter/0000-0001-8635-5678	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005521] Funding Source: NIH RePORTER; NCRR NIH HHS [2 S07 RR05521-28] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BECKLAKE MR, 1990, RESPIRATION, V57, P137; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; CALVERLEY AE, 1995, OCCUP ENVIRON MED, V52, P661, DOI 10.1136/oem.52.10.661; CHANYEUNG M, 1982, J ALLERGY CLIN IMMUN, V70, P32, DOI 10.1016/0091-6749(82)90198-1; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; *EUR COMM RESP HLT, 1993, PROT EUR COMM RESP H; FLOOD DFS, 1985, BRIT J IND MED, V42, P43; GADEK JE, 1979, SCIENCE, V206, P1315, DOI 10.1126/science.316188; GREENBERG M, 1970, BMJ-BRIT MED J, V2, P629, DOI 10.1136/bmj.2.5710.629; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; HOLT PG, 1987, THORAX, V42, P241, DOI 10.1136/thx.42.4.241; JARVIS D, 1995, CLIN EXP ALLERGY, V25, P1083; Johnsen CR, 1997, OCCUP ENVIRON MED, V54, P671, DOI 10.1136/oem.54.9.671; JONES JG, 1983, THORAX, V38, P129, DOI 10.1136/thx.38.2.129; LIN FJ, 1994, CLIN EXP ALLERGY, V24, P949, DOI 10.1111/j.1365-2222.1994.tb02727.x; MCSHARRY C, 1994, CLIN EXP IMMUNOL, V97, P499, DOI 10.1111/j.1365-2249.1994.tb06116.x; Niezborala M, 1996, OCCUP ENVIRON MED, V53, P252, DOI 10.1136/oem.53.4.252; OMENAAS E, 1994, CLIN EXP ALLERGY, V24, P530, DOI 10.1111/j.1365-2222.1994.tb00950.x; ORYSZCZYN M, 1990, ANN ALLERGY, V67, P355; ORYSZCZYN MP, 1995, AM J RESP CRIT CARE, V151, P663; PARK HS, 1991, J ALLERGY CLIN IMMUN, V87, P639, DOI 10.1016/0091-6749(91)90382-X; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1046/j.1365-2222.1997.d01-415.x; ROMANO C, 1995, CLIN EXP ALLERGY, V25, P643, DOI 10.1111/j.1365-2222.1995.tb01112.x; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; WARREN CPW, 1982, J ALLERGY CLIN IMMUN, V69, P370, DOI 10.1016/0091-6749(82)90148-8; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215	29	86	86	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					934	940		10.1016/S0091-6749(99)70071-0	http://dx.doi.org/10.1016/S0091-6749(99)70071-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550735				2022-12-18	WOS:000083778400013
J	Koller, DY; Wojnarowski, C; Herkner, KR; Weinlander, G; Raderer, M; Eichler, I; Frischer, T				Koller, DY; Wojnarowski, C; Herkner, KR; Weinlander, G; Raderer, M; Eichler, I; Frischer, T			High levels of eosinophil cationic protein in wheezing infants predict the development of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil cationic protein; wheezing; infants; asthma	RESPIRATORY-TRACT; CHILDHOOD ASTHMA; CYSTIC-FIBROSIS; RISK-FACTORS; CHILDREN; SERUM; DEGRANULATION; ILLNESS; LIFE; ECP	Background: In association with respiratory tract infections, infants may have episodes of wheezing, which represent the onset of asthma in some of them. Activated eosinophils play a central part in asthmatic inflammation, Objective: We investigated whether, in infants experiencing their first episode of wheezing, eosinophil activation is present and can predict the development of asthma, Methods: In a prospective trial, eosinophil activation was measured by eosinophil cationic protein (ECP) concentrations in serum from 33 nonatopic infants with their first episode of wheezing, 15 nonatopic infants with upper respiratory tract infection without wheezing, and IS healthy nonatopic infants, One rear later, the children were re-evaluated for a diagnosis of infantile asthma. Results: Wheezing infants had higher median serum ECP levels (13.4 mu g/L) than children with nonwheezy respiratory tract infection (7.6 mu g/L, p < 0.005) or healthy subjects (7.1 mu g/L, p < 0.005). In addition, wheezing infants (n = 13) with serum ECP concentrations greater than 20 mu g/L sere more likely to hare asthma within 1 gear than patients with ECP levels less than 20 mu g/L (odds ratio = 12.4; confidence interval, 4.6-33.5). Conclusion: Eosinophil activation measured hg serum ECP is present in infants with their first episode of wheezing illness, especially in those infants in whom asthma subsequently develops within 1 year. These data mac indicate a predictive value of serum ECP measurements in children with wheezing to identify those patients in whom infantile asthma is developing. These findings probably also indicate that serum ECP may be used to identify the children who need early antiinflammatory treatment.	LUDWIG BOLTZMANN INST PEDIAT ENDOCRINOL & IMMUNOL, VIENNA, AUSTRIA; GEN HOSP, DEPT INTERNAL MED 1, VIENNA, AUSTRIA	Ludwig Boltzmann Institute	Koller, DY (corresponding author), UNIV VIENNA, CHILDRENS HOSP, DIV PULM & ALLERGY, WAHRINGER GURTEL 18-20, A-1090 VIENNA, AUSTRIA.							AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; ANDERSON HR, 1981, LANCET, V2, P1030; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BUSSE WW, 1989, CLIN EXP ALLERGY, V19, P1, DOI 10.1111/j.1365-2222.1989.tb02336.x; DUFF AL, 1993, PEDIATRICS, V92, P535; FRY J, 1961, BRIT MED J, V1, P227, DOI 10.1136/bmj.1.5221.227; GAROFALO R, 1992, J PEDIATR-US, V120, P28, DOI 10.1016/S0022-3476(05)80592-X; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GODFREY S, 1983, ASTHMA, P416; INGRAM JM, 1995, J PEDIATR-US, V127, P558, DOI 10.1016/S0022-3476(95)70112-5; KOLLER DY, 1994, THORAX, V49, P496, DOI 10.1136/thx.49.5.496; KOLLER DY, 1995, AM J RESP CRIT CARE, V152, P629, DOI 10.1164/ajrccm.152.2.7633718; KOLLER DY, 1995, ARCH DIS CHILD, V73, P413, DOI 10.1136/adc.73.5.413; KONIG P, 1973, ARCH DIS CHILD, V48, P942, DOI 10.1136/adc.48.12.942; KRAEMER R, 1988, THORAX, V43, P770, DOI 10.1136/thx.43.10.770; KUBO S, 1978, J ASTHMA RES, V15, P99, DOI 10.3109/02770907809106597; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MORGAN WJ, 1992, PEDIATR CLIN N AM, V39, P1185; PETERSON CGB, 1991, CLIN EXP ALLERGY, V21, P561, DOI 10.1111/j.1365-2222.1991.tb00847.x; SILVERMAN M, 1993, THORAX, V48, P1200, DOI 10.1136/thx.48.12.1200; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; SPORIK R, 1991, ARCH DIS CHILD, V66, P1050, DOI 10.1136/adc.66.9.1050; Spry CJ, 1988, EOSINOPHILS COMPREHE; TABACHNIK E, 1981, J ALLERGY CLIN IMMUN, V67, P339, DOI 10.1016/0091-6749(81)90077-4; VENGE P, 1983, IMMUNOBIOLOGY EOSINO, P163; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243; ZIMMERMAN B, 1994, CLIN EXP ALLERGY, V24, P149, DOI 10.1111/j.1365-2222.1994.tb00212.x	28	86	86	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	1				752	756		10.1016/S0091-6749(97)80007-3	http://dx.doi.org/10.1016/S0091-6749(97)80007-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XH193	9215241				2022-12-18	WOS:A1997XH19300006
J	Cheng, JF; Ott, NL; Peterson, EA; George, TJ; Hukee, MJ; Gleich, GJ; Leiferman, KM				Cheng, JF; Ott, NL; Peterson, EA; George, TJ; Hukee, MJ; Gleich, GJ; Leiferman, KM			Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; atopic dermatitis; MBP; cytolytic degeneration; electron microscopy; granule; uropod	MAJOR BASIC-PROTEIN; RECOMBINANT HUMAN INTERLEUKIN-5; LEYDEN CRYSTAL PROTEIN; LATE-PHASE REACTION; GRANULE PROTEINS; CATIONIC PROTEIN; ULTRASTRUCTURAL-LOCALIZATION; PIECEMEAL DEGRANULATION; EXTRACELLULAR-MATRIX; CLINICAL ACTIVITY	Background: Immunofluorescent staining for eosinophil granule proteins in lesional skin of patients with atopic dermatitis shows extensive extracellular deposition throughout the upper dermis with relatively few intact eosinophils, Objective: This study was carried out to determine whether eosinophil granule protein deposition in atopic dermatitis occurs by classical exocytosis, by piecemeal degranulation, or as a result of cytolysis. Methods: Skin biopsy specimens from 10 patients viith atopic dermatitis were examined by electron microscopy. Results: The biopsy specimens showed varying degrees of dermal eosinophil granule major basic protein deposition by indirect immunofluorescence, Specimens from seven patients showed striking alterations of eosinophils by electron microscopy including intact eosinophils with granule alterations (reversal of core staining and/or core lucency) and with uropod processes. Biopsy specimens from six patients showed evidence of eosinophil degeneration with disruption of nuclear and/or plasma membranes. In four patients' specimens, membrane-bound eosinophil granules were present near degenerating eosinophils or were present in the absence of recognizable eosinophils, Evidence of classical exocytotic degranulation was not observed, Two of the specimens were also examined by immunoelectron microscopy for major basic protein localization, In these, major basic protein appeared to be lost from the granule core and distributed in the eosinophil cytoplasm as granules disintegrated and the cell disrupted. Conclusion: These findings support the hypothesis that eosinophils undergo cytolysis with release of granule contents and membrane-bound granules; this is likely the usual mechanism of eosinophil granule protein release in atopic dermatitis.	MAYO CLIN & MAYO FDN,DEPT DERMATOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PEDIAT & ADOLESCENT MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,SECT ALLERG DIS RES,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic					NIAID NIH HHS [AI 34577, AI 15231] Funding Source: Medline; NIAMS NIH HHS [AR 36006] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034577, R01AI015231, R37AI015231, U01AI034577] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGOSTI JM, 1988, NEW ENGL J MED, V319, P1623, DOI 10.1056/NEJM198812223192502; BENDAYAN M, 1983, J HISTOCHEM CYTOCHEM, V31, P101, DOI 10.1177/31.1.6187796; BERMAN EL, 1983, SCAN ELECTRON MICROS, P311; COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; CZECH W, 1992, BRIT J DERMATOL, V126, P351, DOI 10.1111/j.1365-2133.1992.tb00677.x; DELPOZO MA, 1995, J CELL BIOL, V131, P495, DOI 10.1083/jcb.131.2.495; DOTE M, 1996, BLOOD, V87, P2029; DVORAK AM, 1992, AM J PATHOL, V140, P795; DVORAK AM, 1991, AM J PATHOL, V138, P69; DVORAK AM, 1982, J INVEST DERMATOL, V78, P91, DOI 10.1111/1523-1747.ep12505711; DVORAK AM, 1992, INT ARCH ALLERGY IMM, V99, P74, DOI 10.1159/000236338; DVORAK AM, 1990, LAB INVEST, V62, P590; DVORAK AM, 1993, INT ARCH ALLERGY IMM, V102, P33, DOI 10.1159/000236548; DVORAK AM, 1980, J IMMUNOL, V125, P460; DVORAK AM, 1991, BLOOD CELL BIOCH, V2; GALLI SJ, 1981, J IMMUNOL, V126, P1066; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GLEICH GJ, 1984, NEW ENGL J MED, V310, P1621, DOI 10.1056/NEJM198406213102501; GLEICH GJ, 1992, INFLAMMATION BASIC P, P663; GREENWOOD B, 1969, BRIT J DERMATOL, VS 81, P36, DOI 10.1111/j.1365-2133.1969.tb12852.x; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HANKER JS, 1980, HISTOCHEM J, V12, P701, DOI 10.1007/BF01012025; HANKER JS, 1981, HISTOCHEM J, V13, P905, DOI 10.1007/BF01002631; JUHLIN L, 1991, ACTA DERM-VENEREOL, V71, P495; KAGI MK, 1992, DERMATOLOGY, V185, P88, DOI 10.1159/000247419; KAPP A, 1993, ALLERGY, V48, P1, DOI 10.1111/j.1398-9995.1993.tb02167.x; KRUTMANN J, 1992, J AM ACAD DERMATOL, V26, P225, DOI 10.1016/0190-9622(92)70031-A; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; LEIFERMAN KM, 1990, LAB INVEST, V62, P579; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; LEUNG DYM, 1996, ATOPIC DERMATITIS PA; MCDOWELL EM, 1976, ARCH PATHOL LAB MED, V100, P405; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; MINNICOZZI M, 1994, J IMMUNOL, V153, P2664; OTT NL, 1994, J ALLERGY CLIN IMMUN, V94, P120, DOI 10.1016/0091-6749(94)90078-7; PAGANELLI R, 1991, INT ARCH ALLER A IMM, V96, P175, DOI 10.1159/000235490; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; SILBERSTEIN DS, 1989, HEMATOL ONCOL CLIN N, V3, P511, DOI 10.1016/S0889-8588(18)30545-8; SOTER NA, 1989, ALLERGY, V44, P16, DOI 10.1111/j.1398-9995.1989.tb02449.x; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; STOUGHTON RB, 1989, ANNU REV PHARMACOL, V29, P55; TSUDA S, 1992, Journal of Dermatology (Tokyo), V19, P208; UEHARA M, 1990, CLIN EXP DERMATOL, V15, P264, DOI 10.1111/j.1365-2230.1990.tb02086.x; VERCELLI D, 1988, J EXP MED, V167, P1406, DOI 10.1084/jem.167.4.1406; WAGNER JM, 1993, PLACENTA, V14, P671, DOI 10.1016/S0143-4004(05)80384-4; WALKER C, 1993, CLIN EXP ALLERGY, V23, P145, DOI 10.1111/j.1365-2222.1993.tb00310.x; WUTHRICH B, 1992, ARCH DERMATOL RES, V284, P339, DOI 10.1007/BF00372036; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	53	86	87	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					683	692		10.1016/S0091-6749(97)70031-9	http://dx.doi.org/10.1016/S0091-6749(97)70031-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155836	Bronze			2022-12-18	WOS:A1997WY60000017
J	Nakazawa, M; Sugi, N; Kawaguchi, H; Ishii, N; Nakajima, H; Minami, M				Nakazawa, M; Sugi, N; Kawaguchi, H; Ishii, N; Nakajima, H; Minami, M			Predominance of type 2 cytokine-producing CD4(+) and CD8(+) cells in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; Il-4; interferon-gamma; Il-2; CD4(+) cells; CD8(+) cells; flow cytometry	INTERFERON-GAMMA PRODUCTION; SERUM IMMUNOGLOBULIN-E; CD8+ T-CELLS; IGE SYNTHESIS; LYMPHOKINE ACTIVITIES; CYTOLYTIC ACTIVITY; FLOW-CYTOMETRY; IFN-GAMMA; B-CELLS; HELPER	Background: Recently, increased IL-4 and decreased interferon-gamma (IFN-gamma) production in peripheral blood mononuclear cells (PBMCs) from patients with atopic dermatitis have been reported by several groups. They measured the total amount of each cytokine in culture supernatants in their studies. These studies suggested a predominance of type 2 cytokine-producing cells in atopic dermatitis. However, it is still unclear whether the cytokine imbalance is the result of an imbalance of specific T-cell subsets or of dysregulation of the cytokine-producing ability in T-cell subsets. Here, we examined frequencies of IL-4-, IFN-gamma-, or IL-2-producing CD4(+) cells and CD8(+) cells in PBMCs from patients with atopic dermatitis at a single cell level by using how cytometry. Methods: PBMCs from 45 patients with atopic dermatitis and 24 healthy control subjects were stimulated with immobilized anti-CD3 monoclonal antibody for 6 hours in the presence of monensin. Cells were fixed, made permeable, and stained for intracellular cytokines in combination with staining for cell surface markers CD4 and CD8. Results: The frequency of IL-4-producing CD4(+) cells and CD8(+) cells from patients with atopic dermatitis was significantly higher (p < 0.001) than that from healthy control subjects. In contrast, the frequency of IFN-gamma-producing CD4(+) cells and CD8(+) cells was significantly decreased (p < 0.01) in the patients with atopic dermatitis. The frequency of IL-2-producing cells from patients with atopic dermatitis was comparable to that from healthy control subjects. Conclusion: Our findings indicate that frequencies of type 2 cytokine-producing cells, not only among CD4(+) cells but also among CD8(+) cells, were significantly higher in patients with atopic dermatitis than in healthy control subjects.	YOKOHAMA CITY UNIV, SCH MED, DEPT IMMUNOL & PARASITOL, YOKOHAMA, KANAGAWA 236, JAPAN; YOKOHAMA CITY UNIV, SCH MED, DEPT OPHTHALMOL, YOKOHAMA, KANAGAWA 236, JAPAN; YOKOHAMA CITY UNIV, SCH MED, DEPT DERMATOL, YOKOHAMA, KANAGAWA 236, JAPAN	Yokohama City University; Yokohama City University; Yokohama City University								ANDERSSON U, 1988, J IMMUNOL METHODS, V112, P139, DOI 10.1016/0022-1759(88)90044-0; CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; DEVRIES JE, 1994, J INVEST DERMATOL, V102, P141, DOI 10.1111/1523-1747.ep12371750; ERARD F, 1993, SCIENCE, V260, P1802, DOI 10.1126/science.8511588; FONG TAT, 1990, J IMMUNOL, V144, P1744; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GEHA RS, 1992, J ALLERGY CLIN IMMUN, V90, P143, DOI 10.1016/0091-6749(92)90064-9; HAANEN JBAG, 1991, J EXP MED, V174, P583, DOI 10.1084/jem.174.3.583; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P256, DOI 10.1016/0091-6749(75)90145-1; JONES HE, 1975, BRIT J DERMATOL, V92, P17; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; JUNG T, 1995, J ALLERGY CLIN IMMUN, V96, P515, DOI 10.1016/S0091-6749(95)70296-2; MAGGI E, 1994, J EXP MED, V180, P489, DOI 10.1084/jem.180.2.489; MINGARI MC, 1984, EUR J IMMUNOL, V14, P1066, DOI 10.1002/eji.1830141121; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PALIARD X, 1988, J IMMUNOL, V141, P849; PRYSTOWSKY MB, 1982, J IMMUNOL, V129, P2337; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; REINHOLD U, 1990, CLIN EXP IMMUNOL, V79, P374; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; ROUSSET F, 1991, J ALLERGY CLIN IMMUN, V87, P58, DOI 10.1016/0091-6749(91)90213-8; SAD S, 1994, J IMMUNOL, V153, P3514; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SANDER B, 1989, SCAND J IMMUNOL, V30, P315, DOI 10.1111/j.1365-3083.1989.tb01216.x; SEDER RA, 1992, J IMMUNOL, V148, P1652; SWAIN SL, 1990, J IMMUNOL, V145, P3796; TANG M, 1993, CLIN EXP IMMUNOL, V92, P120; THYPHRONITIS G, 1989, P NATL ACAD SCI USA, V86, P5580, DOI 10.1073/pnas.86.14.5580; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3	37	86	90	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					673	682		10.1016/S0091-6749(97)70030-7	http://dx.doi.org/10.1016/S0091-6749(97)70030-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155835	Bronze			2022-12-18	WOS:A1997WY60000016
J	Bousquet, J; Knani, J; Henry, C; Liard, R; Richard, A; Michel, FB; Neukirch, F				Bousquet, J; Knani, J; Henry, C; Liard, R; Richard, A; Michel, FB; Neukirch, F			Under-treatment in a nonselected population of adult patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; epidemiology; undertreatment	INHALED CORTICOSTEROID BUDESONIDE; BRONCHIAL HYPERRESPONSIVENESS; AIRWAY RESPONSIVENESS; SYMPTOMS; CHILDREN; QUESTIONNAIRE; HISTAMINE; BRONCHODILATOR; MANAGEMENT; DIAGNOSIS	Background and aim: The question of undertreatment has frequently been raised concerning the management of asthma but, to date, very few studies have been carried out. In those studies that have been performed, the methodology was inadequate because they were conducted on a selected population of patients with asthma or by interviewing doctors. As part of the European Community Respiratory Health Survey, nonselected patients with asthma (22 to 44 years old) in two French cities (Paris and Montpellier), were examined to assess possible undertreatment. Methods: Patients with asthma were recruited according to a positive response to questions on asthma in a questionnaire and a positive methacholine challenge. The severity of asthma was assessed by a cumulative score, which has previously been shown to be significantly correlated with the validated clinical score of Aas. Patients were asked to attend the clinic and bring with them any medications that they regularly received. The optimal treatment of asthma was based on the International Consensus Report on the Management of Asthma. Results: According to the international guidelines, among the patients who required antiinflammatory treatment, 86.4% were undertreated in Paris and 66.7% were undertreated in Montpellier (p < 0.03, chi square test). Moreover, among the patients with severe asthma, 85% and 60%, respectively; were not receiving an antiinflammatory treatment. Conclusion: This study is the first to highlight the magnitude of undertreatment of patients with asthma in a nonselected population.	UNIV PARIS 07, INSERM, U226, PARIS, FRANCE; SERV PHARMACOECON, LABS GLAXO, PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; GlaxoSmithKline	Bousquet, J (corresponding author), HOP ARNAUD DE VILLENEUVE, CLIN MALAD RESP, SERV MALAD RESP, ROUTE GANGES, F-34295 MONTPELLIER 5, FRANCE.		Bousquet, Jean/O-4221-2019					AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; ABRAMSON MJ, 1991, J ASTHMA, V28, P129, DOI 10.3109/02770909109082737; ADELROTH E, 1985, ALLERGY, V40, P58, DOI 10.1111/j.1398-9995.1985.tb04155.x; [Anonymous], 1990, BRIT MED J, V301, P651; ARCHER LNJ, 1985, ARCH DIS CHILD, V60, P473, DOI 10.1136/adc.60.5.473; BAUMAN A, 1992, MED J AUSTRALIA, V156, P827, DOI 10.5694/j.1326-5377.1992.tb136992.x; BAUMAN A, 1992, AUST NZ J MED, V22, P36, DOI 10.1111/j.1445-5994.1992.tb01706.x; BECKER AB, 1984, AM J DIS CHILD, V138, P574, DOI 10.1001/archpedi.1984.02140440058015; BENATAR SR, 1986, S AFR MED J, V69, P669; BLOOMBERG GR, 1992, PEDIATR CLIN N AM, V39, P1225; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P649, DOI 10.1016/0091-6749(91)90159-L; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRAND PLP, 1992, EUR RESPIR J, V5, P21; BUIST AS, 1988, CHEST, V93, P449, DOI 10.1378/chest.93.3.449; BURNEY P, 1987, CHEST, V91, pS79, DOI 10.1378/chest.91.6.79S; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; CLUZEL M, 1987, J ALLERGY CLIN IMMUN, V80, P195, DOI 10.1016/0091-6749(87)90129-1; COCHRANE GM, 1991, Q J MED, V81, P797; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEKKER FW, 1992, THORAX, V47, P162, DOI 10.1136/thx.47.3.162; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; *EUR COMM RESP HLT, 1994, MED HLTH; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HARGREAVE FE, 1986, RESPIRATION, V50, P72, DOI 10.1159/000195103; HILL RA, 1989, ARCH DIS CHILD, V64, P246, DOI 10.1136/adc.64.2.246; JOSEPHS LK, 1992, EUR RESPIR J, V5, P32; JOSEPHS LK, 1989, AM REV RESPIR DIS, V140, P350, DOI 10.1164/ajrccm/140.2.350; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; KAPTEIN AA, 1987, FAM PRACT, V4, P219, DOI 10.1093/fampra/4.3.219; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; NEVILLE RG, 1992, BRIT J GEN PRACT, V42, P501; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549, DOI 10.1164/ajrccm/142.3.549; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SAMET JM, 1991, CHRONIC OBSTRUCTIVE, P249; Sears M R, 1991, Bull Int Union Tuberc Lung Dis, V66, P79; SEARS MR, 1992, CHEST, V102, P1709, DOI 10.1378/chest.102.6.1709; SPECTOR SL, 1975, J ALLERGY CLIN IMMUN, V56, P308, DOI 10.1016/0091-6749(75)90105-0; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Strub M, 1986, IMJ Ill Med J, V170, P30; *US PHS, 1979, US DHEW PUBL; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VIGNOLA AM, 1993, AM REV RESPIR DIS, V148, P689, DOI 10.1164/ajrccm/148.3.689; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252, DOI 10.1164/ajrccm/148.5.1252; WAALKENS JH, 1993, EUR RESPIR J, V6, P652; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WOOLCOCK A, 1989, MED J AUSTRALIA, V151, P650, DOI 10.5694/j.1326-5377.1989.tb139640.x; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71; WOOLCOCK AJ, 1991, AM REV RESPIR DIS, V143, pS75, DOI 10.1164/ajrccm/143.3_Pt_2.S75; YOUNG L, 1992, AUST FAM PHYSICIAN, V21, P862; 1991, J ALLERGY CLIN IMMUN, V88, P425; 1992, ALLERGY, V47, P1	60	86	88	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					514	521		10.1016/S0091-6749(96)70084-2	http://dx.doi.org/10.1016/S0091-6749(96)70084-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828528				2022-12-18	WOS:A1996VJ42800007
J	Suzuki, H; Takahashi, Y; Wataya, H; Ikeda, K; Nakabayashi, S; Shimomura, A; Takasaka, T				Suzuki, H; Takahashi, Y; Wataya, H; Ikeda, K; Nakabayashi, S; Shimomura, A; Takasaka, T			Mechanism of neutrophil recruitment induced by IL-8 in chronic sinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-8; neutrophil; chemotaxis; chronic sinusitis; nasal discharge	TUMOR-NECROSIS-FACTOR; HUMAN POLYMORPHONUCLEAR NEUTROPHILS; INTERLEUKIN-8 GENE-EXPRESSION; BRONCHIAL EPITHELIAL-CELLS; COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; PSORIATIC SKIN-LESIONS; DIFFUSE PANBRONCHIOLITIS; FUNCTIONAL-CHARACTERIZATION; FACTOR-ALPHA	Background: The mechanism of neutrophil recruitment in patients with chronic sinusitis is unclear. Objective: This study aims to elucidate the role of IL-8 in inducing neutrophil accumulation in the nasal discharge of patients with chronic sinusitis. Methods: Nasal discharge and mucosal specimens were obtained from two groups of patients, those with chronic sinusitis and those with allergic rhinitis. The samples were subjected to immunohistochemical examination and in situ hybridization. The IL-8 level in the nasal discharge was measured by enzyme immunoassay. Results: Immunoreactivity to IL-8 was observed in polymorphonuclear cells of nasal smear, in nasal gland duct cells, and in epithelial cells of the chronic sinusitis group; whereas those of the allergic rhinitis group mostly showed little or no reaction. Similar patterns of localization were shown by in situ hybridization for IL-8 messenger RNA. The IL-8 level in nasal discharge was significantly higher in the chronic sinusitis group than in the allergic rhinitis group. Conclusion: These results suggest that chemotactic factors in sinus effusion, including IL-8 derived from nasal gland duct cells and epithelial cells, attract neutrophils out of mucosa, and the neutrophils that have emigrated into the sinus effusion secrete IL-8. This induces further neutrophil accumulation in the sinus effusion of patients with chronic sinusitis.	TOHOKU UNIV,SCH MED,DEPT CLIN LAB & MED,SENDAI,MIYAGI 980,JAPAN; TOHOKU ROSAI HOSP,DEPT OTOLARYNGOL,SENDAI,MIYAGI,JAPAN	Tohoku University	Suzuki, H (corresponding author), TOHOKU UNIV,SCH MED,DEPT OTOLARYNGOL,AOBA KU,1-1 SEIRYO MACHI,SENDAI,MIYAGI 98077,JAPAN.							AKIRA M, 1993, RADIOLOGY, V189, P559, DOI 10.1148/radiology.189.2.8210390; BAZZONI F, 1991, J EXP MED, V173, P771, DOI 10.1084/jem.173.3.771; BECKER S, 1993, AM J RESP CELL MOL, V8, P20, DOI 10.1165/ajrcmb/8.1.20; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BRENNAN FM, 1990, EUR J IMMUNOL, V20, P2141, DOI 10.1002/eji.1830200938; CAMP RDR, 1986, J IMMUNOL, V137, P3469; CARENFELT C, 1979, ANN OTO RHINOL LARYN, V88, P16, DOI 10.1177/000348947908800104; CICCO NA, 1990, BLOOD, V75, P2049; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; DRISCOLL KE, 1995, J LEUKOCYTE BIOL, V58, P359, DOI 10.1002/jlb.58.3.359; DUBRAVEC DB, 1990, P NATL ACAD SCI USA, V87, P6758, DOI 10.1073/pnas.87.17.6758; FINCHAM NJ, 1988, J IMMUNOL, V140, P4294; FREVERT CW, 1995, INFLAMMATION, V19, P133, DOI 10.1007/BF01534386; FUJISHIMA S, 1993, J CELL PHYSIOL, V154, P478, DOI 10.1002/jcp.1041540305; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; IINO Y, 1993, ARCH OTOLARYNGOL, V119, P648; IINO Y, 1992, ANN OTOL RHINOL LA S, V157, P16; INOUE H, 1994, AM J RESP CELL MOL, V11, P651, DOI 10.1165/ajrcmb.11.6.7946394; ITOH K, 1992, ACTA OTO-LARYNGOL, V112, P882, DOI 10.3109/00016489209137487; JOSE PJ, 1994, BIOCHEM BIOPH RES CO, V205, P788, DOI 10.1006/bbrc.1994.2734; KADOTA J, 1993, AM REV RESPIR DIS, V147, P153, DOI 10.1164/ajrccm/147.1.153; Kennedy D W, 1992, Laryngoscope, V102, P1; KENNEDY DW, 1987, LARYNGOSCOPE, V97, P1, DOI 10.1288/00005537-198708002-00001; KENNEY JS, 1994, J ALLERGY CLIN IMMUN, V93, P1060, DOI 10.1016/S0091-6749(94)70055-9; KING JM, 1994, LARYNGOSCOPE, V104, P404; Koga Takeharu, 1993, Kurume Medical Journal, V40, P139; KOYAMA S, 1991, J IMMUNOL, V147, P4293; LEGENT F, 1994, CHEMOTHERAPY, V40, P8, DOI 10.1159/000239310; LEVINE HL, 1990, LARYNGOSCOPE, V100, P79; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; LINDEMANN A, 1988, J IMMUNOL, V140, P837; LUND VJ, 1993, ACTA OTO-LARYNGOL, V113, P540, DOI 10.3109/00016489309135860; LUND VJ, 1991, J LARYNGOL OTOL, V105, P832, DOI 10.1017/S0022215100117463; MABRY RL, 1994, OTOLARYNG HEAD NECK, V111, P335, DOI 10.1177/01945998941113P201; MALKOWSKI MG, 1995, J BIOL CHEM, V270, P7077, DOI 10.1074/jbc.270.13.7077; MAZZUCCHELLI L, 1994, AM J PATHOL, V144, P997; MILKS LC, 1983, J CELL BIOL, V96, P1241, DOI 10.1083/jcb.96.5.1241; MITSUYAMA K, 1994, CLIN EXP IMMUNOL, V96, P432; MIYAMASU M, 1995, J IMMUNOL, V154, P1339; MUKAE H, 1993, AM REV RESPIR DIS, V148, P744, DOI 10.1164/ajrccm/148.3.744; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; NAGAI H, 1991, RESPIRATION, V58, P145, DOI 10.1159/000195915; NAKAGAWA H, 1994, BIOCHEM J, V301, P545, DOI 10.1042/bj3010545; NAKAJIMA H, 1994, J EXP MED, V179, P1145, DOI 10.1084/jem.179.4.1145; NELSON S, 1987, AM REV RESPIR DIS, V136, P1207, DOI 10.1164/ajrccm/136.5.1207; NICKOLOFF BJ, 1991, AM J PATHOL, V138, P129; ODA H, 1994, CHEST, V106, P1116, DOI 10.1378/chest.106.4.1116; OHASHI Y, 1983, ACTA OTOLARYNGOL S S, V397, P11; OHASHI Y, 1983, ACTA OTOLARYNGOL S S, V397, P3; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PIECHL P, 1991, SCAND J IMMUNOL, V34, P333; POWER CA, 1994, GENE, V151, P333, DOI 10.1016/0378-1119(94)90682-3; PROOST P, 1993, BIOCHEMISTRY-US, V32, P10170, DOI 10.1021/bi00089a037; PROOST P, 1993, J IMMUNOL, V150, P1000; RAAB Y, 1993, GUT, V34, P1203, DOI 10.1136/gut.34.9.1203; RAZ M, 1993, CLIN SCI, V85, P753, DOI 10.1042/cs0850753; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; RICE DH, 1989, OTOLARYNG HEAD NECK, V101, P476, DOI 10.1177/019459988910100412; RICHMANEISENSTAT JBY, 1993, AM J PHYSIOL, V264, pL413, DOI 10.1152/ajplung.1993.264.4.L413; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SCHMOUDER RL, 1995, TRANSPLANTATION, V59, P118, DOI 10.1097/00007890-199501150-00021; SEITZ M, 1991, J CLIN INVEST, V87, P463, DOI 10.1172/JCI115018; SHIRAFUJI N, 1990, BLOOD, V75, P17; STRIETER RM, 1990, BIOCHEM BIOPH RES CO, V173, P725, DOI 10.1016/S0006-291X(05)80095-6; SUGIYAMA Y, 1993, CLIN CHEST MED, V14, P765; TAKASAKA T, 1980, ANN OTO RHINOL LARYN, V89, P37, DOI 10.1177/000348948008900110; TAKEMATSU H, 1993, ARCH DERMATOL, V129, P74, DOI 10.1001/archderm.129.1.74; TAKEUCHI K, 1995, AM J OTOLARYNG, V16, P98, DOI 10.1016/0196-0709(95)90039-X; TOKUSHIGE E, 1994, LARYNGOSCOPE, V104, P1245; TORRE D, 1991, J CHEMOTHERAPY, V3, P236; WALD ER, 1992, NEW ENGL J MED, V326, P319; YING S, 1995, J EXP MED, V181, P2153, DOI 10.1084/jem.181.6.2153; YUO A, 1991, BLOOD, V78, P2708; ZAGORSKI J, 1994, PROTEIN EXPRES PURIF, V5, P337, DOI 10.1006/prep.1994.1050	74	86	88	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					659	670		10.1016/S0091-6749(96)70100-8	http://dx.doi.org/10.1016/S0091-6749(96)70100-8			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828544				2022-12-18	WOS:A1996VJ42800023
J	TOOGOOD, JH; BASKERVILLE, JC; MARKOV, AE; HODSMAN, AB; FRAHER, LJ; JENNINGS, B; HADDAD, RG; DROST, D				TOOGOOD, JH; BASKERVILLE, JC; MARKOV, AE; HODSMAN, AB; FRAHER, LJ; JENNINGS, B; HADDAD, RG; DROST, D			BONE-MINERAL DENSITY AND THE RISK OF FRACTURE IN PATIENTS RECEIVING LONG-TERM INHALED STEROID-THERAPY FOR ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; GLUCOCORTICOIDS; INHALED STEROIDS; BUDESONIDE; BECLOMETHASONE; STEROID COMPLICATIONS; BONE DENSITOMETRY; OSTEOPOROSIS; VERTEBRAL FRACTURE; ESTROGENS	DECREASES SERUM OSTEOCALCIN; INDUCED OSTEOPOROSIS; CORTICOSTEROID TREATMENT; ORAL PREDNISOLONE; ADRENAL-FUNCTION; BUDESONIDE; MASS; TURNOVER; MARKERS; WOMEN	To determine whether high-dose or prolonged inhaled steroid therapy for asthma increases a patient's risk of osteoporosis and fracture, we measured bone density in 26 men and 43 women (41 postmenopausal, all of whom had received supplemental estrogen therapy) after treatment with an inhaled steroid for 10.1 +/- 5.5 years and oral prednisone for 10.7 +/- 9.7 years (mean +/- SD). Most had stopped receiving prednisone since commencing the inhaled steroid therapy. We found that bone densities (adjusted for age and sex to yield a z score) were lower in association with higher daily doses of inhaled steroid (p = 0.013 ANCOVA) and with the duration of past prednisone therapy (p = 0.032). Larger cumulative inhaled steroid doses were associated with higher bone densities (p = 0.002) and a reduction in the numbers of patients at risk of fracture. Bone density also increased with the amount of supplemental estrogen therapy (p = 0.058) and, at equivalent levels of inhaled and oral steroid use, women showed higher bone density z scores es than did men. Women with a lifetime dose of inhaled steroid greater than 3 gm had normal bone density regardless of the amount of past or current prednisone use oi the current dose of inhaled steroid. These data indicate that the daily dose, brit not the duration, of inhaled steroid therapy may adversely affect bone density, and that estrogen therapy may offset this bone-depleting effect in postmenopausal women.	VICTORIA HOSP,DEPT MED,LONDON,ON N6A 4G5,CANADA; VICTORIA HOSP,DEPT RADIOL,LONDON,ON N6A 4G5,CANADA; UNIV WESTERN ONTARIO,DEPT MED,LONDON,ON N6A 3K7,CANADA; UNIV WESTERN ONTARIO,DEPT STAT & ACTUARIAL SCI,LONDON,ON N6A 3K7,CANADA; KIEV PHTHISIATRY & PULMONOL INST,DEPT ALLERGOL,KIEV,UKRAINE; ST JOSEPHS HLTH CTR,LAWSON RES INST,LONDON,ON,CANADA; ST JOSEPHS HLTH CTR,DEPT MED,LONDON,ON,CANADA; ST JOSEPHS HLTH CTR,DEPT NUCL MED,LONDON,ON,CANADA; ASTA PHARMA AG,CLIN RES DEPT,MISSISSAUGA,ON,CANADA	University of Victoria; Western University (University of Western Ontario); University of Victoria; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)			Hodsman, Anthony/G-3303-2011					ALI NJ, 1991, THORAX, V46, P160, DOI 10.1136/thx.46.3.160; [Anonymous], 1989, SAS STAT USERS GUIDE, V2; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BOULET LP, 1993, AM REV RESPIR DIS, V147, pA293; CROMPTON GK, 1987, BRIT MED J, V294, P123, DOI 10.1136/bmj.294.6564.123-a; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DEDEUXCHAISNES CN, 1984, ADV EXP MED BIOL, V171, P210; DYKMAN TR, 1985, ARTHRITIS RHEUM, V28, P361, DOI 10.1002/art.1780280402; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HAHN TJ, 1974, J CLIN ENDOCR METAB, V39, P274, DOI 10.1210/jcem-39-2-274; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HODSMAN AB, 1991, J CLIN ENDOCR METAB, V72, P530, DOI 10.1210/jcem-72-3-530; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; IP MSM, 1993, AM REV RESPIR DIS, V147, pA293; JENNINGS BH, 1991, EUR J CLIN PHARMACOL, V40, P77, DOI 10.1007/BF00315143; JENNINGS BH, 1990, ASSESSMENT SYSTEMIC, V7, P1; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; JOHNSTON CC, 1991, AM J MED, V91, pS47, DOI 10.1016/0002-9343(91)90247-U; KANIS JA, 1993, DRUG AGING, V3, P391, DOI 10.2165/00002512-199303050-00001; KERREBIJN KF, 1990, AM REV RESPIR DIS, V141, pS77; KONIG P, 1993, J PEDIATR-US, V122, P219, DOI 10.1016/S0022-3476(06)80116-2; LUFKIN EG, 1988, AM J MED, V85, P887; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; MANNING P, 1990, OSTEOPOROSIS 1990, P1585; MARKOV AE, 1992, J BONE MINER RES, V7, pS97; MELTON LJ, 1989, CALCIFIED TISSUE INT, V45, P263, DOI 10.1007/BF02556016; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; PACKE GE, 1992, THORAX, V47, P415; POCOCK NA, 1987, ANN INTERN MED, V107, P319, DOI 10.7326/0003-4819-107-2-319; POUW EM, 1991, BRIT MED J, V302, P627, DOI 10.1136/bmj.302.6777.627; PUOLIJOKI H, 1992, BONE, V13, P285, DOI 10.1016/8756-3282(92)90072-5; REID DM, 1986, BMJ-BRIT MED J, V293, P1463, DOI 10.1136/bmj.293.6560.1463; RIZZATO G, 1993, EUR RESPIR J, V6, P116; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; ROSS PD, 1987, BONE, V8, P271, DOI 10.1016/8756-3282(87)90001-9; ROSS PD, 1989, J BONE MINER RES, V4, P649; SELROOS O, 1991, THORAX, V46, P891, DOI 10.1136/thx.46.12.891; SORVA R, 1992, J ALLERGY CLIN IMMUN, V90, P808, DOI 10.1016/0091-6749(92)90106-C; STAMP TCB, 1991, CLIN RHEUM DIS, V12, P636; STEAD R J, 1990, Thorax, V45, P792; STUDD J, 1989, LANCET, V1, P850; Toogood J H, 1994, Int J Risk Saf Med, V5, P1, DOI 10.3233/JRS-1994-5102; TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723; TOOGOOD JH, 1991, J ALLERGY CLIN IMMUN, V88, P572, DOI 10.1016/0091-6749(91)90150-M; TOOGOOD JH, 1991, ANN ALLERGY, V67, P87; TOOGOOD JH, 1992, J ALLERGY CLIN IMMUN, V89, P186; TOOGOOD JH, 1993, BRONCHIAL ASTHMA MEC, P818; WARD MJ, 1993, RESP MED, V87, P33, DOI 10.1016/S0954-6111(05)80255-0; WASNICH RD, 1989, J NUCL MED, V30, P1166; WASNICH RD, 1991, AM J MED, V91, pS54, DOI 10.1016/0002-9343(91)90249-W; WOLFF AH, 1991, ANN ALLERGY, V67, P117; WONG CS, 1993, CLIN EXP ALLERGY, V23, P370, DOI 10.1111/j.1365-2222.1993.tb00341.x; 1991, CAN MED ASSOC J, V145, P637; 1990, BRIT MED J, V301, P651; 1992, INT CONSENSUS REPORT, P1; 1991, 913042 US DEP HLTH H, P1	56	86	87	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					157	166		10.1016/S0091-6749(95)70003-X	http://dx.doi.org/10.1016/S0091-6749(95)70003-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636052				2022-12-18	WOS:A1995RQ00100003
J	KING, TP; HOFFMAN, D; LOWENSTEIN, H; MARSH, DG; PLATTSMILLS, TAE; THOMAS, W				KING, TP; HOFFMAN, D; LOWENSTEIN, H; MARSH, DG; PLATTSMILLS, TAE; THOMAS, W			ALLERGEN NOMENCLATURE (REPRINTED FROM BULLETIN-OF-THE-WORLD-HEALTH-ORGANIZATION, VOL 72, PG 796-806, 1994)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Reprint							AMINO-ACID-SEQUENCE; DUST MITE ALLERGEN; RYE-GRASS POLLEN; SHORT RAGWEED POLLEN; DER-F-II; 3-DIMENSIONAL SOLUTION STRUCTURE; MAGNETIC-RESONANCE SPECTROSCOPY; ANTIGENIC CROSS-REACTIVITY; ALDER ALNUS-GLUTINOSA; JAPANESE CEDAR POLLEN											ANSARI AA, 1989, BIOCHEMISTRY-US, V28, P8665, DOI 10.1021/bi00447a058; ANSARI AA, 1989, J BIOL CHEM, V264, P11181; ANSARI AA, 1987, J ALLERGY CLIN IMMUN, V80, P229, DOI 10.1016/0091-6749(87)90134-5; ARRUDA LK, 1992, J IMMUNOL, V149, P3354; ARRUDA LK, 1993, J ALLERGY CLIN IMMUN, V91, P188; AUKRUST L, 1980, ALLERGY, V35, P206, DOI 10.1111/j.1398-9995.1980.tb01747.x; AVJIOGLU A, 1993, J ALLERGY CLIN IMMUN, V91, P340; BODMER JG, 1991, IMMUNOGENETICS, V33, P301; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BUFE A, 1993, EMBL X70942 ACC; CARDABA B, 1993, J ALLERGY CLIN IMMUN, V91, P338; CHRISTIE JF, 1990, IMMUNOLOGY, V69, P596; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; CLARK AJ, 1984, EMBO J, V3, P1045, DOI 10.1002/j.1460-2075.1984.tb01925.x; CURRAN IHA, 1992, J ALLERGY CLIN IMMUN, V89, P283; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; DAUL CB, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P291; DEGROOT H, 1991, J ALLERGY CLIN IMMUN, V87, P1056, DOI 10.1016/0091-6749(91)92150-Y; DEMEREC M, 1966, GENETICS, V54, P61; DEUELL B, 1991, J IMMUNOL, V147, P96; DILWORTH RJ, 1991, CLIN EXP ALLERGY, V21, P25, DOI 10.1111/j.1365-2222.1991.tb00800.x; EKRAMODDOULLAH AKM, 1982, MOL IMMUNOL, V19, P1527, DOI 10.1016/0161-5890(82)90263-2; ELSAYED S, 1976, INT ARCH ALLER A IMM, V52, P59, DOI 10.1159/000231668; ESCH RE, 1989, MOL IMMUNOL, V26, P557, DOI 10.1016/0161-5890(89)90007-2; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; GHOSH B, 1993, J IMMUNOL, V150, P5391; GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569; GOODFRIEND L, 1985, MOL IMMUNOL, V22, P899, DOI 10.1016/0161-5890(85)90076-8; GOODFRIEND L, 1979, FED PROC, V38, P1415; GRIFFITH I, COMMUNICATION; GRIFFITH IJ, 1991, INT ARCH ALLER A IMM, V96, P296, DOI 10.1159/000235512; GRIFFITH IJ, 1993, J ALLERGY CLIN IMMUN, V91, P339; GRIFFITH IJ, 1992, GENE, V113, P263, DOI 10.1016/0378-1119(92)90405-E; GRIFFITH IJ, 1991, FEBS LETT, V279, P210, DOI 10.1016/0014-5793(91)80151-R; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; HOFFMAN DR, 1983, J ALLERGY CLIN IMMUN, V71, P481, DOI 10.1016/0091-6749(83)90465-7; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P187; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P71, DOI 10.1016/0091-6749(93)90298-T; HOFFMAN DR, 1992, UNPUB; IPSEN H, 1991, MOL IMMUNOL, V28, P1279, DOI 10.1016/0161-5890(91)90015-C; JACOBSON RS, 1992, J ALLERGY CLIN IMMUN, V89, P292; JACOBSON RS, 1993, J ALLERGY CLIN IMMUN, V91, P187; KING T P, 1990, Protein Sequences and Data Analysis, V3, P263; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; KING TP, 1994, B WORLD HEALTH ORGAN, V72, P797; KING TP, 1992, UNPUB; KLAPPER DG, 1980, BIOCHEMISTRY-US, V19, P5729, DOI 10.1021/bi00566a010; KLYSNER S, 1992, CLIN EXP ALLERGY, V22, P491, DOI 10.1111/j.1365-2222.1992.tb00152.x; KONIECZNY A, COMMUNICATION; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; KUMAR A, 1993, J ALLERGY CLIN IMMUN, V91, P1024, DOI 10.1016/0091-6749(93)90215-2; LAFFER S, 1992, 15TH EUR C ALL CLIN; LAKE FR, 1991, J ALLERGY CLIN IMMUN, V87, P1035, DOI 10.1016/0091-6749(91)92147-S; LANGELAND T, 1983, ALLERGY, V38, P493, DOI 10.1111/j.1398-9995.1983.tb02358.x; LAPERCHE Y, 1983, CELL, V32, P453, DOI 10.1016/0092-8674(83)90465-8; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; LIND P, 1988, J IMMUNOL, V140, P4256; LONGBOTTOM JL, 1983, 11 P INT C ALL CLIN, P525; LOWENSTEIN H, 1980, ALLERGY, V35, P188, DOI 10.1111/j.1398-9995.1980.tb01739.x; LU G, 1993, J IMMUNOL, V150, P2823; LU G, 1994, J ALLERGY CLIN IMMUN, V93, P224; LUBAHN B, 1993, J ALLERGY CLIN IMMUN, V91, P338; MARSH DG, 1986, B WORLD HEALTH ORGAN, V64, P767; MARSH DG, 1992, ALBE ALLERGEN DATABA; MATTHIESEN F, 1992, J ALLERGY CLIN IMMUN, V89, P241; MATTHIESEN F, 1991, J ALLERGY CLIN IMMUN, V88, P763, DOI 10.1016/0091-6749(91)90184-P; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P297, DOI 10.1111/j.1365-2222.1991.tb01661.x; MATTHIESEN F, 1992, ALLERGY S, V47, P31; MAZUR G, 1990, MONOGR ALLERGY, V28, P121; MCDONALD B, 1989, J ALLERGY CLIN IMMUN, V83, P251; MECHERI S, 1985, INT ARCH ALLER A IMM, V78, P283, DOI 10.1159/000233899; MENA M, 1992, PLANT MOL BIOL, V20, P451, DOI 10.1007/BF00040604; MENENDEZARIAS L, 1988, EUR J BIOCHEM, V177, P159, DOI 10.1111/j.1432-1033.1988.tb14357.x; METZLER WJ, 1992, BIOCHEMISTRY-US, V31, P5117, DOI 10.1021/bi00137a005; METZLER WJ, 1992, BIOCHEMISTRY-US, V31, P8697, DOI 10.1021/bi00152a003; MONSALVE RI, 1993, BIOCHEM J, V293, P625, DOI 10.1042/bj2930625; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; NILSEN BM, 1991, J BIOL CHEM, V266, P2660; NISHIYAMA C, 1993, INT ARCH ALLERGY IMM, V101, P159, DOI 10.1159/000236514; OLSEN E, 1991, J IMMUNOL, V147, P205; PEREZ M, 1990, J BIOL CHEM, V265, P16210; PETERSEN A, 1992, INT ARCH ALLERGY IMM, V98, P105, DOI 10.1159/000236172; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; ROBERTS AM, 1993, ALLERGY, V48, P615, DOI 10.1111/j.1398-9995.1993.tb00758.x; ROEBBER M, 1991, Journal of Allergy and Clinical Immunology, V87, P324, DOI 10.1016/0091-6749(91)92021-R; ROEBBER M, 1985, J IMMUNOL, V134, P3062; ROEBBER M, 1983, J IMMUNOL, V131, P706; ROGERS BL, 1991, J IMMUNOL, V147, P2547; ROGERS BL, 1993, J ALLERGY CLIN IMMUN, V91, P339; SAKAGUCHI M, 1990, ALLERGY, V45, P309, DOI 10.1111/j.1398-9995.1990.tb00501.x; SCHMIDT M, 1993, FEBS LETT, V319, P138, DOI 10.1016/0014-5793(93)80053-W; SHANTI KN, 1993, J IMMUNOL, V151, P5354; SHEN HD, 1991, CLIN EXP ALLERGY, V21, P675, DOI 10.1111/j.1365-2222.1991.tb03195.x; SHEN HD, 1993, CLIN EXP ALLERGY, V23, P934, DOI 10.1111/j.1365-2222.1993.tb00278.x; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SMITH PM, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P157; SOLDATOVA L, 1993, FEBS LETT, V320, P145, DOI 10.1016/0014-5793(93)80080-E; STANWORTH D R, 1990, Bulletin of the World Health Organization, V68, P109; STEWART GA, 1992, IMMUNOLOGY, V75, P29; TANIAI M, 1988, FEBS LETT, V239, P329, DOI 10.1016/0014-5793(88)80945-1; TESHIMA R, 1993, J ALLERGY CLIN IMMUN, V92, P698, DOI 10.1016/0091-6749(93)90013-6; TOVEY ER, 1989, J EXP MED, V170, P1457, DOI 10.1084/jem.170.4.1457; TRUDINGER M, 1991, CLIN EXP ALLERGY, V21, P33, DOI 10.1111/j.1365-2222.1991.tb00801.x; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VANHAGEHAMSTEN M, 1993, J ALLERGY CLIN IMMUN, V91, P353; VIJAY HM, 1993, J ALLERGY CLIN IMMUN, V91, P826, DOI 10.1016/0091-6749(93)90338-G; VILLALBA M, 1993, EUR J BIOCHEM, V216, P863, DOI 10.1111/j.1432-1033.1993.tb18208.x; VRTALA S, 1992, 15TH EUR C ALL CLIN; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x; WEBER A, 1986, COMP BIOCHEM PHYS B, V83, P321, DOI 10.1016/0305-0491(86)90374-3; YASUEDA H, 1991, 2ND INT WORKSH, P63	116	86	90	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1995	96	1					5	14		10.1016/S0091-6749(95)70027-7	http://dx.doi.org/10.1016/S0091-6749(95)70027-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RK383					2022-12-18	WOS:A1995RK38300002
J	DEMOLY, P; CRAMPETTE, L; MONDAIN, M; CAMPBELL, AM; LEQUEUX, N; ENANDER, I; SCHWARTZ, LB; GUERRIER, B; MICHEL, FB; BOUSQUET, J				DEMOLY, P; CRAMPETTE, L; MONDAIN, M; CAMPBELL, AM; LEQUEUX, N; ENANDER, I; SCHWARTZ, LB; GUERRIER, B; MICHEL, FB; BOUSQUET, J			ASSESSMENT OF INFLAMMATION IN NONINFECTIOUS CHRONIC MAXILLARY SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CHRONIC SINUSITIS; INFLAMMATION; EOSINOPHILS; MAST CELLS; NEUTROPHILS; LYMPHOCYTES; MACROPHAGES; IMMUNOHISTOCHEMISTRY	EOSINOPHIL CATIONIC PROTEIN; MAST-CELL TRYPTASE; MAJOR BASIC-PROTEIN; MONOCLONAL-ANTIBODIES; ALLERGIC RHINITIS; RESPIRATORY ALLERGY; NEUTROPHIL ELASTASE; BRONCHIAL BIOPSIES; ASTHMA; MACROPHAGES	Background and aim: Pathologic examination of the sinus mucosa and titration of inflammatory mediators in the sinus fluid were carried out to characterize inflammation in chronic sinusitis and determine whether patients with chronic allergic rhinitis (CAR) and sinusitis differ from patients with chronic nonallergic rhinitis (CNAR) and sinusitis. Methods: Nine central subjects (patients requiring ear; nose, and throat surgery not related to sinusitis), 12 patients with CAR and sinusitis, and 13 patients with CNAR and sinusitis were investigated. Eosinophil cationic protein, tryptase, myeloperoxidase, histamine, and prostaglandin D-2 were measured in the sinus lavage fluids, and cells were enumerated. The cellular infiltrate was studied by immunohistochemistry with monoclonal antibodies against eosinophil cationic protein (eosinophils), tryptase (mast cells), neutrophil elastase (neutrophils), CD3 (lymphocytes), CD68 (macrophages), and proliferating cell nuclear antigens. Results: Neutrophils were not increased in sinusitis. In comparison with control subjects, patients with CAR and CNAR with sinusitis showed significant increases in eosinophils and macrophages in biopsy specimens and in eosinophil cationic protein in sinus lavage fluids. In comparison with patients with CNAR, patients with CAR had an increased number of intraepithelial mast cells and lymphocytes. Conclusions: These findings suggest chat patients with CNAR and sinusitis can be distinguished from patients with CAR and sinusitis, which resembles nonallergic rhinitis with eosinophilia syndrome.	CHU MONTPELLIER,HOP ARNAUD VILLENEUVE,MALAD RESP CLIN,F-34059 MONTPELLIER,FRANCE; HOP ST CHARLES,SERV OTORHINOLARYNGOL,MONTPELLIER,FRANCE; CTR VAL AURELLE,SERV ANATOMOPATHOL,MONTPELLIER,FRANCE; PHARMACIA AB,S-75182 UPPSALA,SWEDEN; VIRGINIA COMMONWEALTH UNIV,DEPT RHEUMATOL & IMMUNOL,RICHMOND,VA	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Pfizer; Pharmacia Corporation; Virginia Commonwealth University			Bousquet, Jean/O-4221-2019; Demoly, Pascal/Y-9938-2019	Demoly, Pascal/0000-0001-7827-7964				BACHERT C, 1991, INT ARCH ALLER A IMM, V94, P244, DOI 10.1159/000235371; BACHERT C, 1990, Rhinology (Utrecht), V28, P149; BAILEY QR, 1981, J LARYNGOL OTOL, V95, P55, DOI 10.1017/S002221510009040X; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BERNSTEIN IL, 1988, J ALLERGY CLIN IMMUN, V82, P487, DOI 10.1016/0091-6749(88)90958-X; BETJES MGH, 1991, IMMUNOBIOLOGY, V183, P79, DOI 10.1016/S0171-2985(11)80187-7; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P649, DOI 10.1016/0091-6749(91)90159-L; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P418; BROOK I, 1989, ANN OTO RHINOL LARYN, V98, P426, DOI 10.1177/000348948909800605; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; COREY JP, 1992, OTOLARYNG CLIN N AM, V25, P225; COTRAN RS, 1989, ROBBINS PATHOLOGIC B, P71; DEMOLY P, 1992, AM J RESP CELL MOL, V7, P128, DOI 10.1165/ajrcmb/7.2.128; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DREBORG S, 1988, ALLERGY S10, V44, P1; DRUCE HM, 1991, J ALLERGY CLIN IMMUN, V88, P675, DOI 10.1016/0091-6749(91)90161-G; ENANDER I, 1991, J IMMUNOL METHODS, V138, P39, DOI 10.1016/0022-1759(91)90062-K; ERIKSSON NE, 1990, ALLERGY, V45, P285, DOI 10.1111/j.1398-9995.1990.tb00497.x; FRIEDMAN RA, 1991, ANNU REV MED, V42, P471, DOI 10.1146/annurev.me.42.020191.002351; FUJISAWA T, 1990, AM REV RESPIR DIS, V141, P689, DOI 10.1164/ajrccm/141.3.689; GIORNO R, 1984, DIAGN CLIN IMMUNOL, V2, P161; GODARD P, 1991, INT ARCH ALLER A IMM, V95, P97, DOI 10.1159/000235412; GOLDENHERSH MJ, 1990, J ALLERGY CLIN IMMUN, V85, P1030, DOI 10.1016/0091-6749(90)90047-8; GOURLEY DS, 1990, J ALLERGY CLIN IMMUN, V85, P583, DOI 10.1016/0091-6749(90)90097-N; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; HANSEL FK, 1929, J ALLERGY, V1, P43; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; HOLGATE ST, 1985, CLIN ALLERGY, V15, P221, DOI 10.1111/j.1365-2222.1985.tb02279.x; HOWARTH PH, 1991, CLIN EXP ALLERGY, V21, P3, DOI 10.1111/j.1365-2222.1991.tb01751.x; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; KAWABORI S, 1992, AM J RESP CELL MOL, V6, P37, DOI 10.1165/ajrcmb/6.1.37; KAY AB, 1991, INT ARCH ALLER A IMM, V94, P189, DOI 10.1159/000235360; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; LLOYD GAS, 1989, J LARYNGOL OTOL, V103, P453, DOI 10.1017/S0022215100156622; MACLOUF J, 1986, PROSTAGLANDINS, V31, P123, DOI 10.1016/0090-6980(86)90230-3; MASON DY, 1989, J CLIN PATHOL, V42, P1194, DOI 10.1136/jcp.42.11.1194; MOQBEL R, 1992, CLIN EXP ALLERGY, V22, P265, DOI 10.1111/j.1365-2222.1992.tb03082.x; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; NISHIMOTO K, 1988, ACTA OTOLARYNGOL STO, V1065, P291; OLOFSSON T, 1977, SCAND J HAEMATOL, V18, P73; ONORATO J, 1986, J ALLERGY CLIN IMMUN, V78, P1139, DOI 10.1016/0091-6749(86)90263-0; PETERSON CGB, 1988, EUR J HAEMATOL, V40, P415; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; PULFORD KAF, 1988, J CLIN PATHOL, V41, P853, DOI 10.1136/jcp.41.8.853; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; RANKIN JA, 1989, J ALLERGY CLIN IMMUN, V83, P722, DOI 10.1016/0091-6749(89)90005-5; SCHWARTZ LB, 1990, J IMMUNOL, V144, P2304; SLAVIN RG, 1982, ANN ALLERGY, V49, P76; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; THIELE J, 1992, VIRCHOWS ARCH A, V421, P33, DOI 10.1007/BF01607136; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; WALD ER, 1992, NEW ENGL J MED, V326, P319; WASEEM NH, 1990, J CELL SCI, V96, P121; WENZEL S, 1986, J IMMUNOL METHODS, V86, P139, DOI 10.1016/0022-1759(86)90277-2; 1990, NIH90126 DEP HLTH HU	60	86	93	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					95	108		10.1016/0091-6749(94)90076-0	http://dx.doi.org/10.1016/0091-6749(94)90076-0			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	8027503				2022-12-18	WOS:A1994NX39300013
J	NELSON, HS; ROSLONIEC, DM; MCCALL, LI; IKLE, D				NELSON, HS; ROSLONIEC, DM; MCCALL, LI; IKLE, D			COMPARATIVE PERFORMANCE OF 5 COMMERCIAL PRICK SKIN-TEST DEVICES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SKIN TESTS; DEVICES; PRICK; PUNCTURE; FALSE POSITIVE; FALSE NEGATIVE; REPRODUCIBILITY	MORROW-BROWN NEEDLE; SERUM IGE; ALLERGY; DIAGNOSIS; PRECISION; MULTITEST; RAST	Five commercially available devices for performing prick skin testing were compared for reproducibility, patient acceptance, occurrence of false-negative skin test results, and size distribution of reactions at the negative control sites. Reproducibility of skin testing with 10 mg/ml histamine base, as expressed by coefficient of variation, was similar. However a clear range of trauma to the skin was produced by the devices. This trauma was least with the Hollister-Stier and ALK Laboratories lancets, intermediate for the bifurcated needle by either prick or puncture, and greatest for the Multi-Test and DermaPIK devices. The more traumatic devices produced larger mean wheals and more frequent and large reactions at saline control sites, and were less acceptable to subjects. However, except for the Multi- Test device, they less often yielded false-negative responses. It is proposed that for each device a different size of wheal must be produced at the allergen site to have confidence that it exceeds the control site. The wheal size necessary for 99% specificity were as follows: Hollister-Stier lancet, 2 mm; ALK lancet, 3.0 mm; bifurcated needle prick, 4.0 mm; bifurcated needle puncture, 4.5 mm; Multi-Test device, 5.0 mm; and DermaPIK device, 5.5 mm. An additional observation was the presence of a significant gradient of reaction size on the back to both histamine and allergen (p < 0.0001), with the smallest reactions in the upper third and the largest in the lower third of the back.			NELSON, HS (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, 1400 JACKSON ST, DENVER, CO 80206 USA.		Ikle, David/AAK-7541-2020	Ikle, David/0000-0003-0091-5246				ADINOFF AD, 1989, J ALLERGY CLIN IMMUN, V84, P168, DOI 10.1016/0091-6749(89)90321-7; BASOMBA A, 1985, ALLERGY, V40, P395, DOI 10.1111/j.1398-9995.1985.tb02677.x; BERKOWITZ RB, 1992, J ALLERGY CLIN IMMUN, V90, P979, DOI 10.1016/0091-6749(92)90471-D; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; DEMOLY P, 1991, J ALLERGY CLIN IMMUN, V88, P758, DOI 10.1016/0091-6749(91)90183-O; DREBORG S, 1989, ALLERGY S10, V44, P23; ENGLER DB, 1992, J ALLERGY CLIN IMMUN, V90, P985, DOI 10.1016/0091-6749(92)90472-E; GARIBALDI E, 1990, ANN ALLERGY, V65, P481; MAHAN C, 1990, J ALLERGY CLIN IMMUN, V86, P275, DOI 10.1016/S0091-6749(05)80080-6; MALLING HJ, 1982, ALLERGY, V37, P563, DOI 10.1111/j.1398-9995.1982.tb02341.x; MENARDO JL, 1982, ANN ALLERGY, V48, P235; MILLER RG, 1981, SIMULTANEOUS STATIST, P221; MURPHREE JT, 1979, ANN ALLERGY, V43, P279; NELSON HS, 1983, ANN ALLERGY, V51, P411; OSTERBALLE O, 1979, ALLERGY, V34, P175, DOI 10.1111/j.1398-9995.1979.tb01565.x; Pepys J., 1975, BR J HOSP MED, V14, P412; PERRIN LF, 1984, CLIN ALLERGY, V14, P581, DOI 10.1111/j.1365-2222.1984.tb02246.x; REDDY PM, 1978, J ALLERGY CLIN IMMUN, V61, P36, DOI 10.1016/0091-6749(78)90471-2; VANSELOW NA, 1967, MANUAL CLIN ALLERGY, P55; VOORHORST R, 1980, ALLERGY, V35, P247, DOI 10.1111/j.1398-9995.1980.tb01762.x	20	86	89	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					750	756		10.1016/0091-6749(93)90019-C	http://dx.doi.org/10.1016/0091-6749(93)90019-C			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227867				2022-12-18	WOS:A1993MG98200017
J	PROUD, D; BAILEY, GS; NACLERIO, RM; REYNOLDS, CJ; CRUZ, AA; EGGLESTON, PA; LICHTENSTEIN, LM; TOGIAS, AG				PROUD, D; BAILEY, GS; NACLERIO, RM; REYNOLDS, CJ; CRUZ, AA; EGGLESTON, PA; LICHTENSTEIN, LM; TOGIAS, AG			TRYPTASE AND HISTAMINE AS MARKERS TO EVALUATE MAST-CELL ACTIVATION DURING THE RESPONSES TO NASAL CHALLENGE WITH ALLERGEN, COLD, DRY AIR, AND HYPEROSMOLAR SOLUTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RHINITIS; MEDIATORS; INFLAMMATION; SECRETIONS; AIRWAY	MEDIATOR RELEASE; INFLAMMATORY MEDIATORS; LAVAGE FLUID; SECRETIONS; RHINITIS; PURIFICATION; INVIVO; KALLIKREIN; INHIBITION; BASOPHILS	We have used assays for histamine and for the specific mast cell enzyme, tryptase, to examine the response of the nasal mucosa to provocation with several different stimuli and to evaluate the reliability of histamine as a marker of mast cell activation. High levels of histamine detected in baseline lavages of some subjects are not associated with any detectable tryptase, suggesting they are not mast cell derived. During pronounced immediate allergic responses, however, mast cell degranulation clearly occurs, and a striking correlation between histamine and tryptase is observed. This correlation is weaker when a more modest allergic response is induced, possibly reflecting differential diffusion of the two mediators across the epithelium. Provocation of susceptible individuals with cold, dry air leads to increased recoveries of both histamine and tryptase, confirming that mast cell degranulation occurs during this reaction. Although hyperosmolarity of the nasal mucosa may contribute to mast cell degranulation induced by cold, dry air, a brief exposure of the nasal cavity to hyperosmolar mannitol was not associated with measurable production of tryptase. The combined use of histamine and tryptase measurements can therefore provide useful evidence regarding the role of mast cell activation in the pathogenesis of inflammatory responses.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Cruz, Alvaro A/I-1676-2012	Cruz, Alvaro A/0000-0002-7403-3871	NHLBI NIH HHS [HL 32272, HL 37119] Funding Source: Medline; NIAID NIH HHS [AI 31335] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037119, R01HL032272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031335] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baumgarten C R, 1989, Adv Exp Med Biol, V247B, P523; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P1323; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; BROFELDT S, 1986, AM REV RESPIR DIS, V133, P1138; BROIDE DH, 1990, AM REV RESPIR DIS, V141, P563, DOI 10.1164/ajrccm/141.3.563; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; CRUZ AA, 1991, AM REV RESPIR DIS, V143, P761, DOI 10.1164/ajrccm/143.4_Pt_1.761; EGGLESTON PA, 1990, AM REV RESPIR DIS, V141, P960, DOI 10.1164/ajrccm/141.4_Pt_1.960; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; FINDLAY SR, 1981, J CLIN INVEST, V67, P1604, DOI 10.1172/JCI110195; GOMEZ E, 1986, J ALLERGY CLIN IMMUN, V78, P637, DOI 10.1016/0091-6749(86)90082-5; HORWITZ D, 1982, J LAB CLIN MED, V100, P146; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; IMANARI T, 1976, DHEW NIH76791 PUBL, P205; JULIUSSON S, 1991, ALLERGY, V46, P459; KALENDERIAN R, 1988, CHEST, V94, P119, DOI 10.1378/chest.94.1.119; LAWRENCE ID, 1987, J IMMUNOL, V139, P3062; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P689; MACDERMOT J, 1984, PROSTAGLANDINS, V27, P163, DOI 10.1016/0090-6980(84)90071-6; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1988, J INFECT DIS, V157, P133, DOI 10.1093/infdis/157.1.133; OELZ O, 1977, PROSTAGLANDINS, V13, P225, DOI 10.1016/0090-6980(77)90004-1; Peters S P, 1982, Trans Assoc Am Physicians, V95, P221; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; PROUD D, 1988, AM REV RESPIR DIS, V137, P613, DOI 10.1164/ajrccm/137.3.613; PROUD D, 1988, BIOCHEM PHARMACOL, V37, P1473, DOI 10.1016/0006-2952(88)90008-1; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V88, P33, DOI 10.1016/0091-6749(91)90298-3; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; SCHULMAN ES, 1982, J IMMUNOL, V129, P2662; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; SHEINMAN BD, 1986, BMJ-BRIT MED J, V292, P857, DOI 10.1136/bmj.292.6524.857; SILBER G, 1988, AM REV RESPIR DIS, V137, P606, DOI 10.1164/ajrccm/137.3.606; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SMITH TJ, 1984, J BIOL CHEM, V259, P1046; TOGIAS A, 1987, J ALLERGY CLIN IMMUN, V79, P599, DOI 10.1016/S0091-6749(87)80155-0; TOGIAS A, 1990, AM REV RESPIR DIS, V141, P1428, DOI 10.1164/ajrccm/141.6.1428; TOGIAS AG, 1988, AM REV RESPIR DIS, V137, P625, DOI 10.1164/ajrccm/137.3.625; TOGIAS AG, 1986, JAMA-J AM MED ASSOC, V255, P225, DOI 10.1001/jama.255.2.225; TOGIAS AG, 1985, J CLIN INVEST, V76, P1374	44	86	90	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1992	89	6					1098	1110		10.1016/0091-6749(92)90293-B	http://dx.doi.org/10.1016/0091-6749(92)90293-B			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HZ748	1607547				2022-12-18	WOS:A1992HZ74800004
J	POLLART, SM; REID, MJ; FLING, JA; CHAPMAN, MD; PLATTSMILLS, TAE				POLLART, SM; REID, MJ; FLING, JA; CHAPMAN, MD; PLATTSMILLS, TAE			EPIDEMIOLOGY OF EMERGENCY ROOM ASTHMA IN NORTHERN CALIFORNIA - ASSOCIATION WITH IGE ANTIBODY TO RYEGRASS POLLEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV VIRGINIA, DEPT MED, DIV ALLERGY & CLIN IMMUNOL, CHARLOTTESVILLE, VA 22908 USA; WILFORD HALL USAF MED CTR, DIV ALLERGY, LACKLAND AFB, TX 78236 USA	University of Virginia; United States Department of Defense; United States Air Force				Chapman, Martin/0000-0002-0845-3632	PHS HHS [A120565, A107255] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Altounyan REC, 1970, DISODIUM CHROMOGLYCA; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CAVANAUGH MJ, 1977, J ALLERGY CLIN IMMUN, V59, P41, DOI 10.1016/0091-6749(77)90175-0; CHAPMAN M, 1986, J ALLERGY CLIN IMMUN, V77, P204; CHAPMAN MD, 1980, INT ARCH ALLER A IMM, V61, P431, DOI 10.1159/000232471; DANIELE RP, 1985, CECILS TXB MED, P390; DODGE R, 1986, AM REV RESPIR DIS, V133, P981; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; HEYMANN PW, 1986, J IMMUNOL, V137, P2841; LEHRER SB, 1986, J ALLERGY CLIN IMMUN, V78, P478, DOI 10.1016/0091-6749(86)90036-9; MURRAY AB, 1983, PEDIATRICS, V71, P418; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; POLLART SM, UNPUB IGE ANTIBODIES; REED CE, 1985, 12 P INT C ALL CLIN, P366; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P716, DOI 10.1136/adc.49.9.716; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P32; SMITH JM, 1969, BRIT MED J, V2, P723, DOI 10.1136/bmj.2.5659.723; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; Voorhorst R., 1969, HOUSE DUST ATOPY HOU; WHARTON GW, 1976, J MED ENTOMOL, V12, P577, DOI 10.1093/jmedent/12.6.577; WITT C, 1986, J ALLERGY CLIN IMMUN, V77, P698, DOI 10.1016/0091-6749(86)90413-6; 1986, MMWR, V35, P507	25	86	88	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					224	230		10.1016/0091-6749(88)91003-2	http://dx.doi.org/10.1016/0091-6749(88)91003-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	3261307	Bronze			2022-12-18	WOS:A1988P874100013
J	VANDERZEE, JS; DEGROOT, H; VANSWIETEN, P; JANSEN, HM; AALBERSE, RC				VANDERZEE, JS; DEGROOT, H; VANSWIETEN, P; JANSEN, HM; AALBERSE, RC			DISCREPANCIES BETWEEN THE SKIN-TEST AND IGE ANTIBODY-ASSAYS - STUDY OF HISTAMINE-RELEASE, COMPLEMENT ACTIVATION INVITRO, AND OCCURRENCE OF ALLERGEN-SPECIFIC IGG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,POB 9406,1006 AK AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT PULM DIS,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam			van der Zee, Jaring S/M-8462-2013; van der Zee, Jaring/HGU-9235-2022; van der Zee, Jaring/AAQ-6669-2021	van der Zee, Jaring S/0000-0002-8698-6039; 				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; AALBERSE RC, 1986, J IMMUNOL METHODS, V87, P51, DOI 10.1016/0022-1759(86)90343-1; AALBERSE RC, 1983, J IMMUNOL, V130, P722; AALBERSE RC, 1972, INT ARCH ALLERGY APP, V45, P46; ALI M, 1984, ANN ALLERGY, V53, P143; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; BERRENS L, 1975, ACTA ALLERGOL, V30, P169, DOI 10.1111/j.1398-9995.1975.tb01340.x; BERRENS L, 1978, ALLERGOL IMMUNOPATH, V6, P45; BERRENS L, 1971, MONOGR ALLERGY, V7, P137; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; CONROY MC, 1977, J IMMUNOL, V118, P1317; DIAMANT B, 1982, INT ARCH ALLER A IMM, V67, P13, DOI 10.1159/000232981; GWYNN CM, 1982, CLIN ALLERGY, V12, P459, DOI 10.1111/j.1365-2222.1982.tb01644.x; HACK CE, 1981, J IMMUNOL, V127, P1450; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MAYER MM, 1961, EXPT IMMUNOCHEMISTRY, P149; NELSON HS, 1977, J ALLERGY CLIN IMMUN, V60, P266, DOI 10.1016/0091-6749(77)90142-7; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; PARISH WE, 1970, LANCET, V2, P591; PARISH WE, 1981, BRIT J DERMATOL, V105, P223, DOI 10.1111/j.1365-2133.1981.tb01210.x; SANTRACH PJ, 1981, J ALLERGY CLIN IMMUN, V67, P97, DOI 10.1016/0091-6749(81)90003-8; SIRAGANIAN RP, 1977, J ALLERGY CLIN IMMUN, V59, P214, DOI 10.1016/0091-6749(77)90152-X; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; STALLMAN PJ, 1977, INT ARCH ALLER A IMM, V54, P9, DOI 10.1159/000231803; STANWORTH D R, 1973, Clinical Allergy, V3, P37, DOI 10.1111/j.1365-2222.1973.tb01307.x; STANWORTH DR, 1983, CLIN REV ALLERG, V1, P183; VANTOORENENBERGEN AW, 1981, INT ARCH ALLER A IMM, V65, P432, DOI 10.1159/000232784; VANTOORENENBERGEN AW, 1983, INT ARCH ALLER A IMM, V71, P32, DOI 10.1159/000233358; VIJAY HM, 1977, INT ARCH ALLER A IMM, V53, P78, DOI 10.1159/000231734; VIJAY HM, 1978, INT ARCH ALLER A IMM, V56, P517, DOI 10.1159/000232067; WIDE L, 1973, CLIN ALLERGY, V3, P583, DOI 10.1111/j.1365-2222.1973.tb03063.x; WUTHRICH B, 1979, CLIN ALLERGY, V9, P191, DOI 10.1111/j.1365-2222.1979.tb01541.x; ZEISS CR, 1981, J ALLERGY CLIN IMMUN, V67, P105, DOI 10.1016/0091-6749(81)90004-X; ZIMMERMANN EM, 1980, J ALLERGY CLIN IMMUN, V66, P386, DOI 10.1016/0091-6749(80)90118-9	36	86	87	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					270	281		10.1016/0091-6749(88)91011-1	http://dx.doi.org/10.1016/0091-6749(88)91011-1			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	3261308				2022-12-18	WOS:A1988P874100021
J	NASSIF, E; WEINBERGER, M; SHERMAN, B; BROWN, K				NASSIF, E; WEINBERGER, M; SHERMAN, B; BROWN, K			EXTRAPULMONARY EFFECTS OF MAINTENANCE CORTICOSTEROID-THERAPY WITH ALTERNATE-DAY PREDNISONE AND INHALED BECLOMETHASONE IN CHILDREN WITH CHRONIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,JCP,DEPT PEDIAT,DIV ALLERGY & PULM,CLIN RES CTR,IOWA CITY,IA 52242; MCFARLAND CLIN,AMES,IA; UNIV IOWA,DEPT PREVENT MED,DIV BIOSTAT,IOWA CITY,IA 52242	University of Iowa; University of Iowa			Weinberger, Miles/H-6743-2019		NCRR NIH HHS [RR-59] Funding Source: Medline; NIAID NIH HHS [AI-16151] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN GL, 1968, NEW ENGL J MED, V278, P405, DOI 10.1056/NEJM196802222780801; ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; ASRILANT M, 1975, POSTGRAD MED J, V51, P79; BAKRAN I, 1977, INT J CLIN PHARM BI, V15, P57; BHAGAT RG, 1984, PEDIATRICS, V73, P626; BLODGETT FM, 1956, NEW ENGL J MED, V254, P636, DOI 10.1056/NEJM195604052541402; BROWN HM, 1972, BRIT MED J, V1, P585, DOI 10.1136/bmj.1.5800.585; CASTROW FF, 1981, J AM ACAD DERMATOL, V5, P64, DOI 10.1016/S0190-9622(81)70079-3; CHANG KC, 1982, CLIN ALLERGY, V12, P369, DOI 10.1111/j.1365-2222.1982.tb02541.x; CHESNEY RW, 1978, AM J DIS CHILD, V132, P768, DOI 10.1001/archpedi.1978.02120330040010; CHIANG JL, 1980, J ALLERGY CLIN IMMUN, V65, P263, DOI 10.1016/0091-6749(80)90153-0; CLARK TJH, 1972, LANCET, V1, P1361; COLE WG, 1976, AUST PAEDIATR J, V12, P37; CONN HO, 1976, NEW ENGL J MED, V294, P473, DOI 10.1056/NEJM197602262940905; COSTELLO JF, 1974, THORAX, V29, P571, DOI 10.1136/thx.29.5.571; CRUESS RL, 1977, J BONE JOINT SURG BR, V59, P308, DOI 10.1302/0301-620X.59B3.893509; CRUESS RL, 1976, J BONE JOINT SURG BR, V58, P313, DOI 10.1302/0301-620X.58B3.956247; EASTON JG, 1971, J ALLERGY CLIN IMMUN, V48, P355, DOI 10.1016/0091-6749(71)90081-9; EKWO E, 1978, J ALLERGY CLIN IMMUN, V61, P240, DOI 10.1016/0091-6749(78)90198-7; FALLIERS CJ, 1972, J ALLERGY CLIN IMMUN, V49, P156, DOI 10.1016/0091-6749(72)90109-1; FALLIERS CJ, 1963, AM J DIS CHILD, V105, P127, DOI 10.1001/archpedi.1963.02080040129002; FIEL SB, 1983, AM J MED, V75, P259, DOI 10.1016/0002-9343(83)91202-0; FISHER DE, 1971, J BONE JOINT SURG AM, VA 53, P859, DOI 10.2106/00004623-197153050-00002; FLEISHER DS, 1967, J PEDIATR-US, V70, P54, DOI 10.1016/S0022-3476(67)80165-3; FRANCIS RS, 1976, THORAX, V31, P309, DOI 10.1136/thx.31.3.309; GADDIE J, 1973, LANCET, V2, P280; GLUCK OS, 1981, ARTHRITIS RHEUM-US, V24, P892, DOI 10.1002/art.1780240705; GODFREY S, 1974, ARCH DIS CHILD, V49, P591, DOI 10.1136/adc.49.8.591; GOLDSTEIN DE, 1983, PEDIATRICS, V72, P60; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HARRIS JB, 1987, J PEDIATR-US, V110, P627, DOI 10.1016/S0022-3476(87)80567-X; HARTER JG, 1963, NEW ENGL J MED, V269, P591, DOI 10.1056/NEJM196309192691201; HAUSPIE R, 1977, J ALLERGY CLIN IMMUN, V59, P200, DOI 10.1016/0091-6749(77)90150-6; HEMSTREET MPB, 1980, CLIN ALLERGY, V10, P733, DOI 10.1111/j.1365-2222.1980.tb02158.x; HSU TH, 1970, J CLIN ENDOCR METAB, V30, P443, DOI 10.1210/jcem-30-4-443; HUMPHRIES T, 1985, J ALLERGY CLIN IMMUN, V75, P197, DOI 10.1016/0091-6749(85)90504-4; LAW CM, 1986, LANCET, V1, P942; LEWIS DA, 1983, J AFFECT DISORDERS, V5, P319, DOI 10.1016/0165-0327(83)90022-8; LING MHM, 1981, ARCH GEN PSYCHIAT, V38, P471; LITTENBERG B, 1986, NEW ENGL J MED, V314, P150, DOI 10.1056/NEJM198601163140304; LOVERA J, 1976, J ALLERGY CLIN IMMUN, V57, P112, DOI 10.1016/0091-6749(76)90030-0; LUKSZA AR, 1982, BRIT J DIS CHEST, V76, P15, DOI 10.1016/0007-0971(82)90003-1; MALKA S, 1966, SURG GYNECOL OBSTETR, V123, P1057; MARTIN AJ, 1981, ACTA PAEDIATR SCAND, V70, P683, DOI 10.1111/j.1651-2227.1981.tb05768.x; MESSER J, 1983, NEW ENGL J MED, V309, P21, DOI 10.1056/NEJM198307073090105; MESSERLI C, 1975, PNEUMONOLOGIE, V153, P29, DOI 10.1007/BF02096333; MIELANTS H, 1975, J RHEUMATOL, V2, P430; MILAVETZ G, 1986, J PEDIATR-US, V109, P351, DOI 10.1016/S0022-3476(86)80403-6; MORRIS HG, 1974, J ALLERGY CLIN IMMUN, V54, P350, DOI 10.1016/0091-6749(74)90025-6; NUGENT CA, 1966, J CLIN ENDOCR METAB, V26, P1116, DOI 10.1210/jcem-26-10-1116; POSEY WC, 1978, J ALLERGY CLIN IMMUN, V62, P340, DOI 10.1016/0091-6749(78)90134-3; REIMER LG, 1975, J ALLERGY CLIN IMMUN, V55, P224, DOI 10.1016/0091-6749(75)90141-4; RIMZA ME, 1978, AM J DIS CHILD, V132, P806; ROCHE AF, 1980, AM J CLIN NUTR, V33, P2041, DOI 10.1093/ajcn/33.9.2041; RONA RJ, 1980, INT J EPIDEMIOL, V9, P35, DOI 10.1093/ije/9.1.35; ROOKLIN AR, 1979, J ALLERGY CLIN IMMUN, V63, P383, DOI 10.1016/0091-6749(79)90210-0; SADEGHIN.A, 1969, PEDIATRICS, V43, P277; SEALE JP, 1986, MED J AUSTRALIA, V144, P139, DOI 10.5694/j.1326-5377.1986.tb112242.x; SETTIPANE GA, 1978, J ALLERGY CLIN IMMUN, V62, P162, DOI 10.1016/0091-6749(78)90101-X; SEVEL D, 1977, J ALLERGY CLIN IMMUN, V60, P215, DOI 10.1016/0091-6749(77)90132-4; SHARFSTEIN SS, 1982, JAMA-J AM MED ASSOC, V248, P2987, DOI 10.1001/jama.248.22.2987; SHEAGREN JN, 1977, J LAB CLIN MED, V89, P120; SOYKA LF, 1967, AM J DIS CHILD, V113, P693, DOI 10.1001/archpedi.1967.02090210107011; SPIRO HM, 1983, NEW ENGL J MED, V309, P45, DOI 10.1056/NEJM198307073090110; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; VAZ R, 1982, J PEDIATR-US, V100, P660, DOI 10.1016/S0022-3476(82)80781-6; VOGT F, 1976, J ALLERGY CLIN IMMUN, V53, P316; WEINBERGER M, 1983, NEW ENGL J MED, V308, P760, DOI 10.1056/NEJM198303313081306; WEINBERGER M, 1986, AM REV RESPIR DIS, V133, pA41; WILLIAMS AJ, 1983, THORAX, V38, P813, DOI 10.1136/thx.38.11.813; WITTIG HJ, 1978, ALLERGOL IMMUNOPATH, V6, P203; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504; ZORA JA, 1986, J ALLERGY CLIN IMMUN, V77, P9, DOI 10.1016/0091-6749(86)90315-5; 1984, LANCET, V1, P375	74	86	87	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1987	80	4					518	529		10.1016/0091-6749(87)90002-9	http://dx.doi.org/10.1016/0091-6749(87)90002-9			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K5224	3668116	Bronze			2022-12-18	WOS:A1987K522400002
J	SELNER, JC; STAUDENMAYER, H; KOEPKE, JW; HARVEY, R; CHRISTOPHER, K				SELNER, JC; STAUDENMAYER, H; KOEPKE, JW; HARVEY, R; CHRISTOPHER, K			VOCAL CORD DYSFUNCTION - THE IMPORTANCE OF PSYCHOLOGIC FACTORS AND PROVOCATION CHALLENGE TESTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALLERGY RESP INST COLORADO, DENVER, CO USA									ADER R, 1981, PSYCHONEUROIMMUNOLOG, P321; [Anonymous], 1979, AM REV RESPIR DIS, V119, P831; APPELBLATT NH, 1981, ARCH OTOLARYNGOL, V107, P305; BRODSKY CM, 1983, PSYCHOSOMATICS, V24, P731, DOI 10.1016/S0033-3182(83)73168-3; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHAWLA SS, 1984, ANN ALLERGY, V53, P319; CHERNIACK RM, 1971, PULMONARY FUNCTION T; CHRISTOPHER KL, 1983, NEW ENGL J MED, V308, P1566, DOI 10.1056/NEJM198306303082605; DEROGATIS LR, 1982, BRIEF SYMPTOM INVENT, V1; DOWING ET, 1982, JAMA-J AM MED ASSOC, V248, P2878; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; FEHMI LG, 1980, SOMATICS         SPR, P24; FEHMI LG, 1978, EXPANDING DIMENSIONS, P155; FLORHENRY P, 1983, CEREBRAL BASIS PSYCH; FORMAN RE, 1984, LETS LIVE        FEB, P49; KRYGER M, 1976, AM J MED, V61, P85, DOI 10.1016/0002-9343(76)90048-6; LAZARUS A, 1980, MULTIMODAL LIFE HIST; Lindsley DB., 1951, HDB EXPT PSYCHOL, P473; MARTIN I, 1980, TECHNIQUES PSYCHOPHY; NORTON K, 1985, COMMUNICATION    AUG; PATTERSON R, 1974, CLIN ALLERGY, V4, P307, DOI 10.1111/j.1365-2222.1974.tb01390.x; PHILPOTT WH, 1980, BRAIN ALLERGIES; PROKOP D, 1981, RUNNERS WORLD    JUL, P58; RANDOLPH TG, 1980, ALTERNATIVE APPROACH; RODENSTEIN DO, 1983, AM REV RESPIR DIS, V127, P354; RUSSELL M, 1984, SCIENCE, V225, P733, DOI 10.1126/science.6205449; SELNER JC, 1985, ANN ALLERGY, V54, P479; SELNER JC, 1985, ANN ALLERGY, V55, P665; SELNER JC, 1986, PSYCHOBIOLOGICAL ASP, P102; SMITH HM, 1983, MET FINISH       MAR, P55; STARKMAN MN, 1984, PSYCHOSOMATICS, V25, P327, DOI 10.1016/S0033-3182(84)73049-0; TERR AI, 1986, ARCH INTERN MED, V146, P145, DOI 10.1001/archinte.146.1.145; 1986, W J MED, V144, P239	33	86	87	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1987	79	5					726	733		10.1016/0091-6749(87)90203-X	http://dx.doi.org/10.1016/0091-6749(87)90203-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H4349	3571766				2022-12-18	WOS:A1987H434900006
J	SLOAN, AE; POWERS, ME				SLOAN, AE; POWERS, ME			A PERSPECTIVE ON POPULAR PERCEPTIONS OF ADVERSE REACTIONS TO FOODS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SLOAN, AE (corresponding author), GOOD HOUSEKEEPING INST,959 8TH AVE,NEW YORK,NY 10019, USA.							BOCK SA, 1980, AM J DIS CHILD, V134, P973, DOI 10.1001/archpedi.1980.02130220049015; BRENNEMAN JC, 1979, CONT NUTR, V4; FINDLAY S, 1983, USA TODAY       1004; FINK J, 1984, US NEWS WORLD REPORT, V4, P67; MCNUTT KW, 1984, FOOD DRUG LAW J, V39, P86; POWERS ME, 1984, GOOD HOUSEKEEPING CO; POWERS ME, 1982, GOOD HOUSEKEEPING CO; WILEY HW, 1912, GOOD HOUSEKEEPING, V7, P593; WILEY HW, 1913, GOOD HOUSEKEEPING, V8, P235; 1984, SIMMONS MAGAZINE RES; 1983, FED REG, V48, P2749	11	86	88	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	2	S			127	133		10.1016/0091-6749(86)90002-3	http://dx.doi.org/10.1016/0091-6749(86)90002-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	D2997	3722639				2022-12-18	WOS:A1986D299700002
J	MORRIS, HG				MORRIS, HG			MECHANISMS OF ACTION AND THERAPEUTIC ROLE OF CORTICOSTEROIDS IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review																		AGNEW JE, 1983, B EUR PHYSIOPATH RES, V19, P37; AHMED T, 1983, J ALLERGY CLIN IMMUN, V71, P224, DOI 10.1016/0091-6749(83)90103-3; ARNAUD A, 1979, LUNG, V156, P43, DOI 10.1007/BF02713990; ATHENS JW, 1961, J CLIN INVEST, V40, P989, DOI 10.1172/JCI104338; AXELROD, 1983, LANCET, V1, P904; Ballard P L, 1979, Monogr Endocrinol, V12, P25; BALLARD PL, 1974, ENDOCRINOLOGY, V94, P998, DOI 10.1210/endo-94-4-998; BAXTER JD, 1972, AM J MED, V53, P573, DOI 10.1016/0002-9343(72)90154-4; BAXTER JD, 1979, NEW ENGL J MED, V301, P1149, DOI 10.1056/NEJM197911223012104; BAXTER JD, 1979, GLUCOCORTICOID HORMO, P1; BLACK J, 1982, PHARM HISTAMINE RECE, pCH1; BLACKWELL GJ, 1983, ADV PROSTAG THROMB L, V11, P65; BOGGS DR, 1964, AM J PATHOL, V44, P763; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; BRATTSAND R, 1982, EUR J RESPIR DIS, V63, P62; BRAUDE AC, 1983, LANCET, V2, P995; BRITTON MG, 1976, BRIT MED J, V2, P73, DOI 10.1136/bmj.2.6027.73; BROGDEN RN, 1983, STEROIDS ASTHMA REAP, pCH10; BROWN HM, 1977, BR J CLIN PAHRM, V4, P259; BURGE PS, 1982, EUR J RESP DIS S, V122, P163; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; CARRYER HM, 1950, J ALLERGY, V21, P282, DOI 10.1016/0021-8707(50)90059-1; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CLARK TJH, 1982, EUR J RESPIR DIS, V63, P235; CLARKE PS, 1982, J ASTHMA, V19, P91, DOI 10.3109/02770908209104741; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CRABTREE GR, 1979, ARTHRITIS RHEUM, V22, P1246, DOI 10.1002/art.1780221112; CUPPS TR, 1982, IMMUNOL REV, V65, P133, DOI 10.1111/j.1600-065X.1982.tb00431.x; DAERON M, 1982, J IMMUNOL, V129, P1212; DAHL R, 1982, EUR J RESPIR DIS, V63, P167; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DAVIES AO, 1983, J CLIN INVEST, V71, P565, DOI 10.1172/JCI110801; DAVIES AO, 1980, J CLIN ENDOCR METAB, V51, P599, DOI 10.1210/jcem-51-3-599; DAVIES AO, 1981, J CLIN ENDOCR METAB, V53, P703, DOI 10.1210/jcem-53-4-703; DIROSA M, 1979, AGENTS ACTIONS S, V4, P63; DOLOVICH J, 1981, THORAX, V36, P641, DOI 10.1136/thx.36.9.614; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; ELLULMIC.R, 1974, CLIN SCI MOL MED, V47, P105, DOI 10.1042/cs0470105; ELLULMICALLEF R, 1980, BRIT J CLIN PHARMACO, V9, P479, DOI 10.1111/j.1365-2125.1980.tb05843.x; ELLULMICALLEF R, 1982, EUR J RESPIR DIS, V63, P118; ELLULMICALLEF R, 1975, LANCET, V2, P1269; ELLULMICALLEF R, 1980, EUR J RESPIR DIS, V61, P167; FABBRI LM, 1984, AM REV RESPIR DIS, V129, P288; Fahey J, 1981, ADV INFLAMMAT RES, V2, P21; FANTA CH, 1983, AM J MED, V74, P845, DOI 10.1016/0002-9343(83)91076-8; FAUCI AS, 1979, GLUCOCORTICOID HORMO, P449; GHIARA P, 1984, BIOCHEM PHARMACOL, V33, P1445, DOI 10.1016/0006-2952(84)90411-8; GOETZL EJ, 1982, ADV PROSTAG THROMB L, V9, P273; GOODWIN JS, 1980, CLIN IMMUNOL IMMUNOP, V15, P106, DOI 10.1016/0090-1229(80)90024-0; GRANNER DK, 1979, GLUCOCORTICOID HORMO, P341; GRAZIANO FM, 1983, J IMMUNOL, V131, P2675; GWYNN C M, 1974, Clinical Allergy, V4, P325, DOI 10.1111/j.1365-2222.1974.tb01393.x; HARFI H, 1978, PEDIATRICS, V61, P829; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; Harris A W, 1979, Monogr Endocrinol, V12, P423; HARRIS DM, 1975, J STEROID BIOCHEM, V6, P711, DOI 10.1016/0022-4731(75)90057-6; HARTLEY JPR, 1977, BRIT J DIS CHEST, V71, P253, DOI 10.1016/S0007-0971(77)80022-3; HASEGAWA M, 1983, J ALLERGY CLIN IMMUN, V71, P230, DOI 10.1016/0091-6749(83)90104-5; HASKELL RJ, 1983, ARCH INTERN MED, V143, P1324, DOI 10.1001/archinte.143.7.1324; HIRATA F, 1981, J BIOL CHEM, V256, P7730; HIRATA F, 1981, P NATL ACAD SCI-BIOL, V78, P3190, DOI 10.1073/pnas.78.5.3190; HIRATA F, 1983, ADV PROSTAG THROMB L, V11, P73; HOGG JC, 1983, ALLERGY PRINCIPLES P, P833; HOLTZMAN MJ, 1983, BIOCHEM BIOPH RES CO, V114, P1071, DOI 10.1016/0006-291X(83)90671-X; HUI KKP, 1982, CLIN PHARMACOL THER, V32, P566, DOI 10.1038/clpt.1982.204; JEFFERY JL, 1980, P W PHARMACOL SOC, V23, P355; JOHNSON HG, 1982, INT J IMMUNOPHARMACO, V4, P348, DOI 10.1016/0192-0561(82)90345-9; Johnson L K, 1979, Monogr Endocrinol, V12, P305; JOHNSON LK, 1979, J BIOL CHEM, V254, P7785; JOHNSON LK, 1982, BRIT J DERMATOL, V107, P6, DOI 10.1111/j.1365-2133.1982.tb01026.x; JUNIPER E F, 1980, American Review of Respiratory Disease, V121, P76; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; KALSNER S, 1969, CIRC RES, V24, P383, DOI 10.1161/01.RES.24.3.383; KENNEDY MCS, 1981, PHARMATHERAPEUTICA, V2, P648; KIMURA S, 1977, J BIOL CHEM, V252, P1217; KOOPMAN WJ, 1970, J IMMUNOL, V105, P1096; LAN NC, 1984, J STEROID BIOCHEM, V20, P77, DOI 10.1016/0022-4731(84)90192-4; LEE HJ, 1983, STEROIDS, V41, P609, DOI 10.1016/0039-128X(83)90026-0; LEE HJ, 1982, SCIENCE, V215, P989, DOI 10.1126/science.6296999; LEE TH, 1984, P NATL ACAD SCI-BIOL, V81, P4922, DOI 10.1073/pnas.81.15.4922; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LEMANSKE RF, 1983, J IMMUNOL, V131, P929; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LIU AYC, 1981, EUR J BIOCHEM, V114, P539, DOI 10.1111/j.1432-1033.1981.tb05178.x; MANO K, 1979, LIFE SCI, V25, P1925, DOI 10.1016/0024-3205(79)90614-3; MAROM Z, 1983, J CLIN INVEST, V72, P122, DOI 10.1172/JCI110949; MAROM Z, 1984, AM REV RESPIR DIS, V129, P62; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MARQUARDT DL, 1983, J IMMUNOL, V131, P934; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; MELLIS CM, 1977, THORAX, V32, P29, DOI 10.1136/thx.32.1.29; MERCIER L, 1983, ENDOCRINOLOGY, V112, P601, DOI 10.1210/endo-112-2-601; MIDDLETON E, 1980, J PHARM SCI-US, V69, P243, DOI 10.1002/jps.2600690244; MORRIS HG, 1980, J ALLERGY CLIN IMMUN, V66, P343, DOI 10.1016/0091-6749(80)90112-8; MORRIS HG, 1977, J CYCLIC NUCL PROT, V3, P439; MORRIS HG, 1983, J ALLERGY CLIN IMMUN, V71, P266, DOI 10.1016/0091-6749(83)90080-5; MORRIS HG, 1983, ALLERGY PRINCIPLES P, P593; MUNCK A, 1984, J BIOL CHEM, V259, P820; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; MUNCK A, 1978, J TOXICOL ENV HEALTH, V4, P409, DOI 10.1080/15287397809529668; MYGIND N, 1980, TOPICAL STEROID TREA, P171; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; ONG KS, 1978, J ALLERGY CLIN IMMUN, V62, P115, DOI 10.1016/0091-6749(78)90088-X; PECK MJ, 1981, PROSTAGLANDINS, V21, P315, DOI 10.1016/0090-6980(81)90149-0; PEPYS J, 1974, CLIN ALLERGY, V4, P13, DOI 10.1111/j.1365-2222.1974.tb01358.x; PIERSEN WE, 1974, PEDIATRICS, V54, P782; Pratt W B, 1979, Adv Exp Med Biol, V117, P343; RYRFELDT A, 1982, EUR J RESPIR DIS, V63, P86; SAEED SA, 1977, NATURE, V270, P32, DOI 10.1038/270032a0; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHLEIMER RP, 1982, J IMMUNOL, V129, P1632; SCHULMAN ES, 1982, J APPL PHYSIOL, V53, P589, DOI 10.1152/jappl.1982.53.3.589; SCHULMAN ES, 1983, J IMMUNOL, V131, P1936; SELEZNEV IM, 1982, J MOL CELL CARDIOL, V14, P49, DOI 10.1016/0022-2828(82)90129-8; SERHAN CN, 1982, J BIOL CHEM, V257, P4746; SHENFIELD GM, 1975, THORAX, V30, P430, DOI 10.1136/thx.30.4.430; Simons S S Jr, 1979, Monogr Endocrinol, V12, P161; SMITH MJ, 1983, THORAX, V38, P676, DOI 10.1136/thx.38.9.676; SMITH MJ, 1983, LANCET, V1, P265, DOI 10.1016/S0140-6736(83)91686-0; SMITH MJ, 1983, STEROIDS ASTHMA REAP, pCH12; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; STADEL JM, 1983, P NATL ACAD SCI-BIOL, V80, P3173, DOI 10.1073/pnas.80.11.3173; SZEFLER SJ, 1980, J ALLERGY CLIN IMMUN, V66, P447, DOI 10.1016/0091-6749(80)90004-4; SZEFLER SJ, 1982, CLIN PHARMACOL THER, V32, P166, DOI 10.1038/clpt.1982.143; TANAKA RM, 1982, CHEST, V82, P438, DOI 10.1378/chest.82.4.438; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; VADAS P, 1982, LIFE SCI, V30, P155, DOI 10.1016/0024-3205(82)90647-6; WAGNER PD, 1978, AM REV RESPIR DIS, V118, P511; WALDO GL, 1983, J BIOL CHEM, V258, P3900; WANNER A, 1975, J APPL PHYSIOL, V39, P950, DOI 10.1152/jappl.1975.39.6.950; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0; WEINBERGER M, 1977, J ALLERGY CLIN IMMUN, V59, P228, DOI 10.1016/0091-6749(77)90154-3; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P2814, DOI 10.1001/jama.249.20.2814; WESTON WL, 1973, J IMMUNOL, V110, P880; WILLIAMS AJ, 1983, THORAX, V38, P813, DOI 10.1136/thx.38.11.813; WINFIELD CR, 1980, THORAX, V35, P238; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504	146	86	110	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					1	13		10.1016/0091-6749(85)90002-8	http://dx.doi.org/10.1016/0091-6749(85)90002-8			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABF26	2578492	Bronze			2022-12-18	WOS:A1985ABF2600001
J	DOLL, NJ; STANKUS, RP; HUGHES, J; WEILL, H; GUPTA, RC; RODRIGUEZ, M; JONES, RN; ALSPAUGH, MA; SALVAGGIO, JE				DOLL, NJ; STANKUS, RP; HUGHES, J; WEILL, H; GUPTA, RC; RODRIGUEZ, M; JONES, RN; ALSPAUGH, MA; SALVAGGIO, JE			IMMUNE-COMPLEXES AND AUTOANTIBODIES IN SILICOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,SCH MED,PULM SECT,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT RHEUMATOL,NEW ORLEANS,LA 70112; DENVER GEN HOSP,DEPT RHEUMATOL,DENVER,CO 80204	Tulane University; Louisiana State University System; Denver Health Medical Center	DOLL, NJ (corresponding author), TULANE UNIV,SCH MED,CLIN IMMUNOL SECT,NEW ORLEANS,LA 70112, USA.				NHLBI NIH HHS [HL-07376, HL-15092] Funding Source: Medline; PHS HHS [A1-13401] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007376, P50HL015092] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALSPAUGH MA, 1975, J CLIN INVEST, V55, P1067, DOI 10.1172/JCI108007; COCARLA AA, 1977, J HYG EPID MICROB IM, V21, P374; DREISIN RB, 1978, NEW ENGL J MED, V298, P353, DOI 10.1056/NEJM197802162980701; ERASMUS L D, 1957, S Afr J Lab Clin Med, V3, P209; GUPTA RC, 1978, IMMUNOLOGY, V34, P751; GUPTA RC, 1977, AM REV RESPIR DIS, V116, P261; HASLAM PL, 1979, CLIN EXP IMMUNOL, V37, P381; JONES RN, 1976, AM REV RESPIR DIS, V113, P393; KANG KY, 1973, NEW ENGL J MED, V288, P164; LIPPMANN M, 1973, ANN INTERN MED, V79, P807, DOI 10.7326/0003-4819-79-6-807; OUCHTERLONY O, 1953, ACTA PATHOL MIC SC, V32, P231; RODNAN GP, 1967, ANN INTERN MED, V66, P323, DOI 10.7326/0003-4819-66-2-323; ROTHFIEL.NF, 1965, J CLIN INVEST, V44, P62, DOI 10.1172/JCI105127; SONTHEIMER RD, 1978, J LAB CLIN MED, V91, P551; THEOFILOPOULOS AN, 1976, J CLIN INVEST, V57, P169, DOI 10.1172/JCI108257; TURNERWARWICK M, 1970, BMJ-BRIT MED J, V3, P492, DOI 10.1136/bmj.3.5721.492; ZISKIND M, 1976, AM REV RESPIR DIS, V113, P643; 1972, INT LABOUR OFFICE OC, V22	18	86	91	1	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	4					281	285						5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML525	6974746				2022-12-18	WOS:A1981ML52500006
J	TOMASI, TB; LARSON, L; CHALLACOMBE, S; MCNABB, P				TOMASI, TB; LARSON, L; CHALLACOMBE, S; MCNABB, P			MUCOSAL IMMUNITY - ORIGIN AND MIGRATION PATTERNS OF CELLS IN THE SECRETORY SYSTEM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											TOMASI, TB (corresponding author), MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55901 USA.			challacombe, stephen/0000-0002-7327-6927	NICHD NIH HHS [R01 HD017013] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017013] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDRE C, 1975, J EXP MED, V142, P1509, DOI 10.1084/jem.142.6.1509; ARNAUDBATTANDIER F, 1978, J IMMUNOL, V121, P1059; ASHERSON GL, 1977, CELL IMMUNOL, V33, P145, DOI 10.1016/0008-8749(77)90142-3; ATWATER JS, 1978, CLIN IMMUNOL IMMUNOP, V9, P379, DOI 10.1016/0090-1229(78)90110-1; BIENENSTOCK J, 1973, LAB INVEST, V28, P686; BOCKMAN DE, 1973, AM J ANAT, V136, P455, DOI 10.1002/aja.1001360406; BOHL EH, 1974, IMMUNOGLOBULIN A SYS, V45, P337; CEBRA JJ, 1976, COLD SPRING HARB SYM, V41, P201, DOI 10.1101/SQB.1977.041.01.026; CHALLACOMBE SJ, 1979, FED PROC, V38, P4109; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; CRAIG SW, 1971, J EXP MED, V134, P188, DOI 10.1084/jem.134.1.188; CUNNINGHAMRUNDLES C, 1978, P NATL ACAD SCI USA, V75, P3387, DOI 10.1073/pnas.75.7.3387; GUYGRAND D, 1978, J EXP MED, V148, P1661, DOI 10.1084/jem.148.6.1661; GUYGRAND D, 1974, EUR J IMMUNOL, V4, P435, DOI 10.1002/eji.1830040610; HALSTEAD TE, 1972, TRANSPLANTATION, V14, P339, DOI 10.1097/00007890-197209000-00009; HUSBAND AJ, 1978, J EXP MED, V148, P1146, DOI 10.1084/jem.148.5.1146; HUSBAND AJ, 1974, AUST J EXP BIOL MED, V52, P791, DOI 10.1038/icb.1974.78; KAARTINEN M, 1978, SCAND J IMMUNOL, V8, P161; Lamm M E, 1976, Adv Immunol, V22, P223, DOI 10.1016/S0065-2776(08)60550-7; LEMAITRECOELHO I, 1978, J EXP MED, V147, P934, DOI 10.1084/jem.147.3.934; MATTINGLY JA, 1978, J IMMUNOL, V121, P1878; MATTSBY I, 1978, SCAND J IMMUNOL, V8, P165; MCWILLIAMS M, 1975, J IMMUNOL, V115, P54; MCWILLIAMS M, 1974, J IMMUNOL, V113, P1326; MESTECKY J, 1978, J CLIN INVEST, V61, P731, DOI 10.1172/JCI108986; Montgomery P C, 1974, Adv Exp Med Biol, V45, P453; MONTGOMERY PC, 1976, RIC CLIN LAB      S3, V6, P93; NACCACHECORBIC MC, 1976, RIC CLIN LAB      S3, V6, P101; NELSON DL, 1976, CELL IMMUNOL, V22, P165, DOI 10.1016/0008-8749(76)90017-4; OGRA PL, 1969, J IMMUNOL, V102, P1423; OGRA PL, 1974, ADV EXP MED BIOL, V45, P277; ORLANS E, 1978, J EXP MED, V147, P588, DOI 10.1084/jem.147.2.588; Otto H F, 1973, Curr Top Pathol, V57, P81; OWEN RL, 1974, GASTROENTEROLOGY, V66, P189, DOI 10.1016/s0016-5085(74)80102-2; PARROTT DMV, 1974, IMMUNOLOGY, V26, P571; PIERCE NF, 1975, J EXP MED, V142, P1550, DOI 10.1084/jem.142.6.1550; RUDZIK R, 1975, J IMMUNOL, V114, P1599; SHINER M, 1975, LANCET, V1, P136; TOMASI TB, 1965, J EXP MED, V121, P101, DOI 10.1084/jem.121.1.101; TOMASI TB, 1968, IMMUNOL DEFICIENCY, P270; TOMASI TB, 1976, IMMUNE SYSTEM SECRET; UNDERDOWN BJ, 1974, J IMMUNOL, V112, P949; WALKER WA, 1977, NEW ENGL J MED, V297, P767, DOI 10.1056/NEJM197710062971407; WEISZCARRINGTON P, 1978, P NATL ACAD SCI USA, V75, P2928, DOI 10.1073/pnas.75.6.2928; Wells HG, 1911, J INFECT DIS, V9, P147, DOI 10.1093/infdis/9.2.147	45	86	88	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	1					12	19		10.1016/0091-6749(80)90171-2	http://dx.doi.org/10.1016/0091-6749(80)90171-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB459	6153083	Bronze			2022-12-18	WOS:A1980JB45900003
J	ZEIGER, RS; SCHATZ, M; SPERLING, W; SIMON, RA; STEVENSON, DD				ZEIGER, RS; SCHATZ, M; SPERLING, W; SIMON, RA; STEVENSON, DD			EFFICACY OF TROLEANDOMYCIN IN OUTPATIENTS WITH SEVERE, CORTICOSTEROID-DEPENDENT ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN,DIV ALLERGY & IMMUNOL,LA JOLLA,CA 92037; KAISER PERMANENTE MED CTR,DEPT MED,SAN DIEGO,CA 92111	Scripps Research Institute; Kaiser Permanente	ZEIGER, RS (corresponding author), KAISER PERMANENTE MED CTR,DEPT ALLERGY & CLIN IMMUNOL,7060 CLAIREMONT MESA BLVD,SAN DIEGO,CA 92111, USA.			Zeiger, Robert/0000-0001-5788-5063				CABANIEU G, 1975, ANTIBIOTICA      JUN, P110; DASGUPTA A, 1978, ANN ALLERGY, V41, P297; ENGEL MF, 1963, SOUTHERN MED J, V56, P1279, DOI 10.1097/00007611-196311000-00017; FOX JL, 1961, PENN MED J, V64, P634; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; KAPLAN MA, 1959, ANTIBIOTICS ANN 1958, P273; MELBY JC, 1974, ANN INTERN MED, V81, P505, DOI 10.7326/0003-4819-81-4-505; MORRIS HG, 1974, J ALLERGY CLIN IMMUN, V54, P350, DOI 10.1016/0091-6749(74)90025-6; ONG KS, 1978, J ALLERGY CLIN IMMUN, V62, P115, DOI 10.1016/0091-6749(78)90088-X; ROBINSON MM, 1962, AM J MED SCI, V243, P502, DOI 10.1097/00000441-196204000-00012; SELENKE W, 1969, J ALLERGY, V43, P156; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; SZEFLER SJ, 1980, J ALLERGY CLIN IMMUN, V65, P181; TICKTIN HE, 1962, NEW ENGL J MED, V267, P964, DOI 10.1056/NEJM196211082671905; WEINBERGER M, 1977, J ALLERGY CLIN IMMUN, V59, P228, DOI 10.1016/0091-6749(77)90154-3; WEINER ALFRED, 1962, JOUR NEW DRUGS, V2, P307, DOI 10.1177/009127006200200507	16	86	87	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	6					438	446		10.1016/0091-6749(80)90003-2	http://dx.doi.org/10.1016/0091-6749(80)90003-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KV363	6968762				2022-12-18	WOS:A1980KV36300002
J	Mahil, SK; Dand, N; Mason, KJ; Yiu, ZZN; Tsakok, T; Meynell, F; Coker, B; McAteer, H; Moorhead, L; Mackenzie, T; Rossi, MT; Rivera, R; Mahe, E; Carugno, A; Magnano, M; Rech, G; Balogh, EA; Feldman, SR; De La Cruz, C; Choon, SE; Naldi, L; Lambert, J; Spuls, P; Jullien, D; Bachelez, H; McMahon, DE; Freeman, EE; Gisondi, P; Puig, L; Warren, RB; Di Meglio, P; Langan, SM; Capon, F; Griffiths, CEM; Barker, JN; Smith, CH				Mahil, Satveer K.; Dand, Nick; Mason, Kayleigh J.; Yiu, Zenas Z. N.; Tsakok, Teresa; Meynell, Freya; Coker, Bola; McAteer, Helen; Moorhead, Lucy; Mackenzie, Teena; Rossi, Maria Teresa; Rivera, Raquel; Mahe, Emmanuel; Carugno, Andrea; Magnano, Michela; Rech, Giulia; Balogh, Esther A.; Feldman, Steven R.; De La Cruz, Claudia; Choon, Siew Eng; Naldi, Luigi; Lambert, Jo; Spuls, Phyllis; Jullien, Denis; Bachelez, Herve; McMahon, Devon E.; Freeman, Esther E.; Gisondi, Paolo; Puig, Luis; Warren, Richard B.; Di Meglio, Paola; Langan, Sinead M.; Capon, Francesca; Griffiths, Christopher E. M.; Barker, Jonathan N.; Smith, Catherine H.		PsoProtect Study Grp	Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COVID-19; hospitalization; psoriasis; risk factors; biologics; immunosuppressants	RISK; INFECTION; BIOLOGICS	Background: The multimorbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse outcomes of coronavirus disease 2019 (COVID-19), but the data are limited. Objective: Our aim was to characterize the course of COVID-19 in patients with psoriasis and identify factors associated with hospitalization. Methods: Clinicians reported patients with psoriasis with confirmed/suspected COVID-19 via an international registry, Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection. Multiple logistic regression was used to assess the association between clinical and/or demographic characteristics and hospitalization. A separate patient-facing registry characterized risk-mitigating behaviors. Results: Of 374 clinician-reported patients from 25 countries, 71% were receiving a biologic, 18% were receiving a nonbiologic, and 10% were not receiving any systemic treatment for psoriasis. In all, 348 patients (93%) were fully recovered from COVID-19, 77 (21%) were hospitalized, and 9 (2%) died. Increased hospitalization risk was associated with older age (multivariable-adjusted odds ratio [OR] = 1.59 per 10 years; 95% CI = 1.19-2.13), male sex (OR = 2.51; 95% CI = 1.23-5.12), nonwhite ethnicity (OR = 3.15; 95% CI = 1.24-8.03), and comorbid chronic lung disease (OR = 3.87; 95% CI = 1.52-9.83). Hospitalization was more frequent in patients using nonbiologic systemic therapy than in those using biologics (OR = 2.84; 95% CI = 1.31-6.18). No significant differences were found between classes of biologics. Independent patient-reported data (n = 1626 across 48 countries) suggested lower levels of social isolation in individuals receiving nonbiologic systemic therapy than in those receiving biologics (OR = 0.68; 95% CI = 0.50-0.94). Conclusion: In this international case series of patients with moderate-to-severe psoriasis, biologic use was associated with lower risk of COVID-19-related hospitalization than with use of nonbiologic systemic therapies; however, further investigation is warranted on account of potential selection bias and unmeasured confounding. Established risk factors (being older, being male, being of nonwhite ethnicity, and having comorbidities) were associated with higher hospitalization rates.	[Mahil, Satveer K.; Tsakok, Teresa; Meynell, Freya; Moorhead, Lucy; Langan, Sinead M.; Smith, Catherine H.] Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London SE1 9RT, England; [Mahil, Satveer K.; Tsakok, Teresa; Meynell, Freya; Moorhead, Lucy; Langan, Sinead M.; Smith, Catherine H.] Kings Coll London, London, England; [Dand, Nick; Capon, Francesca] Kings Coll London, Dept Med & Mol Genet, Sch Basic & Med Biosci, Fac Life Sci & Med, London, England; [Dand, Nick] Hlth Data Res UK, London, England; [Mason, Kayleigh J.; Yiu, Zenas Z. N.; Warren, Richard B.; Griffiths, Christopher E. M.] Univ Manchester, Dermatol Ctr, Salford Royal NHS Fdn Trust, Manchester Acad Hlth Sci Ctr,Natl Inst Hlth Res M, Manchester, Lancs, England; [Coker, Bola] Guys & St Thomas NHS Fdn Trust, Natl Inst Hlth Res Biomed Res Ctr, London, England; [McAteer, Helen] Psoriasis Assoc, Northampton, England; [Mackenzie, Teena] Churchill Hosp, Dept Dermatol, Oxford, England; [Rossi, Maria Teresa] Spedali Civili Hosp, Dept Dermatol, Brescia, Italy; [Rivera, Raquel] Univ Complutense Madrid, Dept Dermatol, Hosp Univ 12 Octubre, Madrid, Spain; [Mahe, Emmanuel] Hop Victor Dupouy, Dept Dermatol, Argenteuil, France; [Mahe, Emmanuel; Jullien, Denis] Soc Francaise Dermatol, Grp Rech Psoriasis GrPso, Paris, France; [Carugno, Andrea] ASST Papa Giovanni XXIII Hosp, Dermatol Unit, Bergamo, Italy; [Magnano, Michela; Rech, Giulia] Santa Chiara Hosp, Dermatol Unit, Trenton, NJ USA; [Balogh, Esther A.; Feldman, Steven R.] Wake Forest Sch Med, Ctr Dermatol Res, Dept Dermatol, Winston Salem, NC 27101 USA; [De La Cruz, Claudia] Clin Dermacross, Santiago, Chile; [Choon, Siew Eng] Monash Univ, Jeffrey Cheah Sch Med & Hlth Sci, Subang Jaya, Malaysia; [Naldi, Luigi] Ctr GISED, Bergamo, Italy; [Lambert, Jo] Univ Ghent, Dept Dermatol, Ghent, Belgium; [Spuls, Phyllis] Univ Amsterdam, Med Ctr, Amsterdam Publ Hlth Infect & Immunol, Dept Dermatol,AMC, Amsterdam, Netherlands; [Jullien, Denis] Hosp Civils Lyon, Edouard Herriot Hosp, Dept Dermatol, Lyon, France; [Bachelez, Herve] Hop St Louis, AP HP, Dept Dermatol, Paris, France; [Bachelez, Herve] Univ Paris, INSERM U1163, Imagine Inst Human Genet Dis, Paris, France; [McMahon, Devon E.] Harvard Med Sch, Boston, MA 02115 USA; [Freeman, Esther E.] Harvard Med Sch, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Gisondi, Paolo] Univ Verona, Sect Dermatol & Venereol, Verona, Italy; [Puig, Luis] Univ Autonoma Barcelona, Dept Dermatol, Hosp Santa Creu & St Pau, Barcelona, Spain; [Di Meglio, Paola; Barker, Jonathan N.] Kings Coll London, St Johns Inst Dermatol, Sch Basic & Med Biosci, Fac Life Sci & Med, London, England; [Langan, Sinead M.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London; University of London; King's College London; Salford Royal NHS Foundation Trust; University of Manchester; Guy's & St Thomas' NHS Foundation Trust; University of Oxford; Hospital Spedali Civili Brescia; Complutense University of Madrid; Hospital Universitario 12 de Octubre; ASST Papa Giovanni XXIII; Wake Forest University; Monash University; Monash University Sunway; Ghent University; University of Amsterdam; Academic Medical Center Amsterdam; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Verona; Autonomous University of Barcelona; Hospital of Santa Creu i Sant Pau; University of London; King's College London; University of London; London School of Hygiene & Tropical Medicine	Smith, CH (corresponding author), Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London SE1 9RT, England.	catherine.smith@kcl.ac.uk	Mason, Kayleigh/ABW-1652-2022; Carugno, Andrea/AAM-6118-2020; Rivera Díaz, Raquel/HHN-1810-2022; rossi, mariateresa/HGE-3231-2022; Gisondi, Paolo/AGI-4840-2022; CHOON, SIEW ENG/AAU-8192-2021; Mason, Kayleigh J/AAI-5318-2021; Warren, Richard/G-4929-2015; Smith, Catherine/G-5268-2012; Capon, Francesca/F-4763-2011	Carugno, Andrea/0000-0002-8231-2205; rossi, mariateresa/0000-0002-5101-159X; Gisondi, Paolo/0000-0002-1777-9001; CHOON, SIEW ENG/0000-0002-7796-5746; Mason, Kayleigh J/0000-0002-5419-0669; piaserico, stefano/0000-0002-1091-4733; Warren, Richard/0000-0002-2918-6481; Dand, Nick/0000-0002-1805-6278; Langan, Sinead/0000-0002-7022-7441; Mahil, Satveer/0000-0003-4692-3794; De la Cruz, Claudia/0000-0002-8925-0457; Spuls, Phyllis/0000-0002-6035-2863; Hampton, Philip/0000-0001-6797-2697; Di Lernia, Vito/0000-0002-8961-7108; Smith, Catherine/0000-0001-9918-1144; Varela, Paulo/0000-0002-0934-1528; Yiu, Zenas/0000-0002-1831-074X; Pink, Andrew/0000-0001-5151-5539; Valenzuela, Fernando/0000-0003-1032-9347; Skov, Lone/0000-0002-4784-9680; Capon, Francesca/0000-0003-2432-5793	Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London; NIHR Manchester Biomedical Research Centre; Psoriasis Association - Medical Research Council Clinical Academic Research Partnership award [MR/T02383X/1]; Health Data Research UK [LOND1]; UK Medical Research Council, Engineering and Physical Sciences Research Council; Economic and Social Research Council; Department of Health & Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation - NIHR Academic Clinical Lectureship through the University of Manchester; Medical Research Council [MR/101 1808/1]; Wellcome Senior Research Fellowship in clinical science [205039/Z/16/Z]; Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh government); British Heart Foundation; Wellcome Trust; MRC [MR/T02383X/1, MR/S003126/1] Funding Source: UKRI	Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London; NIHR Manchester Biomedical Research Centre(National Institute for Health Research (NIHR)); Psoriasis Association - Medical Research Council Clinical Academic Research Partnership award; Health Data Research UK; UK Medical Research Council, Engineering and Physical Sciences Research Council; Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Department of Health & Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation - NIHR Academic Clinical Lectureship through the University of Manchester; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Senior Research Fellowship in clinical science; Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh government); British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We acknowledge financial support from the Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London, the NIHR Manchester Biomedical Research Centre and the Psoriasis Association. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. S.K.M. is funded by a Medical Research Council Clinical Academic Research Partnership award (MR/T02383X/1). N.D. is funded by Health Data Research UK (MR/S003126/1), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council; Economic and Social Research Council; Department of Health & Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation; andWellcome. Z.Z.N.Y is funded by a NIHR Academic Clinical Lectureship through the University of Manchester. C.E.M.G. is an NIHR Emeritus Senior Investigator and is funded in part by the Medical Research Council (MR/101 1808/1). C.E.M.G. and R.B.W. are in part supported by the NIHR Manchester Biomedical Research Centre. S.M.L. is supported by a Wellcome Senior Research Fellowship in clinical science (205039/Z/16/Z). S.M.L. is also supported by Health Data Research UK (grant LOND1), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh government), Public Health Agency (Northern Ireland), British Heart Foundation,and Wellcome Trust.	[Anonymous], PSOPROTECTME PSORIAS; [Anonymous], STROBE STATEMENT STR; [Anonymous], PHASE 2 TRIAL INFLIX; [Anonymous], CORONAVIRUS DIS COVI; [Anonymous], PSOPROTECTPSORIASIS; [Anonymous], R R PROJECT STAT COM; Blumentals WA, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-158; Brenner EJ, 2020, GASTROENTEROLOGY, V159, P481, DOI 10.1053/j.gastro.2020.05.032; Brownstone ND, 2020, DERMATOLOGY THER, DOI 10.1007/s13555-020-00377-9; Carugno A, 2020, J AM ACAD DERMATOL, V83, P292, DOI 10.1016/j.jaad.2020.04.165; ClinicalTrials.gov, TEST WHETH US BRAIN; Deng GT, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02902-w; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Freeman EE, 2020, J AM ACAD DERMATOL, V83, pE261, DOI 10.1016/j.jaad.2020.06.050; Freeman EE, 2020, J AM ACAD DERMATOL, V83, P509, DOI 10.1016/j.jaad.2020.04.045; Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707; Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI 10.1136/annrheumdis-2020-217871; Gisondi P, 2020, BRIT J DERMATOL, V183, P373, DOI 10.1111/bjd.19158; Gisondi P, 2020, J AM ACAD DERMATOL, V83, P285, DOI 10.1016/j.jaad.2020.04.085; Greb JE, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.82; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Ingraham NE, 2020, LANCET RESP MED, V8, P544, DOI 10.1016/S2213-2600(20)30226-5; Kalb RE, 2015, JAMA DERMATOL, V151, P961, DOI 10.1001/jamadermatol.2015.0718; Magnano M, 2020, DERMATOL THER, V33; Mahil SK, 2020, BRIT J DERMATOL, V183, P404, DOI 10.1111/bjd.19161; Mahil SK, 2016, SEMIN IMMUNOPATHOL, V38, P11, DOI 10.1007/s00281-015-0539-8; Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683; Parisi R, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1590; Shatizadeh Malekshahi S, 2016, INFECT DIS-NOR, V5, DOI [10.5812/pedinfect.36953., DOI 10.1093/CID/CIAA344, DOI 10.1093/cid/ciaa344]; Syed MN, 2020, J AM ACAD DERMATOL, V83, P1523, DOI 10.1016/j.jaad.2020.06.1014; Takeshita J, 2017, J AM ACAD DERMATOL, V76, P377, DOI 10.1016/j.jaad.2016.07.064; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002; van Buuren S, 2011, J STAT SOFTW, V45, P1; Wan MT, 2020, J AM ACAD DERMATOL, V83, P677, DOI 10.1016/j.jaad.2020.05.035; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yiu ZZN, 2019, BRIT J DERMATOL, V180, P329, DOI 10.1111/bjd.17036; Zhong JX, 2020, LANCET RHEUMATOL, V2, pE428, DOI 10.1016/S2665-9913(20)30120-X	41	85	89	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					60	71		10.1016/j.jaci.2020.10.007	http://dx.doi.org/10.1016/j.jaci.2020.10.007		JAN 2021	12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	33075408	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000613645900009
J	Morita, H; Kubo, T; Ruckert, B; Ravindran, A; Soyka, MB; Rinaldi, AO; Sugita, K; Wawrzyniak, M; Wawrzyniak, P; Motomura, K; Tamari, M; Orimo, K; Okada, N; Arae, K; Saito, K; Altunbulakli, C; Castro-Giner, F; Tan, G; Neumann, A; Sudo, K; O'Mahony, L; Honda, K; Nakae, S; Saito, H; Mjosberg, J; Nilsson, G; Matsumoto, K; Akdis, M; Akdis, CA				Morita, Hideaki; Kubo, Terufumi; Ruckert, Beate; Ravindran, Avinash; Soyka, Michael B.; Rinaldi, Arturo Ottavio; Sugita, Kazunari; Wawrzyniak, Marcin; Wawrzyniak, Paulina; Motomura, Kenichiro; Tamari, Masato; Orimo, Keisuke; Okada, Naoko; Arae, Ken; Saito, Kyoko; Altunbulakli, Can; Castro-Giner, Francesc; Tan, Ge; Neumann, Avidan; Sudo, Katsuko; O'Mahony, Liam; Honda, Kenya; Nakae, Susumu; Saito, Hirohisa; Mjosberg, Jenny; Nilsson, Gunnar; Matsumoto, Kenji; Akdis, Mubeccel; Akdis, Cezmi A.			Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory innate lymphoid cells; Group 2 innate lymphoid cells; retinoic acid; IL-33; asthma; chronic rhinosinusitis with nasal polyps; cytotoxic T lymphocyte-associated protein 4	T-CELLS; AIRWAY INFLAMMATION; TGF-BETA; TYPE-2 IMMUNITY; TISSUE; ACTIVATION; EXPRESSION; INTERLEUKIN-33; PLASTICITY; HETEROGENEITY	Background: Group 2 innate lymphoid cells (ILC2s) play critical roles in induction and exacerbation of allergic airway inflammation. Thus clarification of the mechanisms that underlie regulation of ILC2 activation has received significant attention. Although innate lymphoid cells are divided into 3 major subsets that mirror helper effector T-cell subsets, counterpart subsets of regulatory T cells have not been well characterized. Objective: We sought to determine the factors that induce regulatory innate lymphoid cells (ILCregs). Methods: IL-10(+) ILCregs induced from ILC2s by using retinoic acid (RA) were analyzed with RNA-sequencing and flow cytometry. ILCregs were evaluated in human nasal tissue from healthy subjects and patients with chronic rhinosinusitis with nasal polyps and lung tissue from house dust mite- or saline-treated mice. Results: RA induced IL-10 secretion by human ILC2s but not type 2 cytokines. IL-10(+) ILCregs, which were converted from ILC2s by means of RA stimulation, expressed a regulatory T cell-like signature with expression of IL-10, cytotoxic T lymphocyte-associated protein 4, and CD25, with downregulated effector type 2-related markers, such as chemoattractant receptor-homologous molecule on T(H)2 cells and ST2, and suppressed activation of CD4(+) T cells and ILC2s. ILCregs were rarely detected in human nasal tissue from healthy subjects or lung tissue from saline-treated mice, but numbers were increased in nasal tissue from patients with chronic rhinosinusitis with nasal polyps and in lung tissue from house dust mite-treated mice. Enzymes for RA synthesis were upregulated in airway epithelial cells during type 2 inflammation in vivo and by IL-13 in vitro. Conclusion: We have identified a unique immune regulatory and anti-inflammatory pathway by which RA converts ILC2s to ILCregs. Interactions between airway epithelial cells and ILC2s play an important roles in the generation of ILCregs.	[Morita, Hideaki; Kubo, Terufumi; Ruckert, Beate; Rinaldi, Arturo Ottavio; Sugita, Kazunari; Wawrzyniak, Marcin; Wawrzyniak, Paulina; Altunbulakli, Can; Castro-Giner, Francesc; Tan, Ge; Neumann, Avidan; O'Mahony, Liam; Akdis, Mubeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Morita, Hideaki; Kubo, Terufumi; Sugita, Kazunari; Wawrzyniak, Marcin; Wawrzyniak, Paulina; Altunbulakli, Can; Akdis, Mubeccel; Akdis, Cezmi A.] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Morita, Hideaki; Motomura, Kenichiro; Tamari, Masato; Orimo, Keisuke; Okada, Naoko; Arae, Ken; Saito, Kyoko; Saito, Hirohisa; Matsumoto, Kenji] Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan; [Ravindran, Avinash; Nilsson, Gunnar] Karolinska Inst, Dept Med, Immunol & Allergy, Stockholm, Sweden; [Ravindran, Avinash; Nilsson, Gunnar] Karolinska Univ Hosp, Stockholm, Sweden; [Soyka, Michael B.] Univ Hosp Zurich, Dept Otorhinolaryngol Head & Neck Surg, Zurich, Switzerland; [Soyka, Michael B.] Univ Zurich, Zurich, Switzerland; [Arae, Ken] Kyorin Univ, Fac Hlth Sci, Dept Immunol, Tokyo, Japan; [Castro-Giner, Francesc; Tan, Ge] Univ Zurich, Funct Genom Ctr Zurich, ETH Zurich, Zurich, Switzerland; [Sudo, Katsuko] Tokyo Med Univ, Anim Res Ctr, Tokyo, Japan; [O'Mahony, Liam] Univ Coll Cork, Dept Med & Microbiol, APC Microbiome Ireland, Cork, Ireland; [Honda, Kenya] Keio Univ, Dept Microbiol & Immunol, Sch Med, Tokyo, Japan; [Honda, Kenya] RIKEN, Ctr Integrat Med Sci IMS, Yokohama, Kanagawa, Japan; [Nakae, Susumu] Univ Tokyo, Ctr Expt Med & Syst Biol, Inst Med Sci, Lab Syst Biol, Tokyo, Japan; [Nakae, Susumu] Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol PRESTO, Saitama, Japan; [Mjosberg, Jenny] Karolinska Univ Hosp Huddinge, Ctr Infect Med, Karolinska Inst, Dept Med, Stockholm, Sweden	Swiss Institute of Allergy & Asthma Research; University of Zurich; National Center for Child Health & Development - Japan; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of Zurich; University Zurich Hospital; University of Zurich; Kyorin University; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Tokyo Medical University; University College Cork; Keio University; RIKEN; University of Tokyo; Japan Science & Technology Agency (JST); Karolinska Institutet; Karolinska University Hospital	Morita, H (corresponding author), 2-10-1 Okura,Setagaya Ku, Tokyo 1578535, Japan.; Akdis, CA (corresponding author), Obere Str 22,Davos Pl, CH-7270 Davos, Switzerland.	morita-hi@ncchd.go.jp; akdisac@siaf.uzh.ch	Wawrzyniak, Paulina/HCG-8924-2022; O'Mahony, Liam/AAG-5838-2019; Wawrzyniak, Paulina/AAD-7265-2020; Morita, Hideaki/ADL-2008-2022; Rinaldi, Arturo O./G-3332-2019; Wawrzyniak, Paulina/AAG-3548-2019; Wawrzyniak, Marcin/E-5878-2017; Wawrzyniak, Marcin/AAT-9094-2021; Morita, Hideaki/S-2214-2016; Castro-Giner, Francesc/D-7992-2014; 岡田, 直子/GRI-9555-2022; Akdis, Cezmi/AAV-4844-2020	O'Mahony, Liam/0000-0003-4705-3583; Wawrzyniak, Paulina/0000-0001-9641-2103; Rinaldi, Arturo O./0000-0001-8967-3866; Wawrzyniak, Marcin/0000-0002-6911-8010; Morita, Hideaki/0000-0003-0928-8322; Castro-Giner, Francesc/0000-0001-6111-0754; 岡田, 直子/0000-0002-3378-5778; Akdis, Cezmi/0000-0001-8020-019X; Saito, Hirohisa/0000-0002-6630-8337; Ravindran, Avinash/0000-0002-1599-1658; Altunbulakli, Can/0000-0003-2264-7377; Tan, Ge/0000-0003-0026-8739	Swiss National Science Foundation [310030_156823, 320030_140772]; MSD Life Science Foundation; Public Interest Incorporated Foundation; National Center for Child Health and Development [29-2]; Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency; Heart and Lung Foundation; Swedish Research Council; ChAMP (Centre for Allergy Research Highlights Asthma Markers of Phenotype) consortium - Swedish Foundation for Strategic Research; Karolinska Institutet; AstraZeneca; Science for Life Laboratory Joint Research Collaboration	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); MSD Life Science Foundation; Public Interest Incorporated Foundation; National Center for Child Health and Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency(Japan Science & Technology Agency (JST)); Heart and Lung Foundation(Swedish Heart-Lung Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission); ChAMP (Centre for Allergy Research Highlights Asthma Markers of Phenotype) consortium - Swedish Foundation for Strategic Research; Karolinska Institutet(Karolinska Institutet); AstraZeneca(AstraZeneca); Science for Life Laboratory Joint Research Collaboration	Supported by Swiss National Science Foundation grants 310030_156823 and 320030_140772 (to C.A.), Grants-in-Aid for Young Scientists (B; to H.M.), MSD Life Science Foundation, Public Interest Incorporated Foundation (to H.M.), a Grant of National Center for Child Health and Development (#29-2; to H.M.), and Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency (to S.N.), Heart and Lung Foundation, Swedish Research Council, and the ChAMP (Centre for Allergy Research Highlights Asthma Markers of Phenotype) consortium funded by the Swedish Foundation for Strategic Research, the Karolinska Institutet, and AstraZeneca & Science for Life Laboratory Joint Research Collaboration (to J.M. and G.N.).	Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719; Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019; Bernink JH, 2013, NAT IMMUNOL, V14, P221, DOI 10.1038/ni.2534; Bjorklund AK, 2016, NAT IMMUNOL, V17, P451, DOI 10.1038/ni.3368; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Dawson HD, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-27; de Kleer IM, 2016, IMMUNITY, V45, P1285, DOI 10.1016/j.immuni.2016.10.031; Duerr CU, 2016, NAT IMMUNOL, V17, P65, DOI 10.1038/ni.3308; Gasteiger G, 2015, SCIENCE, V350, P981, DOI 10.1126/science.aac9593; Goswami S, 2009, NAT IMMUNOL, V10, P496, DOI 10.1038/ni.1719; Goverse G, 2016, J IMMUNOL, V196, P5148, DOI 10.4049/jimmunol.1501106; Kang SW, 2012, J IMMUNOL, V188, P5276, DOI 10.4049/jimmunol.1101211; Kastner P, 2001, BLOOD, V97, P1314, DOI 10.1182/blood.V97.5.1314; Kim MH, 2015, IMMUNITY, V43, P107, DOI 10.1016/j.immuni.2015.06.009; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Krishnamoorthy N, 2015, J IMMUNOL, V194, P863, DOI 10.4049/jimmunol.1402534; Krohn IK, 2018, ALLERGY, V73, P837, DOI 10.1111/all.13340; Kubo M, 2017, IMMUNOL REV, V278, P162, DOI 10.1111/imr.12557; Kubo T, 2015, J ALLERGY CLIN IMMUN, V136, P1413, DOI 10.1016/j.jaci.2015.05.006; Kudo F, 2016, IMMUNOLOGY, V147, P21, DOI 10.1111/imm.12537; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li BWS, 2016, EUR J IMMUNOL, V46, P1392, DOI 10.1002/eji.201546119; Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95; Lim AI, 2017, CELL, V168, P1086, DOI 10.1016/j.cell.2017.02.021; Lim AI, 2016, J EXP MED, V213, P569, DOI 10.1084/jem.20151750; Mielke LA, 2013, J EXP MED, V210, P1117, DOI 10.1084/jem.20121588; Mjosberg J, 2016, J ALLERGY CLIN IMMUN, V138, P1265, DOI 10.1016/j.jaci.2016.09.009; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Molofsky AB, 2015, IMMUNITY, V43, P161, DOI 10.1016/j.immuni.2015.05.019; Morita H, 2017, J ALLERGY CLIN IMMUN, V140, P381, DOI 10.1016/j.jaci.2017.03.042; Morita H, 2016, J ALLERGY CLIN IMMUN, V138, P1253, DOI 10.1016/j.jaci.2016.09.011; Morita H, 2015, IMMUNITY, V43, P175, DOI 10.1016/j.immuni.2015.06.021; Morita H, 2012, ALLERGOL INT, V61, P265, DOI 10.2332/allergolint.11-OA-0379; Moro K, 2016, NAT IMMUNOL, V17, P76, DOI 10.1038/ni.3309; Moro K, 2015, NAT PROTOC, V10, P792, DOI 10.1038/nprot.2015.047; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Motomura Y, 2014, IMMUNITY, V40, P758, DOI 10.1016/j.immuni.2014.04.013; Mucida D, 2009, IMMUNITY, V30, P471, DOI 10.1016/j.immuni.2009.03.008; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; Ogasawara N, 2018, J ALLERGY CLIN IMMUN, V141, P1147, DOI 10.1016/j.jaci.2017.09.025; Ohne Y, 2016, NAT IMMUNOL, V17, P646, DOI 10.1038/ni.3447; Ravindran A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02193; Rigas D, 2017, J ALLERGY CLIN IMMUN, V139, P1468, DOI 10.1016/j.jaci.2016.08.034; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Bono MR, 2016, NUTRIENTS, V8, DOI 10.3390/nu8060349; Seehus CR, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02023-z; Silver JS, 2016, NAT IMMUNOL, V17, P626, DOI 10.1038/ni.3443; Simoni Y, 2017, IMMUNITY, V46, P148, DOI 10.1016/j.immuni.2016.11.005; Spencer SP, 2014, SCIENCE, V343, P432, DOI 10.1126/science.1247606; Sugita K, 2018, J ALLERGY CLIN IMMUN, V141, P300, DOI 10.1016/j.jaci.2017.02.038; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Tanoue T, 2016, NAT REV IMMUNOL, V16, P295, DOI 10.1038/nri.2016.36; Trabanelli S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00678-2; van de Pavert SA, 2014, NATURE, V508, P123, DOI 10.1038/nature13158; Wang S, 2017, CELL, V171, P201, DOI 10.1016/j.cell.2017.07.027; Wansley Daniel L, 2013, Clin Mol Allergy, V11, P4, DOI 10.1186/1476-7961-11-4; Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-2-r14; Zhou WS, 2016, AM J RESP CRIT CARE, V193, P31, DOI 10.1164/rccm.201410-1793OC	63	85	87	3	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2190	+		10.1016/j.jaci.2018.12.1018	http://dx.doi.org/10.1016/j.jaci.2018.12.1018			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30682454	Green Accepted, Bronze			2022-12-18	WOS:000470113200023
J	Maric, J; Ravindran, A; Mazzurana, L; Bjorklund, AK; Van Acker, A; Rao, A; Friberg, D; Dahlen, SE; Heinemann, A; Konya, V; Mjosberg, J				Maric, Jovana; Ravindran, Avinash; Mazzurana, Luca; Bjorklund, Asa K.; Van Acker, Aline; Rao, Anna; Friberg, Danielle; Dahlen, Sven-Erik; Heinemann, Akos; Konya, Viktoria; Mjosberg, Jenny			Prostaglandin E-2 suppresses human group 2 innate lymphoid cell function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ILC2; allergy; prostaglandin E-2; E-type prostanoid receptor 2; E-type prostanoid receptor 4	TRANSCRIPTION FACTOR GATA3; SMOOTH-MUSCLE-CELLS; EP4 RECEPTOR; AIRWAY INFLAMMATION; LUNG INFLAMMATION; ALLERGIC DISEASES; LIPID MEDIATORS; INHALED PGE(2); INDUCED ASTHMA; T(H)2 CELLS	Background: Group 2 innate lymphoid cells (ILC2s) are involved in the initial phase of type 2 inflammation and can amplify allergic immune responses by orchestrating other type 2 immune cells. Prostaglandin (PG) E-2 is a bioactive lipid that plays protective roles in the lung, particularly during allergic inflammation. Objective: We set out to investigate how PGE(2) regulates human ILC2 function. Methods: The effects of PGE(2) on human ILC2 proliferation and intracellular cytokine and transcription factor expression were assessed by means of flow cytometry. Cytokine production was measured by using ELISA, and real-time quantitative PCR was performed to detect PGE(2) receptor expression. Results: PGE(2) inhibited GATA-3 expression, as well as production of the type 2 cytokines IL-5 and IL-13, from human tonsillar and blood ILC2s in response to stimulation with a combination of IL-25, IL-33, thymic stromal lymphopoietin, and IL-2. Furthermore, PGE(2) downregulated the expression of IL-2 receptor alpha (CD25). In line with this observation, PGE(2) decreased ILC2 proliferation. These effects were mediated by the combined action of E-type prostanoid receptor (EP) 2 and EP4 receptors, which were specifically expressed on ILC2s. Conclusion: Our findings reveal that PGE(2) limits ILC2 activation and propose that selective EP2 and EP4 receptor agonists might serve as a promising therapeutic approach in treating allergic diseases by suppressing ILC2 function.	[Maric, Jovana; Heinemann, Akos; Konya, Viktoria] Med Univ Graz, Inst Expt & Clin Pharmacol, Graz, Austria; [Maric, Jovana; Mazzurana, Luca; Van Acker, Aline; Rao, Anna; Konya, Viktoria; Mjosberg, Jenny] Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden; [Ravindran, Avinash] Karolinska Inst, Dept Med, Immunol & Allergy Unit, Stockholm, Sweden; [Bjorklund, Asa K.] Uppsala Univ, Dept Cell & Mol Biol, Sci Life Lab, Uppsala, Sweden; [Friberg, Danielle] Karolinska Univ Hosp, Dept Otorhinolaryngol, Stockholm, Sweden; [Friberg, Danielle] Karolinska Inst, CLINTEC, Stockholm, Sweden; [Dahlen, Sven-Erik] Karolinska Inst, Inst Environm Med, Expt Asthma & Allergy Res, Stockholm, Sweden; [Mjosberg, Jenny] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden	Medical University of Graz; Karolinska Institutet; Karolinska Institutet; Uppsala University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Linkoping University	Konya, V (corresponding author), Med Univ Graz, Inst Expt & Clin Pharmacol, Graz, Austria.; Mjosberg, J (corresponding author), Karolinska Inst, Ctr Infect Med, F59, S-14186 Stockholm, Sweden.	viktoria.konya@medunigraz.at; jenny.mjosberg@ki.se	; Bjorklund, Asa K/J-4587-2013	Friberg, Danielle/0000-0001-8327-1292; Ravindran, Avinash/0000-0002-1599-1658; Bjorklund, Asa K/0000-0003-2224-7090	Swedish Research Council [521-2013-2791]; Swedish Cancer Society [130396]; Foundation for Strategic Research [ICA12-0023]; Swedish Society for Medical Research; Austrian Science Fund FWF [P25531-B23]	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Foundation for Strategic Research; Swedish Society for Medical Research; Austrian Science Fund FWF(Austrian Science Fund (FWF))	Supported by the Swedish Research Council (521-2013-2791), the Swedish Cancer Society (130396), the Foundation for Strategic Research (ICA12-0023), and the Swedish Society for Medical Research (to J.M.) and the Austrian Science Fund FWF (grant P25531-B23; to V.K.).	Audoly LP, 1999, AM J PHYSIOL-HEART C, V277, pH924, DOI 10.1152/ajpheart.1999.277.3.H924; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Birrell MA, 2015, THORAX, V70, P740, DOI 10.1136/thoraxjnl-2014-206592; Bjorklund AK, 2016, NAT IMMUNOL, V17, P451, DOI 10.1038/ni.3368; Bradbury D, 2005, J BIOL CHEM, V280, P29993, DOI 10.1074/jbc.M414530200; Buckley J, 2011, THORAX, V66, P1029, DOI 10.1136/thx.2010.158568; Cahill KN, 2016, AM J RESP CELL MOL, V54, P34, DOI 10.1165/rcmb.2014-0486OC; Chang YJ, 2013, J LEUKOCYTE BIOL, V94, P933, DOI 10.1189/jlb.0313127; Chemnitz JM, 2006, CANCER RES, V66, P1114, DOI 10.1158/0008-5472.CAN-05-3252; Corrigan CJ, 2012, J ALLERGY CLIN IMMUN, V129, P1636, DOI 10.1016/j.jaci.2012.02.007; Deacon K, 2015, AM J PHYSIOL-LUNG C, V309, pL237, DOI 10.1152/ajplung.00390.2014; Duerr CU, 2016, CYTOKINE, V87, P1, DOI 10.1016/j.cyto.2016.01.018; Fanning LB, 2013, ANN ALLERG ASTHMA IM, V111, P155, DOI 10.1016/j.anai.2013.06.031; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Gauvreau GM, 1999, AM J RESP CRIT CARE, V159, P31, DOI 10.1164/ajrccm.159.1.9804030; Halim TYF, 2016, NAT IMMUNOL, V17, P57, DOI 10.1038/ni.3294; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hams E, 2014, P NATL ACAD SCI USA, V111, P367, DOI 10.1073/pnas.1315854111; Harizi H, 2013, CELL MOL IMMUNOL, V10, P213, DOI 10.1038/cmi.2013.1; Hazenberg MD, 2014, BLOOD, V124, P700, DOI 10.1182/blood-2013-11-427781; Ho J, 2015, CLIN EXP ALLERGY, V45, P394, DOI 10.1111/cea.12462; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Kay LJ, 2006, BRIT J PHARMACOL, V147, P707, DOI 10.1038/sj.bjp.0706664; Kolenko V, 1999, BLOOD, V93, P2308, DOI 10.1182/blood.V93.7.2308.407k16_2308_2318; Konya V., 2015, BR J PHARM; Konya V, 2016, IMMUNOL LETT, V179, P36, DOI 10.1016/j.imlet.2016.07.006; Konya V, 2013, J ALLERGY CLIN IMMUN, V131, P532, DOI 10.1016/j.jaci.2012.05.008; Konya V, 2011, EUR J IMMUNOL, V41, P2379, DOI 10.1002/eji.201141460; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Li BWS, 2013, IMMUNOLOGY, V140, P281, DOI 10.1111/imm.12153; Luschnig-Schratl P, 2011, CELL MOL LIFE SCI, V68, P3573, DOI 10.1007/s00018-011-0642-5; Machado-Carvalho L, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0100-7; MacKenzie KF, 2013, J IMMUNOL, V190, P565, DOI 10.4049/jimmunol.1202462; Maslanka T, 2014, VET IMMUNOL IMMUNOP, V160, P192, DOI 10.1016/j.vetimm.2014.05.003; MELILLO E, 1994, AM J RESP CRIT CARE, V149, P1138, DOI 10.1164/ajrccm.149.5.8173753; Mirchandani AS, 2014, J IMMUNOL, V192, P2442, DOI 10.4049/jimmunol.1300974; Mjosberg J, 2014, CLIN EXP ALLERGY, V44, P1033, DOI 10.1111/cea.12353; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Mjosberg J, 2012, EUR J IMMUNOL, V42, P1916, DOI 10.1002/eji.201242639; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Nagakumar P, 2016, J ALLERGY CLIN IMMUN, V137, P624, DOI 10.1016/j.jaci.2015.06.038; Norel X, 2007, THESCIENTIFICWORLDJO, V7, P1359, DOI 10.1100/tsw.2007.184; Okano M, 2006, IMMUNOLOGY, V118, P343, DOI 10.1111/j.1365-2567.2006.02376.x; Okano M, 2009, J ALLERGY CLIN IMMUN, V123, P868, DOI 10.1016/j.jaci.2009.01.047; PAVORD ID, 1993, AM REV RESPIR DIS, V148, P87, DOI 10.1164/ajrccm/148.1.87; Ratcliffe MJ, 2007, EUR RESPIR J, V29, P986, DOI 10.1183/09031936.00131606; Roediger B, 2015, J ALLERGY CLIN IMMUN, V136, P1653, DOI 10.1016/j.jaci.2015.03.043; Rumzhum NN, 2016, CLIN EXP ALLERGY, V46, P397, DOI 10.1111/cea.12697; Safholm J, 2015, J ALLERGY CLIN IMMUN, V136, P1232, DOI 10.1016/j.jaci.2015.04.002; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Sedej M, 2012, J ALLERGY CLIN IMMUN, V129, P492, DOI 10.1016/j.jaci.2011.08.015; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Sreeramkumar V, 2012, IMMUNOL CELL BIOL, V90, P579, DOI 10.1038/icb.2011.75; Sturm EM, 2008, J IMMUNOL, V181, P7273, DOI 10.4049/jimmunol.181.10.7273; Szczeklik A, 1996, AM J RESP CRIT CARE, V153, P567, DOI 10.1164/ajrccm.153.2.8564099; Takayama K, 2006, CIRC RES, V98, P499, DOI 10.1161/01.RES.0000204451.88147.96; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Xue LZ, 2005, J IMMUNOL, V175, P6531, DOI 10.4049/jimmunol.175.10.6531; Zaslona Z, 2014, J ALLERGY CLIN IMMUN, V133, P379, DOI 10.1016/j.jaci.2013.07.037; Zhou WS, 2016, AM J RESP CRIT CARE, V193, P31, DOI 10.1164/rccm.201410-1793OC	65	85	88	1	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1761	+		10.1016/j.jaci.2017.09.050	http://dx.doi.org/10.1016/j.jaci.2017.09.050			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29217133	Green Published, hybrid			2022-12-18	WOS:000432148200023
J	Schleimer, RP; Berdnikovs, S				Schleimer, Robert P.; Berdnikovs, Sergejs			Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epithelial barrier; differentiation; mesenchyme; extracellular matrix; tight junctions; hormones; metabolism; allergic predisposition; allergic sensitization	ALLERGIC AIRWAY INFLAMMATION; ATOPIC ECZEMA PATIENTS; EOSINOPHILIC ESOPHAGITIS; MESENCHYMAL TRANSITION; CHRONIC RHINOSINUSITIS; STRATUM-CORNEUM; NASAL POLYPOSIS; TIGHT JUNCTIONS; BIRTH COHORT; E-CADHERIN	Epithelial barriers of the skin, gastrointestinal tract, and airway serve common critical functions, such as maintaining a physical barrier against environmental insults and allergens and providing a tissue interface balancing the communication between the internal and external environments. We now understand that in patients with allergic disease, regardless of tissue location, the homeostatic balance of the epithelial barrier is skewed toward loss of differentiation, reduced junctional integrity, and impaired innate defense. Importantly, epithelial dysfunction characterized by these traits appears to pre-date atopy and development of allergic disease. Despite our growing appreciation of the centrality of barrier dysfunction in initiation of allergic disease, many important questions remain to be answered regarding mechanisms disrupting normal barrier function. Although our external environment (proteases, allergens, and injury) is classically thought of as a principal contributor to barrier disruption associated with allergic sensitization, there is a need to better understand contributions of the internal environment (hormones, diet, and circadian clock). Systemic drivers of disease, such as alterations of the endocrine system, metabolism, and aberrant control of developmental signaling, are emerging as new players in driving epithelial dysfunction and allergic predisposition at various barrier sites. Identifying such central mediators of epithelial dysfunction using both systems biology tools and causality-driven laboratory experimentation will be essential in building new strategic interventions to prevent or reverse the process of barrier loss in allergic patients.	[Schleimer, Robert P.; Berdnikovs, Sergejs] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, McGaw Bldg,Rm M-302,240 East Huron St, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Berdnikovs, S (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, McGaw Bldg,Rm M-302,240 East Huron St, Chicago, IL 60611 USA.	s-berdnikovs@northwestern.edu			National Institutes of Health; Intersect ENT; GlaxoSmithKline; Allakos; Aurasense; Sanofi; AstraZEneca/MedImmune; Genentech; Otsuka Inc; NIH [1R21AI115055-01A1, 1R01AI127783-01, U19AI106683]; Bazley; Nemacolin International Asthma Conference; Rush University Seminar Series; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI115055, U19AI106683, R01AI127783] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intersect ENT; GlaxoSmithKline(GlaxoSmithKline); Allakos; Aurasense; Sanofi(Sanofi-Aventis); AstraZEneca/MedImmune(AstraZeneca); Genentech(Roche HoldingGenentech); Otsuka Inc; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bazley; Nemacolin International Asthma Conference; Rush University Seminar Series; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	R. P. Schleimer has received a grant from the National Institutes of Health; has received personal fees Intersect ENT, GlaxoSmithKline, Allakos, Aurasense, Sanofi, AstraZEneca/MedImmune, Genentech, and Otsuka Inc; has stock/stock options with BioMark, Allakos, Aurasense, and Excicure Inc; and has patents related to Siglec-8 and Siglec-8 ligand and may receive royalties for those patents. S. Berdnikovs receives grant support from the NIH (1R21AI115055-01A1, 1R01AI127783-01, and U19AI106683) and Bazley; and receives payments for lectures from Nemacolin International Asthma Conference 2016 and Rush University Seminar Series 2016.	Abdulnour-Nakhoul SM, 2013, CLIN IMMUNOL, V148, P265, DOI 10.1016/j.clim.2013.05.004; Adli M, 2015, J CELL BIOCHEM, V116, P893, DOI 10.1002/jcb.25048; Ahrens K, 2011, J INVEST DERMATOL, V131, P443, DOI 10.1038/jid.2010.289; Alduraywish SA, 2016, ALLERGY, V71, P77, DOI 10.1111/all.12784; Alduraywish SA, 2017, PEDIAT ALLERG IMM-UK, V28, P30, DOI 10.1111/pai.12651; Allen JE, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002003; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Bains SN, 2012, ALLERGY, V67, P1601, DOI 10.1111/all.12021; Balenga NA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7763; Barreto-Luis A, 2017, CLIN EXP ALLERGY; Bartis D, 2014, THORAX, V69, P760, DOI 10.1136/thoraxjnl-2013-204608; Batra H, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00284; Berdnikovs S., 2014, 2014 AAAAI ANN M MIL; Berdnikovs S, 2017, J ALLERGY CLIN IMMUN, V139, pAB263, DOI 10.1016/j.jaci.2016.12.849; Berdnikovs S, 2015, J IMMUNOL, V194; Bernstein JM, 1997, J ALLERGY CLIN IMMUN, V99, P165, DOI 10.1016/S0091-6749(97)70091-5; Blanchard C, 2010, J IMMUNOL, V184, P4033, DOI 10.4049/jimmunol.0903069; Bochkov YA, 2015, P NATL ACAD SCI USA, V112, P5485, DOI 10.1073/pnas.1421178112; Brunner PM, 2017, J INVEST DERMATOL, V137, P18, DOI 10.1016/j.jid.2016.08.022; Cavazza A, 2016, STEM CELL REP, V6, P618, DOI 10.1016/j.stemcr.2016.03.003; Chan LS, 2001, J INVEST DERMATOL, V117, P977, DOI 10.1046/j.0022-202x.2001.01484.x; Chanda D, 2016, SCI REP-UK, V6, DOI 10.1038/srep37445; Chen HY, 2014, STEROIDS, V80, P44, DOI 10.1016/j.steroids.2013.12.001; Cheng E, 2012, AM J PHYSIOL-GASTR L, V303, pG1175, DOI 10.1152/ajpgi.00313.2012; Chittock J, 2016, BRIT J DERMATOL, V175, P713, DOI 10.1111/bjd.14568; Davies DE, 2002, INT J BIOCHEM CELL B, V34, P1520, DOI 10.1016/S1357-2725(02)00048-1; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Dejima K, 2006, ARCH OTOLARYNGOL, V132, P1352, DOI 10.1001/archotol.132.12.1352; Demehri S, 2008, PLOS BIOL, V6, P992, DOI 10.1371/journal.pbio.0060123; Donohue KM, 2013, J ALLERGY CLIN IMMUN, V131, P736, DOI 10.1016/j.jaci.2012.12.1573; Draijer C, 2016, AM J PHYSIOL-LUNG C, V310, pL166, DOI 10.1152/ajplung.00119.2015; Egawa G, 2016, J ALLERGY CLIN IMMUN, V138, P350, DOI 10.1016/j.jaci.2016.06.002; Elliott EN, 2015, CELL MOL LIFE SCI, V72, P4139, DOI 10.1007/s00018-015-1997-9; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Evans CM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7281; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fischer KD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149180; Folmes CDL, 2016, SEMIN CELL DEV BIOL, V52, P68, DOI 10.1016/j.semcdb.2016.02.010; Friedmann Peter S, 2014, Exp Suppl, V104, P51, DOI 10.1007/978-3-0348-0726-5_5; Furmanski AL, 2013, J IMMUNOL, V190, P2641, DOI 10.4049/jimmunol.1202541; Galand C, 2016, J ALLERGY CLIN IMMUN, V138, P1356, DOI 10.1016/j.jaci.2016.03.056; Galvis LA, 2015, DEVELOPMENT, V142, P1458, DOI 10.1242/dev.122077; Garmendia JV, 2014, RECENT PATENTS ENDOC, V8, P60, DOI 10.2174/1872214807666140107151023; Gause WC, 2013, NAT REV IMMUNOL, V13, P607, DOI 10.1038/nri3476; Ge Q, 2015, AM J PHYSIOL-LUNG C, V309, pL1093, DOI 10.1152/ajplung.00019.2015; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Gunschmann C, 2013, DEV CELL, V26, P176, DOI 10.1016/j.devcel.2013.05.017; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hackett TL, 2007, CURR OPIN ALLERGY CL, V7, P63, DOI 10.1097/ACI.0b013e328013d61b; Hackett TL, 2012, CURR OPIN ALLERGY CL, V12, P53, DOI 10.1097/ACI.0b013e32834ec6eb; Hackett TL, 2009, AM J RESP CRIT CARE, V180, P122, DOI 10.1164/rccm.200811-1730OC; Hansmann B, 2012, EXP DERMATOL, V21, P271, DOI 10.1111/j.1600-0625.2012.01449.x; Heijink IH, 2007, J IMMUNOL, V178, P7678, DOI 10.4049/jimmunol.178.12.7678; Hirano M, 2013, ENVIRON TOXICOL, V28, P652, DOI 10.1002/tox.20761; Honkova L, 2014, PEDIAT ALLERG IMM-UK, V25, P593, DOI 10.1111/pai.12275; Horimukai K, 2016, ALLERGOL INT, V65, P103, DOI 10.1016/j.alit.2015.09.004; Huang CC, 2015, BRIT J DERMATOL, V173, P981, DOI 10.1111/bjd.14039; Huang L, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005347; Ijaz T, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-13; Izuhara K, 2016, ALLERGY ASTHMA IMMUN, V8, P491, DOI 10.4168/aair.2016.8.6.491; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jang YJ, 2002, EUR ARCH OTO-RHINO-L, V259, P465, DOI 10.1007/s00405-002-0500-z; Janssens M, 2012, J LIPID RES, V53, P2755, DOI 10.1194/jlr.P030338; Jeffery Peter K, 2004, Proc Am Thorac Soc, V1, P176, DOI 10.1513/pats.200402-009MS; Ji H, 2015, J ALLERGY CLIN IMMUN, V135, P236, DOI 10.1016/j.jaci.2014.08.038; Johnson JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016175; Joo KM, 2015, J DERMATOL SCI, V77, P71, DOI 10.1016/j.jdermsci.2014.10.001; Kagalwalla AF, 2012, J ALLERGY CLIN IMMUN, V129, P1387, DOI 10.1016/j.jaci.2012.03.005; Kale SL, 2017, SCI REP-UK, V7, DOI 10.1038/srep42341; Kalita M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/505864; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Kelleher MM, 2016, J ALLERGY CLIN IMMUN, V137, P1111, DOI 10.1016/j.jaci.2015.12.1312; Kicic A, 2006, AM J RESP CRIT CARE, V174, P1110, DOI 10.1164/rccm.200603-392OC; Klok EJ, 1998, EXP EYE RES, V67, P425, DOI 10.1006/exer.1998.0534; Kypriotou M, 2012, EXP DERMATOL, V21, P643, DOI 10.1111/j.1600-0625.2012.01472.x; Lachowicz-Scroggins ME, 2016, AM J RESP CRIT CARE, V194, P1296; Lafkas D, 2015, NATURE, V528, P127, DOI 10.1038/nature15715; Larkin EK, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0040-0; Lavoie-Charland E, 2016, J ASTHMA, V53, P907, DOI 10.3109/02770903.2016.1165699; Lee HJ, 2016, AM J RHINOL ALLERGY, V30, P173, DOI 10.2500/ajra.2016.30.4295; Lee JJ, 2010, CLIN EXP ALLERGY, V40, P563, DOI 10.1111/j.1365-2222.2010.03484.x; Levy BD, 2005, AM J RESP CRIT CARE, V172, P824, DOI 10.1164/rccm.200410-1413OC; Li S, 2017, BR J DERMATOL; Liu WC, 2017, J NEUROSURG, V127, P8, DOI 10.3171/2016.4.JNS152909; Maki RG, 2010, J CLIN ONCOL, V28, P4985, DOI 10.1200/JCO.2009.27.5040; Meng J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082373; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moheimani F, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0434-4; Morishita R, 2016, J ASTHMA, V53, P478, DOI 10.3109/02770903.2015.1113544; MULLIN GE, 1986, AM FAM PHYSICIAN, V34, P93; Naquet P, 2016, CURR OPIN IMMUNOL, V38, P30, DOI 10.1016/j.coi.2015.10.005; Noti M, 2014, J ALLERGY CLIN IMMUN, V133, P1390, DOI 10.1016/j.jaci.2014.01.021; Ober C, 2016, ANN AM THORAC SOC, V13, pS85, DOI 10.1513/AnnalsATS.201507-459MG; Odze RD, 2009, AM J GASTROENTEROL, V104, P485, DOI 10.1038/ajg.2008.40; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517, DOI 10.1164/ajrccm.163.2.2004039; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Paulenda T, 2016, ALLERGY, V71, P918, DOI 10.1111/all.12877; Paulose T, 2015, REPROD TOXICOL, V54, P58, DOI 10.1016/j.reprotox.2014.09.012; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; PERSSON CGA, 1991, CLIN EXP ALLERGY, V21, P17, DOI 10.1111/j.1365-2222.1991.tb00799.x; Pothoven KL, 2015, J ALLERGY CLIN IMMUN, V136, P737, DOI 10.1016/j.jaci.2015.01.043; Pothoven KL, 2016, J ALLERGY CLIN IMMUN; Ravelli AM, 2006, J PEDIATR GASTR NUTR, V42, P510, DOI 10.1097/01.mpg.0000215312.78664.b9; Rezaee F, 2013, J VIROL, V87, P11088, DOI 10.1128/JVI.01573-13; Roarty K, 2010, CURR OPIN PHARMACOL, V10, P643, DOI 10.1016/j.coph.2010.07.004; Rogers GA, 2011, INT FORUM ALLERGY RH, V1, P50, DOI 10.1002/alr.20014; Rosekrans SL, 2015, AM J PHYSIOL-GASTR L, V309, pG216, DOI 10.1152/ajpgi.00088.2015; Runswick S, 2007, RESPIROLOGY, V12, P834, DOI 10.1111/j.1440-1843.2007.01175.x; Ryall JG, 2015, CELL STEM CELL, V17, P651, DOI 10.1016/j.stem.2015.11.012; Sajjan U, 2008, AM J RESP CRIT CARE, V178, P1271, DOI 10.1164/rccm.200801-136OC; Salazar JJ, 2016, J DIABETES COMPLICAT, V30, P746, DOI 10.1016/j.jdiacomp.2015.12.017; Schleimer RP, 2017, ANNU REV PATHOL-MECH, V12, P331, DOI 10.1146/annurev-pathol-052016-100401; Selman M, 2008, PLOS MED, V5, P373, DOI 10.1371/journal.pmed.0050062; Sevilla LM, 2013, J INVEST DERMATOL, V133, P361, DOI 10.1038/jid.2012.281; Shahana S, 2006, RESP MED, V100, P2018, DOI 10.1016/j.rmed.2006.02.012; Sherrill JD, 2014, MUCOSAL IMMUNOL, V7, P718, DOI 10.1038/mi.2013.90; Shi W, 2009, RESPIROLOGY, V14, P656, DOI 10.1111/j.1440-1843.2009.01565.x; Shikani AH, 2014, AM J OTOLARYNG, V35, P377, DOI 10.1016/j.amjoto.2013.11.011; Song H, 2016, J ALLERGY CLIN IMMUN, V137, P852, DOI 10.1016/j.jaci.2015.08.021; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Steelant B, 2016, J ALLERGY CLIN IMMUN, V137, P1043, DOI 10.1016/j.jaci.2015.10.050; Stefanowicz D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044213; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Stentzel S, 2017, J ALLERGY CLIN IMMUN, V139, P492, DOI 10.1016/j.jaci.2016.03.045; Stremnitzer C, 2014, ALLERGY, V69, P741, DOI 10.1111/all.12399; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Sweerus K, 2017, J ALLERGY CLIN IMMUN, V139, P72, DOI 10.1016/j.jaci.2016.02.035; Tang KT, 2017, ANN ALLERG ASTHMA IM, V118, P351, DOI 10.1016/j.anai.2016.12.005; Thuesen BH, 2009, CLIN EXP ALLERGY, V39, P700, DOI 10.1111/j.1365-2222.2008.03197.x; Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014; Tokumasu R, 2016, P NATL ACAD SCI USA, V113, pE4061, DOI 10.1073/pnas.1525474113; Tomazic PV, 2014, J ALLERGY CLIN IMMUN, V133, P741, DOI 10.1016/j.jaci.2013.09.040; Trautmann A, 2005, INT ARCH ALLERGY IMM, V138, P142, DOI 10.1159/000088436; Tsurikisawa N, 2010, J ASTHMA, V47, P841, DOI 10.3109/02770903.2010.504876; van den Bogaard EH, 2015, J INVEST DERMATOL, V135, P1320, DOI 10.1038/jid.2015.6; van Drongelen V, 2013, EXP DERMATOL, V22, P807, DOI 10.1111/exd.12271; van Smeden J, 2014, EXP DERMATOL, V23, P45, DOI 10.1111/exd.12293; Vinhas R, 2011, ALLERGY, V66, P1088, DOI 10.1111/j.1398-9995.2011.02598.x; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wang ZX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051262; Wawrzyniak P, 2017, J ALLERGY CLIN IMMUN, V139, P93, DOI 10.1016/j.jaci.2016.03.050; Weber S, 2011, DEVELOPMENT, V138, P495, DOI 10.1242/dev.055210; Wight T.N., 2016, MATRIX BIOL; Williamson PA, 2011, CLIN EXP ALLERGY, V41, P1379, DOI 10.1111/j.1365-2222.2011.03793.x; Wilson SJ, 2013, CLIN EXP ALLERGY, V43, P1342, DOI 10.1111/cea.12156; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Yu HS, 2015, J ALLERGY CLIN IMMUN, V135, P827, DOI 10.1016/j.jaci.2014.10.040; Yuki T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161759; Zehethofer N, 2015, CHROMATOGRAPHIA, V78, P403, DOI 10.1007/s10337-014-2787-5; Zhang N, 2016, ALLERGY, V71, P295, DOI 10.1111/all.12809; Zhou CJ, 2011, J ASTHMA, V48, P358, DOI 10.3109/02770903.2011.565848; Zhou J, 2015, INT J CLIN EXP PATHO, V8, P11132	153	85	87	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1752	1761		10.1016/j.jaci.2017.04.010	http://dx.doi.org/10.1016/j.jaci.2017.04.010			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	28583447	Green Accepted, hybrid			2022-12-18	WOS:000402724600003
J	Sordillo, JE; Zhou, YJ; McGeachie, MJ; Ziniti, J; Lange, N; Laranjo, N; Savage, JR; Carey, V; O'Connor, G; Sandel, M; Strunk, R; Bacharier, L; Zeiger, R; Weiss, ST; Weinstock, G; Gold, DR; Litonjua, AA				Sordillo, Joanne E.; Zhou, Yanjiao; McGeachie, Michael J.; Ziniti, John; Lange, Nancy; Laranjo, Nancy; Savage, Jessica R.; Carey, Vincent; O'Connor, George; Sandel, Megan; Strunk, Robert; Bacharier, Leonard; Zeiger, Robert; Weiss, Scott T.; Weinstock, George; Gold, Diane R.; Litonjua, Augusto A.			Factors influencing the infant gut microbiome at age 3-6 months: Findings from the ethnically diverse Vitamin D Antenatal Asthma Reduction Trial (VDAART)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Infant gut microbiome; C-section; race; breast-feeding	INTESTINAL MICROBIOTA; IGE PRODUCTION; BACTERIA; MICROFLORA; RESPONSES; DELIVERY; DISEASE; MOTHERS; SHAPES; HEALTH	Background: The gut microbiome in infancy influences immune system maturation, and may have an important impact on allergic disease risk. Objective: We sought to determine how prenatal and early life factors impact the gut microbiome in a relatively large, ethnically diverse study population of infants at age 3 to 6 months, who were enrolled in Vitamin D Antenatal Asthma Reduction Trial, a clinical trial of vitamin D supplementation in pregnancy to prevent asthma and allergies in offspring. Methods: We performed 16S rRNA gene sequencing on 333 infants' stool samples. Microbial diversity was computed using the Shannon index. Factor analysis applied to the top 25 most abundant taxa revealed 4 underlying bacterial coabundance groups; the first dominated by Firmicutes (Lachnospiraceae/ Clostridiales), the second by Proteobacteria (Klebsiella/ Enterobacter), the third by Bacteriodetes, and the fourth by Veillonella. Scores for coabundance groups were used as outcomes in regression models, with prenatal/birth and demographic characteristics as independent predictors. Multivariate analysis, using all microbial community members, was also conducted. Results: White race/ethnicity was associated with lower diversity but higher Bacteroidetes coabundance scores. C-section birth was associated with higher diversity, but decreased Bacteroidetes coabundance scores. Firmicutes scores were higher for infants born by C-section. Breast-fed infants had lower proportions of Clostridiales. Cord blood vitamin D was linked to increased Lachnobacterium, but decreased Lactococcus. Conclusions: The findings presented here suggest that race, mode of delivery, breast-feeding, and cord blood vitamin D levels are associated with infant gut microbiome composition, with possible long-term implications for immune system modulation and asthma/allergic disease incidence.	[Sordillo, Joanne E.; McGeachie, Michael J.; Ziniti, John; Lange, Nancy; Laranjo, Nancy; Carey, Vincent; Weiss, Scott T.; Gold, Diane R.; Litonjua, Augusto A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Sordillo, Joanne E.; McGeachie, Michael J.; Ziniti, John; Lange, Nancy; Laranjo, Nancy; Carey, Vincent; Weiss, Scott T.; Gold, Diane R.; Litonjua, Augusto A.] Harvard Med Sch, Boston, MA 02115 USA; [Zhou, Yanjiao] Jackson Lab, Farmington, CT USA; [Savage, Jessica R.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [O'Connor, George; Sandel, Megan] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Strunk, Robert; Bacharier, Leonard] Washington Univ, Div Allergy Immunol & Pulm Med, St Louis, MO USA; [Zeiger, Robert] Kaiser Permanente, San Diego, CA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Jackson Laboratory; Harvard University; Brigham & Women's Hospital; Boston University; Washington University (WUSTL); Kaiser Permanente	Litonjua, AA (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Litonjua, AA (corresponding author), Brigham & Womens Hosp, Channing Div Network, 75 Francis St, Boston, MA 02115 USA.	reaal@channing.harvard.edu	Weinstock, George M/C-6314-2013	Weinstock, George M/0000-0002-2997-4592; Zeiger, Robert/0000-0001-5788-5063; Bacharier, Leonard/0000-0003-0432-2704	National Institutes of Health [U01HL091528, R01HL108818]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL091528, R01HL108818, R01HL091075] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by National Institutes of Health grant numbers U01HL091528 and R01HL108818.	Abrahamsson TR, 2014, CLIN EXP ALLERGY, V44, P842, DOI 10.1111/cea.12253; Azad MB, 2016, BJOG-INT J OBSTET GY, V123, P983, DOI 10.1111/1471-0528.13601; Azad MB, 2013, CAN MED ASSOC J, V185, P385, DOI 10.1503/cmaj.121189; Bezirtzoglou E, 1997, ANAEROBE, V3, P173, DOI 10.1006/anae.1997.0102; Biasucci G, 2010, EARLY HUM DEV, V86, pS13, DOI 10.1016/j.earlhumdev.2010.01.004; Bode L, 2009, NUTR REV, V67, pS183, DOI 10.1111/j.1753-4887.2009.00239.x; DiGiulio DB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003056; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Gronlund MM, 2011, GUT MICROBES, V2, P227, DOI 10.4161/gmic.2.4.16799; Guarner F, 2003, LANCET, V361, P512, DOI 10.1016/S0140-6736(03)12489-0; Hanson LA, 2007, P NUTR SOC, V66, P384, DOI 10.1017/S0029665107005654; Hesla HM, 2014, FEMS MICROBIOL ECOL, V90, P791, DOI 10.1111/1574-6941.12434; Jakobsson HE, 2014, GUT, V63, P559, DOI 10.1136/gutjnl-2012-303249; Jimenez E, 2005, CURR MICROBIOL, V51, P270, DOI 10.1007/s00284-005-0020-3; Jin DP, 2015, CLIN THER, V37, P996, DOI 10.1016/j.clinthera.2015.04.004; Johansson MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023031; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; La Rosa PS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048996; Litonjua AA, 2014, CONTEMP CLIN TRIALS, V38, P37, DOI 10.1016/j.cct.2014.02.006; Matamoros S, 2013, TRENDS MICROBIOL, V21, P167, DOI 10.1016/j.tim.2012.12.001; Maynard CL, 2012, NATURE, V489, P231, DOI 10.1038/nature11551; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; Morgan XC, 2014, GASTROENTEROLOGY, V146, P1437, DOI 10.1053/j.gastro.2014.01.049; Morgan XC, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002808; Morgan XC, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r79; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; Ochoa-Reparaz J, 2010, J IMMUNOL, V185, P4101, DOI 10.4049/jimmunol.1001443; Ooi JH, 2013, J NUTR, V143, P1679, DOI 10.3945/jn.113.180794; Penders J, 2013, J ALLERGY CLIN IMMUN, V132, P601, DOI 10.1016/j.jaci.2013.05.043; Rask C, 2005, SCAND J IMMUNOL, V61, P529, DOI 10.1111/j.1365-3083.2005.01598.x; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; Salminen S, 1998, BRIT J NUTR, V80, pS147, DOI 10.1079/BJN19980108; Shida K, 2002, CLIN EXP ALLERGY, V32, P563, DOI 10.1046/j.0954-7894.2002.01354.x; Strauch UG, 2005, GUT, V54, P1546, DOI 10.1136/gut.2004.059451; Sudo N, 1997, J IMMUNOL, V159, P1739; Valles Y, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004406; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; Young VB, 2012, CURR OPIN GASTROEN, V28, P63, DOI 10.1097/MOG.0b013e32834d61e9	39	85	89	2	47	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					482	+		10.1016/j.jaci.2016.08.045	http://dx.doi.org/10.1016/j.jaci.2016.08.045			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27746239	Green Accepted, Bronze			2022-12-18	WOS:000397002400014
J	Clifford, RL; Jones, MJ; Maclsaac, JL; McEwen, LM; Goodman, SJ; Mostafavi, S; Kobor, MS; Carlsten, C				Clifford, Rachel L.; Jones, Meaghan J.; Maclsaac, Julia L.; McEwen, Lisa M.; Goodman, Sarah J.; Mostafavi, Sara; Kobor, Michael S.; Carlsten, Chris			Inhalation of diesel exhaust and allergen alters human bronchial epithelium DNA methylation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; particulate matter; diesel exhaust; air pollution; epigenetics; DNA methylation	AIR-POLLUTION EXPOSURE; PARTICULATE MATTER; GENES; INFLAMMATION; EXPRESSION; CELLS; GAMMA; LUNG	Background: Allergic disease affects 30% to 40% of the world's population, and its development is determined by the interplay between environmental and inherited factors. Air pollution, primarily consisting of diesel exhaust emissions, has increased at a similar rate to allergic disease. Exposure to diesel exhaustmay play a role in the development and progression of allergic disease, in particular allergic respiratory disease. One potential mechanism underlying the connection between air pollution and increased allergic disease incidence isDNAmethylation, an epigenetic process with the capacity to integrate gene-environment interactions. Objective: We sought to investigate the effect of allergen and diesel exhaust exposure on bronchial epithelial DNA methylation. Methods: We performed a randomized crossover-controlled exposure study to allergen and diesel exhaust in humans, and measured single-site (CpG) resolution global DNA methylation in bronchial epithelial cells. Results: Exposure to allergen alone, diesel exhaust alone, or allergen and diesel exhaust together (coexposure) led to significant changes in 7 CpG sites at 48 hours. However, when the same lung was exposed to allergen and diesel exhaust but separated by approximately 4 weeks, significant changes in more than 500 sites were observed. Furthermore, sites of differential methylation differed depending on which exposure was experienced first. Functional analysis of differentially methylated CpG sites found genes involved in transcription factor activity, protein metabolism, cell adhesion, and vascular development, among others. Conclusions: These findings suggest that specific exposures can prime the lung for changes in DNA methylation induced by a subsequent insult.	[Clifford, Rachel L.; Jones, Meaghan J.; Maclsaac, Julia L.; McEwen, Lisa M.; Goodman, Sarah J.; Mostafavi, Sara; Kobor, Michael S.] Univ British Columbia, Child & Family Res Inst, Ctr Mol Med & Therapeut, Vancouver, BC, Canada; [Mostafavi, Sara] Univ British Columbia, Dept Stat, Vancouver, BC, Canada; [Mostafavi, Sara; Kobor, Michael S.] Canadian Inst Adv Res, Toronto, ON, Canada; [Kobor, Michael S.] Univ British Columbia, Sch Populat & Publ Hlth, Human Early Learning Partnership, Vancouver, BC, Canada; [Kobor, Michael S.] Univ British Columbia, Chan Yeung Ctr Occupat & Environm Lung Dis, Air Pollut Exposure Lab, Div Resp Med,Dept Med, Vancouver, BC, Canada; [Clifford, Rachel L.] Univ Nottingham, Dept Resp Med, Nottingham, England; [Clifford, Rachel L.] Univ Nottingham, Nottingham Resp Res Unit, Nottingham, England	Child & Family Research Institute; University of British Columbia; University of British Columbia; Canadian Institute for Advanced Research (CIFAR); University of British Columbia; University of British Columbia; University of Nottingham; University of Nottingham	Carlsten, C (corresponding author), 2775 Laurel St,7th Fl, Vancouver, BC V5Z 1M9, Canada.	carlsten@mail.ubc.ca	Jones, Meaghan J/J-7672-2017	Jones, Meaghan J/0000-0003-1593-997X; McEwen, Lisa M/0000-0002-0500-9173; Kobor, Michael/0000-0003-4140-1743	Canadian Institutes for Health Research [MOP 123319]; WorkSafe BC [RG2011-OG07]; AllerGen NCE; European Respiratory Society (ERS); Canadian Thoracic Surgery (CTS)/Canadian Lung Association	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); WorkSafe BC; AllerGen NCE; European Respiratory Society (ERS); Canadian Thoracic Surgery (CTS)/Canadian Lung Association	This project was supported by funding from the Canadian Institutes for Health Research (MOP 123319), WorkSafe BC (RG2011-OG07), AllerGen NCE (GxE2; GxE4), the European Respiratory Society (ERS) and the Canadian Thoracic Surgery (CTS)/Canadian Lung Association, joint ERS/CTS Long-Term Research Fellowship LTRF 2013 (to R.L.C.), and a Mining for Miracles postdoctoral fellowship (to M.J.J.). C.C. is the Canada Research Chair in Occupational and Environmental Lung Disease. M.S.K. is the Canada Research Chair in Social Epigenetics and a Senior Fellow of the Canadian Institute for Advanced Research (CIFAR). S.M. is the Canada Research Chair in Computational Biology and a Fellow of CIFAR. The funding bodies had no involvement in the study design; collection, analysis, or interpretation of the data; the writing of the report; or the decision to submit the article for publication.	Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC; Begin P, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-27; Birger N, 2011, INHAL TOXICOL, V23, P219, DOI 10.3109/08958378.2011.562256; Boulet LP, 2015, CLIN EXP ALLERGY, V45, P1647, DOI 10.1111/cea.12587; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; Breton CV, 2012, ENVIRON HEALTH PERSP, V120, P1320, DOI 10.1289/ehp.1104439; Carlsten C, 2013, PLOS ONE, V8; Carlsten C, 2014, EMBO REP, V15, P736, DOI 10.15252/embr.201438480; Carlsten C, 2012, CURR OPIN ALLERGY CL, V12, P455, DOI 10.1097/ACI.0b013e328357cc55; Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Holloway JW, 2012, RESPIROLOGY, V17, P590, DOI 10.1111/j.1440-1843.2012.02164.x; HOTCHKISS RD, 1948, J BIOL CHEM, V175, P315; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jiang RW, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/s12989-014-0071-3; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Jones B, 2015, DESIGN ANAL CROSS OV; Jones MJ, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-58; Kohli A, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-17; Kunzli N, 2000, LANCET, V356, P795, DOI 10.1016/S0140-6736(00)02653-2; Lam LL, 2012, P NATL ACAD SCI USA, V109, P17253, DOI 10.1073/pnas.1121249109; Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034; Ludtke THW, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003189; Madrigano J, 2011, ENVIRON HEALTH PERSP, V119, P977, DOI 10.1289/ehp.1002773; Maes T, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-7; Maksimovic J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r44; Matthews J N, 1994, Stat Methods Med Res, V3, P383, DOI 10.1177/096228029400300405; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Medvedeva YA, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-48; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Packer AI, 2000, DEV DYNAM, V217, P62, DOI 10.1002/(SICI)1097-0177(200001)217:1<62::AID-DVDY6>3.0.CO;2-U; Pawankar R, 2011, WAO WHITE BOOK ALLER; Peden DB, 2014, J ALLERGY CLIN IMMUN, V133, P1265, DOI 10.1016/j.jaci.2014.02.027; Pinkerton KE, 2013, TURK THORAC J, V14, P115, DOI 10.5152/ttd.2013.54; Price EM, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-4; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Rossnerova A, 2013, MUTAT RES-FUND MOL M, V741, P18, DOI 10.1016/j.mrfmmm.2013.02.003; Schaumann F, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/s12989-014-0039-3; Senn S, 1993, CROSS OVER TRIALS CL, V2nd; Tang WY, 2012, ENVIRON HEALTH PERSP, V120, P1195, DOI 10.1289/ehp.1103744; Tarantini L, 2009, ENVIRON HEALTH PERSP, V117, P217, DOI 10.1289/ehp.11898; Yang SN, 2014, ALLERGY ASTHMA IMMUN, V6, P478, DOI 10.4168/aair.2014.6.6.478	44	85	87	2	66	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					112	121		10.1016/j.jaci.2016.03.046	http://dx.doi.org/10.1016/j.jaci.2016.03.046			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27321436	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000393996800013
J	Kobayashi, T; Iijima, K; Dent, AL; Kita, H				Kobayashi, Takao; Iijima, Koji; Dent, Alexander L.; Kita, Hirohito			Follicular helper T cells mediate IgE antibody response to airborne allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Follicular T cells; IL-4; IgE; allergy; allergens; T(H)2 cells	THYMIC STROMAL LYMPHOPOIETIN; INNATE LYMPHOID-CELLS; DENDRITIC CELLS; INDUCIBLE COSTIMULATOR; TH2 DIFFERENTIATION; EPITHELIAL-CELLS; IL-21; ICOS; INFLAMMATION; BCL6	Background: T(H)2 cells have long been believed to play a pivotal role in allergic immune responses, including IgE antibody production and type 2 cytokine-mediated inflammation and pathology. A new T-cell subset, follicular helper T (T-FH) cells, is specialized in supporting B-cell maturation and antibody production. Objective: We sought to investigate the roles of TFH cells in allergic immune responses. Methods: Naive mice were exposed to cytokines or natural allergens through the airways. Development of allergic immune responses was analyzed by collecting draining lymph nodes and sera and by challenging the animals. Cytokine reporter mice and gene-deficient mice were used to dissect the immunologic mechanisms. Results: We observed the development of IL-4-producing T-FH cells and T(H)2 cells in draining lymph nodes after airway exposure to IL-1 family cytokines or natural allergens. T-FH and T(H)2 cells demonstrated unique phenotypes, tissue localization, and cytokine responses. T-FH cells supported the sustained production of IgE antibody in vivo in the absence of other T-cell subsets or even when T(H)2 cell functions were severely compromised. Conversely, conditional deficiency of the master regulator Bcl6 in CD4(+) T cells resulted in a marked reduction in T-FH cell numbers and IgE antibody levels, but type 2 cytokine responses and eosinophilic inflammation in the airways remained unaffected. Conclusion: T-FH cells play critical roles in the regulation of IgE antibody production. Allergic immune responses to airborne allergens likely involve 2 distinct subsets of IL-4-producing CD4(+) T cells, namely T-FH and Th2 cells.	[Kobayashi, Takao; Iijima, Koji; Kita, Hirohito] Mayo Clin Rochester, Dept Med & Immunol, Rochester, MN USA; [Dent, Alexander L.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA	Mayo Clinic; Indiana University System; Indiana University Bloomington	Kita, H (corresponding author), Mayo Clin Rochester, Div Allerg Dis, Dept Med, 200 First St SW, Rochester, MN 55905 USA.; Kita, H (corresponding author), Mayo Clin Rochester, Dept Immunol, 200 First St SW, Rochester, MN 55905 USA.	kita.hirohito@mayo.edu			National Institutes of Health [R01 AI71106]; Mayo Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI071106] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institutes of Health (R01 AI71106) and the Mayo Foundation.	Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; Avery DT, 2008, BLOOD, V112, P1784, DOI 10.1182/blood-2008-02-142745; Bousquet J, 2006, ALLERGY, V61, P671, DOI 10.1111/j.1398-9995.2006.01048.x; Choi YS, 2015, NAT IMMUNOL, V16, P980, DOI 10.1038/ni.3226; Choi YS, 2011, IMMUNITY, V34, P932, DOI 10.1016/j.immuni.2011.03.023; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Corry DB, 1999, NATURE, V402, pB18; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Dent AL, 1998, P NATL ACAD SCI USA, V95, P13823, DOI 10.1073/pnas.95.23.13823; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; Douwes J, 2011, CURR ALLERGY ASTHM R, V11, P434, DOI 10.1007/s11882-011-0215-6; Eto D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017739; FINKELMAN FD, 1989, J IMMUNOL, V142, P403; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; Gajewska BU, 2005, J IMMUNOL, V174, P3000, DOI 10.4049/jimmunol.174.5.3000; Gonzalo JA, 2001, NAT IMMUNOL, V2, P597, DOI 10.1038/89739; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Harada Y, 2012, IMMUNITY, V36, P188, DOI 10.1016/j.immuni.2012.02.002; Hollister K, 2013, J IMMUNOL, V191, P3705, DOI 10.4049/jimmunol.1300378; Iijima K, 2014, J IMMUNOL, V193, P1549, DOI 10.4049/jimmunol.1302984; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; Kaji T, 2012, J EXP MED, V209, P2079, DOI 10.1084/jem.20120127; Karnowski A, 2012, J EXP MED, V209, P2049, DOI 10.1084/jem.20111504; Karp CL, 2010, J ALLERGY CLIN IMMUN, V125, P955, DOI 10.1016/j.jaci.2010.03.002; King C, 2009, NAT REV IMMUNOL, V9, P757, DOI 10.1038/nri2644; King IL, 2009, J EXP MED, V206, P1001, DOI 10.1084/jem.20090313; Kobayashi T, 2013, AM J RESP CELL MOL, V49, P989, DOI 10.1165/rcmb.2012-0444OC; Kobayashi T, 2009, J IMMUNOL, V182, P2502, DOI 10.4049/jimmunol.0802773; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Kusam S, 2003, J IMMUNOL, V170, P2435, DOI 10.4049/jimmunol.170.5.2435; Liang HE, 2012, NAT IMMUNOL, V13, P58, DOI 10.1038/ni.2182; Linterman MA, 2010, J EXP MED, V207, P353, DOI 10.1084/jem.20091738; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; Loke P, 2005, P NATL ACAD SCI USA, V102, P9872, DOI 10.1073/pnas.0503961102; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; McKenzie ANJ, 2014, IMMUNITY, V41, P366, DOI 10.1016/j.immuni.2014.09.006; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Mohrs K, 2005, IMMUNITY, V23, P419, DOI 10.1016/j.immuni.2005.09.006; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; Nurieva RI, 2008, IMMUNITY, V29, P138, DOI 10.1016/j.immuni.2008.05.009; Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Palm NW, 2012, NATURE, V484, P465, DOI 10.1038/nature11047; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; Plunkett G, 2008, CURR OPIN OTOLARYNGO, V16, P285, DOI 10.1097/MOO.0b013e3282ff62b0; Poholek AC, 2010, J IMMUNOL, V185, P313, DOI 10.4049/jimmunol.0904023; Reinhardt RL, 2009, NAT IMMUNOL, V10, P385, DOI 10.1038/ni.1715; Schenten D, 2014, IMMUNITY, V40, P78, DOI 10.1016/j.immuni.2013.10.023; Simpson TR, 2010, CURR OPIN IMMUNOL, V22, P326, DOI 10.1016/j.coi.2010.01.001; Suto A, 2002, BLOOD, V100, P4565, DOI 10.1182/blood-2002-04-1115; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; Tesciuba AG, 2001, J IMMUNOL, V167, P1996, DOI 10.4049/jimmunol.167.4.1996; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; Wood N, 2004, CELL IMMUNOL, V231, P133, DOI 10.1016/j.cellimm.2005.01.001; Wu LC, 2014, NAT REV IMMUNOL, V14, P247, DOI 10.1038/nri3632; Zaretsky AG, 2009, J EXP MED, V206, P991, DOI 10.1084/jem.20090303; Zotos D, 2010, J EXP MED, V207, P365, DOI 10.1084/jem.20091777	62	85	90	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					300	+		10.1016/j.jaci.2016.04.021	http://dx.doi.org/10.1016/j.jaci.2016.04.021			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27325434	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000393996800031
J	Lee, S; Moon, JS; Lee, CR; Kim, HE; Baek, SM; Hwang, S; Kang, GH; Seo, JK; Shin, CH; Kang, HJ; Ko, JS; Park, SG; Choi, M				Lee, Sangmoon; Moon, Jin Soo; Lee, Cho-Rong; Kim, Hye-Eun; Baek, Sun-Mi; Hwang, Solha; Kang, Gyeong Hoon; Seo, Jeong Kee; Shin, Choong Ho; Kang, Hyoung Jin; Ko, Jae Sung; Park, Sung Gyoo; Choi, Murim			Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNE DYSREGULATION; HEALTHY-CHILDREN; REFERENCE VALUES; T-CELLS; EXPRESSION; MUTATIONS; SUBSETS		[Lee, Sangmoon; Choi, Murim] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea; [Moon, Jin Soo; Hwang, Solha; Seo, Jeong Kee; Shin, Choong Ho; Kang, Hyoung Jin; Ko, Jae Sung; Choi, Murim] Seoul Natl Univ Hosp, Dept Pediat, Seoul 110744, South Korea; [Lee, Cho-Rong; Kim, Hye-Eun; Baek, Sun-Mi; Park, Sung Gyoo] Gwangju Inst Sci & Technol, Sch Life Sci, Kwangju, South Korea; [Lee, Cho-Rong; Kim, Hye-Eun; Baek, Sun-Mi; Park, Sung Gyoo] Gwangju Inst Sci & Technol, Integrat Aging Res Ctr, Kwangju, South Korea; [Kang, Gyeong Hoon] Seoul Natl Univ Hosp, Dept Pathol, Seoul 110744, South Korea; [Kang, Hyoung Jin] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Gwangju Institute of Science & Technology (GIST); Gwangju Institute of Science & Technology (GIST); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU)	Lee, S (corresponding author), Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.	kojs@snu.ac.kr; sgpark@gist.ac.kr; murimchoi@snu.ac.kr	Park, Sung-Gyoo/H-8652-2019; Ko, Jae Sung/ABD-2701-2021; Kang, Gyeong Hoon/F-1051-2010; Choi, Murim/AAP-9120-2021	Ko, Jae Sung/0000-0002-3064-2974; Kang, Gyeong Hoon/0000-0003-2380-6675; Kim, Hye-Eun/0000-0003-0401-7179; MOON, JIN SOO/0000-0001-9760-297X; Choi, Murim/0000-0002-9195-1455; Park, Sung-Gyoo/0000-0003-3702-5765				Chambers CA, 1997, IMMUNITY, V7, P885, DOI 10.1016/S1074-7613(00)80406-9; Gupta NK, 2014, J CLIN GASTROENTEROL, V48, P55, DOI 10.1097/MCG.0b013e3182a4e0ec; Huber S, 2004, J IMMUNOL, V173, P6526, DOI 10.4049/jimmunol.173.11.6526; JOLLIFF CR, 1982, CLIN CHEM, V28, P126; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; PEACH RJ, 1994, J EXP MED, V180, P2049, DOI 10.1084/jem.180.6.2049; Piatosa B, 2010, CYTOM PART B-CLIN CY, V78B, P372, DOI 10.1002/cyto.b.20536; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Stamper CC, 2001, NATURE, V410, P608, DOI 10.1038/35069118; Tang AL, 2008, J IMMUNOL, V181, P1806, DOI 10.4049/jimmunol.181.3.1806; Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479; Yu C, 2011, J BIOL CHEM, V286, P6685, DOI 10.1074/jbc.M110.182394	14	85	92	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					327	330		10.1016/j.jaci.2015.08.036	http://dx.doi.org/10.1016/j.jaci.2015.08.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26478010	hybrid			2022-12-18	WOS:000367724300032
J	Salzer, E; Kansu, A; Sic, H; Majek, P; Ikinciogullari, A; Dogu, FE; Prengemann, NK; Santos-Valente, E; Pickl, WF; Bilic, I; Ban, SA; Kuloglu, Z; Demir, AM; Ensari, A; Colinge, J; Rizzi, M; Eibel, H; Boztug, K				Salzer, Elisabeth; Kansu, Aydan; Sic, Heiko; Majek, Peter; Ikinciogullari, Aydan; Dogu, Figen E.; Prengemann, Nina Kathrin; Santos-Valente, Elisangela; Pickl, Winfried F.; Bilic, Ivan; Ban, Sol A.; Kuloglu, Zarife; Demir, Arzu Meltem; Ensari, Arzu; Colinge, Jacques; Rizzi, Marta; Eibel, Hermann; Boztug, Kaan			Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-21; early-onset inflammatory bowel disease; common variable immunodeficiency; exome sequencing	RENAL-CELL CARCINOMA; INTERLEUKIN-21 RECEPTOR; METASTATIC MELANOMA; NK CELLS; B-CELLS; PHASE-I; MATURATION; MUTATIONS; PROTEIN; IMMUNOGLOBULIN	Background: Alterations of immune homeostasis in the gut can result in development of inflammatory bowel disease (IBD). Recently, Mendelian forms of IBD have been discovered, as exemplified by deficiency of IL-10 or its receptor subunits. In addition, other types of primary immunodeficiency disorders might be associated with intestinal inflammation as one of their leading clinical presentations. Objective: We investigated a large consanguineous family with 3 children who presented with early-onset IBD within the first year of life, leading to death in infancy in 2 of them. Methods: Homozygosity mapping combined with exome sequencing was performed to identify the molecular cause of the disorder. Functional experiments were performed to assess the effect of IL-21 on the immune system. Results: A homozygous mutation in IL21 was discovered that showed perfect segregation with the disease. Deficiency of IL-21 resulted in reduced numbers of circulating CD19(+) B cells, including IgM(+) naive and class-switched IgG memory B cells, with a concomitant increase in transitional B-cell numbers. In vitro assays demonstrated that mutant IL-21(Leu49Pro) did not induce signal transducer and activator of transcription 3 phosphorylation and immunoglobulin class-switch recombination. Conclusion: Our study uncovers IL-21 deficiency as a novel cause of early-onset IBD in human subjects accompanied by defects in B-cell development similar to those found in patients with common variable immunodeficiency. IBD might mask an underlying primary immunodeficiency, as illustrated here with IL-21 deficiency.	[Salzer, Elisabeth; Majek, Peter; Prengemann, Nina Kathrin; Santos-Valente, Elisangela; Bilic, Ivan; Ban, Sol A.; Colinge, Jacques; Boztug, Kaan] Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1090 Vienna, Austria; [Kansu, Aydan; Kuloglu, Zarife; Demir, Arzu Meltem] Ankara Univ, Dept Pediat Gastroenterol, TR-06100 Ankara, Turkey; [Ikinciogullari, Aydan; Dogu, Figen E.] Ankara Univ, Dept Pediat Immunol, TR-06100 Ankara, Turkey; [Ensari, Arzu] Ankara Univ, Dept Pathol, TR-06100 Ankara, Turkey; [Sic, Heiko; Rizzi, Marta; Eibel, Hermann] Univ Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany; [Boztug, Kaan] Med Univ Vienna, Dept Pediat & Adolescent Med, Vienna, Austria	Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Ankara University; Ankara University; Ankara University; University of Freiburg; Medical University of Vienna	Boztug, K (corresponding author), Austrian Acad Sci, CeMM Res Ctr Mol Med, Lazarettgasse 14 AKH BT 25-3, A-1090 Vienna, Austria.	kboztug@cemm.oeaw.ac.at	ensari, arzu/AAQ-2826-2020; Boztug, Kaan/AAM-4161-2021; Kuloglu, Zarife/AAG-8210-2020; Colinge, Jacques/D-1578-2017; Demir, Arzu Meltem/GRY-6737-2022; Colinge, Jacques/Z-2613-2019; Rizzi, Marta/ABE-7264-2020; Dogu, Figen/AAI-1316-2020; İkinciogullari, Aydan/AAQ-3841-2020; Salzer, Elisabeth/G-8066-2017	ensari, arzu/0000-0001-7036-4457; Boztug, Kaan/0000-0001-8387-9185; Colinge, Jacques/0000-0003-2466-4824; Demir, Arzu Meltem/0000-0002-9176-9100; Colinge, Jacques/0000-0003-2466-4824; Dogu, Figen/0000-0002-7869-4941; İkinciogullari, Aydan/0000-0003-1145-0843; Serwas, Nina/0000-0003-2243-5446; Kuloglu, Zarife/0000-0001-9442-7790; KANSU, AYDAN/0000-0002-3133-9846; Pickl, Winfried F./0000-0003-0430-4952; Salzer, Elisabeth/0000-0002-8118-4934; Rizzi, Marta/0000-0002-5153-6089; Santos-Valente, Elisangela/0000-0001-7074-7482	Austrian Science Fund (FWF) [P24999]; German ministry for Research and Technology; German Cancer Research fund [1098935]; German Federal Ministry of Education and Research (BMBF) [01 EO 0803]; Austrian Science Fund (FWF) [P 24999] Funding Source: researchfish	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); German ministry for Research and Technology; German Cancer Research fund; German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	Supported by funding from the Austrian Science Fund (FWF; grant no. P24999 to K. B.) and the German ministry for Research and Technology, the German Cancer Research fund (grant 1098935, both to H. E.), as well as the German Federal Ministry of Education and Research (BMBF 01 EO 0803; to M.R.).	Agarwal P, 2012, J BIOL CHEM, V287, P22549, DOI 10.1074/jbc.M111.335935; Agarwal S, 2011, INFLAMM BOWEL DIS, V17, P251, DOI 10.1002/ibd.21376; Alangari A, 2012, J ALLERGY CLIN IMMUN, V130, P481, DOI 10.1016/j.jaci.2012.05.043; Arkwright PD, 2002, BLOOD, V99, P2694, DOI 10.1182/blood.V99.8.2694; Barzaghi F, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00211; Bechtel M, 2012, FASEB J, V26, P3637, DOI 10.1096/fj.11-194597; Begin P, 2013, J CLIN IMMUNOL, V33, P520, DOI 10.1007/s10875-012-9833-6; Bondensgaard K, 2007, J BIOL CHEM, V282, P23326, DOI 10.1074/jbc.M701313200; Brady J, 2004, J IMMUNOL, V172, P2048, DOI 10.4049/jimmunol.172.4.2048; Brandt K, 2003, BLOOD, V102, P4090, DOI 10.1182/blood-2003-03-0669; Brandt K, 2003, J INVEST DERMATOL, V121, P1379, DOI 10.1046/j.1523-1747.2003.12603.x; Brant SR, 2011, INFLAMM BOWEL DIS, V17, P1, DOI 10.1002/ibd.21385; Bussone G, 2009, AUTOIMMUN REV, V8, P332, DOI 10.1016/j.autrev.2008.11.004; Cho JH, 2008, NAT REV IMMUNOL, V8, P458, DOI 10.1038/nri2340; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; Distler JHW, 2005, ARTHRITIS RHEUM-US, V52, P856, DOI 10.1002/art.20883; Dupuis-Girod S, 2003, PEDIATRICS, V111, pE622, DOI 10.1542/peds.111.5.e622; ELBER R, 1995, COMPUT PHYS COMMUN, V91, P159, DOI 10.1016/0010-4655(95)00047-J; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Glocker E, 2012, CELL MOL LIFE SCI, V69, P41, DOI 10.1007/s00018-011-0837-9; Glocker EO, 2010, LANCET, V376, P1272, DOI 10.1016/S0140-6736(10)61008-2; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Hamming OJ, 2012, J BIOL CHEM, V287, P9454, DOI 10.1074/jbc.M111.311084; Hashmi MH, 2010, EXPERT OPIN BIOL TH, V10, P807, DOI 10.1517/14712598.2010.480971; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Kienzler AK, 2013, J ALLERGY CLIN IMMUN, V131, P1695, DOI 10.1016/j.jaci.2013.01.018; Kotlarz D, 2013, J EXP MED, V210, P433, DOI 10.1084/jem.20111229; Kotlarz D, 2012, GASTROENTEROLOGY, V143, P347, DOI 10.1053/j.gastro.2012.04.045; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Leonard WJ, 2005, NAT REV IMMUNOL, V5, P688, DOI 10.1038/nri1688; Li J, 2011, MOL BIOL REP, V38, P4077, DOI 10.1007/s11033-010-0527-y; Lichtmann AHAAK, 2003, CELLULAR MOL IMMUNOL; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Lin Q, 1998, J IMMUNOL, V160, P4681; Majek P, 2009, PROTEINS, V76, P822, DOI 10.1002/prot.22388; Marks DJB, 2009, AM J GASTROENTEROL, V104, P117, DOI 10.1038/ajg.2008.72; Monteleone G, 2009, TRENDS PHARMACOL SCI, V30, P441, DOI 10.1016/j.tips.2009.05.006; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; PANNETIER C, 1995, IMMUNOL TODAY, V16, P176, DOI 10.1016/0167-5699(95)80117-0; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; Parthiban V, 2006, NUCLEIC ACIDS RES, V34, pW239, DOI 10.1093/nar/gkl190; Pene J, 2004, J IMMUNOL, V172, P5154, DOI 10.4049/jimmunol.172.9.5154; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Puga I, 2012, NAT IMMUNOL, V13, P170, DOI 10.1038/ni.2194; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Rankin AL, 2011, J IMMUNOL, V186, P667, DOI 10.4049/jimmunol.0903207; Rodrigues F, 2004, J PEDIATR-US, V145, P333, DOI 10.1016/j.jpeds.2004.05.037; Salzer E, 2013, HAEMATOLOGICA, V98, P473, DOI 10.3324/haematol.2012.068791; Sarra M, 2011, EXPERT OPIN THER TAR, V15, P695, DOI 10.1517/14728222.2011.561319; Schmidt H, 2010, CLIN CANCER RES, V16, P5312, DOI 10.1158/1078-0432.CCR-10-1809; Sivendran S, 2010, MT SINAI J MED, V77, P620, DOI 10.1002/msj.20215; Sivori S, 2003, EUR J IMMUNOL, V33, P3439, DOI 10.1002/eji.200324533; Skak K, 2008, NAT REV DRUG DISCOV, V7, P231, DOI 10.1038/nrd2482; Spolski R, 2009, J IMMUNOL, V182, P2859, DOI 10.4049/jimmunol.0802978; Suto A, 2002, BLOOD, V100, P4565, DOI 10.1182/blood-2002-04-1115; Warnatz K, 2008, CYTOM PART B-CLIN CY, V74B, P261, DOI 10.1002/cyto.b.20432; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; WELCH PA, 1995, INT IMMUNOL, V7, P737, DOI 10.1093/intimm/7.5.737; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Yong PFK, 2011, ADV IMMUNOL, V111, P47, DOI 10.1016/B978-0-12-385991-4.00002-7; Yuan FL, 2011, MOL BIOL REP, V38, P1717, DOI 10.1007/s11033-010-0285-x; Zeng R, 2005, J EXP MED, V201, P139, DOI 10.1084/jem.20041057; Zhang Y, 2004, PROTEINS, V57, P702, DOI 10.1002/prot.20264	66	85	95	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1651	+		10.1016/j.jaci.2014.02.034	http://dx.doi.org/10.1016/j.jaci.2014.02.034			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24746753				2022-12-18	WOS:000336672500018
J	Hulse, KE; Norton, JE; Suh, L; Zhong, Q; Mahdavinia, M; Simon, P; Kern, RC; Conley, DB; Chandra, RK; Tan, BK; Peters, AT; Grammer, LC; Harris, KE; Carter, RG; Kato, A; Schleimer, RP				Hulse, Kathryn E.; Norton, James E.; Suh, Lydia; Zhong, Qiu; Mahdavinia, Mahboobeh; Simon, Patrick; Kern, Robert C.; Conley, David B.; Chandra, Rakesh K.; Tan, Bruce K.; Peters, Anju T.; Grammer, Leslie C., III; Harris, Kathleen E.; Carter, Roderick G.; Kato, Atsushi; Schleimer, Robert P.			Chronic rhinosinusitis with nasal polyps is characterized by B-cell inflammation and EBV-induced protein 2 expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; B cells; plasma cells; antibodies; EBV-induced protein 2 (EBI2); chronic inflammation	MIGRATION; PERSPECTIVES; THERAPIES; ETIOLOGY; DISEASES; RECEPTOR	Background: Despite the high prevalence and morbidity of chronic rhinosinusitis (CRS), little is known about the mechanisms that underlie its pathogenesis. Recent studies have suggested that B cells might play an important role in CRS. Objective: We sought to thoroughly characterize B lineage cells within sinus tissues of patients with CRS and healthy control subjects and to determine whether levels of EBV-induced protein 2, which is known to play an important role in the development of B-cell responses, were increased in patients with CRS. Methods: Cells isolated from sinus tissues of patients with CRS and healthy control subjects were characterized by means of flow cytometry and immunohistochemistry. Local production of antibodies was measured in tissue extracts, nasal lavage fluid, and sera by using multiplex bead arrays and ELISA. Quantitative RT-PCR, ELISA, and Western blotting were used to assess gene and protein expression from tissue extracts. Results: Nasal polyps (NPs) from patients with CRS had increased levels of both B cells and plasma cells compared with uncinate tissue from healthy control subjects (P <.05). NPs also contained significantly increased levels of several antibody isotypes compared with normal uncinate tissue (P <.05), but no differences in circulating antibody levels were found. Interestingly, levels of EBV-induced protein 2 were also increased in NPs (P <.05) and were positively correlated with expression of plasma cell markers (CD138 and B lymphocyteinduced maturation protein) in sinus tissue. Conclusion: B cells and plasma cells are enriched in NPs, actively produce antibodies locally, and might contribute to chronic inflammation in patients with CRS. Elucidating the mechanisms that underlie this excessive local B-cell response might provide novel insights for the development of improved therapeutic strategies. (J Allergy Clin Immunol 2013; 131:1075-83.)	[Hulse, Kathryn E.; Norton, James E.; Suh, Lydia; Mahdavinia, Mahboobeh; Simon, Patrick; Peters, Anju T.; Grammer, Leslie C., III; Harris, Kathleen E.; Carter, Roderick G.; Kato, Atsushi; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Dept Med, Chicago, IL 60611 USA; [Zhong, Qiu; Kern, Robert C.; Conley, David B.; Chandra, Rakesh K.; Tan, Bruce K.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Schleimer, RP (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, 240 E Huron St,McGaw Rm M-318, Chicago, IL 60611 USA.	rpschleimer@northwestern.edu		Mahdavinia, mahboobeh/0000-0003-4004-203X; Hulse, Kathryn/0000-0003-0969-999X; Grammer, Leslie/0000-0001-6860-2014; Chandra, Rakesh/0000-0002-3612-0026; Kato, Atsushi/0000-0001-9144-3138	National Institutes of Health [R37 HL068546, R01 HL078860, R01 AI072570]; Ernest S. Bazley Trust; American Academy of Allergy, Asthma & Immunology (AAAAI); Lippincott; UpToDate; BMU; Elsevier; Intersect ENT; GlaxoSmithKline; Allakos; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546, R01HL078860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI106683, R01AI072570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K23DC012067] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Trust; American Academy of Allergy, Asthma & Immunology (AAAAI); Lippincott; UpToDate; BMU; Elsevier; Intersect ENT; GlaxoSmithKline(GlaxoSmithKline); Allakos; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Supported by National Institutes of Health grants R37 HL068546, R01 HL078860, and R01 AI072570 and the Ernest S. Bazley Trust.; Disclosure of potential conflict of interest: J. E. Norton, R. K. Chandra, and A. Kato have received research support from the National Institutes of Health (NIH). A. T. Peters has provided expert witness testimony on drug allergy and has received lecture fees from Baxter. L. C. Grammer III has received research and travel support from the NIH; has received the Bazley Foundation grant; has received consultancy fees from Astellas Pharmaceuticals; is employed by Northwestern University and NorthwesternMedical Faculty Foundation; has received research support from the NIH, the Food Allergy Network, and S&C Electric; has received lecture fees from the American Academy of Allergy, Asthma & Immunology (AAAAI); and receives royalties from Lippincott, UpToDate, BMU, and Elsevier. R. P. Schleimer has received research support from the NIH; has received consultancy fees from Intersect ENT, GlaxoSmithKline, and Allakos; and has stock/stock options in Allakos and Avrasense. The rest of the authors declare that they have no relevant conflicts of interest.	ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; Bachert C, 2009, ALLERGY, V64, P520, DOI 10.1111/j.1398-9995.2009.01964.x; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126; Brandtzaeg P, 2009, SCAND J IMMUNOL, V70, P505, DOI 10.1111/j.1365-3083.2009.02319.x; Cameron L, 2003, J IMMUNOL, V171, P3816, DOI 10.4049/jimmunol.171.7.3816; Chan TD, 2010, IMMUNOL REV, V237, P90, DOI 10.1111/j.1600-065X.2010.00942.x; Dorner T, 2009, NAT REV RHEUMATOL, V5, P433, DOI 10.1038/nrrheum.2009.141; Drolet JP, 2010, CLIN EXP ALLERGY, V40, P841, DOI 10.1111/j.1365-2222.2010.03512.x; Dykewicz MS, 2010, J ALLERGY CLIN IMMUN, V125, pS103, DOI 10.1016/j.jaci.2009.12.989; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Gatto D, 2009, IMMUNITY, V31, P259, DOI 10.1016/j.immuni.2009.06.016; Gevaert P, 2013, ALLERGY, V68, P55, DOI 10.1111/all.12054; Hannedouche S, 2011, NATURE, V475, P524, DOI 10.1038/nature10280; Jeffe JS, 2013, LARYNGOSCOP IN PRESS; Johansen FE, 2011, MUCOSAL IMMUNOL, V4, P598, DOI 10.1038/mi.2011.37; Kato A, 2008, J ALLERGY CLIN IMMUN, V121; Kato A, 2009, J IMMUNOL, V182, P7233, DOI 10.4049/jimmunol.0801375; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; Liu CL, 2011, NATURE, V475, P519, DOI 10.1038/nature10226; Lund FE, 2010, NAT REV IMMUNOL, V10, P236, DOI 10.1038/nri2729; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Pereira JP, 2009, NATURE, V460, P1122, DOI 10.1038/nature08226; Pereira JP, 2010, INT IMMUNOL, V22, P413, DOI 10.1093/intimm/dxq047; Sanchez-Segura A, 2000, LARYNGOSCOPE, V110, P1183; Schleimer RP, 2013, EOSINOPHILS IN HEALTH AND DISEASE, P508; Seshadri S, 2012, ALLERGY, V67, P920, DOI 10.1111/j.1398-9995.2012.02848.x; Takabayashi T, 2012, J ALLERGY CLIN IMMUN, V130, P410, DOI 10.1016/j.jaci.2012.02.046; Tan BK, 2011, J ALLERGY CLIN IMMUN, V128, P1198, DOI 10.1016/j.jaci.2011.08.037; Tan BK, 2010, CURR OPIN OTOLARYNGO, V18, P21, DOI 10.1097/MOO.0b013e3283350053; Tieu DD, 2010, J ALLERGY CLIN IMMUN, V125, P667, DOI 10.1016/j.jaci.2009.11.045; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x	32	85	88	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1075	+		10.1016/j.jaci.2013.01.043	http://dx.doi.org/10.1016/j.jaci.2013.01.043			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23473835	Green Accepted, Bronze			2022-12-18	WOS:000317187200016
J	Staples, KJ; Hinks, TSC; Ward, JA; Gunn, V; Smith, C; Djukanovic, R				Staples, Karl J.; Hinks, Timothy S. C.; Ward, Jon A.; Gunn, Victoria; Smith, Caroline; Djukanovic, Ratko			Phenotypic characterization of lung macrophages in asthmatic patients: Overexpression of CCL17	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; macrophage; chemokine; steroid	ALTERNATIVELY ACTIVATED MACROPHAGES; BRONCHOALVEOLAR LAVAGE FLUID; ALLERGIC AIRWAY INFLAMMATION; FLOW-CYTOMETRIC METHOD; ALVEOLAR MACROPHAGE; INDUCED SPUTUM; T-CELLS; CORTICOSTEROID INSENSITIVITY; REGULATED CHEMOKINE; IN-VITRO	Background: Studies with monocyte-derived macrophages (MDMs) and animal models have suggested a role for alternatively activated (M2) macrophages in asthmatic inflammation, but in vivo evidence for this phenotype in human asthma is lacking. Objective: To characterize the phenotype of lung macrophages from asthmatic patients in relation to disease severity and treatment. Methods: M2 biomarkers were first identified by using MDMs exposed to T(H)2 cytokines and then used to phenotype sputum and bronchoalveolar lavage (BAL) macrophages from 12 healthy control subjects, 12 patients with mild asthma, and 14 patients with moderate asthma and to assess the effects of corticosteroids and phosphatidylinositol 3-kinase (PI3K) inhibitors. Results: Sputum macrophages from asthmatic patients expressed significantly more CCL17 mRNA but less CD163 than macrophages from healthy subjects. However, none of the other M2 biomarkers were differentially expressed in asthmatic patients, and ex vivo BAL cells spontaneously produced similar amounts of M2 cytokines/chemokines (IL-10, CCL17, and CCL22). CCL17 mRNA overexpression correlated weakly but significantly with sputum eosinophilia (P = .0252) and was also observed in macrophages from patients with moderate asthma treated with inhaled steroids, suggesting relative insensitivity to inhibition by corticosteroids. The PI3K inhibitor LY294002 inhibited basal CCL17 release from BAL cells and IL-4-stimulated release from MDMs. Conclusions: This study does not support the existence in human asthma of the full M2 phenotype described to date but points to upregulation of CCL17 in both patients with mild and those with moderate asthma, providing a further source for this ligand of CCR4(+) cells that contributes to airways inflammation. CCL17 expression is corticosteroid resistant but suppressed by PI3K enzyme inhibitors. (J Allergy Clin Immunol 2012;130:1404-12.)	[Staples, Karl J.] Univ Southampton, Southampton Gen Hosp, Inflammatory Cell Biol Grp,Sch Med,Fac Med, Acad Unit Clin & Expt Sci,Sir Henry Wellcome Labs, Southampton SO16 6YD, Hants, England; [Smith, Caroline; Djukanovic, Ratko] Southampton Gen Hosp, Southampton NIHR Resp Biomed Res Unit, Southampton SO9 4XY, Hants, England	University of Southampton; University of Southampton	Staples, KJ (corresponding author), Univ Southampton, Southampton Gen Hosp, Inflammatory Cell Biol Grp,Sch Med,Fac Med, Acad Unit Clin & Expt Sci,Sir Henry Wellcome Labs, Mailpoint 810,Tremona Rd, Southampton SO16 6YD, Hants, England.	k.staples@southampton.ac.uk		Djukanovic, Ratko/0000-0001-6039-5612; Staples, Karl/0000-0003-3844-6457; Hinks, Timothy/0000-0003-0699-2373	Asthma UK [08/026]; Wellcome Trust [088365/z/09/z]; Asthma UK; Wellcome Trust; National Institute for Health Research [ACF-2006-26-005] Funding Source: researchfish	Asthma UK; Wellcome Trust(Wellcome TrustEuropean Commission); Asthma UK; Wellcome Trust(Wellcome TrustEuropean Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by a project grant from Asthma UK (08/026). T.S.C.H. is a Wellcome Trust Clinical Research Fellow (088365/z/09/z).; K. J. Staples has received payment for an invited lecture from Novartis and has received grant support from Asthma UK. T. S. C. Hinks has received research support from the Wellcome Trust. R. Djukanovic has consultant arrangements with and shares in Synairgen PLC. The rest of the authors declare that they have no relevant conflicts of interest.	Alexis NE, 2001, AM J RESP CRIT CARE, V164, P1964, DOI 10.1164/ajrccm.164.10.2104051; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Berin MC, 2001, AM J RESP CELL MOL, V24, P382, DOI 10.1165/ajrcmb.24.4.4360; Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027; Bochner BS, 2003, J ALLERGY CLIN IMMUN, V112, P930, DOI 10.1016/j.jaci.2003.08.012; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Desai B, 2011, EXP LUNG RES, V37, P227, DOI 10.3109/01902148.2010.538132; DJUKANOVIC R, 1991, AM REV RESPIR DIS, V143, P772, DOI 10.1164/ajrccm/143.4_Pt_1.772; Fitzpatrick AM, 2008, J ALLERGY CLIN IMMUN, V121, P1372, DOI 10.1016/j.jaci.2008.03.008; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Heijink IH, 2007, AM J RESP CELL MOL, V36, P351, DOI 10.1165/rcmb.2006-0160OC; Komine M, 2005, J INVEST DERMATOL, V125, P491, DOI 10.1111/j.0022-202X.2005.23840.x; Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575; Lee KS, 2006, FASEB J, V20, P455, DOI 10.1096/fj.05-5045com; Leidi M, 2009, J IMMUNOL, V182, P4415, DOI 10.4049/jimmunol.0713732; Lensmar C, 2006, RESP MED, V100, P918, DOI 10.1016/j.rmed.2005.08.014; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lofdahl JM, 2006, CLIN EXP IMMUNOL, V145, P428, DOI 10.1111/j.1365-2249.2006.03154.x; Madore AM, 2010, HUM IMMUNOL, V71, P144, DOI 10.1016/j.humimm.2009.11.005; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Maus U, 1997, AM J PHYSIOL-LUNG C, V272, pL566, DOI 10.1152/ajplung.1997.272.3.L566; Monick MM, 2007, J IMMUNOL, V179, P1648, DOI 10.4049/jimmunol.179.3.1648; Murray PJ, 2011, J LEUKOCYTE BIOL, V89, P557, DOI 10.1189/jlb.0710409; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Perros F, 2009, ALLERGY, V64, P995, DOI 10.1111/j.1398-9995.2009.02095.x; Peters-Golden M, 2004, AM J RESP CELL MOL, V31, P3, DOI 10.1165/rcmb.f279; Pilette C, 2004, EUR RESPIR J, V23, P876, DOI 10.1183/09031936.04.00102504; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Prasse A, 2007, J ALLERGY CLIN IMMUN, V119, P464, DOI 10.1016/j.jaci.2006.09.030; Prokop S, 2011, AM J PATHOL, V178, P1279, DOI 10.1016/j.ajpath.2010.11.065; Raes G, 2005, J LEUKOCYTE BIOL, V77, P321, DOI 10.1189/jlb.0304212; Rauh MJ, 2005, IMMUNITY, V23, P361, DOI 10.1016/j.immuni.2005.09.003; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sekiya T, 2000, J IMMUNOL, V165, P2205, DOI 10.4049/jimmunol.165.4.2205; Semnani RT, 2011, INFECT IMMUN, V79, P3957, DOI 10.1128/IAI.05191-11; Shaykhiev R, 2009, J IMMUNOL, V183, P2867, DOI 10.4049/jimmunol.0900473; Shirey KA, 2010, MUCOSAL IMMUNOL, V3, P291, DOI 10.1038/mi.2010.6; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Sikkeland LIB, 2007, THORAX, V62, P558, DOI 10.1136/thx.2006.073544; SKOLD CM, 1992, CHEST, V101, P989, DOI 10.1378/chest.101.4.989; SPITERI MA, 1994, EUR RESPIR J, V7, P1431, DOI 10.1183/09031936.94.07081431; St-Laurent J, 2009, J ASTHMA, V46, P1, DOI 10.1080/02770900802444211; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Taylor AE, 2010, EUR RESPIR J, V35, P1039, DOI 10.1183/09031936.00036709; Tiemessen MM, 2007, P NATL ACAD SCI USA, V104, P19446, DOI 10.1073/pnas.0706832104; To Y, 2010, AM J RESP CRIT CARE, V182, P897, DOI 10.1164/rccm.200906-0937OC; Tudhope SJ, 2008, J PHARMACOL EXP THER, V324, P306, DOI 10.1124/jpet.107.127670; Van den Heuvel MM, 1999, J LEUKOCYTE BIOL, V66, P858, DOI 10.1002/jlb.66.5.858; Van Gorp H, 2010, MOL IMMUNOL, V47, P1650, DOI 10.1016/j.molimm.2010.02.008; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; Vijayanand P, 2007, NEW ENGL J MED, V356, P1410, DOI 10.1056/NEJMoa064691; Vijayanand P, 2010, J IMMUNOL, V184, P4568, DOI 10.4049/jimmunol.0901342; Viksman MY, 1997, AM J RESP CRIT CARE, V155, P858, DOI 10.1164/ajrccm.155.3.9117017; VIKSMAN MY, 1994, J IMMUNOL METHODS, V172, P17, DOI 10.1016/0022-1759(94)90374-3; Wirnsberger G, 2006, EUR J IMMUNOL, V36, P1882, DOI 10.1002/eji.200635972; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183	59	85	88	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1404	+		10.1016/j.jaci.2012.07.023	http://dx.doi.org/10.1016/j.jaci.2012.07.023			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	22981793	Green Accepted			2022-12-18	WOS:000311641100022
J	Novak, N; Mete, N; Bussmann, C; Maintz, L; Bieber, T; Akdis, M; Zumkehr, J; Jutel, M; Akdis, C				Novak, Natalija; Mete, Nihal; Bussmann, Caroline; Maintz, Laura; Bieber, Thomas; Akdis, Muebeccel; Zumkehr, Judith; Jutel, Marek; Akdis, Cezmi			Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human; basophils; histamine receptor 2; ultrarush immunotherapy; tolerance	CYCLIC ADENOSINE-MONOPHOSPHATE; PERIPHERAL-BLOOD LEUKOCYTES; VENOM IMMUNOTHERAPY; T-CELL; DENDRITIC CELLS; WASP VENOM; RESPONSES; RELEASE; DISEASE; H1	Background: Early desensitization of FceRI-bearing mast cells and basophils has been demonstrated in allergen-specific immunotherapy and drug desensitization. However, its mechanisms have not been elucidated in detail. Histamine is one of the main mediators released on FceRI triggering of basophils and mast cells, and it exerts its functions through histamine receptors (HRs). Objectives: We sought to investigate HR expression on basophils of patients undergoing venom immunotherapy (VIT) and its effect on allergen, IgE, and FceRI cross-linking-mediated basophil function and mediator release. Methods: Basophils were purified from the peripheral blood of patients undergoing VIT and control subjects and were studied functionally by using real-time PCR, flow cytometry and ELISA assays. Results: Rapid upregulation of H2R within the first 6 hours of the build-up phase of VIT was observed. H2R strongly suppressed FceRI-induced activation and mediator release of basophils, including histamine and sulfidoleukotrienes, as well as cytokine production in vitro. Conclusion: Immunosilencing of FceRI-activated basophils by means of selective suppression mediated by H2R might be highly relevant for the very early induction of allergen tolerance and the so-called desensitization effect of VIT. (J Allergy Clin Immunol 2012;130:1153-8.)	[Novak, Natalija; Bussmann, Caroline; Maintz, Laura; Bieber, Thomas] Univ Bonn, Dept Dermatol & Allergy, D-53105 Bonn, Germany; [Mete, Nihal; Akdis, Muebeccel; Zumkehr, Judith; Akdis, Cezmi] Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Mete, Nihal] Ege Univ, Fac Med, Izmir, Turkey; [Jutel, Marek] Univ Wroclaw, Fac Med, PL-50138 Wroclaw, Poland	University of Bonn; Swiss Institute of Allergy & Asthma Research; Ege University; University of Wroclaw	Novak, N (corresponding author), Univ Bonn, Dept Dermatol & Allergy, Sigmund Freud Str 25, D-53105 Bonn, Germany.	Natalija.Novak@ukb.uni-bonn.de	Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X	Deutsche Forschungsgemeinschaft [DFG NO454/1-4, SFB704 TPA4]; BONFOR grant of the University of Bonn; Swiss National Science Foundation [32-118226]; Christine Kuhne Center for Allergy Research and Education (CK-CARE); DFG [NO4545/5-2]; German Research Council; Swiss National Foundation; European Union; Polish National Science Centre; Novartis; PREDICTA; Swiss National Science Foundation; MeDALL; Global Allergy and Asthma European Network; Christine Kuhne Center for Allergy Research and Education	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); BONFOR grant of the University of Bonn; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Christine Kuhne Center for Allergy Research and Education (CK-CARE); DFG(German Research Foundation (DFG)); German Research Council(German Research Foundation (DFG)); Swiss National Foundation(Swiss National Science Foundation (SNSF)); European Union(European Commission); Polish National Science Centre; Novartis(Novartis); PREDICTA; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); MeDALL; Global Allergy and Asthma European Network; Christine Kuhne Center for Allergy Research and Education	Supported by grants from the Deutsche Forschungsgemeinschaft (DFG NO454/1-4; SFB704 TPA4), a BONFOR grant of the University of Bonn, Swiss National Science Foundation Grant 32-118226, and the Christine Kuhne Center for Allergy Research and Education (CK-CARE). N.N. was supported by a Heisenberg-Professorship of the DFG NO4545/5-2.; Disclosure of potential conflict of interest: N. Novak has received research support from the German Research Council and is on the speakers' bureau for ALK-Abello, Bencard Allergy Therapeutics, and Astellas Pharma. M. Akdis receives research support from the Swiss National Foundation and the European Union. J. Zumkehr is employed by CSL Behring. M. Jutel receives research support from the Polish National Science Centre. C. Akdis receives research support from Novartis, PREDICTA, the Swiss National Science Foundation, MeDALL, the Global Allergy and Asthma European Network, and the Christine Kuhne Center for Allergy Research and Education; has consulted for Actellion, Avantis, Stallergenes, and Allergopharma; is President of the European Academy of Allergy and Clinical Immunology; is a fellow and interest group member of the American Academy of Allergy, Asthma & Immunology; is an ex-committee member of the Global Allergy and Asthma European Network; and is director of the Christine Kuhne Center for Allergy Research and Education. The rest of the authors declare that they have no relevant conflicts of interest.	Adler HS, 2007, EUR J DERMATOL, V17, P476; Akdis CA, 2006, EUR J PHARMACOL, V533, P69, DOI 10.1016/j.ejphar.2005.12.044; Akdis M, 2009, NAT REV DRUG DISCOV, V8, P645, DOI 10.1038/nrd2653; Bauer C, 2007, ANN ALLERG ASTHMA IM, V98, P281, DOI 10.1016/S1081-1206(10)60719-3; Chin KV, 2002, ANN NY ACAD SCI, V968, P49, DOI 10.1111/j.1749-6632.2002.tb04326.x; Dy M, 2004, CYTOKINE GROWTH F R, V15, P393, DOI 10.1016/j.cytogfr.2004.06.003; Gibbs BF, 2008, CLIN EXP ALLERGY, V38, P480, DOI 10.1111/j.1365-2222.2007.02919.x; Gilmartin L, 2008, INT ARCH ALLERGY IMM, V145, P182, DOI 10.1159/000109287; Hofstra CL, 2003, J PHARMACOL EXP THER, V305, P1212, DOI 10.1124/jpet.102.046581; Jutel M, 1996, CLIN EXP ALLERGY, V26, P1112, DOI 10.1111/j.1365-2222.1996.tb00496.x; Jutel M, 2002, CURR OPIN IMMUNOL, V14, P735, DOI 10.1016/S0952-7915(02)00395-3; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Kanda N, 2002, J INVEST DERMATOL, V119, P1411, DOI 10.1046/j.1523-1747.2002.19627.x; Kunzmann S, 2003, FASEB J, V17, P1089, DOI 10.1096/fj.02-1008com; Kunzmann S, 2003, FASEB J, V17, P194, DOI 10.1096/fj.02-0550com; Liu A, 2011, CLIN EXP ALLERGY, V41, P1679, DOI 10.1111/j.1365-2222.2011.03825.x; Maintz L, 2009, J ALLERGY CLIN IMMUN, V123, P701, DOI 10.1016/j.jaci.2008.11.009; Medina V, 2008, CANCER BIOL THER, V7, P28, DOI 10.4161/cbt.7.1.5123; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Muller UR, 2008, J ALLERGY CLIN IMMUN, V122, P1001, DOI 10.1016/j.jaci.2008.08.007; Novak N, 2004, J ALLERGY CLIN IMMUN, V114, P364, DOI 10.1016/j.jaci.2004.05.038; Osna N, 2001, INT IMMUNOPHARMACOL, V1, P85, DOI 10.1016/S0162-3109(00)00268-X; PEACHELL PT, 1988, J IMMUNOL, V140, P571; Pierkes M, 1999, J ALLERGY CLIN IMMUN, V103, P326, DOI 10.1016/S0091-6749(99)70509-9; Ross RN, 2000, CLIN THER, V22, P351, DOI 10.1016/S0149-2918(00)80039-9; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; STEPHAN V, 1989, ALLERGY, V44, P453, DOI 10.1111/j.1398-9995.1989.tb04182.x; Sugata Y, 2007, IMMUNOLOGY, V121, P266, DOI 10.1111/j.1365-2567.2007.02574.x; Thurmond RL, 2008, NAT REV DRUG DISCOV, V7, P41, DOI 10.1038/nrd2465; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329, DOI 10.1136/bmj.287.6402.1329; Zhang M, 2007, PHARMACOL THERAPEUT, V113, P594, DOI 10.1016/j.pharmthera.2006.11.008	31	85	88	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1153	+		10.1016/j.jaci.2012.04.039	http://dx.doi.org/10.1016/j.jaci.2012.04.039			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	22698521				2022-12-18	WOS:000310571400017
J	Oefner, CM; Winkler, A; Hess, C; Lorenz, AK; Holecska, V; Huxdorf, M; Schommartz, T; Petzold, D; Bitterling, J; Schoen, AL; Stoehr, AD; Van, DV; Darcan-Nikolaisen, Y; Blanchard, V; Schmudde, I; Laumonnier, Y; Strover, HA; Hegazy, AN; Eiglmeier, S; Schoen, CT; Mertes, MMM; Loddenkemper, C; Lohning, M; Konig, P; Petersen, A; Luger, EO; Collin, M; Kohl, J; Hutloff, A; Hamelmann, E; Berger, M; Wardemann, H; Ehlers, M				Oefner, Carolin M.; Winkler, Andre; Hess, Constanze; Lorenz, Alexandra K.; Holecska, Vivien; Huxdorf, Melanie; Schommartz, Tim; Petzold, Dominique; Bitterling, Josephine; Schoen, Anna-Lena; Stoehr, Alexander D.; Van, Dana Vu; Darcan-Nikolaisen, Yasemin; Blanchard, Veronique; Schmudde, Inken; Laumonnier, Yves; Stroever, Heike A.; Hegazy, Ahmed N.; Eiglmeier, Susanne; Schoen, Carolin T.; Mertes, Maria M. M.; Loddenkemper, Christoph; Loehning, Max; Koenig, Peter; Petersen, Arnd; Luger, Elke O.; Collin, Mattias; Koehl, Joerg; Hutloff, Andreas; Hamelmann, Eckard; Berger, Markus; Wardemann, Hedda; Ehlers, Marc			Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Tolerance; IgG antibodies; IgG sialylation; dendritic cells; allergy; asthma; antigen-specific immunotherapy; antigen-specific tolerance; antibody therapy	FC-GAMMA RECEPTORS; ANTIINFLAMMATORY ACTIVITY; DENDRITIC CELLS; ANTIBODY-RESPONSES; DEFICIENT MICE; IMMUNOGLOBULIN; IMMUNOTHERAPY; DISEASE; ARTHRITIS; ALLERGENS	Background: Under inflammatory conditions, T cell-dependent (TD) protein antigens induce proinflammatory T-and B-cell responses. In contrast, tolerance induction by TD antigens without costimulation triggers the development of regulatory T cells. Under both conditions, IgG antibodies are generated, but whether they have different immunoregulatory functions remains elusive. Objective: It was shown recently that proinflammatory or anti-inflammatory effector functions of IgG molecules are determined by different Fc N-linked glycosylation patterns. We sought to examine the Fc glycosylation and anti-inflammatory quality of IgG molecules formed on TD tolerance induction. Methods: We administered chicken ovalbumin (OVA) with or without costimulus to mice and analyzed OVA-reactive IgG Fc glycosylation. The anti-inflammatory function of differentially glycosylated anti-OVA IgGs was further investigated in studies with dendritic cell cultures and in an in vivo model of allergic airway disease. Additionally, we analyzed the Fc glycosylation pattern of birch pollen-reactive serum IgGs after successful allergen-specific immunotherapy in patients. Results: Stimulation with TD antigens under inflammatory conditions induces plasma cells expressing low levels of alpha 2,6-sialyltransferase and producing desialylated IgGs. In contrast, plasma cells induced on tolerance induction did not downregulate alpha 2,6-sialyltransferase expression and secreted immunosuppressive sialylated IgGs that were sufficient to block antigen-specific T- and B-cell responses, dendritic cell maturation, and allergic airway inflammation. Importantly, successful specific immunotherapy in allergic patients also induced sialylated allergen-specific IgGs. Conclusions: Our data show a novel antigen-specific immunoregulatory mechanism mediated by anti-inflammatory sialylated IgGs that are formed on TD tolerance induction. These findings might help to develop novel antigen-specific therapies for the treatment of allergy and autoimmunity. (J Allergy Clin Immunol 2012;129:1647-55.)	[Schommartz, Tim; Petzold, Dominique; Bitterling, Josephine; Schoen, Anna-Lena; Ehlers, Marc] Med Univ Lubeck, Inst Syst Inflammat Res, Lab Tolerance & Autoimmun, D-23538 Lubeck, Germany; [Oefner, Carolin M.; Winkler, Andre; Hess, Constanze; Lorenz, Alexandra K.; Holecska, Vivien; Huxdorf, Melanie; Stoehr, Alexander D.; Eiglmeier, Susanne; Schoen, Carolin T.; Mertes, Maria M. M.; Ehlers, Marc] Leibniz Inst, German Rheumatism Res Ctr, Lab Tolerance & Autoimmun, Berlin, Germany; [Van, Dana Vu; Hutloff, Andreas] Leibniz Inst, German Rheumatism Res Ctr, Lab Chron Immune React, Berlin, Germany; [Petzold, Dominique; Blanchard, Veronique; Berger, Markus] Charite Univ Med Berlin, Cent Inst Lab Med & Pathobiochem, Lab Glycodesign & Glycoanalyt, Berlin, Germany; [Darcan-Nikolaisen, Yasemin; Hamelmann, Eckard] Charite Univ Med Berlin, Dept Pediat Pneumol & Immunol, Berlin, Germany; [Hegazy, Ahmed N.; Loehning, Max] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Expt Immunol Lab, Berlin, Germany; [Hegazy, Ahmed N.] Charite Univ Med Berlin, CCM, Dept Gastroenterol Hepatol & Endocrinol, Berlin, Germany; [Loddenkemper, Christoph] Charite Univ Med Berlin, Inst Pathol, Charite Res Ctr ImmunoSci, Berlin, Germany; [Van, Dana Vu; Hutloff, Andreas] Robert Koch Inst, Berlin, Germany; [Schmudde, Inken; Laumonnier, Yves; Stroever, Heike A.; Koehl, Joerg] Med Univ Lubeck, Ctr Struct & Cell Biol Med, Inst System Inflammat Res, D-23538 Lubeck, Germany; [Koenig, Peter] Med Univ Lubeck, Ctr Struct & Cell Biol Med, Inst Anat, D-23538 Lubeck, Germany; [Loddenkemper, Christoph] Tech Univ Munich, Inst Pathol, D-8000 Munich, Germany; [Petersen, Arnd] Res Ctr Borstel, Dept Pneumol, Div Clin & Mol Allergol, Borstel, Germany; [Collin, Mattias] Lund Univ, Dept Clin Sci, Div Infect Med, S-22100 Lund, Sweden; [Hamelmann, Eckard] Ruhr Univ Bochum, Childrens Hosp, Bochum, Germany; [Wardemann, Hedda] Max Planck Inst Infect Biol, Lab Mol Immunol, Berlin, Germany	University of Lubeck; Deutsches Rheuma-Forschungszentrum (DRFZ); Deutsches Rheuma-Forschungszentrum (DRFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Robert Koch Institute; University of Lubeck; University of Lubeck; Technical University of Munich; Forschungszentrum Borstel; Lund University; Ruhr University Bochum; Max Planck Society	Ehlers, M (corresponding author), Med Univ Lubeck, Inst Syst Inflammat Res, Lab Tolerance & Autoimmun, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	Marc.Ehlers@uk-sh.de	Laumonnier, yves/F-6348-2018; Koehl, Joerg/C-8531-2011; König, Peter/AAK-2021-2020; Löhning, Max/AAL-2967-2021; Hamelmann, Eckard/AAJ-9124-2021; Collin, Mattias/C-6398-2009; Ehlers, Marc/C-9441-2011; Hutloff, Andreas/D-1781-2014	Koehl, Joerg/0000-0003-1121-3178; Löhning, Max/0000-0001-6382-7281; Collin, Mattias/0000-0002-6166-7410; Ehlers, Marc/0000-0002-5383-8603; Hutloff, Andreas/0000-0002-0572-8151; Blanchard, Veronique/0000-0002-5980-6450; Hegazy, Ahmed N./0000-0002-2946-8251; Braumann, Dominique/0000-0001-9987-0257; Wardemann, Hedda/0000-0003-3921-5933	German Research Foundation (DFG) [EH221-4, EH221-5, SFB/TR22]; Max Planck Institute for Infection Biology, Berlin, Germany; International Max Planck Research School for Infectious Diseases and Immunology, Berlin, Germany; German Ministry of Research and Education [03IP511]; Sonnefeld Foundation; Swedish Research Council [2010-57X-20240]; Foundation of Wiberg; Foundation of Osterlund; Foundation of Hedlund; Royal Physiographic Society; King Gustaf V's Memorial Fund; Hansa Medical AB	German Research Foundation (DFG)(German Research Foundation (DFG)); Max Planck Institute for Infection Biology, Berlin, Germany; International Max Planck Research School for Infectious Diseases and Immunology, Berlin, Germany; German Ministry of Research and Education(Federal Ministry of Education & Research (BMBF)); Sonnefeld Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Foundation of Wiberg; Foundation of Osterlund; Foundation of Hedlund; Royal Physiographic Society; King Gustaf V's Memorial Fund; Hansa Medical AB	Supported by the German Research Foundation (DFG) to M. E. (EH221-4 and 5), A. P., P.K., and J.K. (SFB/TR22 projects Z1, Z3 and A21). M. E. was a fellow of the Claussen-Simon-Foundation and supported by the Max Planck Institute for Infection Biology, Berlin, Germany. S. E. was supported by the International Max Planck Research School for Infectious Diseases and Immunology, Berlin, Germany. V. B. and M. B. were supported by the German Ministry of Research and Education (03IP511) and the Sonnefeld Foundation. M. C. was supported by grants from the Swedish Research Council (2010-57X-20240) and the Foundations of Wiberg, Osterlund, and Hedlund; the Royal Physiographic Society; King Gustaf V's Memorial Fund; and Hansa Medical AB.	Akdis M, 2006, CURR OPIN IMMUNOL, V18, P738, DOI 10.1016/j.coi.2006.06.003; Anthony RM, 2008, SCIENCE, V320, P373, DOI 10.1126/science.1154315; Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134; Anthony RM, 2008, P NATL ACAD SCI USA, V105, P19571, DOI 10.1073/pnas.0810163105; Aubin E, 2010, BLOOD, V115, P1727, DOI 10.1182/blood-2009-06-225417; Barner M, 1998, CURR BIOL, V8, P669, DOI 10.1016/S0960-9822(98)70256-8; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Boscardin SB, 2006, J EXP MED, V203, P599, DOI 10.1084/jem.20051639; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Collin M, 2001, INFECT IMMUN, V69, P7187, DOI 10.1128/IAI.69.11.7187-7189.2001; Egner W, 2000, J CLIN PATHOL, V53, P424, DOI 10.1136/jcp.53.6.424; Ehlers M, 2006, J EXP MED, V203, P553, DOI 10.1084/jem.20052438; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Mobs C, 2010, J IMMUNOL, V184, P2194, DOI 10.4049/jimmunol.0901379; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Nimmerjahn F, 2006, IMMUNITY, V24, P19, DOI 10.1016/j.immuni.2005.11.010; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; Nimmerjahn F, 2008, ANNU REV IMMUNOL, V26, P513, DOI 10.1146/annurev.immunol.26.021607.090232; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; ROOK GAW, 1991, J AUTOIMMUN, V4, P779, DOI 10.1016/0896-8411(91)90173-A; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Tiller T, 2007, IMMUNITY, V26, P205, DOI 10.1016/j.immuni.2007.01.009; Wernersson S, 1999, J IMMUNOL, V163, P618; Yamazaki S, 2008, J IMMUNOL, V181, P6923, DOI 10.4049/jimmunol.181.10.6923	29	85	85	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1647	+		10.1016/j.jaci.2012.02.037	http://dx.doi.org/10.1016/j.jaci.2012.02.037			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22502800				2022-12-18	WOS:000304764600027
J	Goleva, E; Searing, DA; Jackson, LP; Richers, BN; Leung, DYM				Goleva, Elena; Searing, Daniel A.; Jackson, Leisa P.; Richers, Brittany N.; Leung, Donald Y. M.			Steroid requirements and immune associations with vitamin D are stronger in children than adults with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitamin D; asthma; corticosteroids	D DEFICIENCY; D INSUFFICIENCY; US POPULATION	Background: The effects of serum vitamin D status on atopy, steroid requirement, and functional responsiveness to corticosteroids in children versus adults with asthma have not been studied systematically. Objective: We sought to explore the age-specific effects of vitamin D in asthmatic patients. Methods: Serum vitamin D levels were examined in a prospective study of adults and children (102 healthy control subjects and 103 asthmatic patients). PBMCs were cultured for 3 hours with or without 100 nmol/L dexamethasone, and the expression of corticosteroid-regulated genes was detected by using real-time PCR. Serum IgE levels were measured, and information about asthmatic patients' steroid requirements was collected. Results: Deficient serum vitamin D levels (<20 ng/mL) were found in 47.6% of asthmatic patients and 56.8% of healthy control subjects, with means +/- SDs of 20.7 +/- 9.8 and 19.2 +/- 7.7 ng/mL, respectively. In multivariate regression models a significant positive correlation between serum vitamin D levels and the expression of vitamin D-regulated targets, cytochrome P450, family 24, subfamily a (cyp24a) expression by PBMCs (P = .0084, pediatric asthma group only) and serum LL-37 levels (P = .0006 in the pediatric group but P = .0067 in the adult asthma group), was found. An inverse association between vitamin D and serum IgE levels was observed in the pediatric (P = .0006) asthma group. Serum vitamin D level (P = .05), as well as PBMC cyp24a expression (P = .0312), demonstrated a significant inverse relationship with daily inhaled corticosteroid dose in the pediatric asthma group only. Cyp24a expression in PBMCs correlated positively with in vitro suppression of TNF-alpha by dexamethasone (P = .05) and IL-13 (P = .0094) in PBMCs in the pediatric asthma group only. Conclusions: This study demonstrated significant associations between serum vitamin D status and steroid requirement and in vitro responsiveness to corticosteroids in the pediatric but not the adult asthma group. Vitamin D was also related to IgE levels in children but not in adults. (J Allergy Clin Immunol 2012;129:1243-51.)	[Goleva, Elena; Searing, Daniel A.; Jackson, Leisa P.; Richers, Brittany N.; Leung, Donald Y. M.] Natl Jewish Hlth, Div Pediat Allergy & Immunol, Denver, CO 80206 USA; [Leung, Donald Y. M.] Univ Colorado Denver, Dept Pediat, Aurora, CO USA	National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Leung, DYM (corresponding author), Natl Jewish Hlth, Div Pediat Allergy & Immunol, 1400 Jackson St,K926I, Denver, CO 80206 USA.	leungd@njhealth.org			Diasorin, Inc; National Institutes of Health [AI070140, HL37260]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, R37HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI070140, R01AI070140] Funding Source: NIH RePORTER	Diasorin, Inc; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by a research grant from Diasorin, Inc, as well as National Institutes of Health grants AI070140 and HL37260. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases; the National Heart, Lung, and Blood Institute; or the National Institutes of Health.	Adorini L, 2008, NAT CLIN PRACT RHEUM, V4, P404, DOI 10.1038/ncprheum0855; Bhan I, 2011, J ALLERGY CLIN IMMUN, V127, P1302, DOI 10.1016/j.jaci.2010.12.1097; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Gallo RL, 2002, J ALLERGY CLIN IMMUN, V110, P823, DOI 10.1067/mai.2002.129801; Ginde AA, 2010, J ALLERGY CLIN IMMUN, V126, P59, DOI 10.1016/j.jaci.2010.05.030; Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604; Hewison M, 2011, NAT REV ENDOCRINOL, V7, P336, DOI 10.1038/nrendo.2010.226; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Hollams EM, 2011, EUR RESPIR J, V38, P1320, DOI 10.1183/09031936.00029011; Kumar J, 2009, PEDIATRICS, V124, pE362, DOI 10.1542/peds.2009-0051; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Majak P, 2011, J ALLERGY CLIN IMMUN, V127, P1294, DOI 10.1016/j.jaci.2010.12.016; Misra M, 2008, PEDIATRICS, V122, P398, DOI 10.1542/peds.2007-1894; National Collaborating Centre for Mental Health, 2010, CLIN GUIDELINE, P1; Plum LA, 2010, NAT REV DRUG DISCOV, V9, P941, DOI 10.1038/nrd3318; Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Sharief S, 2011, J ALLERGY CLIN IMMUN, V127, P1195, DOI 10.1016/j.jaci.2011.01.017; Sutherland ER, 2010, AM J RESP CRIT CARE, V181, P699, DOI 10.1164/rccm.200911-1710OC; Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140-6736(10)60588-0; Yetley EA, 2008, AM J CLIN NUTR, V88, p558S, DOI 10.1093/ajcn/88.2.558S	24	85	90	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1243	1251		10.1016/j.jaci.2012.01.044	http://dx.doi.org/10.1016/j.jaci.2012.01.044			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22330698	Green Accepted			2022-12-18	WOS:000303418000010
J	Cox, L; Lieberman, P; Wallace, D; Simons, FER; Finegold, I; Platts-Mills, T; Schwartz, L				Cox, Linda; Lieberman, Phillip; Wallace, Dana; Simons, F. Estelle R.; Finegold, Ira; Platts-Mills, Thomas; Schwartz, Lawrence			American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Cox, Linda; Lieberman, Phillip; Wallace, Dana] Nova SE Univ, Dept Med, Davie, FL USA; [Simons, F. Estelle R.] Univ Manitoba, Dept Pediat & Child Hlth, Dept Immunol, Fac Med, Winnipeg, MB, Canada; [Finegold, Ira] St Lukes Roosevelt Hosp, Dept Allergy, RA Cooke Inst Allergy, New York, NY USA; [Platts-Mills, Thomas] Univ Virginia, Dept Internal Med, Charlottesville, VA USA; [Platts-Mills, Thomas] Univ Virginia, Dept Microbiol, Div Allergy & Clin Immunol, Charlottesville, VA 22908 USA; [Schwartz, Lawrence] Virginia Commonwealth Univ, Dept Med, Div Rheumatol Allergy & Immunol, Richmond, VA 23298 USA	Nova Southeastern University; University of Manitoba; Mount Sinai St. Luke's; Mount Sinai West; University of Virginia; University of Virginia; Virginia Commonwealth University	Cox, L (corresponding author), Nova SE Univ, Dept Med, Davie, FL USA.	lindaswolfcox@msn.com	Cox, Linda/AAP-1697-2021	Cox, Linda/0000-0002-5258-6870; Platts-Mills, Thomas/0000-0002-1263-329X				Barry PJ, 2008, J ALLERGY CLIN IMMUN, V121, P785, DOI 10.1016/j.jaci.2007.12.1184; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, P1373, DOI 10.1016/j.jaci.2007.09.032; Lieberman P, 2010, ANN ALLERG ASTHMA IM, V105, P493, DOI 10.1016/j.anai.2010.10.008; Lin RY, 2009, ANN ALLERG ASTHMA IM, V103, P442, DOI 10.1016/S1081-1206(10)60366-3; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; *US FDA, 2011, US FOOD DRUG ADM APP	6	85	88	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					210	212		10.1016/j.jaci.2011.04.010	http://dx.doi.org/10.1016/j.jaci.2011.04.010			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21531014				2022-12-18	WOS:000292245600027
J	Hofmann, SC; Pfender, N; Weckesser, S; Huss-Marp, J; Jakob, T				Hofmann, Silke C.; Pfender, Nikolai; Weckesser, Steffi; Huss-Marp, Johannes; Jakob, Thilo			Added value of IgE detection to rApi m 1 and rVes v 5 in patients with Hymenoptera venom allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							YELLOW JACKET VENOM; DOUBLE POSITIVITY; IDENTIFICATION; DIAGNOSIS; HONEYBEE; BINDING		[Hofmann, Silke C.; Pfender, Nikolai; Weckesser, Steffi; Jakob, Thilo] Univ Med Ctr, Allergy Res Grp, Dept Dermatol, Freiburg, Germany; [Huss-Marp, Johannes] Phadia GmbH, Freiburg, Germany	University of Freiburg	Hofmann, SC (corresponding author), Univ Med Ctr, Allergy Res Grp, Dept Dermatol, Freiburg, Germany.	thilo.jakob@uniklinik-freiburg.de	Jakob, Thilo/J-1621-2012	Pfender, Nikolai/0000-0003-3933-7463				Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Blank S, 2010, J IMMUNOL, V184, P5403, DOI 10.4049/jimmunol.0803709; Bonifazi F, 2005, ALLERGY, V60, P1459, DOI 10.1111/j.1398-9995.2005.00960.x; Hemmer W, 2004, CLIN EXP ALLERGY, V34, P460, DOI 10.1111/j.1365-2222.2004.01897.x; Hemmer W, 2001, J ALLERGY CLIN IMMUN, V108, P1045, DOI 10.1067/mai.2001.120013; Jappe U, 2006, ALLERGY, V61, P1220, DOI 10.1111/j.1398-9995.2006.01232.x; Jin C, 2010, J ALLERGY CLIN IMMUN, V125, P184, DOI 10.1016/j.jaci.2009.08.037; Mittermann I, 2010, J ALLERGY CLIN IMMUN, V125, P1300, DOI 10.1016/j.jaci.2010.03.017; Muller UR, 2009, ALLERGY, V64, P543, DOI 10.1111/j.1398-9995.2008.01794.x; Seismann Henning, 2010, Clin Mol Allergy, V8, P7, DOI 10.1186/1476-7961-8-7	10	85	85	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					265	267		10.1016/j.jaci.2010.06.042	http://dx.doi.org/10.1016/j.jaci.2010.06.042			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	20719373				2022-12-18	WOS:000285917300039
J	Horvat, JC; Starkey, MR; Kim, RY; Phipps, S; Gibson, PG; Beagley, KW; Foster, PS; Hansbro, PM				Horvat, Jay C.; Starkey, Malcolm R.; Kim, Richard Y.; Phipps, Simon; Gibson, Peter G.; Beagley, Kenneth W.; Foster, Paul S.; Hansbro, Philip M.			Early-life chlamydial lung infection enhances allergic airways disease through age-dependent differences in immunopathology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; Chlamydia; immunologic programming; lung structure; dendritic cell; IL-13; infant; neonate; lung function	MYELOID DENDRITIC CELLS; AIR-FLOW LIMITATION; PNEUMONIAE INFECTION; ASTHMA; IMMUNITY; RESPONSES; INFLAMMATION; CHILDHOOD; ANTIGEN; VIRUS	Background: Asthma typically originates in early-life, and the impact of infection during immunologic, maturation is a critical factor in disease pathogenesis. The progression of aberrant T(H)2 cell responses and disease development has been attributed to a lack of infections. However, exposure to specific pathogens such as Chlamydia may alter immunologic programming and predispose to asthma. Objective: To investigate the effects of chlamydial infection at different ages on allergic airways disease in later life. Methods: Neonatal, infant, or adult BALB/c mice were infected and 6 weeks later were sensitized and subsequently challenged with ovalbumin. Hallmark features of allergic airways disease were compared with uninfected allergic and nonallergic controls. Results: Early-life (neonatal and infant) but not adult chlamydial infection enhanced the development of hallmark features of asthma in ovalbumin-induced allergic airways disease. Notably early-life infection increased mucus-secreting cell numbers, IL-13 expression, and airway hyperresponsiveness. Neonatal infection attenuated eosinophil influx and ovalbumin-specific T(H)2 cytokine release and numbers of activated myeloid dendritic cells (DCs) in lymph nodes. By contrast, infant infection augmented features of allergic inflammation with increased airway eosinophils, T(H)2 cytokine, and DC responses. Both neonatal and infant infection increased systemic DC-induced IL-13 release from CD4(+) T cells. The timing of infection had significant effects on lung structure because neonatal but not infant or adult infection induced increases in alveolar diameter. Conclusion: Early-life respiratory chlamydial infections modulate immune responses, alter lung function and structure, and enhance the severity of allergic airways disease in later life. (J Allergy Clin Immunol 2010;125:617-25.)	[Horvat, Jay C.; Starkey, Malcolm R.; Kim, Richard Y.; Phipps, Simon; Gibson, Peter G.; Foster, Paul S.; Hansbro, Philip M.] Univ Newcastle, Ctr Asthma & Resp Dis, Callaghan, NSW 2308, Australia; [Horvat, Jay C.; Starkey, Malcolm R.; Kim, Richard Y.; Phipps, Simon; Gibson, Peter G.; Foster, Paul S.; Hansbro, Philip M.] Univ Newcastle, Hunter Med Res Inst, Callaghan, NSW 2308, Australia; [Beagley, Kenneth W.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Kelvin Grove, Qld, Australia	University of Newcastle; Hunter Medical Research Institute; University of Newcastle; Queensland University of Technology (QUT)	Hansbro, PM (corresponding author), Discipline Immunol & Microbiol, Level 3,David Maddison Clin Sci Bldg,Corner King, Newcastle, NSW 2300, Australia.	Phil.Hansbro@newcastle.edu.au	Phipps, Simon/F-9170-2010; Beagley, Kenneth/J-1129-2012; Foster, Paul/G-5057-2013; Hansbro, Phil/G-7486-2013; gibson, peter/G-6194-2014	Phipps, Simon/0000-0002-7388-3612; Beagley, Kenneth/0000-0003-3112-6557; Hansbro, Phil/0000-0002-4741-3035; Starkey, Malcolm/0000-0002-7359-7464; Horvat, Jay/0000-0002-8526-0631; gibson, peter/0000-0001-5865-489X; , Paul/0000-0002-0827-8299; Kim, Richard/0000-0002-8709-5270	National Health and Medical Research Foundation of Australia [401238, 569219]; Asthma Foundation of NSW; Rebecca Cooper Medical Research Foundation; University of Newcastle; Brawn Post-doctoral Fellowship; Hunter Medical Research Institute; Australian Research Council [0559210]; NHMRC Australia; ARC Australia; Society for Mucosal Immunology	National Health and Medical Research Foundation of Australia(National Health and Medical Research Council (NHMRC) of Australia); Asthma Foundation of NSW; Rebecca Cooper Medical Research Foundation; University of Newcastle; Brawn Post-doctoral Fellowship; Hunter Medical Research Institute; Australian Research Council(Australian Research Council); NHMRC Australia(National Health and Medical Research Council (NHMRC) of Australia); ARC Australia(Australian Research Council); Society for Mucosal Immunology	Supported by grants from the National Health and Medical Research Foundation of Australia (project grants 401238 and 569219), the Asthma Foundation of NSW, the Rebecca Cooper Medical Research Foundation, the University of Newcastle project grants and Brawn Post-doctoral Fellowship, the Hunter Medical Research Institute, and the Australian Research Council (0559210).; Disclosure of potential conflict of interest: K. W. Beagle), has received research support from NHMRC Australia and ARC Australia and is a councilor for the Society for Mucosal Immunology. The rest of the authors have declared that they have no conflict of interest.	Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Black PN, 2000, EUR RESPIR J, V15, P254, DOI 10.1034/j.1399-3003.2000.15b06.x; Blasi F, 2004, EUR RESPIR J, V24, P171, DOI 10.1183/09031936.04.00135703; Brimnes MK, 2003, J EXP MED, V198, P133, DOI 10.1084/jem.20030266; Bush Andrew, 2005, Paediatr Respir Rev, V6, P101, DOI 10.1016/j.prrv.2005.03.008; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Cunningham AF, 1998, EUR RESPIR J, V11, P345, DOI 10.1183/09031936.98.11020345; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; EMRE U, 1994, ARCH PEDIAT ADOL MED, V148, P727, DOI 10.1001/archpedi.1994.02170070065013; Erb KJ, 1999, IMMUNOL TODAY, V20, P317, DOI 10.1016/S0167-5699(99)01475-9; Esposito S, 2000, EUR RESPIR J, V16, P1142, DOI 10.1034/j.1399-3003.2000.16f21.x; Foster PS, 2002, PHARMACOL THERAPEUT, V94, P253, DOI 10.1016/S0163-7258(02)00220-6; Foster PS, 2002, LAB INVEST, V82, P455, DOI 10.1038/labinvest.3780438; GOGOLAK FM, 1953, J INFECT DIS, V92, P254, DOI 10.1093/infdis/92.3.254; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Hansbro NG, 2008, PHARMACOL THERAPEUT, V117, P313, DOI 10.1016/j.pharmthera.2007.11.002; Hansbro PM, 2004, PHARMACOL THERAPEUT, V101, P193, DOI 10.1016/j.pharmthera.2003.10.007; Horvat JC, 2007, AM J RESP CRIT CARE, V176, P556, DOI 10.1164/rccm.200607-1005OC; Jarman ER, 2004, IMMUNOLOGY, V112, P631, DOI 10.1111/j.1365-2567.2004.01927.x; Jiao L, 2009, EUR J IMMUNOL, V39, P469, DOI 10.1002/eji.200838367; Johnston IDA, 1998, NEW ENGL J MED, V338, P581, DOI 10.1056/NEJM199802263380904; Kaiko GE, 2008, J IMMUNOL, V180, P2225, DOI 10.4049/jimmunol.180.4.2225; Kips JC, 2001, EUR RESPIR J, V18, p24S, DOI 10.1183/09031936.01.00229601; Koya T, 2006, AM J RESP CRIT CARE, V173, P42, DOI 10.1164/rccm.200505-783OC; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Leech MD, 2007, J IMMUNOL, V179, P7050, DOI 10.4049/jimmunol.179.10.7050; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Nigg C, 1944, J EXP MED, V79, P497, DOI 10.1084/jem.79.5.497; Padilla J, 2005, J IMMUNOL, V174, P8097, DOI 10.4049/jimmunol.174.12.8097; Phipps S, 2007, BLOOD, V110, P1578, DOI 10.1182/blood-2007-01-071340; Piippo-Savolainen E, 2006, ALLERGY ASTHMA PROC, V27, P341, DOI 10.2500/aap.2006.27.2912; Pope SM, 2001, J ALLERGY CLIN IMMUN, V108, P594, DOI 10.1067/mai.2001.118600; Prescott SL, 2006, PAEDIATR RESPIR REV, V7, P89, DOI 10.1016/j.prrv.2006.03.001; Preston JA, 2007, VACCINE, V25, P8154, DOI 10.1016/j.vaccine.2007.09.034; Robbesom AA, 2003, MODERN PATHOL, V16, P1, DOI 10.1097/01.MP.0000043519.29370.C2; SAETTA M, 1994, EUR RESPIR J, V7, P1505, DOI 10.1183/09031936.94.07081505; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; SHAHEEN SO, 1994, AM J RESP CRIT CARE, V149, P616, DOI 10.1164/ajrccm.149.3.8118627; Snelgrove RJ, 2008, NAT IMMUNOL, V9, P1074, DOI 10.1038/ni.1637; ten Brinke A, 2001, J ALLERGY CLIN IMMUN, V107, P449, DOI 10.1067/mai.2001.113047; Venkayya R, 2002, AM J RESP CELL MOL, V26, P202, DOI 10.1165/ajrcmb.26.2.4600; Vila-Corcoles A, 2009, RESP MED, V103, P309, DOI 10.1016/j.rmed.2008.08.006; von Mutius E, 2001, THORAX, V56, P153, DOI 10.1136/thorax.56.2.153; Webley WC, 2005, AM J RESP CRIT CARE, V171, P1083, DOI 10.1164/rccm.200407-917OC; Wills-Karp M, 2004, SCIENCE, V305, P1726, DOI 10.1126/science.1104134; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yamamoto N, 2000, EUR J IMMUNOL, V30, P316, DOI 10.1002/1521-4141(200001)30:1<316::AID-IMMU316>3.0.CO;2-0; Yang X, 1999, J IMMUNOL, V162, P1010; Yang X, 1996, J IMMUNOL, V156, P4338	54	85	87	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					617	625		10.1016/j.jaci.2009.10.018	http://dx.doi.org/10.1016/j.jaci.2009.10.018			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20122715				2022-12-18	WOS:000275883200017
J	Pieretti, MM; Chung, D; Pacenza, R; Slotkin, T; Sicherer, SH				Pieretti, Mariah M.; Chung, Danna; Pacenza, Robert; Slotkin, Todd; Sicherer, Scott H.			Audit of manufactured products: Use of allergen advisory labels and identification of labeling ambiguities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; advisory labeling; quality of life; regulation; FALCPA	CONSUMER ATTITUDES; FOOD ALLERGY	Background: The Food Allergy Labeling and Consumer Protection Act became effective January 1, 2006, and mandates disclosure of the 8 major allergens in plain English and as a source of ingredients in the ingredient statement. It does not regulate advisory labels. Objective: We sought to determine the frequency and language used in voluntary advisory labels among commercially available products and to identify labeling ambiguities affecting consumers with allergy. Methods: Trained surveyors performed a supermarket survey of 20,241 unique manufactured food products (from an original assessment of 49,604 products) for use of advisory labels. A second detailed survey of 744 unique products evaluated additional labeling practices. Results: Overall, 17% of 20,241 products surveyed contain advisory labels. Chocolate candy, cookies, and baking mixes were the 3 categories of 24 with the greatest frequency (>= 40%). Categorically, advisory warnings included "may contain" (38%), "shared equipment" (33%), and "within plant" (29%). The subsurvey disclosed 25 different types of advisory terminology. Nonspecific terms, such as "natural flavors" and "spices," were found on 65% of products and were not linked to a specific ingredient for 83% of them. Additional ambiguities included unclear sources of soy (lecithin vs protein), nondisclosure of sources of gelatin and lecithin, and simultaneous disclosure of "contains" and "may contain" for the same allergen, among others. Conclusion: Numerous products have advisory labeling and ambiguities that present challenges to consumers with food allergy. Additional allergen labeling regulation could improve safety and quality of life for individuals with food allergy. (J Allergy Clin Immunol 2009;124:337-41.)	[Pieretti, Mariah M.] Mt Sinai Sch Med, Div Allergy & Immunol, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Pieretti, MM (corresponding author), Mt Sinai Sch Med, Div Allergy & Immunol, Dept Pediat, 1 Gustave L Levy Pl,Box 1198, New York, NY 10029 USA.	mariah.pieretti@mssm.edu			Food Allergy Initiative, New York	Food Allergy Initiative, New York	Supported by the Food Allergy Initiative, New York.	Ahn SS, 2008, J ALLERGY CLIN IMMUN, V121, pS182, DOI 10.1016/j.jaci.2007.12.674; Altschul AS, 2001, J ALLERGY CLIN IMMUN, V108, P468, DOI 10.1067/mai.2001.117794; BUSH RK, 1985, J ALLERGY CLIN IMMUN, V76, P242, DOI 10.1016/0091-6749(85)90709-2; Crevel RWR, 2008, ALLERGY, V63, P597, DOI 10.1111/j.1398-9995.2008.01636.x; *CTR FOOD SAF APPL, 2004, CTR FOOD SAF APPL NU; GERN JE, 1991, NEW ENGL J MED, V324, P976, DOI 10.1056/NEJM199104043241407; Hansen TK, 2004, FOOD CHEM TOXICOL, V42, P2037, DOI 10.1016/j.fct.2004.08.008; Hefle SL, 2007, J ALLERGY CLIN IMMUN, V120, P171, DOI 10.1016/j.jaci.2007.04.013; Joshi P, 2002, J ALLERGY CLIN IMMUN, V109, P1019, DOI 10.1067/mai.2002.123305; McKenna C, 1997, ANN ALLERG ASTHMA IM, V79, P234, DOI 10.1016/S1081-1206(10)63008-6; Mills ENC, 2004, ALLERGY, V59, P1262, DOI 10.1111/j.1398-9995.2004.00720.x; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Simons E, 2005, ANN ALLERG ASTHMA IM, V95, P426, DOI 10.1016/S1081-1206(10)61166-0; Taylor SL, 2006, CURR OPIN ALLERGY CL, V6, P186, DOI 10.1097/01.all.0000225158.75521.ad; Vierk K, 2002, J ALLERGY CLIN IMMUN, V109, P1022, DOI 10.1067/mai.2002.124500; Vierk KA, 2007, J ALLERGY CLIN IMMUN, V119, P1504, DOI 10.1016/j.jaci.2007.03.011	16	85	89	1	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					337	341		10.1016/j.jaci.2009.05.032	http://dx.doi.org/10.1016/j.jaci.2009.05.032			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19596145	Bronze			2022-12-18	WOS:000268860400022
J	Hawkins, GA; Lazarus, R; Smith, RS; Tantisira, KG; Meyers, DA; Peters, SP; Weiss, ST; Bleecker, ER				Hawkins, Gregory A.; Lazarus, Ross; Smith, Richard S.; Tantisira, Kelan G.; Meyers, Deborah A.; Peters, Stephen P.; Weiss, Scott T.; Bleecker, Eugene R.			The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Corticosteroid; pharmacogenetics; glucocorticoid receptor; single nucleotide polymorphism; heat shock protein; heat shock organizing protein; immunophilin	RANDOMIZED CONTROLLED TRIAL; CHAPERONE MACHINERY; PERSISTENT ASTHMA; MODERATE ASTHMA; IN-VITRO; PROTEIN; RESISTANCE; POLYMORPHISMS; HSP90; HOP	Background: Corticosteroids exert their anti-inflammatory action by binding and activating the intracellular glucocorticoid receptor heterocomplex. Objective: We sought to evaluate the genes HSPCB, HSPCA, STIP1, HSPA8, DNAJB1, PTGES3, FKBP5, and FKBP4 on corticosteroid response. Methods: White asthmatic subjects (n = 382) randomized to once-daily flunisolide or conventional inhaled corticosteroid therapy were genotyped. Outcome measures were baseline FEV1, percent predicted FEV1, and percent change in FEV1 after corticosteroid treatment. Multivariable analyses adjusted for age, sex, and height were performed, fitting the most appropriate genetic model based on the quantitative mean derived from ANOVA models to determine whether there was an independent effect of polymorphisms on change in FEV1 independent of baseline level. Results: Positive recessive model correlations for STIP1 single nucleotide polymorphisms were observed for baseline FEV1 (rs4980524, P = .009; rs6591838, P = .0045; rs2236647, P = .002; and rs2236648; P = .013), baseline percent predicted FEV1 (rs4980524, P = .002; rs6591838, P = .017; rs2236647, P = .003, and rs2236648, P = .008), and percent change in FEV1 at 4 weeks (rs4980524, P = .044; rs6591838, P = .016; and rs2236647, P = .01) and 8 weeks (rs4980524, P = .044; rs6591838, P = .016; and rs2236647; P = .01) or therapy. Haplotypic associations were observed for baseline FEV1 and percent change in FEV1 at 4 weeks of therapy (P = .05 and P = .01, respectively). Significant trends toward association were observed for baseline percent predicted FEV1 and percent change in FEV1 at 8 weeks of therapy. Positive correlations between haplotypes and percent change in FEV1 were also observed. Conclusions: STIP1 genetic variations might play a role in regulating corticosteroid response in asthmatic subjects with reduced lung function. Replication in a second asthmatic population is required to confirm these observations. (J Allergy Clin Immunol 2009;123:1376-83.)	[Hawkins, Gregory A.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC 27157 USA; [Lazarus, Ross; Tantisira, Kelan G.; Weiss, Scott T.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Lazarus, Ross; Tantisira, Kelan G.; Weiss, Scott T.] Harvard Univ, Sch Med, Boston, MA USA	Wake Forest University; Wake Forest Baptist Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hawkins, GA (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Sect Pulm Crit Care Allergy & Immunol Dis, Med Ctr Blvd, Winston Salem, NC 27157 USA.	ghawkins@wfubmc.edu	Smith, Richard D/J-3664-2012	Smith, Richard D/0000-0002-2381-2349; lazarus, ross/0000-0003-3939-1961	National Institutes of Health [NHLBI HL077916, NHLBI HL69197, HL076285, NHLBI HL65899]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL065899, R01HL069167, R21HL077916, R01HL076285] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grants NHLBI HL077916 to G.A.H., NHLBI HL69197 and HL076285 to E.R.B., and NHLBI HL65899 to S.T.W.	BAMES PJ, 2006, EUR J PHARMACOL, V533, P2; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bielory L, 2000, CLIN DRUG INVEST, V19, P93, DOI 10.2165/00044011-200019020-00002; Bray PJ, 2003, HUM MUTAT, V21, P557, DOI 10.1002/humu.10213; BRUFSKY AM, 1990, T ASSOC AM PHYSICIAN, V103, P53; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Cortajarena AL, 2006, PROTEIN SCI, V15, P1193, DOI 10.1110/ps.062092506; DeRijk RH, 2002, J STEROID BIOCHEM, V81, P103, DOI 10.1016/S0960-0760(02)00062-6; Deykin A, 2007, AM J RESP CRIT CARE, V175, P228, DOI 10.1164/rccm.200601-112OC; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hawkins GA, 2004, DNA SEQUENCE, V15, P167, DOI 10.1080/10425170410001704517; Hillmann AG, 2000, CANCER RES, V60, P2056; Huizenga NATM, 2000, J CLIN ENDOCR METAB, V85, P2076, DOI 10.1210/jc.85.5.2076; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; KARL M, 1993, J CLIN ENDOCR METAB, V76, P683, DOI 10.1210/jc.76.3.683; Koper JW, 1997, HUM GENET, V99, P663, DOI 10.1007/s004390050425; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Longshaw VM, 2004, J CELL SCI, V117, P701, DOI 10.1242/jcs.00905; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Odunuga OO, 2004, BIOESSAYS, V26, P1058, DOI 10.1002/bies.20107; Pratt WB, 2006, HANDB EXP PHARM, V172, P111; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Rivers C, 1999, J CLIN ENDOCR METAB, V84, P4283, DOI 10.1210/jc.84.11.4283; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; TANTISIRA KG, 2005, RESP GENETICS, P191; Vottero A, 2002, J CLIN ENDOCR METAB, V87, P2658, DOI 10.1210/jc.87.6.2658; Weir B., 1996, GENETIC DATA ANAL; Wenzel S, 2003, MT SINAI J MED, V70, P185	35	85	91	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1376	1383		10.1016/j.jaci.2009.01.049	http://dx.doi.org/10.1016/j.jaci.2009.01.049			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19254810	Green Accepted			2022-12-18	WOS:000266799100032
J	Hesterberg, PE; Banerji, A; Oren, E; Penson, RT; Krasner, CN; Seiden, MV; Wong, JT				Hesterberg, Paul E.; Banerji, Aleena; Oren, Eyal; Penson, Richard T.; Krasner, Carolyn N.; Seiden, Michael V.; Wong, Johnson T.			Risk stratification for desensitization of patients with carboplatin hypersensitivity: Clinical presentation and management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Desensitization; drug allergy; carboplatin; ovarian cancer; skin testing; hypersensitivity	OVARIAN-CANCER; PROTOCOL; ANAPHYLAXIS; CISPLATIN; REPLACEMENT; PACLITAXEL; EXPERIENCE; TRIAL	Background: Women with ovarian cancer treated with chemotherapeutic platinum agents frequently develop hypersensitivity reactions (HSRs). How best to risk-stratify patients for desensitization is uncertain. Objectives: To evaluate skin test (ST) reactivity to carboplatin in patients with recent and remote histories of carboplatin HSR and to review the relationship between skin test reactivity and tolerance of subsequent carboplatin desensitization. Methods: Thirty-eight women with carboplatin HSR were evaluated by ST to carboplatin. Thirty women subsequently underwent 106 desensitizations to carboplatin. Results: Carboplatin ST was positive in 25 of 38 patients (66%). Of patients with recent HSR (<3 months), 20 of 24 (83%) tested positive, whereas 5 of 14 (36%) with remote HSR (>9 months) tested positive (P < .01). Nineteen carboplatin ST+ and 11 ST- patients underwent desensitization to carboplatin. Seven ST+ patients (37%) had mild HSR during desensitization but completed the desensitization with additional treatment or protocol modification. ST- patients with a recent history of HSR (n = 3) tolerated a rapid protocol without HSR and remained ST- with repeated testing. Six of 8 ST- patients (75%) with remote HSR reacted during desensitization. The HSRs were more severe and often associated with an elevated tryptase level. Five of 7 patients retested became ST+ before the second desensitization. Carboplatin desensitization was successfully completed in 105 of 106 (99%) treatment courses. Conclusions: The timing of carboplatin ST in relation to initial HSR is vital for risk stratification and subsequent desensitization. Initial ST- patients with a remote history of HSR are at high risk for conversion to ST+ and can develop more severe HSR. (J Allergy Clin Immunol 2009;123:1262-7.)	[Hesterberg, Paul E.; Banerji, Aleena; Oren, Eyal; Wong, Johnson T.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Penson, Richard T.; Krasner, Carolyn N.] Massachusetts Gen Hosp, Gillette Ctr, Boston, MA 02114 USA; [Penson, Richard T.; Krasner, Carolyn N.] Dana Farber Canc Res Ctr, Boston, MA USA; [Seiden, Michael V.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Fox Chase Cancer Center	Hesterberg, PE (corresponding author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Cox 201,100 Blossom St, Boston, MA 02114 USA.	phesterberg@partners.org	Oren, Eyal/AAD-5561-2019; Banerji, Aleena/ABG-1245-2021		Lev Pharmaceuticals; Genentech, Inc; DARA Biosciences, Inc; Berlex Laboratories; CuraGen Corp; PDL BioPharma; Imclone Systems Inc; Endocyte, Inc; Johnson Johnson; Frewn	Lev Pharmaceuticals; Genentech, Inc(Roche HoldingGenentech); DARA Biosciences, Inc; Berlex Laboratories; CuraGen Corp; PDL BioPharma; Imclone Systems Inc(Eli Lilly); Endocyte, Inc; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Frewn	Disclosure of potential conflict of interest: A. Banerji has received research support from Lev Pharmaceuticals. E. Oren has served on the speakers'bureau for GlaxoSmithKline and Meda Pharmaceuticals, Inc. R. T. Penson has received research support from Genentech, Inc, DARA Biosciences, Inc, Berlex Laboratories, CuraGen Corp, PDL BioPharma, Imclone Systems Inc, and Endocyte, Inc, and has served as an expert witness for Eli Lilly & Co. C. N. Krasner has received research support from Johnson & Johnson, Genentech, and Frewn. J. T Wong has served as an expert witness regarding drug infringement. The rest of the authors have declared that they have no conflict of interest.	American Cancer Society, 2005, CANC FACTS FIG 2005; Broome CB, 1996, MED PEDIATR ONCOL, V26, P105; Callahan MB, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.04.044; CHANG SM, 1995, CANCER, V75, P1171, DOI 10.1002/1097-0142(19950301)75:5<1171::AID-CNCR2820750518>3.0.CO;2-F; Confino-Cohen R, 2005, CANCER-AM CANCER SOC, V104, P640, DOI 10.1002/cncr.21168; Dizon DS, 2003, GYNECOL ONCOL, V91, P584, DOI 10.1016/j.ygyno.2003.08.017; du Bois A, 2003, JNCI-J NATL CANCER I, V95, P1320, DOI 10.1093/jnci/djg036; Fukui M., 2004, Journal of Allergy and Clinical Immunology, V113, pS72, DOI 10.1016/j.jaci.2003.12.231; Goldberg A, 1996, J ALLERGY CLIN IMMUN, V98, P841, DOI 10.1016/S0091-6749(96)70134-3; Gutierrez M, 2002, J CLIN ONCOL, V20, P353; Jones R, 2003, GYNECOL ONCOL, V89, P112, DOI 10.1016/S0090-8258(03)00066-0; Kandel MJ, 2005, INT J GYNECOL CANCER, V15, P780, DOI 10.1111/j.1525-1438.2005.00136.x; Lee CW, 2005, GYNECOL ONCOL, V99, P393, DOI 10.1016/j.ygyno.2005.06.028; Lee CW, 2004, GYNECOL ONCOL, V95, P370, DOI 10.1016/j.ygyno.2004.08.002; Lin RY, 2000, J ALLERGY CLIN IMMUN, V106, P65, DOI 10.1067/mai.2000.107600; Markman M, 1999, J CLIN ONCOL, V17, P1141, DOI 10.1200/JCO.1999.17.4.1141; Markman M, 2003, J CLIN ONCOL, V21, P4611, DOI 10.1200/JCO.2003.05.539; Markman M, 2004, J CANCER RES CLIN, V130, P25, DOI 10.1007/s00432-003-0501-3; MORGAN JS, 1994, EUR J CANCER, V30A, P1205, DOI 10.1016/0959-8049(94)90489-8; Ozols RF, 2003, J CLIN ONCOL, V21, P3194, DOI 10.1200/JCO.2003.02.153; Polyzos A, 2001, ONCOLOGY-BASEL, V61, P129, DOI 10.1159/000055363; Robinson JB, 2001, GYNECOL ONCOL, V82, P550, DOI 10.1006/gyno.2001.6331; Rose PG, 2003, GYNECOL ONCOL, V89, P429, DOI 10.1016/S0090-8258(03)00178-1; Rose PG, 1998, INT J GYNECOL CANCER, V8, P365; Shukunami K, 1999, TUMORI, V85, P297, DOI 10.1177/030089169908500418; Sliesoraitis S, 2005, INT J GYNECOL CANCER, V15, P13, DOI 10.1111/j.1048-891x.2005.14401.x; SOOD AK, 1995, GYNECOL ONCOL, V57, P131, DOI 10.1006/gyno.1995.1111; TONKIN KS, 1993, EUR J CANCER, V29A, P1356, DOI 10.1016/0959-8049(93)90093-U; WEIDMANN B, 1994, CANCER, V73, P2218, DOI 10.1002/1097-0142(19940415)73:8<2218::AID-CNCR2820730830>3.0.CO;2-1; WINDOM HH, 1992, J ALLERGY CLIN IMMUN, V90, P681, DOI 10.1016/0091-6749(92)90142-O; WONG JT, 1994, J ALLERGY CLIN IMMUN, V94, P189, DOI 10.1016/0091-6749(94)90039-6; Zanotti KM, 2001, J CLIN ONCOL, V19, P3126, DOI 10.1200/JCO.2001.19.12.3126; ZWEIZIG S, 1994, GYNECOL ONCOL, V53, P121, DOI 10.1006/gyno.1994.1098	33	85	90	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1262	1267		10.1016/j.jaci.2009.02.042	http://dx.doi.org/10.1016/j.jaci.2009.02.042			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19501233				2022-12-18	WOS:000266799100016
J	Burgler, S; Ouaked, N; Bassin, C; Basinski, TM; Mantel, PY; Siegmund, K; Meyer, N; Akdis, CA; Schmidt-Weber, CB				Burgler, Simone; Ouaked, Nadia; Bassin, Claudio; Basinski, Tomasz M.; Mantel, Pierre-Yves; Siegmund, Kerstin; Meyer, Norbert; Akdis, Cezmi A.; Schmidt-Weber, Carsten B.			Differentiation and functional analysis of human T(H)17 cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-17; regulatory T cells; differentiation; primary bronchial epithelial cells; airway inflammation; transcription factor; TGF-beta	GROWTH-FACTOR-BETA; ROR-GAMMA-T; TGF-BETA; PROINFLAMMATORY CYTOKINES; BONE DESTRUCTION; IFN-GAMMA; IL-17; INDUCTION; INTERLEUKIN-17; INFLAMMATION	Background: T(H)17 cells are of pathologic relevance in autoimmune disorders and presumably also in allergy and asthma. Regulatory T (Treg) cells, in contrast, suppress inflammatory and allergen-driven responses. Despite these disparate functions, both T-cell subsets have been shown to be dependent on TGF-beta for their development. Objective: The aim of the study was to analyze the differentiation and function of human T(H)17 cells in comparison with other T-H cell subsets. Methods: Naive human CD4(+) T cells were differentiated in vitro, and gene expression was analyzed by means of quantitative real-time PCR, ELISA, and immunofluorescence. The function of T-H cell subsets was assessed by monitoring the response of primary bronchial epithelial cells in coculture experiments. Results: In vitro differentiated T(H)17 cells differ from Treg and other T-H cells in their potency to induce IL-6 and IL-1 beta expression in primary bronchial epithelial cells. TGF-beta, IL-1 beta, IL-6, and IL-23 are necessary during T(H)17 cell differentiation to acquire these functions, including IL-17 production. In contrast, TGF-beta alone is necessary and sufficient to induce the transcription factor RORC2. This transcription factor, previously thought to be specific for T(H)17 cells, is also expressed in Treg cells, CD25(+) cells, cytotoxic T cells, and natural killer T cells. Conclusion: This study demonstrates mechanisms of differentiation to human T(H)17 cells, a subset that effectively and uniquely modulates the function of primary bronchial epithelial cells. (J Allergy Clin Immunol 2009;123:588-95.)	[Schmidt-Weber, Carsten B.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England; [Burgler, Simone; Ouaked, Nadia; Bassin, Claudio; Basinski, Tomasz M.; Mantel, Pierre-Yves; Siegmund, Kerstin; Meyer, Norbert; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res, Davos, Switzerland	Imperial College London; Swiss Institute of Allergy & Asthma Research; University of Zurich	Schmidt-Weber, CB (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Exhibition Rd,SAF 365, London SW7 2AZ, England.	c.schmidt-weber@imperial.ac.uk	Schmidt-Weber, Carsten B./AAU-1621-2021; Bellaire-Siegmund, Kerstin/AAA-9702-2021; Akdis, Cezmi/AAV-4844-2020; Bellaire-Siegmund, Kerstin/D-4774-2018; Mantel, Pierre-Yves/N-3065-2015	Schmidt-Weber, Carsten B./0000-0002-3203-8084; Bellaire-Siegmund, Kerstin/0000-0002-3654-1170; Akdis, Cezmi/0000-0001-8020-019X; Bellaire-Siegmund, Kerstin/0000-0002-3654-1170; Mantel, Pierre-Yves/0000-0001-9526-9309	Swiss National Science Foundation [310000-112329, 3200B0-118226]; Bonizzi-Theler Foundation Zurich, Switzerland; European Commission; M Curie Intra-European Fellowship; Medical Research Council [G0400503B] Funding Source: researchfish	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Bonizzi-Theler Foundation Zurich, Switzerland; European Commission(European CommissionEuropean Commission Joint Research Centre); M Curie Intra-European Fellowship; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by the Swiss National Science Foundation Grant no. 310000-112329, 3200B0-118226. Bonizzi-Theler Foundation Zurich, Switzerland.; Disclosure of potential conflict of interest: K. Siegmund has received research support from the European Commission, M Curie Intra-European Fellowship. The rest of the authors have declared that they have no conflict of interest.	Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Evans HG, 2007, P NATL ACAD SCI USA, V104, P17034, DOI 10.1073/pnas.0708426104; Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149; Forlow SB, 2001, BLOOD, V98, P3309, DOI 10.1182/blood.V98.12.3309; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hashimoto T, 2005, INT ARCH ALLERGY IMM, V137, P51, DOI 10.1159/000085432; Ichiyama K, 2008, J BIOL CHEM, V283, P17003, DOI 10.1074/jbc.M801286200; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Liu SJ, 2007, J LEUKOCYTE BIOL, V82, P354, DOI 10.1189/jlb.0207111; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Mantel PY, 2007, PLOS BIOL, V5, P2847, DOI 10.1371/journal.pbio.0050329; Matsunaga K, 2006, J ALLERGY CLIN IMMUN, V118, P84, DOI 10.1016/j.jaci.2006.04.020; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775; Schmidt-Weber CB, 2007, J ALLERGY CLIN IMMUN, V120, P247, DOI 10.1016/j.jaci.2007.06.039; Shin HCK, 1998, CYTOKINE, V10, P841, DOI 10.1006/cyto.1998.0375; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; Wong CK, 2001, CLIN EXP IMMUNOL, V125, P177, DOI 10.1046/j.1365-2249.2001.01602.x; Wong CK, 2000, LUPUS, V9, P589, DOI 10.1191/096120300678828703; Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021; Yang XXO, 2008, J EXP MED, V205, P1063, DOI 10.1084/jem.20071978; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404; Yu JJ, 2007, BLOOD, V109, P3794, DOI 10.1182/blood-2005-09-010116; Zheng SG, 2004, J IMMUNOL, V172, P5213, DOI 10.4049/jimmunol.172.9.5213; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878	38	85	93	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					588	595		10.1016/j.jaci.2008.12.017	http://dx.doi.org/10.1016/j.jaci.2008.12.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19178935				2022-12-18	WOS:000264731200016
J	Mikhak, Z; Fukui, M; Farsidjani, A; Medoff, BD; Tager, AM; Luster, AD				Mikhak, Zamaneh; Fukui, Mieko; Farsidjani, Alireza; Medoff, Benjamin D.; Tager, Andrew M.; Luster, Andrew D.			Contribution of CCR4 and CCR8 to antigen-specific T(H)2 cell trafficking in allergic pulmonary inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CCR4; CCR8; CXCR3; asthma; chemokine; T-cell trafficking	CHEMOKINE RECEPTORS CCR4; T-CELLS; AIRWAY INFLAMMATION; CUTTING EDGE; MOUSE MODEL; TH2 CELLS; RECRUITMENT; EXPRESSION; LUNG; HYPERRESPONSIVENESS	Background: Recruitment of antigen-specific T(H)2 cells into the lung is critical for the development of allergic airway inflammation. Although CCR4 and CCR8 are preferentially expressed on T(H)2 cells and CCR4, CCR8, and CXCR3 ligands are increased in asthma, the specific relative contribution of these receptors to antigen-specific T(H)2 cell trafficking into the allergic lung is not known. Objective: To determine the relative contribution of the chemokine receptors CCR4, CCR8, and CXCR3 to antigen-specific T(H)2 cell trafficking in a murine model of allergic pulmonary inflammation. Methods: We used adoptive transfer experiments to compare the trafficking of wild-type antigen-specific T(H)2 cells with antigen-specific T(H)2 cells deficient in CCR4, CCR8, or CXCR3. Results: CCR4-deficient antigen-specific T(H)2 cells failed to traffic efficiently into the lung and the airways. In contrast, CCR8-deficient antigen-specific T(H)2 cells accumulated in these sites. Trafficking of CXCR3-deficient antigen-specific T(H)2 cells and CCR4-deficient and CCR8-deficient antigen-specific Till cells were comparable to their wild-type counterparts. Approximately 60% of IL-4-producing antigen-specific T cells expressed CCR4. Disruption of CCR4-mediated antigen-specific T(H)2 cell trafficking decreased the levels of T(H)2-type cytokines in the airways and reduced airway eosinophilia and mucus production. Conclusions: Our study demonstrates that CCR4 is required for file efficient entry of antigen-specific T(H)2 cells into the lung and the airways in a murine model of allergic pulmonary inflammation. (J Allergy Clin Immunol 2009;123:67-73.)	[Mikhak, Zamaneh; Fukui, Mieko; Farsidjani, Alireza; Medoff, Benjamin D.; Tager, Andrew M.; Luster, Andrew D.] Harvard Univ, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Sch Med,Div Rheumatol Allergy & Immunol, Charlestown, MA 02129 USA; [Medoff, Benjamin D.; Tager, Andrew M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Luster, AD (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Sch Med,Div Rheumatol Allergy & Immunol, 149 13th St,Room 8301, Charlestown, MA 02129 USA.	aluster@mgh.harvard.edu	Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912; Medoff, Benjamin/0000-0002-2558-0449	National Institutes of Health [R37-AI40618, K08AI67519]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI040618, K08AI067519, R01AI040618] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	supported by the National Institutes of Health (R37-AI40618 to A.D.L. and K08AI67519 to Z.M.).	Bishop B, 2003, J IMMUNOL, V170, P4810, DOI 10.4049/jimmunol.170.9.4810; Bochner BS, 2003, J ALLERGY CLIN IMMUN, V112, P930, DOI 10.1016/j.jaci.2003.08.012; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Campbell JJ, 2001, J IMMUNOL, V166, P2842, DOI 10.4049/jimmunol.166.4.2842; Chensue SW, 2001, J EXP MED, V193, P573, DOI 10.1084/jem.193.5.573; Chung CD, 2003, J IMMUNOL, V170, P581, DOI 10.4049/jimmunol.170.1.581; Chvatchko Y, 2000, J EXP MED, V191, P1755, DOI 10.1084/jem.191.10.1755; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Conroy DM, 2003, J LEUKOCYTE BIOL, V74, P558, DOI 10.1189/jlb.0103030; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Gonzalo JA, 2007, J IMMUNOL, V179, P1740, DOI 10.4049/jimmunol.179.3.1740; Goya I, 2003, J IMMUNOL, V170, P2138, DOI 10.4049/jimmunol.170.4.2138; Hancock WW, 2000, J EXP MED, V192, P1515, DOI 10.1084/jem.192.10.1515; Harris NL, 2002, J EXP MED, V195, P317, DOI 10.1084/jem.20011558; Iellem A, 2001, J EXP MED, V194, P847, DOI 10.1084/jem.194.6.847; Kallinich T, 2005, CLIN EXP ALLERGY, V35, P26, DOI 10.1111/j.1365-2222.2004.02132.x; Kawasaki S, 2001, J IMMUNOL, V166, P2055, DOI 10.4049/jimmunol.166.3.2055; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Lee I, 2005, J EXP MED, V201, P1037, DOI 10.1084/jem.20041709; Mathew A, 2002, J IMMUNOL, V169, P651, DOI 10.4049/jimmunol.169.2.651; Mathew A, 2001, J EXP MED, V193, P1087, DOI 10.1084/jem.193.9.1087; Medoff BD, 2002, J IMMUNOL, V168, P5278, DOI 10.4049/jimmunol.168.10.5278; Meyer EH, 2007, J IMMUNOL, V179, P4661, DOI 10.4049/jimmunol.179.7.4661; Mikhak Z, 2006, J IMMUNOL, V176, P4959, DOI 10.4049/jimmunol.176.8.4959; Ohnmacht C, 2007, J IMMUNOL, V179, P4766, DOI 10.4049/jimmunol.179.7.4766; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Pilette C, 2004, EUR RESPIR J, V23, P876, DOI 10.1183/09031936.04.00102504; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Schaerli P, 2004, J EXP MED, V199, P1265, DOI 10.1084/jem.20032177; Schuh JM, 2002, FASEB J, V16, P1313, DOI 10.1096/fj.02-0193fje; Spinetti G, 2003, J LEUKOCYTE BIOL, V73, P201, DOI 10.1189/jlb.0302105; Thomas SY, 2007, J IMMUNOL, V179, P1901, DOI 10.4049/jimmunol.179.3.1901; Tong JK, 2006, J EXP MED, V203, P1173, DOI 10.1084/jem.20051680; Weninger W, 2001, J EXP MED, V194, P953, DOI 10.1084/jem.194.7.953; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zingoni A, 1998, J IMMUNOL, V161, P547	36	85	87	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					67	73		10.1016/j.jaci.2008.09.049	http://dx.doi.org/10.1016/j.jaci.2008.09.049			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19062085	Green Accepted			2022-12-18	WOS:000262793900010
J	Chapman, MD; Ferreira, F; Villalba, M; Cromwell, O; Bryan, D; Becker, WM; Fernandez-Rivas, M; Durham, S; Vieths, S; van Ree, R				Chapman, Martin D.; Ferreira, Fatima; Villalba, Mayte; Cromwell, Oliver; Bryan, Donna; Becker, Wolf-Meinhard; Fernandez-Rivas, Montserrat; Durham, Stephen; Vieths, Stefan; van Ree, Ronald		Create Consortium	The European Union CREATE Project: A model for international standardization of allergy diagnostics and vaccines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen standardisation; allergic diseases; allergy diagnostics; allergy vaccines; asthma; IgE; immunotherapy; purified allergens; genetic engineering	INDOOR ALLERGENS; THERAPEUTIC VACCINES; IMMUNOTHERAPY; ASTHMA; SENSITIZATION; CHILDREN; POLLEN; MITE; INTERVENTION; DETERMINANTS	Allergen measurements are used extensively in the formulation of allergy diagnostics and vaccines, yet no purified international allergen standards are available for calibration purposes. The aims of the European Union CREATE project were to develop international standards with verifiable allergen content. Purified natural and recombinant allergens were analyzed by means of SDS-PAGE, mass spectrometry, circular dichroism spectra, and small-angle x-ray scattering. IgE reactivity was assessed by means of direct RAST, RAST inhibition, immunoblotting, and basophil histamine release with sera from 961 allergic patients. Three recombinant allergens, rBet v 1, rPh1 p 5a, and rDer p 2, were structurally indistinguishable from their natural counterparts and showed excellent IgE reactivity suitable for use as certified reference materials. A second tier of allergens (rPhl p 5b, rOle e1, rDer p 1, rDer f 1, and rDer f 2) was identified that could provide suitable candidates for certified reference materials with minor improvements to the recombinant proteins. Only rPhl p I was considered unsuitable as a reference material. Quantitative ELISAs were identified that accurately measured each allergen, except for rPhl p 1. The CREATE project has provided a major step forward in allergen standardization and provides a model for the development of a comprehensive panel of international reference preparations that will harmonize allergen measurements worldwide. (J Allergy Clin Immunol 2008;122:882-9.)	[Chapman, Martin D.] Indoor Biotechnol Inc, Charlottesville, VA 22903 USA; [Ferreira, Fatima] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; [Villalba, Mayte] Univ Complutense, Dept Biochem & Mol Biol, E-28040 Madrid, Spain; [Cromwell, Oliver] Allergopharma Joachim Ganzer KG, Reinbeck, IA USA; [Bryan, Donna] Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England; [Becker, Wolf-Meinhard] Forschungszentrum Borstel, Borstel, Germany; [Fernandez-Rivas, Montserrat] Fdn Hosp Alcorcon, Madrid, Spain; [Durham, Stephen] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Vieths, Stefan] Paul Ehrlich Inst, D-6070 Langen, Germany; [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands	INDOOR Biotechnologies; Salzburg University; Complutense University of Madrid; National Institute for Biological Standards & Control; Forschungszentrum Borstel; Alcorcon Foundation University Hospital; Imperial College London; Paul Ehrlich Institute; University of Amsterdam; Academic Medical Center Amsterdam	Chapman, MD (corresponding author), Indoor Biotechnol Inc, 1216 Harris St, Charlottesville, VA 22903 USA.	mdc@inbio.com	Villalba, Mayte/K-5365-2014; Custovic, Adnan/A-2435-2012; Di Felice, Gabriella/B-9985-2016; Barber, Domingo/Y-9516-2019; Ferreira, Fatima/AAB-4321-2019; Villalba, María Teresa/AAW-1067-2020; Ferreira, Fatima/E-4889-2011; Wallner, Michael/L-5437-2015; RODRIGUEZ, ROSALIA/K-4993-2014; MARCO, FRANCISCO M/L-8723-2014	Custovic, Adnan/0000-0001-5218-7071; Di Felice, Gabriella/0000-0001-7387-9683; Barber, Domingo/0000-0002-5488-5700; Ferreira, Fatima/0000-0003-0989-2335; Villalba, María Teresa/0000-0002-0042-9953; Ferreira, Fatima/0000-0003-0989-2335; Wallner, Michael/0000-0001-6568-7892; RODRIGUEZ, ROSALIA/0000-0002-4280-3691; MARCO, FRANCISCO M/0000-0001-5113-3637; Chapman, Martin/0000-0002-0845-3632; Monsalve, Rafael/0000-0002-6838-4472; Valenta, Rudolf/0000-0001-5944-3365	European Union [G6RD-CT-2001-00582]; ALK-Abello; Aliergopharma Joachim Ganzer KG; ASAC Pharmaceutical International SA; Biomay AG; Laboratorios Leti; HAL Allergy BV; Indoor Biotechnologies Ltd; Stallergenes SA; Ministerio de Ciencia y Tecnologia; GlaxoSmithKline; German Research Society; Research Fund of the German Food Industry; Monsanto Company; European Directorate for the Quality of Medicines and Health Care	European Union(European Commission); ALK-Abello; Aliergopharma Joachim Ganzer KG; ASAC Pharmaceutical International SA; Biomay AG; Laboratorios Leti; HAL Allergy BV(HAL Allergy Group); Indoor Biotechnologies Ltd; Stallergenes SA; Ministerio de Ciencia y Tecnologia(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); GlaxoSmithKline(GlaxoSmithKline); German Research Society(German Research Foundation (DFG)); Research Fund of the German Food Industry; Monsanto Company; European Directorate for the Quality of Medicines and Health Care	Supported in part by the 5th Framework Programme of the European Union (contract no. G6RD-CT-2001-00582) and by the following companies: ALK-Abello, Aliergopharma Joachim Ganzer KG, ASAC Pharmaceutical International SA, Biomay AG, Laboratorios Leti, HAL Allergy BV, Indoor Biotechnologies Ltd, and Stallergenes SA.; Disclosure of potential conflict of interest: M. D. Chapman is co-owner of Indoor Biotechnologies and has received research support front the National Institute for Environmerval Health Sciences F Ferreira has received research support front Biomay and the Austrian Science Fund and has served as a consultant for Indoor Biotechnologies and the Allergen Online Database. M. Villalba has received research support from Ministerio de Ciencia y Tecnologia and ALK-Abello. O. Cromwell is employed by Allergopharma Joachim Ganzer. M. Fernandez-Rivas hits received research support from file European Commission. S. Durham has received research support from GlaxoSmithKline and ALK-Abello and has served its a member of the Immune Tolerance Network. S, Vieths hits received honoraria from Phadia and the Food Allergy Resource and Research Program: is an associate for the Institute for Product Quality: has received research support from the European Union, the German Research Society, the Research Fund of the German Food Industry, Monsanto Company, and the European Directorate for the Quality of Medicines and Health Care: and has served as a member of the European Academy of Allergy and Clinical Immunology. the International Union of Immunological Societies, the European Agency for the Evaluation of Medicinal Products, the European Pharmacopeia Commission, the ILSI Health and Environmental Institute, the Protein Allergenicity Technical Committee, CEN. and Deutsche Gesellschaft fir Allergic und Klinische Immunologic. R. van Rec hits consulting arrangements with Stallergenes, MAL Aristegui. and HAL Allergy BV. The rest of the authors have declared that they have no conflict of interest.	AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; *AM AC ALL ASTHM I, 2007, J ALLERGY CLIN IMMUN, V99, P583; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V111, P408, DOI 10.1067/mai.2003.16; Batard T, 2005, INT ARCH ALLERGY IMM, V136, P239, DOI 10.1159/000083950; Becker WM, 2006, CURR OPIN ALLERGY CL, V6, P470, DOI 10.1097/01.all.0000246622.34247.21; Bousquet J, 1998, ANN ALLERG ASTHMA IM, V81, P401, DOI 10.1016/S1081-1206(10)63136-5; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409, DOI 10.1067/mai.2000.109832; Geerlof A, 2006, ACTA CRYSTALLOGR D, V62, P1125, DOI 10.1107/S0907444906030307; Heinrich J, 2006, J ALLERGY CLIN IMMUN, V118, P674, DOI 10.1016/j.jaci.2006.06.012; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; KLEINE BI, 2001, INT ARCH ALLERGY IMM, V126, P277; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Nelson HS, 2007, J ALLERGY CLIN IMMUN, V119, P769, DOI 10.1016/j.jaci.2007.01.036; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P787, DOI 10.1067/mai.2000.110548; PLATTSMILLS TAE, 1991, J ALLERGY CLIN IMMUN, V87, P621, DOI 10.1016/0091-6749(91)90379-3; Reinders J, 2004, PROTEOMICS, V4, P3686, DOI 10.1002/pmic.200400869; SCHEINER O, 1994, ARB PEI GSH, V87, P221; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; Suck R, 2006, BBA-PROTEINS PROTEOM, V1764, P1701, DOI 10.1016/j.bbapap.2006.09.015; Takai T, 2005, J ALLERGY CLIN IMMUN, V115, P555, DOI 10.1016/j.jaci.2004.11.024; Van Ree R, 2008, ALLERGY, V63, P310, DOI 10.1111/j.1398-9995.2007.01612.x; van Ree R, 2007, J ALLERGY CLIN IMMUN, V119, P270, DOI 10.1016/j.jaci.2006.10.033; VANREE R, 2007, REGULATORY CONTROL S, P87; Verdino P, 2004, METHODS, V32, P241, DOI 10.1016/j.ymeth.2003.08.017; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Zock JP, 2006, J ALLERGY CLIN IMMUN, V118, P682, DOI 10.1016/j.jaci.2006.04.060	31	85	95	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					882	889		10.1016/j.jaci.2008.07.030	http://dx.doi.org/10.1016/j.jaci.2008.07.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	18762328				2022-12-18	WOS:000260940100003
J	Akkoc, T; de Koning, PJA; Ruckert, B; Barlan, I; Akdis, M; Akdis, CA				Akkoc, Tunc; de Koning, Pieter J. A.; Ruckert, Beate; Barlan, Isil; Akdis, Mubeccel; Akdis, Cezmi A.			Increased activation-induced cell death of high IFN-gamma-producing T(H)1 cells as a mechanism of T(H)2 predominance in atopic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T cells; activation-induced cell death; apoptosis; atopy; T(H)1 cells; CXCR3	FAS/FASL-MEDIATED APOPTOSIS; SELECTIVE UP-REGULATION; MATURE T-CELLS; CYTOKINE PRODUCTION; ALLERGIC DISEASE; TH2 CELLS; DERMATITIS; KERATINOCYTES; LYMPHOCYTES; EOSINOPHILIA	Background: A dysregulated and T(H)2-biased immune response appears to be a key pathogenetic factor in atopic diseases. Increased activation and massive infiltration of T cells in the dermis without any evidence for the expansion of their numbers in peripheral blood characterize atopic dermatitis. Objective: To investigate differences and mechanisms of T(H)1 and T(H)2 cell activation-induced cell death (AICD) in atopic disease. Methods: Naive (CD4(+)CD45(+)RA) and memory (CD4(+)CD45(+)RO) T cells were isolated from healthy and atopic individuals. T(H)1 and T(H)2 subsets were in vitro differentiated. High IFN-gamma-producing T cells and CXCR3(+) T cells were purified, and AICD of isolated cells was determined in addition to expression of apoptosis receptors and caspase activation. Results: T(H)1 cells, particularly their high IFN-gamma-producing fraction, and CXCR3(+) T cells showed significantly increased apoptosis in atopic individuals. During their in vitro differentiation, both T(H)1 and T(H)2 cells of atopic individuals showed increased apoptosis compared with the healthy control group, with a significantly high apoptosis in T(H)1 cells. Increased expression of Fas, Fas-ligand, tumor necrosis factor receptor-H, and caspase activation was detected on T(H)1 cells that underwent apoptosis. Neutralization experiments demonstrated a dominant role of IFN-gamma and Fas-Fas-ligand interaction-mediated suicide in T(H)1 cell AICD. Conclusion: Predominant T(H)2 profile in atopic diseases might be a result of the increased tendency to activation and apoptosis of high IFN-gamma-producing T(H)1 cells.	[Akkoc, Tunc; de Koning, Pieter J. A.; Ruckert, Beate; Akdis, Mubeccel; Akdis, Cezmi A.] Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; [Akkoc, Tunc; Barlan, Isil] Marmara Univ, Fac Med, Div Pediat Allergy & Immunol, Istanbul, Turkey; [de Koning, Pieter J. A.] Univ Utrecht, Ctr Med, Dept Pathol, Utrecht, Netherlands	Swiss Institute of Allergy & Asthma Research; Marmara University; Utrecht University	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	akdisac@siaf.unizh.ch	Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X				Akdis CA, 2004, CURR OPIN IMMUNOL, V16, P717, DOI 10.1016/j.coi.2004.09.004; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2000, CURR OPIN IMMUNOL, V12, P641, DOI 10.1016/S0952-7915(00)00156-4; Akdis CA, 1999, J INVEST DERMATOL, V113, P628, DOI 10.1046/j.1523-1747.1999.00720.x; Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Akdis M, 2003, FASEB J, V17, P1026, DOI 10.1096/fj.02-1070com; Akdis M, 1999, J IMMUNOL, V163, P466; Albanesi C, 1998, J INVEST DERMATOL, V110, P138; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Cormican L, 2001, CLIN EXP ALLERGY, V31, P731, DOI 10.1046/j.1365-2222.2001.01099.x; De Rose V, 2004, J LEUKOCYTE BIOL, V76, P423, DOI 10.1189/jlb.0503247; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Klunker S, 2003, J IMMUNOL, V171, P1078, DOI 10.4049/jimmunol.171.2.1078; Kumar S, 1997, INT J BIOCHEM CELL B, V29, P393, DOI 10.1016/S1357-2725(96)00146-X; Ledru E, 1998, J IMMUNOL, V160, P3194; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Pastore S, 1998, J ALLERGY CLIN IMMUN, V101, P538, DOI 10.1016/S0091-6749(98)70361-6; Pease JE, 2006, J ALLERGY CLIN IMMUN, V118, P305, DOI 10.1016/j.jaci.2006.06.010; Plaut M, 2003, J ALLERGY CLIN IMMUN, V112, P683, DOI 10.1016/j.jaci.2003.07.002; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3; Romagnani P, 2005, J ALLERGY CLIN IMMUN, V116, P1372, DOI 10.1016/j.jaci.2005.09.035; RUSSELL JH, 1995, CURR OPIN IMMUNOL, V7, P382, DOI 10.1016/0952-7915(95)80114-6; Sabbagh L, 2005, MOL IMMUNOL, V42, P1345, DOI 10.1016/j.molimm.2004.12.011; Scaffidi C, 1999, CURR OPIN IMMUNOL, V11, P277, DOI 10.1016/S0952-7915(99)80045-4; SIMON HU, 1995, IMMUNOL TODAY, V16, P53, DOI 10.1016/0167-5699(95)80086-7; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Varadhachary AS, 1999, J IMMUNOL, V163, P4772; Wollenberg A, 2003, J AM ACAD DERMATOL, V49, P198, DOI 10.1067/S0190-9622(03)00896-X; Wu CY, 2002, NAT IMMUNOL, V3, P852, DOI 10.1038/ni832; Yawalkar N, 2000, EUR J IMMUNOL, V30, P491, DOI 10.1002/1521-4141(200002)30:2<491::AID-IMMU491>3.3.CO;2-8; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	40	85	89	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					652	658		10.1016/j.jaci.2007.12.1171	http://dx.doi.org/10.1016/j.jaci.2007.12.1171			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18328893	Bronze			2022-12-18	WOS:000253918900017
J	Hankin, CS; Cox, L; Lang, D; Levin, A; Gross, G; Eavy, G; Meltzer, E; Burgoyne, D; Bronstone, A; Wang, ZH				Hankin, Cheryl S.; Cox, Linda; Lang, David; Levin, Arthur; Gross, Gary; Eavy, Gene; Meltzer, Eli; Burgoyne, Doug; Bronstone, Amy; Wang, Zhaohui			Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: Patterns of care, resource use, and costs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; immunotherapy; allergic rhinitis; children; use; persistence; cost; Medicaid	GRASS-POLLEN IMMUNOTHERAPY; 6-YEAR FOLLOW-UP; HOUSE-DUST MITE; SUBLINGUAL IMMUNOTHERAPY; SYMPTOMATIC TREATMENT; RESPIRATORY ALLERGY; ECONOMIC-EVALUATION; CLINICAL-EFFICACY; NATURAL-HISTORY; ATOPIC ECZEMA	Background: Although research demonstrates that allergy immunotherapy (IT) improves allergic rhinitis (AR) outcomes, little is known about IT patterns of care and associated resource use and costs among US children with diagnoses of AR. Objective: We sought to examine characteristics associated with receiving IT, patterns of IT care, and health care use and costs incurred in the 6 months before versus after IT. Methods: We performed retrospective Florida Medicaid claims data (1997-2004) analysis of children (< 18 years of age) given new diagnoses of AR. Results: Of 102,390 patients with new diagnoses of AR, 3048 (3.0%) received IT. Male patients, Hispanic patients, and those with concomitant asthma were significantly more likely to receive IT. Approximately 53% completed less than 1 year and 84% completed less than 3 years of IT. Patients who received IT used significantly less pharmacy (12.1 vs 8.9 claims, P < .0001), outpatient (30.7 vs 22.9 visits, P < .0001), and inpatient (1.2 vs 0.4 admissions, P = .02) resources in the 6 months after versus before IT. Pharmacy ($330 vs $60, P < .0001), outpatient ($735 vs $270, P < .0001), and inpatient ($2441 vs $1, P < .0001) costs (including costs for IT care) were significantly reduced after IT. Conclusion: Despite suboptimal treatment persistence (only 16 % of patients completed 3 years of IT), resource use and costs after treatment were significantly reduced from pre-IT levels.	[Hankin, Cheryl S.; Bronstone, Amy; Wang, Zhaohui] BioMed Econ, Moss Beach, CA 94038 USA; [Cox, Linda] Nova SE Univ, Sch Osteopath Med, Ft Lauderdale, FL 33314 USA; [Lang, David] Cleveland Clin, Cleveland, OH USA; [Gross, Gary] Dallas Allergy & Asthma Ctr, Dallas, TX USA; [Meltzer, Eli] Univ Calif San Diego, San Diego, CA USA; [Burgoyne, Doug] PERFORMAX Scrip World, Salt Lake City, UT USA	Nova Southeastern University; Cleveland Clinic Foundation; University of California System; University of California San Diego	Hankin, CS (corresponding author), LLC, POB 129, Moss Beach, CA 94038 USA.	cherylhankin@biomedecon.com	Cox, Linda/AAP-1697-2021	Cox, Linda/0000-0002-5258-6870				Ariano R, 2006, ALLERGY ASTHMA PROC, V27, P159; BERTO P, 2005, ALLERG IMMUNOL PARIS, V37, P303; Berto P, 2006, ANN ALLERG ASTHMA IM, V97, P615, DOI 10.1016/S1081-1206(10)61090-3; Blaiss M, 2004, CLIN THER, V26, P1876, DOI 10.1016/j.clinthera.2004.11.003; COHN JR, 1993, J ALLERGY CLIN IMMUN, V91, P734, DOI 10.1016/0091-6749(93)90192-I; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Donahue JG, 1999, ANN ALLERG ASTHMA IM, V82, P339, DOI 10.1016/S1081-1206(10)63282-6; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Eng PA, 2002, ALLERGY, V57, P306, DOI 10.1034/j.1398-9995.2002.1o3264.x; Greisner WA, 1998, ALLERGY ASTHMA PROC, V19, P271, DOI 10.2500/108854198778557728; Hedlin G, 1995, J ALLERGY CLIN IMMUN, V96, P879, DOI 10.1016/S0091-6749(95)70223-7; *I MED, 2002, UNEQ TREATM CONFR RA; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; Law AW, 2003, J ALLERGY CLIN IMMUN, V111, P296, DOI 10.1067/mai.2003.68; Lombardi C, 2004, J ALLERGY CLIN IMMUN, V113, P1219, DOI 10.1016/j.jaci.2004.03.013; LOWER T, 1993, ANN ALLERGY, V70, P480; Mahr TA, 2005, PEDIATR REV, V26, P284, DOI 10.1542/pir.26-8-284; Malling HJ, 2003, CURR ALLERGY ASTHM R, V3, P204, DOI 10.1007/s11882-003-0040-7; Marogna M, 2004, INT ARCH ALLERGY IMM, V135, P336, DOI 10.1159/000082329; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Marogna M, 2007, INT ARCH ALLERGY IMM, V142, P70, DOI 10.1159/000096001; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; More DR, 2002, ANN ALLERG ASTHMA IM, V88, P391, DOI 10.1016/S1081-1206(10)62370-8; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; *NAT AC AG SOC, 1999, CHRON COND CHALL 21; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Peden D, 2003, ANN ALLERG ASTHMA IM, V90, P1, DOI 10.1016/S1081-1206(10)63601-0; Petersen K D, 2005, Allergol Immunopathol (Madr), V33, P296, DOI 10.1016/S0301-0546(05)73246-8; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P401, DOI 10.1016/S0091-6749(99)70463-X; Rhodes BJ, 1999, ANN ALLERG ASTHMA IM, V82, P281, DOI 10.1016/S1081-1206(10)62609-9; Schadlich PK, 2000, PHARMACOECONOMICS, V17, P37, DOI 10.2165/00019053-200017010-00003; Settipane RA, 1999, ALLERGY ASTHMA PROC, V20, P209, DOI 10.2500/108854199778339053; Shamssain MH, 2001, ANN ALLERG ASTHMA IM, V86, P428, DOI 10.1016/S1081-1206(10)62490-8; Shamssain MH, 1999, ARCH DIS CHILD, V81, P313, DOI 10.1136/adc.81.4.313; Szeinbach SL, 2005, ANN ALLERG ASTHMA IM, V95, P167, DOI 10.1016/S1081-1206(10)61207-0; TINKELMAN D, 1995, ANN ALLERG ASTHMA IM, V74, P241; Valovirta E, 2002, CURR OPIN ALLERGY CL, V2, P553, DOI 10.1097/00130832-200212000-00013; Wieringa MH, 1999, ACTA PAEDIATR, V88, P147, DOI 10.1080/08035259950170295; Woodmansee DP, 2006, J ALLERGY CLIN IMMUN, V117, pS160, DOI 10.1016/j.jaci.2005.12.638	44	85	86	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					227	232		10.1016/j.jaci.2007.10.026	http://dx.doi.org/10.1016/j.jaci.2007.10.026			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18206509				2022-12-18	WOS:000252372000035
J	Wu, AC; Paltiel, AD; Kuntz, KM; Weiss, ST; Fuhlbrigge, AL				Wu, Ann C.; Paltiel, A. David; Kuntz, Karen M.; Weiss, Scott T.; Fuhlbrigge, Anne L.			Cost-effectiveness of omalizumab in adults with severe asthma: Results from the asthma policy model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						omalizumab; cost-effectiveness; asthma; anti-IgE	SEVERE ALLERGIC-ASTHMA; QUALITY-OF-LIFE; ANTI-IGE ANTIBODY; CHRONIC MYELOGENOUS LEUKEMIA; INHALED CORTICOSTEROIDS; DECISION-MAKING; UTILITY; EXACERBATIONS; OUTCOMES; VISITS	Background: Omalizumab (trade name Xolair) is approved by the US Food and Drug Administration for treatment of moderate-to-severe allergic asthma. Given the high acquisition cost of omalizumab, its role and cost-effectiveness in disease management require definition. Objective: We sought to identify the clinical and economic circumstances under which omalizumab might or might not be a cost-effective option by using a mathematic model. Methods: We merged published data on clinical and economic outcomes (including acute event incidence, frequency/severity of hospitalizations, and health-related quality of life) to project 10-year costs, quality-adjusted life years (QALYs), and cost-effectiveness of treatment with omalizurnab in addition to inhaled corticosteroids. Sensitivity analyses were conducted by using input data ranges from a variety of sources (published clinical trials and observational databases). Results: For patients with baseline acute event rates, omalizumab conferred an additional 1.7 quality-adjusted months at an incremental cost of $131,000 over a 10-year planning horizon, implying a cost-effectiveness ratio of $821,000 per QALY gained. For patients with 5 times the baseline acute event rate, the cost-effectiveness ratio was $491,000 per QALY gained. The projected cost-effectiveness ratio could fall within a range of other programs that are widely considered to be cost-effective if the cost of omalizumab decreases to less than $200. Conclusion: Omalizumab is not cost-effective for most patients with severe asthma. The projected cost-effectiveness ratios could fall within a favorable range if the cost of omalizumab decreases significantly. Clinical implications: Based on the high cost of omalizumab, it is especially important that clinicians explore alternative medications for asthma before initiating omalizumab.	Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Childrens Hosp, Boston, MA 02115 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Yale University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Wu, AC (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA.	ann.wu@childrens.harvard.edu	Wu, Ann/AAY-4293-2020	Wu, Ann/0000-0003-0599-9063; Paltiel, A. David/0000-0002-4861-3290	NHLBI NIH HHS [R01 HL68201-01A1, R01 HL068201] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068201] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adcock IM, 2004, CURR OPIN PHARMACOL, V4, P257, DOI 10.1016/j.coph.2004.02.001; Asche CV, 2005, J ALLERGY CLIN IMMUN, V115, P1095, DOI 10.1016/j.jaci.2004.12.1136; Ayres JG, 2004, ALLERGY, V59, P701, DOI 10.1111/j.1398-9995.2004.00533.x; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; Belliveau Paul P, 2005, J Manag Care Pharm, V11, P735; Bousquet J, 2005, ALLERGY, V60, P302, DOI 10.1111/j.1398-9995.2004.00770.x; Brown R, 2007, ALLERGY, V62, P149, DOI 10.1111/j.1398-9995.2006.01310.x; Buhl R, 2002, EUR RESPIR J, V20, P1088, DOI 10.1183/09031936.02.00016502; Buhl R, 2002, EUR RESPIR J, V20, P73, DOI 10.1183/09031936.02.00278102; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Cisternas MG, 2003, J ALLERGY CLIN IMMUN, V111, P1212, DOI 10.1067/mai.2003.1449; Corren J, 2003, J ALLERGY CLIN IMMUN, V111, P87, DOI 10.1067/mai.2003.49; Coventry J A, 1996, J Ambul Care Manage, V19, P9; Davydov L, 2005, AM FAM PHYSICIAN, V71, P341; Earle CC, 2000, J CLIN ONCOL, V18, P3302, DOI 10.1200/JCO.2000.18.18.3302; Eichler HG, 2004, VALUE HEALTH, V7, P518, DOI 10.1111/j.1524-4733.2004.75003.x; Fuhlbrigge AL, 2006, J ALLERGY CLIN IMMUN, V117, P359, DOI 10.1016/j.jaci.2005.10.036; Gold MR, 1996, COST EFFECTIVENESS H; Lanier BQ, 2003, ANN ALLERG ASTHMA IM, V91, P154, DOI 10.1016/S1081-1206(10)62170-9; Lee SJ, 1998, BLOOD, V92, P4047, DOI 10.1182/blood.V92.11.4047.423a04_4047_4052; Lemanske RF, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e55; LEWIS CE, 1984, PEDIATRICS, V74, P478; Liberato NL, 1997, J CLIN ONCOL, V15, P2673, DOI 10.1200/JCO.1997.15.7.2673; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; Miller TP, 2005, J ALLERGY CLIN IMMUN, V115, P429, DOI 10.1016/j.jaci.2004.10.049; Moy ML, 2004, ANN ALLERG ASTHMA IM, V92, P329, DOI 10.1016/S1081-1206(10)61570-0; National Heart Lung and Blood Institute, 2002, MORB MORT 2002; Niebauer K, 2006, ANN ALLERG ASTHMA IM, V96, P316, DOI 10.1016/S1081-1206(10)61242-2; Oba Y, 2004, J ALLERGY CLIN IMMUN, V114, P265, DOI 10.1016/j.jaci.2004.05.049; Paltiel AD, 2001, J ALLERGY CLIN IMMUN, V108, P39, DOI 10.1067/mai.2001.116289; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; REVICKI DA, 1993, QUAL LIFE RES, V2, P477, DOI 10.1007/BF00422222; REVICKI DA, 1992, MED CARE, V30, pMS274, DOI 10.1097/00005650-199205001-00027; ROSS RN, 1988, CLIN THER, V10, P188; RUTTENVANMOLKEN MPMH, 1992, SOC SCI MED, V35, P161; RUTTENVANMOLKEN MPMH, 1995, AM J RESP CRIT CARE, V151, P975; Saini SS, 1999, J IMMUNOL, V162, P5624; Segal R, 1995, Pharm Pract Manag Q, V15, P72; Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Stanford R, 1999, AM J RESP CRIT CARE, V160, P211, DOI 10.1164/ajrccm.160.1.9811040; Strunk RC, 2006, NEW ENGL J MED, V354, P2689, DOI 10.1056/NEJMct055184; Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004; *US BUR LAB STAT, 2006, CONS PRIC IND CPI DE; Walker S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub3; WEEKS JC, 1991, NEW ENGL J MED, V325, P81, DOI 10.1056/NEJM199107113250202; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; 2003, MEDL LETT DRUGS THER, V45, P67	49	85	89	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1146	1152		10.1016/j.jaci.2007.07.055	http://dx.doi.org/10.1016/j.jaci.2007.07.055			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17904628	Green Accepted			2022-12-18	WOS:000250973400025
J	Uekert, SJ; Akan, G; Evans, MD; Li, ZH; Roberg, K; Tisler, C; DaSilva, D; Anderson, E; Gangnon, R; Allen, DB; Gern, JE; Lemanske, RF				Uekert, Sara J.; Akan, Gloria; Evans, Michael D.; Li, Zhanhai; Roberg, Kathy; Tisler, Christopher; DaSilva, Douglas; Anderson, Elizabeth; Gangnon, Ronald; Allen, David B.; Gern, James E.; Lemanske, Robert F., Jr.			Sex-related differences in immune development and the expression of atopy in early childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokine; IFN-gamma; IL-5; IL-13; IL-10; sex; wheezing; atopy; allergic sensitization; birth cohort	INTERFERON-GAMMA PRODUCTION; BLOOD MONONUCLEAR-CELLS; T-CELLS; BRONCHIAL HYPERRESPONSIVENESS; DECREASED PRODUCTION; ANDROGEN RECEPTORS; CYTOKINE RESPONSES; GENERAL-POPULATION; LUNG GROWTH; IFN-GAMMA	Background: Sex and age are known to influence the clinical expression of asthma and allergic diseases. Objective: We sought to evaluate whether immune response profiles also vary by sex and age. Methods: We performed a prospective birth cohort study (Childhood Origins of Asthma) designed to evaluate interactions among age, sex, immune responses, and virus infections on the development of asthma and allergic diseases. Two hundred eighty-nine subjects were enrolled at birth, and 275 maintained prospective follow-up for 3 years. Cytokine response profiles at birth, 1, and 3 years of age; rates of wheezing, atopic dermatitis, and viral illnesses; and biomarkers of atopy, including total and specific IgE levels and peripheral eosinophil counts, were evaluated. Results: PHA-induced IFN-gamma responses were higher in boys at 1 year of age (median, 35 vs 19 pg/mL; P < .001) and at 3 years of age (median, 282 vs 181 pg/mL; P = .07). Among children who wheezed during the third year of life, boys had increased IFN-gamma, IL-5, and IL-13 responses at age 3 years (P < .001, P = .008, and P = .01, respectively). Boys also demonstrated increased rates of sensitization (P = .05 at year 1), total IgE levels (P = .03 at year 1 and P = .006 at year 3), and peripheral eosinophil counts (2.62 vs 1.85; P = .05 at year 3). Conclusion: Sex-specific differences in immune responses develop during early childhood; some of these differences developmentally proceed, whereas others occur in parallel to the clinical expression of various atopic phenotypes. Clinical implications: The differential expression of atopic diseases between boys and girls in early childhood is accompanied by sex-specific differences in immune response profiles.	Univ Wisconsin, Dept Pediat, Madison, WI USA; Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; Univ Wisconsin, Dept Med, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Lemanske, RF (corresponding author), Univ Wisconsin Hosp, K4-916,600 Highland Ave, Madison, WI 53792 USA.	rfl@medicine.wisc.edu		Evans, Michael/0000-0001-7449-3993; Gangnon, Ronald/0000-0003-2587-6714	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061879, P01HL070831] Funding Source: NIH RePORTER; NHLBI NIH HHS [1P01HL70831-01, 1R01HL61879-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benten WPM, 1999, FASEB J, V13, P123, DOI 10.1096/fasebj.13.1.123; COHEN JHM, 1983, J IMMUNOL, V131, P2767; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; DANEL L, 1983, J STEROID BIOCHEM, V18, P559, DOI 10.1016/0022-4731(83)90131-0; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; DOERSHUK CF, 1974, AM REV RESPIR DIS, V109, P452; Gern JE, 2002, PEDIAT ALLERG IMM-UK, V13, P386, DOI 10.1034/j.1399-3038.2002.01093.x; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Groschl M, 2003, CLIN CHEM, V49, P1688, DOI 10.1373/49.10.1688; Hepper PG, 1997, LANCET, V350, P1820, DOI 10.1016/S0140-6736(05)63635-5; HIBBERT M, 1995, PEDIATR PULM, V19, P129, DOI 10.1002/ppul.1950190208; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P1117, DOI 10.1067/mai.2000.105804; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; IRELAND DC, 1993, J MED VIROL, V40, P96, DOI 10.1002/jmv.1890400204; Kondo N, 1998, CLIN EXP ALLERGY, V28, P1340; KOVACS WJ, 1987, J IMMUNOL, V139, P490; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; LESOUEF PN, 1995, AM J RESP CRIT CARE, V152, P576, DOI 10.1164/ajrccm.152.2.7633710; LEWIS DB, 1986, J EXP MED, V163, P1018, DOI 10.1084/jem.163.4.1018; Leynaert B, 1997, AM J RESP CRIT CARE, V156, P1413, DOI 10.1164/ajrccm.156.5.9701060; Liao SY, 1996, CLIN EXP ALLERGY, V26, P397, DOI 10.1111/j.1365-2222.1996.tb00555.x; Manfreda J, 2004, CHEST, V125, P1657, DOI 10.1378/chest.125.5.1657; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Miles E A, 1994, Pediatr Allergy Immunol, V5, P202, DOI 10.1111/j.1399-3038.1994.tb00240.x; Miles EA, 1996, CLIN EXP ALLERGY, V26, P780, DOI 10.1111/j.1365-2222.1996.tb00608.x; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; OLSEN NJ, 1991, ENDOCRINOLOGY, V129, P2471, DOI 10.1210/endo-129-5-2471; PAOLETTI P, 1995, AM J RESP CRIT CARE, V151, P1770, DOI 10.1164/ajrccm.151.6.7767519; PEAT JK, 1992, EUR RESPIR J, V5, P921; Pohl D, 1997, ALLERGY, V52, P732, DOI 10.1111/j.1398-9995.1997.tb01230.x; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Ribeiro-do-Couto LM, 2001, EUR J IMMUNOL, V31, P3394, DOI 10.1002/1521-4141(200111)31:11<3394::AID-IMMU3394>3.0.CO;2-B; Rowe J, 2004, J ALLERGY CLIN IMMUN, V113, P710, DOI 10.1016/j.jaci.2003.12.585; Smart JM, 2002, CLIN EXP ALLERGY, V32, P796, DOI 10.1046/j.1365-2222.2002.01391.x; TANG M, 1993, CLIN EXP IMMUNOL, V92, P120; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; TEPPER RS, 1986, AM REV RESPIR DIS, V134, P513; THURLBECK WM, 1982, THORAX, V37, P564, DOI 10.1136/thx.37.8.564; TORDAY JS, 1987, EXP LUNG RES, V12, P1, DOI 10.3109/01902148709068811; TRIGG CJ, 1990, THORAX, V45, P866, DOI 10.1136/thx.45.11.866; Verthelyi D, 2000, IMMUNOLOGY, V100, P384, DOI 10.1046/j.1365-2567.2000.00047.x; vonMutius E, 1996, THORAX, V51, pS3, DOI 10.1136/thx.51.Suppl_1.S3; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; WEINSTEIN Y, 1981, J IMMUNOL, V126, P998; WILSON CB, 1986, J CLIN INVEST, V77, P860, DOI 10.1172/JCI112383	48	85	86	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1375	1381		10.1016/j.jaci.2006.09.008	http://dx.doi.org/10.1016/j.jaci.2006.09.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157669				2022-12-18	WOS:000242880300027
J	Gerhold, K; Avagyan, A; Seib, C; Frei, R; Steinle, J; Dittrich, AM; Blumchen, K; Lauener, R; Hamelmann, E				Gerhold, Kerstin; Avagyan, Angela; Seib, Christine; Frei, Remo; Steinle, Johanna; Dittrich, Anna-Maria; Blumchen, Katharina; Lauener, Roger; Hamelmann, Eckard			Prenatal initiation of endotoxin airway exposure prevents subsequent allergen-induced sensitization and airway inflammation in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; cytokines; lipopolysaccharides; mice; ovalbumin	REGULATORY T-CELLS; TOLL-LIKE RECEPTOR-4; MURINE MODEL; IN-VIVO; BACTERIAL LIPOPOLYSACCHARIDE; INTERLEUKIN-10 PRODUCTION; SIGNAL-TRANSDUCTION; IMMUNE-RESPONSES; DENDRITIC CELLS; ASTHMA	Background: New preventive strategies against the development of allergic diseases focus on potentially immunomodulatory components, such as bacterial LPSs. Optimal time frames for initiating immunomodulation to receive a sufficient effect against allergen sensitization are still unclear. Objective: Using a mouse model, we investigated the influence of prenatal LPS exposure on later allergen-mediated sensitization and airway inflammation in the offspring. Methods: Pregnant BALB/c mice were repeatedly exposed to acrosolized LPS (LPS Escherichia coli; 3x per week, day 7 of gestation time up to delivery). Some of the offspring were further exposed to aerosolized LPS before allergen sensitization with ovalbumin (OVA; administered intraperitoneally day 28 up to day 42) and OVA airway challenges (days 56-58). Positive control animals were placebo exposed to PBS instead of LPS, and negative control animals were first placebo exposed and later placebo sensitized with PBS instead of OVA. Results: Compared with positive control animals, prenatal LPS exposure suppressed (1) allergen-specific sensitization (IgE production), (2) eosinophilic airway inflammation (reduced numbers of eosinophils in bronchoalveolar lavage fluids), and (3) in vivo airway reactivity in response to methacholine. These effects occurred only when prenatal was combined with further postnatal LPS exposure. Suppression of allergen-mediated inflammatory responses was associated with increased Toll-like receptor and T-bet expression by lung tissues and a shift toward predominantly T(H)1 immune responses in spleen cells cultured with OVA in vitro. Conclusion: Prenatal initiated and postnatal sustained LPS exposure increased endotoxin susceptibility and prevented later allergen sensitization in offspring through inhibition of T(H)2 immune responses. Clinical implications: Immunomodulation with bacterial compounds during gestation time might be an effective mode for first-step primary prevention against allergic diseases.	Univ Hosp Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; Univ Zurich, Childrens Hosp, Div Immunol, Zurich, Switzerland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University Children's Hospital Zurich; University of Zurich	Gerhold, K (corresponding author), Univ Hosp Charite, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.	kerstin.gerhold@charite.de	Dittrich, Anna/GRY-6738-2022; Lauener, Roger P/O-8612-2016; Frei, Remo/AAI-9180-2020; Dittrich, Anna Maria/M-5640-2013; Hamelmann, Eckard/AAJ-9124-2021	Lauener, Roger P/0000-0002-8412-606X; 				Adkins B, 1998, J IMMUNOL, V160, P4217; Adkins P, 2001, J IMMUNOL, V166, P918, DOI 10.4049/jimmunol.166.2.918; Agnello D, 2003, J CLIN IMMUNOL, V23, P147, DOI 10.1023/A:1023381027062; Alexis NE, 2005, J ALLERGY CLIN IMMUN, V115, P345, DOI 10.1016/j.jaci.2004.11.040; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Chaouat G, 2004, INT ARCH ALLERGY IMM, V134, P93, DOI 10.1159/000074300; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Gao JX, 1999, IMMUNOLOGY, V98, P159; Gayle DA, 2004, AM J PHYSIOL-REG I, V286, pR1024, DOI 10.1152/ajpregu.00664.2003; Gentile DA, 2004, ANN ALLERG ASTHMA IM, V92, P538, DOI 10.1016/S1081-1206(10)61761-9; Gerberick GF, 1997, TOXICOL APPL PHARM, V146, P1, DOI 10.1006/taap.1997.8218; Gerhold K, 2003, J ALLERGY CLIN IMMUN, V112, P389, DOI 10.1067/mai.2003.1646; Gerhold K, 2002, J ALLERGY CLIN IMMUN, V110, P110, DOI 10.1067/mai.2002.125831; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; Harju K, 2001, PEDIATR RES, V49, P81, DOI 10.1203/00006450-200101000-00018; Isolauri E, 2004, CLIN EXP ALLERGY, V34, P1007, DOI 10.1111/j.1365-2222.2004.01999.x; KENNEDY JD, 1995, AM J RESP CELL MOL, V12, P613, DOI 10.1165/ajrcmb.12.6.7766426; Knapp S, 2006, J IMMUNOL, V176, P3189, DOI 10.4049/jimmunol.176.5.3189; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x; Rodriguez D, 2003, J IMMUNOL, V171, P1001, DOI 10.4049/jimmunol.171.2.1001; Savage NDL, 2002, EUR J IMMUNOL, V32, P2905, DOI 10.1002/1521-4141(2002010)32:10<2905::AID-IMMU2905>3.0.CO;2-6; Serebrisky D, 2000, J IMMUNOL, V165, P5906, DOI 10.4049/jimmunol.165.10.5906; Silva JRL, 2000, TOXICOLOGY, V152, P31; Smeltz RB, 2001, J EXP MED, V194, P143, DOI 10.1084/jem.194.2.143; Stassen M, 2004, EUR J IMMUNOL, V34, P1303, DOI 10.1002/eji.200324656; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; Takeuchi O, 2001, INT IMMUNOPHARMACOL, V1, P625, DOI 10.1016/S1567-5769(01)00010-8; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Tulic MK, 2001, AM J RESP CELL MOL, V24, P640, DOI 10.1165/ajrcmb.24.5.4265; Unger WWJ, 2003, INT IMMUNOL, V15, P731, DOI 10.1093/intimm/dxg069; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	40	85	85	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					666	673		10.1016/j.jaci.2006.05.022	http://dx.doi.org/10.1016/j.jaci.2006.05.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950286				2022-12-18	WOS:000240649000020
J	Smith, J; Owen, E; Earis, J; Woodcock, A				Smith, J; Owen, E; Earis, J; Woodcock, A			Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						antitussives; chronic bronchitis; placebo; chronic obstructive pulmonary disease; cough; cough monitoring	ANTITUSSIVE EFFICACY; DOSE-RESPONSE; DEXTROMETHORPHAN; CHILDREN; QUALITY; PLACEBO	Background: Codeine is the standard antitussive treatment to which novel agents are compared. Little is known about the objective effect of any treatments on cough in chronic obstructive pulmonary disease (COPD). Objective: To quantify the effect of codeine on objective cough frequency (quantified as time spent coughing: cough seconds, cs/h), citric acid cough threshold, and subjective measures in a double-blind, placebo-controlled crossover study in COPD. Methods: We studied 21 patients with physician-diagnosed, stable disease who complained of cough (76.9% male; mean age, 67.7 years; mean predicted FEV1, 53.4%; median smoking history, 43.5 pack-years). Each subject performed a cough challenge (single breath, citric acid), 10-hour daytime ambulatory and overnight cough recordings, subjective cough scores, and visual analog scales at baseline and on 2 study days, 1 week apart. Codeine phosphate 60 mg or matched placebo were given, in random order, at the start of each cough recording (0 and 12 hours). Results: Median time spent coughing at baseline was 8.27 cs/h (interquartile range [IQR], 5.94-11.67); after placebo treatment, 7.22 cs/h (IQR 4.42-10.40); and after codeine treatment, 6.41 cs[h (IQR 3.86-9.10). Codeine treatment had a significant effect on time spent coughing compared with baseline (P =.02) but not compared with placebo (P =.52). There were no significant differences in cough challenge thresholds (log concentration of tussive agent causing 2 coughs or log concentration of tussive agent causing 5 coughs) or subjective cough measures for codeine compared with placebo. Conclusion: In this study, codeine was no more effective than placebo in patients with COPD complaining of cough. Clinical implications: Codeine is the antitussive agent to which we compare new treatments; however, in a group of stable patients with COPD, it had no effect on cough frequency over placebo.	S Manchester Univ Hosp Trust, NW Lung Ctr, Manchester, Lancs, England; Aintree Univ Hosp NHS Fdn Trust, Aintree Chest Ctr, Liverpool, Merseyside, England	Aintree University Hospitals NHS Foundation Trust	Smith, J (corresponding author), Wythenshawe Hosp, NW Lung Res Ctr, Southmoor Rd, Manchester M23 9LT, Lancs, England.	jackyannsmith@hotmail.com		Smith, Jaclyn/0000-0001-8837-4928; Woodcock, Ashley/0000-0002-5428-8578				AYLWARD M, 1984, EUR J RESPIR DIS, V65, P283; Birring SS, 2003, THORAX, V58, P339, DOI 10.1136/thorax.58.4.339; Chang AB, 1998, EUR RESPIR J, V11, P462, DOI 10.1183/09031936.98.11020462; COX ID, 1984, BRIT J CLIN PHARMACO, V18, P377, DOI 10.1111/j.1365-2125.1984.tb02479.x; DILWORTH JP, 1990, THORAX, V45, P207, DOI 10.1136/thx.45.3.207; Doherty MJ, 2000, THORAX, V55, P643, DOI 10.1136/thorax.55.8.643; ECCLES R, 1992, J CLIN PHARM THER, V17, P175, DOI 10.1111/j.1365-2710.1992.tb01289.x; Eccles R, 2002, PULM PHARMACOL THER, V15, P303, DOI 10.1006/pupt.2002.0364; EMPEY DW, 1979, EUR J CLIN PHARMACOL, V16, P393, DOI 10.1007/BF00568199; Freestone C, 1997, J PHARM PHARMACOL, V49, P1045, DOI 10.1111/j.2042-7158.1997.tb06039.x; FREESTONE C, 1997, PULM PHARMACOL, V9, P365; French CT, 2002, CHEST, V121, P1123, DOI 10.1378/chest.121.4.1123; Hamutcu R, 2002, PEDIATR PULM, V34, P331, DOI 10.1002/ppul.10174; HIEW Y, 2002, IEEE INT C AC SPEECH, V4; HSU JY, 1994, EUR RESPIR J, V7, P1246, DOI 10.1183/09031936.94.07071246; Lee PCL, 2000, J PHARM PHARMACOL, V52, P1137, DOI 10.1211/0022357001774903; MATTHYS H, 1983, J INT MED RES, V11, P92, DOI 10.1177/030006058301100206; Morice AH, 2001, BRIT J CLIN PHARMACO, V52, P365, DOI 10.1046/j.0306-5251.2001.01475.x; Olia P M, 2000, Respirology, V5, P271, DOI 10.1046/j.1440-1843.2000.00259.x; Paul IM, 2004, PEDIATRICS, V114, pE85, DOI 10.1542/peds.114.1.e85; Pavesi L, 2001, CHEST, V120, P1121, DOI 10.1378/chest.120.4.1121; Rennard S, 2002, EUR RESPIR J, V20, P799, DOI 10.1183/09031936.02.03242002; Schroeder K, 2002, BRIT MED J, V324, P329, DOI 10.1136/bmj.324.7333.329; SCHROEDER K, 2004, COCHRANE DATABASE SY, V4; SEVELIUS H, 1966, J NEW DRUGS, V6, P216; SEVELIUS H, 1971, CLIN PHARMACOL THER, V12, P449; Smith JA, 2003, THORAX, V58, P48; THORPE CW, 1992, EUR RESPIR J, V5, P685; WOOLF C R, 1964, Thorax, V19, P125, DOI 10.1136/thx.19.2.125; Yaman MN, 2003, THORAX, V58, P47; [No title captured]	31	85	95	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					831	835		10.1016/j.jaci.2005.09.055	http://dx.doi.org/10.1016/j.jaci.2005.09.055			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630941				2022-12-18	WOS:000236862800017
J	Lowe, AJ; Carlin, JB; Bennett, CM; Abramson, MJ; Hosking, CS; Hill, DJ; Dharmage, SC				Lowe, AJ; Carlin, JB; Bennett, CM; Abramson, MJ; Hosking, CS; Hill, DJ; Dharmage, SC			Atopic disease and breast-feeding - cause or consequence?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						breast-feeding; atopic disease; atopic dermatitis; asthma; allergy prevention	OLD CHILDREN; BIRTH COHORT; ASTHMA; ECZEMA; DERMATITIS; RISK; DURATION; ALLERGY; INFANTS; SENSITIZATION	Background: A number of studies have observed an association between breast-feeding and increased risk of development of asthma and eczema. It has been proposed that these results might be due to early signs of atopic disease in the infant causing mothers to prolong breast-feeding. Objective: We sought to determine whether early symptoms of atopic disease (eczema, food reaction, or asthma) or positive skin prick test responses reduce the likelihood of ceasing breast-feeding. Methods: A prospective birth cohort of 620 infants from Melbourne, Australia, was used. Telephone interviews every 4 weeks were conducted until 64 weeks and then again at 78 and 104 weeks to determine duration of breast-feeding (both exclusive and total) and evidence of atopic disease. Because of the varying time of onset of atopic symptoms, they were modeled as time-varying covariates in Cox models. Results: Only 52 (8.4%) infants did not establish breast-feeding, whereas an additional 103 (25.0%) did not establish exclusive breast-feeding. Early signs of atopic disease or sensitization were independently associated with an approximately 28% reduction in risk of ceasing exclusive breast-feeding (adjusted hazard ratio, 0.72; 95% CI, 0.53-0.97; P = .029), but there was no evidence for a relationship with risk of ceasing breast-feeding completely (adjusted hazard ratio, 1.12; 95% CI, 0.92-1.37; P = .262). Conclusion: Early signs of atopic disease might prolong the duration of exclusive breast-feeding. This could mask a protective effect of breast-feeding or even result in breast-feeding appearing to be a risk factor for the development of atopic diseases. Future investigation of the relationship between breast-feeding and atopic diseases should consider this possibility.	Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Dept Publ Hlth, Fac Med Dent & Hlth Sci, Carlton, Vic 3053, Australia; Monash Univ, Dept Epidemiol & Publ Hlth, Clayton, Vic 3168, Australia; Royal Childrens Hosp, Dept Allergy, Melbourne, Vic, Australia	University of Melbourne; Monash University; Royal Children's Hospital Melbourne	Lowe, AJ (corresponding author), Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Dept Publ Hlth, Fac Med Dent & Hlth Sci, Level 2,723 Swanston St, Carlton, Vic 3053, Australia.	ajlowe@pgrad.unimelb.edu.au	Carlin, John/AAG-4332-2020; Carlin, John B/B-3492-2012; Abramson, Michael/AAQ-2671-2020	Carlin, John/0000-0002-2694-9463; Carlin, John B/0000-0002-2694-9463; Abramson, Michael/0000-0002-9954-0538; Bennett, Catherine/0000-0001-9581-1612; Lowe, Adrian/0000-0002-4691-8162				AAS K, 1973, INT ARCH ALLER A IMM, V45, P57, DOI 10.1159/000231002; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; Donath S, 2000, J PAEDIATR CHILD H, V36, P164, DOI 10.1046/j.1440-1754.2000.00486.x; Donath SM, 2000, J PAEDIATR CHILD H, V36, P482, DOI 10.1046/j.1440-1754.2000.00562.x; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; Grulee CG, 1936, J PEDIATR-US, V9, P223, DOI 10.1016/S0022-3476(36)80058-4; Heine RG, 2004, J PEDIATR-US, V144, P564, DOI 10.1016/j.jpeds.2004.03.001; Hill DJ, 2000, J PEDIATR-US, V137, P475, DOI 10.1067/mpd.2000.108207; HILL DJ, 1984, CLIN REV ALLERG, V2, P125; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P421, DOI 10.1111/j.1399-3038.2004.00178.x; Hoekstra MO, 2005, J ALLERGY CLIN IMMUN, V115, P1324, DOI 10.1016/j.jaci.2005.03.012; Hosmer Jr D.W., 1999, APPL SURVIVAL ANAL T, V1999, P561; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Kull I, 2005, J ALLERGY CLIN IMMUN, V116, P657, DOI 10.1016/j.jaci.2005.04.028; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; McVeagh P, 2002, MED J AUSTRALIA, V177, P128, DOI 10.5694/j.1326-5377.2002.tb04696.x; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Strachan DP, 1996, ARCH DIS CHILD, V74, P422, DOI 10.1136/adc.74.5.422; TAYLOR B, 1983, J EPIDEMIOL COMMUN H, V37, P95, DOI 10.1136/jech.37.2.95; Wetzig H, 2000, INT J HYG ENVIR HEAL, V203, P17, DOI 10.1078/S1438-4639(04)70003-6; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192; YOUNG E, 1994, LANCET, V343, P1127, DOI 10.1016/S0140-6736(94)90234-8	25	85	90	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					682	687		10.1016/j.jaci.2005.10.027	http://dx.doi.org/10.1016/j.jaci.2005.10.027			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522471				2022-12-18	WOS:000236263100027
J	Minh, HBC; Bousquet, PJ; Fontaine, C; Kvedariene, V; Demolly, P				Minh, HBC; Bousquet, PJ; Fontaine, C; Kvedariene, V; Demolly, P			Systemic reactions during skin tests with beta-lactams: A risk factor analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DRUG HYPERSENSITIVITY; ALLERGIC REACTIONS; PENICILLIN; HISTORY; DIAGNOSIS		CHU Montpellier, Hop Arnaud de Villeneuve, INSERM, IFR3,Med U454, F-34295 Montpellier 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Minh, HBC (corresponding author), CHU Montpellier, Hop Arnaud de Villeneuve, INSERM, IFR3,Med U454, F-34295 Montpellier 5, France.		Bousquet, Philippe Jean/AAW-8608-2021; Kvedarienė, Violeta/GON-7937-2022; Bousquet, Jean/O-4221-2019; Kvedariene, Violeta/D-7730-2011	Bousquet, Philippe Jean/0000-0002-0217-5483; Kvedarienė, Violeta/0000-0002-6119-211X; 				ADKINSON NF, 1984, J ALLERGY CLIN IMMUN, V74, P567, DOI 10.1016/0091-6749(84)90108-8; Brockow K, 2002, ALLERGY, V57, P45; Demoly P, 1999, ALLERGY, V54, P999, DOI 10.1034/j.1398-9995.1999.00247.x; GADDE J, 1993, JAMA-J AM MED ASSOC, V270, P2456, DOI 10.1001/jama.270.20.2456; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; Messaad D, 2004, ANN INTERN MED, V140, P1001, DOI 10.7326/0003-4819-140-12-200406150-00009; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; Torres MJ, 2003, ALLERGY, V58, P961, DOI 10.1034/j.1398-9995.2003.00280.x; Torres MJ, 2004, ALLERGY, V59, P219, DOI 10.1046/j.1398-9995.2003.00308.x; Torres MJ, 2002, CLIN EXP ALLERGY, V32, P270, DOI 10.1046/j.1365-2222.2002.01296.x; Torres MJ, 2001, ALLERGY, V56, P850, DOI 10.1034/j.1398-9995.2001.00089.x; Valyasevi MA, 2000, ANN ALLERG ASTHMA IM, V85, P363, DOI 10.1016/S1081-1206(10)62546-X	12	85	91	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					466	468		10.1016/j.jaci.2005.10.020	http://dx.doi.org/10.1016/j.jaci.2005.10.020			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461151				2022-12-18	WOS:000235687300032
J	Choi, IW; Sun-Kim; Kim, YS; Ko, HM; Im, SY; Kim, JH; You, HJ; Lee, YC; Lee, JH; Park, YM; Lee, HK				Choi, IW; Sun-Kim; Kim, YS; Ko, HM; Im, SY; Kim, JH; You, HJ; Lee, YC; Lee, JH; Park, YM; Lee, HK			TNF-alpha induces the late-phase airway hyperresponsiveness and airway inflammation through cytosolic phospholipase A(2) activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; late airway response; TNF-alpha; cytosolic phospholipase A(2); airway inflammation; cyclooxygenase; 5-lipoxygenase; platelet-activating factor	TUMOR-NECROSIS-FACTOR; CELL-DEFICIENT MICE; INDUCED ASTHMATIC RESPONSES; ACTIVE FATAL ANAPHYLAXIS; MAST-CELL; EOSINOPHILIC INFLAMMATION; BRONCHIAL-ASTHMA; IMMUNOGLOBULIN-E; GENE-EXPRESSION; ALLERGEN	Background: Late-phase airway hyperresponsiveness (AHR) in asthma is considered the event leading to persistent inflammation in the lungs, but the molecular mechanisms involved in this process are poorly understood. Objective: To examine the role of TNF-alpha in the development of a late AHR and airway inflammation in asthma. Methods: We established a marine model of asthma with not only biphasic AHR to methacholine but also airway eosinophilia. The effect of TNF-alpha blockade was determined by using anti-TNF-alpha antibody and TNF-alpha knockout mice. Cytosolic phospholipase A(2) (cPLA(2)) mRNA expression and activity were assessed by using RT-PCR and 1-stearoyl-2-[1-C-14] arachidonyl-sn-glycero-3-phosphocholine as the substrate, respectively. Results: TNF-alpha blockade resulted in significant inhibition of the late AHR without affecting the early AHR, and reduction in airway eosinophilia and inflammation. cPLA(2) activity was increased in asthmatic lungs in a TNF-alpha-dependent way, and cPLA2 inhibitor blocked late AHR and airway eosinophilia. TNF-alpha also stimulated the synthesis of cPLA(2) metabolites such as leukotriene B-4 and platelet-activating factor in the airway. Specific inhibitors of cPLA(2) metabolites inhibited the late AHR and airway eosinophilia. Conclusions: TNF-alpha is the proximal key cytokine capable of developing late-phase AHR and subsequent airway inflammation through expression/activation of cPLA(2).	Chonbuk Natl Univ, Sch Med, Dept Immunol, Chonju 561182, Chonbuk, South Korea; Inje Univ, ColMed2, Dept Microbiol, Chonju, Chonbuk, South Korea; Chonbuk Univ, Sch Med, Res Ctr Allerg Immune Dis, Chonju, Chonbuk, South Korea; Chonnam Natl Univ, Coll Nat Sci, Dept Biol Sci, Kwangju, South Korea; Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju, South Korea; Woonkwang Univ, Sch Med, Dept Otolaryngol, Iksan, South Korea; Pusan Natl Univ, Sch Med, Dept Microbiol & Immunol, Pusan 609735, South Korea	Jeonbuk National University; Inje University; Jeonbuk National University; Chonnam National University; Korea University; Gwangju Institute of Science & Technology (GIST); Wonkwang University; Pusan National University; Pusan National University Hospital	Lee, HK (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Immunol, Chonju 561182, Chonbuk, South Korea.	leeh-k@chonbuk.ac.kr	You, Hye Jin/AAF-7666-2019; YOU, HYEJIN/K-8951-2019; Kim, Jae-Hong/B-2530-2009	You, Hye Jin/0000-0001-5566-5171; Kim, Jae-Hong/0000-0002-8019-0208				BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; Choi IH, 1998, J EXP MED, V188, P1587, DOI 10.1084/jem.188.9.1587; Choi IW, 2003, J EXP MED, V198, P145, DOI 10.1084/jem.20022129; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; FISCHER AR, 1995, AM J RESP CRIT CARE, V152, P1203, DOI 10.1164/ajrccm.152.4.7551371; FREITAG A, 1993, THORAX, V48, P594, DOI 10.1136/thx.48.6.594; FREW AJ, 1990, AM REV RESPIR DIS, V141, P407, DOI 10.1164/ajrccm/141.2.407; FULLER RW, 1986, AM REV RESPIR DIS, V133, P252; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Henig NR, 2000, AM J RESP CRIT CARE, V162, P523, DOI 10.1164/ajrccm.162.2.9911084; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; JONES GL, 1992, AM REV RESPIR DIS, V145, P1270, DOI 10.1164/ajrccm/145.6.1270; Keatings VM, 1997, J ALLERGY CLIN IMMUN, V99, P693, DOI 10.1016/S0091-6749(97)70032-0; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332, DOI 10.1164/ajrccm/145.2_Pt_1.332; Korsgren M, 1997, J EXP MED, V185, P885, DOI 10.1084/jem.185.5.885; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; LUKACS NW, 1995, J IMMUNOL, V154, P5411; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Myou S, 2001, NAT IMMUNOL, V2, P145, DOI 10.1038/84244; Oh J, 2000, FEBS LETT, V477, P244, DOI 10.1016/S0014-5793(00)01812-3; Park JS, 1997, J IMMUNOL, V158, P5002; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76, DOI 10.1164/ajrccm.152.1.7599866; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; Waterman WH, 1996, BIOCHEM J, V319, P17, DOI 10.1042/bj3190017; Wu T, 1996, BBA-MOL CELL RES, V1310, P175, DOI 10.1016/0167-4889(95)00143-3; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	36	85	87	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					537	543		10.1016/j.jaci.2005.05.034	http://dx.doi.org/10.1016/j.jaci.2005.05.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159621				2022-12-18	WOS:000235686500011
J	Erwin, EA; Custis, NJ; Satinover, SM; Perzanowski, MS; Woodfolk, JA; Crane, J; Wickens, K; Platts-Mills, TAE				Erwin, EA; Custis, NJ; Satinover, SM; Perzanowski, MS; Woodfolk, JA; Crane, J; Wickens, K; Platts-Mills, TAE			Quantitative measurement of IgE antibodies to purified allergens using streptavidin linked to a high-capacity solid phase	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE antibody; streptavidin; CAP; atopic dermatitis; purified allergens	MODIFIED TH2 RESPONSE; ATOPIC-DERMATITIS; MONOCLONAL-ANTIBODIES; INHALANT ALLERGENS; IMMUNOGLOBULIN-E; ASTHMA SYMPTOMS; CAT ALLERGEN; CHILDREN; SENSITIZATION; EXPOSURE	Background: Commercially available assays for IgE antibody provide results in international units per milliliter for many allergen extracts, but this is not easily achieved with purified or novel allergens. Objective: To develop assays for IgE antibody suitable for purified or novel allergens by using a commercially available immunosorbent. Methods: Streptavidin coupled to a high-capacity immunosorbent (CAP) was used to bind biotinylated purified allergens from mite (Der p 1 and Der p 2), cat (Fel d 1), and dog (Can f 1). Assays for IgE antibody to these allergens were performed on sera from children (asthma and control) as well as adults with atopic dermatitis. Results: The results were validated by serial dilution of sera with high and low levels of IgE antibody and were quantitated in international units per milliliter by using a standard curve. Values for IgE antibody to Der p 1, Der p 2, and Fel d 1 correlated with values obtained with the allergen extracts (r(2) = 0.80, 0.84, and 0.95, respectively; P < .001 in each case). Furthermore, the values for IgE antibody in sera from children with high exposure to mite and cat allergens demonstrated 10-fold higher levels of IgE antibody to Der p 1 and Der p 2 than to Fel d 1 (P < .001). Conclusion: The streptavidin immunosorbent technique provides a new method for quantifying IgE antibody to purified proteins. The results provide evidence about the high quantities of IgE antibody to purified inhalant allergens in patients with atopie dermatitis. In addition, the results demonstrate major differences in IgE antibodies specific for mite and cat allergens among children with high exposure to both allergens.	Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; Columbia Univ, Dept Environm Hlth Sci, New York, NY USA	University of Virginia; Columbia University	Platts-Mills, TAE (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu		Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, P01AI050989, R37AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20565, P01-AI-50989] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aalberse RC, 2004, J ALLERGY CLIN IMMUN, V113, P983, DOI 10.1016/j.jaci.2004.02.046; Asher MI, 1998, EUR RESPIR J, V12, P315; Bayer E A, 1980, Methods Biochem Anal, V26, P1; CHAPMAN MD, 1983, J ALLERGY CLIN IMMUN, V72, P27, DOI 10.1016/0091-6749(83)90048-9; CHAPMAN MD, 1987, J IMMUNOL, V139, P1479; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; HAUN M, 1990, ANAL BIOCHEM, V191, P337, DOI 10.1016/0003-2697(90)90228-2; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; Ide F, 2004, PEDIATR INT, V46, P337, DOI 10.1111/j.1442-200x.2004.01880.x; IIO A, 1977, J CLIN INVEST, V59, P743, DOI 10.1172/JCI108695; ISHIZAKA K, 1967, J IMMUNOL, V98, P490; Jackola DR, 2004, HUM IMMUNOL, V65, P20, DOI 10.1016/j.humimm.2003.10.012; JOHANSSON SG, 1968, IMMUNOLOGY, V14, P265; KEMENY DM, 1986, J IMMUNOL METHODS, V87, P45, DOI 10.1016/0022-1759(86)90342-X; Knutsen AP, 2004, ALLERGY, V59, P198, DOI 10.1046/j.1398-9995.2003.00310.x; MAGNUSSON CGM, 1986, INT ARCH ALLER A IMM, V80, P329, DOI 10.1159/000234074; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; OWNBY DR, 2003, MIDDLETONS ALLERGY P, V2, P1087; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; SANDER I, 2002, STREPTAVIDIN IMMUNOC; Satinover SM, 2005, J ALLERGY CLIN IMMUN, V115, P803, DOI 10.1016/j.jaci.2005.01.018; Scalabrin DMF, 1999, J ALLERGY CLIN IMMUN, V104, P1273, DOI 10.1016/S0091-6749(99)70024-2; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; Strachan E, 2004, J MOL RECOGNIT, V17, P268, DOI 10.1002/jmr.669; Wickens K, 1997, CLIN EXP ALLERGY, V27, P1077, DOI 10.1111/j.1365-2222.1997.tb01260.x; WIDE L, 1967, LANCET, V2, P1105; WILLIAMS PB, 1992, ANN ALLERGY, V68, P35; Yarbrough JA, 1999, J ALLERGY CLIN IMMUN, V104, P704, DOI 10.1016/S0091-6749(99)70347-7; Yunginger JW, 2000, J ALLERGY CLIN IMMUN, V105, P1077, DOI 10.1067/mai.2000.107041	36	85	88	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1029	1035		10.1016/j.jaci.2004.12.1131	http://dx.doi.org/10.1016/j.jaci.2004.12.1131			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867862				2022-12-18	WOS:000229055100020
J	Erwin, EA; Wickens, K; Custis, NJ; Siebers, R; Woodfolk, J; Barry, D; Crane, J; Platts-Mills, TAE				Erwin, EA; Wickens, K; Custis, NJ; Siebers, R; Woodfolk, J; Barry, D; Crane, J; Platts-Mills, TAE			Cat and dust mite sensitivity and tolerance in relation to wheezing among children raised with high exposure to both allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; cat; mite; tolerance; high exposure	MODIFIED TH2 RESPONSE; CHILDHOOD ASTHMA; ATOPIC-DERMATITIS; IMMUNE-RESPONSE; NEW-ZEALAND; SENSITIZATION; ANTIBODIES; DETERMINANTS; PREVALENCE; ENDOTOXIN	Background: Recent evidence has suggested that high exposure to cat allergens is associated with decreased prevalence of sensitization to cat and, in some studies, decreased asthma. Objective: Our objective was to study antibodies to cat and mite allergens and their relationship to wheezing in a country with high exposure to both allergens. Methods: Sera from 112 wheezing and 112 control children aged 10 to 11 years in a nested case-control study in New Zealand were assayed for specific IgE antibody, as well as IgG antibody and IgG4 antibody, to Der p 1 and Fel d 1. Results: IgE antibody to both mite (99/224) and cat (41/224) were strongly associated with wheezing (odds ratios, 5.2 and 6.5, respectively). Children who had ever lived with a cat were less likely to have IgE antibody to cat (20/141 vs 21/83, P <.04); however, cat ownership had no effect on IgE antibody to mite (67/141 vs 32/83, P =.23). Among sensitized children, cat ownership was associated with a lower prevalence of IgE antibody to cat (28% vs 66%, P <.001), and this analysis remained significant after exclusion of children whose families had chosen not to own a cat. Among sensitized subjects, the mean titer of IgE antibody to cat (1.7 IU/mL) was 10-fold lower than for mite (22.1 IU/mL). A cat in the home had no significant effect on endotoxin or mite allergen in house dust, whereas cat allergen was much higher (40.8 vs 3.3 mug/g). Conclusion: The response to these 2 allergens was distinct on the basis of the prevalence of sensitization, the titer of IgE antibody, and the effect of cat ownership. The results suggest that induction of tolerance to cat allergen is an allergen-specific phenomenon that cannot be attributed to endotoxin or family choice. The strength of the IgE antibody response to dust mite in humid climates could contribute to the increased prevalence and severity of asthma.	Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; Wellington Sch Med & Hlth Sci, Wellington Asthma Res Grp, Wellington, New Zealand; Healthcare Hawkes Bay, Hastings, New Zealand	University of Virginia; University of Otago	Platts-Mills, TAE (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu	Siebers, Robert/A-4102-2009	Siebers, Robert/0000-0002-6359-3144; Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020565, P01AI050989, R01AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20565, P01-AI-50989] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asher MI, 1998, EUR RESPIR J, V12, P315; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BURR ML, 1994, INT J EPIDEMIOL, V23, P341, DOI 10.1093/ije/23.2.341; Carneiro R, 2004, J INVEST DERMATOL, V122, P927, DOI 10.1111/j.0022-202X.2004.22407.x; Custis NJ, 2003, CLIN EXP ALLERGY, V33, P986, DOI 10.1046/j.1365-2222.2003.01706.x; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Jeannin P, 1998, J IMMUNOL, V160, P3555; Kaiser L, 2003, J BIOL CHEM, V278, P37730, DOI 10.1074/jbc.M304740200; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Mandal AK, 2004, J EXP MED, V199, P1317, DOI 10.1084/jem.20031666; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; OWMBY DR, 2002, JAMA-J AM MED ASSOC, V288, P963; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2003, J ALLERGY CLIN IMMUN, V111, P123, DOI 10.1067/mai.2003.10; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; Portengen L, 2004, CLIN EXP ALLERGY, V34, P1243, DOI 10.1111/j.1365-2222.2004.02025.x; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; Sawyer G, 1998, J ALLERGY CLIN IMMUN, V102, P765, DOI 10.1016/S0091-6749(98)70016-8; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Shao L, 2001, SEMIN IMMUNOL, V13, P163, DOI 10.1006/smim.2000.0311; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wickens K, 1997, CLIN EXP ALLERGY, V27, P1077, DOI 10.1111/j.1365-2222.1997.tb01260.x; Woodfolk JA, 2002, INT ARCH ALLERGY IMM, V129, P277, DOI 10.1159/000067595	32	85	90	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					74	79		10.1016/j.jaci.2004.10.030	http://dx.doi.org/10.1016/j.jaci.2004.10.030			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637550				2022-12-18	WOS:000226267000010
J	Pastorello, EA; Farioli, L; Pravettoni, V; Robino, AM; Scibilia, J; Fortunato, D; Conti, A; Borgonovo, L; Bengtsson, A; Ortolani, C				Pastorello, EA; Farioli, L; Pravettoni, V; Robino, AM; Scibilia, J; Fortunato, D; Conti, A; Borgonovo, L; Bengtsson, A; Ortolani, C			Lipid transfer protein and vicilin are important walnut allergens in patients not allergic to pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						walnut; food allergy; nuts allergy; anaphylaxis; vicilin; lipid transfer protein	PEACH PRUNUS-PERSICA; MAJOR FOOD ALLERGEN; TREE NUT ALLERGY; ANAPHYLACTIC REACTIONS; CROSS-REACTIVITY; JUGLANS-REGIA; CLONING; PEANUT; IDENTIFICATION; PREVALENCE	Background: Walnut is the most common cause of allergic reactions to tree nuts, as reported by large population studies. Two major allergens of walnut have been identified up until now: a 2S albumin and a vicilin-like protein. Objective: This study was designed to identify the walnut major allergens in the Italian population and to compare the walnut IgE-binding profile in patients with or without pollen allergy. Methods: We selected 46 patients either with oral allergy syndrome confirmed by open oral challenge or with systemic symptoms after ingestion of walnut. These patients' sera were used for the immunoblotting of walnut extract; the identified allergens were purified by HPLC and sequenced. A peach-walnut cross-inhibition study was then performed. Results: The only major allergen recognized by our study population was a 9-kd lipid transfer protein (LTP), recognized by 37 patients. Two other minor allergens of approximately 9-kd molecular weight, both belonging to the vicilin family, were recognized by 10 patients. IgE binding to walnut UP was completely inhibited by peach LTP. Conclusion: In Italian patients with walnut allergy confirmed by documented history of severe systemic reactions or by open oral food challenge, the major allergen is an LTP. The sensitization to this protein seems to be secondary to the sensitization to peach LTP, which acts as the primary sensitizer. LTP and vicilins were able to sensitize patients not allergic to pollen.	IRCCS, Osped Maggiore, Allergy Ctr, Dept Internal Med & Dermatol,Div Internal Med & D, I-20122 Milan, Italy; Ist Clin Perfezionamento, Milan, Italy; Osped Niguarda Ca Granda, Natl Res Council, Milan, Italy; Ist Sci Prod Alimentari, Natl Res Council, Turin, Italy; Pharmacia Diagnost AB, S-75182 Uppsala, Sweden; Ist Allergol Lombardo, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Consiglio Nazionale delle Ricerche (CNR); Istituto Scienze delle Produzioni Alimentari (ISPA-CNR); Pfizer; Pharmacia Corporation	Pastorello, EA (corresponding author), IRCCS, Osped Maggiore, Allergy Ctr, Dept Internal Med & Dermatol,Div Internal Med & D, Via Pace 9, I-20122 Milan, Italy.	elide.pastorello@unimi.it	SCIBILIA, GIUSEPPE/AAC-9673-2022; PASTORELLO, ELIDE ANNA/E-3897-2017	SCIBILIA, GIUSEPPE/0000-0002-5452-4024; PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				Asero R, 2002, ALLERGY, V57, P900, DOI 10.1034/j.1398-9995.2002.t01-1-23541.x; Astwood JD, 2002, J ALLERGY CLIN IMMUN, V110, P26, DOI 10.1067/mai.2002.125690; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; Emmett SE, 1999, ALLERGY, V54, P380, DOI 10.1034/j.1398-9995.1999.00768.x; Fernandez-Rivas M, 1997, J ALLERGY CLIN IMMUN, V100, P728, DOI 10.1016/S0091-6749(97)70265-3; Garcia-Casado G, 2003, J ALLERGY CLIN IMMUN, V112, P599, DOI 10.1037/mai.2003.1638; Lopez-Torrejon G, 2003, J ALLERGY CLIN IMMUN, V112, P1208, DOI 10.1016/j.jaci.2003.08.035; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macdougall CF, 2002, ARCH DIS CHILD, V86, P236, DOI 10.1136/adc.86.4.236; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V104, P1099, DOI 10.1016/S0091-6749(99)70095-3; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Pastorello EA, 1999, BIOL CHEM, V380, P1315, DOI 10.1515/BC.1999.167; Pumphrey RSH, 2000, J CLIN PATHOL, V53, P273, DOI 10.1136/jcp.53.4.273; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Teuber SS, 1998, J ALLERGY CLIN IMMUN, V101, P807, DOI 10.1016/S0091-6749(98)70308-2; Teuber SS, 1999, J ALLERGY CLIN IMMUN, V104, P1311, DOI 10.1016/S0091-6749(99)70029-1; Vierk K, 2002, J ALLERGY CLIN IMMUN, V109, P1022, DOI 10.1067/mai.2002.124500	21	85	94	4	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					908	914		10.1016/j.jaci.2004.06.020	http://dx.doi.org/10.1016/j.jaci.2004.06.020			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480333				2022-12-18	WOS:000224439100027
J	Bates, CA; Silkoff, PE				Bates, CA; Silkoff, PE			Exhaled nitric oxide in asthma: From bench to bedside	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exhaled; nitric oxide; asthma; monitoring	MUCOSAL EOSINOPHILIC INFLAMMATION; AIRWAY INFLAMMATION; MILD ASTHMA; INHALED CORTICOSTEROIDS; SPUTUM EOSINOPHILS; ALLERGIC RHINITIS; DIFFICULT ASTHMA; CHILDREN; HYPERRESPONSIVENESS; THERAPY	With more than 600 publications, exhaled nitric oxide (NO) has been extensively investigated as a noninvasive marker of airway inflammation in a research setting. This clinical rostrum presents a synopsis of the latest research about this novel marker in asthma and suggests how it might move from bench to bedside. Specifically, we review the evidence citing the applicability of exhaled NO in diagnosing asthma, monitoring the response to therapy, evaluating current symptom control, and predicting exacerbations of asthma. These studies support a role for exhaled NO in the evaluation and treatment of asthma in the clinical arena. (J Allergy Clin Immunol 2003;111: 256-62.).	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA	National Jewish Health	Bates, CA (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.		silkoff, philip/S-9037-2016	silkoff, philip/0000-0001-6018-5199				ALVING K, 1993, EUR RESPIR J, V6, P1368; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P262, DOI 10.1164/ajrccm.159.1.9804063; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Beck-Ripp J, 2002, EUR RESPIR J, V19, P1015, DOI 10.1183/09031936.02.01582001; Berlyne GS, 2000, J ALLERGY CLIN IMMUN, V106, P638, DOI 10.1067/mai.2000.109622; Bratton DL, 1999, PEDIATR PULM, V28, P402, DOI 10.1002/(SICI)1099-0496(199912)28:6<402::AID-PPUL3>3.0.CO;2-V; Chatkin JM, 1999, AM J RESP CRIT CARE, V159, P1810, DOI 10.1164/ajrccm.159.6.9809047; Colon-Semidey AJ, 2000, PEDIATR PULM, V30, P385, DOI 10.1002/1099-0496(200011)30:5<385::AID-PPUL4>3.0.CO;2-#; Deykin A, 2002, AM J RESP CRIT CARE, V165, P1597, DOI 10.1164/rccm.2201081; Dupont LJ, 1998, AM J RESP CRIT CARE, V157, P894, DOI 10.1164/ajrccm.157.3.9709064; Franklin PJ, 1999, AM J RESP CRIT CARE, V159, P69, DOI 10.1164/ajrccm.159.1.9804134; Gao PS, 2000, BIOCHEM BIOPH RES CO, V267, P761, DOI 10.1006/bbrc.1999.2030; Girgis RE, 2002, AM J RESP CRIT CARE, V165, P1587, DOI 10.1164/rccm.2104003; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; Henriksen AH, 2000, EUR RESPIR J, V15, P849, DOI 10.1034/j.1399-3003.2000.15e07.x; Henriksen AH, 1999, EUR RESPIR J, V13, P301, DOI 10.1034/j.1399-3003.1999.13b14.x; Henriksen AH, 2001, RESP MED, V95, P122, DOI 10.1053/rmed.2000.1004; Hunt J, 2002, J ALLERGY CLIN IMMUN, V110, P28, DOI 10.1067/mai.2002.124966; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694, DOI 10.1164/ajrccm.161.3.9911005; Hyde RW, 1997, J APPL PHYSIOL, V82, P1290, DOI 10.1152/jappl.1997.82.4.1290; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Jorres RA, 2000, EUR RESPIR J, V16, P555, DOI 10.1034/j.1399-3003.2000.016003555.x; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Khatri SB, 2001, AM J RESP CRIT CARE, V164, P1844, DOI 10.1164/ajrccm.164.10.2106119; Lanz MJ, 1999, ANN ALLERG ASTHMA IM, V82, P161, DOI 10.1016/S1081-1206(10)62591-4; Lehtimaki L, 2000, ANN MED, V32, P417, DOI 10.3109/07853890008995949; Lehtimaki L, 2001, AM J RESP CRIT CARE, V163, P1557, DOI 10.1164/ajrccm.163.7.2010171; Lim S, 2000, THORAX, V55, P184, DOI 10.1136/thorax.55.3.184; Little SA, 2000, THORAX, V55, P232, DOI 10.1136/thorax.55.3.232; Massaro AF, 1996, AM J RESP CRIT CARE, V153, P1510, DOI 10.1164/ajrccm.153.5.8630594; Parameswaran K, 2001, Can Respir J, V8, P239; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Piacentini GL, 1999, J ALLERGY CLIN IMMUN, V104, P1323, DOI 10.1016/S0091-6749(99)70031-X; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; SHELHAMER JH, 1995, ANN INTERN MED, V123, P288, DOI 10.7326/0003-4819-123-4-199508150-00008; Silkoff PE, 1998, J ASTHMA, V35, P473, DOI 10.3109/02770909809071000; Silkoff PE, 2000, J ALLERGY CLIN IMMUN, V105, P438, DOI 10.1067/mai.2000.104938; Silkoff PE, 2001, CHEST, V119, P1322, DOI 10.1378/chest.119.5.1322; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260, DOI 10.1164/ajrccm.155.1.9001322; SILKOFF PE, 2000, AM J RESP CRIT CARE, V161; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Stirling RG, 1998, THORAX, V53, P1030, DOI 10.1136/thx.53.12.1030; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Tsang KW, 2001, LUNG, V179, P83, DOI 10.1007/s004080000050; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653, DOI 10.1152/jappl.1998.85.2.653; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107, DOI 10.1164/ajrccm.164.11.2006165; Wilson AM, 2001, CHEST, V119, P1021, DOI 10.1378/chest.119.4.1021; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892, DOI 10.1164/ajrccm.152.3.7663801	50	85	89	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					256	262		10.1067/mai.2003.103	http://dx.doi.org/10.1067/mai.2003.103			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589342				2022-12-18	WOS:000180942700006
J	Benn, CS; Thorsen, P; Jensen, JS; Kjaer, BB; Bisgaard, H; Andersen, M; Rostgaard, K; Bjorksten, B; Melbye, M				Benn, CS; Thorsen, P; Jensen, JS; Kjaer, BB; Bisgaard, H; Andersen, M; Rostgaard, K; Bjorksten, B; Melbye, M			Maternal vaginal microflora during pregnancy and the risk of asthma hospitalization and use of antiasthma medication in early childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; wheezing; childhood; maternal vaginal microflora; Ureaplasma urealyticum; staphylocci; antibiotics	UREAPLASMA-UREALYTICUM; INTESTINAL MICROFLORA; BACTERIAL VAGINOSIS; FECAL MICROFLORA; INFANTS; NEWBORN; COLONIZATION; TRANSMISSION; FLORA; ATOPY	Background: Infants with wheezing and allergic diseases have a microflora that differs from that of healthy infants. The fetus acquires microorganisms during birth when exposed to the maternal vaginal micronora. It is therefore conceivable that the maternal vaginal microflora might influence the establishment of the infant flora and, as a consequence, the development of wheezing and allergic diseases. Objective: We sought to study the associations between the composition of the maternal vaginal microflora and the development of wheezing and asthma in childhood. Methods: We pet-formed a population-based cohort study in Denmark. Vaginal samples for bacterial analysis were obtained during pregnancy. A total of 2927 women (80% of the invited women) completed the study and had 3003 live infants. Infant wheezing was assessed as one or more hospitalizations for asthma between 0 and 3 years of age. Asthma was assessed as use of 3 or more packages of antiasthma medication between 4 and 5 years of age. Results: Maternal vaginal colonization with Ureaplasma urealyticum during pregnancy was associated with infant wheezing (odds ratio [OR], 2.0; 95% Cl, 1.2-3.6), but not with asthma, during the fifth year of life. Maternal colonization with staphylococci (OR, 2.2; 95 % CI, 1.4-3.4) and use of antibiotics in pregnancy (OR, 1.7, 95% Cl, 1.1-2.6) were associated with asthma during the fifth year of life. Conclusion: The composition of the maternal vaginal microflora might be associated with wheezing and asthma in the offspring up to 5 years of age.	Statens Serum Inst, Dept Epidemiol Res, Danish Epidemiol Sci Ctr, DK-2300 Copenhagen S, Denmark; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Karolinska Inst, Ctr Allergy Res, S-10401 Stockholm, Sweden; Univ So Denmark, Inst Publ Hlth, Dept Clin Pharmacol, Odense, Denmark; Rigshosp, Dept Pediat, DK-2100 Copenhagen, Denmark; Statens Serum Inst, Mycoplasma Lab, DK-2300 Copenhagen S, Denmark; Aarhus Univ, Dept Epidemiol & Social Med, Aarhus, Denmark	Aarhus University; Statens Serum Institut; Karolinska Institutet; Karolinska Institutet; University of Southern Denmark; Rigshospitalet; University of Copenhagen; Statens Serum Institut; Aarhus University	Benn, CS (corresponding author), Statens Serum Inst, Dept Epidemiol Res, Danish Epidemiol Sci Ctr, 5 Artillerivej, DK-2300 Copenhagen S, Denmark.		Kronow, Joern/B-1054-2011; Jensen, Jørgen Skov/H-5159-2019; Andersen, Morten/H-3555-2011; Bisgaard, Hans/N-4761-2016; Jensen, Jørgen/I-2917-2012	Jensen, Jørgen Skov/0000-0002-7464-7435; Andersen, Morten/0000-0001-7029-2860; Bisgaard, Hans/0000-0003-4131-7592; melbye, mads/0000-0001-8264-6785; Rostgaard, Klaus/0000-0001-6220-9414				Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590, DOI 10.1046/j.1365-2222.2000.00982.x; BOWIE WR, 1987, SEX TRANSM DIS, V14, P88, DOI 10.1097/00007435-198704000-00006; BROOK I, 1979, PEDIATRICS, V63, P451; BRUNEL A, 1993, BIOL NEONATE, V63, P236; CASSELL GH, 1991, CLIN PERINATOL, V18, P241, DOI 10.1016/S0095-5108(18)30522-0; CASSELL GH, 1983, SEX TRANSM DIS, V10, P294; CHUN KB, 1999, MED J MALAYSIA, V54, P242; Dodge R, 1996, J ALLERGY CLIN IMMUN, V98, P48, DOI 10.1016/S0091-6749(96)70225-7; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; ESCHENBACH DA, 1991, AM J OBSTET GYNECOL, V164, P734, DOI 10.1016/0002-9378(91)90506-M; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; Gaist D, 1997, DAN MED BULL, V44, P445; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; HALL MA, 1990, ARCH DIS CHILD, V65, P185, DOI 10.1136/adc.65.2.185; Hessle C, 2000, INFECT IMMUN, V68, P3581, DOI 10.1128/IAI.68.6.3581-3586.2000; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; KeskiNisula L, 1997, J REPROD MED, V42, P91; Kundsin RB, 1996, INFECT DIS CLIN PRAC, V5, P551, DOI 10.1097/00019048-199612000-00010; Lindberg E, 2000, PEDIATR RES, V48, P741, DOI 10.1203/00006450-200012000-00007; LONG SS, 1977, J PEDIATR-US, V91, P298, DOI 10.1016/S0022-3476(77)80836-6; LUNDEQUIST B, 1985, ACTA PAEDIATR SCAND, V74, P45, DOI 10.1111/j.1651-2227.1985.tb10919.x; Mandar R, 1996, BIOL NEONATE, V69, P30; NEUT C, 1987, ZBL BAKT-INT J MED M, V266, P330; Povlsen K, 2001, EUR J CLIN MICROBIOL, V20, P65, DOI 10.1007/PL00011237; Royer B, 2001, CLIN EXP ALLERGY, V31, P694, DOI 10.1046/j.1365-2222.2001.01069.x; SANCHEZ PJ, 1987, PEDIATR INFECT DIS J, V6, P825, DOI 10.1097/00006454-198709000-00006; SPORIK R, 1991, ARCH DIS CHILD, V66, P1050, DOI 10.1136/adc.66.9.1050; Stephenson J, 1997, JAMA-J AM MED ASSOC, V278, P2051, DOI 10.1001/jama.278.23.2051; Strachan DP, 1998, THORAX, V53, P204, DOI 10.1136/thx.53.3.204; Stray-Pedersen B, 1999, INT J ANTIMICROB AG, V12, P245, DOI 10.1016/S0924-8579(99)00068-0; SYROGIANNOPOULOS GA, 1990, PEDIATR INFECT DIS J, V9, P236, DOI 10.1097/00006454-199004000-00003; TANNOCK GW, 1990, J CLIN MICROBIOL, V28, P1225, DOI 10.1128/JCM.28.6.1225-1228.1990; Thorsen P, 1998, AM J OBSTET GYNECOL, V178, P580, DOI 10.1016/S0002-9378(98)70442-9; Trefny P, 2000, PEDIATR PULM, V30, P302, DOI 10.1002/1099-0496(200010)30:4<302::AID-PPUL5>3.0.CO;2-R; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766; Wold AE, 1998, ALLERGY, V53, P20, DOI 10.1111/j.1398-9995.1998.tb04953.x; Wright AL, 1999, J ALLERGY CLIN IMMUN, V104, P589, DOI 10.1016/S0091-6749(99)70328-3; 1997, ALLERGY ALLERGIC DIS	42	85	89	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					72	77		10.1067/mai.2002.125833	http://dx.doi.org/10.1067/mai.2002.125833			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110824				2022-12-18	WOS:000176870300016
J	Bandeira-Melo, C; Bozza, PT; Weller, PF				Bandeira-Melo, C; Bozza, PT; Weller, PF			The cellular biology of eosinophil eicosanoid formation and function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						eosinophils; leukotrienes; prostaglandins; arachidonic acid; lipid bodies; perinuclear membrane	PLATELET-ACTIVATING-FACTOR; LEUKOTRIENE C-4 SYNTHASE; CYTOPLASMIC LIPID BODIES; HUMAN BLOOD EOSINOPHILS; ARACHIDONIC-ACID; 5-LIPOXYGENASE PATHWAY; PROSTAGLANDIN E-2; ASTHMATIC AIRWAYS; NUCLEAR-ENVELOPE; BODY FORMATION	Eosinophils are capable of generating eicosanoid derivatives of arachidonic acid by means of cyclooxygenase and the 5- and 15-lipoxygenase (LO) pathways. Moreover, eosinophils, because of their expression of leukotriene (LT) C-4 synthase, are a major source of 5-LO-derived cysteinyl Us, which are potent paracrine mediators of bronchial obstruction and inflammation pertinent to asthma. The regulation of eicosanoid formation within eosinophils involves activation of key enzymes at specific intracellular sites. Calcium ionophore-elicited translocation of 5-LO to the membranes of the nuclear envelope is associated with LTC4 formation. In addition, lipid bodies, the formation of which is initiated by specific receptor-mediated signaling pathways, are sites of cyclooxygenase- and LO-pathway eicosanoid formation. Newly formed LTC4 can be immunolocalized at perinuclear membranes in ionophore-activated eosinophils and at lipid bodies in CCR3 agonist (eg, eotaxin) chemokine-stimulated eosinophils. The local generation of eicosanoids at distinct sites within eosinophils may be important for the roles of these eicosanoids, both as paracrine mediators pertinent to inflammation and as intracrine signal-transducing mediators that help regulate cellular responses of eosinophils.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Charles A Dana Res Inst, Harvard Thorndike Labs,Dept Med, Boston, MA 02215 USA; Inst Oswaldo Cruz, Dept Physiol & Pharmacodynam, Immunopharmacol Lab, BR-20001 Rio De Janeiro, Brazil	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Fundacao Oswaldo Cruz	Weller, PF (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Charles A Dana Res Inst, Harvard Thorndike Labs,Dept Med, DA-617,330 Brookline Ave, Boston, MA 02215 USA.		Bozza, Patricia T./AAM-4537-2021; Bozza, Patricia T./AAE-2933-2021; de Melo, Christianne Bandeira/B-7724-2009; Bandeira-Melo, Christianne/X-5619-2019	Bozza, Patricia T./0000-0001-8349-9529; de Melo, Christianne Bandeira/0000-0003-3305-3865; Bandeira-Melo, Christianne/0000-0003-3305-3865				Bandeira-Melo C, 2000, J IMMUNOL, V164, P1029, DOI 10.4049/jimmunol.164.2.1029; Bandeira-Melo C, 2001, AM J RESP CELL MOL, V24, P653, DOI 10.1165/ajrcmb.24.6.f209; Bandeira-Melo C, 2001, J IMMUNOL, V166, P4813, DOI 10.4049/jimmunol.166.8.4813; Bandeira-Melo C, 2001, J BIOL CHEM, V276, P22779, DOI 10.1074/jbc.M101436200; BandeiraMelo C, 1996, BRIT J PHARMACOL, V118, P2192, DOI 10.1111/j.1476-5381.1996.tb15662.x; Bartemes KR, 1999, J IMMUNOL, V162, P2982; Bhattacharya M, 1999, J BIOL CHEM, V274, P15719, DOI 10.1074/jbc.274.22.15719; Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909; Bozza PT, 1996, P NATL ACAD SCI USA, V93, P11091, DOI 10.1073/pnas.93.20.11091; Bozza PT, 1996, J EXP MED, V183, P1515, DOI 10.1084/jem.183.4.1515; Bozza PT, 1998, J LEUKOCYTE BIOL, V64, P563, DOI 10.1002/jlb.64.4.563; Brock TG, 2001, J BIOL CHEM, V276, P35071, DOI 10.1074/jbc.M105676200; Brock TG, 1999, J IMMUNOL, V162, P1669; BRUIJNZEEL PLB, 1989, EOSINOPHILS ASTHMA, P69; Calabrese C, 2000, ALLERGY, V55, P27, DOI 10.1034/j.1398-9995.2000.00504.x; Christie PE, 2002, CL ALLER IM, V16, P233; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Cowburn AS, 1999, J IMMUNOL, V163, P456; DVORAK AM, 1994, INT ARCH ALLERGY IMM, V105, P245; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; FOEGH ML, 1986, SCAND J IMMUNOL, V23, P599, DOI 10.1111/j.1365-3083.1986.tb01993.x; FORDHUTCHINSON AW, 1991, EICOSANOIDS, V4, P65; Gilmour RS, 2001, EXP BIOL MED, V226, P1; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; HODGES MK, 1988, AM REV RESPIR DIS, V138, P799, DOI 10.1164/ajrccm/138.4.799; Johnson MM, 1999, AM J RESP CELL MOL, V21, P253, DOI 10.1165/ajrcmb.21.2.3489; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LAM BK, 1992, P NATL ACAD SCI USA, V89, P11598, DOI 10.1073/pnas.89.23.11598; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881, DOI 10.1164/ajrccm.161.6.9907054; LEFT AR, 2000, AM J RESP CRIT CAR S, V161, pS125; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; PARSONS WG, 1988, J IMMUNOL, V141, P2413; PENROSE JF, 1995, AM J RESP CRIT CARE, V152, P283, DOI 10.1164/ajrccm.152.1.7599836; PENROSE JF, 1999, NOVEL INHIBITORS LEU, P23; Peters-Golden M, 2001, FEBS LETT, V487, P323, DOI 10.1016/S0014-5793(00)02374-7; Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8; Sala A, 1999, J BIOL CHEM, V274, P28264, DOI 10.1074/jbc.274.40.28264; Sala A, 1996, J BIOL CHEM, V271, P17944, DOI 10.1074/jbc.271.30.17944; Sano A, 2001, AM J PHYSIOL-LUNG C, V281, pL844, DOI 10.1152/ajplung.2001.281.4.L844; SERHAN CN, 1987, FEBS LETT, V217, P242, DOI 10.1016/0014-5793(87)80671-3; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V150, P376, DOI 10.1016/0006-291X(88)90531-1; SOLLEY GO, 1976, MAYO CLIN PROC, V51, P697; Sousa AR, 1997, THORAX, V52, P940, DOI 10.1136/thx.52.11.940; STEWART AG, 1990, P NATL ACAD SCI USA, V87, P3215, DOI 10.1073/pnas.87.8.3215; Taha R, 2000, AM J RESP CRIT CARE, V161, P636, DOI 10.1164/ajrccm.161.2.9811063; TAKAFUJI S, 1991, J IMMUNOL, V147, P3855; Takasaki J, 2000, BIOCHEM BIOPH RES CO, V274, P316, DOI 10.1006/bbrc.2000.3140; Tornhamre S, 2000, BBA-MOL CELL BIOL L, V1484, P298, DOI 10.1016/S1388-1981(00)00017-2; Urasaki T, 2001, J LEUKOCYTE BIOL, V69, P105; Weller Peter F., 1997, Allergology International, V46, P141, DOI 10.2332/allergolint.46.141; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WELLER PF, 1985, BLOOD, V65, P1269; WELLER PF, 1993, IMMUNOPHARMACOLOGY E, P25; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; Yu WG, 1998, AM J PATHOL, V152, P759; Zhu XD, 2001, J IMMUNOL, V167, P461, DOI 10.4049/jimmunol.167.1.461; [No title captured]	60	85	88	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					393	400		10.1067/mai.2002.121529	http://dx.doi.org/10.1067/mai.2002.121529			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897981	Bronze			2022-12-18	WOS:000174586400002
J	Ricca, V; Landi, M; Ferrero, P; Bairo, A; Tazzer, C; Canonica, GW; Ciprandi, G				Ricca, V; Landi, M; Ferrero, P; Bairo, A; Tazzer, C; Canonica, GW; Ciprandi, G			Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pollen allergy; inflammation; adhesion molecules; eosinophils	NASAL EPITHELIAL-CELLS; POLLEN EXPOSURE; HAY-FEVER; MEDIATORS	Background: The allergic reaction is characterized by an inflammatory response, which is correlated to the allergon exposure, and is detectable in mite allergic patients, even when symptoms are absent. Objective: The study was aimed at assessing the presence of inflammation in patients with pollen allergy during a long observation period. Methods: Six patients, sensitized only to Betula alba, were enrolled, Evaluated parameters were (1) nasal symptoms, (2) inflammatory markers (ie, neutrophil and eosinophil number and intercellular adhesion molecule-1 expression on nasal epithelial cells), and (3) pollen count. Patients were examined during the pollen season every 4 days for 40 days and were observed 3 times after the pollen season. Results: A significant inflammatory reaction was evident throughout the pollen season, even during the days with a law pollen count and low or absent symptoms. Conclusions: The results of this study indicate that the global therapeutic strategy for allergic rhinitis should be revised and targeted to inflammatory phenomena rather than to symptoms alone.	Koellider Hosp, Allerg Sect, Turin, Italy; Univ Genoa, Dept Internal Med, Div Community Med, Genoa, Italy; Univ Genoa, Dept Internal Med, Div Allergy & Resp Dis, Genoa, Italy	University of Genoa; University of Genoa	Ciprandi, G (corresponding author), Osped San Martino Genova, Allergy & Immunol Clin, Largo R Benzi 10, I-16132 Genoa, Italy.		Ciprandi, Giorgio/G-7462-2012; canonica, giorgio walter/ABF-2037-2020	Ciprandi, Giorgio/0000-0001-7016-8421; canonica, giorgio walter/0000-0001-8467-2557; Landi, Massimo/0000-0001-7587-4800				ANDERSSON M, 1989, AM REV RESPIR DIS, V139, P911, DOI 10.1164/ajrccm/139.4.911; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; CANONICA GW, 1997, ADHESION MOL ALLERGI, P367; CIPRANDI G, 1994, AM J RESP CRIT CARE, V150, P1653, DOI 10.1164/ajrccm.150.6.7524984; Ciprandi G, 1995, J ALLERGY CLIN IMMUN, V96, P971, DOI 10.1016/S0091-6749(95)70235-0; Ciprandi G, 1997, ANN ALLERG ASTHMA IM, V79, P507, DOI 10.1016/S1081-1206(10)63057-8; CIPRANDI G, 1994, J ALLERGY CLIN IMMUN, V94, P738, DOI 10.1016/0091-6749(94)90182-1; Ciprandi G, 1997, J ALLERGY CLIN IMMUN, V99, P301, DOI 10.1016/S0091-6749(97)70046-0; Ciprandi G, 1999, ALLERGY, V54, P358, DOI 10.1034/j.1398-9995.1999.00920.x; KITA H, 1997, ADHESION MOL ALLERGI, P227; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; SKONER DP, 1990, ANN ALLERGY, V65, P206; WANG DY, 1994, ACTA OTO-LARYNGOL, V114, P552, DOI 10.3109/00016489409126103	13	85	93	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				54	57		10.1016/S0091-6749(00)90177-5	http://dx.doi.org/10.1016/S0091-6749(00)90177-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629452	Bronze			2022-12-18	WOS:000084992100007
J	Lindfors, A; van Hage-Hamsten, M; Rietz, H; Wickman, M; Nordvall, SL				Lindfors, A; van Hage-Hamsten, M; Rietz, H; Wickman, M; Nordvall, SL			Influence of interaction of environmental risk factors and sensitization in young asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; children; cat; dog; allergen; Fel d 1; Can f 1; sensitization	HOUSE-DUST MITE; FEL-D-I; DER-P-I; RESIDENTIAL CHARACTERISTICS; PARENTAL SMOKING; BRONCHIAL RESPONSIVENESS; PULMONARY-FUNCTION; ALLERGIC DISEASES; FOLLOW-UP; F-I	Background: The increasing prevalence of asthma and allergy in many countries demands evaluation of potential risk factors to improve the possibility of prevention, Objective: We studied the association between exposure to cat and dog allergen and allergic sensitization in young children with asthma and interactions with potential environmental risk factors. Methods: One hundred eighty-nine young children with asthma were evaluated, IgE antibodies to cat and dog mere analyzed. Questionnaires were filled in focusing on exposure to cats and dogs, environmental tobacco smoke (ETS), and signs of home dampness as indicated by window pane condensation (WPC) during the first years of life. House dust was analyzed for content of cat (Fel d 1) and dog (Can f 1) allergen. Results: There was a strong association between the degree of reported exposure to cat and dog and the concentration of the respective allergens in floor dust, A dose-response relationship was found between cat exposure, measured as either reported degree of cat exposure or cat allergen levels in dust, and sensitization both to cat and dog. No such relationship was found between exposure and sensitization to dog. WPC increased the risk for sensitization to cat (odds ratio = 2.6, 95% confidence interval 1.2-5.8), whereas ETS strongly tended to do so both to cat and dog. Interaction was found between exposure to ETS, WPC, and high levels of cat allergen (>8 mu g/g dust). The presence of all 3 risk factors revealed a multiplicative interaction with a high risk of sensitization to cat (odds ratio = 42.0, 95% confidence interval 3.7-472.8), Conclusions: Keeping cats indoors may be a health hazard for infants and young children at risk for development of asthma, particularly when they live in a damp house and their parents smoke.	Karolinska Hosp, Astrid Lindgren Childrens Hosp, Allergy Unit, S-10401 Stockholm, Sweden; Karolinska Hosp, Dept Clin Immunol, S-10401 Stockholm, Sweden; Karolinska Hosp, Dept Environm Hlth, S-10401 Stockholm, Sweden; Huddinge Hosp, Dept Pediat, Stockholm, Sweden; Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Uppsala University	Lindfors, A (corresponding author), Karolinska Hosp, Astrid Lindgren Childrens Hosp, Allergy Unit, S-10401 Stockholm, Sweden.		van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596				ABERG N, 1989, ACTA PAEDIATR SCAND, V78, P246, DOI 10.1111/j.1651-2227.1989.tb11064.x; Aberg N, 1996, ALLERGY, V51, P232, DOI 10.1111/j.1398-9995.1996.tb04598.x; ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; ABERG N, 1995, CLIN EXP ALLERGY, V25, P791; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; Braback L, 1991, PEDIATR ALLERGY IMMU, V2, P14; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; CRONER S, 1992, ALLERGY, V47, P150, DOI 10.1111/j.1398-9995.1992.tb00956.x; DODGE R, 1993, J ALLERGY CLIN IMMUN, V92, P744, DOI 10.1016/0091-6749(93)90018-B; FOUCARD T, 1984, ACTA PAEDIATR SCAND, V73, P577, DOI 10.1111/j.1651-2227.1984.tb09977.x; GODDEN DJ, 1994, AM J RESP CRIT CARE, V149, P106, DOI 10.1164/ajrccm.149.1.8111567; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; HALKEN S, 1991, ALLERGY, V46, P507, DOI 10.1111/j.1398-9995.1991.tb00613.x; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408, DOI 10.1136/adc.73.5.408; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; MOSBECH H, 1986, ALLERGY, V41, P373, DOI 10.1111/j.1398-9995.1986.tb00315.x; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; MUNIR AKM, 1995, CLIN EXP ALLERGY, V25, P119, DOI 10.1111/j.1365-2222.1995.tb01016.x; MUNIR AKM, 1994, THESIS LINKOPING U; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; PLATTSMILLS TAE, 1990, ALLERGY PROC, V11, P269, DOI 10.2500/108854190778879729; RONCHETTI R, 1992, ARCH DIS CHILD, V67, P496, DOI 10.1136/adc.67.4.496; Ronmark E, 1998, RESP MED, V92, P316, DOI 10.1016/S0954-6111(98)90115-9; ROORDA RJ, 1994, J ALLERGY CLIN IMMUN, V93, P575, DOI 10.1016/S0091-6749(94)70069-9; RUGTVEIT J, 1990, ALLERGY, V45, P154, DOI 10.1111/j.1398-9995.1990.tb00474.x; RYLANDER E, 1993, EUR J EPIDEMIOL, V9, P517, DOI 10.1007/BF00209530; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x; US Census Bureau, 1994, STAT ABSTR US; VANTO T, 1983, ACTA PAEDIATR SCAND, V72, P571, DOI 10.1111/j.1651-2227.1983.tb09773.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Warner J, 1990, PEDIATR ALLERGY IMMU, V1, P79; WARNER JO, 1990, CLIN EXP ALLERGY, V20, P15, DOI 10.1111/j.1365-2222.1990.tb02465.x; WICKMAN M, 1991, J ALLERGY CLIN IMMUN, V88, P89, DOI 10.1016/0091-6749(91)90305-8; WICKMAN M, 1994, CLIN EXP ALLERGY, V24, P109, DOI 10.1111/j.1365-2222.1994.tb00205.x; WICKMAN M, 1992, J ALLERGY CLIN IMMUN, V89, P752, DOI 10.1016/0091-6749(92)90384-E; WICKMAN M, 1992, PEDIATRIC ALLERGY IM, V3, P128	43	85	86	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				755	762		10.1016/S0091-6749(99)70284-8	http://dx.doi.org/10.1016/S0091-6749(99)70284-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518818				2022-12-18	WOS:000083281200005
J	Grouhi, M; Alshehri, M; Hummel, D; Roifman, CM				Grouhi, M; Alshehri, M; Hummel, D; Roifman, CM			Anaphylaxis and epinephrine auto-injector training: Who will teach the teachers?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; epinephrine; auto-injector; training; medical professionals; therapy	ASTHMA; DEVICE	Background: Anaphylaxis is the most urgent clinical immunologic event. Effective treatment is best achieved by administration of epinephrine, Accidental exposure to the responsible allergen is the most common cause of anaphylaxis, and because it could be fatal within minutes, epinephrine in preloaded syringes and auto-injectors has been introduced. In our experience patients and medical personnel are not familiar with the use of this device. Objective: We sought to assess community-based professionals' knowledge of epinephrine auto-injector use and their ability to educate patients. Methods: Study participants consisted of a medical convention's delegates and emergency department personnel in metropolitan Toronto, as well as pharmacists of the target hospitals and retail pharmacists, Research assistants approached eligible professionals to fill out a questionnaire and demonstrate their ability to use a standard placebo auto-injector trainer. Results: A total of 122 professionals (composed of emergency physicians, family practitioners, and pediatricians) consented to participate in this study. The majority of participants (81%) did not have a placebo trainer to educate their patients; 76% did not know the 2 available dose strengths. To provide instructions and reinforcement, physicians clearly must have the necessary skills and knowledge, Jet only 25% of the study participants were able to demonstrate the 3 steps of injection correctly. Conclusion: Our study highlights a specific and important deficiency in medical professionals' care of patients at risk for anaphylaxis. The results challenge the current methods of educating professionals, as well as patients, when prescribing or using epinephrine auto-injectors. Clearly a new approach to educating and maintaining such skills is required.	Univ Toronto, Hosp Sick Children, Div Allergy Immunol, IIIR Programme, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Roifman, CM (corresponding author), Univ Toronto, Hosp Sick Children, Div Allergy Immunol, IIIR Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							*AAAI BOARD DIR, 1994, J ALLERGY CLIN IMMUN, V95, P666; AMIRAV I, 1995, J ALLERGY CLIN IMMUN, V95, P818, DOI 10.1016/S0091-6749(95)70124-9; AMIRAV I, 1994, J ALLERGY CLIN IMMUN, V94, P669, DOI 10.1016/0091-6749(94)90173-2; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; KESTEN S, 1994, CHEST, V105, P1077, DOI 10.1378/chest.105.4.1077; LEE HS, 1983, CLIN PEDIATR, V22, P440; MARQUADT DL, 1993, ALLERGY PRINCIPLES P; McGovern SJ, 1997, J ACCID EMERG MED, V14, P379; ORANGE RP, 1978, ALLERGY PRINCIPLES P; Rebuck D, 1996, J ASTHMA, V33, P385, DOI 10.3109/02770909609068183; REISMAN RE, 1994, NEW ENGL J MED, V331, P523, DOI 10.1056/NEJM199408253310808; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	12	85	87	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					190	193		10.1016/S0091-6749(99)70134-X	http://dx.doi.org/10.1016/S0091-6749(99)70134-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400860				2022-12-18	WOS:000081738900030
J	Sanchez-Segura, A; Brieva, JA; Rodriguez, C				Sanchez-Segura, A; Brieva, JA; Rodriguez, C			T lymphocytes that infiltrate nasal polyps have a specialized phenotype and produce a mixed T-H1/T-H2 pattern of cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyps; lymphocytes; T lymphocytes; human; phenotype; cytokines; IFN-gamma; IL-5; inflammation	LAMINA PROPRIA; DIFFERENTIAL REGULATION; HOMING RECEPTOR; SINUS SURGERY; L-SELECTIN; B-CELLS; EXPRESSION; ANTIGEN; NAIVE; APOPTOSIS	Background: Nasal polyps (NPs) are inflammatory reactions in the nasal mucose the etiology and pathogenesis of which remains unknown. Objective: The purpose of this study was to study in detail the phenotype and function of T lymphocytes infiltrating NPs by analyzing the expression of surface markers and cytokine secretion. Methods: NP tissue samples and peripheral blood were obtained from 18 patients. Mononuclear cells were purified from these samples, and their phenotype was investigated by triple-color immunofluorescence and flow cytometric analysis. Cytokine production was determined in cultures by using an ELISA technique. Results: NP lymphoid cells mainly consisted of T Lymphocytes. These T lymphocytes showed a CD45RO+CD45RA- phenotype and expressed pan-T cell molecules; the CD8+ subset was predominant. NP T cells showed a Lower density of CD28, CD3, and TCR-alpha beta compared with T cells from peripheral blood. NP T lymphocytes expressed the activation markers DR and CD69 and exhibited the adhesion molecule profile CD54+, CD62L-, and CD103+ CD49d(low). Virtually all NP T cells bore CD95 (FAS), but they did not undergo apoptosis, either spontaneously or induced by CD95 cross-linking with the mAb CH11, The pattern of cytokines secreted by NP T lymphocytes was characterized by the spontaneous and simultaneous production of IFN-gamma and IL-5, Neither IL-2 nor IL-4 were detectable in nonstimulated cultures. Conclusion: This study defines the T lymphocytes that infiltrate NPs as memory T cells in an activated status, with homing properties related to the mucosal immune system, They are resistant to anti-CD95-mediated apoptosis and produced a mixed T-H1/T-H2 cytokine pattern as defined by the simultaneous production of IFN-gamma and IL-5.	Hosp Univ Puerta Del Mar, Serv Inmunol, Cadiz 11009, Spain; Hosp Jerez, Serv Otorrinolaringol, Cadiz, Spain	Universidad de Cadiz; Hospital Universitario Puerta del Mar; Hospital de Jerez	Rodriguez, C (corresponding author), Hosp Univ Puerta Del Mar, Serv Inmunol, Avda Ana Viya 21, Cadiz 11009, Spain.			Rodriguez, Carmen/0000-0002-3495-4430				BAARS PA, 1995, J IMMUNOL, V154, P17; Bachert C, 1997, J ALLERGY CLIN IMMUN, V99, P837, DOI 10.1016/S0091-6749(97)80019-X; Bernstein JM, 1995, OTOLARYNG HEAD NECK, V113, P724, DOI 10.1016/S0194-5998(95)70012-9; BRADLEY LM, 1994, J EXP MED, V180, P2401, DOI 10.1084/jem.180.6.2401; BREZINSCHEK RI, 1995, J IMMUNOL, V154, P3062; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CROFT M, 1994, J IMMUNOL, V152, P2675; Dellacono FR, 1997, LARYNGOSCOPE, V107, P626, DOI 10.1097/00005537-199705000-00013; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Dubey C, 1996, J IMMUNOL, V157, P3280; Fuss IJ, 1996, J IMMUNOL, V157, P1261; GARCIAMONZON C, 1990, GASTROENTEROLOGY, V98, P1029, DOI 10.1016/0016-5085(90)90030-5; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; HOL BEA, 1993, AM REV RESPIR DIS, V148, P643, DOI 10.1164/ajrccm/148.3.643; HOSEMANN W, 1994, AM J OTOLARYNG, V15, P85, DOI 10.1016/0196-0709(94)90056-6; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jankowski R, 1989, Rhinol Suppl, V8, P51; JONES E, 1987, J OTOLARYNGOL, V16, P19; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; LAROCCA LM, 1989, ANN ALLERGY, V63, P508; Linder Arne, 1993, Rhinology (Utrecht), V31, P125; LIU CM, 1994, ANN ALLERGY, V72, P19; MARAZUELA M, 1994, EUR J IMMUNOL, V24, P2483, DOI 10.1002/eji.1830241034; Medina F, 1997, EUR J IMMUNOL, V27, P700, DOI 10.1002/eji.1830270319; MILLER CH, 1994, OTOLARYNG HEAD NECK, V111, P51, DOI 10.1177/019459989411100111; Min YG, 1997, ACTA OTO-LARYNGOL, V117, P302, DOI 10.3109/00016489709117792; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; PICKER LJ, 1993, J IMMUNOL, V150, P1105; PICKER LJ, 1993, J IMMUNOL, V150, P1122; SCHIEFERDECKER HL, 1992, J IMMUNOL, V149, P2816; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; Simon HU, 1997, J IMMUNOL, V158, P3902; SMALL P, 1981, ANN ALLERGY, V46, P317; STOOP AE, 1991, J ALLERGY CLIN IMMUN, V87, P470, DOI 10.1016/0091-6749(91)90004-8; STOOP AE, 1992, EUR ARCH OTO-RHINO-L, V249, P313, DOI 10.1007/BF00179379; Swain SL, 1996, IMMUNOL REV, V150, P143, DOI 10.1111/j.1600-065X.1996.tb00700.x; SYMON FA, 1994, J EXP MED, V180, P371, DOI 10.1084/jem.180.1.371	38	85	96	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				953	960		10.1016/S0091-6749(98)70333-1	http://dx.doi.org/10.1016/S0091-6749(98)70333-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847436				2022-12-18	WOS:000077690700013
J	Hamilton, RG; Adkinson, NF				Hamilton, RG; Adkinson, NF		Multi-Ctr Latex Skin Test Study Task	Diagnosis of natural rubber latex allergy: Multicenter latex skin testing efficacy study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						natural rubber latex; diagnosis; skin testing; serologic testing; glove provocation	HEALTH-CARE WORKERS; SYSTEMIC REACTIONS; ADVERSE REACTIONS; AMMONIATED LATEX; SPINA-BIFIDA; PROTEINS; EXTRACTS; HEV-B-1; GLOVES; SAFETY	Background: No characterized diagnostic natural rubber latex skin testing material is licensed for use in the United States. Objective: We have conducted a multicenter clinical skin testing study to document the safety and diagnostic sensitivity and specificity of a candidate Hevea brasiliensis nonammoniated latex (NAL) extract. These data are intended to support the licensing of this reagent for the diagnosis of latex allergy in high-risk populations, Methods: Three hundred twenty-four subjects (304 adults and 20 children) were classified by their clinical history as having latex allergy (LA group: 124 adults and 10 children) or having no latex allergy (NLA group, 180 adults and 10 children). All subjects provided blood samples and then received sequential puncture skin tests (PSTs) at 1, 100, or 1000 mu g/mL protein with a bifurcated needle and NAL (Greer Laboratories) from Malaysian Hevea brasiliensis (clone 600) sap. A 2-stage glove provocation test was used to clarify latex allergy status of individuals with positive history/negative PST result and negative history/positive PST result mismatches. Results: Twenty-four subjects (15%) originally designated as having LA on the basis of their initial clinical history were reclassified to the NLA group on the basis of a negative glove provocation test result. Of the 134 subjects with LA, 51 (40%) were highly sensitive to latex, with a positive PST result at 1 mu g/mL NAL, The Greer NAL reagent produced a positive PST rate (sensitivity) of 95% and 99% in subjects with LA at 100 mu g/mL and 1 mg/mL, respectively, The negative PST rate (specificity) in 190 subjects with a negative history with the NAL extract at 100 mu g/mL and 1 mg/mL was 100% and 96%, respectively. Immediately after the PST, mild systemic reactions (mainly pruritus) were recorded in 16.1% of the adults in the LA group and 4.4% of the adults in the NLA group. No reactions required treatment with epinephrine. Only mild delayed reactions were observed in 9.6% (LA group) and 2.8% (NLA group) of subjects 24 to 48 hours after PST. Mean wheal and erythema diameters measured in the 10 children in the LA group with spina bifida at 100 mu g/mL and I mg/mL were similar to those observed in the adults in the LA group, suggesting that children are not at increased risk for systemic reactions compared with adults. Conclusions: A suggestive clinical history is necessary but not sufficient for a definitive diagnosis of IgE-dependent latex allergy. These data support the safety and diagnostic efficacy of the Greer NAL skin test reagent at 100 mu g/mL and 1 mg/mL for confirmatory PSTs.	Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol & Allergy, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Hamilton, RG (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol & Allergy, Room 1A20,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031867, U01AI031867] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31867] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHLROTH M, 1995, J ALLERGY CLIN IMMUN, V95, P557; AKASAWA A, 1995, J ALLERGY CLIN IMMUN, V95, P1196, DOI 10.1016/S0091-6749(95)70076-5; BOUSQUET J, 1993, ALLERGY PRINCIPLES P, P579; BRONZERT CT, 1994, J ALLERGY CLIN IMMUN, V93, P306; CHAROUS BL, 1994, J ALLERGY CLIN IMMUN, V94, P12, DOI 10.1016/0091-6749(94)90065-5; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V100, P684, DOI 10.1016/S0091-6749(97)70174-X; Fink JN, 1996, ANN ALLERG ASTHMA IM, V76, P149, DOI 10.1016/S1081-1206(10)63414-X; Hamilton R. G., 1997, MANUAL CLIN LAB IMMU, P881; HAMILTON RG, 1994, J LAB CLIN MED, V123, P594; Hamilton RG, 1996, J ALLERGY CLIN IMMUN, V98, P872, DOI 10.1016/S0091-6749(96)80003-0; Hamilton RG, 1997, ANN ALLERG ASTHMA IM, V79, P266, DOI 10.1016/S1081-1206(10)63013-X; Hunt LW, 1996, J OCCUP ENVIRON MED, V38, P765, DOI 10.1097/00043764-199608000-00011; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V93, P813, DOI 10.1016/0091-6749(94)90370-0; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; Kim KT, 1998, ANN ALLERG ASTHMA IM, V80, P66, DOI 10.1016/S1081-1206(10)62942-0; Kurtz KM, 1998, J ALLERGY CLIN IMMUN, V101, pS204; Lockey RF, 1995, ALLERGY PROC, V16, P293, DOI 10.2500/108854195778667800; MAKINENKILJUNEN S, 1994, J ALLERGY CLIN IMMUN, V93, P990, DOI 10.1016/S0091-6749(94)70046-X; Melton AL, 1997, CLEV CLIN J MED, V64, P76, DOI 10.3949/ccjm.64.2.76; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V101, P153, DOI 10.1016/S0091-6749(98)70409-9; NOVEMBRE E, 1995, ALLERGY, V50, P511, DOI 10.1111/j.1398-9995.1995.tb01187.x; TOMAZIC VJ, 1994, J ALLERGY CLIN IMMUN, V93, P751, DOI 10.1016/0091-6749(94)90255-0; Turjanmaa K, 1997, ALLERGY, V52, P41, DOI 10.1111/j.1398-9995.1997.tb02544.x; TURJANMAA K, 1990, LANCET, V336, P1588, DOI 10.1016/0140-6736(90)93372-V; TURKELTAUB PC, 1989, J ALLERGY CLIN IMMUN, V84, P886, DOI 10.1016/0091-6749(89)90384-9; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; Woods Julia A., 1997, Journal of Emergency Medicine, V15, P71, DOI 10.1016/S0736-4679(96)00256-9; Yeang HY, 1998, J ALLERGY CLIN IMMUN, V101, P145; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0; Young MA, 1997, NURS CLIN N AM, V32, P169	31	85	87	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					482	490		10.1016/S0091-6749(98)70139-3	http://dx.doi.org/10.1016/S0091-6749(98)70139-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768592				2022-12-18	WOS:000076212800025
J	Hamilton, A; Faiferman, I; Stober, P; Watson, RM; O'Byrne, PM				Hamilton, A; Faiferman, I; Stober, P; Watson, RM; O'Byrne, PM			Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; pranlukast; cysteinyl leukotriene receptor antagonist; allergens	SLOW-REACTING SUBSTANCES; INHALED LEUKOTRIENE-D4; GUINEA-PIG; URINARY LEUKOTRIENE-E4; BRONCHIAL REACTIVITY; INDUCED INCREASE; ATOPIC SUBJECTS; SMOOTH-MUSCLE; RESPONSES; HISTAMINE	Background: The cysteinyl leukotrienes (cysLTs) have been implicated in the pathogenesis of allergen-induced airway responses. The purpose of this study was to evaluate the effects of pretreatment with the cysLT receptor antagonist pranlukast on allergen-induced early asthmatic responses (EARs) and late asthmatic responses (LARs) and on allergen-induced airway hyperresponsiveness (AHR). Methods: Ten atopic, nonsmoking patients with mild asthma and previously demonstrated early- and late-phase allergen-induced asthmatic responses participated in a double-blind, placebo-controlled, cross-over study, comparing treatment with either 450 mg pranlukast given twice daily or placebo for 5.5 days, A methacholine challenge was performed before administration of medication, and the result was expressed as the PC20, An allergen inhalation challenge was performed on the morning of the fifth day of treatment 2 hours after administration of medication, Methacholine challenges were also performed 2 hours after medication on days 4 and 6 (24 hours before and 24 hours after allergen administration) to examine allergen-induced AHR. Results: Pranlukast attenuated allergen-induced early responses, late responses, and AHR. The mean (SEM) maximal percent fall in FEV1 from baseline during the early response was 30.0% (5.1%) during placebo treatment and 15.5% (3.5%) during pranlukast treatment (mean difference, 14.5%; 95% confidence interval [CI], 5.3 to 23.7; P =.007), with a mean protection afforded by pranlukast of 48.3%. The mean maximal percent fall in FEV1 during the late response was 34.7% (5.3%) during placebo treatment and 24.0% (4.4%) during pranlukast treatment (mean difference, 10.7%; 95% CI, 4.1 to 17.3; P =.006), with a mean protection afforded by pranlukast of 30.8%. The mean allergen-induced shift in PC20 was -1.76 (0.32) doubling doses during placebo treatment and -0.38 (0.31) doubling doses during pranlukast treatment (mean difference, -1.38 doubling doses; 95% CI, 0.44 to 2.32; P =.012), with a mean protection afforded by pranlukast of 78.4%. Conclusion: These results demonstrate that pranlukast can attenuate allergen-induced early and late airways responses and AHR and adds further support for an important role for the cysLTs in mediating allergen-induced asthmatic responses.	McMaster Univ, Dept Med, Asthma Res Grp, Hamilton, ON L8N 3Z5, Canada; Smithkline Beecham Pharma, Hamilton, ON, Canada	McMaster University; GlaxoSmithKline	O'Byrne, PM (corresponding author), McMaster Univ, Dept Med, Asthma Res Grp, Rm 3U2 Hlth Sci Ctr,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			O'Byrne, Paul/0000-0003-0979-281X				ABRAHAM WM, 1985, PROSTAGLANDINS, V29, P715, DOI 10.1016/0090-6980(85)90132-7; Adaikan P G, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17A, P549; ADAMS GK, 1979, J IMMUNOL, V122, P555; ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; ARM JP, 1988, J ALLERGY CLIN IMMUN, V82, P654, DOI 10.1016/0091-6749(88)90979-7; BARNES N, 1987, J ALLERGY CLIN IMMUN, V79, P816, DOI 10.1016/0091-6749(87)90215-6; Barnes NC, 1997, THORAX, V52, P523, DOI 10.1136/thx.52.6.523; BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; BARNES NC, 1984, AM REV RESPIR DIS, V129, P1; BEL EH, 1989, AM REV RESPIR DIS, V139, P427, DOI 10.1164/ajrccm/139.2.427; Calhoun WJ, 1998, AM J RESP CRIT CARE, V157, P1381, DOI 10.1164/ajrccm.157.5.9609014; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAVIDSON AB, 1987, AM REV RESPIR DIS, V135, P333; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; Diamant Z, 1997, AM J RESP CRIT CARE, V155, P1247, DOI 10.1164/ajrccm.155.4.9105062; DIAMANT Z, 1995, J ALLERGY CLIN IMMUN, V95, P42, DOI 10.1016/S0091-6749(95)70151-6; DIAMANT Z, 1996, AM J RESP CRIT CARE, V153, P346; DRAZEN JM, 1987, AM REV RESPIR DIS, V136, P985, DOI 10.1164/ajrccm/136.4.985; FRIEDMAN BS, 1993, AM REV RESPIR DIS, V147, P839, DOI 10.1164/ajrccm/147.4.839; FUJIMURA M, 1993, RESP MED, V87, P133, DOI 10.1016/0954-6111(93)90141-L; FULLER RW, 1989, J ALLERGY CLIN IMMUN, V83, P439; Grossman J, 1997, J ASTHMA, V34, P321, DOI 10.3109/02770909709067222; Hamilton AL, 1997, THORAX, V52, P348, DOI 10.1136/thx.52.4.348; HANNA CJ, 1981, NATURE, V290, P343, DOI 10.1038/290343a0; HIGGINS DA, 1987, J ALLERGY CLIN IMMUN, V79, P141; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; Inman MD, 1998, J ALLERGY CLIN IMMUN, V101, P342, DOI 10.1016/S0091-6749(98)70246-5; KAYE MG, 1990, AM REV RESPIR DIS, V141, P993, DOI 10.1164/ajrccm/141.4_Pt_1.993; KERN R, 1986, AM REV RESPIR DIS, V133, P1127; KIRBY JG, 1989, J APPL PHYSIOL, V66, P578, DOI 10.1152/jappl.1989.66.2.578; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LEE TH, 1984, P NATL ACAD SCI-BIOL, V81, P4922, DOI 10.1073/pnas.81.15.4922; MANNING PJ, 1990, J ALLERGY CLIN IMMUN, V86, P211, DOI 10.1016/S0091-6749(05)80068-5; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; Obata T, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P229; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, pS35, DOI 10.1164/ajrccm/136.4_Pt_2.S35; OShaughnessy TC, 1997, THORAX, V52, P519, DOI 10.1136/thx.52.6.519; RASMUSSEN JB, 1992, J ALLERGY CLIN IMMUN, V90, P193, DOI 10.1016/0091-6749(92)90071-9; ROQUET A, 1996, AM J RESP CRIT CARE, V153, P214; TAKI F, 1994, ARZNEIMITTEL-FORSCH, V44-1, P330; TANIGUCHI Y, 1993, J ALLERGY CLIN IMMUN, V92, P507, DOI 10.1016/0091-6749(93)90074-P; TAYLOR GW, 1989, LANCET, V1, P584; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; UNDERWOOD DC, 1995, EUR RESPIR J S19, V8, pP1447; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; WOODWARD DF, 1983, EUR J PHARMACOL, V93, P9, DOI 10.1016/0014-2999(83)90025-0; YAMAGUCHI T, 1992, AM REV RESPIR DIS, V146, P923, DOI 10.1164/ajrccm/146.4.923	53	85	89	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					177	183		10.1016/S0091-6749(98)70083-1	http://dx.doi.org/10.1016/S0091-6749(98)70083-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723658	Bronze			2022-12-18	WOS:000075537100005
J	Varela, S; Subiza, J; Subiza, JL; Rodriguez, R; Garcia, B; Jerez, M; Jimenez, JA; Panzani, R				Varela, S; Subiza, J; Subiza, JL; Rodriguez, R; Garcia, B; Jerez, M; Jimenez, JA; Panzani, R			Platanus pollen as an important cause of pollinosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Platanus pollen; London plane tree; airborne pollen; allergenic pollen; pollinosis	BRONCHIAL HYPERRESPONSIVENESS; MEDITERRANEAN AREA; CROSS-REACTIVITY; ASTHMA; ALLERGENS; PREVALENCE	Objective: The existence of Platanus pollinosis is not generally accepted despite the production of very large quantities of airborne Platanus pollen in many cities of the United States and Europe. The aim of this study was to investigate if Platanus pollen really contributes to the symptoms of the patients with pollinosis in the Madrid area. Methods: We carried out systematic skin prick testing with Platanus pollen extract on 47 patients seen in our allergy center with spring-summer pollinosis symptoms. Each patient maintained symptom score diaries before, during, and after the Platanus pollination season. The average symptom scores were calculated and compared with the Platanus pollen counts. Measurements of specific IgE by ELISA and immunoblotting also were performed in each patient. Results: The Platanus skin tests were positive in 33 of the 39 patients first seen with seasonal symptoms during Platanus pollen season and only in three of the eight patients without symptoms during Platanus exposure (Fisher's exact test; p < 0.05). Twenty-two of the 33 Platanus-positive skin test patients also had a positive ELISA result. Furthermore, the average 24-hour rhinitis symptom scores of the 39 patients first seen with seasonal symptoms during March through April showed significant correlation with Platanus pollen counts (r(s) = 0.57, p < 0.05). The immunoblot results suggest that a 17 kd pollen protein could be a major allergen in patients with Platanus pollinosis. Conclusions: Platanus pollen is an important cause of pollinosis in Madrid. A protein with a molecular weight of 17 kd appeared to be its major allergen.	Ctr Asma & Alergia Gen Pardinas, E-28006 Madrid, Spain; Inmunotek Lab, Madrid, Spain; Lab Rech, Marseille, France		Subiza, J (corresponding author), Ctr Asma & Alergia Gen Pardinas, C Gen Pardinas 116, E-28006 Madrid, Spain.							AALBERSE RC, 1981, INT ARCH ALLER A IMM, V66, P259, DOI 10.1159/000232913; AGARWAL MK, 1983, J ALLERGY CLIN IMMUN, V72, P40, DOI 10.1016/0091-6749(83)90050-7; ANFOSSO F, 1977, INT ARCH ALLER A IMM, V54, P481, DOI 10.1159/000231869; ANFOSSO L, 1980, ALLERGY, V35, P196; ASHER MI, 1988, AM REV RESPIR DIS, V138, P524, DOI 10.1164/ajrccm/138.3.524; BELMONTE J, 1988, ORSIS, V3, P67; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; BRITTON WJ, 1986, INT J EPIDEMIOL, V15, P202, DOI 10.1093/ije/15.2.202; DAMATO G, 1994, CLIN EXP ALLERGY, V24, P566, DOI 10.1111/j.1365-2222.1994.tb00954.x; DAMATO G, 1989, J ALLERGY CLIN IMMUN, V83, P116, DOI 10.1016/0091-6749(89)90485-5; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; FRANKLAND AW, 1974, ATLAS EUROPEAN ALLER, P131; HOWLETT BJ, 1982, CLIN ALLERGY, V12, P259, DOI 10.1111/j.1365-2222.1982.tb02526.x; LEWIS WH, 1983, AIRBORNE ALLERGENIC, P77; MILES J, 1995, CLIN EXP ALLERGY, V25, P1074; PEAT JK, 1992, EUR RESPIR J, V5, P921; SOLOMON WR, 1988, ALLERGY PRINCIPLES P, V1, P312; Spieksma F., 1991, ALLERGENIC POLLEN PO, P49; SPIEKSMA FTM, 1995, CLIN EXP ALLERGY, V25, P234, DOI 10.1111/j.1365-2222.1995.tb01034.x; SPIEKSMA FTM, 1993, POLEN ATMOSFERICO EU, P54; SUBIZA E, 1986, TRATADO ALERGOLOGIA, V4, P257; SUBIZA J, 1989, J ALLERGY CLIN IMMUN, V84, P353, DOI 10.1016/0091-6749(89)90420-X; SUBIZA J, 1995, J ALLERGY CLIN IMMUN, V96, P15, DOI 10.1016/S0091-6749(95)70028-5; SUBIZA J, 1994, CLIN EXP ALLERGY, V24, P1123, DOI 10.1111/j.1365-2222.1994.tb03317.x; SUBIZA JL, 1992, J AUTOIMMUN, V5, P363, DOI 10.1016/0896-8411(92)90149-K; SWOBODA I, 1994, BIOCHIM BIOPHYS ACTA, V18, P457; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361	27	85	93	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				748	754		10.1016/S0091-6749(97)70268-9	http://dx.doi.org/10.1016/S0091-6749(97)70268-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438481				2022-12-18	WOS:000071353600005
J	Braun, CM; Huang, SK; Bashian, GG; KageySobotka, A; Lichtenstein, LM; Essayan, DM				Braun, CM; Huang, SK; Bashian, GG; KageySobotka, A; Lichtenstein, LM; Essayan, DM			Corticosteroid modulation of human, antigen-specific Th1 and Th2 responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; Th1/Th2; IL-4; IL-13; interferon-gamma; corticosteroids	BLOOD MONONUCLEAR-CELLS; NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS; T-CELLS; GLUCOCORTICOIDS SUPPRESS; CYTOKINE PRODUCTION; GENE-EXPRESSION; B-CELLS; INTERLEUKIN-13; SUBSETS; IMMUNOSUPPRESSION	Corticosteroids are potent antiinflammatory agents that modulate human T-lymphocyte responses. Controversy remains as to their possible differential effects on Th1 and Th2 subsets. This study explores the kinetics and efficacy of these agents in human, antigen-driven peripheral blood mononuclear cells (PBMCs) and in nontransformed, antigen-specific Th1 and Th2 clones. Ragweed-and tetanus toxoid-driven proliferative responses of PBMCs from dually sensitized individuals were downregulated equally by dexamethasone (inhibitory concentration of 50% [IC50] = 3 x 10(-9) and 2 x 10(-9) mol/L, respectively). The addition of dexamethasone as late as 36 hours after ragweed stimulation still resulted in more than 75% inhibition of the proliferative response, whereas the efficacy of dexamethasone was less than 50% when added 24 hours after tetanus toroid stimulation. Antigen-induced gene expression for proinflammatory cytokines (IL-4, IL-5, IL-13, and interferon-gamma) from PBMCs was also downregulated by dexamethasone. Proliferation of antigen-specific Th1 and Th2 clones was inhibited by several corticosteroids (hydrocortisone < budesonide < dexamethasone; IC50 = 10(-6) to 10(-8) mol/L), but no significant differences between Th1 and Th2 clones were evident. IC50 values in the clones were 10-fold greater than in PBMCs. Gene expression and protein secretion for IL-4, IL-13, and interferon-gamma were downregulated in a concentration-dependent manner by each of the corticosteroids in Th1 and Th2 clones. These data suggest that Th1 and Th2 responses are equally affected by corticosteroids.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University			Huang, Shau-Ku/F-5509-2010		NIAID NIH HHS [AI34002, AI07290] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034002] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARYA SK, 1984, J IMMUNOL, V133, P273; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BRINKMANN V, 1995, J IMMUNOL, V155, P3322; CHIAPPELLI F, 1994, ANN NY ACAD SCI, V746, P204; DAYNES RA, 1989, EUR J IMMUNOL, V19, P2319, DOI 10.1002/eji.1830191221; ESSAYAN DM, 1994, J IMMUNOL, V153, P3408; Essayan DM, 1996, J ALLERGY CLIN IMMUN, V98, P1035, DOI 10.1016/S0091-6749(96)80188-6; ESSAYAN DM, 1995, AM J RESP CELL MOL, V13, P692, DOI 10.1165/ajrcmb.13.6.7576707; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; HUANG SK, 1994, J IMMUNOL METHODS, V168, P167, DOI 10.1016/0022-1759(94)90052-3; MAGAZIN M, 1994, EUR CYTOKINE NETW, V5, P397; MARX J, 1995, SCIENCE, V270, P232, DOI 10.1126/science.270.5234.232; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; ODDERA S, 1995, ANN ALLERG ASTHMA IM, V75, P33; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHLEIMER RP, 1993, EUR J CLIN PHARM S1, V45, P3; SCHMIDT J, 1994, IMMUNOPHARMACOLOGY, V27, P173, DOI 10.1016/0162-3109(94)90013-2; SNIJDEWINT FGM, 1995, IMMUNOPHARMACOLOGY, V29, P93, DOI 10.1016/0162-3109(94)00048-K; WANG Y, 1993, J STEROID BIOCHEM, V44, P203, DOI 10.1016/0960-0760(93)90080-G; WU CY, 1991, EUR J IMMUNOL, V21, P2645, DOI 10.1002/eji.1830211053; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	24	85	87	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					400	407		10.1016/S0091-6749(97)70255-0	http://dx.doi.org/10.1016/S0091-6749(97)70255-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314354	hybrid			2022-12-18	WOS:A1997XX47900019
J	Wasserfallen, JB; Gold, K; Schulman, KA; Baraniuk, JN				Wasserfallen, JB; Gold, K; Schulman, KA; Baraniuk, JN			Development and validation of a rhinoconjunctivitis and asthma symptom score for use as an outcome measure in clinical trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; rhinoconjunctivitis; symptom score; health outcome; questionnaire; validation	QUALITY-OF-LIFE; SICKNESS IMPACT PROFILE; ALLERGIC RHINITIS; HEALTH-STATUS; PHYSIOLOGICAL MEASURES; UNITED-STATES; QUESTIONNAIRE; RESPONSIVENESS	Background: The measurement of health outcomes has become a priority for asses Objective: To develop and fully validate a simple symptom scale assessing both asthma and rhinoconjunctivitis, two interdependent conditions. Methods: A self-administered questionnaire of 31 items was tested in 102 patients with asthma and rhinoconjunctivitis between September 1992 and December 1994, The items were rated on a six-point Likert scale ranging from none to extremely severe and included commonly recorded symptoms of inflammation such as irritation, congestion, and discharge in the skin, eyes, nose, sinus, pharynx, and chest. Results: Validation included (1) responsiveness: scores for 18 patients evaluated during an emergency room visit were statistically significantly different from those recorded after recovery and in a control group of 24 patients with asthma; (2) reliability: external consistency was 0.8 at 1 week, and internal consistency was 0.8 for individual organs and 0.7 for individual symptoms; (3) validity: a five-point scale better captured the distribution of values; irrelevant and redundant items were eliminated, The optimal questionnaire included 21 items. Conclusions: The symptom score was applicable, responsive, reliable, and valid, Used with existing validated tools such as treatment needs and quality of life assessment, it may provide a comprehensive picture of allergic airway disease for quality assurance or research purposes.	GEORGETOWN UNIV, MED CTR, CLIN ECON RES UNIT, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, LOMBARDI CANC CTR, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, DIV RHEUMATOL ALLERGY & IMMUNOL, WASHINGTON, DC 20007 USA	Georgetown University; Georgetown University; Georgetown University				Baraniuk, James Nicholas/0000-0002-1866-4177				BAILEY WC, 1994, AM J RESP CRIT CARE, V149, pS1, DOI 10.1164/ajrccm/149.2_Pt_2.S1; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; BROOKS SM, 1990, J ALLERGY CLIN IMMUN, V85, P17, DOI 10.1016/0091-6749(90)90216-Q; BUSSE WW, 1994, AM J RESP CRIT CARE, V149, pS44, DOI 10.1164/ajrccm/149.2_Pt_2.S44; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; CHANYEUNG M, 1993, AM REV RESPIR DIS, V147, P1056; COOK DJ, 1993, J CLIN EPIDEMIOL, V46, P529, DOI 10.1016/0895-4356(93)90125-K; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; CREER TL, 1992, J ASTHMA, V29, P393, DOI 10.3109/02770909209044803; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; DRUMMOND N, 1994, BRIT MED J, V308, P564, DOI 10.1136/bmj.308.6928.564; ENRIGHT PL, 1994, AM J RESP CRIT CARE, V149, pS9, DOI 10.1164/ajrccm/149.2_Pt_2.S9; GUYATT GH, 1989, J CLIN EPIDEMIOL, V42, P913, DOI 10.1016/0895-4356(89)90105-4; HYLAND ME, 1991, RESP MED, V85, P13, DOI 10.1016/S0954-6111(06)80163-0; JONES PW, 1989, AM REV RESPIR DIS, V140, P1538, DOI 10.1164/ajrccm/140.6.1538; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; JUNIPER EF, 1993, ANN ALLERGY, V70, P225; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; KARLSSON G, 1994, ACTA OTO-LARYNGOL, P26; KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; MCMENAMIN P, 1994, ANN ALLERGY, V73, P35; MORRIS NV, 1994, MED J AUSTRALIA, V160, P68, DOI 10.5694/j.1326-5377.1994.tb126516.x; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; *NAT ASTHM ED PROG, 1991, 913042 DHHS NIH; OCONNOR GT, 1994, AM J RESP CRIT CARE, V149, pS21, DOI 10.1164/ajrccm/149.2_Pt_2.S21; REED CE, 1988, J ALLERGY CLIN IMMUN, V81, P1042, DOI 10.1016/0091-6749(88)90177-7; Spearman C, 1907, AM J PSYCHOL, V18, P161, DOI 10.2307/1412408; STEEN N, 1994, BRIT MED J, V309, P1065, DOI 10.1136/bmj.309.6961.1065; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WEISS ST, 1995, BRONCHIAL ASTHMA MEC, P15	36	85	87	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					16	22		10.1016/S0091-6749(97)70189-1	http://dx.doi.org/10.1016/S0091-6749(97)70189-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257782	hybrid			2022-12-18	WOS:A1997XP42800004
J	Alam, R				Alam, R			Chemokines in allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CYTOKINES				Alam, R (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV ALLERGY & IMMUNOL,GALVESTON,TX 77555, USA.							ALAM R, 1992, J CLIN INVEST, V89, P723, DOI 10.1172/JCI115648; Alam R, 1996, AM J RESP CRIT CARE, V153, P1398, DOI 10.1164/ajrccm.153.4.8616572; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; LUKACS NW, 1995, EUR J IMMUNOL, V25, P245, DOI 10.1002/eji.1830250140; PONATH DP, 1996, J EXP MED, V183, P2437; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SIM TC, 1995, AM J RESP CRIT CARE, V152, P927, DOI 10.1164/ajrccm.152.3.7545059	8	85	92	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					273	277		10.1016/S0091-6749(97)70042-3	http://dx.doi.org/10.1016/S0091-6749(97)70042-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058680				2022-12-18	WOS:A1997WM42200001
J	FERGUSON, AC; VAUGHAN, R; BROWN, H; CURTIS, C				FERGUSON, AC; VAUGHAN, R; BROWN, H; CURTIS, C			EVALUATION OF SERUM EOSINOPHILIC CATIONIC PROTEIN AS A MARKER OF DISEASE-ACTIVITY IN CHRONIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; EOSINOPHIL CATIONIC PROTEIN; BLOOD EOSINOPHIL COUNTS; BRONCHIAL HYPERRESPONSIVENESS	ALLERGEN-INDUCED INCREASE; BRONCHIAL HYPERRESPONSIVENESS; CHILDREN; BLOOD; BUDESONIDE; REACTIVITY; MEDICATION; HISTAMINE; SEVERITY; THERAPY	Background: Serum eosinophil cationic protein (ECP) has been promoted as a direct marker of eosinophilic inflammation of the bronchi, especially helpful in patients with asymptomatic asthma. Objective: To evaluate serum ECP against indirect clinical markers of disease activity, we compared symptom score, bronchial obstruction, bronchial responsiveness, and blood eosinophil counts with serum ECP levels in children with symptomatic and asymptomatic chronic asthma and assessed ECP in others with allergic rhinitis alone. Methods: Twenty-four children with symptomatic asthma, 10 children with asymptomatic asthma, and 16 children with allergic rhinitis were studied. Measurements were made by standardized symptom questionnaire, spirometry, inhalation challenge with histamine or methacholine, blood eosinophil counts, and radioimmunoassay of serum ECP. Results: There was no difference in serum ECP levels between the symptomatic asthma, asymptomatic asthma, or rhinitis groups, and most values were within the normal range. Activated eosinophil counts were higher in subjects with symptomatic asthma than in those with asymptomatic asthma but not in subjects with rhinitis. Serum ECP correlated with eosinophil counts (p < 0.01) but not symptom score, forced expiratory volume in 1 second (FEV(1)), forced expiratory flow, mid-expiratory phase (FEF(25-75)), or provocative concentration causing a 20% fall in FEV(1) (PC20). Symptom scores correlated with PC20 (p < 0.005) and FEF(25-75) (p < 0.01). Conclusion: Serum ECP is a poor indicator of disease activity in chronic asthma and cannot differentiate bronchial from nasal inflammation.			FERGUSON, AC (corresponding author), BRITISH COLUMBIA CHILDRENS HOSP,DEPT PAEDIAT,4480 OAK ST,VANCOUVER,BC V6H 3V4,CANADA.			Ferguson, Alexander C./0000-0002-3143-5619; vaughan, roger/0000-0001-6066-4595				ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; AHLSTEDT S, 1992, Pharmaceutical Medicine (London), V6, P99; ALSTEDT S, 1993, PRACT ALLERGY IMMUNO, V8, P149; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BISGAARD H, 1990, J ALLERGY CLIN IMMUN, V85, P891, DOI 10.1016/0091-6749(90)90074-E; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CARLSON M, 1992, J ALLERGY CLIN IMMUN, V89, P131, DOI 10.1016/S0091-6749(05)80050-8; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DAHL R, 1978, SCAND J RESPIR DIS, V59, P319; DAHL R, 1978, SCAND J RESPIR DIS, V59, P323; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIXON WJ, 1969, INTRO STATISTICAL AN, P193; DOLD S, 1992, ARCH DIS CHILD, V67, P1018, DOI 10.1136/adc.67.8.1018; FERGUSON AC, 1989, CHEST, V96, P988, DOI 10.1378/chest.96.5.988; FERGUSON AC, 1992, J ALLERGY CLIN IMMUN, V90, P609, DOI 10.1016/0091-6749(92)90133-M; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; HEDLIN G, 1993, PEDIATR ALLERGY IMMU, V3, P144; HOLGATE ST, 1991, AM REV RESPIR DIS, V143, pS66, DOI 10.1164/ajrccm/143.3_Pt_2.S66; JUNTUNENBACKMAN K, 1993, J ALLERGY CLIN IMMUN, V92, P34, DOI 10.1016/0091-6749(93)90034-D; MURRAY AB, 1983, PEDIATRICS, V71, P418; MURRAY AB, 1981, J ALLERGY CLIN IMMUN, V68, P119, DOI 10.1016/0091-6749(81)90169-X; ORECHEK J, 1980, AIRWAY REACTIVITY, P201; PIACENTINI GL, UNPUB J ALLERGY CLIN; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; SALOME CM, 1980, CLIN ALLERGY, V10, P541, DOI 10.1111/j.1365-2222.1980.tb02135.x; SUGAI T, 1992, CLIN EXP ALLERGY, V22, P275, DOI 10.1111/j.1365-2222.1992.tb03083.x; VENGE P, 1991, J ALLERGY CLIN IMMUN, V88, P699, DOI 10.1016/0091-6749(91)90175-N; VENGE P, 1988, INT ARCH ALLER A IMM, V87, P306, DOI 10.1159/000234690; VENGE P, 1993, CLIN EXP ALLERGY, V23, P3, DOI 10.1111/j.1365-2222.1993.tb00372.x; WEMPE JB, 1992, J ALLERGY CLIN IMMUN, V90, P757, DOI 10.1016/0091-6749(92)90099-N; WOOLCOCK AJ, 1991, AM REV RESPIR DIS, V143, pS75, DOI 10.1164/ajrccm/143.3_Pt_2.S75; ZIMMERMAN B, 1993, CLIN EXP ALLERGY, V23, P564, DOI 10.1111/j.1365-2222.1993.tb00895.x	32	85	86	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				23	28		10.1016/S0091-6749(95)70148-6	http://dx.doi.org/10.1016/S0091-6749(95)70148-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7822660				2022-12-18	WOS:A1995QC31200004
J	OHMAN, JL; HAGBERG, K; MACDONALD, MR; JONES, RR; PAIGEN, BJ; KACERGIS, JB				OHMAN, JL; HAGBERG, K; MACDONALD, MR; JONES, RR; PAIGEN, BJ; KACERGIS, JB			DISTRIBUTION OF AIRBORNE MOUSE ALLERGEN IN A MAJOR MOUSE BREEDING FACILITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ELISA; MUS M I; VENTILATION; PARTICULATE DISTRIBUTION; AIR SAMPLING	LABORATORY-ANIMAL ALLERGENS; CASCADE IMPACTOR; FELIS-DOMESTICUS; RAT ALLERGENS; PARTICLE-SIZE; ASTHMA; REDUCTION; TRIAL	Background: Occupational allergy to mice is a major cause of disability among workers in mouse breeding and research facilities. Efforts to prevent and treat allergy require a detailed knowledge of exposure levels to allergen. Objective: This study was designed to quantitate the level of major mouse allergen (Mus m I) in central room air and immediate breathing zones under a variety of working conditions. Methods: An Andersen sampler (Groseby Andersen, Spirotech Div., Atlanta, Ga.) was used to collect allergen in each room. A Gillian Personal sampler (Gillian Instrument Corp., West Caldwell, N.J.) collected particles in the worker breathing zone. ELISA was used to quantitate the concentration of Mus m I collected on the two collection devices. Results: Total Mus m I recovered from Andersen samplers ranged from 0.2 to 1.5 ng/m(3) irt rooms without mice and 0.5 to 15.1 ng/m(3) in rooms with mice. Allergen recovered from the zone of worker activity ranged from 1.2 to 2.7 ng/m(3) in rooms without mice and from 16.6 to 563.0 ng/m(3) in rooms with mice. Direct mouse contact was associated with the highest levesl of exposure to Mus m I. Analysis revealed the bulk of allergen to be in mid-particle size ranges (3.3 to 10 mu m) for mouse-containing rooms and in small particle size range (0.43 to 3.3 mu m) for non-mouse-containing rooms, suggesting that small particles were carried along corridors from rooms with mice into non-mouse-containing rooms. Ventilation characteristics of rooms and mouse population density were evaluated with a ''mouse loading'' index (number of mice per cubic meter of ventilated air per hour). Mouse loading correlated strongly with small particles (<3.3 mu m) in ambient air. Conclusions: Mus m I is widely distributed within mouse breeding facilities. Direct worker contact with mice seems to be the major factor in high level exposure.	JACKSON LAB,HLTH OFF,BAR HARBOR,ME; JACKSON LAB,SAFETY OFF,BAR HARBOR,ME	Jackson Laboratory; Jackson Laboratory	OHMAN, JL (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,DEPT ALLERGY,750 WASHINGTON ST,BOSTON,MA 02111, USA.				NIAID NIH HHS [5RO1 AI128586] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		EGGLESTON PA, 1990, J ALLERGY CLIN IMMUN, V86, P63, DOI 10.1016/S0091-6749(05)80124-1; EGGLESTON PA, 1989, J ALLERGY CLIN IMMUN, V84, P347, DOI 10.1016/0091-6749(89)90419-3; FINDLAY SR, 1983, AM REV RESPIR DIS, V128, P1008; GROSS NJ, 1980, J ALLERGY CLIN IMMUN, V66, P158, DOI 10.1016/0091-6749(80)90064-0; HOOK WA, 1984, J ALLERGY CLIN IMMUN, V73, P457, DOI 10.1016/0091-6749(84)90355-5; LINCOLN TA, 1974, J OCCUP ENVIRON MED, V16, P465; LORUSSO JR, 1986, J ALLERGY CLIN IMMUN, V78, P928, DOI 10.1016/0091-6749(86)90242-3; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MCFARLAND AR, 1977, ATMOS ENVIRON, V11, P535, DOI 10.1016/0004-6981(77)90072-5; MOLLER C, 1990, INT ARCH ALLER A IMM, V92, P306, DOI 10.1159/000235194; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; PIACENTINI GL, 1983, J ALLERGY CLIN IMMUN, V92, P644; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PRICE JA, 1988, CLIN ALLERGY, V18, P95, DOI 10.1111/j.1365-2222.1988.tb02848.x; SAKAGUCHI M, 1989, LAB ANIM SCI, V39, P234; SAKAGUCHI M, 1990, LAB ANIM SCI, V40, P613; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; SWANSON MC, 1990, AM REV RESPIR DIS, V141, P1578, DOI 10.1164/ajrccm/141.6.1578; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8	20	85	86	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1994	94	5					810	817		10.1016/0091-6749(94)90147-3	http://dx.doi.org/10.1016/0091-6749(94)90147-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PR240	7963149				2022-12-18	WOS:A1994PR24000004
J	BOUSQUET, J; MICHEL, FB				BOUSQUET, J; MICHEL, FB			SPECIFIC IMMUNOTHERAPY IN ASTHMA - IS IT EFFECTIVE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HOUSE DUST MITE; DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; ALLERGEN-ANTIBODY COMPLEXES; PLACEBO-CONTROLLED IMMUNOTHERAPY; PARTIALLY PURIFIED EXTRACT; GRASS-POLLEN ALLERGOIDS; INDUCED ADULT ASTHMA; DOUBLE-BLIND TRIAL; HAY-FEVER; BRONCHIAL-ASTHMA				BOUSQUET, J (corresponding author), HOP ARNAUD VILLENEUVE, MALAD RESP CLIN, ALLERGY UNIT, F-34059 MONTPELLIER, FRANCE.		Bousquet, Jean/O-4221-2019					AMARALMARQUES R, 1978, ALLERGOL IMMUNOPATH, V6, P231; [Anonymous], 1986, Br Med J (Clin Res Ed), V293, P948; ARMENTIAMEDINA A, 1989, ANN ALLERGY, V63, P127; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1994, DRUG SAFETY, V10, P5, DOI 10.2165/00002018-199410010-00002; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V86, P292, DOI 10.1016/S0091-6749(05)80091-0; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V87, P737, DOI 10.1016/0091-6749(91)90397-7; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P782; BUSH RK, 1991, ALLERGEN IMMUNOTHERA, P25; CITRON K M, 1958, Thorax, V13, P229, DOI 10.1136/thx.13.3.229; COHN JR, 1993, J ALLERGY CLIN IMMUN, V91, P734, DOI 10.1016/0091-6749(93)90192-I; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; CRETICOS PS, 1993, J ALLERGY CLIN IMMUN, V91, P227; CRETICOS PS, 1993, J ALLERGY CLIN IMMUN, V91, P226; CRIMI E, 1991, J ALLERGY CLIN IMMUN, V87, P721, DOI 10.1016/0091-6749(91)90395-5; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DREBORG S, 1988, CLIN IMMUNOL ALLERGY, V2, P245; FRANKLAND AW, 1954, LANCET, V1, P1055; GADDIE J, 1976, BRIT MED J, V2, P561, DOI 10.1136/bmj.2.6035.561; GARCIAORTEGA P, 1993, CHEST, V103, P183, DOI 10.1378/chest.103.1.183; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325, DOI 10.1164/ajrccm/140.5.1325; GRAMMER LC, 1984, J ALLERGY CLIN IMMUN, V73, P484, DOI 10.1016/0091-6749(84)90359-2; GRANT IWB, 1986, CLIN ALLERGY, V16, P7, DOI 10.1111/j.1365-2222.1986.tb01947.x; HAUGAARD L, 1992, ALLERGY, V47, P249, DOI 10.1111/j.1398-9995.1992.tb00658.x; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEJJAOUI A, 1992, J ALLERGY CLIN IMMUN, V89, P925, DOI 10.1016/0091-6749(92)90214-M; HEJJAOUI H, 1992, J ALLERGY CLIN IMMUN, V89, P319; HILL DJ, 1982, BRIT MED J, V284, P306, DOI 10.1136/bmj.284.6312.306; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; JARISCH R, 1988, 5TH P INT P EHRL SEM, P163; LENG X, 1990, ANN ALLERGY, V64, P27; LICHTENSTEIN LM, 1984, AM REV RESPIR DIS, V129, P657, DOI 10.1164/arrd.1984.129.5.657; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MACHIELS JJ, 1993, AM REV RESPIR DIS, V147, P1407, DOI 10.1164/ajrccm/147.6_Pt_1.1407; MACHIELS JJ, 1991, ALLERGY, V46, P335, DOI 10.1111/j.1398-9995.1991.tb00596.x; MACHIELS JJ, 1990, J CLIN INVEST, V85, P1024, DOI 10.1172/JCI114532; MALLING H-J, 1988, Allergy (Copenhagen), V43, P1; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; MALLING HJ, 1993, ALLERGY, V48, P9; MARYGABRIEL SX, 1977, CLIN ALLERGY, V7, P325; MCALLEN MK, 1969, ACTA ALLERGOL, V24, P421, DOI 10.1111/j.1398-9995.1969.tb03756.x; McALLEN MONICA K., 1961, THORAX, V16, P30, DOI 10.1136/thx.16.1.30; MOSBECH H, 1989, ALLERGY, V44, P499, DOI 10.1111/j.1398-9995.1989.tb04189.x; MOSBECH H, 1989, ALLERGY, V44, P487, DOI 10.1111/j.1398-9995.1989.tb04188.x; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; MURRAY AB, 1985, ANN ALLERGY, V54, P541; NEWTON DAG, 1978, BRIT J DIS CHEST, V72, P21, DOI 10.1016/0007-0971(78)90004-9; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; PAGANIN F, 1992, AM REV RESPIR DIS, V146, P1084, DOI 10.1164/ajrccm/146.4.1084; PASTORELLO EA, 1992, ALLERGY, V47, P281, DOI 10.1111/j.1398-9995.1992.tb02054.x; PAULI G, 1984, J ALLERGY CLIN IMMUN, V74, P524, DOI 10.1016/0091-6749(84)90389-0; PEARLMAN DS, 1989, PEDIATR ASTHMA ALLER, V3, P191; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; PENE J, 1994, IMMUNOLOGY, V81, P58; PLATTSMILLS TAE, 1989, PROGRESS IN ALLERGY AND CLINICAL IMMUNOLOGY, P279; PRICE JF, 1984, CLIN ALLERGY, V14, P209, DOI 10.1111/j.1365-2222.1984.tb02200.x; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; RAK S, 1990, J ALLERGY CLIN IMMUN, V86, P706, DOI 10.1016/S0091-6749(05)80174-5; RAK S, 1993, ALLERGY, V48, P460, DOI 10.1111/j.1398-9995.1993.tb00745.x; REED CE, 1989, J ALLERGY CLIN IMMUN, V84, P4, DOI 10.1016/0091-6749(89)90171-1; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; ROCHE WR, 1989, LANCET, V1, P520; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SALVAGGIO JE, 1993, J ALLERGY CLIN IMMUN, V92, P217, DOI 10.1016/0091-6749(93)90164-B; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; TARI MG, 1992, J INVEST ALLERG CLIN, V2, P59; THOMPSON RA, 1989, LANCET, V1, P259; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; VANBEVER HP, 1992, EUR RESPIR J, V5, P318; VANBEVER HP, 1988, ALLERGY, V43, P378, DOI 10.1111/j.1398-9995.1988.tb00432.x; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; WAHN U, 1988, J ALLERGY CLIN IMMUN, V82, P360, DOI 10.1016/0091-6749(88)90007-3; WARNER JO, 1978, LANCET, V2, P912; 1992, ALLERGY S1, V47, P1	88	85	90	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					1	11		10.1016/0091-6749(94)90064-7	http://dx.doi.org/10.1016/0091-6749(94)90064-7			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	8027487				2022-12-18	WOS:A1994NX39300001
J	KANG, BC; JOHNSON, J; VERESTHORNER, C				KANG, BC; JOHNSON, J; VERESTHORNER, C			ATOPIC PROFILE OF INNER-CITY ASTHMA WITH A COMPARATIVE-ANALYSIS ON THE COCKROACH-SENSITIVE AND RAGWEED-SENSITIVE SUBGROUPS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INNER-CITY ASTHMA; AEROALLERGENS; COCKROACH ALLERGY; IGE ANTIBODY; INDOOR ALLERGEN	BRONCHIAL-ASTHMA; HOUSE DUST; ALLERGIC-ASTHMA; SERUM IGE; MITE; CHILDREN; ANTIGENS; CAT; PREVALENCE; POPULATION	Background: Inner-city asthma is well known for its high risk of mortality. To better understand urban asthma, we examined clinical characteristics and aeroallergen sensitivities of 592 of 680 consecutive urban Chicago residents with asthma. Methods: A total of 227 male and 453 female subjects who met the criteria for the study were registered. A comprehensive clinical evaluation was followed by allergy skin testing (prick and intradermal testing) with 10 groupings (5 indoor and 5 outdoor) of common aeroallergens. Serum total IgE and selective antigen-specific IgE levels, including cockroach-specific IgE, were routinely measured. A total of 592 (196 male and 396 female) subjects with an average age of 35 years were skin tested The average duration of asthma was 12 6 years, and 31% of the population was receiving corticosteroids. Results: Aeroallergen sensitivity was noted in 85%, and 94 subjects (15%) were nonallergic. House dust sensitivity (76%) was most prevalent, distantly followed by sensitivity to cockroach (48%), ragweed (45%), other weeds (42%), cat (40%), and dust mite (24%). The average number of aeroallergen sensitivities detected was 4 of 10 groupings of both and outdoor allergens. Twenty percent of subjects were allergic to only indoor allergens, whereas 4% were allergic to outdoor allergens only. Serum IgE was 245 +/- 17.3 IU/ml (geometric mean + SEM), and 74% of 444 serum samples assayed showed IgE antibody levels greater than or equal to 100 IU/ml. A cockroach-sensitive subgroup (283 subjects) had longer duration of asthma (p < 0. 0001) and fewer additional aeroallergen sensitivities (p < 0.0001) than the ragweed-sensitive subgroup (264 subjects). Conclusion: The results indicate that a great majority (85%) of inner-city Chicago residents with asthma have atopic asthma, as demonstrated by highly elevated IgE levels and multiple aeroallergen sensitivities. Sensitivity to indoor allergens is more prevalent than sensitivity to outdoor allergens. The subjects with cockroach-sensitive asthma appear to be a distinctive subgroup characterized by chronicity and elevated serum IgE antibody levels with fewer aeroallergen skin test sensitivities.	MT SINAI HOSP,RUSH MED SCH,CHICAGO,IL	Rush University								BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P919, DOI 10.1016/0091-6749(87)90241-7; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; BERNTON HS, 1970, ANN ALLERGY, V28, P543; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P425; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BUSSE WW, 1988, ALLERGY PRINCIPLES P, V969, P1064; CHANG JL, 1984, MT SINAI J MED, V51, P197; COCKCROFT DW, 1983, LANCET, V2, P253; FORD RM, 1983, ANN ALLERGY, V50, P47; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; HULETT AC, 1979, ANN ALLERGY, V42, P160; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; KALLIEL JN, 1989, CHEST, V96, P1336, DOI 10.1378/chest.96.6.1336; KANG B, 1978, ANN ALLERGY, V41, P333; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG B, 1989, ANN ALLERGY, V62, P30; KANG BC, 1992, ANN ALLERGY, V68, P237; KANG BC, 1988, J ASTHMA, V25, P205, DOI 10.3109/02770908809071367; KANG BC, 1989, ANN ALLERGY, V63, P207; KANG BC, 1990, CLIN REV ALLERG, V8, P87; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; Marchand A M, 1966, Bol Asoc Med P R, V58, P49; MENDOZA J, 1970, ANN ALLERGY, V28, P159; Nye L, 1975, Clin Allergy, V5, P13; PANLOZZI LJ, 1984, ANN ALLERGY, V56, P392; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; PLATTMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P415; PLATTSMILLS TAE, 1982, LANCET, V2, P675; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; ROTH LOUIS M., 1957, SMITHSONIAN MISC COLL, V134, P1; SCHULANER FA, 1970, PEDIATRICS, V45, P465; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SIGEL SC, 1987, J ALLERGY CLIN IMMUN, V80, P458; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; TOMS EM, 1986, J ECON ENTOMOL, V79, P431; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3; YUN D K, 1990, Journal of Allergy and Clinical Immunology, V85, P181; 1962, AM REV RESPIR DIS, V85, P762; 1980, MAJOR URBAN ARTHROPO, P261	46	85	89	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1993	92	6					802	811		10.1016/0091-6749(93)90057-M	http://dx.doi.org/10.1016/0091-6749(93)90057-M			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML893	8258614				2022-12-18	WOS:A1993ML89300005
J	CHARPIN, C; MATA, P; CHARPIN, D; LAVAUT, MN; ALLASIA, C; VERVLOET, D				CHARPIN, C; MATA, P; CHARPIN, D; LAVAUT, MN; ALLASIA, C; VERVLOET, D			FEL-D-I ALLERGEN DISTRIBUTION IN CAT FUR AND SKIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FEL-D-I ALLERGEN; IMMUNOPEROXIDASE; FROZEN SECTIONS; CAT SKIN; CAT FUR; SAMBA ANALYSIS	RECEPTOR IMMUNOCYTOCHEMICAL ASSAY; HUMAN-BREAST CARCINOMAS; IMAGE-ANALYSIS; SAMBA-200; DISORDERS	Immunohistochemical procedures were performed to ascertain Fel d I antigen (Ag) distribution in cat fur and skin biopsy specimens and to analyze Fel d I allergen concentrations in fur. One hundred strands of fur and 24 skin biopsy specimens (6 by 4 by 3 mm) from shaved areas were collected from 11 different cats. Freshly depilated hairs were immunostained by free-floating monoclonal anti-Fel d I, avidin-biotin-peroxidase complex, and either processed for scanning electron microscopic examination or mounted on glass slides for computer-assisted densitometric analysis (SAMBA system). Skin biopsy specimens were promptly frozen and sectioned just before the immunohistochemical processing. Densitometric analysis of fur demonstrated that immunoprecipitate concentrations were tenfold higher at the root than at the tip. However, this finding may be explained by decrease of the thickness of the hair cortex that varied in similar proportions. The Ag accumulated on the strand surface but may focally penetrate into the medulla through the scale-like cortical interstices. In skin biopsy specimens, Fel d I Ag was found in epithelial squamous cells, within the epidermis and hair follicles, on the surface of the epidermis and hair follicles, and in sebaceous gland cells. These data suggest that Fel d I Ag is produced by sebaceous cells and, to a lesser extent, by basal squamous epithelial cells and that it is stored mainly on the surface of the epidermis and fur.	FAC MED MARSEILLE,DEPT QUANTITAT MICROSCOPY,F-13385 MARSEILLE 5,FRANCE; HOP LA TIMONE,DEPT PATHOL,MARSEILLE,FRANCE; HOP ST MARGUERITE,DEPT CHEST DIS & ALLERGOL,MARSEILLE,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	CHARPIN, C (corresponding author), FAC MED MARSEILLE,DEPT PATHOL,27 BD JEAN MOULIN,F-13385 MARSEILLE 5,FRANCE.		oudin, olivier/G-4613-2015					BARTHOLOME K, 1985, J ALLERGY CLIN IMMUN, V76, P503, DOI 10.1016/0091-6749(85)90734-1; BRUGAL G, 1985, QUANTITATIVE IMAGE A, P19; BRUGAL G, 1984, METHODS ACHIEVEMENTS, P1; CHARPIN C, 1989, HISTOPATHOLOGY, V14, P47, DOI 10.1111/j.1365-2559.1989.tb02113.x; CHARPIN C, 1982, INT J GYNECOL PATHOL, V1, P231, DOI 10.1097/00004347-198203000-00001; CHARPIN C, 1988, AM J PATHOL, V132, P199; CHARPIN C, 1989, CANCER, V63, P863, DOI 10.1002/1097-0142(19890301)63:5<863::AID-CNCR2820630512>3.0.CO;2-P; CHARPIN C, 1988, CANCER RES, V48, P1578; CHARPIN C, 1986, HUM PATHOL, V17, P355, DOI 10.1016/S0046-8177(86)80458-0; CHARPIN C, 1988, CANCER RES, V45, P4363; DABROWSKI AJ, 1990, J ALLERGY CLIN IMMUN, V86, P462, DOI 10.1016/S0091-6749(05)80200-3; DIDERLAURENT A, 1984, INT ARCH ALLER A IMM, V73, P27; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MATA P, 1990, AEROBIOLOGIA, V6, P87; VOORSHORST B, 1975, ALLERGY 74, P320	15	85	87	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1991	88	1					77	82		10.1016/0091-6749(91)90303-6	http://dx.doi.org/10.1016/0091-6749(91)90303-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY204	1712804				2022-12-18	WOS:A1991FY20400009
J	RAPHAEL, GD; BARANIUK, JN; KALINER, MA				RAPHAEL, GD; BARANIUK, JN; KALINER, MA			HOW AND WHY THE NOSE RUNS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INDUCED NASAL SECRETIONS; GENE-RELATED PEPTIDE; PATHO-PHYSIOLOGY; INDUCED RHINORRHEA; RHINITIS; LOCALIZATION; LACTOFERRIN; MUCOSA; ANTIHISTAMINE; PROVOCATION		NIAID, CLIN INVEST LAB,ALLERG DIS SECT,BLDG 1,11C207, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Baraniuk, James Nicholas/0000-0002-1866-4177				ANDERSEN IB, 1972, AM REV RESPIR DIS, V106, P438, DOI 10.1164/arrd.1972.106.3.438; BARANIUK JN, 1989, J ALLERGY CLIN IMMUN, V83, P303; BARANIUK JN, IN PRESS SKIN ASS LY; BARANIUK JN, IN PRESS IMMUNOL ALL; BARNES PJ, 1987, AM REV RESPIR DIS, V136, pS77, DOI 10.1164/ajrccm/136.6_Pt_2.S77; BARNES PJ, 1986, LANCET, V1, P242; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BORUM P, 1979, J ALLERGY CLIN IMMUN, V63, P253, DOI 10.1016/0091-6749(79)90109-X; BORUM P, 1978, RHINOLOGY, V16, P1169; BOWES D, 1981, THORAX, V36, P108, DOI 10.1136/thx.36.2.108; BRANDTZAEG P, 1974, J IMMUNOL, V112, P1553; CASALE TB, 1988, AM J RHINOL, V2, P121; CAUNA N, 1969, ANN OTO RHINOL LARYN, V78, P865, DOI 10.1177/000348946907800418; COHEN RA, 1988, CLIN ALLERGY, V18, P435, DOI 10.1111/j.1365-2222.1988.tb02893.x; COLE P, 1984, AM REV RESPIR DIS, V129, P351; GAFFEY MJ, 1987, AM REV RESPIR DIS, V136, P556, DOI 10.1164/ajrccm/136.3.556; GWALTNEY JM, 1966, AM REV RESPIR DIS, V238, P580; HOKFELT T, 1986, PROG BRAIN RES, V68, pR13; HOLTZER P, 1988, NEUROSCIENCE, V24, P739; HUA XY, 1986, ACTA PHYSIOL SCAND, V127, P1; JANSCO G, 1984, ANTIDROMIC VASODILAT, P44; LOMAX KJ, 1989, J CLIN INVEST, V83, P514, DOI 10.1172/JCI113912; LUNDBERG JM, 1987, AM REV RESPIR DIS S, V136, pS1; LUNDBLAD L, 1984, ACTA PHYSIOL SCAND, P1; MARTLING CR, 1987, ACTA PHYSIOL SCAND, V130, P1; MELTZER EO, 1988, J ALLERGY CLIN IMMUN, V82, P447, DOI 10.1016/0091-6749(88)90018-8; MEREDITH SD, 1989, J ALLERGY CLIN IMMUN, V84, P920, DOI 10.1016/0091-6749(89)90390-4; MULLOL J, UNPUB COMP HUMAN NAS; NACLERIO RM, 1983, EUR J RESPIR DIS, V64, P26; OSTBERG B, 1987, ARCH OTOLARYNGOL, V113, P160; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; POLAK JM, 1986, ARCH INT PHARMACOD T, V280, P16; POTTER EK, 1988, PHARMACOL THERAPEUT, V37, P251, DOI 10.1016/0163-7258(88)90028-9; RAPHAEL G, 1989, J ALLERGY CLIN IMMUN, V83, P110, DOI 10.1016/0091-6749(89)90484-3; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; RAPHAEL GD, 1989, J CLIN INVEST, V84, P1528, DOI 10.1172/JCI114329; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; RAPHAEL GD, 1989, J ALLERGY CLIN IMMUN, V84, P914, DOI 10.1016/0091-6749(89)90389-8; SAID SI, 1988, ANN NY ACAD SCI, V527, P1; SUNDAY ME, 1988, LAB INVEST, V59, P5; TOGIAS A, 1987, J ALLERGY CLIN IMMUN, V79, P599, DOI 10.1016/S0091-6749(87)80155-0; TOGIAS A, 1985, AM J MED, V79, P26, DOI 10.1016/0002-9343(85)90084-1; TOMMOY M, 1983, CELL TISSUE RES, V228, P549; UDDMAN R, 1986, CLIN CHEST MED, V7, P201; UDDMAN R, 1987, AM REV RESPIR DIS, V136, pS3, DOI 10.1164/ajrccm/136.6_Pt_2.S3; WRIGHT PF, 1983, INFECT IMMUN, V40, P1092, DOI 10.1128/IAI.40.3.1092-1095.1983	46	85	87	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					457	467		10.1016/0091-6749(91)90001-5	http://dx.doi.org/10.1016/0091-6749(91)90001-5			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1993805				2022-12-18	WOS:A1991EX98700001
J	BONINI, S; BONINI, S; BUCCI, MG; BERRUTO, A; ADRIANI, E; BALSANO, F; ALLANSMITH, MR				BONINI, S; BONINI, S; BUCCI, MG; BERRUTO, A; ADRIANI, E; BALSANO, F; ALLANSMITH, MR			ALLERGEN DOSE-RESPONSE AND LATE SYMPTOMS IN A HUMAN-MODEL OF OCULAR ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							LATE ASTHMATIC REACTIONS; LATE-PHASE; PROVOCATION; CONJUNCTIVA; ANAPHYLAXIS	Eleven ryegrass-sensitive patients were challenged weekly for 4 weeks with incremental doses of ryegrass allergen applied topically to one eye; a buffer was applied to the other eye. A clinical examination and tear-fluid cytology were performed before challenge and at 20 minutes, 1 hour, and 6 hours after challenge. A significant clinical reaction and neutrophil accumulation in the tear film occurred at 20 minutes. At 1 hour, a clinical response and tear cytologic reaction were present only at higher antigen concentrations. Six hours after antigen challenge, only the highest allergen concentration (320,000 BU/ml) produced a clinical late-phase reaction (LPR) (p < 0.01) and tear cytologic change (presence of eosinophils and lymphocytes). Five nonryegrass-sensitive control subjects were unresponsive to a similar challenge. These results indicate that a conjunctival response to allergen challenge is dose dependent, that is, the higher the dose, the more likely an LPR will occur and that an LPR correlates with significant numbers of inflammatory cells in the tear film.	UNIV ROME LA SAPIENZA,DEPT MED,I-00185 ROME,ITALY; HARVARD UNIV,SCH MED,EYE RES INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02115	Sapienza University Rome; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	BONINI, S (corresponding author), UNIV ROMA TOR VERGATA,DEPT OPHTHALMOL,OCULIST CLIN,VIA ORAZIO RAIMONDO 8,I-00173 ROME,ITALY.		Bonini, Sergio/T-6594-2019; Bonini, Stefano/A-2250-2012	Bonini, Sergio/0000-0003-0079-3031; Bonini, Stefano/0000-0002-7787-2144	NEI NIH HHS [EY-07733-01] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLANSMITH MR, 1979, AM J OPHTHALMOL, V87, P544, DOI 10.1016/0002-9394(79)90247-2; ATKINS PC, 1985, J ALLERGY CLIN IMMUN, V75, P239, DOI 10.1016/0091-6749(85)90052-1; BONINI S, 1987, CURR EYE RES, V6, P659, DOI 10.3109/02713688709034828; BONINI S, 1988, J ALLERGY CLIN IMMUN, V82, P462, DOI 10.1016/0091-6749(88)90020-6; CORNELLBELL AH, 1986, CELL IMMUNOL, V97, P1, DOI 10.1016/0008-8749(86)90369-2; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GREINER JV, 1985, AM J OPHTHALMOL, V100, P45, DOI 10.1016/S0002-9394(14)74981-5; HOLLANDER M, 1973, NONPARAMETRIC STAT, P71; KLINE B. S., 1932, JOUR ALLERGY, V3, P531, DOI 10.1016/S0021-8707(32)90148-8; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; LEMANSKE RF, 1988, ALLERGY PRINCIPLES P, P224; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OSTERBALLE O, 1979, ALLERGY, V34, P209, DOI 10.1111/j.1398-9995.1979.tb01700.x; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; UDELL IJ, 1981, AM J OPHTHALMOL, V92, P824, DOI 10.1016/S0002-9394(14)75637-5; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X	22	85	86	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	1				869	876		10.1016/S0091-6749(05)80148-4	http://dx.doi.org/10.1016/S0091-6749(05)80148-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EQ045	2262643	Bronze			2022-12-18	WOS:A1990EQ04500006
J	BECKER, AB; SIMONS, FER; MCMILLAN, JL; FARIDY, T				BECKER, AB; SIMONS, FER; MCMILLAN, JL; FARIDY, T			FORMOTEROL, A NEW LONG-ACTING SELECTIVE BETA2-ADRENERGIC RECEPTOR AGONIST - DOUBLE-BLIND COMPARISON WITH SALBUTAMOL AND PLACEBO IN CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC MED,HLTH SCI CTR RES FDN,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba								AHRENS RC, 1984, AM REV RESPIR DIS, V129, P903; ARVIDSSON P, 1989, EUR RESPIR J, V2, P325; BECKER AB, 1984, NEW ENGL J MED, V310, P743, DOI 10.1056/NEJM198403223101202; BRITTON J, 1988, THORAX, V43, P300, DOI 10.1136/thx.43.4.300; BUSSE WW, 1988, CLIN SCI, V2, P969; CHATHAM M, 1982, AM REV RESPIR DIS, V126, P235; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DUTOIT JI, 1987, AM REV RESPIR DIS, V136, P1174, DOI 10.1164/ajrccm/136.5.1174; EGGLESTON PA, 1981, CLIN PHARMACOL THER, V29, P505, DOI 10.1038/clpt.1981.70; GRONNEBERG R, 1988, NEW ENGL REG ALLERGY, V9, P381; IDA H, 1976, ARZNEIMITTEL-FORSCH, V26, P839; IDA H, 1976, ARZNEIMITTEL-FORSCH, V26, P1337; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; LOFDAHL CG, 1989, ALLERGY, V44, P264, DOI 10.1111/j.1398-9995.1989.tb01068.x; LOFDAHL CG, 1986, ACTA PHARM TOXICOL S, V52, P229; MITA H, 1983, ALLERGY, V38, P547, DOI 10.1111/j.1398-9995.1983.tb04138.x; PALMQVIST M, 1988, NER ALLERGY P, V9, P377; SALOME CM, 1983, THORAX, V38, P854, DOI 10.1136/thx.38.11.854; SIMONS FER, 1985, J ALLERGY CLIN IMMUN, V76, P703, DOI 10.1016/0091-6749(85)90674-8; Steel R.G.D., 1980, PRINCIPLES STAT; TASAKA K, 1986, Drugs of Today, V22, P505; TOMIOKA K, 1981, ARCH INT PHARMACOD T, V250, P279; WEISS JW, 1983, J ALLERGY CLIN IMMUN, V72, P140, DOI 10.1016/0091-6749(83)90521-3	23	85	88	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1989	84	6	1				891	895		10.1016/0091-6749(89)90385-0	http://dx.doi.org/10.1016/0091-6749(89)90385-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CG293	2574732				2022-12-18	WOS:A1989CG29300006
J	SLAVIN, RG				SLAVIN, RG			SINUSITIS IN ADULTS AND ITS RELATION TO ALLERGIC RHINITIS, ASTHMA, AND NASAL POLYPS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CARDINAL GLENNON CHILDRENS HOSP,ST LOUIS,MO		SLAVIN, RG (corresponding author), ST LOUIS UNIV,SCH MED,DIV ALLERGY & IMMUNOL,ALLERGY RES CTR,ST LOUIS,MO 63104, USA.							DRETTNER B, 1982, Rhinology (Utrecht), V20, P149; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; Kennedy D, 1985, ARCH OTOLARYNGOL, V3, P643; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; SLAVIN RG, 1984, J ALLERGY CLIN IMMUN, V73, P712, DOI 10.1016/0091-6749(84)90312-9; SLAVIN RG, 1986, J RESPIR DIS, V7, P61; SLAVIN RG, 1988, ALLERGY PRINCIPLES P, P1291; STAMMBERGER H, 1985, ANN OTO RHINOL LARYN, V94, P1	8	85	93	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	2	S			950	956		10.1016/0091-6749(88)90038-3	http://dx.doi.org/10.1016/0091-6749(88)90038-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R2353	3057048				2022-12-18	WOS:A1988R235300009
J	Guttman-Yassky, E; Pavel, AB; Zhou, LS; Estrada, YD; Zhang, N; Xu, H; Peng, XY; Wen, HC; Govas, P; Gudi, G; Vinu, CA; Fang, H; Salhi, Y; Back, J; Reddy, V; Bissonnette, R; Maari, C; Grossman, F; Wolff, G				Guttman-Yassky, Emma; Pavel, Ana B.; Zhou, Lisa; Estrada, Yeriel D.; Zhang, Ning; Xu, Hui; Peng, Xiangyu; Wen, Huei-Chi; Govas, Panayiota; Gudi, Girish; Vinu, C. A.; Fang, Hui; Salhi, Yacine; Back, Jonathan; Reddy, Venkateshwar; Bissonnette, Robert; Maari, Catherine; Grossman, Fred; Wolff, Gerhard			GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; inflammation; hyperplasia; OX40; costimulation; trial; T(H)1; T(H)2; T(H)17/T(H)22; biomarkers	THYMIC STROMAL LYMPHOPOIETIN; AUTOREACTIVE T-CELLS; OX40; IMMUNE; DUPILUMAB; ADULTS; PSORIASIS; PATHWAYS; BARRIER; CD134	Background: GBR 830 is a humanized mAb against OX40, a costimulatory receptor on activated T cells. OX40 inhibition might have a therapeutic role in T cell-mediated diseases, including atopic dermatitis (AD). Objective: This exploratory phase 2a study investigated the safety, efficacy, and tissue effects of GBR 830 in patients with AD. Methods: Patients with moderate-to-severe AD (affected body surface area, >= 10%; Eczema Area and Severity Index score, >= 12; and inadequate response to topical treatments) were randomized 3:1 to 10 mg/kg intravenous GBR 830 or placebo on day 1 (baseline) and day 29. Biopsy specimens were collected (n = 40) at days 1, 29, and 71. Primary end points included treatment-emergent adverse events (TEAEs) and changes from baseline in biomarkers (epidermal hyperplasia/cytokines) at days 29 and 71. Results: GBR 830 was well tolerated, with equal TEAE distribution (GBR 830, 63.0% [29/46]; placebo, 63.0% [10/16]). One serious TEAE in the GBR 830 group was deemed unrelated to study drug. At day 71, the proportion of intent-to-treat subjects achieving 50% or greater improvement in Eczema Area and Severity Index score was greater with GBR 830 (76.9% [20/26]) versus placebo (37.5% [3/8]). GBR 830 induced significant progressive reductions in T(H)1 (IFN-gamma/CXCL10), T(H)2 (IL-31/CCL11/CCL17), and T(H)17/T(H)22 (IL-23p19/IL-8/S100A12) mRNA expression in lesional skin. Significant progressive reductions until day 71 in the drug group were seen in OX40(+) T cells and OX40L(+) dendritic cells (P < .001). Hyperplasia measures (thickness/keratin 16/Ki67) showed greater reductions with GBR 830 (P < .001). Conclusions: Two doses of GBR 830 administered 4 weeks apart were well tolerated and induced significant progressive tissue and clinical changes until day 71 (42 days after the last dose), highlighting the potential of OX40 targeting in patients with AD.	[Guttman-Yassky, Emma; Pavel, Ana B.; Zhou, Lisa; Estrada, Yeriel D.; Zhang, Ning; Xu, Hui; Peng, Xiangyu; Wen, Huei-Chi; Govas, Panayiota] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Gudi, Girish; Fang, Hui; Salhi, Yacine; Reddy, Venkateshwar; Grossman, Fred; Wolff, Gerhard] Glenmark Pharmaceut Inc, Paramus, NJ USA; [Vinu, C. A.] Glenmark Pharmaceut Ltd, Mumbai, Maharashtra, India; [Back, Jonathan] Glenmark Pharmaceut SA, La Chaux De Fonds, Switzerland; [Bissonnette, Robert; Maari, Catherine] Inovaderm Res, Montreal, PQ, Canada	Icahn School of Medicine at Mount Sinai; Glenmark Pharmaceuticals Limited	Wolff, G (corresponding author), Icahn Sch Med Mt Sinai, Dept Dermatol, 5 E 98th St,5th Floor, New York, NY 10029 USA.	emma.guttman@mountsinai.org	Wen, Huei-Chi/ABD-7417-2021; Govas, Panayiota/ABH-2291-2020	, Ana Brandusa/0000-0002-8155-8553	Glenmark Pharmaceuticals, SA	Glenmark Pharmaceuticals, SA	Supported by Glenmark Pharmaceuticals, SA.	Abhishek Kumar, 2015, J Cutan Aesthet Surg, V8, P239, DOI 10.4103/0974-2077.172206; Abuabara K, 2018, ALLERGY, V73, P696, DOI 10.1111/all.13320; Akdis CA, 2006, ALLERGY, V61, P969, DOI 10.1111/j.1398-9995.2006.01153.x; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Boguniewicz M, 2018, ANN ALLERG ASTHMA IM, V120, P10, DOI 10.1016/j.anai.2017.10.039; Boguniewicz M, 2017, J ALLER CL IMM-PRACT, V5, P1519, DOI 10.1016/j.jaip.2017.08.005; Brunner PM, 2019, J ALLERGY CLIN IMMUN, V143, P142, DOI 10.1016/j.jaci.2018.07.028; Brunner PM, 2018, ANN ALLERG ASTHMA IM, V120, P34, DOI 10.1016/j.anai.2017.09.055; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Bulliard Y, 2014, IMMUNOL CELL BIOL, V92, P475, DOI 10.1038/icb.2014.26; Chen M, 2008, TRANSPLANTATION, V85, P1659, DOI 10.1097/TP.0b013e3181726987; Chitnis T, 2003, J ALLERGY CLIN IMMUN, V112, P837, DOI 10.1016/j.jaci.2003.08.025; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Corren J, 2017, NEW ENGL J MED, V377, P936, DOI 10.1056/NEJMoa1704064; Curti BD, 2013, CANCER RES, V73, P7189, DOI 10.1158/0008-5472.CAN-12-4174; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V139, P1723, DOI 10.1016/j.jaci.2017.04.004; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; Duan W, 2008, J IMMUNOL, V181, P8650, DOI 10.4049/jimmunol.181.12.8650; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Ewald DA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0133-x; Findlay EG, 2014, P NATL ACAD SCI USA, V111, P2289, DOI 10.1073/pnas.1321071111; Fujita H, 2011, J ALLERGY CLIN IMMUN, V128, P574, DOI 10.1016/j.jaci.2011.05.016; Futamura M, 2016, J AM ACAD DERMATOL, V74, P288, DOI 10.1016/j.jaad.2015.09.062; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Gittler JK, 2013, J ALLERGY CLIN IMMUN, V131, P300, DOI 10.1016/j.jaci.2012.06.048; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Gudi G, 2018, INT INV DERM IID M M; Guidance for Industry E6, 1996, GOOD CLINICAL PRACTI; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V143, P155, DOI 10.1016/j.jaci.2018.08.022; Guttman-Yassky E, 2018, J AM ACAD DERMATOL, V78, P872, DOI 10.1016/j.jaad.2018.01.016; Guttman-Yassky E, 2017, CURR OPIN IMMUNOL, V48, P68, DOI 10.1016/j.coi.2017.08.008; Guttman-Yassky E, 2018, EXP DERMATOL, V27, P409, DOI 10.1111/exd.13336; Guttman-Yassky E, 2013, EXPERT OPIN BIOL TH, V13, P549, DOI 10.1517/14712598.2013.758708; Hamilton JD, 2015, IMMUNOTHERAPY-UK, V7, P1043, DOI 10.2217/imt.15.69; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Ito T, 2012, ALLERGOL INT, V61, P35, DOI 10.2332/allergolint.11-RAI-0376; Kaur D, 2012, CHEST, V141, P494, DOI 10.1378/chest.11-1730; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kroemer A, 2007, J IMMUNOL, V179, P5584, DOI 10.4049/jimmunol.179.8.5584; Lathrop SK, 2004, J IMMUNOL, V172, P6735, DOI 10.4049/jimmunol.172.11.6735; Leung DYM, 2017, J ALLERGY CLIN IMMUN, V139, pS47, DOI 10.1016/j.jaci.2017.01.010; Levin EC, 2014, J DERMATOL TREAT, V25, P78, DOI 10.3109/09546634.2013.826341; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Marabelle A, 2013, J CLIN INVEST, V123, P2447, DOI 10.1172/JCI64859; Maxwell JR, 2006, J IMMUNOL, V177, P234, DOI 10.4049/jimmunol.177.1.234; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; Papp KA, 2017, J EUR ACAD DERMATOL, V31, P1324, DOI 10.1111/jdv.14313; Piconese S, 2008, J EXP MED, V205, P825, DOI 10.1084/jem.20071341; Renert-Yuval Y, 2017, CLIN DERMATOL, V35, P387, DOI 10.1016/j.clindermatol.2017.03.012; Ring J, 2012, J EUR ACAD DERMATOL, V26, P1176, DOI 10.1111/j.1468-3083.2012.04636.x; Schneider L, 2013, J ALLERGY CLIN IMMUN, V131, P295, DOI 10.1016/j.jaci.2012.12.672; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Spitz C, 2016, CELL MOL LIFE SCI, V73, P901, DOI 10.1007/s00018-015-2080-2; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Stuber E, 2000, EUR J CLIN INVEST, V30, P594; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Ungar B, 2017, J INVEST DERMATOL, V137, P603, DOI 10.1016/j.jid.2016.09.037; Vekaria Anjali S, 2017, F1000Res, V6, P1712, DOI 10.12688/f1000research.12422.1; Voo KS, 2013, J IMMUNOL, V191, P3641, DOI 10.4049/jimmunol.1202752; Vu MD, 2007, BLOOD, V110, P2501, DOI 10.1182/blood-2007-01-070748; Wahie S, 2007, ARCH DERMATOL, V143, P1267, DOI 10.1001/archderm.143.10.1267; Wang YH, 2009, CLIN EXP ALLERGY, V39, P798, DOI 10.1111/j.1365-2222.2009.03241.x; Webb GJ, 2016, CLIN REV ALLERG IMMU, V50, P312, DOI 10.1007/s12016-015-8498-3; Weinberg AD, 1998, MOL MED TODAY, V4, P76, DOI 10.1016/S1357-4310(97)01181-7; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Ziegler SF, 2006, NAT IMMUNOL, V7, P709, DOI 10.1038/ni1360	73	84	86	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					482	+		10.1016/j.jaci.2018.11.053	http://dx.doi.org/10.1016/j.jaci.2018.11.053			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	30738171	hybrid			2022-12-18	WOS:000478789300016
J	Esensten, JH; Muller, YD; Bluestone, JA; Tang, QZ				Esensten, Jonathan H.; Muller, Yannick D.; Bluestone, Jeffrey A.; Tang, Qizhi			Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory T cell; cell therapy; transplant; autoimmune disease; clinical trials; Good Medical Practice manufacturing	UMBILICAL-CORD BLOOD; ADOPTIVE TRANSFER; EX-VIVO; ALLOGRAFT-REJECTION; DENDRITIC CELLS; IL-33 PROMOTES; ADIPOSE-TISSUE; MOUSE MODEL; HUMAN TREGS; ANTIGEN	Forkhead box P3-expressing regulatory T (Treg) cells are essential for self-tolerance, with an emerging role in tissue repair and regeneration. Their ability to traffic to tissue and perform complex therapeutic tasks in response to the tissue microenvironment make them an attractive candidate for drug development. Early experiences of Treg cell therapy in patients with graft-versus-host disease, type 1 diabetes, and organ transplantation have shown that it is feasible, safe, and potentially efficacious in some settings. Many ongoing trials in patients with a wide variety of diseases will further enhance our knowledge about the optimal approaches for Treg cell manufacturing and dosing. We review the current preclinical rationale supporting Treg cell therapy in a variety of disease settings ranging from tissue transplantation, autoimmune diseases, and non-immunemediated inflammatory settings. We point out challenges in development of Treg cell therapy and speculate how synthetic biology can be used to enhance the feasibility and efficacy of Treg cell therapy for autoimmune and autoinflammatory diseases.	[Esensten, Jonathan H.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Muller, Yannick D.; Tang, Qizhi] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA; [Bluestone, Jeffrey A.; Tang, Qizhi] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA; [Bluestone, Jeffrey A.] Univ Calif San Francisco, Sean N Parker Autoimmune Res Lab, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bluestone, JA (corresponding author), Univ Calif San Francisco, 513 Parnassus Ave,HSW 1112 Box 0540, San Francisco, CA 94143 USA.; Tang, QZ (corresponding author), Univ Calif San Francisco, 513 Parnassus Ave,Room HSE 520,Box 0780, San Francisco, CA 94143 USA.	Jeff.Bluestone@ucsf.edu; Qizhi.Tang@ucsf.edu		Muller, Yannick/0000-0003-0513-7156; Tang, Qizhi/0000-0001-7313-3574	Leukemia and Lymphoma Society [5459-17]; Swiss National Science Foundation [P300PB_174500]	Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	J.H.E. is supported by a fellowship from the Leukemia and Lymphoma Society (grant no. 5459-17). Y.D.M. was supported by the Swiss National Science Foundation (Advanced Postdoc. Mobility Grant no. P300PB_174500).	Ali N, 2017, CELL, V169, P1119, DOI 10.1016/j.cell.2017.05.002; Arpaia N, 2015, CELL, V162, P1078, DOI 10.1016/j.cell.2015.08.021; Blat D, 2014, MOL THER, V22, P1018, DOI 10.1038/mt.2014.41; Bluestone JA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad4134; Boardman DA, 2017, AM J TRANSPLANT, V17, P931, DOI 10.1111/ajt.14185; Boissonnas A, 2010, IMMUNITY, V32, P266, DOI 10.1016/j.immuni.2009.11.015; Brunstein CG, 2016, BLOOD, V127, P1044, DOI 10.1182/blood-2015-06-653667; Brunstein CG, 2013, BIOL BLOOD MARROW TR, V19, P1271, DOI 10.1016/j.bbmt.2013.06.004; Brunstein CG, 2011, BLOOD, V117, P1061, DOI 10.1182/blood-2010-07-293795; Brusko TM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011726; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Canavan JB, 2016, GUT, V65, P584, DOI 10.1136/gutjnl-2014-306919; Chan CHF, 2004, MOL THER, V9, P775, DOI 10.1016/j.ymthe.2004.03.009; Chandran S, 2017, AM J TRANSPLANT, V17, P2945, DOI 10.1111/ajt.14415; Chaudhry A, 2009, SCIENCE, V326, P986, DOI 10.1126/science.1172702; Chinen T, 2016, NAT IMMUNOL, V17, P1322, DOI 10.1038/ni.3540; Christen U, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122007; Cohen JL, 2002, J EXP MED, V196, P401, DOI 10.1084/jem.20020090; Comte D, 2017, ARTHRITIS RHEUMATOL, V69, P808, DOI 10.1002/art.40014; Costa N, 2017, CLIN EXP IMMUNOL, V189, P318, DOI 10.1111/cei.12991; Dall'Era M, 2018, ARTHRITIS RHEUMATOL; Desreumaux P, 2012, GASTROENTEROLOGY, V143, P1207, DOI 10.1053/j.gastro.2012.07.116; DIIANNI M, 2011, BLOOD, V117, P3921, DOI [DOI 10.1182/blood-2010-10-311894, DOI 10.1182/BLOOD-2010-10-311894]; Dombrowski Y, 2017, NAT NEUROSCI, V20, P674, DOI 10.1038/nn.4528; Dominguez-Villar M, 2018, NAT IMMUNOL, V19, P665, DOI 10.1038/s41590-018-0120-4; Duhen T, 2012, BLOOD, V119, P4430, DOI 10.1182/blood-2011-11-392324; Edinger M, 2003, NAT MED, V9, P1144, DOI 10.1038/nm915; Elinav E, 2008, GASTROENTEROLOGY, V134, P2014, DOI 10.1053/j.gastro.2008.02.060; Esensten JH, 2009, J IMMUNOL, V183, P75, DOI 10.4049/jimmunol.0804154; Fantini MC, 2009, GASTROENTEROLOGY, V136, P1308, DOI 10.1053/j.gastro.2008.12.053; Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Foussat A, 2003, J IMMUNOL, V171, P5018, DOI 10.4049/jimmunol.171.10.5018; Friedmann-Morvinski D, 2005, BLOOD, V105, P3087, DOI 10.1182/blood-2004-09-3737; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Gliwinski M, 2017, BIODRUGS, V31, P335, DOI 10.1007/s40259-017-0228-3; Hardtke-Wolenski M, 2015, HEPATOLOGY, V61, P1295, DOI 10.1002/hep.27639; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; He J, 2016, NAT MED, V22, P991, DOI 10.1038/nm.4148; Hoeppli R, 2018, AM J TRANSPLANT; Hull CM, 2017, J AUTOIMMUN, V79, P63, DOI 10.1016/j.jaut.2017.01.001; Humrich JY, 2010, P NATL ACAD SCI USA, V107, P204, DOI 10.1073/pnas.0903158107; Jeffery HC, 2016, J HEPATOL, V64, P1118, DOI 10.1016/j.jhep.2015.12.017; Kiesler P, 2015, CELL MOL GASTROENTER, V1, P154, DOI 10.1016/j.jcmgh.2015.01.006; Kim BS, 2017, CELL REP, V21, P195, DOI 10.1016/j.celrep.2017.09.021; Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731; Kolodin D, 2015, CELL METAB, V21, P543, DOI 10.1016/j.cmet.2015.03.005; Lee JH, 2007, CLIN EXP IMMUNOL, V148, P53, DOI 10.1111/j.1365-2249.2007.03329.x; Lee K, 2014, AM J TRANSPLANT, V14, P27, DOI 10.1111/ajt.12509; Legoux FP, 2015, IMMUNITY, V43, P896, DOI 10.1016/j.immuni.2015.10.011; Levine AG, 2017, NATURE, V546, P421, DOI 10.1038/nature22360; Levine AG, 2014, NAT IMMUNOL, V15, P1070, DOI 10.1038/ni.3004; Li JT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00585; Lin YJ, 2008, TRANSPLANTATION, V86, P1452, DOI 10.1097/TP.0b013e318188acb0; Longhi MS, 2004, J HEPATOL, V41, P31, DOI 10.1016/j.jhep.2004.03.008; MacDonald KG, 2016, J CLIN INVEST, V126, P1413, DOI 10.1172/JCI82771; Marek-Trzonkowska N, 2014, CLIN IMMUNOL, V153, P23, DOI 10.1016/j.clim.2014.03.016; Marek-Trzonkowska N, 2012, DIABETES CARE, V35, P1817, DOI 10.2337/dc12-0038; Martelli MF, 2014, BLOOD, V124, P638, DOI 10.1182/blood-2014-03-564401; Massoud AH, 2016, NAT MED, V22, P1013, DOI 10.1038/nm.4147; Mathew JM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25574-7; Maul J, 2005, GASTROENTEROLOGY, V128, P1868, DOI 10.1053/j.gastro.2005.03.043; Mckenna DH, 2017, CYTOTHERAPY, V19, P250, DOI 10.1016/j.jcyt.2016.10.011; Miyara M, 2011, AUTOIMMUN REV, V10, P744, DOI 10.1016/j.autrev.2011.05.004; Monticelli LA, 2015, P NATL ACAD SCI USA, V112, P10762, DOI 10.1073/pnas.1509070112; Nosbaum A, 2016, J IMMUNOL, V196, P2010, DOI 10.4049/jimmunol.1502139; Noyan F, 2017, AM J TRANSPLANT, V17, P917, DOI 10.1111/ajt.14175; Oderup C, 2006, IMMUNOLOGY, V118, P240, DOI 10.1111/j.1365-2567.2006.02362.x; Ohkura N, 2012, IMMUNITY, V37, P785, DOI 10.1016/j.immuni.2012.09.010; Onishi Y, 2008, P NATL ACAD SCI USA, V105, P10113, DOI 10.1073/pnas.0711106105; Panduro M, 2016, ANNU REV IMMUNOL, V34, P609, DOI 10.1146/annurev-immunol-032712-095948; Peiseler M, 2012, J HEPATOL, V57, P125, DOI 10.1016/j.jhep.2012.02.029; Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105; Provoost S, 2009, ALLERGY, V64, P1539, DOI 10.1111/j.1398-9995.2009.02056.x; Putnam AL, 2013, AM J TRANSPLANT, V13, P3010, DOI 10.1111/ajt.12433; Putnam AL, 2009, DIABETES, V58, P652, DOI 10.2337/db08-1168; Qureshi OS, 2011, SCIENCE, V332, P600, DOI 10.1126/science.1202947; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P639, DOI 10.1016/j.jaci.2016.06.003; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Scalapino KJ, 2006, J IMMUNOL, V177, P1451, DOI 10.4049/jimmunol.177.3.1451; Scalapino KJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006031; Schiering C, 2014, NATURE, V513, P564, DOI 10.1038/nature13577; Schmidt A, 2017, IMMUNOL RES, V65, P551, DOI 10.1007/s12026-017-8904-4; Schmidt A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148474; Schmidt T, 2016, EXP DERMATOL, V25, P293, DOI 10.1111/exd.12919; Seay HR, 2017, MOL THER-METH CLIN D, V4, P178, DOI 10.1016/j.omtm.2016.12.003; Sebode M, 2018, LIVER INT, V38, P15, DOI 10.1111/liv.13458; Smigiel KS, 2014, J EXP MED, V211, P121, DOI 10.1084/jem.20131142; Sockolosky JT, 2018, SCIENCE, V359, P1037, DOI 10.1126/science.aar3246; Spence A, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0807-6; Stadinski BD, 2010, NAT IMMUNOL, V11, P225, DOI 10.1038/ni.1844; Sugiyama H, 2007, DERMATOLOGY, V214, P210, DOI 10.1159/000099585; Tang Q, 2013, COLD SPRING HARB PER, V3; Tang Q, 2008, IMMUNITY, V28, P687, DOI 10.1016/j.immuni.2008.03.016; Tang QZ, 2004, J EXP MED, V199, P1455, DOI 10.1084/jem.20040139; Taubert R, 2014, J HEPATOL, V61, P1106, DOI 10.1016/j.jhep.2014.05.034; Theil A, 2015, CYTOTHERAPY, V17, P473, DOI 10.1016/j.jcyt.2014.11.005; Thonhoff JR, 2018, NEUROL-NEUROIMMUNOL, V5, DOI 10.1212/NXI.0000000000000465; Todo S, 2016, HEPATOLOGY, V64, P632, DOI 10.1002/hep.28459; Toker A, 2013, J IMMUNOL, V190, P3180, DOI 10.4049/jimmunol.1203473; Trzonkowski P, 2009, CLIN IMMUNOL, V133, P22, DOI 10.1016/j.clim.2009.06.001; van Wijk F, 2007, CLIN EXP ALLERGY, V37, P572, DOI 10.1111/j.1365-2222.2007.02681.x; Vasanthakumar A, 2015, NAT IMMUNOL, V16, P276, DOI 10.1038/ni.3085; Veerapathran A, 2011, BLOOD, V118, P5671, DOI 10.1182/blood-2011-02-337097; Voehringer D, 2000, J IMMUNOL, V165, P2415, DOI 10.4049/jimmunol.165.5.2415; Wang LL, 2013, MOL MED REP, V8, P1432, DOI 10.3892/mmr.2013.1692; Yadav M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00232; Yeh WI, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01313; Yokoyama T, 2011, INT IMMUNOL, V23, P365, DOI 10.1093/intimm/dxr020; Zaiss DMW, 2013, IMMUNITY, V38, P275, DOI 10.1016/j.immuni.2012.09.023; Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674	112	84	86	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1710	1718		10.1016/j.jaci.2018.10.015	http://dx.doi.org/10.1016/j.jaci.2018.10.015			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	30367909	Green Submitted, Bronze			2022-12-18	WOS:000452315800003
J	Stein, MM; Thompson, EE; Schoettler, N; Helling, BA; Magnaye, KM; Stanhope, C; Igartua, C; Morin, A; Washington, C; Nicolae, D; Bonnelykke, K; Ober, C				Stein, Michelle M.; Thompson, Emma E.; Schoettler, Nathan; Helling, Britney A.; Magnaye, Kevin M.; Stanhope, Catherine; Igartua, Catherine; Morin, Andreanne; Washington, Charles, III; Nicolae, Dan; Bonnelykke, Klaus; Ober, Carole			A decade of research on the 17q12-21 asthma locus: Piecing together the puzzle	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Wheezing; genome-wide association study; immune cells; lung cells; ORMDL3; GSDMB; PGAP3; GSDMA; gene expression	GENOME-WIDE ASSOCIATION; GENETIC-VARIANTS; CHILDHOOD ASTHMA; AIRWAY RESPONSIVENESS; ALLERGIC RHINITIS; TOTAL IGE; SUSCEPTIBILITY LOCI; DNA METHYLATION; 17Q21 VARIANTS; TOBACCO-SMOKE	Chromosome 17q12-21 remains the most highly replicated and significant asthma locus. Genotypes in the core region defined by the first genome-wide association study correlate with expression of 2 genes, ORM1-like 3 (ORMDL3) and gasdermin B (GSDMB), making these prime candidate asthma genes, although recent studies have implicated gasdermin A (GSDMA) distal to and post-GPI attachment to proteins 3 (PGAP3) proximal to the core region as independent loci. We review 10 years of studies on the 17q12-21 locus and suggest that genotype-specific risks for asthma at the proximal and distal loci are not specific to early-onset asthma and mediated by PGAP3, ORMDL3, and/or GSDMA expression. We propose that the weak and inconsistent associations of 17q single nucleotide polymorphisms with asthma in African Americans is due to the high frequency of some 17q alleles, the breakdown of linkage disequilibrium on African-derived chromosomes, and possibly different early-life asthma endotypes in these children. Finally, the inconsistent association between asthma and gene expression levels in blood or lung cells from older children and adults suggests that genotype effects may mediate asthma risk or protection during critical developmental windows and/or in response to relevant exposures in early life. Thus studies of young children and ethnically diverse populations are required to fully understand the relationship between genotype and asthma phenotype and the gene regulatory architecture at this locus.	[Stein, Michelle M.; Thompson, Emma E.; Schoettler, Nathan; Helling, Britney A.; Magnaye, Kevin M.; Stanhope, Catherine; Igartua, Catherine; Morin, Andreanne; Washington, Charles, III; Nicolae, Dan; Ober, Carole] Univ Chicago, Dept Human Genet, 920 E 58th St, Chicago, IL 60637 USA; [Schoettler, Nathan] Univ Chicago, Sect Pulm & Crit Care Med, Dept Med, Chicago, IL 60637 USA; [Nicolae, Dan] Univ Chicago, Dept Stat, Chicago, IL 60637 USA; [Nicolae, Dan] Univ Chicago, Med Genet Sect, Dept Med, Chicago, IL 60637 USA; [Bonnelykke, Klaus] Univ Copenhagen, Herlev & Gentofte Hosp, COPSAC, Copenhagen, Denmark	University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Copenhagen	Ober, C (corresponding author), Univ Chicago, Dept Human Genet, 920 E 58th St, Chicago, IL 60637 USA.	c-ober@genetics.uchicago.edu		Ober, Carole/0000-0003-4626-9809; Nicolae, Dan/0000-0002-0918-4630; Stein, Michelle/0000-0002-7680-9012; Helling, Britney/0000-0002-3895-5107; Bonnelykke, Klaus/0000-0003-2003-1018	 [R01 HL085197];  [P01 HL070831];  [R01 HL129735];  [U19 AI095230];  [R01 HL122712];  [R01 HL113395];  [T32 GM007197];  [T32 HL007605]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL122712, R01HL113395, T32HL007605, R01HL085197, R01HL129735, F31HL143891, P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI095230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007197] Funding Source: NIH RePORTER	; ; ; ; ; ; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by grants R01 HL085197, P01 HL070831, R01 HL129735, U19 AI095230, R01 HL122712, and R01 HL113395. K.M.M. and C.W. are supported by grant T32 GM007197, and M.M.S., N.S., and B.A.H. are supported by grant T32 HL007605.	Acevedo N, 2015, HUM MOL GENET, V24, P875, DOI 10.1093/hmg/ddu479; Adegunsoye A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00516; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Almoguera B, 2017, AM J RESP CRIT CARE, V195, P456, DOI 10.1164/rccm.201604-0861OC; Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Anantharaman R, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-170; Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764; Andiappan AK, 2016, J ALLERGY CLIN IMMUN, V137, P758, DOI 10.1016/j.jaci.2015.08.038; Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Barrett JC, 2009, NAT GENET, V41, P703, DOI 10.1038/ng.381; Berlivet S, 2012, HUM GENET, V131, P1161, DOI 10.1007/s00439-012-1142-x; Bhakta NR, 2017, AM J RESP CRIT CARE; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Blekic M, 2013, ANN ALLERG ASTHMA IM, V110, P347, DOI 10.1016/j.anai.2013.01.021; Bonnelykke K, 2016, J ALLERGY CLIN IMMUN, V137, P667, DOI 10.1016/j.jaci.2016.01.006; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Bonnelykke K, 2013, NAT GENET, V45, P902, DOI 10.1038/ng.2694; Bouzigon E, 2015, CLIN EXP ALLERGY, V45, P797, DOI 10.1111/cea.12461; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Brauner EV, 2012, GENES IMMUN, V13, P94, DOI 10.1038/gene.2011.51; Breslow DK, 2010, NATURE, V463, P1048, DOI 10.1038/nature08787; Caliskan M, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005111; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Cantero-Recasens G, 2010, HUM MOL GENET, V19, P111, DOI 10.1093/hmg/ddp471; Chen J, 2015, TISSUE ANTIGENS, V86, P443, DOI 10.1111/tan.12688; Das S, 2017, ADV IMMUNOL, V135, P1, DOI 10.1016/bs.ai.2017.06.001; Das S, 2016, P NATL ACAD SCI USA, V113, P13132, DOI 10.1073/pnas.1610433113; Demenais F, 2018, NAT GENET, V50, P42, DOI 10.1038/s41588-017-0014-7; Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Fang QR, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-133; Ferreira MAR, 2011, EUR J HUM GENET, V19, P458, DOI 10.1038/ejhg.2010.191; Fuertes E, 2015, J ALLERGY CLIN IMMUN, V135, P573, DOI 10.1016/j.jaci.2014.08.016; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Galanter JM, 2014, J ALLERGY CLIN IMMUN, V134, P295, DOI 10.1016/j.jaci.2013.08.055; Gern JE, 2012, J INFECT DIS, V206, P1342, DOI 10.1093/infdis/jis504; Granada M, 2012, J ALLERGY CLIN IMMUN, V129, P840, DOI 10.1016/j.jaci.2011.09.029; Granell R, 2013, J ALLERGY CLIN IMMUN, V131, P685, DOI 10.1016/j.jaci.2012.09.021; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Ha SG, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3479; Halapi E, 2010, EUR J HUM GENET, V18, P902, DOI 10.1038/ejhg.2010.38; Hao K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003029; Hirota T, 2008, J ALLERGY CLIN IMMUN, V121, P769, DOI 10.1016/j.jaci.2007.09.038; Hirschfield GM, 2009, NEW ENGL J MED, V360, P2544, DOI 10.1056/NEJMoa0810440; Huang CR, 2015, GASTROENTEROLOGY, V149, P1575, DOI 10.1053/j.gastro.2015.07.065; Igartua C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6965; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Joost O, 2002, AM J RESP CRIT CARE, V165, P795, DOI 10.1164/ajrccm.165.6.2102057; Kang MJ, 2012, HUM IMMUNOL, V73, P954, DOI 10.1016/j.humimm.2012.06.009; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim KW, 2015, J ALLERGY CLIN IMMUN, V136, P678, DOI 10.1016/j.jaci.2015.03.030; Kreiner E, 2017, J ALLERGY CLIN IMMUN, V140, P771, DOI 10.1016/j.jaci.2016.10.055; Kreiner-Moller E, 2015, ALLERGY, V70, P107, DOI 10.1111/all.12537; Lappalainen T, 2013, NATURE, V501, P506, DOI 10.1038/nature12531; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Lazaar AL, 2001, METH MOLEC MED, V56, P155, DOI 10.1385/1-59259-151-5:155; Leek JT, 2010, NAT REV GENET, V11, P733, DOI 10.1038/nrg2825; Levin AM, 2013, J ALLERGY CLIN IMMUN, V131, P1176, DOI 10.1016/j.jaci.2012.10.002; Li FX, 2012, GENET MOL RES, V11, P340, DOI 10.4238/2012.February.10.5; Li MY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.76; Li X, 2015, ALLERGY, V70, P1309, DOI 10.1111/all.12683; Li XN, 2012, J ALLERGY CLIN IMMUN, V130, P861, DOI 10.1016/j.jaci.2012.04.041; Liu YP, 2017, CLIN EXP ALLERGY, V47, P371, DOI 10.1111/cea.12903; Lluis A, 2011, J ALLERGY CLIN IMMUN, V127, P1587, DOI 10.1016/j.jaci.2011.03.015; Loser S, 2017, J ALLERGY CLIN IMMUN, V139, P1496, DOI 10.1016/j.jaci.2016.07.033; Loss GJ, 2016, AM J RESP CRIT CARE, V193, P889, DOI 10.1164/rccm.201507-1493OC; Marinho S, 2012, ANN ALLERG ASTHMA IM, V108, P402, DOI 10.1016/j.anai.2012.03.002; Mathias RA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12522; Mells GF, 2011, NAT GENET, V43, P329, DOI 10.1038/ng.789; Miller M, 2017, J IMMUNOL, V198, P3017, DOI 10.4049/jimmunol.1601848; Miller M, 2017, J ALLERGY CLIN IMMUN, V139, P1373, DOI 10.1016/j.jaci.2016.08.053; Miller M, 2014, J IMMUNOL, V192, P3475, DOI 10.4049/jimmunol.1303047; Miller M, 2012, P NATL ACAD SCI USA, V109, P16648, DOI 10.1073/pnas.1204151109; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Morrison FS, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-627; Murphy A, 2010, HUM MOL GENET, V19, P4745, DOI 10.1093/hmg/ddq392; Nicodemus-Johnson J, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.90151; Nicodemus-Johnson J, 2016, AM J RESP CRIT CARE, V193, P376, DOI 10.1164/rccm.201506-1243OC; Nieuwenhuis MA, 2016, ALLERGY, V71, P1712, DOI 10.1111/all.12990; Noguchi E, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002170; Oyeniran C, 2015, J ALLERGY CLIN IMMUN, V136, P1035, DOI 10.1016/j.jaci.2015.02.031; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Pickrell JK, 2014, AM J HUM GENET, V94, P559, DOI 10.1016/j.ajhg.2014.03.004; Pino-Yanes M, 2015, J ALLERGY CLIN IMMUN, V135, P1502, DOI 10.1016/j.jaci.2014.10.033; Ramasamy A, 2011, J ALLERGY CLIN IMMUN, V128, P996, DOI 10.1016/j.jaci.2011.08.030; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Saleh NM, 2011, DIABETES-METAB RES, V27, P838, DOI 10.1002/dmrr.1259; Schedel M, 2015, J ALLERGY CLIN IMMUN, V136, P893, DOI 10.1016/j.jaci.2015.03.014; Schmiedel BJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13426; Scholtens S, 2014, J ALLERGY CLIN IMMUN, V133, P885, DOI 10.1016/j.jaci.2013.08.049; Sharma S, 2014, J ALLERGY CLIN IMMUN, V134, P1153, DOI 10.1016/j.jaci.2014.04.011; Shukla S, 2011, NATURE, V479, P74, DOI 10.1038/nature10442; Sleiman PMA, 2008, J ALLERGY CLIN IMMUN, V122, P1225, DOI 10.1016/j.jaci.2008.06.041; Smit LAM, 2010, EUR RESPIR J, V36, P57, DOI 10.1183/09031936.00154509; Soler Artigas M, 2011, NAT GENET, V43, P1082, DOI 10.1038/ng.941; Stahl EA, 2010, NAT GENET, V42, P508, DOI 10.1038/ng.582; Stokholm J, 2017, J ALLERGY CLIN IMMUN; Tang MF, 2016, PEDIAT ALLERG IMM-UK, V27, P185, DOI 10.1111/pai.12505; Tang WB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100776; Tomita K, 2013, ALLERGY, V68, P92, DOI 10.1111/all.12066; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; van der Valk RJP, 2012, ALLERGY, V67, P767, DOI 10.1111/j.1398-9995.2012.02819.x; van der Valk RJP, 2014, J ALLERGY CLIN IMMUN, V134, P46, DOI 10.1016/j.jaci.2013.08.053; Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007; Wan YI, 2012, THORAX, V67, P762, DOI 10.1136/thoraxjnl-2011-201262; Wang XH, 2017, INT J BIOCHEM CELL B, V87, P8, DOI 10.1016/j.biocel.2017.03.007; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; White MJ, 2016, IMMUNOGENETICS, V68, P391, DOI 10.1007/s00251-016-0914-1; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yan Q, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01505-2016; Yang FF, 2012, GENET MOL RES, V11, P4646, DOI 10.4238/2012.October.19.1; Yao TC, 2014, J ALLERGY CLIN IMMUN, V133, P248, DOI 10.1016/j.jaci.2013.06.018; Yatagai Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080941; Yu F, 2017, MOL MED REP, V15, P2969, DOI 10.3892/mmr.2017.6413; Yu J, 2011, PEDIATR PULM, V46, P701, DOI 10.1002/ppul.21424; Yu X, 2014, TISSUE ANTIGENS, V83, P330, DOI 10.1111/tan.12342; Zhakupova A, 2016, FASEB J, V30, P4289, DOI 10.1096/fj.201600639R	121	84	85	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					749	+		10.1016/j.jaci.2017.12.974	http://dx.doi.org/10.1016/j.jaci.2017.12.974			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29307657	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000443726500005
J	Chung, KF				Chung, Kian Fan			Airway microbial dysbiosis in asthmatic patients: A target for prevention and treatment?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Airway microbiota; airway microbiome; gut microbiota; asthma; microbial dysbiosis; gut-lung axis	PLACEBO-CONTROLLED TRIAL; REGULATORY T-CELLS; GUT MICROBIOTA; EARLY-LIFE; DOUBLE-BLIND; BREAST-MILK; EXPOSURE; INFLAMMATION; BACTERIA; ALLERGY	There has been long-standing interest in the role of bacterial communities in the complex and heterogeneous disease of asthma. With the advent of 16s rRNA sequencing replacing traditional culture methods, a strong association between the presence of bacterial communities with asthma has emerged. These microbiota can be modulated by various environmental factors, including diet, antibiotics, and early-life microbial exposures. Microbiota in the gut and lungs can influence both the inception and progress of asthma. In babies and infants the presence of pathogenic bacteria in the lungs and gut has been associated with subsequent development of allergic sensitization and asthma. Lung microbiota are present in the airways of healthy subjects but are dysregulated in adults with asthma, with a reduced diversity and community composition that has been linked to severity and inflammatory phenotypes. Causality between certain gut microbiota and the development of allergic asthma has been shown in experiments conducted in neonatal mice. Manipulation of the airway microbiome, particularly in early life, might be a strategy to prevent or treat asthma, although the results of studies of probiotics used together with prebiotics have been overall negative. A better understanding of the regulation of both the lung and gut microbiota to derive appropriate targets for prevention or treatment of asthma is needed.	Imperial Coll, Natl Heart & Lung Inst, London, England; Royal Brompton & Harefield NHS Trust, Resp Biomed Res Unit, London, England; Imperial Coll London, London, England	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; Imperial College London	Chung, KF (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	f.chung@imperial.ac.uk	Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426	UK Medical Research Council; European Union Horizon 2020; National Institute of Environmental Health Sciences; UK Natural Environment Research Council; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre, MRC-Asthma UK Centre] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union Horizon 2020; National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); UK Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	K.F.C. has been the recipient of grants from the UK Medical Research Council, European Union Horizon 2020, National Institute of Environmental Health Sciences, and UK Natural Environment Research Council.	Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Bassis CM, 2015, MBIO, V6, DOI 10.1128/mBio.00037-15; Bilate AM, 2012, ANNU REV IMMUNOL, V30, P733, DOI 10.1146/annurev-immunol-020711-075043; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brusselle GG, 2013, THORAX, V68, P322, DOI 10.1136/thoraxjnl-2012-202698; CAZZOLA M, 1991, CLIN THER, V13, P157; Chen YS, 2010, PEDIATR PULM, V45, P1111, DOI 10.1002/ppul.21296; Chung KF, 2016, J INTERN MED, V279, P192, DOI 10.1111/joim.12382; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; de Lafaille MAC, 2008, IMMUNITY, V29, P114, DOI 10.1016/j.immuni.2008.05.010; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Denner DR, 2016, J ALLERGY CLIN IMMUN, V137, P1398, DOI 10.1016/j.jaci.2015.10.017; Depner M., 2016, J ALLERGY CLIN IMMUN, V6749, P30710; Dickson RP, 2015, AM J PHYSIOL-LUNG C, V309, pL1047, DOI 10.1152/ajplung.00279.2015; Durack J, 2016, J ALLERGY CLIN IMMUN; Fall T, 2015, JAMA PEDIATR, V169, DOI 10.1001/jamapediatrics.2015.3219; Ferrer M, 2016, BIOCH PHARM; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378; Gibeon D, 2013, CHEST, V143, P406, DOI 10.1378/chest.12-0872; Gilbert JA, 2016, NATURE, V535, P94, DOI 10.1038/nature18850; Goleva E, 2013, AM J RESP CRIT CARE, V188, P1193, DOI 10.1164/rccm.201304-0775OC; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; Gomez-Gallego C, 2016, SEMIN FETAL NEONAT M, V21, P400, DOI 10.1016/j.siny.2016.05.003; Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645; Gutkowski P, 2010, CENT EUR J IMMUNOL, V35, P233; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Hauptmann M, 2016, FEBS LETT, V590, P3721, DOI 10.1002/1873-3468.12421; He Y, 2017, CRIT REV MICROBIOL, V43, P81, DOI [10.1080/1040841X.2016.1176988, 10.1080/1040841x.2016.1176988]; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Johnston SL, 2016, JAMA INTERN MED, V176, P1630, DOI 10.1001/jamainternmed.2016.5664; Kim HY, 2014, NAT MED, V20, P54, DOI 10.1038/nm.3423; Kuo CS, 2017, EUR RESP J IN PRESS, P49; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lefaudeux D, 2016, J ALLERGY CLIN IMMUN; Lodge CJ, 2015, ACTA PAEDIATR, V104, P38, DOI 10.1111/apa.13132; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Mackenzie BW, 2017, ENVIRON MICROBIOL, V19, P381, DOI 10.1111/1462-2920.13632; Mamessier E, 2008, ALLERGY, V63, P1202, DOI 10.1111/j.1398-9995.2008.01687.x; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; Marsland BJ, 2015, ANN AM THORAC SOC, V12, pS150, DOI 10.1513/AnnalsATS.201503-133AW; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Molyneaux PL, 2013, AM J RESP CRIT CARE, V188, P1224, DOI 10.1164/rccm.201302-0341OC; Nembrini C, 2011, THORAX, V66, P755, DOI 10.1136/thx.2010.152512; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Palm NW, 2015, CLIN IMMUNOL, V159, P122, DOI 10.1016/j.clim.2015.05.014; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Ramesh R, 2014, J EXP MED, V211, P89, DOI 10.1084/jem.20130301; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rogier EW, 2014, P NATL ACAD SCI USA, V111, P3074, DOI 10.1073/pnas.1315792111; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Schuijt TJ, 2016, GUT, V65, P575, DOI 10.1136/gutjnl-2015-309728; Segal LN, 2017, THORAX, V72, P13, DOI 10.1136/thoraxjnl-2016-208599; Shore SA, 2016, AM J RESP CELL MOL, V54, P609, DOI 10.1165/rcmb.2016-0052PS; Silvers KM, 2012, J PEDIATR-US, V160, DOI 10.1016/j.jpeds.2011.11.055; Simpson JL, 2016, EUR RESPIR J, V47, P792, DOI 10.1183/13993003.00405-2015; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sverrild A, 2016, J ALLERGY CLIN IMMUN; Sze MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111228; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Thorburn AN, 2010, THORAX, V65, P1053, DOI 10.1136/thx.2009.131508; Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Valkonen M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131594; van de Pol MA, 2011, ALLERGY, V66, P39, DOI 10.1111/j.1398-9995.2010.02454.x; Venkataraman A, 2015, MBIO, V6, DOI 10.1128/mBio.02284-14; Vliagoftis H, 2008, ANN ALLERG ASTHMA IM, V101, P570, DOI 10.1016/S1081-1206(10)60219-0; Walker WA, 2015, PEDIATR RES, V77, P220, DOI 10.1038/pr.2014.160; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Wojno EDT, 2016, J EXP MED, V213, P2229, DOI 10.1084/jem.20160525; Wood LG, 2010, FREE RADICAL RES, V44, P146, DOI 10.3109/10715760903362576; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yadav V, 2013, INT J PHARMACEUT, V457, P268, DOI 10.1016/j.ijpharm.2013.09.007; Zhang QL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152724; Zhang QL, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-35	86	84	94	6	45	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1071	1083		10.1016/j.jaci.2017.02.004	http://dx.doi.org/10.1016/j.jaci.2017.02.004			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	28390574				2022-12-18	WOS:000398771800001
J	Gauvreau, GM; Arm, JP; Boulet, LP; Leigh, R; Cockcroft, DW; Davis, BE; Mayers, I; FitzGerald, JM; Dahlen, B; Killian, KJ; Laviolette, M; Carlsten, C; Lazarinis, N; Watson, RM; Milot, J; Swystun, V; Bowen, M; Hui, L; Lantz, AS; Meiser, K; Maahs, S; Lowe, PJ; Skerjanec, A; Drollmann, A; O'Byrne, PM				Gauvreau, Gail M.; Arm, Jonathan P.; Boulet, Louis-Philippe; Leigh, Richard; Cockcroft, Donald W.; Davis, Beth E.; Mayers, Irvin; FitzGerald, J. Mark; Dahlen, Barbro; Killian, Kieran J.; Laviolette, Michel; Carlsten, Christopher; Lazarinis, Nikolaos; Watson, Richard M.; Milot, Joanne; Swystun, Veronica; Bowen, Miranda; Hui, Linda; Lantz, Ann-Sofie; Meiser, Karin; Maahs, Suzanne; Lowe, Philip J.; Skerjanec, Andrej; Drollmann, Anton; O'Byrne, Paul M.			Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen- induced early asthmatic responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma management; allergy; immunology; IgE; ligelizumab; mAb; QGE031; biologics	FC-EPSILON-RI; ANTI-IGE ANTIBODY; HUMANIZED MONOCLONAL-ANTIBODY; MEDIATED ASTHMA; HUMAN BASOPHILS; INFLAMMATION; PHARMACOKINETICS; PHARMACODYNAMICS; ACTIVATION; EXPRESSION	Background: Omalizumab is an established anti-IgE therapy for the treatment of allergic diseases that prevents IgE from binding to its receptor. QGE031 is an investigational anti-IgE antibody that binds IgE with higher affinity than omalizumab. Objective: This study compared the effects of QGE031 with those of omalizumab on clinical efficacy, IgE levels, and Fc epsilon RI expression in a clinical model of allergic asthma. Methods: Thirty-seven patients with mild allergic asthma were randomized to subcutaneous omalizumab, placebo, or QGE031 at 24, 72, or 240 mg every 2 weeks for 10 weeks in a doubleblind, parallel-group multicenter study. Inhaled allergen challenges and skin tests were conducted before dosing and at weeks 6, 12, and 18, and blood was collected until 24 weeks after the first dose. Results: QGE031 elicited a concentration- and time-dependent change in the provocative concentration of allergen causing a 15% decrease in FEV1 (allergen PC15) that was maximal and approximately 3-fold greater than that of omalizumab (P = .10) and 16-fold greater than that of placebo (P = .0001) at week 12 in the 240-mg cohort. Skin responses reached 85% suppression at week 12 in the 240-mg cohort and were maximal at week 18. The top doses of QGE031 consistently suppressed skin test responses among subjects but had a variable effect on allergen PC15 (2-fold to 500-fold change). QGE031 was well tolerated. Conclusion: QGE031 has greater efficacy than omalizumab on inhaled and skin allergen responses in patients with mild allergic asthma. These data support the clinical development of QGE031 as a treatment of asthma.	[Gauvreau, Gail M.; Killian, Kieran J.; Watson, Richard M.; O'Byrne, Paul M.] McMaster Univ, Dept Med, Hamilton, NY USA; [Arm, Jonathan P.; Meiser, Karin; Lowe, Philip J.; Skerjanec, Andrej; Drollmann, Anton] Novartis Pharmaceut, E Hanover, NJ USA; [Arm, Jonathan P.; Lowe, Philip J.; Skerjanec, Andrej; Drollmann, Anton] Novartis Pharma AG, Bldg WSJ 386-12-48-50, CH-4002 Basel, Switzerland; [Boulet, Louis-Philippe; Laviolette, Michel; Milot, Joanne] Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada; [Leigh, Richard; Swystun, Veronica] Univ Calgary, Dept Physiol & Med, Calgary, AB T2N 1N4, Canada; [Cockcroft, Donald W.; Davis, Beth E.] Univ Calgary, Dept Pharmacol, Calgary, AB T2N 1N4, Canada; [Bowen, Miranda] Univ Saskatchewan, Dept Med, Saskatoon, SK, Canada; [Mayers, Irvin; Bowen, Miranda] Univ Alberta, Dept Med, Edmonton, AB, Canada; [FitzGerald, J. Mark] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Dahlen, Barbro; Lazarinis, Nikolaos] Karolinska Univ, Dept Med, Karolinska Inst, Stockholm, Sweden; [Maahs, Suzanne] Novartis Pharmaceut, E Hanover, NJ USA	Novartis; Novartis; University of Calgary; University of Calgary; University of Saskatchewan; University of Alberta; University of British Columbia; Karolinska Institutet; Karolinska University Hospital; Novartis	Drollmann, A (corresponding author), Novartis Pharma AG, Bldg WSJ 386-12-48-50, CH-4002 Basel, Switzerland.	anton.drollmann@novartis.com	Lowe, Phil/K-8483-2019	O'Byrne, Paul/0000-0003-0979-281X	Novartis Pharma AG	Novartis Pharma AG	Supported by Novartis Pharma AG.	Arm JP, 2014, CLIN EXP ALLERGY, V44, P1371, DOI 10.1111/cea.12400; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Boitano S, 2011, AM J PHYSIOL-LUNG C, V300, pL605, DOI 10.1152/ajplung.00359.2010; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; Chanez P, 2010, RESP MED, V104, P1608, DOI 10.1016/j.rmed.2010.07.011; Cockcroft DW, 2005, ALLERGY, V60, P56, DOI 10.1111/j.1398-9995.2004.00612.x; Cockcroft DW, 1985, AIRWAY RESPONSIVENES, P22; D'Amato G, 2014, MULTIDISCIP RESP MED, V9, DOI 10.1186/2049-6958-9-23; Davis BE, 2009, EUR RESPIR J, V33, P1302, DOI 10.1183/09031936.00169008; Diamant Z, 2013, J ALLERGY CLIN IMMUN, V132, P1045, DOI 10.1016/j.jaci.2013.08.023; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Holgate S, 2009, ALLERGY, V64, P1728, DOI 10.1111/j.1398-9995.2009.02201.x; Kaur D, 2015, ALLERGY, V70, P556, DOI 10.1111/all.12593; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; Lowe PJ, 2009, BRIT J CLIN PHARMACO, V68, P61, DOI 10.1111/j.1365-2125.2009.03401.x; Lowe PJ, 2016, ADME TRANSLATIONAL P; MacGlashan D, 2009, J ALLERGY CLIN IMMUN, V123, P114, DOI 10.1016/j.jaci.2008.10.053; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Massanari M, 2010, RESP MED, V104, P188, DOI 10.1016/j.rmed.2009.09.011; Meno-Tetang GML, 2005, BASIC CLIN PHARMACOL, V96, P182, DOI 10.1111/j.1742-7843.2005.pto960307.x; Neighbour H, 2014, CLIN EXP ALLERGY, V44, P508, DOI 10.1111/cea.12244; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; Oliver JM, 2010, INT ARCH ALLERGY IMM, V151, P275, DOI 10.1159/000250436; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; Salter BM, 2015, J ALLERGY CLIN IMMUN, V136, P1636, DOI 10.1016/j.jaci.2015.03.039; Saluja R, 2016, EUR J PHARMACOL, V778, P68, DOI 10.1016/j.ejphar.2015.04.047; Slavin RG, 2009, J ALLERGY CLIN IMMUN, V123, P107, DOI 10.1016/j.jaci.2008.09.050; Zhu R, 2013, AAPS J, V15, P559, DOI 10.1208/s12248-013-9463-9; Zielen S, 2013, INT ARCH ALLERGY IMM, V160, P102, DOI 10.1159/000339243	34	84	89	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1051	1059		10.1016/j.jaci.2016.02.027	http://dx.doi.org/10.1016/j.jaci.2016.02.027			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27185571	Bronze			2022-12-18	WOS:000385499400010
J	Shi, BC; Bangayan, NJ; Curd, E; Taylor, PA; Gallo, RL; Leung, DYM; Li, HY				Shi, Baochen; Bangayan, Nathanael J.; Curd, Emily; Taylor, Patricia A.; Gallo, Richard L.; Leung, Donald Y. M.; Li, Huiying			The skin microbiome is different in pediatric versus adult atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							STAPHYLOCOCCUS-AUREUS; AIRWAY INFLAMMATION; ALLERGIC-ASTHMA; LEBRIKIZUMAB; OMALIZUMAB; CHILDREN; DISEASE; SHIFTS		[Shi, Baochen; Bangayan, Nathanael J.; Curd, Emily; Li, Huiying] Univ Calif Los Angeles, David Geffen Sch Med, Crump Inst Mol Imaging, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Curd, Emily] Univ Calif Los Angeles, Dept Ecol & Evolutionary Biol, Los Angeles, CA USA; [Taylor, Patricia A.; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA; [Gallo, Richard L.] Univ Calif San Diego, Div Dermatol, La Jolla, CA 92093 USA; [Leung, Donald Y. M.] Univ Colorado Denver, Dept Pediat, Aurora, CO 80045 USA; [Li, Huiying] Univ Calif Los Angeles, UCLA DOE Inst Genom & Prote, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; National Jewish Health; University of California System; University of California San Diego; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; United States Department of Energy (DOE); University of California System; University of California Los Angeles	Li, HY (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Crump Inst Mol Imaging, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.; Leung, DYM (corresponding author), Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA.; Leung, DYM (corresponding author), Univ Colorado Denver, Dept Pediat, Aurora, CO 80045 USA.; Li, HY (corresponding author), Univ Calif Los Angeles, UCLA DOE Inst Genom & Prote, Los Angeles, CA 90095 USA.	Leungd@njhealth.org; huiying@mednet.ucla.edu	Gallo, Richard L/A-8931-2009; SHI, BAOCHEN/P-6406-2017	Gallo, Richard L/0000-0002-1401-7861; 	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI117673] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR001082] Funding Source: Medline; NIAID NIH HHS [HHSN272201000020C, HHSN272201000017C, U01 AI147462, U19 AI117673] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arron JR, 2014, EUR RESPIR J, V43, P627, DOI 10.1183/09031936.00117013; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bourgon R, 2010, P NATL ACAD SCI USA, V107, P9546, DOI 10.1073/pnas.0914005107; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Flores GE, 2014, J DRUGS DERMATOL, V13, P1365; Hanania NA, 2015, THORAX, V70, P748, DOI 10.1136/thoraxjnl-2014-206719; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Hanania NA, 2011, ANN INTERN MED, V154, P573, DOI 10.7326/0003-4819-154-9-201105030-00002; Hannigan GD, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a015362; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Oh J, 2012, GENOME MED, V4, DOI 10.1186/gm378; Orenstein A, 1997, FEMS IMMUNOL MED MIC, V19, P307, DOI 10.1016/S0928-8244(97)00097-7; Regev-Yochay G, 2006, J BACTERIOL, V188, P4996, DOI 10.1128/JB.00317-06; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sherman J, 2014, CLIN CHEM, V60, P9546; Shu MY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055380; Wang Y, 2014, BENEF MICROBES, V5, P161, DOI 10.3920/BM2013.0031	21	84	89	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1233	1236		10.1016/j.jaci.2016.04.053	http://dx.doi.org/10.1016/j.jaci.2016.04.053			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27474122	Green Accepted, Bronze			2022-12-18	WOS:000385499400041
J	Denner, DR; Sangwan, N; Becker, JB; Hogarth, DK; Oldham, J; Castillo, J; Sperling, AI; Solway, J; Naureckas, ET; Gilbert, JA; White, SR				Denner, Darcy R.; Sangwan, Naseer; Becker, Julia B.; Hogarth, D. Kyle; Oldham, Justin; Castillo, Jamee; Sperling, Anne I.; Solway, Julian; Naureckas, Edward T.; Gilbert, Jack A.; White, Steven R.			Corticosteroid therapy and airflow obstruction influence the bronchial microbiome, which is distinct from that of bronchoalveolar lavage in asthmatic airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; microbiome; corticosteroids; FEV1; bacteria; 16S ribosomal RNA	CHILDHOOD ASTHMA; AZITHROMYCIN; INFLAMMATION; HYPERRESPONSIVENESS; ANTIBIOTICS; BACTERIAL; EXPOSURE; SPUTUM	Background: The lung has a diverse microbiome that is modest in biomass. This microbiome differs in asthmatic patients compared with control subjects, but the effects of clinical characteristics on the microbial community composition and structure are not clear. Objectives: We examined whether the composition and structure of the lower airway microbiome correlated with clinical characteristics of chronic persistent asthma, including airflow obstruction, use of corticosteroid medications, and presence of airway eosinophilia. Methods: DNA was extracted from endobronchial brushings and bronchoalveolar lavage fluid collected from 39 asthmatic patients and 19 control subjects, along with negative control samples. 16S rRNA V4 amplicon sequencing was used to compare the relative abundance of bacterial genera with clinical characteristics. Results: Differential feature selection analysis revealed significant differences in microbial diversity between brush and lavage samples from asthmatic patients and control subjects. Lactobacillus, Pseudomonas, and Rickettsia species were significantly enriched in samples from asthmatic patients, whereas Prevotella, Streptococcus, and Veillonella species were enriched in brush samples from control subjects. Generalized linear models on brush samples demonstrated oral corticosteroid use as an important factor affecting the relative abundance of the taxa that were significantly enriched in asthmatic patients. In addition, bacteriala-diversity in brush samples from asthmatic patients was correlated with FEV1 and the proportion of lavage eosinophils. Conclusion: The diversity and composition of the bronchial airway microbiome of asthmatic patients is distinct from that of nonasthmatic control subjects and influenced by worsening airflow obstruction and corticosteroid use.	[Denner, Darcy R.; Becker, Julia B.; Hogarth, D. Kyle; Oldham, Justin; Castillo, Jamee; Sperling, Anne I.; Solway, Julian; Naureckas, Edward T.; White, Steven R.] Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, Chicago, IL 60637 USA; [Gilbert, Jack A.] Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; [Gilbert, Jack A.] Univ Chicago, Dept Surg, Chicago, IL 60637 USA; [Gilbert, Jack A.] Univ Chicago, Inst Genet Gen & Syst Biol, Chicago, IL 60637 USA; [Sangwan, Naseer; Gilbert, Jack A.] Argonne Natl Lab, Biosci Div BIO, 9700 S Cass Ave, Argonne, IL 60439 USA; [Gilbert, Jack A.] Marine Biol Lab, Woods Hole, MA 02543 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; United States Department of Energy (DOE); Argonne National Laboratory; Marine Biological Laboratory - Woods Hole	White, SR (corresponding author), Univ Chicago, Sect Pulm & Crit Care Med, 5841 S Maryland Ave,MC6076, Chicago, IL 60637 USA.	swhite@bsd.uchicago.edu	Gilbert, Jack/AAF-3270-2019; Sperling, Anne/ACZ-2351-2022	Sangwan, Naseer/0000-0002-2407-769X; Sperling, Anne I./0000-0002-4265-9212	National Institutes for Allergy and Infectious Diseases [U19-AI095230]; National Heart, Lung, and Blood Institute [T32-HL007605]; National Center for Advancing Translational Sciences of the National Institutes of Health [UL1-TR000430]; Institute for Translational Medicine of the University of Chicago; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000430] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI095230] Funding Source: NIH RePORTER	National Institutes for Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Institute for Translational Medicine of the University of Chicago; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grant U19-AI095230 from the National Institutes for Allergy and Infectious Diseases; grant T32-HL007605 from the National Heart, Lung, and Blood Institute; grant UL1-TR000430 from the National Center for Advancing Translational Sciences of the National Institutes of Health; and the Institute for Translational Medicine of the University of Chicago.	Altenburg J, 2011, RESPIRATION, V81, P67, DOI 10.1159/000320319; BAUGHMAN RP, 1987, CHEST, V91, P233, DOI 10.1378/chest.91.2.233; Beck JM, 2012, TRANSL RES, V160, P258, DOI 10.1016/j.trsl.2012.02.005; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Blasi F, 2007, INT J ANTIMICROB AG, V29, P485, DOI 10.1016/j.ijantimicag.2006.11.029; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brusselle GG, 2013, THORAX, V68, P322, DOI 10.1136/thoraxjnl-2012-202698; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Charlson ES, 2012, AM J RESP CRIT CARE, V186, P536, DOI 10.1164/rccm.201204-0693OC; Charlson ES, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042786; Charlson ES, 2011, AM J RESP CRIT CARE, V184, P957, DOI 10.1164/rccm.201104-0655OC; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ekici A, 2002, J ASTHMA, V39, P181, DOI 10.1081/JAS-120002199; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; Goleva E, 2013, AM J RESP CRIT CARE, V188, P1193, DOI 10.1164/rccm.201304-0775OC; Hahn DL, 2012, J AM BOARD FAM MED, V25, P442, DOI 10.3122/jabfm.2012.04.110309; Han MK, 2012, THORAX, V67, P456, DOI 10.1136/thoraxjnl-2011-201183; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782; Little SA, 2002, AM J MED, V112, P446, DOI 10.1016/S0002-9343(02)01047-1; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Nicodemus-Johnson J, 2013, J ALLERGY CLIN IMMUN, V131, P1496, DOI 10.1016/j.jaci.2013.01.037; Paulson JN, 2013, NAT METHODS, V10, P1200, DOI [10.1038/NMETH.2658, 10.1038/nmeth.2658]; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Segal LN, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-19; Spycher BD, 2010, CLIN EXP ALLERGY, V40, P1130, DOI 10.1111/j.1365-2222.2010.03541.x; Walker ML, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00447; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; White JR, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000352; White SR, 2010, EUR RESPIR J, V35, P925, DOI 10.1183/09031936.00164809; Woodruff PG, 2001, J ALLERGY CLIN IMMUN, V108, P753, DOI 10.1067/mai.2001.119411	38	84	84	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1398	+		10.1016/j.jaci.2015.10.017	http://dx.doi.org/10.1016/j.jaci.2015.10.017			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26627545	Bronze, Green Accepted			2022-12-18	WOS:000376180200014
J	Krueger, J; Clark, JD; Suarez-Farinas, M; Fuentes-Duculan, J; Cueto, I; Wang, CQ; Tan, HM; Wolk, R; Rottinghaus, ST; Whitley, MZ; Valdez, H; von Schack, D; O'Neil, SP; Reddy, PS; Tatulych, S				Krueger, James; Clark, James D.; Suarez-Farinas, Mayte; Fuentes-Duculan, Judilyn; Cueto, Inna; Wang, Claire Q.; Tan, Huaming; Wolk, Robert; Rottinghaus, Scott T.; Whitley, Maryann Z.; Valdez, Hernan; von Schack, David; O'Neil, Shawn P.; Reddy, Padmalatha S.; Tatulych, Svitlana		A3921147 Study Investigators	Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-17; IL-22 family; IL-23; inflammation; Janus kinase; keratinocyte; psoriasis; phosphorylated signal transducer and activator of transcription; T(H)17 cell; tofacitinib	PLAQUE PSORIASIS; SKIN; ACTIVATION; ARTHRITIS; MODERATE	Background: Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. Objective: We sought to elucidate the molecular mechanisms underlying the clinical efficacy of tofacitinib in patients with psoriasis. Methods: Twelve patients with plaque psoriasis were randomized (3: 1) to receive 10 mg of tofacitinib or placebo twice daily for 12 weeks. Biopsy specimens were taken from nonlesional (baseline) and lesional (baseline, days 1 and 3, and weeks 1, 2, 4, and 12) skin. Biopsy specimens were examined for psoriatic epidermal features (thickness, Ki67(+) keratinocytes and keratin 16 [KRT16] mRNA expression, and phosphorylated signal transducer and activator of transcription [pSTAT](+) nuclei) and T-cell and dendritic cell (DC) subsets by using immunohistochemistry, and mRNA transcripts were quantified by using a microarray. Results: In lesional skin keratinocyte pSTAT1 and pSTAT3 staining was increased at baseline but reduced after 1 day of tofacitinib (baseline, median of 1290 pSTAT1(+) cells/mu m(2); day 1, median of 332 pSTAT1(+) cells/mu m(2); and nonlesional, median of 155 pSTAT1(+) cells/mu m(2)). Epidermal thickness and KRT16 mRNA expression were significantly and progressively reduced after days 1 and 3 of tofacitinib administration, respectively (eg, KRT16 decreased 2.74-fold, day 3 vs baseline, P = .016). Decreases in DC and T-cell numbers were observed after weeks 1 and 2, respectively. At week 4, significant decreases in IL-23/T(H)17 pathways were observed that persisted through week 12. Improvements in clinical and histologic features were strongly associated with changes in expression of psoriasis-related genes and reduction in IL-17 gene expression. Conclusions: Tofacitinib has a multitiered response in patients with psoriasis: (1) rapid attenuation of keratinocyte Janus kinase/STAT signaling; (2) removal of keratinocyte-induced cytokine signaling, leading to reductions in pathologic DC and T-cell numbers to nonlesional levels; and (3) inhibition of the IL-23/T(H)17 pathway.	[Krueger, James; Suarez-Farinas, Mayte; Fuentes-Duculan, Judilyn; Cueto, Inna; Wang, Claire Q.] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA; [Clark, James D.; Whitley, Maryann Z.; von Schack, David; O'Neil, Shawn P.; Reddy, Padmalatha S.] Pfizer Inc, Cambridge, MA USA; [Tan, Huaming; Wolk, Robert; Rottinghaus, Scott T.; Tatulych, Svitlana] Pfizer Inc, Groton, CT 06340 USA; [Valdez, Hernan] Pfizer Inc, New York, NY USA	Rockefeller University; Pfizer; Pfizer; Pfizer	Tatulych, S (corresponding author), 558 Eastern Point Rd, Groton, CT 06340 USA.	svitlana.tatulych@pfizer.com		Wang, Qiufan/0000-0002-7331-070X; Clark, James D./0000-0002-4801-0123	Pfizer Inc.	Pfizer Inc.(Pfizer)	This study was sponsored by Pfizer Inc. Both Pfizer Inc and non-Pfizer Inc authors have participated in the study design, data collection, data analysis, and open scientific discussion of the data; its interpretation; and the development of the associated manuscript. The views and opinions expressed within the manuscript are those of all authors and do not necessarily represent those of the funding organization. Medical writing support was funded by Pfizer Inc.	Bachelez H, 2015, LANCET, V386, P552, DOI 10.1016/S0140-6736(14)62113-9; Bioconductor, 2015, BIOC OP SOURC SOFTW; Bissonnette R, 2015, BRIT J DERMATOL, V172, P1395, DOI 10.1111/bjd.13551; Chiricozzi A, 2014, EXPERT OPIN THER TAR, V18, P513, DOI 10.1517/14728222.2014.889686; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Dowty M, 2014, ANN RHEUM DIS, V73, P116, DOI 10.1136/annrheumdis-2014-eular.2490; Dowty ME, 2014, J PHARMACOL EXP THER, V348, P165, DOI 10.1124/jpet.113.209304; Foster AM, 2014, J IMMUNOL, V192, P6053, DOI 10.4049/jimmunol.1301481; Fuentes-Duculan J, 2010, J INVEST DERMATOL, V130, P2412, DOI 10.1038/jid.2010.165; Ghoreschi K, 2011, J IMMUNOL, V186, P4234, DOI 10.4049/jimmunol.1003668; Heath WR, 2013, NAT IMMUNOL, V14, P978, DOI 10.1038/ni.2680; Jabbari A, 2012, J INVEST DERMATOL, V132, P246, DOI 10.1038/jid.2011.267; Logsdon NJ, 2012, P NATL ACAD SCI USA, V109, P12704, DOI 10.1073/pnas.1117551109; Lonnberg AS, 2014, CLIN COSMET INVESTI, V7, P251, DOI 10.2147/CCID.S67534; Lowes MA, 2013, TRENDS IMMUNOL, V34, P174, DOI 10.1016/j.it.2012.11.005; Meyer DM, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-41; Mudigonda Parvathi, 2012, Dermatol Online J, V18, P1; Papp KA, 2015, J AM ACAD DERMATOL, V72, pAB66; Perera GK, 2012, ANNU REV PATHOL-MECH, V7, P385, DOI 10.1146/annurev-pathol-011811-132448; Russell CB, 2014, J IMMUNOL, V192, P3828, DOI 10.4049/jimmunol.1301737; Schon MP, 2005, NEW ENGL J MED, V352, P1899, DOI 10.1056/NEJMra041320; Suarez-Farinas M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010247; Teng X, 2014, J IMMUNOL, V192, P1815, DOI 10.4049/jimmunol.1300047; The R Foundation, 2015, R PROJECT STAT COMPU; Tian SY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044274	25	84	90	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1079	1090		10.1016/j.jaci.2015.12.1318	http://dx.doi.org/10.1016/j.jaci.2015.12.1318			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	27059729	hybrid			2022-12-18	WOS:000373351200014
J	Rudmik, L; Hopkins, C; Peters, A; Smith, TL; Schlosser, RJ; Soler, ZM				Rudmik, Luke; Hopkins, Claire; Peters, Anju; Smith, Timothy L.; Schlosser, Rodney J.; Soler, Zachary M.			Patient-reported outcome measures for adult chronic rhinosinusitis: A systematic review and quality assessment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Chronic rhinosinusitis; sinusitis; patient-reported outcome measure; quality of life; systematic review; evidence-based medicine	OF-LIFE; MEASUREMENT INSTRUMENTS; CLINIMETRIC VALIDITY; SURGERY; VALIDATION; SYMPTOMS; DECISION; CRITERIA; DOMAINS; INFORM	Background: With a focus on patient-centered care, there is increasing policy interest in patient-reported outcome measures (PROMs) to inform improvements in health care delivery. Given the importance of understanding patient-reported outcomes during the management of chronic rhinosinusitis (CRS), PROMs will play an essential role in informing and tailoring the right intervention to the right patient. Objective: The objective of this systematic review was to identify and assess the quality of PROMs being used for adults with CRS. Methods: A systematic review of Ovid MEDLINE (R) (1947-May 2015), Embase, and the Cochrane databases was performed using the following key terms: ["chronic'' AND "*sinusitis''] AND [PROM OR patient reported outcome measure* OR quality of life OR questionnaire OR survey OR valid* OR develop*]. An unlimited truncation strategy (placement of *) was used to capture all variations of terms used. The quality of each PROM was assessed and reported using standardized criteria from the COnsensus-based Standards for the selection of health status Measurement INstruments checklist. Results: A total of 15 PROMs validated for use in adult patients with CRS were identified. Fourteen instruments were specific to adults with CRS, and one was a generic quality-of-life instrument (EuroQol five-dimensional questionnaire [EQ-5D]). There was significant variation in the quality of development and reporting of psychometric properties. Overall, the highest quality validated PROMs for adults with CRS were (1) the 22-item Sinonasal Outcome Test (19 points), (2) the Questionnaire of Olfactory Disorders (14 points), (3) the Sinusitis Control Test (14 points), and (4) the EQ-5D (13 points). Most of the PROMs were developed for research purposes such as determining changes in health-related quality of life or symptoms after an intervention as opposed to improving clinical decision making. Conclusions: Based on quality assessment, the 22-item Sinonasal Outcome Test, the Questionnaire of Olfactory Disorders, and the Sinusitis Control Test provided the highest quality CRS-specific PROMs, whereas the EQ-5D provided the highest quality generic quality-of-life instrument. Future CRS PROMs will need to incorporate clinical domains that assess common comorbid diseases along with patient values and preferences to improve clinical decision making.	[Rudmik, Luke] Univ Calgary, Div Otolaryngol Head & Neck Surg, Dept Surg, Calgary, AB T2T 5C7, Canada; [Hopkins, Claire] Guys & St Thomas NHS Trust, Dept ENT, London, England; [Peters, Anju] Northwestern Univ, Dept Internal Med, Allergy Div, Chicago, IL 60611 USA; [Smith, Timothy L.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Oregon Sinus Ctr, Div Rhinol & Sinus Surg, Portland, OR 97201 USA; [Schlosser, Rodney J.; Soler, Zachary M.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Div Rhinol & Sinus Surg, Charleston, SC 29425 USA	University of Calgary; Guy's & St Thomas' NHS Foundation Trust; Northwestern University; Oregon Health & Science University; Medical University of South Carolina	Rudmik, L (corresponding author), Univ Calgary, Richmond Rd Diagnost & Treatment Ctr, Dept Surg, Div Otolaryngol Head & Neck Surg, 1820 Richmond Rd SW, Calgary, AB T2T 5C7, Canada.	Lukerudmik@gmail.com			Acclarent; Baxter; Greer; National Institute of Health/NIDCD [DC005805]; Olympus; Meda; Entellus; Intersect ENT; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005805] Funding Source: NIH RePORTER	Acclarent; Baxter; Greer; National Institute of Health/NIDCD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Olympus; Meda; Entellus; Intersect ENT; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	C. Hopkins is on the Journal of Laryngology and Otology Board of Directors; has received consultancy fees from Acclarent; has received funds as an advisor to Wellcome Trust; and has access to the CPRD Database provided by Johnson & Johnson. A. Peters has received consultancy fees from Baxter and Greer. T. L. Smith has received research support from the National Institute of Health/NIDCD (grant #DC005805). R. J. Schlosser has received consultancy fees from Olympus and Meda, and has received research support from Entellus and Intersect ENT. Z. M. Soler has received consultancy fees from Olympus.	Abdalla S, 2012, CLIN OTOLARYNGOL, V37, P276, DOI 10.1111/j.1749-4486.2012.02527.x; Anderson ER, 1999, OTOLARYNG HEAD NECK, V121, P702, DOI 10.1053/hn.1999.v121.a100114; [Anonymous], 2012, COMMONWEALTH FUND RE; [Anonymous], 2015, PROMIS DATABASE; [Anonymous], 2015, GREY LIT DATABASE; Atlas SJ, 2005, LARYNGOSCOPE, V115, P846, DOI 10.1097/01.MLG.0000157693.92975.02; Bachert C, 2010, CURR ALLERGY ASTHM R, V10, P194, DOI 10.1007/s11882-010-0096-0; Banglawala SM, 2015, INT FORUM A IN PRESS; Benninger MS, 1997, ARCH OTOLARYNGOL, V123, P1175; Bhattacharyya N, 2003, AM J RHINOL, V17, P27, DOI 10.1177/194589240301700106; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Canadian Institute of Health Information, 2014, MEAS PAT CTR CAR; Conrad DA, 2014, MILBANK Q, V92, P568, DOI 10.1111/1468-0009.12078; DeConde AS, 2014, INT FORUM ALLERGY RH, V4, P972, DOI 10.1002/alr.21408; Desrosiers M, 2011, ALLERGY ASTHMA CL IM, V7, DOI 10.1186/1710-1492-7-2; Dixon AE, 2009, CHEST, V136, P1324, DOI 10.1378/chest.08-1983; Dykewicz MS, 2010, J ALLERGY CLIN IMMUN, V125, pS103, DOI 10.1016/j.jaci.2009.12.989; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Frank L, 2014, JAMA-J AM MED ASSOC, V312, P1513, DOI 10.1001/jama.2014.11100; GLIKLICH RE, 1995, LARYNGOSCOPE, V105, P387, DOI 10.1288/00005537-199504000-00010; Gregorio LL, 2015, CLIN OTOLARYNGOL, V40, P115, DOI 10.1111/coa.12334; Hopkins C, 2009, CLIN OTOLARYNGOL, V34, P447, DOI 10.1111/j.1749-4486.2009.01995.x; Hopkins C, 2015, LARYNGOSCOPE, V125, P1779, DOI 10.1002/lary.25318; Kacha S, 2012, EUR ARCH OTO-RHINO-L, V269, P143, DOI 10.1007/s00405-011-1690-z; Kerr EA, 2013, JAMA-J AM MED ASSOC, V310, P137, DOI 10.1001/jama.2013.6828; Lange B, 2016, CLIN OTOLARYNGOL, V41, P127, DOI 10.1111/coa.12481; Ling FTK, 2007, AM J RHINOL, V21, P495, DOI 10.2500/ajr.2007.21.3052; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; McNair AGK, 2015, COLORECTAL DIS, V17, pO217, DOI 10.1111/codi.13021; Mokkink LB, 2010, QUAL LIFE RES, V19, P539, DOI 10.1007/s11136-010-9606-8; Mortuaire G, 2010, EUR ANN OTORHINOLARY, V127, P91, DOI 10.1016/j.anorl.2010.06.002; Naidoo Y, 2013, J LARYNGOL OTOL, V127, pS24, DOI 10.1017/S0022215113000558; NHS, 2015, PAT REP OUTC MEAS PR; Ocampo CJ, 2013, J ALLER CL IMM-PRACT, V1, P205, DOI 10.1016/j.jaip.2012.12.001; Ocampo CJ, 2013, J ALLERGY CLIN IMMUN, V1, P12; Piccirillo JF, 2002, OTOLARYNG HEAD NECK, V126, P41, DOI 10.1067/mhn.2002.121022; Piccirillo JF, 1995, AM J RHINOL, V9, P297, DOI 10.2500/105065895781808711; Prinsen CAC, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-247; Pynnonen MA, 2009, AM J RHINOL ALLERGY, V23, P40, DOI 10.2500/ajra.2009.23.3259; Remenschneider AK, 2015, LARYNGOSCOPE, V125, P1056, DOI 10.1002/lary.25054; Remenschneider AK, 2015, LARYNGOSCOPE, V125, P7, DOI 10.1002/lary.24715; Rosenfeld RM, 2015, OTOLARYNG HEAD NECK, V152, pS1, DOI 10.1177/0194599815572097; Rubin R, 2015, JAMA-J AM MED ASSOC, V313, P1089, DOI 10.1001/jama.2015.0957; Rudmik L, 2015, JAMA-J AM MED ASSOC, V314, P926, DOI 10.1001/jama.2015.7544; Rudmik L, 2015, LARYNGOSCOPE, V125, P1517, DOI 10.1002/lary.25108; Rudmik L, 2014, LARYNGOSCOPE, V124, P2007, DOI 10.1002/lary.24630; Rudmik L, 2011, CURR ALLERGY ASTHM R, V11, P247, DOI 10.1007/s11882-010-0175-2; Simopoulos E, 2012, LARYNGOSCOPE, V122, P1450, DOI 10.1002/lary.23349; Soler ZM, 2013, LARYNGOSCOPE, V123, P2341, DOI 10.1002/lary.24027; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Worth A, 2012, PRIM CARE RESP J, V21, P455, DOI 10.4104/pcrj.2012.00084	51	84	87	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1532	+		10.1016/j.jaci.2015.10.012	http://dx.doi.org/10.1016/j.jaci.2015.10.012			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26654198	Bronze			2022-12-18	WOS:000366044300014
J	Resch, Y; Michel, S; Kabesch, M; Lupinek, C; Valenta, R; Vrtala, S				Resch, Yvonne; Michel, Sven; Kabesch, Michael; Lupinek, Christian; Valenta, Rudolf; Vrtala, Susanne			Different IgE recognition of mite allergen components in asthmatic and nonasthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						House dust mite allergy; asthma; allergen microarray; recombinant allergens; IgE; IgG; diagnosis	IMMUNOGLOBULIN-E ANTIBODIES; DERMATOPHAGOIDES-PTERONYSSINUS; AIRWAY HYPERRESPONSIVENESS; REACTIVITY PROFILES; MAJOR ALLERGEN; CHILDHOOD; DIAGNOSIS; RECOMBINANT; EXPOSURE; EXPRESSION	Background: House dust mites (HDMs) represent one of the most important inducers of respiratory allergies worldwide. Objective: We sought to investigate the IgE and IgG reactivity profiles to a comprehensive panel of HDM allergens in children with allergic asthma and to compare them with those of nonasthmatic atopic children. Methods: Sera from clinically well-characterized asthmatic children with HDM allergy (n = 105), nonasthmatic children (n = 53), and nonatopic nonasthmatic children (n = 53) were analyzed for IgE and IgG reactivity to a panel of 7 HDM allergens (nDer p 1, rDer p 2, rDer p 5 , rDer p 7, rDer p 10, rDer p 21, and rDer p 23) by means of allergen microarray technology. Results: Asthmatic children with HDM allergy more frequently showed an IgE response to each of the HDM allergens and recognized more allergens than nonasthmatic children with HDM allergy. Furthermore, IgE levels to certain HDM allergens (nDer p 1, P = .002; rDer p 2, P = .007; rDer P = , P = .031; and rDer p 23, P < .001) were significantly higher in asthmatic children than in children without asthma. By contrast, fewer asthmatic children showed IgG reactivity to HDM allergens than nonasthmatic children, but allergen-specific IgG levels were comparable. Conclusion: The IgE and IgG reactivity profiles to HDM allergens, as well as IgE levels to certain allergen components, differed considerably between children with and without asthmatic symptoms caused by HDM allergy. In fact, asthmatic children were characterized by an expanded IgE repertoire regarding the numbers of recognized allergen components and by increased specific IgE levels.	[Resch, Yvonne; Lupinek, Christian; Valenta, Rudolf; Vrtala, Susanne] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Div Immunopathol, Ctr Pathophysiol Infectiol & Immunol, A-1090 Vienna, Austria; [Michel, Sven; Kabesch, Michael] Univ Childrens Hosp Regensburg KUNO, Dept Pediat Pneumol & Allergy, Regensburg, Germany; [Vrtala, Susanne] Med Univ Vienna, Christian Doppler Lab Dev Allergen Chips, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna	Vrtala, S (corresponding author), Med Univ Vienna, Dept Pathophysiol & Allergy Res, Christian Doppler Lab Dev Allergen Chips, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	susanne.vrtala@meduniwien.ac.at	Kabesch, Michael/AAB-5701-2020; Kabesch, Michael/GZM-1583-2022; Lupinek, Christian/I-3311-2019	Lupinek, Christian/0000-0002-8612-8245; Michel, Sven/0000-0003-3604-3187; Resch, Yvonne/0000-0002-7933-2547; Valenta, Rudolf/0000-0001-5944-3365; Vrtala, Susanne/0000-0003-4250-8243	Austrian Science Fund FWF [F 4605, F 4602] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Banerjee S, 2015, J INVEST DERMATOL, V135, P102, DOI 10.1038/jid.2014.271; Barber D, 2012, CLIN EXP ALLERGY, V42, P1129, DOI 10.1111/j.1365-2222.2012.03993.x; Bousquet J, 2014, J ALLERGY CLIN IMMUN, V133, P1535, DOI 10.1016/j.jaci.2014.01.018; Bousquet J, 2013, INT ARCH ALLERGY IMM, V161, P1, DOI 10.1159/000343018; Cabrera-Freitag P, 2011, CLIN EXP ALLERGY, V41, P1440, DOI 10.1111/j.1365-2222.2011.03818.x; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; Chen KW, 2008, MOL IMMUNOL, V45, P2486, DOI 10.1016/j.molimm.2008.01.006; Curin M, 2014, J ALLERGY CLIN IMMUN, V133, P918, DOI 10.1016/j.jaci.2013.10.058; Eibensteiner P, 2000, IMMUNOLOGY, V101, P112, DOI 10.1046/j.1365-2567.2000.00078.x; Gadisseur R, 2011, CLIN CHEM LAB MED, V49, P277, DOI 10.1515/CCLM.2011.052; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; Hales BJ, 2006, J ALLERGY CLIN IMMUN, V118, P361, DOI 10.1016/j.jaci.2006.04.001; Hales BJ, 2000, CLIN EXP ALLERGY, V30, P927, DOI 10.1046/j.1365-2222.2000.00900.x; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Jacquet A, 2013, ISRN ALLERGY, V2013, DOI [10.1155/2013/735031, DOI 10.1155/2013/735031]; Kern RA., 1921, MED CLIN N AM, V5, P751; Ladics GS, 2008, REGUL TOXICOL PHARM, V51, P288, DOI 10.1016/j.yrtph.2008.04.012; Li J, 2014, ANN ALLERG ASTHMA IM, V113, P173, DOI 10.1016/j.anai.2014.05.004; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Lupinek C, 2012, J ALLERGY CLIN IMMUN, V130, P1418, DOI 10.1016/j.jaci.2012.06.028; Lynch NR, 1998, ALLERGY, V53, P808, DOI 10.1111/j.1398-9995.1998.tb03979.x; Melioli G, 2012, PEDIAT ALLERG IMM-UK, V23, P433, DOI 10.1111/j.1399-3038.2011.01228.x; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; Potaczek DP, 2013, PEDIAT ALLERG IMM-UK, V24, P441, DOI 10.1111/pai.12083; Resch Y, 2011, CLIN EXP ALLERGY, V41, P1468, DOI 10.1111/j.1365-2222.2011.03798.x; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P711, DOI 10.1136/adc.49.9.711; Sastre J, 2012, ALLERGY, V67, P709, DOI 10.1111/j.1398-9995.2012.02808.x; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Shakib F, 2008, TRENDS IMMUNOL, V29, P633, DOI 10.1016/j.it.2008.08.007; Sidenius KE, 2002, ANN AGR ENV MED, V9, P163; Simpson A, 2005, J ALLERGY CLIN IMMUN, V116, P744, DOI 10.1016/j.jaci.2005.06.032; Soto-Quiros M, 2012, J ALLERGY CLIN IMMUN, V129, P1499, DOI 10.1016/j.jaci.2012.03.040; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TePas EC, 2006, CHEST, V129, P1500, DOI 10.1378/chest.129.6.1500; Lizaso MT, 2011, ANN ALLERG ASTHMA IM, V107, P35, DOI 10.1016/j.anai.2011.03.017; Thomas WR, 2007, PROTEIN PEPTIDE LETT, V14, P943, DOI 10.2174/092986607782541169; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; VANDERHEIDE S, 1994, J ALLERGY CLIN IMMUN, V93, P470, DOI 10.1016/0091-6749(94)90356-5; Vogel L, 2005, ALLERGY, V60, P1021, DOI 10.1111/j.1398-9995.2005.00803.x; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; Vrtala S, 2014, METHODS, V66, P67, DOI 10.1016/j.ymeth.2013.07.034; Weghofer M, 2008, EUR J CLIN INVEST, V38, P959, DOI 10.1111/j.1365-2362.2008.02048.x; Weghofer M, 2008, ALLERGY, V63, P758, DOI 10.1111/j.1398-9995.2008.01647.x; Weghofer M, 2008, INT ARCH ALLERGY IMM, V147, P101, DOI 10.1159/000135696; Weghofer M, 2013, J IMMUNOL, V190, P3059, DOI 10.4049/jimmunol.1202288; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Westman M, 2014, J ALLERGY CLIN IMMUN; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038	52	84	88	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1083	1091		10.1016/j.jaci.2015.03.024	http://dx.doi.org/10.1016/j.jaci.2015.03.024			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25956509	hybrid, Green Published			2022-12-18	WOS:000362976300027
J	Brandt, EB; Myers, JMB; Acciani, TH; Ryan, PH; Sivaprasad, U; Ruff, B; LeMasters, GK; Bernstein, DI; Lockey, JE; LeCras, TD; Hershey, GKK				Brandt, Eric B.; Myers, Jocelyn M. Biagini; Acciani, Thomas H.; Ryan, Patrick H.; Sivaprasad, Umasundari; Ruff, Brandy; LeMasters, Grace K.; Bernstein, David I.; Lockey, James E.; LeCras, Timothy D.; Hershey, Gurjit K. Khurana			Exposure to allergen and diesel exhaust particles potentiates secondary allergen-specific memory responses, promoting asthma susceptibility	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic asthma; traffic pollution; house dust mite; diesel exhaust particle; memory; recall; children	T-CELLS; SENSITIZATION; FREQUENCY; CONTRIBUTES; MODELS; MICE	Background: Exposure to traffic pollution particulate matter, predominantly diesel exhaust particles (DEPs), increases the risk of asthma and asthma exacerbation; however, the underlying mechanisms remain poorly understood. Objective: We sought to examine the effect of DEP exposure on the generation and persistence of allergen-specific memory T cells in asthmatic patients and translate these findings by determining the effect of early DEP exposure on the prevalence of allergic asthma in children. Methods: The effect of DEPs on house dust mite (HDM)-specific memory responses was determined by using an asthma model. Data from children enrolled in the Cincinnati Childhood Allergy and Air Pollution Study birth cohort were analyzed to determine the effect of DEP exposure on asthma outcomes. Results: DEP coexposure with HDM resulted in persistent T(H)2/T(H)17 CD127(+) effector/memory cells in the lungs, spleen, and lymph nodes of adult and neonatal mice. After 7 weeks of rest, a single exposure to HDM resulted in airway hyperresponsiveness and increased T(H)2 cytokine levels in mice that had been previously exposed to both HDM and DEPs versus those exposed to HDM alone. On the basis of these data, we examined whether DEP exposure was similarly associated with increased asthma prevalence in children in the presence or absence of allergen exposure/sensitization in the Cincinnati Childhood Allergy and Air Pollution Study birth cohort. Early-life exposure to high DEP levels was associated with significantly increased asthma prevalence among allergic children but not among nonallergic children. Conclusion: These findings suggest that DEP exposure results in accumulation of allergen-specific T(H)2/T(H)17 cells in the lungs, potentiating secondary allergen recall responses and promoting the development of allergic asthma.	[Brandt, Eric B.; Myers, Jocelyn M. Biagini; Sivaprasad, Umasundari; Ruff, Brandy; LeMasters, Grace K.; Hershey, Gurjit K. Khurana] Univ Cincinnati, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH 45221 USA; [Ryan, Patrick H.] Univ Cincinnati, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Div Epidemiol & Biostat, Cincinnati, OH 45221 USA; [Acciani, Thomas H.; LeCras, Timothy D.] Univ Cincinnati, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Cincinnati, OH 45221 USA; [Bernstein, David I.] Univ Cincinnati, Dept Internal Med, Cincinnati, OH 45221 USA; [LeMasters, Grace K.; Lockey, James E.] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45221 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Hershey, GKK (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, 3333 Burnet Ave,MLC 7037, Cincinnati, OH 45229 USA.	Gurjit.Hershey@cchmc.org	Ryan, Patrick H/L-7062-2015; Ryan, Patrick/HDO-1133-2022	Biagini, Jocelyn/0000-0002-4378-6133; Le Cras, Timothy/0000-0001-8538-2703; Brandt, Eric/0000-0003-0617-4100; Khurana Hershey, Gurjit/0000-0001-6663-977X	National Heart, Lung, and Blood Institute (NHLBI) [R01HL097135]; National Institute of Environmental Health Sciences (NIEHS) [T32 ES010957, R01 ES019890-01A1, R01ES011170]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL097135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011170, T32ES010957, R01ES019890] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Heart, Lung, and Blood Institute (NHLBI) grant R01HL097135 (to T.D.L. and G.K.K.H.), National Institute of Environmental Health Sciences (NIEHS) grant T32 ES010957 (to E.B.B.), R01 ES019890-01A1 (to P.H.R.), and R01ES011170 (to G.K.L.).	Acciani TH, 2013, CLIN EXP ALLERGY, V43, P1406, DOI 10.1111/cea.12200; Appatova AS, 2008, J ENVIRON PLANN MAN, V51, P631, DOI 10.1080/09640560802208173; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Chen WG, 2008, J ALLERGY CLIN IMMUN, V122, P625, DOI 10.1016/j.jaci.2008.06.022; Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567; Guarnieri M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; Hamada K, 2000, AM J RESP CRIT CARE, V161, P1285, DOI 10.1164/ajrccm.161.4.9906137; Hamilton RG, 2014, J ALLERGY CLIN IMMUN, V134, P360, DOI 10.1016/j.jaci.2014.02.022; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Iwamura C, 2012, P NATL ACAD SCI USA, V109, P16992, DOI 10.1073/pnas.1203494109; Jenkins MK, 2012, J IMMUNOL, V188, P4135, DOI 10.4049/jimmunol.1102661; Kurtulus S, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00404; LeMasters GK, 2006, J PEDIATR-US, V149, P505, DOI 10.1016/j.jpeds.2006.06.035; Leverkoehne I, 2002, J HISTOCHEM CYTOCHEM, V50, P829, DOI 10.1177/002215540205000609; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Maes T, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-7; Manners S, 2014, J ALLERGY CLIN IMMUN, V134, P63, DOI 10.1016/j.jaci.2013.10.047; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Moon JJ, 2007, IMMUNITY, V27, P203, DOI 10.1016/j.immuni.2007.07.007; Mueller SN, 2013, ANNU REV IMMUNOL, V31, P137, DOI 10.1146/annurev-immunol-032712-095954; NICE, 2016, TRAFFIC RELATED AIR; Park EJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026749; Redeker A, 2014, EUR J IMMUNOL, V44, P1046, DOI 10.1002/eji.201343946; Reponen T, 2012, J ALLERGY CLIN IMMUN, V130, P639, DOI 10.1016/j.jaci.2012.05.030; Reponen T, 2011, ANN ALLERG ASTHMA IM, V107, P120, DOI 10.1016/j.anai.2011.04.018; Ryan PH, 2007, ENVIRON HEALTH PERSP, V115, P278, DOI 10.1289/ehp.9480; Ryan PH, 2009, AM J RESP CRIT CARE, V180, P1068, DOI 10.1164/rccm.200808-1307OC; Saravia J, 2014, MUCOSAL IMMUNOL, V7, P694, DOI 10.1038/mi.2013.88; Seddon B, 2003, NAT IMMUNOL, V4, P680, DOI 10.1038/ni946; Shin H, 2013, IMMUNOL REV, V255, P165, DOI 10.1111/imr.12087; Spira-Cohen A, 2011, ENVIRON HEALTH PERSP, V119, P559, DOI 10.1289/ehp.1002653; Stevens T, 2009, TOXICOL SCI, V107, P522, DOI 10.1093/toxsci/kfn248; Turner DL, 2014, MUCOSAL IMMUNOL, V7, P501, DOI 10.1038/mi.2013.67; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376	36	84	88	0	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					295	+		10.1016/j.jaci.2014.11.043	http://dx.doi.org/10.1016/j.jaci.2014.11.043			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25748065	Green Accepted			2022-12-18	WOS:000359004900010
J	Simons, FER; Sampson, HA				Simons, F. Estelle R.; Sampson, Hugh A.			Anaphylaxis: Unique aspects of clinical diagnosis and management in infants (birth to age 2 years)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Infants (birth to 2 years); food allergy; epinephrine; adrenaline; epinephrine autoinjectors; antihistamines; clinical	COWS MILK ALLERGY; ORAL IMMUNOTHERAPY; NATURAL-HISTORY; TRYPTASE LEVELS; PEANUT ALLERGY; CHILDREN; EPINEPHRINE; PREDICTORS; CONSENSUS; FOODS	In this rostrum we aim to increase awareness of anaphylaxis in infancy in order to improve clinical diagnosis, management, and prevention of recurrences. Anaphylaxis is increasingly reported in this age group. Foods are the most common triggers. Presentation typically involves the skin (generalized urticaria), the respiratory tract (cough, wheeze, stridor, and dyspnea), and/or the gastrointestinal tract (persistent vomiting). Tryptase levels are seldom increased because of infant anaphylaxis, although baseline tryptase levels can be increased in the first few months of life, reflecting mast cell burden in the developing immune system. The differential diagnosis of infant anaphylaxis includes consideration of age-unique entities, such as food protein-induced enterocolitis syndrome with acute presentation. Epinephrine (adrenaline) treatment is underused in health care and community settings. No epinephrine autoinjectors contain an optimal dose for infants weighing 10 kg or less. After treatment of an anaphylactic episode, follow-up with a physician, preferably an allergy/immunology specialist, is important for confirmation of anaphylaxis triggers and prevention of recurrences through avoidance of confirmed specific triggers. Natural desensitization to milk and egg can occur. Future research should include validation of the clinical criteria for anaphylaxis diagnosis in infants, prospective longitudinal monitoring of baseline serum tryptase levels in healthy and atopic infants during the first year of life, studies of infant comorbidities and cofactors that increase the risk of severe anaphylaxis, development of autoinjectors containing a 0.1-mg epinephrine dose suitable for infants, and inclusion of infants in prospective studies of immune modulation to prevent anaphylaxis recurrences.	[Simons, F. Estelle R.] Univ Manitoba, Fac Med, Dept Immunol, Dept Pediat & Child Hlth, Winnipeg, MB R3E 0W3, Canada; [Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Dept Pediat Allergy & Immunol, New York, NY 10029 USA	University of Manitoba; Icahn School of Medicine at Mount Sinai	Simons, FER (corresponding author), Room FE125,820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	lmcniven@hsc.mb.ca			National Institute of Allergy and Infectious Diseases/National Institutes of Health [AI44236, AI66738, RR026134]; Food Allergy Research and Education; Chair of the PhARF Award review committee; Allertein Therapeutics; Regeneron; Danone Research Institute; Thermo Fisher Scientific; UCB; Pfizer; MedImmune; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI066738] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Food Allergy Research and Education; Chair of the PhARF Award review committee; Allertein Therapeutics; Regeneron(Regeneron); Danone Research Institute(Danone Nutricia); Thermo Fisher Scientific; UCB(UCB Pharma SA); Pfizer(Pfizer); MedImmune(AstraZenecaMedimmune); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	F. E. R. Simons is a member of the Sanofi Canada Medical Advisory Board. H. A. Sampson has received research support from the National Institute of Allergy and Infectious Diseases (grant nos. AI44236 and AI66738)/National Institutes of Health (grant no. RR026134) and from Food Allergy Research and Education; is Chair of the PhARF Award review committee; has received consultancy fees from Allertein Therapeutics, Regeneron, and Danone Research Institute; and has received lecture fees from Thermo Fisher Scientific, UCB, Pfizer, and MedImmune.	Alvarez-Twose I, 2012, ALLERGY, V67, P813, DOI 10.1111/j.1398-9995.2012.02812.x; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Arga M, 2011, PEDIAT ALLERG IMM-UK, V22, P590, DOI 10.1111/j.1399-3038.2011.01143.x; Belhocine W, 2011, PEDIAT ALLERG IMM-UK, V22, P600, DOI 10.1111/j.1399-3038.2011.01166.x; Brown J, 2013, PEDIAT ALLERG IMM-UK, V24, P173, DOI 10.1111/pai.12048; Brozek JL, 2012, CLIN EXP ALLERGY, V42, P363, DOI 10.1111/j.1365-2222.2011.03948.x; Chad L, 2013, ALLERGY, V68, P1605, DOI 10.1111/all.12262; Choo KJ, 2012, COCHRANE DB SYST REV, V4; Dhami S, 2014, ALLERGY, V69, P168, DOI 10.1111/all.12318; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; Ford LS, 2013, J ALLERGY CLIN IMMUN, V131, P180, DOI 10.1016/j.jaci.2012.06.003; Grossman SL, 2013, J PEDIATR-US, V163, P841, DOI 10.1016/j.jpeds.2013.02.050; Huang F, 2012, J ALLERGY CLIN IMMUN, V129, P162, DOI 10.1016/j.jaci.2011.09.018; Jacobs TS, 2012, PEDIAT ALLERG IMM-UK, V23, P582, DOI 10.1111/j.1399-3038.2012.01315.x; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Kelso JM, 2012, J ALLERGY CLIN IMMUN, V130, P25, DOI 10.1016/j.jaci.2012.04.003; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Komarow HD, 2009, J ALLERGY CLIN IMMUN, V124, P845, DOI 10.1016/j.jaci.2009.06.040; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Mehr S, 2009, CLIN EXP ALLERGY, V39, P1390, DOI 10.1111/j.1365-2222.2009.03276.x; Nurmatov U, 2012, COCHRANE DB SYST REV, V9; Nurmatov UB, 2014, ANN ALLERG ASTHMA IM, V112, P126, DOI 10.1016/j.anai.2013.11.010; Peters RL, 2014, J ALLERGY CLIN IMMUN, V133, P485, DOI 10.1016/j.jaci.2013.11.032; Rudders SA, 2011, J PEDIATR-US, V158, P326, DOI 10.1016/j.jpeds.2010.10.017; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Sheikh A, 2007, ALLERGY, V62, P830, DOI 10.1111/j.1398-9995.2007.01435.x; Sheikh A, 2012, COCHRANE DB SYST REV, V8; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, P537, DOI 10.1016/j.jaci.2007.06.025; Simons FER, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-9; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, P587, DOI 10.1016/j.jaci.2011.01.038; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Simons KJ, 2010, CURR OPIN ALLERGY CL, V10, P354, DOI 10.1097/ACI.0b013e32833bc670; Topal E, 2013, ALLERGY ASTHMA PROC, V34, P233, DOI 10.2500/aap.2013.34.3658; van Esch BCAM, 2011, TOXICOL LETT, V201, P264, DOI 10.1016/j.toxlet.2011.01.010; Vetander M, 2012, CLIN EXP ALLERGY, V42, P568, DOI 10.1111/j.1365-2222.2011.03954.x; Wolbing F, 2013, ALLERGY, V68, P1085, DOI 10.1111/all.12193; Wood RA, 2014, J ALLER CL IMM-PRACT, V2, P97, DOI 10.1016/j.jaip.2013.11.010; Wood RA, 2013, J ALLERGY CLIN IMMUN, V131, P805, DOI 10.1016/j.jaci.2012.10.060	41	84	88	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1125	1131		10.1016/j.jaci.2014.09.014	http://dx.doi.org/10.1016/j.jaci.2014.09.014			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25441636				2022-12-18	WOS:000353980700004
J	Pino-Yanes, M; Thakur, N; Gignoux, CR; Galanter, JM; Roth, LA; Eng, C; Nishimura, KK; Oh, SS; Vora, H; Huntsman, S; Nguyen, EA; Hu, DL; Drake, KA; Conti, DV; Moreno-Estrada, A; Sandoval, K; Winkler, CA; Borrell, LN; Lurmann, F; Islam, TS; Davis, A; Farber, HJ; Meade, K; Avila, PC; Serebrisky, D; Bibbins-Domingo, K; Lenoir, MA; Ford, JG; Brigino-Buenaventura, E; Rodriguez-Cintron, W; Thyne, SM; Sen, S; Rodriguez-Santana, JR; Bustamante, CD; Williams, LK; Gilliland, FD; Gauderman, WJ; Kumar, R; Torgerson, DG; Burchard, EG				Pino-Yanes, Maria; Thakur, Neeta; Gignoux, Christopher R.; Galanter, Joshua M.; Roth, Lindsey A.; Eng, Celeste; Nishimura, Katherine K.; Oh, Sam S.; Vora, Hita; Huntsman, Scott; Nguyen, Elizabeth A.; Hu, Donglei; Drake, Katherine A.; Conti, David V.; Moreno-Estrada, Andres; Sandoval, Karla; Winkler, Cheryl A.; Borrell, Luisa N.; Lurmann, Fred; Islam, Talat S.; Davis, Adam; Farber, Harold J.; Meade, Kelley; Avila, Pedro C.; Serebrisky, Denise; Bibbins-Domingo, Kirsten; Lenoir, Michael A.; Ford, Jean G.; Brigino-Buenaventura, Emerita; Rodriguez-Cintron, William; Thyne, Shannon M.; Sen, Saunak; Rodriguez-Santana, Jose R.; Bustamante, Carlos D.; Williams, L. Keoki; Gilliland, Frank D.; Gauderman, W. James; Kumar, Rajesh; Torgerson, Dara G.; Burchard, Esteban G.			Genetic ancestry influences asthma susceptibility and lung function among Latinos	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							GENOME-WIDE ASSOCIATION; NATIVE-AMERICAN ANCESTRY; PUERTO-RICAN; CHILDHOOD ASTHMA; AFRICAN ANCESTRY; UNITED-STATES; LOCAL ANCESTRY; SKIN COLOR; GALA II; ADMIXTURE	Background: Childhood asthma prevalence and morbidity varies among Latinos in the United States, with Puerto Ricans having the highest and Mexicans the lowest. Objective: To determine whether genetic ancestry is associated with the odds of asthma among Latinos, and secondarily whether genetic ancestry is associated with lung function among Latino children. Methods: We analyzed 5493 Latinos with and without asthma from3 independent studies. For each participant, we estimated the proportion of African, European, and Native American ancestry using genome-wide data. We tested whether genetic ancestry was associated with the presence of asthma and lung function among subjects with and without asthma. Odds ratios ( OR) and effect sizes were assessed for every 20% increase in each ancestry. Results: Native American ancestry was associated with lower odds of asthma ( OR 5 0.72, 95% CI: 0.66-0.78, P 5 8.0 3 10 215), while African ancestry was associated with higher odds of asthma ( OR 5 1.40, 95% CI: 1.14-1.72, P 5.001). These associations were robust to adjustment for covariates related to early life exposures, air pollution, and socioeconomic status. Among children with asthma, African ancestry was associated with lower lung function, including both pre-and postbronchodilator measures of FEV1 ( 277 6 19 mL; P 5 5.8 3 10 25 and 283 6 19 mL; P 5 1.1 x 10 25, respectively) and forced vital capacity ( 2100 6 21 mL; P 5 2.7 3 10 26 and 2107 6 22 mL; P 5 1.0 x 10 26, respectively). Conclusion: Differences in the proportions of genetic ancestry can partially explain disparities in asthma susceptibility and lung function among Latinos. ( J Allergy Clin Immunol 2015; 135: 228-35.)	[Pino-Yanes, Maria; Thakur, Neeta; Galanter, Joshua M.; Roth, Lindsey A.; Eng, Celeste; Nishimura, Katherine K.; Oh, Sam S.; Huntsman, Scott; Nguyen, Elizabeth A.; Hu, Donglei; Torgerson, Dara G.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Pino-Yanes, Maria; Burchard, Esteban G.] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain; [Gignoux, Christopher R.; Galanter, Joshua M.; Drake, Katherine A.; Burchard, Esteban G.] UCSF, Dept Bioengn & Therapeut Sci, San Francisco, CA USA; [Vora, Hita; Conti, David V.; Islam, Talat S.; Gilliland, Frank D.; Gauderman, W. James] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA; [Moreno-Estrada, Andres; Sandoval, Karla; Bustamante, Carlos D.] Stanford Univ, Dept Genet, Palo Alto, CA 94304 USA; [Winkler, Cheryl A.] NCI, Basic Res Lab, SAIC Frederick Inc, Ctr Canc Res, Frederick, MD 21701 USA; [Borrell, Luisa N.] CUNY, Dept Hlth Sci, Grad Program Publ Hlth, Bronx, NY USA; [Lurmann, Fred] Sonoma Technol Inc, Petaluma, CA USA; [Davis, Adam; Meade, Kelley] Childrens Hosp & Res Ctr Oakland, Oakland, CA USA; [Farber, Harold J.] Baylor Coll Med, Dept Pediat, Sect Pulmonol, Houston, TX 77030 USA; [Farber, Harold J.] Texas Childrens Hosp, Houston, TX 77030 USA; [Avila, Pedro C.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA; [Serebrisky, Denise] Jacobi Med Ctr, Pediat Pulm Div, Bronx, NY USA; [Bibbins-Domingo, Kirsten] UCSF, Div Gen Internal Med, San Francisco, CA USA; [Lenoir, Michael A.] Bay Area Pediat, Oakland, CA USA; [Ford, Jean G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Brigino-Buenaventura, Emerita] Kaiser Permanente Vallejo Med Ctr, Dept Allergy & Immunol, Vallejo, CA USA; [Rodriguez-Cintron, William] Vet Caribbean Hlth Care Syst, San Juan, PR USA; [Thyne, Shannon M.] UCSF, San Francisco Gen Hosp, Dept Pediat, San Francisco, CA USA; [Sen, Saunak] UCSF, Dept Epidemiol & Biostat, San Francisco, CA USA; [Rodriguez-Santana, Jose R.] Ctr Neumol Pediat, San Juan, PR USA; [Williams, L. Keoki] Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA; [Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA; [Kumar, Rajesh] Northwestern Univ, Childrens Mem Hosp, Chicago, IL 60614 USA; [Kumar, Rajesh] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	University of California System; University of California San Francisco; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; University of California System; University of California San Francisco; University of Southern California; Stanford University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; City University of New York (CUNY) System; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Baylor College of Medicine; Baylor College of Medicine; Northwestern University; Jacobi Medical Center; University of California System; University of California San Francisco; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Kaiser Permanente; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Henry Ford Health System; Henry Ford Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Northwestern University; Feinberg School of Medicine	Pino-Yanes, M (corresponding author), Univ Calif San Francisco, Dept Med, 1550 4th St,Rock Hall Room 582,UCSF Box 2911, San Francisco, CA 94143 USA.	mdelpino@ull.edu.es	, Talat/AAV-6834-2020; Borrell, Luisa N./G-8753-2018; Moreno-Estrada, Andres/AAP-4657-2021; Moreno-Estrada, Andres/R-3950-2017; Pino-Yanes, Maria/C-8498-2017	, Talat/0000-0002-2837-865X; Borrell, Luisa N./0000-0002-0560-4853; Moreno-Estrada, Andres/0000-0001-8329-8292; Moreno-Estrada, Andres/0000-0001-8329-8292; Pino-Yanes, Maria/0000-0003-0332-437X; Galanter, Joshua/0000-0002-2561-6384; Bustamante, Carlos D./0000-0002-4187-7920; Kumar, Rajesh/0000-0002-1962-7108; Sandoval, Karla/0000-0002-6175-2463; Nguyen, Elizabeth/0000-0002-8070-6382	National Institutes of Health (NIH) [R01-ES015794, U19-AI077439, R01-HL088133, R01-HL078885, R25-CA113710, T32-GM007546, R01-HL004464, R01-HL104608, R01AI079139, R01AI061774, P30ES007048, P01ES011627, R01ES023262, R01ES021801, K23-HL093023]; National Institute onMinorityHealthAndHealth Disparities [P60MD006902, M01-RR00188]; NationalCancer Institute, National Institutes ofHealth [HHSN26120080001E]; NATIONAL CANCER INSTITUTE [R25CA113710, ZIABC010022] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000143] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL104608, R01HL088133, R01HL118267, K23HL093023, K23HL111636, K23HL004464, R01HL078885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI079139, R01AI061774, U19AI077439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015794, R01ES025786, P30ES007048, R01ES021801, R01ES023262, P01ES011627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007546] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [P60MD006902] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute onMinorityHealthAndHealth Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NationalCancer Institute, National Institutes ofHealth(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This study was supported in part by National Institutes of Health (NIH) R01-ES015794, U19-AI077439, R01-HL088133, R01-HL078885, R25-CA113710, T32-GM007546, R01-HL004464, R01-HL104608 to E. G. B., R01AI079139 and R01AI061774 to L. K. W., P30ES007048, P01ES011627, R01ES023262, R01ES021801 to F. G., and K23-HL093023 to R. K.; the National Institute onMinorityHealthAndHealth Disparities under award number P60MD006902 to K. B. D and E. G. B. and M01-RR00188 to the Texas Children's Hospital General Clinical Research Center; Flight Attendant Medical Research Institute, RWJFAmosMedical FacultyDevelopmentAward, the Sandler Foundation to E. G. B.; theAmerican Asthma Foundation to L. K. W. and E. G. B.; Ernest S. BazleyGrant to P. C. A.; and theNationalCancer Institute, National Institutes ofHealth, under contract HHSN26120080001E by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research to C. A. W. C. R. G. was supported in part by the UCSF Chancellor's Research Fellowship, Dissertation Year Fellowship, and National Institutes of Health Training Grant T32 GM007175. J. M. G. was supported in part by National Institutes of Health Training Grant T32 (GM007546) and career development awards from the NHLBI K23 (K23HL111636) and NCATS KL2 (KL2TR000143), aswell as the Hewett Fellowship. M. P. Y. was funded by a postdoctoral fellowship from Fundaci ~ on Ram ~ on Areces, Madrid, Spain.	Akinbami LJ, 2005, PEDIATRICS, V115, P1254, DOI 10.1542/peds.2004-0897; Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Baran Y, 2012, BIOINFORMATICS, V28, P1359, DOI 10.1093/bioinformatics/bts144; Brehm JM, 2012, J ALLERGY CLIN IMMUN, V129, P1484, DOI 10.1016/j.jaci.2012.03.035; Bruse S, 2011, AM J RESP CRIT CARE, V184, P1254, DOI 10.1164/rccm.201103-0568OC; Bryc K, 2010, P NATL ACAD SCI USA, V107, P8954, DOI 10.1073/pnas.0914618107; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; Chen W, 2014, CHEST, V145, P704, DOI 10.1378/chest.13-1308; Choudhry S, 2006, AM J RESP CRIT CARE, V174, P1086, DOI [10.1164/RCCM.200605-596OC, 10.1164/rccm.200605-596OC]; Claudio L, 2006, ANN EPIDEMIOL, V16, P332, DOI 10.1016/j.annepidem.2005.06.046; Cohen RT, 2008, AM J RESP CRIT CARE, V178, P453, DOI 10.1164/rccm.200711-1629OC; Drake KA, 2014, J ALLERGY CLIN IMMUN, V133, P370, DOI 10.1016/j.jaci.2013.06.043; Fagnani C, 2008, TWIN RES HUM GENET, V11, P121, DOI 10.1375/twin.11.2.121; Figueiredo CA, 2013, J ALLERGY CLIN IMMUN, V131, P1683, DOI 10.1016/j.jaci.2012.10.043; Flores C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0026807; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Fumagalli M, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002355; Fumagalli M, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-264; Galanter JM, 2014, J ALLERGY CLIN IMMUN, V134, P295, DOI 10.1016/j.jaci.2013.08.055; Galanter JM, 2011, J ALLERGY CLIN IMMUN, V128, P37, DOI 10.1016/j.jaci.2011.03.050; Genovese G, 2010, SCIENCE, V329, P841, DOI 10.1126/science.1193032; Hancock DB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000623; Hankinson JL, 2010, CHEST, V137, P138, DOI 10.1378/chest.09-0919; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; KLAG MJ, 1991, JAMA-J AM MED ASSOC, V265, P599, DOI 10.1001/jama.265.5.599; Krieger N, 1998, AM J PUBLIC HEALTH, V88, P1308, DOI 10.2105/AJPH.88.9.1308; Kumar R, 2012, CLIN EXP ALLERGY, V42, P265, DOI 10.1111/j.1365-2222.2011.03873.x; Kumar R, 2010, NEW ENGL J MED, V363, P321, DOI 10.1056/NEJMoa0907897; Lara M, 2006, PEDIATRICS, V117, P43, DOI 10.1542/peds.2004-1714; Li JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/science.1153717; Martinez-Cruzado JC, 2001, HUM BIOL, V73, P491, DOI 10.1353/hub.2001.0056; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Moorman Jeanne E., 2011, Morbidity and Mortality Weekly Report, V60, P84; Nazario S, 2012, P R HEALTH SCI J, V31, P24; Nishimura KK, 2013, AM J RESP CRIT CARE, V188, P309, DOI 10.1164/rccm.201302-0264OC; Oh SS, 2012, J ALLERGY CLIN IMMUN, V129, P1478, DOI 10.1016/j.jaci.2012.03.017; Pasaniuc B, 2013, BIOINFORMATICS, V29, P1407, DOI 10.1093/bioinformatics/btt166; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Rajeevan H, 2012, NUCLEIC ACIDS RES, V40, pD1010, DOI 10.1093/nar/gkr924; Rao DR, 2012, J ASTHMA, V49, P586, DOI 10.3109/02770903.2012.690481; Rumpel JA, 2012, J ALLERGY CLIN IMMUN, V130, P1302, DOI 10.1016/j.jaci.2012.09.001; Salari K, 2005, GENET EPIDEMIOL, V29, P76, DOI 10.1002/gepi.20079; Thakur N, 2013, AM J RESP CRIT CARE, V188, P1202, DOI 10.1164/rccm.201306-1016OC; Torgerson DG, 2012, J ALLERGY CLIN IMMUN, V130, P76, DOI 10.1016/j.jaci.2012.02.040; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Tsai HJ, 2006, HUM GENET, V118, P626, DOI 10.1007/s00439-005-0080-2; Vergara C, 2013, GENET EPIDEMIOL, V37, P393, DOI 10.1002/gepi.21702; Vergara C, 2009, HUM GENET, V125, P565, DOI 10.1007/s00439-009-0649-2; Via M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016513; Wang S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000037; Willemsen G, 2008, TWIN RES HUM GENET, V11, P132, DOI 10.1375/twin.11.2.132	53	84	84	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					228	235		10.1016/j.jaci.2014.07.053	http://dx.doi.org/10.1016/j.jaci.2014.07.053			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25301036	Green Accepted			2022-12-18	WOS:000347298200027
J	Bunyavanich, S; Rifas-Shiman, SL; Platts-Mills, TA; Workman, L; Sordillo, JE; Camargo, CA; Gillman, MW; Gold, DR; Litonjua, AA				Bunyavanich, Supinda; Rifas-Shiman, Sheryl L.; Platts-Mills, Thomas A.; Workman, Lisa; Sordillo, Joanne E.; Camargo, Carlos A., Jr.; Gillman, Matthew W.; Gold, Diane R.; Litonjua, Augusto A.			Peanut, milk, and wheat intake during pregnancy is associated with reduced allergy and asthma in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Maternal diet; pregnancy; food allergy; sensitization; asthma; allergic rhinitis; peanut; milk; wheat; childhood	MATERNAL FOOD-CONSUMPTION; ANTIOXIDANT INTAKE; ATOPIC DISEASE; RISK-FACTORS; FOLLOW-UP; PREVALENCE; ECZEMA; DIET; SENSITIZATION; INFANCY	Background: Maternal diet during pregnancy may affect childhood allergy and asthma. Objective: We sought to examine the associations between maternal intake of common childhood food allergens during early pregnancy and childhood allergy and asthma. Methods: We studied 1277 mother-child pairs from a US prebirth cohort unselected for any disease. Using food frequency questionnaires administered during the first and second trimesters, we assessed maternal intake of common childhood food allergens during pregnancy. In mid-childhood (mean age, 7.9 years), we assessed food allergy, asthma, allergic rhinitis, and atopic dermatitis by questionnaire and serum-specific IgE levels. We examined the associations between maternal diet during pregnancy and childhood allergy and asthma. We also examined the cross-sectional associations between specific food allergies, asthma, and atopic conditions in mid-childhood. Results: Food allergy was common (5.6%) in mid-childhood, as was sensitization to at least 1 food allergen (28.0%). Higher maternal peanut intake (each additional z score) during the first trimester was associated with 47% reduced odds of peanut allergic reaction (odds ratio [OR], 0.53; 95% CI, 0.30-0.94). Higher milk intake during the first trimester was associated with reduced asthma (OR, 0.83; 95% CI, 0.69-0.99) and allergic rhinitis (OR, 0.85; 95% CI, 0.74-0.97). Higher maternal wheat intake during the second trimester was associated with reduced atopic dermatitis (OR, 0.64; 95% CI, 0.46-0.90). Peanut, wheat, and soy allergy were each cross-sectionally associated with increased childhood asthma, atopic dermatitis, and allergic rhinitis (ORs, 3.6 to 8.1). Conclusion: Higher maternal intake of peanut, milk, and wheat during early pregnancy was associated with reduced odds of mid-childhood allergy and asthma.	[Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Div Pediat Allergy & Immunol, Dept Pediat, New York, NY 10029 USA; [Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA; [Rifas-Shiman, Sheryl L.; Gillman, Matthew W.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA; [Rifas-Shiman, Sheryl L.; Sordillo, Joanne E.; Camargo, Carlos A., Jr.; Gillman, Matthew W.; Gold, Diane R.; Litonjua, Augusto A.] Harvard Univ, Sch Med, Boston, MA USA; [Platts-Mills, Thomas A.; Workman, Lisa] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; [Sordillo, Joanne E.; Camargo, Carlos A., Jr.; Gold, Diane R.; Litonjua, Augusto A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA; [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Gold, Diane R.; Litonjua, Augusto A.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; University of Virginia; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Bunyavanich, S (corresponding author), Icahn Sch Med Mt Sinai, One Gustave L Levy Pl 1198, New York, NY 10029 USA.	supinda@post.harvard.edu	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654; Platts-Mills, Thomas/0000-0002-1263-329X	National Institutes of Health [AI093538, HL61907, HL64925, HD34568, AI35786, HL68041, AI102960, HL007427]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD034568, R01HD034568] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064925, U01HL065899, R01HL061907, R37HL066289, K24HL068041, T32HL007427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI035786, K08AI093538, R01AI102960, R01AI035786] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the National Institutes of Health (grant nos. AI093538, HL61907, HL64925, HD34568, AI35786, HL68041, AI102960, and HL007427).	Akinbami LJ, 2012, TRENDS ASTHMA PREVAL, P1; Alm B, 2009, ARCH DIS CHILD, V94, P11, DOI 10.1136/adc.2008.140418; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Baker SS, 2000, PEDIATRICS, V106, P346; Belsley DA, 2004, REGRESSION DIAGNOSTI; BONATI A, 1992, BLOOD, V79, P1472; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Bunyavanich S, 2010, ALLERGY, V65, P256, DOI 10.1111/j.1398-9995.2009.02159.x; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Centers for Disease Control and Prevention, 2011, LIF ASTHM PREV PERC; Devereux G, 2006, NAT REV IMMUNOL, V6, P869, DOI 10.1038/nri1958; Devereux G, 2006, AM J RESP CRIT CARE, V174, P499, DOI 10.1164/rccm.200512-1946OC; Dorshkind K, 2007, NAT REV IMMUNOL, V7, P213, DOI 10.1038/nri2019; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Erkkola M, 2012, PEDIAT ALLERG IMM-UK, V23, P186, DOI 10.1111/j.1399-3038.2012.01272.x; FALTHMAGNUSSON K, 1992, J ALLERGY CLIN IMMUN, V89, P709, DOI 10.1016/0091-6749(92)90378-F; FALTHMAGNUSSON K, 1987, J ALLERGY CLIN IMMUN, V80, P868, DOI 10.1016/S0091-6749(87)80279-8; Fawzi WW, 2004, ANN EPIDEMIOL, V14, P754, DOI 10.1016/j.annepidem.2004.03.001; Fleischer DM, 2013, J ALLER CL IMM-PRACT, V1, P29, DOI 10.1016/j.jaip.2012.09.003; FOSTER CA, 1986, J INVEST DERMATOL, V86, P240, DOI 10.1111/1523-1747.ep12285201; Frank L, 1999, PEDIATR ALLERGY IMMU, V10, P27, DOI 10.1034/j.1399-3038.1999.101010.x; GEORGE JF, 1992, J IMMUNOL, V148, P1230; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; GUPTA RS, 2013, ANN ALLERG ASTHMA IM, V111, P194, DOI DOI 10.1016/j.anai.2013.06.026; Gupta RS, 2012, CLIN PEDIATR, V51, P856, DOI 10.1177/0009922812448526; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hadley C, 2006, EMBO REP, V7, P1080, DOI 10.1038/sj.embor.7400846; Herrmann ME, 1996, EUR J PEDIATR, V155, P770, DOI 10.1007/BF02002904; Jackson K.D., 2013, TRENDS ALLERGIC COND, P1; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Kramer MS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000133.pub3; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Litonjua AA, 2006, AM J CLIN NUTR, V84, P903, DOI 10.1093/ajcn/84.4.903; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Loibichler C., 2002, Clinical and Experimental Allergy, V32, P1546, DOI 10.1046/j.1365-2222.2002.01479.x; Maheshwari A, DEV IMMUNE CELLS FET; Martindale S, 2005, AM J RESP CRIT CARE, V171, P121, DOI 10.1164/rccm.200402-220OC; Maslova E, 2012, J ALLERGY CLIN IMMUN, V130, P724, DOI 10.1016/j.jaci.2012.05.014; Milner JD, 2004, PEDIATRICS, V114, P27, DOI 10.1542/peds.114.1.27; Nwaru BI, 2014, ALLERGY, V69, P62, DOI 10.1111/all.12305; Nwaru BI, 2010, PEDIAT ALLERG IMM-UK, V21, P29, DOI 10.1111/j.1399-3038.2009.00949.x; Oken E, 2003, OBSTET GYNECOL, V102, P346, DOI 10.1016/S0029-7844(03)00484-8; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; PUNNONEN J, 1992, J IMMUNOL, V148, P3398; Rudders SA, 2010, ANN ALLERG ASTHMA IM, V104, P413, DOI 10.1016/j.anai.2010.01.022; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sausenthaler S, 2007, AM J CLIN NUTR, V85, P530; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V126, P1191, DOI 10.1016/j.jaci.2010.08.036; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Thompson RL, 2010, BRIT J NUTR, V103, P1278, DOI 10.1017/S000711450999376X; [US Bureau of Labor Statistics US Census Bureau], 2013, CURR POP SURV CPS; Venter C, 2010, ALLERGY, V65, P103, DOI 10.1111/j.1398-9995.2009.02176.x; Venter C, 2009, PEDIAT ALLERG IMM-UK, V20, P320, DOI 10.1111/j.1399-3038.2008.00832.x; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003; Warner JO, 1999, PEDIAT ALLERG IMM-UK, V10, P14, DOI 10.1034/j.1399-3038.1999.101011.x; Willers SM, 2008, AM J RESP CRIT CARE, V178, P124, DOI 10.1164/rccm.200710-1544OC; Yaqoob P, 2007, BRIT J NUTR, V98, pS41, DOI 10.1017/S0007114507832995; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	63	84	100	4	51	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1373	1382		10.1016/j.jaci.2013.11.040	http://dx.doi.org/10.1016/j.jaci.2013.11.040			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24522094	Green Accepted			2022-12-18	WOS:000335450700020
J	Cheng, HM; Kim, S; Park, GH; Chang, SE; Bang, S; Won, CH; Lee, MW; Choi, JH; Moon, KC				Cheng, Hui Mei; Kim, Sunmi; Park, Gyeong-Hun; Chang, Sung Eun; Bang, Seunghyun; Won, Chong Hyun; Lee, Mi Woo; Choi, Jee Ho; Moon, Kee Chan			Low vitamin D levels are associated with atopic dermatitis, but not allergic rhinitis, asthma, or IgE sensitization, in the adult Korean population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitamin D; allergy; atopic dermatitis; asthma; allergic rhinitis; IgE; Asian; Korean; adult; KNHANES	RESPIRATORY SYNCYTIAL VIRUS; SERUM 25-HYDROXYVITAMIN D; EXAMINATION SURVEY KNHANES; D DEFICIENCY; NATIONAL-HEALTH; ANTIMICROBIAL PEPTIDE; BIRTH-COHORT; CHILDREN; DISEASE; RISK	Background: The effect of vitamin D on allergic conditions is unclear. In particular, large-scale, population-based studies examining this relationship in adult Asian populations are lacking. Objective: To evaluate the association between serum vitamin D levels and allergic conditions in the general adult Korean population. Methods: A cross-sectional study was performed by using data collected from 15,212 individuals 19 years or older who participated in the Korean National Health and Nutrition Examination Survey from 2008 to 2010. The confounder-adjusted mean serum 25-hydroxyvitamin D (25[OH]D) levels of participants with and without allergic conditions (including atopic dermatitis, asthma, allergic rhinitis, and increased total and allergen-specific serum IgE) were compared by using multiple linear regression analyses. Multiple logistic regression analyses with confounder adjustment estimated the odds ratios (ORs) for developing each condition according to adequate, inadequate, or deficient serum 25(OH)D levels. Results: After adjusting for potential confounders, mean serum 25(OH)D levels were significantly lower in participants diagnosed with atopic dermatitis than in those without this diagnosis (mean +/- SE, 18.58 +/- 0.29 ng/mL vs 19.20 +/- 0.15 ng/mL; P = .02). Compared with participants with adequate vitamin D levels (>= 20 ng/mL), confounder-adjusted ORs of atopic dermatitis were significantly higher in those with inadequate (12-19.99 ng/mL) or deficient (<12 ng/mL) levels (OR [95% CI], 1.50 [1.10-2.06] and 1.48 [1.04-2.12], respectively; P = .02). This relationship was not observed in participants with the other allergic conditions. Conclusion: Vitamin D-insufficient adult individuals within the general Korean population have an increased likelihood of atopic dermatitis, but not asthma, allergic rhinitis, or IgE sensitization.	[Cheng, Hui Mei] Royal Perth Hosp, Perth, WA 6001, Australia; [Kim, Sunmi] Kangwon Natl Univ Hosp, Dept Family Med, Chunchon, South Korea; [Park, Gyeong-Hun] Hallym Univ, Coll Med, Dept Dermatol, Dongtan Sacred Heart Hosp, Hwaseong, South Korea; [Chang, Sung Eun; Won, Chong Hyun; Lee, Mi Woo; Choi, Jee Ho; Moon, Kee Chan] Univ Ulsan, Coll Med, Dept Dermatol, Asan Med Ctr, Seoul, South Korea; [Bang, Seunghyun] Asan Inst Life Sci, Seoul, South Korea	Royal Perth Hospital; University of Western Australia; Kangwon National University; Kangwon National University Hospital; Hallym University; University of Ulsan	Park, GH (corresponding author), Hallym Univ, Coll Med 7, Dept Dermatol, Dongtan Sacred Heart Hosp, Keunjaebong Gil, Gyeonggi Do 445170, South Korea.	borelalgebra@gmail.com	bang, sunghyun/AAH-1201-2020; chang, sungeun/AAH-1247-2020	Bang, Seunghyun/0000-0002-3211-7209				Adorini L, 2003, J CELL BIOCHEM, V88, P227, DOI 10.1002/jcb.10340; Akbar NA, 2011, CURR OPIN OTOLARYNGO, V19, P224, DOI 10.1097/MOO.0b013e3283465687; [Anonymous], 2009, WHAT AR EQ SCAL; [Anonymous], 2000, AS PAC PERSP RED OB; Arshi S, 2012, ASIA PAC ALLERGY, V2, P45, DOI 10.5415/apallergy.2012.2.1.45; Back O, 2009, ACTA DERM-VENEREOL, V89, P28, DOI 10.2340/00015555-0541; Belderbos ME, 2011, PEDIATRICS, V127, pE1513, DOI 10.1542/peds.2010-3054; Benson AA, 2012, ALLERGY, V67, P296, DOI 10.1111/j.1398-9995.2011.02755.x; Bikle DD, 2004, J INVEST DERMATOL, V122, P984, DOI 10.1111/j.0022-202X.2004.22424.x; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Cantorna MT, 2004, EXP BIOL MED, V229, P1136, DOI 10.1177/153537020422901108; Carroll KN, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.04.002; Choi CJ, 2013, J CLIN ENDOCR METAB, V98, P1703, DOI 10.1210/jc.2012-3901; Choi HS, 2011, J CLIN ENDOCR METAB, V96, P643, DOI 10.1210/jc.2010-2133; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Devereux G, 2010, ALLERGY, V65, P666, DOI 10.1111/j.1398-9995.2009.02220.x; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Erkkola M, 2009, CLIN EXP ALLERGY, V39, P875, DOI 10.1111/j.1365-2222.2009.03234.x; Gale CR, 2008, EUR J CLIN NUTR, V62, P68, DOI 10.1038/sj.ejcn.1602680; Goleva E, 2012, J ALLERGY CLIN IMMUN, V129, P1243, DOI 10.1016/j.jaci.2012.01.044; Hansdottir S, 2010, J IMMUNOL, V184, P965, DOI 10.4049/jimmunol.0902840; Heine G, 2013, BRIT J DERMATOL, V168, P855, DOI 10.1111/bjd.12077; Hollams EM, 2011, EUR RESPIR J, V38, P1320, DOI 10.1183/09031936.00029011; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1; Institute of Medicine of the National Academies, 2010, DIETARY REFERENCE IN; Kim S, 2012, DIABETES RES CLIN PR, V96, P230, DOI 10.1016/j.diabres.2012.01.001; Krouse JH, 2008, OTOLARYNG CLIN N AM, V41, P257, DOI 10.1016/j.otc.2007.11.002; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Littel-van den Hurk SV, 2012, CURR OPIN VIROL, V2, P300, DOI 10.1016/j.coviro.2012.01.008; Mai XM, 2012, AM J EPIDEMIOL, V176, P1169, DOI 10.1093/aje/kws235; Mai XM, 2013, THORAX, V68, P25, DOI 10.1136/thoraxjnl-2012-202061; Muehleisen B, 2013, J ALLERGY CLIN IMMUN, V131, P324, DOI 10.1016/j.jaci.2012.12.1562; Nam GE, 2014, PUBLIC HEALTH NUTR, V17, P186, DOI 10.1017/S1368980012004855; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; Oren E, 2008, J ALLERGY CLIN IMMUN, V121, P533, DOI 10.1016/j.jaci.2007.11.005; Peroni DG, 2011, BRIT J DERMATOL, V164, P1078, DOI 10.1111/j.1365-2133.2010.10147.x; Peroni DG, 2013, CURR OPIN ALLERGY CL, V13, P287, DOI 10.1097/ACI.0b013e328360ed9c; Reinholz M, 2012, ANN DERMATOL, V24, P126, DOI 10.5021/ad.2012.24.2.126; Rhee SY, 2012, DIABETIC MED, V29, P1003, DOI 10.1111/j.1464-5491.2012.03575.x; Schauber J, 2007, J CLIN INVEST, V117, P803, DOI 10.1172/JCI30142; Schwarze J, 2002, EUR RESPIR J, V19, P341, DOI 10.1183/09031936.02.00254302; Sharief S, 2011, J ALLERGY CLIN IMMUN, V127, P1195, DOI 10.1016/j.jaci.2011.01.017; Szekely JI, 2012, EXPERT REV RESP MED, V6, P683, DOI [10.1586/ERS.12.57, 10.1586/ers.12.57]; Tanei R, 2008, J DERMATOL, V35, P562, DOI 10.1111/j.1346-8138.2008.00524.x; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Vimaleswaran KS, 2012, ALLERGY, V67, P1033, DOI 10.1111/j.1398-9995.2012.02856.x; Wang TJ, 2008, CIRCULATION, V117, P503, DOI 10.1161/CIRCULATIONAHA.107.706127; Wintergerst ES, 2007, ANN NUTR METAB, V51, P301, DOI 10.1159/000107673; Wjst M, 2007, ALLERGY, V62, P1085, DOI 10.1111/j.1398-9995.2007.01437.x	50	84	90	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1048	1055		10.1016/j.jaci.2013.10.055	http://dx.doi.org/10.1016/j.jaci.2013.10.055			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24388009				2022-12-18	WOS:000333531700015
J	Wambre, E; DeLong, JH; James, EA; Torres-Chinn, N; Pfutzner, W; Mobs, C; Durham, SR; Till, SJ; Robinson, D; Kwok, WW				Wambre, Erik; DeLong, Jonathan H.; James, Eddie A.; Torres-Chinn, Nadia; Pfuetzner, Wolfgang; Moebs, Christian; Durham, Stephen R.; Till, Stephen J.; Robinson, David; Kwok, William W.			Specific immunotherapy modifies allergen-specific CD4(+) T-cell responses in an epitope-dependent manner	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunotherapy; allergy; epitope; pollen; T cells; CD4; peptide-MHC class II tetramer; peripheral tolerance; ex vivo	SUBLINGUAL IMMUNOTHERAPY; DENDRITIC CELLS; MECHANISMS; EXPRESSION; EFFICACY; TABLETS; MEMORY	Background: Understanding the mechanisms by which the immune system induces and controls allergic inflammation at the T-cell epitope level is critical for the design of new allergy vaccine strategies. Objective: We sought to characterize allergen-specific T-cell responses linked with allergy or peripheral tolerance and to determine how CD4(+) T-cell responses to individual allergen-derived epitopes change over allergen-specific immunotherapy. Methods: Timothy grass pollen (TGP) allergy was used as a model for studying grass pollen allergies. The breadth, magnitude, epitope hierarchy, and phenotype of the DR04: 01-restricted TGP-specific T-cell responses in 10 subjects with grass pollen allergy, 5 nonatopic subjects, and 6 allergy vaccine-treated subjects was determined by using an ex vivo peptide-MHC class II tetramer approach. Results: CD4(+) T cells in allergic subjects are directed to a broad range of TGP epitopes characterized by defined immunodominance hierarchy patterns and with distinct functional profiles that depend on the epitope recognized. Epitopes that are restricted specifically to either T(H)2 or T(H)1/T(R)1 responses were identified. Allergen-specific immunotherapy was associated with preferential deletion of allergen-specific T(H)2 cells and without a significant change in the frequency of T(H)1/T(R)1 cells. Conclusions: Preferential allergen-specific T(H)2 cell deletion after repeated high-dose antigen stimulation can be another independent mechanism to restore tolerance to allergen during immunotherapy.	[Wambre, Erik; DeLong, Jonathan H.; James, Eddie A.; Torres-Chinn, Nadia; Kwok, William W.] Benaroya Res Inst Virginia Mason, Seattle, WA 98101 USA; [Pfuetzner, Wolfgang; Moebs, Christian] Univ Med Ctr, Dept Dermatol & Allergol, Marburg, Germany; [Durham, Stephen R.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Allergy & Clin Immunol, London, England; [Till, Stephen J.] Kings Coll London, London, England; [Robinson, David] Virginia Mason Med Ctr, Seattle, WA 98101 USA; [Kwok, William W.] Univ Washington, Dept Med, Seattle, WA USA	Benaroya Research Institute; Virginia Mason Medical Center; Imperial College London; University of London; King's College London; Virginia Mason Medical Center; University of Washington; University of Washington Seattle	Kwok, WW (corresponding author), Benaroya Res Inst Virginia Mason, 1201 9th Ave, Seattle, WA 98101 USA.	bkwok@benaroyaresearch.org	James, Eddie/V-4929-2019	James, Eddie/0000-0002-7217-5729; Till, Stephen/0000-0003-4518-3093; Mobs, Christian/0000-0002-5197-7669	National Institutes of Health (NIH) [HHSN272200700046C]; NIH [AI095074]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI095074] Funding Source: NIH RePORTER; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre] Funding Source: researchfish	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	Supported by National Institutes of Health (NIH) contract HHSN272200700046C and NIH grant AI095074.	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akkoc T, 2011, ALLERGY ASTHMA IMMUN, V3, P11, DOI 10.4168/aair.2011.3.1.11; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Fujita H, 2012, CHEM IMMUNOL ALLERGY, V96, P30, DOI 10.1159/000331868; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Hendricks J, 2003, J EXP MED, V198, P1369, DOI 10.1084/jem.20030916; HINTZEN RQ, 1993, J IMMUNOL, V151, P2426; Kwok WW, 2010, J ALLERGY CLIN IMMUN, V125, P1407, DOI 10.1016/j.jaci.2010.03.037; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Lissina A, 2009, J IMMUNOL METHODS, V340, P11, DOI 10.1016/j.jim.2008.09.014; Maggi E, 2010, CLIN EXP IMMUNOL, V161, P10, DOI 10.1111/j.1365-2249.2010.04148.x; Margot CD, 2005, J IMMUNOL, V174, P3352, DOI 10.4049/jimmunol.174.6.3352; Mobs C, 2012, J ALLERGY CLIN IMMUN, V130, P1108, DOI 10.1016/j.jaci.2012.07.056; Muller WD, 1998, CLIN EXP ALLERGY, V28, P1538; Novak EJ, 1999, J CLIN INVEST, V104, pR63, DOI 10.1172/JCI8476; Novak EJ, 2001, J IMMUNOL, V166, P6665, DOI 10.4049/jimmunol.166.11.6665; Oseroff C, 2008, J IMMUNOL, V180, P7193, DOI 10.4049/jimmunol.180.11.7193; Oseroff C, 2010, J IMMUNOL, V185, P943, DOI 10.4049/jimmunol.1000405; Pepper M, 2010, NAT IMMUNOL, V11, P83, DOI 10.1038/ni.1826; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; Shafiani S, 2010, J EXP MED, V207, P1409, DOI 10.1084/jem.20091885; Skokos D, 2007, NAT IMMUNOL, V8, P835, DOI 10.1038/ni1490; Steinman RM, 2008, IMMUNITY, V29, P319, DOI 10.1016/j.immuni.2008.08.001; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, P544, DOI 10.1016/j.jaci.2011.08.034; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Zhao JX, 2011, J EXP MED, V208, P1571, DOI 10.1084/jem.20110236	35	84	90	3	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					872	+		10.1016/j.jaci.2013.10.054	http://dx.doi.org/10.1016/j.jaci.2013.10.054			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24373351	Green Accepted			2022-12-18	WOS:000332397600032
J	Simons, FER; Schatz, M				Simons, F. Estelle R.; Schatz, Michael			Anaphylaxis during pregnancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; pregnancy; labor; delivery; penicillin allergy; neuromuscular blocker allergy; latex allergy; neonatal group B streptococcal infection; amniotic fluid embolism; resuscitation	GROUP-B STREPTOCOCCUS; AMNIOTIC-FLUID EMBOLISM; HEREDITARY ANGIOEDEMA; OBSTETRIC MANAGEMENT; SPINAL-ANESTHESIA; CESAREAN DELIVERY; PENICILLIN; GUIDELINES; HISTORY; WOMAN	Anaphylaxis during pregnancy, labor, and delivery can be catastrophic for the mother and, especially, the infant. Symptoms and signs can include intense vulvar and vaginal itching, low back pain, uterine cramps, fetal distress, and preterm labor. During the first 3 trimesters, etiologies are similar to those in nonpregnant women. During labor and delivery, common etiologies are beta-lactam antibiotics, natural rubber latex, and other agents used in medical and perioperative settings. Important caveats in management include injecting epinephrine (adrenaline) promptly, providing high-flow supplemental oxygen, positioning the mother on her left side to improve venous return to the heart, maintaining a minimum maternal systolic blood pressure of 90 mm Hg to ensure adequate placental perfusion, and continuous electronic monitoring. Cardiopulmonary resuscitation and emergency cesarean delivery should be performed when indicated. In all women of child-bearing age, allergy/immunology specialists can help to prevent anaphylaxis in pregnancy through prepregnancy risk assessment and risk reduction strategies, such as confirming the etiology of systemic allergic reactions, providing written instructions for allergen avoidance, and initiating relevant immune modulation. In pregnant women the benefits versus risks of skin tests, challenge tests, desensitization, and initiation of immunotherapy with allergens should be carefully weighed; if possible, these procedures should be deferred until after parturition. Prospective interdisciplinary studies of anaphylaxis during pregnancy are needed. (J Allergy Clin Immunol 2012;130:597-606.)	[Simons, F. Estelle R.] Univ Manitoba, Dept Pediat & Child Hlth, Dept Immunol, Fac Med, Winnipeg, MB R3T 2N2, Canada; [Schatz, Michael] Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA USA	University of Manitoba; Kaiser Permanente	Simons, FER (corresponding author), Room FE125,820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	lmcniven@hsc.mb.ca						Antico A, 2011, INT ARCH ALLERGY IMM, V156, P427, DOI 10.1159/000324461; Bangash MN, 2011, MED LETT DRUGS THER, V53, P90; Barbieri RL, 2012, HARRISONS PRINCIPLES, P55; Berg CJ, 2010, OBSTET GYNECOL, V116, P1302, DOI 10.1097/AOG.0b013e3181fdfb11; Braveman FR, 2008, STOELTINGS ANESTHESI, P557; Brown SGA, 2011, CLIN EXP ALLERGY, V41, P1660, DOI 10.1111/j.1365-2222.2011.03893.x; Caballero T, 2012, J ALLERGY CLIN IMMUN, V129, P308, DOI 10.1016/j.jaci.2011.11.025; Chaudhuri K, 2008, INT J OBSTET ANESTH, V17, P350, DOI 10.1016/j.ijoa.2008.05.002; Chisholm CA, 1997, AM J PERINAT, V14, P553, DOI 10.1055/s-2007-994332; Conde-Agudelo A, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.04.052; Coppola A, 2010, HAEMOPHILIA, V16, P560, DOI 10.1111/j.1365-2516.2009.02147.x; Cousins L, 1999, J ALLERGY CLIN IMMUN, V103, pS343, DOI 10.1016/S0091-6749(99)70260-5; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Czaller I, 2010, EUR J OBSTET GYN R B, V152, P44, DOI 10.1016/j.ejogrb.2010.05.008; Draisci G, 2007, INT J OBSTET ANESTH, V16, P63, DOI 10.1016/j.ijoa.2006.08.006; Draisci G, 2011, ANESTHESIOLOGY, V114, P565, DOI 10.1097/ALN.0b013e318206ff50; Fontaine C, 2007, ALLERGY, V62, P47, DOI 10.1111/j.1398-9995.2006.01268.x; Gei AF, 2003, OBSTET GYNECOL, V102, P1332, DOI 10.1016/S0029-7844(03)00167-4; Gin T, 2011, ANESTHETIC PHARM, P948; Harboe T, 2006, ACTA ANAESTH SCAND, V50, P324, DOI 10.1111/j.1399-6576.2006.00962.x; Heinly TL, 2000, IMMUNOL ALLERGY CLIN, V20, P831, DOI 10.1016/S0889-8561(05)70185-5; Jensen-Jarolim E, 1998, J ALLERGY CLIN IMMUN, V102, P1041, DOI 10.1016/S0091-6749(98)70345-8; Kaneko Kazuhiro, 2003, J Anesth, V17, P199, DOI 10.1007/s00540-003-0178-4; Karakurt F, 2010, J INVEST ALLERG CLIN, V20, P431; Khan R, 2008, J OBSTET GYNAECOL, V28, P751, DOI 10.1080/01443610802260595; Kishimoto TK, 2008, NEW ENGL J MED, V358, P2457, DOI 10.1056/NEJMoa0803200; Knight M, 2010, OBSTET GYNECOL, V115, P910, DOI 10.1097/AOG.0b013e3181d9f629; Kramer MS, 2006, LANCET, V368, P1444, DOI 10.1016/S0140-6736(06)69607-4; Kuwata Y, 2009, J OBSTET GYNAECOL RE, V35, P790, DOI 10.1111/j.1447-0756.2009.01021.x; Lin Ming-Chung, 2007, Acta Anaesthesiol Taiwan, V45, P233; Lombaard H, 2009, BEST PRACT RES CL OB, V23, P339, DOI 10.1016/j.bpobgyn.2009.01.005; Lukehart SA, 2012, HARRISONS PRINCIPLES, P1386; Macy E, 2006, ANN ALLERG ASTHMA IM, V97, P164, DOI 10.1016/S1081-1206(10)60007-5; Matsuo K, 2008, AM J OBSTET GYNECOL, V198, pE8, DOI 10.1016/j.ajog.2007.09.035; McKinney KK, 2011, ALLERGY, V66, P435, DOI 10.1111/j.1398-9995.2010.02486.x; MEGGS WJ, 1984, NEW ENGL J MED, V311, P1236, DOI 10.1056/NEJM198411083111907; Mulla ZD, 2010, ANN ALLERG ASTHMA IM, V104, P55, DOI 10.1016/j.anai.2009.11.005; Ngan Kee WD, 2008, ANAESTHESIA, V63, P1319, DOI 10.1111/j.1365-2044.2008.05635.x; Ngan Kee WD, 2009, ANESTHESIOLOGY, V111, P506, DOI 10.1097/ALN.0b013e3181b160a3; Ogata J, 2007, BRIT J ANAESTH, V98, P845, DOI 10.1093/bja/aem113; Oi H, 2010, GYNECOL OBSTET INVES, V70, P138, DOI 10.1159/000313302; Pant D, 2009, INT J OBSTET ANESTH, V18, P85, DOI 10.1016/j.ijoa.2008.09.004; Pedersen DJA, 2012, ANN ALLERG ASTHMA IM, V108, P94, DOI 10.1016/j.anai.2011.11.009; Philipson EH, 2007, J REPROD MED, V52, P480; Porter BJ, 1998, ALLERGY, V53, P455, DOI 10.1111/j.1398-9995.1998.tb03926.x; Powrie RO, 2010, CRITICAL CARE OBSTETRICS, 5TH EDITION, P596; Rac MWF, 2010, OBSTET GYNECOL, V116, P552, DOI 10.1097/AOG.0b013e3181e7d065; Riley ET, 2004, BRIT J ANAESTH, V92, P459, DOI 10.1093/bja/aeh084; Romero R, 2010, J MATERN-FETAL NEO M, V23, P351, DOI 10.3109/14767050903177193; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Schatz M, 2009, NEW ENGL J MED, V360, P1862, DOI 10.1056/NEJMcp0809942; Sengupta A, 2008, J OBSTET GYNAECOL RE, V34, P252, DOI 10.1111/j.1447-0756.2008.00775.x; Shaikh WA, 2012, ALLERGY, V67, P741, DOI 10.1111/j.1398-9995.2012.02815.x; Shank JJ, 2009, OBSTET GYNECOL, V114, P415, DOI 10.1097/AOG.0b013e3181a20721; Sheikh J, 2007, ANN ALLERG ASTHMA IM, V99, P287, DOI 10.1016/S1081-1206(10)60667-9; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, P593; Smaill FM, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007482.pub2; SMITH HS, 1985, BRIT J OBSTET GYNAEC, V92, P1196, DOI 10.1111/j.1471-0528.1985.tb03038.x; Soar J, 2010, RESUSCITATION, V81, P1400, DOI 10.1016/j.resuscitation.2010.08.015; Stoll BJ, 2011, PEDIATRICS, V127, P817, DOI 10.1542/peds.2010-2217; Suresh MS, 2010, BEST PRACT RES CL OB, V24, P383, DOI 10.1016/j.bpobgyn.2010.01.002; Turillazzi E, 2008, FORENSIC SCI INT, V179, pE5, DOI 10.1016/j.forsciint.2008.03.021; Verani Jennifer R., 2010, Morbidity and Mortality Weekly Report, V59, P1; Villalta D, 2007, Eur Ann Allergy Clin Immunol, V39, P26; Watson KD, 2012, OBSTET GYNECOL, V119, P486, DOI 10.1097/AOG.0b013e318242d3c5	66	84	85	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					597	606		10.1016/j.jaci.2012.06.035	http://dx.doi.org/10.1016/j.jaci.2012.06.035			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22871389				2022-12-18	WOS:000308463500004
J	Fujita, H; Shemer, A; Suarez-Farinas, M; Johnson-Huang, LM; Tintle, S; Cardinale, I; Fuentes-Duculan, J; Novitskaya, I; Carucci, JA; Krueger, JG; Guttman-Yassky, E				Fujita, Hideki; Shemer, Avner; Suarez-Farinas, Mayte; Johnson-Huang, Leanne M.; Tintle, Suzanne; Cardinale, Irma; Fuentes-Duculan, Judilyn; Novitskaya, Inna; Carucci, John A.; Krueger, James G.; Guttman-Yassky, Emma			Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; psoriasis; dendritic cells; T-cell polarity; T(H)1; T(H)2; T(H)17; T(H)22; chemokine; skin	EPIDERMAL LANGERHANS CELLS; ALLERGEN PRESENTATION; HUMAN SKIN; INDUCE; TSLP; INFLAMMATION; PATHOGENESIS; EXPRESSION; EFALIZUMAB; CHEMOKINE	Background: Atopic dermatitis (AD) and psoriasis represent polar immune diseases. AD is a T(H)2/T(H)22-dominant disease, whereas psoriasis is considered a T(H)1/T(H)17 disease. Local immune deviation is suggested to be regulated by dendritic cell (DC)-induced T-cell polarization and recruitment of specific T-cell subsets by chemokines. Although the role of chemokines is well documented, the actual contribution of DCs to activate polar T-cell subsets in human subjects is still a matter of speculation. Objective: We sought to elucidate the significance of each cutaneous DC subset in disease-specific T-cell immune deviation. Methods: We performed a comprehensive analysis of major cutaneous resident (Langerhans cells and blood dendritic cell antigen 1-positive dermal DCs) and inflammatory (inflammatory dendritic epidermal cells and blood dendritic cell antigen 1-negative dermal DCs) DC subsets directly isolated from the lesional skin of patients with AD and those with psoriasis. Results: The ability of each DC subset to expand T(H)1, T(H)2, T(H)17, and T(H)22 subsets was similar between the 2 diseases, despite the association of both with accumulation of resident and inflammatory DCs. We also confirmed differential upregulation of chemokine expression in patients with AD (CCL17, CCL18, and CCL22) and psoriasis (CXCL1, IL-8, and CCL20). The expression of CCL17 and CCL22 was higher in Langerhans cells from patients with AD than from patients with psoriasis, whereas the opposite was observed for CXCL9 and CXCL10. Conclusion: Our results suggest that DC polarity does not directly drive differential T-cell subset responses. Alternatively, disease-specific chemokines might recruit specific memory T-cell subsets into the skin, which in turn might be activated and expanded by DCs at the site of inflammation, maintaining differential immune polarity in these diseases. (J Allergy Clin Immunol 2011;128:574-82.)	[Fujita, Hideki; Suarez-Farinas, Mayte; Johnson-Huang, Leanne M.; Tintle, Suzanne; Cardinale, Irma; Fuentes-Duculan, Judilyn; Novitskaya, Inna; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Investigat Dermatol, New York, NY 10065 USA; [Suarez-Farinas, Mayte] Rockefeller Univ, Ctr Clin & Translat Sci, New York, NY 10065 USA; [Shemer, Avner] Tel Hashomer Med Ctr, Dept Dermatol, Ramat Gan, Israel; [Carucci, John A.] Cornell Univ, Weill Med Coll, Dept Dermatol, New York, NY 10021 USA	Rockefeller University; Rockefeller University; Cornell University	Guttman-Yassky, E (corresponding author), Rockefeller Univ, Lab Investigat Dermatol, New York, NY 10065 USA.	eguttman@rockefeller.edu	Suarez-Farinas, Mayte/I-3558-2012	Suarez-Farinas, Mayte/0000-0001-8712-3553; carucci, john/0000-0001-6817-9439	NYSDOH [C023046]; Clinical and Translational Science Award grant	NYSDOH; Clinical and Translational Science Award grant	Supported in part by the Empire State Stem Cell Fund through NYSDOH contract no. C023046. Opinions expressed here are solely those of the authors and do not necessarily reflect those of the Empire State Stem Cell Fund, the NYSDOH, or the State of New York. S. T. and E. G.-Y. were supported by a Clinical and Translational Science Award grant.	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Akhavan A, 2008, SEMIN CUTAN MED SURG, V27, P151, DOI 10.1016/j.sder.2008.04.004; Amor KT, 2010, J AM ACAD DERMATOL, V63, P925, DOI 10.1016/j.jaad.2010.02.063; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Bieber T, 2009, CURR ALLERGY ASTHM R, V9, P291, DOI 10.1007/s11882-009-0041-2; Bowcock AM, 2005, NAT REV IMMUNOL, V5, P699, DOI 10.1038/nri1689; Brand U, 1999, J ALLERGY CLIN IMMUN, V104, P1052, DOI 10.1016/S0091-6749(99)70088-6; Chacko M, 2007, DERMATOL THER, V20, P265, DOI 10.1111/j.1529-8019.2007.00139.x; Clark RA, 2010, J INVEST DERMATOL, V130, P362, DOI 10.1038/jid.2009.247; Di Cesare A, 2009, J INVEST DERMATOL, V129, P1339, DOI 10.1038/jid.2009.59; Di Lernia V, 2010, INT J DERMATOL, V49, P631, DOI 10.1111/j.1365-4632.2010.04475.x; Dubrac S, 2010, IMMUNOL CELL BIOL, V88, P400, DOI 10.1038/icb.2010.33; Duraisingham SS, 2009, J IMMUNOL, V183, P2242, DOI 10.4049/jimmunol.0900474; Fujita H, 2009, P NATL ACAD SCI USA, V106, P21795, DOI 10.1073/pnas.0911472106; Guttman-Yassky E, 2007, BRIT J DERMATOL, V157, P1103, DOI 10.1111/j.1365-2133.2007.08135.x; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Irizarry RA, 2009, STAT METHODS MED RES, V18, P565, DOI 10.1177/0962280209351908; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jariwala SP, 2007, ARCH DERMATOL RES, V299, P359, DOI 10.1007/s00403-007-0775-4; Johnson-Huang LM, 2009, J CLIN IMMUNOL, V29, P247, DOI 10.1007/s10875-009-9278-8; Klechevsky E, 2008, IMMUNITY, V29, P497, DOI 10.1016/j.immuni.2008.07.013; Kube DM, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-25; Lebre MC, 2005, IMMUNOL CELL BIOL, V83, P525, DOI 10.1111/j.1440-1711.2005.01365.x; Lombardi V, 2009, J IMMUNOL, V182, P3372, DOI 10.4049/jimmunol.0801969; Lonsdorf AS, 2009, J INVEST DERMATOL, V129, P2552, DOI 10.1038/jid.2009.122; Lowes MA, 2005, P NATL ACAD SCI USA, V102, P19057, DOI 10.1073/pnas.0509736102; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; Nestle FO, 2005, J EXP MED, V202, P135, DOI 10.1084/jem.20050500; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Novak N, 2005, J AM ACAD DERMATOL, V53, pS171, DOI 10.1016/j.jaad.2005.04.060; Ong PY, 2006, CURR ALLERGY ASTHM R, V6, P384, DOI 10.1007/s11882-996-0008-5; Oyoshi MK, 2009, ADV IMMUNOL, V102, P135, DOI 10.1016/S0065-2776(09)01203-6; Pivarcsi A, 2004, J IMMUNOL, V173, P5810, DOI 10.4049/jimmunol.173.9.5810; Ryan C, 2010, J AM ACAD DERMATOL, V63, P949, DOI 10.1016/j.jaad.2010.02.062; Singh SP, 2008, J IMMUNOL, V180, P214, DOI 10.4049/jimmunol.180.1.214; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24, DOI 10.1159/000237499; Suarez-Farinas M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-294; Suarez-Farinas M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010247; Takiguchi R, 2007, J AM ACAD DERMATOL, V56, P222, DOI 10.1016/j.jaad.2006.08.031; Toebak MJ, 2009, CONTACT DERMATITIS, V60, P2, DOI 10.1111/j.1600-0536.2008.01443.x; Wang YH, 2009, CLIN EXP ALLERGY, V39, P798, DOI 10.1111/j.1365-2222.2009.03241.x; Watanabe N, 2005, BLOOD, V105, P4749, DOI 10.1182/blood-2004-09-3622; Wollenberg A, 1999, CYTOMETRY, V37, P147, DOI 10.1002/(SICI)1097-0320(19991001)37:2<147::AID-CYTO8>3.0.CO;2-Y; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Zaba LC, 2007, J CLIN INVEST, V117, P2517, DOI 10.1172/JCI32282; Zaba LC, 2010, J ALLERGY CLIN IMMUN, V125, P1261, DOI 10.1016/j.jaci.2010.03.018; Zaba LC, 2009, J INVEST DERMATOL, V129, P302, DOI 10.1038/jid.2008.225; Zaba LC, 2009, J INVEST DERMATOL, V129, P79, DOI 10.1038/jid.2008.194; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	57	84	89	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					574	U216		10.1016/j.jaci.2011.05.016	http://dx.doi.org/10.1016/j.jaci.2011.05.016			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21704361				2022-12-18	WOS:000294283400017
J	Lluis, A; Schedel, M; Liu, J; Illi, S; Depner, M; von Mutius, E; Kabesch, M; Schaub, B				Lluis, Anna; Schedel, Michaela; Liu, Jing; Illi, Sabina; Depner, Martin; von Mutius, Erika; Kabesch, Michael; Schaub, Bianca			Asthma-associated polymorphisms in 17q21 influence cord blood ORMDL3 and GSDMA gene expression and IL-17 secretion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chromosome 17q21 locus; cord blood; cytokines; GSDMA; IL-17; ORMDL3; polymorphism; T-cells	VARIANTS; IMPAIRMENT; ONSET	Background: In a genome-wide association study, genetic variants on chromosome 17q21 were strongly associated with childhood asthma and orosomucoid 1-like 3 (ORMDL3) gene expression. Regulation of the 17q21 locus and its immunologic relevance early in life have not been well characterized. Objective: We investigated the relation between polymorphisms and mRNA expression of 17q21 locus genes and their influence on T-cell subsets in cord blood. Methods: In 200 children of our cord blood study, 17q21 polymorphisms were genotyped by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Gene expression was assessed for ORMDL3; gasdermin A (GSDMA, alias GSDM1); gasdermin B (GSDMB, alias GSDML); Ikaros family zinc finger 3 (ZNFN1A3), zona pellucida binding protein 2 (ZPBP2); and proteasome (prosome, macropain) 26S subunit, non-ATPase, 3 (PSMD3), in cord blood mononuclear cells (CBMCs) and for ORMDL3 in peripheral blood (real-time RT-PCR). Mononuclear cells were assessed before and after microbial (lipid A/peptidoglycan), phytohemagglutinin, or allergen (Der p 1) stimulation. Regulatory T-associated markers (forkhead box protein 3, glucocorticoid-induced TNF receptor, lymphocyte activation gene 3 mRNA expression) and T(H)2/T(H)1/T(H)17 cytokines were examined. Results: In CBMCs, single genetic risk variants within 17q21 were associated with increased ORMDL3 (Der p 1 stimulation; P <= .01) and GSDMA expression (phytohemagglutinin/Der p 1 stimulation; P <= .05). Children homozygous for all 4 risk alleles for 17q21 tagging single nucleotide polymorphisms showed increased expression for ORMDL3 (Der p 1; P = .002) and GSDMA (phytohemagglutinin; P = .0009/Der p 1; P = .004). CBMC ORMDL3 expression was lower compared with PBMCs (P <= .0003) and increased in both CBMC and PBMC after stimulation (phytohemagglutinin/lipid A/peptidoglycan/Der p 1; P <= .006 and phytohemagglutinin/peptidoglycan; P < .05, respectively). No correlation between 17q21 polymorphisms and regulatory T/T(H)2/T(H)1 lineages was detectable. However, 17q21 risk allele carriers showed significantly increased IL-17 secretion (unstimulated, phytohemagglutinin-stimulated). Conclusion: Our results suggest an association of 17q21 polymorphisms with ORMDL3, GSDMA expression, and IL-17 secretion early in life. These observations may imply a functional role of the 17q21 locus affecting T-cell development during immune maturation. (J Allergy Clin Immunol 2011;127:1587-94.)	[Schaub, Bianca] Ludwig Maximilians Univ Munchen, Univ Childrens Hosp Munich, Dr Von Haunerschen Kinderspital, Dept Pulm & Allergy, D-80337 Munich, Germany; [Schedel, Michaela; Kabesch, Michael] Hannover Med Sch, Dept Pneumol Allergol & Neonatol, D-3000 Hannover, Germany; [Liu, Jing] Jilin Univ, Hosp 2, Dept Resp Med, Changchun 130023, Peoples R China	University of Munich; Hannover Medical School; Jilin University	Schaub, B (corresponding author), Ludwig Maximilians Univ Munchen, Univ Childrens Hosp Munich, Dr Von Haunerschen Kinderspital, Dept Pulm & Allergy, Lindwurmstr 4, D-80337 Munich, Germany.	Bianca.Schaub@med.uni-muenchen.de	Kabesch, Michael/AAB-5701-2020; Schaub, Bianca/B-9935-2019; Kabesch, Michael/GZM-1583-2022; Schedel, Michaela/B-3065-2019	Schaub, Bianca/0000-0003-1652-8873; Schedel, Michaela/0000-0001-8465-2986; von Mutius, Erika/0000-0002-8893-4515	Bavarian Research Association [PIZ-140-08]; Marie Curie research grant [MEST-CT-2005-020524-GALTRAIN]; National Genome Research Network [NGFN 01GS 0810]; German Research Foundation [A22, Z3]; Airsonett; German Research Foundation; Bundesministerium fur Bildung und Forschung; European Union	Bavarian Research Association; Marie Curie research grant(European Commission); National Genome Research Network; German Research Foundation(German Research Foundation (DFG)); Airsonett; German Research Foundation(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); European Union(European Commission)	Supported by the Bavarian Research Association PIZ-140-08 (B. S., J.L.), a Marie Curie research grant (MEST-CT-2005-020524-GALTRAIN, A. L.), National Genome Research Network research grant NGFN 01GS 0810, and the German Research Foundation as part of the transregional collaborative research program TR22 "Allergic Immune Responses of the Lung," A22 (B. S., A. L.), and grant Z3 (M. S., M. K.).; E. von Mutius has consultant arrangements with GlaxoSmithKline, UCB, Protectimmun, and Novartis and receives research support from Airsonett AB. M. Kabesch has financial interests in Roxall, Glaxo Wellcome, Novartis, Sanofi Aventis, and Allergopharma and receives research support from the German Research Foundation, Bundesministerium fur Bildung und Forschung, and the European Union. B. Schaub receives research support from the German Research Foundation and the European Union. The rest of the authors have declared that they have no conflict of interest.	Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Breslow DK, 2010, NATURE, V463, P1048, DOI 10.1038/nature08787; Cantero-Recasens G, 2010, HUM MOL GENET, V19, P111, DOI 10.1093/hmg/ddp471; Ding CM, 2003, P NATL ACAD SCI USA, V100, P3059, DOI 10.1073/pnas.0630494100; Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Gallo EM, 2006, NAT IMMUNOL, V7, P25, DOI 10.1038/ni1295; Halapi E, 2010, EUR J HUM GENET, V18, P902, DOI 10.1038/ejhg.2010.38; Hirota T, 2008, J ALLERGY CLIN IMMUN, V121, P769, DOI 10.1016/j.jaci.2007.09.038; Hjelmqvist L, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-6-research0027; Ivanov S, 2007, AM J RESP CELL MOL, V36, P442, DOI 10.1165/rcmb.2006-0020OC; Leung TF, 2009, ALLERGY, V64, P621, DOI 10.1111/j.1398-9995.2008.01873.x; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Madore AM, 2008, HUM GENET, V123, P93, DOI 10.1007/s00439-007-0444-x; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Schaub B, 2008, ALLERGY, V63, P1438, DOI 10.1111/j.1398-9995.2008.01685.x; Schaub B, 2008, J ALLERGY CLIN IMMUN, V121, P1491, DOI 10.1016/j.jaci.2008.04.010; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Sleiman PMA, 2008, J ALLERGY CLIN IMMUN, V122, P1225, DOI 10.1016/j.jaci.2008.06.041; Tavendale R, 2008, J ALLERGY CLIN IMMUN, V121, P860, DOI 10.1016/j.jaci.2008.01.015; Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007; Verlaan DJ, 2009, GENOME RES, V19, P118, DOI 10.1101/gr.084798.108; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Wu H, 2009, ALLERGY, V64, P629, DOI 10.1111/j.1398-9995.2008.01912.x	26	84	87	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1587	U414		10.1016/j.jaci.2011.03.015	http://dx.doi.org/10.1016/j.jaci.2011.03.015			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21546069				2022-12-18	WOS:000291048500041
J	DunnGalvin, A; Daly, D; Cullinane, C; Stenke, E; Keeton, D; Erlewyn-Lajeunesse, M; Roberts, GC; Lucas, J; Hourihane, JO				DunnGalvin, Audrey; Daly, Deirdre; Cullinane, Claire; Stenke, Emily; Keeton, Diane; Erlewyn-Lajeunesse, Mich; Roberts, Graham C.; Lucas, Jane; Hourihane, Jonathan O'B.			Highly accurate prediction of food challenge outcome using routinely available clinical data	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food challenge; predictive model; validation; calculator; outcomes	SKIN PRICK; IGE CONCENTRATIONS; ALLERGIC DISORDERS; DOUBLE-BLIND; NUT ALLERGY; CHILDREN; RISK; UTILITY; PEANUT; QUESTIONNAIRE	Background: Serum specific IgE or skin prick tests are less useful at levels below accepted decision points. Objectives: We sought to develop and validate a model to predict food challenge outcome by using routinely collected data in a diverse sample of children considered suitable for food challenge. Methods: The proto-algorithm was generated by using a limited data set from 1 service (phase 1). We retrospectively applied, evaluated, and modified the initial model by using an extended data set in another center (phase 2). Finally, we prospectively validated the model in a blind study in a further group of children undergoing food challenge for peanut, milk, or egg in the second center (phase 3). Allergen-specific models were developed for peanut, egg, and milk. Results: Phase 1 (N = 429) identified 5 clinical factors associated with diagnosis of food allergy by food challenge. In phase 2 (N = 289), we examined the predictive ability of 6 clinical factors: skin prick test, serum specific IgE, total IgE minus serum specific IgE, symptoms, sex, and age. In phase 3 (N = 70), 97% of cases were accurately predicted as positive and 94% as negative. Our model showed an advantage in clinical prediction compared with serum specific IgE only, skin prick test only, and serum specific IgE and skin prick test (92% accuracy vs 57%, and 81%, respectively). Conclusion: Our findings have implications for the improved delivery of food allergy-related health care, enhanced food allergy-related quality of life, and economized use of health service resources by decreasing the number of food challenges performed. (J Allergy Clin Immunol 2011;127:633-9.)	[DunnGalvin, Audrey; Daly, Deirdre; Cullinane, Claire; Stenke, Emily; Lucas, Jane; Hourihane, Jonathan O'B.] Univ Coll Cork, Cork, Ireland; [Keeton, Diane; Erlewyn-Lajeunesse, Mich; Roberts, Graham C.; Lucas, Jane] Southampton Univ Hosp NHS Trust, Southampton, Hants, England; [Roberts, Graham C.; Lucas, Jane] Univ Southampton, Sch Med, Southampton SO9 5NH, Hants, England	University College Cork; University of Southampton; University Hospital Southampton NHS Foundation Trust; University of Southampton	DunnGalvin, A (corresponding author), Cork Univ Hosp, Clin Invest Unit, Dept Paediat & Child Hlth, Cork, Ireland.	a.dunngalvin@ucc.ie	DunnGalvin, Audrey/G-1741-2012; Lucas, Jane S/C-3620-2013	Lucas, Jane/0000-0001-8701-9975; Roberts, Graham/0000-0003-2252-1248; Erlewyn-Lajeunesse, Michel/0000-0003-1982-1397	King Pharmaceuticals; ALK-Abello; Mead Johnson; Phadia; DANONE; Children's Research Center; Food Standards Agency	King Pharmaceuticals; ALK-Abello; Mead Johnson; Phadia(Phadia); DANONE(Danone Nutricia); Children's Research Center; Food Standards Agency	J. O'B. Hourihane receives speaker fees from King Pharmaceuticals, ALK-Abello, Mead Johnson, and Phadia; receives research support from DANONE, the Children's Research Center, and the Food Standards Agency; has provided legal consultation services or expert witness testimony in cases related to food allergy death; is honorary secretary of the Irish Association of Allergy and Immunology; is a medical advisor for the Anaphylaxis Campaign UK; and has a patent application relating to electronic use of the algorithm developed in this project. D. Daly receives research support from DANONE and Mead Johnson. The rest of the authors have declared that they have no conflict of interest.	Anandan C, 2009, J ROY SOC MED, V102, P431, DOI 10.1258/jrsm.2009.090027; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Blok BMJF, 2008, J ALLERGY CLIN IMMUN, V122, P139, DOI 10.1016/j.jaci.2008.05.008; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Cohen BL, 2004, J ALLERGY CLIN IMMUN, V114, P1159, DOI 10.1016/j.jaci.2004.08.007; DunnGalvin A, 2008, CLIN EXP ALLERGY, V38, P977, DOI 10.1111/j.1365-2222.2008.02978.x; DunnGalvin A, 2009, ALLERGY, V64, P560, DOI 10.1111/j.1398-9995.2008.01862.x; DunnGalvin A, 2009, PEDIATRICS, V124, pE503, DOI 10.1542/peds.2008-3642; Ewan PW, 2005, CLIN EXP ALLERGY, V35, P751, DOI 10.1111/j.1365-2222.2005.02266.x; Ewan PW, 2001, LANCET, V357, P111, DOI 10.1016/S0140-6736(00)03543-1; Fleischer D, 2005, JACI, V115, pS482; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Gupta R, 2003, BRIT MED J, V327, P1142, DOI 10.1136/bmj.327.7424.1142; Herman WH, 2009, ANN INTERN MED, V150, P812, DOI 10.7326/0003-4819-150-11-200906020-00010; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P435, DOI 10.1111/j.1399-3038.2004.00188.x; Hippisley-Cox J, 2008, BMJ-BRIT MED J, V336, P1475, DOI 10.1136/bmj.39609.449676.25; Hourihane JO, 2005, CLIN EXP ALLERGY, V35, P1227, DOI 10.1111/j.1365-2222.2005.02312.x; Hughes D A, 2001, Biologist (London), V48, P201; Hui AY, 2005, AM J GASTROENTEROL, V100, P616, DOI 10.1111/j.1572-0241.2005.41289.x; Knight AK, 2006, J ALLERGY CLIN IMMUN, V117, P842, DOI 10.1016/j.jaci.2005.12.1304; Komata T, 2007, J ALLERGY CLIN IMMUN, V119, P1272, DOI 10.1016/j.jaci.2007.01.038; Mehl A, 2005, ALLERGY, V60, P1034, DOI 10.1111/j.1398-9995.2005.00806.x; Menard S., 2000, APPL LOGISTIC REGRES; Miles S, 2005, ALLERGY, V60, P996, DOI 10.1111/j.1398-9995.2005.00868.x; Nakas CT, 2004, STAT MED, V23, P3437, DOI 10.1002/sim.1917; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; RICHARD A. J., 2002, APPL MULTIVARIATE ST; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Roberts G, 2000, CLIN EXP ALLERGY, V30, P1495, DOI 10.1046/j.1365-2222.2000.00960.x; Roberts S, 2005, ARCH DIS CHILD, V90, P564, DOI 10.1136/adc.2003.036814; Roehr CC, 2001, J ALLERGY CLIN IMMUN, V107, P548, DOI 10.1067/mai.2001.112849; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Simpson CR, 2008, J ROY SOC MED, V101, P558, DOI 10.1258/jrsm.2008.080196; Szpurek D, 2005, INT J GYNECOL CANCER, V15, P817, DOI 10.1111/j.1525-1438.2005.00142.x; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	38	84	85	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					633	U145		10.1016/j.jaci.2010.12.004	http://dx.doi.org/10.1016/j.jaci.2010.12.004			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21377032				2022-12-18	WOS:000288018400012
J	Bublin, M; Pfister, M; Radauer, C; Oberhuber, C; Bulley, S; DeWitt, AM; Lidholm, J; Reese, G; Vieths, S; Breiteneder, H; Hoffmann-Sommergruber, K; Ballmer-Weber, BK				Bublin, Merima; Pfister, Marina; Radauer, Christian; Oberhuber, Christina; Bulley, Sean; DeWitt, Asa Marknell; Lidholm, Jonas; Reese, Gerald; Vieths, Stefan; Breiteneder, Heimo; Hoffmann-Sommergruber, Karin; Ballmer-Weber, Barbara K.			Component-resolved diagnosis of kiwifruit allergy with purified natural and recombinant kiwifruit allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Actinidin; allergens; diagnosis; ImmunoCAP; in vitro test; kiwifruit; food allergy	CONTROLLED FOOD CHALLENGE; KIWI FRUIT ALLERGY; BIRCH POLLEN; CROSS-REACTIVITY; IDENTIFICATION; ACTINIDIN; GREEN; SENSITIZATION; PURIFICATION; PREVALENCE	Background: Kiwifruit is one of the most common causes of food allergic reactions. Component-resolved diagnostics may enable significantly improved detection of sensitization to kiwifruit. Objective: To evaluate the use of individual allergens for component-resolved in vitro diagnosis of kiwifruit allergy. Methods: Thirty patients with a positive double-blind placebo-controlled food challenge to kiwifruit, 10 atopic subjects with negative open provocation to kiwifruit, and 5 nonatopic subjects were enrolled in the study. Specific IgE to 7 individual allergens (nAct d 1-5 and rAct d 8-9) and allergen extracts was measured by ImmunoCAP. Results: The diagnostic sensitivities of the commercial extract and of the sum of single allergens were 17% and 77%, respectively, whereas diagnostic specificities were 100% and 30%. A combination of the kiwi allergens Act d 1, Act d 2, Act d 4, and Act d 5 gave a diagnostic sensitivity of 40%, whereas diagnostic specificity remained high (90%). Exclusion of the Bet v 1 homolog recombinant (r) Act d 8 and profilin rAct d 9 from this allergen panel reduced sensitivity to 50% but increased specificity to 40%. Kiwifruit-monosensitized patients reacted more frequently (P < .001) with Act d 1 than polysensitized patients, whereas the latter group reacted more frequently with rAct d 8 (P = .004). Conclusion: Use of single kiwifruit allergen ImmunoCAP increases the quantitative test performance and diagnostic sensitivity compared with the commercial extract. Bet v 1 homolog and profilin are important allergens in pollen-related kiwifruit allergy, whereas actinidin is important in monoallergy to kiwifruit, in which symptoms are often more severe. (J Allergy Clin Immunol 2010;125:687-94.)	[Pfister, Marina; Ballmer-Weber, Barbara K.] Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; [Bublin, Merima; Radauer, Christian; Breiteneder, Heimo; Hoffmann-Sommergruber, Karin] Med Univ Vienna, Dept Pathophysiol, Vienna, Austria; [Oberhuber, Christina] Biomay AG, Vienna, Austria; [Bulley, Sean] Plant & Food Res Inst New Zealand, Auckland, New Zealand; [DeWitt, Asa Marknell; Lidholm, Jonas] Phadia AB, Uppsala, Sweden; [Reese, Gerald; Vieths, Stefan] Paul Ehrlich Inst, Div Allergol, D-6070 Langen, Germany	University of Zurich; University Zurich Hospital; Medical University of Vienna; New Zealand Institute for Plant & Food Research Ltd; Thermo Fisher Scientific; Phadia; Paul Ehrlich Institute	Ballmer-Weber, BK (corresponding author), Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Gloriastr 31, CH-8091 Zurich, Switzerland.	Barbara.Ballmer@usz.ch	Radauer, Christian/AAN-6260-2021; Bulley, Sean/Q-9747-2019; Bulley, Sean M/B-3989-2008	Radauer, Christian/0000-0001-9920-4449; Bulley, Sean/0000-0001-6142-5414; Bulley, Sean M/0000-0001-6142-5414; Bublin, Merima/0000-0002-7191-9431; Lidholm, Jonas/0000-0002-7779-3411; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X	EU [FOOD-CT-2005-514000]; Austrian Science Fund [SFB-F01802]; German Research Foundation; German Food Industry; Monsanto; Pioneer Hi-Bred International; Food Allergy Research and Resource Program; European Directorate for the Quality of Medicines and Health Care	EU(European Commission); Austrian Science Fund(Austrian Science Fund (FWF)); German Research Foundation(German Research Foundation (DFG)); German Food Industry; Monsanto; Pioneer Hi-Bred International; Food Allergy Research and Resource Program; European Directorate for the Quality of Medicines and Health Care	Supported by the EU through the Euro Prevail project (FOOD-CT-2005-514000) and grant SFB-F01802 from the Austrian Science Fund to H.B.; Disclosure of potential conflict of interest: A. M. DeWitt and J. Lidholm are employed by Phadia. S. Vieths is an associate of the Institute for Product Quality (Germany), has received honoraria from Phadia and the Food Allergy Resource and Research Program (United States), is a consultant for Mars Chocolate UK Ltd, and has received research support from the European Union, the German Research Foundation, the Research Fund of the German Food Industry, Monsanto, Pioneer Hi-Bred International, the Food Allergy Research and Resource Program, and the European Directorate for the Quality of Medicines and Health Care. The rest of the authors have declared that they have no conflict of interest.	Aleman A, 2004, J ALLERGY CLIN IMMUN, V113, P543, DOI 10.1016/j.jaci.2003.11.043; Ballmer-Weber BK, 2001, J ALLERGY CLIN IMMUN, V108, P301, DOI 10.1067/mai.2001.116430; Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; BROCKLEHURST K, 1981, BIOCHEM J, V197, P739, DOI 10.1042/bj1970739; Bublin M, 2004, J ALLERGY CLIN IMMUN, V114, P1169, DOI 10.1016/j.jaci.2004.07.016; Bublin M, 2008, MOL NUTR FOOD RES, V52, P1130, DOI 10.1002/mnfr.200700167; Ciardiello MA, 2009, J AGR FOOD CHEM, V57, P1565, DOI 10.1021/jf802966n; DeWitt AM, 2002, CLIN EXP ALLERGY, V32, P1329, DOI 10.1046/j.1365-2222.2002.01467.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; GALL H, 1994, J ALLERGY CLIN IMMUN, V94, P70, DOI 10.1016/0091-6749(94)90073-6; Gavrovic-Jankulovic M, 2002, J INVEST ALLERG CLIN, V12, P279; Gavrovic-Jankulovic M, 2002, J ALLERGY CLIN IMMUN, V110, P805, DOI 10.1067/mai.2002.128947; Kim KT, 1999, ALLERGY ASTHMA PROC, V20, P95, DOI 10.2500/108854199778612572; LATASA M, 1995, J INVEST ALLERG CLIN, V5, P97; Love CA, 1996, GENE, V176, P49, DOI 10.1016/0378-1119(96)00208-9; Lucas JSA, 2004, CLIN EXP ALLERGY, V34, P1115, DOI 10.1111/j.1365-2222.2004.01982.x; Lucas JSA, 2003, PEDIAT ALLERG IMM-UK, V14, P420, DOI 10.1046/j.0905-6157.2003.00095.x; Mattila L, 2003, CLIN EXP ALLERGY, V33, P600, DOI 10.1046/j.1365-2222.2003.01661.x; Mittag D, 2004, J ALLERGY CLIN IMMUN, V113, P148, DOI 10.1016/j.jaci.2003.09.030; Palacin A, 2008, CLIN EXP ALLERGY, V38, P1220, DOI 10.1111/j.1365-2222.2007.02927.x; Pastorello EA, 1996, J ALLERGY CLIN IMMUN, V98, P601, DOI 10.1016/S0091-6749(96)70094-5; Pastorello EA, 1998, J ALLERGY CLIN IMMUN, V101, P531, DOI 10.1016/S0091-6749(98)70360-4; Rance F, 2005, CLIN EXP ALLERGY, V35, P167, DOI 10.1111/j.1365-2222.2005.02162.x; Rassam M, 2004, PHYTOCHEMISTRY, V65, P19, DOI 10.1016/j.phytochem.2003.09.019; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Tuppo L, 2008, J AGR FOOD CHEM, V56, P3812, DOI 10.1021/jf703620m	29	84	86	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					687	694		10.1016/j.jaci.2009.10.017	http://dx.doi.org/10.1016/j.jaci.2009.10.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20061012				2022-12-18	WOS:000275883200027
J	Swindle, EJ; Collins, JE; Davies, DE				Swindle, Emily J.; Collins, Jane E.; Davies, Donna E.			Breakdown in epithelial barrier function in patients with asthma: Identification of novel therapeutic approaches	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; epithelium; tight junction; innate immunity; permeability; allergen; virus	EPIDERMAL-GROWTH-FACTOR; HOUSE-DUST MITE; THYMIC STROMAL LYMPHOPOIETIN; RESPIRATORY SYNCYTIAL VIRUS; TIGHT JUNCTION PERMEABILITY; STEM-CELL FACTOR; BRONCHIAL EPITHELIUM; DENDRITIC CELLS; MAST-CELLS; IN-VITRO	The bronchial epithelium is pivotally involved in the provision of chemical, physical, and immunologic barriers to the inhaled environment. These barriers serve to maintain normal homeostasis, but when compromised, the immunologic barrier becomes activated to protect the internal milieu of the lung. We discuss what is currently understood about abnormalities in these barrier functions in patients with asthma and consider novel therapeutic opportunities that target this key structure. (J Allergy Clin Immunol 2009;124:23-34.)	[Swindle, Emily J.; Collins, Jane E.; Davies, Donna E.] Univ Southampton, Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Immun, Southampton SO16 6YD, Hants, England	University of Southampton	Davies, DE (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Immun, Mailpoint 810, Southampton SO16 6YD, Hants, England.	donnad@soton.ac.uk	Davies, Donna E/H-2993-2012	Davies, Donna/0000-0002-5117-2991; Swindle, Emily/0000-0003-3644-7747; Collins, Jane/0000-0002-9914-3890	MRC [G0501506] Funding Source: UKRI; National Centre for the Replacement [G0700636/1] Funding Source: researchfish; Medical Research Council [G0501506] Funding Source: Medline; National Centre for the Replacement, Refinement and Reduction of Animals in Research [G0700636/1] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Centre for the Replacement; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Centre for the Replacement, Refinement and Reduction of Animals in Research(UK Research & Innovation (UKRI)National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs))		ABDELAZIZ MM, 1995, AM J RESP CELL MOL, V13, P728, DOI 10.1165/ajrcmb.13.6.7576711; Ahdieh M, 2001, AM J PHYSIOL-CELL PH, V281, pC2029, DOI 10.1152/ajpcell.2001.281.6.C2029; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; Allmers H, 2005, J ALLERGY CLIN IMMUN, V116, P859, DOI 10.1016/j.jaci.2005.07.019; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Balda MS, 2009, BBA-BIOMEMBRANES, V1788, P761, DOI 10.1016/j.bbamem.2008.11.024; Basuroy S, 2006, BIOCHEM J, V393, P69, DOI 10.1042/BJ20050959; Beasley R, 2008, LANCET, V372, P1039, DOI 10.1016/S0140-6736(08)61445-2; Bertorelli G, 1998, CLIN EXP ALLERGY, V28, P551; Bingle CD, 2004, INT J BIOCHEM CELL B, V36, P2144, DOI 10.1016/j.biocel.2004.05.002; Bleck B, 2006, J IMMUNOL, V176, P7431, DOI 10.4049/jimmunol.176.12.7431; Boivin MA, 2007, AM J PHYSIOL-GASTR L, V292, pG590, DOI 10.1152/ajpgi.00252.2006; BONFIELD TL, 1995, AM J RESP CELL MOL, V13, P257, DOI 10.1165/ajrcmb.13.3.7544594; Boogaard R, 2008, THORAX, V63, P141, DOI 10.1136/thx.2007.081703; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; Brown A, 2003, AM J RESP CELL MOL, V29, P381, DOI 10.1165/rcmb.2003-0060OC; Bruewer M, 2006, ANN NY ACAD SCI, V1072, P242, DOI 10.1196/annals.1326.017; Burgler S, 2009, J ALLERGY CLIN IMMUN, V123, P588, DOI 10.1016/j.jaci.2008.12.017; Burke-Gaffney A, 1998, AM J RESP CELL MOL, V19, P408, DOI 10.1165/ajrcmb.19.3.3179; Cairns JA, 1996, J IMMUNOL, V156, P275; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Comhair SAA, 2005, AM J PATHOL, V166, P663, DOI 10.1016/S0002-9440(10)62288-2; Comhair SAA, 2001, FASEB J, V15, P70, DOI 10.1096/fj.00-0085com; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; COX G, 1991, AM J RESP CELL MOL, V4, P525, DOI 10.1165/ajrcmb/4.6.525; Darveau ME, 2008, J ALLERGY CLIN IMMUN, V121, P692, DOI 10.1016/j.jaci.2007.11.023; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI [10.1139/Y08-004, 10.1139/y08-004]; Dorscheid DR, 2006, AM J PHYSIOL-LUNG C, V291, pL794, DOI 10.1152/ajplung.00322.2005; Dorscheid DR, 2001, AM J RESP CRIT CARE, V164, P1939, DOI 10.1164/ajrccm.164.10.2103013; EHRCHEN JM, 2009, J LEUKOC BI IN PRESS; Evans SM, 2002, AM J RESP CELL MOL, V27, P446, DOI 10.1165/rcmb.4776; Farrell RJ, 2003, NEW ENGL J MED, V349, P395, DOI 10.1056/NEJMe030075; FASANO A, 1991, P NATL ACAD SCI USA, V88, P5242, DOI 10.1073/pnas.88.12.5242; Fasano A, 2008, AM J PATHOL, V173, P1243, DOI 10.2353/ajpath.2008.080192; Fitzpatrick AM, 2009, J ALLERGY CLIN IMMUN, V123, P146, DOI 10.1016/j.jaci.2008.10.047; Garofalo R, 1996, J IMMUNOL, V157, P2506; Garrod D, 2008, BBA-BIOMEMBRANES, V1778, P572, DOI 10.1016/j.bbamem.2007.07.014; Ghosh S, 2006, J IMMUNOL, V176, P5587, DOI 10.4049/jimmunol.176.9.5587; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Gonzalez-Mariscal L, 2008, BBA-BIOMEMBRANES, V1778, P729, DOI 10.1016/j.bbamem.2007.08.018; Gray RD, 2008, AM J RESP CRIT CARE, V178, P444, DOI 10.1164/rccm.200703-409OC; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Hamilton LM, 2005, EUR RESPIR J, V25, P978, DOI 10.1183/09031936.05.00098604; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; HAYASHI T, 1988, J PHARMACOBIO-DYNAM, V11, P146, DOI 10.1248/bpb1978.11.146; Heinecke L, 2008, J ALLERGY CLIN IMMUN, V121, P1155, DOI 10.1016/j.jaci.2008.02.009; Herr C, 2007, EXPERT OPIN BIOL TH, V7, P1449, DOI 10.1517/14712598.7.9.1449; Heyman M, 2005, EUR J GASTROEN HEPAT, V17, P1279, DOI 10.1097/00042737-200512000-00003; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Holgate ST, 2007, TRENDS IMMUNOL, V28, P248, DOI 10.1016/j.it.2007.04.007; Holgate ST, 2006, J ALLERGY CLIN IMMUN, V118, P587, DOI 10.1016/j.jaci.2006.06.023; Hsieh FH, 2005, P NATL ACAD SCI USA, V102, P14380, DOI 10.1073/pnas.0503948102; Ikenouchi J, 2008, MOL BIOL CELL, V19, P4687, DOI 10.1091/mbc.E08-05-0530; Jeon SK, 2008, J INVEST DERMATOL, V128, P1930, DOI 10.1038/jid.2008.13; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kato Y, 2002, CLIN EXP ALLERGY, V32, P889, DOI 10.1046/j.1365-2222.2002.01362.x; Kelly FJ, 2005, P NUTR SOC, V64, P510, DOI 10.1079/PNS2005457; Kelly FK, 1999, LANCET, V354, P482, DOI 10.1016/S0140-6736(99)01812-7; Kim J, 2005, AM J RESP CELL MOL, V33, P280, DOI 10.1165/rcmb.2004-0129OC; Kirkham S, 2002, BIOCHEM J, V361, P537, DOI 10.1042/0264-6021:3610537; Krause G, 2008, BBA-BIOMEMBRANES, V1778, P631, DOI 10.1016/j.bbamem.2007.10.018; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; Lammers KM, 2008, GASTROENTEROLOGY, V135, P194, DOI 10.1053/j.gastro.2008.03.023; Leung TF, 2006, GENES IMMUN, V7, P59, DOI 10.1038/sj.gene.6364279; Li HL, 2006, AM J PHYSIOL-CELL PH, V291, pC966, DOI 10.1152/ajpcell.00571.2005; Ma L, 2000, AM J PHYSIOL-GASTR L, V278, pG10, DOI 10.1152/ajpgi.2000.278.1.G10; Malerba Giovanni, 2005, Journal of Applied Genetics, V46, P93; Martinez FD, 2002, PEDIATRICS, V109, P362; McGrath JA, 2008, TRENDS MOL MED, V14, P20, DOI 10.1016/j.molmed.2007.10.006; Mizoguchi E, 2006, GASTROENTEROLOGY, V130, P398, DOI 10.1053/j.gastro.2005.12.007; MONTEFORT S, 1993, RESP MED, V87, P9, DOI 10.1016/0954-6111(93)90118-J; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Nelson WJ, 2008, BIOCHEM SOC T, V36, P149, DOI 10.1042/BST0360149; Nicholas B, 2006, PROTEOMICS, V6, P4390, DOI 10.1002/pmic.200600011; Nuttall SL, 2003, J CLIN PHARM THER, V28, P251, DOI 10.1046/j.1365-2710.2003.00492.x; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Olivera DS, 2007, INHAL TOXICOL, V19, P13, DOI 10.1080/08958370600985768; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517, DOI 10.1164/ajrccm.163.2.2004039; Otsuka H, 1998, J ALLERGY CLIN IMMUN, V102, P757, DOI 10.1016/S0091-6749(98)70015-6; Oxford GE, 2000, J DIABETES COMPLICAT, V14, P140, DOI 10.1016/S1056-8727(00)00073-8; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Papi A, 2000, J INFECT DIS, V181, P1780, DOI 10.1086/315463; Paterson BM, 2007, ALIMENT PHARM THER, V26, P757, DOI 10.1111/j.1365-2036.2007.03413.x; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Pichavant M, 2006, J IMMUNOL, V177, P5912, DOI 10.4049/jimmunol.177.9.5912; Polosa R, 1999, AM J RESP CELL MOL, V20, P914, DOI 10.1165/ajrcmb.20.5.3308; Pompen M, 2000, CLIN EXP ALLERGY, V30, P1104; Prasad S, 2005, LAB INVEST, V85, P1139, DOI 10.1038/labinvest.3700316; Proud D, 2006, CURR ALLERGY ASTHM R, V6, P81, DOI 10.1007/s11882-006-0015-6; Puddicombe SM, 2003, AM J RESP CELL MOL, V28, P61, DOI 10.1165/rcmb.4715; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Puddicombe SM, 2006, P AM THORAC SOC, V3, pA424; Rao RK, 2002, BIOCHEM J, V368, P471, DOI 10.1042/BJ20011804; Rate A, 2009, J IMMUNOL, V182, P72, DOI 10.4049/jimmunol.182.1.72; Regamey N, 2007, AM J RESP CELL MOL, V37, P75, DOI 10.1165/rcmb.2006-0235OC; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Richer SL, 2008, AM J RHINOL, V22, P228, DOI 10.2500/ajr.2008.22.3162; Riedl MA, 2008, CURR OPIN ALLERGY CL, V8, P49, DOI 10.1097/ACI.0b013e3282f3d913; Sackesen C, 2008, J ALLERGY CLIN IMMUN, V122, P78, DOI 10.1016/j.jaci.2008.03.035; Sajjan U, 2008, AM J RESP CRIT CARE, V178, P1271, DOI 10.1164/rccm.200801-136OC; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Samarin S, 2009, FRONT BIOSCI-LANDMRK, V14, P1129, DOI 10.2741/3298; Sanmugalingam D, 2000, J LEUKOCYTE BIOL, V68, P38; Schade J, 2008, J HISTOCHEM CYTOCHEM, V56, P147, DOI 10.1369/jhc.7A7319.2007; Sears MR, 2008, J ALLERGY CLIN IMMUN, V122, P662, DOI 10.1016/j.jaci.2008.08.003; Sekiya T, 2000, J IMMUNOL, V165, P2205, DOI 10.4049/jimmunol.165.4.2205; SERTL K, 1986, J EXP MED, V163, P436, DOI 10.1084/jem.163.2.436; Shaheen SO, 2002, THORAX, V57, P958, DOI 10.1136/thorax.57.11.958; Shin CE, 2000, J PEDIATR SURG, V35, P173, DOI 10.1016/S0022-3468(00)90005-8; Simon HU, 2003, ALLERGY, V58, P1250, DOI 10.1046/j.1398-9995.2003.00424.x; Sinha A, 2003, NEW ENGL J MED, V349, P350, DOI 10.1056/NEJMoa013136; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; SOLOPERTO M, 1991, AM J PHYSIOL, V260, pL530, DOI 10.1152/ajplung.1991.260.6.L530; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; SOUSA AR, 1994, AM J RESP CELL MOL, V10, P142, DOI 10.1165/ajrcmb.10.2.8110469; STADDON JM, 1995, J CELL SCI, V108, P609; Stanciu LA, 2006, J INFECT DIS, V193, P404, DOI 10.1086/499275; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; Su LP, 2009, GASTROENTEROLOGY, V136, P551, DOI 10.1053/j.gastro.2008.10.081; SWEETENHAM JW, 1990, BRIT J CANCER, V62, P459, DOI 10.1038/bjc.1990.318; Tai HY, 2006, ALLERGY, V61, P382, DOI 10.1111/j.1398-9995.2005.00958.x; Takafuji S, 1996, J IMMUNOL, V156, P3980; Takano K, 2005, J HISTOCHEM CYTOCHEM, V53, P611, DOI 10.1369/jhc.4A6539.2005; Thornton DJ, 2008, ANNU REV PHYSIOL, V70, P459, DOI 10.1146/annurev.physiol.70.113006.100702; Tillie-Leblond I, 2007, EUR RESPIR J, V30, P31, DOI 10.1183/09031936.00011606; Toback FG, 2003, AM J PHYSIOL-GASTR L, V285, pG344, DOI 10.1152/ajpgi.00455.2002; Trautmann A, 2002, J ALLERGY CLIN IMMUN, V109, P329, DOI 10.1067/mai.2002.121460; TROISI RJ, 1995, AM J RESP CRIT CARE, V151, P1401, DOI 10.1164/ajrccm.151.5.7735592; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Tsukita S, 2008, ONCOGENE, V27, P6930, DOI 10.1038/onc.2008.344; Turato G, 2008, AM J RESP CRIT CARE, V178, P476, DOI 10.1164/rccm.200712-1818OC; Uddin M, 2008, EUR RESPIR J, V31, P714, DOI 10.1183/09031936.00144307; van der Schans CP, 2007, RESP CARE, V52, P1150; Van der Sluis M, 2006, GASTROENTEROLOGY, V131, P117, DOI 10.1053/j.gastro.2006.04.020; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; Vikstrom E, 2009, EXP CELL RES, V315, P313, DOI 10.1016/j.yexcr.2008.10.044; Vliagoftis Harissios, 2008, Inflammation & Allergy Drug Targets, V7, P288, DOI 10.2174/187152808786848379; Wadsworth SJ, 2006, J CLIN IMMUNOL, V26, P376, DOI 10.1007/s10875-006-9029-z; Walsh-Reitz MM, 2005, AM J PHYSIOL-GASTR L, V289, pG163, DOI 10.1152/ajpgi.00013.2005; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wang WL, 2000, J CELL SCI, V113, P4435; WANG YH, 2009, CLIN EXP AL IN PRESS; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2007, J ALLERGY CLIN IMMUN, V120, P586, DOI 10.1016/j.jaci.2007.04.046; Willart MAM, 2009, CLIN EXP ALLERGY, V39, P12, DOI 10.1111/j.1365-2222.2008.03118.x; Xu YL, 2004, NEURON, V43, P487, DOI 10.1016/j.neuron.2004.08.005; Yang IA, 2008, THORAX, V63, P555, DOI 10.1136/thx.2007.079426; Yang W, 2006, ALLERGY, V61, P569, DOI 10.1111/j.1398-9995.2006.01041.x; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183	154	84	90	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					23	34		10.1016/j.jaci.2009.05.037	http://dx.doi.org/10.1016/j.jaci.2009.05.037			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19560576				2022-12-18	WOS:000267909700002
J	Mullins, RJ; Dear, KBG; Tang, MLK				Mullins, Raymond James; Dear, Keith B. G.; Tang, Mimi L. K.			Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; peanut allergy; anaphylaxis; epidemiology; time trends	TREE NUT ALLERGY; FOOD ALLERGY; PREVENTION; PREVALENCE; TRENDS; RISK	Background: It is unknown whether clinical features of peanut allergy have changed in the past decade alongside possible increasing prevalence. Objective: The clinical features of peanut allergy over 13 years were examined with regard to age of onset, sex distribution, severity, and incidence. Methods: Retrospective study of 778 patients (age 4 months to 66 years) diagnosed with peanut allergy at a community-based specialist allergy practice in the Australian Capital Territory. Results: Most peanut allergy (90%) developed by age 72 months. In this group, there were no significant time-dependent changes in sex distribution, reaction severity, or age of first reaction (mean/median 12/15.1 months). Later age of first reaction was associated with an increased risk of anaphylaxis in the overall population (P < .01) and in those with onset by 72 months, in whom, risk increased by 22.7% (CI, 3.3-45.7) for every additional year of age (P < .02). Asthma was associated with increased risk of anaphylaxis (odds ratio, 1.9; P < .001). In children with peanut allergy, 22% experienced anaphylaxis with first exposure and 30% with anaphylaxis had preceding milder reactions. The estimated minimum incidences of peanut allergy and sensitization by age 72 months for children born in the Australian Capital Territory in 2004 were 1.15% and 1.53%, respectively (by end December 2007), compared with 0.73% and 0.84% for those born in 2001. Conclusion: Although most characteristics of peanut allergy have changed little over the period of the last 13 years (Onset age, sex, comorbidity, severity), later onset was associated with greater risk of anaphylaxis. Our data are consistent with a rise in incidence. (J Allergy Clin Immunol 2009;123:689-93.)	[Mullins, Raymond James] John James Med Ctr, Deakin, ACT 2600, Australia; [Mullins, Raymond James] Australian Natl Univ, Sch Med, Canberra, ACT, Australia; [Dear, Keith B. G.] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia; [Tang, Mimi L. K.] Royal Childrens Hosp, Melbourne, Vic, Australia; [Tang, Mimi L. K.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Tang, Mimi L. K.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia	Australian National University; Australian National University; Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; University of Melbourne	Mullins, RJ (corresponding author), John James Med Ctr, Suite 1,175 Strickland Crescent, Deakin, ACT 2600, Australia.	rmullins@allergycapital.com.au	Mullins, Raymond James/H-8013-2019; Tang, Mimi/ABD-8350-2020	Mullins, Raymond James/0000-0002-0267-1591; Tang, Mimi/0000-0002-3839-5293; Dear, Keith/0000-0002-0788-7404				*ACT DEP HLTH, 2005, INTRO FOODS POT FOOD; ALLEN CW, 2008, PEDIAT ALLERGY  0915; *AUSTR BUR STAT, CENS POP HOUS 2006; *AUSTR BUR STAT, 2007, 32010 AUSTR BUR STAT; Australasian Society for Clinical Immunology and Allergy, 2007, EC IMP ALL DIS AUSTR; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Clark AT, 2005, PEDIATR ALLERGY IMMU, V16, P507, DOI 10.1111/j.1399-3038.2005.00310.x; Fiocchi A, 2006, ANN ALLERG ASTHMA IM, V97, P10, DOI 10.1016/S1081-1206(10)61364-6; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hamelmann E, 2008, CLIN EXP ALLERGY, V38, P233, DOI 10.1111/j.1365-2222.2007.02901.x; Hill DJ, 1997, ENVIRON TOXICOL PHAR, V4, P101, DOI 10.1016/S1382-6689(97)10049-7; Koplin J, 2008, J ALLERGY CLIN IMMUN, V121, P1455, DOI 10.1016/j.jaci.2008.03.017; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; LOBLAY R, 2006, INT MED J S6, V36, pA209; Mullins RJ, 2007, MED J AUSTRALIA, V186, P618, DOI 10.5694/j.1326-5377.2007.tb01077.x; *PEAN CO AUSTR LTD, 2008, RIGHTS ISS PROSP; Poulos LM, 2007, J ALLERGY CLIN IMMUN, V120, P878, DOI 10.1016/j.jaci.2007.07.040; Prescott SL, 2008, PEDIAT ALLERG IMM-UK, V19, P375, DOI 10.1111/j.1399-3038.2008.00718.x; Sampson HA, 1996, BRIT MED J, V312, P1050; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P717, DOI 10.1016/j.jaci.2007.07.027; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Todd DG, 2007, PEDIATRICS, V120, P1304, DOI 10.1542/peds.2007-0350; *UK DEP HLTH, 1998, WORK GROUP PEAN ALL; Wainstein BK, 2007, PEDIAT ALLERG IMM-UK, V18, P231, DOI 10.1111/j.1399-3038.2007.00517.x	30	84	85	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					689	693		10.1016/j.jaci.2008.12.1116	http://dx.doi.org/10.1016/j.jaci.2008.12.1116			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19217654	Bronze			2022-12-18	WOS:000264731200032
J	Yang, CWO; Hung, SI; Juo, CG; Lin, YP; Fang, WH; Lu, IH; Chen, ST; Chen, YT				Yang, Chih-Wen Ou; Hung, Shuen-Iu; Juo, Chiun-Gung; Lin, Ya-Ping; Fang, Wu-Hsiang; Lu, I.-Hsuan; Chen, Shui-Tein; Chen, Yuan-Tsong			HLA-B*1502-bound peptides: Implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adverse drug reactions; carbamazepine; drug antigen; epitope peptide; HLA-B; Stevens-Johnson syndrome	TOXIC EPIDERMAL NECROLYSIS; MICROSOMAL EPOXIDE HYDROLASE; CYTOTOXIC T-CELLS; HEAVY-CHAIN; IN-VIVO; HYPERSENSITIVITY; MOLECULES; POLYMORPHISM; ANTIGEN; BINDING	Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) can involve MHC-restricted presentation of a drug or its metabolites for T-cell activation. HLA-B*1502 tightly associated with carbamazepine (CBZ) induced these conditions in a Han Chinese population. Objective: We sought to identify HLA-B*1502-bound peptides that might be involved in CBZ-induced SJS/TEN. Methods: Soluble HLA-B*1502 was used to identify bound peptides in the presence and absence of CBZ by using liquid chromatography-tandem mass spectrometry. Peptide-binding assays were performed to detect the specific interaction between the HLA molecule and the identified peptides. Mass spectra were compared to detect CBZ-modified peptides. Results: We identified more than 145 peptides bound to HLA. B*1502. In 13 of 15 peptides examined, we functionally confirmed their specificity with binding assays. Preferable uses of these peptides at the anchoring residues P2 and P9 were similar to those observed in other HLA-B alleles in the Han Chinese population. However, the preferable use of serine residues at the nonanchoring position (P) 5, P6, P7, and P8 appeared to be unique for the B*1502 peptides. No specific CBZ-modified peptides were detected when we compared the mass spectra of peptides detected in the presence or absence of the drug. Conclusion: Noncovalent interaction between a drug and an HLA complex might contribute to cytotoxic T cell-mediated cell death in patients with SJS/TEN. Clinical implications: An understanding of pharmacologic interaction of drugs with an HLA complex might lead to safer drugs that avoid SJS/TEN.	Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 112, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; Acad Sinica, Inst Biol Chem, Taipei, Taiwan; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; Duke University	Hung, SI (corresponding author), Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 112, Taiwan.	sihung@ym.edu.tw; chen0010@ibms.sinica.edu.tw	Hung, Shuen-Iu/ABB-2139-2021	Hung, Shuen-Iu/0000-0001-6531-5538				Alfirevic A, 2006, PHARMACOGENOMICS, V7, P813, DOI 10.2217/14622416.7.6.813; Arnett KL, 1998, IMMUNOGENETICS, V48, P56, DOI 10.1007/s002510050400; BARBER LD, 1995, CURR BIOL, V5, P179, DOI 10.1016/S0960-9822(95)00039-X; Barber LD, 1996, J EXP MED, V184, P735, DOI 10.1084/jem.184.2.735; Barber LD, 1997, J IMMUNOL, V158, P1660; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; DAVIS CD, 1995, BIOCHEM PHARMACOL, V50, P1361, DOI 10.1016/0006-2952(95)02008-X; DOMENA JD, 1993, TISSUE ANTIGENS, V42, P509; FALK K, 1995, IMMUNOGENETICS, V41, P162, DOI 10.1007/BF00182332; FALK K, 1993, IMMUNOGENETICS, V38, P161, DOI 10.1007/BF00190906; FALK K, 1995, IMMUNOGENETICS, V41, P165, DOI 10.1007/BF00182333; FLEISCHHAUER K, 1994, TISSUE ANTIGENS, V44, P311, DOI 10.1111/j.1399-0039.1994.tb02401.x; Garcia F, 1997, TISSUE ANTIGENS, V49, P580, DOI 10.1111/j.1399-0039.1997.tb02805.x; Garcia F, 1997, TISSUE ANTIGENS, V49, P215, DOI 10.1111/j.1399-0039.1997.tb02741.x; Hickman HD, 2004, J IMMUNOL, V172, P2944, DOI 10.4049/jimmunol.172.5.2944; Hickman HD, 2000, HUM IMMUNOL, V61, P1339, DOI 10.1016/S0198-8859(00)00216-0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; Hsu JL, 2003, ANAL CHEM, V75, P6843, DOI 10.1021/ac0348625; Hung Shuen-Iu, 2005, Per Med, V2, P225, DOI 10.2217/17410541.2.3.225; Hung SL, 2006, PHARMACOGENET GENOM, V16, P297, DOI 10.1097/01.fpc.0000199500.46842.4a; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Kehren J, 1999, J EXP MED, V189, P779, DOI 10.1084/jem.189.5.779; Krovat BC, 2000, TOXICOL SCI, V55, P352, DOI 10.1093/toxsci/55.2.352; Lonjou C, 2006, PHARMACOGENOMICS J, V6, P265, DOI 10.1038/sj.tpj.6500356; Martin AM, 2004, P NATL ACAD SCI USA, V101, P4180, DOI 10.1073/pnas.0307067101; MartinezNaves E, 1997, TISSUE ANTIGENS, V50, P258, DOI 10.1111/j.1399-0039.1997.tb02869.x; Naisbitt DJ, 2003, J ALLERGY CLIN IMMUN, V111, P1393, DOI 10.1067/mai.2003.1507; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Nassif A, 2002, J INVEST DERMATOL, V118, P728, DOI 10.1046/j.1523-1747.2002.01622.x; Nilges K, 2003, J VIROL, V77, P5464, DOI 10.1128/JVI.77.9.5464-5474.2003; Paul C, 1996, BRIT J DERMATOL, V134, P710, DOI 10.1111/j.1365-2133.1996.tb06976.x; Pichler WJ, 2002, CURR OPIN ALLERGY CL, V2, P301, DOI 10.1097/00130832-200208000-00003; Prilliman K, 1997, IMMUNOGENETICS, V45, P379, DOI 10.1007/s002510050219; Prilliman KR, 1999, TISSUE ANTIGENS, V54, P450, DOI 10.1034/j.1399-0039.1999.540502.x; Prilliman KR, 1999, IMMUNOGENETICS, V49, P144, DOI 10.1007/s002510050474; Roujeau JC, 2005, TOXICOLOGY, V209, P123, DOI 10.1016/j.tox.2004.12.022; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Schnyder B, 1997, J CLIN INVEST, V100, P136, DOI 10.1172/JCI119505; Smith KD, 1996, IMMUNOGENETICS, V43, P27; Weltzien HU, 1996, TOXICOLOGY, V107, P141, DOI 10.1016/0300-483X(95)03253-C; Wu Y, 2007, J ALLERGY CLIN IMMUN, V119, P973, DOI 10.1016/j.jaci.2006.12.617; Wu Y, 2006, J ALLERGY CLIN IMMUN, V118, P233, DOI 10.1016/j.jaci.2006.03.005; Yague J, 2001, J BIOL CHEM, V276, P43699, DOI 10.1074/jbc.M105981200; DATABASE MHC LIGANDS; ALLE FREQUENCIES WOR	46	84	97	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					870	877		10.1016/j.jaci.2007.06.017	http://dx.doi.org/10.1016/j.jaci.2007.06.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17697703				2022-12-18	WOS:000250157700022
J	Maric, I; Robyn, J; Metcalfe, DD; Fay, MP; Carter, M; Wilson, T; Fu, WM; Stoddard, J; Scott, L; Hartsell, M; Kirshenbaum, A; Akin, C; Nutman, TB; Noel, P; Klion, AD				Maric, Irina; Robyn, Jamie; Metcalfe, Dean D.; Fay, Michael P.; Carter, Melody; Wilson, Todd; Fu, Weiming; Stoddard, Jennifer; Scott, Linda; Hartsell, Marilyn; Kirshenbaum, Arnold; Akin, Cem; Nutman, Thomas B.; Noel, Pierre; Klion, Amy D.			KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						systemic mastocytosis; hypereosinophilic syndrome; HES; mast cell disease; eosinophilia; FIP1L1/PDGFRA; imatinib; KIT D816V mutation	MAST-CELL DISEASE; IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; CHRONIC MYELOID DISORDERS; ELEVATED SERUM TRYPTASE; C-KIT; IMATINIB MESYLATE; MYELOPROLIFERATIVE VARIANT; FIP1L1-PDGFRA FUSION; WILD-TYPE; INHIBITOR	Background: The broad and overlapping clinical manifestations of D816V KIT-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia (CEL), coupled with the increase in activated eosinophils and mast cells seen in both disorders, have led to confusion in the nomenclature. It is of paramount importance, however, to distinguish between these 2 groups of patients because of differences in clinical sequelae, prognoses, and selection of treatment. Objective: We thus sought to identify clinical and laboratory features that could be used to distinguish these 2 diagnoses. Methods: We compared 12 patients with D816V-positive systemic mastocytosis with eosinophilia with 17 patients with FIP1L1/PDGFRA-positive CEL. Distinguishing features were used to create a risk factor scoring system. Results: This system correctly classified 16 of 17 FIP1L1/ PDGFRA-positive patients with CEL and all 12 patients with systemic mastocytosis with eosinophilia. Thirty-four FIP1L1/ PDGFRA-positive patients described in the literature were also classified using this system, and although a complete set of data was not available for any of the historical patients, 21 were correctly classified. Conclusion: These results reinforce the hypothesis that the FIP1L1/PDGFRA gene fusion and D816V-KIT mutation cause distinct clinical syndromes. Clinical implications: This novel diagnostic approach should prove helpful in clinical practice in the evaluation of patients with increased mast cells and peripheral eosinophilia.	NIAID, Lab Allerg Dis, Bethesda, MD 20892 USA; NIAID, Biostat Res Branch, Bethesda, MD 20892 USA; NIAID, Parasit Dis Lab, Bethesda, MD 20892 USA; Univ Michigan, Sch Med, Div Allergy & Immunol, Ann Arbor, MI 48109 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Michigan System; University of Michigan	Maric, I (corresponding author), NIH, Hematol Sect, Dept Lab Med, Ctr Clin, 10 Ctr Dr,Bldg 10-Room 2C390, Bethesda, MD 20892 USA.	marici@mail.nih.gov	Fay, Michael P/A-2974-2008	Fay, Michael P/0000-0002-8643-9625; Akin, Cem/0000-0001-6301-4520; Klion, Amy/0000-0002-4986-5326	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000805, Z01AI000805, Z01AI000439, Z01AI000249, ZIAAI000439, ZIAAI000249] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL080005, ZIACL080004, Z01CL080004, ZIACL080005] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER; Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Akin C, 2004, ANNU REV MED, V55, P419, DOI 10.1146/annurev.med.55.091902.103822; Akin C, 2000, EXP HEMATOL, V28, P140, DOI 10.1016/S0301-472X(99)00145-9; Akin C, 2003, EXP HEMATOL, V31, P686, DOI 10.1016/S0301-472X(03)00112-7; Akin C, 2006, J MOL DIAGN, V8, P412, DOI 10.2353/jmoldx.2006.060022; Ayoub WS, 2005, J CLIN GASTROENTEROL, V39, P75; Bain BJ, 2004, AM J HEMATOL, V77, P82, DOI 10.1002/ajh.20088; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Cortes J, 2003, BLOOD, V101, P4714, DOI 10.1182/blood-2003-01-0081; EFRATI P, 1957, BLOOD, V12, P869, DOI 10.1182/blood.V12.10.869.869; Fumo G, 2004, BLOOD, V103, P1078, DOI 10.1182/blood-2003-07-2477; Gilliland G, 2004, HEMATOL J, V5, pS133, DOI 10.1038/sj.thj.6200439; Gleich GJ, 2002, LANCET, V359, P1577, DOI 10.1016/S0140-6736(02)08505-7; Gotlib J, 2005, BLOOD, V106, P2865, DOI 10.1182/blood-2005-04-1568; Growney JD, 2005, BLOOD, V106, P721, DOI 10.1182/blood-2004-12-4617; Kerkela R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446; Klion AD, 2004, BLOOD, V103, P473, DOI 10.1182/blood-2003-08-2798; Klion AD, 2003, BLOOD, V101, P4660, DOI 10.1182/blood-2003-01-0006; LAWRENCE JB, 1991, AM J MED, V91, P612, DOI 10.1016/0002-9343(91)90214-I; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; Pardanani A, 2004, BLOOD, V104, P3038, DOI 10.1182/blood-2004-03-0787; Pardanani A, 2003, LEUKEMIA RES, V27, P739, DOI 10.1016/S0145-2126(02)00303-X; Pardanani A, 2003, BLOOD, V102, P3093, DOI 10.1182/blood-2003-05-1627; Pardanani A, 2004, LEUKEMIA RES, V28, P127, DOI 10.1016/S0145-2126(03)00185-1; Pardanani A, 2003, LEUKEMIA RES, V27, P883, DOI 10.1016/S0145-2126(03)00065-1; Quintas-Cardama A, 2004, CANCER-AM CANCER SOC, V100, P2592, DOI 10.1002/cncr.20285; Robyn J, 2006, BRIT J HAEMATOL, V132, P286, DOI 10.1111/j.1365-2141.2005.05863.x; Roche-Lestienne C, 2005, LEUKEMIA, V19, P792, DOI 10.1038/sj.leu.2403722; Shah NP, 2004, BLOOD, V104, p228A, DOI 10.1182/blood.V104.11.797.797; Tefferi A, 2003, BLOOD, V102, P3073, DOI 10.1182/blood-2003-07-2274; Tefferi A, 2001, NEW ENGL J MED, V344, P307, DOI 10.1056/NEJM200101253440415; Tefferi A, 2006, BEST PRACT RES CL HA, V19, P365, DOI 10.1016/j.beha.2005.07.001; TRAVIS WD, 1988, MEDICINE, V67, P345, DOI 10.1097/00005792-198811000-00001; Valent P, 2001, WHO CLASSIFICATION T, P291; Vandenberghe P, 2004, LEUKEMIA, V18, P734, DOI 10.1038/sj.leu.2403313	34	84	89	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					680	687		10.1016/j.jaci.2007.05.024	http://dx.doi.org/10.1016/j.jaci.2007.05.024			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17628645				2022-12-18	WOS:000249505400030
J	Taylor, A; Akdis, M; Joss, A; Akkoc, T; Wenig, R; Colonna, M; Daigle, I; Flory, E; Blaser, K; Akdis, CA				Taylor, Alison; Akdis, Muebeccel; Joss, Andrea; Akkoc, Tunc; Wenig, Renate; Colonna, Marco; Daigle, Isabelle; Flory, Egbert; Blaser, Kurt; Akdis, Cezmi A.			IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-10; T cell; suppression; costimulation; anergy; SHP-1; phosphorylation; tolerance; inhibition	TYROSINE-PHOSPHATASE SHP-1; PHOSPHATIDYLINOSITOL 3-KINASE; IMMUNE-RESPONSES; REGULATORY CELLS; ACTIVATION; PROTEIN; BINDING; PHOSPHORYLATION; KINASE; MOTIF	Background: Specific T-cell activation requires T-cell receptor stimulation and the generation of costimulatory signals. Major costimulatory signals are delivered to T cells by the interaction of CD28 and inducible costimulator (ICOS). Objective: To investigate the molecular pathways involved in direct T-cell suppression by IL-10. Methods: T-cell proliferation analysis, immunoprecipitations, and Western blots were performed after T-cell receptor and CD28 and ICOS stimulations in the absence or presence of IL-10. Dominant-negative src homology 2 domain-containing protein tyrosine phosphatase I (SHP-1) overexpression, small inhibitory RNA, and SHP-1-deficient and IL-10-deficient mice were used. Results: IL-10 receptor-associated tyrosine kinase Tyk-2 acts as a constitutive reservoir for SHP-1 in resting T cells, and then tyrosine phosphorylates SHP-1 on IL-10 binding. SHP-1 rapidly binds to CD28 and ICOS costimulatory receptors and dephosphorylates them within minutes. In consequence, the binding of phosphatidylinositol 3-kinase to either costimulatory receptor no longer occurs, and downstream signaling is inhibited. Accordingly, spleen cells from SHP-1-deficient mice showed increased proliferation with CD28 and ICOS stimulation in comparison with wild-type mice, which was not suppressed by IL-10. Generation of dominant-negative SHP-1-overexpressing T cells or silencing of the SHP-1 gene by small inhibitory RNA both altered SHP-1 functions and abolished the T-cell suppressive effect of IL-10. Conclusion: The rapid inhibition of the CD28 or ICOS costimulatory pathways by SHP-1 represents a novel mechanism for direct T-cell suppression by IL-10. Clinical implications: Molecular mechanisms of direct T-cell suppression by IL-10 may provide a novel target for therapy of allergy/asthma and autoimmune disease.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England; Marmara Univ, Dept Pediat Allergol, Istanbul, Turkey; Paul Ehrlich Inst, Langen, Germany; Washington Univ, Sch Med, St Louis, MO 63130 USA	Swiss Institute of Allergy & Asthma Research; University of East Anglia; Marmara University; Paul Ehrlich Institute; Washington University (WUSTL)	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	akdisac@siaf.unizh.ch	Akdis, Cezmi/AAV-4844-2020; Taylor, Alison/ABE-5809-2021	Akdis, Cezmi/0000-0001-8020-019X; Taylor, Alison/0000-0003-2295-2611; Colonna, Marco/0000-0001-5222-4987				Akdis CA, 2000, FASEB J, V14, P1666; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Baxter AG, 2002, NAT REV IMMUNOL, V2, P439, DOI 10.1038/nri823; BOUSSIOTIS VA, 1994, CURR OPIN IMMUNOL, V6, P797, DOI 10.1016/0952-7915(94)90087-6; Brockdorff J, 1999, EUR J IMMUNOL, V29, P2539, DOI 10.1002/(SICI)1521-4141(199908)29:08<2539::AID-IMMU2539>3.0.CO;2-M; Burshtyn DN, 1997, J BIOL CHEM, V272, P13066, DOI 10.1074/jbc.272.20.13066; Campbell KS, 1999, INT J BIOCHEM CELL B, V31, P631, DOI 10.1016/S1357-2725(99)00022-9; Cong YZ, 2002, J IMMUNOL, V169, P6112, DOI 10.4049/jimmunol.169.11.6112; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DUBEY C, 1995, J IMMUNOL, V155, P45; Egen JG, 2002, NAT IMMUNOL, V3, P611, DOI 10.1038/ni0702-611; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; Gavrieli M, 2003, BIOCHEM BIOPH RES CO, V312, P1236, DOI 10.1016/j.bbrc.2003.11.070; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Jin YJ, 1999, J BIOL CHEM, V274, P28301, DOI 10.1074/jbc.274.40.28301; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Miller MJ, 2002, SCIENCE, V296, P1869, DOI 10.1126/science.1070051; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; Riley JL, 2001, J IMMUNOL, V166, P4943, DOI 10.4049/jimmunol.166.8.4943; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Stefanova I, 2003, NAT IMMUNOL, V4, P248, DOI 10.1038/ni895; Steidl S, 2002, VIROLOGY, V300, P205, DOI 10.1006/viro.2001.1565; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Wang LL, 1999, J IMMUNOL, V162, P1318; Wehinger J, 1996, FEBS LETT, V394, P365, DOI 10.1016/0014-5793(96)00990-8; Yang J, 2003, J BIOL CHEM, V278, P6516, DOI 10.1074/jbc.M210430200; Yang J, 2000, J BIOL CHEM, V275, P4066, DOI 10.1074/jbc.275.6.4066; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582	33	84	89	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					76	83		10.1016/j.jaci.2007.04.004	http://dx.doi.org/10.1016/j.jaci.2007.04.004			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17531298				2022-12-18	WOS:000248066400011
J	Jaakkola, MS; Ieromnimon, A; Jaakkola, JJK				Jaakkola, MS; Ieromnimon, A; Jaakkola, JJK			Are atopy and specific IgE to mites and molds important for adult asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; asthma; IgE antibodies; case-control study; general population; molds; mites; Phadiatop	BRONCHIAL RESPONSIVENESS; ONSET ASTHMA; INDOOR DAMPNESS; ANTIBODIES; SENSITIZATION; PREVALENCE; ALLERGIES; PHADIATOP; EXPOSURE; CHILDREN	Background: Atopy is known to be important for childhood asthma, but this is to our knowledge the first study on its relation with development of asthma in adulthood. Objectives: We addressed the role of atopy, measured as total IgE and Phadiatop, and of specific IgE antibodies to mites and molds in development of adult-onset asthma. Methods: A population-based incident case-control study was conducted in the Pirkanmaa District in Southern Finland. All new clinically diagnosed cases of asthma 21-63 years of age were recruited 1997-2000 in the study district. A random sample of the source population formed the controls. A total of 485 cases and 665 controls provided a serum sample. Diagnosis of asthma was based on demonstration of reversibility in lung function investigations. Subjects with previous asthma were excluded. Phadiatop score and IgE antibodies were analyzed with the UniCAP system. Results: The adjusted odds ratio of asthma increased with total IgE and Phadiatop score in a dose-dependent pattern. IgE antibodies to house dust mite and storage mite were significantly related to an increased risk of asthma. Among molds,, increased risk of asthma was seen in relation to IgE antibodies to Aspergillus fumigatus and Cladosporium herbarum. Population attributable fraction due to sensitization to common aeroallergens was 30% (95% CI, 23-41). Conclusion: Atopy is a strong determinant of asthma in adulthood. Specific IgE antibodies to mites and some molds are significantly related to increased risk of adult-onset asthma. A considerable fraction of adult asthma could be prevented by measures to reduce atopy.	Univ Birmingham, Inst Occupat & Environm Med, Birmingham B15 2TT, W Midlands, England; Finnish Inst Occupat Hlth, Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, Environm Epidemiol Unit, FIN-00014 Helsinki, Finland	University of Birmingham; Finnish Institute of Occupational Health; University of Helsinki	Jaakkola, MS (corresponding author), Univ Birmingham, Inst Occupat & Environm Med, Birmingham B15 2TT, W Midlands, England.	M.Jaakkola@bham.ac.uk	Jaakkola, Jouni J.K./G-4314-2012	Jaakkola, Jouni/0000-0003-4168-4683; Jaakkola, Maritta S./0000-0003-1373-7784				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Barraclough R, 2002, EUR RESPIR J, V20, P826, DOI 10.1183/09031936.02.00822002; Boezen HM, 1996, AM J RESP CRIT CARE, V154, P30, DOI 10.1164/ajrccm.154.1.8680695; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; Chinn S, 1999, EUR RESPIR J, V14, P876, DOI 10.1034/j.1399-3003.1999.14d25.x; *COMM NAT ASTHM PR, 1994, ASTHM PROGR 1994 200, P16; ERIKSSON NE, 1990, ALLERGY, V45, P285, DOI 10.1111/j.1398-9995.1990.tb00497.x; Greenland S, 1998, MODERN EPIDEMIOLOGY; Holt PG, 2000, AM J RESP CRIT CARE, V161, pS172, DOI 10.1164/ajrccm.161.supplement_2.a1q4-5; JAAKKOLA JJK, 1995, AM J EPIDEMIOL, V141, P755, DOI 10.1093/oxfordjournals.aje.a117498; Jaakkola JJK, 2002, J ALLERGY CLIN IMMUN, V109, P784, DOI 10.1067/mai.2002.123870; Jaakkola MS, 1999, AM J EPIDEMIOL, V150, P1223; Jaakkola MS, 2003, AM J PUBLIC HEALTH, V93, P2055, DOI 10.2105/AJPH.93.12.2055; Jaakkola MS, 2004, ADV APPL MICROBIOL, V55, P309, DOI 10.1016/S0065-2164(04)55012-8; Jaakkola MS, 2002, ENVIRON HEALTH PERSP, V110, P543, DOI 10.1289/ehp.02110543; Jaakkola MS, 2002, CLIN EXP IMMUNOL, V129, P107, DOI 10.1046/j.1365-2249.2002.01884.x; Li DW, 2004, ADV APPL MICROBIOL, V55, P31, DOI 10.1016/S0065-2164(04)55002-5; Magnus P, 1997, BRIT MED J, V314, P1795, DOI 10.1136/bmj.314.7097.1795; MATRICARDI PM, 1990, CLIN EXP ALLERGY, V20, P151, DOI 10.1111/j.1365-2222.1990.tb02660.x; Maziak W, 2003, ALLERGY, V58, P572, DOI 10.1034/j.1398-9995.2003.00161.x; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; Norback D, 1999, INT J TUBERC LUNG D, V3, P368; Omenaas E, 1996, EUR RESPIR J, V9, P919, DOI 10.1183/09031936.96.09050919; Paganelli R, 1998, ALLERGY, V53, P763; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Robertson CF, 2004, MED J AUSTRALIA, V180, P273, DOI 10.5694/j.1326-5377.2004.tb05924.x; *SAS I INC, 2003, SAS SOFTW PACK VERS; Soriano JB, 1999, INT J EPIDEMIOL, V28, P728, DOI 10.1093/ije/28.4.728; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; VILJANEN AA, 1982, SCAND J CLIN LAB INV, V42, P5; Zock JP, 2002, J ALLERGY CLIN IMMUN, V110, P285, DOI 10.1067/mai.2002.126383	31	84	92	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					642	648		10.1016/j.jaci.2005.11.003	http://dx.doi.org/10.1016/j.jaci.2005.11.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522465				2022-12-18	WOS:000236263100021
J	Okumura, S; Sagara, H; Fukuda, T; Saito, H; Okayama, Y				Okumura, S; Sagara, H; Fukuda, T; Saito, H; Okayama, Y			Fc epsilon RI-mediated amphiregulin production by human mast cells increases mucin gene expression in epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; amphiregulin; bronchial asthma; goblet cell hyperplasia; dexamethasone	STRUCTURAL AIRWAY CHANGES; ALPHA-CONVERTING ENZYME; GOBLET CELL; ALLERGEN EXPOSURE; IN-VITRO; ASTHMA; HYPERRESPONSIVENESS; IL-13; DEXAMETHASONE; PROLIFERATION	Background: Topical application of a glucocorticoid is now widely recognized as the first-line therapy for bronchial asthma. However, glucocorticoid treatment is largely ineffective in relation to overproduction of sputum and lung tissue remodeling. Objective: The purpose of the current study was to identify human mast cell (MC) products that are related to goblet cell hyperplasia. Methods: The FcepsilonRI-mediated gene expression profile of MCs was examined by using high-density oligonucleotide probe arrays and RT-PCR. Secretion of a protein, amphiregulin, by the MCs was measured by ELISA. Upregulation of mucin genes in NCI-H292 cells by amphiregulin was evaluated by real-time RT-PCR. The expression levels of amphiregulin on histological sections obtained from 40 subjects with asthma and 6 healthy control subjects were estimated by immunohistochemical staining, and the correlation with the number of goblet cells was studied. Results: Amphiregulin was secreted by human MCs after aggregation of FcepsilonRI, and its expression was not inhibited by a glucocorticoid (dexamethasone). Amphiregulin upregulated mucin gene expression in airway epithelial cells. Upregulation of amphiregulin expression was observed in MCs of patients with asthma, but not normal control subjects. Furthermore, upregulation of amphiregulin in MCs significantly correlated with the extent of goblet cell hyperplasia in the mucosa of patients with bronchial asthma. Conclusion: These results suggest that after exposure to antigens, human MCs may induce sputum production via release of amphiregulin. Therefore, amphiregulin may be a new target molecule for treatment of overproduction of sputum in bronchial asthma.	RIKEN, Yokohama Inst, Res Ctr Allergy & Immunol, Res Unit Allergy Transcriptone,Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Natl Res Inst Child Hlth & Dev, Dept Allergy & Immunol, Tokyo, Japan; Tokyo Dent Coll, Dept Microbiol, Chiba, Japan; Dokkyo Univ, Sch Med, Dept Pulm Med & Clin Immunol, Tochigi, Japan	RIKEN; National Center for Child Health & Development - Japan; Tokyo Dental College; Dokkyo Medical University	Okayama, Y (corresponding author), RIKEN, Yokohama Inst, Res Ctr Allergy & Immunol, Res Unit Allergy Transcriptone,Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	yokayama@rcai.riken.go.jp	Okayama, Yoshimichi/AAG-4352-2021	Saito, Hirohisa/0000-0002-6630-8337				Borchers MT, 1999, AM J PHYSIOL-LUNG C, V276, pL549, DOI 10.1152/ajplung.1999.276.4.L549; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Chokki M, 2004, AM J RESP CELL MOL, V30, P470, DOI 10.1165/rcmb.2003-0199OC; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Fahy JV, 2002, CHEST, V122, p320S, DOI 10.1378/chest.122.6_suppl.320S; Falk A, 2002, J NEUROSCI RES, V69, P757, DOI 10.1002/jnr.10410; Gollub EG, 1995, BIOCHEM BIOPH RES CO, V217, P1006, DOI 10.1006/bbrc.1995.2870; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guzman K, 1996, AM J PHYSIOL-LUNG C, V271, pL1023, DOI 10.1152/ajplung.1996.271.6.L1023; Hurbin A, 2002, J BIOL CHEM, V277, P49127, DOI 10.1074/jbc.M207584200; Jenkins HA, 2003, CHEST, V124, P32, DOI 10.1378/chest.124.1.32; Kai H, 1996, AM J PHYSIOL-LUNG C, V271, pL484, DOI 10.1152/ajplung.1996.271.3.L484; Kamachi A, 2001, THORAX, V56, P19, DOI 10.1136/thorax.56.1.19; Kato M, 2003, BIOCHEM BIOPH RES CO, V301, P1109, DOI 10.1016/S0006-291X(03)00093-7; Kibe A, 2003, AM J RESP CRIT CARE, V167, P50, DOI 10.1164/rccm.2110084; Kumar RK, 2004, CLIN EXP ALLERGY, V34, P567, DOI 10.1111/j.1365-2222.2004.1917.x; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Le Gall SM, 2003, J BIOL CHEM, V278, P45255, DOI 10.1074/jbc.M307745200; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927; Makino S, 2003, J ASTHMA, V40, P701, DOI 10.1081/JAS-120023492; MAKINO S, 1984, JPN J ALLERGOL, V33, P167; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Okumura S, 2003, BLOOD, V102, P2547, DOI 10.1182/blood-2002-12-3929; Palmans E, 2000, AM J RESP CRIT CARE, V161, P627, DOI 10.1164/ajrccm.161.2.9902094; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Schuger L, 1996, DEVELOPMENT, V122, P1759; Shao MXG, 2003, P NATL ACAD SCI USA, V100, P11618, DOI 10.1073/pnas.1534804100; Shim JJ, 2001, AM J PHYSIOL-LUNG C, V280, pL134, DOI 10.1152/ajplung.2001.280.1.L134; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Taube C, 2004, J IMMUNOL, V172, P6398, DOI 10.4049/jimmunol.172.10.6398; TOKUYAMA K, 1990, AM J PHYSIOL, V259, pL108, DOI 10.1152/ajplung.1990.259.2.L108; Vanacker NJ, 2001, AM J RESP CRIT CARE, V163, P674, DOI 10.1164/ajrccm.163.3.2004160; Zhou YH, 2001, AM J RESP CELL MOL, V25, P486, DOI 10.1165/ajrcmb.25.4.4578	38	84	98	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					272	279		10.1016/j.jaci.2004.10.004	http://dx.doi.org/10.1016/j.jaci.2004.10.004			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696081				2022-12-18	WOS:000227043600010
J	Ng, B; Yang, F; Huston, DP; Yan, Y; Yang, Y; Xiong, ZY; Peterson, LE; Wang, H; Yang, XF				Ng, B; Yang, F; Huston, DP; Yan, Y; Yang, Y; Xiong, ZY; Peterson, LE; Wang, H; Yang, XF			Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						autoantigens; alternative splicing; exons; isoforms; antigen epitopes; immunogenicity; immune tolerance; autoimmune diseases	ALTERNATIVE TRANSCRIPT; MESSENGER-RNAS; SS-A/RO; GENE; PROTEIN; IDENTIFICATION; ALPHA; MECHANISM; ANTIGENS; CLONING	Background: Alternative splicing is important for increasing the complexity of the human proteome from a limited genome. Previous studies have shown that for some autoantigens, there is differential immunogenicity among alternatively spliced isoforms. Objectives: Herein, we tested the hypothesis that alternative splicing is a common feature for transcripts of autologous proteins that are autoantigens. The corollary hypothesis tested was that nonautoantigen transcripts have a lower frequency of alternative splicing. Methods: The extent of alternative splicing within 45 randomly selected self-proteins associated with autoimmune diseases was compared with 9554 randomly selected proteins in the human genome by using bioinformatics analyses. Isoform-specific regions that resulted from alternative splicing were studied for their potential to be epitopes for antibodies or T-cell receptors. Results: Alternative splicing occurred in 100% of the autoantigen transcripts. This was significantly higher than the approximately 42% rate of alternative splicing observed in the 9554 randomly selected human gene transcripts (P <.001). Within the isoform-specific regions of the autoantigens, 92% and 88% encoded MHC class I and class II-restrieted T-cell antigen epitopes, respectively, and 70% encoded antibody binding domains. Furthermore, 80% of the autoantigen transcripts underwent noncanonical alternative splicing, which is also significantly higher than the less than 1% rate in randomly selected gene transcripts (P <.001). Conclusion: These studies suggest that noncanonical alternative splicing may be an important mechanism for the generation of untolerized epitopes that may lead to autoimmunity. Furthermore, the product of a transcript that does not undergo alternative splicing is unlikely to be a target antigen in autoimmunity.	Baylor Coll Med, Sect Immunol Allergy & Rheumatol, Dept Med, Biol Inflammat Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Yang, XF (corresponding author), Baylor Coll Med, Sect Immunol Allergy & Rheumatol, Dept Med, Biol Inflammat Ctr, 1 Baylor Plaza,BCM 285,Suite 672E, Houston, TX 77030 USA.	xyang1@bcm.tmc.edu		Huston, David/0000-0002-2332-0010; Ng, Bernard/0000-0002-0126-1275; Peterson, Leif/0000-0002-1187-0883	NCI NIH HHS [P20 CA103698] Funding Source: Medline; NIAID NIH HHS [AI054514, R01 AI036936, K08 AI054514, AI36936] Funding Source: Medline; NIDDK NIH HHS [P30 DK56238, R01 DK056238] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P20CA103698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036936, K08AI054514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056238] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Brett D, 2000, FEBS LETT, V474, P83, DOI 10.1016/S0014-5793(00)01581-7; Burchert A, 2003, BLOOD, V101, P259, DOI 10.1182/blood-2002-02-0659; Casciola-Rosen L, 1999, J EXP MED, V190, P815, DOI 10.1084/jem.190.6.815; CHAN EKL, 1995, J EXP MED, V182, P983, DOI 10.1084/jem.182.4.983; CHAN EKL, 1994, GENOMICS, V23, P298, DOI 10.1006/geno.1994.1502; Cianci CD, 1999, BIOCHEMISTRY-US, V38, P15721, DOI 10.1021/bi991458k; Cui L, 1996, J BIOL CHEM, V271, P24817, DOI 10.1074/jbc.271.40.24817; Diez J, 2001, DIABETES, V50, P895, DOI 10.2337/diabetes.50.4.895; Hutchison S, 2002, J BIOL CHEM, V277, P29745, DOI 10.1074/jbc.M203633200; Jakymiw A, 2000, J BIOL CHEM, V275, P4137, DOI 10.1074/jbc.275.6.4137; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; Kaufman KM, 2001, BIOCHEM BIOPH RES CO, V285, P1206, DOI 10.1006/bbrc.2001.5302; Kelavkar U, 2002, ADV EXP MED BIOL, V507, P469; Klein L, 2000, NAT MED, V6, P56, DOI 10.1038/71540; Klein L, 2000, J MOL MED, V78, P483, DOI 10.1007/s001090000146; Ladd AN, 2002, GENOME BIOL, V3; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Machiels BM, 1996, J BIOL CHEM, V271, P9249, DOI 10.1074/jbc.271.16.9249; Mahler M, 2003, CLIN IMMUNOL, V107, P65, DOI 10.1016/S1521-6616(03)00037-8; Matera AG, 1997, GENOMICS, V41, P135, DOI 10.1006/geno.1997.4647; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Modrek B, 2001, NUCLEIC ACIDS RES, V29, P2850, DOI 10.1093/nar/29.13.2850; Nagaraju K, 2000, P NATL ACAD SCI USA, V97, P9209, DOI 10.1073/pnas.97.16.9209; Niccoli P, 1997, J BIOL CHEM, V272, P29487, DOI 10.1074/jbc.272.47.29487; Okumura M, 2002, J BIOL CHEM, V277, P6682, DOI 10.1074/jbc.M109209200; Park YS, 2000, DIABETOLOGIA, V43, P1293, DOI 10.1007/s001250051525; Renkvist N, 2001, CANCER IMMUNOL IMMUN, V50, P3, DOI 10.1007/s002620000169; Richardson RT, 2000, J BIOL CHEM, V275, P30378, DOI 10.1074/jbc.M003781200; ROTH HJ, 1987, J NEUROSCI RES, V17, P321, DOI 10.1002/jnr.490170402; Scofield RH, 1999, ARTHRITIS RHEUM, V42, P199, DOI 10.1002/1529-0131(199902)42:2<199::AID-ANR1>3.0.CO;2-1; Shlomchik MJ, 2001, NAT REV IMMUNOL, V1, P147, DOI 10.1038/35100573; Stamm S, 2002, HUM MOL GENET, V11, P2409, DOI 10.1093/hmg/11.20.2409; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TANG TK, 1993, J CELL SCI, V104, P249; TROSTER H, 1994, J EXP MED, V180, P2059, DOI 10.1084/jem.180.6.2059; Utz PJ, 2000, ARTHRITIS RES, V2, P101, DOI 10.1186/ar75; Will CL, 1999, SCIENCE, V284, P2003, DOI 10.1126/science.284.5422.2003; Wolfsberg TG, 1997, NUCLEIC ACIDS RES, V25, P1626, DOI 10.1093/nar/25.8.1626; Yan Y, 2004, J IMMUNOL, V172, P651, DOI 10.4049/jimmunol.172.1.651; Yu Q, 1997, BIOCHEMISTRY-US, V36, P5868, DOI 10.1021/bi962400y; Zinkernagel RM, 2001, SCIENCE, V293, P251, DOI 10.1126/science.1063005	42	84	89	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1463	1470		10.1016/j.jaci.2004.09.006	http://dx.doi.org/10.1016/j.jaci.2004.09.006			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577853	Green Accepted			2022-12-18	WOS:000225577400032
J	Vrieze, A; Postma, DS; Kerstjens, HAM				Vrieze, A; Postma, DS; Kerstjens, HAM			Perimenstrual asthma: A syndrome without known cause or cure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; perimenstrual asthma; severe asthma; sex differences; inflammation	ESTROGEN REPLACEMENT THERAPY; SEVERE PREMENSTRUAL ASTHMA; SEX-STEROID HORMONES; MENSTRUAL-CYCLE; ORAL-CONTRACEPTIVES; BRONCHIAL-ASTHMA; LYMPHOCYTE BETA(2)-ADRENOCEPTORS; ADENOSINE-MONOPHOSPHATE; AIRWAY RESPONSIVENESS; FEMALE ASTHMATICS	Perimenstrual worsening of asthma has been documented in 30% to 40% of asthmatic women. This increase in symptoms has been backed up by increased health care use perimenstrually, as well as by cyclic variation in peak expiratory flows. The cause of perimenstrual asthma (PMA) remains unclear. Fluctuations in hormone levels, their ratios, or both are a plausible explanation but have not been demonstrated with any consistency. Influences of sex hormones on inflammation is an area of future research, as are hormone-induced changes in smooth muscle function and beta-adrenergic receptors, prostaglandin levels, and fluid retention in the bronchial mucosa. In the light of the high prevalence of PMA, it is difficult to understand why there has been no randomized controlled trial of hormone therapy. Nevertheless, several case reports have suggested beneficial effects of estrogens, progestins, and their combination. In light of these positive case reports, well-designed, double-blind studies of sufficient sample size should now be performed to give treatment of PMA an evidence base.	Univ Groningen Hosp, Dept Pulm Med, NL-9700 RB Groningen, Netherlands	University of Groningen	Kerstjens, HAM (corresponding author), Univ Groningen Hosp, Dept Pulm Med, POB 30001, NL-9700 RB Groningen, Netherlands.		Kerstjens, Huib/N-4754-2017	Kerstjens, Huib/0000-0001-7705-7927				ABDULKARIM RW, 1970, AM J OBSTET GYNECOL, V107, P641, DOI 10.1016/S0002-9378(16)33953-9; ABDULKARIM RW, 1970, AM J OBSTET GYNECOL, V108, P1098, DOI 10.1016/0002-9378(70)90459-X; Agarwal AK, 1997, J ASTHMA, V34, P539, DOI 10.3109/02770909709055398; Agarwal SK, 1999, ANN ALLERG ASTHMA IM, V83, P222, DOI 10.1016/S1081-1206(10)62644-0; AHMED SA, 1985, AM J PATHOL, V121, P531; BAIN BJ, 1975, BRIT MED J, V2, P473, DOI 10.1136/bmj.2.5969.473; BEDWANI JR, 1975, BRIT J PHARMACOL, V53, P547, DOI 10.1111/j.1476-5381.1975.tb07393.x; BEYNON HLC, 1988, LANCET, V2, P370; BLUMENFELD Z, 1994, FERTIL STERIL, V62, P197; BODEL P, 1972, J LAB CLIN MED, V80, P373; Brannstrom M, 1999, EUR J OBSTET GYN R B, V83, P213, DOI 10.1016/S0301-2115(99)00003-2; Chandler MHH, 1997, PHARMACOTHERAPY, V17, P224; CHEN HI, 1989, AM REV RESPIR DIS, V140, P1359, DOI 10.1164/ajrccm/140.5.1359; CHIRAY M, 1940, PRESSE MED, V16, P201; Claude F., 1938, PRESSE MED, V38, P755; COLLINS LC, 1993, CHEST, V104, P1300, DOI 10.1378/chest.104.4.1300; DALES RE, 1989, AM REV RESPIR DIS, V139, P1459, DOI 10.1164/ajrccm/139.6.1459; Derimanov GS, 1998, ANN ALLERG ASTHMA IM, V81, P243, DOI 10.1016/S1081-1206(10)62820-7; DOMBOVY ML, 1987, MED SCI SPORT EXER, V19, P111; ELIASSON O, 1987, AM REV RESPIR DIS, V136, P1515, DOI 10.1164/ajrccm/136.6.1515; ELIASSON O, 1986, J ALLERGY CLIN IMMUN, V77, P87, DOI 10.1016/0091-6749(86)90328-3; Eliasson O, 1984, Conn Med, V48, P777; ELIASSON O, 1987, J ALLERGY CLIN IMMUN, V79, P909, DOI 10.1016/0091-6749(87)90240-5; ENRIGHT T, 1987, ANN ALLERGY, V58, P405; Ensom MHH, 1999, PHARMACOTHERAPY, V19, P374, DOI 10.1592/phco.19.6.374.31050; Faas M, 2000, FERTIL STERIL, V74, P1008, DOI 10.1016/S0015-0282(00)01553-3; FOSTER PS, 1983, BRIT J PHARMACOL, V78, P441, DOI 10.1111/j.1476-5381.1983.tb09409.x; Frank RT, 1931, ARCH NEURO PSYCHIATR, V26, P1053, DOI 10.1001/archneurpsyc.1931.02230110151009; Garcia-Velasco JA, 1999, FERTIL STERIL, V71, P983, DOI 10.1016/S0015-0282(99)00120-X; GIBBS CJ, 1984, THORAX, V39, P833, DOI 10.1136/thx.39.11.833; Gilmore W, 1997, J IMMUNOL, V158, P446; Gotthardt M, 1996, J Ky Med Assoc, V94, P105; HACKNEY JF, 1981, J STEROID BIOCHEM, V14, P971, DOI 10.1016/0022-4731(81)90204-1; Hamano N, 1998, ALLERGY ASTHMA PROC, V19, P263, DOI 10.2500/108854198778557773; HANLEY SP, 1981, BRIT J DIS CHEST, V75, P306, DOI 10.1016/0007-0971(81)90010-3; HOMODELARCHE F, 1991, J STEROID BIOCHEM, V40, P619, DOI 10.1016/0960-0760(91)90285-D; HORAN JD, 1968, CAN MED ASSOC J, V99, P130; HOSENPUD JD, 1983, RESP PHYSIOL, V52, P259, DOI 10.1016/0034-5687(83)90010-5; JEZIORSKA M, 1995, BIOL REPROD, V53, P312, DOI 10.1095/biolreprod53.2.312; JUNIPER EF, 1987, AM REV RESPIR DIS, V135, P1039; KALOGEROMITROS D, 1995, CLIN EXP ALLERGY, V25, P461, DOI 10.1111/j.1365-2222.1995.tb01078.x; KELLY RW, 1994, HUM REPROD, V9, P253, DOI 10.1093/oxfordjournals.humrep.a138491; Kljakovic M., 1997, Allergy (Copenhagen), V52, P681, DOI 10.1111/j.1398-9995.1997.tb01057.x; KONNO A, 1986, ORL J OTO-RHINO-LARY, V48, P45, DOI 10.1159/000275841; KOULLAPIS EN, 1980, ACTA ENDOCRINOL-COP, V93, P123, DOI 10.1530/acta.0.0930123; Lam S M, 1998, J Microbiol Immunol Infect, V31, P197; LENOIR RJ, 1987, ANAESTHESIA, V42, P1287, DOI 10.1111/j.1365-2044.1987.tb05275.x; LIEBERMAN D, 1995, MATURITAS, V21, P153, DOI 10.1016/0378-5122(94)00890-J; LIEBERMAN D, 1995, RESPIRATION, V62, P205; Makinoda S, 1996, INT J GYNECOL OBSTET, V55, P265, DOI 10.1016/S0020-7292(96)02769-5; MATHUR S, 1979, CLIN IMMUNOL IMMUNOP, V13, P246, DOI 10.1016/0090-1229(79)90069-2; Matsuo N, 1999, CHEST, V116, P252, DOI 10.1378/chest.116.1.252; Mirdal GM, 1998, BRIT J MED PSYCHOL, V71, P47, DOI 10.1111/j.2044-8341.1998.tb01366.x; MITTMAN RJ, 1989, J ALLERGY CLIN IMMUN, V84, P304, DOI 10.1016/0091-6749(89)90412-0; MOAWAD AH, 1982, AM J OBSTET GYNECOL, V144, P608, DOI 10.1016/0002-9378(82)90235-6; MORRIS D, 1988, LANCET, V2, P844; MUNAKATA M, 1993, CHEST, V104, P1718, DOI 10.1378/chest.104.6.1718; Murray RD, 1999, EUR RESPIR J, V14, P966, DOI 10.1034/j.1399-3003.1999.14d39.x; MYERS JR, 1994, CHEST, V106, P318, DOI 10.1378/chest.106.1.318; Nagata K, 1997, J ALLERGY CLIN IMMUN, V100, P39, DOI 10.1016/S0091-6749(97)70192-1; Nakasato H, 1999, J ALLERGY CLIN IMMUN, V104, P585, DOI 10.1016/S0091-6749(99)70327-1; OGAWA K, 1983, J CLIN ENDOCR METAB, V56, P121, DOI 10.1210/jcem-56-1-121; Ohrui T, 1997, LANCET, V350, P1178, DOI 10.1016/S0140-6736(05)63825-1; PAULI BD, 1989, AM REV RESPIR DIS, V140, P358, DOI 10.1164/ajrccm/140.2.358; PEPE GJ, 1982, STEROIDS, V39, P471, DOI 10.1016/0039-128X(82)90048-4; PERRIN B, 1988, LANCET, V2, P843; PETERS SP, 1985, AM REV RESPIR DIS, V132, P367; PICCINNI MP, 1995, J IMMUNOL, V155, P128; Prescott E, 1997, THORAX, V52, P287, DOI 10.1136/thx.52.3.287; PRIDE SM, 1984, CAN MED ASSOC J, V131, P763; REES L, 1963, J PSYCHOSOM RES, V7, P191, DOI 10.1016/0022-3999(63)90003-5; Rubio RL, 1988, ALLERGOL IMMUNOPATH, V16, P263; SANSORES RH, 1995, AM J RESP CRIT CARE, V152, P381, DOI 10.1164/ajrccm.152.1.7599851; SCHOENE RB, 1981, J APPL PHYSIOL, V50, P1300, DOI 10.1152/jappl.1981.50.6.1300; Shames RS, 1998, ANN ALLERG ASTHMA IM, V81, P65, DOI 10.1016/S1081-1206(10)63111-0; SHIBASAKI M, 1992, ANN ALLERGY, V68, P315; SIMPSON LO, 1988, NEW ZEAL MED J, V101, P225; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; Skobeloff EM, 1996, ARCH INTERN MED, V156, P1837, DOI 10.1001/archinte.156.16.1837; SVEC F, 1980, ENDOCRINOLOGY, V107, P566, DOI 10.1210/endo-107-2-566; Tan KS, 1997, AM J RESP CRIT CARE, V155, P1273, DOI 10.1164/ajrccm.155.4.9105066; Tan KS, 1997, THORAX, V52, P608, DOI 10.1136/thx.52.7.608; Tan KS, 1998, CHEST, V113, P278, DOI 10.1378/chest.113.2.278; Tan KS, 1996, BRIT J CLIN PHARMACO, V41, P414, DOI 10.1046/j.1365-2125.1996.3311.x; Tan KS, 2001, DRUGS, V61, P2079, DOI 10.2165/00003495-200161140-00005; Tan KS, 1997, CHEST, V111, P847, DOI 10.1378/chest.111.4.847; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368; Van den Berge M, 2001, AM J RESP CRIT CARE, V164, P1127, DOI 10.1164/ajrccm.164.7.2102135; Van dn Berge M, 2001, AM J RESP CRIT CARE, V163, P1546, DOI 10.1164/ajrccm.163.7.2010145; van Hooff MHA, 1998, HUM REPROD, V13, P2252, DOI 10.1093/humrep/13.8.2252; VLIAGOFTIS H, 1992, INT ARCH ALLERGY IMM, V98, P398, DOI 10.1159/000236217; WEINMANN GG, 1987, J ALLERGY CLIN IMMUN, V79, P634, DOI 10.1016/S0091-6749(87)80160-4; WHEELDON NM, 1994, BRIT J CLIN PHARMACO, V37, P583, DOI 10.1111/j.1365-2125.1994.tb04308.x; WULFSOHN NL, 1964, BRONCHIAL ASTHMA MEN, P173; Yu CK, 1999, CLIN EXP ALLERGY, V29, P414, DOI 10.1046/j.1365-2222.1999.00484.x; Zhao XJ, 2001, THORAX, V56, P205, DOI 10.1136/thorax.56.3.205	96	84	87	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					271	282		10.1067/mai.2003.1676	http://dx.doi.org/10.1067/mai.2003.1676			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897732				2022-12-18	WOS:000184650600010
J	Strachan, DR; Wong, HJ; Spector, TD				Strachan, DR; Wong, HJ; Spector, TD			Concordance and interrelationship of atopic diseases and markers of allergic sensitization among adult female twins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; hay fever; eczema; atopy; twins	SERUM IGE LEVELS; HAY-FEVER; RISK-FACTORS; BRONCHIAL REACTIVITY; MONOZYGOTIC TWINS; GENETIC-FACTORS; ASTHMA; WOMEN; PAIRS; ENVIRONMENT	Background: Previous twin studies of asthma and allergy implicate both genetic and environmental factors in disease risk, but few have related the occurrence of clinical disease to objective markers of allergic sensitization in twins. Objective: We sought to investigate the concordance and interrelationships of self-reported allergic disease and total and aeroallergen-specific IgE levels within pairs of British adult female twins. Methods: Three hundred forty monozygotic and 533 dizygotic pairs, aged 18 to 72 years, completed questionnaires about allergic disease. Of these, 282 monozygotic and 270 dizygotic pairs were tested for total IgE and specific IgE to Der p 1, mixed grass pollen, and cat dander by means of fluoroimmunoassay. Results: Concordance rates for all variables were higher for monozygotic than for dizygotic twins, significantly (P < .05) so for hay fever, eczema, and specific IgE positivity but not (P > .05) for self-reported asthma or allergies. Within-pair correlations of log-transformed IgE were 0.59 for monozygotic twins and 0.29 for dizygotic twins, implying heritability of 60%. Within both monozygotic and dizygotic pairs discordant for hay fever or reported allergies, the affected twin had significantly higher total and specific IgE levels. Within pairs who were doubly discordant for 3 allergic diseases, associations between diseases were of similar strength for monozygotic and dizygotic pairs. Conclusions: These results confirm that genetic factors influence susceptibility to aeroallergen sensitization and clinical allergic disease. However, genetically identical twins are often discordant in their expression of atopy, suggesting a substantial modifying role for environmental factors.	St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Queen Marys Univ Hosp, Dept Chem Pathol, London, England; St Thomas Hosp, Twin Res & Genet Epidemiol Unit, London, England	St Georges University London; University of London; Queen Mary University London; Guy's & St Thomas' NHS Foundation Trust	Strachan, DR (corresponding author), St George Hosp, Sch Med, Dept Publ Hlth Sci, Cranmer Terrace, London SW17 0RE, England.		Spector, Tim D/F-6533-2012					ANDREW T, 2001, IN PRESS TWIN RES; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; Boomsma D I, 1998, Twin Res, V1, P34, DOI 10.1375/twin.1.1.34; Braback L, 1998, CLIN EXP ALLERGY, V28, P936; Burney P, 1996, EUR RESPIR J, V9, P687; Chinn S, 1998, THORAX, V53, P662, DOI 10.1136/thx.53.8.662; Duffy DL, 1998, AM J RESP CRIT CARE, V157, P840, DOI 10.1164/ajrccm.157.3.9702070; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; ERICSSON CH, 1991, ANN ALLERGY, V67, P53; FALLIERS CJ, 1971, J ALLERGY, V47, P207, DOI 10.1016/S0091-6749(71)80466-9; Harris JR, 1997, AM J RESP CRIT CARE, V156, P43, DOI 10.1164/ajrccm.156.1.9609094; HOLM NV, 1983, ACTA GENET MED GEMEL, V32, P37, DOI 10.1017/S000156600000814X; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; HOPPER JL, 1990, GENET EPIDEMIOL, V7, P277, DOI 10.1002/gepi.1370070406; HRUBEC Z, 1984, NEW ENGL J MED, V310, P435, DOI 10.1056/NEJM198402163100706; Huovinen E, 1999, CHEST, V115, P928, DOI 10.1378/chest.115.4.928; JENSEN AR, 1967, P NATL ACAD SCI USA, V58, P149, DOI 10.1073/pnas.58.1.149; Koppelman GH, 1999, EUR RESPIR J, V13, P2, DOI 10.1183/09031936.99.13100299; Laitinen T, 1998, AM J RESP CRIT CARE, V157, P1073, DOI 10.1164/ajrccm.157.4.9704041; Lichtenstein P, 1997, ALLERGY, V52, P1079, DOI 10.1111/j.1398-9995.1997.tb00179.x; LYKKEN DT, 1978, SOC BIOL, V25, P1, DOI 10.1080/19485565.1978.9988312; NIEMINEN MM, 1991, CHEST, V100, P70, DOI 10.1378/chest.100.1.70; RAMAKRISHNAN V, 1992, GENET EPIDEMIOL, V9, P273, DOI 10.1002/gepi.1370090406; Rasanen M, 1997, CLIN EXP ALLERGY, V27, P515, DOI 10.1111/j.1365-2222.1997.tb00739.x; SARAFINO EP, 1995, ARCH DIS CHILD, V73, P112, DOI 10.1136/adc.73.2.112; SARNA S, 1978, HUM HERED, V28, P241, DOI 10.1159/000152964; *SAS SYST INC, 1990, SAS STAT US GUID; Schlesselman J. J, 1982, CASE CONTROL STUDIES, P207; SCHULTZLARSEN F, 1986, J AM ACAD DERMATOL, V15, P487; SISTONEN P, 1980, HUM HERED, V30, P155, DOI 10.1159/000153120; Skadhauge LR, 1999, EUR RESPIR J, V13, P8, DOI 10.1183/09031936.99.13100899; Spector TD, 1996, BRIT MED J, V312, P940; SPECTOR TD, 1995, BRIT MED J, V310, P1357, DOI 10.1136/bmj.310.6991.1357; Strachan DP, 2000, BRIT MED J, V321, P732, DOI 10.1136/bmj.321.7263.732; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P151; Strachan DP, 1999, LANCET, V353, P1457, DOI 10.1016/S0140-6736(99)90038-7; SVARTENGREN M, 1990, ANN ALLERGY, V64, P124; TOWNLEY R, 1976, J ALLERGY CLIN IMMUN, V57, P227; WUTHRICH B, 1981, CLIN ALLERGY, V11, P147, DOI 10.1111/j.1365-2222.1981.tb01578.x	41	84	87	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					901	907		10.1067/mai.2001.119408	http://dx.doi.org/10.1067/mai.2001.119408			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742265	Bronze			2022-12-18	WOS:000172938400003
J	Elliott, PJ; Pien, CS; McCormack, TA; Chapman, ID; Adams, J				Elliott, PJ; Pien, CS; McCormack, TA; Chapman, ID; Adams, J			Proteasome inhibition: A novel mechanism to combat asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; cell adhesion molecules; cytokines; delayed-type hypersensitivity; eosinophils; leukocytes; nuclear transcription factor-kappa B; proteasome; steroids	NF-KAPPA-B; COLONY-STIMULATING FACTOR; PLATELET-ACTIVATING-FACTOR; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; MOLECULAR MECHANISMS; CONTACT SENSITIVITY; ADHESION MOLECULES; HUMAN EOSINOPHILS; GENE-EXPRESSION	Background: Nuclear factor-kappa B (NF-kappa B) is a critical transcription factor required for the regulation of many genes involved in inflammatory responses to noxious stimuli, On activation, NF-kappa B induces the transcription of numerous proinflammatory cytokines, enzymes, and cellular adhesion molecules, Blockade of the proteasome with selective inhibitors attenuates the effects of NF-kappa B, leading to suppression of the inflammatory response, Objective: We sought to determine whether proteasome inhibitors would be active in a model of asthma, Methods: The mouse delayed-type hypersensitivity model was used to screen a panel of compounds for in vivo activity, The proteasome inhibitor, PS-519, was shown to be the most active in this model and was selected for further development. Allergen-induced pulmonary eosinophilia in Brown Norway rats was used subsequently to determine anti-inflammatory activity in an animal model. Results: Direct administration of PS-519 into the lungs significantly reduced leukocyte numbers, particularly the selective increase in eosinophils, Because steroids are the mainstay antiinflammatory therapy in asthma, and data is available to suggest their possible interaction to suppress the activation of NF-kappa B, rats were also treated by inhalation with combinations of a steroid and the proteasome inhibitor, In both the delayed-type hypersensitivity and the animal eosinophil. model, low doses of proteasome inhibitors were shown to be effective when given with low doses of steroids. Conclusion: Taken together, the present data suggest that proteasome inhibition may represent a novel strategy for the treatment of inflammatory lung diseases such as asthma.	ProScript Inc, Cambridge, MA 02319 USA; Quintiles Ltd, Edinburgh, Midlothian, Scotland	IQVIA	Elliott, PJ (corresponding author), ProScript Inc, 38 Sidney St, Cambridge, MA 02319 USA.							ASHERSON GL, 1968, IMMUNOLOGY, V15, P405; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARNES PJ, 1995, ANN MED, V27, P389, DOI 10.3109/07853899509002592; BARNES PJ, 1995, ANN MED, V27, P531, DOI 10.3109/07853899509002464; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Barnes PJ, 1997, TRENDS PHARMACOL SCI, V18, P46, DOI 10.1016/S0165-6147(97)89796-9; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Busse W, 1998, ANN ALLERG ASTHMA IM, V81, P17, DOI 10.1016/S1081-1206(10)63106-7; Busse WW, 1998, J ALLERGY CLIN IMMUN, V102, pS17, DOI 10.1016/S0091-6749(98)70002-8; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CANNON WC, 1983, AM IND HYG ASSOC J, V44, P923, DOI 10.1080/15298668391405959; CHAPMAN ID, 1996, AM J RESP CRIT CARE, V153, pA219; CHAPMAN ID, 1997, AM J RESP CRIT CARE, V155, pA881; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHOMCZYNSKI P, 1986, BIOCHEM BIOPH RES CO, V134, P812, DOI 10.1016/S0006-291X(86)80493-4; CLAMAN HN, 1980, J INVEST DERMATOL, V74, P263, DOI 10.1111/1523-1747.ep12543348; Cobb RR, 1996, EUR J IMMUNOL, V26, P839, DOI 10.1002/eji.1830260417; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dick LR, 1997, J BIOL CHEM, V272, P182; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; DRAZEN JM, 1995, ANNU REV PHYSIOL, V57, P151; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; ELWOOD W, 1992, AM REV RESPIR DIS, V145, P1289, DOI 10.1164/ajrccm/145.6.1289; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; FRIGAS E, 1980, LAB INVEST, V42, P35; GEDDES DM, 1992, THORAX, V47, P404, DOI 10.1136/thx.47.6.404; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; GRILLI M, 1993, INT REV CYTOL, V143, P1; HASS R, 1992, BIOCHEM PHARMACOL, V44, P1569, DOI 10.1016/0006-2952(92)90474-W; HOLGATE ST, 1991, INT ARCH ALLER A IMM, V94, P210, DOI 10.1159/000235363; KATZ AM, 1991, INT J DERMATOL, V30, P153, DOI 10.1111/j.1365-4362.1991.tb03843.x; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; MONTEFORT S, 1993, EUR RESPIR J, V6, P1044; MOQBEL R, 1991, J EXP MED, V174, P749, DOI 10.1084/jem.174.3.749; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PAGE CP, 1992, AM REV RESPIR DIS, V145, pS31, DOI 10.1164/ajrccm/145.2_Pt_2.S31; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Palombella VJ, 1998, P NATL ACAD SCI USA, V95, P15671, DOI 10.1073/pnas.95.26.15671; PATES PC, 1994, EXPERT OPINION THERA, V4, P917; PHANUPHAK P, 1974, J IMMUNOL, V112, P115; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHIMMER BP, 1995, GOODMAN GILMANS PHAR, P1459; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SERAFIN WE, 1995, GOODMAN GILMANS PHAR, P659; SMITH LJ, 1991, AM REV RESPIR DIS, V143, pS100, DOI 10.1164/ajrccm/143.5_Pt_2.S100; SOUCY F, 1999, Patent No. 60055848; Stein RL, 1996, BIOCHEMISTRY-US, V35, P3899, DOI 10.1021/bi952262x; TEELUCKSINGH S, 1991, LANCET, V338, P60, DOI 10.1016/0140-6736(91)90058-W; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THORNE PS, 1991, FUND APPL TOXICOL, V17, P790, DOI 10.1016/0272-0590(91)90186-8; UNLAP T, 1995, NEUROSCI LETT, V198, P41, DOI 10.1016/0304-3940(95)11963-W; VANLOVEREN H, 1983, J EXP MED, V157, P1604, DOI 10.1084/jem.157.5.1604; WOOLLEY KL, 1994, EUR RESPIR J, V7, P1576, DOI 10.1183/09031936.94.07091576	71	84	94	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				294	300		10.1016/S0091-6749(99)70369-6	http://dx.doi.org/10.1016/S0091-6749(99)70369-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452747				2022-12-18	WOS:000082364800018
J	Schwarze, J; Hamelmann, E; Cieslewicz, G; Tomkinson, A; Joetham, A; Bradley, K; Gelfand, EW				Schwarze, J; Hamelmann, E; Cieslewicz, G; Tomkinson, A; Joetham, A; Bradley, K; Gelfand, EW			Local treatment with IL-12 is an effective inhibitor of airway hyperresponsiveness and lung eosinophilia after airway challenge in sensitized mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-12; respiratory hypersensitivity; airway inflammation; allergen; body plethysmography; adverse effects; mice	CELL STIMULATORY FACTOR; GAMMA IN-VIVO; CD4+ T-CELLS; INTERFERON-GAMMA; BRONCHOALVEOLAR LAVAGE; FACTOR INTERLEUKIN-12; CYTOKINE PRODUCTION; ISOTYPE SELECTION; PERIPHERAL-BLOOD; MOUSE AIRWAYS	Background: Systemic administration of IL-12 can prevent airway hyperresponsiveness (AHR) in mice after sensitization and repeated allergen challenge. However, systemic IL-12 has been associated with severe adverse effects. Objective: We determined whether IL-12 administration to the airways in a dose sufficiently low so as not to result in systemic effects can modify allergic inflammation and AHR after allergen challenge. Methods: Mice were sensitized to ovalbumin by intraperitoneal injection and challenged with ovalbumin aerosol on 3 consecutive days. During the period of challenge, IL-12 was administered intranasally following 2 regimens, designated high (500 ng) or low (50 ng). We monitored airway responsiveness to inhaled methacholine by barometric body plethysmography, lung inflammatory cells, local cytokine production, and, to assess systemic effects of IL-12 treatment, spleen weights and numbers of eosinophils in the bone marrow. Results: Allergen challenge resulted in increases in airway responsiveness and in numbers of lung eosinophils. These increases were prevented by both high- and ion-dose IL-12, Additionally, IL-12 administration resulted in enhanced local interferon-gamma production and prevented the increases in Local IL-4 and IL-5 production after airway challenge. A high dose, but not a low dose, of IL-12 resulted in increased spleen weights and prevented the increase in numbers of bone marrow eosinophils after allergen challenge. Conclusion: These data indicate that local administration of IL-12 can prevent AHR and reduce lung eosinophilia after allergen challenge in sensitized mice without eliciting systemic adverse effects. IL-12 exerts these effects by inducing local T-H1-type responses in the airways in a setting that is normally dominated by T-H2-type responses.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA	National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.		Hamelmann, Eckard/AAJ-9124-2021; Schwarze, Jürgen/F-7396-2011	Schwarze, Jurgen/0000-0002-6899-748X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36577] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASMUNDSSON T, 1973, AM REV RESPIR DIS, V1089, P506; BELLONE G, 1994, J IMMUNOL, V153, P930; CAR BD, 1995, AM J PATHOL, V147, P1693; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DESAI BB, 1992, J IMMUNOL, V148, P3125; ENG VM, 1995, J EXP MED, V181, P1893, DOI 10.1084/jem.181.5.1893; Erb KJ, 1996, IMMUNOL CELL BIOL, V74, P206, DOI 10.1038/icb.1996.29; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GARLISI CG, 1995, CLIN IMMUNOL IMMUNOP, V75, P75, DOI 10.1006/clin.1995.1055; GATELY MK, 1994, INT IMMUNOL, V6, P157, DOI 10.1093/intimm/6.1.157; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; HALL SS, 1995, SCIENCE, V268, P1432, DOI 10.1126/science.7770767; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; HENDRZAK JA, 1995, LAB INVEST, V72, P619; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Iwamoto I, 1996, AM J RESP CRIT CARE, V154, P1257, DOI 10.1164/ajrccm.154.5.8912732; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; KIPS JC, 1995, INT ARCH ALLERGY IMM, V107, P115, DOI 10.1159/000236947; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535, DOI 10.1164/ajrccm.153.2.8564093; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; LACK G, 1994, J IMMUNOL, V152, P2546; Lack G, 1996, J IMMUNOL, V157, P1432; LAVNIKOVA N, 1993, AM J RESP CELL MOL, V8, P384, DOI 10.1165/ajrcmb/8.4.384; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MORRIS SC, 1994, J IMMUNOL, V152, P1047; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SARMIENTO UM, 1994, LAB INVEST, V71, P862; SCHUMACHER JH, 1988, J IMMUNOL, V141, P1576; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; Sur S, 1996, J IMMUNOL, V157, P4173; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; Ying S, 1997, J IMMUNOL, V158, P3539	40	84	88	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					86	93		10.1016/S0091-6749(98)70058-2	http://dx.doi.org/10.1016/S0091-6749(98)70058-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	102DX	9679851				2022-12-18	WOS:000074909500013
J	Gibson, PG; Zlatic, K; Scott, J; Sewell, W; Woolley, K; Saltos, N				Gibson, PG; Zlatic, K; Scott, J; Sewell, W; Woolley, K; Saltos, N			Chronic cough resembles asthma with IL-5 and granulocyte-macrophage colony-stimulating factor gene expression in bronchoalveolar cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; cough; cytokine; IL-5; GM-CSF; PCR; eosinophil airway responsiveness	EOSINOPHILIC BRONCHITIS; AIRWAY INFLAMMATION; GM-CSF; CYTOKINE; INTERLEUKIN-5; CHILDREN; HYPERRESPONSIVENESS	Background: Chronic cough is a multifactorial condition, which, like asthma, can be associated with eosinophilic air-way inflammation, In asthma, airway eosinophilia is believed to be mediated by cytokines such as interleukin-5 and granulocyte macrophage colony stimulating: factor (GM-CSF). The role of these cytokines in chronic cough is unclear. Objective: The aim of this study this to examine gene expression for IL-5 and GM-CSF in chronic cough and compare the results with those found in asthma. Methods: We studied adults with asthma (n = 12), chronic cough responsive to inhaled corticosteroid (ICS-responsive cough) (n = 9), and chronic cough not responsive to inhaled corticosteroid (non-ICS-responsive cough) (n = 4). Bronchoalveolar lavage (BAL) was performed and cytokine gene expression was assessed by using a semiquantitative reverse transcriptase polymerase chain reaction. Results: IL-5 mRNA was expressed by BAL cells from nine of 12 asthmatic subjects and six of nine subjects with ICS-responsive chronic cough. IL-5 mRNA was not detected in subjects with non-ICS-responsive chronic cough (zero of four subjects, p < 0.05). GM-CSF mRNA was expressed in BAL cells from seven of 12 asthmatic subject's and six of nine subjects with ICS-responsive cough. GM-CSF mRNA was not detected in non-ICS responsive cough subjects (zero of four subjects, p < 0.05). GM-CSF gene expression was related to the degree of methacholine airway responsiveness in asthmatic subjects (r = -0.59). Conclusion: We conclude that chronic cough, like asthma, if associated with airway inflammation and gene expression for IL-5 and GM-CSF. Ongoing expression of these cytokines is likely to be related to the persistence of airway inflammation and chronic cough.	Univ Newcastle, Fac Med & Hlth Sci, Canc Res Unit, Newcastle, NSW 2308, Australia; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; John Hunter Hosp, Resp Med Unit, Newcastle, NSW 2310, Australia	University of Newcastle; St Vincents Hospital Sydney; John Hunter Hospital	Gibson, PG (corresponding author), John Hunter Hosp, Resp Med Unit, Locked Bag 1, Newcastle, NSW 2310, Australia.		gibson, peter/G-6194-2014; Woolley, Karen/K-5041-2013	gibson, peter/0000-0001-5865-489X; Woolley, Karen/0000-0003-4626-7723				BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; BOULET LP, 1994, AM J RESP CRIT CARE, V149, P482, DOI 10.1164/ajrccm.149.2.8306050; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Carney IK, 1997, AM J RESP CRIT CARE, V156, P211, DOI 10.1164/ajrccm.156.1.9605044; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DODGE R, 1993, J ALLERGY CLIN IMMUN, V92, P744, DOI 10.1016/0091-6749(93)90018-B; DOLOVICH J, 1988, PEDIATR CLIN N AM, V35, P969; GIBSON P, 1993, BRIT MED J, V306, P1514, DOI 10.1136/bmj.306.6891.1514; GIBSON PG, 1989, LANCET, V1, P1346; GIBSON PG, 1995, CLIN EXP ALLERGY, V25, P127, DOI 10.1111/j.1365-2222.1995.tb01017.x; HEINO M, 1990, AM REV RESPIR DIS, V141, P428, DOI 10.1164/ajrccm/141.2.428; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640, DOI 10.1164/ajrccm/141.3.640; KRISHNASWAMY G, 1993, AM J RESP CELL MOL, V9, P279, DOI 10.1165/ajrcmb/9.3.279; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; PIN I, 1993, EUR RESPIR J, V6, P1249; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; RAMSDALE EH, 1985, GLUCOCORTICOIDS INFL, P91; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROLFE FG, 1992, IMMUNOLOGY, V77, P494; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557, DOI 10.1164/ajrccm/147.6_Pt_1.1557; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	24	84	88	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					320	326		10.1016/S0091-6749(98)70242-8	http://dx.doi.org/10.1016/S0091-6749(98)70242-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525446				2022-12-18	WOS:000072593900007
J	Minshall, EM; Hogg, JC; Hamid, QA				Minshall, EM; Hogg, JC; Hamid, QA			Cytokine mRNA expression in asthma is not restricted to the large airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokines; asthma; inflammation; lung resection; lymphocytes	PREDNISOLONE TREATMENT; BRONCHIAL BIOPSIES; GENE-EXPRESSION; ATOPIC ASTHMA; MESSENGER-RNA; INTERLEUKIN-5; EOSINOPHILS; MODULATION; IL-4	Background: Although previous studies have established the presence of an eosinophil-rich cellular Infiltrate in the small airways of asthmatic lungs, the expression of cytokines within the peripheral airways has been largely unexplored. The purpose of our study was to test the hypothesis that T-H2-type. cytokines are increased in the peripheral airways and parenchyma of asthmatic lungs. Methods: The presence of messenger ribonucleic acid (mRNA) encoding both T helper (T-H1)-type (IL-2, interferon-gamma) and T-H2-type (IL-4, IL-5) cytokines in surgically resected lungs from six asthmatic and 10 nonasthmatic subjects was determined by in situ hybridization. Colocalization of IL-5 mRNA within the large and smell airways was performed bu simultaneous in situ hybridization and immunocytochemistry. Results: Expression of IL-5 mRNA-positive cells wits significantly increased in the large and small airways and in the lung parenchyma of asthmatic subjects compared with non-asthmatic subjects. In the asthmatic individuals, the expression of IL-5 mRNA was increased in the small airways compared with the large airways. There was also an increase in the number of cells expressing IL-4 mRNA in the large and small asthmatic airways compared with the nonasthmatic airways. In contrast, the numbers of IL-2 and interferon-gamma mRNA-positive cells did not differ between asthmatic and nonasthmatic individuals. Conclusions: We conclude that there is an increased expression of T-H2-type cytokines within the peripheral airways of asthmatic lungs and suggest that the small airways contribute to the pathophysiology of asthma.	McGill Univ, Meakins Christie Labs, Quebec City, PQ H2X 2P2, Canada; Univ British Columbia, St Pauls Hosp, Pulm Res Lab, Vancouver, BC V5Z 1M9, Canada	McGill University; St. Paul's Hospital; University of British Columbia; University of Saskatchewan	Hamid, QA (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Quebec City, PQ H2X 2P2, Canada.							AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BEL EH, 1990, AM REV RESPIR DIS, V141, P21, DOI 10.1164/ajrccm/141.1.21; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Gonzalez S, 1996, EUR RESPIR J, V9, P1995, DOI 10.1183/09031936.96.09101995; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; KAWANO K, 1993, AM RESP REV DIS, V148, P1220; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Shi HZ, 1997, AM J RESP CELL MOL, V16, P220, DOI 10.1165/ajrcmb.16.3.9070605; Simon HU, 1997, J IMMUNOL, V158, P3902; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012	20	84	85	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					386	390		10.1016/S0091-6749(98)70252-0	http://dx.doi.org/10.1016/S0091-6749(98)70252-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525456				2022-12-18	WOS:000072593900017
J	Vermeeren, A; O'Hanlon, JF				Vermeeren, A; O'Hanlon, JF			Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fexofenadine; clemastine; antihistamines; alcohol interactions; healthy volunteers; car driving; psychomotor performance	PSYCHOMETRIC TEST-PERFORMANCE; HEALTHY-VOLUNTEERS; ANTIHISTAMINES; TERFENADINE; CETIRIZINE; EBASTINE	Background: Fexofenadine is the hydrochloride salt of terfenadine's active metabolite. Objective: Fexofenadine's effects on performance were assessed in this study for the purpose of determining its safety of use by patients wire engage in potentially dangerous activities, especially car driving. Methods: Fexofenadine was administered in daily doses of 120 or 240 mg, each in single and divided units given over 5 days. Two milligrams of clemastine given twice daily and placebo were given in similar series. Twenty-Four healthy volunteers (12 men, 12 women; age range, 21 to 45 years) participated in a double-blind six-way crossover study. Psychomotor tests (critical tracking, choice reaction time, and sustained attention) and a standardized actual driving test were undertaken between 1.5 to 4 hours after administration of the morning dose on days I, 4, and 5 of each series. On day 5, subjects were challenged with a moderate alcohol dose before testing. Results: Fexofenadine did not impair driving performance. On the contrary, driving performance was consistently better during twice daily treatment with 120 mg fexofenadine than during treatment with placebo, significantly so on day 4. Both of the 240 mg/day regimens significantly attenuated alcohol's adverse effect: on driving on dag 5, Effects in psychomotor tests acre mot significant, with the exception of the critical tracking test in which the first single doses of fexofenadine, 120 and 240 mg. had significantly impairing effects. Conclusion: It was concluded that fexofenadine has no effect ore performance after being taken in the recommended dosage of 60 mg twice daily.	Maastricht Univ, Dept Biol Psychol, Inst Human Psychopharmacol, NL-6200 MD Maastricht, Netherlands	Maastricht University	Vermeeren, A (corresponding author), Maastricht Univ, Dept Biol Psychol, Inst Human Psychopharmacol, POB 616, NL-6200 MD Maastricht, Netherlands.							Bernstein D., 1996, Journal of Allergy and Clinical Immunology, V97, P435, DOI 10.1016/S0091-6749(96)81228-0; BETTS T, 1989, J PSYCHOPHARMACOL, V3, P101; BROOKHUIS KA, 1993, BRIT J CLIN PHARMACO, V36, P67, DOI 10.1111/j.1365-2125.1993.tb05894.x; CLARKE CH, 1978, BRIT J CLIN PHARMACO, V6, P31, DOI 10.1111/j.1365-2125.1978.tb01678.x; Day J. H., 1996, Journal of Allergy and Clinical Immunology, V97, P434, DOI 10.1016/S0091-6749(96)81225-5; ESTELLE F, 1994, DRUG SAFETY, V10, P350, DOI 10.2165/00002018-199410050-00002; *HOECHST MAR ROUSS, 1995, FEX HYDR MDL 16455A; JEX HR, 1966, IEEE TRANS HUM FACT, VHFE7, P138, DOI 10.1109/THFE.1966.232660; KOELEGA HS, 1993, PSYCHOPHARMACOLOGY, V111, P1, DOI 10.1007/BF02257400; Krendel, 1959, J FRANKLIN I, V267, P381, DOI [10.1016/0016-0032(59)90091-2, DOI 10.1016/0016-0032(59)90091-2]; LING KHJ, 1995, DRUG METAB DISPOS, V23, P631; Lippert C, 1995, PHARM RES-DORDR, V12, P390; Mackworth N. H., 1950, 268 MRC; MANNING C, 1993, EFFECTS DRUGS HUMAN, P52; MATTILA MJ, 1992, EUR J CLIN PHARMACOL, V43, P179, DOI 10.1007/BF01740667; MCRUER DT, 1967, IEEE TRANS HUM FACT, VHFE8, P231, DOI 10.1109/THFE.1967.234304; MOSKOWITZ H, 1988, J RESP DIS S, V8, pS1; OHANLON JF, 1995, NEUROPSYCHOBIOLOGY, V31, P81, DOI 10.1159/000119177; OHANLON JF, 1995, ALLERGY, V50, P234, DOI 10.1111/j.1398-9995.1995.tb01140.x; RAMAEKERS JG, 1992, EUR J CLIN PHARMACOL, V42, P363; RAMAEKERS JG, 1994, EUR J CLIN PHARMACOL, V47, P261, DOI 10.1007/BF02570506; RIEDEL WJ, 1989, MANAGEMENT OF ALLERGY IN THE 1990S, P38; ROSE C, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1171; Simons FER, 1996, CLIN EXP ALLERGY, V26, P1092; Tinkelman D, 1996, J ALLERGY CLIN IMMUN, V97, P1009; VOLKERTS ER, 1992, HUM PSYCHOPHARM CLIN, V7, P227, DOI 10.1002/hup.470070402; VUURMAN EFPM, 1994, EUR J CLIN PHARMACOL, V47, P253, DOI 10.1007/BF02570505; Vuurman EFPM, 1996, EUR J CLIN PHARMACOL, V50, P475, DOI 10.1007/s002280050144	28	84	86	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					306	311		10.1016/S0091-6749(98)70240-4	http://dx.doi.org/10.1016/S0091-6749(98)70240-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525444				2022-12-18	WOS:000072593900005
J	Meltzer, EO; Nathan, RA; Selner, JC; Storms, W				Meltzer, EO; Nathan, RA; Selner, JC; Storms, W			Quality of life and rhinitic symptoms: Results of a nationwide survey with the SF-36 and ROLO questionnaires	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; quality of lifesurvey; RQLQ SF-36; Medical Outcomes Study; self-administered questionnaire	OF-LIFE; ALLERGIC RHINITIS; CLINICAL-TRIALS; HEALTH-STATUS; RHINOCONJUNCTIVITIS; OUTCOMES; VALIDITY; ASTHMA	Health care delivery is increasingly driven by results of outcomes studies. The best single instrument or combination of instruments for measurement of outcome in patients with symptoms of rhinitis has not been determined. The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), a generic instrument, and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), a disease-specific instrument, have both been used. We carried out a population-based study in 312 subjects with nasal/ocular symptoms who filled out both questionnaires. We then compared their responses with those of healthy controls. Statistically significant differences between patients and controls were observed in seven of nine dimensions in the SF-36 questionnaire and in all of the seven dimensions and the aggregate score of the RQLQ. In all cases, the direction of the changes in health status indicated impairment of quality of life, particularly in ability to perform normal physical roles. Patients were troubled by repeated nose blowing, had a disrupted sleep pattern, were fatigued, and had a reduced ability to concentrate. We conclude that these outcomes should be incorporated into clinical trials, effectiveness research, and therapeutic strategies.	ALLERGY & ASTHMA MED GRP & RES CTR, SAN DIEGO, CA USA; ASTHMA & ALLERGY ASSOCIATES, COLORADO SPRINGS, CO USA; ALLERGY RESP INST COLORADO, DENVER, CO USA									BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; EVANS R, 1993, ALLERGY PRINCIPLES P, V2, P1109; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; KALINER M, 1987, JAMA-J AM MED ASSOC, V258, P2851, DOI 10.1001/jama.258.20.2851; MACKOWIAK JI, 1994, ANN ALLERGY, V72, P99; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; OBRIEN B, 1994, DRUG INF J, V28, P45; RELMAN AS, 1988, NEW ENGL J MED, V319, P1220, DOI 10.1056/NEJM198811033191810; RICE WR, 1990, BIOMETRICS, V46, P303, DOI 10.2307/2531435; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; Ware JE., 1993, HLTH SURVEY MANUAL I; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59	17	84	87	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	2	S			S815	S819		10.1016/S0091-6749(97)80041-3	http://dx.doi.org/10.1016/S0091-6749(97)80041-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XJ363					2022-12-18	WOS:A1997XJ36300003
J	Yang, WH; Drouin, MA; Herbert, M; Mao, Y; Karsh, J				Yang, WH; Drouin, MA; Herbert, M; Mao, Y; Karsh, J			The monosodium glutamate symptom complex: Assessment in a double-blind, placebo-controlled, randomized study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						monosodium glutamate; monosodium glutamate symptom complex; randomized double-blind challenge	CHINESE RESTAURANT SYNDROME; ADVERSE REACTIONS; FOOD-ADDITIVES; GRANULOMATOSIS; INTOLERANCE; PREVALENCE; ASTHMA	Background: Considerable debate swirls about the validity of symptoms described by many people after ingestion of monosodium glutamate (MSG), and the question has remained unresolved largely because of a paucity of well-designed challenge studies. Methods: We conducted oral challenge studies in self-identified MSG-sensitive subjects to determine whether they had a statistically significant difference in the incidence of their specific symptoms after ingestion of MSG compared with placebo. First, 5 gm MSG or placebo was administered in random sequence in a double-blind fashion. Subjects who reacted only to a single test agent then underwent rechallenge in random sequence in a double-blind fashion with placebo and 1.25, 2.5, and 5 gm MSG. A positive response to challenge was defined as the reproduction of greater than or equal to 2 of the specific symptoms in a subject ascertained on prechallenge interview. Results: Sixty-one subjects entered the study. On initial challenge, 18 (29.5%) responded to neither MSG nor placebo, 6 (9.8%) to both, 15 (24.6%) to placebo, and 22 (36.1%) to MSG (p = 0.324). Total and average severity of symptoms after ingestion of MSG (374 and 80) were greater than respective values after placebo ingestion (232 and 56; p = 0.026 and 0.018, respectively). Rechallenge revealed an apparent threshold dose for reactivity of 2.5 gm MSG. Headache (p < 0.023), muscle tightness (p < 0.004), numbness/tingling (p < 0.007), general weakness (p < 0.040), and Bushing (p < 0.016) occurred more frequently after MSG than placebo ingestion. Conclusions: Oral challenge with MSG reproduced symptoms in alleged sensitive persons. The mechanism of the reaction remains unknown, but symptom characteristics do not support an IgE-mediated mechanism. According to Food and Drug Administration recommendations, the symptoms, originally called the Chinese restaurant syndrome, are better referred to as the MSG symptom complex.	UNIV OTTAWA, DEPT MED, OTTAWA, ON, CANADA; HLTH CANADA, LAB CTR DIS CONTROL, OTTAWA, ON K1A 0L2, CANADA; HLTH CANADA, BUR CHRON DIS EPIDEMIOL, OTTAWA, ON K1A 0L2, CANADA	University of Ottawa; Health Canada; Health Canada								ALLEN DH, 1981, NEW ENGL J MED, V305, P1154; ALLEN DH, 1987, J ALLERGY CLIN IMMUN, V80, P530, DOI 10.1016/0091-6749(87)90003-0; ASNES RS, 1980, CLIN PEDIATR, V19, P705, DOI 10.1177/000992288001901014; BENDER AE, 1981, BRIT J NUTR, V46, P403, DOI 10.1079/BJN19810048; COLMAN AD, 1978, NEW ENGL J MED, V299, P902; FOLKERS K, 1984, H-S Z PHYSIOL CHEM, V365, P405, DOI 10.1515/bchm2.1984.365.1.405; FREED DLJ, 1982, ANN ALLERGY, V48, P96; GANN D, 1977, SOUTHERN MED J, V70, P879, DOI 10.1097/00007611-197707000-00036; GEHA R, 1993, J ALLERGY CLIN IMMUN, V92, P513, DOI 10.1016/0091-6749(93)90075-Q; GOLDBERG LH, 1982, ANN EMERG MED, V11, P333, DOI 10.1016/S0196-0644(82)80140-6; Kandall S R, 1968, N Engl J Med, V278, P1123; GORE ME, 1980, LANCET, V1, P251; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P192; Hosen H, 1988, J Asthma, V25, P111; KENNEY RA, 1986, FOOD CHEM TOXICOL, V24, P351, DOI 10.1016/0278-6915(86)90014-1; KENNEY RA, 1972, AM J CLIN NUTR, V25, P140; Kenney RA, 1979, GLUTAMIC ACID ADV BI, P363; KERR GR, 1979, J AM DIET ASSOC, V75, P29; KERR GR, 1979, ADV BIOCH PHYSL, P375; KWOK RHM, 1968, NEW ENGL J MED, V278, P796; *LIF SCI RES OFF F, 1995, AN ADV REACT MON GLU; MONERET-VAUTRIN D A, 1987, Allergie et Immunologie (Paris), V19, P29; OLIVER AJ, 1991, ORAL SURG ORAL MED O, V71, P560, DOI 10.1016/0030-4220(91)90362-G; PEACE KE, 1990, STAT TXB MONOGRAPHS, V106, P27; RANDOLPH TG, 1950, J LAB CLIN MED, V36, P407; RATNER D, 1984, ISRAEL J MED SCI, V20, P252; REIFLEHRER L, 1976, FED PROC, V35, P2205; REIFLEHRER L, 1975, NEW ENGL J MED, V293, P1204; REIFLEHRER L, 1977, FED PROC, V36, P1617; ROSENBLUM I, 1971, TOXICOL APPL PHARM, V18, P367, DOI 10.1016/0041-008X(71)90129-3; ROSENZWEIG P, 1993, CLIN PHARMACOL THER, V54, P578, DOI 10.1038/clpt.1993.190; SCHAUMBU.HH, 1968, NEW ENGL J MED, V279, P105; SCHAUMBURG H, 1968, NEW ENGL J MED, V278, P1122; SIMON RA, 1986, NEW ENGL REG ALLERGY, V7, P533; SMITH SJ, 1982, BRIT MED J, V285, P1205, DOI 10.1136/bmj.285.6349.1205-a; Stegink LD, 1979, GLUTAMIC ACID ADV BI, P333; SWEATMAN MC, 1986, CLIN ALLERGY, V16, P331, DOI 10.1111/j.1365-2222.1986.tb01965.x; TANPHAICHITR V, 1983, NUTR REP INT, V28, P783; TARASOFF L, 1993, FOOD CHEM TOXICOL, V31, P1019, DOI 10.1016/0278-6915(93)90012-N; VANBEVER HP, 1989, ALLERGY, V44, P588; ZANDA G, 1973, BIOMEDICINE, V19, P202	41	84	87	2	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	1				757	762		10.1016/S0091-6749(97)80008-5	http://dx.doi.org/10.1016/S0091-6749(97)80008-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XH193	9215242				2022-12-18	WOS:A1997XH19300007
J	Nelson, HS; Oppenheimer, J; Buchmeier, A; Kordash, TR; Freshwater, LL				Nelson, HS; Oppenheimer, J; Buchmeier, A; Kordash, TR; Freshwater, LL			An assessment of the role of intradermal skin testing in the diagnosis of clinically relevant allergy to timothy grass	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						intradermal skin testing; timothy grass; skin prick test; seasonal allergic rhinitis; pollen	TEST REACTIVITY; IGE	Background: Immediate skin resting is generally the preferred method for establishing the presence of allergy in clinical practice. There is no agreement however as to whether intradermal testing should be routinely performed if skin prick test results are negative. Purpose: The study was done to address the value of intradermal skin testing in the diagnosis of clinically significant sensitivity to grass pollen in patients exhibiting negative skin prick test responses to timothy extract. Methods: Four groups were studied. Group I had a history of seasonal allergic rhinitis, negative skin prick test responses to timothy and Bermuda grass, but positive intradermal skin test responses to timothy grass. Group II had a history of seasonal allergic rhinitis and positive skin prick test responses to timothy grass. Group III had a history of seasonal allergic rhinitis but had negative responses to both prick and intradermal testing with timothy and Bermuda grass. Group IV had no history of rhinitis, had negative responses to skin testing with a panel of locally important allergens, as well as Bermuda and timothy grass, and had a serum IgE value of less than 20 IU/ml. Clinical sensitivity to grass was assessed by two methods: (1) nasal challenge with threefold increasing amounts of timothy pollen performed out of the pollen season and (2) correlation of subjects' daily symptom and medication scores with daily grass pollen counts during the grass pollen season. Results: On the basis of nasal challenge with timothy grass, pollen allergic reactions were present in 11% of group I, 68% of group II, 11% of group III, and 0% of group IV. As determined by correlation of symptoms during the grass pollen season with grass pollen counts, 22% of group I, 64% of group II, 21% of group III, and 0% of group IV were considered allergic. If both criteria were required for a diagnosis of clinical allergy to grass, the percent positive was 0 for group I, 46 for group II, 0 for group III, and 0 for group IV. Conclusion: Under the conditions of this study the presence of a positive intradermal skin test response to timothy grass (1000 AU/ml) in the presence of a negative skin prick test response to timothy grass (100,000 AU/ml) did not indicate the presence of clinically significant sensitivity to timothy grass, and by inference, to other cross-reacting grasses.	MILES INC, ALLERGY PROD DIV, SPOKANE, WA USA; MILES INC, ELKHART, IN USA		Nelson, HS (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, 1400 JACKSON ST, DENVER, CO 80206 USA.							ADINOFF AD, 1990, J ALLERGY CLIN IMMUN, V86, P766, DOI 10.1016/S0091-6749(05)80181-2; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; KEMP JP, 1988, ANN ALLERGY, V60, P349; Malling HJ., 2003, ALLERGY, V48, P55; MARTIN BG, 1985, ANN ALLERGY, V54, P99; MOYER DB, 1985, ANN ALLERGY, V55, P680; Nelson H, 1995, PROVOCATION TESTING, P703; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P750, DOI 10.1016/0091-6749(93)90019-C; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; REDDY PM, 1978, J ALLERGY CLIN IMMUN, V61, P36, DOI 10.1016/0091-6749(78)90471-2; TAYLOR G, 1973, J ALLERGY CLIN IMMUN, V52, P193, DOI 10.1016/0091-6749(73)90057-2	13	84	88	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1193	1201		10.1016/S0091-6749(96)70184-7	http://dx.doi.org/10.1016/S0091-6749(96)70184-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648012				2022-12-18	WOS:A1996VD60700004
J	SAKAGUCHI, M; OGURA, H; INOUYE, S				SAKAGUCHI, M; OGURA, H; INOUYE, S			IGE ANTIBODY TO GELATIN IN CHILDREN WITH IMMEDIATE-TYPE REACTIONS TO MEASLES AND MUMPS VACCINES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							RUBELLA VACCINE		NATL HIGASHI KOCHI HOSP,KOCHI,JAPAN		SAKAGUCHI, M (corresponding author), NIH,DEPT EPIDEMIOL,SHINJUKU KU,TOYAMA 1-23-1,TOKYO 162,JAPAN.		Inouye, Sharon/R-7216-2019					BUSINCO L, 1994, ANN ALLERGY, V72, P1; Businco L, 1991, PEDIATR ALLERGY IMMU, V4, P195; FASANO MB, 1992, J PEDIATR-US, V120, P878, DOI 10.1016/S0022-3476(05)81953-5; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; OGURA H, 1993, J PEDIATR PRACT, V56, P2209	5	84	87	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					563	565		10.1016/S0091-6749(95)70304-7	http://dx.doi.org/10.1016/S0091-6749(95)70304-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560672				2022-12-18	WOS:A1995TA09500021
J	KUEHR, J; FRISCHER, T; MEINERT, R; BARTH, R; SCHRAUB, S; URBANEK, R; KARMAUS, W; FORSTER, J				KUEHR, J; FRISCHER, T; MEINERT, R; BARTH, R; SCHRAUB, S; URBANEK, R; KARMAUS, W; FORSTER, J			SENSITIZATION TO MITE ALLERGENS IS A RISK FACTOR FOR EARLY AND LATE-ONSET OF ASTHMA AND FOR PERSISTENCE OF ASTHMATIC SIGNS IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; SENSITIZATION; MITE; INCIDENCE; CHILDREN; RISK FACTOR; POPULATION-BASED	HOUSE-DUST MITE; RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; FOLLOW-UP; EXPOSURE; IGE; SCHOOLCHILDREN; SENSITIVITY; HISTORY; DISEASE	Background: To describe the natural history of asthma between the ages of 7 and 10 years and to analyze risk factors for prevalences, as well as new onset of asthma-like symptoms, a longitudinal study of 1812 children was conducted. Methods: In four surveys, each 1 year apart four asthma-like symptoms and several hypothetical risk factors were ascertained through standardized questionnaires. Sensitization to seven common inhalant allergens was measured by skirt prick testing. Exposure to mite allergens (Der p I, Der f I) was assessed by measuring the antigen concentrations in the dust of each child's mattress. Occurrence of more than one asthma-like symptom closely related to the practioner's diagnoses of bronchial asthma and recurrent wheezy bronchitis was used as the outcome variable. Results: After art initial prevalence of 14.5%, new onset of symptoms in children unaffected at the beginning was reported in 7.2% during the 3 years. Of the factors explaining prevalence and persistence of asthma-like symptoms (sensitization to mite allergens and animal danders, history of hay fever and eczema, low gestational age, male gender, parental atopy), only sensitization to mite allergens (odds ratio = 2.3, 95% confidence interval = 1.1-4.7) and parental atopy (odds ratio = 2.1, 95% confidence interval = 1.2-3. 7) were also significantly associated with new onset. In a relatively small number of sensitized subjects with new onset of symptoms (n = 31), mite antigen concentration did not appear to be associated with incidence of symptoms. Conclusion: Sensitization to mite allergens antedated the onset of asthma-like symptoms, and no strong effect of allergen exposure on clinical development could be found. Thus the primary focus should be on preventing sensitization to mite allergens by implementing avoidance measures in infancy ol at early school age in order to reduce the onset of asthma at a later stage.	UNIV VIENNA,CHILDRENS HOSP,VIENNA,AUSTRIA; NORDIG,INST HLTH RES & PREVENT,HAMBURG,GERMANY	University of Vienna	KUEHR, J (corresponding author), UNIV FREIBURG,CHILDRENS HOSP,MATHILDENSTR 1,D-79106 FREIBURG,GERMANY.							BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; CHAN KN, 1989, ARCH DIS CHILD, V64, P1284, DOI 10.1136/adc.64.9.1284; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1118, DOI 10.1136/adc.64.8.1118; CRONER S, 1990, PEDIATR ALLERGY IMMU, V1, P14, DOI DOI 10.1111/J.1399-3038.1990.TB00003.X; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; HAGY GW, 1971, J ALLERGY CLIN IMMUN, V48, P201; KIVITY S, 1993, J ALLERGY CLIN IMMUN, V91, P844, DOI 10.1016/0091-6749(93)90341-C; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; KUEHR J, 1992, ALLERGY, V47, P650, DOI 10.1111/j.1398-9995.1992.tb02390.x; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; KUEHR J, 1992, J ALLERGY CLIN IMMUN, V90, P358, DOI 10.1016/S0091-6749(05)80015-6; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355; OHMAN JL, 1993, J ALLERGY CLIN IMMUN, V91, P752, DOI 10.1016/0091-6749(93)90195-L; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; POYSA L, 1989, ACTA PAEDIATR SCAND, V78, P902, DOI 10.1111/j.1651-2227.1989.tb11172.x; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SHERMAN CB, 1990, AM J EPIDEMIOL, V132, P83, DOI 10.1093/oxfordjournals.aje.a115646; SHIBASAKI M, 1988, J ALLERGY CLIN IMMUN, V82, P86, DOI 10.1016/0091-6749(88)90056-5; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STRACHAN DP, 1985, ARCH DIS CHILD, V60, P457, DOI 10.1136/adc.60.5.457	23	84	85	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					655	662		10.1016/S0091-6749(95)70168-0	http://dx.doi.org/10.1016/S0091-6749(95)70168-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897146				2022-12-18	WOS:A1995QM01700003
J	OTT, NL; GLEICH, GJ; PETERSON, EA; FUJISAWA, T; SUR, S; LEIFERMAN, KM				OTT, NL; GLEICH, GJ; PETERSON, EA; FUJISAWA, T; SUR, S; LEIFERMAN, KM			ASSESSMENT OF EOSINOPHIL AND NEUTROPHIL PARTICIPATION IN ATOPIC-DERMATITIS - COMPARISON WITH THE IGE-MEDIATED LATE-PHASE REACTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EOSINOPHIL; NEUTROPHIL; IGE-MEDIATED LATE-PHASE REACTION; ATOPIC DERMATITIS	MAJOR BASIC-PROTEIN; ELEVATED SERUM LEVELS; CATIONIC PROTEIN; GRANULE PROTEINS; LOCALIZATION; DEPOSITION; IMMEDIATE; ALLERGEN; ELASTASE; DISEASE	We hypothesized that repeated IgE-mediated late-phase reactions are critical in the pathogenesis of atopic dermatitis (AD). Prior studies have shown that extracellular deposition of eosinophil granule major basic protein (MBP) occurs in lesional AD skin, despite a paucity of infiltrating eosinophils, and that deposition of both neutrophil and eosinophil granule proteins occurs in the IgE-mediated late-phase reaction. We evaluated the participation of both eosinophil and neutrophil granule proteins in AD. Cutaneous biopsy specimens and serum and urine samples were obtained from 22 patients with AD. Lesional tissue was examined by means of immunofluorescence for neutrophil elastase and lactoferrin and for eosinophil granule MBP: eosinophil-derived neurotoxin (EDN), and eosinophil cationic protein (ECP). Serum levels of elastase, MBE: EDN and ECP and urine levels of MBP: EDN and ECP were measured. Marked extracellular deposition of at least one of the eosinophil granule proteins was present in the dermis of 15 of the 22 AD skin specimens, but minimal or no extracellular neutrophil elastase or lactoferrin deposition was observed in any specimens. Serum and urine levels of MBE: EDN and ECP in the patients were elevated when compared with those of normal controls, whereas serum levels of neutrophil elastase were not elevated. Serum MPB levels correlated with extent of body surface involvement. These results suggest that eosinophil degranulation occurs in AD but that neutrophil degranulation does not. Although eosinophil degranulation is prominent in both the late-phase reaction and in AD, the lack of neutrophil degranulation in AD demonstrates differences in the inflamamtory reactions.	MAYO CLIN & MAYO FDN,DEPT PEDIAT & ADOLESCENT MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT DERMATOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic					NIAID NIH HHS [AI 15231] Funding Source: Medline; NIAMS NIH HHS [AR36008] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015231, R37AI015231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R23AR036008, R01AR036008] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; ADINOFF AD, 1988, J ALLERGY CLIN IMMUN, V81, P736, DOI 10.1016/0091-6749(88)91047-0; BENNETT RM, 1978, BRIT J HAEMATOL, V39, P509, DOI 10.1111/j.1365-2141.1978.tb03620.x; BURKE JF, 1979, DERMATOLOGY GENERAL, P932; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CZECH W, 1992, BRIT J DERMATOL, V126, P351, DOI 10.1111/j.1365-2133.1992.tb00677.x; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FILLEY WV, 1981, J IMMUNOL METHODS, V47, P227, DOI 10.1016/0022-1759(81)90123-X; FUJISAWA T, 1990, J IMMUNOL, V144, P642; FUJISAWA T, 1990, AM REV RESPIR DIS, V141, P689, DOI 10.1164/ajrccm/141.3.689; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GLEICH GJ, 1992, INFLAMMATION BASIC P, P663; GUNDEL RH, 1990, J APPL PHYSIOL, V68, P779, DOI 10.1152/jappl.1990.68.2.779; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; JAKOB T, 1991, ARCH DERMATOL RES, V283, P5, DOI 10.1007/BF01207241; JOHNSON NW, 1974, J IMMUNOL METHODS, V2, P189; KAGI MK, 1992, DERMATOLOGY, V185, P88, DOI 10.1159/000247419; KAPP A, 1991, J AM ACAD DERMATOL, V24, P555, DOI 10.1016/0190-9622(91)70081-C; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KRENIK KD, 1989, J IMMUNOL METHODS, V117, P91, DOI 10.1016/0022-1759(89)90122-1; KRUTMANN J, 1992, J AM ACAD DERMATOL, V26, P225, DOI 10.1016/0190-9622(92)70031-A; LEIFERMAN KM, 1990, LAB INVEST, V62, P579; LEIFERMAN KM, 1989, ALLERGY, V44, P20, DOI 10.1111/j.1398-9995.1989.tb02450.x; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; MADDOX DE, 1983, J EXP MED, V158, P1211, DOI 10.1084/jem.158.4.1211; MAEDA K, 1992, Journal of Dermatological Science, V3, P151, DOI 10.1016/0923-1811(92)90029-B; PEREZ GL, 1993, ARCH DERMATOL, V129, P861, DOI 10.1001/archderm.129.7.861; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1987, HOSP PRAC, V15, P111; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SODHI N, 1990, Journal of Allergy and Clinical Immunology, V85, P204; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SPITZNAGEL JK, 1974, LAB INVEST, V30, P774; STONE SP, 1973, ARCH DERMATOL, V108, P806, DOI 10.1001/archderm.108.6.806; SUR S, 1991, FASEB J, V5, pA641; TSUDA S, 1992, Journal of Dermatology (Tokyo), V19, P208; WAGNER JM, 1993, PLACENTA, V14, P671, DOI 10.1016/S0143-4004(05)80384-4; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; WIEDOW O, 1992, J INVEST DERMATOL, V99, P306, DOI 10.1111/1523-1747.ep12616644; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	43	84	84	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					120	128		10.1016/0091-6749(94)90078-7	http://dx.doi.org/10.1016/0091-6749(94)90078-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	8027490	Bronze			2022-12-18	WOS:A1994NX39300015
J	KURUP, VP; SEYMOUR, BWP; CHOI, HY; COFFMAN, RL				KURUP, VP; SEYMOUR, BWP; CHOI, HY; COFFMAN, RL			PARTICULATE ASPERGILLUS-FUMIGATUS ANTIGENS ELICIT A T-H2 RESPONSE IN BALB/C MICE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASPERGILLUS; MURINE MODEL; CYTOKINE; IGE; EOSINOPHIL; T-H2 CELL; INTERLEUKINS; INTERFERON-GAMMA	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; HELPER T-CELLS; INTERFERON-GAMMA; IGE PRODUCTION; MURINE MODEL; EOSINOPHILIA	Background: In order to understand the immunoregulation in allergic aspergillosis, a murine model was developed by exposing animals to particulate and soluble antigens of Aspergillus fumigatus. Methods: BALB/c mice were exposed to soluble Aspergillus antigen intranasally. Animals showing moderate levels of IgE were subsequently exposed to soluble antigen or antigen conjugated to polystyrene beads intranasally. The IgE and IgG(1) in the sera and the eosinophils in the blood and lungs were studied. The spleen and lung mononuclear cells were stimulated with both concanavalin A and antigen 2 and evaluated for production of interleukin (IL)-4, IL-5, IL-10, and interferon-gamma. Results: Animals exposed to particulate antigens shelved more elevated serum IgE levels and increased members of eosinophils in the blood and lungs than those exposed to soluble antigen. Lung cell cultures from animals exposed to particulate antigens when stimulated with Aspergillus produced IL-4 and IL-5, indicating a T-H2 type of response. Animals exposed to soluble antigens showed a weaker T-H2 response, as evidenced by low IgE levels in sera, fewer eosinophils in the blood and low levels of cytokine production from lung and spleen cells. Conclusion: The results indicate that the physical nature of the antigen may have a major role in determining the type of immune response of the host.	VET AFFAIRS MED CTR, MILWAUKEE, WI USA; DNAX RES INST MOLEC & CELLULAR BIOL INC, PALO ALTO, CA 94304 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	KURUP, VP (corresponding author), MED COLL WISCONSIN, VET ADM MED CTR, RES SERV 151I, 5000 W NAT AVE, MILWAUKEE, WI 53295 USA.							BASS H, 1989, J EXP MED, V170, P1495, DOI 10.1084/jem.170.5.1495; COFFMAN RL, 1986, J IMMUNOL, V136, P949; COLLEY DG, 1972, EXP PARASITOL, V32, P520, DOI 10.1016/0014-4894(72)90070-7; GREENBERGER PA, 1988, CLIN CHEST MED, V9, P599; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; KRAMER MN, 1989, AM REV RESPIR DIS, V140, P1086, DOI 10.1164/ajrccm/140.4.1086; KUBIN R, 1992, INT ARCH ALLERGY IMM, V98, P266, DOI 10.1159/000236196; KURUP VP, 1991, CLIN MICROBIOL REV, V4, P439, DOI 10.1128/CMR.4.4.439-456.1991; KURUP VP, 1988, INT ARCH ALLER A IMM, V86, P176, DOI 10.1159/000234568; KURUP VP, 1992, J IMMUNOL, V148, P3783; KURUP VP, 1986, J ALLERGY CLIN IMMUN, V78, P1166, DOI 10.1016/0091-6749(86)90267-8; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; MURALI PS, 1992, INFECT IMMUN, V60, P1952, DOI 10.1128/IAI.60.5.1952-1956.1992; SAVELKOUL HFJ, 1991, J IMMUNOL, V146, P1801; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125	15	84	87	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1994	93	6					1013	1020		10.1016/S0091-6749(94)70050-8	http://dx.doi.org/10.1016/S0091-6749(94)70050-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT172	8006306				2022-12-18	WOS:A1994NT17200010
J	IGARASHI, Y; SKONER, DP; DOYLE, WJ; WHITE, MV; FIREMAN, P; KALINER, MA				IGARASHI, Y; SKONER, DP; DOYLE, WJ; WHITE, MV; FIREMAN, P; KALINER, MA			ANALYSIS OF NASAL SECRETIONS DURING EXPERIMENTAL RHINOVIRUS UPPER RESPIRATORY-INFECTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC RHINITIS; NASAL SECRETION; GLANDULAR SECRETION; RHINOVIRUS; VASCULAR PERMEABILITY	HISTAMINE-RELEASING ACTIVITY; PATHO-PHYSIOLOGY; MAST-CELLS; MEDIATOR RELEASE; RHINITIS; PROTEIN; BRADYKININ; MUCOSA; COLDS; MUCUS	Background: To determine the underlying mechanisms for rhinovirus-induced nasal secretions, nasal lavage fluids were analyzed during experimental rhinovirus infections. Methods: Twenty patients with allergic rhinitis and 18 nonallergic control subjects were inoculated with rhinovirus type 39. Nasal lavage was performed before and on days 2 through 7 after viral inoculation, and the lavage fluids were assayed for proteins and mast cell mediators. Results: The secretion of total protein and both plasma proteins (albumin and IgG) and glandular proteins (lactoferrin, lysozyme, and secretory IgA) increased after rhinovirus inoculation. Analysis of the specific protein constituents revealed that nasal secretions during the initial response to the rhinovirus infection were predominantly due to increased vascular permeability. Allergic subjects tended to have fewer symptoms and more vascular permeability than control subjects, and increased histamine secretion after rhinovirus inoculation was more frequently seen in the allergy group. Conclusion: Nasal secretions found early in the course of a viral upper respiratory infection are due to increased vascular permeability, whereas glandular secretions predominate later in the infection.	NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20892; UNIV PITTSBURGH,SCH MED,CHILDRENS HOSP PITTSBURGH,DEPT OTOLARYNGOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,CHILDRENS HOSP PITTSBURGH,DEPT ALLERGY IMMUNOL & RHEUMATOL,PITTSBURGH,PA 15261	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019262] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1RR00084] Funding Source: Medline; NIAID NIH HHS [AI19262] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARANIUK JN, 1990, J CLIN INVEST, V85, P998, DOI 10.1172/JCI114577; BARANIUK JN, 1991, AM J RESP CELL MOL, V4, P228, DOI 10.1165/ajrcmb/4.3.228; BARANIUK JN, 1990, AM REV RESPIR DIS, V141, P706, DOI 10.1164/ajrccm/141.3.706; BISSET GW, 1962, BRIT J PHARM CHEMOTH, V19, P168; BUTLER WT, 1970, J IMMUNOL, V105, P584; COHAN VL, 1991, BIOCHEM PHARMACOL, V41, P293, DOI 10.1016/0006-2952(91)90489-R; DOUGLAS RG, 1968, ANTIMICROBIAL AGENTS, P340; DOYLE WJ, 1992, J ALLERGY CLIN IMMUN, V89, P968, DOI 10.1016/0091-6749(92)90219-R; DOYLE WJ, 1992, J ALLERGY CLIN IMMUN, V89, P9688; EGGLESTON PA, 1984, ACTA OTOLARYNGOL S S, V413, P25; FIREMAN P, 1991, American Review of Respiratory Disease, V143, pA420; Granstrom E, 1978, Adv Prostaglandin Thromboxane Res, V5, P119; GWALTNEY JM, 1966, NEW ENGL J MED, V275, P1261, DOI 10.1056/NEJM196612082752301; GWALTNEY JM, 1966, AM REV RESPIR DIS, V93, P362; HAMORY BH, 1977, P SOC EXP BIOL MED, V155, P577, DOI 10.3181/00379727-155-39854; HEGNHOJ J, 1985, SCAND J CLIN LAB INV, V45, P489, DOI 10.3109/00365518509155248; HOLMBERG K, 1990, EUR J PHARMACOL, V175, P35, DOI 10.1016/0014-2999(90)90149-Z; HUMPARIAN VV, 1979, DIAGNOSTIC PROCEDURE, P535; IGARASHI Y, 1992, J ALLERGY CLIN IMMUN, V89, P1085, DOI 10.1016/0091-6749(92)90292-A; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; KLOCKARS M, 1975, J HISTOCHEM CYTOCHEM, V23, P932, DOI 10.1177/23.12.1104708; KNIGHT V, 1964, PROG MED VIROL, V6, P1; LEME JG, 1978, HDB EXP PHARMACOL, V50, P464; LEVISCHAFFER F, 1989, INT ARCH ALLER A IMM, V90, P352, DOI 10.1159/000235052; Lewis G.P., 1970, HDB EXP PHARM, P516; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDGREN JD, 1991, J ALLERGY CLIN IMMUN, V87, P689, DOI 10.1016/0091-6749(91)90390-A; MACGLASHAN DW, 1983, FED PROC, V42, P2504; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MCBRIDE P, 1988, J ALLERGY CLIN IMMUN, V82, P638, DOI 10.1016/0091-6749(88)90977-3; MEREDITH SD, 1989, J ALLERGY CLIN IMMUN, V84, P920, DOI 10.1016/0091-6749(89)90390-4; METCALF J, 1986, LABORATORY MANUAL NE, P153; METCALF JA, 1986, LABORATORY MANUAL NE, P149; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1988, J INFECT DIS, V157, P133, DOI 10.1093/infdis/157.1.133; OKUDA M, 1983, ANN ALLERGY, V51, P51; PAREKH HH, 1992, AM J RHINOL, V6, P107, DOI 10.2500/105065892781874685; PERSSON CGA, 1990, EUR RESPIR J, V3, pS652; PROUD D, 1990, J INFECT DIS, V161, P120, DOI 10.1093/infdis/161.1.120; RAPHAEL G, 1989, J ALLERGY CLIN IMMUN, V83, P110, DOI 10.1016/0091-6749(89)90484-3; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V88, P33, DOI 10.1016/0091-6749(91)90298-3; RAPHAEL GD, 1989, J CLIN INVEST, V84, P1528, DOI 10.1172/JCI114329; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; REMINGTON JS, 1964, J CLIN INVEST, V43, P1613, DOI 10.1172/JCI105037; ROSSEN RD, 1971, PROGR MED VIROLOGY, P194; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SKONER D, 1991, Journal of Allergy and Clinical Immunology, V87, P306, DOI 10.1016/0091-6749(91)91947-R; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; TURNER RB, 1982, J INFECT DIS, V145, P849, DOI 10.1093/infdis/145.6.849; WHITE MV, 1987, J IMMUNOL, V139, P1624; WINTHER B, 1992, AM J RHINOL, V6, P149, DOI 10.2500/105065892781874621	53	84	90	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					722	731		10.1016/0091-6749(93)90016-9	http://dx.doi.org/10.1016/0091-6749(93)90016-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227864	Bronze			2022-12-18	WOS:A1993MG98200014
J	VANDENPLAS, O; CARTIER, A; LESAGE, J; CLOUTIER, Y; PERREAULT, G; GRAMMER, LC; SHAUGHNESSY, MA; MALO, JL				VANDENPLAS, O; CARTIER, A; LESAGE, J; CLOUTIER, Y; PERREAULT, G; GRAMMER, LC; SHAUGHNESSY, MA; MALO, JL			PREPOLYMERS OF HEXAMETHYLENE DIISOCYANATE AS A CAUSE OF OCCUPATIONAL ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; OCCUPATIONAL DISEASES; BRONCHIAL PROVOCATION TESTS; ISOCYANATES	ISOCYANATE-INDUCED ASTHMA; RESPIRATORY-DISEASE; IGE ANTIBODIES; EXPOSURE; HISTAMINE; HDI; HYPERSENSITIVITY; REACTIVITY; MEDICINE; PAINTERS	Background: Occupational asthma (OA) caused by products that contain hexamethylene diisocyanate (HDI) has been ascribed to the highly volatile monomer of HDI. Most two-component paints are now made up primarily of nonvolatile prepolymers of HDI (30% to 60%) with only trace amounts (<0.1%) of the monomer. The respective role of the two chemical forms of HDI in causing OA has never been investigated. Methods: Twenty workers who were consecutively referred for possible OA that resulted from exposure to spray paints underwent inhalation challenges on separate days with pure HDI monomer and the commercial formulation of HDI prepolymers to which they had been exposed at work. Results: Specific inhalation challenges elicited a positive asthmatic reaction in 10 of the 20 subjects. Among these subjects, four had positive bronchial reactions (two early, one late, and one dual) to both the monomer and the prepolymers. Four other subjects had asthmatic reactions (two early, one late, and one dual) after exposure to the prepolymers but not after exposure to the monomer. The discordance in bronchial response elicited by the monomer and the prepolymers could not be due to differences in the level of baseline nonspecific bronchial reactivity or in HDI concentrations during the tests. One subject showed an atypical progressive reaction after exposure to the monomer but not after exposure to the prepolymer. In this case, the discordant response could be explained by differences in HDI concentration. Conclusion: These observations show that, although they are nonvolatile, the prepolymers of HDI can induce OA and that asthmatic reactions as a result of exposure to prepolymers but not the monomer is not a rare occurrence.	SACRE COEUR HOSP, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, PQ, CANADA; INST RECH SANTE & SECURITE TRAVAIL, MONTREAL, PQ, CANADA; NORTHWESTERN UNIV, SCH MED, DEPT MED, DIV ALLERGY IMMUNOL, CHICAGO, IL 60611 USA	Universite de Montreal; Northwestern University				Grammer, Leslie/0000-0001-6860-2014				AGIUS RM, 1991, ANN OCCUP HYG, V35, P129, DOI 10.1093/annhyg/35.2.129; BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; BELIN L, 1981, SCAND J WORK ENV HEA, V7, P310, DOI 10.5271/sjweh.2543; BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P24, DOI 10.1016/0091-6749(82)90197-X; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P823, DOI 10.1016/0091-6749(89)90346-1; COCKCROFT DW, 1979, CAN MED ASSOC J, V121, P602; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DAVIES RJ, 1984, CLIN IMMUNOL ALLERGY, V4, P103; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; GRAMMER LC, 1990, J ALLERGY CLIN IMMUN, V86, P94, DOI 10.1016/S0091-6749(05)80128-9; GRAMMER LC, 1988, J ALLERGY CLIN IMMUN, V82, P627, DOI 10.1016/0091-6749(88)90975-X; HARDY HL, 1979, ANN OCCUP HYG, V22, P421, DOI 10.1093/annhyg/22.4.421; INNOCENTI A, 1988, CLIN ALLERGY, V18, P323, DOI 10.1111/j.1365-2222.1988.tb02879.x; KESKINEN H, 1988, CLIN ALLERGY, V18, P597, DOI 10.1111/j.1365-2222.1988.tb02911.x; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LAGIER F, 1990, REV MAL RESPIR, V7, P337; LESAGE J, IN PRESS AM IND HYG; MALO JL, 1983, J ALLERGY CLIN IMMUN, V72, P413, DOI 10.1016/0091-6749(83)90508-0; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MAPP C E, 1992, American Review of Respiratory Disease, V145, pA502; MEREDITH SK, 1991, BRIT J IND MED, V48, P292; MUSK AW, 1988, AM J IND MED, V13, P331, DOI 10.1002/ajim.4700130304; NIELSEN J, 1985, SCAND J WORK ENV HEA, V11, P51, DOI 10.5271/sjweh.2253; OBRIEN IM, 1979, CLIN ALLERGY, V9, P1, DOI 10.1111/j.1365-2222.1979.tb01516.x; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PERRIN B, 1991, J ALLERGY CLIN IMMUN, V87, P630, DOI 10.1016/0091-6749(91)90381-W; PEZZINI A, 1984, CLIN ALLERGY, V14, P453, DOI 10.1111/j.1365-2222.1984.tb02229.x; ROSENBERG C, 1984, AM IND HYG ASSOC J, V45, P117, DOI 10.1080/15298668491399479; SCHAUERTE K, 1985, SONDERDRUCK OERTEL P, P116; SELDEN AI, 1989, SCAND J WORK ENV HEA, V15, P234, DOI 10.5271/sjweh.1857; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; SILK SJ, 1983, ANN OCCUP HYG, V27, P333, DOI 10.1093/annhyg/27.4.333; SNYDER S, 1977, ANAL BIOCHEM, V64, P284; TORNLING G, 1990, AM J IND MED, V17, P299, DOI 10.1002/ajim.4700170302; TYRER FH, 1979, J SOC OCCUP MED, V29, P22; VANDENPLAS O, 1992, AM REV RESPIR DIS, V145, P582, DOI 10.1164/ajrccm/145.3.582; VANDENPLAS O, 1992, J ALLERGY CLIN IMMUN, V89, P1183, DOI 10.1016/0091-6749(92)90303-J; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WELINDER H, 1988, CLIN ALLERGY, V18, P85, DOI 10.1111/j.1365-2222.1988.tb02847.x; 1987, AM REV RESPIR DIS, V136, P225; 1987, TLVS THRESHOLD LIMIT; 1978, US DHEW78215 PUBL	43	84	84	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1993	91	4					850	861		10.1016/0091-6749(93)90342-D	http://dx.doi.org/10.1016/0091-6749(93)90342-D			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KY251	8473673	Bronze			2022-12-18	WOS:A1993KY25100005
J	COWART, BJ; FLYNNRODDEN, K; MCGEADY, SJ; LOWRY, LD				COWART, BJ; FLYNNRODDEN, K; MCGEADY, SJ; LOWRY, LD			HYPOSMIA IN ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HYPOSMIA; NASAL RESISTANCE; ALLERGIC RHINITIS; OLFACTION; SINUSITIS; NASAL POLYPS	NASAL OBSTRUCTION; RESISTANCE; SMELL	Background: The association between nasal allergy and loss or diminution of smell is frequently alluded to in the literature; however, neither the true prevalence of hyposmia in individuals with allergic rhinitis nor its bases have been established. Methods: We assessed olfactory threshold for phenylethyl alcohol in 91 patients with symptoms of allergic rhinitis and 80 nonatopic control subjects. To determine the degree to which nasal congestion contributes to hyposmia in allergic rhinitis, total nasal resistance was measured in 64 of the patients and 72 of the control subjects. Results: Olfactory thresholds were significantly higher in allergic patients than in control subjects (p < 0.001), with 23.1% of the patients demonstrating a clinically significant smell loss (defined as threshold at or above the 2.5th percentile of control values). Although nasal resistance was significantly higher among patients than among controls (p < 0.001), it was not related to olfactory threshold in either group. Clinical or radiographic evidence of sinusitis or nasal polyps or both in allergy patients was found to be significantly associated with hyposmia (p < 0.006). Conclusions: The observed prevalence of hyposmia among patients with allergic rhinitis suggests that this is a major etiologic factor contributing to smell disorders. Sinusitis or nasal polyps or both may underlie many cases of allergy-related hyposmia.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, PHILADELPHIA, PA 19107 USA	Jefferson University	COWART, BJ (corresponding author), MONELL CHEM SENSES CTR, 3500 MARKET ST, PHILADELPHIA, PA 19104 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P50DC000214] Funding Source: NIH RePORTER; NIDCD NIH HHS [5 P50 DC00214] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Baroody FM, 1991, SMELL TASTE HLTH DIS, P529; CHURCH JA, 1978, ANN ALLERGY, V40, P105; COWART BJ, 1989, ANN NY ACAD SCI, V561, P39, DOI 10.1111/j.1749-6632.1989.tb20968.x; COWART BJ, UNPUB DISCREPANCY OD; DEEMS DA, 1991, ARCH OTOLARYNGOL, V117, P519; Doty R L, 1979, Am J Otolaryngol, V1, P57, DOI 10.1016/S0196-0709(79)80010-1; DOTY RL, 1978, PHYSIOL BEHAV, V20, P175, DOI 10.1016/0031-9384(78)90070-7; DOTY RL, 1989, OTOLARYNG CLIN N AM, V22, P397; DOTY RL, 1986, CLIN MEASUREMENT TAS, P377; ECCLES R, 1989, ACTA OTO-LARYNGOL, V108, P268, DOI 10.3109/00016488909125527; FADAL RG, 1987, OTOLARYNGOLOGY, V2, P1; FEIN BT, 1966, ANN ALLERGY, V24, P278; HENKIN RI, 1982, OTOLARYNGOLOGY, V2, P1; JALOWAYSKI AA, 1983, LARYNGOSCOPE, V93, P341; KOBAL K, 1982, EVENT RELATED POTENT, P455; MCCAFFREY TV, 1979, ARCH OTOLARYNGOL, V105, P542; McCaffrey TV, 1991, SMELL TASTE HLTH DIS, P493; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P789; PALLANCH JF, 1985, OTOLARYNG HEAD NECK, V93, P778, DOI 10.1177/019459988509300616; SEEBOLM PM, 1978, ALLERGY PRINCIPLES P, V2, P868; SEIDEN A M, 1989, Chemical Senses, V14, P746; TANNENBAUMJI, 1972, ALLERGIC DISEASES DI, P161; WETHERILL GB, 1965, BRIT J MATH STAT PSY, V18, P1, DOI 10.1111/j.2044-8317.1965.tb00689.x; ZILSTORFF K, 1972, ORL DIGEST, V34, P37; 1979, NIH791914 PHS PUBL, P319	25	84	88	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1993	91	3					747	751		10.1016/0091-6749(93)90194-K	http://dx.doi.org/10.1016/0091-6749(93)90194-K			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KU203	8454797				2022-12-18	WOS:A1993KU20300007
J	LAKE, FR; WARD, LD; SIMPSON, RJ; THOMPSON, PJ; STEWART, GA				LAKE, FR; WARD, LD; SIMPSON, RJ; THOMPSON, PJ; STEWART, GA			HOUSE DUST MITE-DERIVED AMYLASE - ALLERGENICITY AND PHYSICOCHEMICAL CHARACTERIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DERMATOPHAGOIDES-PTERONYSSINUS; CROSSED RADIOIMMUNOELECTROPHORESIS; P-II; COMPONENTS; IDENTIFICATION; ANTIGENS; EXTRACTS; SEQUENCE; PROTEIN	Amylase activity was found in extracts of both Dermatophagoides pteronyssinus whole mite (0.16 U/mg) and spent growth medium (0.01 U/mg) but not in unused growth medium. It was also detected in all extracts of house dust obtained from mattresses (n = 20; geometric mean, 1.95 U/gm) and in 18 extracts of dust obtained from lounge room carpets (n = 20; geometric mean, 0.54 U/gm). Although the origins of amylase in dust are unclear, enzyme activity correlated with mite counts (n = 40; r = 0.35; p < 0.05) and Der p I concentrations (r = 0.41; p < 0.01). Mite amylase was purified from spent growth medium by affinity chromatography, gel filtration, and chromatofocusing. It was physicochemically similar to mammalian amylase with regard to molecular weight (60,000), charge heterogeneity (isoelectric point, 5 to 7) and the capacity to bind to an organomercurial affinity matrix. The optimum pH for enzymatic activity was revealed to be 6.4. IgE immunoblot studies demonstrated that the enzyme was allergenic and that its expression was dependent on the integrity of intrachain disulfide bonds. Sera from 25% of mite-allergic children and 46% of mite-allergic adults contained specific IgE to mite amylase. IgE to amylase was associated (p < 0.01) with increased concentrations of total mite-specific IgE determined with a direct RAST assay.	PRINCESS MARGARET HOSP,WESTERN AUSTRALIAN RES INST CHILD HLTH,THOMAS ST,PERTH,WA 6008,AUSTRALIA; UNIV WESTERN AUSTRALIA,DEPT MED,PERTH,WA,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,LUDWIG INST CANC RES,JOINT PROT STRUCT LAB,PARKVILLE,VIC 3050,AUSTRALIA	Telethon Kids Institute; University of Western Australia; University of Western Australia; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute				Simpson, Richard/0000-0002-9834-0796				Baldo B.A., 1989, Advances in the Biosciences, V74, P13; BAUR X, 1984, DEUT MED WOCHENSCHR, V109, P257, DOI 10.1055/s-2008-1069177; BAUR X, 1986, LANCET, V1, P43; BEGG GS, 1989, METHODS PROTEIN SEQU, P108; BOWMAN CE, 1985, COMP BIOCHEM PHYS B, V81, P353, DOI 10.1016/0305-0491(85)90325-6; BOWMAN CE, 1982, COMP BIOCHEM PHYS B, V72, P551, DOI 10.1016/0305-0491(82)90505-3; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; COLLOFF MJ, IN PRESS CLIN EXP AL; FLINDT MLH, 1979, LANCET, V1, P1407; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; JOHANSSON E, 1988, INT ARCH ALLER A IMM, V85, P8, DOI 10.1159/000234468; Karn R.C., 1978, ADVANCES IN COMPARATIVE PHYSIOLOGY AND BIOCHEMISTRY, V7, P1; KRILIS S, 1984, J ALLERGY CLIN IMMUN, V74, P142, DOI 10.1016/0091-6749(84)90277-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LOYTER A, 1962, BIOCHIM BIOPHYS ACTA, V65, P200, DOI 10.1016/0006-3002(62)91039-9; MCWILLIAM AS, 1989, J IMMUNOL METHODS, V121, P53, DOI 10.1016/0022-1759(89)90419-5; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; STEWART GA, 1989, LANCET, V2, P154, DOI 10.1016/S0140-6736(89)90203-1; STEWART GA, 1986, J ALLERGY CLIN IMMUN, V77, P14, DOI 10.1016/0091-6749(86)90316-7; STEWART GA, UNPUB INT ARCH ALLER; STEWART GA, 1988, N ENGL REG ALLERGY P, V9, P294; TANG RB, 1988, J ASTHMA, V25, P83, DOI 10.3109/02770908809071358; TODA H, 1982, P JPN ACAD B-PHYS, V58, P208, DOI 10.2183/pjab.58.208; TOVEY ER, 1989, ELECTROPHORESIS, V10, P243, DOI 10.1002/elps.1150100405; TOVEY ER, 1987, J ALLERGY CLIN IMMUN, V79, P93, DOI 10.1016/S0091-6749(87)80022-2; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; WARD LD, 1990, CURRENT RES PROTEIN, P179; WEISMANN KJ, 1985, EUR J RESPIR DIS, V66, P13; WOJTOWICZ MB, 1972, COMP BIOCHEM PHYSIOL, V42, P295, DOI 10.1016/0305-0491(72)90274-X; 1988, B WORLD HEALTH ORGAN, V66, P769; [No title captured]	33	84	89	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1991	87	6					1035	1042		10.1016/0091-6749(91)92147-S	http://dx.doi.org/10.1016/0091-6749(91)92147-S			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR066	1710630				2022-12-18	WOS:A1991FR06600001
J	MOSCICKI, RA; SOCKIN, SM; CORSELLO, BF; OSTRO, MG; BLOCH, KJ				MOSCICKI, RA; SOCKIN, SM; CORSELLO, BF; OSTRO, MG; BLOCH, KJ			ANAPHYLAXIS DURING INDUCTION OF GENERAL-ANESTHESIA - SUBSEQUENT EVALUATION AND MANAGEMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MASSACHUSETTS GEN HOSP,GEN MED SERV,ALLERGY UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	MOSCICKI, RA (corresponding author), MASSACHUSETTS GEN HOSP,GEN MED SERV,CLIN IMMUNOL UNIT,32 FRUIT ST BULFINCH 422,BOSTON,MA 02114, USA.							BALDO BA, 1983, MOL IMMUNOL, V20, P1393, DOI 10.1016/0161-5890(83)90171-2; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BIELORY L, 1985, ANAPHYLACTOID REACTI, P97; CHARPIN D, 1988, J ALLERGY CLIN IMMUN, V82, P356, DOI 10.1016/0091-6749(88)90006-1; CHEEMA A, 1988, J ALLERGY CLIN IMMUN, V81, P220, DOI 10.1016/0091-6749(88)90443-5; CLARK MM, 1971, BRIT J ANAESTH, V43, P185, DOI 10.1093/bja/43.2.185; CLARKE RSJ, 1981, DRUGS, V22, P26, DOI 10.2165/00003495-198122010-00002; CLARKE RSJ, 1975, BRIT J ANAESTH, V47, P575, DOI 10.1093/bja/47.5.575; DESWARTE RD, 1985, ALLERGIC DISEASES DI, P595; DOLOVICH J, 1980, CAN MED ASSOC J, V123, P292; FISHER M M, 1976, Anaesthesia and Intensive Care, V4, P97; FISHER MM, 1984, ANAESTHESIA, V39, P213, DOI 10.1111/j.1365-2044.1984.tb07229.x; FISHER MM, 1984, CRIT CARE MED, V12, P351, DOI 10.1097/00003246-198404000-00002; FISHER MM, 1981, ANAESTH INTENS CARE, V9, P235, DOI 10.1177/0310057X8100900305; FISHER MM, 1989, ANAESTH INTENS CARE, V17, P361, DOI 10.1177/0310057X8901700322; FISHER MM, 1981, ANAESTH INTENS CARE, V9, P226, DOI 10.1177/0310057X8100900304; FISHER MM, 1983, ANESTH ANALG, V62, P559; FISHER MM, 1981, ANAESTH INTENS CARE, V9, P242, DOI 10.1177/0310057X8100900306; FISHER MM, 1980, ANESTHESIOLOGY, V52, P318, DOI 10.1097/00000542-198004000-00006; FISHER MM, 1979, ANAESTH INTENS CARE, V7, P58, DOI 10.1177/0310057X7900700110; FISHER MM, 1987, BRIT J ANAESTH, V59, P690, DOI 10.1093/bja/59.6.690; FISHER MM, 1984, CLIN ANAESTHESIOL, V2, P677; FOX GS, 1971, ANESTHESIOLOGY, V35, P655, DOI 10.1097/00000542-197112000-00024; GREENBERGER PA, 1985, ARCH INTERN MED, V145, P2197, DOI 10.1001/archinte.145.12.2197; GULDAGER H, 1987, ACTA ANAESTH SCAND, V31, P728, DOI 10.1111/j.1399-6576.1987.tb02653.x; HAGY GW, 1971, J ALLERGY CLIN IMMUN, V48, P200, DOI 10.1016/0091-6749(71)90066-2; HARLE DG, 1987, INT ARCH ALLER A IMM, V84, P277, DOI 10.1159/000234435; HARLE DG, 1984, LANCET, V1, P930; HARLE DG, 1986, CLIN ALLERGY, V16, P493, DOI 10.1111/j.1365-2222.1986.tb01984.x; HIRSHMAN CA, 1982, ANESTHESIOLOGY, V56, P64, DOI 10.1097/00000542-198201000-00018; LAFOREST M, 1980, ANAESTH INTENS CARE, V8, P454, DOI 10.1177/0310057X8000800412; LAXENAIRE MC, 1982, KLIN WOCHENSCHR, V60, P1006, DOI 10.1007/BF01716963; LAXENAIRE MG, 1985, ANAPHYLACTOID REACTI, P145; LEYNADIER F, 1987, BRIT J ANAESTH, V59, P683, DOI 10.1093/bja/59.6.683; LILLY JK, 1980, ANESTHESIOLOGY, V53, P335, DOI 10.1097/00000542-198010000-00009; LORENZ W, 1985, ANESTHESIOLOGY, V63, P351, DOI 10.1097/00000542-198510000-00001; LORENZ W, 1972, BRIT J ANAESTH, V44, P355, DOI 10.1093/bja/44.4.355; LORENZ W, 1981, ADVERSE REACTIONS AN, P169; MOSS J, 1981, ANESTHESIOLOGY, V55, P19, DOI 10.1097/00000542-198107000-00006; RING J, 1985, ANAPHYLACTOID REACTI, P67; SAGE D, 1981, ANAESTH INTENS CARE, V9, P381, DOI 10.1177/0310057X8100900411; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SOLATER JE, 1989, NEW ENGL J MED, V320, P1126; STOELTING RK, 1983, ANESTH ANALG, V62, P341; TANNENBAUM H, 1975, J ALLERGY CLIN IMMUN, V56, P226, DOI 10.1016/0091-6749(75)90094-9; VERVLOET D, 1983, J ALLERGY CLIN IMMUN, V71, P552, DOI 10.1016/0091-6749(83)90436-0; VERVLOET D, 1985, J ALLERGY CLIN IMMUN, V75, P338, DOI 10.1016/0091-6749(85)90069-7; VERVLOET D, 1979, J ALLERGY CLIN IMMUN, V63, P348, DOI 10.1016/0091-6749(79)90130-1; WATKINS J, 1979, BRIT J ANAESTH, V51, P51, DOI 10.1093/bja/51.1.51; WATKINS J, 1981, ADVERSE REACTIONS AN, P137; YOUNGMAN PR, 1983, LANCET, V2, P597	51	84	85	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1990	86	3	1				325	332		10.1016/S0091-6749(05)80095-8	http://dx.doi.org/10.1016/S0091-6749(05)80095-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA859	2212407				2022-12-18	WOS:A1990EA85900006
J	HOLGATE, ST; FINNERTY, JP				HOLGATE, ST; FINNERTY, JP			ANTIHISTAMINES IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SOUTHAMPTON,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND	University of Southampton	HOLGATE, ST (corresponding author), SOUTHAMPTON GEN HOSP,IMMUNOPHARMACOL GRP,LEVEL D,CTR BLOCK,TREMONA RD,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							ABRAHAM WM, 1983, AM REV RESPIR DIS, V128, P839; ALTOUNYAN REC, 1986, EUR J RESPIR DIS, V69, P274; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; BARNES PJ, 1987, TRENDS PHARMACOL SCI, V8, P24, DOI 10.1016/0165-6147(87)90029-0; BARNES PJ, 1981, CLIN SCI, V61, P159, DOI 10.1042/cs0610159; BEASLEY CRW, 1987, J CLIN INVEST, V79, P978, DOI 10.1172/JCI112909; BEASLEY R, 1987, AM REV RESPIR DIS, V136, P1140, DOI 10.1164/ajrccm/136.5.1140; BEASLEY RC, 1988, THORAX, V43, P812; BENYON RC, 1987, J IMMUNOL, V138, P861; BENYON RC, 1987, BRIT J PHARMACOL, V92, P635, DOI 10.1111/j.1476-5381.1987.tb11366.x; BENYON RC, 1988, J ALLERGY CLIN IMMUN, V81, P297, DOI 10.1016/0091-6749(88)90749-X; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BRAUDE S, 1984, LANCET, V2, P372; CHAN TB, 1987, BRIT J DIS CHEST, V81, P260, DOI 10.1016/0007-0971(87)90159-8; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; CHURCH MK, 1982, CLIN ALLERGY, V12, P223, DOI 10.1111/j.1365-2222.1982.tb02522.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; CURRY JJ, 1946, J CLIN INVEST, V25, P792, DOI 10.1172/JCI101765; CURZEN N, 1987, THORAX, V42, P946, DOI 10.1136/thx.42.12.946; Dale HH, 1919, J PHYSIOL-LONDON, V52, P355; DAVIES SE, 1968, BRIT MED J, V3, P593, DOI 10.1136/bmj.3.5618.593; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DEMONCHY JGR, 1985, AGENTS ACTIONS, V16, P252; DIXON CMS, IN PRESS BR J CLIN P; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; DVORAK AM, 1988, MAST CELLS MEDIATORS, P29; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; FINDLAY SR, 1981, J CLIN INVEST, V67, P1604, DOI 10.1172/JCI110195; FINNERTY JP, 1988, J ALLERGY CLIN IMMUN, V81, P240, DOI 10.1016/0091-6749(88)90524-6; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; FLINT KC, 1987, BLOOMSBURY SERIES CL, P35; FLINT KC, 1987, BLOOMSBURY SERIES CL, P13; FREED AN, 1987, J APPL PHYSIOL, V62, P574, DOI 10.1152/jappl.1987.62.2.574; GRAVELYN TR, 1988, AM REV RESPIR DIS, V137, P641, DOI 10.1164/ajrccm/137.3.641; GROGGINS RC, 1979, BRIT J DIS CHEST, V73, P297, DOI 10.1016/0007-0971(79)90056-1; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; HIRXHEIMER H, 1949, BRIT MED J, V2, P901; HOLGATE ST, 1984, J IMMUNOL, V133, P2138; HOLGATE ST, 1986, J ALLERGY CLIN IMMUN, V77, P274, DOI 10.1016/S0091-6749(86)80104-X; HOLGATE ST, 1987, CLIN SCI, V73, P561, DOI 10.1042/cs0730561; HOLGATE ST, 1985, INT ARCH ALLER A IMM, V77, P47, DOI 10.1159/000233752; HOLGATE ST, 1987, ALLERGY, V42, P727; HOLGATE ST, 1988, Q J MED, V149, P5; HOWARTH PH, 1985, J ALLERGY CLIN IMMUN, V75, P166, DOI 10.1016/0091-6749(85)90383-5; HOWARTH PH, 1984, J ALLERGY CLIN IMMUN, V73, P391, DOI 10.1016/0091-6749(84)90414-7; HOWARTH PH, 1987, J ALLERGY CLIN IMMUN, V80, P703, DOI 10.1016/0091-6749(87)90291-0; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; HUTSON PA, 1988, AM REV RESPIR DIS, V137, P548, DOI 10.1164/ajrccm/137.3.548; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; KARLIN JM, 1972, ANN ALLERGY, V30, P342; KASUYA S, 1988, Pharmatherapeutica, V5, P177; KEMP JP, 1987, J ALLERGY CLIN IMMUN, V79, P893, DOI 10.1016/0091-6749(87)90238-7; KIMANI G, 1988, J IMMUNOL, V140, P3161; LARSEN GL, 1987, ALLERGY INFLAMMATION, P225; LEE TH, 1984, J ALLERGY CLIN IMMUN, V73, P634, DOI 10.1016/0091-6749(84)90296-3; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LEUNG KBP, 1986, AGENTS ACTIONS, V18, P100; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; LOZEWICZ S, 1988, THORAX, V43, P238; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MANN JS, 1985, BRIT J CLIN PHARMACO, V19, P685, DOI 10.1111/j.1365-2125.1985.tb02696.x; MAYRHOFER G, 1979, IMMUNOLOGY, V37, P145; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; MCFADDEN ER, 1984, J ALLERGY CLIN IMMUN, V73, P413, DOI 10.1016/0091-6749(84)90347-6; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; MISZKIEL KA, 1988, BRIT J CLIN PHARMACO, V26, P295, DOI 10.1111/j.1365-2125.1988.tb05280.x; MORTAGY AK, 1986, BRIT MED J, V293, P525, DOI 10.1136/bmj.293.6546.525; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; NATHAN RA, 1981, J ALLERGY CLIN IMMUN, V67, P171, DOI 10.1016/0091-6749(81)90057-9; NORGRADY SG, 1978, THORAX, V33, P700; PATEL KR, 1984, BRIT MED J, V288, P1496, DOI 10.1136/bmj.288.6429.1496; PATEL KR, 1987, J ALLERGY CLIN IMMUN, V79, P355, DOI 10.1016/0091-6749(87)90155-2; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PETERS SP, 1982, AM REV RESPIR DIS, V126, P1034; PHILLIPS GD, 1987, THORAX, V42, P939, DOI 10.1136/thx.42.12.939; PHILLIPS MJ, 1984, THORAX, V39, P345, DOI 10.1136/thx.39.5.345; POPA VT, 1977, J ALLERGY CLIN IMMUN, V59, P54, DOI 10.1016/0091-6749(77)90177-4; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; RAFFERTY P, UNPUB BR J CLIN PHAR; RAFFERTY P, IN PRESS J ALLERGY C; ROCKLIN RE, 1983, ADV INTERNAL MED, V28, P225; SCHWARTZ LB, 1987, AM REV RESPIR DIS, V135, P1186; SMITH CM, 1986, J ALLERGY CLIN IMMUN, V77, P729, DOI 10.1016/0091-6749(86)90419-7; STORMS W, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90386-0; TASHKIN DP, 1987, ANN ALLERGY, V2, P59; TAYTARD A, 1987, BRIT J CLIN PHARMACO, V24, P743, DOI 10.1111/j.1365-2125.1987.tb03240.x; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; TUNG R, 1982, J IMMUNOL, V129, P2113; WHITE J, 1983, BRIT J DIS CHEST, V77, P215; WILMOT C, 1988, THORAX, V43, P865	100	84	86	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	2				537	547		10.1016/0091-6749(89)90035-3	http://dx.doi.org/10.1016/0091-6749(89)90035-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4491	2563745				2022-12-18	WOS:A1989T449100006
J	STRUNK, RC				STRUNK, RC			IDENTIFICATION OF THE FATALITY-PRONE SUBJECT WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST LOUIS CHILDRENS HOSP, DIV PULM MED, ST LOUIS, MO 63178 USA; ST LOUIS CHILDRENS HOSP, DIV ALLERGY IMMUNOL, ST LOUIS, MO 63178 USA	St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	STRUNK, RC (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PEDIAT, 400 S KINGSHIGHWAY BLVD, ST LOUIS, MO 63110 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K07AI000543] Funding Source: NIH RePORTER; NIAID NIH HHS [KO7-AI 00543] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER HL, 1963, J ALLERGY, V34, P305, DOI 10.1016/0021-8707(63)90039-X; ATTAWAY NJ, 1988, J ALLERGY CLIN IMMUN, V81, P306, DOI 10.1016/0091-6749(88)90786-5; BATEMAN JRM, 1979, THORAX, V34, P40, DOI 10.1136/thx.34.1.40; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; British Thoracic Association, 1982, BR MED J CLIN RES ED, V285, P1251; DIRKS JF, 1982, J ASTHMA, V19, P177, DOI 10.3109/02770908209104755; DRISLANE FW, 1987, AM REV RESPIR DIS, V135, P498; DWORETZK.M, 1968, J ALLERGY, V41, P181, DOI 10.1016/0021-8707(68)90041-5; EARLE BV, 1953, THORAX, V8, P195, DOI 10.1136/thx.8.3.195; EASON J, 1987, BRIT MED J, V294, P1255, DOI 10.1136/bmj.294.6582.1255; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; Fraser P M, 1971, Br J Dis Chest, V65, P71; FRITZ GK, 1987, AM J ORTHOPSYCHIAT, V57, P253, DOI 10.1111/j.1939-0025.1987.tb03535.x; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; KRAVIS LP, 1985, AM J DIS CHILD, V139, P558, DOI 10.1001/archpedi.1985.02140080028026; KRAVIS LP, 1978, ADV ASTHMA ALLERGY P, V4, P26; KURLAND G, 1979, J ALLERGY CLIN IMMUN, V63, P407, DOI 10.1016/0091-6749(79)90214-8; MACDONALD JB, 1976, BRIT MED J, V1, P1493, DOI 10.1136/bmj.1.6024.1493; MATSON JR, 1978, J PEDIATR-US, V92, P776, DOI 10.1016/S0022-3476(78)80150-4; MELLIS CM, 1977, THORAX, V32, P29, DOI 10.1136/thx.32.1.29; MILLER BD, 1988, J ALLERGY CLIN IMMUN, V81, P306, DOI 10.1016/0091-6749(88)90785-3; NGUYEN MT, 1985, ANN ALLERGY, V55, P448; OHOLLAREN MT, 1988, J ALLERGY CLIN IMMUN, V81, P246, DOI 10.1016/0091-6749(88)90547-7; OHOLLAREN MT, 1986, J ALLERGY CLIN IMMUN, V77, P199; RACKEMANN FM, 1952, NEW ENGL J MED, V246, P815, DOI 10.1056/NEJM195205222462104; RACKEMANN FM, 1944, J ALLERGY, V15, P249; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; REA HH, 1987, NEW ZEAL MED J, V100, P10; RICHARDS W, 1965, AM J DIS CHILD, V110, P4, DOI 10.1001/archpedi.1965.02090030010003; ROE P F, 1965, Br J Dis Chest, V59, P158, DOI 10.1016/S0007-0971(65)80006-7; ROOT RK, 1987, WESTERN J MED, V147, P314; ROTHWELL RPG, 1987, NEW ZEAL MED J, V100, P199; SEARS MR, 1985, NEW ZEAL MED J, V98, P271; SEARS MR, 1986, ARCH DIS CHILD, V61, P6, DOI 10.1136/adc.61.1.6; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P319, DOI 10.1016/0091-6749(87)90038-8; SIEGEL SC, 1987, J ALLERGY CLIN IMMUN, V80, P458, DOI 10.1016/0091-6749(87)90075-3; SLY RM, 1984, ANN ALLERGY, V53, P20; SLY RM, 1986, ANN ALLERGY, V56, P207; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; STRUNK RC, 1987, J ALLERGY CLIN IMMUN, V80, P455, DOI 10.1016/0091-6749(87)90073-X; STRUNK RC, 1987, PEDIATR ASTHMA ALLER, V1, P5; SUTHERLAND DC, 1984, NEW ZEAL MED J, V97, P845; WILSONPESSANO SR, 1987, J ALLERGY CLIN IMMUN, V80, P487, DOI 10.1016/0091-6749(87)90081-9; 1987, BR J DIS CHEST, V81, P30	46	84	84	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	1				477	485		10.1016/0091-6749(89)90137-1	http://dx.doi.org/10.1016/0091-6749(89)90137-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4489	2645346	Bronze			2022-12-18	WOS:A1989T448900018
J	BERNSTEIN, IL				BERNSTEIN, IL			PROCEEDINGS OF THE TASK-FORCE ON GUIDELINES FOR STANDARDIZING OLD AND NEW TECHNOLOGIES USED FOR THE DIAGNOSIS AND TREATMENT OF ALLERGIC DISEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BERNSTEIN, IL (corresponding author), UNIV CINCINNATI,MED CTR,CINCINNATI,OH 45267, USA.							AAS K, 1980, ALLERGY, V36, P250; ADKINSON NF, 1981, J ALLERGY CLIN IMMUN, V67, P87, DOI 10.1016/0091-6749(81)90001-4; AGRUP G, 1968, BRIT J DERMATOL, V80, P631, DOI 10.1111/j.1365-2133.1968.tb11912.x; ARCHER CB, 1984, BRIT J DERMATOL, V110, P45, DOI 10.1111/j.1365-2133.1984.tb07310.x; ATKINS PC, 1988, ANN ALLERGY, V60, P27; BASOMBA A, 1985, ALLERGY, V40, P395, DOI 10.1111/j.1398-9995.1985.tb02677.x; BASRAN GS, 1984, CLIN ALLERGY, V14, P75, DOI 10.1111/j.1365-2222.1984.tb02193.x; BATES SE, 1979, CANCER, V43, P2306, DOI 10.1002/1097-0142(197906)43:6<2306::AID-CNCR2820430621>3.0.CO;2-K; BEAVEN MA, 1982, KLIN WOCHENSCHR, V60, P873, DOI 10.1007/BF01716943; BELIN LGA, 1977, CLIN ALLERGY, V7, P55, DOI 10.1111/j.1365-2222.1977.tb01425.x; BENDIXIN G, 1967, ACTA MED SCAND, V181, P247; BENNICH H, 1967, IMMUNOLOGY, V13, P381; BJORKSTEN F, 1984, J ALLERGY CLIN IMMUN, V73, P324, DOI 10.1016/0091-6749(84)90404-4; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; BORISH L, 1986, MANUAL CLIN LABORATO, P282; BOULET LP, 1984, CLIN ALLERGY, V14, P379, DOI 10.1111/j.1365-2222.1984.tb02219.x; BOYDEN SV, 1956, ADV TUBERC RES, V7, P17; BRIGHTON WD, 1979, CLIN ALLERGY, V9, P591, DOI 10.1111/j.1365-2222.1979.tb00484.x; BROWN HM, 1981, CLIN ALLERGY, V11, P95, DOI 10.1111/j.1365-2222.1981.tb01571.x; BRUYNZEEL DP, 1986, ARCH DERMATOL, V122, P323, DOI 10.1001/archderm.122.3.323; BUCKLEY CE, 1982, J ALLERGY CLIN IMMUN, V69, P25, DOI 10.1016/0091-6749(82)90083-5; CHRISTENSEN OB, 1987, CONTACT DERMATITIS, V16, P21, DOI 10.1111/j.1600-0536.1987.tb02610.x; CLAUSEN JE, 1971, ACTA ALLERGOL, V26, P56, DOI 10.1111/j.1398-9995.1971.tb01399.x; CRONIN E, 1978, CONTACT DERMATITIS, V4, P301; DALE HH, 1969, EXCERPTS CLASSICS AL, P44; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; DEFILIPPI I, 1981, ANN ALLERGY, V46, P249; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DESHAZO RD, 1982, J ALLERGY CLIN IMMUN, V69, P729; DIAMANT B, 1982, INT ARCH ALLER A IMM, V67, P13, DOI 10.1159/000232981; DIRKSEN A, 1985, ALLERGY, V40, P620, DOI 10.1111/j.1398-9995.1985.tb00893.x; DOLOVICH J, 1983, ANN ALLERGY, V50, P241; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DOR PJ, 1983, J ALLERGY CLIN IMMUN, V71, P363, DOI 10.1016/0091-6749(83)90063-5; DOVORAK HF, 1986, HUM PATHOL, V17, P122; DUNN JA, 1978, BRIT MED J, V1, P1451; ESCH RE, 1988, J BIOL STAND, V16, P33, DOI 10.1016/0092-1157(88)90027-3; FEINBERG SM, 1946, ALLERGY PRACTICE; Fisher A. A., 1986, CONTACT DERMATITIS; FRAZER IH, 1985, CLIN IMMUNOL IMMUNOP, V35, P182, DOI 10.1016/0090-1229(85)90064-9; Fregert S, 1969, Trans St Johns Hosp Dermatol Soc, V55, P17; GELL PGH, 1951, BRIT J EXP PATHOL, V32, P516; GEORGE M, 1962, P SOC EXP BIOL MED, V111, P514; GERGEN PJ, 1986, DHHS PHS861685 PUBL; GMELIGMEYLING F, 1980, J IMMUNOL METHODS, V33, P1, DOI 10.1016/0022-1759(80)90077-0; GRONNEBERG R, 1985, CLIN ALLERGY, V15, P167, DOI 10.1111/j.1365-2222.1985.tb02270.x; GRONNEBERG R, 1984, ALLERGY, V39, P115, DOI 10.1111/j.1398-9995.1984.tb01942.x; GRONNEBERG R, 1984, ALLERGY, V39, P119, DOI 10.1111/j.1398-9995.1984.tb01943.x; GRONNEBERG R, 1985, ALLERGY, V40, P223; GRONNEBERG R, 1981, ALLERGY, V36, P201, DOI 10.1111/j.1398-9995.1981.tb01835.x; HAMILTON RG, 1986, CLIN IMMUNOL NEWSLET, V7, P1; HANNUKSELA M, 1986, CONTACT DERMATITIS, V14, P221, DOI 10.1111/j.1600-0536.1986.tb01229.x; HARRINGTON JT, 1973, J IMMUNOL, V110, P752; HOLGERSSON M, 1985, ALLERGY S4, V40, P64; HORDLE DA, 1984, J IMMUNOL METHODS, V75, P369, DOI 10.1016/0022-1759(84)90121-2; HUBER B, 1983, CLIN ALLERGY, V13, P467, DOI 10.1111/j.1365-2222.1983.tb02623.x; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; JADASSOHN J, 1969, EXCERPTS CLASSICS AL, P26; JORDAN WP, 1986, ARCH DERMATOL, V122, P1127, DOI 10.1001/archderm.122.10.1127; KELLEY KW, 1982, AM J VET RES, V43, P775; KEMENY DM, 1986, J IMMUNOL METHODS, V87, P45, DOI 10.1016/0022-1759(86)90342-X; KNAUER KA, 1983, ALLERGY PRINCIPLES P, P673; KONTTINEN YT, 1983, CLIN IMMUNOL IMMUNOP, V28, P441, DOI 10.1016/0090-1229(83)90111-3; LEMANSKE R, 1981, CLIN IMMUNOL REV, V4, P547; LEMANSKE RF, 1983, INT J DERMATOL, V22, P401, DOI 10.1111/j.1365-4362.1983.tb02158.x; LEWIS RA, 1981, J EXP MED, V154, P1243, DOI 10.1084/jem.154.4.1243; Lewis T, 1924, HEART-J STUD CIRC, V11, P119; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; LOCKEY RF, 1976, BRONCHIAL ASTHMA MEC, P613; MALLING HJ, 1982, ALLERGY, V37, P563, DOI 10.1111/j.1398-9995.1982.tb02341.x; MALLING HJ, 1985, ALLERGY, V40, P400, DOI 10.1111/j.1398-9995.1985.tb02678.x; MATHIAS CGT, 1979, INT J DERMATOL, V18, P127; MCCOY JL, 1977, J IMMUNOL METHODS, V15, P355, DOI 10.1016/0022-1759(77)90097-7; MENARDO JL, 1982, ANN ALLERGY, V48, P235; MENEGHINI CL, 1972, ANN DERMATOL VENEREO, V99, P276; NELSON HS, 1983, ANN ALLERGY, V51, P411; NIEROP G, 1981, ANN ALLERGY, V46, P105; NOWELL PC, 1960, CANCER RES, V20, P462; OPPENHEIM JJ, 1975, LABORATORY DIAGNOSIS, P87; OWNBY DR, 1982, J ALLERGY CLIN IMMUN, V69, P533, DOI 10.1016/0091-6749(82)90179-8; OWNBY DR, 1984, J ALLERGY CLIN IMMUN, V69, P536; PELTONEN L, 1981, CONTACT DERMATITIS, V7, P192, DOI 10.1111/j.1600-0536.1981.tb04041.x; Pepys J., 1975, BR J HOSP MED, V14, P412; PLATT JL, 1983, J EXP MED, V158, P1227, DOI 10.1084/jem.158.4.1227; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; PRICE JF, 1982, CLIN EXP IMMUNOL, V47, P587; PRZYBYSZEWSKI VA, 1983, ALLERGEN SPECIFIC IM; REINBERG A, 1969, J ALLERGY, V44, P292, DOI 10.1016/0021-8707(69)90034-3; RIETSCHEL RL, IN PRESS J AM ACAD D; ROCKLIN R, 1978, FED PROC, V37, P2743; ROCKLIN RE, 1970, J IMMUNOL, V104, P95; ROCKLIN RE, 1974, J IMMUNOL, V112, P1461; ROCKLIN RE, 1970, NEW ENGL J MED, V232, P1340; ROCKLIN RE, 1970, 5 P LEUK CULT C, P639; RUDZKI E, 1976, CONTACT DERMATITIS, V2, P309; SCHATZ M, 1976, ANN INTERN MED, V84, P261, DOI 10.7326/0003-4819-84-3-261; SCHERR MS, 1971, ANN ALLERGY, V29, P30; SELTZER JM, 1985, ANN ALLERGY, V54, P25; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; Siraganian RP, 1986, MANUAL CLIN LABORATO, P675; SKOG E, 1978, CONTACT DERMATITIS, V4, P362, DOI 10.1111/j.1600-0536.1978.tb03851.x; SKOG E, 1965, ARCH DERMATOL, V92, P276, DOI 10.1001/archderm.92.3.276; SKOV PS, 1985, ALLERGY, V40, P213; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; SNIDER DE, 1982, AM REV RESPIR DIS, V125, P108; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SQUIRE JR, 1950, CLIN SCI, V9, P127; STABERG B, 1984, ARCH DERMATOL, V120, P741, DOI 10.1001/archderm.120.6.741; TAYLOR G, 1971, Clinical Allergy, V1, P407, DOI 10.1111/j.1365-2222.1971.tb00792.x; TAYLOR RN, 1981, PROFICIENCY TESTING; THOMPSON NJ, 1979, AM REV RESPIR DIS, V119, P587; THRESTRUPPETERS.K, 1975, IMMUNOLOGY, V28, P343; TURKELTAUB PC, 1986, CLIN REV ALLERG, V4, P371; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; WARNER JO, 1976, ARCH DIS CHILD, V51, P905, DOI 10.1136/adc.51.12.905; WEISER WY, 1981, J IMMUNOL, V126, P1958; WIDE L, 1967, LANCET, V2, P1105; WOODRUFF WW, 1984, INFECT IMMUN, V43, P860, DOI 10.1128/IAI.43.3.860-869.1984; 1984, Patent No. 5783; [No title captured]; METHODS LABORATORY A	123	84	84	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	2				487	526		10.1016/0091-6749(88)90958-X	http://dx.doi.org/10.1016/0091-6749(88)90958-X			40	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q4609					2022-12-18	WOS:A1988Q460900001
J	TOVEY, ER; BALDO, BA				TOVEY, ER; BALDO, BA			COMPARISON BY ELECTROBLOTTING OF IGE-BINDING COMPONENTS IN EXTRACTS OF HOUSE DUST MITE BODIES AND SPENT MITE CULTURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL N SHORE HOSP,KOLLING INST MED RES,ST LEONARDS,NSW 2065,AUSTRALIA; UNIV SYDNEY,DEPT MED,SYDNEY,NSW 2006,AUSTRALIA	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; University of Sydney			Tovey, Euan R/G-8604-2017	Tovey, Euan R/0000-0002-1802-7266				ANDERSON NL, 1982, ELECTROPHORESIS, V3, P135, DOI 10.1002/elps.1150030304; BALDO BA, 1986, J BIOCHEM BIOPH METH, V12, P271, DOI 10.1016/0165-022X(86)90063-1; BERS G, 1985, Biotechniques, V3, P276; BJERRUM OJ, 1983, MODERN METHODS PROTE, P111; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1978, CLIN EXP IMMUNOL, V34, P126; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; FORD A, 1983, REPORT COLLABORATIVE; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; FORD SA, 1985, INT ARCH ALLER A IMM, V78, P15, DOI 10.1159/000233855; FORD SA, INT ARCH ALLERGY APP; GERSHONI JM, 1982, ANAL BIOCHEM, V124, P396, DOI 10.1016/0003-2697(82)90056-2; ISHII A, 1982, ALLERGY, V37, P285, DOI 10.1111/j.1398-9995.1982.tb01912.x; KLINMAN NR, 1969, CLIN EXP IMMUNOL, V4, P473; KRILIS S, 1984, J ALLERGY CLIN IMMUN, V74, P142, DOI 10.1016/0091-6749(84)90277-X; LEMAO J, 1983, J ALLERGY CLIN IMMUN, V71, P588, DOI 10.1016/0091-6749(83)90441-4; LIN W, 1983, ANAL BIOCHEM, V128, P302, DOI 10.1016/0003-2697(83)90379-2; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LIND P, 1980, ALLERGY, V35, P227, DOI 10.1111/j.1398-9995.1980.tb01756.x; LIND P, 1984, ALLERGY, V39, P259, DOI 10.1111/j.1398-9995.1984.tb00863.x; NEUHOFF V, 1984, ELECTROPHORESIS 84, P317; PEPYS J, 1968, LANCET, V1, P1270; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P711, DOI 10.1136/adc.49.9.711; STEWART GA, 1980, AUST J EXP BIOL MED, V58, P259, DOI 10.1038/icb.1980.26; STEWART GA, 1982, INT ARCH ALLER A IMM, V69, P224, DOI 10.1159/000233175; TOVEY ER, 1984, INT ARCH ALLER A IMM, V75, P322, DOI 10.1159/000233641; TOVEY ER, 1985, INT ARCH ALLER A IMM, V76, P82, DOI 10.1159/000233667; TOVEY ER, 1978, CLIN ALLERGY, V8, P329, DOI 10.1111/j.1365-2222.1978.tb00468.x; TOVEY ER, J BIOCH BIOPHYS METH; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHARTON GW, 1976, J MED ENTOMOL, V12, P577, DOI 10.1093/jmedent/12.6.577	31	84	91	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					93	102		10.1016/S0091-6749(87)80022-2	http://dx.doi.org/10.1016/S0091-6749(87)80022-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810	2433323				2022-12-18	WOS:A1987F881000018
J	GERVAIS, P; REINBERG, A; GERVAIS, C; SMOLENSKY, M; DEFRANCE, O				GERVAIS, P; REINBERG, A; GERVAIS, C; SMOLENSKY, M; DEFRANCE, O			24-HOUR RHYTHM IN BRONCHIAL HYPERREACTIVITY TO HOUSE DUST IN ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FONDAT ROTHSCHILD,CNRS,EQUIPE RECH CHRONOBIOL HUMAINE 105,F-75010 PARIS,FRANCE; FONDAT ROTHSCHILD,DEPT ALLERGOL,F-75010 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite								Aschoff J, 1965, CIRCADIAN CLOCKS, P214; CHAI H, 1968, J ALLERGY, V41, P23, DOI 10.1016/0021-8707(68)90005-1; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; GAULTIER C, 1975, CR ACAD SCI PARIS, V238, P1253; GERVAIS P, 1976, CHRONOBIOLOGY ALLERG; HALBERG F, 1975, PHYSIOL TEACHER, V1, P35; Halberg F., 1967, CELLULAR ASPECTS BIO, P20, DOI DOI 10.1007/978-3-642-88394-1; MCGOVERN JP, 1976, CHRONOBIOLOGY ALLERG; REINBERG A, 1971, CR ACAD SCI D NAT, V272, P1879; REINBERG A, 1972, B PHYSIO-PATHOL RESP, V8, P663; REINBERG A, 1969, J ALLERGY, V44, P292, DOI 10.1016/0021-8707(69)90034-3; Reinberg A, 1974, Chronobiologia, V1 Suppl 1, P157; REINBERG A, 1971, ANNU REV PHARMACOLOG, V11, P455, DOI 10.1146/annurev.pa.11.040171.002323; REINBERG A, 1975, Folia Allergologica et Immunologica Clinica, V22, P559; REINBERG A, 1974, CHRONOBIOLOGIA, V1, P333; REINBERG A, 1970, PRESSE MED, V78, P1817; REINBERG A, 1971, 2ND P INT CLEAN AIR, P217; Reinberg A, 1974, BIORHYTHMS HUMAN REP, P241; REINBERG A, 1974, 1971 INT SOC CHRON M, P174; REINBERG A, 1976, CHRONOBIOLOGY ALLERG; Reindl K, 1969, Rass Neurol Veg, V23, P5; SMOLENSKY H, 1972, ADV CLIMATIC PHYSIOL, P281; SMOLENSKY M, 1975, MAY P INT C ASTHM RE, P35; SMOLENSKY MH, 1974, BIORHYTHMS HUMAN REP, P287; TAMMELING G J, 1976, International Journal of Chronobiology, V3, P155; TAMMELING GJ, 1976, CHRONOBIOLOGY ALLERG	26	84	84	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	3					207	213		10.1016/0091-6749(77)90151-8	http://dx.doi.org/10.1016/0091-6749(77)90151-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CZ249	838991	Bronze			2022-12-18	WOS:A1977CZ24900004
J	WOOD, DW; SCHEINKOPF, H; LECKS, HI; DOWNES, JJ				WOOD, DW; SCHEINKOPF, H; LECKS, HI; DOWNES, JJ			INTRAVENOUS ISOPROTERENOL IN MANAGEMENT OF RESPIRATORY FAILURE IN CHILDHOOD STATUS ASTHMATICUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BEAM LR, 1965, J AMER MED ASSOC, V194, P968, DOI 10.1001/jama.194.9.968; BLOOM B, 1962, LANCET, V2, P1174; COHEN EN, 1949, ANESTHESIOLOGY, V10, P451, DOI 10.1097/00000542-194907000-00012; COLLINSWILLIAMS C, 1968, ANN ALLERGY, V26, P117; COMROE JH, 1962, LUNG, P339; CONWAY WD, 1968, J PHARM SCI-US, V57, P1135, DOI 10.1002/jps.2600570710; DOWNES JJ, 1968, PEDIATRICS, V42, P238; GLASER J, 1956, ALLERGY CHILDHOOD, P249; HARWOOD CW, 1968, PERSONAL COMMUNICATI; INOUE S, 1967, J ALLERGY, V40, P337, DOI 10.1016/0021-8707(67)90023-8; KIRKPATRICK CH, 1967, AM REV RESPIR DIS, V96, P692; KNUDSON RJ, 1967, J APPL PHYSIOL, V22, P402, DOI 10.1152/jappl.1967.22.3.402; LANOFF G, 1964, ANN ALLERGY, V22, P349; LECKS HI, 1969, J ALLERGY, V44, P261, DOI 10.1016/0021-8707(69)90031-8; LOCKEY SD, 1967, J ALLERGY, V40, P349, DOI 10.1016/0021-8707(67)90024-X; MANSMANN HC, 1967, ANN ALLERGY, V25, P11; MORGAN CD, 1969, BIOCHEM J, V114, P8; PALMER KNV, 1967, LANCET, V2, P1232; PORTMANN GA, 1965, J PHARM SCI, V54, P973, DOI 10.1002/jps.2600540705; REES HA, 1967, LANCET, V2, P1164; RICHARDS W, 1965, AM J DIS CHILD, V110, P4, DOI 10.1001/archpedi.1965.02090030010003; RONA G, 1959, AMA ARCH PATHOL, V67, P99; ROSENBLUM I, 1965, TOXICOL APPL PHARM, V7, P9, DOI 10.1016/0041-008X(65)90068-2; SCHWARTZ SP, 1959, AM HEART J, V57, P849, DOI 10.1016/0002-8703(59)90294-7; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; WOOD DW, 1968, J ALLERGY, V42, P261, DOI 10.1016/0021-8707(68)90020-8; WOOD DW, 1972, AM J DIS CHILD, V123, P227, DOI 10.1001/archpedi.1972.02110090097011	27	84	85	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	2					75	+		10.1016/0091-6749(72)90002-4	http://dx.doi.org/10.1016/0091-6749(72)90002-4			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N1795	5067981				2022-12-18	WOS:A1972N179500002
J	HAGY, GW; SETTIPANE, GA				HAGY, GW; SETTIPANE, GA			PROGNOSIS OF POSITIVE ALLERGY SKIN TESTS IN AN ASYMPTOMATIC POPULATION - 3 YEAR FOLLOW-UP OF COLLEGE STUDENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BRODER I, 1962, J ALLERGY, V33, P524, DOI 10.1016/0021-8707(62)90020-5; BRODER I, 1962, J ALLERGY, V33, P513, DOI 10.1016/0021-8707(62)90019-9; CHAMBERS VV, 1958, J ALLERGY, V29, P249, DOI 10.1016/0021-8707(58)90009-1; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; SHERMAN WB, 1957, ALLERGY PEDIATRIC PR, P116	5	84	84	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	4					200	+		10.1016/0091-6749(71)90066-2	http://dx.doi.org/10.1016/0091-6749(71)90066-2			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K5566	5285772				2022-12-18	WOS:A1971K556600002
J	Lee, A; Leon, HH; Chiu, YHM; Bose, S; Rosa, MJ; Kloog, I; Wilson, A; Schwartz, J; Cohen, S; Coull, BA; Wright, RO; Wright, RJ				Lee, Alison; Leon, Hsiao-Hsien; Chiu, Yueh-Hsiu Mathilda; Bose, Sonali; Rosa, Maria Jose; Kloog, Itai; Wilson, Ander; Schwartz, Joel; Cohen, Sheldon; Coull, Brent A.; Wright, Robert O.; Wright, Rosalind J.			Prenatal fine particulate exposure and early childhood asthma: Effect of maternal stress and fetal sex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Particulate matter; ambient air pollution; negative life events; prenatal stress; childhood asthma; sex- and temporal-specific effects	AIR-POLLUTION; LUNG DEVELOPMENT; PARTICLE CONCENTRATIONS; CHILDRENS HEALTH; BIRTH COHORT; WINDOWS; VULNERABILITY; RELIABILITY; AMBIENT; WHEEZE	Background: The impact of prenatal ambient air pollution on child asthma may be modified by maternal stress, child sex, and exposure dose and timing. Objective: We prospectively examined associations between coexposure to prenatal particulate matter with an aerodynamic diameter of less than 2.5 microns (PM2.5) and maternal stress and childhood asthma (n = 736). Methods: Daily PM2.5 exposure during pregnancy was estimated using a validated satellite-based spatiotemporally resolved prediction model. Prenatal maternal negative life events (NLEs) were dichotomized around the median (high: NLE >= 3; low: NLE < 3). We used Bayesian distributed lag interaction models to identify sensitive windows for prenatal PM2.5 exposure on children's asthma by age 6 years, and determine effect modification by maternal stress and child sex. Results: Bayesian distributed lag interaction models identified a critical window of exposure (19-23 weeks' gestation, cumulative odds ratio, 1.15; 95% CI, 1.03-1.26; per interquartile range [1.7 mu g/m(3)] increase in prenatal PM2.5 level) during which children concomitantly exposed to prenatal PM2.5 and maternal stress had increased risk of asthma. No significant association was seen in children born to women reporting low prenatal stress. When examining modifying effects of prenatal stress and fetal sex, we found that boys born to mothers with higher prenatal stress were most vulnerable (19-21 weeks' gestation; cumulative odds ratio, 1.28; 95% CI, 1.15-1.41; per interquartile range increase in PM2.5). Conclusions: Prenatal PM2.5 exposure during sensitive windows is associated with increased risk of child asthma, especially in boys concurrently exposed to elevated maternal stress.	[Lee, Alison; Bose, Sonali] Icahn Sch Med Mt Sinai, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA; [Leon, Hsiao-Hsien; Chiu, Yueh-Hsiu Mathilda; Rosa, Maria Jose; Wright, Robert O.; Wright, Rosalind J.] Icahn Sch Med Mt Sinai, Dept Environm Med & Publ Hlth, New York, NY 10029 USA; [Leon, Hsiao-Hsien; Chiu, Yueh-Hsiu Mathilda; Wright, Robert O.; Wright, Rosalind J.] Icahn Sch Med Mt Sinai, Dept Pediat, Kravis Childrens Hosp, New York, NY 10029 USA; [Kloog, Itai] Ben Gurion Univ Negev, Fac Human & Social Sci, Dept Geog & Environm Dev, Beer Sheva, Israel; [Wilson, Ander] Colorado State Univ, Dept Stat, Ft Collins, CO 80523 USA; [Schwartz, Joel] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Cohen, Sheldon] Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA; [Coull, Brent A.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Ben Gurion University; Colorado State University; Harvard University; Harvard T.H. Chan School of Public Health; Carnegie Mellon University; Harvard University; Harvard T.H. Chan School of Public Health	Wright, RJ (corresponding author), 1236 Pk Ave,First Fl, New York, NY 10029 USA.	rosalind.wright@mssm.edu	Rosa, Maria José/AAX-6620-2020	Rosa, Maria José/0000-0002-1509-7664; Chiu, Yueh-Hsiu Mathilda/0000-0003-1656-660X; Hsu, Hsiao-Hsien/0000-0001-8704-197X; Cohen, Sheldon/0000-0003-2248-4600; Wright, Robert/0000-0003-1180-6459	National Institutes of Health (NIH) [R01 ES010932, U01 HL072494, R01 HL080674]; NIH [P30 ES023515, P30 ES000002, T32 ES007142, K23 HL135349, T32 HD049311-09]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD049311] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080674, K23HL135349, U01HL072494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, P30ES023515, T32ES007142, R01ES010932] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R01MD006086] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	The Asthma Coalition on Community, Environment, and Social Stress (ACCESS) project has been funded by the National Institutes of Health (NIH; grant nos. R01 ES010932, U01 HL072494, and R01 HL080674 to R.J.W., principal investigator), and phenotyping and biostatistical support was funded by NIH grant numbers P30 ES023515, P30 ES000002, and T32 ES007142. During the preparation of this manuscript, A.L. was supported by NIH grant number K23 HL135349 and M.J.R. was supported by NIH grant number T32 HD049311-09.	Been JV, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001596; Berry CA, 2006, PSYCHOL REP, V98, P123, DOI 10.2466/PRO.98.1.123-132; Chen E, 2008, ENVIRON HEALTH PERSP, V116, P970, DOI 10.1289/ehp.11076; Chiu YHM, 2012, AM J RESP CRIT CARE, V186, P147, DOI 10.1164/rccm.201201-0162OC; Copland Ian, 2004, Paediatr Respir Rev, V5 Suppl A, pS259, DOI 10.1016/S1526-0542(04)90049-8; Gasparrini A, 2014, STAT MED, V33, P881, DOI 10.1002/sim.5963; Gauderman WJ, 2015, NEW ENGL J MED, V372, P905, DOI 10.1056/NEJMoa1414123; Gidron Y, 2006, BIOL PSYCHOL, V72, P291, DOI 10.1016/j.biopsycho.2005.11.011; Gortner L, 2013, KLIN PADIATR, V225, P64, DOI 10.1055/s-0033-1333758; Gupta S, 2014, J ALLERGY CLIN IMMUN, V133, P729, DOI 10.1016/j.jaci.2013.09.039; Hislop Alison, 2005, Paediatr Respir Rev, V6, P35, DOI 10.1016/j.prrv.2004.11.009; Hsu HHL, 2015, AM J RESP CRIT CARE, V192, P1052, DOI 10.1164/rccm.201504-0658OC; Ishak N, 2014, EXP LUNG RES, V40, P30, DOI 10.3109/01902148.2013.858197; Islam T, 2011, AM J RESP CRIT CARE, V184, P822, DOI 10.1164/rccm.201104-0720OC; Jedrychowski WA, 2015, SCI TOTAL ENVIRON, V502, P502, DOI 10.1016/j.scitotenv.2014.09.051; JORGENSEN A, 2013, DAN MED J, V60; Keglowich L F, 2015, Open Respir Med J, V9, P70, DOI 10.2174/1874306401509010070; Kloog I, 2014, ATMOS ENVIRON, V95, P581, DOI 10.1016/j.atmosenv.2014.07.014; Kloog I, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-40; Kloog I, 2011, ATMOS ENVIRON, V45, P6267, DOI 10.1016/j.atmosenv.2011.08.066; Latzin P, 2009, EUR RESPIR J, V33, P594, DOI 10.1183/09031936.00084008; Lee A, 2016, J ALLERGY CLIN IMMUN, V138, P740, DOI 10.1016/j.jaci.2016.01.014; Lingappan K, 2016, AM J PHYSIOL-LUNG C, V311, pL481, DOI 10.1152/ajplung.00047.2016; Liu J, 2013, AM J RESP CELL MOL, V48, P53, DOI 10.1165/rcmb.2011-0344OC; McCormack MC, 2009, ENVIRON HEALTH PERSP, V117, P294, DOI 10.1289/ehp.11770; Minghetti L, 2013, J MATERN-FETAL NEO M, V26, P259, DOI 10.3109/14767058.2012.733751; Shalowitz MU, 1998, HEALTH SERV RES, V33, P1381; Stieb DM, 2012, ENVIRON RES, V117, P100, DOI 10.1016/j.envres.2012.05.007; TORDAY JS, 1981, AM REV RESPIR DIS, V123, P205; TORDAY JS, 1987, EXP LUNG RES, V12, P1, DOI 10.3109/01902148709068811; Wallace LA, 2003, ENVIRON HEALTH PERSP, V111, P1265, DOI 10.1289/ehp.6135; Wilson A, 2017, AM J EPIDEMIOL, V186, P1281, DOI 10.1093/aje/kwx184; Wilson A, 2017, BIOSTATISTICS, V18, P537, DOI 10.1093/biostatistics/kxx002; Wilson WE, 2000, J AIR WASTE MANAGE, V50, P1167, DOI 10.1080/10473289.2000.10464164; Wright RJ, 2013, AM J RESP CRIT CARE, V187, P1186, DOI 10.1164/rccm.201208-1530OC; Wright RJ, 2013, CURR OPIN PEDIATR, V25, P232, DOI 10.1097/MOP.0b013e32835e78cc; Wright RJ, 2008, CIENC SAUDE COLETIVA, V13, P1729, DOI 10.1590/S1413-81232008000600008; Yao XJ, 2016, RESPIROLOGY, V21, P638, DOI 10.1111/resp.12707; Zanobetti A, 2000, Biostatistics, V1, P279, DOI 10.1093/biostatistics/1.3.279	39	83	84	2	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1880	1886		10.1016/j.jaci.2017.07.017	http://dx.doi.org/10.1016/j.jaci.2017.07.017			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	GF7KX	28801196	Bronze, Green Accepted			2022-12-18	WOS:000432148200032
J	Tran, MM; Lefebvre, DL; Dharma, C; Dai, D; Lou, WYW; Subbarao, P; Becker, AB; Mandhane, PJ; Turvey, SE; Sears, MR				Tran, Maxwell M.; Lefebvre, Diana L.; Dharma, Christoffer; Dai, David; Lou, Wendy Y. W.; Subbarao, Padmaja; Becker, Allan B.; Mandhane, Piush J.; Turvey, Stuart E.; Sears, Malcolm R.		Canadian Hlth Infant Longitudinal	Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic march; asthma; allergic rhinitis; food allergy; atopic dermatitis; birth cohort; additive interaction; multiplicative interaction	FILAGGRIN MUTATIONS; ALLERGIC SENSITIZATION; FOOD SENSITIZATION; ASTHMA; DERMATITIS; CHILDREN; DISEASE; ECZEMA; ASSOCIATION; MECHANISMS	Background: The atopic march describes the progression from atopic dermatitis during infancy to asthma and allergic rhinitis in later childhood. In a Canadian birth cohort we investigated whether concomitant allergic sensitization enhances subsequent development of these allergic diseases at age 3 years. Methods: Children completed skin prick testing at age 1 year. Children were considered sensitized if they produced a wheal 2 mm or larger than that elicited by the negative control to any of 10 inhalant or food allergens. Children were also assessed for atopic dermatitis by using the diagnostic criteria of the UK Working Party. At age 3 years, children were assessed for asthma, allergic rhinitis, food allergy, and atopic dermatitis. Data from 2311 children were available. Results: Atopic dermatitis without allergic sensitization was not associated with an increased risk of asthma at age 3 years after adjusting for common confounders (relative risk [RR], 0.46; 95% CI, 0.11-1.93). Conversely, atopic dermatitis with allergic sensitization increased the risk of asthma more than 7-fold (RR, 7.04; 95% CI, 4.13-11.99). Atopic dermatitis and allergic sensitization had significant interactions on both the additive (relative excess risk due to interaction, 5.06; 95% CI, 1.33-11.04) and multiplicative (ratio of RRs, 5.80; 95% CI, 1.20-27.83) scales in association with asthma risk. There was also a positive additive interaction between atopic dermatitis and allergic sensitization in their effects on food allergy risk (relative excess risk due to interaction, 15.11; 95% CI, 4.19-35.36). Conclusions: Atopic dermatitis without concomitant allergic sensitization was not associated with an increased risk of asthma. In combination, atopic dermatitis and allergic sensitization had strong interactive effects on both asthma and food allergy risk at age 3 years.	[Tran, Maxwell M.; Lefebvre, Diana L.; Dharma, Christoffer; Dai, David; Sears, Malcolm R.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Lou, Wendy Y. W.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Subbarao, Padmaja] Univ Toronto, Dept Pediat, Toronto, ON, Canada; [Subbarao, Padmaja] Univ Toronto, Hosp Sick Children, Toronto, ON, Canada; [Becker, Allan B.] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, Canada; [Mandhane, Piush J.] Univ Alberta, Dept Pediat, Edmonton, AB, Canada; [Turvey, Stuart E.] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada	McMaster University; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Manitoba; University of Alberta; University of British Columbia	Sears, MR (corresponding author), St Josephs Healthcare, Firestone Inst Resp Hlth, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.; Sears, MR (corresponding author), McMaster Univ, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	searsm@mcmaster.ca	Dharma, Christoffer/ABH-5987-2020; Brauer, Michael/Y-2810-2019; Tran, Maxwell/V-4554-2019; Befus, Dean/C-5561-2009; Scott, James A/A-8598-2011; Turvey, Stuart/HGV-1191-2022	Brauer, Michael/0000-0002-9103-9343; Tran, Maxwell/0000-0001-5503-613X; Befus, Dean/0000-0002-1611-2897; Scott, James A/0000-0002-5073-0832; Hegele, Richard/0000-0003-1073-8044; Laprise, Catherine/0000-0001-5526-9945; Subbarao, Padmaja/0000-0003-0394-1933; Kollmann, Tobias/0000-0003-2403-9762; Eiwegger, Thomas/0000-0002-2914-7829; Dharma, Christoffer/0000-0002-5223-5755; Turvey, Stuart/0000-0003-1599-1065; Kobor, Michael/0000-0003-4140-1743; Dell, Sharon/0000-0003-2169-9407	Canadian Institutes of Health Research (CIHR) [AEC-85761]; Allergy, Genes and Environment Network of Centers of Excellence (AllerGen NCE) [12CHILD]; Canadian Institutes of Health Research (CIHR); Allergy, Genes and Environment (AllerGen) Network of Centres of Excellence (NCE); Health Canada; Environment Canada; Canada Mortgage and Housing Corporation; Sick Children's Hospital Foundation; Silver Thread Foundation; Childhood Asthma Foundation	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Allergy, Genes and Environment Network of Centers of Excellence (AllerGen NCE); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Allergy, Genes and Environment (AllerGen) Network of Centres of Excellence (NCE); Health Canada; Environment Canada(CGIAR); Canada Mortgage and Housing Corporation; Sick Children's Hospital Foundation; Silver Thread Foundation; Childhood Asthma Foundation	Supported by the Canadian Institutes of Health Research (CIHR; AEC-85761), and Allergy, Genes and Environment Network of Centers of Excellence (AllerGen NCE; 12CHILD).; The Canadian Institutes of Health Research (CIHR) and the Allergy, Genes and Environment (AllerGen) Network of Centres of Excellence (NCE) provided core funding for the CHILD study. Additional support has been provided by Health Canada, Environment Canada, the Canada Mortgage and Housing Corporation, the Sick Children's Hospital Foundation, Don and Debbie Morrison, the Silver Thread Foundation, and the Childhood Asthma Foundation. We also acknowledge the generosity of ALK-Abello, Mississauga, Ontario, Canada, in supplying all allergens for the study, and Lincoln Diagnostics, Decatur, Ill, for supplying the Duotip-Test II devices and skin testing kits. M.R.S. holds the AstraZeneca endowed chair in Respiratory Epidemiology.	Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Azad MB, 2015, CLIN EXP ALLERGY, V45, P632, DOI 10.1111/cea.12487; Belgrave DCM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001748; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Burgess JA, 2009, J ASTHMA, V46, P429, DOI 10.1080/02770900902846356; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Hancox RJ, 2008, J ALLERGY CLIN IMMUN, V121, P38, DOI 10.1016/j.jaci.2007.09.052; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Hill DA, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0673-z; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Knol MJ, 2012, INT J EPIDEMIOL, V41, P514, DOI 10.1093/ije/dyr218; Kurukulaaratchy RJ, 2005, ALLERGY, V60, P1280, DOI 10.1111/j.1398-9995.2005.00890.x; Larsen FS, 2002, IMMUNOL ALLERGY CLIN, V22, P1, DOI 10.1016/S0889-8561(03)00066-3; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P536, DOI 10.1111/j.1365-2222.2007.02691.x; Marenholz I, 2009, J ALLERGY CLIN IMMUN, V123, P911, DOI 10.1016/j.jaci.2009.01.051; McGrath JA, 2008, TRENDS MOL MED, V14, P20, DOI 10.1016/j.molmed.2007.10.006; Morar N, 2007, J INVEST DERMATOL, V127, P1667, DOI 10.1038/sj.jid.5700739; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Sbihi H, 2015, ENVIRON HEALTH PERSP, V123, P902, DOI 10.1289/ehp.1408700; Schneider L, 2016, PEDIATR DERMATOL, V33, P388, DOI 10.1111/pde.12867; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Shaker M, 2014, CURR OPIN PEDIATR, V26, P516, DOI 10.1097/MOP.0000000000000120; Subbarao P, 2015, THORAX, V70, P998, DOI 10.1136/thoraxjnl-2015-207246; Tran MM, 2017, PEDIAT ALLERG IMM-UK, V28, P471, DOI 10.1111/pai.12739; VanderWeele TJ., 2014, EPIDEMIOL METHODS, V3, P33, DOI DOI 10.1515/EM-2013-0005; Wadonda-Kabondo N, 2003, BRIT J DERMATOL, V149, P1023, DOI 10.1111/j.1365-2133.2003.05605.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Zheng T, 2011, ALLERGY ASTHMA IMMUN, V3, P67, DOI 10.4168/aair.2011.3.2.67; Ziyab AH, 2014, INT ARCH ALLERGY IMM, V164, P308, DOI 10.1159/000365990; Zou GY, 2008, AM J EPIDEMIOL, V168, P212, DOI 10.1093/aje/kwn104; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	36	83	90	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					601	+		10.1016/j.jaci.2017.08.024	http://dx.doi.org/10.1016/j.jaci.2017.08.024			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	29153857	Bronze			2022-12-18	WOS:000424410800016
J	Ricciardolo, FLM; Sorbello, V; Folino, A; Gallo, F; Massaglia, GM; Favata, G; Conticello, S; Vallese, D; Gani, F; Malerba, M; Folkerts, G; Rolla, G; Profita, M; Mauad, T; Di Stefano, A; Ciprandi, G				Ricciardolo, Fabio L. M.; Sorbello, Valentina; Folino, Anna; Gallo, Fabio; Massaglia, Gian Mario; Favata, Gabriella; Conticello, Salvatore; Vallese, Davide; Gani, Federica; Malerba, Mario; Folkerts, Gert; Rolla, Giovanni; Profita, Mirella; Mauad, Thais; Di Stefano, Antonino; Ciprandi, Giorgio			Identification of IL-17F/frequent exacerbator endotype in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; bronchial biopsy; nasal biopsy; IL-17F; neutrophils; frequent exacerbators; phenotype; endotype	ALLERGIC RHINITIS; T-CELLS; INFLAMMATION; EXPRESSION; INTERLEUKIN-17; IL-17; LUNG; CYTOKINE; AIRWAYS; DIFFERENTIATION	Background: Severe asthma might be associated with overexpression of T(H)17 cytokines, which induce neutrophil recruitment via neutrophil-mobilizing cytokines in airways. Objective: To study IL-17-related cytokines in nasal/bronchial biopsies from controls and mild asthmatics (MAs) to severe asthmatics (SAs) in relation to exacerbation rate. Methods: Inflammatory cells and IL-17A(+), IL-17F(+), IL-21(+), IL-22(+), and IL-23(+) cells were examined by immunohistochemistry in cryostat sections of bronchial/nasal biopsies obtained from 33 SAs (21 frequent exacerbators [FEs]), 31 MAs (3 FEs), and 14 controls. IL-17F protein was also measured by ELISA in bronchial/nasal lysates and by immunohistochemistry in bronchial tissue obtained from subjects who died because of fatal asthma. Immunofluorescence/confocal microscopy was used for IL-17F colocalization. Results: Higher number (P < .05) of neutrophils, IL-17A(+), IL-17F(+), and IL-21(+) cells in bronchial biopsies and higher numbers (P < .01) of IL-17F(+) and IL-21(+) cells in nasal biopsies were observed in SAs compared with MAs. Bronchial IL-17F(+) cells correlated with bronchial neutrophils (r = 0.54), exacerbation rate (r = 0.41), and FEV1 (r 5 20.46). Nasal IL-17F(+) cells correlated with bronchial IL-17F (r = 0.35), exacerbation rate (r = 0.47), and FEV1 (r520.61). FEs showed increased number of bronchial neutrophils/eosinophils/CD4(+)/CD8(+) cells and bronchial/nasal IL-17F(1) cells. Receiver operating characteristic curve analysis evidenced predictive cutoff values of bronchial neutrophils and nasal/bronchial IL-17F for discriminating between asthmatics and controls, between MAs and SAs and between FEs and non-FEs. IL-17F protein increased in bronchial/nasal lysates of SAs and FEs and in bronchial tissue of fatal asthma. IL-17F colocalized in CD4(+) /CD8(+) cells. Conclusions: IL-17-related cytokines expression was amplified in bronchial/nasal mucosa of neutrophilic asthma prone to exacerbation, suggesting a pathogenic role of IL-17F in FEs.	[Ricciardolo, Fabio L. M.; Sorbello, Valentina; Folino, Anna] Univ Torino, Azienda Osped Univ AOU San Luigi Hosp, Dept Clin & Biol Sci, Turin, Italy; [Gallo, Fabio] Univ Genoa, Hlth Sci Dept, Genoa, Italy; [Massaglia, Gian Mario; Gani, Federica] AOU San Luigi Hosp, Div Resp Dis, Turin, Italy; [Favata, Gabriella; Conticello, Salvatore] AOU San Luigi Hosp, Div Ear Nose & Throat, Turin, Italy; [Vallese, Davide; Di Stefano, Antonino] Fdn S Maugeri, IRCCS, Pulm Div, Novara, Italy; [Malerba, Mario] Univ Brescia, Dept Internal Med, Brescia, Italy; [Folkerts, Gert] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmacol & Pathophysiol, Utrecht, Netherlands; [Rolla, Giovanni] Univ Torino, Allergol & Immunol Clin, Osped Ordine Mauriziano Umberto 1, Turin, Italy; [Profita, Mirella] Italian Natl Res Council, Inst Biomed & Mol Immunol, Palermo, Italy; [Mauad, Thais] Univ Sao Paulo, Med Sch, Dept Pathol, Sao Paulo, Brazil; [Ciprandi, Giorgio] IRCCS AOU San Martino, Genoa, Italy	University of Turin; University of Genoa; Istituti Clinici Scientifici Maugeri IRCCS; University of Brescia; Utrecht University; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR); Universidade de Sao Paulo	Ricciardolo, FLM (corresponding author), Univ Torino, AOU San Luigi Hosp, Dept Clin & Biol Sci, Reg Gonzole 10, I-10043 Turin, Italy.	fabioluigimassimo.ricciardolo@unito.it	Di Stefano, Antonino/AAB-8041-2020; Ricciardolo, F. L. M./K-5330-2018; Profita, Mirella/AAY-3165-2020; Profita, Mirella/AFU-7423-2022; Ciprandi, Giorgio/G-7462-2012; Profita, Mirella/D-8957-2018	Di Stefano, Antonino/0000-0003-3479-0875; Ricciardolo, F. L. M./0000-0003-1826-5018; Ciprandi, Giorgio/0000-0001-7016-8421; Folino, Anna/0000-0003-3140-9151; MALERBA, Mario/0000-0003-1246-4892; Profita, Mirella/0000-0002-7821-8283	Ricerca Sanitaria Finalizzata Regione Piemonte [2472, 38097]; Regione Piemonte	Ricerca Sanitaria Finalizzata Regione Piemonte(Regione Piemonte); Regione Piemonte(Regione Piemonte)	Supported by Ricerca Sanitaria Finalizzata Regione Piemonte 2007 (protocol 2472) and 2008 (protocol 38097).; F. L. M. Riccardiolo has received a grant from Regione Piemonte. The rest of the authors declare that they have no relevant conflicts of interest.	Agache I, 2012, ALLERGY, V67, P835, DOI 10.1111/j.1398-9995.2012.02832.x; Agache I, 2010, RESP MED, V104, P1131, DOI 10.1016/j.rmed.2010.02.018; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Amin K, 2000, AM J RESP CRIT CARE, V162, P2295, DOI 10.1164/ajrccm.162.6.9912001; Amorim MM, 2010, CLIN EXP ALLERGY, V40, P867, DOI 10.1111/j.1365-2222.2009.03439.x; Annunziato F, 2015, J ALLERGY CLIN IMMUN, V135, P626, DOI 10.1016/j.jaci.2014.11.001; Archer E., 2016, RFPERMUTE ESTIMATE P; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chalmers GW, 2001, CHEST, V120, P1917, DOI 10.1378/chest.120.6.1917; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Chung YS, 2006, CELL RES, V16, P902, DOI 10.1038/sj.cr.7310106; Ciprandi G, 2009, ALLERGY, V64, P1375, DOI 10.1111/j.1398-9995.2009.02010.x; Ciprandi G, 2006, J ALLERGY CLIN IMMUN, V118, P1105, DOI 10.1016/j.jaci.2006.05.010; Ciprandi G, 2012, INT ARCH ALLERGY IMM, V159, P183, DOI 10.1159/000336418; Doe C, 2010, CHEST, V138, P1140, DOI 10.1378/chest.09-3058; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Fuhlbrigge A, 2012, J ALLERGY CLIN IMMUN, V129, pS34, DOI 10.1016/j.jaci.2011.12.983; Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA), 2016, NHLBI WHO WORKSH; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hizawa N, 2006, CLIN EXP ALLERGY, V36, P1109, DOI 10.1111/j.1365-2222.2006.02550.x; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kawaguchi M, 2001, J IMMUNOL, V167, P4430, DOI 10.4049/jimmunol.167.8.4430; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Kupczyk M, 2014, CLIN EXP ALLERGY, V44, P212, DOI 10.1111/cea.12179; Li YC, 2014, RESPIROLOGY, V19, P663, DOI 10.1111/resp.12299; Linden A, 2014, EUR RESPIR J, V44, P1319, DOI 10.1183/09031936.00002314; Liu Y, 2015, CLIN EXP ALLERGY, V45, P602, DOI 10.1111/cea.12378; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; Makihara S, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.014; Mauad T, 2008, REV PANAM SALUD PUBL, V23, P418, DOI 10.1590/S1020-49892008000600007; McAleer JP, 2014, IMMUNOL REV, V260, P129, DOI 10.1111/imr.12183; McDonald VM, 2012, CLIN EXP ALLERGY, V42, P670, DOI 10.1111/j.1365-2222.2012.03981.x; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Murcia RY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154755; Nembrini C, 2009, J ALLERGY CLIN IMMUN, V123, P986, DOI 10.1016/j.jaci.2009.03.033; Newcomb DC, 2013, CURR OPIN IMMUNOL, V25, P755, DOI 10.1016/j.coi.2013.08.002; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Rahman MS, 2006, J IMMUNOL, V177, P4064, DOI 10.4049/jimmunol.177.6.4064; Ricciardolo FLM, 2013, THORAX, V68, P803, DOI 10.1136/thoraxjnl-2012-202741; Rimmer J, 2006, MED J AUSTRALIA, V185, P565, DOI 10.5694/j.1326-5377.2006.tb00693.x; Saffar AS, 2011, CURR DRUG TARGETS, V12, P556; Sorbello V, 2015, ALLERGY, V70, P236, DOI 10.1111/all.12547; Sun YC, 2005, CHINESE MED J-PEKING, V118, P953; Vazquez-Tello A, 2013, J CLIN IMMUNOL, V33, P466, DOI 10.1007/s10875-012-9828-3; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	51	83	87	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					395	406		10.1016/j.jaci.2016.10.034	http://dx.doi.org/10.1016/j.jaci.2016.10.034			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	27931975	Bronze, Green Submitted			2022-12-18	WOS:000406855500012
J	Koplin, JJ; Peters, RL; Dharmage, SC; Gurrin, L; Tang, MLK; Ponsonby, AL; Matheson, M; Togias, A; Lack, G; Allen, KJ				Koplin, Jennifer J.; Peters, Rachel L.; Dharmage, Shyamali C.; Gurrin, Lyle; Tang, Mimi L. K.; Ponsonby, Anne-Louise; Matheson, Melanie; Togias, Alkis; Lack, Gideon; Allen, Katrina J.		HealthNuts Study Investigators	Understanding the feasibility and implications of implementing early peanut introduction for prevention of peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; infant feeding; guidelines; skin prick test; specific IgE; prevention	EARLY CONSUMPTION; PREVALENCE; HEALTHNUTS; PREDICTORS; DIAGNOSIS; CRITERIA; COHORT; RISK	Background: A recent randomized trial (the Learning Early About Peanut Allergy [LEAP] study) provided evidence that earlier dietary peanut introduction reduces peanut allergy prevalence in high-risk infants. However, questions remain as to how to identify and target the "at-risk'' population to facilitate timely introduction of peanut. Objective: We sought to use population-based infant peanut allergy data to understand feasibility and implications of implementing the LEAP trial intervention. Methods: Using the HealthNuts study cohort (n = 5276) of 1-year-old infants, we explored the impact of using various criteria to identify infants at high risk of developing peanut allergy, and the implications of skin prick test (SPT) screening before peanut introduction. Results: Screening all infants with early onset eczema and/or egg allergy could require testing 16% of the population and would still miss 23% of peanut allergy cases; 29% of screened infants would require clinical follow-up because of being SPT-positive. Around 11% of high-risk infants were excluded from the LEAP study because of an SPT wheal size of more than 4 mm to peanut at baseline; data from the HealthNuts study suggest that 80% of these would be peanut allergic on food challenge. There were no life-threatening events among either low-or high-risk infants whose parents chose to introduce peanut at home in the first year of life, or in 150 peanut-allergic infants during hospital-based challenges. Conclusions: Based on this large epidemiological study, a population program aiming to identify and screen all infants at risk of peanut allergy would pose major cost and logistic challenges that need to be carefully considered. Further research might be required to provide data for low-risk infants.	[Koplin, Jennifer J.; Peters, Rachel L.; Tang, Mimi L. K.; Ponsonby, Anne-Louise; Allen, Katrina J.] Univ Melbourne, Dept Paediat, Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Koplin, Jennifer J.; Peters, Rachel L.; Tang, Mimi L. K.; Ponsonby, Anne-Louise; Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Clin Immunol, Parkville, Vic, Australia; [Koplin, Jennifer J.; Dharmage, Shyamali C.; Gurrin, Lyle; Matheson, Melanie] Univ Melbourne, Sch Populat & Global Hlth, Parkville, Vic, Australia; [Togias, Alkis] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Lack, Gideon] Kings Coll London, Dept Pediat Allergy, Div Asthma Allergy & Lung Biol, London, England; [Lack, Gideon] Guys & St Thomas Natl Hlth Serv Fdn Trust, London, England; [Allen, Katrina J.] Univ Manchester, Sch Inflammat & Repair, Manchester, Lancs, England	Murdoch Children's Research Institute; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of Manchester	Allen, KJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Ponsonby, Anne-Louise/AAE-4351-2019; Allen, Katrina/I-4361-2018; Matheson, Melanie C/O-4721-2015; Tang, Mimi/ABD-8350-2020	Allen, Katrina/0000-0002-1921-4493; Matheson, Melanie C/0000-0002-5822-3499; Tang, Mimi/0000-0002-3839-5293; Peters, Rachel/0000-0002-2411-6628; Ponsonby, Anne-Louise/0000-0002-6581-3657; Gurrin, Lyle/0000-0001-7052-1969; Koplin, Jennifer/0000-0002-7576-5142; Lack, Gideon/0000-0001-7350-4021	National Health & Medical Research Council (NHMRC) of Australia; Australian Food Allergy Foundation; Anaphylaxi-Stop; Victorian Government's Operational Infrastructure Support Program	National Health & Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Food Allergy Foundation; Anaphylaxi-Stop; Victorian Government's Operational Infrastructure Support Program	This work was supported by funding from the National Health & Medical Research Council (NHMRC) of Australia, Australian Food Allergy Foundation, Anaphylaxi-Stop, and the Victorian Government's Operational Infrastructure Support Program. The study sponsors had no involvement in the study design, collection, analysis, and interpretation of data, writing of the report, or decision to submit the article for publication.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Australasian Society of Clinical Immunology and Allergy, 2010, ASCIA INF FEED ADV; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Fleischer DM, 2015, J ALLERGY CLIN IMMUN, V136, P258, DOI 10.1016/j.jaci.2015.06.001; Gruchalla RS, 2015, NEW ENGL J MED, V372, P875, DOI 10.1056/NEJMe1500186; Koplin JJ, 2015, INT J EPIDEMIOL, V44, P1161, DOI 10.1093/ije/dyu261; Koplin JJ, 2012, J ALLERGY CLIN IMMUN, V129, P1145, DOI 10.1016/j.jaci.2011.09.044; McBride D, 2012, PEDIAT ALLERG IMM-UK, V23, P230, DOI 10.1111/j.1399-3038.2011.01254.x; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Peters RL, 2013, J ALLERGY CLIN IMMUN, V132, P874, DOI 10.1016/j.jaci.2013.05.038; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Tey D, 2014, J ALLERGY CLIN IMMUN, V133, P476, DOI 10.1016/j.jaci.2013.11.019; Venter C, 2008, ALLERGY, V63, P354, DOI 10.1111/j.1398-9995.2007.01570.x; Venter C, 2010, ALLERGY, V65, P103, DOI 10.1111/j.1398-9995.2009.02176.x; Xepapadaki P, 2016, ALLERGY, V71, P350, DOI 10.1111/all.12801	19	83	89	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1131	+		10.1016/j.jaci.2016.04.011	http://dx.doi.org/10.1016/j.jaci.2016.04.011			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27260320	Bronze, Green Submitted			2022-12-18	WOS:000385499400019
J	Lee, JB; Chen, CY; Liu, B; Mugge, L; Angkasekwinai, P; Facchinetti, V; Dong, C; Liu, YJ; Rothenberg, ME; Hogan, SP; Finkelman, FD; Wang, YH				Lee, Jee-Boong; Chen, Chun-Yu; Liu, Bo; Mugge, Luke; Angkasekwinai, Pornpimon; Facchinetti, Valeria; Dong, Chen; Liu, Yong-Jun; Rothenberg, Marc E.; Hogan, Simon P.; Finkelman, Fred D.; Wang, Yui-Hsi			IL-25 and CD4(+) T(H)2 cells enhance type 2 innate lymphoid cell-derived IL-13 production, which promotes IgE-mediated experimental food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-25; type 2 innate lymphoid cells; CD4(+) T(H)2 cells; IL-13; food allergy	THYMIC STROMAL LYMPHOPOIETIN; MAST-CELLS; T-CELLS; IMMUNE-RESPONSES; INFLAMMATION; INTERLEUKIN-25; EXPRESSION; ANTIGEN; ANAPHYLAXIS; CYTOKINE	Background: Food-mediated allergic reactions have emerged as a major health problem. The underlying mechanisms that promote uncontrolled type 2 immune responses to dietary allergens in the gastrointestinal tract remain elusive. Objective: We investigated whether altering IL-25 signaling enhances or attenuates allergic responses to food allergens. Methods: Mice of an IL-25 transgenic mouse line (iIL-25Tg mice), which constitutively overexpress intestinal IL-25, and Il17rb(-/-) mice, in which Il17rb gene expression is disrupted, were sensitized and gavage fed with ovalbumin (OVA). We assessed symptomatic characteristics of experimental food allergy, including incidence of diarrhea, incidence of hypothermia, intestinal T(H)2 immune response, and serum OVA-specific IgE and mast cell protease 1 production. Results: Rapid induction of Il25 expression in the intestinal epithelium preceded onset of the anaphylactic response to ingested OVA antigen. iIL-25Tg mice were more prone and Il17rb(-/-) mice were more resistant to experimental food allergy. Resident intestinal type 2 innate lymphoid cells (ILC2s) were identified as the major producers of IL-5 and IL-13 in response to IL-25. Reconstituting irradiated wild-type mice with Rora(-/-) or Il17rb(-/-) bone marrow resulted in a deficiency or dysfunction of the ILC2 compartment, respectively, and resistance to experimental food allergy. Repeated intragastric antigen challenge induced a significant increase in numbers of CD4(+) T(H)2 cells, which enhance IL-25-stimulated IL-13 production by ILC2s ex vivo and in vivo. Finally, reconstituted IL-13-deficient ILC2s had reduced capability to promote allergic inflammation, resulting in increased resistance to experimental food allergy. Conclusion: IL-25 and CD4(+) T(H)2 cells induced by ingested antigens enhance ILC2-derived IL-13 production, thereby promoting IgE-mediated experimental food allergy.	[Lee, Jee-Boong; Chen, Chun-Yu; Liu, Bo; Mugge, Luke; Rothenberg, Marc E.; Hogan, Simon P.; Wang, Yui-Hsi] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, MLC 7028,3333 Burnet Ave, Cincinnati, OH 45220 USA; [Finkelman, Fred D.] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, MLC 7028,3333 Burnet Ave, Cincinnati, OH 45220 USA; [Angkasekwinai, Pornpimon] Thammasat Univ, Fac Allied Hlth Sci, Dept Med Technol, Bangkok, Thailand; [Facchinetti, Valeria; Dong, Chen] Univ Texas Houston, Dept Immunol, Houston, TX USA; [Facchinetti, Valeria; Dong, Chen] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Liu, Yong-Jun] Medimmune Inc, Gaithersburg, MD 20878 USA; [Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH USA; [Finkelman, Fred D.] Univ Cincinnati, Coll Med, Div Immunol Allergy & Rheumatol, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Thammasat University; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; AstraZeneca; Medimmune; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati	Wang, YH (corresponding author), Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Allergy & Immunol, MLC 7028,3333 Burnet Ave, Cincinnati, OH 45220 USA.	yui_hsi.wang@cchmc.org	dong, chen/B-3181-2009; Angkasekwinai, Pornpimon/AAX-6124-2020	dong, chen/0000-0002-0084-9130; Angkasekwinai, Pornpimon/0000-0003-0303-9544; Mugge, Luke/0000-0001-7238-5665	National Institutes of Health [AI090129, A1073553]; Digestive Health Center [P30 DK078392]; American Partnership For Eosinophilic Disorders (APFED; HOPE Pilot Grant); Campaign Urging Research For Eosinophilic Diseases (CURED) Foundation; Buckeye Foundation; Food Allergy Research Education Fund; VA Merit Award; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI090129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Digestive Health Center; American Partnership For Eosinophilic Disorders (APFED; HOPE Pilot Grant); Campaign Urging Research For Eosinophilic Diseases (CURED) Foundation; Buckeye Foundation; Food Allergy Research Education Fund; VA Merit Award(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the National Institutes of Health (AI090129-1 to Y.H.-W. and A1073553 to S.P.H.), the Digestive Health Center (P30 DK078392, Pilot and Feasibility Award to Y.H.-W.), American Partnership For Eosinophilic Disorders (APFED; HOPE Pilot Grant to Y.H.W.), Campaign Urging Research For Eosinophilic Diseases (CURED) Foundation, the Buckeye Foundation, and the Food Allergy Research Education Fund to M.E.R. and the VA Merit Award to F.D.F.	Ahrens R, 2012, AM J PATHOL, V180, P1535, DOI 10.1016/j.ajpath.2011.12.036; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Angkasekwinai P, 2013, INFECT IMMUN, V81, P3731, DOI 10.1128/IAI.00646-13; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Brandt EB, 2009, J ALLERGY CLIN IMMUN, V123, P53, DOI 10.1016/j.jaci.2008.10.001; Brown SGA, 2011, CLIN EXP ALLERGY, V41, P1660, DOI 10.1111/j.1365-2222.2011.03893.x; Caruso R, 2009, GASTROENTEROLOGY, V136, P2270, DOI 10.1053/j.gastro.2009.02.049; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Chu DK, 2014, MUCOSAL IMMUNOL, V7, P1395, DOI 10.1038/mi.2014.29; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Iijima K, 2014, J IMMUNOL, V193, P1549, DOI 10.4049/jimmunol.1302984; Imai Y, 2013, P NATL ACAD SCI USA, V110, P13921, DOI 10.1073/pnas.1307321110; Kashiwakura J, 2008, J LEUKOCYTE BIOL, V84, P357, DOI 10.1189/jlb.1207841; Kim MR, 2002, BLOOD, V100, P2330, DOI 10.1182/blood-2002-01-0012; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Madden KB, 2002, J IMMUNOL, V169, P4417, DOI 10.4049/jimmunol.169.8.4417; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Mirchandani AS, 2014, J IMMUNOL, V192, P2442, DOI 10.4049/jimmunol.1300974; Mjosberg J, 2012, EUR J IMMUNOL, V42, P1916, DOI 10.1002/eji.201242639; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Muto T, 2014, INT IMMUNOL, V26, P539, DOI 10.1093/intimm/dxu058; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Oliphant CJ, 2014, IMMUNITY, V41, P283, DOI 10.1016/j.immuni.2014.06.016; Osterfeld H, 2010, J ALLERGY CLIN IMMUN, V125, P469, DOI 10.1016/j.jaci.2009.09.054; Owyang AM, 2006, J EXP MED, V203, P843, DOI 10.1084/jem.20051496; Pan GH, 2001, J IMMUNOL, V167, P6559, DOI 10.4049/jimmunol.167.11.6559; Park KW, 2008, MOL ENDOCRINOL, V22, P2038, DOI 10.1210/me.2007-0454; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P85, DOI 10.1016/j.jaci.2009.11.031; Smit JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028917; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; SPANGRUDE GJ, 1990, J IMMUNOL, V145, P3661; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Swaidani S, 2009, J IMMUNOL, V182, P1631, DOI 10.4049/jimmunol.182.3.1631; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; Walker JA, 2013, NAT REV IMMUNOL, V13, P75, DOI 10.1038/nri3349; Wang Q, 2015, J ALLERGY CLIN IMMUN, V135, P781, DOI 10.1016/j.jaci.2014.09.015; Wang YH, 2009, CLIN EXP ALLERGY, V39, P798, DOI 10.1111/j.1365-2222.2009.03241.x; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133; Wojno EDT, 2012, CELL HOST MICROBE, V12, P445, DOI 10.1016/j.chom.2012.10.003; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; Wu D, 2011, J BIOL CHEM, V286, P13357, DOI 10.1074/jbc.M110.214965; Yamashita N, 2006, AM J PHYSIOL-LUNG C, V290, pL1045, DOI 10.1152/ajplung.00195.2005; Yang Q, 2011, J IMMUNOL, V187, P5505, DOI 10.4049/jimmunol.1102039; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Zaph C, 2008, J EXP MED, V205, P2191, DOI 10.1084/jem.20080720; Zhao AP, 2010, J IMMUNOL, V185, P6921, DOI 10.4049/jimmunol.1000450	63	83	90	1	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1216	+		10.1016/j.jaci.2015.09.019	http://dx.doi.org/10.1016/j.jaci.2015.09.019			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26560039	Green Accepted			2022-12-18	WOS:000373351200029
J	Martin, LJ; Franciosi, JP; Collins, MH; Abonia, JP; Lee, JJ; Hommel, KA; Varni, JW; Grotjan, JT; Eby, M; He, H; Marsolo, K; Putnam, PE; Garza, JM; Kaul, A; Wen, T; Rothenberg, ME				Martin, Lisa J.; Franciosi, James P.; Collins, Margaret H.; Abonia, J. Pablo; Lee, James J.; Hommel, Kevin A.; Varni, James W.; Grotjan, J. Tommie; Eby, Michael; He, Hua; Marsolo, Keith; Putnam, Philip E.; Garza, Jose M.; Kaul, Ajay; Wen, Ting; Rothenberg, Marc E.			Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; reflux; quality of life; surveys; mast cells; molecular genetics; pediatrics; microarray; patient-reported outcomes	QUALITY-OF-LIFE; SWALLOWED FLUTICASONE; MAST-CELLS; CHILDREN; EXPRESSION; INFLAMMATION; OUTCOMES; IDENTIFICATION; PROTEIN; ADULTS	Background: The Pediatric Eosinophilic Esophagitis Symptom Score (PEESS v2.0) measures patient-relevant outcomes. However, whether patient-identified domains (dysphagia, gastroesophageal reflux disease [GERD], nausea/vomiting, and pain) align with clinical symptomology and histopathologic and molecular features of eosinophilic esophagitis (EoE) is unclear. Objective: The purpose of this study was to determine whether clinical features of EoE, measured through PEESS v2.0, associate with histopathologic and molecular features of EoE. This represents a novel approach for analysis of allergic diseases, given the availability of allergic tissue biopsy specimens. Methods: We systematically recruited treated and untreated pediatric patients with EoE (aged 2-18 years) and examined parent proxy reported symptoms using the PEESS v2.0. Clinical symptomology was collected by questionnaire Esophageal biopsy samples were quantified for levels of eosinophils, eosinophil peroxidase (EPX) immunohistochemical staining, and mast cells. Molecular features were assessed by using the EoE Diagnostic Panel (94 EoE-related gene transcripts). Associations between domain scores and clinical symptoms and biological features were analyzed with Wilcoxon rank sum and Spearman correlation. Results: The PEESS v2.0 domains correlated to specific parent-reported symptoms: dysphagia (P = .0012), GERD (P = .0001), and nausea/vomiting (P < .0001). Pain correlated with multiple symptoms (P < .0005). Dysphagia correlated most strongly with overall histopathology, particularly in the proximal esophagus (P < .0049). Markers of esophageal activity (EPX) were significantly associated with dysphagia (strongest r = 0.37, P = .02). Eosinophil levels were more associated with pain (r = 0.27, P = .06) than dysphagia (r = 0.24, P = .13). The dysphagia domain correlated most with esophageal gene transcript levels, predominantly with mast cell specific genes. Conclusion: We have (1) established a validated, parent proxy reported measure for pediatric EoE, the PEESS v2.0; (2) verified that the parent proxy effectively captures symptoms; (3) determined that the dysphagia domain most closely aligns with symptoms and tissue-based molecular biomarkers; (4) established that symptoms correlate with EPX staining; and (5) observed association between mast cells and dysphagia.	[Martin, Lisa J.; He, Hua] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA; [Collins, Margaret H.] Cincinnati Childrens Hosp Med Ctr, Div Pathol, Cincinnati, OH 45229 USA; [Abonia, J. Pablo; Grotjan, J. Tommie; Eby, Michael; Wen, Ting; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Hommel, Kevin A.] Cincinnati Childrens Hosp Med Ctr, Div Behav Med & Clin Psychol, Cincinnati, OH 45229 USA; [Marsolo, Keith] Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH 45229 USA; [Putnam, Philip E.; Kaul, Ajay] Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH 45229 USA; [Martin, Lisa J.; Collins, Margaret H.; Abonia, J. Pablo; Marsolo, Keith; Putnam, Philip E.; Kaul, Ajay; Wen, Ting; Rothenberg, Marc E.] Univ Cincinnati, Sch Med, Dept Pediat, Cincinnati, OH 45221 USA; [Franciosi, James P.] Nemours Childrens Hlth Syst, Dept Pediat, Div Gastroenterol, Orlando, FL USA; [Lee, James J.] Mayo Clin Arizona, Dept Biochem & Mol Biol, Scottsdale, AZ USA; [Varni, James W.] Texas A&M Univ, Coll Architecture, Dept Landscape Architecture & Urban Planning, Coll Med,Dept Pediat, College Stn, TX 77843 USA; [Garza, Jose M.] Childrens Ctr Digest Hlth Care, Atlanta, GA USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Mayo Clinic; Mayo Clinic Phoenix; Texas A&M University System; Texas A&M University College Station	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave,MLC 7028, Cincinnati, OH 45229 USA.	Marc.Rothenberg@cchmc.org	Martin, Lisa/E-2425-2016	Martin, Lisa/0000-0001-8702-9946; Abonia, Juan/0000-0003-3788-6485	National Institutes of Health [R01 DK076893-03S1]; Campaign Urging Research for Eosinophilic Disease (CURED); Buckeye Foundation; Food Allergy Research and Education (FARE); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077, UL1TR001425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392, R01DK076893] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Campaign Urging Research for Eosinophilic Disease (CURED); Buckeye Foundation; Food Allergy Research and Education (FARE); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by National Institutes of Health R01 DK076893-03S1, the Campaign Urging Research for Eosinophilic Disease (CURED), the Buckeye Foundation, and Food Allergy Research and Education (FARE).	Abonia JP, 2011, EXPERT REV CLIN IMMU, V7, P411, DOI [10.1586/ECI.11.27, 10.1586/eci.11.27]; Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Arias A, 2015, CLIN EXP ALLERGY; Arias A, 2014, GASTROENTEROLOGY, V146, P1639, DOI 10.1053/j.gastro.2014.02.006; Baines KJ, 2014, J ALLERGY CLIN IMMUN, V133, P997, DOI 10.1016/j.jaci.2013.12.1091; Baxi S, 2006, GASTROINTEST ENDOSC, V64, P473, DOI 10.1016/j.gie.2006.03.931; Bhattacharya B, 2007, HUM PATHOL, V38, P1744, DOI 10.1016/j.humpath.2007.05.008; Bjerke T, 1996, RESP MED, V90, P271, DOI 10.1016/S0954-6111(96)90098-0; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Blatman KSH, 2011, J ALLERGY CLIN IMMUN, V127, P1307, DOI 10.1016/j.jaci.2010.12.1118; Boldorini R, 2013, J CLIN PATHOL, V66, P399, DOI 10.1136/jclinpath-2012-201253; BUTTERFIELD JH, 1986, J ALLERGY CLIN IMMUN, V78, P450, DOI 10.1016/0091-6749(86)90032-1; Collins MH, 2014, DIGEST DIS, V32, P68, DOI 10.1159/000357012; Corren J, 2012, DISCOV MED, V13, P305; DeBrosse CW, 2011, J ALLERGY CLIN IMMUN, V128, P132, DOI 10.1016/j.jaci.2011.05.006; DeBrosse CW, 2010, J ALLERGY CLIN IMMUN, V126, P112, DOI 10.1016/j.jaci.2010.05.027; Eroglu Y, 2009, PEDIATR INT, V51, P612, DOI 10.1111/j.1442-200X.2008.02796.x; Fiorentino R, 2012, J ALLERGY CLIN IMMUN, V130, P613, DOI 10.1016/j.jaci.2012.07.011; Franciosi JP, 2012, CHILD CARE HLTH DEV, V38, P477, DOI 10.1111/j.1365-2214.2011.01265.x; Franciosi JP, 2013, J PEDIATR GASTR NUTR, V57, P57, DOI 10.1097/MPG.0b013e31828f1fd2; Franciosi JP, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-135; Franciosi JP, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-126; Furuta GT, 2013, GUT, V62, P1395, DOI 10.1136/gutjnl-2012-303171; Hasosah MY, 2011, SAUDI J GASTROENTERO, V17, P119, DOI 10.4103/1319-3767.77242; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; Kern E, 2013, EXPERT OPIN EMERG DR, V18, P353, DOI 10.1517/14728214.2013.829039; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Matoso A, 2013, MODERN PATHOL, V26, P665, DOI 10.1038/modpathol.2013.41; Miehlke S, 2014, DIGEST DIS, V32, P61, DOI 10.1159/000357011; Moawad FJ, 2013, AM J GASTROENTEROL, V108, P366, DOI 10.1038/ajg.2012.443; Niranjan R, 2013, AM J PHYSIOL-GASTR L, V304, pG1087, DOI 10.1152/ajpgi.00070.2013; Noel RJ, 2004, CLIN GASTROENTEROL H, V2, P568, DOI 10.1016/S1542-3565(04)00240-X; Orenstein SR, 2000, AM J GASTROENTEROL, V95, P1422; Papadopoulou A, 2014, J PEDIATR GASTR NUTR, V58, P107, DOI 10.1097/MPG.0b013e3182a80be1; Protheroe C, 2009, CLIN GASTROENTEROL H, V7, P749, DOI 10.1016/j.cgh.2009.03.022; Rezende Erica Rodrigues Mariano de Almeida, 2014, BMC Res Notes, V7, P47, DOI 10.1186/1756-0500-7-47; Rodrigues M, 2013, J PEDIAT-BRAZIL, V89, P197, DOI 10.1016/j.jped.2013.03.001; Rolland AMGASAS, 2004, J PEDIATR GASTR NUTR, V39, P373, DOI 10.1097/00005176-200410000-00013; Roman K, 2014, PAIN, V155, P1328, DOI 10.1016/j.pain.2014.04.009; Rothenberg ME, 2015, J ALLERGY CLIN IMMUN, V135, P500, DOI 10.1016/j.jaci.2014.07.049; Rothenberg ME, 2012, J ALLERGY CLIN IMMUN, V130, P617, DOI 10.1016/j.jaci.2012.06.051; Schlag C, 2014, J CLIN GASTROENTEROL, V48, P600, DOI 10.1097/01.mcg.0000436439.67768.8d; Schoepfer AM, 2014, GASTROENTEROLOGY, V147, P1255, DOI 10.1053/j.gastro.2014.08.028; Shaik-Dasthagirisaheb YB, 2013, INT J IMMUNOPATH PH, V26, P327, DOI 10.1177/039463201302600206; Spik I, 2005, J IMMUNOL, V174, P3703, DOI 10.4049/jimmunol.174.6.3703; Taft TH, 2011, J CLIN GASTROENTEROL, V45, P769, DOI 10.1097/MCG.0b013e3182166a5a; Uchida T, 2001, BIOCHEM BIOPH RES CO, V288, P137, DOI 10.1006/bbrc.2001.5722; WELLER PF, 1980, P NATL ACAD SCI-BIOL, V77, P7440, DOI 10.1073/pnas.77.12.7440; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046; Zhang S, 2014, DIS ESOPHAGUS, V27, P601, DOI 10.1111/dote.12118	53	83	87	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1519	U206		10.1016/j.jaci.2015.03.004	http://dx.doi.org/10.1016/j.jaci.2015.03.004			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	26051952	Green Accepted, Bronze			2022-12-18	WOS:000355933400015
J	de Koning, HD; van Gijn, ME; Stoffels, M; Jongekrijg, J; Zeeuwen, PLJM; Elferink, MG; Nijman, IJ; Jansen, PAM; Neveling, K; van der Meer, JWM; Schalkwijk, J; Simon, A				de Koning, Heleen D.; van Gijn, Marielle E.; Stoffels, Monique; Jongekrijg, Johanna; Zeeuwen, Patrick L. J. M.; Elferink, Martin G.; Nijman, Isaac J.; Jansen, Patrick A. M.; Neveling, Kornelia; van der Meer, Jos W. M.; Schalkwijk, Joost; Simon, Anna			Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CIAS1 MUTATIONS		[de Koning, Heleen D.; Zeeuwen, Patrick L. J. M.; Jansen, Patrick A. M.; Schalkwijk, Joost] Radboud Univ Nijmegen, Med Ctr, Dept Dermatol, NL-6525 ED Nijmegen, Netherlands; [de Koning, Heleen D.; Stoffels, Monique; Jongekrijg, Johanna; van der Meer, Jos W. M.; Simon, Anna] Radboud Univ Nijmegen, Dept Internal Med, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Neveling, Kornelia] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands; [de Koning, Heleen D.; Zeeuwen, Patrick L. J. M.; Jansen, Patrick A. M.; Schalkwijk, Joost; Simon, Anna] Radboud Inst Mol Life Sci, Nijmegen, Netherlands; [de Koning, Heleen D.; Stoffels, Monique; Jongekrijg, Johanna; Zeeuwen, Patrick L. J. M.; Jansen, Patrick A. M.; van der Meer, Jos W. M.; Schalkwijk, Joost; Simon, Anna] Nijmegen Ctr Immunodeficiency & Autoinflammat, Nijmegen, Netherlands; [van Gijn, Marielle E.; Elferink, Martin G.; Nijman, Isaac J.] Univ Med Ctr Utrecht, Dept Med Genet, Utrecht, Netherlands; [Neveling, Kornelia] Inst Genet & Metab Dis, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center	de Koning, HD (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Dermatol, NL-6525 ED Nijmegen, Netherlands.	heleen.dekoning@radboudumc.nl; joost.schalkwijk@radboudumc.nl	Neveling, K./L-4544-2015; Simon, Anna/D-3757-2009; Schalkwijk, Joost/R-7509-2019; Schalkwijk, Joost/N-1774-2013; van der Meer, Jos W.M./C-8521-2013; Jansen, Patrick AM/P-5602-2015; de Koning, Heleen/A-5374-2011; Zeeuwen, Patrick/N-1779-2013	Simon, Anna/0000-0002-6141-7921; Schalkwijk, Joost/0000-0002-1308-1319; van der Meer, Jos W.M./0000-0001-5120-3690; Zeeuwen, Patrick/0000-0002-6878-2438				Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Aksentijevich I, 2011, NAT REV RHEUMATOL, V7, P468, DOI 10.1038/nrrheum.2011.94; de Koning HD, 2006, ANN RHEUM DIS, V65, P542, DOI 10.1136/ard.2005.045245; de Koning HD, 2013, ANN RHEUM DIS, V72, P1634, DOI 10.1136/annrheumdis-2012-202192; Loock J, 2010, J ALLERGY CLIN IMMUN, V125, P500, DOI 10.1016/j.jaci.2009.10.066; Neveling K, 2013, AM J HUM GENET, V92, P946, DOI 10.1016/j.ajhg.2013.04.011; Rowczenio DM, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4171; Ryan JG, 2008, J ALLERGY CLIN IMMUN, V121, P260, DOI 10.1016/j.jaci.2007.09.021; Saito M, 2008, BLOOD, V111, P2132, DOI 10.1182/blood-2007-06-094201; Sharma D, 2004, J MOL CELL CARDIOL, V37, P79, DOI 10.1016/j.yjmcc.2004.03.015; Simon A, 2013, ALLERGY, V68, P562, DOI 10.1111/all.12129; Tanaka N, 2011, ARTHRITIS RHEUM-US, V63, P3625, DOI 10.1002/art.30512; Vissers LELM, 2010, NAT GENET, V42, P1109, DOI 10.1038/ng.712; Zeeuwen PLJM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002301	14	83	83	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					561	U390		10.1016/j.jaci.2014.07.050	http://dx.doi.org/10.1016/j.jaci.2014.07.050			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25239704				2022-12-18	WOS:000349372300034
J	Gupta, S; Hartley, R; Khan, UT; Singapuri, A; Hargadon, B; Monteiro, W; Pavord, ID; Sousa, AR; Marshall, RP; Subramanian, D; Parr, D; Entwisle, JJ; Siddiqui, S; Raj, V; Brightling, CE				Gupta, Sumit; Hartley, Ruth; Khan, Umair T.; Singapuri, Amisha; Hargadon, Beverly; Monteiro, William; Pavord, Ian D.; Sousa, Ana R.; Marshall, Richard P.; Subramanian, Deepak; Parr, David; Entwisle, James J.; Siddiqui, Salman; Raj, Vimal; Brightling, Christopher E.			Quantitative computed tomography-derived clusters: Redefining airway remodeling in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway remodeling; distal airway; CT; quantitative imaging; phenotypes; cluster analysis; fractal analysis	HIGH-RESOLUTION CT; WALL THICKNESS; GEOMETRY; DISEASE; LUNGS; BRONCHIECTASIS; EXACERBATIONS; SEGMENTATION; ATTENUATION; MORPHOMETRY	Background: Asthma heterogeneity is multidimensional and requires additional tools to unravel its complexity. Computed tomography (CT)-assessed proximal airway remodeling and air trapping in asthmatic patients might provide new insights into underlying disease mechanisms. Objectives: The aim of this study was to explore novel, quantitative, CT-determined asthma phenotypes. Methods: Sixty-five asthmatic patients and 30 healthy subjects underwent detailed clinical, physiologic characterization and quantitative CT analysis. Factor and cluster analysis techniques were used to determine 3 novel, quantitative, CT-based asthma phenotypes. Results: Patients with severe and mild-to-moderate asthma demonstrated smaller mean right upper lobe apical segmental bronchus (RB1) lumen volume (LV) in comparison with healthy control subjects (272.3 mm(3) [SD, 112.6 mm(3)], 259.0 mm(3) [SD, 53.3 mm(3)], 366.4 mm(3) [SD, 195.3 mm(3)], respectively; P = .007) but no difference in RB1 wall volume (WV). Air trapping measured based on mean lung density expiratory/inspiratory ratio was greater in patients with severe and mild-to-moderate asthma compared with that seen in healthy control subjects (0.861 [SD, 0.05)], 0.866 [SD, 0.07], and 0.830 [SD, 0.06], respectively; P = .04). The fractal dimension of the segmented airway tree was less in asthmatic patients compared with that seen in control subjects (P = .007). Three novel, quantitative, CT-based asthma clusters were identified, all of which demonstrated air trapping. Cluster 1 demonstrates increased RB1 WV and RB1 LV but decreased RB1 percentage WV. On the contrary, cluster 3 subjects have the smallest RB1 WV and LV values but the highest RB1 percentage WV values. There is a lack of proximal airway remodeling in cluster 2 subjects. Conclusions: Quantitative CT analysis provides a new perspective in asthma phenotyping, which might prove useful in patient selection for novel therapies.	[Gupta, Sumit; Hartley, Ruth; Khan, Umair T.; Singapuri, Amisha; Hargadon, Beverly; Monteiro, William; Pavord, Ian D.; Siddiqui, Salman; Brightling, Christopher E.] Univ Leicester, Inst Lung Hlth, Dept Infect Inflammat & Immun, Leicester LE3 9QP, Leics, England; [Gupta, Sumit; Raj, Vimal] Univ Hosp Leicester NHS Trust, Glenfield Hosp, Dept Radiol, Leicester, Leics, England; [Sousa, Ana R.; Marshall, Richard P.] GlaxoSmithKline, Resp Therapy Unit, Uxbridge, Middx, England; [Subramanian, Deepak; Parr, David] Univ Hosp Coventry & Warwickshire, Dept Resp Med, Coventry, W Midlands, England; [Entwisle, James J.] Capital & Coast Dist Hlth Board, Wellington Hosp, Dept Radiol, Wellington, New Zealand	University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; GlaxoSmithKline; University of Warwick	Gupta, S (corresponding author), Univ Leicester, Inst Lung Hlth, Leicester LE3 9QP, Leics, England.	drsumitgupta@yahoo.com		raj, vimal/0000-0003-1566-5403; Siddiqui, Salman/0000-0003-3770-7870; Pavord, Ian/0000-0002-4288-5973; Gupta, Sumit/0000-0002-7123-6139; PARR, DAVID/0000-0002-0099-7918; brightling, chris/0000-0002-9345-4903	GlaxoSmithKline; Wellcome Trust; Airway Disease Predicting Outcomes through Patient Specific Computational Modelling (AirPROM) project; FP7 EU grant; National Institute for Health Research (NIHR); National Institute for Health Research [CL-2008-11-005, CL-2012-11-002, NF-SI-0512-10018, NF-SI-0510-10157] Funding Source: researchfish	GlaxoSmithKline(GlaxoSmithKline); Wellcome Trust(Wellcome TrustEuropean Commission); Airway Disease Predicting Outcomes through Patient Specific Computational Modelling (AirPROM) project; FP7 EU grant; National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported in part by GlaxoSmithKline, Wellcome Trust Senior Fellowship, and the Airway Disease Predicting Outcomes through Patient Specific Computational Modelling (AirPROM) project (funded through FP7 EU grant). This article presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health.	Abramoff M.D., 2004, BIOPHOT INT, V11, P36; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Awadh N, 1998, THORAX, V53, P248, DOI 10.1136/thx.53.4.248; Aysola RS, 2008, CHEST, V134, P1183, DOI 10.1378/chest.07-2779; BALL GH, 1967, BEHAV SCI, V12, P153, DOI 10.1002/bs.3830120210; BARTLETT MS, 1954, J ROY STAT SOC B, V16, P296; Beigelman-Aubry C, 2002, RADIOLOGY, V223, P181, DOI 10.1148/radiol.2231010779; Boser SR, 2005, AM J RESP CRIT CARE, V172, P817, DOI 10.1164/rccm.200411-1463OC; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Brown RH, 1996, J APPL PHYSIOL, V80, P1581, DOI 10.1152/jappl.1996.80.5.1581; Busacker A, 2009, CHEST, V135, P48, DOI 10.1378/chest.08-0049; Castro M, 2011, J ALLERGY CLIN IMMUN, V128, P467, DOI 10.1016/j.jaci.2011.04.051; Coxson HO, 2003, THORAX, V58, P510, DOI 10.1136/thorax.58.6.510; Frey U, 2005, NATURE, V438, P667, DOI 10.1038/nature04176; Galban CJ, 2012, NAT MED, V18, P1711, DOI 10.1038/nm.2971; Gevenois PA, 1996, AM J RESP CRIT CARE, V154, P187, DOI 10.1164/ajrccm.154.1.8680679; GEVENOIS PA, 1995, AM J RESP CRIT CARE, V152, P653, DOI 10.1164/ajrccm.152.2.7633722; Gierada DS, 2001, RADIOLOGY, V220, P448, DOI 10.1148/radiology.220.2.r01au46448; GINA, 2010, GLOB STRAT ASTHM MAN; Goldberger AL, 2002, P NATL ACAD SCI USA, V99, P2466, DOI 10.1073/pnas.012579499; Gono H, 2003, EUR RESPIR J, V22, P965, DOI 10.1183/09031936.03.00085302; Grenier P, 1996, EUR RADIOL, V6, P199; Gupta S, 2010, THORAX, V65, P775, DOI 10.1136/thx.2010.136374; Gupta S, 2009, CHEST, V136, P1521, DOI 10.1378/chest.09-0174; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2007, J ALLERGY CLIN IMMUN, V119, P1043, DOI 10.1016/j.jaci.2007.02.042; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; HANSELL DM, 1994, RADIOLOGY, V193, P369, DOI 10.1148/radiology.193.2.7972745; Hu SY, 2001, IEEE T MED IMAGING, V20, P490, DOI 10.1109/42.929615; ImPACT, 2012, IMPACTS CT DOS TOOL; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V101, pS177; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; KAISER HF, 1970, PSYCHOMETRIKA, V35, P401, DOI 10.1007/BF02291817; KAISER HF, 1974, PSYCHOMETRIKA, V39, P31, DOI 10.1007/BF02291575; KAISER HF, 1960, EDUC PSYCHOL MEAS, V20, P141, DOI 10.1177/001316446002000116; Kaminska M, 2009, J ALLERGY CLIN IMMUN, V124, P45, DOI 10.1016/j.jaci.2009.03.049; Karperien A, FRACLAC IMAGEJ VERSI, V2; Kemerink GJ, 1996, J COMPUT ASSIST TOMO, V20, P24, DOI 10.1097/00004728-199601000-00006; Matsuoka S, 2008, AM J ROENTGENOL, V190, P762, DOI 10.2214/AJR.07.2820; MAYO JR, 1987, RADIOLOGY, V163, P507, DOI 10.1148/radiology.163.2.3562834; Mishima M, 1999, P NATL ACAD SCI USA, V96, P8829, DOI 10.1073/pnas.96.16.8829; Mitsunobu F, 2003, AM J RESP CRIT CARE, V167, P411, DOI 10.1164/rccm.2112070; Montaudon M, 2009, RADIOLOGY, V253, P844, DOI 10.1148/radiol.2533090303; Nakano Y, 2002, CHEST, V122, p271S, DOI 10.1378/chest.122.6_suppl.271S-a; Ng CS, 1999, J THORAC IMAG, V14, P279, DOI 10.1097/00005382-199910000-00008; Niimi A, 2000, AM J RESP CRIT CARE, V162, P1518, DOI 10.1164/ajrccm.162.4.9909044; Okazawa M, 1996, AM J RESP CRIT CARE, V154, P1557, DOI 10.1164/ajrccm.154.5.8912780; PAGANIN F, 1992, AM REV RESPIR DIS, V146, P1084, DOI 10.1164/ajrccm/146.4.1084; Palagyi K, 2003, LECT NOTES COMPUT SC, V2732, P222; Parr DG, 2004, AM J RESP CRIT CARE, V170, P883, DOI 10.1164/rccm.200403-326OC; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Shrimpton PC, 1991, SURVEY CT PRACTICE 2; Siddiqui S, 2009, ALLERGY, V64, P951, DOI 10.1111/j.1398-9995.2009.01951.x; Stern G, 2011, J ALLERGY CLIN IMMUN, V128, P293, DOI 10.1016/j.jaci.2011.03.010; Takemura M, 2004, CHEST, V125, P1352, DOI 10.1378/chest.125.4.1352; Taylor DR, 2008, EUR RESPIR J, V32, P545, DOI 10.1183/09031936.00155307; Tschirren J, 2005, IEEE T MED IMAGING, V24, P1529, DOI 10.1109/TMI.2005.857654; Tschirren Juerg, 2005, Proc Am Thorac Soc, V2, P484, DOI 10.1513/pats.200507-078DS; Venegas JG, 2005, NATURE, V434, P777, DOI 10.1038/nature03490; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; Williamson JP, 2011, AM J RESP CRIT CARE, V183, P612, DOI 10.1164/rccm.201002-0178OC; WONGYOUCHEONG JJ, 1992, CLIN RADIOL, V45, P256, DOI 10.1016/S0009-9260(05)80010-8	63	83	87	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					729	+		10.1016/j.jaci.2013.09.039	http://dx.doi.org/10.1016/j.jaci.2013.09.039			28	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24238646	Green Published, hybrid			2022-12-18	WOS:000332397600014
J	Koinis-Mitchell, D; Craig, T; Esteban, CA; Klein, RB				Koinis-Mitchell, Daphne; Craig, Timothy; Esteban, Cynthia A.; Klein, Robert B.			Sleep and allergic disease: A summary of the literature and future directions for research	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sleep; allergic disease; asthma; allergic rhinitis; atopic dermatitis	QUALITY-OF-LIFE; SCHOOL-AGED CHILDREN; INNER-CITY CHILDREN; ATOPIC-DERMATITIS; NOCTURNAL ASTHMA; DAYTIME SLEEPINESS; GENERAL-POPULATION; HISPANIC CHILDREN; CHILDHOOD ASTHMA; LATINO CHILDREN	Atopic diseases, such as asthma and allergic rhinitis, are common conditions that can influence sleep and subsequent daytime functioning. Children and patients with allergic conditions from ethnic minority groups might be particularly vulnerable to poor sleep and compromised daytime functioning because of the prevalence of these illnesses in these groups and the high level of morbidity. Research over the past 10 years has shed light on the pathophysiologic mechanisms (eg, inflammatory mediators) involved in many atopic diseases that can underlie sleep disruptions as a consequence of the presence of nocturnal symptoms. Associations between nocturnal symptoms and sleep and poorer quality of life as a result of missed sleep have been demonstrated across studies. Patients with severe illness and poor control appear to bear the most burden in terms of sleep impairment. Sleep-disordered breathing is also more common in patients with allergic diseases. Upper and lower airway resistance can increase the risk for sleep-disordered breathing events. In patients with allergic rhinitis, nasal congestion is a risk factor for apnea and snoring. Finally, consistent and appropriate use of medications can minimize nocturnal asthma or allergic symptoms that might disrupt sleep. Despite these advances, there is much room for improvement in this area. A summary of the sleep and allergic disease literature is reviewed, with methodological, conceptual, and clinical suggestions presented for future research. (J Allergy Clin Immunol 2012;130:1275-81.)	[Koinis-Mitchell, Daphne; Esteban, Cynthia A.; Klein, Robert B.] Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI 02903 USA; [Koinis-Mitchell, Daphne; Esteban, Cynthia A.; Klein, Robert B.] Brown Med Sch, Bradley Hasbro Childrens Res Ctr, Providence, RI 02903 USA; [Craig, Timothy] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA	Brown University; Brown University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Koinis-Mitchell, D (corresponding author), Brown Med Sch, Dept Psychiat & Human Behav, Coro W 2nd Floor,1 Hoppin St, Providence, RI 02903 USA.	Daphne_Koinis-Mitchell@Brown.edu			Eunice Kennedy Shriver National Institute of Child Health and Human Development [R01 HD057220]; Viropharma; CSL Behring; Shire; Dyax; Pharming; Forrest; Genentech; Merck; GlaxoSmithKline; Novartis; Teva; Vietnam Education Foundation; National Institute of Child Health and Human Development; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD057220] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Viropharma; CSL Behring; Shire; Dyax; Pharming; Forrest; Genentech(Roche HoldingGenentech); Merck(Merck & Company); GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); Teva(Teva Pharmaceutical Industries); Vietnam Education Foundation; National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01 HD057220 to D.K.M.).; T. Craig is an Interest Section Leader for the American Academy of Allergy, Asthma & Immunology; is a board member for the American College of Allergy, Asthma & Immunology and the Joint Council of Allergy, Asthma & Immunology; has consultant arrangements with CSL Behring, Dyax, and Viropharma; has provided expert testimony in a case related to anaphylaxis; has received grants from Viropharma, CSL Behring, Shire, Dyax, Pharming, Forrest, Genentech, Merck, and GlaxoSmithKline; has received payment for lectures from Viropharma, CSL Behring, Dyax, Merck, Novartis, Shire, and Teva; and has received payment for development of educational presentations from the Vietnam Education Foundation. C. A. Esteban has received a grant from the National Institute of Child Health and Human Development. The rest of the authors declare that they have no relevant conflicts of interest.	Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Bender BG, 2005, J ALLERGY CLIN IMMUN, V116, P1200, DOI 10.1016/j.jaci.2005.09.041; Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P598, DOI 10.1067/mai.2003.174; Bender BG, 2008, J AM ACAD DERMATOL, V58, P415, DOI 10.1016/j.jaad.2007.10.010; Bixler EO, 2009, SLEEP, V32, P731, DOI 10.1093/sleep/32.6.731; Blaiss MS, 2003, ALLERGY ASTHMA PROC, V24, P231; Boergers J, 2010, J PEDIATR PSYCHOL, V35, P915, DOI 10.1093/jpepsy/jsq016; Buckhalt JA, 2007, CHILD DEV, V78, P213, DOI 10.1111/j.1467-8624.2007.00993.x; BUTZ AM, 1995, CLIN PEDIATR, V34, P581, DOI 10.1177/000992289503401103; Camhi SL, 2000, SLEEP MED, V1, P117, DOI 10.1016/S1389-9457(99)00005-2; Canino G, 2006, SOC SCI MED, V63, P2926, DOI 10.1016/j.socscimed.2006.07.017; Cheng Lei, 2011, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V46, P437; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; Colas C, 2012, CLIN EXP ALLERGY, V42, P1080, DOI 10.1111/j.1365-2222.2011.03935.x; Crabtree VM, 2005, SLEEP MED, V6, P319, DOI 10.1016/j.sleep.2005.02.001; Craig TJ, 2010, CURR ALLERGY ASTHM R, V10, P113, DOI 10.1007/s11882-010-0091-5; Craig TJ, 1998, J ALLERGY CLIN IMMUN, V101, P633, DOI 10.1016/S0091-6749(98)70171-X; Crosby B, 2005, PEDIATRICS, V115, P225, DOI 10.1542/peds.2004-0815D; Dean BB, 2010, J ASTHMA, V47, P539, DOI 10.3109/02770900903580868; Derebery J, 2008, OTOLARYNG HEAD NECK, V139, P198, DOI 10.1016/j.otohns.2008.05.019; Desager KN, 2005, J SLEEP RES, V14, P77, DOI 10.1111/j.1365-2869.2004.00432.x; Diette GB, 2000, ARCH PEDIAT ADOL MED, V154, P923, DOI 10.1001/archpedi.154.9.923; Esteban C, 2012, BIOL PSYCH IN PRESS; Fagnano M, 2011, ACAD PEDIATR, V11, P493, DOI 10.1016/j.acap.2011.05.006; Fagnano M, 2009, PEDIATRICS, V124, P218, DOI 10.1542/peds.2008-2525; Ferguson BJ, 2004, OTOLARYNG HEAD NECK, V130, P617, DOI 10.1016/j.otohns.2004.02.001; Fisher L, 2005, CURR OPIN ALLERGY CL, V5, P11, DOI 10.1097/00130832-200502000-00004; Garrison MM, 2011, ARCH PEDIAT ADOL MED, V165, P826, DOI 10.1001/archpediatrics.2011.139; Goodwin JL, 2003, CHEST, V124, P196, DOI 10.1378/chest.124.1.196; Gozal D, 2009, PEDIATRICS, V123, P13, DOI 10.1542/peds.2008-0228; Grossman J, 1997, CHEST, V111, pS11, DOI 10.1378/chest.111.2_Supplement.11S; Gumustekin K, 2004, INT J NEUROSCI, V114, P1433, DOI 10.1080/00207450490509168; Halterman JS, 2006, PEDIATRICS, V117, pE192, DOI 10.1542/peds.2005-1140; Hanson MD, 2008, J PEDIATR PSYCHOL, V33, P312, DOI 10.1093/jpepsy/jsm120; Horner CC, 2011, J ALLERGY CLIN IMMUN, V128, P977, DOI 10.1016/j.jaci.2011.07.018; Hughes K, 2003, ALLERGY, V58, P380, DOI 10.1034/j.1398-9995.2003.00093.x; International Conference on Allergic Rhinitis in Childhood, 1999, ALLERGY S, V54, pS7; Jandasek B, 2011, MED CARE RES REV, V68, P683, DOI 10.1177/1077558711404434; Janson C, 1996, EUR RESPIR J, V9, P2132, DOI 10.1183/09031936.96.09102132; JOHNS MW, 1991, MED J AUSTRALIA, V155, P303, DOI 10.5694/j.1326-5377.1991.tb142286.x; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; Juniper EF, 2003, J ALLERGY CLIN IMMUN, V111, P484, DOI 10.1067/mai.2003.137; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Kakumanu Sujani, 2002, Am J Respir Med, V1, P195; Kelsay K, 2006, J ALLERGY CLIN IMMUN, V118, P198, DOI 10.1016/j.jaci.2006.04.038; Kieckhefer GM, 2008, J DEV BEHAV PEDIATR, V29, P338, DOI 10.1097/DBP.0b013e318182a99e; Koinis Mitchell DE, 2012, BIOL PSYCH IN PRESS; Koinis-Mitchell D, 2007, J PEDIATR PSYCHOL, V32, P582, DOI 10.1093/jpepsy/jsl050; Koinis-Mitchell D, 2009, HEALTH PSYCHOL, V28, P226, DOI 10.1037/a0013169; Lara M, 2006, PEDIATRICS, V117, P43, DOI 10.1542/peds.2004-1714; Larsson LG, 2001, RESP MED, V95, P423, DOI 10.1053/rmed.2001.1054; LAVIE P, 1981, ACTA OTO-LARYNGOL, V92, P529, DOI 10.3109/00016488109133292; Leger D, 2006, ARCH INTERN MED, V166, P1744, DOI 10.1001/archinte.166.16.1744; Lunn M, 2011, SLEEP MED REV, V15, P293, DOI 10.1016/j.smrv.2010.12.001; Luyster FS, 2011, SLEEP BREATH; McColley SA, 1997, CHEST, V111, P170, DOI 10.1378/chest.111.1.170; MCNICHOLAS WT, 1982, AM REV RESPIR DIS, V126, P625; Meijer GG, 1995, EUR RESPIR J, V8, P2076, DOI 10.1183/09031936.95.08122076; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; Mullol J, 2008, J INVEST ALLERG CLIN, V18, P327; Mullol J, 2008, J INVEST ALLERG CLIN, V18, P415; *NAT HEART LUNG BL, 2007, GUID DIAGN MAN ASTHM; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; [National Institutes of Health US Department of Health and Human Services National Heart Lung and Blood Institute National Center on Sleep Disorders Research Trans-NIH Sleep Research Co-ordinating Committee], 2003, 2003 NAT SLEEP DIS R; Ng DK, 2005, CHEST, V127, P2285, DOI 10.1378/chest.127.6.2285; Ozturk L, 1999, Sleep Res Online, V2, P107; Pratt EL, 2007, CURR OPIN ALLERGY CL, V7, P249, DOI 10.1097/ACI.0b013e3280f3c09f; Qidwai Julie C, 2002, Curr Allergy Asthma Rep, V2, P216, DOI 10.1007/s11882-002-0022-1; Rand CS, 2005, J PEDIATR-US, V146, P157, DOI 10.1016/j.jpeds.2004.11.021; Rappai M, 2003, CHEST, V124, P2309, DOI 10.1378/chest.124.6.2309; Redline S, 1997, AM J RESP CRIT CARE, V155, P186, DOI 10.1164/ajrccm.155.1.9001310; Rimmer J, 2009, ANN ALLERG ASTHMA IM, V103, P190, DOI 10.1016/S1081-1206(10)60180-9; Ross KR, 2012, J PEDIATR-US, V160, P736, DOI 10.1016/j.jpeds.2011.10.008; Sardana N, 2011, ASIAN PAC J ALLERGY, V29, P297; Sogut A, 2005, PEDIATR PULM, V39, P251, DOI 10.1002/ppul.20179; Spilsbury JC, 2004, ARCH PEDIAT ADOL MED, V158, P988, DOI 10.1001/archpedi.158.10.988; Staevska MT, 2004, CURR ALLERGY ASTHM R, V4, P193, DOI 10.1007/s11882-004-0026-0; Stores G, 1998, ARCH DIS CHILD, V78, P413, DOI 10.1136/adc.78.5.413; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174, DOI 10.1136/adc.70.3.174; Strunk RC, 2002, J ALLERGY CLIN IMMUN, V110, P395, DOI 10.1067/mai.2002.127433; Stuck BA, 2004, J ALLERGY CLIN IMMUN, V113, P663, DOI 10.1016/j.jaci.2003.12.589; Sulit LG, 2005, AM J RESP CRIT CARE, V171, P659, DOI 10.1164/rccm.200403-398OC; Sundar KM, 2011, J CLIN SLEEP MED, V7, P669, DOI 10.5664/jcsm.1482; Tashiro M, 2002, LIFE SCI, V72, P409, DOI 10.1016/S0024-3205(02)02276-2; Warman KL, 1999, PEDIATRICS, V103, P422, DOI 10.1542/peds.103.2.422; Watson Wade, 2011, Allergy Asthma Clin Immunol, V7 Suppl 1, pS4, DOI 10.1186/1710-1492-7-S1-S4; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Yarrington A, 1998, Pediatr Transplant, V2, P51; Young T, 1997, J ALLERGY CLIN IMMUN, V99, pS757, DOI 10.1016/S0091-6749(97)70124-6; Zahran Hatice S., 2011, Morbidity and Mortality Weekly Report, V60, P547	91	83	83	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1275	1281		10.1016/j.jaci.2012.06.026	http://dx.doi.org/10.1016/j.jaci.2012.06.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	044RP	22867694	Bronze, Green Accepted			2022-12-18	WOS:000311641100005
J	Roduit, C; Frei, R; Loss, G; Buchele, G; Weber, J; Depner, M; Loeliger, S; Dalphin, ML; Roponen, M; Hyvarinen, A; Riedler, J; Dalphin, JC; Pekkanen, J; von Mutius, E; Braun-Fahrlander, C; Lauener, R				Roduit, Caroline; Frei, Remo; Loss, Georg; Buechele, Gisela; Weber, Juliane; Depner, Martin; Loeliger, Susanne; Dalphin, Marie-Laure; Roponen, Marjut; Hyvarinen, Anne; Riedler, Josef; Dalphin, Jean-Charles; Pekkanen, Juha; von Mutius, Erika; Braun-Fahrlaender, Charlotte; Lauener, Roger		Protection Allergy-Study Rural Env	Development of atopic dermatitis according to age of onset and association with early-life exposures	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; diversity; complementary food	FARM MILK CONSUMPTION; SOLID FOOD INTRODUCTION; ALLERGIC DISEASES; INVERSE ASSOCIATION; GUT MICROBIOTA; ASTHMA; ECZEMA; SENSITIZATION; CHILDREN; RISK	Background: Environmental factors can affect the development of atopic dermatitis, and this was described to be already effective during pregnancy and in early life. An important early postnatal exposure is nutrition, although its association with allergic disease remains unclear. Objective: We sought to determine prospectively whether early postnatal exposures, such as the introduction to complementary food in the first year of life, are associated with the development of atopic dermatitis, taking into account the reverse causality. Methods: One thousand forty-one children who participated in the Protection Against Allergy-Study in Rural Environments birth cohort study were included in the current study. Atopic dermatitis was defined by a doctor's diagnosis reported by the parents of children up to 4 years of age, by questionnaires, and/or by positive SCORAD scores from 1 year of age and according to the age of onset within or after the first year of life. Feeding practices were reported by parents in monthly diaries between the 3rd and 12th months of life. Results: The diversity of introduction of complementary food in the first year of life was associated with a reduction in the risk of having atopic dermatitis with onset after the first year of life (adjusted odds ratio for atopic dermatitis with each additional major food item introduced, 0.76; 95% CI, 0.65-0.88). The introduction of yogurt in the first year of life also reduced the risk for atopic dermatitis (adjusted odds ratio, 0.41; 95% CI, 0.23-0.73). Conclusion: As early-life exposure, the introduction of yogurt and the diversity of food introduced in the first year of life might have a protective effect against atopic dermatitis. (J Allergy Clin Immunol 2012;130:130-6.)	[Roduit, Caroline; Loeliger, Susanne; Lauener, Roger] Univ Zurich, Childrens Hosp, Zurich, Switzerland; [Roduit, Caroline; Frei, Remo; Loeliger, Susanne; Lauener, Roger] Christine Kuhne Ctr Allergy Res & Educ, Zurich, Switzerland; [Frei, Remo] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Zurich, Switzerland; [Loss, Georg; Braun-Fahrlaender, Charlotte] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Braun-Fahrlaender, Charlotte] Univ Basel, Basel, Switzerland; [Lauener, Roger] Childrens Allergy & Asthma Hosp, Hochgebirgsklin, Davos, Switzerland; [Lauener, Roger] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Buechele, Gisela] Univ Ulm, Inst Epidemiol, Ulm, Germany; [Weber, Juliane; Depner, Martin; von Mutius, Erika] Univ Childrens Hosp Munich, Munich, Germany; [Dalphin, Marie-Laure] Univ Hosp Besancon, Dept Pediat, Besancon, France; [Roponen, Marjut] Univ Eastern Finland, Dept Environm Sci, Kuopio, Finland; [Hyvarinen, Anne; Pekkanen, Juha] Natl Inst Hlth & Welf, Dept Environm Hlth, Kuopio, Finland; [Riedler, Josef] Childrens Hosp Schwarzach, Schwarzach, Austria; [Dalphin, Jean-Charles] Univ Hosp Besancon, Dept Resp Dis, UMR CNRS Chronoenvironm 6249, Besancon, France	University Children's Hospital Zurich; University of Zurich; Swiss Institute of Allergy & Asthma Research; University of Zurich; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Ulm University; University of Munich; Universite de Franche-Comte; CHU Besancon; University of Eastern Finland; Finland National Institute for Health & Welfare; Universite de Franche-Comte; CHU Besancon	Roduit, C (corresponding author), Kinderspital Zurich, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	Caroline.Roduit@kispi.uzh.ch	riedler, josef/AAQ-4666-2020; Roponen, Marjut/C-2086-2017; Loss, Georg/AAE-7296-2019; Genuneit, Jon/I-9323-2012; Frei, Remo/AAI-9180-2020; Lauener, Roger P/O-8612-2016; Loss, Georg/F-1557-2013; Schaub, Bianca/B-9935-2019; Roduit, Caroline/S-4928-2017; Ege, Markus/C-1962-2012	Roponen, Marjut/0000-0002-4442-9090; Loss, Georg/0000-0003-1090-812X; Genuneit, Jon/0000-0001-5764-1528; Lauener, Roger P/0000-0002-8412-606X; Schaub, Bianca/0000-0003-1652-8873; Ege, Markus/0000-0001-6643-3923; von Mutius, Erika/0000-0002-8893-4515; Roduit, Caroline/0000-0002-5988-0570; Hyvarinen, Anne/0000-0002-2823-0866	European Union research grants PASTURE/EFRAIM [QRLT4-CT 2001-00250, KBBE-2-2-06]; Kuhne Foundation; European Commission/European Research Council; European Union; Academy of Finland; EVO; Farmers' Social Insurance Institution; GlaxoSmithKline; Protectimmun; Novartis; InfectoPharm; Nestle Research; European Commission	European Union research grants PASTURE/EFRAIM; Kuhne Foundation; European Commission/European Research Council(European CommissionEuropean Commission Joint Research CentreEuropean Research Council (ERC)); European Union(European Commission); Academy of Finland(Academy of Finland); EVO; Farmers' Social Insurance Institution; GlaxoSmithKline(GlaxoSmithKline); Protectimmun; Novartis(Novartis); InfectoPharm; Nestle Research(Nestle SA); European Commission(European CommissionEuropean Commission Joint Research Centre)	Supported by European Union research grants PASTURE/EFRAIM (QRLT4-CT 2001-00250, KBBE-2-2-06) and the Kuhne Foundation.; Disclosure of potential conflict of interest: M. Depner receives research support from the European Commission/European Research Council. M. Roponen receives research support from the European Union FP7 and the Academy of Finland. A. Hyvarinen receives research support from the European Union FP7. J. Pekkanen receives research support from the European Union FP7, the Academy of Finland, EVO, and Farmers' Social Insurance Institution. E. von Mutius receives consultation fees from GlaxoSmithKline, Protectimmun, and Novartis; receives lecture fees from InfectoPharm and Nestle Research; receives research support from the European Commission; has provided legal consultation/expert witness testimony for the UK Research Excellence Framework; and is Associate Editor of the Journal of Allergy and Clinical Immunology. R. Lauener receives research support from the Kuhne Foundation and the European Union. The rest of the authors declare that they have no relevant conflicts of interest.	Agostoni C, 2008, J PEDIATR GASTR NUTR, V46, P99, DOI 10.1097/01.mpg.0000304464.60788.bd; Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Alm B, 2009, ARCH DIS CHILD, V94, P11, DOI 10.1136/adc.2008.140418; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; KAY J, 1994, J AM ACAD DERMATOL, V30, P35, DOI 10.1016/S0190-9622(94)70004-4; Kuitunen M, 2009, J ALLERGY CLIN IMMUN, V123, P335, DOI 10.1016/j.jaci.2008.11.019; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Matsumoto M, 2007, CLIN EXP ALLERGY, V37, P358, DOI 10.1111/j.1365-2222.2007.02642.x; Nwaru BI, 2010, PEDIATRICS, V125, P50, DOI 10.1542/peds.2009-0813; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Prescott SL, 2008, PEDIAT ALLERG IMM-UK, V19, P375, DOI 10.1111/j.1399-3038.2008.00718.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rizkalla SW, 2000, AM J CLIN NUTR, V72, P1474; Roduit C, 2011, J ALLERGY CLIN IMMUN, V127, P179, DOI 10.1016/j.jaci.2010.10.010; Sariachvili M, 2010, PEDIAT ALLERG IMM-UK, V21, P74, DOI 10.1111/j.1399-3038.2009.00899.x; Schuttelaar MLA, 2009, ALLERGY, V64, P1758, DOI 10.1111/j.1398-9995.2009.02080.x; Shaheen SO, 2009, AM J RESP CRIT CARE, V180, P690, DOI 10.1164/rccm.200906-0893ED; Snijders BEP, 2008, PEDIATRICS, V122, pE115, DOI 10.1542/peds.2007-1651; Sunyer J, 2001, CLIN EXP ALLERGY, V31, P1352, DOI 10.1046/j.1365-2222.2001.01187.x; Tarini BA, 2006, ARCH PEDIAT ADOL MED, V160, P502, DOI 10.1001/archpedi.160.5.502; Tedelind S, 2007, WORLD J GASTROENTERO, V13, P2826, DOI 10.3748/wjg.v13.i20.2826; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521; Zutavern A, 2008, PEDIATRICS, V121, pE44, DOI 10.1542/peds.2006-3553	36	83	87	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					130	+		10.1016/j.jaci.2012.02.043	http://dx.doi.org/10.1016/j.jaci.2012.02.043			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22521248				2022-12-18	WOS:000306644800019
J	Moeller, A; Diefenbacher, C; Lehmann, A; Rochat, M; Brooks-Wildhaber, J; Hall, GL; Wiidhaber, JH				Moeller, Alexander; Diefenbacher, Corinne; Lehmann, Andrea; Rochat, Mascha; Brooks-Wildhaber, Joanne; Hall, Graham L.; Wiidhaber, Johannes H.			Exhaled nitric oxide distinguishes between subgroups of preschool children with respiratory symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exhaled nitric oxide; early childhood asthma; infants young children	MUCOSAL EOSINOPHILIC INFLAMMATION; AIRWAY RESPONSIVENESS; 1ST YEAR; INHALED CORTICOSTEROIDS; PARENTAL SMOKING; TRACT ILLNESS; LUNG-FUNCTION; ASTHMA; INFANTS; RISK	Background: Respiratory symptoms are common in early childhood. The clinical characterization of disease presentation and hence its likely disease progression has so far been proven difficult. Objective: To investigate whether exhaled nitric oxide (NO) could be helpful to distinguish between subgroups of nonwheezy and wheezy young children less than 4 years of age. Methods: Exhaled NO was measured in 391 children (age 3-47 months) with nonwheezy and wheezy respiratory symptoms. Children were divided into 3 groups: children with recurrent cough but no history of wheeze (group 1), with early recurrent wheeze and a loose index for the prediction of asthma at school age (group 2), and with frequent recurrent wheeze and a stringent index for the prediction of asthma at school age (group 3). Results: Children from group 3 showed significantly higher median (interquartile range) fractional exhaled NO (FeNO) levels (11.7 [11.85]) than children from groups 1 (6.5 [5.5]; P <.001) and 2 (6.4 [6.5]; P <.001). No difference in FeNO levels was found between children from groups 1 and 2 (P =.91). Conclusion: Wheezy young children less than 4 years of age with a stringent index for the prediction of asthma at school age have elevated levels of FeNO compared with children with recurrent wheeze and a loose index for the prediction of asthma at school age or children with recurrent cough.	[Moeller, Alexander; Diefenbacher, Corinne; Lehmann, Andrea; Rochat, Mascha; Wiidhaber, Johannes H.] Univ Childrens Hosp, Div Resp Med, CH-8032 Zurich, Switzerland; [Moeller, Alexander; Diefenbacher, Corinne; Lehmann, Andrea; Rochat, Mascha; Wiidhaber, Johannes H.] Univ Childrens Hosp, Swiss Pediat Resp Res Grp, CH-8032 Zurich, Switzerland; [Brooks-Wildhaber, Joanne] Alpine Childrens Hosp, Davos, Switzerland; [Hall, Graham L.] Univ Western Australia, Princess Margaret Hosp Children, Dept Resp Med, Perth, WA 6009, Australia; [Hall, Graham L.] Univ Western Australia, Sch Pediat & Child Hlth, Perth, WA 6009, Australia	University Children's Hospital Zurich; University Children's Hospital Zurich; University of Western Australia; University of Western Australia	Moeller, A (corresponding author), Univ Childrens Hosp, Div Resp Med, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	alexander.moeller@kispi.unizh.ch	Hall, Graham/AAB-6418-2019; Hall, Graham/C-4775-2008	Hall, Graham/0000-0002-6217-9494; Moeller, Alexander/0000-0001-7284-4251				Aldous MB, 1996, AM J EPIDEMIOL, V143, P423; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Artlich A, 2001, BIOL NEONATE, V79, P21, DOI 10.1159/000047061; Avital A, 2001, PEDIATR PULM, V32, P308, DOI 10.1002/ppul.1124; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P1284, DOI 10.1164/ajrccm.159.4.9807084; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Brussee JE, 2005, EUR RESPIR J, V25, P455, DOI 10.1183/09031936.05.00079604; Buchvald F, 2003, CLIN EXP ALLERGY, V33, P1735, DOI 10.1111/j.1365-2222.2003.01822.x; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Franklin PJ, 2006, EUR RESPIR J, V28, P730, DOI 10.1183/09031936.06.00007206; Franklin PJ, 2003, THORAX, V58, P1048, DOI 10.1136/thorax.58.12.1048; Gabriele C, 2006, PEDIATR RES, V60, P461, DOI 10.1203/01.pdr.0000238242.39881.64; Griese M, 2000, Eur J Med Res, V5, P334; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hall GL, 2002, J APPL PHYSIOL, V92, P59, DOI 10.1152/jappl.2002.92.1.59; HOLBERG CJ, 1993, PEDIATRICS, V91, P885; HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135, DOI 10.1093/oxfordjournals.aje.a115826; Jatakanon A, 1999, THORAX, V54, P108, DOI 10.1136/thx.54.2.108; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Lim S, 2000, THORAX, V55, P184, DOI 10.1136/thorax.55.3.184; Malmberg LP, 2006, PEDIATR PULM, V41, P635, DOI 10.1002/ppul.20417; Malmberg LP, 2003, THORAX, V58, P494, DOI 10.1136/thorax.58.6.494; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1992, AM J EPIDEMIOL, V136, P1258, DOI 10.1093/oxfordjournals.aje.a116434; Moeller A, 2004, PEDIATR PULM, V38, P250, DOI 10.1002/ppul.20055; Nordvall SL, 2005, ALLERGY, V60, P469, DOI 10.1111/j.1398-9995.2005.00735.x; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37, DOI 10.1164/ajrccm.163.1.2005013; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Piacentini GL, 1999, EUR RESPIR J, V13, P1386, DOI 10.1034/j.1399-3003.1999.13f25.x; Piacentini GL, 2000, EUR RESPIR J, V15, P839, DOI 10.1034/j.1399-3003.2000.15e05.x; Pijnenburg MW, 2005, AM J RESP CRIT CARE, V172, P831, DOI 10.1164/rccm.200503-458OC; Pijnenburg MWH, 2005, CLIN EXP ALLERGY, V35, P920, DOI 10.1111/j.1365-2222.2005.02279.x; Ratjen F, 2000, PEDIATR ALLERGY IMMU, V11, P230, DOI 10.1034/j.1399-3038.2000.00093.x; Rytila P, 2000, EUR RESPIR J, V16, P824, DOI 10.1183/09031936.00.16582400; Schuepp KG, 2004, J AEROSOL MED, V17, P153, DOI 10.1089/0894268041457228; Stocks J, 2006, PAEDIATR RESPIR REV, V7, pS26, DOI 10.1016/j.prrv.2006.04.015; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Trindade JC, 1998, PEDIAT ALLERG IMM-UK, V9, P23; Tsai YG, 2001, J PEDIATR-US, V139, P433, DOI 10.1067/mpd.2001.116295; Visser MJ, 2000, PEDIATR PULM, V29, P434; Warke TJ, 2002, THORAX, V57, P383, DOI 10.1136/thorax.57.5.383; WRIGHT AL, 1991, J PEDIATR-US, V118, P207, DOI 10.1016/S0022-3476(05)80484-6; WRIGHT AL, 1989, BRIT MED J, V299, P946, DOI 10.1136/bmj.299.6705.946; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892, DOI 10.1164/ajrccm.152.3.7663801; Zacharasiewicz A, 2005, AM J RESP CRIT CARE, V171, P1077, DOI 10.1164/rccm.200409-1242OC; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	46	83	85	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					705	709		10.1016/j.jaci.2007.11.008	http://dx.doi.org/10.1016/j.jaci.2007.11.008			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18177695				2022-12-18	WOS:000253918900025
J	Sears, MR; Johnston, NW				Sears, Malcolm R.; Johnston, Neil W.			Understanding the September asthma epidemic	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHILDREN; EXACERBATIONS; INFECTIONS; MONTELUKAST; SCHOOL	The highly predictable increase in emergency department visits, hospital admissions, and unscheduled physician consultations for childhood asthma in North America every September is uniquely related to school return. Rhinovirus infection is likely the major trigger, initially affecting asthma in school-age children, followed by similar but lesser increases in asthma morbidity in younger children and in adults. Low use of asthma medications during summer may fuel the epidemic, which may be attenuated by the short-term addition of an effective controller therapy.	St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Hamilton, ON, Canada	McMaster University; McMaster University	Sears, MR (corresponding author), St Josephs Healthcare, Firestone Inst Resp Hlth, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	searsm@mcmaster.ca						Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; HENDLEY JO, 1969, AM J EPIDEMIOL, V89, P184, DOI 10.1093/oxfordjournals.aje.a120928; Johnston NW, 2006, THORAX, V61, P722, DOI 10.1136/thx.2005.045161; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; JOHNSTON NW, 2007, IN PRESS PEDIATRICS; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; MANDHANE PJ, 2005, P AM THROACIC SOC, pA688; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X	12	83	89	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					526	529		10.1016/j.jaci.2007.05.047	http://dx.doi.org/10.1016/j.jaci.2007.05.047			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17658590	Green Published, Bronze			2022-12-18	WOS:000249505400005
J	Bacharier, LB; Phillips, BR; Bloomberg, GR; Zeiger, RS; Paul, IM; Krawlec, M; Guilbert, T; Chinchilli, VM; Strunk, RC				Bacharier, Leonard B.; Phillips, Brenda R.; Bloomberg, Gordon R.; Zeiger, Robert S.; Paul, Ian M.; Krawlec, Marzena; Guilbert, Theresa; Chinchilli, Vernon M.; Strunk, Robert C.		Childhood Asthma Res Ed Network	Severe intermittent wheezing in preschool children: A distinct phenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						childhood asthma; wheezing; intermittent asthma	QUALITY-OF-LIFE; INHALED CORTICOSTEROIDS; CHILDHOOD ASTHMA; PEDIATRIC ASTHMA; FLUTICASONE; TRENDS; RISK	Background: Young children with wheezing predominantly with respiratory tract illnesses experience severe exacerbations separated by extended periods of wellness and may be described as having "severe intermittent wheezing," a diagnostic category not currently recognized in national guidelines. Objective: We sought to characterize a cohort of children with recurrent severe wheezing. Methods: A total of 238 children 12 to 59 months enrolled in the Acute Intervention Management Strategies trial were characterized through comprehensive allergy, asthma, environmental, and quality of life assessments. Results: Asthma symptoms over the period of the preceding year occurred at frequencies consistent with intermittent asthma, as 94.5% of children experienced activity limitation : 2 times per month. However, frequent severe exacerbations were common, because 71% experienced >= 4 wheezing episodes over the period of the preceding year, 95% made at least I primary care visit, 52% missed school or daycare, 40% made an emergency department visit, and 8% were hospitalized for wheezing illnesses. Atopic features were common, including eczema (37%), aeroallergen sensitization (46.8%), and positive asthma predictive index (59.7%). Oral corticosteroid use in the previous year (59.7% of the cohort) identified a subgroup with more severe disease documented by a higher incidence of urgent care visits (P =.0048), hospitalizations (P = .0061), aeroallergen sensitization (P = .007), and positive asthma predictive indices (P = .007). Conclusion: Among preschool children enrolled in the Acute Intervention Management Strategies trial, a subgroup was identified with severe intermittent wheezing characterized by atopic features and substantial illness-related symptom burden despite prolonged periods of wellness. Clinical implications: Preschool children with recurrent severe wheezing episodes experience significant illness-related morbidity and exhibit features of atopic predisposition.	Washington Univ, St Louis Childrens Hosp, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Dept Pediat, St Louis, MO 63130 USA; Penn State Univ, Dept Hlth Evaluat Sci, University Pk, PA 16802 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Kaiser Permanente, Dept Allergy, San Diego, CA USA; Natl Jewis Med & Res Ctr, Dept Pediat, Denver, CO USA; Univ Arizona, Arizona Res Ctr, Tucson, AZ 85721 USA	St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of California System; University of California San Diego; Kaiser Permanente; National Jewish Health; University of Arizona	Bacharier, LB (corresponding author), Washington Univ, St Louis Childrens Hosp, Dept Pediat, 1 Childrens Pl, St Louis, MO 63110 USA.	bacharier_L@kids.wustl.edu	Paul, Ian/AAD-9813-2020	Guilbert, Theresa/0000-0002-6932-712X; Bacharier, Leonard/0000-0003-0432-2704; Zeiger, Robert/0000-0001-5788-5063; Paul, Ian/0000-0002-6344-8609	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051, M01RR000036] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064287, U10HL064288, U10HL064313, U10HL064305, U10HL064307, U10HL064295] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00036, M01 RR00051] Funding Source: Medline; NHLBI NIH HHS [U10HL064288, U10HL064305, U10HL064307, U10HL064313, U10HL064295, U10HL064287] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Bisgaard H, 2005, AM J RESP CRIT CARE, V172, P783, DOI 10.1164/ajrccm.172.6.954; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bloomberg GR, 2003, AM J RESP CRIT CARE, V167, P1068, DOI 10.1164/rccm.2201015; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; *CDCP, 2000, MMWR-MORBID MORTAL W, V49, P929; CONNETT G, 1993, ARCH DIS CHILD, V68, P85, DOI 10.1136/adc.68.1.85; Doull IJM, 1997, BMJ-BRIT MED J, V315, P858, DOI 10.1136/bmj.315.7112.858; Getahun D, 2005, J ASTHMA, V42, P373, DOI 10.1081/JAS-200062995; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; *NAT ASTHM ED PREV, 1997, EXP PAN REP 2 GUID D; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Roorda RJ, 2001, J ALLERGY CLIN IMMUN, V108, P540, DOI 10.1067/mai.2001.118789; Santanello NC, 2000, J ALLERGY CLIN IMMUN, V106, P861, DOI 10.1067/mai.2000.110478; Svedmyr J, 1999, ACTA PAEDIATR, V88, P42; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Varni JW, 2004, J BEHAV MED, V27, P297, DOI 10.1023/B:JOBM.0000028500.53608.2c; WILSON N, 1995, ARCH DIS CHILD, V72, P317, DOI 10.1136/adc.72.4.317; WILSON NM, 1990, ARCH DIS CHILD, V65, P407, DOI 10.1136/adc.65.4.407	22	83	87	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					604	610		10.1016/j.jaci.2006.12.607	http://dx.doi.org/10.1016/j.jaci.2006.12.607			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17336610				2022-12-18	WOS:000244925000012
J	Li, JT; Oppenheimer, J; Bernstein, IL; Nicklas, RA				Li, JT; Oppenheimer, J; Bernstein, IL; Nicklas, RA			Attaining optimal asthma control: A practice parameter	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EXHALED NITRIC-OXIDE; HEALTH-CARE UTILIZATION; DISEASE-CONTROL; INHALED CORTICOSTEROIDS; CHILDREN; ASSOCIATION; VARIABILITY; QUALITY; MONTELUKAST; EOSINOPHILS	These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology; the Amercian College of Allergy, Asthma and Immunology; and the Joint Council of Allergy, Asthma and Immunology. The American Academy of Allergy. Asthma and Immunology (AAAAl) and the American College of Allergy, Asthma and Immunology (ACAAl) have jointly accepted responsibility for establishing "Attaining optimal asthma control: A practice parameter. " This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or the ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAl, and the Joint Council of Allergy. Asthma and Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.	Joint Council Allergy Asthma & Immunol, Palatine, IL 60067 USA		Li, JT (corresponding author), Joint Council Allergy Asthma & Immunol, 50 N Brockway St,3-3, Palatine, IL 60067 USA.							Bateman ED, 2002, EUR RESPIR J, V20, P588, DOI 10.1183/09031936.02.00294702; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Baumgartner RA, 2003, EUR RESPIR J, V21, P123, DOI 10.1183/09031936.03.00028803; Boulet Louis-Philippe, 2002, Can Respir J, V9, P417; Calhoun WJ, 2003, J ALLERGY CLIN IMMUN, V112, P1088, DOI 10.1016/j.jaci.2003.09.044; Cockcroft DW, 1996, J ALLERGY CLIN IMMUN, V98, P1016, DOI 10.1016/S0091-6749(96)80185-0; Combescure C, 2003, EUR RESPIR J, V22, P298, DOI 10.1183/09031936.03.00081102; Covar RA, 2003, J PEDIATR-US, V142, P469, DOI 10.1067/mpd.2003.187; Delgado-Corcoran Claudia, 2004, Pediatr Crit Care Med, V5, P48, DOI 10.1097/01.CCM.0000105310.00799.51; Ducharme Francine M, 2004, Can Respir J, V11, P541; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Halterman JS, 2003, AMBUL PEDIATR, V3, P102, DOI 10.1367/1539-4409(2003)003<0102:APPIPA>2.0.CO;2; Hawkins G, 2003, BMJ-BRIT MED J, V326, P1115, DOI 10.1136/bmj.326.7399.1115; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Laforest L, 2004, ANN ALLERG ASTHMA IM, V93, P265, DOI 10.1016/S1081-1206(10)61499-8; Lai CKW, 2003, J ALLERGY CLIN IMMUN, V111, P263, DOI 10.1067/mai.2003.30; Leung DYM, 2004, ANN ALLERG ASTHMA IM, V93, pS1, DOI 10.1016/S1081-1206(10)61385-3; Liard R, 2000, EUR RESPIR J, V16, P615, DOI 10.1034/j.1399-3003.2000.16d08.x; LIPWORTH B, 1997, LANCET, V350, P995; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; *NAT ASTHM ED PREV, 1997, NIH PUBL; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Asthma Education and Prevention Program, 1991, NIH PUBL, V91- 3642; Osborne ML, 1999, CHEST, V115, P85, DOI 10.1378/chest.115.1.85; Patel Pankaj H, 2004, Dis Manag, V7, P102, DOI 10.1089/1093507041253235; Perng DW, 2004, CHEST, V125, P1693, DOI 10.1378/chest.125.5.1693; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Sippel JM, 2000, J ALLERGY CLIN IMMUN, V106, P645, DOI 10.1067/mai.2000.109618; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Soriano JB, 2003, J ASTHMA, V40, P803, DOI 10.1081/JAS-120023572; Stempel DA, 2005, J ALLERGY CLIN IMMUN, V115, P935, DOI 10.1016/j.jaci.2005.01.054; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Szende A, 2004, PHARMACOECONOMICS, V22, P537; Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594, DOI 10.1164/ajrccm.160.2.9811100; Van Ganse E, 2002, EUR RESPIR J, V20, P260, DOI 10.1183/09031936.02.02542001; Vermeire PA, 2002, RESP MED, V96, P142, DOI 10.1053/rmed.2001.1241; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Zhang J, 2002, EUR RESPIR J, V20, P1102, DOI 10.1183/09031936.02.02402001; 1995, J ALLERGY CLIN IMM S, V96, pS707; 1998, ANN ALLERGY, V81, P415	49	83	83	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					S3	S11		10.1016/j.jaci.2005.08.017	http://dx.doi.org/10.1016/j.jaci.2005.08.017			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16334921				2022-12-18	WOS:000235686700045
J	Arshad, SH				Arshad, SH			Primary prevention of asthma and allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; allergy; atopy; prevention; allergen avoidance; house dust mite	HOUSE-DUST-MITE; HIGH-RISK INFANTS; FATTY-ACID MODIFICATION; EARLY BCG VACCINATION; 5-YEAR FOLLOW-UP; CORD SERUM IGE; ATOPIC DISEASE; WHEY HYDROLYSATE; CONTROLLED-TRIAL; EARLY-CHILDHOOD	The relentless increase in the prevalence of asthma and allergic diseases highlights the need for devising effective preventive strategies. Although the genetics of these disorders are being investigated, manipulation of known environmental risk factors remains the best available approach to this problem. However, the large number of potential environmental risk factors and our inability to accurately predict the development of asthma and allergy has led to conflicting data from recent prevention studies. Nonetheless, some useful recommendations can be made. Exclusive breast-feeding and avoidance of exposure to environmental tobacco smoke exposure can be safely recommended for the whole population, not only for prevention of allergy but also for other known benefits. Additionally, for children at high risk of allergy, maternal exclusion diet during lactation and protein hydrolysate as a supplement or alternative for children who could not be breast-fed seems to provide further protection. The preventive effect of avoidance of house dust mite allergen alone during pregnancy or after birth is disappointing. However, prospective randomized studies evaluating a combined food and house dust mite allergen avoidance regimen show some protection against atopic dermatitis in infancy and asthma in later childhood. Urgent research is needed to accurately identify children at high risk and to test novel preventative measures with the potential for immunomodulation. Further randomized controlled trials are also needed with long-term follow up to evaluate combined approaches that might provide maximum benefit.	Univ Keele, Keele ST5 5BG, Staffs, England	Keele University	Arshad, SH (corresponding author), Univ Hosp N Staffordshire, Dept Resp Med, Newcastle Rd, Stoke On Trent ST4 6QG, Staffs, England.	sha@soton.ac.uk						Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x; Allmers H, 2002, J ALLERGY CLIN IMMUN, V110, P318, DOI 10.1067/mai.2002.126461; Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Arshad SH, 2002, CLIN EXP ALLERGY, V32, P843, DOI 10.1046/j.1365-2222.2002.01378.x; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; Bergmann R, 1998, EUR RESPIR J, V12, p9S; Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Bloch AM, 2002, ACTA PAEDIATR, V91, P275, DOI 10.1080/08035250252833914; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Bruno G, 1996, Minerva Pediatr, V48, P413; Carlsen KCL, 2001, CURR OPIN ALLERGY CL, V1, P139; Chan YH, 2002, J PAEDIATR CHILD H, V38, P84, DOI 10.1046/j.1440-1754.2002.00725.x; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657, DOI 10.1001/archpedi.154.7.657; CHANDRA RK, 1989, BMJ-BRIT MED J, V299, P228, DOI 10.1136/bmj.299.6693.228; CHANDRA RK, 1991, ANN ALLERGY, V67, P129; Chandra RK, 1997, J PEDIATR GASTR NUTR, V24, P380, DOI 10.1097/00005176-199704000-00005; Cook DG, 1997, THORAX, V52, P1081, DOI 10.1136/thx.52.12.1081; Cullinan P, 2003, EUR RESPIR J, V22, P853, DOI 10.1183/09031936.03.00119502; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; de Meer G, 2004, J ALLERGY CLIN IMMUN, V113, P433, DOI 10.1016/j.jaci.2003.10.008; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.1139; Dinakar C, 2004, CURR OPIN ALLERGY CL, V4, P131, DOI [10.1097/00130832-200404000-00011, 10.1097/01.all.0000123968.96233.63]; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Eduard W, 2004, THORAX, V59, P381, DOI 10.1136/thx.2004.013326; FALTHMAGNUSSON K, 1992, J ALLERGY CLIN IMMUN, V89, P709, DOI 10.1016/0091-6749(92)90378-F; FALTHMAGNUSSON K, 1987, J ALLERGY CLIN IMMUN, V80, P868, DOI 10.1016/S0091-6749(87)80279-8; Fergusson D M, 1994, Pediatr Allergy Immunol, V5, P44, DOI 10.1111/j.1399-3038.1994.tb00347.x; Fogarty A, 2000, CLIN EXP ALLERGY, V30, P615, DOI 10.1046/j.1365-2222.2000.00766.x; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; Fukushima Y, 1997, J NUTR SCI VITAMINOL, V43, P397, DOI 10.3177/jnsv.43.397; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Gilliland FD, 2003, AM J RESP CRIT CARE, V167, P917, DOI 10.1164/rccm.200206-616OC; Gruber C, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e282; GRUSKAY FL, 1982, CLIN PEDIATR, V21, P486, DOI 10.1177/000992288202100807; Halken S, 2000, PEDIATR ALLERGY IMMU, V11, P149, DOI 10.1034/j.1399-3038.2000.00081.x; Halmerbauer G, 2002, PEDIAT ALLERG IMM-UK, V13, P47, DOI 10.1034/j.1399-3038.13.s.15.11.x; Hattevig G, 1999, ACTA PAEDIATR, V88, P7, DOI 10.1080/080352599750029268; Hernell O, 2003, AM J CLIN NUTR, V78, P296, DOI 10.1093/ajcn/78.2.296; Herrmann ME, 1996, EUR J PEDIATR, V155, P770, DOI 10.1007/BF02002904; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HIDE DW, 1991, CLIN EXP ALLERGY, V21, P739, DOI 10.1111/j.1365-2222.1991.tb03204.x; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Holloway JA, 2000, LANCET, V356, P1900, DOI 10.1016/S0140-6736(00)03265-7; Holt PG, 1997, CIBA F SYMP, V206, P35; HOLT PG, 1997, CIBA F SYMP, V206, P106; Horak F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/j.1365-2222.2004.02024.x; Iikura Y, 1991, Arerugi, V40, P132; Jaakkola JJK, 2004, AM J PUBLIC HEALTH, V94, P136, DOI 10.2105/AJPH.94.1.136; Jacobsen L, 2001, ANN ALLERG ASTHMA IM, V87, P43, DOI 10.1016/S1081-1206(10)62194-1; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kihlstrom A, 2002, J ALLERGY CLIN IMMUN, V110, P78, DOI 10.1067/mai.2002.125829; KOH YY, 2003, CURR OPIN ALLERGY CL, V31, P159; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; Korppi M, 2004, PEDIATR PULM, V38, P155, DOI 10.1002/ppul.20058; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; Kramer MS, 2004, CLIN EXP ALLERGY, V34, P753, DOI 10.1111/j.1365-2222.2004.1940.x; Kramer MS, 2003, COCHRANE DB SYST REV; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829, DOI 10.1164/ajrccm.164.10.2103137; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; MALLET E, 1992, J PEDIATR-US, V121, pS95, DOI 10.1016/S0022-3476(05)81415-5; Marini A, 1996, ACTA PAEDIATR, V85, P1, DOI 10.1111/j.1651-2227.1996.tb14267.x; Marks GB, 2002, CLIN EXP ALLERGY, V32, P355, DOI 10.1046/j.1365-2222.2002.01292.x; McCune A, 2003, EUR J GASTROEN HEPAT, V15, P637, DOI 10.1097/00042737-200306000-00010; McKeever TM, 2004, AM J RESP CRIT CARE, V170, P725, DOI 10.1164/rccm.200405-611PP; Medeiros M, 2003, J ALLERGY CLIN IMMUN, V111, P947, DOI 10.1067/mai.2003.1381; Melkild I, 2002, CLIN EXP ALLERGY, V32, P1370, DOI 10.1046/j.1365-2745.2002.01458.x; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Nafstad P, 2003, J ASTHMA, V40, P343, DOI 10.1081/JAS-120018633; *NAT HEART LUNG BL, 1999, ASTM STAT; O'Connor GT, 2005, J ALLERGY CLIN IMMUN, V116, P26, DOI 10.1016/j.jaci.2005.02.013; Oddy WH, 2002, J ALLERGY CLIN IMMUN, V110, P65, DOI 10.1067/mai.2002.125296; Oddy WH, 2004, J ASTHMA, V41, P319, DOI 10.1081/JAS-120026089; Oldaeus G, 1997, ARCH DIS CHILD, V77, P4, DOI 10.1136/adc.77.1.4; OSBORN DA, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003741.pub2; Osborn DA, 2003, COCHRANE DB SYST REV, V4; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Phipatanakul W, 2004, PEDIATRICS, V114, P13, DOI 10.1542/peds.114.1.13; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P441; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Ram F.S., 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003795, DOI 10.1002/14651858.CD003795]; Rautava S, 2005, J ALLERGY CLIN IMMUN, V116, P31, DOI 10.1016/j.jaci.2005.02.010; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Schiessl B, 2003, INT ARCH ALLERGY IMM, V130, P125, DOI 10.1159/000069011; Schoetzau A, 2002, PEDIAT ALLERG IMM-UK, V13, P234, DOI 10.1034/j.1399-3038.2002.01050.x; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Shaheen SO, 2005, CLIN EXP ALLERGY, V35, P18, DOI 10.1111/j.1365-2222.2005.02151.x; SIGURS N, 1992, PEDIATRICS, V89, P735; Siltanen M, 2003, ALLERGY, V58, P524, DOI 10.1034/j.1398-9995.2003.00150.x; Simpson A, 2003, CLIN EXP ALLERGY, V33, P1183, DOI 10.1046/j.1365-2745.2003.01679.x; Singleton RJ, 2003, PEDIATRICS, V112, P285, DOI 10.1542/peds.112.2.285; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stein Renato T, 2004, Paediatr Respir Rev, V5, P155, DOI 10.1016/j.prrv.2004.01.007; Svanes C, 2003, J ALLERGY CLIN IMMUN, V112, P289, DOI 10.1067/mai.2003.1596; Szepfalusi Z, 2000, J ALLERGY CLIN IMMUN, V106, P530; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Tariq SM, 1999, CLIN EXP ALLERGY, V29, P1042; Tariq SM, 2000, PEDIATR ALLERGY IMMU, V11, P162, DOI 10.1034/j.1399-3038.2000.00077.x; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Tsitoura S, 2002, ARCH PEDIAT ADOL MED, V156, P1021, DOI 10.1001/archpedi.156.10.1021; van den Bemt L, 2004, J ALLERGY CLIN IMMUN, V114, P858, DOI 10.1016/j.jaci.2004.05.069; van Gool CJAW, 2003, AM J CLIN NUTR, V77, P943, DOI 10.1093/ajcn/77.4.943; van Strien RT, 2003, CLIN EXP ALLERGY, V33, P490, DOI 10.1046/j.1365-2222.2003.01626.x; VANDENPLAS Y, 1992, ANN ALLERGY, V68, P419; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P116; Waser M, 2005, ALLERGY, V60, P177, DOI 10.1111/j.1398-9995.2004.00645.x; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Wijga AH, 2003, THORAX, V58, P567, DOI 10.1136/thorax.58.7.567; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4; Zutavern A, 2004, ARCH DIS CHILD, V89, P303, DOI 10.1136/adc.2002.025353	131	83	94	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					3	14		10.1016/j.jaci.2005.03.043	http://dx.doi.org/10.1016/j.jaci.2005.03.043			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990764				2022-12-18	WOS:000235686300001
J	Newson, RB; Shaheen, SO; Henderson, AJ; Emmett, PM; Sherriff, A; Calder, PC				Newson, RB; Shaheen, SO; Henderson, AJ; Emmett, PM; Sherriff, A; Calder, PC		ALSPAC Study Team	Umbilical cord and maternal blood red cell fatty acids and early childhood wheezing and eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						n-3/n-6 Fatty acids; wheezing; eczema; birth cohort; prenatal	AIRWAY RESPONSES; ATOPIC DISEASE; BIRTH-WEIGHT; CHILDREN; PROSTAGLANDIN-E2; ALLERGY; LYMPHOCYTES; PREGNANCY; GAMMA; RISK	Background: Few studies have explored whether fetal exposure to n-6 and n-3 fatty acids influences the inception of atopic disease. Objective: To assess prenatal fatty acid exposures as predictors of early childhood wheezing and eczema. Methods: In the Avon Longitudinal Study of Parents and Children, late pregnancy maternal blood samples and umbilical cord blood samples were assayed for n-6 and n-3 fatty acids (percentage of total red cell phospholipid), and mothers were asked about wheezing and eczema in their children. We measured associations of 11 n-6 and n-3 fatty acid exposures with wheezing at 30 to 42 months, with wheezing patterns defined by presence (+) or absence (-) of wheezing during 2 periods, 0 to 6 months and 30 to 42 months (transient infant, +/-; later-onset, -/+; persistent, +/+; n = 1191 and n = 2764 for cord and maternal analyses, respectively), and with eczema at 18 to 30 months (n = 1238 and n = 2945 for cord and maternal analyses, respectively). Results: In cord blood red cells, the ratio of arachidonic:eicosapentaenoic acid was positively associated with eczema (adjusted odds ratio [OR] per doubling, 1.14; 95% CI, 1.00-1.31; P = .044), the ratio of linoleic acid: a-linolenic acid was positively associated with later-onset wheeze (OR, 1.30; CI, 1.04-1.61; P = .019), and the ratio of a-linolenic acid:n-3 products was negatively associated with later-onset wheeze (OR, 0.86; CI, 0.75-0.99; P = .040). However, these associations were no longer significant after adjusting for multiple comparisons. Conclusions: It seems unlikely that fetal exposure to n-6 and n-3 fatty acids is an important determinant of early childhood wheezing and atopic disease.	Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, London SE1 3QD, England; Univ Bristol, Inst Child Hlth, Unit Paediat & Perinatal Epidemiol, Bristol, Avon, England; Univ Southampton, Inst Human Nutr, Southampton, Hants, England	University of London; King's College London; University of Bristol; University of Southampton	Shaheen, SO (corresponding author), Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, Capital House,42 Weston St, London SE1 3QD, England.	seif.shaheen@kcl.ac.uk	Calder, Philip C/E-9739-2013; Emmett, Pauline/AAL-6815-2021	Calder, Philip C/0000-0002-6038-710X; sherriff, andrea/0000-0002-1016-037X; Henderson, Alexander John/0000-0001-9650-231X; Emmett, Pauline/0000-0003-1076-4779				Benbernou N, 1997, IMMUNOLOGY, V91, P361, DOI 10.1046/j.1365-2567.1997.00260.x; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; BETZ M, 1991, J IMMUNOL, V146, P108; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Calder PC, 2000, PEDIAT ALLERG IMM-UK, V11, P29, DOI 10.1034/j.1399-3038.2000.00508.x; Duchen K, 2000, PEDIAT ALLERG IMM-UK, V11, P29, DOI 10.1034/j.1399-3038.2000.00052.x; Dunstan JA, 2003, CLIN EXP ALLERGY, V33, P442, DOI 10.1046/j.1365-2222.2003.01590.x; Elias SL, 2001, AM J CLIN NUTR, V73, P807; GALLI E, 1994, BRIT J DERMATOL, V130, P752, DOI 10.1111/j.1365-2133.1994.tb03413.x; Gauvreau GM, 1999, AM J RESP CRIT CARE, V159, P31, DOI 10.1164/ajrccm.159.1.9804030; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; HORROBIN DF, 2000, AM J CLIN NUTR S, V71, pS72; MANKU MS, 1982, PROSTA LEUKOTR MED, V9, P615, DOI 10.1016/0262-1746(82)90019-1; Martin JG, 2002, J IMMUNOL, V169, P3963, DOI 10.4049/jimmunol.169.7.3963; MATLOFF SM, 1983, J ALLERGY CLIN IMMUN, V72, P359, DOI 10.1016/0091-6749(83)90500-6; PAVORD ID, 1995, LANCET, V345, P436, DOI 10.1016/S0140-6736(95)90409-3; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rump P, 2001, AM J CLIN NUTR, V73, P797; Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; *STAT CORP, 2001, STAT STAT SOFTW REL; University of Bristol, AV LONG STUD PAR CHI; Wijendran V, 1999, AM J CLIN NUTR, V70, P53; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; WRIGHT S, 1990, OMEGA 6 ESSENTIAL FA, P55; Yu G, 1998, PEDIAT ALLERG IMM-UK, V9, P133, DOI 10.1111/j.1399-3038.1998.tb00359.x; Yu G, 1998, EUR J PEDIATR, V157, P298, DOI 10.1007/s004310050815; Yu G, 1996, ACTA PAEDIATR, V85, P679, DOI 10.1111/j.1651-2227.1996.tb14124.x	29	83	84	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					531	537		10.1016/j.jaci.2004.05.010	http://dx.doi.org/10.1016/j.jaci.2004.05.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356553				2022-12-18	WOS:000223799600010
J	Robinson, DS				Robinson, DS			The role of the mast cell in asthma: Induction of airway hyperresponsiveness by interaction with smooth muscle?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; asthma; chemokines; airway smooth muscle	MITOGEN-INDUCED PROLIFERATION; GROWTH-FACTOR; BRONCHIAL BIOPSIES; PERIPHERAL-BLOOD; UP-REGULATION; T-CELLS; C-KIT; EXPRESSION; RECEPTOR; IGE	In a recent study, the difference between asthma and eosinophilic bronchitis (a condition characterized by cough but not airway hyperresponsiveness or airflow obstruction) was infiltration of airway smooth muscle (ASM) by mast cells. Mast cells produce a variety of lipid mediators, chemokines, cytokines, and enzymes that may interact with ASM cells to cause hyperreactivity to constrictive stimuli and proliferation, and activated ASM can produce stem cell factor and other chemokines, cytokines, and growth factors that may act in recruitment, differentiation, and retention of mast cells. Mast cell infiltration of the airways in asthma is T-cell-dependent, and T(H)2 cytokines from T cells and other sources act in mast cell expansion from circulating and tissue precursors. The recent data on interactions of mast cells and ASM suggest that this could be an important contributor to airway hyperresponsiveness in asthma. Why this occurs in asthma and how it is sustained remain to be established.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, Leukocyte Biol Sect, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst Div, London SW7 2AZ, England	Imperial College London; Imperial College London	Robinson, DS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, Leukocyte Biol Sect, Room 365,Sir Alexander Fleming Bldg,S Kensington, London SW7 2AZ, England.	d.s.robinson@imperial.ac.uk						Akdis CA, 2003, J ALLERGY CLIN IMMUN, V112, P15, DOI 10.1067/mai.2003.1585; Ali FR, 2004, AM J RESP CRIT CARE, V169, P20, DOI 10.1164/rccm.200305-690OC; Ammit AJ, 1997, AM J RESP CRIT CARE, V155, P1123, DOI 10.1164/ajrccm.155.3.9116997; ANTICEVICH SZ, 1995, EUR J PHARMACOL, V284, P221, DOI 10.1016/0014-2999(95)00463-U; Austen KF, 2001, LEUKEMIA RES, V25, P511, DOI 10.1016/S0145-2126(01)00030-3; Berger P, 2003, FASEB J, V17, P2139, DOI 10.1096/fj.03-0041fje; Boyce JA, 2003, J ALLERGY CLIN IMMUN, V111, P24, DOI 10.1067/mai.2003.60; Boyce JA, 2002, BLOOD, V99, P2890, DOI 10.1182/blood.V99.8.2890; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Burgess JK, 2003, AM J RESP CRIT CARE, V167, P71, DOI 10.1164/rccm.200205-416OC; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Caughey GH, 2002, MOL IMMUNOL, V38, P1353, DOI 10.1016/S0161-5890(02)00087-1; Chambers LS, 2001, AM J PHYSIOL-LUNG C, V281, pL1369, DOI 10.1152/ajplung.2001.281.6.L1369; Cho SH, 2003, J IMMUNOL, V170, P4045, DOI 10.4049/jimmunol.170.8.4045; Cohen MD, 1997, AM J RESP CELL MOL, V16, P85, DOI 10.1165/ajrcmb.16.1.8998083; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Espinosa K, 2003, J ALLERGY CLIN IMMUN, V111, P1032, DOI 10.1067/mai.2003.1451; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Forsythe P, 2003, AM J RESP CELL MOL, V28, P405, DOI 10.1165/rcmb.F265; Friend DS, 1998, J IMMUNOL, V160, P5537; Ghaffar O, 1999, AM J RESP CRIT CARE, V159, P1933, DOI 10.1164/ajrccm.159.6.9805039; GIBSON PG, 1993, AM REV RESPIR DIS, V148, P80, DOI 10.1164/ajrccm/148.1.80; GIBSON PG, 1989, LANCET, V1, P1346; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Haselden BM, 2001, J ALLERGY CLIN IMMUN, V108, P394, DOI 10.1067/mai.2001.117460; Hawker KM, 1998, AM J PHYSIOL-LUNG C, V275, pL469, DOI 10.1152/ajplung.1998.275.3.L469; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hirst SJ, 1996, AM J PHYSIOL-LUNG C, V270, pL415, DOI 10.1152/ajplung.1996.270.3.L415; Hirst SJ, 2003, RESP PHYSIOL NEUROBI, V137, P309, DOI 10.1016/S1569-9048(03)00155-1; Hirst SJ, 2002, AM J RESP CRIT CARE, V165, P1161, DOI 10.1164/ajrccm.165.8.2107158; HOLGATE ST, 1985, CLIN ALLERGY, V15, P221, DOI 10.1111/j.1365-2222.1985.tb02279.x; Holgate Stephen T., 2003, Journal of Allergy and Clinical Immunology, V111, pS18, DOI 10.1067/mai.2003.25; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; Ito A, 2003, BLOOD, V101, P2601, DOI 10.1182/blood-2002-07-2265; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; John M, 1998, AM J RESP CELL MOL, V18, P84, DOI 10.1165/ajrcmb.18.1.2813; Johnson PRA, 1997, EUR RESPIR J, V10, P38, DOI 10.1183/09031936.97.10010038; Kassel O, 1999, EUR RESPIR J, V13, P951, DOI 10.1034/j.1399-3003.1999.13e04.x; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P492; Kitaura J, 2003, P NATL ACAD SCI USA, V100, P12911, DOI 10.1073/pnas.1735525100; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Lazaar AL, 2002, J IMMUNOL, V169, P1014, DOI 10.4049/jimmunol.169.2.1014; LeviSchaffer F, 1997, CLIN EXP ALLERGY, V27, P64, DOI 10.1111/j.1365-2222.1997.tb01829.x; Lora JM, 2003, J ALLERGY CLIN IMMUN, V112, P1119, DOI 10.1016/j.jaci.2003.08.042; Lynch KR, 1999, NATURE, V399, P789; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Malaviya R, 1999, P NATL ACAD SCI USA, V96, P8110, DOI 10.1073/pnas.96.14.8110; McCurdy JD, 2003, J IMMUNOL, V170, P1625, DOI 10.4049/jimmunol.170.4.1625; Mellor EA, 2003, P NATL ACAD SCI USA, V100, P11589, DOI 10.1073/pnas.2034927100; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Miller HRP, 1999, BLOOD, V93, P3473, DOI 10.1182/blood.V93.10.3473.410k01_3473_3486; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; Mwamtemi HH, 2001, J IMMUNOL, V166, P4672, DOI 10.4049/jimmunol.166.7.4672; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Ochi H, 2000, P NATL ACAD SCI USA, V97, P10509, DOI 10.1073/pnas.180318697; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Okona-Mensah KB, 1998, BRIT J PHARMACOL, V125, P599, DOI 10.1038/sj.bjp.0702046; Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971; Page S, 2001, AM J PHYSIOL-LUNG C, V281, pL1313, DOI 10.1152/ajplung.2001.281.6.L1313; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; Price KS, 2003, AM J RESP CELL MOL, V28, P420, DOI 10.1165/rcmb.2002-0155OC; Robinson DS, 1999, AM J RESP CELL MOL, V20, P9, DOI 10.1165/ajrcmb.20.1.3449; Rodewald HR, 1996, SCIENCE, V271, P818, DOI 10.1126/science.271.5250.818; ROTTEM M, 1994, BLOOD, V84, P2489; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; TAM EK, 1990, AM J RESP CELL MOL, V3, P27, DOI 10.1165/ajrcmb/3.1.27; Valenta R, 1998, J INVEST DERMATOL, V111, P1178, DOI 10.1046/j.1523-1747.1998.00413.x; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Wong GW, 2002, J BIOL CHEM, V277, P41906, DOI 10.1074/jbc.M205868200; Ying S, 2001, J ALLERGY CLIN IMMUN, V107, P686, DOI 10.1067/mai.2001.114339	84	83	89	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					58	65		10.1016/j.jaci.2004.03.034	http://dx.doi.org/10.1016/j.jaci.2004.03.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241345	Bronze			2022-12-18	WOS:000222534300009
J	Arbes, SJ; Sever, M; Archer, J; Long, EH; Gore, JC; Schal, C; Walter, M; Nuebler, B; Vaughn, B; Mitchell, H; Liu, E; Collette, N; Adler, P; Sandel, M; Zeldin, DC				Arbes, SJ; Sever, M; Archer, J; Long, EH; Gore, JC; Schal, C; Walter, M; Nuebler, B; Vaughn, B; Mitchell, H; Liu, E; Collette, N; Adler, P; Sandel, M; Zeldin, DC			Abatement of cockroach allergen (Bla g 1) in low-income, urban housing: A randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cockroaches; cockroach allergen; Bla g 1; intervention	INNER-CITY HOMES; ASTHMA; EXPOSURE; EXTERMINATION; CHILDREN	Background: Clinically relevant reductions in exposure to cockroach allergen, an important risk factor for asthma in inner-city households, have proven difficult to achieve in intervention trials. Objective: This study investigated a method for the abatement of cockroach allergen in low-income, urban homes. The goal was to reduce mean Bla g 1 concentrations below the previously proposed thresholds for allergic sensitization and asthma morbidity. Methods: A prerandomized, nonmasked trial with 16 intervention and 15 control homes was conducted. Study inclusion was based on 50 to 500 cockroaches trapped in a 3-day period. The interventions consisted of occupant education, placement of insecticide bait, and professional cleaning. Vacuumed dust and multiple swab samples were collected at 0, 1, 2, 4, and 6 months in intervention homes and at 0 and 6 months in control homes. Room maps containing cockroach and allergen data were used to guide and monitor the interventions. Results: From 0 to 6 months among intervention homes, geometric mean Bla g 1 concentrations (U/g dust) decreased from 633 to 24 on kitchen floors (96% reduction), from 25 to 4.3 on living room floors/sofas (83% reduction), from 46 to 7.3 on bedroom floors (84% reduction), and from 6.1 to 1.0 in bedroom beds (84% reduction). These reductions, with the exception of that on the bedroom floor (P = .06), were statistically significant relative to changes in control homes. Conclusions: Substantial reductions in cockroach allergen levels can be achieved in inner-city homes. In this study, allergen levels were reduced below the sensitization threshold (2 U/g) in beds, arguably the most relevant site for exposure, and below the asthma morbidity threshold (8 U/g) on bedroom floors and living room floors/sofas. The level on kitchen floors, although reduced 96%, remained above the asthma morbidity threshold. Future studies will test the intervention's effectiveness in asthma prevention trials.	NIEHS, NIH, Div Intramural Res, Res Triangle Pk, NC 27709 USA; CODA Inc, Durham, NC USA; Univ N Carolina, Dept Entomol, Raleigh, NC 27515 USA; Rho Inc, Chapel Hill, NC USA; Boston Univ, Sch Med, Boston, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; Rho; Boston University	Zeldin, DC (corresponding author), NIEHS, NIH, Div Intramural Res, 111 Alexander Dr,Bldg 101,D236, Res Triangle Pk, NC 27709 USA.		Schal, Coby/A-8717-2010; Zeldin, Darryl C/Y-7091-2018	Schal, Coby/0000-0001-7195-6358; Zeldin, Darryl C/0000-0002-2087-7307; Walter, Michelle/0000-0002-3251-487X; Sandel, Megan/0000-0001-6244-9418; Sever, Michelle/0000-0002-2435-1214; Sandel, Megan/0000-0001-7324-6325	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES025043, Z01ES025043, Z01ES025041, ZIAES025041] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842, DOI 10.1016/S0091-6749(99)70296-4; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; PLATTSMILLS TA, 1997, J ALLERGY CLIN IMM S, V100, P2; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Rauh VA, 2002, ENVIRON HEALTH PERSP, V110, P323, DOI 10.1289/ehp.02110s2323; Rogers L, 2002, CHEST, V122, P1580, DOI 10.1378/chest.122.5.1580; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SCHAL C, 1988, J ECON ENTOMOL, V81, P536, DOI 10.1093/jee/81.2.536; Stanford R, 1999, AM J RESP CRIT CARE, V160, P211, DOI 10.1164/ajrccm.160.1.9811040; Williams LW, 1999, J ALLERGY CLIN IMMUN, V104, P702, DOI 10.1016/S0091-6749(99)70346-5; Wood RA, 2001, ANN ALLERG ASTHMA IM, V87, P60, DOI 10.1016/S1081-1206(10)62324-1	13	83	83	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					339	345		10.1067/mai.2003.1597	http://dx.doi.org/10.1067/mai.2003.1597			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897740				2022-12-18	WOS:000184650600018
J	Chulada, PC; Arbes, SJ; Dunson, D; Zeldin, DC				Chulada, PC; Arbes, SJ; Dunson, D; Zeldin, DC			Breast-feeding and the prevalence of asthma and wheeze in children: Analyses from the Third National Health and Nutrition Examination Survey, 1988-1994	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; recurrent wheeze; breast-feeding; atopy; environmental tobacco smoke; National Health and Nutrition Examination; Survey III	ENVIRONMENTAL TOBACCO-SMOKE; DAY-CARE ATTENDANCE; MATERNAL SMOKING; CHILDHOOD ASTHMA; PARENTAL SMOKING; UNITED-STATES; 1ST YEAR; ASSOCIATION; EXPOSURE; ILLNESS	Background: Asthma prevalence has increased dramatically in recent years, especially among children. Breast-feeding might protect children against asthma and related conditions (recurrent wheeze), and this protective effect might depend on the duration and exclusivity of the breast-feeding regimen. Objective: We sought to determine whether there is an association between breast-feeding and asthma, recurrent wheeze, or both in children up to 72 months of age and whether the duration and exclusivity of breast-feeding affect this association. Methods: Data were from the third National Health and Nutrition Examination Survey, a nationally representative cross-sectional survey conducted from 1988 to 1994. We tested for significant associations between breast-feeding and physician-diagnosed asthma and recurrent wheeze (>3 episodes in the past 12 months) before and after adjusting for potential confounders. Results: Crude analyses showed that breast-feeding was associated with significantly reduced risks for asthma and recurrent wheeze in children 2 to 71 months of age, but after adjusting for potential confounders, these overall protective associations attenuated and were no longer statistically significant. However, 2 new and important associations were revealed after adjusting for confounders: (1) compared with never breast-fed children, ever breast-fed children had significantly reduced odds of being diagnosed with asthma and of having recurrent wheeze before 24 months of age, and (2) among children 2 to 71 months of age who had been exposed to environmental tobacco smoke, those who had ever been breast-fed had significantly reduced risks of asthma and wheeze compared with those who had never been breast-fed. Conclusions: Breast-feeding might delay the onset of or actively protect children less than 24 months of age against asthma and recurrent wheeze. Breast-feeding might reduce the prevalence of asthma and recurrent wheeze in children exposed to environmental tobacco smoke. (J Allergy Clin Immunol 2003;111:328-36.).	NIEHS, Off Clin Res, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Pulm Pathobiol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Biostat Branch, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Chulada, PC (corresponding author), NIEHS, Off Clin Res, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES025041, Z01ES025041, Z01ES040013, Z01ES025043, Z01ES100490, ZIAES025043] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], 2000, ACT ASTHM STRAT PLAN; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; COX DR, 1972, J R STAT SOC B, V34, P187; CUNNINGHAM J, 1994, AM J EPIDEMIOL, V139, P1139, DOI 10.1093/oxfordjournals.aje.a116961; Dell S, 2001, ARCH PEDIAT ADOL MED, V155, P1261, DOI 10.1001/archpedi.155.11.1261; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Fergusson D M, 1985, Pediatr Pulmonol, V1, P99, DOI 10.1002/ppul.1950010208; Gergen PJ, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e8; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; HAKONARSON H, 1997, ASTHMA, P1847; Hanson LA, 1998, ANN ALLERG ASTHMA IM, V81, P523, DOI 10.1016/S1081-1206(10)62704-4; HARLAP S, 1974, LANCET, V1, P529; Howard TD, 1999, CLIN EXP ALLERGY, V29, P86; Huss K, 2000, NURS CLIN N AM, V35, P695; Infante-Rivard C, 2001, AM J EPIDEMIOL, V153, P653, DOI 10.1093/aje/153.7.653; Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P579, DOI 10.2307/3455031; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Lanphear BP, 2001, PEDIATRICS, V107, P505, DOI 10.1542/peds.107.3.505; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Massey JT, 1992, SAMPLE DESIGN 3 NATL; Miller JE, 2000, AM J PUBLIC HEALTH, V90, P428, DOI 10.2105/AJPH.90.3.428; MURRAY AB, 1990, J ALLERGY CLIN IMMUN, V86, P732, DOI 10.1016/S0091-6749(05)80177-0; *NAT CTR ENV HLTH, ASTHM IMP CHILDR AD; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Oddy WH, 2002, J ALLERGY CLIN IMMUN, V110, P65, DOI 10.1067/mai.2002.125296; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; PEDREIRA FA, 1985, PEDIATRICS, V75, P594; Raisler J, 1999, AM J PUBLIC HEALTH, V89, P25, DOI 10.2105/AJPH.89.1.25; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617, DOI 10.1164/ajrccm.160.5.9811002; SCHRAMM CM, 1997, ASTHMA, P1415; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SILVERMAN M, 1997, ASTHMA, P1405; Strachan DP, 1998, THORAX, V53, P117, DOI 10.1136/thx.53.2.117; Strachan DP, 1998, THORAX, V53, P204, DOI 10.1136/thx.53.3.204; WILSON AC, 1998, BMJ-BRIT MED J, V315, P21; WOLD AE, 1994, CURR OPIN GASTROEN, V10, P652, DOI 10.1097/00001574-199411000-00014; Wold AE, 1998, ACTA PAEDIATR, V87, P19, DOI 10.1080/08035259850157804; WRIGHT AL, 1989, BRIT MED J, V299, P946, DOI 10.1136/bmj.299.6705.946; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192; 1994, VITAL HLTH STAT 1, V32, P1	43	83	89	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					328	336		10.1067/mai.2003.127	http://dx.doi.org/10.1067/mai.2003.127			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589353	Bronze			2022-12-18	WOS:000180942700017
J	Ketchell, RI; Jensen, MW; Lumley, P; Wright, AM; Allenby, MI; O'Connor, BJ				Ketchell, RI; Jensen, MW; Lumley, P; Wright, AM; Allenby, MI; O'Connor, BJ			Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5 '-monophosphate in mild asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adenosine 5 '-monophosphate; AMP; fluticasone propionate; induced bronchoconstriction; atopic asthma; asthma; airway responsiveness; airway mast cells	BUDESONIDE	Inhaled adenosine 5'-monophosphate (AMP) has an "indirect" bronchoconstrictive effect through mast cell degranulation and mediator release, whereas inhaled histamine has a "direct" effect on smooth muscle. Prolonged treatment with inhaled glucocorticosteroids attenuates airway responsiveness (AR) to AMP and histamine. We investigated the early effects of inhaled fluticasone propionate (FP) therapy on AR in 3 consecutive double-blind, randomized, placebo-controlled crossover studies in steroid-naive subjects with mild asthma. In one study, each of 12 subjects received FP 1000 mug or matched placebo for 7 inhalations at. 12 hourly intervals; AR to AMP and FEV1 were measured 2 hours after the 3rd and 7th inhalations. In a second study, each of 12 subjects received FP 100, 250, or 1000 mug or matched placebo for 3 inhalations at 12 hourly intervals; AR to AMP and FEV1 were measured 2 hours after the 1st and 3rd inhalations. In a third study, each of 8 subjects received a single inhalation of FP 1000 mug or matched placebo; AR to histamine was measured 2 hours later. In the first study, FP 1000 mug significantly attenuated AR to AMP by 2.7 and 2.5 doubling doses after 3 and 7 inhalations, respectively (P less than or equal to .0001). In the second study, FP 100, 250, and 1000 mug significantly attenuated AR to AMP by 1.9, 2.2, and 2.7 doubling doses, respectively, after I inhalation and by 2.4, 2.2, and 3.2 doubling doses, respectively, after 3 inhalations (P :.0001); a small but significant increase in FEV1 (>0.15 L) was observed after 3 inhalations but not after I inhalation of FP irrespective of dose (P less than or equal to .05). In the third study, a single inhalation of FP 1000 mug had no effect on AR to histamine. We have demonstrated a reduction in AR to AMP but not AR to histamine within 2 hours of a single inhalation of FP. This reflects a rapid, topical anti-inflammatory action of inhaled FP by a mechanism of action that remains unknown.	Kings Coll London, GKT Sch Med, Dept Resp Med & Allergy, London SE5 9PJ, England; GlaxoSmithKline Inc, Res & Dev, Greenford, Middx, England	University of London; King's College London; GlaxoSmithKline	Ketchell, RI (corresponding author), Kings Coll London, GKT Sch Med, Dept Resp Med & Allergy, Bessemer Rd, London SE5 9PJ, England.							BOSCHETTO P, 1991, AM REV RESPIR DIS, V143, P605, DOI 10.1164/ajrccm/143.3.605; Falkenstein E, 2000, EUR J CLIN INVEST, V30, P51, DOI 10.1046/j.1365-2362.2000.0300s3051.x; Gibson PG, 2001, AM J RESP CRIT CARE, V163, P32, DOI 10.1164/ajrccm.163.1.9807061; Kumar SD, 2000, AM J RESP CRIT CARE, V161, P918, DOI 10.1164/ajrccm.161.3.9904106; Linden M, 2000, AM J RESP CRIT CARE, V162, P1705, DOI 10.1164/ajrccm.162.5.9910094; OCONNOR BJ, 1992, AM REV RESPIR DIS, V146, P560, DOI 10.1164/ajrccm/146.3.560; PAGGIARO PL, 1994, AM J RESP CRIT CARE, V149, P1447, DOI 10.1164/ajrccm.149.6.8004297; Polosa R, 1997, THORAX, V52, P919, DOI 10.1136/thx.52.10.919; Rodrigo G, 1998, AM J RESP CRIT CARE, V157, P698, DOI 10.1164/ajrccm.157.3.9704022; Taylor DA, 1999, AM J RESP CRIT CARE, V160, P237, DOI 10.1164/ajrccm.160.1.9809046	10	83	88	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2002	110	4					603	606		10.1067/mai.2002.128486	http://dx.doi.org/10.1067/mai.2002.128486			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	602JJ	12373268				2022-12-18	WOS:000178501900010
J	Christodoulopoulos, P; Cameron, L; Nakamura, Y; Lemiere, C; Muro, S; Dugas, M; Boulet, LP; Laviolette, M; Olivenstein, R; Hamid, Q				Christodoulopoulos, P; Cameron, L; Nakamura, Y; Lemiere, C; Muro, S; Dugas, M; Boulet, LP; Laviolette, M; Olivenstein, R; Hamid, Q			T(H)2 cytokine-associated transcription factors in atopic and nonatopic asthma: Evidence for differential signal transducer and activator of transcription 6 expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic asthma; nonatopic asthma; transcription factors; cMAF; GATA-3; STAT-6; IL-4	INTERFERON-GAMMA; HUMAN EOSINOPHILS; INTRINSIC ASTHMA; BRONCHIAL-MUCOSA; GENE-EXPRESSION; MESSENGER-RNA; FACTOR GATA-3; T-CELLS; C-MAF; IL-4	Background: The expression of IL-4 and IL-5 is increased in patients with atopic asthma compared with control subjects and correlates with indices of pulmonary function, In nonatopic asthma the expression of IL-4, unlike IL-5, fails to correlate with pulmonary function, and compared with their atopic counterparts, these patients have fewer cells expressing IL-4 receptor (IL-4R), As such, a deficiency in the IL-4 signaling pathway may be implicated in nonatopic asthma. The transcription factors GATA-3 and cMAF mediate IL-4 and IL-5 synthesis, whereas signal transducer and activator of transcription 6 (STAT-6) is critical for IL-4R signaling. Objective: This study examines the expression profile of these transcription factors in asthma, according to atopic status. Methods: With immunocytochemistry, the expression of GATA-3, cMAF, and STAT-B protein was determined in sections of bronchial biopsy specimens from patients with atopic asthma (n = 7), patients with nonatopic asthma (n = 8), and control subjects (n = 8), Results: Higher numbers of cells expressing GATA-3 and cMAF were observed in patients with atopic and those with nonatopic asthma than in control subjects and patients with tuberculosis (P < .001). There were also more STAT-6-immunoreactive cells in patients with atopic and those with nonatopic asthma than in control subjects (P < .0001, P < .05). Notably, however, fewer cells expressing STAT-6 protein were observed in nonatopic versus atopic asthma (P < .0001), Conclusions: These results demonstrate the upregulation of GATA-3 and cMAF in both variants of asthma and indicate that reduced IL-4R signaling, because of lower STAT-6 expression, may be a feature of nonatopic asthma.	McGill Univ, Meakins Christie Labs, Montreal, PQ H3A 2T5, Canada; Univ Laval, Sacre Coeur Hosp, Montreal, PQ, Canada	McGill University; Laval University; Universite de Montreal	Olivenstein, R (corresponding author), Montreal Chest Inst, 3650 St Urbain St, Montreal, PQ H2X 2P4, Canada.							Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1987, Am Rev Respir Dis, V136, P1066; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; Curiel RE, 1997, EUR J IMMUNOL, V27, P1982, DOI 10.1002/eji.1830270823; DEL PG, 1988, J IMMUNOL, V140, P4193; FERNANDEZBOTRAN R, 1986, P NATL ACAD SCI USA, V83, P9689, DOI 10.1073/pnas.83.24.9689; FREW AJ, 1988, J IMMUNOL, V141, P4158; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; Ghaffar O, 2000, CLIN EXP ALLERGY, V30, P86; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Goenka S, 1999, J IMMUNOL, V163, P4663; HAMID Q, 1992, BLOOD, V80, P1496; Hessel EM, 1997, AM J RESP CELL MOL, V16, P325, DOI 10.1165/ajrcmb.16.3.9070618; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; Kotsimbos TC, 1998, J ALLERGY CLIN IMMUN, V102, P859, DOI 10.1016/S0091-6749(98)70029-6; Kubo M, 1997, EMBO J, V16, P4007, DOI 10.1093/emboj/16.13.4007; Lacy P, 1999, BLOOD, V94, P23, DOI 10.1182/blood.V94.1.23.413k13_23_32; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Linehan LA, 1998, J IMMUNOL, V161, P302; Mitsuyasu H, 1999, J IMMUNOL, V162, P1227; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Park HJ, 1998, MOL IMMUNOL, V35, P239, DOI 10.1016/S0161-5890(98)00022-4; RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Rosa-Rosa L, 1999, J ALLERGY CLIN IMMUN, V104, P1008, DOI 10.1016/S0091-6749(99)70082-5; Ryan JJ, 1998, J IMMUNOL, V161, P1811; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; WALKER C, 1994, AM J RESP CRIT CARE, V150, P1038, DOI 10.1164/ajrccm.150.4.7921434; Wang LH, 2000, BLOOD, V95, P1249, DOI 10.1182/blood.V95.4.1249.004k39_1249_1257; YAMAGUCHI Y, 1991, BLOOD, V78, P2542; Yasruel Z, 1997, AM J RESP CRIT CARE, V155, P1413, DOI 10.1164/ajrccm.155.4.9105087; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	42	83	94	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					586	591		10.1067/mai.2001.114883	http://dx.doi.org/10.1067/mai.2001.114883			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295643				2022-12-18	WOS:000168190100004
J	Cover, RA; Leung, DYM; McCormick, D; Steelman, J; Zeitler, P; Spahn, JD				Cover, RA; Leung, DYM; McCormick, D; Steelman, J; Zeitler, P; Spahn, JD			Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adrenal suppression; asthma; cataracts; cushingoid features; glucocorticoid-dependent asthma; glucocorticoid; growth suppression; hypertension; myopathy; osteopenia; osteoporosis	BONE-MINERAL DENSITY; POSTERIOR SUBCAPSULAR CATARACTS; CORTICOSTEROID TREATMENT; INHALED CORTICOSTEROIDS; DOUBLE-BLIND; GROWTH; CHILDHOOD; PLACEBO; BECLOMETHASONE; OSTEOPOROSIS	Background: Although high-dose inhaled glucocorticoids (GCs) with or without chronically administered oral GCs are often used in children with severe persistent asthma, the adverse effects associated with their use have not been well-described in this patient population. Objective: We sought to determine the CC-induced adverse effects profile of older children with severe persistent asthma, Methods: A chart review of 163 consecutive children 9 years of age or older admitted to National Jewish for difficult to control asthma was done. Results: The population studied consisted mostly of adolescents (mean +/- SD age, 14.4 +/- 2.1 years) with severe asthma receiving high-dose inhaled GC therapy (1675 +/- 94 mug/d) and averaging 6 systemic GC bursts per year. 50% required chronic oral GC therapy. CC-associated adverse effects were common and included hypertension (88%), cushingoid features (66%), adrenal suppression (56%), myopathy (50%), osteopenia (46%), growth suppression (39%), obesity and hypercholesterolemia (30%), and cataracts (14%), Height standard deviation scores of -0.44, -1.22, and -0.93 for those receiving intermittent, alternate day, and daily oral GCs, respectively, were smaller (less suppressed) than published values from the same institution before inhaled GC therapy (standard deviation scores of -1.26, -1.91, and -1.95, respectively). Osteopenia was strongly associated with growth suppression (odds ratio, 5.6; confidence interval, 2.7-11.8; P <.0001) and was found to be more common in female than male subjects, even after correcting for short stature (42% vs 18%, P <.006), Conclusions: CC-associated adverse effects are still unacceptably common among children with severe asthma, even in those not receiving chronically administered oral GC therapy yet receiving high-dose Inhaled GCs. Therefore close monitoring and proper intervention are warranted, especially in female subjects, who appear to be at greater risk for osteopenia. There is clearly a need to consider alternative therapy or earlier intervention. The magnitude of growth suppression, while still a problem, appeared to be less severe with the addition of inhaled GC therapy. This observation suggests that high-dose inhaled GC therapy, by affording better asthma control and allowing less use of systemic therapy, has attenuated the growth-suppressive effects of poorly controlled asthma.	Natl Jewish Med & Res Ctr, Div Clin Pharmacol, Ira J & Jacqueline Neimark Lab Clin Pharmacol Ped, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Clin Immunol & Allergy, Dept Pediat, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Biostat, Denver, CO 80206 USA; Childrens Hosp, Pediat Endocrine & Growth Ctr, Denver, CO 80218 USA	National Jewish Health; National Jewish Health; National Jewish Health; Children's Hospital Colorado	Spahn, JD (corresponding author), Natl Jewish Med & Res Ctr, Div Clin Pharmacol, Ira J & Jacqueline Neimark Lab Clin Pharmacol Ped, 1400 Jackson St K-926, Denver, CO 80206 USA.			Zeitler, Philip/0000-0001-5756-7858	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NCRR NIH HHS [5MO1RR00051] Funding Source: Medline; NHLBI NIH HHS [HL36577] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; BARONE MA, 1996, H LANE HDB, P170; BHAGAT RG, 1984, PEDIATRICS, V73, P626; Boot AM, 1997, J CLIN ENDOCR METAB, V82, P57, DOI 10.1210/jc.82.1.57; BROWN DCP, 1989, ANN ALLERGY, V63, P47; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; CHANG KC, 1982, CLIN ALLERGY, V12, P369, DOI 10.1111/j.1365-2222.1982.tb02541.x; COX J, 1996, H LANE HDB, P413; CRONER S, 1992, ALLERGY, V47, P150, DOI 10.1111/j.1398-9995.1992.tb00956.x; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; Ebeling PR, 1998, J BONE MINER RES, V13, P1283, DOI 10.1359/jbmr.1998.13.8.1283; Gokhale R, 1998, GASTROENTEROLOGY, V114, P902, DOI 10.1016/S0016-5085(98)70309-9; Greulich WW, 1959, RADIOGRAPHIC ATLAS S; HANANIA NA, 1995, J ALLERGY CLIN IMMUN, V96, P571, DOI 10.1016/S0091-6749(95)70254-7; IP M, 1994, CHEST, V105, P1722, DOI 10.1378/chest.105.6.1722; James JM, 1997, J ASTHMA, V34, P387, DOI 10.3109/02770909709055380; KROGER H, 1992, BONE MINER, V17, P75, DOI 10.1016/0169-6009(92)90712-M; LAURSEN LC, 1986, EUR J RESPIR DIS, V68, P19; Ledford D, 1998, J ALLERGY CLIN IMMUN, V102, P353, DOI 10.1016/S0091-6749(98)70120-4; LIEBERMAN P, 1972, J ALLERGY CLIN IMMUN, V49, P329, DOI 10.1016/0091-6749(72)90131-5; MARTIN AJ, 1980, AM REV RESPIR DIS, V122, P609; MORRIS HG, 1975, PEDIATR RES, V9, P579, DOI 10.1203/00006450-197507000-00005; *NAT HEART LUNG BL, 1997, NIH PUBICATION; Nelson HS, 1998, CHEST, V113, P1264, DOI 10.1378/chest.113.5.1264; OBERGER E, 1990, ACTA PAEDIATR SCAND, V79, P77, DOI 10.1111/j.1651-2227.1990.tb11335.x; Pitt P, 1998, THORAX, V53, P351, DOI 10.1136/thx.53.5.351; POTTER DE, 1978, KIDNEY INT, V14, P378, DOI 10.1038/ki.1978.140; REID IR, 1992, OSTEOPOROSIS INT, V2, P103, DOI 10.1007/BF01623844; REIMER LG, 1975, J ALLERGY CLIN IMMUN, V55, P224, DOI 10.1016/0091-6749(75)90141-4; RICHARDS W, 1978, ANN ALLERGY, V41, P274; ROOKLIN AR, 1979, J ALLERGY CLIN IMMUN, V63, P383, DOI 10.1016/0091-6749(79)90210-0; RUSSELL G, 1994, RESP MED, V88, P31, DOI 10.1016/S0954-6111(05)80038-1; SCHATZ M, 1993, ALLERGY PROC, V14, P341, DOI 10.2500/108854193778774047; SHAPIRO GG, 1977, ANN ALLERGY, V38, P237; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; TANNER JM, 1985, J PEDIATR-US, V107, P317, DOI 10.1016/S0022-3476(85)80501-1; TINKELMAN DG, 1993, PEDIATRICS, V92, P144; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; WOLTHERS OD, 1990, BRIT MED J, V301, P145, DOI 10.1136/bmj.301.6744.145	40	83	90	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					651	659						9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031335				2022-12-18	WOS:000089980600008
J	Cameron, L; Hamid, Q; Wright, E; Nakamura, Y; Christodoulopoulos, P; Muro, S; Frenkiel, S; Lavigne, F; Durham, S; Gould, H				Cameron, L; Hamid, Q; Wright, E; Nakamura, Y; Christodoulopoulos, P; Muro, S; Frenkiel, S; Lavigne, F; Durham, S; Gould, H			Local synthesis of epsilon germline gene transcripts, IL-4, and IL-13 in allergic nasal mucosa after ex vivo allergen exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal mucosa; ex vivo allergen exposure; B lymphocytes; local epsilon germline transcription; IgE; IL-4; IL-13	CLASS SWITCH RECOMBINATION; GERMINAL CENTER FORMATION; HUMAN B-CELLS; MESSENGER-RNA; IGE SYNTHESIS; MAST-CELLS; INDUCED RHINITIS; CIRCULAR DNA; EXPRESSION; INTERLEUKIN-4	Background: The production of epsilon germline gene transcripts (I epsilon(+)/C epsilon(+) RNA) precedes class switch recombination to IgE and is induced by IL-4 and/or IL-13, Although I epsilon and C epsilon RNA(+) B cells have been identified within nasal tissue after in vivo allergen exposure, suggesting local germline transcription, whether these were resident or infiltrating B lymphocytes was not clear. Objective: We sought to examine whether B cells resident to the nasal mucosa undergo epsilon germline transcription. Methods: Nasal mucosal biopsy specimens were obtained from asymptomatic patients with seasonal allergic rhinitis and exposed to allergen ex vivo. Using immunocytochemistry, B lymphocytes were enumerated; with in situ hybridization, the number of cells expressing I epsilon, C epsilon, IL-4, and IL-13 messenger (m)RNA(+) cells was examined. Results: Tissue cultured in medium containing specific allergen exhibited significantly more IE and CE RNA(+) cells compared with medium alone (P < .05). IL-4 and IL-13 mRNA synthesis also resulted from ex vivo allergen exposure; there were significantly more cells expressing transcripts for these cytokines within allergic nasal mucosal tissue cultured with allergen than medium alone (P < .05). Within allergen-stimulated tissue obtained from allergic patients, 30% of total B cells were Ie RNA(+), and the majority of IL-4 and IL-13 mRNA(+) cells were T cells (68% and 44%, respectively) and mast cells (32% and 19%, respectively). Conclusion: These results demonstrate that the nasal mucosa is a site of epsilon germline gene transcription and suggest that local T fell and mast cell production of IL-4 and IL-13 may regulate this event.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada; Univ Montreal, Notre Dame Hosp, Montreal, PQ H3C 3J7, Canada; Royal Brompton Hosp, Natl Heart & Lung Inst, London SW3 6LY, England; Univ London Kings Coll, Randall Ctr Mol Mech Cell Fus, London WC2R 2LS, England	McGill University; McGill University; Universite de Montreal; Imperial College London; Royal Brompton Hospital; University of London; King's College London	Cameron, L (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.							Cameron LA, 1998, J ALLERGY CLIN IMMUN, V101, P330, DOI 10.1016/S0091-6749(98)70244-1; Chvatchko Y, 1996, J EXP MED, V184, P2353, DOI 10.1084/jem.184.6.2353; DANDURAND RJ, 1994, AM J RESP CRIT CARE, V149, P1499, DOI 10.1164/ajrccm.149.6.8004305; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; Ezernieks J, 1996, EUR J BIOCHEM, V240, P667, DOI 10.1111/j.1432-1033.1996.0667h.x; FREW AJ, 1988, J IMMUNOL, V141, P4158; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507, DOI 10.1165/ajrcmb.19.3.3143; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; Ghaffar O, 1997, AM J RESP CELL MOL, V17, P17, DOI 10.1165/ajrcmb.17.1.2696; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; Hodgkin PD, 1996, J EXP MED, V184, P277, DOI 10.1084/jem.184.1.277; HUGGINS KG, 1975, LANCET, V2, P148; Iciek LA, 1997, J IMMUNOL, V158, P4769; ILLUM P, 1978, ACTA OTO-LARYNGOL, V86, P135; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; LUNDGREN M, 1995, EUR J IMMUNOL, V25, P2042, DOI 10.1002/eji.1830250736; Minshall E, 1997, CAN J PHYSIOL PHARM, V75, P911, DOI 10.1139/cjpp-75-7-911; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; OKAMOTO Y, 1993, J IMMUNOL, V151, P4391; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; SCHMITZ GG, 1991, ANAL BIOCHEM, V192, P222, DOI 10.1016/0003-2697(91)90212-C; Thienes CP, 1997, J IMMUNOL, V158, P5874; VONSCHWEDLER U, 1990, NATURE, V345, P452, DOI 10.1038/345452a0; Xu M, 1990, Dev Immunol, V1, P11, DOI 10.1155/1990/47659; YING S, 1994, IMMUNOLOGY, V82, P200; ZOLA H, 1987, IMMUNOL TODAY, V8, P308, DOI 10.1016/0167-5699(87)90018-1	31	83	86	1	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				46	52						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887304				2022-12-18	WOS:000088393300006
J	van Ree, R; Aalberse, RC				van Ree, R; Aalberse, RC			Specific IgE without clinical allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							POLLEN		Netherlands Red Cross, Blood Transfus Serv, Cent Lab, NL-1006 CX Amsterdam, Netherlands		van Ree, R (corresponding author), Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Plesmanlaan 125, NL-1006 CX Amsterdam, Netherlands.							AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; Lerouge P, 1998, PLANT MOL BIOL, V38, P31, DOI 10.1023/A:1006012005654; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; van Ree R, 1998, J ALLERGY CLIN IMMUN, V102, P184, DOI 10.1016/S0091-6749(98)70084-3; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8	8	83	86	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1000	1001		10.1016/S0091-6749(99)70169-7	http://dx.doi.org/10.1016/S0091-6749(99)70169-7			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359876				2022-12-18	WOS:000080929500003
J	Benjaponpitak, S; Oro, A; Maguire, P; Marinkovich, V; DeKruyff, RH; Umetsu, DT				Benjaponpitak, S; Oro, A; Maguire, P; Marinkovich, V; DeKruyff, RH; Umetsu, DT			The kinetics of change in cytokine production by CD4(+)T cells during conventional allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; allergen desensitization; immunotherapy; desensitization; IL-4	GRASS-POLLEN IMMUNOTHERAPY; BEE VENOM IMMUNOTHERAPY; MESSENGER-RNA EXPRESSION; PERIPHERAL T-LYMPHOCYTES; ANTIGEN-SPECIFIC IGE; IMMUNE-RESPONSE; INTERFERON-GAMMA; DERMATOPHAGOIDES-PTERONYSSINUS; INTERLEUKIN-4 PRODUCTION; IFN-GAMMA	Background: The effect of conventional allergen immunotherapy on allergen-specific T lymphocyte cytokine production is incompletely understood, particularly during the initial phase of treatment. Objective: The purpose of this study was to prospectively follow the kinetics of change in CD4(+) T cell cytokine secretion during the course of conventional immunotherapy Methods: Six allergic individuals sere treated with extracts of Dermatophagoides farinae/Dermatophagoides pteronyssinus or with rye grass pollen (Lolium perenne) allergen, but not both, by using an internally controlled conventional immunotherapy protocol, CD4(+) T cells from peripheral blood were examined in vitro at varying intervals after the initiation of immunotherapy by stimulation with D farinae or L perenne group I antigen. The quantity of IL-4 and IFN-gamma produced and its relationship to clinical improvement nas determined. Results: The ratio of allergen-specific IL-4/IFN-gamma production by CD4(+) T cells from 4 of 6 individuals receiving immunotherapy greatly increased during the period when the dose of allergen was increasing. However, after high-dose maintenance therapy was achieved, this ratio decreased in subjects responding clinically to, but not in those failing, immunotherapy In addition, late-phase skin reactions and allergen-specific IgE levels in responding, but not in nonresponding, subjects diminished over the course of immunotherapy Conclusion: Conventional immunotherapy may initially exacerbate allergic disease by increasing allergen-specific IL-4 and allergen-specific IgE production Later clinical improvement is associated with a reduction in allergen-specific IL-4 production and in allergen-specific serum IgE.	Stanford Univ, Dept Pediat, Div Immunol & Transplantat Biol, Stanford, CA 94305 USA; MAST Immunosyst, Mountain View, CA USA	Stanford University	Umetsu, DT (corresponding author), Stanford Univ, Dept Pediat, Div Immunol & Transplantat Biol, Rm H307, Stanford, CA 94305 USA.				NCRR NIH HHS [M01-RR00070] Funding Source: Medline; NIAID NIH HHS [AI26322, KO7AI01026] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026322, K07AI001026] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akoum H, 1996, IMMUNOLOGY, V87, P593, DOI 10.1046/j.1365-2567.1996.506585.x; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; CRITCHFIELD JM, 1995, CLIN IMMUNOL IMMUNOP, V75, P13, DOI 10.1006/clin.1995.1046; DeKruyff R, 1998, J IMMUNOL, V160, P2231; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Elenkov IJ, 1998, J IMMUNOL, V161, P2586; Hoekstra MO, 1997, CLIN EXP ALLERGY, V27, P1254; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; JUTEL M, 1995, J IMMUNOL, V154, P4187; KABELITZ D, 1993, IMMUNOL TODAY, V14, P338, DOI 10.1016/0167-5699(93)90231-9; Kim TS, 1997, J IMMUNOL, V158, P4137; KULLBERG MC, 1992, J IMMUNOL, V148, P3264; Maecker HT, 1997, VACCINE, V15, P1687, DOI 10.1016/S0264-410X(97)00088-1; MARSHALL JD, 1993, CELL IMMUNOL, V152, P18, DOI 10.1006/cimm.1993.1264; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; MCHUGH SM, 1990, J ALLERGY CLIN IMMUN, V86, P521, DOI 10.1016/S0091-6749(05)80208-8; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NAGAYA H, 1985, J ALLERGY CLIN IMMUN, V75, P388, DOI 10.1016/0091-6749(85)90077-6; Nicklas RA, 1996, J ALLERGY CLIN IMMUN, V98, P1001, DOI 10.1016/S0091-6749(96)80183-7; NORMAN PS, 1993, CURR OPIN IMMUNOL, V5, P968, DOI 10.1016/0952-7915(93)90114-8; NORMAN PS, 1981, J ALLERGY CLIN IMMUN, V68, P460, DOI 10.1016/0091-6749(81)90200-1; OBrien RM, 1997, CLIN EXP ALLERGY, V27, P46, DOI 10.1046/j.1365-2222.1997.d01-424.x; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; PENG ZK, 1992, J ALLERGY CLIN IMMUN, V89, P519, DOI 10.1016/0091-6749(92)90318-V; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; Soderlund A, 1997, IMMUNOL LETT, V57, P177, DOI 10.1016/S0165-2478(97)00051-5; Tamada K, 1998, J IMMUNOL, V161, P1239; UMETSU DT, 1988, J IMMUNOL, V140, P4211; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; WEINBERG AD, 1990, J IMMUNOL, V144, P1800; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	38	83	89	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				468	475		10.1016/S0091-6749(99)70473-2	http://dx.doi.org/10.1016/S0091-6749(99)70473-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069882				2022-12-18	WOS:000079175700017
J	Nakayama, T; Aizawa, C; Kuno-Sakai, H				Nakayama, T; Aizawa, C; Kuno-Sakai, H			A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						gelatin; acellular pertussis vaccine combined with diphtheria and tetanus toxoids (DTaP); anaphylaxis; live vaccines	IMMEDIATE-TYPE REACTIONS; MUMPS; CHILDREN; MEASLES; RUBELLA; IGE; IMMUNIZATION; ANAPHYLAXIS	Background: The number of patients with allergic reactions after administration of gelatin-containing live vaccines is increasingly reported in Japan. These allergic reactions appear to be caused by gelatin allergy. It is still unknown how the patients mere sensitized to gelatin. Objective: To determine the incidence of gelatin allergy and to identify contributing factors to gelatin allergy, me investigated the following clinical aspects: the development of IgE antibodies to gelatin and the relationship of the patients' past history of acellular pertussis vaccine combined with diphtheria and tetanus toroid (DTaP) to the development of gelatin allergy. Methods: We evaluated 366 patient reports, submitted from 1994 to 1997, of adverse reactions after immunization with monovalent measles, mumps, and rubella vaccines containing 0.2% gelatin as stabilizer. On the basis of physician reports, the patients were categorized as to the nature of the adverse reaction. We determined the presence of IgE antibodies to gelatin and obtained past immunization history. Results: The 366 reported patients were categorized as follows: 34 with anaphylaxis, 76 with urticaria, 215 with nonurticarial generalized eruption, and 41 with local reactions only. In 206 patients from whom serum was available, IgE antibodies to gelatin were detected in 25 of 27 (93%) with anaphylaxis, 27 of 48 (56%) with urticaria, and 8 of 90 (9%) with a generalized eruption. None of a group of 41 patients with only local reactions at the injected site and none of a control group of 29 subjects with no adverse reaction had such antibodies. Among 202 patients for whom prior vaccine information was available, all had received DTaP vaccines. Among those for whom the prior DTaP vaccine could be determined to contain gelatin or be free of gelatin, 155 of 158 (98%) subjects had received gelatin-containing DTaP vaccines. This rate is higher than mould be expected on the basis of the market share of gelatin-containing (vs gelatin-free) DTaP vaccines (75%). Furthermore, before 1993, when a trivalent measles, mumps, and rubella vaccine (with the same 0.2% gelatin content as the monovalent vaccines) was used and administered before DTaP vaccination, no reports of anaphylaxis to the measles, mumps, and rubella vaccine were received. Conclusion: Most anaphylactic reactions and some urticarial reactions to gelatin-containing measles, mumps, and rubella monovalent vaccines are associated with IgE-mediated gelatin allergy. DTaP immunization histories suggest that the gelatin-containing DTaP vaccine may have a causal relationship to the development of this gelatin allergy.	Kitasato Inst, Dept Virol, Minato Ku, Tokyo 1088642, Japan; Tokai Univ, Sch Med, Dept Pediat, Kanagawa, Japan	Tokai University	Nakayama, T (corresponding author), Kitasato Inst, Dept Virol, Minato Ku, Shirokane 5-9-1, Tokyo 1088642, Japan.							BUSINCO L, 1994, ANN ALLERGY, V72, P1; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; KIMURA M, 1990, LANCET, V336, P30, DOI 10.1016/0140-6736(90)91530-N; Kumagai T, 1997, J ALLERGY CLIN IMMUN, V100, P130, DOI 10.1016/S0091-6749(97)70204-5; KUNOSAKAI H, 1996, CLIN VIROL, V24, P210; MOCHIZUKI Y, 1995, J JPN PEDIAT SOC, V99, P873; NAKAYAMA T, 1996, CLIN VIROL, V24, P198; SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V96, P563, DOI 10.1016/S0091-6749(95)70304-7; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6; Sakaguchi M, 1997, J ALLERGY CLIN IMMUN, V99, P263, DOI 10.1016/S0091-6749(97)70108-8; SUGIURA A, 1991, PEDIATR INFECT DIS J, V10, P209, DOI 10.1097/00006454-199103000-00008; 1998, MMWR, V47, P8	12	83	89	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				321	325		10.1016/S0091-6749(99)70508-7	http://dx.doi.org/10.1016/S0091-6749(99)70508-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949325				2022-12-18	WOS:000078630100021
J	HIGGINS, JA; THORPE, CJ; HAYBALL, JD; OHEHIR, RE; LAMB, JR				HIGGINS, JA; THORPE, CJ; HAYBALL, JD; OHEHIR, RE; LAMB, JR			OVERLAPPING T-CELL EPITOPES IN THE GROUP-I ALLERGEN OF DERMATOPHAGOIDES SPECIES RESTRICTED BY HLA-DP AND HLA-DR CLASS-II MOLECULES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PEPTIDES; HOUSE DUST MITE; DER P I; HLA-DR; HLA-DP; T-CELL EPITOPES	HOUSE DUST MITE; DER-P-I; LYMPHOCYTES-T; CROSSED RADIOIMMUNOELECTROPHORESIS; INFLUENZA HEMAGGLUTININ; SEQUENCE-ANALYSIS; ATOPIC PATIENTS; PTERONYSSINUS; SPECIFICITY; ANTIGEN	The induction of IgE antibodies reactive with the group I allergen of Dermatophagoides species (house dust mite [HDM]), which comprise a major component of the allergic immune response in HDM-atopic individuals, is dependent on the functional activity of specific CD4 + T cells. In this report we demonstrate that for a particular HDM-atopic individual the T-cell response to the group I allergen of Dermatophagoides pteronyssinus (Der p I) is limited to a single region (residues 101-143) of the protein. By mapping the fine antigen specificity with T-cell clones, we observed that the sequence 101-131 of Der p I contains a cluster of at least three overlapping T-cell epitopes. Analysis of the HLA class II restriction specificity of the T-cell clones revealed that the T-cell epitope, residues 110-131, was restricted by HLA-DRB1*0101. In contrast, peptide Der p I, 110-119 was recognized in association with HLA-DPB1*0402. However; the ability of cloned T cells to proliferate to the peptide Der p I, 107-119 presented by HLA-DPB1*0401, HLA-DPB1*0402, and HLA-DPB1*0501 expressing accessory cells illustrates the heterogeneity of the restriction specificity of this region of Der p I. The application of this information in the design of peptide-based immunotherapy in the management of allergic responses to HDM is discussed.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,DEPT IMMUNOL,LONDON W2 1PG,ENGLAND; UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,MOLEC BIOL LAB,LONDON,ENGLAND	Imperial College London; University of London; Birkbeck University London			Thorpe, Christopher John/AGF-7062-2022; O'Hehir, Robyn E/H-3627-2011; Hayball, John D/F-4137-2013	Thorpe, Christopher John/0000-0002-4341-0320; O'Hehir, Robyn E/0000-0002-3489-7595; Hayball, John D/0000-0002-3089-4506	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALDO BA, 1990, MONOGR ALLERGY, V28, P138; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BURT DS, 1989, J EXP MED, V170, P383, DOI 10.1084/jem.170.2.383; BUSCH R, 1991, J IMMUNOL, V147, P1292; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; DILWORTH RJ, 1991, CLIN EXP ALLERGY, V21, P25, DOI 10.1111/j.1365-2222.1991.tb00800.x; ECKELS DD, 1983, NATURE, V301, P716, DOI 10.1038/301716a0; EURA M, 1991, P HLA INT S YOKUHAMA, P235; GASTON JSH, 1991, INT IMMUNOL, V3, P965, DOI 10.1093/intimm/3.10.965; GREENE WK, 1992, MOL IMMUNOL, V29, P257, DOI 10.1016/0161-5890(92)90107-9; HIGGINS JA, 1992, J ALLERGY CLIN IMMUN, V90, P749, DOI 10.1016/0091-6749(92)90098-M; ISHIZAKA K, 1984, ANNU REV IMMUNOL, V2, P159, DOI 10.1146/annurev.immunol.2.1.159; KRILIS S, 1984, J ALLERGY CLIN IMMUN, V74, P142, DOI 10.1016/0091-6749(84)90277-X; LAMB JR, 1983, IMMUNOLOGY, V50, P659; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LANZAVECCHIA A, 1983, CLIN EXP IMMUNOL, V52, P21; Lett-Brown M A, 1989, Year Immunol, V5, P195; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; OBRIEN RM, 1992, J ALLERGY CLIN IMMUN, V89, P1021, DOI 10.1016/0091-6749(92)90225-Q; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; OHEHIR RE, 1988, IMMUNOLOGY, V64, P627; OHEHIR RE, 1987, IMMUNOLOGY, V62, P635; OHEHIR RE, 1990, INT IMMUNOL, V2, P885, DOI 10.1093/intimm/2.9.885; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; RAWLE FC, 1984, J IMMUNOL, V133, P195; WATSON AJ, 1983, NATURE, V304, P358, DOI 10.1038/304358a0; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; YOUNG RP, 1992, EUR J ALLERGY CLIN I, V47, P8; YSSEL H, 1992, J IMMUNOL, V148, P738	30	83	91	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					891	899		10.1016/0091-6749(94)90383-2	http://dx.doi.org/10.1016/0091-6749(94)90383-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	7514196				2022-12-18	WOS:A1994NL91900014
J	ALTMAN, LC; AYARS, GH; BAKER, C; LUCHTEL, DL				ALTMAN, LC; AYARS, GH; BAKER, C; LUCHTEL, DL			CYTOKINES AND EOSINOPHIL-DERIVED CATIONIC PROTEINS UP-REGULATE INTERCELLULAR-ADHESION MOLECULE-1 ON HUMAN NASAL EPITHELIAL-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ICAM-1; EOSINOPHILS; MBP; ECP; NASAL EPITHELIUM	VASCULAR ENDOTHELIAL-CELLS; HYDROGEN-PEROXIDE; INTERFERON-GAMMA; INVITRO; ICAM-1; NEUTROPHIL; ADHERENCE; INJURY; EXPRESSION; DISORDERS	Background: Allergic and nonallergic rhinitis with eosinophilia syndrome are characterized by tissue eosinophilia and nasal mucosal injury. Recently, it has been shown that the adherence of eosinophils and other leukocytes to epithelial cells is mediated by intercellular adhesion molecule-1 (ICAM-1) and related adherence-promoting glycoproteins. Methods: In this study we examined the constitutive expression of ICAM-1 on human nasal epithelial cells (HNECs), and the effects of interferon-gamma, tumor necrosis factor-gamma eosinophil major basic protein, and eosinophil cationic protein on the regulation of ICAM-1 expression on these cells. Similar studies were performed with A549 pneumo tes as comparative epithelial cells. Results: Constitutive expression of ICAM-1 was significantly higher on cultured HNECs than on A549 cells, although nasal epithelial cells in tissue specimens did not demonstrate detectable levels of ICAM-1. This spontaneous expression of ICAM-1 on cultured HNECs may explain the unique susceptibility of the nasal mucosa to rhinovirus infection, because ICAM-1 is the epithelial cell receptor for most rhinoviruses. Physiologic concentrations of major basic protein and eosinophil cationic protein stimulated significant upregulation of ICAM-1 on HNECs, which was comparable to that produced by interferon-gamma and tumor necrosis factor-alpha. In contrast, these eosinophil constituents did not stimulate ICAM-1 upregulation on A549 alveolar epithelial cells, although A549 cells did respond to interferon-gamma and tumor necrosis factor-alpha. Conclusion: The observation that eosinophil products upregulate ICAM-1 on HNECs suggests a positive feedback mechanism, in which the products released from migrating eosinophils might promote additional HNEC-leukocyte adherence by enhancing interactions between leukocyte beta2 integrins (CD11/18) and nasal epithelial ICAM-1.	UNIV WASHINGTON,DEPT ENVIRONM HLTH,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	ALTMAN, LC (corresponding author), UNIV WASHINGTON,DEPT MED,DIV ALLERGY & INFECT DIS,SJ-10,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005650] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 08229-04] Funding Source: Medline; NIEHS NIH HHS [NIEHS ES-05650] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AGOSTI JM, 1987, J ALLERGY CLIN IMMUN, V79, P496, DOI 10.1016/0091-6749(87)90368-X; ALBELDA SM, 1991, AM J RESP CELL MOL, V4, P195, DOI 10.1165/ajrcmb/4.3.195; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTMAN LC, 1992, J PERIODONTAL RES, V27, P70; ALTMAN LC, 1990, IMMUNOL ALLERGY CLIN, V10, P263; ALTMAN LC, 1988, J PERIODONTAL RES, V23, P91, DOI 10.1111/j.1600-0765.1988.tb01340.x; AYARS GH, 1989, AM REV RESPIR DIS, V140, P125; AYARS GH, 1985, J ALLERGY CLIN IMMUN, V76, P595, DOI 10.1016/0091-6749(85)90781-X; BUTCHER EC, 1990, AM J PATHOL, V136, P3; CARLOS TM, 1990, BLOOD, V76, P965; COOK RM, 1987, INT ARCH ALLER A IMM, V83, P428, DOI 10.1159/000234380; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; DUSTIN ML, 1988, J EXP MED, V167, P1323, DOI 10.1084/jem.167.4.1323; DUSTIN ML, 1986, J IMMUNOL, V137, P245; KIMANI G, 1988, J IMMUNOL, V140, P3161; KYANAUNG U, 1991, J IMMUNOL, V146, P521; LAMAS AM, 1988, J IMMUNOL, V140, P1500; LEVIN J, 1970, J LAB CLIN MED, V75, P903; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; LOOK DC, 1992, AM J PHYSIOL, V263, pL79, DOI 10.1152/ajplung.1992.263.1.L79; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393, DOI 10.1165/ajrcmb/7.4.393; MONTEFORT S, 1992, EUR RESPIR J, V5, P815; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; NUTMAN TB, 1989, ALLERGY PROC, V10, P47, DOI 10.2500/108854189778968579; NUTMAN TB, 1989, ALLERGY PROC, V10, P33, DOI 10.2500/108854189778968560; PATARROYO M, 1987, FEBS LETT, V210, P127, DOI 10.1016/0014-5793(87)81321-2; PROBER JS, 1987, J IMMUNOL, V138, P3319; ROSEN SD, 1990, AM J RESP CELL MOL, V3, P397, DOI 10.1165/ajrcmb/3.5.397; SMITH CW, 1990, AM J RESP CELL MOL, V2, P487, DOI 10.1165/ajrcmb/2.6.487; SPRY CJF, 1988, EOSINOPHILS COMPREHE, P131; STACKER SA, 1991, J IMMUNOL, V146, P648; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; TOSI MF, 1992, AM J RESP CELL MOL, V7, P214, DOI 10.1165/ajrcmb/7.2.214; VENGE P, 1988, AM REV RESPIR DIS, V138, pS54, DOI 10.1164/ajrccm/138.6_Pt_2.S54; WALSH GM, 1991, J IMMUNOL, V146, P3419; WAWRYK SO, 1989, IMMUNOL REV, V108, P135, DOI 10.1111/j.1600-065X.1989.tb00016.x; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; YUKAWA T, 1990, AM J RESP CELL MOL, V2, P341, DOI 10.1165/ajrcmb/2.4.341	40	83	84	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1993	92	4					527	536		10.1016/0091-6749(93)90077-S	http://dx.doi.org/10.1016/0091-6749(93)90077-S			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MC590	8104967	Bronze			2022-12-18	WOS:A1993MC59000005
J	ARLIAN, LG; VYSZENSKIMOHER, DL; FERNANDEZCALDAS, E				ARLIAN, LG; VYSZENSKIMOHER, DL; FERNANDEZCALDAS, E			ALLERGENICITY OF THE MITE, BLOMIA-TROPICALIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BLOMIA-TROPICALIS; DERMATOPHAGOIDES-FARINAE; DERMATOPHAGOIDES-PTERONYSSINUS; TYROPHAGUS-PUTRESCENTIAE; ANTIGENS; ALLERGENS; PHYLOGENETIC; CROSS-REACTIVITY; MITES; HOUSE DUST	HOUSE DUST MITE; DERMATOPHAGOIDES-PTERONYSSINUS; CROSS-ANTIGENICITY; TYROPHAGUS-PUTRESCENTIAE; SARCOPTES-SCABIEI; HUMAN IGE; FARINAE; BODY; PYROGLYPHIDAE; ALLERGY	Background: Blomia tropicalis (BT) occurs in a significant percentage of homes in tropical and subtropical geographic regions of the United States and Europe and in countries in South America and Asia along with the pyroglyphid mites, Euroglyphus maynei (EM), Dermatophagoides pteronyssinus, and D. farinae. Blomia species may be major sources of allergens in house dust in addition to Dermatophagoides species and E. maynei. Methods: Crossed immunoelectrophoresis and crossed radioimmunoelectrophoresis were used to identify the antigens and allergens of BT and to determine the cross-reactivity between BT and the house dust mites, D. farinae, D. pteronyssinus, and the stored product mite, Tyrophagus putrescentiae. Results: Homologous crossed immunoelectrophoresis of BT resulted in 27 antigen-antibody complexes. Crossed radioimmunoelectrophoresis of these gels showed 21 different immunoglobulin E binding antigens when they were incubated in the sera from 14 patients with asthma whose radioallergosorbent test and skin test results were positive. Heterologous crossed immunoelectrophoresis reactions with BT and rabbit D. farinae body and feces, D. pteronyssinus body and feces, and T. putrescentiae body and feces antisera resulted in one to four precipitin lines. BT extract, reacted with rabbit antisera produced against the bodies of D. farinae, D. pteronyssinus, and T. putrescentiae, produced 3, 2, and 4 antigenic peaks, respectively; whereas crossed radioimmunoelectrophoresis of these gels with the sera of the 14 patients with asthma resulted in immunoglobulin E binding to 2, 2, and 4 peaks, respectively. Conclusions: The results of this study indicated that BT contained multiple allergens of which most were species-specific. There was a limited amount of cross-reactivity between BT and the two common house dust mite species and the stored product mite. The amount of cross-reactivity appears to parallel the phylogenetic relatedness.	UNIV S FLORIDA,DIV ALLERGY & CLIN IMMUNOL,TAMPA,FL 33620	State University System of Florida; University of South Florida	ARLIAN, LG (corresponding author), WRIGHT STATE UNIV,DEPT BIOL SCI,DAYTON,OH 45435, USA.							ARLIAN LG, 1991, J INVEST DERMATOL, V96, P349, DOI 10.1111/1523-1747.ep12465257; ARLIAN LG, 1988, J MED ENTOMOL, V25, P240, DOI 10.1093/jmedent/25.4.240; ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; ARLIAN LG, 1984, J ALLERGY CLIN IMMUN, V74, P172, DOI 10.1016/0091-6749(84)90282-3; ARLIAN LG, 1984, J ALLERGY CLIN IMMUN, V74, P166, DOI 10.1016/0091-6749(84)90281-1; ARLIAN LG, 1987, J MED ENTOMOL, V24, P252, DOI 10.1093/jmedent/24.2.252; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P457, DOI 10.1016/0091-6749(87)90363-0; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P467, DOI 10.1016/0091-6749(87)90364-2; ARLIAN LG, 1992, INPRESS ALLERGENICIT; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; Bronswijk J.E. van, 1973, ACAROLOGIA, V15, P477; CHARLET LD, 1978, INT J ACAR, V3, P23; FERNANDEZCALDAS E, 1990, ALLERGY PROC, V11, P263, DOI 10.2500/108854190778879710; FERNANDEZCALDAS E, 1986, THESIS U LA LAGUNA T; GABRIEL M, 1982, CLIN ALLERGY, V12, P157, DOI 10.1111/j.1365-2222.1982.tb01635.x; HEYMANN PW, 1986, J IMMUNOL, V137, P2841; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; HILL MR, 1990, DUST MITE ALLERGENS, P65; Hughes AM, 1961, MINISTRY AGR FISHERI, V9; HURTADO I, 1987, ANN ALLERGY, V59, P128; JORGE N, 1980, REV BRAS ALERG IMUNO, V2, P140; Krantz GW, 1978, MANUAL ACAROLOGY, V2nd; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LLERENA LP, 1991, J ALLERGY CLIN IMMUN, V88, P943, DOI 10.1016/0091-6749(91)90252-J; MIYAMOTO T, 1969, J ALLERGY, V44, P228, DOI 10.1016/0021-8707(69)90089-6; OCONNOR BM, 1982, ANNU REV ENTOMOL, V27, P385, DOI 10.1146/annurev.en.27.010182.002125; Rosa A.E., 1979, International Journal of Acarology, V5, P195; SCHUHL JF, 1977, ALLERGOL IMMUNOPATH, V5, P117; SOMORIN AO, 1978, IRISH J MED SCI, V147, P26, DOI 10.1007/BF02939363; THOMAS WR, 1990, DUST MITE ALLERGENS, P58; TOVEY ER, 1989, J EXP MED, V170, P1457, DOI 10.1084/jem.170.4.1457; van Bronswijk J.E.M.H., 1972, Entomologische Berichten, V32, P162; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P23	33	83	87	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1993	91	5					1042	1050		10.1016/0091-6749(93)90218-5	http://dx.doi.org/10.1016/0091-6749(93)90218-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LC978	8491936				2022-12-18	WOS:A1993LC97800012
J	ANDO, M; KONISHI, K; YONEDA, R; TAMURA, M				ANDO, M; KONISHI, K; YONEDA, R; TAMURA, M			DIFFERENCE IN THE PHENOTYPES OF BRONCHOALVEOLAR LAVAGE LYMPHOCYTES IN PATIENTS WITH SUMMER-TYPE HYPERSENSITIVITY PNEUMONITIS, FARMERS LUNG, VENTILATION PNEUMONITIS, AND BIRD FANCIERS LUNG - REPORT OF A NATIONWIDE EPIDEMIOLOGIC-STUDY IN JAPAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							TRICHOSPORON-CUTANEUM; MICROPOLYSPORA-FAENI; T-CELLS; PATIENTS HOMES	We performed a nationwide epidemiologic study of hypersensitivity pneumonitis (HP) in Japan by questionnaire and found that 835 cases of HP were recognized during the 1980s; 74.4% were summer-type HP, 8.1% farmer's lung, 4.3% ventilation pneumonitis, 4.1% bird fancier's lung, 2.3% other types, such as chemical worker's lung, and 6.8% of unknown causative agent. It was found that the CD4/CD8 ratios of bronchoalveolar lavage (BAL) lymphocytes were significantly different with the type of disease. The ratio was 0.6 +/- 0.1 (mean +/- SEM) in summer-type HP (N = 271), 4.4 +/- 0.7 in farmer's lung (N = 22), 1.6 +/- 0.3 in ventilation pneumonitis (N = 19), and 2.0 +/- 0.5 in bird fancier's lung (N = 19). In farmer's lung, the CD4/CD8 ratio in smokers was 6.2 +/- 1.9 (N = 6) in contrast with 3.4 +/- 0.7 for nonsmokers (N = 16) (p < 0.05). It has been generally considered that the phenotypes of BAL lymphocytes in patients with HP are predominately CD8 cells. Our present results, however indicate that the phenotypes of BAL lymphocytes vary with the type of HP, probably depending on factors such as causative agent, smoking, or staging of the disease.	TOKYO NATL CHEST HOSP,TOKYO,JAPAN; IWATE UNIV,DEPT INTERNAL MED 3,MORIOKA,IWATE 020,JAPAN	Iwate University	ANDO, M (corresponding author), KUMAMOTO UNIV,SCH MED,DEPT INTERNAL MED 1,1-1-1 HONJO,KUMAMOTO 860,JAPAN.							ANDO M, 1990, J ALLERGY CLIN IMMUN, V85, P36, DOI 10.1016/0091-6749(90)90218-S; BICE DE, 1977, INT ARCH ALLER A IMM, V55, P267; BRUMMUND W, 1988, J ALLERGY CLIN IMMUN, V82, P190, DOI 10.1016/0091-6749(88)90998-0; CORMIER Y, 1987, AM REV RESPIR DIS, V135, P692; COSTABEL U, 1985, AM REV RESPIR DIS, V131, P337; FINK JN, 1984, J ALLERGY CLIN IMMUN, V74, P1, DOI 10.1016/0091-6749(84)90077-0; FINK JN, 1987, MONOGR ALLERGY, V21, P59; KAWANAMI O, 1983, AM J PATHOL, V110, P275; KELLER RH, 1984, AM REV RESPIR DIS, V130, P766; KONISHI K, 1985, TOHOKU J EXP MED, V147, P135, DOI 10.1620/tjem.147.135; LEATHERMAN JW, 1984, ANN INTERN MED, V100, P390, DOI 10.7326/0003-4819-100-3-390; LOPEZ M, 1987, MONOGRAPHY ALLERGY, P70; MARX JJ, 1976, J ALLERGY CLIN IMMUN, V57, P328, DOI 10.1016/0091-6749(76)90089-0; MURAO M, 1980, Japanese Journal of Thoracic Diseases, V18, P373; MURAYAMA J, 1990, AM REV RESPIR DIS, V141, P317; PEPY J, 1969, MONOGR ALLERGY, P1; REYNOLDS HY, 1986, ANN NY ACAD SCI, V465, P287, DOI 10.1111/j.1749-6632.1986.tb18505.x; RICHERSON HB, 1989, J ALLERGY CLIN IMMUN, V84, P839, DOI 10.1016/0091-6749(89)90349-7; SEMENZATO G, 1988, AM REV RESPIR DIS, V137, P70, DOI 10.1164/ajrccm/137.1.70; SEMENZATO G, 1986, J IMMUNOL, V137, P1164; SHIMAZU K, 1984, AM REV RESPIR DIS, V130, P407; SMITH SM, 1980, J ALLERGY CLIN IMMUN, V65, P298, DOI 10.1016/0091-6749(80)90159-1; TAMURA M, 1986, RESPIRATION RES, V5, P120; TAMURA M, 1986, INTERNAL MED EXCERPT, P99; TANEICHI K, 1984, JAP J INTERN MED, V74, P1237; Tomichi N, 1989, Arerugi, V38, P508; YAMASAKI H, IN PRESS AM J RESPIR; YONEDA R, 1983, PATHOL CLIN MED, V1, P599; YOSHIDA K, 1989, ARCH ENVIRON HEALTH, V44, P317, DOI 10.1080/00039896.1989.9935900; YOSHIDA K, 1988, J ALLERGY CLIN IMMUN, V81, P475, DOI 10.1016/0091-6749(88)90920-7	30	83	85	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1991	87	5					1002	1009		10.1016/0091-6749(91)90423-L	http://dx.doi.org/10.1016/0091-6749(91)90423-L			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FM095	1902851				2022-12-18	WOS:A1991FM09500013
J	KLINK, M; CLINE, MG; HALONEN, M; BURROWS, B				KLINK, M; CLINE, MG; HALONEN, M; BURROWS, B			PROBLEMS IN DEFINING NORMAL LIMITS FOR SERUM IGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV ARIZONA,COLL MED,DIV RESP SCI,TUCSON,AZ 85724	University of Arizona				Halonen, Marilyn/0000-0001-9606-935X	NHLBI NIH HHS [HL14136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; Braunwald E., 1987, HARRISONS PRINCIPLES; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; LEBOWITZ MD, 1975, AM J EPIDEMIOL, V102, P137, DOI 10.1093/oxfordjournals.aje.a112141; SEARS MR, 1980, CLIN ALLERGY, V10, P423, DOI 10.1111/j.1365-2222.1980.tb02125.x; VANARSDEL PP, 1989, ANN INTERN MED, V110, P304, DOI 10.7326/0003-4819-110-4-304; 1977, PHARM PHADEBAS IGE P	9	83	83	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1990	85	2					440	444		10.1016/0091-6749(90)90153-U	http://dx.doi.org/10.1016/0091-6749(90)90153-U			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP511	2303647				2022-12-18	WOS:A1990CP51100004
J	REINBERG, A; GERVAIS, P; LEVI, F; SMOLENSKY, M; DELCERRO, L; UGOLINI, C				REINBERG, A; GERVAIS, P; LEVI, F; SMOLENSKY, M; DELCERRO, L; UGOLINI, C			CIRCADIAN AND CIRCANNUAL RHYTHMS OF ALLERGIC RHINITIS - AN EPIDEMIOLOGIC-STUDY INVOLVING CHRONOBIOLOGIC METHODS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,HLTH SCI CTR,SCH PUBL HLTH,POB 20186,HOUSTON,TX 77225; UNIV TEXAS,HLTH SCI CTR,GRAD SCH BIOMED SCI,HOUSTON,TX 77225; FDN A DE ROTHSCHILD,NATL CTR SCI RES & MED INTERNE ALLERGOL,F-75019 PARIS,FRANCE; HOP FERNAND WIDAL,POLICLIN MED,F-75475 PARIS 10,FRANCE	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite								BARNES P, 1980, NEW ENGL J MED, V303, P263, DOI 10.1056/NEJM198007313030506; BESSON J, 1986, ALLERGOLOGIE, P367; CHARPIN J, 1986, PNEUMALLERGENES POLL, P217; De Prins J., 1986, ANN REV CHRONOPHARMA, V2, P27, DOI 10.1016/B978-0-08-034135-4.50006-X; FELDMANN M, 1986, RECHERCHE, V17, P672; FOLKARD S, 1979, MEM COGNITION, V7, P247, DOI 10.3758/BF03197596; HALBERG F, 1983, International Journal of Chronobiology, V8, P225; KUNKEL G, 1984, NEW PERSPECTIVES THE, P149; LEVI F, 1985, CLIN PHARMACOL THER, V37, P77, DOI 10.1038/clpt.1985.15; LEVI F, 1985, CHRONOBIOLOGIA, V12, P256; LEVI FA, 1985, J IMMUNOL, V134, P217; LU MC, 1980, RECENT ADV CHRONOBIO, P275; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; Nicholson P A, 1973, Curr Med Res Opin, V1, P395, DOI 10.1185/03007997309111700; REINBERG A, 1983, J ALLERGY CLIN IMMUN, V71, P425, DOI 10.1016/0091-6749(83)90073-8; REINBERG A, 1986, ANN REV CHRONOPHARMA, V3, P441; REINBERG A, 1977, CHRONOBIOLOGY ALLERG, P36; REINBERG A, 1984, ANN REV CHRONOPHARMA, V1, P61; REINBERG A, 1980, RECENT ADV CHRONOBIO, P251; Reinberg A, 1983, BIOL RHYTHMS MED; SMOLENSKY MH, 1981, ANN ALLERGY, V47, P234; SMOLENSKY MH, 1986, J ASTHMA, V23, P321, DOI 10.3109/02770908609073179; SMOLENSKY MH, 1986, ANN REV CHRONOPHARMA, V2, P229; SMOLENSKY MH, 1983, BIOL RHYTHMS MED CEL, P131; Trousseau A, 1865, CLIN MED HOTEL DIEU, V2, P373	25	83	83	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					51	62		10.1016/0091-6749(88)90220-5	http://dx.doi.org/10.1016/0091-6749(88)90220-5			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	3339191	Bronze			2022-12-18	WOS:A1988M027400009
J	BARNETT, D; BONHAM, B; HOWDEN, MEH				BARNETT, D; BONHAM, B; HOWDEN, MEH			ALLERGENIC CROSS-REACTIONS AMONG LEGUME FOODS - AN INVITRO STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MACQUARIE UNIV,SCH CHEM,N RYDE,NSW 2113,AUSTRALIA; CSIRO,DIV FOOD RES,N RYDE,NSW 2113,AUSTRALIA	Macquarie University; Commonwealth Scientific & Industrial Research Organisation (CSIRO)								AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; BALDO BA, 1980, ALLERGY, V35, P45, DOI 10.1111/j.1398-9995.1980.tb01716.x; BARNETT D, 1983, J ALLERGY CLIN IMMUN, V72, P61, DOI 10.1016/0091-6749(83)90053-2; BAUR X, 1979, CLIN ALLERGY, V9, P451, DOI 10.1111/j.1365-2222.1979.tb02508.x; BELITZ HD, 1982, Z LEBENSM UNTERS FOR, V174, P442, DOI 10.1007/BF01042722; BOULTER D, 1983, PLANT PROTEINS HUMAN, P43; CHUA YY, 1976, J ALLERGY CLIN IMMUN, V58, P299, DOI 10.1016/0091-6749(76)90135-4; FREED DLJ, 1982, LECTINS BIOL BIOCH C, V2, P34; FRIES JH, 1982, ANN ALLERGY, V48, P220; GILLESPIE DN, 1976, J ALLERGY CLIN IMMUN, V57, P302, DOI 10.1016/0091-6749(76)90086-5; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; KALVERAM KJ, 1978, INT ARCH ALLER A IMM, V57, P549, DOI 10.1159/000232151; KEMP AS, 1985, CLIN ALLERGY, V15, P73, DOI 10.1111/j.1365-2222.1985.tb02258.x; KING TP, 1976, ADV IMMUNOL, V23, P77, DOI 10.1016/S0065-2776(08)60319-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESSOF MH, 1980, Q J MED, V49, P259; SPEER F, 1975, ANN ALLERGY, V34, P71; WILSON KA, 1983, PLANT PHYSIOL, V71, P341, DOI 10.1104/pp.71.2.341	18	83	84	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1987	79	3					433	438		10.1016/0091-6749(87)90359-9	http://dx.doi.org/10.1016/0091-6749(87)90359-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G4795	3493279				2022-12-18	WOS:A1987G479500004
J	ZORA, JA; ZIMMERMAN, D; CAREY, TL; OCONNELL, EJ; YUNGINGER, JW				ZORA, JA; ZIMMERMAN, D; CAREY, TL; OCONNELL, EJ; YUNGINGER, JW			HYPOTHALAMIC-PITUITARY-ADRENAL AXIS SUPPRESSION AFTER SHORT-TERM, HIGH-DOSE GLUCOCORTICOID THERAPY IN CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,406 GUGGENHEIM BLDG,ROCHESTER,MN 55905; MAYO GRAD SCH MED,DEPT PEDIAT,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic					NCRR NIH HHS [RR-585] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABBOUD CF, 1979, J NEUROSURG, V51, P271, DOI 10.3171/jns.1979.51.3.0271; AXELROD L, 1976, MEDICINE, V55, P39, DOI 10.1097/00005792-197601000-00003; BAXTER JD, 1981, ENDOCRINOL METAB, P385; HARRISON BDW, 1982, CLIN ENDOCRINOL, V17, P109, DOI 10.1111/j.1365-2265.1982.tb01570.x; JACOBS HS, 1969, Q J MED, V38, P475; MALONE DNS, 1970, LANCET, V2, P733; MELLIS CM, 1977, THORAX, V32, P29, DOI 10.1136/thx.32.1.29; MORRIS HG, 1971, J PEDIATR-US, V79, P480, DOI 10.1016/S0022-3476(71)80163-4; MORRIS HG, 1983, ALLERGY PRINCIPLES P, P593; MURPHY BEP, 1967, J CLIN ENDOCR METAB, V27, P973, DOI 10.1210/jcem-27-7-973; SHAPIRO GG, 1983, PEDIATRICS, V71, P510; STRECK WF, 1979, AM J MED, V66, P910, DOI 10.1016/0002-9343(79)90444-3; VAZ R, 1982, J PEDIATR-US, V100, P660, DOI 10.1016/S0022-3476(82)80781-6; WILSON KS, 1977, POSTGRAD MED J, V53, P745, DOI 10.1136/pgmj.53.626.745	14	83	84	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	1				9	13		10.1016/0091-6749(86)90315-5	http://dx.doi.org/10.1016/0091-6749(86)90315-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD36	3944378	Bronze			2022-12-18	WOS:A1986AZD3600003
J	DEWAIR, M; BAUR, X; ZIEGLER, K				DEWAIR, M; BAUR, X; ZIEGLER, K			USE OF IMMUNOBLOT TECHNIQUE FOR DETECTION OF HUMAN IGE AND IGG ANTIBODIES TO INDIVIDUAL SILK PROTEINS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DEUTSCH WOLLFORSCHUNGSINST,D-5100 AACHEN,FED REP GER		DEWAIR, M (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,MED KLIN 1,PNEUMOL ABT,D-8000 MUNICH 70,FED REP GER.							BATTEIGER B, 1982, J IMMUNOL METHODS, V55, P297, DOI 10.1016/0022-1759(82)90089-8; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; DEWAIR M, 1984, J IMMUNOL METHODS, V75, P117, DOI 10.1016/0022-1759(84)90231-X; FUCHS E, 1955, DEUT MED WOCHENSCHR, V80, P36; HACKI, 1982, DEUT MED WOCHENSCHR, V107, P166; KINO T, 1979, J ALLERGY CLIN IMMUN, V64, P131, DOI 10.1016/0091-6749(79)90047-2; KOBAYASHI S, 1974, ALLERGOLOGY, P128; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; SHIMIZO M, 1976, J ALLERGY CLIN IMMUN, V57, P211; SPRAGUE KU, 1975, BIOCHEMISTRY-US, V14, P925, DOI 10.1021/bi00676a008; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSANG VCW, 1983, METHODS ENZYMOL, V92, pE377; ZIEGLER K, 1982, ULLMANN ENZYKLOPADIE, V21, P201	14	83	89	0	11	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	4					537	542		10.1016/0091-6749(85)90772-9	http://dx.doi.org/10.1016/0091-6749(85)90772-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ATH66	4056241				2022-12-18	WOS:A1985ATH6600003
J	NORMAN, PS; LICHTENSTEIN, LM; MARSH, DG				NORMAN, PS; LICHTENSTEIN, LM; MARSH, DG			STUDIES ON ALLERGOIDS FROM NATURALLY-OCCURRING ALLERGENS .4. EFFICACY AND SAFETY OF LONG-TERM ALLERGOID TREATMENT OF RAGWEED HAY-FEVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOWARD HUGHES MED INST,BALTIMORE,MD	Howard Hughes Medical Institute	NORMAN, PS (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239, USA.							CANONICA GW, 1979, J IMMUNOL, V123, P2669; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; ISHIZAKA K, 1970, J IMMUNOL, V105, P1459; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MARSH DG, 1970, IMMUNOLOGY, V18, P705; MARSH DG, 1981, J ALLERGY CLIN IMMUN, V68, P449, DOI 10.1016/0091-6749(81)90199-8; MARSH DG, 1981, J ALLERGY CLIN IMMUN, V67, P206, DOI 10.1016/0091-6749(81)90063-4; MARSH DT, UNPUBLISHED; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1980, J ALLERGY CLIN IMMUN, V65, P87, DOI 10.1016/0091-6749(80)90191-8; NORMAN PS, 1965, J ALLERGY, V36, P284, DOI 10.1016/0021-8707(65)90087-0; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577	17	83	83	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	6					460	470		10.1016/0091-6749(81)90200-1	http://dx.doi.org/10.1016/0091-6749(81)90200-1			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MU790	7031112				2022-12-18	WOS:A1981MU79000009
J	EGGLESTON, PA				EGGLESTON, PA			COMPARISON OF THE ASTHMATIC RESPONSE TO METHACHOLINE AND EXERCISE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											EGGLESTON, PA (corresponding author), UNIV VIRGINIA,MED CTR,SCH MED,DEPT PEDIAT,CHARLOTTESVILLE,VA 22901, USA.							ASTRAND PO, 1964, J APPL PHYSIOL, V19, P268, DOI 10.1152/jappl.1964.19.2.268; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CROPP GJA, 1975, PEDIATRICS, V56, P868; EGGLESTON PA, 1976, J ALLERGY CLIN IMMUN, V58, P414, DOI 10.1016/0091-6749(76)90122-6; EGGLESTON PA, 1972, J ALLERGY CLIN IMMUN, V50, P57, DOI 10.1016/0091-6749(72)90079-6; FISH JE, 1978, J ALLERGY CLIN IMMUN, V61, P140, DOI 10.1016/0091-6749(78)90277-4; GAYRARD P, 1975, AM REV RESPIR DIS, V111, P433; GODFREY S, 1975, PEDIATRICS, V56, P930; GODFREY S, 1973, J ALLERGY CLIN IMMUN, V52, P109; HAYNES RL, 1976, AM REV RESPIR DIS, V114, P739; KAWABORI I, 1976, J ALLERGY CLIN IMMUN, V58, P447, DOI 10.1016/0091-6749(76)90188-3; KIVILOOG J, 1973, SCAND J RESPIR DIS, V54, P347; LAITINEN LA, 1974, SCAND J RESPIR DIS S, P86; MCFADDEN ER, 1977, J APPL PHYSIOL, V42, P746, DOI 10.1152/jappl.1977.42.5.746; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; OROHEK J, 1977, AM REV RESPIR DIS, V115, P937; SELLICK H, 1971, J APPL PHYSIOL, V31, P15, DOI 10.1152/jappl.1971.31.1.15; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; SLY RM, 1967, J ALLERGY, V40, P95; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; TOWNLEY RG, 1976, J ALLERGY CLIN IMMUN, V57, P358, DOI 10.1016/0091-6749(76)90093-2; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; TOWNLEY RG, 1968, J ALLERGY, V29, P177; 1962, AM REV RESPIR DIS, V85, P762	25	83	83	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	2					104	110		10.1016/0091-6749(79)90199-4	http://dx.doi.org/10.1016/0091-6749(79)90199-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GJ748	759463				2022-12-18	WOS:A1979GJ74800007
J	MURRAY, AB; ZUK, P				MURRAY, AB; ZUK, P			SEASONAL-VARIATION IN A POPULATION OF HOUSE DUST MITES IN A NORTH-AMERICAN CITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV BRITISH COLUMBIA,DEPT PAEDIAT,VANCOUVER V6T 1W5,BC,CANADA; AGR CANADA,VANCOUVER V6T 1X2,BC,CANADA	University of British Columbia; Agriculture & Agri Food Canada									0	83	87	1	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	4					266	269		10.1016/0091-6749(79)90142-8	http://dx.doi.org/10.1016/0091-6749(79)90142-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HQ469	479478				2022-12-18	WOS:A1979HQ46900006
J	KALINER, M				KALINER, M			CHOLINERGIC NERVOUS-SYSTEM AND IMMEDIATE HYPERSENSITIVITY .1. ECCRINE SWEAT RESPONSES IN ALLERGIC PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									USAF,MED CTR,DEPT MED,KEESLER AFB,MS 39534	United States Department of Defense; United States Air Force								Allen JA, 1972, BRIT J PHARMACOL, V47, P487; BOURNE HR, 1972, J IMMUNOL, V108, P695; CHALMERS TM, 1951, J PHYSIOL-LONDON, V114, P510, DOI 10.1113/jphysiol.1951.sp004640; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; Dale HH, 1934, J PHYSIOL-LONDON, V82, P121, DOI 10.1113/jphysiol.1934.sp003166; GIBSON TE, 1948, J INVEST DERMATOL, V11, P137, DOI 10.1038/jid.1948.78; GOLDBERG ND, 1974, CYCLIC AMP CELL GROW, P247; HAIMOVICI H, 1949, J APPL PHYSIOL, V2, P512; JENKINSON DM, 1973, BRIT J DERMATOL, V88, P397, DOI 10.1111/j.1365-2133.1973.tb07573.x; Kahn David, 1942, JOUR INVEST DERMAT, V5, P431; KALINER M, 1973, J EXP MED, V138, P1077, DOI 10.1084/jem.138.5.1077; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; KALINER M, 1974, BIOCHEM PHARMACOL, V23, P763, DOI 10.1016/0006-2952(74)90206-8; KALINER M, 1974, CYCLIC AMP CELL GROW, P163; KARCZEWSKI W, 1969, J PHYSIOL-LONDON, V201, P293, DOI 10.1113/jphysiol.1969.sp008756; Larsell O, 1921, J COMP NEUROL, V33, P105, DOI 10.1002/cne.900330202; LICHTENSTEIN LM, 1971, IMMUNOLOGICAL DISEAS, P825; NADEL J A, 1973, P29; NADEL JA, 1968, ARCH ENVIRON HEALTH, V16, P171, DOI 10.1080/00039896.1968.10665039; ORANGE RP, 1971, FED PROC, V30, P1725; RANDALL WC, 1955, PHARMACOL REV, V7, P365; REED CE, 1974, J ALLERGY CLIN IMMUN, V53, P34, DOI 10.1016/0091-6749(74)90097-9; SATO F, 1974, EXPERIENTIA, V30, P40, DOI 10.1007/BF01921584; SILVER A, 1964, J INVEST DERMATOL, V43, P255, DOI 10.1038/jid.1964.153; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; SONNENSCHEIN RR, 1951, J APPL PHYSIOL, V3, P573, DOI 10.1152/jappl.1951.3.10.573; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; WARNDORF.JA, 1970, BRIT J DERMATOL, V83, P306, DOI 10.1111/j.1365-2133.1970.tb15705.x; WARNDORFF JA, 1974, BRIT J DERMATOL, V90, P263, DOI 10.1111/j.1365-2133.1974.tb06400.x; WIDDICOMBE JG, 1970, ARCH INTERN MED, V126, P311, DOI 10.1001/archinte.126.2.311; YU DYC, 1972, J APPL PHYSIOL, V32, P823, DOI 10.1152/jappl.1972.32.6.823	31	83	83	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	2					308	315		10.1016/0091-6749(76)90136-6	http://dx.doi.org/10.1016/0091-6749(76)90136-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA661	947982				2022-12-18	WOS:A1976CA66100008
J	PENCE, HL; MITCHELL, DQ; GREELY, RL; UPDEGRAFF, BR; SELFRIDGE, HA				PENCE, HL; MITCHELL, DQ; GREELY, RL; UPDEGRAFF, BR; SELFRIDGE, HA			IMMUNOTHERAPY FOR MOUNTAIN CEDAR POLLINOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									USA,DEPT MED,BROOKE MED CTR,SERV ALLERGY,FT SAM HOUSTON,TX 78234; USA,DEPT MED,BROOKE MED CTR,SERV CLIN IMMUNOL & DERMATOL,FT SAM HOUSTON,TX 78234; USAF,WILFORD HALL MED CTR,ALLERGY & CLIN IMMUNOL SERV,LACKLAND AFB,TX	United States Department of Defense; United States Air Force								AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; EVANS R, 1974, J ALLERGY CLIN IMMUN, V53, P114; FEIN BT, 1962, J ALLERGY, V33, P141; FRANKLAND AW, 1954, LANCET, V1, P1055; FRANKLIN W, 1967, JAMA-J AM MED ASSOC, V201, P95; FUJITA Y, 1974, J ALLERGY CLIN IMMUN, V53, P80; Ipsen J., 1970, BANCROFTS INTRO BIOS; IRONS JS, 1975, J ALLERGY CLIN IMMUN, V55, P78; ISHIZAKA T, 1973, J ALLERGY CLIN IMMUN, V51, P79, DOI 10.1016/S0091-6749(73)80005-3; JOHANSSO.SG, 1974, CLIN ALLERGY, V4, P57, DOI 10.1111/j.1365-2222.1974.tb01363.x; JOHANSSON SG, 1974, CLIN ALLERGY, V4, P255, DOI 10.1111/j.1365-2222.1974.tb01383.x; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENS.LM, 1969, AM J MED, V46, P163, DOI 10.1016/0002-9343(69)90001-1; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MELAM H, 1971, J ALLERGY, V47, P262, DOI 10.1016/S0091-6749(71)80004-0; MILLER FF, 1964, J ALLERGY, V35, P7, DOI 10.1016/0021-8707(64)90043-7; NELSON HS, 1975, J ALLERGY CLIN IMMUN, V55, P77; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1969, J ALLERGY, V44, P129, DOI 10.1016/0021-8707(69)90137-3; PRUZANSKY JJ, 1968, J AMER MED ASSOC, V203, P805, DOI 10.1001/jama.203.9.805; REISMAN RE, 1969, J ALLERGY, V44, P82, DOI 10.1016/0021-8707(69)90004-5; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SAMTER M, 1955, REGIONAL ALLERGY US; VERVLOET D, 1974, Clinical Allergy, V4, P359, DOI 10.1111/j.1365-2222.1974.tb01397.x; WIDE L, 1967, LANCET, V2, P1105; YOO TJ, 1974, J ALLERGY CLIN IMMUN, V53, P71	27	83	85	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					39	50		10.1016/0091-6749(76)90105-6	http://dx.doi.org/10.1016/0091-6749(76)90105-6			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX742	780406	Bronze			2022-12-18	WOS:A1976BX74200005
J	de Loos, DD; Lourijsen, ES; Wildeman, MAM; Freling, NJM; Wolvers, MDJ; Reitsma, S; Fokkens, WJ				de Loos, Dirk Dietz; Lourijsen, Evelijn S.; Wildeman, Maarten A. M.; Freling, Nicole J. M.; Wolvers, Marije D. J.; Reitsma, Sietze; Fokkens, Wytske J.			Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; epidemiology; imaging; population	INCIDENTAL ABNORMALITIES; ALLERGIC RHINITIS; PARANASAL SINUSES; NASAL ENDOSCOPY; RISK-FACTORS; SYMPTOMS; HEALTH; EPIDEMIOLOGY; ASSOCIATION; RELIABILITY	Background: The prevalence of chronic rhinosinusitis (CRS) measured in epidemiologic studies is 5% to 12%. This might be an overestimation because of overlap with other diseases, such as allergic rhinitis. Objective: We aimed to calculate the prevalence of CRS using a combination of epidemiologically based CRS according to the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) together with sinonasal opacification on imaging. Methods: Subjects who underwent a computed tomographic or magnetic resonance imaging scan of the head for any nonrhinologic indication were asked to fill in the Global Allergy and Asthma European Network survey containing EPOS symptom criteria. The scans were evaluated according to the Lund-Mackay (LM) scoring system. Epidemiologically based CRS is based on nasal symptoms according to EPOS; clinically based CRS also encompasses endoscopy and/or CT scanning. Results: Eight hundred thirty-four subjects were included. One hundred seven (12.8%) had epidemiologically based CRS according to EPOS. Of these subjects, 50% had an LM score of 0, 26% had an LM score of 1 to 3, and 23% had an LM score of 4 or greater. Twenty-five (3.0%) subjects had clinically based CRS (based on LM score >= 4), and 53 (6.4%) subjects had clinically based CRS (based on LM score > 0). Allergic rhinitis was reported by 167 (20%) subjects. In subjects who did not report upper airway symptoms, 57% had an LM score of 0, 30% had an LM score of 1 to 3, and 12% had an LM score of 4 or greater. Conclusion: We found a prevalence of 3.0% to 6.4% of clinically based CRS (depending on an LM cutoff point; ie, LM > 4 or LM > 0, respectively) in a relatively randomly selected group of subjects.	[de Loos, Dirk Dietz; Lourijsen, Evelijn S.; Wildeman, Maarten A. M.; Wolvers, Marije D. J.; Reitsma, Sietze; Fokkens, Wytske J.] Univ Amsterdam, Amsterdam UMC, Dept Otorhinolaryngol, Room A2-230,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Freling, Nicole J. M.] Univ Amsterdam, Amsterdam UMC, Dept Radiol, Amsterdam, Netherlands	University of Amsterdam; University of Amsterdam	Fokkens, WJ (corresponding author), Univ Amsterdam, Amsterdam UMC, Dept Otorhinolaryngol, Room A2-230,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	w.j.fokkens@amc.nl	Fokkens, Wytske WJ/ABF-2185-2020	Reitsma, Sietze/0000-0003-1734-2632				Ahn JC, 2016, JAMA OTOLARYNGOL, V142, P162, DOI 10.1001/jamaoto.2015.3142; Anand VK, 2004, ANN OTO RHINOL LARYN, V113, P3, DOI 10.1177/00034894041130S502; Ashraf N, 2001, OTOLARYNG HEAD NECK, V125, P483, DOI 10.1016/S0194-5998(01)43777-6; Bhattacharyya N, 2010, OTOLARYNG HEAD NECK, V143, P147, DOI 10.1016/j.otohns.2010.04.012; Biino G, 2000, J Outcome Meas, V4, P740; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Brook CD, 2017, AM J RHINOL ALLERGY, V31, P12, DOI 10.2500/ajra.2017.31.4394; Canova C, 2012, RESP MED, V106, P1226, DOI 10.1016/j.rmed.2012.05.008; Cole M, 2018, ALLERGY, V73, P1715, DOI 10.1111/all.13470; COOKE LD, 1991, J LARYNGOL OTOL, V105, P278, DOI 10.1017/S0022215100115609; Pilan RRD, 2012, RHINOLOGY, V50, P129, DOI [10.4193/Rhino11.256, 10.4193/Rhin11.256]; FLINN J, 1994, CLIN OTOLARYNGOL, V19, P287, DOI 10.1111/j.1365-2273.1994.tb01232.x; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Grassi M, 2003, J CLIN EPIDEMIOL, V56, P238, DOI 10.1016/S0895-4356(02)00613-3; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; Hastan D, 2011, ALLERGY, V66, P1216, DOI 10.1111/j.1398-9995.2011.02646.x; HAVAS TE, 1988, ARCH OTOLARYNGOL, V114, P856; Hirsch AG, 2017, ALLERGY, V72, P274, DOI 10.1111/all.13042; Hoffmans R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192330; Kanagalingam J, 2009, LARYNGOSCOPE, V119, P8, DOI 10.1002/lary.20037; Kim JH, 2016, RHINOLOGY, V54, P329, DOI [10.4193/Rhin15.157, 10.4193/Rhino15.157]; Leipzig JR, 1996, J ALLERGY CLIN IMMUN, V98, P1130, DOI 10.1016/S0091-6749(96)80206-5; Lin HW, 2009, AM J RHINOL ALLERGY, V23, P36, DOI 10.2500/ajra.2009.23.3260; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; Makowska JS, 2016, ALLERGY, V71, P1603, DOI 10.1111/all.12941; Pavord ID, 2018, LANCET, V391, P350, DOI 10.1016/S0140-6736(17)30879-6; Shi JB, 2015, ALLERGY, V70, P533, DOI 10.1111/all.12577; Soler ZM, 2011, LARYNGOSCOPE, V121, P656, DOI 10.1002/lary.21392; Stankiewicz JA, 2002, OTOLARYNG HEAD NECK, V126, P623, DOI 10.1067/mhn.2002.125602; Statistics Netherlands (CBS), POP BY AG; Tahamiler R, 2007, ALLERGY, V62, P1029, DOI 10.1111/j.1398-9995.2007.01397.x; Teeter JG, 1998, CHEST, V113, P272, DOI 10.1378/chest.113.2.272; Toma S, 2016, RHINOLOGY, V54, P129, DOI [10.4193/Rhino15.072, 10.4193/Rhin15.072]; Tomassen P, 2011, ALLERGY, V66, P556, DOI 10.1111/j.1398-9995.2010.02503.x; Vallo J, 2010, ORAL SURG ORAL MED O, V109, pE80, DOI 10.1016/j.tripleo.2009.10.031; Vermeulen F, 2017, J ASTHMA, V54, P570, DOI 10.1080/02770903.2016.1242138; Wilson KF, 2014, INT FORUM ALLERGY RH, V4, P93, DOI 10.1002/alr.21258; Zhang L, 2017, RHINOLOGY, V55, P363, DOI [10.4193/Rhino17.109, 10.4193/Rhin17.109]; Zheng YB, 2010, AM J RHINOL ALLERGY, V24, pE41, DOI 10.2500/ajra.2010.24.3430	39	82	84	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1207	1214		10.1016/j.jaci.2018.12.986	http://dx.doi.org/10.1016/j.jaci.2018.12.986			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30578880	Bronze			2022-12-18	WOS:000460272900040
J	Ghebre, MA; Pang, PH; Diver, S; Desai, D; Bafadhel, M; Haldar, K; Kebadze, T; Cohen, S; Newbold, P; Rapley, L; Woods, J; Rugman, P; Pavord, ID; Johnston, SL; Barer, M; May, RD; Brightling, CE				Ghebre, Michael A.; Pang, Pee Hwee; Diver, Sarah; Desai, Dhananjay; Bafadhel, Mona; Haldar, Koirobi; Kebadze, Tatiana; Cohen, Suzanne; Newbold, Paul; Rapley, Laura; Woods, Joanne; Rugman, Paul; Pavord, Ian D.; Johnston, Sebastian L.; Barer, Michael; May, Richard D.; Brightling, Christopher E.			Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; chronic obstructive pulmonary disease; asthma and chronic obstructive pulmonary disease heterogeneity; inflammatory profiles; microbiome abundances; phylum and genus levels; factor and cluster analyses	PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; SEVERE EOSINOPHILIC ASTHMA; CONTROLLED PHASE-3 TRIAL; DOUBLE-BLIND; RHINOVIRUS INFECTION; SPUTUM EOSINOPHILIA; COPD; AZITHROMYCIN; MEPOLIZUMAB	Background: Exacerbations of asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous. Objective: We sought to investigate the sputum cellular, mediator, and microbiome profiles of both asthma and COPD exacerbations. Methods: Patients with severe asthma or moderate-to-severe COPD were recruited prospectively to a single center. Sputum mediators were available in 32 asthmatic patients and 73 patients with COPD assessed at exacerbation. Biologic clusters were determined by using factor and cluster analyses on a panel of sputum mediators. Patterns of clinical parameters, sputum mediators, and microbiome communities were assessed across the identified clusters. Results: The asthmatic patients and patients with COPD had different clinical characteristics and inflammatory profiles but similar microbial ecology. Three exacerbation biologic clusters were identified. Cluster 1 was COPD predominant, with 27 patients with COPD and 7 asthmatic patients exhibiting increased blood and sputum neutrophil counts, proinflammatory mediators (IL-1 beta, IL-6, IL-6 receptor, TNF-alpha, TNF receptors 1 and 2, and vascular endothelial growth factor), and proportions of the bacterial phylum Proteobacteria. Cluster 2 had 10 asthmatic patients and 17 patients with COPD with increased blood and sputum eosinophil counts, type 2 mediators (IL-5, IL-13, CCL13, CCL17, and CCL26), and proportions of the bacterial phylum Bacteroidetes. Cluster 3 had 15 asthmatic patients and 29 patients with COPD with increased type 1 mediators (CXCL10, CXCL11, and IFN-gamma) and proportions of the phyla Actinobacteria and Firmicutes. Conclusions: A biologic clustering approach revealed 3 subgroups of asthma and COPD exacerbations, each with different percentages of patients with overlapping asthma and COPD. The sputum mediator and microbiome profiles were distinct between clusters.	[Ghebre, Michael A.; Diver, Sarah; Desai, Dhananjay; Haldar, Koirobi; Barer, Michael; Brightling, Christopher E.] Univ Leicester, Inst Lung Hlth, NIHR Leicester Biomed Res Ctr, Dept Infect Immun & Inflammat, Leicester, Leics, England; [Ghebre, Michael A.; Diver, Sarah; Desai, Dhananjay; Haldar, Koirobi; Barer, Michael; Brightling, Christopher E.] Univ Hosp Leicester NHS Trust, Leicester, Leics, England; [Pang, Pee Hwee] Tan Tock Seng Hosp, Dept Resp & Crit Care Med, Singapore, Singapore; [Bafadhel, Mona; Pavord, Ian D.] Univ Oxford, Resp Med Unit, Nuffield Dept Med, NDM Res Bldg,Old Rd Campus, Oxford, England; [Kebadze, Tatiana; Johnston, Sebastian L.] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Kebadze, Tatiana; Johnston, Sebastian L.] Imperial Coll London, MRC, London, England; [Kebadze, Tatiana; Johnston, Sebastian L.] Imperial Coll London, Asthma UK Ctr Allerg Mech Asthma, London, England; [Cohen, Suzanne; Newbold, Paul; Rapley, Laura; Woods, Joanne; Rugman, Paul; May, Richard D.] MedImmune, Cambridge, England	University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; Tan Tock Seng Hospital; University of Oxford; Imperial College London; Imperial College London; Imperial College London; University of London; King's College London; AstraZeneca; Medimmune	Brightling, CE (corresponding author), Univ Hosp Leicester, Inst Lung Hlth, Groby Rd, Leicester LE3 9QP, Leics, England.	ceb17@le.ac.uk	haldar, kairabi/HDO-4827-2022; Bafadhel, Mona/ABB-1170-2021; Ghebre, Michael A/K-5958-2013; Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200; Pang, Pee Hwee/0000-0002-0027-5026; Barer, Michael/0000-0002-0377-3100; May, Richard/0000-0001-7825-2716; brightling, chris/0000-0002-9345-4903	MedImmune; Wellcome Trust; European Regional Development Fund [ERDF 05567]; Medical Research Council; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, United Kingdom; AirPROM [FP7-270194]; Asthma UK Clinical Chair [CH11SJ]; MRC [G1000758]; MRC [G0601369, G0801980] Funding Source: UKRI; Medical Research Council [G1000758] Funding Source: researchfish	MedImmune(AstraZenecaMedimmune); Wellcome Trust(Wellcome Trust); European Regional Development Fund(European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, United Kingdom; AirPROM; Asthma UK Clinical Chair; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by MedImmune and a Wellcome Trust Senior Fellowship (to C.E.B.). The research was performed in laboratories funded in part by the European Regional Development Fund (ERDF 05567). This study was also part supported by the Medical Research Council; the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, United Kingdom; and AirPROM (FP7-270194). S.L.J. was supported by the Asthma UK Clinical Chair (CH11SJ) and an MRC Centre grant (no. G1000758). The views expressed are those of the author or authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health.	Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623; [Anonymous], 2017, GLOB STRAT ASTHM MAN; Bafadhel M, 2012, RESPIRATION, V83, P36, DOI 10.1159/000330667; Bafadhel M, 2012, AM J RESP CRIT CARE, V186, P48, DOI 10.1164/rccm.201108-1553OC; Bafadhel M, 2011, AM J RESP CRIT CARE, V184, P662, DOI 10.1164/rccm.201104-0597OC; Bjermer L, 2016, CHEST, V150, P789, DOI 10.1016/j.chest.2016.03.032; Bleecker ER, 2016, LANCET, V388, P2115, DOI 10.1016/S0140-6736(16)31324-1; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; Brightling CE, 2014, LANCET RESP MED, V2, P891, DOI 10.1016/S2213-2600(14)70187-0; Brusselle GG, 2013, THORAX, V68, P322, DOI 10.1136/thoraxjnl-2012-202698; Burgel PR, 2010, EUR RESPIR J, V36, P531, DOI 10.1183/09031936.00175109; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]; Corren J, 2016, CHEST, V150, P799, DOI 10.1016/j.chest.2016.03.018; Dasgupta A, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02486-2016; Desai D, 2013, AM J RESP CRIT CARE, V188, P657, DOI 10.1164/rccm.201208-1470OC; FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]; Ghebre MA, 2015, J ALLERGY CLIN IMMUN, V135, P63, DOI 10.1016/j.jaci.2014.06.035; Gibson PG, 2017, LANCET, V390, P659, DOI 10.1016/S0140-6736(17)31281-3; Global Initiative for Chronic Obstructive Lung Disease, 2020, GLOBAL STRATEGY DIAG; Haldar K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182833; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Johnston SL, 2016, JAMA INTERN MED, V176, P1630, DOI 10.1001/jamainternmed.2016.5664; Johnston SL, 2006, NEW ENGL J MED, V354, P1589, DOI 10.1056/NEJMoa044080; Mallia P, 2011, AM J RESP CRIT CARE, V183, P734, DOI 10.1164/rccm.201006-0833OC; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Nouira S, 2001, LANCET, V358, P2020, DOI 10.1016/S0140-6736(01)07097-0; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Pavord ID, 2017, NEW ENGL J MED, V377, P1613, DOI 10.1056/NEJMoa1708208; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Quint JK, 2010, CHEST, V137, P812, DOI 10.1378/chest.09-1541; Seemungal TAR, 2008, AM J RESP CRIT CARE, V178, P1139, DOI 10.1164/rccm.200801-145OC; Siroux V, 2011, EUR RESPIR J, V38, P310, DOI 10.1183/09031936.00120810; Siva R, 2007, EUR RESPIR J, V29, P906, DOI 10.1183/09031936.00146306; Vollenweider DJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010257; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31678-6, 10.1016/S0140-6736(16)31012-1]; Wang Z, 2018, THORAX, V73, P331, DOI 10.1136/thoraxjnl-2017-210741; Wang Z, 2016, EUR RESPIR J, V47, P1082, DOI 10.1183/13993003.01406-2015; Wark PAB, 2007, J ALLERGY CLIN IMMUN, V120, P586, DOI 10.1016/j.jaci.2007.04.046	40	82	84	2	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2027	+		10.1016/j.jaci.2018.04.013	http://dx.doi.org/10.1016/j.jaci.2018.04.013			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29709671	Green Published, hybrid			2022-12-18	WOS:000434701600010
J	Paternoster, L; Savenije, OEM; Heron, J; Evans, DM; Vonk, JM; Brunekreef, B; Wijga, AH; Henderson, AJ; Koppelman, GH; Brown, SJ				Paternoster, Lavinia; Savenije, Olga E. M.; Heron, Jon; Evans, David M.; Vonk, Judith M.; Brunekreef, Bert; Wijga, Alet H.; Henderson, A. John; Koppelman, Gerard H.; Brown, Sara J.			Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; eczema; environmental; genetic; latent class analysis; PIAMA; ALSPAC	GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; FILAGGRIN MUTATIONS; NULL MUTATIONS; CAT EXPOSURE; RISK-FACTORS; ECZEMA; POPULATION; ASTHMA; PREVALENCE	Background: Atopic dermatitis (AD) is a prevalent disease with variable natural history. Longitudinal birth cohort studies provide an opportunity to define subgroups on the basis of disease trajectories, which may represent different genetic and environmental pathomechanisms. Objectives: We sought to investigate the existence of distinct longitudinal phenotypes of AD and test whether these findings are reproducible in 2 independent cohorts. Methods: The presence of AD was examined in 2 birth cohort studies including 9894 children from the United Kingdom (ALSPAC) and 3652 from the Netherlands (PIAMA). AD was defined by parental report of a typical itchy and/or flexural rash. Longitudinal latent class analysis was used to investigate patterns of AD from birth to the age of 11 to 16 years. We investigated associations with known AD risk factors, including FLG null mutations, 23 other established AD-genetic risk variants, and atopic comorbidity. Results: Six latent classes were identified, representing subphenotypes of AD, with remarkable consistency between the 2 cohorts. The most prevalent class was early-onset-early-resolving AD, which was associated with male sex. Two classes of persistent disease were identified (early-onset-persistent and early-onset-late-resolving); these were most strongly associated with the AD-genetic risk score as well as personal and parental history of atopic disease. A yet unrecognized class of mid-onset-resolving AD, not associated with FLG mutations, but strongly associated with asthma, was identified. Conclusions: Six classes based on temporal trajectories of rash were consistently identified in 2 population-based cohorts. The differing risk factor profiles and diverse prognoses demonstrate the potential importance of a stratified medicine approach for AD.	[Paternoster, Lavinia; Evans, David M.] Univ Bristol, Sch Social & Community Med, Integrat Epidemiol Unit, MRC, Bristol, Avon, England; [Savenije, Olga E. M.; Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Paediat Pulmonol & Paediat Allergol, Groningen, Netherlands; [Savenije, Olga E. M.; Vonk, Judith M.; Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma, Groningen, Netherlands; [Heron, Jon; Henderson, A. John] COPD, Groningen, Netherlands; [Heron, Jon; Henderson, A. John] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England; [Evans, David M.] Univ Queensland, Diamantina Inst, Princess Alexandra Hosp, Translat Res Inst, Brisbane, Qld, Australia; [Vonk, Judith M.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [Brunekreef, Bert] Utrech Univ, Inst Risk Assessment Sci, Utrecht, Netherlands; [Brunekreef, Bert] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Wijga, Alet H.] Ctr Nutr Prevent & Hlth Serv, Natl Inst Publ Hlth & Environm, Bilthoven, Netherlands; [Brown, Sara J.] Univ Dundee, Sch Med, Skin Res Grp, Dundee, Scotland; [Brown, Sara J.] Ninewells Hosp, Dept Dermatol, Dundee, Scotland	University of Bristol; University of Groningen; University of Groningen; University of Bristol; University of Queensland; University of Groningen; Utrecht University; Utrecht University; Utrecht University Medical Center; Netherlands National Institute for Public Health & the Environment; University of Dundee; University of Dundee	Paternoster, L (corresponding author), Univ Bristol, Bristol Med Sch, Integrat Epidemiol Unit, MRC, Oakfield House, Bristol BS8 2BN, Avon, England.	l.paternoster@bristol.ac.uk	Vonk, Judith/K-8477-2019; Heron, Jon/D-5884-2011; Koppelman, Gerard/AAG-9187-2020; Evans, David M/H-6325-2013; Vonk, Judith M/ABA-3009-2020; Paternoster, Lavinia/C-1292-2015	Vonk, Judith/0000-0001-7531-4547; Heron, Jon/0000-0001-6199-5644; Evans, David M/0000-0003-0663-4621; Vonk, Judith M/0000-0001-7531-4547; Koppelman, Gerard/0000-0001-8567-3252; Paternoster, Lavinia/0000-0003-2514-0889	UK Medical Research Council [MR/J012165/1]; Medical Research Council; University of Bristol [MC_UU_12013/4]; Australian Research Council [FT130101709]; Wellcome Trust Senior Research Fellowship in Clinical Science [106865/Z/15/Z]; Wellcome Trust [102215/2/13/2]; Netherlands Organization for Health Research and Development; Netherlands Organization for Scientific Research; Lung Function of the Netherlands; Netherlands Ministry of Spatial Planning, Housing, and the Environment; Netherlands Ministry of Health, Welfare, and Sport; Medical Research Council [MR/J012165/1, MC_UU_12013/4, G9815508, MC_PC_15018] Funding Source: researchfish; MRC [MR/J012165/1, MC_UU_12013/4] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University of Bristol; Australian Research Council(Australian Research Council); Wellcome Trust Senior Research Fellowship in Clinical Science(Wellcome Trust); Wellcome Trust(Wellcome Trust); Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Lung Function of the Netherlands(Netherlands Government); Netherlands Ministry of Spatial Planning, Housing, and the Environment; Netherlands Ministry of Health, Welfare, and Sport; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work and L.P. were supported by a UK Medical Research Council Fellowship (MR/J012165/1). L.P. and D.M.E. work in the Medical Research Council Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council and the University of Bristol (MC_UU_12013/4) . D.M.E. is supported by an Australian Research Council Future Fellowship (FT130101709). S.J.B. holds a Wellcome Trust Senior Research Fellowship in Clinical Science (106865/Z/15/Z). The UK Medical Research Council and the Wellcome Trust (grant reference 102215/2/13/2) and the University of Bristol provide core support for the Avon Longitudinal Study of Parents and Children. The Prevention and Incidence of Asthma and Mite Allergy birth cohort was funded by the Netherlands Organization for Health Research and Development, the Netherlands Organization for Scientific Research, the Lung Function of the Netherlands, the Netherlands Ministry of Spatial Planning, Housing, and the Environment, and the Netherlands Ministry of Health, Welfare, and Sport.	Belgrave DCM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001748; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Boyd A, 2013, INT J EPIDEMIOL, V42, P111, DOI 10.1093/ije/dys064; Brown SJ, 2008, J ALLERGY CLIN IMMUN, V121, P940, DOI 10.1016/j.jaci.2008.01.013; Brown SJ, 2008, J INVEST DERMATOL, V128, P1591, DOI 10.1038/sj.jid.5701206; Dirven-Meijer PC, 2008, BRIT J DERMATOL, V158, P846, DOI 10.1111/j.1365-2133.2007.08407.x; Ellinghaus D, 2013, NAT GENET, V45, P808, DOI 10.1038/ng.2642; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Garcia-Aymerich J, 2015, ALLERGY, V70, P973, DOI 10.1111/all.12640; Govaere E, 2009, PEDIATR DERMATOL, V26, P129, DOI 10.1111/j.1525-1470.2008.00801.x; Granell R, 2016, J ALLERGY CLIN IMMUN, V138, P1060, DOI 10.1016/j.jaci.2016.01.046; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Heron J, 2015, LONGITUD LIFE COURSE, V6, P420, DOI 10.14301/llcs.v6i4.322; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Ip Stanley, 2007, Evid Rep Technol Assess (Full Rep), P1; Johansson EK, 2015, BRIT J DERMATOL, V173, P962, DOI 10.1111/bjd.13901; Kim JP, 2016, J AM ACAD DERMATOL, V75, P681, DOI 10.1016/j.jaad.2016.05.028; Koppelman GH, 2017, AM J RESP CRIT CARE, V195, P545, DOI 10.1164/rccm.201610-1982ED; Moore MM, 2004, PEDIATRICS, V113, P468, DOI 10.1542/peds.113.3.468; Mortz CG, 2015, ALLERGY, V70, P836, DOI 10.1111/all.12619; Munafo M, 2008, NICOTINE TOB RES, V10, P1609, DOI 10.1080/14622200802412895; Muthen L., 2017, STAT ANAL LATENT VAR, V8th; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Purvis DJ, 2005, BRIT J DERMATOL, V152, P742, DOI 10.1111/j.1365-2133.2005.06540.x; Schuttelaar MLA, 2009, ALLERGY, V64, P1758, DOI 10.1111/j.1398-9995.2009.02080.x; Sun LD, 2011, NAT GENET, V43, P690, DOI 10.1038/ng.851; Weidinger S, 2013, HUM MOL GENET, V22, P4841, DOI 10.1093/hmg/ddt317; Wen HJ, 2009, BRIT J DERMATOL, V161, P1166, DOI 10.1111/j.1365-2133.2009.09412.x; Wijga AH, 2014, INT J EPIDEMIOL, V43, P527, DOI 10.1093/ije/dys231; Williams HC, 2005, NEW ENGL J MED, V352, P2314, DOI 10.1056/NEJMcp042803	32	82	84	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					964	971		10.1016/j.jaci.2017.09.044	http://dx.doi.org/10.1016/j.jaci.2017.09.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29129583	Green Published, hybrid			2022-12-18	WOS:000426974800016
J	Li, SL; Zhu, GN; Yang, YQ; Jian, Z; Guo, S; Dai, W; Shi, Q; Ge, R; Ma, JJ; Liu, L; Li, K; Luan, Q; Wang, G; Gao, TW; Li, CY				Li, Shuli; Zhu, Guannan; Yang, Yuqi; Jian, Zhe; Guo, Sen; Dai, Wei; Shi, Qiong; Ge, Rui; Ma, Jingjing; Liu, Ling; Li, Kai; Luan, Qi; Wang, Gang; Gao, Tianwen; Li, Chunying			Oxidative stress drives CD8(+) T-cell skin trafficking in patients with vitiligo through CXCL16 upregulation by activating the unfolded protein response in keratinocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Oxidative stress; unfolded protein response; CXCL16; CXCR6; CD8(+) T cells; skin migration	HUMAN-MELANOMA CELLS; ENDOPLASMIC-RETICULUM; AUTOIMMUNE VITILIGO; GENERALIZED VITILIGO; RHEUMATOID-ARTHRITIS; HYDROGEN-PEROXIDE; HUMAN MELANOCYTES; CHEMOKINE CXCL16; IMMUNE-RESPONSE; MOUSE MODEL	Background: In patients with vitiligo, an increased reactive oxygen species (ROS) level has been proved to be a key player during disease initiation and progression in melanocytes. Nevertheless, little is known about the effects of ROS on other cells involved in the aberrant microenvironment, such as keratinocytes and the following immune events. CXCL16 is constitutively expressed in keratinocytes and was recently found to mediate homing of CD8(+) T cells in human skin. Objective: We sought to explicate the effect of oxidative stress on human keratinocytes and its capacity to drive CD8(+) T-cell trafficking through CXCL16 regulation. Methods: We first detected putative T-cell skin-homing chemokines and ROS in serum and lesions of patients with vitiligo. The production of candidate chemokines was detected by using quantitative real-time PCR and ELISA in keratinocytes exposed to H2O2. Furthermore, the involved mediators were analyzed by using quantitative real-time PCR, Western blotting, ELISA, and immunofluorescence. Next, we tested the chemotactic migration of CD8(+) T cells from patients with vitiligo mediated by the CXCL16-CXCR6 pair using the transwell assay. Results: CXCL16 expression increased and showed a positive correlation with oxidative stress levels in serum and lesions of patients with vitiligo. The H2O2-induced CXCL16 expression was due to the activation of 2 unfolded protein response pathways: kinase RNA (PKR)-like ER kinase-eukaryotic initiation factor 2 alpha and inositol-requiring enzyme 1 alpha-X-box binding protein 1. CXCL16 produced by stressed keratinocytes induced migration of CXCR6+ CD8+ T cells derived from patients with vitiligo. CXCR6+ CD8+ T-cell skin infiltration is accompanied by melanocyte loss in lesions of patients with vitiligo. Conclusion: Our study demonstrated that CXCL16-CXCR6 mediates CD8+ T-cell skin trafficking under oxidative stress in patients with vitiligo. The CXCL16 expression in human keratinocytes induced by ROS is, at least in part, caused by unfolded protein response activation.	[Li, Shuli; Zhu, Guannan; Yang, Yuqi; Jian, Zhe; Guo, Sen; Dai, Wei; Shi, Qiong; Ge, Rui; Ma, Jingjing; Liu, Ling; Li, Kai; Luan, Qi; Wang, Gang; Gao, Tianwen; Li, Chunying] Fourth Mil Med Univ, Xijing Hosp, Dept Dermatol, 127 West Changle Rd, Xian 710032, Shaanxi, Peoples R China	Air Force Military Medical University	Li, CY (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Dermatol, 127 West Changle Rd, Xian 710032, Shaanxi, Peoples R China.	lichying@fmmu.edu.cn	guo, sen/GWQ-3573-2022; Ge, Rui/HHC-4312-2022; Wang, Gang/H-6710-2019; Jian, Zhe/AAJ-7339-2020	Wang, Gang/0000-0002-5842-8080	National Natural Science Foundation of China [81472863, 81130032, 81402599, 81472893]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Supported by the National Natural Science Foundation of China (nos. 81472863, 81130032, 81402599, and 81472893).	ALBADRI AMT, 1993, J PATHOL, V170, P149, DOI 10.1002/path.1711700209; Birlea SA, 2011, J INVEST DERMATOL, V131, P371, DOI 10.1038/jid.2010.337; BOISSY RE, 1991, J INVEST DERMATOL, V97, P395, DOI 10.1111/1523-1747.ep12480976; Bromley SK, 2008, NAT IMMUNOL, V9, P970, DOI 10.1038/ni.f.213; Dell'Anna ML, 2007, J INVEST DERMATOL, V127, P1226, DOI 10.1038/sj.jid.5700700; Denat L, 2014, J INVEST DERMATOL, V134, P1512, DOI 10.1038/jid.2014.65; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Denman CJ, 2008, J INVEST DERMATOL, V128, P2041, DOI 10.1038/jid.2008.45; Giustizieri ML, 2004, J ALLERGY CLIN IMMUN, V114, P1176, DOI 10.1016/j.jaci.2004.07.054; Glassman SJ, 2011, CLIN SCI, V120, P99, DOI 10.1042/CS20090603; Gregg RK, 2010, J IMMUNOL, V184, P1909, DOI 10.4049/jimmunol.0902778; Gunther C, 2012, J INVEST DERMATOL, V132, P626, DOI 10.1038/jid.2011.371; Harris JE, 2012, J INVEST DERMATOL, V132, P1869, DOI 10.1038/jid.2011.463; Hattermann K, 2014, ONCOL REP, V32, P270, DOI 10.3892/or.2014.3214; Huang Y, 2008, J IMMUNOL, V180, P2367, DOI 10.4049/jimmunol.180.4.2367; IM S, 1994, INT J DERMATOL, V33, P556, DOI 10.1111/j.1365-4362.1994.tb02895.x; Jian Z, 2014, J INVEST DERMATOL, V134, P2221, DOI 10.1038/jid.2014.152; Jian Z, 2011, J INVEST DERMATOL, V131, P1420, DOI 10.1038/jid.2011.56; Jiang CC, 2009, CARCINOGENESIS, V30, P197, DOI 10.1093/carcin/bgn220; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021; Kim CH, 2001, J CLIN INVEST, V107, P595, DOI 10.1172/JCI11902; Koca R, 2004, CLIN EXP DERMATOL, V29, P406, DOI 10.1111/j.1365-2230.2004.01524.x; Kroll TM, 2005, J INVEST DERMATOL, V124, P798, DOI 10.1111/j.0022-202X.2005.23653.x; Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310; Laddha NC, 2013, EXP DERMATOL, V22, P245, DOI 10.1111/exd.12103; Lee AY, 2012, ANN DERMATOL, V24, P115, DOI 10.5021/ad.2012.24.2.115; Luan Q, 2015, AUTOPHAGY, V11, P975, DOI 10.1080/15548627.2015.1049800; Mosenson JA, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12208; Mosenson JA, 2012, PIGM CELL MELANOMA R, V25, P88, DOI 10.1111/j.1755-148X.2011.00916.x; Ogg GS, 1998, J EXP MED, V188, P1203, DOI 10.1084/jem.188.6.1203; ORTONNE JP, 1993, PIGM CELL RES, V6, P61, DOI 10.1111/j.1600-0749.1993.tb00584.x; Pelle E, 2005, J INVEST DERMATOL, V124, P793, DOI 10.1111/j.0022-202X.2005.23661.x; Pfaffenbach KT, 2010, J NUTR, V140, P879, DOI 10.3945/jn.109.119883; Rashighi M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007811; Ren YQ, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000523; Richmond JM, 2013, CURR OPIN IMMUNOL, V25, P676, DOI 10.1016/j.coi.2013.10.010; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Ruth JH, 2006, ARTHRITIS RHEUM-US, V54, P765, DOI 10.1002/art.21662; Schallreuter KU, 1999, J INVEST DERM SYMP P, V4, P91, DOI 10.1038/sj.jidsp.5640189; Scholz F, 2007, J INVEST DERMATOL, V127, P1444, DOI 10.1038/sj.jid.5700751; Shalbaf M, 2008, EXP DERMATOL, V17, P761, DOI 10.1111/j.1600-0625.2008.00697.x; Shi Q, 2016, CELL DEATH DIFFER, V23, P496, DOI 10.1038/cdd.2015.117; Sugiura K, 2013, J DERMATOL SCI, V69, P181, DOI 10.1016/j.jdermsci.2012.12.002; Thomas SY, 2003, J IMMUNOL, V171, P2571, DOI 10.4049/jimmunol.171.5.2571; Tohyama M, 2007, INT IMMUNOL, V19, P1095, DOI 10.1093/intimm/dxm083; Toosi S, 2012, J INVEST DERMATOL, V132, P2601, DOI 10.1038/jid.2012.181; Unutmaz D, 2000, J IMMUNOL, V165, P3284, DOI 10.4049/jimmunol.165.6.3284; van den Boorn JG, 2009, J INVEST DERMATOL, V129, P2220, DOI 10.1038/jid.2009.32; van den Wijngaard R, 2000, LAB INVEST, V80, P1299, DOI 10.1038/labinvest.3780138; van Lieshout AWT, 2009, ANN RHEUM DIS, V68, P1036, DOI 10.1136/ard.2007.086611; Volkmann K, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.199737; Wankowicz-Kalinska A, 2003, LAB INVEST, V83, P683, DOI 10.1097/01.LAB.0000069521.42488.1B; Wilbanks A, 2001, J IMMUNOL, V166, P5145, DOI 10.4049/jimmunol.166.8.5145; Xie H, 2016, J DERMATOL SCI, V81, P3, DOI 10.1016/j.jdermsci.2015.09.003; Zhang YJ, 2014, J INVEST DERMATOL, V134, P183, DOI 10.1038/jid.2013.268	56	82	89	3	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					177	+		10.1016/j.jaci.2016.10.013	http://dx.doi.org/10.1016/j.jaci.2016.10.013			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	27826097	hybrid			2022-12-18	WOS:000404542000018
J	Marquardt, N; Kekalainen, E; Chen, P; Kvedaraite, E; Wilson, JN; Ivarsson, MA; Mjosberg, J; Berglin, L; Safholm, J; Manson, ML; Adner, M; Al-Ameri, M; Bergman, P; Orre, AC; Svensson, M; Dahlen, B; Dahlen, SE; Ljunggren, HG; Michaelsson, J				Marquardt, Nicole; Kekalainen, Eliisa; Chen, Puran; Kvedaraite, Egle; Wilson, Jennifer N.; Ivarsson, Martin A.; Mjosberg, Jenny; Berglin, Lena; Safholm, Jesper; Manson, Martijn L.; Adner, Mikael; Al-Ameri, Mamdoh; Bergman, Per; Orre, Ann-Charlotte; Svensson, Mattias; Dahlen, Barbro; Dahlen, Sven-Erik; Ljunggren, Hans-Gustaf; Michaelsson, Jakob			Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69(-)CD56(dim) cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Natural killer cells; innate lymphoid cells; lung; differentiation; killer cell immunoglobulin-like receptor; CD69; tissue residency	INNATE LYMPHOID-CELLS; MHC CLASS-I; NK CELLS; INHIBITORY RECEPTORS; EXPRESSION; INFECTION; INFLAMMATION; EDUCATION; PHENOTYPE; SUBSETS	Background: In contrast to the extensive knowledge about human natural killer (NK) cells in peripheral blood, relatively little is known about NK cells in the human lung. Knowledge about the composition, differentiation, and function of human lung NK cells is critical to better understand their role in diseases affecting the lung, including asthma, chronic obstructive pulmonary disease, infections, and cancer. Objective: We sought to analyze and compare the phenotypic and functional characteristics of NK cells in the human lung and peripheral blood at the single-cell level. Methods: NK cells in human lung tissue and matched peripheral blood from 132 subjects were analyzed by using 16-color flow cytometry and confocal microscopy. Results: CD56(dim)CD16(+) NK cells made up the vast majority of NK cells in human lungs, had a more differentiated phenotype, and more frequently expressed educating killer cell immunoglobulin-like receptors compared with NK cells in peripheral blood. Despite this, human lung NK cells were hyporesponsive toward target cell stimulation, even after priming with IFN-alpha. Furthermore, we detected a small subset of NK cells expressing CD69, a marker of tissue residency. These CD69(+) NK cells in the lung consisted predominantly of immature CD56(bright)CD16(-) NK cells and less differentiated CD56(dim)CD16(+) NK cells. Conclusion: Here, we characterize the major NK cell populations in the human lung. Our data suggest a model in which the majority of NK cells in the human lung dynamically move between blood and the lung rather than residing in the lung as bona fide tissue-resident CD69(+) NK cells.	[Marquardt, Nicole; Kekalainen, Eliisa; Chen, Puran; Kvedaraite, Egle; Wilson, Jennifer N.; Ivarsson, Martin A.; Mjosberg, Jenny; Berglin, Lena; Svensson, Mattias; Ljunggren, Hans-Gustaf; Michaelsson, Jakob] Karolinska Inst, Karolinska Univ Hosp, Ctr Infect Med, Dept Med, Stockholm, Sweden; [Al-Ameri, Mamdoh; Bergman, Per; Orre, Ann-Charlotte] Karolinska Inst, Karolinska Univ Hosp, Thorac Surg, Dept Mol Med & Surg, Stockholm, Sweden; [Safholm, Jesper; Manson, Martijn L.; Adner, Mikael; Dahlen, Barbro; Dahlen, Sven-Erik] Karolinska Inst, Inst Environm Med, Unit Expt Asthma & Allergy Res, Ctr Allergy Res, Stockholm, Sweden; [Manson, Martijn L.] AstraZeneca R&D, Innovat Med, RIA, Gothenburg, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; AstraZeneca	Michaelsson, J (corresponding author), Karolinska Inst, Karolinska Univ Hosp, Ctr Infect Med, S-14186 Stockholm, Sweden.	jakob.michaelsson@ki.se	Manson, Martijn L/AAE-8606-2019; , eliisa.kekalainen@helsinki.fi/G-6140-2010; Ivarsson, Martin/AAE-2406-2020; Kvedaraite, Egle/AAA-5257-2021; /K-2942-2013; Manson, Martijn/GQI-3438-2022	Manson, Martijn L/0000-0002-5508-8615; , eliisa.kekalainen@helsinki.fi/0000-0001-6045-108X; Ivarsson, Martin/0000-0002-7745-1331; /0000-0003-3186-4752; Wilson, Jennifer/0000-0003-4599-0311; Mjosberg, Jenny/0000-0002-1119-0976	Swedish Medical Research Council; Strategic Research Foundation; Swedish Cancer Society; German Research Foundation [MA-5449/1-1]; Swedish Heart-Lung Foundation; Stockholm County Research Funds (ALF); Karolinska Institutet Foundations; AZ Translational Medicine unconditional grant for the ChAMP project	Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Strategic Research Foundation; Swedish Cancer Society(Swedish Cancer Society); German Research Foundation(German Research Foundation (DFG)); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Stockholm County Research Funds (ALF); Karolinska Institutet Foundations(Karolinska Institutet); AZ Translational Medicine unconditional grant for the ChAMP project	Supported by the Swedish Medical Research Council, the Strategic Research Foundation, the Swedish Cancer Society, the German Research Foundation (Grant MA-5449/1-1), the Swedish Heart-Lung Foundation, the Stockholm County Research Funds (ALF), the Karolinska Institutet Foundations, and the AZ Translational Medicine unconditional grant for the ChAMP project.	Allende ML, 2010, J EXP MED, V207, P1113, DOI 10.1084/jem.20092210; Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Bjorkstrom NK, 2016, NAT REV IMMUNOL, V16, P310, DOI 10.1038/nri.2016.34; Bjorkstrom NK, 2010, BLOOD, V116, P3853, DOI 10.1182/blood-2010-04-281675; Burt BM, 2009, J IMMUNOL, V183, P1789, DOI 10.4049/jimmunol.0900541; Carrega P, 2008, CANCER-AM CANCER SOC, V112, P863, DOI 10.1002/cncr.23239; Coker RK, 1996, EUR RESPIR J, V9, P2501, DOI 10.1183/09031936.96.09122501; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Culley FJ, 2009, IMMUNOLOGY, V128, P151, DOI 10.1111/j.1365-2567.2009.03167.x; Fehniger TA, 2003, BLOOD, V101, P3052, DOI 10.1182/blood-2002-09-2876; Freeman CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103840; Gasteiger G, 2015, SCIENCE, V350, P981, DOI 10.1126/science.aac9593; Ge N, 2004, INT ARCH ALLERGY IMM, V135, P235, DOI 10.1159/000081309; Goodridge JP, 2015, IMMUNOL REV, V267, P197, DOI 10.1111/imr.12325; Gregoire C, 2007, IMMUNOL REV, V220, P169, DOI 10.1111/j.1600-065X.2007.00563.x; Ivarsson MA, 2013, J CLIN INVEST, V123, P3889, DOI 10.1172/JCI68989; Juelke K, 2010, BLOOD, V116, P1299, DOI 10.1182/blood-2009-11-253286; Karimi K, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00159; Keskin DB, 2007, P NATL ACAD SCI USA, V104, P3378, DOI 10.1073/pnas.0611098104; Kim S, 2008, P NATL ACAD SCI USA, V105, P3053, DOI 10.1073/pnas.0712229105; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; Kumagai Y, 2007, IMMUNITY, V27, P240, DOI 10.1016/j.immuni.2007.07.013; Kvedaraite E, 2016, GUT, V65, P1632, DOI 10.1136/gutjnl-2014-309014; Lopez-Verges S, 2010, BLOOD, V116, P3865, DOI 10.1182/blood-2010-04-282301; Mackay LK, 2015, J IMMUNOL, V194, P2059, DOI 10.4049/jimmunol.1402256; Marquardt N, 2015, J IMMUNOL, V194, P2467, DOI 10.4049/jimmunol.1402756; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Ottaviani C, 2006, EUR J IMMUNOL, V36, P118, DOI 10.1002/eji.200535243; Platonova S, 2011, CANCER RES, V71, P5412, DOI 10.1158/0008-5472.CAN-10-4179; ROBINSON BWS, 1984, J CLIN INVEST, V74, P942, DOI 10.1172/JCI111513; Sathaliyawala T, 2013, IMMUNITY, V38, P187, DOI 10.1016/j.immuni.2012.09.020; Schenkel JM, 2014, IMMUNITY, V41, P886, DOI 10.1016/j.immuni.2014.12.007; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Sojka DK, 2014, ELIFE, V3, DOI 10.7554/eLife.01659; Staempfli MR, 2009, NAT REV IMMUNOL, V9, P377, DOI 10.1038/nri2530; Trotta R, 2008, J IMMUNOL, V181, P3784, DOI 10.4049/jimmunol.181.6.3784; Wang J, 2012, IMMUNOLOGY, V137, P37, DOI 10.1111/j.1365-2567.2012.03607.x; Yawata M, 2008, BLOOD, V112, P2369, DOI 10.1182/blood-2008-03-143727	39	82	84	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1321	+		10.1016/j.jaci.2016.07.043	http://dx.doi.org/10.1016/j.jaci.2016.07.043			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27670241	Bronze			2022-12-18	WOS:000398771800027
J	Virkud, YV; Burks, AW; Steele, PH; Edwards, LJ; Berglund, JP; Jones, SM; Scurlock, AM; Perry, TT; Pesek, RD; Vickery, BP				Virkud, Yamini V.; Burks, A. Wesley; Steele, Pamela H.; Edwards, Lloyd J.; Berglund, Jelena P.; Jones, Stacie M.; Scurlock, Amy M.; Perry, Tamara T.; Pesek, Robert D.; Vickery, Brian P.			Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; oral immunotherapy; safety; adverse events	FOOD ALLERGY; EOSINOPHILIC ESOPHAGITIS; NATURAL-HISTORY; SAFETY; PREVALENCE; SEVERITY	Background: Though peanut oral immunotherapy (OIT) is a promising investigational therapy, its potential is limited by substantial adverse events (AEs), whichare relatively understudied. Objective: A retrospective analysis was conducted, pooling data from 3 pediatric peanut OIT trials, comprising the largest analysis of peanut OIT safety to date. Methods: We pooled data from 104 children with peanut allergy from 3 peanut OIT studies. We catalogued AEs from parental reports, daily symptom diaries, and dose escalations. We included events that were considered likely related to OIT and identified potential baseline predictors of higher AE rates using generalized linear regression models. Results: Eighty percent of subjects experienced likely related AEs during OIT (72% during buildup and 47% during maintenance). Of these AEs, over 90% occurred while at home. Approximately 42% of subjects experienced systemic reactions, and 49% experienced gastrointestinal symptoms. Twenty percent of subjects dropped out, with half (10% of the overall group) due to persistent gastrointestinal symptoms. Baseline allergic rhinitis (AR) and peanut SPT wheal size were significant predictors of higher overall AE rates. SPT wheal size predicted increased gastrointestinal AEs, and AR predicted increased systemic reactions. Over the course of OIT, 61% of subjects received treatment for likely related AEs, 59% with antihistamines and 12% with epinephrine. Conclusions: Peanut OIT is associated with frequent AEs, with rates declining over time, and most graded mild. However, systemic reactions and intolerable gastrointestinal AEs do occur and are significantly associated with AR and peanut SPT wheal size, respectively. Further study is needed of predictive biomarkers and the overall risks and benefits of OIT.	[Virkud, Yamini V.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Burks, A. Wesley; Steele, Pamela H.; Vickery, Brian P.] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Edwards, Lloyd J.] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA; [Berglund, Jelena P.] Duke Univ, Duke Translat Med Inst, Durham, NC 27706 USA; [Jones, Stacie M.; Scurlock, Amy M.; Perry, Tamara T.; Pesek, Robert D.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA	Harvard University; Massachusetts General Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University; University of Arkansas System; University of Arkansas Medical Sciences	Vickery, BP (corresponding author), CB 7231,Genome Sci Bldg,Bell Tower Dr, Chapel Hill, NC 27599 USA.	bvickery@email.unc.edu	Edwards, Lloyd/N-2759-2019	Edwards, Lloyd/0000-0002-7788-4575; Vickery, Brian/0000-0002-7243-5543; Burks, Wesley/0000-0003-1873-5702	Food Allergy and Anaphylaxis Network; Gerber Foundation; National Institutes of Health (NIH) [R01-AI068074, K23-AI-099083, 5T32HL098099-03 [T32]]; Food Allergy Project; Clinical and Translational Science Award [5M01-R000030-45]; National Peanut Board; NIH National Center For Advancing Translational Sciences award [UL1TR001117]; Wallace Research Foundation; Dorothy O. Robins and Family Endowment in Peanut Allergy; Alex Orum Peanut Allergy Fund; Harvard Catalyst; Harvard Clinical and Translational Science Center (the National Center for Research Resources, NIH) [UL1 TR001102]; Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, NIH) [UL1 TR001102]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068074, K23AI099083] Funding Source: NIH RePORTER	Food Allergy and Anaphylaxis Network; Gerber Foundation; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy Project; Clinical and Translational Science Award; National Peanut Board; NIH National Center For Advancing Translational Sciences award; Wallace Research Foundation; Dorothy O. Robins and Family Endowment in Peanut Allergy; Alex Orum Peanut Allergy Fund; Harvard Catalyst; Harvard Clinical and Translational Science Center (the National Center for Research Resources, NIH); Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, NIH); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Food Allergy and Anaphylaxis Network, the Gerber Foundation, National Institutes of Health (NIH) (R01-AI068074, K23-AI-099083, and 5T32HL098099-03 [T32]); the Food Allergy Project; a Clinical and Translational Science Award (5M01-R000030-45); the National Peanut Board; an NIH National Center For Advancing Translational Sciences award (UL1TR001117); the Wallace Research Foundation; the Dorothy O. Robins and Family Endowment in Peanut Allergy; the Alex Orum Peanut Allergy Fund; Harvard Catalyst; and the Harvard Clinical and Translational Science Center (the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH award UL1 TR001102).	Anagnostou K, 2011, CLIN EXP ALLERGY, V41, P1273, DOI 10.1111/j.1365-2222.2011.03699.x; Anagnostou K, 2014, LANCET, V383, P1297, DOI 10.1016/S0140-6736(13)62301-6; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2014, ANN ALLERG ASTHMA IM, V112, P222, DOI 10.1016/j.anai.2013.12.007; Kim JS, 2005, J ALLERGY CLIN IMMUN, V116, P164, DOI 10.1016/j.jaci.2005.03.039; Lucendo AJ, 2014, ANN ALLERG ASTHMA IM, V113, P624, DOI 10.1016/j.anai.2014.08.004; Neuman-Sunshine DL, 2012, ANN ALLERG ASTHMA IM, V108, P326, DOI 10.1016/j.anai.2011.11.010; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sampson HA, 2014, J ALLERGY CLIN IMMUN, V134, P1016, DOI 10.1016/j.jaci.2014.05.013; Sampson HA, 2013, J ALLER CL IMM-PRACT, V1, P15, DOI 10.1016/j.jaip.2012.10.009; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Soon IS, 2013, J PEDIATR GASTR NUTR, V57, P72, DOI 10.1097/MPG.0b013e318291fee2; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Varshney P, 2009, J ALLERGY CLIN IMMUN, V124, P1351, DOI 10.1016/j.jaci.2009.09.042; Vazquez-Ortiz M, 2013, CLIN EXP ALLERGY, V43, P92, DOI 10.1111/cea.12012; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Wasserman R, 2011, J ALLERGY CLIN IMMUN, V127; Wasserman RL, 2014, J ALLER CL IMM-PRACT, V2, P91, DOI 10.1016/j.jaip.2013.10.001; Yu GP, 2012, INT ARCH ALLERGY IMM, V159, P179, DOI 10.1159/000336391	28	82	82	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					882	+		10.1016/j.jaci.2016.07.030	http://dx.doi.org/10.1016/j.jaci.2016.07.030			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27609653	Green Submitted, Bronze, Green Accepted			2022-12-18	WOS:000397295800021
J	Sweerus, K; Lachowicz-Scroggins, M; Gordon, E; LaFemina, M; Huang, XZ; Parikh, M; Kanegai, C; Fahy, JV; Frank, JA				Sweerus, Kelly; Lachowicz-Scroggins, Marrah; Gordon, Erin; LaFemina, Michael; Huang, Xiaozhu; Parikh, Mihir; Kanegai, Cindy; Fahy, John V.; Frank, James A.			Claudin-18 deficiency is associated with airway epithelial barrier dysfunction and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; epithelium; epithelial barrier function; tight junction; antigen sensitization; airway hyperresponsiveness	INTRAEPITHELIAL MAST-CELLS; HUMAN TRACHEAL EPITHELIUM; TIGHT JUNCTION; ATOPIC-DERMATITIS; EXPRESSION; MICE; GENE; INTERLEUKIN-13; INFLAMMATION; EXPOSURE	Background: Epithelial barrier dysfunction and increased permeability may contribute to antigen sensitization and disease progression in asthma. Claudin-18.1 is the only known lung-specific tight junction protein, but its contribution to airway barrier function or asthma is unclear. Objectives: We sought to test the hypotheses that claudin-18 is a determinant of airway epithelial barrier function that is downregulated by IL-13 and that claudin-18 deficiency results in increased aeroantigen sensitization and airway hyperresponsiveness. Methods: Claudin-18.1 mRNA levels were measured in airway epithelial brushings from healthy controls and patients with asthma. In patients with asthma, claudin-18 levels were compared with a three-gene-mean marker of T(H)2 inflammation. Airway epithelial permeability changes due to claudin-18 deficiency were measured in 16HBE cells and claudin-18 null mice. The effect of IL-13 on claudin expression was determined in primary human airway epithelial cells and in mice. Airway hyperresponsiveness and serum IgE levels were compared in claudin-18 null and wild-type mice following aspergillus sensitization. Results: Epithelial brushings from patients with asthma (n = 67) had significantly lower claudin-18 mRNA levels than did those from healthy controls (n = 42). Claudin-18 levels were lowest among T(H)2-high patients with asthma. Loss of claudin-18 was sufficient to impair epithelial barrier function in 16HBE cells and in mouse airways. IL-13 decreased claudin-18 expression in primary human cells and in mice. Claudin-18 null mice had significantly higher serum IgE levels and increased airway responsiveness following intranasal aspergillus sensitization. Conclusions: These data support the hypothesis that claudin-18 is an essential contributor to the airway epithelial barrier to aeroantigens. Furthermore, T(H)2 inflammation suppresses claudin-18 expression, potentially promoting sensitization and airway hyperresponsiveness.	[Sweerus, Kelly; Lachowicz-Scroggins, Marrah; Gordon, Erin; LaFemina, Michael; Huang, Xiaozhu; Parikh, Mihir; Kanegai, Cindy; Fahy, John V.; Frank, James A.] Univ Calif San Francisco, Div Pulm Crit Care Sleep & Allergy Med, San Francisco, CA 94143 USA; [Sweerus, Kelly; LaFemina, Michael; Parikh, Mihir; Frank, James A.] San Francisco VA Med Ctr, San Francisco, CA USA; [Sweerus, Kelly; LaFemina, Michael; Parikh, Mihir; Frank, James A.] Northern Calif Inst Res & Educ, San Francisco, CA USA; [Lachowicz-Scroggins, Marrah; Huang, Xiaozhu; Fahy, John V.] Univ Calif San Francisco, Sandler Asthma Basic Res Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; Northern California Institute for Research & Education; University of California System; University of California San Francisco	Frank, JA (corresponding author), Univ Calif San Francisco, San Francisco VA Med Ctr, 4150 Clement St,Box 111D, San Francisco, CA 94121 USA.	James.frank@ucsf.edu		Lachowicz-Scroggins, Marrah/0000-0002-3173-5662; Gordon, Erin/0000-0001-7723-2297	National Institutes of Health/National Heart, Lung, and Blood Institute [R21HL111707]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL111707, R56HL088440] Funding Source: NIH RePORTER	National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was funded by the National Institutes of Health/National Heart, Lung, and Blood Institute (grant no. R21HL111707 to J.A.F.).	Angelow S, 2008, AM J PHYSIOL-RENAL, V295, pF867, DOI 10.1152/ajprenal.90264.2008; Antony AB, 2002, J ALLERGY CLIN IMMUN, V110, P589, DOI 10.1067/mai.2002.127798; Bhakta Nirav R, 2013, Clin Transl Allergy, V3, P24, DOI 10.1186/2045-7022-3-24; Capaldo CT, 2015, SEMIN CELL DEV BIOL, V42, P22, DOI 10.1016/j.semcdb.2015.04.003; Coyne CB, 2002, MOL BIOL CELL, V13, P3218, DOI 10.1091/mbc.E02-03-0134; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI [10.1139/Y08-004, 10.1139/y08-004]; Dolganov GM, 2001, GENOME RES, V11, P1473, DOI 10.1101/gr.191301; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; GODFREY RWA, 1992, AM J RESP CELL MOL, V6, P453, DOI 10.1165/ajrcmb/6.4.453; Gordon ED, 2012, CLIN EXP ALLERGY, V42, P144, DOI 10.1111/j.1365-2222.2011.03840.x; Hayashi D, 2012, GASTROENTEROLOGY, V142, P292, DOI 10.1053/j.gastro.2011.10.040; Heijink IH, 2014, CLIN EXP ALLERGY, V44, P620, DOI 10.1111/cea.12296; Heller F, 2005, GASTROENTEROLOGY, V129, P550, DOI 10.1053/j.gastro.2005.05.002; Holgate ST, 2011, J ALLERGY CLIN IMMUN, V128, P495, DOI 10.1016/j.jaci.2011.06.052; Ierodiakonou D, 2011, EUR RESPIR J, V38, P1044, DOI 10.1183/09031936.00194710; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; LaFemina MJ, 2014, AM J RESP CELL MOL, V51, P550, DOI 10.1165/rcmb.2013-0456OC; LaFemina MJ, 2010, AM J PHYSIOL-LUNG C, V299, pL724, DOI 10.1152/ajplung.00233.2010; Li GL, 2014, AM J RESP CELL MOL, V51, P210, DOI 10.1165/rcmb.2013-0353OC; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Niimi T, 2001, MOL CELL BIOL, V21, P7380, DOI 10.1128/MCB.21.21.7380-7390.2001; Reinhardt AK, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-30; Saatian B, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.24333; Sachs LA, 2003, IN VITRO CELL DEV-AN, V39, P56; SCHNEEBERGER EE, 1980, ANAT REC, V198, P193, DOI 10.1002/ar.1091980207; Sidhaye VK, 2008, P NATL ACAD SCI USA, V105, P3345, DOI 10.1073/pnas.0712287105; Sugimoto K, 2012, J CLIN INVEST, V122, P748, DOI 10.1172/JCI58815; Swindle EJ, 2009, J ALLERGY CLIN IMMUN, V124, P23, DOI 10.1016/j.jaci.2009.05.037; Trautmann A, 2005, INT ARCH ALLERGY IMM, V138, P142, DOI 10.1159/000088436; Wan H, 2000, CLIN EXP ALLERGY, V30, P685, DOI 10.1046/j.1365-2222.2000.00820.x; Wan H, 2000, EUR RESPIR J, V15, P1058, DOI 10.1034/j.1399-3003.2000.01514.x; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Widdicombe JH, 2005, BIOTECHNIQUES, V39, P249, DOI 10.2144/05392RR02; Wise SK, 2014, INT FORUM ALLERGY RH, V4, P361, DOI 10.1002/alr.21298; Wise SK, 2013, INT FORUM ALLERGY RH, V3, P439, DOI 10.1002/alr.21158; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Xu R, 2013, BIOSCIENCE REP, V33, P847, DOI 10.1042/BSR20130087; Yu HS, 2015, J ALLERGY CLIN IMMUN, V135, P827, DOI 10.1016/j.jaci.2014.10.040; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	42	82	82	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					72	+		10.1016/j.jaci.2016.02.035	http://dx.doi.org/10.1016/j.jaci.2016.02.035			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27215490	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000393996800009
J	Di Meglio, P; Villanova, F; Navarini, AA; Mylonas, A; Tosi, I; Nestle, FO; Conrad, C				Di Meglio, Paola; Villanova, Federica; Navarini, Alexander A.; Mylonas, Alessio; Tosi, Isabella; Nestle, Frank O.; Conrad, Curdin			Targeting CD8(+) T cells prevents psoriasis development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IFN-GAMMA; SKIN		[Di Meglio, Paola; Villanova, Federica; Tosi, Isabella; Nestle, Frank O.] Kings Coll London, St Johns Inst Dermatol, London, England; [Villanova, Federica; Tosi, Isabella; Nestle, Frank O.] Kings Coll London, NIHR Biomed Res Ctr, London, England; [Navarini, Alexander A.] Univ Zurich Hosp, Dept Dermatol, Zurich, Switzerland; [Mylonas, Alessio; Conrad, Curdin] Univ Hosp Lausanne CHUV, Dept Dermatol, Lausanne, Switzerland; [Di Meglio, Paola] Francis Crick Inst, Mill Hill Lab, London, England	University of London; King's College London; University of London; King's College London; University of Zurich; University Zurich Hospital; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Francis Crick Institute	Conrad, C (corresponding author), Univ Hosp Lausanne CHUV, Dept Dermatol, Lausanne, Switzerland.	curdin.conrad@chuv.ch	Mylonas, Alessio/AAC-7732-2020; Navarini, Alexander/C-5504-2014	Mylonas, Alessio/0000-0001-6220-1973; Navarini, Alexander/0000-0001-7059-632X; Conrad, Curdin/0000-0002-2547-3440; Di Meglio, Paola/0000-0002-2066-7780				Cheuk S, 2014, J IMMUNOL, V192, P3111, DOI 10.4049/jimmunol.1302313; Conrad C, 2007, NAT MED, V13, P836, DOI 10.1038/nm1605; Di Meglio P, 2014, COLD SPRING HARB PER, V4; Gunderson AJ, 2013, J INVEST DERMATOL, V133, P955, DOI 10.1038/jid.2012.390; Hijnen D, 2013, J INVEST DERMATOL, V133, P973, DOI 10.1038/jid.2012.456; Lande R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6621; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Tsoi LC, 2012, NAT GENET, V44, P1341, DOI 10.1038/ng.2467; Watanabe R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010302	10	82	85	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					274	276		10.1016/j.jaci.2015.10.046	http://dx.doi.org/10.1016/j.jaci.2015.10.046			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26782974	hybrid, Green Published			2022-12-18	WOS:000379659100029
J	Gorelik, M; Narisety, SD; Guerrerio, AL; Chichester, KL; Keet, CA; Bieneman, AP; Hamilton, RG; Wood, RA; Schroeder, JT; Frischmeyer-Guerrerio, PA				Gorelik, Mark; Narisety, Satya D.; Guerrerio, Anthony L.; Chichester, Kristin L.; Keet, Corinne A.; Bieneman, Anja P.; Hamilton, Robert G.; Wood, Robert A.; Schroeder, John T.; Frischmeyer-Guerrerio, Pamela A.			Suppression of the immunologic response to peanut during immunotherapy is often transient	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; oral immunotherapy; sublingual immunotherapy; sustained unresponsiveness; basophil activation; dendritic cells; food allergy	ORAL IMMUNOTHERAPY; DENDRITIC CELLS; HUMAN BASOPHILS; MODULATION; CHILDREN; ALLERGEN; RELEASE; CD80	Background: Studies suggest that oral immunotherapy (OIT) and sublingual immunotherapy (SLIT) for food allergy hold promise; however, the immunologic mechanisms underlying these therapies are not well understood. Objective: We sought to generate insights into the mechanisms and duration of suppression of immune responses to peanut during immunotherapy. Methods: Blood was obtained from subjects at baseline and at multiple time points during a placebo-controlled trial of peanut OIT and SLIT. Immunologic outcomes included measurement of spontaneous and stimulated basophil activity by using automated fluorometry (histamine) and flow cytometry (activation markers and IL-4), measurement of allergen-induced cytokine expression in dendritic cell (DC)-T-cell cocultures by using multiplexing technology, and measurement of MHC II and costimulatory molecule expression on DCs by using flow cytometry. Results: Spontaneous and allergen-induced basophil reactivity (histamine release, CD63 expression, and IL-4 production) were suppressed during dose escalation and after 6 months of maintenance dosing. Peanut-and dust mite-induced expression of T(H)2 cytokines was reduced in DC-T-cell cocultures during immunotherapy. This was associated with decreased levels of CD40, HLA-DR, and CD86 expression on DCs and increased expression of CD80. These effects were most striking in myeloid DC-T-cell cocultures from subjects receiving OIT. Many markers of immunologic suppression reversed after withdrawal from immunotherapy and in some cases during ongoing maintenance therapy. Conclusion: OITand SLIT for peanut allergy induce rapid suppression of basophil effector functions, DC activation, and TH2 cytokine responses during the initial phases of immunotherapy in an antigen-nonspecific manner. Although there was some interindividual variation, in many patients suppression appeared to be temporary.	[Gorelik, Mark; Chichester, Kristin L.; Keet, Corinne A.; Wood, Robert A.; Frischmeyer-Guerrerio, Pamela A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Bieneman, Anja P.; Hamilton, Robert G.; Schroeder, John T.] Johns Hopkins Univ, Sch Med, Dept Med, Div Allergy & Immunol, Baltimore, MD 21205 USA; [Guerrerio, Anthony L.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Gastroenterol & Nutr, Baltimore, MD 21205 USA; [Narisety, Satya D.] Univ Med & Dent New Jersey, Dept Pediat, Div Allergy Immunol & Infect Dis, Newark, NJ 07103 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Frischmeyer-Guerrerio, PA (corresponding author), NIAID, Lab Allerg Dis, 4 Mem Dr,Bldg 4,Room 228, Bethesda, MD 20892 USA.	pamela.guerrerio@nih.gov	Guerrerio, Pamela/S-9360-2019; Guerrerio, Anthony/T-2632-2019	Guerrerio, Anthony/0000-0003-2458-7160	National Center for Advancing Translational Sciences (NCATS) [UL1TR001079]; NIH Roadmap for Medical Research; Research Training in Pediatric Allergy and Immunology [5T32AI007007]; NIH [K23AI091869, AI079853]; ARTrust Faculty Development Award; Johns Hopkins University Clinician Scientist Award; NIH Asthma and Allergic Diseases Cooperative Research Centers grant [U19AI070345-01]; Food Allergy Research and Education grant; Eudowood Foundation; Winkelstein fellowship; Division of Intramural Research, NIAID, NIH; National Center for Research Resources; National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health [101872]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R21HD073557] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI103187, U19AI070345, R21AI079853, K23AI091869, T32AI007007] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research Training in Pediatric Allergy and Immunology; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ARTrust Faculty Development Award; Johns Hopkins University Clinician Scientist Award; NIH Asthma and Allergic Diseases Cooperative Research Centers grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy Research and Education grant; Eudowood Foundation; Winkelstein fellowship; Division of Intramural Research, NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grant no. UL1TR001079 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research; a Research Training in Pediatric Allergy and Immunology grant (no. 5T32AI007007 to R.A.W. and M.G.); an NIH K23 Mentored Research Development Award (K23AI091869 to P.A.F.-G.); an ARTrust Faculty Development Award (to P.A.F.-G.); a Johns Hopkins University Clinician Scientist Award (to P.A.F.-G.); an NIH R21 Research Award (AI079853 to J.T.S.); NIH Asthma and Allergic Diseases Cooperative Research Centers grant (U19AI070345-01 to J.T.S.); a Food Allergy Research and Education grant (to R.A.W.); the Eudowood Foundation; and a Winkelstein fellowship (to M.G.). This work was supported in part by the Division of Intramural Research, NIAID, NIH (to P.A.F.-G.).; We thank Dr Xuhang Li and the Johns Hopkins Digestive Diseases Basic and Translational Research Core Center for their assistance with cytokine multiplexing and Dr Mark Liu for providing dust mite extracts. Assistance with statistics was provided by Carol B. Thompson, Assistant Scientist, Johns Hopkins Biostatistics Center, who was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health through grant no. 101872.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Denzel A, 2008, NAT IMMUNOL, V9, P733, DOI 10.1038/ni.1621; Dreschler K, 2011, J ALLERGY CLIN IMMUN, V127, P487, DOI 10.1016/j.jaci.2010.12.003; Farkas L, 2004, J ALLERGY CLIN IMMUN, V114, P436, DOI 10.1016/j.jaci.2004.04.035; Ford LS, 2013, J ALLERGY CLIN IMMUN, V131, P180, DOI 10.1016/j.jaci.2012.06.003; Frischmeyer-Guerrerio PA, 2011, CLIN EXP ALLERGY, V41, P61, DOI 10.1111/j.1365-2222.2010.03606.x; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; MacGlashan D, 2010, CLIN EXP ALLERGY, V40, P1365, DOI 10.1111/j.1365-2222.2010.03572.x; Mousallem T, 2012, CLIN EXP IMMUNOL, V167, P26, DOI 10.1111/j.1365-2249.2011.04499.x; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, P1275, DOI 10.1016/j.jaci.2014.11.005; Qureshi OS, 2011, SCIENCE, V332, P600, DOI 10.1126/science.1202947; Ruiter B, 2012, SEMIN IMMUNOPATHOL, V34, P617, DOI 10.1007/s00281-012-0334-8; Ruiter B, 2012, J ALLERGY CLIN IMMUN, V129, P921, DOI 10.1016/j.jaci.2012.01.080; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; Schroeder JT, 2006, MANUAL OF MOLECULAR AND CLINICAL LABORATORY IMMUNOLOGY, 7TH EDITION, P964; Schroeder JT, 2013, J ALLERGY CLIN IMMUN, V132, P1428, DOI 10.1016/j.jaci.2013.08.033; Schroeder JT, 2001, ADV IMMUNOL, V77, P93, DOI 10.1016/S0065-2776(01)77015-0; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; Shreffler WG, 2006, CURR OPIN ALLERGY CL, V6, P226, DOI 10.1097/01.all.0000225165.83144.2f; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Suarez-Fueyo A, 2014, J ALLERGY CLIN IMMUN, V133, P130, DOI 10.1016/j.jaci.2013.09.043; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Thyagarajan A, 2012, CLIN EXP ALLERGY, V42, P1197, DOI 10.1111/j.1365-2222.2012.04028.x; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Zheng Y, 2004, J IMMUNOL, V172, P2778, DOI 10.4049/jimmunol.172.5.2778	31	82	84	2	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1283	1292		10.1016/j.jaci.2014.11.010	http://dx.doi.org/10.1016/j.jaci.2014.11.010			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25542883	Green Accepted			2022-12-18	WOS:000353980700022
J	Yoshida, K; Kubo, A; Fujita, H; Yokouchi, M; Ishii, K; Kawasaki, H; Nomura, T; Shimizu, H; Kouyama, K; Ebihara, T; Nagao, K; Amagai, M				Yoshida, Kazue; Kubo, Akiharu; Fujita, Harumi; Yokouchi, Mariko; Ishii, Ken; Kawasaki, Hiroshi; Nomura, Toshifumi; Shimizu, Hiroshi; Kouyama, Keisuke; Ebihara, Tamotsu; Nagao, Keisuke; Amagai, Masayuki			Distinct behavior of human Langerhans cells and inflammatory dendritic epidermal cells at tight junctions in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Langerhans cell; inflammatory dendritic epidermal cell; tight junction; stratum corneum; atopic dermatitis; langerin; FceRI	FC-EPSILON-RI; ANTIGEN-PRESENTING CELLS; HIGH-AFFINITY RECEPTOR; OF-FUNCTION MUTATIONS; REGULATORY T-CELLS; FUNCTION VARIANTS; BARRIER FUNCTION; FILAGGRIN GENE; PATCH TEST; SKIN	Background: The stratum corneum and tight junctions (TJs) form physical barriers in the epidermis. Dendrites of activated Langerhans cells (LCs) extend beyond the TJs to capture external antigens in mice. LCs and inflammatory dendritic epidermal cells (IDECs) are observed in the skin of patients with atopic dermatitis (AD). Objective: We sought to investigate the characteristics of LCs and IDECs and the distribution of their antigen capture receptors in relation to TJs in normal and AD skin. Methods: We characterized the interactions of LCs and IDECs with TJs and the expression patterns of langerin and FceRI by using whole-mount epidermal sheets from healthy subjects and patients with AD, ichthyosis vulgaris, and psoriasis vulgaris. Results: As in mouse skin, activated LCs penetrate TJs in human skin. The number of LCs with TJ penetration increased approximately 5-fold in erythematous lesional skin of patients with AD but not in nonlesional skin of patients with AD or lesions of patients with ichthyosis vulgaris or psoriasis. In contrast, IDECs localized in the lower part of the epidermis, and their dendrites extended horizontally without penetration through TJs. Although langerin accumulated on the tips of dendrites of activated LCs, FceRI was expressed diffusely on the cell surfaces on LCs and IDECs in lesional skin from patients with AD. Conclusions: These findings highlight interesting differences between LCs and IDECs in epidermis of patients with AD, where LCs, but not IDECs, extend dendrites through the TJs, likely to capture antigens from outside the TJ barrier with a polarized distribution of langerin but not FceRI. These behavioral differences between skin dendritic cells might reflect an important pathophysiology of AD.	[Yoshida, Kazue; Kubo, Akiharu; Fujita, Harumi; Yokouchi, Mariko; Ishii, Ken; Kawasaki, Hiroshi; Ebihara, Tamotsu; Nagao, Keisuke; Amagai, Masayuki] Keio Univ, Sch Med, Dept Dermatol, Tokyo 1608582, Japan; [Kubo, Akiharu; Amagai, Masayuki] Keio Univ, Sch Med, Keio Maruho Lab Skin Barriol, Tokyo 1608582, Japan; [Fujita, Harumi; Amagai, Masayuki] Keio Univ, Sch Med, KOSE Endowed Program Skin Care & Allergy Prevent, Tokyo 1608582, Japan; [Kouyama, Keisuke] Keio Univ, Sch Med, Clin Res Ctr, Tokyo 1608582, Japan; [Yoshida, Kazue] Natl Ctr Child Hlth & Dev, Dept Dermatol, Tokyo, Japan; [Ishii, Ken] Toho Univ, Sch Med, Dept Dermatol, Tokyo, Japan; [Nomura, Toshifumi; Shimizu, Hiroshi] Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido, Japan	Keio University; Keio University; Keio University; Keio University; National Center for Child Health & Development - Japan; Toho University; Hokkaido University	Kubo, A (corresponding author), Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	akiharu@a5.keio.jp	Nagao, Keisuke/P-3837-2018; Kubo, Akiharu/I-2711-2014; Nomura, Toshifumi/A-5454-2012; Amagai, Masayuki/K-5325-2013; Nagao, Keisuke/J-5116-2013	Nagao, Keisuke/0000-0002-7005-3138; Kubo, Akiharu/0000-0003-0902-3586; Nomura, Toshifumi/0000-0002-9954-6446; Amagai, Masayuki/0000-0003-3314-7052; Nagao, Keisuke/0000-0002-7005-3138; Yoshida, Kazue/0000-0002-8128-1849; Fujita, Harumi/0000-0003-2133-845X	Ministry of Education, Culture, Sports, Science and Technology of Japan; Health Labour Sciences Research Grant for Research on Allergic Diseases and Immunology from the Ministry of Health, Labour and Welfare of Japan; Research Grants for Life Sciences and Medicine from Keio University Medical Science Fund; Mochida Memorial Foundation for Medical and Pharmaceutical Research; Cosmetology Research Foundation; Keio University; Grants-in-Aid for Scientific Research [26893260] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Health Labour Sciences Research Grant for Research on Allergic Diseases and Immunology from the Ministry of Health, Labour and Welfare of Japan; Research Grants for Life Sciences and Medicine from Keio University Medical Science Fund; Mochida Memorial Foundation for Medical and Pharmaceutical Research; Cosmetology Research Foundation; Keio University; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported in parts by Grants-in-Aid for Scientific Research and "Promotion of Environmental Improvement for Independence of Young Researchers'' program from the Ministry of Education, Culture, Sports, Science and Technology of Japan; a Health Labour Sciences Research Grant for Research on Allergic Diseases and Immunology from the Ministry of Health, Labour and Welfare of Japan; Research Grants for Life Sciences and Medicine from Keio University Medical Science Fund; a Keio University Grant-in-Aid for Encouragement of Young medical Scientists; the Mochida Memorial Foundation for Medical and Pharmaceutical Research; and a Research Grant from the Cosmetology Research Foundation.	AIBA S, 1990, J IMMUNOL, V145, P2791; Anderson JM, 2001, NEWS PHYSIOL SCI, V16, P126; Basu K, 2008, ALLERGY, V63, P1211, DOI 10.1111/j.1398-9995.2008.01660.x; BIEBER T, 1988, BRIT J DERMATOL, V118, P385, DOI 10.1111/j.1365-2133.1988.tb02432.x; BIEBER T, 1989, J INVEST DERMATOL, V93, P215, DOI 10.1111/1523-1747.ep12277574; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bieber T, 2007, IMMUNOBIOLOGY, V212, P499, DOI 10.1016/j.imbio.2007.03.001; Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Chen YH, 1997, J CELL BIOL, V138, P891, DOI 10.1083/jcb.138.4.891; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Darsow U, 2004, ALLERGY, V59, P1318, DOI 10.1111/j.1398-9995.2004.00556.x; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Goto T, 2001, J DERMATOL SCI, V27, P156, DOI 10.1016/S0923-1811(01)00130-X; HASHIMOTO K, 1971, ARCH DERMATOL, V104, P148, DOI 10.1001/archderm.104.2.148; Hoetzenecker W, 2005, J ALLERGY CLIN IMMUN, V115, P1276, DOI 10.1016/j.jaci.2005.02.011; Ishida-Yamamoto A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031641; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P869, DOI 10.1067/mai.2003.1347; Kirschner N, 2010, EUR J CELL BIOL, V89, P839, DOI 10.1016/j.ejcb.2010.07.010; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; Kubo A, 2009, J EXP MED, V206, P2937, DOI 10.1084/jem.20091527; McGrath JA, 2008, TRENDS MOL MED, V14, P20, DOI 10.1016/j.molmed.2007.10.006; Nagao K, 2012, NAT IMMUNOL, V13, P744, DOI 10.1038/ni.2353; Nakajima S, 2012, J ALLERGY CLIN IMMUN, V129, P1048, DOI 10.1016/j.jaci.2012.01.063; Nemoto-Hasebe I, 2009, J INVEST DERMATOL, V129, P682, DOI 10.1038/jid.2008.280; Novak N, 2004, CURR ALLERGY ASTHM R, V4, P263, DOI 10.1007/s11882-004-0069-2; Novak N, 2005, CLIN EXP DERMATOL, V30, P160, DOI 10.1111/j.1365-2230.2005.01709.x; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Novak N, 2008, J INVEST DERMATOL, V128, P1430, DOI 10.1038/sj.jid.5701190; Ouchi T, 2011, J EXP MED, V208, P2607, DOI 10.1084/jem.20111718; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; REYNOLDS NJ, 1995, BRIT J DERMATOL, V133, P157, DOI 10.1111/j.1365-2133.1995.tb02611.x; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Roehr CC, 2001, J ALLERGY CLIN IMMUN, V107, P548, DOI 10.1067/mai.2001.112849; Schempp C, 2009, J DTSCH DERMATOL GES, V7, P750, DOI 10.1111/j.1610-0387.2009.07193.x; Schuller E, 2004, J ALLERGY CLIN IMMUN, V114, P137, DOI 10.1016/j.jaci.2004.03.021; Schuttelaar MLA, 2009, ALLERGY, V64, P1758, DOI 10.1111/j.1398-9995.2009.02080.x; Seneschal J, 2012, IMMUNITY, V36, P873, DOI 10.1016/j.immuni.2012.03.018; Shklovskaya E, 2011, P NATL ACAD SCI USA, V108, P18049, DOI 10.1073/pnas.1110076108; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; UNO H, 1980, J INVEST DERMATOL, V75, P52, DOI 10.1111/1523-1747.ep12521130; van der Aar AMG, 2013, J INVEST DERMATOL, V133, P1240, DOI 10.1038/jid.2012.500; Wollenberg A, 2002, J INVEST DERMATOL, V118, P327, DOI 10.1046/j.0022-202x.2001.01665.x; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Wollenberg A, 2001, J ALLERGY CLIN IMMUN, V107, P519, DOI 10.1067/mai.2001.112942; Yoshida K, 2013, J DERMATOL SCI, V71, P89, DOI 10.1016/j.jdermsci.2013.04.021; Yoshida Y, 2001, ARCH DERMATOL RES, V293, P239, DOI 10.1007/s004030100221; Yuki T, 2011, J INVEST DERMATOL, V131, P744, DOI 10.1038/jid.2010.385	48	82	85	2	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					856	864		10.1016/j.jaci.2014.08.001	http://dx.doi.org/10.1016/j.jaci.2014.08.001			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25282566				2022-12-18	WOS:000343155700011
J	Forno, E; Acosta-Perez, E; Brehm, JM; Han, YY; Alvarez, M; Colon-Semidey, A; Canino, G; Celedon, JC				Forno, Erick; Acosta-Perez, Edna; Brehm, John M.; Han, Yueh-Ying; Alvarez, Maria; Colon-Semidey, Angel; Canino, Glorisa; Celedon, Juan C.			Obesity and adiposity indicators, asthma, and atopy in Puerto Rican children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma; obesity; adiposity; body mass index; percent of body fat; obesity and asthma; obesity and atopy	BODY-MASS INDEX; CHILDHOOD ASTHMA; UNITED-STATES; OVERWEIGHT; FAT; ASSOCIATION; RISK; SCHOOLCHILDREN; SENSITIZATION; WEIGHT	Background: Whether adiposity indicators other than body mass index (BMI) should be used in studies of childhood asthma is largely unknown. The role of atopy in "obeseasthma'' is also unclear. Objectives: To examine the relationship among adiposity indicators, asthma, and atopy in Puerto Rican children, and to assess whether atopy mediates the obesity-asthma association. Methods: In a study of Puerto Rican children with (n = 351) and without (n = 327) asthma, we measured BMI, percent of body fat, waist circumference, and waist-to-hip ratio. The outcomes studied included asthma, lung function, measures of atopy, and, among cases, indicators of asthma severity or control. We performed mediation analysis to assess the contribution of atopy to the relationship between adiposity and asthma. Results: BMI, percent of body fat, and waist circumference were associated with increased odds of asthma. Among cases, all 3 measures were generally associated with lung function, asthma severity/control, and atopy; however, there were differences depending on the adiposity indicator analyzed. Atopy considerably mediated the adiposity-asthma association in this population: allergic rhinitis accounted for 22% to 53% of the association with asthma, and sensitization to cockroach mediated 13% to 20% of the association with forced vital capacity and 29% to 42% of the association with emergency department visits for asthma. Conclusions: Adiposity indicators are associated with asthma, asthma severity/control, and atopy in Puerto Rican children. Atopy significantly mediates the effect of adiposity on asthma outcomes. Longitudinal studies are needed to further investigate the causal role, if any, of adiposity distribution and atopy on `` obese asthma'' in childhood.	[Forno, Erick; Brehm, John M.; Han, Yueh-Ying; Celedon, Juan C.] Univ Pittsburgh, Childrens Hosp Pittsburgh, UPMC, Div Pediat Pulm Med Allergy & Immunol, Pittsburgh, PA 15213 USA; [Acosta-Perez, Edna; Alvarez, Maria; Colon-Semidey, Angel; Canino, Glorisa] Univ Puerto Rico, Behav Sci Res Inst, Dept Pediat, San Juan, PR 00936 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus	Celedon, JC (corresponding author), UPMC, Childrens Hosp Pittsburgh, Div Pediat Pulm Med Allergy & Immunol, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	juan.celedon@chp.edu	Pérez, Edna Acosta/AAW-6672-2021; Alvarez, Maria/GZH-1345-2022; Forno, Erick/I-1476-2019	Forno, Erick/0000-0001-6497-9885; acosta, edna/0000-0001-7101-3157	National Institutes of Health [HL079966]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079966, R01HL117191] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the National Institutes of Health (grant no. HL079966).	Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], PREV TRENDS DAT OV O; Beuther DA, 2006, AM J RESP CRIT CARE, V174, P112, DOI 10.1164/rccm.200602-231PP; Bird HR, 2006, J AM ACAD CHILD PSY, V45, P1032, DOI 10.1097/01.chi.0000227879.65651.cf; Borrell LN, 2013, AM J RESP CRIT CARE, V187, P697, DOI 10.1164/rccm.201211-2116OC; Breen R, 2013, SOCIOL METHOD RES, V42, P164, DOI 10.1177/0049124113494572; Brehm JM, 2012, J ALLERGY CLIN IMMUN, V129, P1484, DOI 10.1016/j.jaci.2012.03.035; Bureau UC, 2010, HOUS INC STAT 2008 2; Celedon JC, 2004, CHEST, V125, P85, DOI 10.1378/chest.125.1.85; Centers for Disease Control and Prevention, 2011, SAS PROGR CDC GROWTH; Chrysant SG, 2013, J AM SOC HYPERTENS, V7, P85, DOI 10.1016/j.jash.2012.11.008; Cibella F, 2011, ANN ALLERG ASTHMA IM, V107, P330, DOI 10.1016/j.anai.2011.08.001; Cohen RT, 2007, CHEST, V131, P1331, DOI 10.1378/chest.06-1917; Coutinho T, 2013, J AM COLL CARDIOL, V61, P553, DOI 10.1016/j.jacc.2012.10.035; Dietze J, 2012, ALLERGY, V67, P1519, DOI 10.1111/all.12031; Fenger RV, 2012, CLIN EXP ALLERGY, V42, P1237, DOI 10.1111/j.1365-2222.2012.03972.x; Flaherman V, 2006, ARCH DIS CHILD, V91, P334, DOI 10.1136/adc.2005.080390; Forno E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040383; Forno E, 2011, J ALLERGY CLIN IMMUN, V127, P741, DOI 10.1016/j.jaci.2010.12.010; Garcia-Marcos L, 2008, MATERN CHILD NUTR, V4, P304, DOI 10.1111/j.1740-8709.2008.00144.x; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; Heo M, 2013, INT J OBESITY, V37, P1154, DOI 10.1038/ijo.2012.201; Hoffstedt J, 2010, DIABETOLOGIA, V53, P2496, DOI 10.1007/s00125-010-1889-3; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; Jones RL, 2006, CHEST, V130, P827, DOI 10.1378/chest.130.3.827; Karlson KB, 2011, RES SOC STRAT MOBIL, V29, P221, DOI 10.1016/j.rssm.2010.12.005; Kattan M, 2010, J ALLERGY CLIN IMMUN, V125, P584, DOI 10.1016/j.jaci.2010.01.053; Kodama S, 2012, AM J EPIDEMIOL, V176, P959, DOI 10.1093/aje/kws172; Kohler U, 2011, STATA J, V11, P420, DOI 10.1177/1536867X1101100306; Lam YY, 2011, OBESITY, V19, P2113, DOI 10.1038/oby.2011.68; Laurson KR, 2011, AM J PREV MED, V41, pS87, DOI 10.1016/j.amepre.2011.06.044; Li JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/science.1153717; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Lugogo NL, 2010, J APPL PHYSIOL, V108, P729, DOI 10.1152/japplphysiol.00845.2009; Maffeis C, 2008, J CLIN ENDOCR METAB, V93, P2122, DOI 10.1210/jc.2007-2089; Monyeki KD, 2008, J HUM HYPERTENS, V22, P311, DOI 10.1038/jhh.2008.3; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Papoutsakis C, 2013, J ACAD NUTR DIET, V113, P77, DOI 10.1016/j.jand.2012.08.025; Rastogi D, 2012, CHEST, V141, P895, DOI 10.1378/chest.11-0930; Rzehak P, 2013, J ALLERGY CLIN IMMUN, V131, P1528, DOI 10.1016/j.jaci.2013.01.001; Sankararaman S, 2008, AM J HUM GENET, V82, P290, DOI 10.1016/j.ajhg.2007.09.022; Schachter LM, 2003, THORAX, V58, P1031, DOI 10.1136/thorax.58.12.1031; Sidoroff V, 2010, PEDIAT PULMONOL; Stream AR, 2012, CURR OPIN ALLERGY CL, V12, P76, DOI 10.1097/ACI.0b013e32834eca41; Sutherland ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036631; Tang H, 2007, AM J HUM GENET, V81, P626, DOI 10.1086/520769; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; Thorisson GA, 2005, GENOME RES, V15, P1592, DOI 10.1101/gr.4413105; Van Gysel D, 2009, PEDIAT ALLERG IMM-UK, V20, P246, DOI 10.1111/j.1399-3038.2008.00774.x; Vangeepuram N, 2011, J OBES, V2011, DOI 10.1155/2011/517417; Vieira VJ, 2005, AM J CLIN NUTR, V82, P504, DOI 10.1093/ajcn/82.3.504; Visness CM, 2010, J ASTHMA, V47, P822, DOI 10.3109/02770903.2010.489388; Visness CM, 2009, J ALLERGY CLIN IMMUN, V123, P1163, DOI 10.1016/j.jaci.2008.12.1126; Vo P, 2013, J ASTHMA, V50, P56, DOI 10.3109/02770903.2012.744035; Wang Y, 2006, INT J PEDIATR OBES, V1, P11, DOI 10.1080/17477160600586747	57	82	83	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1308	U516		10.1016/j.jaci.2013.09.041	http://dx.doi.org/10.1016/j.jaci.2013.09.041			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24290290	Green Accepted			2022-12-18	WOS:000335450700010
J	McKinnon, ML; Rozmus, J; Fung, SY; Hirschfeld, AF; Del Bel, KL; Thomas, L; Marr, N; Martin, SD; Marwaha, AK; Priatel, JJ; Tan, R; Senger, C; Tsang, A; Prendiville, J; Junker, AK; Seear, M; Schultz, KR; Sly, LM; Holt, RA; Patel, MS; Friedman, JM; Turvey, SE				McKinnon, Margaret L.; Rozmus, Jacob; Fung, Shan-Yu; Hirschfeld, Aaron F.; Del Bel, Kate L.; Thomas, Leah; Marr, Nico; Martin, Spencer D.; Marwaha, Ashish K.; Priatel, John J.; Tan, Rusung; Senger, Christof; Tsang, Angela; Prendiville, Julie; Junker, Anne K.; Seear, Michael; Schultz, Kirk R.; Sly, Laura M.; Holt, Robert A.; Patel, Millan S.; Friedman, Jan M.; Turvey, Stuart E.			Combined immunodeficiency associated with homozygous MALT1 mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LYMPHOCYTE-ACTIVATION; 11 CARD11; FAMILY; DEFICIENCY; VARIANTS; CELL		[McKinnon, Margaret L.; Patel, Millan S.; Friedman, Jan M.] Univ British Columbia, Child & Family Res Inst, Dept Med Genet, Vancouver, BC V5Z 1M9, Canada; [Rozmus, Jacob; Fung, Shan-Yu; Hirschfeld, Aaron F.; Del Bel, Kate L.; Thomas, Leah; Marr, Nico; Prendiville, Julie; Junker, Anne K.; Seear, Michael; Schultz, Kirk R.; Sly, Laura M.; Turvey, Stuart E.] Univ British Columbia, Child & Family Res Inst, Dept Pediat, Vancouver, BC V5Z 1M9, Canada; [Martin, Spencer D.; Holt, Robert A.] British Columbia Canc Agcy, Michael Smith Genome Sci Ctr, Vancouver, BC, Canada; [Marwaha, Ashish K.; Priatel, John J.; Tan, Rusung; Senger, Christof; Tsang, Angela] Univ British Columbia, Child & Family Res Inst, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada	Child & Family Research Institute; University of British Columbia; Child & Family Research Institute; University of British Columbia; British Columbia Cancer Agency; Child & Family Research Institute; University of British Columbia	McKinnon, ML (corresponding author), Univ British Columbia, Child & Family Res Inst, Dept Med Genet, Vancouver, BC V5Z 1M9, Canada.	sturvey@cw.bc.ca	Schultz, Kirk R/AAA-3440-2022; Fung, Shan-Yu/E-3477-2014; Turvey, Stuart/HGV-1191-2022; Marr, Nico/T-7741-2019; Holt, Robert A/C-3303-2009	Fung, Shan-Yu/0000-0002-4547-8740; Marr, Nico/0000-0002-1927-7072; Holt, Robert A/0000-0002-7259-1247; McKinnon, Margaret/0000-0002-3161-414X; Marwaha, Ashish/0000-0003-1234-0224; Seear, Michael/0000-0002-5899-7208; Del Bel, Kate/0000-0001-7669-9530; Priatel, John/0000-0001-8794-6306; , Jacob/0000-0003-4036-2105; Schultz, Kirk/0000-0002-0001-6438; Martin, Spencer/0000-0001-7002-1083; Turvey, Stuart/0000-0003-1599-1065; /0000-0001-7061-6837; Sly, Laura/0000-0002-1673-467X; Friedman, Jan/0000-0002-7482-9570; Tan, Rusung/0000-0002-2204-2004	Canadian Institutes of Health Research Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Greil J, 2013, J ALLERGY CLIN IMMUN, V131, P1376, DOI 10.1016/j.jaci.2013.02.012; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Hirschfeld AF, 2007, CLIN IMMUNOL, V122, P271, DOI 10.1016/j.clim.2006.10.012; Jabara HH, 2013, J ALLERGY CLIN IMMUN, V132, P151, DOI 10.1016/j.jaci.2013.04.047; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Schimke LF, 2010, J ALLERGY CLIN IMMUN, V126, P611, DOI 10.1016/j.jaci.2010.06.029; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Stepensky P, 2013, J ALLERGY CLIN IMMUN, V131, P477, DOI 10.1016/j.jaci.2012.11.050; Tusche MW, 2009, J EXP MED, V206, P2671, DOI 10.1084/jem.20091802; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Xue LQ, 2003, NAT IMMUNOL, V4, P857, DOI 10.1038/ni963	17	82	87	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1458	U373		10.1016/j.jaci.2013.10.045	http://dx.doi.org/10.1016/j.jaci.2013.10.045			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24332264				2022-12-18	WOS:000335450700030
J	Grabenhenrich, LB; Gough, H; Reich, A; Eckers, N; Zepp, F; Nitsche, O; Forster, J; Schuster, A; Schramm, D; Bauer, CP; Hoffmann, U; Beschorner, J; Wagner, P; Bergmann, R; Bergmann, K; Matricardi, PM; Wahn, U; Lau, S; Keil, T				Grabenhenrich, Linus B.; Gough, Hannah; Reich, Andreas; Eckers, Nora; Zepp, Fred; Nitsche, Oliver; Forster, Johannes; Schuster, Antje; Schramm, Dirk; Bauer, Carl-Peter; Hoffmann, Ute; Beschorner, John; Wagner, Petra; Bergmann, Renate; Bergmann, Karl; Matricardi, Paolo Maria; Wahn, Ulrich; Lau, Susanne; Keil, Thomas			Early-life determinants of asthma from birth to age 20 years: A German birth cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Infant; child; preschool; adolescent; heredity; risk factors; epidemiologic factors; survival analysis; hypersensitivity; immunization	GENE-ENVIRONMENT INTERACTIONS; CHILDHOOD ASTHMA; SOCIOECONOMIC-STATUS; PRESCHOOL-CHILDREN; ALLERGEN AVOIDANCE; PRIMARY PREVENTION; MATERNAL SMOKING; TOBACCO-SMOKE; RISK-FACTOR; FOLLOW-UP	Background: The lack of longitudinal data analyses from birth to adulthood is hampering long-term asthma prevention strategies. Objective: We aimed to determine early-life predictors of asthma incidence up to age 20 years in a birth cohort study by applying time-to-event analysis. Methods: In 1990, the Multicenter Allergy Study included 1314 newborns in 5 German cities. Children were evaluated from birth to age 20 years at 19 time points. Using a Cox regression model, we examined the associations between 36 early-life factors and onset of asthma based on a doctor's diagnosis or asthma medication (primary outcome), typical asthma symptoms, or allergic asthma (including positive IgE measurements). Results: Response at 20 years was 71.6%. Two hundred eighteen subjects met the primary outcome criteria within 16,257 person years observed. Asthma incidence was lower in participants who were vaccinated (measles, mumps, and rubella vaccine/tickborne encephalitis vaccine/BCG vaccine: adjusted hazard ratio [HR], 0.66 [95% CI, 0.47-0.93]). Up to age 20 years, asthma incidence was higher in subjects who had parents with allergic rhinitis (adjusted HR, 2.24 [95% CI, 1.67-3.02]), started day care early or late (before 18 months: adjusted HR, 1.79 [95% CI, 1.03-3.10]; after 3 years: adjusted HR, 1.64 [95% CI, 0.96-2.79]), had mothers who smoked during pregnancy (adjusted HR, 1.79 [95% CI, 1.20-2.67]), had poor parents (adjusted HR, 1.55 [95% CI, 1.09-2.22]), and had parents with asthma (adjusted HR, 1.65 [95% CI, 1.17-2.31]). Not associated with asthma were aspects of diet and breast-feeding, pet ownership, presence of older siblings, and passive smoking. Conclusion: Parental asthma and nasal allergy increase asthma incidence in offspring up to adulthood. Avoiding tobacco smoke exposure during pregnancy, receiving vaccinations in early childhood, and starting day care between 1.5 and 3 years of age might prevent or delay the development of asthma.	[Grabenhenrich, Linus B.; Gough, Hannah; Reich, Andreas; Eckers, Nora; Keil, Thomas] Charite, Inst Social Med Epidemiol & Hlth Econ, D-10117 Berlin, Germany; [Wagner, Petra; Matricardi, Paolo Maria; Wahn, Ulrich; Lau, Susanne] Charite, Dept Pediat Pneumol & Immunol, D-10117 Berlin, Germany; [Zepp, Fred; Nitsche, Oliver] Univ Med Ctr Mainz, Ctr Pediat & Adolescent Med, Mainz, Germany; [Forster, Johannes] St Josefs Hosp, Dept Pediat, Freiburg, Germany; [Schuster, Antje; Schramm, Dirk] Univ Dusseldorf, Dept Pediat, Dusseldorf, Germany; [Bauer, Carl-Peter; Hoffmann, Ute] Tech Univ Munich, Dept Pediat, D-80290 Munich, Germany; [Beschorner, John] Westmecklenburg Hosp, Dept Pediat, Hagenow, Germany; [Bergmann, Renate; Bergmann, Karl] Charite, Dept Obstet, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johannes Gutenberg University of Mainz; Heinrich Heine University Dusseldorf; Technical University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Grabenhenrich, LB (corresponding author), Charite, Inst Social Med Epidemiol & Hlth Econ, Luisen Str 57, D-10117 Berlin, Germany.	linus.grabenhenrich@charite.de	Reich, Andreas/B-1204-2016	Reich, Andreas/0000-0002-3729-0772; Lau, Susanne/0000-0002-5189-4265; Grabenhenrich, Linus/0000-0002-9300-6625	German Federal Ministry of Education and Research [07015633, 07 ALE 27, 01EE9405/5, 01EE9406, FKZ: 01GI1121A]; German Research Foundation [KE 1462/2-1]; Kompetenznetz Adipositas (Obesity Competence Network); German Federal Ministry of Education and Research; German Research Foundation; Obesity Competence Network; Allergopharma; Novartis; Infectopharm; GlaxoSmithKline; Merck Sharp Dohme; Forest Labs; Roche; ALK-Abello; HAL Allergy; Grunenthal; Asche-Chiesi; Thermo Fisher Scientific; Nestle; Medapharm; Symbiopharm	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); German Research Foundation(German Research Foundation (DFG)); Kompetenznetz Adipositas (Obesity Competence Network); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); German Research Foundation(German Research Foundation (DFG)); Obesity Competence Network; Allergopharma; Novartis(Novartis); Infectopharm; GlaxoSmithKline(GlaxoSmithKline); Merck Sharp Dohme(Merck & Company); Forest Labs; Roche(Roche Holding); ALK-Abello; HAL Allergy(HAL Allergy Group); Grunenthal(HAL Allergy Group); Asche-Chiesi(Chiesi Pharmaceuticals Inc); Thermo Fisher Scientific; Nestle(Nestle SA); Medapharm; Symbiopharm	The Multicenter Allergy Study (MAS) was funded by grants from the German Federal Ministry of Education and Research (07015633, 07 ALE 27, 01EE9405/5, and 01EE9406) and the German Research Foundation (KE 1462/2-1). This work was further supported by the Kompetenznetz Adipositas (Obesity Competence Network) funded by the German Federal Ministry of Education and Research (FKZ: 01GI1121A).; L. B. Grabenhenrich, A. Reich, N. Eckers, F. Zepp, D. Schramm, U. Hoffmann, J. Beschorner, P. Wagner, R. Bergmann, K. Bergmann, U. Wahn, and T. Keil have received research support from the German Federal Ministry of Education and Research, the German Research Foundation, and the Obesity Competence Network. H. Gough has received research support from the German Federal Ministry of Education and Research, the German Research Foundation, and the Obesity Competence Network and has received travel support from the European Academy of Allergology and Clinical Immunology. O. Nitsche has received research support from the German Federal Ministry of Education and Research, the German Research Foundation, and the Obesity Competence Network; has received payment for lectures from Allergopharma; and has received payment for manuscript preparation from Novartis; and has received travel support from Chiesi, Allergopharma, Abbott, Infectopharm, and Novartis. J. Forster has received research support from the German Federal Ministry of Education and Research, the German Research Foundation, and the Obesity Competence Network and has received payment for expert testimony from Infectopharm. A. Schuster has received research support from the German Federal Ministry of Education and Research, the German Research Foundation, and the Obesity Competence Network; has consultant arrangements from HAL Allergy/Leiden and ALK-Abello; and has received payment for lectures from GlaxoSmithKline, Merck Sharp Dohme, Forest Labs, Roche, Novartis, ALK-Abello, HAL Allergy, Grunenthal, Asche-Chiesi, and Thermo Fisher Scientific. C.-P. Bauer has received research support from the German Federal Ministry of Education and Research, the German Research Foundation, and the Obesity Competence Network and has received payment for lectures from Nestle, Merck Sharp Dohme, and Medapharm. P. M. Matricardi has received research support from the German Federal Ministry of Education and Research, the German Research Foundation, the Obesity Competence Network, and Trial Form Support and has received payment for lectures from Allergopharma and Trial Form Support. S. Lau has received research support from the German Federal Ministry of Education and Research, the German Research Foundation, the Obesity Competence Network, Symbiopharm Herborn, Germany, and Allergopharma and has received payment for lectures from Symbiopharm and GlaxoSmithKline.	Almqvist C, 2005, CLIN EXP ALLERGY, V35, P612, DOI 10.1111/j.1365-2222.2005.02243.x; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bergmann R L, 1993, Pediatr Allergy Immunol, V4, P130, DOI 10.1111/j.1399-3038.1993.tb00081.x; Brew BK, 2011, PAEDIATR PERINAT EP, V25, P507, DOI 10.1111/j.1365-3016.2011.01233.x; Burke H, 2012, PEDIATRICS, V129, P735, DOI 10.1542/peds.2011-2196; Carlsen KCL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043214; Carlsen KCL, 2006, ALLERGY, V61, P454, DOI 10.1111/j.1398-9995.2005.00938.x; COLE TJ, 1990, EUR J CLIN NUTR, V44, P45; Cookson W, 2011, J ALLERGY CLIN IMMUN, V128, P266, DOI 10.1016/j.jaci.2011.06.026; COX DR, 1972, J R STAT SOC B, V34, P187; Custovic A, 2012, EXPERT REV RESP MED, V6, P301, DOI [10.1586/ERS.12.24, 10.1586/ers.12.24]; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; El-Zein M, 2010, INT J EPIDEMIOL, V39, P469, DOI 10.1093/ije/dyp307; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; Gehring U, 2012, ALLERGY, V67, P248, DOI 10.1111/j.1398-9995.2011.02739.x; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429, DOI 10.1164/ajrccm.163.2.2006009; Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008; Gruber C, 2002, PEDIAT ALLERG IMM-UK, V13, P177, DOI 10.1034/j.1399-3038.2002.01006.x; Gruber C, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e282; Guerra S, 2008, ANNU REV MED, V59, P327, DOI 10.1146/annurev.med.59.060406.213232; Hafkamp-de Groen E, 2012, J EPIDEMIOL COMMUN H, V66, P1017, DOI 10.1136/jech-2011-200333; Hancox RJ, 2004, THORAX, V59, P376, DOI 10.1136/thx.2003.010363; Koeppen-Schomerus G, 2001, ARCH DIS CHILD, V85, P398, DOI 10.1136/adc.85.5.398; Kramer MS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003517.pub2; Kulig M, 1999, ALLERGY, V54, P220, DOI 10.1034/j.1398-9995.1999.00753.x; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Martino D, 2011, CHEST, V139, P640, DOI 10.1378/chest.10-1800; Mielck A, 1996, INT J EPIDEMIOL, V25, P388, DOI 10.1093/ije/25.2.388; Neuman A, 2012, AM J RESP CRIT CARE, V186, P1037, DOI 10.1164/rccm.201203-0501OC; Nicolaou NC, 2008, J ALLERGY CLIN IMMUN, V122, P500, DOI 10.1016/j.jaci.2008.06.033; Nissen SP, 2013, PEDIAT ALLERG IMM-UK, V24, P549, DOI 10.1111/pai.12108; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Pesonen M, 2009, PEDIAT ALLERG IMM-UK, V20, P12, DOI 10.1111/j.1399-3038.2008.00736.x; Prescott SL, 2010, P NUTR SOC, V69, P366, DOI 10.1017/S0029665110001874; Rona RJ, 2000, THORAX, V55, P239, DOI 10.1136/thorax.55.3.239; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Savenije OEM, 2012, J ALLERGY CLIN IMMUN, V130, P325, DOI 10.1016/j.jaci.2012.05.007; Simpson A, 2004, CURR OPIN ALLERGY CL, V4, P45, DOI [10.1097/00130832-200402000-00010, 10.1097/01.all.0000113678.18759.38]; Sly PD, 2011, CURR OPIN ALLERGY CL, V11, P24, DOI 10.1097/ACI.0b013e328342309d; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1998, THORAX, V53, P204, DOI 10.1136/thx.53.3.204; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Tischer CG, 2011, ALLERGY, V66, P1570, DOI 10.1111/j.1398-9995.2011.02712.x; Turner S, 2011, THORAX, V66, P1104, DOI 10.1136/thoraxjnl-2011-200213; van Schayck OCP, 2007, J ALLERGY CLIN IMMUN, V119, P1323, DOI 10.1016/j.jaci.2007.02.024; von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P3, DOI 10.1016/j.jaci.2008.10.046; White IR, 2009, STAT MED, V28, P1982, DOI 10.1002/sim.3618	50	82	84	1	37	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					979	+		10.1016/j.jaci.2013.11.035	http://dx.doi.org/10.1016/j.jaci.2013.11.035			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24461583				2022-12-18	WOS:000333531700005
J	Oyoshi, MK; Oettgen, HC; Chatila, TA; Geha, RS; Bryce, PJ				Oyoshi, Michiko K.; Oettgen, Hans C.; Chatila, Talal A.; Geha, Raif S.; Bryce, Paul J.			Food allergy: Insights into etiology, prevention, and treatment provided by murine models	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; anaphylaxis; murine model; microbiota; regulatory T cells	REGULATORY T-CELLS; THYMIC STROMAL LYMPHOPOIETIN; EXERCISE-INDUCED ANAPHYLAXIS; OF-FUNCTION VARIANTS; DENDRITIC CELLS; ORAL TOLERANCE; MOUSE MODEL; MAST-CELLS; EPICUTANEOUS SENSITIZATION; FULL EXPRESSION	Food allergy is a rapidly growing public health concern because of its increasing prevalence and life-threatening potential. Animal models of food allergy have emerged as a tool for identifying mechanisms involved in the development of sensitization to normally harmless food allergens, as well as delineating the critical immune components of the effector phase of allergic reactions to food. However, the role animal models might play in understanding human diseases remains contentious. This review summarizes how animal models have provided insights into the etiology of human food allergy, experimental corroboration for epidemiologic findings that might facilitate prevention strategies, and validation for the utility of new therapies for food allergy. Improved understanding of food allergy from the study of animal models together with human studies is likely to contribute to the development of novel strategies to prevent and treat food allergy.	[Oyoshi, Michiko K.; Oettgen, Hans C.; Chatila, Talal A.; Geha, Raif S.] Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Oyoshi, Michiko K.; Oettgen, Hans C.; Chatila, Talal A.; Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Bryce, Paul J.] Northwestern Univ, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60611 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Northwestern University; Feinberg School of Medicine	Oyoshi, MK (corresponding author), Boston Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	michiko.oyoshi@childrens.harvard.edu; p-bryce@northwestern.edu		Oettgen, Hans/0000-0003-1199-1391; Chatila, Talal/0000-0001-7439-2762	National Institutes of Health (NIH) [R21 AI 080002, R56 AI100889-01, R56 AI105839-01]; Department of Defense [11-1-0553]; Bunning Foundation; Harvard Digestive Disease Center, NIH [P30 DK34845]; Children's Hospital Boston Faculty Career Development Fellowship/Eleanor and Miles Shore Program for Scholars in Medicine at Harvard Medical School; Children's Hospital Pediatric Associates Award; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI100889, R56AI105839, R21AI080002, R01AI105839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Bunning Foundation; Harvard Digestive Disease Center, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Hospital Boston Faculty Career Development Fellowship/Eleanor and Miles Shore Program for Scholars in Medicine at Harvard Medical School; Children's Hospital Pediatric Associates Award; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by National Institutes of Health (NIH) grants R21 AI 080002 (to T.A.C.), R56 AI100889-01 (to H.C.O.), and R56 AI105839-01 (to P.J.B.); Department of Defense grant award 11-1-0553 (to T.A.C.); and the Bunning Foundation (to R.S.G.). M.K.O. was supported by the Harvard Digestive Disease Center, NIH grant P30 DK34845, the Children's Hospital Boston Faculty Career Development Fellowship/Eleanor and Miles Shore Program for Scholars in Medicine at Harvard Medical School, and a Children's Hospital Pediatric Associates Award.	Ahrens R, 2012, AM J PATHOL, V180, P1535, DOI 10.1016/j.ajpath.2011.12.036; Ando T, 2013, J INVEST DERMATOL, V133, P2695, DOI 10.1038/jid.2013.250; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Arias K, 2011, J ALLERGY CLIN IMMUN, V127, P1552, DOI 10.1016/j.jaci.2011.03.044; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Bartnikas LM, 2013, J ALLERGY CLIN IMMUN, V131, P451, DOI 10.1016/j.jaci.2012.11.032; Bashir MEH, 2004, J IMMUNOL, V172, P6978, DOI 10.4049/jimmunol.172.11.6978; Berin MC, 2006, ALLERGY, V61, P64, DOI 10.1111/j.1398-9995.2006.01012.x; Birmingham NP, 2007, INT ARCH ALLERGY IMM, V144, P203, DOI 10.1159/000103993; Blazquez AB, 2008, J IMMUNOL, V180, P4441, DOI 10.4049/jimmunol.180.7.4441; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Brandt EB, 2009, J ALLERGY CLIN IMMUN, V123, P53, DOI 10.1016/j.jaci.2008.10.001; Brightbill HD, 2010, J CLIN INVEST, V120, P2218, DOI 10.1172/JCI40141; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Burton OT, 2013, MUCOSAL IMMUNOL, V6, P740, DOI 10.1038/mi.2012.112; Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Curciarello R, 2008, CLIN EXP ALLERGY, V38, P1559, DOI 10.1111/j.1365-2222.2008.03062.x; Dehlink E, 2009, CLIN EXP ALLERGY, V39, P246, DOI 10.1111/j.1365-2222.2008.03125.x; Dunkin D, 2011, J ALLERGY CLIN IMMUN, V128, P1251, DOI 10.1016/j.jaci.2011.06.007; Faeste CK, 2009, J ALLERGY CLIN IMMUN, V123, P187, DOI 10.1016/j.jaci.2008.09.012; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Flokstra-de Blok BMJ, 2010, ALLERGY, V65, P238, DOI 10.1111/j.1398-9995.2009.02121.x; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Fox DE, 1998, LANCET, V352, P741, DOI 10.1016/S0140-6736(05)60863-X; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Ganeshan K, 2012, J IMMUNOL, V188, P594, DOI 10.4049/jimmunol.1102389; Geuking MB, 2011, IMMUNITY, V34, P794, DOI 10.1016/j.immuni.2011.03.021; Gonipeta B, 2010, INT ARCH ALLERGY IMM, V152, P219, DOI 10.1159/000283028; Groschwitz KR, 2009, J ALLERGY CLIN IMMUN, V124, P3, DOI 10.1016/j.jaci.2009.05.038; Grotenboer NS, 2013, J ALLERGY CLIN IMMUN, V131, P856, DOI 10.1016/j.jaci.2012.11.028; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Hammerschmidt SI, 2011, J CLIN INVEST, V121, P3051, DOI 10.1172/JCI44262; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; JUJI F, 1994, ANN ALLERGY, V72, P452; Khodoun MV, 2011, P NATL ACAD SCI USA, V108, P12413, DOI 10.1073/pnas.1105695108; Knight AK, 2007, AM J PHYSIOL-GASTR L, V293, pG1234, DOI 10.1152/ajpgi.00323.2007; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lathrop SK, 2011, NATURE, V478, P250, DOI 10.1038/nature10434; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V129, P1579, DOI 10.1016/j.jaci.2012.04.009; Lin RY, 2000, ANN EMERG MED, V36, P462, DOI 10.1067/mem.2000.109445; Lopez-Exposito I, 2009, J ALLERGY CLIN IMMUN, V124, P1039, DOI 10.1016/j.jaci.2009.08.024; Lutterotti A, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006168; Mancardi DA, 2013, BLOOD, V121, P1563, DOI 10.1182/blood-2012-07-442541; Marrs T, 2013, PEDIAT ALLERG IMM-UK, V24, DOI 10.1111/pai.12064; Martos Gustavo, 2011, J Allergy Clin Immunol, V127, P990, DOI 10.1016/j.jaci.2011.01.057; Martos G, 2011, J ALLERGY CLIN IMMUN, V127, P990, DOI 10.1016/j.jaci.2011.01.057; Mathias CB, 2011, J ALLERGY CLIN IMMUN, V127, P795, DOI 10.1016/j.jaci.2010.11.009; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; Miller SD, 2007, NAT REV IMMUNOL, V7, P665, DOI 10.1038/nri2153; Mondoulet L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031967; Moneret-Vautrin DA, 1999, J ALLERGY CLIN IMMUN, V104, P883, DOI 10.1016/S0091-6749(99)70303-9; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; Mosconi E, 2010, MUCOSAL IMMUNOL, V3, P461, DOI 10.1038/mi.2010.23; Motzer RJ, 2006, EXPERT OPIN INV DRUG, V15, P553, DOI 10.1517/13543784.15.5.553; Nurmatov U, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009014.pub2; Osterfeld H, 2010, J ALLERGY CLIN IMMUN, V125, P469, DOI 10.1016/j.jaci.2009.09.054; Otsuka A, 2013, J ALLERGY CLIN IMMUN; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Oyoshi MK, 2011, J CLIN INVEST, V121, P2210, DOI 10.1172/JCI43586; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, P976, DOI 10.1016/j.jaci.2010.08.041; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Pabst O, 2012, MUCOSAL IMMUNOL, V5, P232, DOI 10.1038/mi.2012.4; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Patil SP, 2011, J ALLERGY CLIN IMMUN, V128, P1259, DOI 10.1016/j.jaci.2011.06.015; Perlman H, 2013, AM J RESP CRIT CARE, V187, P898, DOI 10.1164/rccm.201303-0489ED; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Rozenfeld P, 2002, CLIN EXP IMMUNOL, V130, P49, DOI 10.1046/j.1365-2249.2002.t01-1-01935.x; Ruiter B, 2012, J ALLERGY CLIN IMMUN, V129, P921, DOI 10.1016/j.jaci.2012.01.080; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Scholl I, 2007, FASEB J, V21, P1264, DOI 10.1096/fj.06-7223com; Scholl L, 2005, AM J CLIN NUTR, V81, P154; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V126, P1191, DOI 10.1016/j.jaci.2010.08.036; Smaldini P, 2012, INT ARCH ALLERGY IMM, V158, P335, DOI 10.1159/000333562; Smarr CB, 2011, J IMMUNOL, V187, P5090, DOI 10.4049/jimmunol.1100608; Smit JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028917; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Srivastava KD, 2009, J ALLERGY CLIN IMMUN, V123, P443, DOI 10.1016/j.jaci.2008.12.1107; Strait RT, 2011, J ALLERGY CLIN IMMUN, V127, P982, DOI 10.1016/j.jaci.2011.01.034; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Sugimura T, 2009, CLIN PEDIATR, V48, P945, DOI 10.1177/0009922809337528; Untersmayr E, 2005, FASEB J, V19, P656, DOI 10.1096/fj.04-3170fje; Untersmayr E, 2008, J ALLERGY CLIN IMMUN, V121, P1301, DOI 10.1016/j.jaci.2008.04.025; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; Vickery BP, 2010, CURR OPIN PEDIATR, V22, P765, DOI 10.1097/MOP.0b013e32833f5fc0; Wang JL, 2013, CURR OPIN ALLERGY CL, V13, P386, DOI 10.1097/ACI.0b013e3283615bc4; Wang J, 2011, J CLIN INVEST, V121, P827, DOI [10.1172/JCI45434, 10.1186/1710-1492-7-S1-S7]; Wechsler JB, 2013, ALLERGY, V68, P1338, DOI 10.1111/all.12227; Yamaki K, 2012, ALLERGY, V67, P1259, DOI 10.1111/all.12000; Yamaki K, 2012, ALLERGY, V67, P114, DOI 10.1111/j.1398-9995.2011.02717.x; Yamamoto T, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/721085; Yang PC, 2007, GASTROENTEROLOGY, V133, P1522, DOI 10.1053/j.gastro.2007.08.006; Yu M, 2011, J CLIN INVEST, V121, P3133, DOI 10.1172/JCI43598	105	82	84	1	42	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					309	317		10.1016/j.jaci.2013.12.1045	http://dx.doi.org/10.1016/j.jaci.2013.12.1045			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24636470	Green Accepted			2022-12-18	WOS:000332397100002
J	Olmedo, O; Goldstein, IF; Acosta, L; Divjan, A; Rundle, AG; Chew, GL; Mellins, RB; Hoepner, L; Andrews, H; Lopez-Pintado, S; Quinn, JW; Perera, FP; Miller, RL; Jacobson, JS; Perzanowski, MS				Olmedo, Omar; Goldstein, Inge F.; Acosta, Luis; Divjan, Adnan; Rundle, Andrew G.; Chew, Ginger L.; Mellins, Robert B.; Hoepner, Lori; Andrews, Howard; Lopez-Pintado, Sara; Quinn, James W.; Perera, Frederica P.; Miller, Rachel L.; Jacobson, Judith S.; Perzanowski, Matthew S.			Neighborhood differences in exposure and sensitization to cockroach, mouse, dust mite, cat, and dog allergens in New York City	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; urban; cockroach; mouse; dust mite; allergy	INNER-CITY; ENVIRONMENTAL INTERVENTION; NATIONAL PREVALENCE; INDOOR ALLERGENS; ASTHMA; CHILDREN; RISK; WHEEZE; OWNERSHIP; MORBIDITY	Background: Asthma prevalence varies widely among neighborhoods within New York City. Exposure to mouse and cockroach allergens has been suggested as a cause. Objective: To test the hypotheses that children living in high asthma prevalence neighborhoods (HAPNs) would have higher concentrations of cockroach and mouse allergens in their homes than children in low asthma prevalence neighborhoods (LAPNs), and that these exposures would be related to sensitization and asthma. Methods: In the New York City Neighborhood Asthma and Allergy Study, a case-control study of asthma, children 7 to 8 years old from HAPNs (n = 120) and LAPNs (n = 119) were recruited through the same middle-income health insurance plan. Children were classified as asthma cases (n = 128) or controls without asthma (n = 111) on the basis of reported symptoms or medication use. Allergens were measured in bed dust. Results: HAPN homes had higher Bla g 2 (P = .001), Mus m 1 (P = .003), and Fel d 1 (P = .003) and lower Der f 1 (P = .001) than LAPN homes. Sensitization to indoor allergens was associated with asthma, but relevant allergens differed between LAPNs and HAPNs. Sensitization to cockroach was more common among HAPN than LAPN children (23.7% vs 10.8%; P = .011). Increasing allergen exposure was associated with increased probability of sensitization (IgE) to cockroach (P < .001), dust mite (P = .009), and cat (P = .001), but not mouse (P = .58) or dog (P = .85). Conclusion: These findings further demonstrate the relevance of exposure and sensitization to cockroach and mouse in an urban community and suggest that cockroach allergen exposure could contribute to the higher asthma prevalence observed in some compared with other New York City neighborhoods. (J Allergy Clin Immunol 2011;128:284-92.)	[Olmedo, Omar; Acosta, Luis; Divjan, Adnan; Chew, Ginger L.; Hoepner, Lori; Perera, Frederica P.; Miller, Rachel L.; Perzanowski, Matthew S.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA; [Goldstein, Inge F.; Rundle, Andrew G.; Jacobson, Judith S.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA; [Hoepner, Lori; Andrews, Howard] Columbia Univ, Mailman Sch Publ Hlth, Data Coordinating Ctr, New York, NY 10032 USA; [Andrews, Howard; Lopez-Pintado, Sara] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY 10032 USA; [Mellins, Robert B.; Miller, Rachel L.] Columbia Univ, Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; [Miller, Rachel L.] Columbia Univ, Coll Phys & Surg, Dept Med, Div Pulm, New York, NY 10032 USA; [Quinn, James W.] Columbia Univ, Inst Social & Econ Res & Policy, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Perzanowski, MS (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, 60 Haven Ave,B-1, New York, NY 10032 USA.	mp2217@columbia.edu	Rundle, Andrew G/A-5282-2009	Rundle, Andrew G/0000-0003-0211-7707; Divjan, Adnan/0000-0002-8895-5965; Hoepner, Lori/0000-0002-4404-8140	National Institute of Environmental Health Sciences [ES 014400, P30 ES009089, P01 ES09600, P50 ES015905, RO1 ES08977]; National Institutes of Health; US Environmental Protection Agency; Phadia; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P50ES015905, P01ES009600, R01ES014400, P30ES009089, R01ES008977] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Environmental Protection Agency(United States Environmental Protection Agency); Phadia(Phadia); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institute of Environmental Health Sciences grant nos. ES 014400, P30 ES009089, P01 ES09600, P50 ES015905, and RO1 ES08977.; R. L. Miller has received research support from the National Institutes of Health and the US Environmental Protection Agency and is a member of the American Thoracic Society and the American Academy of Allergy, Asthma & Immunology. M. S. Perzanowski has received travel funding for EAACI from Phadia. The rest of the authors have declared that they have no conflict of interest.	Al-Mousawi MSH, 2004, J ALLERGY CLIN IMMUN, V114, P1389, DOI 10.1016/j.jaci.2004.09.005; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V111, P408, DOI 10.1067/mai.2003.16; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P803, DOI 10.1016/j.jaci.2009.11.048; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P529, DOI 10.1016/j.jaci.2010.01.036; Chapman Martin D, 2009, Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess, V96, P21; CHAPMAN MD, 2009, ARB PAUL EHRLICH I B, V96, P5; Chew GL, 2008, J ALLERGY CLIN IMMUN, V121, P240, DOI 10.1016/j.jaci.2007.08.024; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Chew GL, 2005, INDOOR AIR, V15, P228, DOI 10.1111/j.1600-0668.2005.00363.x; Chew GL, 2003, ENVIRON HEALTH PERSP, V111, P1348, DOI 10.1289/ehp.6124; Cohn RD, 2006, ENVIRON HEALTH PERSP, V114, P522, DOI 10.1289/ehp.8561; Cohn RD, 2004, J ALLERGY CLIN IMMUN, V113, P1167, DOI 10.1016/j.jaci.2003.12.592; CRAIN EF, 1994, PEDIATRICS, V94, P356; Donohue KM, 2008, J ALLERGY CLIN IMMUN, V122, P914, DOI 10.1016/j.jaci.2008.08.034; Earle CD, 2007, J ALLERGY CLIN IMMUN, V119, P428, DOI 10.1016/j.jaci.2006.11.004; Garg R., 2003, ASTHMA FACTS, VSecond; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gupta RS, 2008, J ALLERGY CLIN IMMUN, V121, P639, DOI 10.1016/j.jaci.2007.11.036; Gupta RS, 2009, J ALLERGY CLIN IMMUN, V123, P1297, DOI 10.1016/j.jaci.2009.03.039; Holt PG, 2009, ADV IMMUNOL, V104, P51, DOI 10.1016/S0065-2776(08)04003-0; Jacobson JS, 2008, ALLERGY, V63, P87, DOI 10.1111/j.1398-9995.2007.01529.x; KASS D, 2005, NYC VITAL SIGNS, V4, P1; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Lin S, 1999, J ASTHMA, V36, P239, DOI 10.3109/02770909909075407; Lovasi GS, 2009, EPIDEMIOL REV, V31, P7, DOI 10.1093/epirev/mxp005; Matricardi PM, 2009, CLIN EXP ALLERGY, V39, P1551, DOI 10.1111/j.1365-2222.2009.03348.x; Matsui EC, 2005, J ALLERGY CLIN IMMUN, V115, P358, DOI 10.1016/j.jaci.2004.11.007; Melen E, 2001, ALLERGY, V56, P646, DOI 10.1034/j.1398-9995.2001.00387.x; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Perzanowski MS, 2008, J ALLERGY CLIN IMMUN, V121, P1047, DOI 10.1016/j.jaci.2008.02.005; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Pongracic JA, 2008, ANN ALLERG ASTHMA IM, V101, P35, DOI 10.1016/S1081-1206(10)60832-0; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Togias A, 2010, J ALLERGY CLIN IMMUN, V125, P540, DOI 10.1016/j.jaci.2010.01.040	40	82	83	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					284	U291		10.1016/j.jaci.2011.02.044	http://dx.doi.org/10.1016/j.jaci.2011.02.044			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21536321	Green Accepted			2022-12-18	WOS:000293280800006
J	Shaheen, SO; Newson, RB; Ring, SM; Rose-Zerilli, MJ; Holloway, JW; Henderson, AJ				Shaheen, Seif O.; Newson, Roger B.; Ring, Susan M.; Rose-Zerilli, Matthew J.; Holloway, John W.; Henderson, A. John			Prenatal and infant acetaminophen exposure, antioxidant gene polymorphisms, and childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; acetaminophen; paracetamol; glutathione-S-transferase; Nrf2; prenatal exposure; delayed effects; ALSPAC; pregnancy; birth cohort; genotype; gene-environment interaction	PARACETAMOL USE; LUNG-FUNCTION; RISK; CHILDREN; NRF2; GLUTATHIONE; PREGNANCY; HEPATOTOXICITY; SENSITIZATION; SYMPTOMS	Background: Prenatal and infant acetaminophen exposure has been associated with an increased risk of childhood asthma phenotypes. Demonstration of biologically plausible interactions between these exposures and maternal and child antioxidant gene polymorphisms would strengthen causal inference. Objective: To explore potential interactions between prenatal and infant acetaminophen exposure and antioxidant genotypes on childhood asthma. Methods: In the Avon Longitudinal Study of Parents and Children, we typed a functional nuclear erythroid 2 p45-related factor 2 (Nrf2) polymorphism and glutathione S-transferase (GST) M1, T1, and P1 polymorphisms. Effects of prenatal and infant acetaminophen exposure on asthma phenotypes at 7 years were stratified by genotype in >4000 mothers and >5000 children. Results: Risk of asthma and wheezing associated with early gestation acetaminophen exposure was increased when maternal copies of the minor T allele of Nrf2 were present (P interactions, .02 and .04, respectively). Risk of asthma associated with late gestation exposure was higher when maternal GSTT1 genotype was present rather than absent (P interaction, .006), and risk of wheezing was increased when maternal GSTM1 was present (P interaction,.04). Although acetaminophen use in infancy was associated with an increased risk of atopy, child antioxidant genotype did not modify associations between infant acetaminophen use and asthma phenotypes. However, the increased risk of asthma and wheezing associated with late gestation acetaminophen exposure in the presence of maternal GSTM1 was further enhanced when GSTM1 was also present in the child. Conclusion: Maternal antioxidant gene polymorphisms may modify the relation between prenatal acetaminophen exposure and childhood asthma, strengthening evidence for a causal association. In contrast, relations between infant acetaminophen use and asthma and atopy were not modified by child genotype and may be confounded by pre-existing wheeze or allergy. (J Allergy Clin Immunol 2010;126:1141-8.)	[Shaheen, Seif O.; Newson, Roger B.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Resp Epidemiol & Publ Hlth Grp, London, England; [Ring, Susan M.] Univ Bristol, Dept Social Med, Bristol, Avon, England; [Henderson, A. John] Univ Bristol, Dept Community Based Med, Bristol, Avon, England; [Rose-Zerilli, Matthew J.; Holloway, John W.] Univ Southampton, Div Infect Inflammat & Immun, Resp Genet Grp, Southampton SO9 5NH, Hants, England; [Rose-Zerilli, Matthew J.; Holloway, John W.] Univ Southampton, Div Human Genet, Southampton SO9 5NH, Hants, England	Imperial College London; University of Bristol; University of Bristol; University of Southampton; University of Southampton	Shaheen, SO (corresponding author), Barts & London Queen Marys Sch Med & Dent, Ctr Hlth Sci, MRC, 2 Newark St, London E1 2AT, England.	s.shaheen@qmul.ac.uk	Holloway, John W/B-5424-2009	Holloway, John W/0000-0001-9998-0464; Rose-Zerilli, Matthew/0000-0002-1064-5350; Henderson, Alexander John/0000-0001-9650-231X	British Lung Foundation; Asthma UK; Medical Research Council; UK Department of Health; Wellcome Trust; European Union; Medical Research Council UK; MRC [G0401540] Funding Source: UKRI; Medical Research Council [G9815508, G0401540] Funding Source: researchfish	British Lung Foundation; Asthma UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Department of Health; Wellcome Trust(Wellcome Trust); European Union(European Commission); Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The UK Medical Research Council, the Wellcome Trust, and the University of Bristol provide core support for the Avon Longitudinal Study of Parents and Children. This study was funded by the British Lung Foundation. S.O.S. was an Asthma UK Senior Research Fellow.; Disclosure of potential conflict of interest: S. O. Shaheen receives research support from Asthma UK and the Medical Research Council. R. B. Newson receives compensation from the UK Department of Health Policy Research Programme. S. M. Ring receives research support from the Wellcome Trust, the Medical Research Council, and the European Union. J. W. Holloway receives research support from the Medical Research Council UK and Asthma UK. A. J. Henderson receives research support from the Medical Research Council UK and the Wellcome Trust. M. J. Rose-Zerilli has declared that he has no conflict of interest.	[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Arets HGM, 2001, EUR RESPIR J, V18, P655, DOI 10.1183/09031936.01.00204301; Barr RG, 2008, LANCET, V372, P1011, DOI 10.1016/S0140-6736(08)61417-8; Beasley R, 2008, LANCET, V372, P1039, DOI 10.1016/S0140-6736(08)61445-2; Bisgaard H, 2009, J ALLERGY CLIN IMMUN, V123, P651, DOI 10.1016/j.jaci.2008.11.036; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; CHEN TC, 1990, ARCH NEUROL-CHICAGO, V47, P1227, DOI 10.1001/archneur.1990.00530110087022; CHINN S, 1992, THORAX, V47, pP236; Cho HY, 2006, ANTIOXID REDOX SIGN, V8, P76, DOI 10.1089/ars.2006.8.76; Cho HY, 2010, TOXICOL APPL PHARM, V244, P43, DOI 10.1016/j.taap.2009.07.024; COLES B, 1988, ARCH BIOCHEM BIOPHYS, V264, P253, DOI 10.1016/0003-9861(88)90592-9; Davey G, 2005, J ALLERGY CLIN IMMUN, V116, P863, DOI 10.1016/j.jaci.2005.05.045; Dimova S, 2005, INT J BIOCHEM CELL B, V37, P1727, DOI 10.1016/j.biocel.2005.03.005; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Etminan M, 2009, CHEST, V136, P1316, DOI 10.1378/chest.09-0865; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Henderson CJ, 2000, P NATL ACAD SCI USA, V97, P12741, DOI 10.1073/pnas.220176997; Hernan MA, 2002, AM J EPIDEMIOL, V155, P176, DOI 10.1093/aje/155.2.176; LARREY D, 1986, J PHARMACOL EXP THER, V237, P283; LEVY G, 1975, PEDIATRICS, V55, P895; Lu B, 2001, J AM STAT ASSOC, V96, P1245, DOI 10.1198/016214501753381896; Marzec JM, 2007, FASEB J, V21, P2237, DOI 10.1096/fj.06-7759com; Newson RB, 2000, EUR RESPIR J, V16, P817, DOI 10.1183/09031936.00.16581700; Nuttall SL, 2003, J CLIN PHARM THER, V28, P289, DOI 10.1046/j.1365-2710.2003.00493.x; Persky V, 2008, ANN ALLERG ASTHMA IM, V101, P271, DOI 10.1016/S1081-1206(10)60492-9; Perzanowski MS, 2010, THORAX, V65, P118, DOI 10.1136/thx.2009.121459; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rebordosa C, 2008, INT J EPIDEMIOL, V37, P583, DOI 10.1093/ije/dyn070; Rebordosa C, 2009, INT J EPIDEMIOL, V38, P706, DOI 10.1093/ije/dyp151; Reisman SA, 2009, TOXICOL SCI, V109, P31, DOI 10.1093/toxsci/kfp047; Roberts G, 2005, CLIN EXP ALLERGY, V35, P933, DOI 10.1111/j.1365-2222.2005.02280.x; ROLLINS DE, 1979, SCIENCE, V205, P1414, DOI 10.1126/science.38505; Rose-Zerilli MJ, 2009, CLIN CHEM, V55, P1680, DOI 10.1373/clinchem.2008.120105; Shaheen SO, 2010, INT J EPIDEMIOL, V39, P790, DOI 10.1093/ije/dyq049; Shaheen SO, 2005, CLIN EXP ALLERGY, V35, P18, DOI 10.1111/j.1365-2222.2005.02151.x; Shaheen SO, 2000, THORAX, V55, P266, DOI 10.1136/thorax.55.4.266; Shaheen SO, 2002, THORAX, V57, P958, DOI 10.1136/thorax.57.11.958; Siedlinski M, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-73; StataCorp, 2009, STAT STAT SOFTW; Wolf CR, 2001, CHEM-BIOL INTERACT, V133, P280; Yamamoto T, 2004, BIOCHEM BIOPH RES CO, V321, P72, DOI 10.1016/j.bbrc.2004.06.112; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	42	82	84	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1141	U124		10.1016/j.jaci.2010.08.047	http://dx.doi.org/10.1016/j.jaci.2010.08.047			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21051083	Green Accepted			2022-12-18	WOS:000284947800009
J	Sicherer, SH; Wood, RA; Stablein, D; Burks, AW; Liu, AH; Jones, SM; Fleischer, DM; Leung, DYM; Grishin, A; Mayer, L; Shreffler, W; Lindblad, R; Sampson, HA				Sicherer, Scott H.; Wood, Robert A.; Stablein, Donald; Burks, A. Wesley; Liu, Andrew H.; Jones, Stacie M.; Fleischer, David M.; Leung, Donald Y. M.; Grishin, Alexander; Mayer, Lloyd; Shreffler, Wayne; Lindblad, Robert; Sampson, Hugh A.			Immunologic features of infants with milk or egg allergy enrolled in an observational study (Consortium of Food Allergy Research) of food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; sensitization; atopy	PEANUT ALLERGY; NATURAL-HISTORY; ATOPIC-DERMATITIS; T-CELLS; CHILDREN; PREVALENCE; BASOPHILS; IGE; HYPERSENSITIVITY; DIFFERENTIATION	Background: Immune features of infants with food allergy have not been delineated. Objectives: We sought to explore the basic mechanisms responsible for food allergy and identify biomarkers, such as skin prick test (SPT) responses, food-specific IgE levels, and mononuclear cell responses, in a cohort of infants with likely milk/egg allergy at increased risk of peanut allergy. Methods: Infants aged 3 to 15 months were enrolled with a positive SPT response to milk or egg and either a corresponding convincing clinical history of allergy to milk or egg or moderate-to-severe atopic dermatitis. Infants with known peanut allergy were excluded. Results: Overall, 512 infants (67% male) were studied, with 308 (60%) having a history of a clinical reaction. Skin test responses, detectable food-specific IgE, or both revealed sensitization as follows: milk, 78%; egg, 89%; and peanut, 69%. SPT responses and food-specific IgE levels were discrepant for peanut (15% for IgE >= 0.35 kU(A)/L and negative SPT response vs 8% for positive SPT response and IgE <0.35 kU(A)/L, P = .001). Mononuclear cell allergen stimulation screening for CD25, cytokine-inducible SH2-containing protein (CISH), forkhead box protein 3 (FOXP3), GATA3, IL10, IL4, IFNG, and T-box transcription factor (TBET) expression by using casein, egg white, and peanut revealed that only allergen-induced 11,4 expression was significantly increased in those with clinical allergy to milk (compared with nonallergic subjects) and in those sensitized to peanut, despite the absence of an increase in GATA3 mRNA expression. Conclusions: Infants with likely milk/egg allergy are at considerably high risk of having increased peanut-specific IgE levels (potential allergy). Peanut-specific serum IgE levels were a more sensitive indicator of sensitization than SPT responses. Allergen-specific IL4 expression might be a marker of allergic risk. Absence of an increase in GATA3 mRNA expression suggests that allergen-specific IL-4 might not be of T-cell origin. (J Allergy Clin Immunol 2010;125:1077-83.)	[Sicherer, Scott H.; Grishin, Alexander; Mayer, Lloyd; Shreffler, Wayne; Sampson, Hugh A.] Mt Sinai Hosp, Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol,Dept Pediat, New York, NY 10029 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; [Stablein, Donald; Lindblad, Robert] EMMES Corp, Rockville, MD USA; [Burks, A. Wesley] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27706 USA; [Liu, Andrew H.; Fleischer, David M.; Leung, Donald Y. M.] Natl Jewish Hlth, Div Pediat Allergy & Clin Immunol, Denver, CO USA; [Jones, Stacie M.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA	Icahn School of Medicine at Mount Sinai; Johns Hopkins University; Emmes Corporation; Duke University; National Jewish Health; University of Arkansas System; University of Arkansas Medical Sciences	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu			National Institutes of Health/National Institute of Allergy and Infectious Diseases [U19AI066738, U01AI066560]; National Center for Research Resources [RR-024128, RR-00052]; National Jewish Health [UL1 RR025780]; Mount Sinai [UL1 RR 029887]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025005, UL1RR024128, UL1RR025780, UL1RR029887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI066560, U19AI066738] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Jewish Health; Mount Sinai; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases U19AI066738 and U01AI066560. The authors also acknowledge the National Center for Research Resources supported Clinical Research Centers, RR-024128 (Duke) and RR-00052 (Johns Hopkins University School of Medicine), and the Clinical and Translational Science Award: UL1 RR025780 (National Jewish Health) and UL1 RR 029887 (Mount Sinai).	Anderson T. W, 1984, INTRO MULTIVARIATE S; Baker SS, 2000, PEDIATRICS, V106, P346; Ben-Shoshan M, 2009, J ALLERGY CLIN IMMUN, V123, P783, DOI 10.1016/j.jaci.2009.02.004; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; Cohen BL, 2004, J ALLERGY CLIN IMMUN, V114, P1159, DOI 10.1016/j.jaci.2004.08.007; Denzel A, 2008, NAT IMMUNOL, V9, P733, DOI 10.1038/ni.1621; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811, DOI 10.1016/S0091-6749(99)70292-7; Eggesbo M, 2001, ALLERGY, V56, P403, DOI 10.1034/j.1398-9995.2001.056005403.x; Eggesbo M, 2001, ALLERGY, V56, P393, DOI 10.1034/j.1398-9995.2001.056005393.x; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Grogan JL, 2002, CURR OPIN IMMUNOL, V14, P366, DOI 10.1016/S0952-7915(02)00340-0; Hill DJ, 2008, CLIN EXP ALLERGY, V38, P161, DOI 10.1111/j.1365-2222.2007.02861.x; HILL DJ, 1995, EUR J CLIN NUTR, V49, pS1; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; LEBMAN DA, 1988, J EXP MED, V168, P853, DOI 10.1084/jem.168.3.853; Leung DYM, 2004, ANN ALLERG ASTHMA IM, V93, pS1, DOI 10.1016/S1081-1206(10)61385-3; MENARDO JL, 1985, J ALLERGY CLIN IMMUN, V75, P646, DOI 10.1016/0091-6749(85)90088-0; Min B, 2004, J EXP MED, V200, P507, DOI 10.1084/jem.20040590; Mukai K, 2005, IMMUNITY, V23, P191, DOI 10.1016/j.immuni.2005.06.011; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Tiemessen MM, 2004, J ALLERGY CLIN IMMUN, V113, P932, DOI 10.1016/j.jaci.2003.12.016; Todd DG, 2007, PEDIATRICS, V120, P1304, DOI 10.1542/peds.2007-0350; Tsuge I, 2006, CLIN EXP ALLERGY, V36, P1538, DOI 10.1111/j.1365-2222.2006.02600.x; 2006, ANN ALLERGY ASTHMA S, V96, pS1	38	82	85	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1077	1083		10.1016/j.jaci.2010.02.038	http://dx.doi.org/10.1016/j.jaci.2010.02.038			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20451041	Green Accepted			2022-12-18	WOS:000277686700017
J	Mueller, GA; Edwards, LL; Aloor, JJ; Fessler, MB; Glesner, J; Pomes, A; Chapman, MD; London, RE; Pedersen, LC				Mueller, Geoffrey A.; Edwards, Lori L.; Aloor, Jim J.; Fessler, Michael B.; Glesner, Jill; Pomes, Anna; Chapman, Martin D.; London, Robert E.; Pedersen, Lars C.			The structure of the dust mite allergen Der p 7 reveals similarities to innate immune proteins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergens; dust mites; Der p 7; LPS-binding protein; Toll-like receptor 4; lipopeptide; innate immunity	T-CELL RESPONSES; CRYSTAL-STRUCTURE; CROSS-REACTIVITY; ANTIBODY-BINDING; IGE; RECOMBINANT; EXPOSURE; COMPLEX; ASTHMA; FOLD	Background: Sensitization to house dust mite allergens is strongly correlated with asthma. Der p 7 elicits strong IgE antibody and T-cell responses in patients with mite allergy. However, the structure and biological function of this important allergen are unknown. Allergen function might contribute to allergenicity, as shown for the protease activity of group I mite allergens and the interaction with the innate immune system by group 2 mite allergens. Objective: We sought to determine the crystal structure of Der p 7 and to investigate its biological function. Methods: X-ray crystallography was used to determine the Der p 7 structure. Nuclear magnetic resonance analysis and biochemical assays were used to examine the binding of Der p 7 to predicted ligands. Results: Der p 7 has an elongated structure, with two 4-stranded antiparallel beta-sheets that wrap around a long C-terminal helix. The fold of Der p 7 is similar to that of LPS-binding protein (LBP), which interacts with Toll-like receptors after binding LPS and other bacterially derived lipid ligands. Nuclear magnetic resonance and biochemical assays indicate that Der p 7 does not bind I,PS but binds with weak affinity to the bacterial lipopeptide polymyxin B in the predicted binding site of Der p 7. Conclusions: Der p 7 binds a bacterially derived lipid product, a common feature of some allergens. The finding that the group 7, as well as the group 2, mite allergens are structurally similar to different proteins in the Toll-like receptor pathway further strengthens the connections between dust mites, innate immunity, and allergy. (J Allergy Clin Immunol 2010;125:909-17.)	[Mueller, Geoffrey A.; Edwards, Lori L.; London, Robert E.; Pedersen, Lars C.] Natl Inst Environm Hlth Sci, Struct Biol Lab, Res Triangle Pk, NC 27709 USA; [Edwards, Lori L.] Natl Inst Environm Hlth Sci, Prot Express Core Facil, Res Triangle Pk, NC 27709 USA; [Aloor, Jim J.; Fessler, Michael B.] Natl Inst Environm Hlth Sci, Lab Resp Biol, Res Triangle Pk, NC 27709 USA; [Glesner, Jill; Pomes, Anna; Chapman, Martin D.] INDOOR Biotechnol Inc, Charlottesville, VA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); INDOOR Biotechnologies	Mueller, GA (corresponding author), Natl Inst Environm Hlth Sci, Struct Biol Lab, 111 TW Alexander Dr MD-MR01, Res Triangle Pk, NC 27709 USA.	mueller3@niehs.nih.gov	Pomés, Anna/H-7010-2019; Fessler, Michael B/C-6323-2019; London, Robert E/F-7990-2019; Mueller, Geoffrey A/I-2909-2017; Pedersen, Lars/C-6173-2019	Pomés, Anna/0000-0002-8729-1829; Fessler, Michael B/0000-0002-8262-8613; London, Robert E/0000-0001-9108-8463; Mueller, Geoffrey A/0000-0001-8361-5323; Pedersen, Lars/0000-0002-4488-4077; Chapman, Martin/0000-0002-0845-3632	National Institutes of Health (NIH) [AI077653]; National Institute of Environmental Health Sciences; National Institute for Allergy and Infectious Diseases; National Institute for Environmental Health Sciences; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR007707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES102906, ZIAES102005, ZIAES102645] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute for Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute for Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported in part by the Intramural Research Program of the National Institutes of Health (NIH), National Institute of Environmental Health Sciences, and by NIH grant AI077653 (A.P. and M.D.C.) from the National Institute for Allergy and Infectious Diseases.; Disclosure of potential conflict of interest: M. D. Chapman is an owner of Indoor Biotechnologies, Inc, and Indoor Biotechnologies Ltd and has received research support front the National Institute for Environmental Health Sciences. The rest of the authors have declare that they have no conflict of interest.	Bahrami A, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000307; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254; Center RJ, 1998, PROTEIN SCI, V7, P1612, DOI 10.1002/pro.5560070715; Chapman MD, 2007, CURR ALLERGY ASTHM R, V7, P363, DOI 10.1007/s11882-007-0055-6; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; Chisholm D, 2004, J ALLERGY CLIN IMMUN, V113, P448, DOI 10.1016/j.jaci.2003.12.011; Cuff AL, 2009, NUCLEIC ACIDS RES, V37, pD310, DOI 10.1093/nar/gkn877; Dauwalder B, 2002, GENE DEV, V16, P2879, DOI 10.1101/gad.1010302; Derewenda ZS, 2004, STRUCTURE, V12, P529, DOI 10.1016/j.str.2004.03.008; Didierlaurent A, 2004, J IMMUNOL, V172, P6922, DOI 10.4049/jimmunol.172.11.6922; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Finn RD, 2008, NUCLEIC ACIDS RES, V36, pD281, DOI 10.1093/nar/gkm960; Gafvelin G, 2007, J BIOL CHEM, V282, P3778, DOI 10.1074/jbc.M607938200; Glesner J, 2009, J ALLERGY CLIN IMMUN, V123, pS227, DOI 10.1016/j.jaci.2008.12.871; Hales BJ, 2000, CLIN EXP ALLERGY, V30, P934, DOI 10.1046/j.1365-2222.2000.00901.x; Hales BJ, 2000, CLIN EXP ALLERGY, V30, P927, DOI 10.1046/j.1365-2222.2000.00900.x; Hamiaux C, 2009, J BIOL CHEM, V284, P3496, DOI 10.1074/jbc.M807467200; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Holm L, 2008, BIOINFORMATICS, V24, P2780, DOI 10.1093/bioinformatics/btn507; Ichikawa K, 1999, CLIN EXP ALLERGY, V29, P754; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jung YS, 2004, J BIOMOL NMR, V30, P11, DOI 10.1023/B:JNMR.0000042954.99056.ad; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; King C, 1998, J IMMUNOL, V161, P3645; Kleiger G, 2000, J MOL BIOL, V299, P1019, DOI 10.1006/jmbi.2000.3805; Kolodziejczyk R, 2008, J MOL BIOL, V377, P870, DOI 10.1016/j.jmb.2008.01.026; Li M, 2008, J BIOL CHEM, V283, P22806, DOI 10.1074/jbc.M800937200; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; Mirza O, 2000, J IMMUNOL, V165, P331, DOI 10.4049/jimmunol.165.1.331; Mueller GA, 2001, J BIOL CHEM, V276, P9359, DOI 10.1074/jbc.M010812200; Mueller GA, 2007, BIOMOL NMR ASSIGM, V1, P33, DOI 10.1007/s12104-007-9007-2; Naik MT, 2008, STRUCTURE, V16, P125, DOI 10.1016/j.str.2007.10.022; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; Niemi M, 2007, STRUCTURE, V15, P1413, DOI 10.1016/j.str.2007.09.012; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Radauer C, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-286; Redecke V, 2004, J IMMUNOL, V172, P2739, DOI 10.4049/jimmunol.172.5.2739; Salo PM, 2008, J ALLERGY CLIN IMMUN, V121, pS231, DOI 10.1016/j.jaci.2007.12.915; Schroder NWJ, 2004, J IMMUNOL, V173, P2683, DOI 10.4049/jimmunol.173.4.2683; Schroder NWJ, 2008, IMMUNOBIOLOGY, V213, P329, DOI 10.1016/j.imbio.2007.11.003; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; SHEN HD, 1993, CLIN EXP ALLERGY, V23, P934, DOI 10.1111/j.1365-2222.1993.tb00278.x; Shen HD, 1996, CLIN EXP ALLERGY, V26, P308, DOI 10.1111/j.1365-2222.1996.tb00096.x; Shen HD, 1997, CLIN EXP ALLERGY, V27, P824, DOI 10.1046/j.1365-2222.1997.650890.x; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; Thomas CJ, 1999, J BIOL CHEM, V274, P29624, DOI 10.1074/jbc.274.42.29624; Thomas WR, 2007, IMMUNOL RES, V37, P187, DOI 10.1007/BF02697369; Thomas WR, 2005, CURR ALLERGY ASTHM R, V5, P388, DOI 10.1007/s11882-005-0012-1; Thomas WR, 1999, INT ARCH ALLERGY IMM, V118, P214, DOI 10.1159/000024073; Tomee JFC, 1998, J ALLERGY CLIN IMMUN, V102, P75, DOI 10.1016/S0091-6749(98)70057-0; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Ullah H, 2008, PROTEIN SCI, V17, P1771, DOI 10.1110/ps.035121.108; Walgraffe D, 2009, J ALLERGY CLIN IMMUN, V123, P1150, DOI 10.1016/j.jaci.2008.11.038	57	82	83	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					909	917		10.1016/j.jaci.2009.12.016	http://dx.doi.org/10.1016/j.jaci.2009.12.016			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20226507	Green Accepted			2022-12-18	WOS:000276787900018
J	Kahn, JE; Grandpeix-Guyodo, C; Marroun, I; Catherinot, E; Mellot, F; Roufosse, F; Bletry, O				Kahn, Jean-Emmanuel; Grandpeix-Guyodo, Catherine; Marroun, Ibrahim; Catherinot, Emilie; Mellot, Francois; Roufosse, Florence; Bletry, Oliver			Sustained response to mepolizumab in refractory Churg-Strauss syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA		[Kahn, Jean-Emmanuel] Univ Lille 2, CHRU Lille, Dept Immunol, French Eosinophil Network, F-59800 Lille, France; [Kahn, Jean-Emmanuel; Grandpeix-Guyodo, Catherine; Marroun, Ibrahim; Bletry, Oliver] Univ Versailles St Quentin en Yvelines, Hop Foch, Dept Internal Med, Suresnes, France; [Catherinot, Emilie] Univ Versailles St Quentin en Yvelines, Hop Foch, Dept Pneumol, Suresnes, France; [Mellot, Francois] Univ Versailles St Quentin en Yvelines, Hop Foch, Dept Radiol, Suresnes, France; [Roufosse, Florence] Univ Libre Bruxelles, Hop Erasme, Dept Internal Med, Brussels, Belgium	Universite de Lille - ISITE; CHU Lille; Universite de Lille; Hospital Foch; UDICE-French Research Universities; Universite Paris Saclay; Hospital Foch; UDICE-French Research Universities; Universite Paris Saclay; Hospital Foch; UDICE-French Research Universities; Universite Paris Saclay; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Kahn, JE (corresponding author), Univ Lille 2, CHRU Lille, Dept Immunol, French Eosinophil Network, F-59800 Lille, France.	je.kahn@hopital-foch.org	KAHN, Jean-Emmanuel/S-8509-2018	KAHN, Jean-Emmanuel/0000-0002-9565-6074				Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Kojima K, 1996, INT J HEMATOL, V63, P149; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Shiota Y, 1997, INTERNAL MED, V36, P709, DOI 10.2169/internalmedicine.36.709; Sinico RA, 2005, ARTHRITIS RHEUM, V52, P2926, DOI 10.1002/art.21250; Stein ML, 2008, J ALLERGY CLIN IMMUN, V121, P1473, DOI 10.1016/j.jaci.2008.02.033; Termeer CC, 2001, ARCH DERMATOL, V137, P136	9	82	89	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					267	270		10.1016/j.jaci.2009.10.014	http://dx.doi.org/10.1016/j.jaci.2009.10.014			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109753				2022-12-18	WOS:000273660500035
J	LeBovidge, JS; Strauch, H; Kalish, LA; Schneider, LC				LeBovidge, Jennifer S.; Strauch, Heather; Kalish, Leslie A.; Schneider, Lynda C.			Assessment of psychological distress among children and adolescents with food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; child; adolescent; parent; anxiety; psychological distress; risk factors	QUALITY-OF-LIFE; CHILDHOOD; ATTITUDE; ANXIETY; QUESTIONNAIRE; FAMILIES; PARENTS; ADULTS; IMPACT; SCALE	Background: Youth with food allergy may experience psychosocial stressors including limitations in activities, differences from peers, and anxiety. Factors such as allergy-related medical history, children's attitudes toward their allergies, and parental anxiety may function as risk and resilience factors associated with psychological distress in this population. Objective: To assess mean scores and rates of elevated scores on standardized measures of psychological distress among youth with food allergy and identify factors associated with distress. Methods: A total of 141 mothers of children age 2 to 17 years with food allergy completed questionnaires about child medical history, child anxiety and depressive symptoms, and maternal anxiety symptoms. A total of 69 children age 8 to 17 years completed self-report measures of anxiety and depressive symptoms, social stress, and attitudes toward food allergy. Results: Mean scores on self-report and parent-report measures of child anxiety symptoms, depressive symptoms, and social stress fell in the average range on standardized measures of child distress. Comparisons with normative scores generally indicated either no differences or lower rates of distress in our sample of youth with food allergy, with the exception of child-reported anxious coping and separation anxiety symptoms, which were significantly higher than normative scores. Maternal reports of child symptoms were significantly higher than child self-reports. Multiple regression analyses yielded models in which child attitudes toward food allergy and maternal anxiety were associated with child distress for children 8 to 17 years old. Conclusion: Results suggest targets for prevention of distress, including assessment of attitudes toward food allergy and support for parental anxiety management. (J Allergy Clin Immunol 2009;124:1282-8.)	[LeBovidge, Jennifer S.; Strauch, Heather; Schneider, Lynda C.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Kalish, Leslie A.] Childrens Hosp, Clin Res Program, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	LeBovidge, JS (corresponding author), Childrens Hosp, Div Immunol, Fegan 6,300 Longwood Ave, Boston, MA 02115 USA.	jennifer.lebovidge@childrens.harvard.edu			Jaffe Family Foundation; Food Allergy Project	Jaffe Family Foundation; Food Allergy Project	Supported by the Jaffe Family Foundation and the Food Allergy Project.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; AUSTIN JK, 1993, J PEDIATR PSYCHOL, V18, P467, DOI 10.1093/jpepsy/18.4.467; Avery NJ, 2003, PEDIAT ALLERG IMM-UK, V14, P378, DOI 10.1034/j.1399-3038.2003.00072.x; Blok BMJF, 2008, J ALLERGY CLIN IMMUN, V122, P139, DOI 10.1016/j.jaci.2008.05.008; Bollinger ME, 2006, ANN ALLERG ASTHMA IM, V96, P415, DOI 10.1016/S1081-1206(10)60908-8; Cohen BL, 2004, J ALLERGY CLIN IMMUN, V114, P1159, DOI 10.1016/j.jaci.2004.08.007; DunnGalvin A, 2008, CLIN EXP ALLERGY, V38, P977, DOI 10.1111/j.1365-2222.2008.02978.x; DunnGalvin A, 2009, ALLERGY, V64, P560, DOI 10.1111/j.1398-9995.2008.01862.x; Flokstra-de Blok BMJ, 2009, CLIN EXP ALLERGY, V39, P127, DOI [10.1111/j.1365-2222.2008.03120.x, 10.1111/j.1365-2222.2009.03376.x]; Forman S.G, 1993, COPING SKILLS INTERV; Ginsburg GS, 2002, INT REV PSYCHIATR, V14, P143, DOI 10.1080/09540260220132662; Gupta RS, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-36; Heimlich TE, 2000, J PEDIATR PSYCHOL, V25, P339, DOI 10.1093/jpepsy/25.5.339; Klinnert MD, 2008, CURR ALLERGY ASTHM R, V8, P195, DOI 10.1007/s11882-008-0033-7; LeBovidge JS, 2008, ANN ALLERG ASTHMA IM, V101, P160, DOI 10.1016/S1081-1206(10)60204-9; LeBovidge JS, 2005, J PEDIATR PSYCHOL, V30, P273, DOI 10.1093/jpepsy/jsi037; Mandell D, 2005, HEALTH SOC WORK, V30, P325, DOI 10.1093/hsw/30.4.325; Mandell D, 2002, ACI INT, V14, P96; March J. S., 1999, J ATTEN DISORD, V3, P85, DOI [10.1177/108705479900300202, DOI 10.1177/108705479900300202]; March JS, 1997, J AM ACAD CHILD PSY, V36, P554, DOI 10.1097/00004583-199704000-00019; March JS., 2013, MULTIDIMENSIONAL ANX, V2nd; MASIA CL, 1998, EDUC TREAT CHILD, V21, P514; Monga S, 2006, J AM ACAD CHILD PSY, V45, P1007, DOI 10.1097/01.chi.0000222877.f1; Noone S. A., 2003, Journal of Allergy and Clinical Immunology, V111, pS133, DOI 10.1016/S0091-6749(03)80417-7; Novy D. M., 1993, PSYCHOL ASSESSMENT, V5, P343, DOI [10.1037/1040-3590.5.3.343, DOI 10.1037/1040-3590.5.3.343]; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Reynolds CR, 2004, BEHAV ASSESSMENT SYS; Rynn MA, 2006, J ANXIETY DISORD, V20, P139, DOI 10.1016/j.janxdis.2005.01.004; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sampson MA, 2006, J ALLERGY CLIN IMMUN, V117, P1440, DOI 10.1016/j.jaci.2006.03.009; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461, DOI 10.1016/S1081-1206(10)62258-2; Spielberger Charles D., 1970, STATE TRAIT ANXIETY; US Food and Drug Administration, 2009, UPD INF LEUK INH MON; Wood RA, 2003, PEDIATRICS, V111, P1631	35	82	82	1	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1282	1288		10.1016/j.jaci.2009.08.045	http://dx.doi.org/10.1016/j.jaci.2009.08.045			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	536VH	19910035	Bronze			2022-12-18	WOS:000273071500021
J	Cooper, PR; Panettieri, RA				Cooper, Philip R.; Panettieri, Reynold A., Jr.			Steroids completely reverse albuterol-induced beta(2)-adrenergic receptor tolerance in human small airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway smooth muscle; airway remodeling; asthma; chronic obstructive pulmonary disease	BETA-ADRENERGIC-RECEPTORS; DOWN-REGULATION; IN-VIVO; INHALED BUDESONIDE; PERSISTENT ASTHMA; SMOOTH-MUSCLE; HUMAN-LUNG; DESENSITIZATION; FORMOTEROL; AGONIST	Background: Evidence suggests that chronic stimulation Of beta(2)-adrenergic receptors (beta(2)-ARs) induces receptor tolerance that limits the efficacy of beta-agonists in the treatment of asthma. The precise mechanisms that induce beta(2)-AR tolerance remain unclear. Objective: We sought to determine whether steroids modulate albuterol-induced beta(2)-AR tolerance in human small airways. Methods: beta(2)-AR responsiveness to isoproterenol was characterized in human precision-cut lung slices (PCLSs) precontracted to carbachol after pretreatment with albuterol. Results: Incubation of PCLSs with albuterol for 3, 6, or 12 hours attenuated subsequent isoproterenol-induced relaxation in a dose- and time-dependent manner. A 40% decrease (P < .0001) in maximum relaxation and a 45% decrease (P = .0011) in airway sensitivity from control values occurred after the maximum time and concentration of albuterol incubation. Desensitization was not evident when airways were relaxed to forskolin. Dexamethasone pretreatment of PCLSs (1 hour) prevented albuterol-induced beta(2)-AR desensitization by increasing the maximum drug effect (P = .0023) and decreasing the log half-maximum effective concentration values (P < .0001) from that of albuterol alone. Albuterol (12-hour incubation) decreased the beta(2)-AR cell-surface number (P = .013), which was not significantly reversed by 1 hour of preincubation with dexamethasone. Conclusion: These data suggest that beta(2)-AR desensitization occurs with prolonged treatment of human small airways with albuterol through mechanisms upstream of protein kinase A and that steroids prevent or reverse this desensitization. Clarifying the precise molecular mechanisms by which beta(2)-AR tolerance occurs might offer new therapeutic approaches to improve the efficacy of bronchodilators in asthma and chronic obstructive pulmonary disease.	[Cooper, Philip R.; Panettieri, Reynold A., Jr.] Univ Penn, Sch Med, Dept Med & Airways Biol Initiat, Philadelphia, PA 19104 USA	University of Pennsylvania	Panettieri, RA (corresponding author), Airways Biol Initiat TRL, Suite 1200,125 S 31st St, Philadelphia, PA 19104 USA.	RAP@mail.med.upenn.edu	panettieri, reynold/AAG-9485-2019		NHLBI NIH HHS [HL064063, R01 HL080676, R01 HL064063, HL081824, R01 HL081824, HL080676] Funding Source: Medline; NIEHS NIH HHS [ES013508] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080676, R01HL064063, R01HL081824] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aziz I, 1999, CHEST, V115, P623, DOI 10.1378/chest.115.3.623; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; Chong BTY, 1998, J PHARMACOL TOXICOL, V40, P109, DOI 10.1016/S1056-8719(98)00046-X; Finney PA, 2000, J CLIN INVEST, V106, P125, DOI 10.1172/JCI8374; FRASER CM, 1980, BIOCHEM BIOPH RES CO, V94, P390, DOI 10.1016/S0006-291X(80)80233-6; GUILLOT C, 1984, J ALLERGY CLIN IMMUN, V74, P713, DOI 10.1016/0091-6749(84)90235-5; Hancox RJ, 2001, BIODRUGS, V15, P11, DOI 10.2165/00063030-200115010-00002; Haney S, 2005, RESP MED, V99, P566, DOI 10.1016/j.rmed.2004.10.014; Kaur M, 2008, MOL PHARMACOL, V73, P203, DOI 10.1124/mol.107.040121; MAK JCW, 1995, J CLIN INVEST, V96, P99, DOI 10.1172/JCI118084; Mak JCW, 2002, BRIT J PHARMACOL, V135, P987, DOI 10.1038/sj.bjp.0704545; MAK JCW, 1995, AM J PHYSIOL-LUNG C, V268, pL41, DOI 10.1152/ajplung.1995.268.1.L41; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Penn RB, 1998, AM J RESP CELL MOL, V19, P338, DOI 10.1165/ajrcmb.19.2.3025; SCHWINN DA, 1991, CIRCULATION, V84, P2559, DOI 10.1161/01.CIR.84.6.2559; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Wohlsen A, 2003, EUR RESPIR J, V21, P1024, DOI 10.1183/09031936.03.00027502	18	82	83	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					734	740		10.1016/j.jaci.2008.07.040	http://dx.doi.org/10.1016/j.jaci.2008.07.040			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	18774166	Bronze			2022-12-18	WOS:000259989000017
J	Prescott, SL; Noakes, P; Chow, BWY; Breckler, L; Thornton, CA; Hollams, EM; Ali, M; van den Biggelaar, AHJ; Tulic, MK				Prescott, Susan L.; Noakes, Paul; Chow, Bonita W. Y.; Breckler, Liza; Thornton, Catherine A.; Hollams, Elysia M.; Ali, May; van den Biggelaar, Anita H. J.; Tulic, Meri K.			Presymptomatic differences in toll-like receptor function in infants who have allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Toll-like receptors; hygiene hypothesis; cord blood; allergic disease; cytokines; endotoxin	INTERFERON-GAMMA PRODUCTION; REGULATORY T-CELLS; IMMUNE-RESPONSES; CORD-BLOOD; EXPRESSION; AGE; ENDOTOXIN; DISEASE; ATOPY; RISK	Background: Microbial exposure might play a key role in allergy development, but little is known about the role of Toll-like receptors (TLRs). Objective: This study explored the association between neonatal TLR microbial recognition/function, allergy risk (maternal allergy), and prospective allergy development. Methods: Cord blood mononuclear cells (n = 111) were cultured either alone or with optimal concentrations of TLR ligands: lipoteichoic acid (TLR2), polyinosinicpolycytidylic acid (TLR3), LPS with IFN-gamma (TLR4), flagellin (TLR5), imiquimod R837 (TLR7), or CpG (TLR9). Cytokine responses were assessed in relation to allergy risk (maternal allergy) and allergy outcomes (sensitization, food allergy, and atopic dermatitis) at 12 months of age. Results: Maternal allergy (n = 59) was associated with significantly higher neonatal IL-12 and IFN-gamma responses to TLR2, TLR3, and TLR4 activation, whereas TNF-alpha and IL-6 responses to TLR2, TLR4, and TLR5 activation were significantly higher in newborns who subsequently had allergic disease (n = 32). Notably, consistent with previous reports, newborns who had disease had lower T(H)1 IFN-gamma response to mitogens (PHA). Conclusion: Allergic disease was associated with increased (rather than decreased) perinatal TLR responses. Further studies are needed to determine how these responses track in the postnatal period and whether this relative hyperresponsiveness is a product of intrauterine influences, including maternal atopy, functional genetic polymorphisms, or both.	[Prescott, Susan L.; Noakes, Paul; Chow, Bonita W. Y.; Breckler, Liza; Ali, May; Tulic, Meri K.] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6001, Australia; [Hollams, Elysia M.; van den Biggelaar, Anita H. J.; Tulic, Meri K.] Telethon Inst Child Hlth Res, Perth, WA, Australia; [Thornton, Catherine A.] Univ Swansea, Sch Med, Swansea, W Glam, Wales	University of Western Australia; Telethon Kids Institute; University of Western Australia; Swansea University	Prescott, SL (corresponding author), Univ Western Australia, Sch Paediat & Child Hlth, POB D184, Perth, WA 6001, Australia.	sprescott@meddent.uwa.edu.au	Tulic, Meri/P-6613-2016; Tulic, Meri K/ABB-5138-2020; Prescott, Susan/H-5665-2014	Tulic, Meri/0000-0002-2661-2369; Tulic, Meri K/0000-0002-2661-2369; Hollams, Elysia/0000-0002-3481-6396; Noakes, Paul/0000-0002-2678-1971	National Health and Medical Research Council (NHMRC)	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia)	Supported by the National Health and Medical Research Council (NHMRC) of Australia.	Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Amoudruz P, 2005, J ALLERGY CLIN IMMUN, V115, P1304, DOI 10.1016/j.jaci.2005.02.036; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Haddeland U, 2005, PEDIAT ALLERG IMM-UK, V16, P104, DOI 10.1111/j.1399-3038.2005.00250.x; Hamalainen HK, 2001, ANAL BIOCHEM, V299, P63, DOI 10.1006/abio.2001.5369; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; HOLT P, 1999, ALLERGY S49, V54, pS12; Infante-Rivard C, 2001, AM J EPIDEMIOL, V153, P653, DOI 10.1093/aje/153.7.653; Kondo N, 1998, CLIN EXP ALLERGY, V28, P1340; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Krauss-Etschmann S, 2006, CLIN IMMUNOL, V118, P292, DOI 10.1016/j.clim.2005.10.003; LeBouder E, 2006, J IMMUNOL, V176, P3742, DOI 10.4049/jimmunol.176.6.3742; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Noakes PS, 2006, EUR RESPIR J, V28, P721, DOI 10.1183/09031936.06.00050206; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P39; Prescott SL, 1998, J IMMUNOL, V160, P4730; Savidge TC, 2006, PEDIATR RES, V59, P89, DOI 10.1203/01.pdr.0000195101.74184.e3; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; Weatherill AR, 2005, J IMMUNOL, V174, P5390, DOI 10.4049/jimmunol.174.9.5390; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Yerkovich ST, 2007, PEDIATR RES, V62, P547, DOI 10.1203/PDR.0b013e3181568105	28	82	87	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					391	399		10.1016/j.jaci.2008.04.042	http://dx.doi.org/10.1016/j.jaci.2008.04.042			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18571707				2022-12-18	WOS:000258426300028
J	Feng, BS; Chen, X; He, SH; Zheng, PY; Foster, J; Xing, Z; Bienenstock, J; Yang, PC				Feng, Bai-Sui; Chen, Xiao; He, Shao-Heng; Zheng, Peng-Yuan; Foster, Jane; Xing, Zhou; Bienenstock, John; Yang, Ping-Chang			Disruption of T-cell immunoglobulin and mucin domain molecule (TIM)-1/TIM4 interaction as a therapeutic strategy in a dendritic cell-induced peanut allergy model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						intestine; peanut allergy; T-H cell; dendritic cell; bacteria	FOOD ALLERGY; CHOLERA-TOXIN; MURINE MODEL; ACTIVATION; TOLERANCE; DISEASE; TIM-4	Background: Recent reports indicate that dendritic cell (DC)derived T-cell immunoglobulin and mucin domain molecule (TIM)-4 plays an important role in the initiation of T(H)2 polarization. This study aims to elucidate the mechanisms of peanut allergy mediated by microbial products and DCs and the relationship between peanut allergy and TIM4. Methods: Mouse bone marrow-derived DCs (BMDCs) were generated and exposed to cholera toxin (CT) or/and peanut extract (PE) for 224 hours and then adoptively transferred to naive mice. After re-exposure to specific antigen PE, the mice were killed; intestinal allergic status was determined. Results: Increased expression of TIM4 and costimulatory molecules was detected in BMDCs after concurrent exposure to CT and PE. Adoptively transferred CT/PE-conditioned BMDCs resulted in the increases in serum PE-specific IgE and skewed TH2 polarization in the intestine. Oral challenge with specific antigen PE induced mast cell activation in the intestine. Treating with Toll-like receptor 4 small interfering RNA abolished increased expression of TIM4 and costimulatory molecules by BMDCs. Pretreatment with anti-TIM1 or anti-TIM4 antibody abolished PE-specific TH2 polarization and allergy in the intestine. Conclusion: Concurrent exposure to microbial product CT and food antigen PE increases TIM4 expression in DCs and promotes DC maturation, which plays an important role in the initiation of PE-specific TH2 polarization and allergy in the intestine. Modulation of TIM4 production in DCs represents a novel therapeutic approach for the treatment of peanut allergy.	[Feng, Bai-Sui; Chen, Xiao; Foster, Jane; Bienenstock, John; Yang, Ping-Chang] McMaster Univ, Brain Body Inst, Hamilton, ON L8S 4L8, Canada; [Feng, Bai-Sui; Chen, Xiao; Xing, Zhou; Bienenstock, John; Yang, Ping-Chang] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4L8, Canada; [Foster, Jane] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON L8S 4L8, Canada; [He, Shao-Heng] Nanjing Med Univ, Affiliated Hosp 1, Clin Expt Ctr, Nanjing, Peoples R China; [Zheng, Peng-Yuan] Zhengzhou Univ, Dept Gastroenterol, Zhengzhou, Peoples R China	McMaster University; McMaster University; McMaster University; Nanjing Medical University; Zhengzhou University	Yang, PC (corresponding author), St Josephs Hosp, BBI, Room T3330,50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	yangp@mcmaster.ca	Foster, Jane/AAW-7163-2021; Yang, Ping-Chang/K-4669-2019					Bahna SL, 2003, ANN ALLERG ASTHMA IM, V90, P77, DOI 10.1016/S1081-1206(10)61665-1; Bashir MEH, 2004, J IMMUNOL, V172, P6978, DOI 10.4049/jimmunol.172.11.6978; Burks W, 2006, MOL NUTR FOOD RES, V50, P595, DOI 10.1002/mnfr.200500269; Cardona ID, 2006, AM J CLIN DERMATOL, V7, P273, DOI 10.2165/00128071-200607050-00001; de Jonge JD, 2007, METHODS, V41, P99, DOI 10.1016/j.ymeth.2006.09.004; Frossard CP, 2007, J ALLERGY CLIN IMMUN, V119, P952, DOI 10.1016/j.jaci.2006.12.615; Haines GK, 2005, INFECT IMMUN, V73, P6157, DOI 10.1128/IAI.73.9.6157-6164.2005; Inaba K, 2005, INT J HEMATOL, V81, P181, DOI 10.1532/IJH97.04200; Isomura I, 2005, MICROBIOL IMMUNOL, V49, P79, DOI 10.1111/j.1348-0421.2005.tb03632.x; Jacob C, 2005, J BIOL CHEM, V280, P31936, DOI 10.1074/jbc.M506338200; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Liu T, 2007, MOL IMMUNOL, V44, P3580, DOI 10.1016/j.molimm.2007.03.004; Meraner P, 2007, J IMMUNOL, V178, P2262, DOI 10.4049/jimmunol.178.4.2262; Meyers JH, 2005, NAT IMMUNOL, V6, P455, DOI 10.1038/ni1185; Owen CE, 2007, PHARMACOL THERAPEUT, V113, P121, DOI 10.1016/j.pharmthera.2006.07.003; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Takayama N, 2007, CLIN IMMUNOL, V123, P199, DOI 10.1016/j.clim.2007.01.007; Umetsu SE, 2005, NAT IMMUNOL, V6, P447, DOI 10.1038/ni1186; Venarske D, 2003, SOUTH MED J, V96, P1049, DOI 10.1097/01.SMJ.0000097887.04639.39; Vierk KA, 2007, J ALLERGY CLIN IMMUN, V119, P1504, DOI 10.1016/j.jaci.2007.03.011; Wu L, 2007, IMMUNOL CELL BIOL, V85, P538, DOI 10.1038/sj.icb.7100079; Yang PC, 2007, GASTROENTEROLOGY, V133, P1522, DOI 10.1053/j.gastro.2007.08.006	23	82	99	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					55	61		10.1016/j.jaci.2008.04.036	http://dx.doi.org/10.1016/j.jaci.2008.04.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18547633				2022-12-18	WOS:000257605100009
J	Tovey, ER; Almqvist, C; Li, Q; Crisafulli, D; Marks, GB				Tovey, Euan R.; Almqvist, Catarina; Li, Qiang; Crisafulli, Daniele; Marks, Guy B.			Nonlinear relationship of mite allergen exposure to mite sensitization and asthma in a birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; Der p 1; house dust mite; asthma; sensitization; high-dose tolerance; childhood	HOUSE-DUST-MITE; EARLY-LIFE; CHITIN MICROPARTICLES; ENVIRONMENTAL-FACTORS; CHILDHOOD ASTHMA; FAMILY-HISTORY; P-I; CAT; PREVENTION; CHILDREN	Background: There is uncertainty about the nature of the relationship between mite allergen exposure during infancy and the expression of allergic diseases in childhood. Objective: We sought to explore the relationships between repeated measurements of mite allergen exposure during the first 5 years of life and clinical allergic disease outcomes at age 5 years. Methods: In a birth cohort of 516 at-risk children, 13 bed dust samples were collected between birth and 5 years of age and analyzed for mite allergen. At age 5 years, the presence of mite atopy was assessed based on skin prick test results, and clinical assessments for asthma, eczema, and wheeze were conducted. The association of allergen exposure with each clinical outcome was examined by means of logistic regression, with adjustments for potential confounders. Results: The lowest and highest mite exposure quintiles, expressed as mean allergen concentration averaged over 0 to 5 years, were associated with a lower prevalence of mite atopy and of asthma compared with intermediate levels of exposure. These relationships, when determined by using average allergen concentration over 0 to 18 months, were weaker. Conclusions: This study demonstrates a nonlinear relationship between mite allergen exposure and clinical outcomes in this generally high mite allergen environment.	[Tovey, Euan R.; Almqvist, Catarina; Crisafulli, Daniele; Marks, Guy B.] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; [Tovey, Euan R.; Almqvist, Catarina; Li, Qiang; Crisafulli, Daniele; Marks, Guy B.] Woolcock Inst Med Res, Sydney, NSW 2050, Australia; [Almqvist, Catarina; Crisafulli, Daniele; Marks, Guy B.] Cooperat Res Ctr Asthma, Sydney, NSW, Australia; [Almqvist, Catarina] Karolinska Inst, Dept Woman & Child Hlth, Stockholm, Sweden; [Almqvist, Catarina] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Li, Qiang] George Inst Int Hlth, Sydney, NSW, Australia	University of Sydney; University of Sydney; Woolcock Institute of Medical Research; Karolinska Institutet; Karolinska Institutet; University of Sydney	Tovey, ER (corresponding author), Woolcock Inst Med Res, POB M77,Missenden Rd Post Off, Sydney, NSW 2050, Australia.	ert@med.usyd.edu.au	Tovey, Euan R/G-8604-2017; Marks, Guy B./F-5058-2013	Tovey, Euan R/0000-0002-1802-7266; Marks, Guy B./0000-0002-8976-8053				AALBERSE RC, 1992, CLIN EXP ALLERGY, V22, P1003, DOI 10.1111/j.1365-2222.1992.tb03028.x; Almqvist C, 2005, CLIN REV ALLERG IMMU, V28, P25, DOI 10.1385/CRIAI:28:1:025; Antens CJM, 2006, CLIN EXP ALLERGY, V36, P1525, DOI 10.1111/j.1365-2222.2006.02603.x; Anto JM, 2004, ALLERGY, V59, P121, DOI 10.1111/j.1398-9995.2003.00480.x; Armitage P., 2001, STAT METHODS MED RES; Brussee JE, 2005, J ALLERGY CLIN IMMUN, V115, P946, DOI 10.1016/j.jaci.2005.02.035; Burton OT, 2007, TRENDS IMMUNOL, V28, P419, DOI 10.1016/j.it.2007.08.005; Carter PM, 2003, ANN ALLERG ASTHMA IM, V90, P41, DOI 10.1016/S1081-1206(10)63612-5; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Crisafulli D, 2007, ALLERGY, V62, P1394, DOI 10.1111/j.1398-9995.2007.01533.x; Cullinan P, 2004, THORAX, V59, P855, DOI 10.1136/thx.2003.019877; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Douwes J, 2006, J ALLERGY CLIN IMMUN, V117, P1067, DOI 10.1016/j.jaci.2006.02.002; Gore RB, 2006, J ALLERGY CLIN IMMUN, V117, P649, DOI 10.1016/j.jaci.2005.12.1351; Gore RB, 2002, CLIN EXP ALLERGY, V32, P856, DOI 10.1046/j.1365-2222.2002.01403.x; Harris JM, 2007, BRIT J DERMATOL, V156, P698, DOI 10.1111/j.1365-2133.2006.07710.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holt PG, 1999, NATURE, V402, pB12; Jarvis D, 2007, J ALLERGY CLIN IMMUN, V119, P697, DOI 10.1016/j.jaci.2006.10.042; Johnson CC, 2004, J ALLERGY CLIN IMMUN, V114, P105, DOI 10.1016/j.jaci.2004.04.007; Kramer U, 2006, BRIT J DERMATOL, V154, P99, DOI 10.1111/j.1365-2133.2005.07003.x; Kuiper S, 2007, J ALLERGY CLIN IMMUN, V120, P388, DOI 10.1016/j.jaci.2007.03.038; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Marks GB, 2006, CLIN EXP PHARMACOL P, V33, P285, DOI 10.1111/j.1440-1681.2006.04360.x; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Ozdemir C, 2006, CLIN EXP ALLERGY, V36, P960, DOI 10.1111/j.1365-2222.2006.02515.x; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; Portengen L, 2004, CLIN EXP ALLERGY, V34, P1243, DOI 10.1111/j.1365-2222.2004.02025.x; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Schram-Bijkerk D, 2006, ALLERGY, V61, P640, DOI 10.1111/j.1398-9995.2006.01079.x; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Strong P, 2002, CLIN EXP ALLERGY, V32, P1794, DOI 10.1046/j.1365-2222.2002.01551.x; Torrent M, 2007, AM J RESP CRIT CARE, V176, P446, DOI 10.1164/rccm.200607-916OC; Torrent M, 2006, J ALLERGY CLIN IMMUN, V118, P742, DOI 10.1016/j.jaci.2006.04.059; TOVEY ER, 1992, CLIN EXP ALLERGY, V22, P67, DOI 10.1111/j.1365-2222.1992.tb00116.x; Tovey ER, 2003, NEW ENGL J MED, V349, P1669; Umetsu DT, 2005, LANCET, V365, P98, DOI 10.1016/S0140-6736(05)17714-9; Williams H, 2006, J ALLERGY CLIN IMMUN, V118, P209, DOI 10.1016/j.jaci.2006.04.043	43	82	83	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					114	118		10.1016/j.jaci.2008.05.010	http://dx.doi.org/10.1016/j.jaci.2008.05.010			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18602569				2022-12-18	WOS:000257605100019
